PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Martin, MJ; Muotri, A; Gage, F; Varki, A				Martin, MJ; Muotri, A; Gage, F; Varki, A			Human embryonic stem cells express an immunogenic nonhuman sialic acid	NATURE MEDICINE			English	Article							PROLONGED UNDIFFERENTIATED GROWTH; HUMAN FEEDERS; DIFFERENTIATION; CULTURE; SERUM; LINES; DERIVATION	Human embryonic stem cells (HESC) can potentially generate every body cell type, making them excellent candidates for cell- and tissue-replacement therapies. HESC are typically cultured with animal-derived 'serum replacements' on mouse feeder layers. Both of these are sources of the nonhuman sialic acid Neu5Gc, against which many humans have circulating antibodies. Both HESC and derived embryoid bodies metabolically incorporate substantial amounts of Neu5Gc under standard conditions. Exposure to human sera with antibodies specific for Neu5Gc resulted in binding of immunoglobulin and deposition of complement, which would lead to cell killing in vivo. Levels of Neu5Gc on HESC and embryoid bodies dropped after culture in heat-inactivated anti-Neu5Gc antibody-negative human serum, reducing binding of antibodies and complement from high-titer sera, while allowing maintenance of the undifferentiated state. Complete elimination of Neu5Gc would be likely to require using human serum with human feeder layers, ideally starting with fresh HESC that have never been exposed to animal products.	Univ Calif San Diego, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute	Varki, A (corresponding author), Univ Calif San Diego, Glycobiol Res & Training Ctr, 9500 Gilman Dr,Mailcode 0687, La Jolla, CA 92093 USA.	varkiadmin@ucsd.edu						Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; Badcock G, 1999, CANCER RES, V59, P4715; BARDOR M, 2004, J BIOL CHEM     1129; Bradley JA, 2002, NAT REV IMMUNOL, V2, P859, DOI 10.1038/nri934; Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193; Cheng LZ, 2003, STEM CELLS, V21, P131, DOI 10.1634/stemcells.21-2-131; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Conley BJ, 2004, INT J BIOCHEM CELL B, V36, P555, DOI 10.1016/j.biocel.2003.07.003; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; D'Amour K, 2000, NAT BIOTECHNOL, V18, P381, DOI 10.1038/74429; Draper JS, 2004, STEM CELLS DEV, V13, P325, DOI 10.1089/1547328041797525; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; DUBOIS C, 1990, J BIOL CHEM, V265, P2797; Gearhart J, 2004, NEW ENGL J MED, V350, P1275, DOI 10.1056/NEJMp048045; Hovatta O, 2003, HUM REPROD, V18, P1404, DOI 10.1093/humrep/deg290; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Keller G, 1999, NAT MED, V5, P151, DOI 10.1038/5512; Koivisto H, 2004, REPROD BIOMED ONLINE, V9, P330, DOI 10.1016/S1472-6483(10)62150-5; Miyamoto K, 2004, STEM CELLS, V22, P433, DOI 10.1634/stemcells.22-4-433; Nakashima K, 2004, NAT MED, V10, P23, DOI 10.1038/nm0104-23; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Richards M, 2002, NAT BIOTECHNOL, V20, P933, DOI 10.1038/nbt726; Richards M, 2003, STEM CELLS, V21, P546, DOI 10.1634/stemcells.21-5-546; Rosler ES, 2004, DEV DYNAM, V229, P259, DOI 10.1002/dvdy.10430; Tangvoranuntakul P, 2003, P NATL ACAD SCI USA, V100, P12045, DOI 10.1073/pnas.2131556100; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Varki A, 2001, YEARB PHYS ANTHROPOL, V44, P54, DOI 10.1002/ajpa.10018; Yamaguchi M, 2002, TRANSFUSION, V42, P921, DOI 10.1046/j.1537-2995.2002.00149.x; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	31	711	800	1	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					228	232		10.1038/nm1181	http://dx.doi.org/10.1038/nm1181			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685172				2022-12-27	WOS:000226797300032
J	Uchida, T; Nakamura, T; Hashimoto, N; Matsuda, T; Kotani, K; Sakaue, H; Kido, Y; Hayashi, Y; Nakayama, KI; White, MF; Kasuga, M				Uchida, T; Nakamura, T; Hashimoto, N; Matsuda, T; Kotani, K; Sakaue, H; Kido, Y; Hayashi, Y; Nakayama, KI; White, MF; Kasuga, M			Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice	NATURE MEDICINE			English	Article							FORKHEAD TRANSCRIPTION FACTOR; CELL-CYCLE PROGRESSION; KINASE INHIBITOR P27(KIP1); LEPTIN RECEPTOR GENE; CYTOPLASMIC LOCALIZATION; PROTEIN-KINASE; DEPENDENT PHOSPHORYLATION; INSULIN-RECEPTOR; FACTOR FOXO1; EXPRESSION	The protein p27(Kip1) regulates cell cycle progression in mammals by inhibiting the activity of cyclin-dependent kinases (CDKs). Here we show that p27(Kip1) progressively accumulates in the nucleus of pancreatic beta cells in mice that lack either insulin receptor substrate 2 (Irs2(-/-)) or the long form of the leptin receptor (Lepr(-/-) or db/db). Deletion of the gene encoding p27(Kip1) (Cdkn1b) ameliorated hyperglycemia in these animal models of type 2 diabetes mellitus by increasing islet mass and maintaining compensatory hyperinsulinemia, effects that were attributable predominantly to stimulation of pancreatic beta-cell proliferation. Thus, p27(Kip1) contributes to beta-cell failure during the development of type 2 diabetes in Irs2(-/-) and Lepr(-/-) mice and represents a potential new target for the treatment of this condition.	Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Div Mol Med & Med Genet, Int Ctr Med Res, Kobe, Hyogo 6500017, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr, Boston, MA 02215 USA	Kobe University; Kobe University; Kyushu University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	Kasuga, M (corresponding author), Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.	kasuga@med.kobe-u.ac.jp	Sakaue, Hiroshi/ABE-2337-2021	Sakaue, Hiroshi/0000-0002-2468-2363				Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; HELLERSTROM C, 1976, ACTA ENDOCRINOL-COP, V83, P145; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; Schreyer SA, 1998, J CLIN INVEST, V102, P402, DOI 10.1172/JCI2849; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Tanabe K, 1997, BIOCHEM BIOPH RES CO, V241, P765, DOI 10.1006/bbrc.1997.7894; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Uchida T, 2000, MOL CELL BIOL, V20, P126, DOI 10.1128/MCB.20.1.126-138.2000; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wolf G, 2001, J MOL MED, V79, P382, DOI 10.1007/s001090100241; Wolf G, 1998, KIDNEY INT, V53, P869, DOI 10.1046/j.1523-1755.1998.00829.x; Xuan SH, 2002, J CLIN INVEST, V110, P1011, DOI 10.1172/JCI200215276; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	45	170	177	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					175	182		10.1038/nm1187	http://dx.doi.org/10.1038/nm1187			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685168				2022-12-27	WOS:000226797300025
J	Iwamoto, T; Kita, S; Zhang, J; Blaustein, MP; Arai, Y; Yoshida, S; Wakimoto, K; Komuro, I; Katsuragi, T				Iwamoto, T; Kita, S; Zhang, J; Blaustein, MP; Arai, Y; Yoshida, S; Wakimoto, K; Komuro, I; Katsuragi, T			Salt-sensitive hypertension is triggered by Ca2+ entry via Na+/Ca2+ exchanger type-1 in vascular smooth muscle	NATURE MEDICINE			English	Article							TISSUE-SPECIFIC EXPRESSION; SODIUM-CALCIUM EXCHANGE; SYSTOLIC BLOOD-PRESSURE; NA+-CA2+ EXCHANGER; ENDOGENOUS OUABAIN; ISOFORMS NCX1; INHIBITOR; PUMP; RAT; NA+	Excessive salt intake is a major risk factor for hypertension. Here we identify the role of Na+/Ca2+ exchanger type 1 (NCX1) in salt-sensitive hypertension using SEA0400, a specific inhibitor of Ca2+ entry through NCX1, and genetically engineered mice. SEA0400 lowers arterial blood pressure in salt-dependent hypertensive rat models, but not in other types of hypertensive rats or in normotensive rats. Infusion of SEA0400 into the femoral artery in salt-dependent hypertensive rats increases arterial blood flow, indicating peripheral vasodilation. SEA0400 reverses ouabain-induced cytosolic Ca2+ elevation and vasoconstriction in arteries. Furthermore, heterozygous NCX1-deficient mice have low salt sensitivity, whereas transgenic mice that specifically express NCX1.3 in smooth muscle are hypersensitive to salt. SEA0400 lowers the blood pressure in salt-dependent hypertensive mice expressing NCX1.3, but not in SEA0400-insensitive NCX1.3 mutants. These findings indicate that salt-sensitive hypertension is triggered by Ca2+ entry through NCX1 in arterial smooth muscle and suggest that NCX1 inhibitors might be useful therapeutically.	Fukuoka Univ, Sch Med, Dept Pharmacol, Fukuoka 8140180, Japan; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Osaka 5658565, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Osaka 5658565, Japan; Taisho Pharmaceut Co Ltd, Med Res Labs, Saitama 3308530, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Osaka 5328505, Japan; Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chiba 2608670, Japan	Fukuoka University; University System of Maryland; University of Maryland Baltimore; National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan; Taisho Pharmaceutical Holdings Co Ltd; Mitsubishi Tanabe Pharma Corporation; Chiba University	Iwamoto, T (corresponding author), Fukuoka Univ, Sch Med, Dept Pharmacol, Fukuoka 8140180, Japan.	tiwamoto@cis.fukuoka-u.ac.jp			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045215] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45215] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aizman O, 2001, P NATL ACAD SCI USA, V98, P13420, DOI 10.1073/pnas.221315298; Arnon A, 2000, AM J PHYSIOL-HEART C, V279, pH679, DOI 10.1152/ajpheart.2000.279.2.H679; Bagrov AY, 1998, HYPERTENSION, V31, P1097, DOI 10.1161/01.HYP.31.5.1097; BERNE RM, 2001, CARDIOVASCULAR PHYSL, P115; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; BLAUSTEIN MP, 1977, AM J PHYSIOL, V232, pC165, DOI 10.1152/ajpcell.1977.232.5.C165; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; COWLEY AW, 1992, PHYSIOL REV, V72, P231, DOI 10.1152/physrev.1992.72.1.231; Fedorova OV, 2000, CIRCULATION, V102, P3009; Ferrari P, 1998, J PHARMACOL EXP THER, V285, P83; Fujioka Y, 1998, J PHYSIOL-LONDON, V509, P457, DOI 10.1111/j.1469-7793.1998.457bn.x; Goto A, 2000, HYPERTENS RES, V23, pS7, DOI 10.1291/hypres.23.Supplement_S7; HADDY FJ, 1995, J AM COLL NUTR, V14, P428; HAMLYN JM, 1982, NATURE, V300, P650, DOI 10.1038/300650a0; Hamlyn JM, 1996, J HYPERTENS, V14, P151, DOI 10.1097/00004872-199602000-00002; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; HASEGAWA T, 1987, J CLIN HYPERTENS, V3, P419; Iwamoto T, 2004, J BIOL CHEM, V279, P7544, DOI 10.1074/jbc.M310491200; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Juhaszova M, 1997, ANN NY ACAD SCI, V834, P524, DOI 10.1111/j.1749-6632.1997.tb52310.x; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Krushkal J, 1999, CIRCULATION, V99, P1407, DOI 10.1161/01.CIR.99.11.1407; LEE SL, 1994, J BIOL CHEM, V269, P14849; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Manunta P, 1999, HYPERTENSION, V34, P450, DOI 10.1161/01.HYP.34.3.450; MANUNTA P, 1994, J HYPERTENS, V12, P549; Matsuda T, 2001, J PHARMACOL EXP THER, V298, P249; Matsumura Y, 2000, CIRCULATION, V102, P2765, DOI 10.1161/01.CIR.102.22.2765; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Poburko D, 2004, TRENDS PHARMACOL SCI, V25, P8, DOI 10.1016/j.tips.2003.10.011; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Reuter H, 2002, CIRC RES, V90, P305, DOI 10.1161/hh0302.104562; Schneider R, 1998, J BIOL CHEM, V273, P784, DOI 10.1074/jbc.273.2.784; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; Slodzinski MK, 1998, AM J PHYSIOL-CELL PH, V275, pC251, DOI 10.1152/ajpcell.1998.275.1.C251; SLODZINSKI MK, 1995, AM J PHYSIOL-CELL PH, V269, pC1340, DOI 10.1152/ajpcell.1995.269.5.C1340; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Takahashi H, 2000, HYPERTENS RES, V23, pS1, DOI 10.1291/hypres.23.Supplement_S1; Tanaka H, 2002, BRIT J PHARMACOL, V135, P1096, DOI 10.1038/sj.bjp.0704574; Wakimoto K, 2000, J BIOL CHEM, V275, P36991, DOI 10.1074/jbc.M004035200; Yamashita J, 2003, J PHARMACOL EXP THER, V304, P284, DOI 10.1124/jpet.102.039024; YUAN CM, 1993, HYPERTENSION, V22, P178, DOI 10.1161/01.HYP.22.2.178; Zhang J, 2002, AM J PHYSIOL-HEART C, V283, pH2692, DOI 10.1152/ajpheart.00260.2002	50	221	229	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1193	1199		10.1038/nm1118	http://dx.doi.org/10.1038/nm1118			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15475962				2022-12-27	WOS:000224785900040
J	Lleo, A; Berezovska, O; Herl, L; Raju, S; Deng, A; Bacskai, BJ; Frosch, MP; Irizarry, M; Hyman, BT				Lleo, A; Berezovska, O; Herl, L; Raju, S; Deng, A; Bacskai, BJ; Frosch, MP; Irizarry, M; Hyman, BT			Nonsteroidal anti-inflammatory drugs lower A beta(42) and change presenilin 1 conformation	NATURE MEDICINE			English	Article							GAMMA-SECRETASE; ALZHEIMERS-DISEASE; INHIBITORS; COMPLEX; NSAIDS; MODEL	Recent reports suggest that some commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) unexpectedly shift the cleavage products of amyloid precursor protein (APP) to shorter, less fibrillogenic forms, although the underlying mechanism remains unknown. We now demonstrate, using a fluorescence resonance energy transfer method, that Abeta(42)-lowering NSAIDs specifically affect the proximity between APP and presenilin 1 and alter presenilin 1 conformation both in vitro and in vivo, suggesting a novel allosteric mechanism of action.	Massachusetts Gen Hosp, Alzheimers Res Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Hyman, BT (corresponding author), Massachusetts Gen Hosp, Alzheimers Res Unit, 114 16th St, Charlestown, MA 02129 USA.	bhyman@partners.org	Lleó, Alberto/K-5783-2019; Bacskai, Brian/AAE-9583-2021; Frosch, Matthew P/ABD-7456-2021	Frosch, Matthew P/0000-0002-3940-9861	NIA NIH HHS [AG15379] Funding Source: Medline; NIBIB NIH HHS [EB00768] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015379] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; Berezovska O, 2003, J NEUROSCI, V23, P4560; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Yan Q, 2003, J NEUROSCI, V23, P7504	12	177	202	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1065	1066		10.1038/nm1112	http://dx.doi.org/10.1038/nm1112			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15448688				2022-12-27	WOS:000224245800035
J	Ross, CA; Poirier, MA				Ross, CA; Poirier, MA			Protein aggregation and neurodegenerative disease	NATURE MEDICINE			English	Review							AMYLOID-BETA-PROTEIN; SOLID-STATE NMR; NEURONAL INTRANUCLEAR INCLUSIONS; UBIQUITIN-PROTEASOME SYSTEM; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; MUTANT HUNTINGTIN; FIBRIL FORMATION	Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and prion diseases are increasingly being realized to have common cellular and molecular mechanisms including protein aggregation and inclusion body formation. The aggregates usually consist,of fibers containing misfolded protein with a beta-sheet conformation, termed amyloid. There is partial but not perfect overlap among the cells in which abnormal proteins are deposited and the cells that degenerate. The most likely explanation is that inclusions and other visible protein aggregates represent an end stage of a molecular cascade of several steps, and that earlier steps in the cascade may be more directly tied to pathogenesis than the inclusions themselves. For several diseases, genetic variants assist in explaining the pathogenesis of the more common sporadic forms and developing mouse and other models. There is now increased understanding of the pathways involved in protein aggregation, and some recent clues have emerged as to the molecular mechanisms of cellular toxicity. These are leading to approaches toward rational therapeutics.	Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Ross, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Ross Res Bldg,Room 618,720 Rutland Ave, Baltimore, MD 21205 USA.	caross@jhu.edu	Ross, Christopher A/H-8395-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377, P01NS016375, R01NS034172, P50NS016375, R01NS038144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER; NIA NIH HHS [AG05146] Funding Source: Medline; NINDS NIH HHS [NS38144, NS34172, NS38377, NS16375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Benzinger TLS, 2000, BIOCHEMISTRY-US, V39, P3491, DOI 10.1021/bi991527v; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Bohrmann B, 2000, J STRUCT BIOL, V130, P232, DOI 10.1006/jsbi.2000.4241; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Buxbaum JN, 2003, TRENDS BIOCHEM SCI, V28, P585, DOI 10.1016/j.tibs.2003.09.009; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Citron M, 2002, NAT NEUROSCI, V5, P1055, DOI 10.1038/nn940; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cordeiro Y, 2004, J BIOL CHEM, V279, P5346, DOI 10.1074/jbc.M312262200; Davidson BL, 2004, LANCET NEUROL, V3, P145, DOI 10.1016/S1474-4422(04)00678-7; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; de Almeida LP, 2002, J NEUROSCI, V22, P3473; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; EANES ED, 1968, J HISTOCHEM CYTOCHEM, V16, P673, DOI 10.1177/16.11.673; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goedert M, 2004, SEMIN CELL DEV BIOL, V15, P45, DOI 10.1016/j.semcdb.2003.12.015; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Heiser V, 2002, P NATL ACAD SCI USA, V99, P16400, DOI 10.1073/pnas.182426599; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Iwatsubo T, 1996, AM J PATHOL, V148, P1517; Iwatsubo T, 2003, J NEUROL, V250, P11, DOI 10.1007/s00415-003-1303-x; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; John V, 2003, J MED CHEM, V46, P4625, DOI 10.1021/jm030247h; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; Lee EN, 2004, BIOCHEMISTRY-US, V43, P3704, DOI 10.1021/bi0356707; Lindquist S, 2001, PHILOS T ROY SOC B, V356, P169, DOI 10.1098/rstb.2000.0762; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Mattson MP, 2003, SCIENCE, V301, P1847, DOI 10.1126/science.301.5641.1847; May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Miller VM, 2003, P NATL ACAD SCI USA, V100, P7195, DOI 10.1073/pnas.1231012100; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; MYERS RH, 1988, NEUROLOGY, V38, P341, DOI 10.1212/WNL.38.3.341; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Nucifora FC, 2003, J BIOL CHEM, V278, P13047, DOI 10.1074/jbc.M211224200; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Orr HT, 2001, HUM MOL GENET, V10, P2307, DOI 10.1093/hmg/10.20.2307; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Piper P W, 2001, Curr Opin Investig Drugs, V2, P1606; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Pollitt SK, 2003, NEURON, V40, P685, DOI 10.1016/S0896-6273(03)00697-4; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Reixach N, 2000, J STRUCT BIOL, V130, P247, DOI 10.1006/jsbi.2000.4245; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; ROSS CA, 2004, TRENDS CELL BIOL; Sacchettini JC, 2002, NAT REV DRUG DISCOV, V1, P267, DOI 10.1038/nrd769; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scheibel T, 2004, P NATL ACAD SCI USA, V101, P2287, DOI 10.1073/pnas.0308754101; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Sen S, 2003, PROTEIN SCI, V12, P953, DOI 10.1110/ps.0224403; Serpell LC, 2000, J MOL BIOL, V299, P225, DOI 10.1006/jmbi.2000.3650; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Singleton A, 2004, HUM MOL GENET, V13, pR123, DOI 10.1093/hmg/ddh093; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Thakur AK, 2002, P NATL ACAD SCI USA, V99, P17014, DOI 10.1073/pnas.252523899; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tycko R, 2003, BIOCHEMISTRY-US, V42, P3151, DOI 10.1021/bi027378p; Uversky VN, 2003, CELL MOL LIFE SCI, V60, P1852, DOI 10.1007/s00018-003-3096-6; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Verhoef LGGC, 2002, HUM MOL GENET, V11, P2689, DOI 10.1093/hmg/11.22.2689; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Weiner HL, 2002, NATURE, V420, P879, DOI 10.1038/nature01325; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Wood SJ, 1996, J BIOL CHEM, V271, P4086; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	125	2310	2366	18	877	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7		S			S10	S17		10.1038/nm1066	http://dx.doi.org/10.1038/nm1066			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	844YU	15272267				2022-12-27	WOS:000223202100003
J	Pearse, DD; Pereira, FC; Marcillo, AE; Bates, ML; Berrocal, YA; Filbin, MT; Bunge, MB				Pearse, DD; Pereira, FC; Marcillo, AE; Bates, ML; Berrocal, YA; Filbin, MT; Bunge, MB			cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; ADENYLATE-CYCLASE; MESSENGER-RNA; RATING-SCALE; REGENERATION; ACTIVATION; INHIBITION; APOPTOSIS	Central neurons regenerate axons if a permissive environment is provided; after spinal cord injury, however, inhibitory molecules are present that make the local environment nonpermissive. A promising new strategy for inducing neurons to overcome inhibitory signals is to activate cAMP signaling. Here we show that cAMP levels fall in the rostral spinal cord, sensorimotor cortex and brainstem after spinal cord contusion. Inhibition of cAMP hydrolysis by the phosphodiesterase IV inhibitor rolipram prevents this decrease and when combined with Schwann cell grafts promotes significant supraspinal and proprioceptive axon sparing and myelination. Furthermore, combining rolipram with an injection of db-cAMP near the graft not only prevents the drop in cAMP levels but increases them above those in uninjured controls. This further enhances axonal sparing and myelination, promotes growth of serotonergic fibers into and beyond grafts, and significantly improves locomotion. These findings show that cAMP levels are key for protection, growth and myelination of injured CNS axons in vivo and recovery of function.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; Univ Sao Paulo, Inst Biomed Sci, Dept Anat, BR-05508900 Sao Paulo, Brazil; CUNY Hunter Coll, Dept Biol, New York, NY 10021 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA	University of Miami; Universidade de Sao Paulo; City University of New York (CUNY) System; Hunter College (CUNY); University of Miami; University of Miami	Pearse, DD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA.	dpearse@miamiproject.med.miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X; Berrocal, Yerko/0000-0002-1089-6563	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS038665, R01NS009923] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; AZHDERIAN EM, 1994, NEURON, V12, P1223, DOI 10.1016/0896-6273(94)90439-1; BARBEAU H, 1991, BRAIN RES, V546, P250, DOI 10.1016/0006-8993(91)91489-N; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bunge MB, 2002, PROG BRAIN RES, V137, P275; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; Bunge MB, 2001, NEUROSCIENTIST, V7, P325, DOI 10.1177/107385840100700409; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Cohen J.E., 1988, STAT POWER ANAL BEHA; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Howe DG, 2000, J NEUROSCI, V20, P3513, DOI 10.1523/JNEUROSCI.20-10-03513.2000; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; LUDWIN SK, 1978, LAB INVEST, V39, P597; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; MORGAN L, 1994, DEVELOPMENT, V120, P1399; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Nijjar MS, 2000, INT J MOL MED, V6, P377; NUYDENS R, 1993, NEUROREPORT, V4, P179, DOI 10.1097/00001756-199302000-00016; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; SCHULTZ JE, 1988, PHARMACOPSYCHIATRY, V21, P83, DOI 10.1055/s-2007-1014653; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Souness JE, 2000, IMMUNOPHARMACOLOGY, V47, P127, DOI 10.1016/S0162-3109(00)00185-5; Takami T, 2002, J NEUROSCI, V22, P6670; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Troadec JD, 2002, MOL PHARMACOL, V62, P1043, DOI 10.1124/mol.62.5.1043; VIALA D, 1969, BRAIN RES, V12, P437, DOI 10.1016/0006-8993(69)90011-0; WEST NR, 1989, J NEUROPATH EXP NEUR, V48, P94, DOI 10.1097/00005072-198901000-00008; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; YAMAMOTO M, 1993, NEUROSCI LETT, V152, P37, DOI 10.1016/0304-3940(93)90477-3; Zidek Z, 1999, EUR CYTOKINE NETW, V10, P319	50	560	592	3	64	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					610	616		10.1038/nm1056	http://dx.doi.org/10.1038/nm1056			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15156204				2022-12-27	WOS:000221759600026
J	Haik, S; Faucheux, BA; Sazdovitch, V; Privat, N; Kemeny, JL; Perret-Liaudet, A; Hauw, JJ				Haik, S; Faucheux, BA; Sazdovitch, V; Privat, N; Kemeny, JL; Perret-Liaudet, A; Hauw, JJ			The sympathetic nervous system is involved in variant Creutzfeldt-Jakob disease	NATURE MEDICINE			English	Article							PRION PROTEIN; NEURONS; CJD	Prion epizoonoses spread from animals consumed by humans raise the question of which pathways lead to prion neuroinvasion after oral exposure of humans. Here we show that neurons of sympathetic ganglia of patients with variant Creutzfeldt-Jakob disease (vCJD) accumulate the abnormal isoform of the protein prion. This observation shows the involvement of the sympathetic nervous system in the pathogenesis of vCJD and suggests a role for GUT-associated sympathetic neurons in prion propagation in humans after oral contamination.	Hop La Pitie Salpetriere, Assoc Claude Bernard, Raymond Escourolle Neuropathol Lab, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, U360, F-75013 Paris, France; G Montpied Hosp, Dept Pathol Anat, F-63000 Clermont Ferrand, France; Neurol Hosp, Biochem Lab, Ctr Diagnost & Treatment Prions Dis, F-69003 Lyon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU Clermont Ferrand; CHU Lyon	Haik, S (corresponding author), Hop La Pitie Salpetriere, Assoc Claude Bernard, Raymond Escourolle Neuropathol Lab, F-75013 Paris, France.		Haik, Stephane/M-7247-2018					Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Glatzel M, 2001, NEURON, V31, P25, DOI 10.1016/S0896-6273(01)00331-2; GOTO S, 1991, ANN NEUROL, V30, P192, DOI 10.1002/ana.410300211; Haik S, 2002, ANN NEUROL, V51, P797, DOI 10.1002/ana.10195; Koperek O, 2002, AM J PATHOL, V161, P1979, DOI 10.1016/S0002-9440(10)64474-4; Kovacs GG, 2002, BRAIN PATHOL, V12, P1; McBride PA, 2001, J VIROL, V75, P9320, DOI 10.1128/JVI.75.19.9320-9327.2001; Oppenheim C, 2000, LANCET, V356, P253, DOI 10.1016/S0140-6736(05)74505-0; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Schulz-Schaeffer WJ, 2000, AM J PATHOL, V156, P51, DOI 10.1016/S0002-9440(10)64705-0; Shmakov AN, 2000, NAT MED, V6, P840, DOI 10.1038/78558; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	15	64	64	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1121	1123		10.1038/nm922	http://dx.doi.org/10.1038/nm922			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12937415				2022-12-27	WOS:000185061600021
J	Schaible, UE; Winau, F; Sieling, PA; Fischer, K; Collins, HL; Hagens, K; Modlin, RL; Brinkmann, V; Kaufmann, SHE				Schaible, UE; Winau, F; Sieling, PA; Fischer, K; Collins, HL; Hagens, K; Modlin, RL; Brinkmann, V; Kaufmann, SHE			Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis	NATURE MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; DENDRITIC CELLS; INFECTED MACROPHAGES; ANTIMICROBIAL ACTIVITY; PRESENTING CELLS; RECOGNITION; PHAGOSOMES; COMPARTMENTS; TRAFFICKING; GLYCOLIPIDS	Protective immunity against Mycobacterium tuberculosis involves major histocompatibility complex class I (MHC-I)- and CD1-restricted CD8 T cells, but the mechanisms underlying antigen delivery to antigen-presenting molecules remain enigmatic. Macrophages, the primary host cells for mycobacteria, are CD1-negative. Here we show that M. tuberculosis phagosomes are secluded from the cytosolic MHC-I processing pathway and that mycobacteria-infected cells lose their antigen-presenting capacity. We also show that mycobacteria induce apoptosis in macrophages, causing the release of apoptotic vesicles that carry mycobacterial antigens to uninfected antigen-presenting cells (APCs). Inhibition of apoptosis reduced transfer of antigens to bystander cells and activation of CD8 T cells. Uninfected dendritic cells, which engulfed extracellular vesicles, were indispensable for subsequent cross-presentation of antigens, through MHC-I and CD1b, to T cells from mycobacteria-sensitized donors. This new 'detour' pathway for presentation of antigens from a phagosome-contained pathogen shows the functional significance of infection-induced apoptosis in the activation of CD8 T cells specific for both protein and glycolipid antigens in tuberculosis.	Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Max Planck Inst Infect Biol, Cent Core Facil Microscopy, D-10117 Berlin, Germany	Max Planck Society; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Max Planck Society	Schaible, UE (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Schumannstr 21-22, D-10117 Berlin, Germany.		Modlin, Robert L/M-7941-2014; Brinkmann, Volker/A-6015-2009; Kaufmann, Stefan HE/I-5454-2014	Modlin, Robert L/0000-0003-4720-031X; Kaufmann, Stefan HE/0000-0001-9866-8268				Beatty WL, 2000, TRAFFIC, V1, P235, DOI 10.1034/j.1600-0854.2000.010306.x; Beatty WL, 2000, INFECT IMMUN, V68, P6997, DOI 10.1128/IAI.68.12.6997-7002.2000; Beauregard KE, 1997, J EXP MED, V186, P1159, DOI 10.1084/jem.186.7.1159; Behar SM, 1999, J EXP MED, V189, P1973, DOI 10.1084/jem.189.12.1973; BEHAR SM, 1995, J EXP MED, V182, P2007, DOI 10.1084/jem.182.6.2007; Canaday DH, 1999, J IMMUNOL, V162, P372; Cho S, 2000, P NATL ACAD SCI USA, V97, P12210, DOI 10.1073/pnas.210391497; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; den Haan JMM, 2001, CURR OPIN IMMUNOL, V13, P437, DOI 10.1016/S0952-7915(00)00238-7; Denzer K, 2000, J CELL SCI, V113, P3365; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Fayyazi A, 2000, J PATHOL, V191, P417, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH664&gt;3.0.CO;2-R; Fischer K, 2001, J IMMUNOL, V167, P2187, DOI 10.4049/jimmunol.167.4.2187; Herrmann JL, 1996, EMBO J, V15, P3547, DOI 10.1002/j.1460-2075.1996.tb00724.x; Jiao XN, 2002, J IMMUNOL, V168, P1294, DOI 10.4049/jimmunol.168.3.1294; Kaufmann SHE, 2000, NAT MED, V6, P955, DOI 10.1038/79631; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; Larsson M, 2001, TRENDS IMMUNOL, V22, P141, DOI 10.1016/S1471-4906(01)01860-9; Mazzaccaro RJ, 1996, P NATL ACAD SCI USA, V93, P11786, DOI 10.1073/pnas.93.21.11786; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Ochoa MT, 2001, NAT MED, V7, P174, DOI 10.1038/84620; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; Rojas M, 1997, J IMMUNOL, V159, P1352; Rolph MS, 2001, EUR J IMMUNOL, V31, P1944, DOI 10.1002/1521-4141(200106)31:6<1944::AID-IMMU1944>3.0.CO;2-R; Ronchetti A, 1999, J IMMUNOL, V163, P130; Russell DG, 1997, PHILOS T ROY SOC B, V352, P1303, DOI 10.1098/rstb.1997.0114; Schaible U E, 1999, Adv Immunol, V71, P267; Schaible UE, 2000, J IMMUNOL, V164, P4843, DOI 10.4049/jimmunol.164.9.4843; Schaible UE, 1999, J CELL SCI, V112, P681; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Stenger S, 1998, J IMMUNOL, V161, P3582; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Teitelbaum R, 1999, P NATL ACAD SCI USA, V96, P15190, DOI 10.1073/pnas.96.26.15190; Wilhelm S, 1999, EUR J CELL BIOL, V78, P127, DOI 10.1016/S0171-9335(99)80014-4; XU SM, 1994, J IMMUNOL, V153, P2568; Yrlid U, 2000, J EXP MED, V191, P613, DOI 10.1084/jem.191.4.613; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zocchi MR, 1997, AIDS, V11, P1227, DOI 10.1097/00002030-199710000-00005	40	400	420	0	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1039	1046		10.1038/nm906	http://dx.doi.org/10.1038/nm906			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12872166				2022-12-27	WOS:000184484900028
J	Veazey, RS; Shattock, RJ; Pope, M; Kirijan, JC; Jones, J; Hu, QX; Ketas, T; Marx, PA; Klasse, PJ; Burton, DR; Moore, JP				Veazey, RS; Shattock, RJ; Pope, M; Kirijan, JC; Jones, J; Hu, QX; Ketas, T; Marx, PA; Klasse, PJ; Burton, DR; Moore, JP			Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120	NATURE MEDICINE			English	Article							SIMIAN/HUMAN IMMUNODEFICIENCY VIRUS; SEXUAL TRANSMISSION; DENDRITIC CELLS; IN-VITRO; NEUTRALIZATION; REDUCTION; INFECTION; SEMEN; LOAD	A topical microbicide reduces the probability of virus transmission when applied to the vagina or rectum of a person at risk of sexually acquiring HIV-1 infection(1-3). An effective microbicide could significantly reduce the global spread of HIV-1, particularly if women were able to use it covertly to protect themselves. A microbicide could target the incoming virus and either permanently inactivate it or reduce its infectivity, or it could block receptors on susceptible cells near the sites of transmission(1-3). We describe here how vaginal administration of the broadly neutralizing human monoclonal antibody b12 can protect macaques from simian-human immunodeficiency virus (SHIV) infection through the vagina. Only 3 of 12 animals receiving 5 mg b12 vaginally in either saline or a gel and then challenged vaginally (up to 2 h later) with SHIV-162P4 became infected. In contrast, infection occurred in 12 of 13 animals given various control agents under similar conditions. Lower amounts of b12 were less effective, suggesting that protection was dose dependent. These observations support the concept that viral entry inhibitors can help prevent the sexual transmission of HIV-1 to humans.	Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA; Tulane Univ, Tulane Natl Primate Res Ctr, Hlth Sci Ctr, Covington, LA USA; Univ London St Georges Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England; Populat Council, Ctr Biomed Res, New York, NY 10021 USA; Univ London Imperial Coll Sci Technol & Med, Jefferiss Res Trust Labs, Wright Fleming Inst, London, England; Scripps Res Inst, Dept Immunol, La Jolla, CA USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA USA	Cornell University; Tulane University; St Georges University London; Population Council; Imperial College London; Scripps Research Institute; Scripps Research Institute	Moore, JP (corresponding author), Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA.		Klasse, P.J./AEX-0142-2022	Klasse, P.J./0000-0001-8222-278X; Hu, Qinxue/0000-0002-4594-9215	NCRR NIH HHS [RR00164] Funding Source: Medline; NIAID NIH HHS [AI40877, AI52048, AI52057, AI49080, AI33292] Funding Source: Medline; NICHD NIH HHS [HD36310] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD036310] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI052048, R37AI033292, R01AI049080, R01AI052057, R01AI033292, R37AI040877, R01AI040877] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Chakraborty H, 2001, AIDS, V15, P621, DOI 10.1097/00002030-200103300-00012; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Dove A, 2002, NAT BIOTECHNOL, V20, P777, DOI 10.1038/nbt0802-777; Dyer JR, 1996, J VIROL METHODS, V60, P161, DOI 10.1016/0166-0934(96)02063-0; Frank I., 2002, Current Molecular Medicine (Hilversum), V2, P229, DOI 10.2174/1566524024605716; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Greenhead P, 2000, J VIROL, V74, P5577, DOI 10.1128/JVI.74.12.5577-5586.2000; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Haase AT, 2001, AIDS, V15, pS10, DOI 10.1097/00002030-200102001-00013; Harouse JM, 1999, SCIENCE, V284, P816, DOI 10.1126/science.284.5415.816; Harouse JM, 2001, J VIROL, V75, P1990, DOI 10.1128/JVI.75.4.1990-1995.2001; Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000; Idemyor V, 2002, PHARMACOTHERAPY, V22, P1074, DOI 10.1592/phco.22.12.1074.33610; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; MILLER CJ, IN PRESS MICROBES IN; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Parren PWHI, 2001, ADV IMMUNOL, V77, P195, DOI 10.1016/S0065-2776(01)77018-6; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Saltzman WM, 2000, BIOTECHNOL BIOENG, V67, P253, DOI 10.1002/(SICI)1097-0290(20000205)67:3<253::AID-BIT1>3.0.CO;2-T; Shattock RJ, 2000, NAT MED, V6, P607, DOI 10.1038/76138; Sherwood JK, 1996, BIOL REPROD, V54, P264, DOI 10.1095/biolreprod54.1.264; Turpin JA, 2002, EXPERT OPIN INV DRUG, V11, P1077, DOI 10.1517/13543784.11.8.1077; van de Wijgert Janneke, 2002, BETA, V15, P23; Vernazza PL, 1999, AIDS, V13, P155, DOI 10.1097/00002030-199902040-00003	26	396	417	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					343	346		10.1038/nm833	http://dx.doi.org/10.1038/nm833			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12579198				2022-12-27	WOS:000181312300036
J	Chen, A; Ganor, Y; Rahimipour, S; Ben-Aroya, N; Koch, Y; Levite, M				Chen, A; Ganor, Y; Rahimipour, S; Ben-Aroya, N; Koch, Y; Levite, M			The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs	NATURE MEDICINE			English	Article							GONADOTROPIN-RELEASING-HORMONE; BINDING PROTEIN; LYMPHOCYTES; BRAIN; INTEGRIN; ISOFORMS; PEPTIDE; SYSTEM; LINES	Can T cells be directly activated to de novo gene expression by gonadotropin-releasing hormone-II (GnRH-II), a unique 10-amino-acid neuropeptide conserved through 500 million years of evolution? GnRH-II, which has been identified in mammals(1,2), shares 70% homology with the mammalian hypothalamic neurohormone GnRH (GnRH-I), the primary regulator of reproduction, but is encoded by a different gene(3). Although both neuropeptides are produced mainly in brain, their localization(1,2) and promoter regulation(4,5) differ, suggestive of distinct functions. Indeed, GnRH-II barely affects reproduction(1) and its role in mammalian physiology is unknown. We find here that human normal and leukemic T cells produce GnRH-II and GnRH-I. Further, exposure of normal or cancerous human or mouse T cells to GnRH-II or GnRH-I triggered de novo gene transcription and cell-surface expression of a 67-kD non-integrin laminin receptor that is involved in cellular adhesion and migration and in tumor invasion and metastasis. GnRH-II or GnRH-I also induced adhesion to laminin and chemotaxis toward SDF-1alpha, and augmented entry in vivo of metastatic T-lymphoma into the spleen and bone marrow. Homing of normal T cells into specific organs was reduced in mice lacking GnRH-I. A specific GnRH-I-receptor antagonist blocked GnRH-I- but not GnRH-II-induced effects, which is suggestive of signaling through distinct receptors. We suggest that GnRH-II and GnRH-I, secreted from nerves or autocrine or paracrine sources, interact directly with T cells and trigger gene transcription, adhesion, chemotaxis and homing to specific organs, which may be of clinical relevance.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Levite, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Rahimipour, Shai/P-4770-2019; Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Ganor, Yonatan/0000-0003-4430-7744; Chen, Alon/0000-0003-3625-8233; Rahimipour, Shai/0000-0002-3210-1645				AZAD N, 1993, ENDOCRINOLOGY, V133, P215, DOI 10.1210/en.133.1.215; Canfield SM, 1999, J IMMUNOL, V163, P3430; Chen A, 2002, CANCER RES, V62, P1036; Chen A, 2002, J MOL NEUROSCI, V18, P67; Chen A, 2001, ENDOCRINOLOGY, V142, P3483, DOI 10.1210/en.142.8.3483; Chen A, 1998, FEBS LETT, V435, P199, DOI 10.1016/S0014-5793(98)01064-3; Chen AL, 2001, ENDOCRINOLOGY, V142, P830, DOI 10.1210/en.142.2.830; Dorsam G, 2000, ANN NY ACAD SCI, V921, P79; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; HAND PH, 1985, CANCER RES, V45, P2713; Josefsson E, 1996, IMMUNOLOGY, V88, P140, DOI 10.1046/j.1365-2567.1996.d01-653.x; Krantic S, 2000, PEPTIDES, V21, P1941, DOI 10.1016/S0196-9781(00)00347-8; Lescheid DW, 1997, ENDOCRINOLOGY, V138, P5618, DOI 10.1210/en.138.12.5618; Levite M, 1998, P NATL ACAD SCI USA, V95, P12544, DOI 10.1073/pnas.95.21.12544; Levite M, 2001, EUR J IMMUNOL, V31, P3504, DOI 10.1002/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; Levite M, 1998, J IMMUNOL, V160, P993; Millar R, 2001, P NATL ACAD SCI USA, V98, P9636, DOI 10.1073/pnas.141048498; Neill JD, 2001, BIOCHEM BIOPH RES CO, V282, P1012, DOI 10.1006/bbrc.2001.4678; SARZOTTI M, 1987, INT J CANCER, V39, P118, DOI 10.1002/ijc.2910390121; SATOH K, 1992, CANCER LETT, V62, P199, DOI 10.1016/0304-3835(92)90096-E; Sixt M, 2001, J CELL BIOL, V153, P933, DOI 10.1083/jcb.153.5.933; Suzuki H, 1999, HUM PATHOL, V30, P361, DOI 10.1016/S0046-8177(99)90023-0; Tham TN, 2001, EUR J NEUROSCI, V13, P845, DOI 10.1046/j.0953-816x.2000.01451.x; White RB, 1998, P NATL ACAD SCI USA, V95, P305, DOI 10.1073/pnas.95.1.305	25	95	102	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1421	1426		10.1038/nm801	http://dx.doi.org/10.1038/nm801			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12447356				2022-12-27	WOS:000179552000039
J	Wada, T; Nakashima, T; Oliveira-dos-Santos, AJ; Gasser, J; Hara, H; Schett, G; Penninger, JM				Wada, T; Nakashima, T; Oliveira-dos-Santos, AJ; Gasser, J; Hara, H; Schett, G; Penninger, JM			The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis	NATURE MEDICINE			English	Article							BONE-RESORPTION; DOCKING PROTEIN; GROWTH-FACTOR; RECEPTOR; DIFFERENTIATION; ACTIVATION; MICE; OSTEOPETROSIS; TRANSDUCTION; MECHANISMS	Morphogenesis and remodeling of bone involve synthesis of bone matrix by osteoblasts and coordinate resorption of bone by osteoclasts. Defective bone remodeling caused by altered osteoclast activity underlies a multitude of osteopenic disorders. Receptor activator of NF-kappa B (RANK) and its ligand RANKL have been identified as essential factors involved in osteoclast development and bone remodeling, but their mechanism and interacting factors have not been fully characterized. Here we report that the molecular adapter Grb-2-associated binder-2 (Gab2) associates with RANK and mediates RANK-induced activation of NF-kappa B, Akt and Jnk. Inactivation of the gene encoding Gab2 in mice results in osteopetrosis and decreased bone resorption as a result of defective osteoclast differentiation. We also show that Gab2 has a crucial role in the differentiation of human progenitor cells into osteoclasts. We have thus identified a new, key regulatory scaffold molecule, Gab2, that controls select RANK signaling pathways and is essential for osteoclastogenesis and bone homeostasis.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; Univ Toronto, Dept Immunol, Univ Hlth Network, Toronto, ON M5G 2C1, Canada; Arthrit & Bone Metab Dept, CH-4002 Basel, Switzerland; Univ Vienna, Dept Internal Med 3, Div Rheumatol, A-1090 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Vienna	Wada, T (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohrgasse 3-5, A-1030 Vienna, Austria.	teiji.wada@imba.oeaw.ac.at; josef.penninger@imba.oeaw.ac.at	Gasser, Juerg Andreas/AAT-5389-2020; Penninger, Josef M/I-6860-2013	Gasser, Juerg Andreas/0000-0002-0106-364X; Penninger, Josef M/0000-0002-8194-3777				Baron R, 1996, REV RHUM, V63, P633; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nishida K, 2002, BLOOD, V99, P1866, DOI 10.1182/blood.V99.5.1866; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Seiffert M, 2003, MOL CELL BIOL, V23, P2415, DOI 10.1128/MCB.23.7.2415-2424.2003; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Yamasaki S, 2001, J BIOL CHEM, V276, P45175, DOI 10.1074/jbc.M105384200	28	143	158	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					394	399		10.1038/nm1203	http://dx.doi.org/10.1038/nm1203			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15750601				2022-12-27	WOS:000228180500030
J	Blower, SM; Chou, T				Blower, SM; Chou, T			Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance	NATURE MEDICINE			English	Article							INTRINSIC TRANSMISSION DYNAMICS; MDR-TB; SENSITIVITY; UNCERTAINTY; EPIDEMICS; THERAPY; COMPLEX; EXAMPLE; IMPACT; TREAT	`Hot zones' are areas that have >5% prevalence (or incidence) of multidrug-resistant tuberculosis (MDRTB). We present a new mathematical model (the amplifier model) that tracks the emergence and evolution of multiple (pre-MDR, MDR and post-MDR) strains of drug-resistant Mycobacterium tuberculosis. We reconstruct possible evolutionary trajectories that generated hot zones over the past three decades, and identify the key causal factors. Results are consistent with recently reported World Health Organization (WHO) data. Our analyses yield three important insights. First, paradoxically we found that areas with programs that successfully reduced wild-type pansensitive strains often evolved into hot zones. Second, some hot zones emerged even when MDR strains were substantially less fit (and thus less transmissible) than wild-type pansensitive strains. Third, levels of MDR are driven by case-finding rates, cure rates and amplification probabilities. To effectively control MDRTB in the hot zones, it is essential that the WHO specify a goal for minimizing the amplification probability.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, UCLA AIDS Inst, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Blower, SM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, 1100 Glendon Ave,Penthouse 2, Los Angeles, CA 90024 USA.	sblower@mednet.ucla.edu			NIAID NIH HHS [R01 AI041935] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041935] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], [No title captured]; Bankes SC, 2002, P NATL ACAD SCI USA, V99, P7263, DOI 10.1073/pnas.092081399; Blower S, 1999, NAT MED, V5, P358, DOI 10.1038/7328; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1998, J MOL MED, V76, P624, DOI 10.1007/s001090050260; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1998, NAT MED, V4, P673, DOI 10.1038/nm0698-673; Blower SM, 2002, LANCET INFECT DIS, V2, P374, DOI 10.1016/S1473-3099(02)00292-X; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; CastilloChavez C, 1997, J MATH BIOL, V35, P629, DOI 10.1007/s002850050069; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P661; Cohen T, 2003, LANCET INFECT DIS, V3, P13, DOI 10.1016/S1473-3099(03)00483-3; Dye C, 2000, P NATL ACAD SCI USA, V97, P8180, DOI 10.1073/pnas.140102797; Dye C, 2002, J INFECT DIS, V185, P1197, DOI 10.1086/339818; Elzinga G, 2004, LANCET, V363, P814, DOI 10.1016/S0140-6736(04)15698-5; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Espinal MA, 2003, INT J TUBERC LUNG D, V7, P607; ESPINAL MA, 2003, 2 WHO; Farmer P, 1998, INT J TUBERC LUNG D, V2, P869; FARMER P, 1999, GLOBAL IMPACT DRUG R; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; Hopewell PC, 2002, B WORLD HEALTH ORGAN, V80, P427; ISEMAN MD, 1994, P NATL ACAD SCI USA, V91, P2428, DOI 10.1073/pnas.91.7.2428; Iseman MD, 2002, EUR RESPIR J, V20, p87S, DOI 10.1183/09031936.02.00309102; Lietman T, 2000, CLIN INFECT DIS, V30, pS316, DOI 10.1086/313881; Migliori GB, 2002, INT J TUBERC LUNG D, V6, P858; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2; PABLOSMENDEZ A, 2000, 1 WHO; Porco TC, 1998, THEOR POPUL BIOL, V54, P117, DOI 10.1006/tpbi.1998.1366; Porco TC, 2001, J ACQ IMMUN DEF SYND, V28, P437, DOI 10.1097/00042560-200112150-00005; Reichman L. B., 2002, TIMEBOMB GLOBAL EPID; Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127; Sterling TR, 2003, BMJ-BRIT MED J, V326, P574, DOI 10.1136/bmj.326.7389.574; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; Ziv E, 2001, AM J EPIDEMIOL, V153, P381, DOI 10.1093/aje/153.4.381	36	163	173	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1111	1116		10.1038/nm1102	http://dx.doi.org/10.1038/nm1102			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15378053				2022-12-27	WOS:000224245800042
J	Schubert, C				Schubert, C			Mitochondria's secret weapon	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-27	WOS:000224245800028
J	Soto, C; Castilla, J				Soto, C; Castilla, J			The controversial protein-only hypothesis of prion propagation	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE PRION; TRANSGENIC MICE; SPONGIFORM ENCEPHALOPATHY; NEUROBLASTOMA-CELLS; NUCLEIC-ACID; AGENT; TRANSMISSION; RESISTANT; CONFORMATIONS	Prion diseases are some of the most intriguing infectious disorders affecting the brains of humans and animals. The prevalent hypothesis proposes that the infectious agent is a misfolded protein that propagates in the absence of nucleic acid by transmission of its altered folding to the normal host version of the protein. This article details the evidence for and against the prion hypothesis, including results of recent studies in yeast, in which a prion phenomenon has also been identified. The evidence in favor of the prion model is very strong, but final proof-consisting of the generation of infectious prions in vitro-is still missing.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Soto, C (corresponding author), Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77550 USA.	clsoto@utmb.edu	Castilla, Joaquin/D-5261-2011; Castilla, Joaquín/J-8414-2019	Castilla, Joaquin/0000-0002-2216-1361; Castilla, Joaquín/0000-0002-2216-1361				ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; ALPER T, 1966, BIOCHEM BIOPH RES CO, V22, P278, DOI 10.1016/0006-291X(66)90478-5; Barret A, 2003, J VIROL, V77, P8462, DOI 10.1128/JVI.77.15.8462-8469.2003; Barron RM, 2003, CLIN LAB MED, V23, P161, DOI 10.1016/S0272-2712(02)00067-7; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CHANDLER RL, 1961, LANCET, V1, P1378; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; CHO HJ, 1976, NATURE, V262, P411, DOI 10.1038/262411a0; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; CULLIE J, 1939, CR HEBD ACAD SCI, V208, P1058; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Derrington E, 2002, CR BIOL, V325, P17, DOI 10.1016/S1631-0691(02)01388-4; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kane MD, 2000, J NEUROSCI, V20, P3606, DOI 10.1523/JNEUROSCI.20-10-03606.2000; KIMBERLIN RH, 1982, NATURE, V297, P107, DOI 10.1038/297107a0; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; Lundmark K, 2002, P NATL ACAD SCI USA, V99, P6979, DOI 10.1073/pnas.092205999; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; Narang H, 2002, EXP BIOL MED, V227, P4, DOI 10.1177/153537020222700103; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; RUBENSTEIN R, 1984, J GEN VIROL, V65, P2191, DOI 10.1099/0022-1317-65-12-2191; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	55	69	75	3	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2004	10	7		S			S63	S67		10.1038/nm1069	http://dx.doi.org/10.1038/nm1069			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	844YU	15272271				2022-12-27	WOS:000223202100010
J	Merad, M; Hoffmann, P; Ranheim, E; Slaymaker, S; Manz, MG; Lira, SA; Charo, I; Cook, DN; Weissman, IL; Strober, S; Engleman, EG				Merad, M; Hoffmann, P; Ranheim, E; Slaymaker, S; Manz, MG; Lira, SA; Charo, I; Cook, DN; Weissman, IL; Strober, S; Engleman, EG			Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease	NATURE MEDICINE			English	Article							DENDRITIC CELLS; LYMPH-NODES; PERIPHERAL LYMPH; STEADY-STATE; TOLERANCE; RESPONSES; MICE	Skin is the most commonly affected organ in graft-versus-host disease (GVHD). To explore the role of Langerhans cells in GVHD, the principal dendritic cells of the skin, we studied the fate of these cells in mice transplanted with allogeneic bone marrow. In contrast to other dendritic cells, host Langerhans cells were replaced by donor Langerhans cells only when donor T cells were administered along with bone marrow, and the extent of Langerhans cell chimerism correlated with the dose of donor T cells injected. Donor T cells depleted host Langerhans cells through a Fas-dependent pathway and induced the production in skin of CCL20, which was required for the recruitment of donor Langerhans cells. Administration of donor T cells to bone marrow-chimeric mice with persistent host Langerhans cells, but not to mice whose Langerhans cells had been replaced, resulted in marked skin GVHD. These findings indicate a crucial role for donor T cells in host Langerhans cell replacement, and show that host dendritic cells can persist in nonlymphoid tissue for the duration of an animal's life and can trigger GVHD despite complete blood chimerism.	Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94104 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94104 USA; CUNY Mt Sinai Sch Med, Dept Immunobiol, New York, NY 10029 USA; Duke Univ, Med Ctr, Dept Med, Div Pulm & Crit Care, Durham, NC 27710 USA	Stanford University; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Duke University	Merad, M (corresponding author), CUNY Mt Sinai Sch Med, Carl C Icahn Inst Gene Therapy & Mol Med, New York, NY 10029 USA.	miriam.merad@mssm.edu	Manz, Markus G/C-7588-2011; Cook, Donald/E-5079-2019	Cook, Donald/0000-0002-0052-3755; Manz, Markus/0000-0002-4676-7931	NHLBI NIH HHS [HL57443, P01 HL057443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Belz GT, 2002, J EXP MED, V196, P1099, DOI 10.1084/jem.20020861; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Caux C, 2000, SPRINGER SEMIN IMMUN, V22, P345, DOI 10.1007/s002810000053; Cook DN, 2000, IMMUNITY, V12, P495, DOI 10.1016/S1074-7613(00)80201-0; CVETOVICCVRLJE M, 2001, BLOOD, V98, P1607; DREXHAGE HA, 1979, CELL TISSUE RES, V202, P407, DOI 10.1007/BF00220434; Emile JF, 1997, BRIT J HAEMATOL, V98, P480, DOI 10.1046/j.1365-2141.1997.2293046.x; Ferrara J L, 1999, Biol Blood Marrow Transplant, V5, P347, DOI 10.1016/S1083-8791(99)70011-X; FRELINGER JG, 1979, NATURE, V282, P321, DOI 10.1038/282321a0; Goker H, 2001, EXP HEMATOL, V29, P259, DOI 10.1016/S0301-472X(00)00677-9; Hemmi H, 2001, INT IMMUNOL, V13, P695, DOI 10.1093/intimm/13.5.695; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; KATZ SI, 1987, AM J DERMATOPATH, V9, P343; KELLY RH, 1978, ANAT RECORD, V190, P5, DOI 10.1002/ar.1091900103; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; PERREAULT C, 1985, BRIT J HAEMATOL, V60, P253, DOI 10.1111/j.1365-2141.1985.tb07411.x; PUGH CW, 1983, J EXP MED, V157, P1758, DOI 10.1084/jem.157.6.1758; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; STINGL G, 1980, IMMUNOL REV, V53, P149, DOI 10.1111/j.1600-065X.1980.tb01043.x; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Teshima T, 2002, SEMIN HEMATOL, V39, P15, DOI 10.1053/shem.2002.29246; Vogelsang GB, 2001, BLOOD, V97, P1196, DOI 10.1182/blood.V97.5.1196; Zeng DF, 1999, J EXP MED, V189, P1073, DOI 10.1084/jem.189.7.1073; Zeng DF, 1997, BLOOD, V90, P453; Zhang Y, 2002, J IMMUNOL, V169, P7111, DOI 10.4049/jimmunol.169.12.7111; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989	37	257	265	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					510	517		10.1038/nm1038	http://dx.doi.org/10.1038/nm1038			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15098028	Green Accepted			2022-12-27	WOS:000221242400029
J	Karpowicz, P; Cohen, CB; van der Kooy, D				Karpowicz, P; Cohen, CB; van der Kooy, D			It is ethical to transplant human stem cells into nonhuman embryos	NATURE MEDICINE			English	Editorial Material							CHIMERAS; TISSUE; SHEEP	Human/nonhuman stem cell chimeras will be increasingly applied to study human cells in developing nonhuman animals. Such experiments raise a number of issues that may create further controversy in the stem cell field. Here we outline the scientific value and ethical ramifications of such studies, and suggest how such experiments may be conducted ethically.	Univ Toronto, Inst Med Sci, Toronto, ON M5R 1A8, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5R 1A8, Canada; Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA	University of Toronto; University of Toronto; Georgetown University	Karpowicz, P (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON M5R 1A8, Canada.	phillip.karpowicz@utoronto.ca	Karpowicz, Phillip/C-3334-2016	Karpowicz, Phillip/0000-0002-3116-4804				[Anonymous], J MEC THEOR APPL; BALABAN E, 1988, SCIENCE, V241, P1339, DOI 10.1126/science.3413496; Bazopoulou-Kyrkanidou E, 2001, AM J MED GENET, V100, P66; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; BOER GJ, 1994, J NEUROL, V242, P1, DOI 10.1007/BF00920568; Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001; Check E, 2003, NATURE, V421, P4, DOI [10.1038/421004b, 10.1038/421004a]; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Cohen CB, 2003, AM J BIOETHICS, V3, pW3; Cohen CB, 1999, J MED PHILOS, V24, P288, DOI 10.1076/jmep.24.3.288.2525; DESOUSA R, 1980, ZYGON, V15, P169, DOI 10.1111/j.1467-9744.1980.tb00384.x; DESOUSA R, 1984, CAN J PHILOS, V14, P561; Goldstein RS, 2002, DEV DYNAM, V225, P80, DOI 10.1002/dvdy.10108; Heeger R, 2001, J AGR ENVIRON ETHIC, V14, P241, DOI 10.1023/A:1011319921159; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KANT I, 1964, METAPHYSICAL PRINC 2, P1; Karpowicz P, 2003, AM J BIOETHICS, V3, pW17; KASS L, 2002, LIFE LIBERTY DEFENSE, P120; KASS L, 1985, MORE NATURAL SCI BIO, P249; Kaufmann R, 1993, Exp Dermatol, V2, P209, DOI 10.1111/j.1600-0625.1993.tb00035.x; Kornack DR, 1998, P NATL ACAD SCI USA, V95, P1242, DOI 10.1073/pnas.95.3.1242; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; PAPAIOANNOU VE, 1984, CHIMERAS DEV BIOL, P3; POLZIN VJ, 1987, J ANIM SCI, V65, P325, DOI 10.2527/jas1987.651325x; Raychaudhuri SP, 2001, BRIT J DERMATOL, V144, P931, DOI 10.1046/j.1365-2133.2001.04178.x; Robert JS, 2003, AM J BIOETHICS, V3, P1, DOI 10.1162/15265160360706417; Schneider RA, 2003, SCIENCE, V299, P565, DOI 10.1126/science.1077827; Stout J., 1988, ETHICS BABEL LANGUAG, P145; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; WELLS HG, 1996, ISLAND MOREAU, P1; ZANJANI ED, 1991, BLOOD CELLS, V17, P349	32	53	54	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					331	335		10.1038/nm0404-331	http://dx.doi.org/10.1038/nm0404-331			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15057220				2022-12-27	WOS:000220587000014
J	Chen, CD; Welsbie, DS; Tran, C; Baek, SH; Chen, R; Vessella, R; Rosenfeld, MG; Sawyers, CL				Chen, CD; Welsbie, DS; Tran, C; Baek, SH; Chen, R; Vessella, R; Rosenfeld, MG; Sawyers, CL			Molecular determinants of resistance to antiandrogen therapy	NATURE MEDICINE			English	Article							HUMAN ANDROGEN RECEPTOR; INDEPENDENT PROSTATE-CANCER; DNA-BINDING DOMAIN; ESTROGEN-RECEPTOR; STRUCTURAL BASIS; IN-VITRO; GENE; EXPRESSION; PHOSPHORYLATION; CELLS	Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Mol Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Urol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Diego; University of Washington; University of Washington Seattle	Sawyers, CL (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA 90095 USA.	csawyers@mednet.ucla.edu	Tran, Chau/GRX-4633-2022; Sawyers, Charles/G-5327-2016					Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Craft N, 1999, CANCER RES, V59, P5030; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DePrimo SE, 2002, GENOME BIOL, V3; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Ellis WJ, 1996, CLIN CANCER RES, V2, P1039; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Glass CK, 2000, GENE DEV, V14, P121; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Gregory CW, 2001, CANCER RES, V61, P2892; Gregory CW, 2001, CANCER RES, V61, P4315; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huang ZQ, 2002, MOL ENDOCRINOL, V16, P924, DOI 10.1210/me.16.5.924; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kinoshita H, 2000, CANCER RES, V60, P3623; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Laitinen S, 2002, GENE CHROMOSOME CANC, V35, P66, DOI 10.1002/gcc.10097; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Lobaccaro JM, 1996, MOL CELL ENDOCRINOL, V116, P137, DOI 10.1016/0303-7207(95)03709-8; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Matias PM, 2002, J MED CHEM, V45, P1439, DOI 10.1021/jm011072j; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; RAFFO AJ, 1995, CANCER RES, V55, P4438; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Schellhammer PF, 1997, J UROLOGY, V157, P1731, DOI 10.1016/S0022-5347(01)64846-8; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	49	1570	1723	8	94	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2004	10	1					33	39		10.1038/nm972	http://dx.doi.org/10.1038/nm972			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702632				2022-12-27	WOS:000187743600036
J	Windrem, MS; Nunes, MC; Rashbaum, WK; Schwartz, TH; Goodman, RA; Mckhann, G; Roy, NS; Goldman, SA				Windrem, MS; Nunes, MC; Rashbaum, WK; Schwartz, TH; Goodman, RA; Mckhann, G; Roy, NS; Goldman, SA			Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; SUBCORTICAL WHITE-MATTER; SHIVERER MUTANT MICE; TRANSPLANTED OLIGODENDROCYTES; EXTENSIVE MYELINATION; STEM-CELLS; IDENTIFICATION; PRECURSORS; FOREBRAIN; TOLERANCE	Both late-gestation and adult human forebrain both contain large numbers of oligodendrocyte progenitor cells (OPCs). These cells may be identified by their A2B5(+)PSA-NCAM(-) phenotype (positive for the early oligodendrocyte marker A2B5 and negative for the polysialylated neural cell adhesion molecule). We used dual-color fluorescence-activated cell sorting (FACS) to extract OPCs from 21- to 23-week-old fetal human forebrain, and A2B5 selection to extract these cells from adult white matter. When xenografted to the forebrains of newborn shiverer mice, fetal OPCs dispersed throughout the white matter and developed into oligodendrocytes and astrocytes. By 12 weeks, the host brains showed extensive myelin production, compaction and axonal myelination. Isolates of OPCs derived from adult human white matter also myelinated shiverer mouse brain, but much more rapidly than their fetal counterparts, achieving widespread and dense myelin basic protein (MBP) expression by 4 weeks after grafting. Adult OPCs generated oligodendrocytes more efficiently than fetal OPCs, and ensheathed more host axons per donor cell than fetal cells. Both fetal and adult OPCS phenotypes mediated the extensive and robust myelination of congenitally dysmyelinated host brain, although their differences suggested their use for different disease targets.	Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Obstet & Gynecol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Neurosurg, New York, NY 10021 USA; Columbia Univ, Sch Med, Dept Neurosurg, New York, NY 10032 USA; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA	Cornell University; Cornell University; Cornell University; Columbia University; University of Rochester	Goldman, SA (corresponding author), Cornell Univ, Coll Med, Dept Neurol & Neurosci, 1300 York Ave, New York, NY 10021 USA.		Schwartz, Theodore/AAK-3320-2020; Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Goldman, Steven/0000-0002-5498-4303; Nunes, Marta/0000-0003-3788-878X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039559, R01NS033106] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS33106, R01NS39559] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; Franklin RJM, 1997, J ANAT, V190, P23, DOI 10.1046/j.1469-7580.1997.19010023.x; GANSMULLER A, 1986, DEV NEUROSCI-BASEL, V8, P197, DOI 10.1159/000112253; GOLDMAN SA, 1993, GLIA, V8, P150, DOI 10.1002/glia.440080303; GUMPEL M, 1987, ANN NY ACAD SCI, V495, P71, DOI 10.1111/j.1749-6632.1987.tb23666.x; GUMPEL M, 1989, DEV NEUROSCI-BASEL, V11, P132, DOI 10.1159/000111894; Keyoung HM, 2001, NAT BIOTECHNOL, V19, P843, DOI 10.1038/nbt0901-843; Lachapelle F, 1983, DEV NEUROSCI, V6, P326; Learish RD, 1999, ANN NEUROL, V46, P716, DOI 10.1002/1531-8249(199911)46:5<716::AID-ANA6>3.0.CO;2-M; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Mitome M, 2001, BRAIN, V124, P2147, DOI 10.1093/brain/124.11.2147; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; OLeary MT, 1997, J NEUROSCI RES, V48, P159, DOI 10.1002/(SICI)1097-4547(19970415)48:2<159::AID-JNR8>3.0.CO;2-B; Piper DR, 2001, J NEUROSCI RES, V66, P356, DOI 10.1002/jnr.1228; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; ROSER BJ, 1989, IMMUNOL REV, V107, P179, DOI 10.1111/j.1600-065X.1989.tb00009.x; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Seilhean D, 1996, ACTA NEUROPATHOL, V91, P82; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Zhang SC, 1999, P NATL ACAD SCI USA, V96, P4089, DOI 10.1073/pnas.96.7.4089	25	320	342	0	17	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					93	97		10.1038/nm974	http://dx.doi.org/10.1038/nm974			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702638				2022-12-27	WOS:000187743600044
J	Marin, M; Rose, KM; Kozak, SL; Kabat, D				Marin, M; Rose, KM; Kozak, SL; Kabat, D			HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VIF; REVERSE TRANSCRIPTION; BOX MOTIF; DNA; VIRIONS; RNA; COMPLEX; CELLS; IDENTIFICATION	The viral infectivity factor (Vif) encoded by HIV-1 neutralizes a potent antiviral pathway that occurs in human T lymphocytes and several leukemic T-cell lines termed nonpermissive, but not in other cells termed permissive. In the absence of Vif, this antiviral pathway efficiently inactivates HIV-1. It was recently reported that APOBEC3G (also known as CEM-15), a cytidine deaminase nucleic acid-editing enzyme, confers this antiviral phenotype on permissive cells. Here we describe evidence that Vif binds APOBEC3G and induces its rapid degradation, thus eliminating it from cells and preventing its incorporation into HIV-1 virions. Studies of Vif mutants imply that it contains two domains, one that binds APOBEC3G and another with a conserved SLQ(Y/F)LA motif that mediates APOBEC3G degradation by a proteasome-dependent pathway. These results provide promising approaches for drug discovery.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Kabat, D (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd,Mail Code L224, Portland, OR 97239 USA.				NIAID NIH HHS [AI49729] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049729, R21AI049729] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gaddis NC, 2003, J VIROL, V77, P5810, DOI 10.1128/JVI.77.10.5810-5820.2003; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; Madani N, 2000, J VIROL, V74, P5982, DOI 10.1128/JVI.74.13.5982-5987.2000; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2000, J VIROL, V74, P8085, DOI 10.1128/JVI.74.17.8085-8093.2000; OBERSTE MS, 1992, VIRUS GENES, V6, P95, DOI 10.1007/BF01703760; Ochsenbauer C, 1997, J GEN VIROL, V78, P627, DOI 10.1099/0022-1317-78-3-627; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; Platt EJ, 2001, J VIROL, V75, P12266, DOI 10.1128/JVI.75.24.12266-12278.2001; Sambrook J., 2002, MOL CLONING LAB MANU; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Tailor CS, 1999, P NATL ACAD SCI USA, V96, P927, DOI 10.1073/pnas.96.3.927; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	40	654	673	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1398	1403		10.1038/nm946	http://dx.doi.org/10.1038/nm946			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528301				2022-12-27	WOS:000186319700030
J	Letvin, NL; Walker, BD				Letvin, NL; Walker, BD			Immunopathogenesis and immunotherapy in AIDS virus infections	NATURE MEDICINE			English	Review							CYTOTOXIC T-LYMPHOCYTES; NEUTRALIZING ANTIBODY-RESPONSES; CELLULAR IMMUNE-RESPONSES; AMINO-ACID CHANGE; SIMIAN IMMUNODEFICIENCY; HIV-1 INFECTION; ANTIRETROVIRAL THERAPY; MONOCLONAL-ANTIBODIES; RHESUS-MONKEYS; TREATMENT INTERRUPTIONS	The heterogeneity of HIV and the different human leukocyte antigen (HLA) backgrounds of infected individuals have posed challenges to understanding the pathogenesis of HIV infection. But continuing advances in our knowledge of the role of immune responses in controlling HIV viremia should help to define goals for immune-based therapies and vaccine strategies against AIDS.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA; Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div AIDS, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Walker, BD (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA.	bwalker@partners.org						Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Altfeld M, 2002, J CLIN INVEST, V109, P837, DOI 10.1172/JCI0214789; Altfeld M, 2001, J EXP MED, V193, P169, DOI 10.1084/jem.193.2.169; ALTFELD M, IN PRESS J VIROL; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405; Brodie SJ, 1999, NAT MED, V5, P34, DOI 10.1038/4716; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; CDC, 1981, MMWR MORB MORTAL WKL, V30, P305; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; CHEN ZW, 1995, J EXP MED, V182, P21, DOI 10.1084/jem.182.1.21; Chen ZW, 2000, J VIROL, V74, P7442, DOI 10.1128/JVI.74.16.7442-7450.2000; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Dalod M, 1999, J CLIN INVEST, V104, P1431, DOI 10.1172/JCI7162; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Garcia F, 2001, AIDS, V15, pF29, DOI 10.1097/00002030-200106150-00002; Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; Hay CM, 1999, J VIROL, V73, P5509, DOI 10.1128/JVI.73.7.5509-5519.1999; Jacobson JM, 1998, MT SINAI J MED, V65, P22; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Kaslow RA, 2001, J VIROL, V75, P8681, DOI 10.1128/JVI.75.18.8681-8689.2001; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Kuroda MJ, 1999, J IMMUNOL, V162, P5127; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; Lieberman J, 2001, BLOOD, V98, P1667, DOI 10.1182/blood.V98.6.1667; LISZIEWICZ J, 2003, NEW ENGL J MED, V340, P1683; Lu W, 2003, NAT MED, V9, P27, DOI 10.1038/nm806; Luzuriaga K, 2000, J VIROL, V74, P6984, DOI 10.1128/JVI.74.15.6984-6991.2000; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; Markowitz M, 2002, J INFECT DIS, V186, P634, DOI 10.1086/342559; Mascola JR, 1997, J VIROL, V71, P7198, DOI 10.1128/JVI.71.10.7198-7206.1997; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; MATLOUBIAN M, 1990, J EXP MED, V172, P1043, DOI 10.1084/jem.172.4.1043; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; McKay PF, 2003, J VIROL, V77, P4695, DOI 10.1128/JVI.77.8.4695-4702.2003; McNeil AC, 2001, P NATL ACAD SCI USA, V98, P13878, DOI 10.1073/pnas.251539598; MEYERHANS A, 1991, EUR J IMMUNOL, V21, P2637, DOI 10.1002/eji.1830211051; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Montefiori DC, 1996, J INFECT DIS, V173, P60, DOI 10.1093/infdis/173.1.60; Moog C, 1997, J VIROL, V71, P3734, DOI 10.1128/JVI.71.5.3734-3741.1997; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Ogg GS, 1999, J VIROL, V73, P797, DOI 10.1128/JVI.73.1.797-800.1999; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199; Pal R, 2002, J VIROL, V76, P292, DOI 10.1128/JVI.76.1.292-302.2002; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; ROBBINS G, IN PRESS AIDS; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Schmitz JE, 2003, J VIROL, V77, P2165, DOI 10.1128/JVI.77.3.2165-2173.2003; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Seth A, 2000, J VIROL, V74, P2502, DOI 10.1128/JVI.74.6.2502-2509.2000; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893; Trimble LA, 2000, J VIROL, V74, P7320, DOI 10.1128/JVI.74.16.7320-7330.2000; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997; Yang OO, 2002, J VIROL, V76, P1626, DOI 10.1128/JVI.76.4.1626-1631.2002; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993; Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002; Zhang D, 2003, BLOOD, V101, P226, DOI 10.1182/blood-2002-03-0791; Zhang LQ, 2002, SCIENCE, V298, P995, DOI 10.1126/science.1076185	106	184	200	0	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					861	866		10.1038/nm0703-861	http://dx.doi.org/10.1038/nm0703-861			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835706	Bronze			2022-12-27	WOS:000183979300025
J	Paramithiotis, E; Pinard, M; Lawton, T; LaBoissiere, S; Leathers, VL; Zou, WQ; Estey, LA; Lamontagne, J; Lehto, MT; Kondejewski, LH; Francoeur, GP; Papadopoulos, M; Haghighat, A; Spatz, SJ; Head, M; Will, R; Ironside, J; O'Rourke, K; Tonelli, Q; Ledebur, HC; Chakrabartty, A; Cashman, NR				Paramithiotis, E; Pinard, M; Lawton, T; LaBoissiere, S; Leathers, VL; Zou, WQ; Estey, LA; Lamontagne, J; Lehto, MT; Kondejewski, LH; Francoeur, GP; Papadopoulos, M; Haghighat, A; Spatz, SJ; Head, M; Will, R; Ironside, J; O'Rourke, K; Tonelli, Q; Ledebur, HC; Chakrabartty, A; Cashman, NR			A prion protein epitope selective for the pathologically misfolded conformation	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; FOLLICULAR DENDRITIC CELLS; SCRAPIE PRION; MONOCLONAL-ANTIBODY; DOMAIN PRP(121-231); CELLULAR ISOFORM; ACIDIC PH; CONVERSION; VARIANT; PATHOGENESIS	Conformational conversion of proteins in disease is likely to be accompanied by molecular surface exposure of previously sequestered amino-acid side chains. We found that induction of beta-sheet structures in recombinant prion proteins is associated with increased solvent accessibility of tyrosine. Antibodies directed against the prion protein repeat motif, tyrosine-tyrosine-arginine, recognize the pathological isoform of the prion protein but not the normal cellular isoform, as assessed by immunoprecipitation, plate capture immunoassay and flow cytometry. Antibody binding to the pathological epitope is saturable and specific, and can be created in vitro by partial denaturation of normal brain prion protein. Conformation-selective exposure of Tyr-Tyr-Arg provides a probe for the distribution and structure of pathologically misfolded prion protein, and may lead to new diagnostics and therapeutics for prion diseases.	Caprion Pharmaceut Inc, St Laurent, PQ H4S 2C8, Canada; IDEXX Labs Inc, Westbrook, ME 04092 USA; Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Washington State Univ, USDA ARS, ADRU, Pullman, WA 99164 USA; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ctr Res Neurodegenrat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	University of Edinburgh; United States Department of Agriculture (USDA); Washington State University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Cashman, NR (corresponding author), Caprion Pharmaceut Inc, 7150 Alexander Fleming, St Laurent, PQ H4S 2C8, Canada.		Zou, Wenquan/GWQ-3489-2022; Zou, Wenquan/ABF-2875-2020	Chakrabartty, Avi/0000-0001-7002-8381; Head, Mark/0000-0003-2034-8613; Ledebur, Harry/0000-0001-8011-8655; Ironside, James/0000-0001-5869-2108				Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Cioni P, 2000, BIOPHYS CHEM, V87, P15, DOI 10.1016/S0301-4622(00)00174-5; Coulthart MB, 2001, CAN MED ASSOC J, V165, P51; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; GAJDUSEK DC, 1986, VIROLOGY, P1516; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Lezmi S, 2001, VET IMMUNOL IMMUNOP, V82, P1, DOI 10.1016/S0165-2427(01)00323-3; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; Mabbott NA, 2001, J GEN VIROL, V82, P2307, DOI 10.1099/0022-1317-82-10-2307; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RACE RE, 1992, J GEN VIROL, V73, P3319, DOI 10.1099/0022-1317-73-12-3319; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; RUBENSTEIN R, 1991, J INFECT DIS, V164, P29, DOI 10.1093/infdis/164.1.29; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; SELA M, 1992, BEHRING I MITT, V91, P54; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; SZAKAL AK, 1985, J IMMUNOL, V134, P1349; SZAKAL AK, 1992, CANCER RES, V52, pS5554; Tang L, 2001, VET IMMUNOL IMMUNOP, V80, P259, DOI 10.1016/S0165-2427(01)00318-X; Tatzelt J, 1999, J NEUROPATH EXP NEUR, V58, P1244, DOI 10.1097/00005072-199912000-00005; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200	45	219	236	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					893	899		10.1038/nm883	http://dx.doi.org/10.1038/nm883			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12778138	Green Submitted			2022-12-27	WOS:000183979300030
J	Valdiserri, RO; Ogden, LL; McCray, E				Valdiserri, RO; Ogden, LL; McCray, E			Accomplishments in HIV prevention science: implications for stemming the epidemic	NATURE MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED-DISEASES; TO-CHILD TRANSMISSION; SHORT-COURSE ZIDOVUDINE; INCREASED LEGAL ACCESS; RISK BEHAVIOR; ANTIRETROVIRAL THERAPY; EXCHANGE PROGRAMS; AIDS-PREVENTION; HOMOSEXUAL-MEN	The past two decades have witnessed substantial advances in the science of preventing HIV infection. Although important issues remain and there is a need for continuing research, arguably the biggest challenge in preventing HIV transmission is the full implementation of existing preventive interventions worldwide.	Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Valdiserri, RO (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd E-07, Atlanta, GA 30333 USA.	rovl@cdc.gov						ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; Amornwichet P, 2002, JAMA-J AM MED ASSOC, V288, P245, DOI 10.1001/jama.288.2.245; [Anonymous], 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; BEEKER C, 1999, AM J PUBLIC HEALTH, V89, P336; Bell David M., 1997, American Journal of Medicine, V102, P9, DOI 10.1016/S0002-9343(97)89441-7; Berkman A, 2001, AM J PUBLIC HEALTH, V91, P1348, DOI 10.2105/AJPH.91.9.1348; Bond V, 2002, EVAL PROGRAM PLANN, V25, P347, DOI 10.1016/S0149-7189(02)00046-0; *CDC, 2003, MMWR-MORBID MORTAL W, V52, P329; *CDC, 2001, MMWR-MORBID MORTAL W, V50, P599; Celentano DD, 1998, AIDS, V12, pF29, DOI 10.1097/00002030-199805000-00004; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P853; Coates TJ, 2000, LANCET, V356, P103, DOI 10.1016/S0140-6736(00)02446-6; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; FOX R, 1987, AIDS, V1, P241; Gayle HD, 2003, NEW ENGL J MED, V348, P1802, DOI 10.1056/NEJMsb030352; Gibson DR, 1999, AIDS, V13, P1807, DOI 10.1097/00002030-199910010-00002; Gibson DR, 2001, AIDS, V15, P1329, DOI 10.1097/00002030-200107270-00002; *GLOB HIV PREV WOR, 2002, GLOB MOB HIV PREV BL; GROSECLOSE SL, 1995, J ACQ IMMUN DEF SYND, V10, P82; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hartel D M, 1998, Public Health Rep, V113 Suppl 1, P107; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOGLE JA, 2002, WHAT HAPPENED UGANDA; Holtgrave DR, 2002, AIDS, V16, P2347, DOI 10.1097/00002030-200211220-00020; HOLTGRAVE DR, 1995, PUBLIC HEALTH REP, V110, P134; Hosseinipour M, 2002, CLIN INFECT DIS, V34, P1391, DOI 10.1086/340403; Hurley SF, 1997, LANCET, V349, P1797, DOI 10.1016/S0140-6736(96)11380-5; Janssen RS, 2001, AM J PUBLIC HEALTH, V91, P1019, DOI 10.2105/AJPH.91.7.1019; Jemmott JB, 1998, JAMA-J AM MED ASSOC, V279, P1529, DOI 10.1001/jama.279.19.1529; *JOINT UN PROGR HI, 2001, HIV PREV NEEDS SUCC; *JOINT UN PROGR HI, 1998, DRUG US HIV AIDS FAC; *JOINT UN PROGR HI, 2002, AIDS EP UPD; *JOINT UN PROGR HI, 2002, REP GLOB HIV AIDS EP; Kahn JO, 2001, J INFECT DIS, V183, P707, DOI 10.1086/318829; Kamali A, 2003, LANCET, V361, P645, DOI 10.1016/S0140-6736(03)12598-6; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; Kanshana S, 2000, AIDS, V14, P1617, DOI 10.1097/00002030-200007280-00018; Kelly JA, 1997, LANCET, V350, P1500, DOI 10.1016/S0140-6736(97)07439-4; Korenromp EL, 2002, AIDS, V16, P2209, DOI 10.1097/00002030-200211080-00014; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; LAMPTEY P, 2003, DAWNING ANSWERS HIV, P177; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; LEVITON LC, 1989, PREVENTING AIDS DESI, P42; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; Mason JO, 1987, MMWR MORB MORTAL WKL, V36; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; Merzel C, 2003, AM J PUBLIC HEALTH, V93, P557, DOI 10.2105/AJPH.93.4.557; Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention, 1998, MMWR RECOMMENDATIONS, V47, P1; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; Sagoe-Moses C, 2001, NEW ENGL J MED, V345, P538, DOI 10.1056/NEJM200108163450711; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Shain RN, 1999, NEW ENGL J MED, V340, P93, DOI 10.1056/NEJM199901143400203; Stover J, 2002, LANCET, V360, P73, DOI 10.1016/S0140-6736(02)09339-X; Strathdee SA., 2001, AIDSCIENCE, V1, P1; Sweat M D, 1995, AIDS, V9 Suppl A, pS251; VALDISERRI RO, 1989, AIDS, V3, P21, DOI 10.1097/00002030-198903010-00005; VALDISERRI RO, 2003, DAWNING ANSWERS HIV, P3; VALDISERRI RO, 2002, AM J PUBLIC HEALTH, V92, P5; VALLEROY LA, 1995, J ACQ IMMUN DEF SYND, V10, P73; VANGRIENSVEN GJP, 1988, AM J PUBLIC HEALTH, V78, P1575, DOI 10.2105/AJPH.78.12.1575; Velasco-Hernandez JX, 2002, LANCET INFECT DIS, V2, P487, DOI 10.1016/S1473-3099(02)00346-8; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3; *WHO, 2001, ENS BLOOD TRANSF SAF; *WHO, 2002, BLOOD SAF CLIN TECHN; *WHO, 2003, POS PAP MOD TRANSM H; Wiebel WW, 1996, J ACQ IMMUN DEF SYND, V12, P282, DOI 10.1097/00042560-199607000-00008; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	77	50	51	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					881	886		10.1038/nm0703-881	http://dx.doi.org/10.1038/nm0703-881			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835709				2022-12-27	WOS:000183979300028
J	Cleaver, O; Melton, DA				Cleaver, O; Melton, DA			Endothelial signaling during development	NATURE MEDICINE			English	Article							VIVO PHAGE DISPLAY; GROWTH-FACTOR; IN-VIVO; CELL-DIFFERENTIATION; TGF-BETA; ZEBRAFISH GENE; TIE2 RECEPTOR; MOUSE EMBRYO; EXPRESSION; VEGF	Blood vessels perfuse all tissues in the body and mediate vital metabolic exchange between tissues and blood. Increasing evidence, however, points to a direct role for paracrine signaling between blood vessel cells and surrounding target organ cells, during embryonic development and cell differentiation. Understanding the nature of this signaling and its heterogeneity, both in the embryo and in adult tissues, may not only provide insights into mechanisms for normal developmental cell fate decisions, but could also lead to novel targeted therapeutic approaches for a variety of diseases such as heart disease, diabetes or cancer.	Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University	Cleaver, O (corresponding author), Harvard Univ, Howard Hughes Med Inst, 7 Divin Ave, Cambridge, MA 02138 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Cleaver, Ondine/0000-0003-2454-6641				Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Aird WC, 1997, J CELL BIOL, V138, P1117, DOI 10.1083/jcb.138.5.1117; AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; Bittner K, 1998, EXP CELL RES, V238, P491, DOI 10.1006/excr.1997.3849; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Brutsaert DL, 1998, CARDIOVASC RES, V38, P281, DOI 10.1016/S0008-6363(98)00044-3; Carson-Walter EB, 2001, CANCER RES, V61, P6649; D'Amore PA, 2002, CELL, V110, P289, DOI 10.1016/S0092-8674(02)00869-3; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dor Y, 2001, DEVELOPMENT, V128, P1531; Drake CJ, 2000, BLOOD, V95, P1671, DOI 10.1182/blood.V95.5.1671.005k39_1671_1679; Ennett AB, 2002, EXPERT OPIN BIOL TH, V2, P805, DOI 10.1517/14712598.2.8.805; Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998; ESTRADA C, 1990, J NEUROPATH EXP NEUR, V49, P539, DOI 10.1097/00005072-199011000-00001; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Field HA, 2003, DEV BIOL, V253, P279, DOI 10.1016/S0012-1606(02)00017-9; FLOREY L, 1966, BMJ-BRIT MED J, V5512, P487; Galloway JL, 2003, CURR TOP DEV BIOL, V53, P139, DOI 10.1016/S0070-2153(03)53004-6; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Gerber HP, 1999, DEVELOPMENT, V126, P1149; GERRITSEN ME, 1987, BIOCHEM PHARMACOL, V36, P2701, DOI 10.1016/0006-2952(87)90252-8; Hanke CJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE846, DOI 10.1152/ajpendo.2000.279.4.E846; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hogan BLM, 2002, NAT REV GENET, V3, P513, DOI 10.1038/nrg840; Hungerford JE, 1999, J VASC RES, V36, P2, DOI 10.1159/000025622; Hutley LJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1037, DOI 10.1152/ajpendo.2001.281.5.E1037; Kitamoto Y, 1997, J CLIN INVEST, V99, P2351, DOI 10.1172/JCI119416; Kmiec Z, 2001, ADV ANAT EMBRYOL CEL, V161, P1; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lawson ND, 2002, NAT REV GENET, V3, P674, DOI 10.1038/nrg888; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; LI K, 1993, J MOL CELL CARDIOL, V25, P529, DOI 10.1006/jmcc.1993.1063; Liao W, 1997, DEVELOPMENT, V124, P381; Linas SL, 1999, KIDNEY INT, V55, P1251, DOI 10.1046/j.1523-1755.1999.00360.x; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Majno G, 1978, Adv Exp Med Biol, V104, P169; MAJNO G, 1978, ADV EXP MED BIOL, V104, P481; Majumdar A, 1999, DEV GENET, V24, P220, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<220::AID-DVG5>3.3.CO;2-T; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Mi HY, 2001, J NEUROSCI, V21, P1538, DOI 10.1523/JNEUROSCI.21-05-01538.2001; MIZRACHI Y, 1990, P NATL ACAD SCI USA, V87, P6161, DOI 10.1073/pnas.87.16.6161; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Muller AM, 2002, EXP MOL PATHOL, V73, P171, DOI 10.1006/exmp.2002.2446; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Pasqualini R, 2000, CANCER RES, V60, P722; Pasqualini R, 2002, TRENDS MOL MED, V8, P563, DOI 10.1016/S1471-4914(02)02429-2; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; Ramsdell AF, 1997, DEV BIOL, V188, P64, DOI 10.1006/dbio.1997.8637; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Reissmann E, 1996, DEVELOPMENT, V122, P2079; Rosolowsky LJ, 1999, ENDOCRINOLOGY, V140, P4411, DOI 10.1210/en.140.10.4411; Samoylova TI, 1999, MUSCLE NERVE, V22, P460, DOI 10.1002/(SICI)1097-4598(199904)22:4<460::AID-MUS6>3.3.CO;2-C; Serluca FC, 2002, CURR BIOL, V12, P492, DOI 10.1016/S0960-9822(02)00694-2; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; St Croix B, 2000, SCIENCE, V289, P1197; STAINIER DYR, 1995, DEVELOPMENT, V121, P3141; Stainier DYR, 1996, DEVELOPMENT, V123, P285; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; STOOS BA, 1992, J CLIN INVEST, V89, P761, DOI 10.1172/JCI115653; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; SUTER ER, 1965, J CELL BIOL, V27, P163, DOI 10.1083/jcb.27.1.163; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; Thorin E, 1998, PHARMACOL THERAPEUT, V78, P155, DOI 10.1016/S0163-7258(98)00005-9; Tufro A, 1999, J AM SOC NEPHROL, V10, P2125; Vapaatalo H, 2001, Med Sci Monit, V7, P1075; VARZANEH FE, 1994, METABOLISM, V43, P906, DOI 10.1016/0026-0495(94)90275-5; Villars F, 2002, AM J PHYSIOL-CELL PH, V282, pC775, DOI 10.1152/ajpcell.00310.2001; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Yoder EJ, 2002, GLIA, V38, P137, DOI 10.1002/glia.10016; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; ZERWES HG, 1987, J CELL BIOL, V105, P2037, DOI 10.1083/jcb.105.5.2037; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	88	384	409	2	29	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					661	668		10.1038/nm0603-661	http://dx.doi.org/10.1038/nm0603-661			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12778164				2022-12-27	WOS:000183444100020
J	Brentjens, RJ; Latouche, JB; Santos, E; Marti, F; Gong, MC; Lyddane, C; King, PD; Larson, S; Weiss, M; Riviere, I; Sadelain, M				Brentjens, RJ; Latouche, JB; Santos, E; Marti, F; Gong, MC; Lyddane, C; King, PD; Larson, S; Weiss, M; Riviere, I; Sadelain, M			Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; ANTIGEN-PRESENTING CELLS; IN-VIVO; IMMUNOTHERAPY; LEUKEMIA; EXPRESSION; RECEPTORS; CANCER; DEATH; CHAIN	The genetic transfer of antigen receptors provides a means to rapidly generate autologous tumor-reactive T lymphocytes. However, recognition of tumor antigens by cytotoxic T cells is only one step towards effective cancer immunotherapy. Other crucial biological prerequisites must be fulfilled to expand tumor-reactive T cells that retain a functional phenotype, including in vivo cytolytic activity and the ability to travel to tumor sites without prematurely succumbing to apoptosis. We show that these requirements are met by expanding peripheral blood T cells genetically targeted to the CD19 antigen in the presence of CD80 and interleukin-15 (IL-15). T cells expanded in the presence of IL-15 uniquely persist in tumor-bearing severe combined immunodeficiency (SCID)-Beige mice and eradicate disseminated intramedullary tumors. Their anti-tumor activity is further enhanced by in vivo co-stimulation. In addition, transduced T cells from patients with chronic lymphocytic leukemia (CLL) effectively lyse autologous tumor cells. These findings strongly support the clinical feasibility of this therapeutic strategy.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Nucl Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Gene Transfer & Somat Cell Engn Lab, New York, NY 10021 USA; Cornell Univ, Hosp Special Surg, Dept Immunol, Weill Med Coll, New York, NY 10021 USA; Cornell Univ, Grad Sch, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	m-sadelain@ski.mskcc.org	King, Phil/C-7104-2013	Latouche, Jean-Baptiste/0000-0003-4802-5429	NATIONAL CANCER INSTITUTE [P30CA008748, P50CA086438, P01CA059350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044926] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748, CA-83084, CA-86438, CA-59350, CA-08748] Funding Source: Medline; NIAID NIH HHS [AI44926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adonai N, 2002, P NATL ACAD SCI USA, V99, P3030, DOI 10.1073/pnas.052709599; Blazar BR, 1997, J IMMUNOL, V159, P3460; Boussiotis VA, 1997, J IMMUNOL, V159, P3156; Brocker T, 2000, BLOOD, V96, P1999, DOI 10.1182/blood.V96.5.1999.h8001999_1999_2001; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Byrd JC, 2001, J CLIN ONCOL, V19, P2153, DOI 10.1200/JCO.2001.19.8.2153; Chen X, 2000, BRIT J HAEMATOL, V111, P817, DOI 10.1046/j.1365-2141.2000.02415.x; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Dudley ME, 2002, J IMMUNOTHER, V25, P243, DOI 10.1097/00002371-200205000-00007; Eshhar Z, 1996, SPRINGER SEMIN IMMUN, V18, P199, DOI 10.1007/BF00820666; Fehniger TA, 2002, CYTOKINE GROWTH F R, V13, P169, DOI 10.1016/S1359-6101(01)00021-1; Gallardo HF, 1997, GENE THER, V4, P1115, DOI 10.1038/sj.gt.3300506; Geiger TL, 2001, BLOOD, V98, P2364, DOI 10.1182/blood.V98.8.2364; Gong Michael C., 1999, Neoplasia (New York), V1, P123, DOI 10.1038/sj.neo.7900018; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hanson HL, 2000, IMMUNITY, V13, P265, DOI 10.1016/S1074-7613(00)00026-1; Haynes NM, 2002, BLOOD, V100, P3155, DOI 10.1182/blood-2002-04-1041; Hombach A, 2001, J IMMUNOL, V167, P6123, DOI 10.4049/jimmunol.167.11.6123; Jourdan P, 2000, J IMMUNOL, V165, P716, DOI 10.4049/jimmunol.165.2.716; Krause A, 1998, J EXP MED, V188, P619, DOI 10.1084/jem.188.4.619; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Li XC, 2001, NAT MED, V7, P114, DOI 10.1038/83253; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Maric M, 1998, CANCER RES, V58, P3376; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; Melief CJM, 2000, ADV IMMUNOL, V75, P235, DOI 10.1016/S0065-2776(00)75006-1; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Oppenheimer-Marks N, 1998, J CLIN INVEST, V101, P1261, DOI 10.1172/JCI1986; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rossi E, 1996, LEUKEMIA, V10, P494; Sadelain M, 2003, NAT REV CANCER, V3, P35, DOI 10.1038/nrc971; Sadelain M, 2002, MOL THER, V5, P655, DOI 10.1006/mthe.2002.0619; Savoldo B, 2000, LEUKEMIA LYMPHOMA, V39, P455, DOI 10.3109/10428190009113376; Schumacher TNM, 2002, NAT REV IMMUNOL, V2, P512, DOI 10.1038/nri841; TEDDER TF, 1989, J IMMUNOL, V143, P712; UCKUN FM, 1988, BLOOD, V71, P13; Vella AT, 1997, J IMMUNOL, V158, P4714; Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(01)00093-0; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	44	467	549	2	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					279	286		10.1038/nm827	http://dx.doi.org/10.1038/nm827			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12579196				2022-12-27	WOS:000181312300027
J	Song, EW; Lee, SK; Wang, J; Ince, N; Ouyang, N; Min, J; Chen, JS; Shankar, P; Lieberman, J				Song, EW; Lee, SK; Wang, J; Ince, N; Ouyang, N; Min, J; Chen, JS; Shankar, P; Lieberman, J			RNA interference targeting Fas protects mice from fulminant hepatitis	NATURE MEDICINE			English	Article							GENE-EXPRESSION; CONCANAVALIN-A; CELL-CULTURE; LIVER; LIGAND; APOPTOSIS; INJURY; INVOLVEMENT; INHIBITION; FIBROSIS	RNA interference (RNAi) is a powerful tool to silence gene expression post-transcriptionally(1). However, its potential to treat or prevent disease remains unproven. Fas-mediated apoptosis is implicated in a broad spectrum of liver diseases, where inhibiting hepatocyte death is life-saving(2). We investigated the in vivo silencing effect of small interfering RNA (siRNA) duplexes targeting the gene Fas (also known as Tnfrsf6), encoding the Fas receptor, to protect mice from liver failure and fibrosis in two models of autoimmune hepatitis. Intravenous injection of Fas siRNA specifically reduced Fas mRNA levels and expression of Fas protein in mouse hepatocytes, and the effects persisted without diminution for 10 days. Hepatocytes isolated from mice treated with Fas siRNA were resistant to apoptosis when exposed to Fas-specific antibody or co-cultured with concanavalin A (ConA)-stimulated hepatic mononuclear cells. Treatment with Fas siRNA 2 days before ConA challenge abrogated hepatocyte necrosis and inflammatory infiltration and markedly reduced serum concentrations of transaminases. Administering Fas siRNA beginning one week after initiating weekly ConA injections protected mice from liver fibrosis. In a more fulminant hepatitis induced by injecting agonistic Fas-specific antibody, 82% of mice treated with siRNA that effectively silenced Fas survived for 10 days of observation, whereas all control mice died within 3 days. Silencing Fas expression with RNAi holds therapeutic promise to prevent liver injury by protecting hepatocytes from cytotoxicity.	Harvard Med Sch, Ctr Blood Res, Boston, MA 02115 USA; Harvard Med Sch, Dept Pediat, Boston, MA USA; Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou, Peoples R China; Guangzhou Med Inst, Dept Cell Pathol, Guangzhou, Peoples R China	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Sun Yat Sen University	Lieberman, J (corresponding author), Harvard Med Sch, Ctr Blood Res, Boston, MA 02115 USA.	lieberman@cbr.med.harvard.edu	Lieberman, Judy/A-2717-2015	Ince, Nedim/0000-0003-3451-3421	NIAID NIH HHS [AI45306, AI49792, AI45406, AI42510] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045406, R21AI049792, R21AI045306] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Badawy AA, 1996, PHARMACOL RES, V33, P319, DOI 10.1006/phrs.1996.0044; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Canbay A, 2002, GASTROENTEROLOGY, V123, P1323, DOI 10.1053/gast.2002.35953; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Dhiman RK, 1998, DIGEST DIS SCI, V43, P1311, DOI 10.1023/A:1018876328561; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faouzi S, 2001, J BIOL CHEM, V276, P49077, DOI 10.1074/jbc.M109791200; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Kimura K, 1999, INT IMMUNOL, V11, P1491, DOI 10.1093/intimm/11.9.1491; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Li XK, 2001, TRANSPLANTATION, V71, P503, DOI 10.1097/00007890-200102270-00004; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Miyazawa Y, 1998, HEPATOLOGY, V27, P497, DOI 10.1002/hep.510270225; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rust C, 2000, AM J MED, V108, P567, DOI 10.1016/S0002-9343(00)00370-3; Ryo K, 2000, AM J GASTROENTEROL, V95, P2047; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Siegel RM, 1999, J ALLERGY CLIN IMMUN, V103, P729, DOI 10.1016/S0091-6749(99)70412-4; TAKAHASHI S, 1987, BIOCHEM J, V241, P49, DOI 10.1042/bj2410049; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Takeda K, 2000, P NATL ACAD SCI USA, V97, P5498, DOI 10.1073/pnas.040566697; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734; Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475	30	900	1160	3	221	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					347	351		10.1038/nm828	http://dx.doi.org/10.1038/nm828			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12579197				2022-12-27	WOS:000181312300037
J	Winer, S; Tsui, H; Lau, A; Song, AH; Li, XM; Cheung, RK; Sampson, A; Afifiyan, F; Elford, A; Jackowski, G; Becker, DJ; Santamaria, P; Ohashi, P; Dosch, HM				Winer, S; Tsui, H; Lau, A; Song, AH; Li, XM; Cheung, RK; Sampson, A; Afifiyan, F; Elford, A; Jackowski, G; Becker, DJ; Santamaria, P; Ohashi, P; Dosch, HM			Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive	NATURE MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; CD8(+) T-CELLS; SCHWANN-CELLS; MULTIPLE-SCLEROSIS; NERVOUS-SYSTEM; SELF-ANTIGEN; MICE; EXPRESSION; MELLITUS; MOUSE	Pancreatic islets of Langerhans are enveloped by peri-islet Schwann cells (pSC), which express glial fibrillary acidic protein (GFAP) and S100beta. SC-autoreactive T- and B-cell responses arise in 3- to 4-week- old diabetes-prone non-obese diabetic (NOD) mice, followed by progressive pSC destruction before detectable beta-cell death. Humans with probable prediabetes generate similar autoreactivities, and autoantibodies in islet-cell autoantibody (lCA)-positive sera co-localize to pSC. Moreover, GFAP-specific NOD T- cell lines transferred pathogenic peri-insulitis to NOD/severe combined immunodeficient (NOD/SCID) mice, and immunotherapy with GFAP or S100beta prevented diabetes. pSC survived in rat insulin promoter lymphocytic choriomeningitis virus (rip-LCMV) glycoprotein/CD8(+) T-cell receptor(9p) double-transgenic mice with virus-induced diabetes, suggesting that pSC death is not an obligate consequence of local inflammation and cell destruction. However, pSC were deleted in spontaneously diabetic NOD mice carrying the CD8(+) /8.3 T-cell receptor transgene, a T cell receptor commonly expressed in earliest islet infiltrates. Autoimmune targeting of pancreatic nervous system tissue elements seems to be an integral, early part of natural type 1 diabetes.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada; Syn X Pharma Inc, Toronto, ON, Canada; UHN, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada; UHN, Ontario Canc Inst, Dept Immunol, Toronto, ON, Canada; Childrens Hosp, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Fac Med, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Julia MacFarlane Diabet Res Ctr, Fac Med, Calgary, AB, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Dosch, HM (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hmdosch@sickkids.ca	Santamaria, Pere/ABF-6823-2021	Ohashi, Pamela S./0000-0003-2915-9317				Amrani A, 2000, NATURE, V406, P739, DOI 10.1038/35021081; Andre I, 1996, P NATL ACAD SCI USA, V93, P2260, DOI 10.1073/pnas.93.6.2260; Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442; Austen BM, 2000, J PEPT SCI, V6, P459, DOI 10.1002/1099-1387(200009)6:9<459::AID-PSC286>3.0.CO;2-B; Brooks-Worrell B, 2001, J IMMUNOL, V166, P5265, DOI 10.4049/jimmunol.166.8.5265; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Delaney CL, 1996, J NEUROSCI, V16, P6908; DiLorenzo TP, 1998, P NATL ACAD SCI USA, V95, P12538, DOI 10.1073/pnas.95.21.12538; DONEV SR, 1984, CELL TISSUE RES, V237, P343, DOI 10.1007/BF00217154; Dosch HM, 1999, J IMMUNOL, V163, P6933; Hahn von Dorsche H, 1994, Adv Anat Embryol Cell Biol, V130, P1; Karges W, 1996, DIABETES, V45, P513, DOI 10.2337/diabetes.45.4.513; KARGES WJP, 1995, MOL ASPECTS MED, V16, P79, DOI 10.1016/0098-2997(95)00001-W; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KIM J, 1993, DIABETES, V42, P1799, DOI 10.2337/diabetes.42.12.1799; Leitenberg D, 1999, SEMIN IMMUNOL, V11, P283, DOI 10.1006/smim.1999.0184; LIPTON RB, 1992, AM J EPIDEMIOL, V136, P503; Lu J, 1996, P NATL ACAD SCI USA, V93, P2307, DOI 10.1073/pnas.93.6.2307; Marrosu MG, 2002, LANCET, V359, P1461, DOI 10.1016/S0140-6736(02)08431-3; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Merchant M, 2000, ELECTROPHORESIS, V21, P1164, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1164::AID-ELPS1164>3.0.CO;2-0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Salomon B, 2001, J EXP MED, V194, P677, DOI 10.1084/jem.194.5.677; SANTAMARIA P, 1995, J IMMUNOL, V154, P2494; SaraviaFernandez F, 1996, ENDOCRINOLOGY, V137, P3497, DOI 10.1210/en.137.8.3497; SERREZE DV, 1994, CURR OPIN IMMUNOL, V6, P900, DOI 10.1016/0952-7915(94)90011-6; Serreze DV, 2001, J IMMUNOL, V166, P1352, DOI 10.4049/jimmunol.166.2.1352; Shimada A, 1996, DIABETES, V45, P1063, DOI 10.2337/diabetes.45.8.1063; SMITH PH, 1975, AM J ANAT, V144, P513, DOI 10.1002/aja.1001440412; Spierings E, 2001, J IMMUNOL, V166, P5883, DOI 10.4049/jimmunol.166.10.5883; Sunami E, 2001, ARCH HISTOL CYTOL, V64, P191, DOI 10.1679/aohc.64.191; Teitelman G, 1998, J NEUROBIOL, V34, P304, DOI 10.1002/(SICI)1097-4695(199803)34:4<304::AID-NEU2>3.0.CO;2-A; Tisch R, 1999, J IMMUNOL, V163, P1178; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Verdaguer J, 1997, J EXP MED, V186, P1663, DOI 10.1084/jem.186.10.1663; Verdaguer J, 1996, J IMMUNOL, V157, P4726; WEKERLE H, 1986, EUR J IMMUNOL, V16, P1551, DOI 10.1002/eji.1830161214; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; WICKER LS, 1986, DIABETES, V35, P855, DOI 10.2337/diabetes.35.8.855; Winer S, 2001, J IMMUNOL, V166, P2831, DOI 10.4049/jimmunol.166.4.2831; Winer S, 2002, J IMMUNOL, V168, P475, DOI 10.4049/jimmunol.168.1.475; Winer S, 2000, J IMMUNOL, V165, P4086, DOI 10.4049/jimmunol.165.7.4086; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465	44	159	176	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					198	205		10.1038/nm818	http://dx.doi.org/10.1038/nm818			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539039				2022-12-27	WOS:000180801900024
J	Niethammer, AG; Xiang, R; Becker, JC; Wodrich, H; Pertl, U; Karsten, G; Eliceiri, BP; Reisfeld, RA				Niethammer, AG; Xiang, R; Becker, JC; Wodrich, H; Pertl, U; Karsten, G; Eliceiri, BP; Reisfeld, RA			A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth	NATURE MEDICINE			English	Article							PROTECTIVE IMMUNITY; GENE-THERAPY; MICE; EXPRESSION; INDUCTION; ANTIGEN; IMMUNOTHERAPY; ENDOTHELIUM; ENDOSTATIN; VESSELS	Tumor cells are elusive targets for immunotherapy due to their heterogeneity and genetic instability. Here we describe a novel, oral DNA vaccine that targets stable, proliferating endothelial cells in the tumor vasculature rather than tumor cells. Targeting occurs through upregulated vascular-endothelial growth factor receptor 2 (FLK-1) of proliferating endothelial cells in the tumor vasculature. This vaccine effectively protected mice from lethal challenges with melanoma, colon carcinoma and lung carcinoma cells and reduced growth of established metastases in a therapeutic setting. CTL-mediated killing of endothelial cells indicated breaking of peripheral immune tolerance against this self antigen, resulting in markedly reduced dissemination of spontaneous and experimental pulmonary metastases. Angiogenesis in the tumor vasculature was suppressed without impairment of fertility, neuromuscular performance or hematopoiesis, albeit with a slight delay in wound healing. Our strategy circumvents problems in targeting of genetically unstable tumor cells. This approach may provide a new strategy for the rational design of cancer therapies.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Wurzburg, Hautklin, Wurzburg, Germany; La Jolla Inst Mol Med, San Diego, CA USA	Scripps Research Institute; Scripps Research Institute; University of Wurzburg	Reisfeld, RA (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.	reisfeld@scripps.edu	Wodrich, Harald/P-1777-2019	Wodrich, Harald/0000-0002-4764-1708; Eliceiri, Brian/0000-0003-1811-1916	NATIONAL CANCER INSTITUTE [R01CA083856] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073396] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83856] Funding Source: Medline; NHLBI NIH HHS [HL 69046, R01 HL073396, R01 HL073396-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Augustin HG, 1998, TRENDS PHARMACOL SCI, V19, P216, DOI 10.1016/S0165-6147(98)01211-5; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Cheng WF, 2001, J CLIN INVEST, V108, P669, DOI 10.1172/JCI200112346; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Drake CJ, 2000, DEV BIOL, V224, P178, DOI 10.1006/dbio.2000.9744; Eberhard A, 2000, CANCER RES, V60, P1388; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Folkman J, 1997, EXS, V79, P1; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; Folkman J, 2001, P NATL ACAD SCI USA, V98, P398, DOI 10.1073/pnas.98.2.398; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Goede V, 1998, ANTICANCER RES, V18, P2199; Hata Y, 1999, DIABETES, V48, P1145, DOI 10.2337/diabetes.48.5.1145; Heidenreich R, 2000, CANCER RES, V60, P6142; Hicklin DJ, 1999, MOL MED TODAY, V5, P178, DOI 10.1016/S1357-4310(99)01451-3; Kaesler S, 2002, CYTOKINE, V17, P157, DOI 10.1006/cyto.2001.0981; Kisker O, 2001, CANCER RES, V61, P7669; Lode HN, 1998, P NATL ACAD SCI USA, V95, P2475, DOI 10.1073/pnas.95.5.2475; McMahon G, 2000, Oncologist, V5 Suppl 1, P3; Niethammer AG, 2001, VACCINE, V20, P421, DOI 10.1016/S0264-410X(01)00362-0; Niethammer AG, 2001, CANCER RES, V61, P6178; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; ORTEGA N, 1999, FRONT BIOSCI, V4, P141; Paylor R, 1998, LEARN MEMORY, V5, P302; Ruiter D J, 1991, Semin Cancer Biol, V2, P35; Schrama D, 2001, IMMUNITY, V14, P111, DOI 10.1016/S1074-7613(01)00094-2; St Croix B, 2000, SCIENCE, V289, P1197; Strawn LM, 1996, CANCER RES, V56, P3540; Taraboletti Giulia, 2001, Current Opinion in Pharmacology, V1, P378, DOI 10.1016/S1471-4892(01)00065-0; Wei YQ, 2000, NAT MED, V6, P1160, DOI 10.1038/80506; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	37	313	350	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1369	1375		10.1038/nm794	http://dx.doi.org/10.1038/nm794			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12415261				2022-12-27	WOS:000179552000032
J	Obici, S; Zhang, BB; Karkanias, G; Rossetti, L				Obici, S; Zhang, BB; Karkanias, G; Rossetti, L			Hypothalamic insulin signaling is required for inhibition of glucose production	NATURE MEDICINE			English	Article							SENSITIVE K+ CHANNELS; Y GENE-EXPRESSION; BODY-WEIGHT; FOOD-INTAKE; MELANOCORTIN RECEPTORS; MESSENGER-RNA; RAT-BRAIN; INFUSION; NEURONS; HYPERPHAGIA	Circulating insulin inhibits endogenous glucose production. Here we report that bidirectional changes in hypothalamic insulin signaling affect glucose production. The infusion of either insulin or a small-molecule insulin mimetic in the third cerebral ventricle suppressed glucose production independent of circulating levels of insulin and of other glucoregulatory hormones. Conversely, central antagonism of insulin signaling impaired the ability of circulating insulin to inhibit glucose production. Finally, third-cerebral-ventricle administration of inhibitors of ATP-sensitive potassium channels, but not of antagonists of the central melanocortin receptors, also blunted the effect of hyperinsulinemia on glucose production. These results reveal a new site of action of insulin on glucose production and suggest that hypothalamic insulin resistance can contribute to hyperglycemia in type 2 diabetes mellitus.	Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Mol Pharmacol, Bronx, NY 10467 USA; Merck Res Labs, Rahway, NJ USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Merck & Company	Rossetti, L (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10467 USA.	rossetti@aecom.yu.edu			NIDDK NIH HHS [DK 45024, DK 48321, DK 20541] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045024, P60DK020541, R01DK048321, R29DK045024, R37DK048321] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Air EL, 2002, NAT MED, V8, P179, DOI 10.1038/nm0202-179; BASKIN DG, 1993, REGUL PEPTIDES, V48, P257, DOI 10.1016/0167-0115(93)90355-C; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; DAVIS SN, 1995, J CLIN INVEST, V95, P593, DOI 10.1172/JCI117703; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Gerozissis K, 1998, PHYSIOL BEHAV, V65, P271, DOI 10.1016/S0031-9384(98)00158-9; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; Hopkins DFC, 1997, DIABETIC MED, V14, P1044, DOI 10.1002/(SICI)1096-9136(199712)14:12<1044::AID-DIA508>3.0.CO;2-F; Lewis GF, 1997, DIABETES, V46, P1111, DOI 10.2337/diabetes.46.7.1111; LIANG CS, 1982, J CLIN INVEST, V69, P1321, DOI 10.1172/JCI110572; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; MARKS JL, 1990, ENDOCRINOLOGY, V127, P3234, DOI 10.1210/endo-127-6-3234; MCGOWAN MK, 1992, PHYSIOL BEHAV, V51, P753, DOI 10.1016/0031-9384(92)90112-F; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; Numan S, 1999, MOL BRAIN RES, V72, P97, DOI 10.1016/S0169-328X(99)00160-6; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; REBRIN K, 1995, DIABETES, V44, P1038, DOI 10.2337/diabetes.44.9.1038; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; RICHARDSON RD, 1994, AM J PHYSIOL, V266, pR59, DOI 10.1152/ajpregu.1994.266.1.R59; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SAHU A, 1995, ENDOCRINOLOGY, V136, P5718, DOI 10.1210/en.136.12.5718; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SCHWARTZ MW, 1992, ENDOCRINOLOGY, V130, P3608, DOI 10.1210/en.130.6.3608; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Sindelar DK, 1998, DIABETES, V47, P523, DOI 10.2337/diabetes.47.4.523; Sindelar DK, 1997, DIABETES, V46, P187, DOI 10.2337/diabetes.46.2.187; SIPOLS AJ, 1995, DIABETES, V44, P147, DOI 10.2337/diabetes.44.2.147; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; Unger JW, 1998, HISTOL HISTOPATHOL, V13, P1215, DOI 10.14670/HH-13.1215; Wang J, 1997, BRAIN RES, V777, P231, DOI 10.1016/S0006-8993(97)00963-3; WILLIAMS P, 1997, AM J PHYSIOL, V272, pE567; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	42	690	710	1	25	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1376	1382		10.1038/nm798	http://dx.doi.org/10.1038/nm798			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12426561				2022-12-27	WOS:000179552000033
J	Weiss, RA; McMichael, AJ				Weiss, RA; McMichael, AJ			Social and environmental risk factors in the emergence of infectious diseases	NATURE MEDICINE			English	Article							WEST-NILE-VIRUS; HIV-INFECTION; TRANSMISSION; AIDS; MORTALITY; INFLUENZA; ENCEPHALITIS; TRANSFUSION; RETROVIRUS; COUNTRIES	Fifty years ago, the age-old scourge of infectious disease was receding in the developed world in response to improved public health measures, while the advent of antibiotics, better vaccines, insecticides and improved surveillance held the promise of eradicating residual problems. By the late twentieth century, however, an increase in the emergence and reemergence of infectious diseases was evident in many parts of the world. This upturn looms as the fourth major transition in human-microbe relationships since the advent of agriculture around 10,000 years ago. About 30 new diseases have been identified, including Legionnaires' disease, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), hepatitis C, bovine spongiform encephalopathy (BSE)/variant Creutzfeldt-Jakob disease (vCJD), Nipah virus, several viral hemorrhagic fevers and, most recently, severe acute respiratory syndrome (SARS) and avian influenza. The emergence of these diseases, and resurgence of old ones like tuberculosis and cholera, reflects various changes in human ecology: rural-to-urban migration resulting in high-density peri-urban slums; increasing long-distance mobility and trade; the social disruption of war and conflict; changes in personal behavior; and, increasingly, human-induced global changes, including widespread forest clearance and climate change. Political ignorance, denial and obduracy (as with HIV/AIDS) further compound the risks. The use and misuse of medical technology also pose risks, such as drug-resistant microbes and contaminated equipment or biological medicines. A better understanding of the evolving social dynamics of emerging infectious diseases ought to help us to anticipate and hopefully ameliorate current and future risks.	UCL, Wohl Vir Ctr, Div Infect & Immun, London W1T 4JF, England; Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia	University of London; University College London; Australian National University	Weiss, RA (corresponding author), UCL, Wohl Vir Ctr, Div Infect & Immun, London W1T 4JF, England.	r.weiss@ucl.ac.uk; tony.mcmichael@anu.edu.au						ANDERSON R M, 1991; Auvert B, 2001, AIDS, V15, pS15, DOI 10.1097/00002030-200108004-00003; Bell D, 2004, PHILOS T R SOC B, V359, P1107, DOI 10.1098/rstb.2004.1492; Blower SM, 2004, NAT MED, V10, P1111, DOI 10.1038/nm1102; BROCKMANN D, 2005, SARS CASE STUDY EMER; Burnet FM, 1972, NATURAL HIST INFECT; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butler C, 2000, LANCET, V356, P1445, DOI 10.1016/S0140-6736(05)74091-5; Caldwell JC, 2000, POPUL DEV REV, V26, P117, DOI 10.1111/j.1728-4457.2000.00117.x; Chua KB, 1999, LANCET, V354, P1257, DOI 10.1016/S0140-6736(99)04299-3; COHEN A, 2003, INT J ENVIRON HEAL R, V13, pS29; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; De Clercq E, 2004, NAT REV MICROBIOL, V2, P704, DOI 10.1038/nrmicro975; Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9; Diamond J., 1997, GUNS GERMS STEEL SHO; Drancourt M, 2004, EMERG INFECT DIS, V10, P1585, DOI 10.3201/eid1009.030933; Drucker E, 2001, LANCET, V358, P1989, DOI 10.1016/S0140-6736(01)06967-7; DUFFY JOHN, 1951, BULL HIST MED, V25, P324; Engelthaler DM, 1999, EMERG INFECT DIS, V5, P87, DOI 10.3201/eid0501.990110; Frenzen PD, 2004, EMERG INFECT DIS, V10, P1536, DOI 10.3201/eid1009.030403; Garrett L., 2000, BETRAYAL TRUST COLLA; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Hale P, 2001, NATURE, V412, P271, DOI 10.1038/35085650; Halpin K, 1999, VET MICROBIOL, V68, P83, DOI 10.1016/S0378-1135(99)00063-2; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Koopmans M, 2004, LANCET, V363, P587, DOI 10.1016/S0140-6736(04)15589-X; Lee HC, 1996, BIOL SIGNAL, V5, P101; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144; Magre S, 2004, J VIROL, V78, P5812, DOI 10.1128/JVI.78.11.5812-5819.2004; Mahy BWJ, 1998, DEV BIOL STAND, V93, P31; McMichael AJ, 2004, PHILOS T ROY SOC B, V359, P1049, DOI 10.1098/rstb.2004.1480; McMichael AJ, 2004, LANCET, V363, P1155, DOI 10.1016/S0140-6736(04)15902-3; McMichael AJ, 2001, HUMAN FRONTIERS ENV, DOI [10.1017/CBO9781139106924, DOI 10.1017/CBO9781139106924]; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; Palese P, 2004, NAT MED, V10, pS82, DOI 10.1038/nm1141; PARMENTER RR, 1993, SEVILLETA LTER PUBLI, V41, P1; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Patz JA, 2004, ENVIRON HEALTH PERSP, V112, P1092, DOI 10.1289/ehp.6877; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143; Perel P, 2004, BMJ-BRIT MED J, V328, P895, DOI 10.1136/bmj.328.7444.895; Raoult D, 1997, EMERG INFECT DIS, V3, P357, DOI 10.3201/eid0303.970313; Schwartz M., 2003, COWS TURNED MAD; Speck Reinhard S., 1993, P642, DOI 10.1017/CHOL9780521332866.089; Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888; Tiemersma EW, 2004, EMERG INFECT DIS, V10, P1627, DOI 10.3201/eid1009.040069; Webby R, 2004, NAT MED, V10, pS77, DOI 10.1038/nm1151; Weiss RA, 2004, PHILOS T R SOC B, V359, P1137, DOI 10.1098/rstb.2004.1487; Weiss RA, 1998, NATURE, V391, P327, DOI 10.1038/34772; Weiss RA, 2002, TRENDS MICROBIOL, V10, P314, DOI 10.1016/S0966-842X(02)02391-0; Weiss RA, 2001, NATURE, V410, P963, DOI 10.1038/35073632; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Wilson K, 2004, LANCET, V364, P477, DOI 10.1016/S0140-6736(04)16820-7; Wolfe ND, 2004, LANCET, V363, P932, DOI 10.1016/S0140-6736(04)15787-5; zur Hansen H, 2003, INT J CANCER, V107, P687, DOI 10.1002/ijc.11517	60	352	383	2	225	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12		S			S70	S76		10.1038/nm1150	http://dx.doi.org/10.1038/nm1150			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577934	Green Published			2022-12-27	WOS:000225733900002
J	Qi, Y; Takahashi, N; Hileman, SM; Patel, HR; Berg, AH; Pajvani, UB; Scherer, PE; Ahima, RS				Qi, Y; Takahashi, N; Hileman, SM; Patel, HR; Berg, AH; Pajvani, UB; Scherer, PE; Ahima, RS			Adiponectin acts in the brain to decrease body weight	NATURE MEDICINE			English	Article							FATTY-ACID OXIDATION; INSULIN-RESISTANCE; UNCOUPLING PROTEIN; LEPTIN; EXPRESSION; ADIPOSITY; ACRP30; AGOUTI	Adiponectin (ADP) is an adipocyte hormone involved in glucose and lipid metabolism. We detected a rise in ADP in cerebrospinal fluid after intravenous (i.v.) injection, consistent with brain transport. In contrast to leptin, intracerebroventricular (i.c.v.) administration of ADP decreased body weight mainly by stimulating energy expenditure. Full-length ADP, mutant ADP with Cys39 replaced with serine, and globular ADP were effective, whereas the collagenous tail fragment was not. Lep(ob/ob) mice were especially sensitive to i.c.v. and systemic ADP, which resulted in increased thermogenesis, weight loss and reduction in serum glucose and lipid levels. ADP also potentiated the effect of leptin on thermogenesis and lipid levels. While both hormones increased expression of hypothalamic corticotropin-releasing hormone (CRH), ADP had no substantial effect on other neuropeptide targets of leptin. In addition, ADP induced distinct Fos immunoreactivity. Agouti (A(y)/a) mice did not respond to ADP or leptin, indicating the melanocortin pathway may be a common target. These results show that ADP has unique central effects on energy homeostasis.	Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Penn Diabet Ctr, Philadelphia, PA 19104 USA; W Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	University of Pennsylvania; University of Pennsylvania; West Virginia University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Ahima, RS (corresponding author), Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.	ahima@mail.med.upenn.edu	Scherer, Philipp E/K-7819-2012; Ahima, Rexford/W-1394-2019	Scherer, Philipp E/0000-0003-0680-3392; Takahashi, Nobuhiko/0000-0003-2028-5405	NIDDK NIH HHS [R01-DK62348, R01-DK55758, P30-DK19525] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK055758, R01DK062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahima RS, 2000, REGUL PEPTIDES, V92, P1, DOI 10.1016/S0167-0115(00)00142-7; Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Ahima RS, 2002, DIABETES, V51, P2099, DOI 10.2337/diabetes.51.7.2099; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Combs TP, 2004, ENDOCRINOLOGY, V145, P367, DOI 10.1210/en.2003-1068; Combs TP, 2003, DIABETES, V52, P268, DOI 10.2337/diabetes.52.2.268; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Elias CF, 2000, J COMP NEUROL, V423, P261; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Masaki T, 2003, DIABETES, V52, P2266, DOI 10.2337/diabetes.52.9.2266; Masaki T, 2003, ENDOCRINOLOGY, V144, P3547, DOI 10.1210/en.2003-0301; Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; PAXINOS G, 1997, MOUSE BRAIN STEREOTA, P36; STE ML, 2000, P NATL ACAD SCI USA, V97, P12339; Tsao TS, 2002, EUR J PHARMACOL, V440, P213, DOI 10.1016/S0014-2999(02)01430-9; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	25	641	678	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					524	529		10.1038/nm1029	http://dx.doi.org/10.1038/nm1029			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15077108				2022-12-27	WOS:000221242400031
J	Ruggero, D; Montanaro, L; Ma, L; Xu, W; Londei, P; Cardon-Cardo, C; Pandolfi, PP				Ruggero, D; Montanaro, L; Ma, L; Xu, W; Londei, P; Cardon-Cardo, C; Pandolfi, PP			The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis	NATURE MEDICINE			English	Article							INITIATION-FACTOR 4E; PROTEIN; TRANSFORMATION; FIBROBLASTS; EXPRESSION; APOPTOSIS; PTEN	The mammalian target of rapamycin, mTOR, regulates cell growth and proliferation. Here we show that the initiation factor of translation (eIF-4E), a downstream effector of mTOR, has oncogenic effects in vivo and cooperates with c-Myc in B-cell lymphomagenesis. We found that c-Myc overrides eIF-4E-induced cellular senescence, whereas eIF-4E antagonizes c-Myc-dependent apoptosis in vivo. Our results implicate activation of eIF-4E as a key event in oncogenic transformation by phosphoinositide-3 kinase and Akt.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Univ Bari, Dipartimento Biochim Med & Biol Med, I-70124 Bari, Italy	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Universita degli Studi di Bari Aldo Moro	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Montanaro, Lorenzo/I-4236-2019; Ma, Li/GQR-1313-2022	Montanaro, Lorenzo/0000-0001-9776-9518; Ma, Li/0000-0001-9965-989X				Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Seki N, 2002, CLIN CANCER RES, V8, P3046; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	15	463	478	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					484	486		10.1038/nm1042	http://dx.doi.org/10.1038/nm1042			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15098029				2022-12-27	WOS:000221242400025
J	Pearson, H				Pearson, H			Mark Mattson - Profile	NATURE MEDICINE			English	Biographical-Item																		MATTSON M, PUBLICATION LIST	1	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2004	10	4					324	324		10.1038/nm0404-324	http://dx.doi.org/10.1038/nm0404-324			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15057216	Bronze			2022-12-27	WOS:000220587000010
J	Hommel, JD; Sears, RM; Georgescu, D; Simmons, DL; DiLeone, RJ				Hommel, JD; Sears, RM; Georgescu, D; Simmons, DL; DiLeone, RJ			Local gene knockdown in the brain using viral-mediated RNA interference	NATURE MEDICINE			English	Article							DOUBLE-STRANDED-RNA; TYROSINE-HYDROXYLASE; PARKINSONS-DISEASE; MAMMALIAN-CELLS; EXPRESSION; MICE; DROSOPHILA; DOPAMINE; VECTORS; ELEGANS	Conditional mutant techniques that allow spatial and temporal control over gene expression can be used to create mice with restricted genetic modifications. These mice serve as powerful disease models in which gene function in adult tissues can be specifically dissected. Current strategies for conditional genetic manipulation are inefficient, however, and often lack sufficient spatial control. Here we use viral- mediated RNA interference (RNAi) to generate a specific knockdown of Th, the gene encoding the dopamine synthesis enzyme tyrosine hydroxylase, within midbrain neurons of adult mice. This localized gene knockdown resulted in behavioral changes, including a motor performance deficit and reduced response to a psychostimulant. These results underscore the potential of using viral- mediated RNAi for the rapid production and testing of new genetic disease models. Similar strategies may be used in other model species, and may ultimately find applications in human gene therapy.	Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DiLeone, RJ (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Hommel, Jonathan/0000-0001-8305-3746; DiLeone, Ralph/0000-0002-4770-2590; , robert/0000-0001-5688-1853				Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Chamberlin NL, 1998, BRAIN RES, V793, P169, DOI 10.1016/S0006-8993(98)00169-3; CHUANG D, 1975, MOL PHARMACOL, V11, P784; COLOTLA VA, 1990, NEUROTOXICOL TERATOL, V12, P405, DOI 10.1016/0892-0362(90)90061-G; DiLeone RJ, 1998, GENETICS, V148, P401; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fitzsimons HL, 2001, GENE THER, V8, P1675, DOI 10.1038/sj.gt.3301582; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Georgescu D, 2003, J NEUROSCI, V23, P3106; Gibb WRG, 1997, EUR NEUROL, V38, P21, DOI 10.1159/000113472; Girod A, 1999, NAT MED, V5, P1052, DOI 10.1038/12491; Gossen M, 2002, ANNU REV GENET, V36, P153, DOI 10.1146/annurev.genet.36.041002.120114; HAN VKM, 1987, J NEUROSCI RES, V17, P11, DOI 10.1002/jnr.490170103; Kalidas S, 2002, NEURON, V33, P177, DOI 10.1016/S0896-6273(02)00560-3; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; MCGEER EG, 1971, J NEUROCHEM, V18, P1647, DOI 10.1111/j.1471-4159.1971.tb03738.x; MOORE KE, 1977, BIOL PSYCHIAT, V12, P451; Paxinos G, 2000, MOUSE BRAIN STEREOTA; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rozas G, 1998, J NEUROSCI METH, V83, P165, DOI 10.1016/S0165-0270(98)00078-8; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Yu JY, 2003, MOL THER, V7, P228, DOI 10.1016/S1525-0016(02)00037-0; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	36	278	306	0	16	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1539	1544		10.1038/nm964	http://dx.doi.org/10.1038/nm964			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14634645				2022-12-27	WOS:000186845400039
J	Fahmy, RG; Dass, CR; Sun, LQ; Chesterman, CN; Khachigian, LM				Fahmy, RG; Dass, CR; Sun, LQ; Chesterman, CN; Khachigian, LM			Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth	NATURE MEDICINE			English	Article							BREAST-CARCINOMA CELLS; RESPONSE FACTOR-I; MESSENGER-RNA; FACTOR RECEPTOR; DNA ENZYME; GENE-EXPRESSION; CANCER CELLS; ACTIVATION; INJURY; METASTASIS	Current understanding of key transcription factors regulating angiogenesis is limited. Here we show that RNA-cleaving phosphodiester- linked DNA-based enzymes (DNAzymes), targeting a specific motif in the 5 untranslated region of early growth response (Egr-1) mRNA, inhibit Egr-1 protein expression, microvascular endothelial cell replication and migration, and microtubule network formation on basement membrane matrices. Egr-1 DNAzymes blocked angiogenesis in subcutaneous Matrigel plugs in mice, an observation that was independently confirmed by plug analysis in Egr-1-deficient animals, and inhibited MCF-7 human breast carcinoma growth in nude mice. Egr-1 DNAzymes suppressed tumor growth without influencing body weight, wound healing, blood coagulation or other hematological parameters. These agents inhibited endothelial expression of fibroblast growth factor (FGF)-2, a proangiogenic factor downstream of Egr-1, but not that of vascular endothelial growth factor (VEGF). Egr-1 DNAzymes also repressed neovascularization of rat cornea. Thus, microvascular endothelial cell growth, neovascularization, tumor angiogenesis and tumor growth are processes that are critically dependent on Egr-1.	Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia; Johnson & Johnson Res Labs, Sydney, NSW, Australia	University of New South Wales Sydney; Johnson & Johnson	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.		Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				BATTEGAY EJ, 1995, J MOL MED, V73, P333; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002-9440(10)63015-5; Cieslak M, 2002, J BIOL CHEM, V277, P6779, DOI 10.1074/jbc.M102325200; DENNIS PA, 1990, J CELL PHYSIOL, V144, P84, DOI 10.1002/jcp.1041440112; EYETECH, 2002, RETINA, V22, P143; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; FOURNIER GA, 1981, INVEST OPHTH VIS SCI, V21, P351; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Goldberg EP, 2002, J PHARM PHARMACOL, V54, P159, DOI 10.1211/0022357021778268; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Herold-Mende C, 1999, LAB INVEST, V79, P1573; Karpanen T, 2001, CANCER RES, V61, P1786; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Khachigian LM, 2002, CURR OPIN MOL THER, V4, P119; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Khachigian LM, 2002, J BIOL CHEM, V277, P22985, DOI 10.1074/jbc.M200977200; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Li YW, 2002, J EXP MED, V195, P1575, DOI 10.1084/jem.20020072; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; McLeskey SW, 1998, AM J PATHOL, V153, P1993, DOI 10.1016/S0002-9440(10)65713-6; McLeskey SW, 1996, BRIT J CANCER, V73, P1053, DOI 10.1038/bjc.1996.204; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; Ogawa T, 2002, CANCER GENE THER, V9, P633, DOI 10.1038/sj.cgt.7700478; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Prewett M, 1999, CANCER RES, V59, P5209; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; Shiose S, 2000, INVEST OPHTH VIS SCI, V41, P2395; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Usman N, 2000, J CLIN INVEST, V106, P1197, DOI 10.1172/JCI11631; Visvanathan S, 2000, J IMMUNOL, V165, P2258, DOI 10.4049/jimmunol.165.4.2258; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Wedge SR, 2002, CANCER RES, V62, P4645; Zhang LR, 1999, CANCER RES, V59, P5023; Zhang LR, 1998, CANCER RES, V58, P352	45	296	312	0	36	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1026	1032		10.1038/nm905	http://dx.doi.org/10.1038/nm905			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12872165				2022-12-27	WOS:000184484900026
J	Khodorova, A; Navarro, B; Jouaville, LS; Murphy, E; Rice, FL; Mazurkiewicz, JE; Long-Woodward, D; Stoffel, M; Strichartz, GR; Yukhananov, R; Davar, G				Khodorova, A; Navarro, B; Jouaville, LS; Murphy, E; Rice, FL; Mazurkiewicz, JE; Long-Woodward, D; Stoffel, M; Strichartz, GR; Yukhananov, R; Davar, G			Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury	NATURE MEDICINE			English	Article							PAIN-LIKE BEHAVIOR; SELECTIVE ANTAGONIST; LOCAL INJECTION; RAT; IDENTIFICATION; INVOLVEMENT; MECHANISMS; CHANNEL; POTENT; OPIATE	Endothelin-1 (ET-1) is a newly described pain mediator that is involved in the pathogenesis of pain states ranging from trauma to cancer. ET-1 is synthesized by keratinocytes in normal skin and is locally released after cutaneous injury. While it is able to trigger pain through its actions on endothelin-A (ETA) receptors of local nociceptors, it can coincidentally produce analgesia through endothelin-B (ETB) receptors. Here we map a new endogenous analgesic circuit, in which ETB receptor activation induces the release of beta-endorphin from keratinocytes and the activation of G-protein-coupled inwardly rectifying potassium channels (GIRKs, also named Kir-3) linked to opioid receptors on nociceptors. These results indicate the existence of an intrinsic feedback mechanism to control peripheral pain in skin, and establish keratinocytes as an ETB receptor-operated opioid pool.	Brigham & Womens Hosp, Mol Neurobiol Pain Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Cardiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Sensory Neurophysiol Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Harvard Skin Dis Res Ctr, Boston, MA 02115 USA; Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA; Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Pain Res Ctr, Neurogenom Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Albany Medical College; Rockefeller University; Harvard University; Brigham & Women's Hospital	Davar, G (corresponding author), Brigham & Womens Hosp, Mol Neurobiol Pain Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	gdavar@zeus.bwh.harvard.edu						Ahn Gun Young, 1998, Journal of Dermatology (Tokyo), V25, P78; AKIL H, 1976, SCIENCE, V191, P961, DOI 10.1126/science.1251210; AKIL H, 1972, CR ACAD SCI D NAT, V274, P3603; Blanchet C, 2002, P NATL ACAD SCI USA, V99, P4674, DOI 10.1073/pnas.072075399; BLEDNOV YA, 2003, P NATL ACAD SCI USA, V100, P77; Broadbear JH, 2000, J PHARMACOL EXP THER, V294, P933; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carducci MA, 2002, J CLIN ONCOL, V20, P2171, DOI 10.1200/JCO.2002.08.028; Davar G, 1998, NEUROREPORT, V9, P2279, DOI 10.1097/00001756-199807130-00025; De-Melo JD, 1998, PAIN, V77, P261, DOI 10.1016/S0304-3959(98)00098-0; Fareed MU, 2000, J PAIN, V1, P46, DOI 10.1016/S1526-5900(00)90087-7; FERREIRA SH, 1989, J CARDIOVASC PHARM, V13, pS220, DOI 10.1097/00005344-198900135-00065; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; Gokin AP, 2001, J NEUROSCI, V21, P5358, DOI 10.1523/JNEUROSCI.21-14-05358.2001; Gutstein HB, 1998, NEUROREPORT, V9, P1777, DOI 10.1097/00001756-199806010-00019; HARGREAVES KM, 1990, AM J PHYSIOL, V258, pE235, DOI 10.1152/ajpendo.1990.258.2.E235; Harris JA, 1996, J PHYSIOL-PARIS, V90, P15, DOI 10.1016/0928-4257(96)87165-8; HICKEY KA, 1985, AM J PHYSIOL, V248, pC550, DOI 10.1152/ajpcell.1985.248.5.C550; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; Ikeda K, 2000, NEUROSCI RES, V38, P113, DOI 10.1016/S0168-0102(00)00144-9; Jarvis MF, 2000, EUR J PHARMACOL, V388, P29, DOI 10.1016/S0014-2999(99)00865-1; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Khodorova A, 2002, J NEUROSCI, V22, P7788; Luscher TF, 2000, CIRCULATION, V102, P2434, DOI 10.1161/01.CIR.102.19.2434; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Mark MD, 2000, EUR J BIOCHEM, V267, P5830, DOI 10.1046/j.1432-1327.2000.01670.x; MCQUAY H, 1998, EVIDENCE BASED RESOU, P23; Mitrovic I, 2003, P NATL ACAD SCI USA, V100, P271, DOI 10.1073/pnas.0136822100; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Piovezan AP, 2000, BRIT J PHARMACOL, V129, P961, DOI 10.1038/sj.bjp.0703154; Pomonis JD, 2001, J NEUROSCI, V21, P999, DOI 10.1523/JNEUROSCI.21-03-00999.2001; Rogalski SL, 1999, J NEUROCHEM, V72, P1409, DOI 10.1046/j.1471-4159.1999.721409.x; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; STEIN C, 1993, ANESTH ANALG, V76, P182; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Torrecilla M, 2002, J NEUROSCI, V22, P4328, DOI 10.1523/JNEUROSCI.22-11-04328.2002; Wacnik PW, 2001, J NEUROSCI, V21, P9355, DOI 10.1523/JNEUROSCI.21-23-09355.2001; Wettstein JG, 1996, PHARMACOL BIOCHEM BE, V53, P411, DOI 10.1016/0091-3057(95)02043-8; Wintzen M, 1996, J INVEST DERMATOL, V106, P673, DOI 10.1111/1523-1747.ep12345496; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zanello SB, 1999, ANN NY ACAD SCI, V885, P85; Zhou QL, 2001, NEUROREPORT, V12, P3853, DOI 10.1097/00001756-200112040-00050; Zhou ZR, 2002, J NEUROSCI, V22, P6325; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	49	185	188	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2003	9	8					1055	1061		10.1038/nm885	http://dx.doi.org/10.1038/nm885			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847519				2022-12-27	WOS:000184484900030
J	Ferrara, N; Gerber, HP; LeCouter, J				Ferrara, N; Gerber, HP; LeCouter, J			The biology of VEGF and its receptors	NATURE MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; LINDAU TUMOR-SUPPRESSOR; GLAND-DERIVED VEGF; CELL GROWTH; SIGNAL-TRANSDUCTION; TYROSINE KINASE; MICROVASCULAR PERMEABILITY; INDUCED ANGIOGENESIS; MONOCLONAL-ANTIBODY	Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Ferrara, N (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	nf@gene.com						Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; Adini A, 2002, CANCER RES, V62, P2749; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687; Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Dor Y, 2001, AM J PHYSIOL-CELL PH, V280, pC1367, DOI 10.1152/ajpcell.2001.280.6.C1367; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Ferrara N, 2003, AM J PATHOL, V162, P1881, DOI 10.1016/S0002-9440(10)64322-2; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Fraser HM, 2000, ENDOCRINOLOGY, V141, P995, DOI 10.1210/en.141.3.995; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Garner Alec, 1994, P1625; Gerber HP, 2000, CANCER RES, V60, P6253; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Goede V, 1998, LAB INVEST, V78, P1385; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Haigh JJ, 2000, DEVELOPMENT, V127, P1445; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitamoto Y, 1997, J CLIN INVEST, V99, P2351, DOI 10.1172/JCI119416; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; LeCouter J, 2002, NAT MED, V8, P913, DOI 10.1038/nm0902-913; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Lee CG, 2000, CANCER RES, V60, P5565; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638; MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028; Maru Y, 1998, ONCOGENE, V16, P2585, DOI 10.1038/sj.onc.1201786; Matsumoto T., 2001, SCI STKE, V112, P1; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815; Mole DR, 2001, IUBMB LIFE, V52, P43; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARK JE, 1994, J BIOL CHEM, V269, P25646; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; POOLE AR, 1991, CARTILAGE MOL ASPECT, P179; Presta LG, 1997, CANCER RES, V57, P4593; Prewett M, 1999, CANCER RES, V59, P5209; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Siemeister G, 1996, CANCER RES, V56, P2299; Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tsuzuki Y, 2000, CANCER RES, V60, P6248; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wood JM, 2000, CANCER RES, V60, P2178; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YANG JC, IN PRESS N ENGL J ME; Yang RH, 1996, J CARDIOVASC PHARM, V27, P838, DOI 10.1097/00005344-199606000-00011; YEN SSC, 1999, REPROD ENDOCRINOLOGY, P436; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zelzer E, 2002, DEVELOPMENT, V129, P1893; Zimmermann RC, 2001, J CLIN ENDOCR METAB, V86, P768, DOI 10.1210/jc.86.2.768	136	7183	7668	42	1225	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					669	676		10.1038/nm0603-669	http://dx.doi.org/10.1038/nm0603-669			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12778165				2022-12-27	WOS:000183444100021
J	Hammes, HP; Du, XL; Edelstein, D; Taguchi, T; Matsumura, T; Ju, QD; Lin, JH; Bierhaus, A; Nawroth, P; Hannak, D; Neumaier, M; Bergfeld, R; Giardino, I; Brownlee, M				Hammes, HP; Du, XL; Edelstein, D; Taguchi, T; Matsumura, T; Ju, QD; Lin, JH; Bierhaus, A; Nawroth, P; Hannak, D; Neumaier, M; Bergfeld, R; Giardino, I; Brownlee, M			Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy	NATURE MEDICINE			English	Article							CULTURED ENDOTHELIAL-CELLS; PKC-BETA INHIBITOR; FACTOR-KAPPA-B; ADVANCED GLYCATION; MESANGIAL EXPANSION; GLUCOSE-TRANSPORT; THIAMINE; RATS; ACTIVATION; AMINOGUANIDINE	Three of the major biochemical pathways implicated in the pathogenesis of hyperglycemia induced vascular damage (the hexosamine pathway, the advanced glycation end product (AGE) formation pathway and the diacylglycerol (DAG)-protein kinase C (PKC) pathway) are activated by increased availability of the glycolytic metabolites glyceraldehyde-3-phosphate and fructose-6-phosphate. We have discovered that the lipid-soluble thiamine derivative benfotiamine can inhibit these three pathways, as well as hyperglycemia-associated NF-kappaB activation, by activating the pentose phosphate pathway enzyme transketolase, which converts glyceraldehyde-3-phosphate and fructose-6-phosphate into pentose-5-phosphates and other sugars. In retinas of diabetic animals, benfotiamine treatment inhibited these three pathways and NF-kappaB activation by activating transketolase, and also prevented experimental diabetic retinopathy. The ability of benfotiamine to inhibit three major pathways simultaneously might be clinically useful in preventing the development and progression of diabetic complications.	Albert Einstein Coll Med, Ctr Diabet Res, Bronx, NY 10467 USA; Sch Clin Med, Med Clin V, Mannheim, Germany; Univ Heidelberg, Dept Internal Med 1, Heidelberg, Germany; Sch Clin Med, Inst Clin Chem, Mannheim, Germany; Univ Giessen, Dept Med 3, Giessen, Germany	Yeshiva University; Albert Einstein College of Medicine; Ruprecht Karls University Heidelberg; Justus Liebig University Giessen	Brownlee, M (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res, Bronx, NY 10467 USA.		Hammes, Hans-Peter/S-3719-2019					Ascher E, 2001, SURGERY, V130, P851, DOI 10.1067/msy.2001.117194; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; BITSCH R, 1991, ANN NUTR METAB, V35, P292, DOI 10.1159/000177659; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Hammes HP, 1997, DIABETOLOGIA, V40, P629, DOI 10.1007/s001250050726; Hammes HP, 1996, DIABETOLOGIA, V39, P251; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Kurose I, 1997, J CLIN INVEST, V99, P867, DOI 10.1172/JCI119251; LaSelva M, 1996, DIABETOLOGIA, V39, P1263; Loew D, 1996, INT J CLIN PHARM TH, V34, P47; LUKIENKO PI, 2000, B EXP BIOL MED, V9, P303; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pieper GM, 1997, J CARDIOVASC PHARM, V30, P528, DOI 10.1097/00005344-199710000-00019; ROSSETTI L, 1993, J CLIN INVEST, V92, P2963, DOI 10.1172/JCI116919; SAITO N, 1987, J NUTR SCI VITAMINOL, V33, P421, DOI 10.3177/jnsv.33.421; Schenk G, 1998, INT J BIOCHEM CELL B, V30, P1297, DOI 10.1016/S1357-2725(98)00095-8; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; Stepuro II, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1409; STEVENS VJ, 1977, J BIOL CHEM, V252, P2998; Stracke H, 2001, EXP CLIN ENDOCR DIAB, V109, P330, DOI 10.1055/s-2001-17399; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167	31	603	642	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					294	299		10.1038/nm834	http://dx.doi.org/10.1038/nm834			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12592403				2022-12-27	WOS:000181312300029
J	Economides, AN; Carpenter, LR; Rudge, JS; Wong, V; Koehler-Stec, EM; Hartnett, C; Pyles, EA; Xu, XB; Daly, TJ; Young, MR; Fandl, JP; Lee, F; Carver, S; McNnay, J; Bailey, K; Ramakanth, S; Hutabarat, R; Huang, TT; Radziejewski, C; Yancopoulos, GD; Stahl, N				Economides, AN; Carpenter, LR; Rudge, JS; Wong, V; Koehler-Stec, EM; Hartnett, C; Pyles, EA; Xu, XB; Daly, TJ; Young, MR; Fandl, JP; Lee, F; Carver, S; McNnay, J; Bailey, K; Ramakanth, S; Hutabarat, R; Huang, TT; Radziejewski, C; Yancopoulos, GD; Stahl, N			Cytokine traps: multi-component, high-affinity blockers of cytokine action	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; INTERLEUKIN-1 RECEPTOR ANTAGONIST; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODIES; IL-4; ALPHA; MODEL	Cytokines can initiate and perpetuate human diseases, and are among the best-validated of therapeutic targets. Cytokines can be blocked by the use of soluble receptors; however, the use of this approach for cytokines such as interleukin (IL)-1, IL-4, IL-6 and IL-13 that use multi-component receptor systems is limited because monomeric soluble receptors generally exhibit low affinity or function as agonists. We describe here a generally applicable method to create very high-affinity blockers called 'cytokine traps' consisting of fusions between the constant region of IgG and the extracellular domains of two distinct cytokine receptor components involved in binding the cytokine. Traps potently block cytokines in vitro and in vivo and represent a substantial advance in creating novel therapeutic candidates for cytokine-driven diseases.	Regeneron Pharmaceut Inc, Dept Biomol Sci, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Preclin Pharmacol, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Prot Chem Sci, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Prot Express Sci, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Preclin Mfg & Proc Dev, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Pharmacokinet, Tarrytown, NY 10591 USA; Regeneron Pharmaceut Inc, Dept Prot Biochem, Tarrytown, NY 10591 USA	Regeneron; Regeneron; Regeneron; Regeneron; Regeneron; Regeneron; Regeneron	Stahl, N (corresponding author), Regeneron Pharmaceut Inc, Dept Biomol Sci, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	neil.stahl@regeneron.com		Economides, Aris/0000-0002-6508-8942				BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; BECK JT, 1994, NEW ENGL J MED, V330, P602, DOI 10.1056/NEJM199403033300904; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; Bresnihan B, 2001, BIODRUGS, V15, P87, DOI 10.2165/00063030-200115020-00003; Campion GV, 1996, ARTHRITIS RHEUM, V39, P1092, DOI 10.1002/art.1780390704; Carpenter LR, 1999, ADV PROTEIN CHEM, V52, P109; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; Cohen S, 1999, ARTHRITIS RHEUM, V42, pS273; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; FOOTE J, 1995, P NATL ACAD SCI USA, V92, P1254, DOI 10.1073/pnas.92.5.1254; Goldenberg MM, 1999, CLIN THER, V21, P75, DOI 10.1016/S0149-2918(00)88269-7; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guler HP, 2001, ARTHRITIS RHEUM, V44, pS370; Gundel R, 1996, CLIN EXP ALLERGY, V26, P719; Haddad E, 2001, BLOOD, V97, P1590, DOI 10.1182/blood.V97.6.1590; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; JOOSTEN LAB, 1994, CLIN EXP IMMUNOL, V97, P204; Joosten LAB, 1996, ARTHRITIS RHEUM, V39, P797, DOI 10.1002/art.1780390513; Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399; LEGOUFFE E, 1994, CLIN EXP IMMUNOL, V98, P323; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Nuki George, 1997, Arthritis and Rheumatism, V40, pS224; Reimers JI, 1998, DAN MED BULL, V45, P157; Richard-Miceli C, 2001, BIODRUGS, V15, P251, DOI 10.2165/00063030-200115040-00005; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; van den Berg WB, 1998, SPRINGER SEMIN IMMUN, V20, P149, DOI 10.1007/BF00832004; van Deventer SJH, 1999, ANN RHEUM DIS, V58, P114; VANDENBERG WB, 1994, CLIN EXP IMMUNOL, V95, P237; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WOOLEY PH, 1993, ARTHRITIS RHEUM, V36, P1305, DOI 10.1002/art.1780360915	37	293	356	2	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					47	52		10.1038/nm811	http://dx.doi.org/10.1038/nm811			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12483208				2022-12-27	WOS:000180209900021
J	Orive, G; Hernandez, RM; Gascon, AR; Calafiore, R; Chang, TMS; De Vos, P; Hortelano, G; Hunkeler, D; Lacik, I; Shapiro, AMJ; Pedraz, JL				Orive, Gorka; Maria Hernandez, Rosa; Gascon, Alicia R.; Calafiore, Riccardo; Chang, Thomas M. S.; De Vos, Paul; Hortelano, Gonzalo; Hunkeler, David; Lacik, Igor; Shapiro, A. M. James; Luis Pedraz, Jose			Cell encapsulation: Promise and progress	NATURE MEDICINE			English	Article								In cell encapsulation, transplanted cells are protected from immune rejection by an artificial, semipermeable membrane, potentially allowing transplantation (allo-or xenotransplantation) without the need for immunosuppression. Yet, despite some promising results in animal studies, the field has not lived up to expectations, and clinical products based on encapsulated cell technology continue to elude the scientific community. This commentary discusses the reasons for this, summarizes recent progress in the field and outlines what is needed to bring this technology closer to clinical application.	[Orive, Gorka; Maria Hernandez, Rosa; Gascon, Alicia R.; Luis Pedraz, Jose] Univ Basque Country, Fac Pharm, Lab Pharm & Pharmaceut Technol, Vitoria, Spain; [Calafiore, Riccardo] Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy; [Chang, Thomas M. S.] McGill Univ, Fac Med, Artificial Cells & Organs Res Ctr, Montreal, PQ, Canada; [De Vos, Paul] Dept Pathol & Lab Med, Groningen, Netherlands; [Hortelano, Gonzalo] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Hortelano, Gonzalo] Canadian Blood Serv, Hamilton, ON, Canada; [Hunkeler, David] AQUA TECH Specialties SA, Geneva, Switzerland; [Lacik, Igor] Slovak Acad Sci, Inst Polymer, Dept Special Polymers & Biopolymers, Bratislava, Slovakia; [Shapiro, A. M. James] Univ Alberta, Clin Islet Transplant Program, Edmonton, AB, Canada	University of Basque Country; University of Perugia; McGill University; McMaster University; Canadian Blood Services; Slovak Academy of Sciences; University of Alberta	Pedraz, JL (corresponding author), Univ Basque Country, Fac Pharm, Lab Pharm & Pharmaceut Technol, Vitoria, Spain.	knppemuj@vc.ehu.es	de Vos, Paul/A-3170-2013; Hernandez, Rosa Maria/S-6332-2017; Hernández, Rosa/GRF-5998-2022; Pedraz, Jose Luis/AAR-1338-2021	Hernandez, Rosa Maria/0000-0002-3947-409X; ORIVE, GORKA/0000-0002-0773-300X; Lacik, Igor/0000-0001-6037-3747; PEDRAZ MUNOZ, JOSE LUIS/0000-0002-3938-2267; Rodriguez-Gascon, Alicia/0000-0002-3195-6385; de vos, paul/0000-0001-9618-2408				Aebischer P, 1999, NAT MED, V5, P852, DOI 10.1038/11271; Anilkumar AV, 2001, BIOTECHNOL BIOENG, V75, P581, DOI 10.1002/bit.10077; Bach FH, 1998, NATURE, V391, P326, DOI 10.1038/34766; Calafiore R, 1999, ANN NY ACAD SCI, V875, P219, DOI 10.1111/j.1749-6632.1999.tb08506.x; Calafiore R, 2001, ANN NY ACAD SCI, V944, P240; CHANG TMS, 1964, SCIENCE, V146, P524, DOI 10.1126/science.146.3643.524; Check E, 2002, NATURE, V419, P5, DOI 10.1038/419005b; Cirone P, 2002, HUM GENE THER, V13, P1157, DOI 10.1089/104303402320138943; de Vos P, 2002, TRENDS MOL MED, V8, P363, DOI 10.1016/S1471-4914(02)02381-X; de Vos P, 2003, BIOMATERIALS, V24, P305, DOI 10.1016/S0142-9612(02)00319-8; de Vos P, 2002, DIABETOLOGIA, V45, P159, DOI 10.1007/s00125-001-0729-x; Desai TA, 2002, EXPERT OPIN BIOL TH, V2, P633, DOI 10.1517/14712598.2.6.633; Dove A, 2002, NAT BIOTECHNOL, V20, P339, DOI 10.1038/nbt0402-339; Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299; Gunzburg WH, 2000, MOL MED TODAY, V6, P199, DOI 10.1016/S1357-4310(00)01708-1; Hasse C, 1997, LANCET, V350, P1296, DOI 10.1016/S0140-6736(05)62473-7; Hortelano G, 1996, BLOOD, V87, P5095, DOI 10.1182/blood.V87.12.5095.bloodjournal87125095; Hunkeler D, 2001, ANN NY ACAD SCI, V944, P456; Hunkeler D, 1999, NAT BIOTECHNOL, V17, P1045, DOI 10.1038/14989; Hunkeler D, ANN NY ACAD SCI, V944, P1; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; King A., J BIOMED MA IN PRESS; Lanza RP, 1996, NAT BIOTECHNOL, V14, P1107, DOI 10.1038/nbt0996-1107; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Lohr M, 2001, LANCET, V357, P1591, DOI 10.1016/S0140-6736(00)04749-8; Mares-Guia M., 2001, US Patent, Patent No. [6281341, 6,281,341]; Murphy FA, 1996, SCIENCE, V273, P746, DOI 10.1126/science.273.5276.746; Orive G, 2002, TRENDS BIOTECHNOL, V20, P382, DOI 10.1016/S0167-7799(02)02037-1; Pelegrin M, 1998, GENE THER, V5, P828, DOI 10.1038/sj.gt.3300632; Prakash S, 1996, NAT MED, V2, P883, DOI 10.1038/nm0896-883; Read TA, 2001, NAT BIOTECHNOL, V19, P29, DOI 10.1038/83471; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1; Strand BL, 2001, CELL TRANSPLANT, V10, P263, DOI 10.3727/000000001783986800; Sun YL, 1996, J CLIN INVEST, V98, P1417, DOI 10.1172/JCI118929; Thomas LL, 2002, FASEB J, V16, pA1238, DOI 10.1096/fj.01-0590fje; US Pharmacopeia and National Formulary (Rockville Maryland), 2002, US PHARMACOPEIA NATL, V1046, P2762; Wang T, 1997, NAT BIOTECHNOL, V15, P358, DOI 10.1038/nbt0497-358	38	463	511	1	104	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					104	107		10.1038/nm0103-104	http://dx.doi.org/10.1038/nm0103-104			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514721	Green Published			2022-12-27	WOS:000208640400003
J	Ito, H; Koefoed, M; Tiyapatanaputi, P; Gromov, K; Goater, JJ; Carmouche, J; Zhang, XP; Rubery, PT; Rabinowitz, J; Samulski, RJ; Nakamura, T; Soballe, K; O'Keefe, RJ; Boyce, BF; Schwarz, EM				Ito, H; Koefoed, M; Tiyapatanaputi, P; Gromov, K; Goater, JJ; Carmouche, J; Zhang, XP; Rubery, PT; Rabinowitz, J; Samulski, RJ; Nakamura, T; Soballe, K; O'Keefe, RJ; Boyce, BF; Schwarz, EM			Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy	NATURE MEDICINE			English	Article							DEBRIS-INDUCED OSTEOLYSIS; IN-VIVO; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR; REPAIR; BIOLOGY; CELL; REGENERATION; CARTILAGE	Structural allograft healing is limited because of a lack of vascularization and remodeling. To study this we developed a mouse model that recapitulates the clinical aspects of live autograft and processed allograft healing. Gene expression analyses showed that there is a substantial decrease in the genes encoding RANKL and VEGF during allograft healing. Loss-of-function studies showed that both factors are required for autograft healing. To determine whether addition of these signals could stimulate allograft vascularization and remodeling, we developed a new approach in which rAAV can be freeze-dried onto the cortical surface without losing infectivity. We show that combination rAAV-RANKL- and rAAV-VEGF-coated allografts show marked remodeling and vascularization, which leads to a new bone collar around the graft. In conclusion, we find that RANKL and VEGF are necessary and sufficient for efficient autograft remodeling and can be transferred using rAAV to revitalize structural allografts.	Univ Rochester, Ctr Musculoskeletal Res, Rochester, NY 14642 USA; Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto 6068507, Japan; Aarhus Univ Hosp, Dept Orthoped, DK-8000 Aarhus, Denmark; Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of Rochester; Kyoto University; Aarhus University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Schwarz, EM (corresponding author), Univ Rochester, Ctr Musculoskeletal Res, 601 Elmwood Ave,Box 665, Rochester, NY 14642 USA.	edward_schwarz@urmc.rochester.edu	Gromov, Kirill/AAP-3737-2020; Gromov, Kirill/AAM-2270-2020	Gromov, Kirill/0000-0002-8114-5193; Soballe, Kjeld/0000-0001-8872-9856	NHLBI NIH HHS [P01 HL066973, P01 HL051818, HL066973] Funding Source: Medline; NIAMS NIH HHS [R01 AR048681, R01 AR051469-01, R01 AR048149, AR43510, R01 AR043510, AR48149, AR48681, AR51469, R01 AR051469] Funding Source: Medline; NIEHS NIH HHS [P01 ES011854, ES011854] Funding Source: Medline; NIGMS NIH HHS [P01 GM059299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066973, P01HL051818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051469, R01AR043510, R01AR048681, R01AR048149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM059299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baltzer AWA, 2004, GENE THER, V11, P344, DOI 10.1038/sj.gt.3302195; BERREY BH, 1990, J BONE JOINT SURG AM, V72A, P825, DOI 10.2106/00004623-199072060-00005; Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632-200212010-00005; Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473; BOS GD, 1983, J BONE JOINT SURG AM, V65, P89, DOI 10.2106/00004623-198365010-00012; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; BURCHARDT H, 1987, ORTHOP CLIN N AM, V18, P187; Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192; Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623-200112000-00004; Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559; Deckers M, 2001, LAB INVEST, V81, P5, DOI 10.1038/labinvest.3780207; Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7; Enneking WE, 2001, J BONE JOINT SURG AM, V83A, P971, DOI 10.2106/00004623-200107000-00001; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS160; Gamradt SC, 2004, ANN BIOMED ENG, V32, P136, DOI 10.1023/B:ABME.0000007798.78548.b8; Garbuz DS, 1998, ORTHOP CLIN N AM, V29, P199, DOI 10.1016/S0030-5898(05)70318-7; Goater J, 2000, J RHEUMATOL, V27, P983; Goldberg V M, 1993, Semin Arthroplasty, V4, P58; Gould SE, 2000, J ORTHOP RES, V18, P920, DOI 10.1002/jor.1100180611; Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200; Hidaka C, 2003, J ORTHOPAED RES, V21, P573, DOI 10.1016/S0736-0266(02)00264-4; Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lieberman JR, 2002, MOL THER, V6, P141, DOI 10.1006/mthe.2000.0663; LORD CF, 1988, J BONE JOINT SURG AM, V70A, P369, DOI 10.2106/00004623-198870030-00008; Musatov S, 2004, P NATL ACAD SCI USA, V101, P3627, DOI 10.1073/pnas.0308289101; Musgrave DS, 2000, CLIN ORTHOP RELAT R, P290; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Rabinowitz JE, 2000, VIROLOGY, V278, P301, DOI 10.1006/viro.2000.0707; Sandhu HS, 2003, SPINE, V28, pS85, DOI 10.1097/00007632-200308011-00014; Schwarz EM, 2000, CLIN ORTHOP RELAT R, pS31, DOI 10.1097/00003086-200010001-00005; Stevenson S, 1997, J BONE JOINT SURG AM, V79A, P1; Tiyapatanaputi P, 2004, J ORTHOP RES, V22, P1254, DOI 10.1016/j.orthres.2004.03.017; Ulrich-Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623-200208000-00017; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Wu D, 2003, J CELL BIOCHEM, V88, P467, DOI 10.1002/jcb.10332; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Zhang R, 2003, J BIOL CHEM, V278, P51267, DOI 10.1074/jbc.M310678200; Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681	40	218	226	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					291	297		10.1038/nm1190	http://dx.doi.org/10.1038/nm1190			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711561	Green Accepted, Green Submitted			2022-12-27	WOS:000227541300024
J	Frey, N; Barrientos, T; Shelton, JM; Frank, D; Rutten, H; Gehring, D; Kuhn, C; Lutz, M; Rothermel, B; Bassel-Duby, R; Richardson, JA; Katus, HA; Hill, JA; Olson, EN				Frey, N; Barrientos, T; Shelton, JM; Frank, D; Rutten, H; Gehring, D; Kuhn, C; Lutz, M; Rothermel, B; Bassel-Duby, R; Richardson, JA; Katus, HA; Hill, JA; Olson, EN			Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress	NATURE MEDICINE			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; MUSCLE LIM PROTEIN; SKELETAL-MUSCLE; CARDIAC-HYPERTROPHY; DILATED CARDIOMYOPATHY; TARGETED INHIBITION; Z-DISC; GENE-EXPRESSION; FILAMIN-BINDING; ACTININ-BINDING	Signaling by the calcium-dependent phosphatase calcineurin profoundly influences the growth and gene expression of cardiac and skeletal muscle. Calcineurin binds to calsarcins, a family of muscle-specific proteins of the sarcomeric Z-disc, a focal point in the pathogenesis of human cardiomyopathies. We show that calsarcin-1 negatively modulates the functions of calcineurin, such that calcineurin signaling was enhanced in striated muscles of mice that do not express calsarcin-1. As a consequence of inappropriate calcineurin activation, mice with a null mutation in calsarcin-1 showed an excess of slow skeletal muscle fibers. The absence of calsarcin-1 also activated a hypertrophic gene program, despite the absence of hypertrophy, and enhanced the cardiac growth response to pressure overload. In contrast, cardiac adaptation to other hypertrophic stimuli, such as chronic catecholamine stimulation or exercise, was not affected. These findings show important roles for calsarcins as modulators of calcineurin signaling and the transmission of a specific subset of stress signals leading to cardiac remodeling in vivo.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Heidelberg Univ, Dept Internal Med 2, D-69120 Heidelberg, Germany; Aventis Pharma GmbH, DG Cardiovasc, D-65926 Frankfurt, Germany; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Donald W Reynolds Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Ruprecht Karls University Heidelberg; Sanofi-Aventis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Frey, N (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	norbert.frey@med.uni-heidelberg.de; eric.olson@utsouthwestern.edu	Frey, Norbert/M-7749-2019; Frey, Norbert/A-9695-2010	Frey, Norbert/0000-0001-7611-378X; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072016] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL072016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Arimura T, 2004, J BIOL CHEM, V279, P6746, DOI 10.1074/jbc.M311849200; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Faulkner G, 2000, J BIOL CHEM, V275, P41234, DOI 10.1074/jbc.M007493200; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Frey N, 2002, J BIOL CHEM, V277, P13998, DOI 10.1074/jbc.M200712200; Frey N, 2000, P NATL ACAD SCI USA, V97, P14632, DOI 10.1073/pnas.260501097; Furukawa T, 2001, J MOL BIOL, V313, P775, DOI 10.1006/jmbi.2001.5053; Heineke J, 2003, CIRCULATION, V107, P1424, DOI 10.1161/01.CIR.0000055319.94801.FC; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hill JA, 2000, CIRCULATION, V101, P2863, DOI 10.1161/01.CIR.101.24.2863; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; Kovacic-Milivojevic B, 2001, MOL BIOL CELL, V12, P2290, DOI 10.1091/mbc.12.8.2290; Lim HW, 2000, CIRCULATION, V101, P2431, DOI 10.1161/01.CIR.101.20.2431; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; Mohapatra B, 2003, MOL GENET METAB, V80, P207, DOI 10.1016/S1096-7192(03)00142-2; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Parsons SA, 2003, MOL CELL BIOL, V23, P4331, DOI 10.1128/MCB.23.12.4331-4343.2003; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; Sah R, 2002, CIRCULATION, V105, P1850, DOI 10.1161/01.CIR.0000014211.47830.4D; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; Schiaffino S, 2002, TRENDS PHARMACOL SCI, V23, P569, DOI 10.1016/S0165-6147(02)02111-9; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Sussman MA, 1999, AM J PATHOL, V155, P2101, DOI 10.1016/S0002-9440(10)65528-9; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Takada F, 2001, P NATL ACAD SCI USA, V98, P1595, DOI 10.1073/pnas.041609698; Vatta M, 2003, J AM COLL CARDIOL, V42, P2014, DOI 10.1016/j.jacc.2003.10.021; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Wang YL, 2002, AM J PHYSIOL-HEART C, V283, pH533, DOI 10.1152/ajpheart.00002.2002; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	47	168	181	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1336	1343		10.1038/nm1132	http://dx.doi.org/10.1038/nm1132			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15543153				2022-12-27	WOS:000225500900027
J	Voura, EB; Jaiswal, JK; Mattoussi, H; Simon, SM				Voura, EB; Jaiswal, JK; Mattoussi, H; Simon, SM			Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy	NATURE MEDICINE			English	Article							GENE-EXPRESSION; MELANOMA-CELLS; IN-VIVO; MIGRATION; BEHAVIOR; GROWTH; MODEL	Metastasis is an impediment to the development of effective cancer therapies. Our understanding of metastasis is limited by our inability to follow this process in vivo. Fluorescence microscopy offers the potential to follow cells at high resolution in living animals. Semiconductor nanocrystals, quantum dots (QDs), offer considerable advantages over organic fluorophores for this purpose. We used QDs and emission spectrum scanning multiphoton microscopy to develop a means to study extravasation in vivo. Although QD labeling shows no deleterious effects on cultured cells, concern over their potential toxicity in vivo has caused resistance toward their application to such studies. To test if effects of QD labeling emerge in vivo, tumor cells labeled with QDs were intravenously injected into mice and followed as they extravasated into lung tissue. The behavior of QD-labeled tumor cells in vivo was indistinguishable from that of unlabeled cells. QDs and spectral imaging allowed the simultaneous identification of five different populations of cells using multiphoton laser excitation. Besides establishing the safety of QDs for in vivo studies, our approach permits the study of multicellular interactions in vivo.	Rockefeller Univ, New York, NY 10021 USA; USN, Res Lab, Div Opt Sci, Washington, DC 20375 USA	Rockefeller University; United States Department of Defense; United States Navy; Naval Research Laboratory	Simon, SM (corresponding author), Rockefeller Univ, Box 304,1230 York Ave, New York, NY 10021 USA.	simon@rockefeller.edu	Jaiswal, Jyoti/AAD-5386-2020; Jaiswal, Jyoti/ABI-1666-2020; Jaiswal, JK/M-5891-2013	Jaiswal, Jyoti/0000-0002-5992-5185; Jaiswal, JK/0000-0002-5992-5185; Simon, Sanford/0000-0002-8615-4224				Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Ballou B, 2004, BIOCONJUGATE CHEM, V15, P79, DOI 10.1021/bc034153y; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3; Clark PR, 1999, CURR OPIN MOL THER, V1, P158; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334; Dickinson ME, 2003, J BIOMED OPT, V8, P329, DOI 10.1117/1.1583734; Dove A, 2002, NAT MED, V8, P95, DOI 10.1038/nm0202-95; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FIDLER IJ, 1975, CANCER RES, V35, P218; FIDLER IJ, 1984, 4 INT WORKSH IMM DEF, P328; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt767; JAISWAL JK, IN PRESS TRENDS CELL; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Lewalle JM, 1997, EXP CELL RES, V237, P347, DOI 10.1006/excr.1997.3799; Lim DS, 2003, CHEMOTHERAPY, V49, P146, DOI 10.1159/000070621; Lim Yong Taik, 2003, Mol Imaging, V2, P50, DOI 10.1162/153535003765276282; Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y; Mattoussi H., 2002, OPTICAL BIOSENSORS P, P537; Naumov GN, 2002, CANCER RES, V62, P2162; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Voura EB, 2001, CLIN EXP METASTAS, V18, P527, DOI 10.1023/A:1011884807746; Wang WG, 2002, CANCER RES, V62, P6278; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976; Zuhorn IS, 2002, J MEMBRANE BIOL, V189, P167, DOI 10.1007/s00232-002-1015-7	30	551	591	1	120	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					993	998		10.1038/nm1096	http://dx.doi.org/10.1038/nm1096			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15334072				2022-12-27	WOS:000223658400038
J	Zhou, XY; Shibusawa, N; Naik, K; Porras, D; Temple, K; Ou, HS; Kaihara, K; Roe, MW; Brady, MJ; Wondisford, FE				Zhou, XY; Shibusawa, N; Naik, K; Porras, D; Temple, K; Ou, HS; Kaihara, K; Roe, MW; Brady, MJ; Wondisford, FE			Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein	NATURE MEDICINE			English	Article							GENE-TRANSCRIPTION; COACTIVATOR PGC-1; RESISTANCE; RECEPTOR; GROWTH; MICE; CBP	Hepatic gluconeogenesis is essential for maintenance of normal blood glucose concentrations and is regulated by opposing stimulatory (cyclic adenosine monophosphate, cAMP) and inhibitory (insulin) signaling pathways(1). The cAMP signaling pathway leads to phosphorylation of cAMP response element-binding (CREB) protein, resulting in recruitment of the coactivators CREB-binding protein (CBP) and p300 and subsequent activation of gluconeogenesis(2-5). Insulin signaling leads to phosphorylation of CBP at serine 436, a residue near its CREB-interacting domain, but it is unknown whether this event modulates cAMP signaling(6). Here, we show in vitro and in 'knock-in' mice that a mutant CBP (S436A) is aberrantly recruited to CREB protein, resulting in inappropriate activation of gluconeogenesis in the fed state and glucose intolerance resulting from increased hepatic glucose production. We propose that insulin signaling may directly regulate many cAMP signaling pathways at the transcriptional level by controlling CBP recruitment.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Div Biol Sci, Comm Mol Metab & Nutr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Wondisford, FE (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	fwondisf@medicine.bsd.uchicago.edu		Kaihara, Kelly/0000-0002-1277-6418	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R01DK063349] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60-DK20595, R01 DK-63349] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boileau P, 2002, DIABETES, V51, pS343, DOI 10.2337/diabetes.51.2007.S343; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Crosson SM, 2003, J CLIN INVEST, V111, P1423, DOI 10.1172/JCI200317975; Fisher SJ, 2003, J CLIN INVEST, V111, P463, DOI 10.1172/JCI16426; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Greenberg CC, 2003, J BIOL CHEM, V278, P30835, DOI 10.1074/jbc.M303846200; Hall Robert K., 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P119; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Jiang GQ, 2003, AM J PHYSIOL-ENDOC M, V284, pE671, DOI 10.1152/ajpendo.00492.2002; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LIU JS, 1991, J BIOL CHEM, V266, P19095; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; ROE MW, 1994, AM J PHYSIOL, V266, pE852, DOI 10.1152/ajpendo.1994.266.6.E852; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zanger K, 2001, MOL CELL, V7, P551, DOI 10.1016/S1097-2765(01)00202-7	20	112	114	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					633	637		10.1038/nm1050	http://dx.doi.org/10.1038/nm1050			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15146178				2022-12-27	WOS:000221759600029
J	Belting, M; Dorrell, MI; Sandgren, S; Aguilar, E; Ahamed, J; Dorfleutner, A; Carmeliet, P; Mueller, BM; Friedlander, M; Ruf, W				Belting, M; Dorrell, MI; Sandgren, S; Aguilar, E; Ahamed, J; Dorfleutner, A; Carmeliet, P; Mueller, BM; Friedlander, M; Ruf, W			Regulation of angiogenesis by tissue factor cytoplasmic domain signaling	NATURE MEDICINE			English	Article							PROTEASE-ACTIVATED RECEPTORS; ENDOTHELIAL-CELLS; THROMBIN RECEPTOR; GROWTH-FACTOR; FACTOR VIIA; IN-VITRO; INHIBITORS; DISEASE; MICE; PDGF	Hemostasis initiates angiogenesis-dependent wound healing, and thrombosis is frequently associated with advanced cancer. Although activation of coagulation generates potent regulators of angiogenesis, little is known about how this pathway supports angiogenesis in vivo. Here we show that the tissue factor (TF)-VIIa protease complex, independent of triggering coagulation, can promote tumor and developmental angiogenesis through protease-activated receptor-2 (PAR-2) signaling. In this context, the TF cytoplasmic domain negatively regulates PAR-2 signaling. Mice from which the TF cytoplasmic domain has been deleted (TFDeltaCT mice) show enhanced PAR-2-dependent angiogenesis, in synergy with platelet-derived growth factor BB (PDGF-BB). Ocular tissue from diabetic patients shows PAR-2 colocalization with phosphorylated TF specifically on neovasculature, suggesting that phosphorylation of the TF cytoplasmic domain releases its negative regulatory control of PAR-2 signaling in angiogenesis. Targeting the TF-VIIa signaling pathway may thus enhance the efficacy of angiostatic treatments for cancer and neovascular eye diseases.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Lund Univ, Biomed Ctr, SE-22184 Lund, Sweden; Katholieke Univ Leuven VIB, B-3000 Leuven, Belgium; La Jolla Inst Mol Med, Div Canc Biol, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Lund University; Flanders Institute for Biotechnology (VIB); KU Leuven	Friedlander, M (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	friedlan@scripps.edu; ruf@scripps.edu	Carmeliet, Peter/AAQ-5140-2020; Dorfleutner, Andrea/AAG-5504-2021; Dorrell, Michael I/U-8648-2019	Carmeliet, Peter/0000-0001-7961-1821; Dorfleutner, Andrea/0000-0003-4406-2986; Dorrell, Michael I/0000-0002-7258-6288; Belting, Mattias/0000-0003-1585-5434	NATIONAL CANCER INSTITUTE [R01CA085405] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011254] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL060742] Funding Source: NIH RePORTER; NCI NIH HHS [CA-85405] Funding Source: Medline; NEI NIH HHS [EY-11254] Funding Source: Medline; NHLBI NIH HHS [HL-60742, CHL-16411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663; AHAMED J, J BIOL CHEM; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Buschmann I, 2003, MICROCIRCULATION, V10, P371, DOI 10.1038/sj.mn.7800199; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Dorfleutner A, 2003, BLOOD, V102, P3998, DOI 10.1182/blood-2003-04-1149; Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hembrough TA, 2003, CANCER RES, V63, P2997; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Melis E, 2001, BIOCHEM BIOPH RES CO, V286, P580, DOI 10.1006/bbrc.2001.5425; Milia AF, 2002, CIRC RES, V91, P346, DOI 10.1161/01.RES.0000031958.92781.9E; Mody RS, 1997, BIOCHEMISTRY-US, V36, P7869, DOI 10.1021/bi9701235; NICOSIA RF, 1990, LAB INVEST, V63, P115; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Parat MO, 2002, BIOCHEM J, V361, P681, DOI 10.1042/0264-6021:3610681; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Ruf W, 2003, J THROMB HAEMOST, V1, P1495, DOI 10.1046/j.1538-7836.2003.00300.x; Siegbahn A, 2000, BLOOD, V96, P3452, DOI 10.1182/blood.V96.10.3452.h8003452_3452_3458; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621; ZIONCHECK TF, 1992, J BIOL CHEM, V267, P3561	44	292	306	0	26	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2004	10	5					502	509		10.1038/nm1037	http://dx.doi.org/10.1038/nm1037			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15098027	Green Published			2022-12-27	WOS:000221242400028
J	Evans, RM; Barish, GD; Wang, YX				Evans, RM; Barish, GD; Wang, YX			PPARs and the complex journey to obesity	NATURE MEDICINE			English	Review							ACTIVATED-RECEPTOR-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; MITOCHONDRIAL UNCOUPLING PROTEIN; FAMILIAL PARTIAL LIPODYSTROPHY; REVERSES INSULIN-RESISTANCE; PEROXISOMAL BETA-OXIDATION; BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; METABOLIC SYNDROME; MICE LACKING	Obesity and the related disorders of dyslipidemia and diabetes (components of syndrome X) have become global health epidemics. Over the past decade, the elucidation of key regulators of energy balance and insulin signaling have revolutionized our understanding of fat and sugar metabolism and their intimate link. The three 'lipid-sensing' peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-gamma and PPAR-delta) exemplify this connection, regulating diverse aspects of lipid and glucose homeostasis, and serving as bona fide therapeutic targets. With molecular underpinnings now in place, new pharmacologic approaches to metabolic disease and new questions are emerging.	Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Med, Div Endocrinol & Metab, San Francisco, CA 94121 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Francisco	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA.	evans@salk.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chou CJ, 2002, J BIOL CHEM, V277, P24484, DOI 10.1074/jbc.M202449200; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Drazen DL, 2003, CURR OPIN CLIN NUTR, V6, P621, DOI 10.1097/00075197-200311000-00003; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Guerra C, 2001, J CLIN INVEST, V108, P1205, DOI 10.1172/JCI200113103; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim H, 2003, DIABETES, V52, P1770, DOI 10.2337/diabetes.52.7.1770; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kim JK, 2003, DIABETES, V52, P1311, DOI 10.2337/diabetes.52.6.1311; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Koutnikova H, 2003, P NATL ACAD SCI USA, V100, P14457, DOI 10.1073/pnas.2336090100; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Levine JA, 1999, SCIENCE, V283, P212, DOI 10.1126/science.283.5399.212; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rangwala SM, 2003, DEV CELL, V5, P657, DOI 10.1016/S1534-5807(03)00274-0; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; Ricote M, 2004, ARTERIOSCL THROM VAS, V24, P230, DOI 10.1161/01.ATV.0000103951.67680.B1; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Savage DB, 2003, DIABETES, V52, P910, DOI 10.2337/diabetes.52.4.910; Seeley RJ, 2003, NAT REV NEUROSCI, V4, P901, DOI 10.1038/nrn1245; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; STUNKARD AJ, 1986, JAMA-J AM MED ASSOC, V256, P51, DOI 10.1001/jama.256.1.51; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	104	1220	1288	2	133	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2004	10	4					355	361		10.1038/nm1025	http://dx.doi.org/10.1038/nm1025			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15057233				2022-12-27	WOS:000220587000024
J	Edinger, M; Hoffmann, P; Ermann, J; Drago, K; Fathman, CG; Strober, S; Negrin, RS				Edinger, M; Hoffmann, P; Ermann, J; Drago, K; Fathman, CG; Strober, S; Negrin, RS			CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation	NATURE MEDICINE			English	Article							IN-VITRO; LEUKEMIA; ACTIVATION; INDUCTION; MECHANISM; DEPLETION	Mature donor T cells cause graft-versus-host disease (GVHD), but they are also the main mediators of the beneficial graft-versus-tumor (GVT) activity of allogeneic bone marrow transplantation. Suppression of GVHD with maintenance of GVT activity is a desirable outcome for clinical transplantation. We have previously shown that donor-derived CD4(+)CD25(+) regulatory T cells inhibit lethal GVHD after allogeneic bone marrow transplantation across major histocompatibility complex (MHC) class I and II barriers in mice. Here we demonstrate that in host mice with leukemia and lymphoma, CD4(+)CD25(+) regulatory T cells suppress the early expansion of alloreactive donor T cells, their interleukin-2-receptor (IL-2R) alpha-chain expression and their capacity to induce GVHD without abrogating their GVT effector function, mediated primarily by the perforin lysis pathway. Thus, CD4(+)CD25(+) T cells are potent regulatory cells that can separate GVHD from GVT activity mediated by conventional donor T cells.	Stanford Univ, Sch Med, Dept Med, Div Bone Marrow Transplantat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; Univ Hosp Regensburg, Dept Hematol & Oncol, D-93053 Regensburg, Germany	Stanford University; Stanford University; University of Regensburg	Negrin, RS (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Bone Marrow Transplantat, 300 Pasteur Dr, Stanford, CA 94305 USA.	negrs@stanford.edu	Ermann, Joerg/ABE-4495-2021	Ermann, Joerg/0000-0003-3836-9404; Edinger, Matthias/0000-0003-2889-2533	NCI NIH HHS [CA92225, R01S CA8006, P01-CA49605, CA65237] Funding Source: Medline; NHLBI NIH HHS [HL57443, HL58520] Funding Source: Medline; NIAID NIH HHS [AI49903] Funding Source: Medline; NIDDK NIH HHS [DK61925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092225, R01CA065237, P01CA049605] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK061925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ailles L, 2002, MOL THER, V6, P615, DOI 10.1006/mthe.2002.0720; Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008; Annunziato F, 2002, J EXP MED, V196, P379, DOI 10.1084/jem.20020110; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Costa GL, 2001, J IMMUNOL, V167, P2379, DOI 10.4049/jimmunol.167.4.2379; Curtis RE, 1999, BLOOD, V94, P2208; Dieckmann D, 2002, J EXP MED, V196, P247, DOI 10.1084/jem.20020642; Edinger M, 2003, BLOOD, V101, P640, DOI 10.1182/blood-2002-06-1751; Edinger Matthias, 1999, Neoplasia (New York), V1, P303, DOI 10.1038/sj.neo.7900048; Ermann J, 2001, J IMMUNOL, V167, P4271, DOI 10.4049/jimmunol.167.8.4271; FERRARA J, 1997, GRAFT HOST DIS; Ferrara J L, 1999, Biol Blood Marrow Transplant, V5, P347, DOI 10.1016/S1083-8791(99)70011-X; Field EH, 2001, IMMUNOL REV, V182, P99, DOI 10.1034/j.1600-065X.2001.1820108.x; HAKIM FT, 1997, GRAFT VS HOST DIS, P257; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; HOROWITZ MM, 1990, BLOOD, V75, P555; Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Krenger W, 1997, TRANSPLANTATION, V64, P553, DOI 10.1097/00007890-199708270-00001; MARTIN PJ, 1985, BLOOD, V66, P664; Molldrem JJ, 2000, NAT MED, V6, P1018, DOI 10.1038/79526; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Murakami M, 2002, P NATL ACAD SCI USA, V99, P8832, DOI 10.1073/pnas.132254399; Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Schmaltz C, 2001, BLOOD, V97, P2886, DOI 10.1182/blood.V97.9.2886; Shevach EM, 1998, CIBA F SYMP, V215, P200; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; SIADAK M, 1994, BLOOD REV, V8, P154, DOI 10.1016/0268-960X(94)90076-T; SPRENT J, 1986, J EXP MED, V163, P998, DOI 10.1084/jem.163.4.998; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Truitt R L, 1995, Biol Blood Marrow Transplant, V1, P61; WARNKE RA, 1979, J IMMUNOL, V123, P1181; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; Zeng DF, 2002, BLOOD, V99, P1449, DOI 10.1182/blood.V99.4.1449	44	991	1033	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2003	9	9					1144	1150		10.1038/nm915	http://dx.doi.org/10.1038/nm915			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925844				2022-12-27	WOS:000185061600026
J	Towers, GJ; Hatziioannou, T; Cowan, S; Goff, SP; Luban, J; Bieniasz, PD				Towers, GJ; Hatziioannou, T; Cowan, S; Goff, SP; Luban, J; Bieniasz, PD			Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLOSPORINE-A; RETROVIRUS RESTRICTION; REVERSE TRANSCRIPTION; SIMIAN CELLS; REPLICATION; PROTEIN; BLOCK; GENE; INFECTIVITY	Many mammalian species express restriction factors that confer host resistance to retroviral infection. Here we show that HIV-1 sensitivity to restriction factors is modulated by cyclophilin A (CypA), a host cell protein that binds the HIV-1 capsid protein (CA). In certain nonhuman primate cells, the CA-CypA interaction is essential for restriction: HIV-1 infectivity is increased >100-fold by cyclosporin A (CsA), a competitive inhibitor of the interaction, or by an HIV-1 CA mutation that disrupts CypA binding. Conversely, disruption of CA-CypA interaction in human cells reveals that CypA protects HIV-1 from the Ref-1 restriction factor. These findings suggest that HIV-1 has co-opted a host cell protein to counteract restriction factors expressed by human cells and that this adaptation can confer sensitivity to restriction in unnatural hosts. Manipulation of HIV-1 CA recognition by restriction factors promises to advance animal models and new therapeutic strategies for HIV-1 and AIDS.	Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Rockefeller Univ, New York, NY 10016 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; UCL, Windeyer Inst, Dept Immunol & Mol Pathol, Wohl Virion Ctr, London W1T 4JF, England; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Rockefeller University; Columbia University; University of London; University College London; Columbia University; Howard Hughes Medical Institute; Columbia University	Bieniasz, PD (corresponding author), Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	pbienias@adarc.org	Goff, Stephen P/K-6337-2014; Towers, Greg J/H-8892-2012	Goff, Stephen P/0000-0003-0693-5547; Towers, Gregory/0000-0002-7707-0264; Luban, Jeremy/0000-0001-5650-4054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036199, R01AI050111] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI36199, R01AI50111, R01 AI036199] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; Besnier C, 2002, P NATL ACAD SCI USA, V99, P11920, DOI 10.1073/pnas.172384599; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; Bukovsky AA, 1997, P NATL ACAD SCI USA, V94, P10943, DOI 10.1073/pnas.94.20.10943; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499; DESGROSEILLERS L, 1983, J VIROL, V48, P685, DOI 10.1128/JVI.48.3.685-696.1983; Dorfman T, 1996, J VIROL, V70, P5751, DOI 10.1128/JVI.70.9.5751-5757.1996; Franke EK, 1996, VIROLOGY, V222, P279, DOI 10.1006/viro.1996.0421; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Goff SP, 1996, CELL, V86, P691, DOI 10.1016/S0092-8674(00)80141-5; Hatziioannou T, 2003, EMBO J, V22, P385, DOI 10.1093/emboj/cdg042; Kootstra NA, 2003, P NATL ACAD SCI USA, V100, P1298, DOI 10.1073/pnas.0337541100; Kozak CA, 1996, VIROLOGY, V225, P300, DOI 10.1006/viro.1996.0604; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Munk C, 2002, P NATL ACAD SCI USA, V99, P13843, DOI 10.1073/pnas.212400099; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; SHIBATA R, 1995, J GEN VIROL, V76, P2723, DOI 10.1099/0022-1317-76-11-2723; Stoye JP, 2002, P NATL ACAD SCI USA, V99, P11549, DOI 10.1073/pnas.192449399; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Towers G, 2002, J VIROL, V76, P2548, DOI 10.1128/JVI.76.5.2548-2550.2002; Towers G, 2000, P NATL ACAD SCI USA, V97, P12295, DOI 10.1073/pnas.200286297; Wiegers K, 2002, VIROLOGY, V294, P289, DOI 10.1006/viro.2001.1347; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051	27	315	326	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1138	1143		10.1038/nm910	http://dx.doi.org/10.1038/nm910			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12897779				2022-12-27	WOS:000185061600025
J	Deane, R; Yan, SD; Submamaryan, RK; LaRue, B; Jovanovic, S; Hogg, E; Welch, D; Manness, L; Lin, C; Yu, J; Zhu, H; Ghiso, J; Frangione, B; Stern, A; Schmidt, AM; Armstrong, DL; Arnold, B; Liliensiek, B; Nawroth, P; Hofman, F; Kindy, M; Stern, D; Zlokovic, B				Deane, R; Yan, SD; Submamaryan, RK; LaRue, B; Jovanovic, S; Hogg, E; Welch, D; Manness, L; Lin, C; Yu, J; Zhu, H; Ghiso, J; Frangione, B; Stern, A; Schmidt, AM; Armstrong, DL; Arnold, B; Liliensiek, B; Nawroth, P; Hofman, F; Kindy, M; Stern, D; Zlokovic, B			RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; TRANSGENIC MICE; MOUSE MODEL; PRECURSOR PROTEIN; SQUIRREL-MONKEY; IN-VIVO; RECEPTOR; CLEARANCE; FLOW	Amyloid-beta peptide (Abeta) interacts with the vasculature to influence Abeta levels in the brain and cerebral blood flow, providing a means of amplifying the Abeta-induced cellular stress underlying neuronal dysfunction and dementia. Systemic Abeta infusion and studies in genetically manipulated mice show that Abeta interaction with receptor for advanced glycation end products (RAGE)-bearing cells in the vessel wall results in transport of Abeta across the blood-brain barrier (BBB) and expression of proinflammatory cytokines and endothelin-1 (ET-1), the latter mediating Abeta-induced vasoconstriction. Inhibition of RAGE-ligand interaction suppresses accumulation of Abeta in brain parenchyma in a mouse transgenic model. These findings suggest that vascular RAGE is a target for inhibiting pathogenic consequences of Abeta-vascular interactions, including development of cerebral amyloidosis.	Univ Rochester, Med Ctr, Dept Neurosurg, Frank P Smith Labs Neurosurg, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Aging & Dev Biol, Div Neurovasc Biol, Rochester, NY 14642 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Univ So Calif, Sch Med, Dept Neurosurg, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ Kentucky, Sch Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; NYU Med Ctr, Dept Pathol, New York, NY 10016 USA; Heidelberg Univ, Dept Internal Med, D-69117 Heidelberg, Germany; Heidelberg Univ, Inst Canc Res, D-69117 Heidelberg, Germany; Med Coll Georgia, Deans Off, Augusta, GA 30912 USA	University of Rochester; University of Rochester; Columbia University; Columbia University; University of Southern California; University of Southern California; University of Kentucky; New York University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University System of Georgia; Augusta University	Zlokovic, B (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, Frank P Smith Labs Neurosurg, Rochester, NY 14642 USA.	Berislav_Zlokovic@urmc.rochester.edu		Armstrong, Don/0000-0002-4904-638X	NIA NIH HHS [AG16223] Funding Source: Medline; NINDS NIH HHS [NS34467] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034467, R01NS034467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG016223] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bading JR, 2002, J DRUG TARGET, V10, P359, DOI 10.1080/10611860290031831; Carro E, 2002, NAT MED, V8, P1390, DOI 10.1038/nm793; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; DEMATTOS RB, 2003, ABETA METABOLISM ALZ, P123; ESTRADA C, 1995, J CEREBR BLOOD F MET, V15, P920, DOI 10.1038/jcbfm.1995.117; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; Ghilardi JR, 1996, NEUROREPORT, V7, P2607, DOI 10.1097/00001756-199611040-00040; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iadecola C, 1999, NAT NEUROSCI, V2, P157, DOI 10.1038/5715; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Khalil Z, 1996, BRAIN RES, V736, P206; Mackic JB, 2002, VASC PHARMACOL, V38, P303, DOI 10.1016/S1537-1891(02)00198-2; Mackic JB, 1998, J NEUROCHEM, V70, P210; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; Maeda K, 2000, J CEREBR BLOOD F MET, V20, P10, DOI 10.1097/00004647-200001000-00003; MANESS LM, 1994, LIFE SCI, V55, P1643, DOI 10.1016/0024-3205(94)00331-9; Martel CL, 1996, NEUROSCI LETT, V206, P157, DOI 10.1016/S0304-3940(96)12462-9; Martel CL, 1997, J NEUROCHEM, V69, P1995; Matsuoka Y, 2003, J NEUROSCI, V23, P29; Monro OR, 2002, NEUROBIOL AGING, V23, P405, DOI 10.1016/S0197-4580(01)00317-7; Niwa K, 2002, NEUROBIOL DIS, V9, P61, DOI 10.1006/nbdi.2001.0460; Niwa K, 2000, P NATL ACAD SCI USA, V97, P9735, DOI 10.1073/pnas.97.17.9735; Paris D, 2000, NEUROBIOL AGING, V21, P183, DOI 10.1016/S0197-4580(99)00111-6; Poduslo JF, 1999, NEUROBIOL DIS, V6, P190, DOI 10.1006/nbdi.1999.0238; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; TUREEN J, 1995, J CLIN INVEST, V95, P1086, DOI 10.1172/JCI117755; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; Wengenack TM, 2000, NAT BIOTECHNOL, V18, P868, DOI 10.1038/78482; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yan SD, 2000, NAT MED, V6, P643, DOI 10.1038/76216; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Zlokovic BV, 2000, NAT MED, V6, P718, DOI 10.1038/77397; ZLOKOVIC BV, 1993, BIOCHEM BIOPH RES CO, V197, P1034, DOI 10.1006/bbrc.1993.2582; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	45	1068	1151	1	102	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					907	913		10.1038/nm890	http://dx.doi.org/10.1038/nm890			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808450				2022-12-27	WOS:000183979300032
J	Chen, LW; Egan, L; Li, ZW; Greten, FR; Kagnoff, MF; Karin, M				Chen, LW; Egan, L; Li, ZW; Greten, FR; Kagnoff, MF; Karin, M			The two faces of IKK and NF-kappa B inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR; MICE LACKING; ACTIVATION; KINASE; ALPHA; SEPSIS; APOPTOSIS; RECEPTOR; DISEASE; SUBUNIT	We studied the role of NF-kappaB in acute inflammation caused by gut ischemia-reperfusion through selective ablation of IkappaB kinase (IKK)-beta, the catalytic subunit of IKK that is essential for NF-kappaB activation. Ablation of IKK-beta in enterocytes prevented the systemic inflammatory response, which culminates in multiple organ dysfunction syndrome (MODS) that is normally triggered by gut ischemia-reperfusion. IKK-beta removal from enterocytes, however, also resulted in severe apoptotic damage to the reperfused intestinal mucosa. These results show the dual function of the NF-kappaB system, which is responsible for both tissue protection and systemic inflammation, and underscore the caution that should be exerted in using NF-kappaB and IKK inhibitors.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Med, Lab Mucosal Immun, San Diego, CA 92103 USA; Natl Yang Ming Med Univ, Kaohsiung Vet Gen Hosp, Dept Surg, Taipei, Taiwan	University of California System; University of California San Diego; University of California System; University of California San Diego; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, San Diego, CA 92103 USA.		Greten, Florian R/AAF-5196-2020	Greten, Florian R/0000-0002-3928-6080				Arnalich F, 2000, INFECT IMMUN, V68, P1942, DOI 10.1128/IAI.68.4.1942-1945.2000; Balk RA, 2000, CRIT CARE CLIN, V16, P337, DOI 10.1016/S0749-0704(05)70113-5; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; CATY MG, 1990, ANN SURG, V212, P694, DOI 10.1097/00000658-199012000-00007; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fukatsu K, 2001, ANN SURG, V233, P660, DOI 10.1097/00000658-200105000-00010; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Lewis Susan E., 1996, Methods (Orlando), V10, P301, DOI 10.1006/meth.1996.0107; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LI ZW, IN PRESS J IMMUNOL; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Pennington C, 2000, AM SURGEON, V66, P914; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; SCHMELING DJ, 1989, SURGERY, V106, P201; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Song Y, 2001, AM J PHYSIOL-LUNG C, V281, pL677, DOI 10.1152/ajplung.2001.281.3.L677	29	403	423	1	23	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					575	581		10.1038/nm849	http://dx.doi.org/10.1038/nm849			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692538				2022-12-27	WOS:000182610600039
J	Rabbitts, TH; Stocks, MR				Rabbitts, TH; Stocks, MR			Chromosomal translocation products engender new intracellular therapeutic technologies	NATURE MEDICINE			English	Editorial Material							EMBRYONIC LETHALITY; MYELOID-LEUKEMIA; EXPRESSION; SELECTION; CANCER; RECOMBINATION; TRANSDUCTION; PROTEINS; DELIVERY; GENES	Chromosomal translocations occur in leukemias, lymphomas, sarcomas and some epithelial tumors and some generate unique fusion proteins. These translocation products may provide tumor-specific targets for the development of new therapeutic strategies tailored to a malignant cell.	MRC, Mol Biol Lab, Cambridge, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Cambridge, England.		Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Druker B, 2001, SEMIN HEMATOL, V38, P9, DOI 10.1053/shem.2001.27079; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Geyer CR, 2000, METHOD ENZYMOL, V328, P171, DOI 10.1016/S0076-6879(00)28398-5; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Kuwabara T, 1998, MOL CELL, V2, P617, DOI 10.1016/S1097-2765(00)80160-4; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Pinilla-Ibarz J, 2000, BLOOD REV, V14, P111, DOI 10.1054/blre.2000.0127; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; STOCKS MR, 2002, EMBO REPORTS, V11, P59; TANAKA T, IN PRESS EMBO J; Tse E, 2000, P NATL ACAD SCI USA, V97, P12266, DOI 10.1073/pnas.97.22.12266; Ullu E, 2002, PHILOS T ROY SOC B, V357, P65, DOI 10.1098/rstb.2001.0952; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	23	39	42	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					383	386		10.1038/nm0403-383	http://dx.doi.org/10.1038/nm0403-383			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12669051				2022-12-27	WOS:000181987400017
J	Kathuria, S; Gaetani, S; Fegley, D; Valino, F; Duranti, A; Tontini, A; Mor, M; Tarzia, G; La Rana, G; Calignano, A; Giustino, A; Tattoli, M; Palmery, M; Cuomo, V; Piomelli, D				Kathuria, S; Gaetani, S; Fegley, D; Valino, F; Duranti, A; Tontini, A; Mor, M; Tarzia, G; La Rana, G; Calignano, A; Giustino, A; Tattoli, M; Palmery, M; Cuomo, V; Piomelli, D			Modulation of anxiety through blockade of anandamide hydrolysis	NATURE MEDICINE			English	Article							ACID AMIDE HYDROLASE; CB1 CANNABINOID RECEPTORS; ELEVATED ZERO-MAZE; ENDOGENOUS CANNABINOIDS; BRAIN; ANTAGONIST; INHIBITORS; LOCALIZATION; ANXIOLYTICS; ACTIVATION	The psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Delta(9)-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA; Univ Urbino, Inst Med Chem, I-61029 Urbino, Italy; Univ Parma, Dept Pharmaceut, I-43100 Parma, Italy; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; Univ Bari, Dept Pharmacol & Human Physiol, Bari, Italy; Univ Roma La Sapienza, Dept Pharmacol & Gen Physiol, Rome, Italy	University of California System; University of California Irvine; University of Urbino; University of Parma; University of Naples Federico II; Universita degli Studi di Bari Aldo Moro; Sapienza University Rome	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA.	piomelli@uci.edu	Gaetani, Silvana/D-3455-2009; cuomo, vincenzo/J-6777-2012; Cuomo, Vincenzo/D-2772-2009; Mor, Marco/D-2394-2009	Mor, Marco/0000-0003-0199-1849; giustino, arcangela/0000-0002-7962-9797; CALIGNANO, Antonio/0000-0002-1742-3179; TATTOLI, MARIA/0000-0002-4970-264X				Ali MM, 2000, NEUROSCI LETT, V284, P57, DOI 10.1016/S0304-3940(00)00958-7; Arevalo C, 2001, PHARMACOL BIOCHEM BE, V70, P123, DOI 10.1016/S0091-3057(01)00578-0; Beinfeld MC, 2001, NEUROSCI LETT, V301, P69, DOI 10.1016/S0304-3940(01)01591-9; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Beltramo M, 1997, FEBS LETT, V403, P263, DOI 10.1016/S0014-5793(97)00061-6; BICKERDIKE MJ, 1994, EUR J PHARMACOL, V271, P403, DOI 10.1016/0014-2999(94)90800-1; Boger DL, 2000, P NATL ACAD SCI USA, V97, P5044, DOI 10.1073/pnas.97.10.5044; Cahill L, 1998, TRENDS NEUROSCI, V21, P294, DOI 10.1016/S0166-2236(97)01214-9; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Chaperon F, 1999, CRIT REV NEUROBIOL, V13, P243, DOI 10.1615/CritRevNeurobiol.v13.i3.20; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; CUOMO V, 1987, NEUROPHARMACOLOGY, V26, P701, DOI 10.1016/0028-3908(87)90230-9; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050; DePetrocellis L, 1997, BIOCHEM BIOPH RES CO, V231, P82, DOI 10.1006/bbrc.1997.6000; Deutsch DG, 1997, BIOCHEM BIOPH RES CO, V231, P217, DOI 10.1006/bbrc.1997.6072; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Fink H, 1998, EXP BRAIN RES, V123, P77, DOI 10.1007/s002210050546; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Glass M, 1997, NEUROSCIENCE, V77, P299, DOI 10.1016/S0306-4522(96)00428-9; Hall W, 1998, LANCET, V352, P1611, DOI 10.1016/S0140-6736(98)05021-1; HALLER J, IN PRESS EUR J NEURO; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; INSEL TR, 1986, PHARMACOL BIOCHEM BE, V24, P1263, DOI 10.1016/0091-3057(86)90182-6; Iversen L, 2002, CURR OPIN PHARMACOL, V2, P50, DOI 10.1016/S1471-4892(01)00120-5; Katona I, 2001, J NEUROSCI, V21, P9506, DOI 10.1523/JNEUROSCI.21-23-09506.2001; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Martin M, 2002, PSYCHOPHARMACOLOGY, V159, P379, DOI 10.1007/s00213-001-0946-5; McDonald AJ, 2001, NEUROSCIENCE, V107, P641, DOI 10.1016/S0306-4522(01)00380-3; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MICZEK KA, 1995, PSYCHOPHARMACOLOGY, V121, P38, DOI 10.1007/BF02245590; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P9804, DOI 10.1021/bi990637z; Piomelli D, 1999, P NATL ACAD SCI USA, V96, P5802, DOI 10.1073/pnas.96.10.5802; Robson P, 2001, BRIT J PSYCHIAT, V178, P107, DOI 10.1192/bjp.178.2.107; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Tseng AH, 2001, EUR J PHARMACOL, V430, P41, DOI 10.1016/S0014-2999(01)01267-5; Wedzony K, 2000, NEUROPSYCHOPHARMACOL, V23, P547, DOI 10.1016/S0893-133X(00)00150-0; WINSLOW JT, 1991, PROG NEURO-PSYCHOPH, V15, P745, DOI 10.1016/0278-5846(91)90003-J	45	1174	1232	2	84	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					76	81		10.1038/nm803	http://dx.doi.org/10.1038/nm803			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12461523	Green Submitted			2022-12-27	WOS:000180209900025
J	Andersen, JK				Andersen, JK			Oxidative stress in neurodegeneration: cause or consequence?	NATURE MEDICINE			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; MANGANESE SUPEROXIDE-DISMUTASE; TRANSGENIC MOUSE MODEL; VESICULAR MONOAMINE TRANSPORTER; PROTECTS DOPAMINERGIC-NEURONS; SHOW INCREASED VULNERABILITY; OXIDE SYNTHASE PROTECTS; NEUROTOXICITY IN-VIVO; ALPHA-SYNUCLEIN; NITRIC-OXIDE	Oxidative stress has long been linked to the neuronal cell death that is associated with certain neurodegenerative conditions. Whether it is a primary cause or merely a downstream consequence of the neurodegenerative process is still an open question, however. The advent of a growing number of in vitro and in vivo models that emulate human disease pathology is aiding scientists in deciphering just where oxidative stress intersects with other cellular events in the emerging roadmap leading to neurodegeneration. Here I review the evidence for oxidative stress in neurodegeneration and how this relates to other cellular events.	Buck Inst, Novato, CA 94945 USA	Buck Institute for Research on Aging	Andersen, JK (corresponding author), Buck Inst, 8001 Redwood Blvd, Novato, CA 94945 USA.	jandersen@buckinstitute.org		Andersen, Julie/0000-0003-1324-4875				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Alexander MD, 2002, ANN NEUROL, V52, P680, DOI 10.1002/ana.10369; Andreassen OA, 2001, EXP NEUROL, V167, P189, DOI 10.1006/exnr.2000.7525; Aoyama K, 2000, ANN NEUROL, V47, P524, DOI 10.1002/1531-8249(200004)47:4<524::AID-ANA19>3.0.CO;2-5; Barker JE, 1996, BRAIN RES, V716, P118, DOI 10.1016/0006-8993(96)00003-0; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Beretta S, 2003, NEUROBIOL DIS, V13, P213, DOI 10.1016/S0969-9961(03)00043-3; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Butterfield DA, 2002, NEUROBIOL AGING, V23, P655; Canals S, 2001, J NEUROCHEM, V79, P1183, DOI 10.1046/j.1471-4159.2001.00635.x; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; CONNOR JR, 1994, DEV NEUROSCI-BASEL, V16, P233, DOI 10.1159/000112115; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; Cudkowicz ME, 2002, NEUROLOGY, V59, P729, DOI 10.1212/WNL.59.5.729; DalCanto MC, 1996, CLIN NEUROSCI, V3, P332; Dehmer T, 2000, J NEUROCHEM, V74, P2213, DOI 10.1046/j.1471-4159.2000.0742213.x; Desnuelle C, 2001, AMYOTROPH LATERAL SC, V2, P9, DOI 10.1080/146608201300079364; DEXTER DT, 1994, ANN NEUROL, V35, P38, DOI 10.1002/ana.410350107; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x; Gainetdinov RR, 1998, J NEUROCHEM, V70, P1973; German DC, 2000, NEUROSCIENCE, V101, P1063, DOI 10.1016/S0306-4522(00)00385-7; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; Gurney ME, 1998, NEUROLOGY, V50, P62, DOI 10.1212/WNL.50.1.62; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; Haque ME, 2003, BBA-GEN SUBJECTS, V1619, P39, DOI 10.1016/S0304-4165(02)00440-3; Hensley K, 1998, J NEUROSCI, V18, P8126; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Itzhak Y, 1999, SYNAPSE, V34, P305, DOI 10.1002/(SICI)1098-2396(19991215)34:4<305::AID-SYN6>3.0.CO;2-#; JELLINGER KA, 1993, ADV NEUROL, V60, P267; Jha N, 2002, J NEUROCHEM, V80, P555, DOI 10.1046/j.0022-3042.2001.00009.x; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Khan SM, 2000, ANN NEUROL, V48, P148, DOI 10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-7; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Klivenyi P, 2000, NEUROREPORT, V11, P1265, DOI 10.1097/00001756-200004270-00024; Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191; Klivenyi P, 2000, J NEUROSCI, V20, P1; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Kruman II, 1999, EXP NEUROL, V160, P28, DOI 10.1006/exnr.1999.7190; Lee M, 2001, J NEUROCHEM, V76, P957, DOI 10.1046/j.1471-4159.2001.00107.x; Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x; Liberatore GT, 1999, NAT MED, V5, P1403; Liu RG, 2002, J NEUROCHEM, V80, P488, DOI 10.1046/j.0022-3042.2001.00720.x; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Manning-Bog AB, 2003, J NEUROSCI, V23, P3095; Marques CA, 2003, J BIOL CHEM, V278, P28294, DOI 10.1074/jbc.M212265200; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; McNaught KSP, 1999, J NEUROCHEM, V73, P2469, DOI 10.1046/j.1471-4159.1999.0732469.x; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; PAPPOLLA MA, 1992, AM J PATHOL, V140, P621; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; PERRY TL, 1986, NEUROSCI LETT, V67, P269, DOI 10.1016/0304-3940(86)90320-4; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Smith MA, 1997, J NEUROSCI, V17, P2653; SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Staal RGW, 2000, J PHARMACOL EXP THER, V293, P336; Stokes AH, 2000, BRAIN RES, V858, P1, DOI 10.1016/S0006-8993(99)02329-X; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Takahashi N, 1997, MOL BRAIN RES, V49, P7, DOI 10.1016/S0169-328X(97)00116-2; Takeuchi H, 2002, BRAIN RES, V949, P11, DOI 10.1016/S0006-8993(02)02568-4; Tortarolo M, 2003, MOL CELL NEUROSCI, V23, P180, DOI 10.1016/S1044-7431(03)00022-8; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Wang WY, 2004, NEUROSCI RES, V48, P195, DOI 10.1016/j.neures.2003.10.012; WARD RJ, 1995, BIOCHEM PHARMACOL, V49, P1821, DOI 10.1016/0006-2952(94)00521-M; Warita H, 2001, MOL BRAIN RES, V89, P147, DOI 10.1016/S0169-328X(01)00029-8; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Winklhofer KF, 2003, J BIOL CHEM, V278, P47199, DOI 10.1074/jbc.M306769200; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Xie Z, 2002, J NEUROSCI, V22, P3484; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; ZEMLAN FP, 1989, BRAIN RES, V476, P160, DOI 10.1016/0006-8993(89)91550-3; Zhang J, 2000, J NEUROPATH EXP NEUR, V59, P53, DOI 10.1093/jnen/59.1.53; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	108	1399	1446	6	132	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7		S			S18	S25		10.1038/nrn1434	http://dx.doi.org/10.1038/nrn1434			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	844YU	15298006				2022-12-27	WOS:000223202100004
J	Kim, MS; Park, JY; Namkoong, C; Jang, PG; Ryu, JW; Song, HS; Yun, JY; Namgoong, IS; Ha, J; Park, IS; Lee, IK; Viollet, B; Youn, JH; Lee, HK; Lee, KU				Kim, MS; Park, JY; Namkoong, C; Jang, PG; Ryu, JW; Song, HS; Yun, JY; Namgoong, IS; Ha, J; Park, IS; Lee, IK; Viollet, B; Youn, JH; Lee, HK; Lee, KU			Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; FOOD-INTAKE; GLUCOSE-TRANSPORT; BODY-WEIGHT; INTRACEREBROVENTRICULAR INFUSION; SKELETAL-MUSCLE; ADIPOSE-TISSUE; MALONYL-COA; EXPRESSION; LEPTIN	AMP-activated protein kinase (AMPK) functions as a fuel sensor in the cell and is activated when cellular energy is depleted. Here we report that alpha-lipoic acid (alpha-LA), a cofactor of mitochondrial enzymes, decreases hypothalamic AMPK activity and causes profound weight loss in rodents by reducing food intake and enhancing energy expenditure. Activation of hypothalamic AMPK reverses the effects of alpha-LA on food intake and energy expenditure. Intracerebroventricular (i.c.v.) administration of glucose decreases hypothalamic AMPK activity, whereas inhibition of intracellular glucose utilization through the administration of 2-deoxyglucose increases hypothalamic AMPK activity and food intake. The 2-deoxyglucose-induced hyperphagia is reversed by inhibiting hypothalamic AMPK. Our findings indicate that hypothalamic AMPK is important in the central regulation of food intake and energy expenditure and that alpha-LA exerts anti-obesity effects by suppressing hypothalamic AMPK activity.	Univ Ulsan, Coll Med, Dept Internal Med, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Kyung Hee Univ, Coll Med, Dept Mol Biol, Seoul 130701, South Korea; Inha Univ, Coll Med, Dept Anat, Inchon 400103, South Korea; Keimyung Univ, Sch Med, Dept Internal Med, Taegu 700310, South Korea; Univ Paris 05, CNR, INSERM, Inst Cochin,Dept Genet Dev & Mol Pathol, F-75014 Paris, France; Univ So Calif, Dept Physiol & Biophys, Keck Sch Med, Los Angeles, CA 90089 USA; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea	University of Ulsan; University of Ulsan; Kyung Hee University; Inha University; Keimyung University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Southern California; Seoul National University (SNU)	Lee, KU (corresponding author), Univ Ulsan, Coll Med, Dept Internal Med, 138-736 Poongnap Dong, Seoul 138736, South Korea.	kulee@amc.seoul.kr	Viollet, Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; NAM-GOONG, IL SEONG/0000-0002-0492-0467; NamKoong, Cherl/0000-0002-1869-4405				Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Benoit SC, 2003, INT J OBESITY, V27, P550, DOI 10.1038/sj.ijo.0802280; BROWN NF, 1994, J BIOL CHEM, V269, P26438; Commins SP, 2000, J BIOL CHEM, V275, P33059, DOI 10.1074/jbc.M006328200; Dalgaard LT, 2001, DIABETOLOGIA, V44, P946, DOI 10.1007/s001250100596; DAVIS JD, 1981, SCIENCE, V212, P81, DOI 10.1126/science.7193909; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Henriksen EJ, 1997, LIFE SCI, V61, P805, DOI 10.1016/S0024-3205(97)00562-6; Jacob S, 1996, DIABETES, V45, P1024, DOI 10.2337/diabetes.45.8.1024; Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Morton GJ, 2003, ENDOCRINOLOGY, V144, P2016, DOI 10.1210/en.2002-0115; Niimi M, 1999, J NEUROENDOCRINOL, V11, P605; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Ryu JW, 2003, BIOCHEM BIOPH RES CO, V303, P726, DOI 10.1016/S0006-291X(03)00409-1; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; SMITH GP, 1969, AM J PHYSIOL, V217, P1083, DOI 10.1152/ajplegacy.1969.217.4.1083; Tritos NA, 1998, ENDOCRINOLOGY, V139, P4634, DOI 10.1210/en.139.11.4634; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Yaworsky K, 2000, DIABETOLOGIA, V43, P294, DOI 10.1007/s001250050047; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603; ZIMMER G, 1991, ARCH BIOCHEM BIOPHYS, V288, P609, DOI 10.1016/0003-9861(91)90243-C	36	421	447	0	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					727	733		10.1038/nm1061	http://dx.doi.org/10.1038/nm1061			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195087				2022-12-27	WOS:000222460400027
J	Nicot, C; Dundr, M; Johnson, JM; Fullen, JR; Alonzo, N; Fukumoto, R; Princler, GL; Derse, D; Misteli, T; Franchini, G				Nicot, C; Dundr, M; Johnson, JM; Fullen, JR; Alonzo, N; Fukumoto, R; Princler, GL; Derse, D; Misteli, T; Franchini, G			HTLV-1-encoded p30(II) is a post-transcriptional negative regulator of viral replication	NATURE MEDICINE			English	Article							HTLV-I; LYMPHOTROPIC VIRUS; PX; PROTEINS; GENE; TAX; REV; EXPRESSION; CELLS; REQUIREMENT	Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) persists despite a vigorous virus-specific host immune response, and causes adult T-cell leukemia and lymphoma in approximately 2% of infected individuals. Here we report that HTLV-1 has evolved a genetic function to restrict its own replication by a novel post-transcriptional mechanism. The HTLV-1-encoded p30(II) is a nuclear-resident protein that binds to, and retains in the nucleus, the doubly spliced mRNA encoding the Tax and Rex proteins. Because Tex and Rex are positive regulators of viral gene expression(1,2), their inhibition by p30(II) reduces virion production. p30(II) inhibits virus expression by reducing Tax and Rex protein expression.	NCI, Anim Models & Retroviral Vaccines Sect, Bethesda, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA; NCI, Basic Res Lab, Ctr Canc Res, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Franchini, G (corresponding author), NCI, Anim Models & Retroviral Vaccines Sect, 41-D804, Bethesda, MD 20892 USA.	franchig@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005645, Z01BC010003, ZIABC010309, ZIABC010003, Z01BC005645, Z01BC010309] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; ALDOVINI A, 1986, P NATL ACAD SCI USA, V83, P38, DOI 10.1073/pnas.83.1.38; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; Derse D, 1996, J ACQ IMMUN DEF SYND, V12, P1, DOI 10.1097/00042560-199605010-00001; DIMAIO D, 1996, FIELDS VIROLOGY, P119; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; Goon PKC, 2002, BLOOD, V99, P3335, DOI 10.1182/blood.V99.9.3335; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; KIMATA JT, 1994, VIROLOGY, V204, P656, DOI 10.1006/viro.1994.1581; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MUCHARDT C, 1992, NEW BIOL, V4, P541; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; NICOT C, 1993, VIRUS RES, V30, P317, DOI 10.1016/0168-1702(93)90099-9; Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823; Princler GL, 2003, VIROLOGY, V317, P136, DOI 10.1016/j.virol.2003.09.010; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; WACHSMAN W, 1985, SCIENCE, V228, P1534, DOI 10.1126/science.2990032	30	139	148	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					197	201		10.1038/nm984	http://dx.doi.org/10.1038/nm984			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14730358				2022-12-27	WOS:000188719600041
J	Moatti, JP; N'Doye, I; Hammer, SM; Hale, P; Kazatchkine, M				Moatti, JP; N'Doye, I; Hammer, SM; Hale, P; Kazatchkine, M			Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm	NATURE MEDICINE			English	Editorial Material							COST-EFFECTIVENESS; RISK BEHAVIOR; THERAPY; ACCESS; AIDS; TRANSMISSION; ADHERENCE; AFRICA; HAART; CARE	Scaling up access to antiretroviral drugs (ARVs) for HIV- infected adults and children in developing countries can no longer be refused for medical or economic reasons, or on the grounds of inequality, lack of infrastructure, risk of viral resistance or alternative priorities. Access to ARVs is an appropriate, rational and cost- effective investment choice in developing countries.	Univ Mediterrannee, F-13008 Marseille, France; INSERM, Res Unit 379, F-13008 Marseille, France; SIDA, Programme Natl Lutte, Dakar, Senegal; Columbia Univ, Div Infect Dis, New York, NY 10032 USA; Hop Europeen Georges Pompidou, INSERM, Res Unit 430, F-75908 Paris, France; Univ Paris 05, F-75013 Paris, France; Agence Natl Rech SIDA, F-75013 Paris, France	UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Moatti, JP (corresponding author), Univ Mediterrannee, F-13008 Marseille, France.	moatti@marseille.inserm.fr						Ainsworth M, 2000, LANCET, V356, P55, DOI 10.1016/S0140-6736(00)02440-5; Bouhnik AD, 2002, J EPIDEMIOL COMMUN H, V56, P349, DOI 10.1136/jech.56.5.349; Boulle A, 2002, SAMJ S AFR MED J, V92, P811; Bozzette SA, 2001, NEW ENGL J MED, V344, P817, DOI 10.1056/NEJM200103153441107; Carrieri P, 2001, J ACQ IMMUN DEF SYND, V28, P232, DOI 10.1097/00042560-200111010-00005; Castro-Leal F, 2000, B WORLD HEALTH ORGAN, V78, P66; Chakraborty H, 2001, AIDS, V15, P621, DOI 10.1097/00002030-200103300-00012; Cohen J, 2003, SCIENCE, V301, P1658, DOI 10.1126/science.301.5640.1658; Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; DYER G, 2003, FINANCIAL TIMES 0715; *ECOWAS CEDEAO ACC, 2002, M MIN HLTH SUBR OBS; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2; Garber AM, 2000, HANDB ECON, V17, P181; Guimaraes MDC, 2001, INT J STD AIDS, V12, P334, DOI 10.1258/0956462011923057; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Hertogs K, 2000, AIDS, V14, P1203, DOI 10.1097/00002030-200006160-00018; Hogg RS, 2002, AIDS, V16, P787, DOI 10.1097/00002030-200203290-00015; Katzenstein D, 2003, AIDS, V17, pS1, DOI 10.1097/00002030-200317003-00001; Kilian AHD, 1999, AIDS, V13, P391, DOI 10.1097/00002030-199902250-00012; Law MG, 2001, AIDS, V15, P1287, DOI 10.1097/00002030-200107060-00011; Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001; Lopez-Casasnovas G, 2000, HEALTH POLICY, V54, P87, DOI 10.1016/S0168-8510(00)00100-7; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; Meda N, 1999, AIDS, V13, P1397, DOI 10.1097/00002030-199907300-00018; MOATTI JP, 2003, EC AIDS ACCESS HIV A, P121; MSELLATI P, 2001, ACCES TRAITEMENTS VI, P233; Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/00002030-200306130-00011; OVER M, 2003, CURRENT ISSUES EC HI; Rosen S, 2003, HARVARD BUS REV, V81, P80; Scheer S, 2001, LANCET, V357, P432, DOI 10.1016/S0140-6736(00)04007-1; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Skordis J, 2002, J HEALTH ECON, V21, P405, DOI 10.1016/S0167-6296(01)00133-3; *UNAIDS, 2003, PROGR REP GLOB RESP; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; *WHO, 2002, ESS DRUGS MED POL PI; *WHO HIV AIDS DEP, 2002, SCAL ANT THER RES LT; Wolff M, 2001, REV MED CHILE, V129, P886	39	28	29	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2003	9	12					1449	1452		10.1038/nm1203-1449	http://dx.doi.org/10.1038/nm1203-1449			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14647513				2022-12-27	WOS:000186845400014
J	Perez, JM; Rathz, DA; Petrashevskaya, NN; Hahn, HS; Wagoner, LE; Schwartz, A; Dorn, GW; Liggett, SB				Perez, JM; Rathz, DA; Petrashevskaya, NN; Hahn, HS; Wagoner, LE; Schwartz, A; Dorn, GW; Liggett, SB			beta(1)-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure	NATURE MEDICINE			English	Article							CARDIAC-HYPERTROPHY; EXERCISE CAPACITY; DOWN-REGULATION; GI-ALPHA; OVEREXPRESSION; DESENSITIZATION; EXPRESSION; INCREASE; CYCLASE; KINASE	Catecholamines stimulate cardiac contractility through beta(1)-adrenergic receptors (beta(1)-ARs), which in humans are polymorphic at amino acid residue 389 (Arg/Gly). We used cardiac-targeted transgenesis in a mouse model to delineate mechanisms accounting for the association of Arg389 with human heart failure phenotypes. Hearts from young Arg389 mice had enhanced receptor function and contractility compared with Gly389 hearts. Older Arg389 mice displayed a phenotypic switch, with decreased beta-agonist signaling to adenylyl cyclase and decreased cardiac contractility compared with Gly 389 hearts. Arg389 hearts had abnormal expression of fetal and hypertrophy genes and calcium-cycling proteins, decreased adenylyl cyclase and Galpha(s) expression, and fibrosis with heart failure This phenotype was recapitulated in homozygous, end-stage, failing human hearts. In addition, hemodynamic responses to beta-receptor blockade were greater in Arg389 mice, and homozygosity for Arg389 was associated with improvement in ventricular function during carvedilol treatment in heart failure patients. Thus the human Arg389 variant predisposes to heart failure by instigating hyperactive signaling programs leading to depressed receptor coupling and ventricular dysfunction, and influences the therapeutic response to beta-receptor blockade.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Inst Mol Pharmacol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012; MIALET-PEREZ, Jeanne/Y-7487-2018	MIALET-PEREZ, Jeanne/0000-0002-1765-0283; Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL22619, HL52318] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, P50HL052318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bengtsson K, 2001, CIRCULATION, V104, P187, DOI 10.1161/01.CIR.104.2.187; BOHM M, 1990, CIRCULATION, V82, P1249, DOI 10.1161/01.CIR.82.4.1249; BOHM M, 1992, HYPERTENSION, V20, P103, DOI 10.1161/01.HYP.20.1.103; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dorn GW, 2000, MOL PHARMACOL, V57, P278; Dunigan CD, 2002, BIOCHEMISTRY-US, V41, P8019, DOI 10.1021/bi025538r; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; ESCHENHAGEN T, 1992, CIRC RES, V70, P688, DOI 10.1161/01.RES.70.4.688; Franz WM, 2001, LANCET, V358, P1627, DOI 10.1016/S0140-6736(01)06657-0; Givertz MM, 2000, NEW ENGL J MED, V342, P1120, DOI 10.1056/NEJM200004133421509; Liggett SB, 2000, CIRCULATION, V101, P1707; Liggett SB, 2001, J CLIN INVEST, V107, P947, DOI 10.1172/JCI12774; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; Moore MM, 1999, MUTAGENESIS, V14, P271, DOI 10.1093/mutage/14.3.271; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rathz DA, 2003, J BIOL CHEM, V278, P10784, DOI 10.1074/jbc.M206054200; Serikov VB, 2001, CIRC RES, V88, P9, DOI 10.1161/01.RES.88.1.9; Small KM, 2002, METHOD ENZYMOL, V343, P459; Small KM, 2002, NEW ENGL J MED, V347, P1135, DOI 10.1056/NEJMoa020803; Tepe NM, 1999, BIOCHEMISTRY-US, V38, P16706, DOI 10.1021/bi991619k; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; van Campen LCMC, 1998, J CARDIOVASC PHARM, V32, pS31, DOI 10.1097/00005344-199806321-00006; Wagoner LE, 2002, AM HEART J, V144, P840, DOI 10.1067/mhj.2002.125325; Wagoner LE, 2000, CIRC RES, V86, P834, DOI 10.1161/01.RES.86.8.834; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719	29	165	175	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2003	9	10					1300	1305		10.1038/nm930	http://dx.doi.org/10.1038/nm930			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502278				2022-12-27	WOS:000185669700042
J	Xing, HR; Cordon-Cardo, C; Deng, XZ; Tong, W; Campodonico, L; Fuks, Z; Kolesnick, R				Xing, HR; Cordon-Cardo, C; Deng, XZ; Tong, W; Campodonico, L; Fuks, Z; Kolesnick, R			Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer	NATURE MEDICINE			English	Article							KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; C-ELEGANS; CELLS	Inhibition of the kinase suppressor of ras-1 (KSR1) gene by continuous infusion of phosphorothioate antisense oligonucleotides (ODNs) prevented growth of K-Ras-dependent human PANC-1 pancreatic and A549 non-small-cell lung carcinoma xenografts in nude mice, effected regression of established PANC-1 tumors and inhibited A549 lung metastases, all without apparent toxicity. These studies suggest KSR1 antisense ODNs as a treatment for Ras-dependent human malignancies, in particular pancreatic cancer, which lacks effective curative therapy.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Clin Chem Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOS JL, 1989, CANCER RES, V49, P4682; Huron DR, 2003, CLIN CANCER RES, V9, P1267; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; XING RH, 2003, CLIN CANCER RES, V9, P1267	9	45	52	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1266	1268		10.1038/nm927	http://dx.doi.org/10.1038/nm927			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12960962				2022-12-27	WOS:000185669700036
J	Cui, Y; Kelleher, E; Straley, E; Fuchs, E; Gorski, K; Levitsky, H; Borrello, I; Civin, CI; Schoenberger, SP; Cheng, LZ; Pardoll, DM; Whartenby, KA				Cui, Y; Kelleher, E; Straley, E; Fuchs, E; Gorski, K; Levitsky, H; Borrello, I; Civin, CI; Schoenberger, SP; Cheng, LZ; Pardoll, DM; Whartenby, KA			Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells	NATURE MEDICINE			English	Article							PULSED DENDRITIC CELLS; IN-VIVO; ANTITUMOR IMMUNITY; T-CELLS; VACCINATION; INDUCTION; LIGAND; RESPONSES; MELANOMA; VACCINES	A major focus of cancer immunotherapy is to develop strategies to induce T-cell responses through presentation of tumor antigens by dendritic cells (DCs). Current vaccines are limited in their ability to efficiently transfer antigens to DCs in vivo. Ex vivo-generated DCs can be efficiently loaded with antigen but after reinjection, few DCs traffic to secondary lymphoid organs, the critical sites for antigen presentation. To enhance efficiency and durability of antigen presentation by DCs, we transduced hematopoietic stem-progenitor cells (HSCs) with a model tumor antigen and then transplanted the gene-modified cells into irradiated recipient mice, which resulted in efficient expression of the transgene in a large proportion of donor derived DCs in lymphoid organs. The combination of bone marrow transplantion (BMT) using transduced HSCs, systemic agents that generate and activate DCs, and mature T-cell infusion resulted in substantial expansion and activation of antigen-specific T cells. This tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tumor.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Immunol & Hematopoiesis Div, Baltimore, MD 21231 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, La Jolla, CA 92024 USA	Johns Hopkins University; Johns Hopkins Medicine; La Jolla Institute for Immunology	Whartenby, KA (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Immunol & Hematopoiesis Div, Baltimore, MD 21231 USA.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Cui, Yan/0000-0002-2800-6039	NCI NIH HHS [CA96888-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA096888] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson LD, 2000, BLOOD, V95, P2426, DOI 10.1182/blood.V95.7.2426.007k28_2426_2433; Asavaroengchai W, 2002, P NATL ACAD SCI USA, V99, P931, DOI 10.1073/pnas.022634999; Banchereau J, 2001, CANCER RES, V61, P6451; Borges L, 1999, J IMMUNOL, V163, P1289; Borrello I, 2000, BLOOD, V95, P3011; Borrello Ivan M, 2002, Cancer Control, V9, P138; Cayeux S, 1999, EUR J IMMUNOL, V29, P225, DOI 10.1002/(SICI)1521-4141(199901)29:01<225::AID-IMMU225>3.0.CO;2-W; Chang AE, 2002, CLIN CANCER RES, V8, P1021; Cui Y, 2002, BLOOD, V99, P399, DOI 10.1182/blood.V99.2.399; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Eggert AAO, 1999, CANCER RES, V59, P3340; Fong L, 2001, P NATL ACAD SCI USA, V98, P8809, DOI 10.1073/pnas.141226398; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Lynch DH, 1998, CRIT REV IMMUNOL, V18, P99, DOI 10.1615/CritRevImmunol.v18.i1-2.110; Mackall CL, 1996, J IMMUNOL, V156, P4609; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; Merad M, 2002, BLOOD, V99, P1676, DOI 10.1182/blood.V99.5.1676; Murphy GP, 1999, PROSTATE, V39, P54, DOI 10.1002/(SICI)1097-0045(19990401)39:1<54::AID-PROS9>3.0.CO;2-U; Nair SK, 2002, ANN SURG, V235, P540, DOI 10.1097/00000658-200204000-00013; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; Teshima T, 2001, CANCER RES, V61, P162; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; Whartenby KA, 2002, BLOOD, V100, P3147, DOI 10.1182/blood-2002-01-0118; Woods NB, 2002, LEUKEMIA, V16, P563, DOI 10.1038/sj.leu.2402447	28	46	46	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					952	958		10.1038/nm882	http://dx.doi.org/10.1038/nm882			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12778137				2022-12-27	WOS:000183979300038
J	Krieg, AM				Krieg, AM			CpG motifs: the active ingredient in bacterial extracts?	NATURE MEDICINE			English	Article							HEPATITIS-B-VACCINE; TOLL-LIKE RECEPTORS; T-CELL RESPONSES; IMMUNE-RESPONSE; DENDRITIC CELLS; ESTABLISHED TUMORS; MURINE MODEL; DNA; OLIGODEOXYNUCLEOTIDES; ANTIGEN	The use of bacteria and bacterial extracts for immunotherapy has a checkered past. Recent developments in immunology reveal that these nonspecific immune activators actually work by triggering specific receptors that are expressed by subsets of immune cells. Identification of these receptors and the molecular signaling pathways that they activate has enabled a new era of specific targeted immunotherapy using chemically synthesized mimics of pathogen molecules.	Coley Pharmaceut Grp, Wellesley, MA 02481 USA	Coley Pharmaceutical Group	Krieg, AM (corresponding author), Coley Pharmaceut Grp, Wellesley, MA 02481 USA.	akrieg@coleypharma.com	Krieg, Art/R-6166-2019; Krieg, Arthur M/K-8109-2019					Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Ahonen CL, 1999, CELL IMMUNOL, V197, P62, DOI 10.1006/cimm.1999.1555; Ambrosch F, 2000, VACCINE, V18, P2095, DOI 10.1016/S0264-410X(99)00566-6; Ballas ZK, 2001, J IMMUNOL, V167, P4878, DOI 10.4049/jimmunol.167.9.4878; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Biron CA, 2002, CURR TOP MICROBIOL, V263, P7; Blazar BR, 2001, BLOOD, V98, P1217, DOI 10.1182/blood.V98.4.1217; Brown WC, 1998, INFECT IMMUN, V66, P5423, DOI 10.1128/IAI.66.11.5423-5432.1998; Carpentier AF, 2000, CLIN CANCER RES, V6, P2469; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Cooley W.B., 1893, AM J MED SCI, V105, P487, DOI [10.1097/00000441-189305000-00001, DOI 10.1097/00000441-189305000-00001]; Creticos PS, 2002, J ALLERGY CLIN IMMUN, V109, P743; Davila E, 2000, J IMMUNOL, V165, P539, DOI 10.4049/jimmunol.165.1.539; Davis HL, 2000, VACCINE, V18, P1920, DOI 10.1016/S0264-410X(99)00443-0; Davis HL, 2000, CURR TOP MICROBIOL, V247, P171; Egeter O, 2000, CANCER RES, V60, P1515; Ferguson TA, 2002, J IMMUNOL, V168, P5589, DOI 10.4049/jimmunol.168.11.5589; Goeckeritz BE, 1999, INT IMMUNOL, V11, P1693, DOI 10.1093/intimm/11.10.1693; Grossmann ME, 2001, J IMMUNOTHER, V24, P237, DOI 10.1097/00002371-200105000-00007; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Heckelsmiller K, 2002, EUR J IMMUNOL, V32, P3235, DOI 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Ito T, 2002, J EXP MED, V195, P1507, DOI 10.1084/jem.20020207; Jain VV, 2002, J ALLERGY CLIN IMMUN, V110, P867, DOI 10.1067/mai.2002.129371; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jones TR, 1999, VACCINE, V17, P3065, DOI 10.1016/S0264-410X(99)00145-0; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kawarada Y, 2001, J IMMUNOL, V167, P5247, DOI 10.4049/jimmunol.167.9.5247; Kim SK, 1999, VACCINE, V18, P597, DOI 10.1016/S0264-410X(99)00316-3; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1999, IMMUNITY, V11, P123, DOI 10.1016/S1074-7613(00)80087-4; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 2002, NAT IMMUNOL, V3, P423, DOI 10.1038/ni0502-423; Krieg AM, 1998, P NATL ACAD SCI USA, V95, P12631, DOI 10.1073/pnas.95.21.12631; Krieg Arthur M., 2002, Trends in Immunology, V23, P64, DOI 10.1016/S1471-4906(01)02150-0; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Kuwana M, 2001, EUR J IMMUNOL, V31, P2547, DOI 10.1002/1521-4141(200109)31:9<2547::AID-IMMU2547>3.0.CO;2-J; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lenert P, 2001, ANTISENSE NUCLEIC A, V11, P247, DOI 10.1089/108729001317022241; Lipford GB, 1997, EUR J IMMUNOL, V27, P2340, DOI 10.1002/eji.1830270931; Liu HM, 1998, BLOOD, V92, P3730, DOI 10.1182/blood.V92.10.3730.422k20_3730_3736; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; Martin P, 2002, BLOOD, V100, P383, DOI 10.1182/blood.V100.2.383; Miconnet I, 2002, J IMMUNOL, V168, P1212, DOI 10.4049/jimmunol.168.3.1212; Mor G, 1997, HUM GENE THER, V8, P293, DOI 10.1089/hum.1997.8.3-293; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51; Sandler AD, 2003, CANCER RES, V63, P394; Sethi S, 2002, LANCET, V360, P229, DOI 10.1016/S0140-6736(02)09513-2; Sfondrini L, 2002, FASEB J, V16, P1749, DOI 10.1096/fj.02-0383com; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146; Sparwasser T, 2000, EUR J IMMUNOL, V30, P3591, DOI 10.1002/1521-4141(200012)30:12<3591::AID-IMMU3591>3.0.CO;2-J; Stacey KJ, 2003, J IMMUNOL, V170, P3614, DOI 10.4049/jimmunol.170.7.3614; Stern BV, 2002, J IMMUNOL, V168, P6099, DOI 10.4049/jimmunol.168.12.6099; Thoelen S, 1998, VACCINE, V16, P708, DOI 10.1016/S0264-410X(97)00254-5; Tokunaga T, 1999, JPN J INFECT DIS, V52, P1; VANOJIK H, 2003, ANN ONCOL, V13, P157; Vasilakos JP, 2000, CELL IMMUNOL, V204, P64, DOI 10.1006/cimm.2000.1689; Wang YQ, 2003, INT IMMUNOL, V15, P223, DOI 10.1093/intimm/dxg020; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833; WIEMANN B, 1994, PHARMACOL THERAPEUT, V64, P529, DOI 10.1016/0163-7258(94)90023-X; Wild J, 1999, J IMMUNOL, V163, P1880; Yamaji M, 2002, PHOTOCH PHOTOBIO SCI, V1, P169, DOI 10.1039/b110092k; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yi AK, 1998, J IMMUNOL, V160, P4755; Zeuner RA, 2002, ARTHRITIS RHEUM, V46, P2219, DOI 10.1002/art.10423; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625; Zwaveling S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/jimmunol.169.1.350	75	234	342	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					831	835		10.1038/nm0703-831	http://dx.doi.org/10.1038/nm0703-831			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835699				2022-12-27	WOS:000183979300020
J	Lee, SW; Kim, WJ; Choi, YK; Song, HS; Son, MJ; Gelman, IH; Kim, YJ; Kim, KW				Lee, SW; Kim, WJ; Choi, YK; Song, HS; Son, MJ; Gelman, IH; Kim, YJ; Kim, KW			SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; KINASE-C SUBSTRATE; TUMOR-SUPPRESSOR ACTIVITY; CYTOSKELETAL ARCHITECTURE; IN-VIVO; EXPRESSION; GENE; HYPOXIA; ANGIOPOIETIN-1; CELLS	The blood-brain barrier (BBB) is essential for maintaining brain homeostasis and low permeability. BBB maintenance is important in the central nervous system (CNS) because disruption of the BBB may contribute to many brain disorders, including Alzheimer disease and ischemic stroke. The molecular mechanisms of BBB development remain ill-defined, however. Here we report that src-suppressed C-kinase substrate (SSeCKS) decreases the expression of vascular endothelial growth factor (VEGF) through AP-1 reduction and stimulates expression of angiopoietin-1 (Ang-1), an anti permeability factor in astrocytes. Conditioned media from SSeCKS-overexpressing astrocytes (SSeCKS-CM) blocked angiogenesis in vivo and in vitro. Moreover, SSeCKS-CM increased tight junction proteins in endothelial cells, consequently decreasing [H-3]sucrose permeability. Furthermore, immunoreactivity to SSeCKS gradually increased during the BBB maturation period, and SSeCKS-expressing astrocytes closely interacted with zonula occludens (ZO)-1-expressing blood vessels in vivo. Collectively, our results suggest that SSeCKS regulates BBB differentiation by modulating both brain angiogenesis and tight junction formation.	Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, Div Infect Dis, New York, NY 10029 USA	Seoul National University (SNU); Pusan National University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Kim, KW (corresponding author), Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.		Choi, Yoon Kyung/AGX-0481-2022	Choi, Yoon Kyung/0000-0003-0242-9612				Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; BREIER G, 1992, DEVELOPMENT, V114, P521; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; Gelman IH, 2000, HISTOCHEM J, V32, P13, DOI 10.1023/A:1003950027529; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Krikun G, 2002, AM J PATHOL, V161, P979, DOI 10.1016/S0002-9440(10)64258-7; Lee MS, 2001, CANCER RES, V61, P3290; Lee YM, 2001, DEV DYNAM, V220, P175, DOI 10.1002/1097-0177(20010201)220:2<175::AID-DVDY1101>3.0.CO;2-F; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Liebner S, 2000, ACTA NEUROPATHOL, V100, P323, DOI 10.1007/s004010000180; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Maltepe E, 1998, J MOL MED-JMM, V76, P391, DOI 10.1007/s001090050231; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Nag S, 2002, TRENDS MOL MED, V8, P38, DOI 10.1016/S1471-4914(01)02221-3; Nico B, 1999, DEV BRAIN RES, V114, P161, DOI 10.1016/S0165-3806(99)00008-5; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petty MA, 2001, BRAIN RES REV, V36, P23, DOI 10.1016/S0165-0173(01)00062-5; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001; Prat A, 2001, GLIA, V36, P145, DOI 10.1002/glia.1104; RADANY EH, 1992, P NATL ACAD SCI USA, V89, P6467, DOI 10.1073/pnas.89.14.6467; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Song HS, 2002, BIOCHEM BIOPH RES CO, V290, P325, DOI 10.1006/bbrc.2001.6205; Staddon JM, 1996, CURR OPIN NEUROBIOL, V6, P622, DOI 10.1016/S0959-4388(96)80094-8; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434, DOI 10.1152/ajpheart.2001.280.1.H434; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Xia W, 2001, CANCER RES, V61, P5644; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	45	352	368	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					900	906		10.1038/nm889	http://dx.doi.org/10.1038/nm889			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808449				2022-12-27	WOS:000183979300031
J	Siliciano, JD; Kajdas, J; Finzi, D; Quinn, TC; Chadwick, K; Margolick, JB; Kovacs, C; Gange, SJ; Siliciano, RF				Siliciano, JD; Kajdas, J; Finzi, D; Quinn, TC; Chadwick, K; Margolick, JB; Kovacs, C; Gange, SJ; Siliciano, RF			Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells	NATURE MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS INFECTION; COMBINATION THERAPY; VIRAL LOAD; REPLICATION; PERSISTENCE; INDINAVIR; PLASMA; ADULTS; DECAY	Latent HIV-1 persists in resting memory CD4(+) T cells, even in patients receiving highly active antiretroviral therapy (HAART). It has been unclear how stable this latent reservoir is and whether its persistence reflects replenishment by low-level viremia. Here we show that even in treated patients who have had no detectable viremia for as long as 7 years, the reservoir decays so slowly (t(1/2) = 44 months) that eradication is unlikely.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; NIAID, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Univ Toronto, Dept Med, Toronto, ON M5B 1L6, Canada; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Toronto; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.		Gange, Stephen/AGY-5004-2022; Abrams, William R/A-5782-2008; Quinn, Thomas/A-2494-2010	Gange, Stephen/0000-0001-7842-512X; 	NIAID NIH HHS [AI43222] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000361, R01AI043222] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	15	1211	1249	1	44	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					727	728		10.1038/nm880	http://dx.doi.org/10.1038/nm880			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12754504				2022-12-27	WOS:000183444100027
J	Kojima, H; Fujimiya, M; Matsumura, K; Younan, P; Imaeda, H; Maeda, M; Chan, L				Kojima, H; Fujimiya, M; Matsumura, K; Younan, P; Imaeda, H; Maeda, M; Chan, L			NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice	NATURE MEDICINE			English	Article							DEPENDENT ADENOVIRAL VECTOR; HEPATIC STEM-CELLS; LUMINAL RELEASE; INSULIN; EXPRESSION; TRANSPLANTATION; ALPHA(1)-ANTITRYPSIN; DIFFERENTIATION; TOXICITY	To explore induced islet neogenesis in the liver as a strategy for the treatment of diabetes, we used helper-dependent adenovirus (HDAD) to deliver the pancreatic duodenal homeobox-1 gene (Ipf1; also known as Pdx-1) to streptozotocin (STZ)-treated diabetic mice. HDAD is relatively nontoxic as it is devoid of genes encoding viral protein. Mice treated with HDAD-Ipf1 developed fulminant hepatitis, however, because of the exocrine-differentiating activity of Ipf1. The diabetes of STZ mice was partially reversed by HDAD-mediated transfer of NeuroD (Neurod), a factor downstream of Ipf1, and completely reversed by a combination of Neurod and betacellulin (Btc), without producing hepatitis. Treated mice were healthy and normoglycemic for the duration of the experiment (>120 d). We detected in the liver insulin and other islet-specific transcripts, including proinsulin-processing enzymes, beta-cell-specific glucokinase and sulfonylurea receptor. Immunocytochemistry detected the presence of insulin, glucagon, pancreatic polypeptide and somatostatin-producing cells organized into islet clusters; immunoelectron microscopy showed typical insulin-containing granules. Our data suggest that Neurod-Btc gene therapy is a promising regimen to induce islet neogenesis for the treatment of insulin-dependent diabetes.	Baylor Coll Med, Dept Med, Sect Diabet Endocrinol & Metab, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Shiga Univ Med Sci, Dept Anat, Otsu, Shiga 52021, Japan	Baylor College of Medicine; Baylor College of Medicine; Shiga University of Medical Science	Chan, L (corresponding author), Baylor Coll Med, Dept Med, Sect Diabet Endocrinol & Metab, Houston, TX 77030 USA.		Imaeda, Hirotsugu/B-9907-2016	Imaeda, Hirotsugu/0000-0002-5516-8527	NHLBI NIH HHS [HL-51586, HL-16512, HL-59314] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL059314, R37HL016512, R01HL016512, P01HL059314] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Auricchio A, 2002, GENE THER, V9, P963, DOI 10.1038/sj.gt.3301746; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; Dong HJ, 2001, TRENDS ENDOCRIN MET, V12, P441, DOI 10.1016/S1043-2760(01)00491-X; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Fujimiya M, 1997, HISTOCHEM CELL BIOL, V108, P105, DOI 10.1007/s004180050151; FUJIMIYA M, 1992, NEUROSCI LETT, V145, P229, DOI 10.1016/0304-3940(92)90029-7; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Halban PA, 2001, DIABETES, V50, P2181, DOI 10.2337/diabetes.50.10.2181; Kim IH, 2001, P NATL ACAD SCI USA, V98, P13282, DOI 10.1073/pnas.241506298; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; KOJIMA H, 1986, FEBS LETT, V201, P271, DOI 10.1016/0014-5793(86)80622-6; Kojima H, 2002, DIABETES, V51, P1398, DOI 10.2337/diabetes.51.5.1398; Lee HC, 2000, NATURE, V408, P483, DOI 10.1038/35044106; Lozier JN, 1999, BLOOD, V94, P3968, DOI 10.1182/blood.V94.12.3968.424k43_3968_3975; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morral N, 1998, HUM GENE THER, V9, P2709, DOI 10.1089/hum.1998.9.18-2709; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; O'Neal WK, 1998, HUM GENE THER, V9, P1587, DOI 10.1089/hum.1998.9.11-1587; Oka K, 2001, CIRCULATION, V103, P1274; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Paty BW, 2002, DIABETES, V51, P3428, DOI 10.2337/diabetes.51.12.3428; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Ryan EA, 2002, DIABETES, V51, P2148, DOI 10.2337/diabetes.51.7.2148; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SHING Y, 1993, SCIENCE, V259, P2681; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Theise ND, 1999, HEPATOLOGY, V30, P1425, DOI 10.1002/hep.510300614; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WATARI N, 1975, ENDOCRINE GUT PANCRA, P179; Yang LJ, 2002, P NATL ACAD SCI USA, V99, P8078, DOI 10.1073/pnas.122210699; Yoon JW, 2002, TRENDS MOL MED, V8, P62, DOI 10.1016/S1471-4914(02)02279-7	32	353	382	0	27	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					596	603		10.1038/nm867	http://dx.doi.org/10.1038/nm867			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12704384				2022-12-27	WOS:000182610600042
J	Snyder, JE; Bowers, WJ; Livingstone, AM; Lee, FEH; Federoff, HJ; Mosmann, TR				Snyder, JE; Bowers, WJ; Livingstone, AM; Lee, FEH; Federoff, HJ; Mosmann, TR			Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing	NATURE MEDICINE			English	Article							MEMORY CELLS; PROLIFERATION; INFECTION; EFFECTOR; IMMUNITY; VIRUS	Antigen-specific T cells demonstrate several potent effector functions during immune responses. Direct killing of infected cells is crucial for clearing viruses and other intracellular pathogens, but it has been difficult to measure the frequency of cytolytic cells. We have now developed a single-cell assay to measure the number of cytotoxic cells in a population, using a herpes simplex virus amplicon vector to express Escherichia coli beta-galactosidase in mouse or human target cells, and an Elispot to detect release of beta-galactosidase from killed target cells. This antigen-specific, perforin-dependent Lysispot assay has been combined with a cytokine Elispot in a two-color assay to confirm that cytotoxicity and interferon-gamma secretion are regulated independently. The simultaneous enumeration of cytokine-secreting and cytotoxic cells should be invaluable for ex vivo analysis of immune responses during infection and autoimmunity.	Univ Rochester, Med Ctr, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Aging & Dev Biol, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Mosmann, TR (corresponding author), Univ Rochester, Med Ctr, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY 14642 USA.			Snyder-Cappione, Jennifer/0000-0002-0941-5582	NIAID NIH HHS [R01 AI48414] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048414] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bachmann MF, 1999, EUR J IMMUNOL, V29, P291, DOI 10.1002/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO;2-K; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; BUCY RP, 1994, J EXP MED, V180, P1251, DOI 10.1084/jem.180.4.1251; Federoff Howard J., 1995, P109, DOI 10.1016/B978-012397570-6/50009-5; Foxwell AR, 2001, INFECT IMMUN, V69, P2636, DOI 10.1128/IAI.69.4.2636-2642.2001; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Karulin AY, 2000, J IMMUNOL, V164, P1862, DOI 10.4049/jimmunol.164.4.1862; Lim DG, 2000, J IMMUNOL, V165, P6214, DOI 10.4049/jimmunol.165.11.6214; MALEY DT, 1990, J IMMUNOL METHODS, V134, P61, DOI 10.1016/0022-1759(90)90112-9; Marten NW, 2001, VIRAL IMMUNOL, V14, P1, DOI 10.1089/08828240151061329; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Rininsland FH, 2000, J IMMUNOL METHODS, V240, P143, DOI 10.1016/S0022-1759(00)00191-5; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454; Stenger S, 1999, IMMUNOL TODAY, V20, P390, DOI 10.1016/S0167-5699(99)01449-8; Topham DJ, 1997, J IMMUNOL, V159, P5197; Vizler C, 2000, J IMMUNOL, V165, P6314, DOI 10.4049/jimmunol.165.11.6314	20	70	75	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2003	9	2					231	235		10.1038/nm821	http://dx.doi.org/10.1038/nm821			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539041				2022-12-27	WOS:000180801900029
J	Lu, W; Wu, XX; Lu, YZ; Guo, WZ; Andrieu, JM				Lu, W; Wu, XX; Lu, YZ; Guo, WZ; Andrieu, JM			Therapeutic dendritic-cell vaccine for simian AIDS	NATURE MEDICINE			English	Article							CD8(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; SUSTAINED VIRAL SUPPRESSION; HIV-INFECTED PATIENTS; IN-VITRO; IMMUNODEFICIENCY; LYMPHOCYTES; RESPONSES; MEMORY; HAART	An effective immune response against human immunodeficiency virus or simian immunodeficiency virus (SIV) is critical in achieving control of viral replication. Here, we show in SIV-infected rhesus monkeys that an effective and durable SIV-specific cellular and humoral immunity is elicited by a vaccination with chemically inactivated SIV-pulsed dendritic cells. After three immunizations made at two-week intervals, the animals exhibited a 50-fold decrease of SIV DNA and a 1,000-fold decrease of SIV RNA in peripheral blood. Such reduced viral load levels were maintained over the remaining 34 weeks of the study. Molecular and cellular analyses of axillary and inguinal node lymphocytes of vaccinated monkeys revealed a correlation between decreased SIV DNA and RNA levels and increased SIV-specific T-cell responses. Neutralizing antibody responses were augmented and remained elevated. Inactivated whole virus-pulsed dendritic cell vaccines are promising means to control diseases caused by immunodeficiency viruses.	Inst Rech Vaccins & Immunotherapie Canc & Sida, Paris, France; Univ Paris 05, Ctr Biomed St Peres, Lab Oncol & Virol Mol, Paris, France; Inst Trop Med, Lab Pathol & Virol, Guangzhou, Peoples R China	UDICE-French Research Universities; Universite Paris Cite	Lu, W (corresponding author), Inst Rech Vaccins & Immunotherapie Canc & Sida, Paris, France.	louis.wei-lu@biomedicale.univ-paris5.fr						ANDRIEU JM, 1995, IMMUNOL TODAY, V16, P5, DOI 10.1016/0167-5699(95)80062-X; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Buseyne F, 2001, NAT MED, V7, P344, DOI 10.1038/85493; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chougnet C, 1999, J IMMUNOL, V163, P1666; Cohen OJ, 1997, IMMUNOL REV, V159, P31, DOI 10.1111/j.1600-065X.1997.tb01005.x; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574; Feldman S, 2001, CLIN IMMUNOL, V101, P201, DOI 10.1006/clim.2001.5111; Fenyo EM, 1996, IMMUNOL LETT, V51, P95, DOI 10.1016/0165-2478(96)02561-8; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Grassi F, 1999, AIDS, V13, P759, DOI 10.1097/00002030-199905070-00004; Gray CM, 1999, J IMMUNOL, V162, P1780; Hatano H, 2000, AIDS, V14, P1357, DOI 10.1097/00002030-200007070-00008; Hermans IF, 2000, J IMMUNOL, V164, P3095, DOI 10.4049/jimmunol.164.6.3095; Hirsch V M, 2000, Adv Pharmacol, V49, P437; Jin X, 2000, MOL MED, V6, P803, DOI 10.1007/BF03402195; Kalams SA, 1999, J VIROL, V73, P6721, DOI 10.1128/JVI.73.8.6721-6728.1999; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505; Lederman MM, 2000, JAMA-J AM MED ASSOC, V284, P223, DOI 10.1001/jama.284.2.223; Lieberman J, 2001, BLOOD, V98, P1667, DOI 10.1182/blood.V98.6.1667; Lu W, 2000, BLOOD, V96, P250, DOI 10.1182/blood.V96.1.250.013k28_250_258; Lu W, 1999, NAT MED, V5, P1081, DOI 10.1038/12520; Lu W, 2001, J IMMUNOL, V167, P2929, DOI 10.4049/jimmunol.167.5.2929; LU W, 1995, ADV EXP MED BIOL, V374, P235; Lu W, 2001, J VIROL, V75, P8949, DOI 10.1128/JVI.75.19.8949-8956.2001; Ludewig B, 1999, J IMMUNOL, V163, P1839; McIlroy D, 1998, AIDS RES HUM RETROV, V14, P505, DOI 10.1089/aid.1998.14.505; Mehlhop E, 2002, J IMMUNOL METHODS, V260, P219, DOI 10.1016/S0022-1759(01)00544-0; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Norbury CC, 2002, NAT IMMUNOL, V3, P265, DOI 10.1038/ni762; Pacanowski J, 2001, BLOOD, V98, P3016, DOI 10.1182/blood.V98.10.3016; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Salerno-Goncalves R, 2000, J VIROL, V74, P6648, DOI 10.1128/JVI.74.14.6648-6651.2000; Sapp M, 1999, IMMUNOL LETT, V66, P121, DOI 10.1016/S0165-2478(98)00169-2; Zimmer MI, 2002, BLOOD, V99, P2859, DOI 10.1182/blood.V99.8.2859	37	192	215	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					27	32		10.1038/nm806	http://dx.doi.org/10.1038/nm806			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12496959				2022-12-27	WOS:000180209900018
J	Rotz, LD; Hughes, JM				Rotz, LD; Hughes, JM			Advances in detecting and responding to threats from bioterrorism and emerging infectious disease	NATURE MEDICINE			English	Editorial Material							BIOLOGICAL WARFARE AGENTS; SYNDROMIC SURVEILLANCE; OUTBREAK; TIME; ATTACK; CRITERIA; SYSTEMS	Much progress has been made in recent years to strengthen local, state, national and international capacities to detect and respond to bioterrorism events and naturally occurring outbreaks of disease. New tools and systems are available to estimate the potential impact of a biological event and predict resource needs for effective response, enable earlier detection of an attack or outbreak, enhance diagnostic capacity and facilitate rapid intervention to mitigate the impact of an event on a community. These advances have required new approaches to preparedness, planning and surveillance, as well as new partnerships and collaborations across a range of disciplines. We examine some of these developments, discuss potential uses and limitations of these approaches, and identify priorities for the future.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Rotz, LD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.	lrotz@cdc.gov						*AG HEALTHC RES QU, 2004, COMM BAS MASS PROPH; American Psychological Association Guidelines for Preventing Health-Care-Associated Pneumonia, 2004, REC CDC HLTHC INF CO, DOI [10.1037/e548652006-001, DOI 10.1037/E548652006-001]; Andress Knox, 2003, Disaster Manag Response, V1, P54, DOI 10.1016/S1540-2487(03)00004-X; [Anonymous], 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; BERGER E, 2003, HOUSTON TX CHRO 1010; Bravata DM, 2004, ANN INTERN MED, V140, P910, DOI 10.7326/0003-4819-140-11-200406010-00013; Bravata DM, 2004, MED DECIS MAKING, V24, P192, DOI 10.1177/0272989X04263254; BRAVATA DM, 2002, BIOTERRORISM PREPARE, P1; Brookmeyer R, 2003, P NATL ACAD SCI USA, V100, P10129, DOI 10.1073/pnas.1631983100; Buehler JW, 2003, EMERG INFECT DIS, V9, P1197, DOI 10.3201/eid0910.030231; *CDCP, 2000, J AM STAT ASSOC, V95, P992; Das D, 2003, J URBAN HEALTH, V80, pI76; Fitch JP, 2003, SCIENCE, V302, P1350, DOI 10.1126/science.1085922; Fitch JP, 2002, P IEEE, V90, P1708, DOI 10.1109/JPROC.2002.804680; FLEISCHAUER AT, IN PRESS ACAD EMERGE; Gani R, 2004, EMERG INFECT DIS, V10, P608, DOI 10.3201/eid1004.030509; Gerhold DL, 2002, NAT GENET, V32, P547, DOI 10.1038/ng1042; Gilfillan L, 2004, BIOSECUR BIOTERROR, V2, P320, DOI 10.1089/bsp.2004.2.320; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grunow R, 2002, CLIN MICROBIOL INFEC, V8, P510, DOI 10.1046/j.1469-0691.2002.00524.x; Heffernan R, 2004, EMERG INFECT DIS, V10, P858, DOI 10.3201/eid1005.030646; Heymann D L, 2001, Lancet Infect Dis, V1, P345, DOI 10.1016/S1473-3099(01)00148-7; Heymann DL, 2004, EMERG INFECT DIS, V10, P173, DOI 10.3201/eid1002.031038; Hoffmaster AR, 2002, EMERG INFECT DIS, V8, P1178, DOI 10.3201/eid0810.020393; Hutwagner L, 2003, J URBAN HEALTH, V80, pI89; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; KLEIN RW, 1993, MED DECIS MAKING, V13, P347, DOI 10.1177/0272989X9301300411; LANGLOIS RG, 2000, P JOINT C POINT DET; LeDuc J. W., 1999, Emerging infections 3., P219; Lober WB, 2003, J URBAN HEALTH, V80, pI97; Lombardo J, 2003, J URBAN HEALTH, V80, pI32; McBride MT, 2003, ANAL CHEM, V75, P1924, DOI 10.1021/ac026379k; Meltzer MI, 2001, EMERG INFECT DIS, V7, P959, DOI 10.3201/eid0706.010607; Morse SA, 2003, ASM NEWS, V69, P433; Mostashari F, 2003, J URBAN HEALTH, V80, pI43; Noah DL, 1998, MIL MED, V163, P198, DOI 10.1093/milmed/163.4.198; O'Toole T, 2002, CLIN INFECT DIS, V34, P972, DOI 10.1086/339909; PAVLIN JA, 2001, ESSENCE ELECT SURVEI; Quenel P, 1998, EUR J EPIDEMIOL, V14, P275, DOI 10.1023/A:1007467814485; Rao RS, 2004, J PROTEOME RES, V3, P736, DOI 10.1021/pr034130t; Reingold Arthur, 2003, Biosecur Bioterror, V1, P77, DOI 10.1089/153871303766275745; Reis BY, 2004, ANN EMERG MED, V44, P235, DOI 10.1016/j.annemergmed.2004.03.030; Reissman Dori B, 2003, Biosecur Bioterror, V1, P111, DOI 10.1089/153871303766275772; Rotz LD, 2002, EMERG INFECT DIS, V8, P225, DOI 10.3201/eid0802.010164; Schuler A, 2004, BIOSECUR BIOTERROR, V2, P86, DOI 10.1089/153871304323146388; Steyn B, 2001, NATO SCI PRT 1 DISAR, V35, P87; American Medical Association, 2004, MMWR Recomm Rep, V53, P1; Takahashi T, 2001, JPN J INFECT DIS, V54, P27; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; Treadwell TA, 2003, PUBLIC HEALTH REP, V118, P92, DOI 10.1016/S0033-3549(04)50224-8; Tsui FC, 2003, J AM MED INFORM ASSN, V10, P399, DOI 10.1197/jamia.M1345; Walden J, 2004, EMERG INFECT DIS, V10, P1202, DOI 10.3201/eid1007.030632; Wein LM, 2003, P NATL ACAD SCI USA, V100, P4346, DOI 10.1073/pnas.0636861100; Zubieta Juan Carlos, 2003, Int J Health Geogr, V2, P8, DOI 10.1186/1476-072X-2-8	54	40	40	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12		S			S130	S136		10.1038/nm1152	http://dx.doi.org/10.1038/nm1152			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577931	Bronze			2022-12-27	WOS:000225733900009
J	Webby, R; Hoffmann, E; Webster, R				Webby, R; Hoffmann, E; Webster, R			Molecular constraints to interspecies transmission of viral pathogens	NATURE MEDICINE			English	Article							INFLUENZA-A VIRUSES; 1918 PANDEMIC VIRUS; DOUBLE-STRANDED-RNA; NS1 PROTEIN; RECEPTOR SPECIFICITY; V-PROTEIN; NUCLEAR ACCUMULATION; SPIKE GLYCOPROTEIN; PREVENTING STAT1; HOST-RANGE	The successful replication of a viral pathogen in a host is a complex process involving many interactions. These interactions develop from the coevolution of pathogen and host and often lead to a species specificity of the virus that can make interspecies transmissions difficult. Nevertheless, viruses do sporadically cross species barriers into other host populations, including humans. In zoonotic infections, many of these interspecies transfer events are dead end, where transmission is confined only to the animal-to-human route but sometimes viruses adapt to enable spread from human to human. A pathogen must overcome many hurdles to replicate successfully in a foreign host. The viral pathogen must enter the host cell, replicate with the assistance of host factors, evade inhibitory host products, exit the first cell and move on to the next, and possibly leave the initial host and transmit to another. Each of these stages may require adaptive changes in the pathogen. Although the factors that influence each stage of the replication and transmission of most agents have not been resolved, the genomics of both hosts and pathogens are now at hand and we have begun to understand some of the molecular changes that enable some viruses to adapt to a new host.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Webster, R (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	robert.webster@stjude.org	Webby, Richard J/N-5657-2018		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI95357, N01AI95357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baranowski E, 2001, SCIENCE, V292, P1102, DOI 10.1126/science.1058613; BEARE AS, 1991, ARCH VIROL, V119, P37, DOI 10.1007/BF01314321; Bieniasz PD, 2003, TRENDS MICROBIOL, V11, P286, DOI 10.1016/S0966-842X(03)00123-9; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Chen ZY, 1999, EMBO J, V18, P2273, DOI 10.1093/emboj/18.8.2273; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Fujii Y, 2003, P NATL ACAD SCI USA, V100, P2002, DOI 10.1073/pnas.0437772100; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Goff SP, 2004, ANNU REV GENET, V38, P61, DOI 10.1146/annurev.genet.38.072902.094136; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Harcourt BH, 1998, VIROLOGY, V252, P179, DOI 10.1006/viro.1998.9446; HINSHAW VS, 1983, VIROLOGY, V128, P260, DOI 10.1016/0042-6822(83)90337-9; HINSHAW VS, 1981, INFECT IMMUN, V34, P354, DOI 10.1128/IAI.34.2.354-361.1981; Holmes KV, 2001, ADV EXP MED BIOL, V494, P173; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; ISAACS A, 1958, NATURE, V182, P1073, DOI 10.1038/1821073a0; Ito T, 1998, J VIROL, V72, P7367, DOI 10.1128/JVI.72.9.7367-7373.1998; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Krug RM, 2003, VIROLOGY, V309, P181, DOI 10.1016/S0042-6822(03)00119-3; LAI MMC, 1992, CURR TOP MICROBIOL, V176, P21; LERNEY P, 2003, P NATL ACAD SCI USA, V100, P6588; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; Matrosovich M, 1999, J VIROL, V73, P1146, DOI 10.1128/JVI.73.2.1146-1155.1999; Matrosovich MN, 2004, P NATL ACAD SCI USA, V101, P4620, DOI 10.1073/pnas.0308001101; Matrosovich MN, 2001, VIROLOGY, V281, P156, DOI 10.1006/viro.2000.0799; Meyer BJ, 2002, CURR TOP MICROBIOL, V262, P139; MURPHY BR, 1982, INFECT IMMUN, V37, P1119, DOI 10.1128/IAI.37.3.1119-1126.1982; Nagy PD, 1997, VIROLOGY, V235, P1, DOI 10.1006/viro.1997.8681; NELSON J, 1993, VIRUS RES, V29, P155, DOI 10.1016/0168-1702(93)90056-S; Nemeroff ME, 1998, MOL CELL, V1, P991, DOI 10.1016/S1097-2765(00)80099-4; Nie YC, 2004, BIOCHEM BIOPH RES CO, V321, P994, DOI 10.1016/j.bbrc.2004.07.060; Parisien JP, 2002, J VIROL, V76, P6435, DOI 10.1128/JVI.76.13.6435-6441.2002; Park MS, 2003, J VIROL, V77, P1501, DOI 10.1128/JVI.77.2.1501-1511.2003; Rodriguez JJ, 2003, J VIROL, V77, P11842, DOI 10.1128/JVI.77.21.11842-11845.2003; Rodriguez JJ, 2002, J VIROL, V76, P11476, DOI 10.1128/JVI.76.22.11476-11483.2002; SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8; Sevilla N, 2002, CURR TOP MICROBIOL, V263, P197; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Suarez DL, 2004, EMERG INFECT DIS, V10, P693, DOI 10.3201/eid1004.030396; Thackray LB, 2004, VIROLOGY, V324, P510, DOI 10.1016/j.virol.2004.04.005; Tumpey TM, 2004, P NATL ACAD SCI USA, V101, P3166, DOI 10.1073/pnas.0308391100; Webby RJ, 2004, LANCET, V363, P1099, DOI 10.1016/S0140-6736(04)15892-3; Webster RG, 2004, LANCET, V363, P234, DOI 10.1016/S0140-6736(03)15329-9	47	84	92	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2004	10	12		S			S77	S81		10.1038/nm1151	http://dx.doi.org/10.1038/nm1151			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577935	Green Published			2022-12-27	WOS:000225733900003
J	Curiel, TJ; Coukos, G; Zou, LH; Alvarez, X; Cheng, P; Mottram, P; Evdemon-Hogan, M; Conejo-Garcia, JR; Zhang, L; Burow, M; Zhu, Y; Wei, S; Kryczek, I; Daniel, B; Gordon, A; Myers, L; Lackner, A; Disis, ML; Knutson, KL; Chen, LP; Zou, WP				Curiel, TJ; Coukos, G; Zou, LH; Alvarez, X; Cheng, P; Mottram, P; Evdemon-Hogan, M; Conejo-Garcia, JR; Zhang, L; Burow, M; Zhu, Y; Wei, S; Kryczek, I; Daniel, B; Gordon, A; Myers, L; Lackner, A; Disis, ML; Knutson, KL; Chen, LP; Zou, WP			Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival	NATURE MEDICINE			English	Article							DENDRITIC CELLS; CUTTING EDGE; TUMOR-IMMUNITY; LUNG-CANCER; EXPRESSION; QUANTIFICATION; ALLOANTIGEN; INDUCTION; TOLERANCE; ALPHA	Regulatory T (T-reg) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells. Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-associated antigen - reactive lymphocytes mediated by T-reg cells; however, definitive evidence that T-reg cells have an immunopathological role in human cancer is lacking. Here we show, in detailed studies of CD4(+) CD25(+) FOXP3(+) T-reg cells in 104 individuals affected with ovarian carcinoma, that human tumor T-reg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo. We also show that tumor T-reg cells are associated with a high death hazard and reduced survival. Human T-reg cells preferentially move to and accumulate in tumors and ascites, but rarely enter draining lymph nodes in later cancer stages. Tumor cells and microenvironmental macrophages produce the chemokine CCL22, which mediates trafficking of T-reg cells to the tumor. This specific recruitment of T-reg cells represents a mechanism by which tumors may foster immune privilege. Thus, blocking T-reg cell migration or function may help to defeat human cancer.	Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA; Univ Penn, Div Gynecol Oncol, Philadelphia, PA 19104 USA; Baylor Univ, Med Ctr, Dallas, TX 75249 USA; Univ Washington, Div Oncol, Seattle, WA 98195 USA; Johns Hopkins Univ, Dept Dermatol, Baltimore, MD 21287 USA	Tulane University; University of Pennsylvania; Baylor University; Baylor University Medical Center; University of Washington; University of Washington Seattle; Johns Hopkins University	Zou, WP (corresponding author), Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA.	wzou@tulane.edu	Zhang, Lin/K-8478-2012; Burow, Matthew/D-6351-2013; Coukos, George/ABG-7389-2020; Conejo-Garcia, Jose R/V-1897-2019	Burow, Matthew/0000-0002-0642-6630; Conejo-Garcia, Jose R/0000-0001-6431-4074; Mottram, Peter/0000-0001-8560-2358; Coukos, George/0000-0001-8813-7367	NATIONAL CANCER INSTITUTE [R01CA092562, P50CA083638, R21CA100227, R01CA097085] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; NCI NIH HHS [CA092562, CA100227, P01-CA83638, CA97085] Funding Source: Medline; NCRR NIH HHS [RR00164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bach JF, 2003, NAT REV IMMUNOL, V3, P189, DOI 10.1038/nri1026; Baecher-Allan C, 2002, J IMMUNOL, V169, P6210, DOI 10.4049/jimmunol.169.11.6210; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Dunbar PR, 2000, J IMMUNOL, V165, P6644, DOI 10.4049/jimmunol.165.11.6644; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Knutson KL, 2001, J CLIN INVEST, V107, P477, DOI 10.1172/JCI11752; Lecoeur H, 2001, J IMMUNOL METHODS, V253, P177, DOI 10.1016/S0022-1759(01)00359-3; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Maeurer MJ, 1996, MELANOMA RES, V6, P11, DOI 10.1097/00008390-199602000-00003; Maio M, 1996, IMMUNOL TODAY, V17, P405, DOI 10.1016/0167-5699(96)30014-5; Markman M, 2003, HEMATOL ONCOL CLIN N, V17, P957, DOI 10.1016/S0889-8588(03)00058-3; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Pardoll D, 2001, NATURE, V411, P1010, DOI 10.1038/35082676; Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Salio M, 2001, J IMMUNOL, V167, P1188, DOI 10.4049/jimmunol.167.3.1188; Schreiber H, 2002, SEMIN CANCER BIOL, V12, P25, DOI 10.1006/scbi.2001.0401; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shimizu J, 1999, J IMMUNOL, V163, P5211; Steitz J, 2001, CANCER RES, V61, P8643; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Taylor PA, 2001, J EXP MED, V193, P1311, DOI 10.1084/jem.193.11.1311; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; van Maurik A, 2002, J IMMUNOL, V169, P5401; von Herrath MG, 2003, NAT REV IMMUNOL, V3, P223, DOI 10.1038/nri1029; Woo EY, 2002, J IMMUNOL, V168, P4272, DOI 10.4049/jimmunol.168.9.4272; Woo EY, 2001, CANCER RES, V61, P4766; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Wu MT, 2001, J IMMUNOL, V167, P4791, DOI 10.4049/jimmunol.167.9.4791; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zou WP, 2000, J IMMUNOL, V165, P4388, DOI 10.4049/jimmunol.165.8.4388; Zou WP, 1995, EUR CYTOKINE NETW, V6, P257; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339	48	3783	4062	7	324	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					942	949		10.1038/nm1093	http://dx.doi.org/10.1038/nm1093			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15322536				2022-12-27	WOS:000223658400031
J	Gregorevic, P; Blankinship, MJ; Allen, JM; Crawford, RW; Meuse, L; Miller, DG; Russell, DW; Chamberlain, JS				Gregorevic, P; Blankinship, MJ; Allen, JM; Crawford, RW; Meuse, L; Miller, DG; Russell, DW; Chamberlain, JS			Systemic delivery of genes to striated muscles using adeno-associated viral vectors	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; ENDOTHELIAL GROWTH-FACTOR; FULL-LENGTH DYSTROPHIN; MDX MICE; VIRUS VECTORS; ADENOVIRAL VECTORS; SKELETAL-MUSCLE; HEMOPHILIA-B; THERAPY; EXPRESSION	A major obstacle limiting gene therapy for diseases of the heart and skeletal muscles is an inability to deliver genes systemically to muscles of an adult organism. Systemic gene transfer to striated muscles is hampered by the vascular endothelium, which represents a barrier to distribution of vectors via the circulation. Here we show the first evidence of widespread transduction of both cardiac and skeletal muscles in an adult mammal, after a single intravenous administration of recombinant adeno-associated virus pseudotype 6 vectors. The inclusion of vascular endothelium growth factor/vascular permeability factor, to achieve acute permeabilization of the peripheral microvasculature, enhanced tissue transduction at lower vector doses. This technique enabled widespread muscle-specific expression of a functional micro-dystrophin in the skeletal muscles of dystrophin-deficient mdx mice, which model Duchenne muscular dystrophy. We propose that these methods may be applicable for systemic delivery of a wide variety of genes to the striated muscles of adult mammals.	Univ Washington, Dept Neurol, Senator Paul D Wellstone Muscular Dystrophy Coope, Seattle, WA 98195 USA; Univ Washington, Dept Med, Senator Paul D Wellstone Muscular Dystrophy Coope, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Senator Paul D Wellstone Muscular Dystrophy Coope, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chamberlain, JS (corresponding author), Univ Washington, Dept Neurol, Senator Paul D Wellstone Muscular Dystrophy Coope, Seattle, WA 98195 USA.	jsc5@u.washington.edu	Gregorevic, Paul/AAH-6040-2021	Gregorevic, Paul/0000-0002-7418-8945; Miller, Daniel/0000-0002-5700-3048; Chamberlain, Jeffrey/0000-0001-5299-0059	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK062100, R01DK055759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015434] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG015434] Funding Source: Medline; NIDDK NIH HHS [K08 DK062100, R01 DK055759] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad A, 2000, HUM MOL GENET, V9, P2507, DOI 10.1093/hmg/9.17.2507; Arruda VR, 2001, MOL THER, V4, P586, DOI 10.1006/mthe.2001.0491; Bridges CR, 2002, ANN THORAC SURG, V73, P1939, DOI 10.1016/S0003-4975(02)03509-9; Cho WK, 2000, HUM GENE THER, V11, P701, DOI 10.1089/10430340050015608; DelloRusso C, 2002, P NATL ACAD SCI USA, V99, P12979, DOI 10.1073/pnas.202300099; Eppler SM, 2002, CLIN PHARMACOL THER, V72, P20, DOI 10.1067/mcp.2002.126179; Greelish JP, 1999, NAT MED, V5, P439, DOI 10.1038/7439; Gregorevic P, 2003, EXPERT OPIN BIOL TH, V3, P803, DOI 10.1517/14712598.3.5.803; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Grimm D, 2003, BLOOD, V102, P2412, DOI 10.1182/blood-2003-02-0495; Halbert CL, 2001, J VIROL, V75, P6615, DOI 10.1128/JVI.75.14.6615-6624.2001; Halbert CL, 2000, J VIROL, V74, P1524, DOI 10.1128/JVI.74.3.1524-1532.2000; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; Hartigan-O'Connor D, 2001, MOL THER, V4, P525, DOI 10.1006/mthe.2001.0496; Hauser MA, 2000, MOL THER, V2, P16, DOI 10.1006/mthe.2000.0089; Herzog RW, 2002, HUM GENE THER, V13, P1281, DOI 10.1089/104303402760128513; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; HUARD J, 1995, GENE THER, V2, P107; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Pinson KI, 1998, DEV DYNAM, V211, P109, DOI 10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Rutledge EA, 1998, J VIROL, V72, P309, DOI 10.1128/JVI.72.1.309-319.1998; Sakamoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1265, DOI 10.1016/S0006-291X(02)00362-5; Scott JM, 2002, NEUROMUSCULAR DISORD, V12, pS23, DOI 10.1016/S0960-8966(02)00078-0; SENGER DR, 1986, CANCER RES, V46, P5629; Watchko J, 2002, HUM GENE THER, V13, P1451, DOI 10.1089/10430340260185085; Yuasa K, 2002, GENE THER, V9, P1576, DOI 10.1038/sj.gt.3301829; Zhang GF, 2002, METHOD ENZYMOL, V346, P125	33	483	511	1	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					828	834		10.1038/nm1085	http://dx.doi.org/10.1038/nm1085			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15273747	Green Accepted			2022-12-27	WOS:000223055700037
J	Wang, XH; Arcuino, G; Takano, T; Lin, J; Peng, WG; Wan, PL; Li, PJ; Xu, QW; Liu, QS; Goldman, SA; Nedergaard, M				Wang, XH; Arcuino, G; Takano, T; Lin, J; Peng, WG; Wan, PL; Li, PJ; Xu, QW; Liu, QS; Goldman, SA; Nedergaard, M			P2X7 receptor inhibition improves recovery after spinal cord injury	NATURE MEDICINE			English	Article							P2X(7) RECEPTOR; EXTRACELLULAR CALCIUM; SYNAPTIC-TRANSMISSION; GLUTAMATE RELEASE; WAVE-PROPAGATION; BRAIN-INJURY; AMINO-ACIDS; ASTROCYTES; ATP; MECHANISMS	Secondary injury exacerbates the extent of spinal cord insults, yet the mechanistic basis of this phenomenon has largely been unexplored. Here we report that broad regions of the peritraumatic zone are characterized by a sustained process of pathologic, high ATP release. Spinal cord neurons expressed P2X7 purine receptors (P2X7R), and exposure to ATP led to high-frequency spiking, irreversible increases in cytosolic calcium and cell death. To assess the potential effect of P2X7R blockade in ameliorating acute spinal cord injury (SCI), we delivered P2X7R antagonists OxATP or PPADS to rats after acute impact injury. We found that both OxATP and PPADS significantly improved functional recovery and diminished cell death in the peritraumatic zone. These observations demonstrate that SCI is associated with prolonged purinergic receptor activation, which results in excitotoxicity-based neuronal degeneration. P2X7R antagonists inhibit this process, reducing both the histological extent and functional sequelae of acute SCI.	Univ Rochester, Med Ctr, Ctr Aging & Dev Biol, Dept Neurosurg, Rochester, NY 14642 USA; New York Med Coll, Dept Cell Biol, Valhalla, NY 10595 USA; New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA	University of Rochester; New York Medical College; New York Medical College; University of Rochester; Cornell University	Nedergaard, M (corresponding author), Univ Rochester, Med Ctr, Ctr Aging & Dev Biol, Dept Neurosurg, Rochester, NY 14642 USA.	Nedergaard@urmc.rochester.edu		Takano, Takahiro/0000-0002-6235-6673; Goldman, Steven/0000-0002-5498-4303; Wang, Xiaohai/0000-0001-5814-4072				Agrawal SK, 1997, J NEUROSCI, V17, P1055; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Armstrong JN, 2002, J NEUROSCI, V22, P5938; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014-2999(99)00350-7; CAWTHON DF, 1980, J NEUROSURG, V52, P801, DOI 10.3171/jns.1980.52.6.0801; Chow SC, 1997, NEUROPHARMACOLOGY, V36, P1149, DOI 10.1016/S0028-3908(97)00123-8; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Cook SP, 2002, PAIN, V95, P41, DOI 10.1016/S0304-3959(01)00372-4; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; Egan TM, 2004, J NEUROSCI, V24, P3413, DOI 10.1523/JNEUROSCI.5429-03.2004; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Fam SR, 2000, J NEUROSCI, V20, P2800; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Goldman SA, 2002, NAT MED, V8, P785, DOI 10.1038/nm0802-785; Grafe P, 1999, J PHYSIOL-LONDON, V515, P377, DOI 10.1111/j.1469-7793.1999.377ac.x; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Haghighi SS, 1996, NEUROL RES, V18, P509; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; Le Feuvre RA, 2003, J CEREBR BLOOD F MET, V23, P381, DOI 10.1097/01.WCB.0000048519.34839.97; Lin JHC, 2003, J NEUROSCI, V23, P430, DOI 10.1523/JNEUROSCI.23-02-00430.2003; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Michel AD, 2000, BRIT J PHARMACOL, V130, P513, DOI 10.1038/sj.bjp.0703368; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; Newman EA, 2003, TRENDS NEUROSCI, V26, P536, DOI 10.1016/S0166-2236(03)00237-6; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Roy NS, 2004, NAT BIOTECHNOL, V22, P297, DOI 10.1038/nbt944; Scemes E, 2000, J NEUROSCI, V20, P1435; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; Stout C, 2003, GLIA, V43, P265, DOI 10.1002/glia.10257; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Wang Z, 1997, J NEUROSCI, V17, P7359	52	409	436	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					821	827		10.1038/nm1082	http://dx.doi.org/10.1038/nm1082			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15258577				2022-12-27	WOS:000223055700036
J	van der Hoek, L; Pyrc, K; Jebbink, MF; Vermeulen-Oost, W; Berkhout, RJM; Wolthers, KC; Wertheim-van Dillen, PME; Kaandorp, J; Spaargaren, J; Berkhout, B				van der Hoek, L; Pyrc, K; Jebbink, MF; Vermeulen-Oost, W; Berkhout, RJM; Wolthers, KC; Wertheim-van Dillen, PME; Kaandorp, J; Spaargaren, J; Berkhout, B			Identification of a new human coronavirus	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING; SARS-CORONAVIRUS; ORGAN CULTURES; SPIKE PROTEIN; S-GENE; VIRUS; DISEASE; GENOME; OC43	Three human coronaviruses are known to exist: human coronavirus 229E (HCoV-229E), HCoV-OC43 and severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). Here we report the identification of a fourth human coronavirus, HCoV-NL63, using a new method of virus discovery. The virus was isolated from a 7-month-old child suffering from bronchiolitis and conjunctivitis. The complete genome sequence indicates that this virus is not a recombinant, but rather a new group 1 coronavirus. The in vitro host cell range of HCoV-NL63 is notable because it replicates on tertiary monkey kidney cells and the monkey kidney LLC-MK2 cell line. The viral genome contains distinctive features, including a unique N-terminal fragment within the spike protein. Screening of clinical specimens from individuals suffering from respiratory illness identified seven additional HCoV-NL63-infected individuals, indicating that the virus was widely spread within the human population.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands; Municipal Hlth Serv, Publ Hlth Lab, NL-1018 WT Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol Clin Virol, NL-1105 AZ Amsterdam, Netherlands; Slotervaart Hosp, Dept Pediat, NL-1066 EC Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.berkhout@amc.uva.nl	van der Hoek, Lia/Y-6412-2019; Wolthers, Katja C./E-5140-2018	Wolthers, Katja C./0000-0003-1617-7049; Spaargaren, Joke/0000-0001-8728-316X				Almeida J D, 1967, J Gen Virol, V1, P175, DOI 10.1099/0022-1317-1-2-175; Bachem CWB, 1996, PLANT J, V9, P745, DOI 10.1046/j.1365-313X.1996.9050745.x; Boivin G, 2003, EMERG INFECT DIS, V9, P634; Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRADBURNE AF, 1967, BMJ-BRIT MED J, V3, P767, DOI 10.1136/bmj.3.5568.767; Chen LL, 2003, BIOCHEM BIOPH RES CO, V307, P382, DOI 10.1016/S0006-291X(03)01192-6; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; DUARTE M, 1994, VIROLOGY, V198, P466, DOI 10.1006/viro.1994.1058; GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Guy JS, 2000, J CLIN MICROBIOL, V38, P4523, DOI 10.1128/JCM.38.12.4523-4526.2000; Hamparian W, 1979, DIAGNOSTIC PROCEDURE, P562; HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734; HENDLEY JO, 1972, AM REV RESPIR DIS, V105, P805; Holmes KV, 1996, FIELDS VIROLOGY, P1075; Jubelt B, 2001, NEUROLOGY, V57, P945, DOI 10.1212/WNL.57.6.945; Krempl C, 2000, J GEN VIROL, V81, P489, DOI 10.1099/0022-1317-81-2-489; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; KUNKEL F, 1993, VIROLOGY, V195, P195, DOI 10.1006/viro.1993.1360; Lai MMC, 2003, J BIOMED SCI, V10, P664, DOI [10.1007/BF02256318, 10.1159/000074077]; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502; MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933; MOUNIR S, 1993, ADV EXP MED BIOL, V342, P61; MOUNIR S, 1993, VIROLOGY, V192, P355, DOI 10.1006/viro.1993.1043; MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Sawicki S G, 1995, Adv Exp Med Biol, V380, P499; Shingadia D, 2002, LANCET INFECT DIS, V2, P310, DOI 10.1016/S1473-3099(02)00265-7; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9; Stohlman SA, 2001, BRAIN PATHOL, V11, P92; Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273; TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467; van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056; VAUGHN EM, 1995, J VIROL, V69, P3176, DOI 10.1128/JVI.69.5.3176-3184.1995	41	916	972	6	71	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					368	373		10.1038/nm1024	http://dx.doi.org/10.1038/nm1024			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034574	Green Published, Bronze			2022-12-27	WOS:000220587000027
J	Sato, N; Meijer, L; Skaltsounis, L; Greengard, P; Brivanlou, AH				Sato, N; Meijer, L; Skaltsounis, L; Greengard, P; Brivanlou, AH			Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor	NATURE MEDICINE			English	Article							BETA-CATENIN; TRANSCRIPTION FACTOR; SELF-RENEWAL; ES CELLS; HUMAN BLASTOCYSTS; COLON-CARCINOMA; AXIS FORMATION; POU-DOMAIN; DIFFERENTIATION; EXPRESSION	Human and mouse embryonic stem cells (HESCs and MESCs, respectively) self-renew indefinitely while maintaining the ability to generate all three germ-layer derivatives. Despite the importance of ESCs in developmental biology and their potential impact on tissue replacement therapy, the molecular mechanism underlying ESC self-renewal is poorly understood. Here we show that activation of the canonical Wnt pathway is sufficient to maintain self-renewal of both HESCs and MESCs. Although Stat-3 signaling is involved in MESC self-renewal, stimulation of this pathway does not support self-renewal of HESCs. Instead we find that Wnt pathway activation by 6-bromoindirubin-3'-oxime (BIO), a specific pharmacological inhibitor of glycogen synthase kinase-3 (GSK-3), maintains the undifferentiated phenotype in both types of ESCs and sustains expression of the pluripotent state-specific transcription factors Oct-3/4, Rex-1 and Nanog. Wnt signaling is endogenously activated in undifferentiated MESCs and is downregulated upon differentiation. In addition, BIO-mediated Wnt activation is functionally reversible, as withdrawal of the compound leads to normal multidifferentiation programs in both HESCs and MESCs. These results suggest that the use of GSK-3-specific inhibitors such as BIO may have practical applications in regenerative medicine.	Rockefeller Univ, Lab Mol Vertebrate Embryol, New York, NY 10021 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; CNRS, Biol Stn, Cell Cycle Grp, F-29680 Roscoff, France; Univ Athens, Dept Pharmacognosy, Athens, Greece	Rockefeller University; Rockefeller University; Centre National de la Recherche Scientifique (CNRS); National & Kapodistrian University of Athens	Brivanlou, AH (corresponding author), Rockefeller Univ, Lab Mol Vertebrate Embryol, 1230 York Ave, New York, NY 10021 USA.		skaltsounis, alexios leandros/AAE-9617-2019	, laurent/0000-0003-3511-4916				Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; Ding S, 2003, P NATL ACAD SCI USA, V100, P7632, DOI 10.1073/pnas.0732087100; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hori Y, 2002, P NATL ACAD SCI USA, V99, P16105, DOI 10.1073/pnas.252618999; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kubo F, 2003, DEVELOPMENT, V130, P587, DOI 10.1242/dev.00244; Lloyd S, 2003, GENE EXPR PATTERNS, V3, P309, DOI 10.1016/S1567-133X(03)00046-2; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MEIJER L, IN PRESS CHEM BIOL; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Rossant J, 2001, STEM CELLS, V19, P477, DOI 10.1634/stemcells.19-6-477; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Vonica A, 2002, DEV BIOL, V250, P112, DOI 10.1006/dbio.2002.0786; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971	47	1623	1865	1	176	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					55	63		10.1038/nm979	http://dx.doi.org/10.1038/nm979			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702635				2022-12-27	WOS:000187743600039
J	Trachtenberg, E; Korber, B; Sollars, C; Kepler, TB; Hraber, PT; Hayes, E; Funkhouser, R; Fugate, M; Theiler, J; Hsu, YS; Kunstman, K; Wu, S; Phair, J; Erlich, H; Wolinsky, S				Trachtenberg, E; Korber, B; Sollars, C; Kepler, TB; Hraber, PT; Hayes, E; Funkhouser, R; Fugate, M; Theiler, J; Hsu, YS; Kunstman, K; Wu, S; Phair, J; Erlich, H; Wolinsky, S			Advantage of rare HLA supertype in HIV disease progression	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE RESPONSES; CLASS-I; POLYMORPHISM; DIVERSITY; SELECTION; EPITOPES; PATTERNS; ALLELES; CTL	The highly polymorphic human leukocyte antigen (HLA) class I molecules help to determine the specificity and repertoire of the immune response. The great diversity of these antigen-binding molecules confers differential advantages in responding to pathogens, but presents a major obstacle to distinguishing HLA allele-specific effects. HLA class I supertypes provide a functional classification for the many different HLA alleles that overlap in their peptide-binding specificities. We analyzed the association of these discrete HLA supertypes with HIV disease progression rates in a population of HIV-infected men. We found that HLA supertypes alone and in combination conferred a strong differential advantage in responding to HIV infection, independent of the contribution of single HLA alleles that associate with progression of the disease. The correlation of the frequency of the HLA supertypes with viral load suggests that HIV adapts to the most frequent alleles in the population, providing a selective advantage for those individuals who express rare alleles.	Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Duke Univ, Med Ctr, Durham, NC 27708 USA; Roche Mol Syst, Alameda, CA 94501 USA	Northwestern University; Feinberg School of Medicine; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; United States Department of Energy (DOE); Los Alamos National Laboratory; The Santa Fe Institute; Duke University; Roche Holding	Wolinsky, S (corresponding author), Northwestern Univ, Feinberg Sch Med, 676 N St Clair St, Chicago, IL 60611 USA.	s-wolinsky@northwestern.edu	Wolinsky, Steven/B-2893-2012	Hraber, Peter/0000-0002-2920-4897; Korber, Bette/0000-0002-2026-5757; Kepler, Thomas/0000-0002-1383-6865; Wolinsky, Steven/0000-0002-9625-6697	NCI NIH HHS [P30-CA79458] Funding Source: Medline; NIAID NIH HHS [U01-AI-35039] Funding Source: Medline; NICHD NIH HHS [R01-HD37356] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037356] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA079458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Altfeld MA, 2001, J VIROL, V75, P1301, DOI 10.1128/JVI.75.3.1301-1311.2001; Anastos K, 2000, J ACQ IMMUN DEF SYND, V24, P218; BEGOVICH AB, 1992, J IMMUNOL, V148, P249; Bertoni R, 1997, J CLIN INVEST, V100, P503, DOI 10.1172/JCI119559; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BODMER WF, 1972, NATURE, V237, P139, DOI 10.1038/237139a0; Boon ACM, 2002, J VIROL, V76, P582, DOI 10.1128/JVI.76.2.582-590.2002; BUGAWAN TL, 1991, IMMUNOGENETICS, V33, P163, DOI 10.1007/BF01719235; BUGAWAN TL, 1991, IMMUNOGENETICS, V34, P413, DOI 10.1007/BF01787493; BUGAWAN TL, 1994, TISSUE ANTIGENS, V44, P137, DOI 10.1111/j.1399-0039.1994.tb02371.x; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; Cao K, 2001, HUM IMMUNOL, V62, P1009, DOI 10.1016/S0198-8859(01)00298-1; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Clark B., 1976, Symposia Br Soc Parasit, V14, P87; de Groot NG, 2002, P NATL ACAD SCI USA, V99, P11748, DOI 10.1073/pnas.182420799; ERLICH HA, 2001, MOL EPIDEMIOLOGY PRA, V181; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Hendel H, 1999, J IMMUNOL, V162, P6942; HILL A, 1993, IMMUNOGENETICS, V37, P95; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOPE ACA, 1968, J ROY STAT SOC B, V30, P582; Howard J.C., 1987, P397; HUGHES AL, 1990, MOL BIOL EVOL, V7, P515; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Keet IPM, 1999, J INFECT DIS, V180, P299, DOI 10.1086/314862; LI M, 1993, INTRO KOLMOGOROV COM, V546; Little A M, 1999, Rev Immunogenet, V1, P105; MacDonald KS, 2001, IMMUNOL LETT, V79, P151, DOI 10.1016/S0165-2478(01)00277-2; MARSH SGE, 2002, HLA FACTSBOOK, V398; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Nelson GW, 1997, P NATL ACAD SCI USA, V94, P9802, DOI 10.1073/pnas.94.18.9802; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; Propato A, 2001, HUM IMMUNOL, V62, P561, DOI 10.1016/S0198-8859(01)00245-2; Rissanen J, 1999, COMPUT J, V42, P260, DOI 10.1093/comjnl/42.4.260; RISSANEN J, 1989, STOCHASTIC COMPLEXIT, V171; Roger M, 1998, FASEB J, V12, P625, DOI 10.1096/fasebj.12.9.625; SAAH AJ, 1992, AM J EPIDEMIOL, V135, P1147, DOI 10.1093/oxfordjournals.aje.a116215; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594; Slatkin M, 2000, GENETICS, V156, P2119; Tomiyama H, 2000, EUR J IMMUNOL, V30, P2521, DOI 10.1002/1521-4141(200009)30:9<2521::AID-IMMU2521>3.0.CO;2-Q; Trachtenberg E. A., 2001, HIV MOL IMMUNOLOGY D, P1; TROWSDALE J, 1992, EUR J IMMUNOGENET, V19, P45; vanderBurg SH, 1997, J IMMUNOL, V159, P3648; VENABLES WN, 1999, MODERN APPL STAT S P, V501; Williams A, 2002, TISSUE ANTIGENS, V59, P3, DOI 10.1034/j.1399-0039.2002.590103.x; Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002	49	266	274	0	24	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					928	935		10.1038/nm893	http://dx.doi.org/10.1038/nm893			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12819779				2022-12-27	WOS:000183979300035
J	Cao, RH; Brakenhielm, E; Pawliuk, R; Wariaro, D; Post, MJ; Wahlberg, E; Leboulch, P; Cao, YH				Cao, RH; Brakenhielm, E; Pawliuk, R; Wariaro, D; Post, MJ; Wahlberg, E; Leboulch, P; Cao, YH			Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CORONARY-ARTERY DISEASE; CLINICAL-APPLICATIONS; GENE-THERAPY; RECEPTOR; DELIVERY; MICE	The establishment of functional and stable vascular networks is essential for angiogenic therapy. Here we report that a combination of two angiogenic factors, platelet-derived growth factor (PDGF)-BB and fibroblast growth factor (FGF)-2, synergistically induces vascular networks, which remain stable for more than a year even after depletion of angiogenic factors. In both rat and rabbit ischemic hind limb models, PDGF-BB and FGF-2 together markedly stimulated collateral arteriogenesis after ligation of the femoral artery, with a significant increase in vascularization and improvement in paw blood flow. A possible mechanism of angiogenic synergism between PDGF-BB and FGF-2 involves upregulation of the expression of PDGF receptor (PDGFR)-alpha and PDGFR-beta by FGF-2 in newly formed blood vessels. Our data show that a specific combination of angiogenic factors establishes functional and stable vascular networks, and provides guidance for the ongoing clinical trials of angiogenic factors for the treatment of ischemic diseases.	Karolinska Inst, Lab Angiogenesis Res, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Genetix Pharmaceut Inc, Cambridge, MA USA; Karolinska Hosp, Dept Vasc Surg, S-10401 Stockholm, Sweden; Dartmouth Coll Sch Med, Dept Med, Lebanon, NH USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Hop St Louis, INSERM EMI 0111, Paris, France	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Dartmouth College; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Cao, YH (corresponding author), Karolinska Inst, Lab Angiogenesis Res, Ctr Microbiol & Tumor Biol, Stockholm, Sweden.		Brakenhielm, Ebba/E-9758-2011	Brakenhielm, Ebba/0000-0003-3378-8300				Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Carmeliet P, 2001, NAT BIOTECHNOL, V19, P1019, DOI 10.1038/nbt1101-1019; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; ESSEX TJH, 1991, J BIOMED ENG, V13, P189, DOI 10.1016/0141-5425(91)90125-Q; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Freedman SB, 2002, ANN INTERN MED, V136, P54, DOI 10.7326/0003-4819-136-1-200201010-00011; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hendel RC, 2000, CIRCULATION, V101, P118, DOI 10.1161/01.CIR.101.2.118; Holmgren L, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026929; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Lee RJ, 2000, CIRCULATION, V102, P898; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; PASSANITI A, 1992, INT J CANCER, V51, P318, DOI 10.1002/ijc.2910510224; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; SEIFERT FC, 1985, J CARDIOVASC SURG, V26, P502; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; Simons M, 2002, CIRCULATION, V105, P788, DOI 10.1161/hc0802.104407; Waltenberger J, 1997, CIRCULATION, V96, P4083; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zetter BR, 2001, J CELL BIOL, V152, pF35, DOI 10.1083/jcb.152.6.F35	30	563	612	4	57	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					604	613		10.1038/nm848	http://dx.doi.org/10.1038/nm848			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12669032				2022-12-27	WOS:000182610600043
J	Qi, JH; Ebrahem, Q; Moore, N; Murphy, G; Claesson-Welsh, L; Bond, M; Baker, A; Anand-Apte, B				Qi, JH; Ebrahem, Q; Moore, N; Murphy, G; Claesson-Welsh, L; Bond, M; Baker, A; Anand-Apte, B			A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SORSBYS-FUNDUS-DYSTROPHY; RETINAL-PIGMENT EPITHELIUM; MESSENGER-RNA EXPRESSION; TYROSINE KINASE; VASCULAR ENDOTHELIUM; SIGNAL-TRANSDUCTION; TUMOR-GROWTH; CELL-DEATH; GENE	Tissue inhibitor of metalloproteinases-3 (TIMP3) is one of four members of a family of proteins that were originally classified according to their ability to inhibit matrix metalloproteinases (MMP). TIMP3, which encodes a potent angiogenesis inhibitor, is mutated in Sorsby fundus dystrophy, a macular degenerative disease with submacular choroidal neovascularization. In this study we demonstrate the ability of TIMP3 to inhibit vascular endothelial factor (VEGF)-mediated angiogenesis and identify the potential mechanism by which this occurs: TIMP3 blocks the binding of VEGF to VEGF receptor-2 and inhibits downstream signaling and angiogenesis. This property seems to be independent of its MMP-inhibitory activity, indicating a new function for this molecule.	Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44195 USA; Univ Cambridge, Inst Med Res, Dept Oncol, Cambridge, England; Uppsala Univ, Dept Genet, Vasc Biol Unit, Rudbeck Lab, Uppsala, Sweden; Uppsala Univ, Dept Pathol, Vasc Biol Unit, Rudbeck Lab, Uppsala, Sweden; Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol, Avon, England; Univ Glasgow, Dept Med & Therapeut, Glasgow, Lanark, Scotland; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; University of Cambridge; Uppsala University; Uppsala University; Bristol Royal Infirmary; University of Bristol; University of Glasgow; Cleveland Clinic Foundation	Anand-Apte, B (corresponding author), Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Baker, Andy/AAO-5250-2021; Bond, Mark/AAG-9293-2019	Baker, Andy/0000-0003-1441-5576; 	NCI NIH HHS [R01 CA106415] Funding Source: Medline; NEI NIH HHS [1 R29 EY12109-01, R29 EY012109, R01 EY016490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106415] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY012109, R01EY016490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1998, J HISTOCHEM CYTOCHEM, V46, P437, DOI 10.1177/002215549804600403; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; BYRNE JA, 1995, MOL MED, V1, P418, DOI 10.1007/BF03401579; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Itoh T, 1998, CANCER RES, V58, P1048; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; Langton KP, 2000, J BIOL CHEM, V275, P27027; McElligott Anthony M., 1997, Biochemical Society Transactions, V25, p147S; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Powe DG, 1997, BRIT J CANCER, V75, P1678, DOI 10.1038/bjc.1997.285; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RUIZ A, 1996, INVEST OPHTH VIS SCI, V37, pS1143; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/PL00008707; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; URIA JA, 1994, CANCER RES, V54, P2091; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; Zeng ZS, 2001, DIS COLON RECTUM, V44, P1290, DOI 10.1007/BF02234786	46	504	524	0	16	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					407	415		10.1038/nm846	http://dx.doi.org/10.1038/nm846			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12652295				2022-12-27	WOS:000181987400030
J	Weissleder, R; Ntziachristos, V				Weissleder, Ralph; Ntziachristos, Vasilis			Shedding light onto live molecular targets	NATURE MEDICINE			English	Review								Optical sensing of specific molecular targets and pathways deep inside living mice has become possible as a result of a number of advances. These include design of biocompatible near-infrared fluorochromes, development of targeted and activatable 'smart' imaging probes, engineered photoproteins and advances in photon migration theory and reconstruction. Together, these advances will provide new tools making it possible to understand more fully the functioning of protein networks, diagnose disease earlier and speed along drug discovery.	[Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA USA; Harvard Univ, Sch Med, Charlestown, MA USA	Harvard University; Massachusetts General Hospital; Harvard University	Weissleder, R (corresponding author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA USA.	weissleder@helix.mgh.harvard.edu		/0000-0003-0828-4143				Achilefu S, 2000, INVEST RADIOL, V35, P479, DOI 10.1097/00004424-200008000-00004; Alfano RR, 1998, ANN NY ACAD SCI, V838, P14, DOI 10.1111/j.1749-6632.1998.tb08184.x; BALLOU B, 1995, CANCER IMMUNOL IMMUN, V41, P257, DOI 10.1007/s002620050226; Becker A, 2001, NAT BIOTECHNOL, V19, P327, DOI 10.1038/86707; Benaron DA, 2000, J CEREBR BLOOD F MET, V20, P469, DOI 10.1097/00004647-200003000-00005; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Boas DA, 2001, IEEE SIGNAL PROC MAG, V18, P57, DOI 10.1109/79.962278; Bogdanov AA, 2002, NEOPLASIA, V4, P228, DOI 10.1038/sj.neo.7900238; Bogdanov A, 2002, MOL IMAGING, V1, P16, DOI 10.1162/153535002753395671; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Burns S M, 2001, Contrib Microbiol, V9, P71; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Contag C H, 2001, J Perinatol, V21 Suppl 1, pS119, DOI 10.1038/sj.jp.7210647; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Costa GL, 2001, J IMMUNOL, V167, P2379, DOI 10.4049/jimmunol.167.4.2379; Demos SG, 2000, OPT EXPRESS, V7, P23, DOI 10.1364/OE.7.000023; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Farkas DL, 2001, PIGM CELL RES, V14, P2, DOI 10.1034/j.1600-0749.2001.140102.x; FOLLI S, 1994, CANCER RES, V54, P2643; Franceschini MA, 1997, P NATL ACAD SCI USA, V94, P6468, DOI 10.1073/pnas.94.12.6468; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Georgakoudi I., 2002, FLUORESCENCE BIOMEDI; Gonzalez S, 1999, J CUTAN PATHOL, V26, P201, DOI 10.1111/j.1600-0560.1999.tb01829.x; Gratton G, 2001, TRENDS COGN SCI, V5, P357, DOI 10.1016/S1364-6613(00)01701-0; Gurskaya NG, 2001, FEBS LETT, V507, P16, DOI 10.1016/S0014-5793(01)02930-1; Hastings JW, 1996, GENE, V173, P5, DOI 10.1016/0378-1119(95)00676-1; Hawrysz DJ, 2000, NEOPLASIA, V2, P388, DOI 10.1038/sj.neo.7900118; Hoffman RM, 2001, BIOTECHNIQUES, V30, P1016, DOI 10.2144/01305bi01; Honigman A, 2001, MOL THER, V4, P239, DOI 10.1006/mthe.2001.0437; HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529; Huber MM, 1998, BIOCONJUGATE CHEM, V9, P242, DOI 10.1021/bc970153k; Ito S, 2001, ENDOSCOPY, V33, P849, DOI 10.1055/s-2001-17328; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; Josephson L, 2001, ANGEW CHEM INT EDIT, V40, P3204, DOI 10.1002/1521-3773(20010903)40:17<3204::AID-ANIE3204>3.0.CO;2-H; Josephson L, 2002, BIOCONJUGATE CHEM, V13, P554, DOI 10.1021/bc015555d; Kuroiwa T, 2001, MINIM INVAS NEUROSUR, V44, P240, DOI 10.1055/s-2001-19929; Labas YA, 2002, P NATL ACAD SCI USA, V99, P4256, DOI 10.1073/pnas.062552299; Licha K, 2001, BIOCONJUGATE CHEM, V12, P44, DOI 10.1021/bc000040s; Licha K, 2000, PHOTOCHEM PHOTOBIOL, V72, P392, DOI 10.1562/0031-8655(2000)072<0392:HCDACA>2.0.CO;2; Lin YH, 2002, BIOCONJUGATE CHEM, V13, P605, DOI 10.1021/bc0155723; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; Mahmood U, 1999, RADIOLOGY, V213, P866, DOI 10.1148/radiology.213.3.r99dc14866; Marten K, 2002, GASTROENTEROLOGY, V122, P406, DOI 10.1053/gast.2002.30990; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Moats RA, 1997, ANGEW CHEM INT EDIT, V36, P726, DOI 10.1002/anie.199707261; Moore A, 1998, MICROVASC RES, V56, P145, DOI 10.1006/mvre.1998.2102; Moore Anna, 1998, Invasion and Metastasis, V18, P192, DOI 10.1159/000024512; Muguruma N, 1998, J GASTROENTEROL, V33, P467, DOI 10.1007/s005350050116; Muller MG, 2001, APPL OPTICS, V40, P4633, DOI 10.1364/AO.40.004633; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; Ntziachristos V, 2000, P NATL ACAD SCI USA, V97, P2767, DOI 10.1073/pnas.040570597; Ntziachristos V, 2002, NEOPLASIA, V4, P347, DOI 10.1038/sj.neo.7900244; Ntziachristos V, 2001, BREAST CANCER RES, V3, P41, DOI 10.1186/bcr269; Ntziachristos V, 2002, MED PHYS, V29, P803, DOI 10.1118/1.1470209; Ntziachristos V., 2002, NAT MED, V8, P575; Perez JM, 2002, J AM CHEM SOC, V124, P2856, DOI 10.1021/ja017773n; Perez JM, 2002, NAT BIOTECHNOL, V20, P816, DOI 10.1038/nbt720; Pham TH, 2000, APPL OPTICS, V39, P6487, DOI 10.1364/AO.39.006487; PISTON DW, 1995, J MICROSC-OXFORD, V178, P20, DOI 10.1111/j.1365-2818.1995.tb03576.x; Pogue BW, 2001, RADIOLOGY, V218, P261, DOI 10.1148/radiology.218.1.r01ja51261; Ray P, 2002, P NATL ACAD SCI USA, V99, P3105, DOI 10.1073/pnas.052710999; RichardsKortum R, 1996, ANNU REV PHYS CHEM, V47, P555, DOI 10.1146/annurev.physchem.47.1.555; Riefke B, 1996, P SOC PHOTO-OPT INS, V2927, P199, DOI 10.1117/12.260652; Slakter J S, 1995, Curr Opin Ophthalmol, V6, P25; Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037; Tung CH, 2000, CANCER RES, V60, P4953; Tung CH, 2002, CHEMBIOCHEM, V3, P784, DOI 10.1002/1439-7633(20020802)3:8<784::AID-CBIC784>3.0.CO;2-X; Vanzetta I, 1999, SCIENCE, V286, P1555, DOI 10.1126/science.286.5444.1555; Villringer A, 1997, TRENDS NEUROSCI, V20, P435, DOI 10.1016/S0166-2236(97)01132-6; Vooijs M, 2002, CANCER RES, V62, P1862; Wang TD, 1999, GASTROINTEST ENDOSC, V49, P447, DOI 10.1016/S0016-5107(99)70041-6; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; Weng YH, 2000, AM J PHYSIOL-LUNG C, V278, pL1273, DOI 10.1152/ajplung.2000.278.6.L1273; Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002-9440(10)64934-6; Williams RM, 2001, CURR OPIN CHEM BIOL, V5, P603, DOI 10.1016/S1367-5931(00)00241-6; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460; Wunderbaldinger P, 2002, MAGN RESON MED, V47, P292, DOI 10.1002/mrm.10068; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; Yang M, 2000, P NATL ACAD SCI USA, V97, P1206, DOI 10.1073/pnas.97.3.1206; Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201-1148; Zhang WS, 2001, TRANSGENIC RES, V10, P423, DOI 10.1023/A:1012042506002; Zonios G, 2001, J INVEST DERMATOL, V117, P1452, DOI 10.1046/j.0022-202x.2001.01577.x	85	1539	1620	10	330	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					123	128		10.1038/nm0103-123	http://dx.doi.org/10.1038/nm0103-123			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514725				2022-12-27	WOS:000208640400007
J	Hirasawa, A; Tsumaya, K; Awaji, T; Katsuma, S; Adachi, T; Yamada, M; Sugimoto, Y; Miyazaki, S; Tsujimoto, G				Hirasawa, A; Tsumaya, K; Awaji, T; Katsuma, S; Adachi, T; Yamada, M; Sugimoto, Y; Miyazaki, S; Tsujimoto, G			Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120	NATURE MEDICINE			English	Article							PROTEIN-COUPLED RECEPTORS; GREEN FLUORESCENT PROTEIN; INSULIN-SECRETION; GENE-EXPRESSION; ALPHA(1B)-ADRENOCEPTOR; CELLS; GPR40	Diabetes, a disease in which the body does not produce or use insulin properly, is a serious global health problem(1-3). Gut polypeptides secreted in response to food intake, such as glucagon-like peptide-1 (GLP-1), are potent incretin hormones that enhance the glucose-dependent secretion of insulin from pancreatic beta cells(4-6). Free fatty acids (FFAs) provide an important energy source and also act as signaling molecules in various cellular processes, including the secretion of gut incretin peptides(7,8). Here we show that a G-protein-coupled receptor, GPR120, which is abundantly expressed in intestine, functions as a receptor for unsaturated long-chain FFAs. Furthermore, we show that the stimulation of GPR120 by FFAs promotes the secretion of GLP-1 in vitro and in vivo, and increases circulating insulin. Because GLP-1 is the most potent insulinotropic incretin(9,10), our results indicate that GPR120-mediated GLP-1 secretion induced by dietary FFAs is important in the treatment of diabetes.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, Kyoto 6068501, Japan; Natl Res Inst Child Hlth & Dev, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 1548567, Japan; Keio Univ, Tokyo 1608582, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1628666, Japan; Kyoto Univ, Inst Chem Res, Bioinformat Ctr, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; National Center for Child Health & Development - Japan; Keio University; Tokyo Women's Medical University; Kyoto University; Kyoto University	Tsujimoto, G (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, 46-29 Yoshida Shimoadachi Cho, Kyoto 6068501, Japan.	gtsuji@pharm.kyoto-u.ac.jp	Sugimoto, Yukihiko/AAV-6470-2021; Adachi, Tetsuya/A-3330-2014	Sugimoto, Yukihiko/0000-0001-6973-932X; Adachi, Tetsuya/0000-0002-5746-5031				Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; Awaji T, 2001, BIOCHEM BIOPH RES CO, V289, P457, DOI 10.1006/bbrc.2001.6004; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Cao XM, 2003, ENDOCRINOLOGY, V144, P2025, DOI 10.1210/en.2002-0049; CREUTZFELDT W, 1985, DIABETOLOGIA, V28, P565, DOI 10.1007/BF00281990; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; Drucker DJ, 2003, MOL ENDOCRINOL, V17, P161, DOI 10.1210/me.2002-0306; Fredriksson R, 2003, FEBS LETT, V554, P381, DOI 10.1016/S0014-5793(03)01196-7; Gadsby R, 2002, ADV DRUG DELIVER REV, V54, P1165, DOI 10.1016/S0169-409X(02)00094-7; Gevrey JC, 2002, J BIOL CHEM, V277, P22407, DOI 10.1074/jbc.M201624200; Guimbaud R, 1997, PANCREAS, V14, P76, DOI 10.1097/00006676-199701000-00012; Hirasawa A, 1997, MOL PHARMACOL, V52, P764, DOI 10.1124/mol.52.5.764; Holst JJ, 2001, SCAND J CLIN LAB INV, V61, P75, DOI 10.1080/713783697; HORIE K, 1994, EUR J PHARM-MOLEC PH, V268, P399, DOI 10.1016/0922-4106(94)90065-5; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jovanovic L, 1999, ANN CLIN LAB SCI, V29, P33; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; KREYMANN B, 1987, LANCET, V2, P1300; MacDonald PE, 2002, DIABETES, V51, pS434, DOI 10.2337/diabetes.51.2007.S434; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; Nilsson NE, 2003, BIOCHEM BIOPH RES CO, V303, P1047, DOI 10.1016/S0006-291X(03)00488-1; Nunez EA, 1997, PROSTAG LEUKOTR ESS, V57, P107, DOI 10.1016/S0952-3278(97)90500-7; Reimer RA, 2001, ENDOCRINOLOGY, V142, P4522, DOI 10.1210/en.142.10.4522; Sidhu SS, 2000, J PHYSIOL-LONDON, V528, P165, DOI 10.1111/j.1469-7793.2000.00165.x; Thomsen C, 2003, AM J CLIN NUTR, V77, P605, DOI 10.1093/ajcn/77.3.605; Trogan E, 2002, P NATL ACAD SCI USA, V99, P2234, DOI 10.1073/pnas.042683999; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Vilsboll T, 2003, J CLIN ENDOCR METAB, V88, P2706, DOI 10.1210/jc.2002-021873; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	30	1083	1168	3	159	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					90	94		10.1038/nm1168	http://dx.doi.org/10.1038/nm1168			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619630				2022-12-27	WOS:000226124900038
J	Uhrbom, L; Nerio, E; Holland, EC				Uhrbom, L; Nerio, E; Holland, EC			Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model	NATURE MEDICINE			English	Article							IN-VIVO; LIVING MAMMALS; EXPRESSION; CANCER; MICE	Bioluminescence imaging has previously been used to monitor the formation of grafted tumors in vivo and measure cell number during tumor progression and response to therapy. The development and optimization of successful cancer therapy strategies may well require detailed and specific assessment of biological processes in response to mechanistic intervention. Here, we use bioluminescence imaging to monitor the cell cycle in a genetically engineered, histologically accurate model of glioma in vivo. In these platelet-derived growth factor (PDGF)-driven oligodendrogliomas, G1 cell-cycle arrest is generated by blockade of either the PDGF receptor or mTOR using small-molecule inhibitors.	Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA; Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Uppsala University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Holland, EC (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, RRL 917B,1275 York Ave, New York, NY 10021 USA.	hollande@mskcc.org						Burgos JS, 2003, BIOTECHNIQUES, V34, P1184, DOI 10.2144/03346st01; Choy G, 2003, BIOTECHNIQUES, V35, P1022, DOI 10.2144/03355rr02; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; DAI C, IN PRESS NEOPLASIA; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rehemtulla A, 2000, NEOPLASIA, V2, P491, DOI 10.1038/sj.neo.7900121; Rehemtulla A, 2002, MOL IMAGING, V1, P43, DOI 10.1162/153535002753395707; Shah K, 2003, ONCOGENE, V22, P6865, DOI 10.1038/sj.onc.1206748; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHIH A, IN PRESS CANC RES; Tjuvajev JG, 2003, CANCER CELL, V3, P327, DOI 10.1016/S1535-6108(03)00082-5	19	111	120	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1257	1260		10.1038/nm1120	http://dx.doi.org/10.1038/nm1120			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502845				2022-12-27	WOS:000224785900050
J	Mandavilli, A				Mandavilli, A			Malik Peiris - Profile	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2004	10	9					886	886		10.1038/nm0904-886	http://dx.doi.org/10.1038/nm0904-886			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15340403	Green Published			2022-12-27	WOS:000223658400009
J	Ceradini, DJ; Kulkarni, AR; Callaghan, MJ; Tepper, OM; Bastidas, N; Kleinman, ME; Capla, JM; Galiano, RD; Levine, JP; Gurtner, GC				Ceradini, DJ; Kulkarni, AR; Callaghan, MJ; Tepper, OM; Bastidas, N; Kleinman, ME; Capla, JM; Galiano, RD; Levine, JP; Gurtner, GC			Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CHEMOKINE RECEPTOR CXCR4; BONE-MARROW; STEM/PROGENITOR CELLS; INDUCIBLE FACTOR-1; STEM-CELLS; MICE; MOBILIZATION; EXPRESSION; NEOVASCULARIZATION	The trafficking of circulating stem and progenitor cells to areas of tissue damage is poorly understood. The chemokine stromal cell - derived factor-1 (SDF-1 or CXCL12) mediates homing of stem cells to bone marrow by binding to CXCR4 on circulating cells(1,2). SDF-1 and CXCR4 are expressed in complementary patterns during embryonic organogenesis and guide primordial stem cells to sites of rapid vascular expansion(3). However, the regulation of SDF-1 and its physiological role in peripheral tissue repair remain incompletely understood(4). Here we show that SDF-1 gene expression is regulated by the transcription factor hypoxia-inducible factor-1 (HIF-1) in endothelial cells, resulting in selective in vivo expression of SDF-1 in ischemic tissue in direct proportion to reduced oxygen tension. HIF-1-induced SDF-1 expression increases the adhesion, migration and homing of circulating CXCR4-positive progenitor cells to ischemic tissue. Blockade of SDF-1 in ischemic tissue or CXCR4 on circulating cells prevents progenitor cell recruitment to sites of injury. Discrete regions of hypoxia in the bone marrow compartment also show increased SDF-1 expression and progenitor cell tropism. These data show that the recruitment of CXCR4-positive progenitor cells to regenerating tissues is mediated by hypoxic gradients via HIF-1-induced expression of SDF-1.	NYU, Sch Med, Inst Reconstruct Plast Surg, Lab Microvasc Res & Vasc Tissue Engn, New York, NY 10016 USA	New York University	Gurtner, GC (corresponding author), NYU, Sch Med, Inst Reconstruct Plast Surg, Lab Microvasc Res & Vasc Tissue Engn, New York, NY 10016 USA.	geoffrey.gurtner@med.nyu.edu	/ABE-5226-2021		NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB002265] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB002265] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hitchon C, 2002, ARTHRITIS RHEUM, V46, P2587, DOI 10.1002/art.10520; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Kawamoto A, 2001, CIRCULATION, V103, P634; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Ratajczak MZ, 2003, STEM CELLS, V21, P363, DOI 10.1634/stemcells.21-3-363; Reiss K, 2002, NEUROSCIENCE, V115, P295, DOI 10.1016/S0306-4522(02)00307-X; Rivard A, 2000, J BIOL CHEM, V275, P29643, DOI 10.1074/jbc.M001029200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Sweeney EA, 2002, BLOOD, V99, P44, DOI 10.1182/blood.V99.1.44; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	30	2067	2226	2	167	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					858	864		10.1038/nm1075	http://dx.doi.org/10.1038/nm1075			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15235597				2022-12-27	WOS:000223055700041
J	Majumder, PK; Febbo, PG; Bikoff, R; Berger, R; Xue, Q; McMahon, LM; Manola, J; Brugarolas, J; McDonnell, TJ; Golub, TR; Loda, M; Lane, HA; Sellers, WR				Majumder, PK; Febbo, PG; Bikoff, R; Berger, R; Xue, Q; McMahon, LM; Manola, J; Brugarolas, J; McDonnell, TJ; Golub, TR; Loda, M; Lane, HA; Sellers, WR			mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways	NATURE MEDICINE			English	Article							TUMOR-SUPPRESSOR; SIGNAL-TRANSDUCTION; CANCER CELLS; BCL-2; EXPRESSION; PHOSPHORYLATION; TARGET; GENE; TSC2; PROLIFERATION	Loss of PTEN function leads to activation of phosphoinositide 3-kinase (PI3K) signaling and Akt. Clinical trials are now testing whether mammalian target of rapamycin (mTOR) inhibition is useful in treating PTEN-null cancers. Here, we report that mTOR inhibition induced apoptosis of epithelial cells and the complete reversal of a neoplastic phenotype in the prostate of mice expressing human AKT1 in the ventral prostate. Induction of cell death required the mitochondrial pathway, as prostate-specific coexpression of BCL2 blocked apoptosis. Thus, there is an mTOR-dependent survival signal required downstream of Akt. Bcl2 expression, however, only partially restored intraluminal cell growth in the setting of mTOR inhibition. Expression profiling showed that Hif-1alpha targets, including genes encoding most glycolytic enzymes, constituted the dominant transcriptional response to AKT activation and mTOR inhibition. These data suggest that the expansion of AKT-driven prostate epithelial cells requires mTOR-dependent survival signaling and activation of HIF-1alpha, and that clinical resistance to mTOR inhibitors may emerge through BCL2 expression and/or upregulation of HIF-1alpha activity.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Novartis Pharmaceut, E Hanover, NJ 07936 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Harvard Univ, Broad Inst, Cambridge, MA 02142 USA; MIT, Broad Inst, Cambridge, MA 02142 USA; Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Novartis; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Novartis	Sellers, WR (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	william_sellers@dfci.harvard.edu		Brugarolas, James/0000-0002-8575-499X	NATIONAL CANCER INSTITUTE [P01CA089021] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA89021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Baltaci S, 2000, BJU INT, V85, P155, DOI 10.1046/j.1464-410x.2000.00388.x; Bruckheimer EM, 2000, ONCOGENE, V19, P2404, DOI 10.1038/sj.onc.1203571; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Chi KN, 2001, CLIN CANCER RES, V7, P3920; COLOMBEL M, 1993, AM J PATHOL, V143, P390; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; delPeso L, 1997, SCIENCE, V278, P687; DiPaolo RS, 1999, J CLIN ONCOL, V17, P2213, DOI 10.1200/JCO.1999.17.7.2213; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Friedland D, 1999, SEMIN ONCOL, V26, P19; Furuya Y, 1996, CLIN CANCER RES, V2, P389; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Krajewska M, 1996, AM J PATHOL, V148, P1567; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McMenamin ME, 1999, CANCER RES, V59, P4291; Mita Monica M, 2003, Clin Breast Cancer, V4, P126, DOI 10.3816/CBC.2003.n.018; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morris MJ, 2002, CLIN CANCER RES, V8, P679; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nashan B, 2002, THER DRUG MONIT, V24, P53, DOI 10.1097/00007691-200202000-00010; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; SELLERS WR, 2002, PROSTATE CANC PRINCI; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Suzuki H, 1998, CANCER RES, V58, P204; Taesch S, 1994, Transpl Int, V7 Suppl 1, pS263; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zhong H, 2000, CANCER RES, V60, P1541	50	800	853	2	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					594	601		10.1038/nm1052	http://dx.doi.org/10.1038/nm1052			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15156201				2022-12-27	WOS:000221759600024
J	Mall, M; Grubb, BR; Harkema, JR; O'Neal, WK; Boucher, RC				Mall, M; Grubb, BR; Harkema, JR; O'Neal, WK; Boucher, RC			Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice	NATURE MEDICINE			English	Article							NEUTROPHIL ELASTASE; SALT CONTROVERSY; SODIUM-CHANNELS; ION-TRANSPORT; EXPRESSION; GENE; CFTR; SECRETIONS; LIQUID; MUCUS	Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in defective epithelial cAMP-dependent Cl- secretion and increased airway Na+ absorption. The mechanistic links between these altered ion transport processes and the pathogenesis of cystic fibrosis lung disease, however, are unclear. To test the hypothesis that accelerated Na+ transport alone can produce cystic fibrosis-like lung disease, we generated mice with airway-specific overexpression of epithelial Na+ channels (ENaC). Here we show that increased airway Na+ absorption in vivo caused airway surface liquid (ASL) volume depletion, increased mucus concentration, delayed mucus transport and mucus adhesion to airway surfaces. Defective mucus transport caused a severe spontaneous lung disease sharing features with cystic fibrosis, including mucus obstruction, goblet cell metaplasia, neutrophilic inflammation and poor bacterial clearance. We conclude that increasing airway Na+ absorption initiates cystic fibrosis-like lung disease and produces a model for the study of the pathogenesis and therapy of this disease.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Michigan State Univ, Dept Pathobiol & Diagnost Invest, E Lansing, MI 48824 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Michigan State University	Mall, M (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, 7011 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	mmall@med.unc.edu; rboucher@med.unc.edu	Mall, Marcus A./AAA-1498-2022	Mall, Marcus A./0000-0002-4057-2199				Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; Berger M, 2002, AM J RESP CRIT CARE, V165, P857, DOI 10.1164/ajrccm.165.7.2202030a; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BREUER R, 1987, AM REV RESPIR DIS, V136, P698, DOI 10.1164/ajrccm/136.3.698; Brody SL, 2000, AM J RESP CELL MOL, V23, P45, DOI 10.1165/ajrcmb.23.1.4070; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fujii T, 2001, AM J RESP CELL MOL, V25, P265, DOI 10.1165/ajrcmb.25.3.4445; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Grubb Barbara R., 1999, Physiological Reviews, V79, pS193; Grubb BR, 2004, AM J PHYSIOL-LUNG C, V286, pL588, DOI 10.1152/ajplung.00302.2003; Grubb BR, 2001, AM J PHYSIOL-CELL PH, V281, pC615, DOI 10.1152/ajpcell.2001.281.2.C615; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; HACKETT BP, 1992, P NATL ACAD SCI USA, V89, P9079, DOI 10.1073/pnas.89.19.9079; Ibanez-Tallon I, 2002, HUM MOL GENET, V11, P715, DOI 10.1093/hmg/11.6.715; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIM CS, 1986, J APPL PHYSIOL, V60, P901, DOI 10.1152/jappl.1986.60.3.901; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kobayashi Y, 2002, MOL CELL BIOL, V22, P2769, DOI 10.1128/MCB.22.8.2769-2776.2002; Loffing J, 2000, AM J PHYSIOL-RENAL, V279, pF252, DOI 10.1152/ajprenal.2000.279.2.F252; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MATTHEWS LW, 1963, AM REV RESPIR DIS, V88, P199; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; Ostrowski LE, 2003, MOL THER, V8, P637, DOI 10.1016/S1525-0016(03)00221-1; PUCHELLE E, 1995, RESPIRATION, V62, P2; Sims DE, 1997, AM J PHYSIOL-LUNG C, V273, pL1036; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Takeyama K, 1998, AM J PHYSIOL-LUNG C, V275, pL294, DOI 10.1152/ajplung.1998.275.2.L294; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; van Heeckeren A, 1997, J CLIN INVEST, V100, P2810, DOI 10.1172/JCI119828; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; ZUELZER WW, 1949, PEDIATRICS, V4, P53	50	683	707	2	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					487	493		10.1038/nm1028	http://dx.doi.org/10.1038/nm1028			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15077107				2022-12-27	WOS:000221242400026
J	Wadia, JS; Stan, RV; Dowdy, SF				Wadia, JS; Stan, RV; Dowdy, SF			Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL; ENDOCYTOSIS; DELIVERY; SURFACE; INTERNALIZATION; DOMAINS; MACROPHAGES; CAVEOLAE; PATHWAY	The TAT protein transduction domain (PTD) has been used to deliver a wide variety of biologically active cargo for the treatment of multiple preclinical disease models, including cancer and stroke. However, the mechanism of transduction remains unknown. Because of the TAT PTD's strong cell-surface binding, early assumptions regarding cellular uptake suggested a direct penetration mechanism across the lipid bilayer by a temperature- and energy-independent process. Here we show, using a transducible TAT-Cre recombinase reporter assay on live cells, that after an initial ionic cell-surface interaction, TAT-fusion proteins are rapidly internalized by lipid raft-dependent macropinocytosis. Transduction was independent of interleukin-2 receptor/raft-, caveolar- and clathrin-mediated endocytosis and phagocytosis. Using this information, we developed a transducible, pH-sensitive, fusogenic dTAT-HA2 peptide that markedly enhanced TAT-Cre escape from macropinosomes. Taken together, these observations provide a scientific basis for the development of new, biologically active, transducible therapeutic molecules.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Dowdy, SF (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	sdowdy@ucsd.edu	wadia, jay/AAQ-9944-2021; Stan, Radu/AAE-7574-2021	Stan, Radu/0000-0003-2969-1725	NATIONAL CANCER INSTITUTE [R01CA096098] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065418] Funding Source: NIH RePORTER; NCI NIH HHS [CA96098, R01 CA096098] Funding Source: Medline; NHLBI NIH HHS [R01 HL065418-01A1, R01 HL065418-02, R01 HL065418-03, HL065418, R01 HL065418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Cao GD, 2002, J NEUROSCI, V22, P5423; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Liu NQ, 2002, J VIROL, V76, P6689, DOI 10.1128/JVI.76.13.6689-6700.2002; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; OLIVER JM, 1984, METHOD ENZYMOL, V108, P336; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x; Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x; Skehel JJ, 2001, BIOCHEM SOC T, V29, P623, DOI 10.1042/BST0290623; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306; Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731	30	1347	1503	2	208	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					310	315		10.1038/nm996	http://dx.doi.org/10.1038/nm996			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14770178				2022-12-27	WOS:000189297700045
J	Tanaka, M; Machida, Y; Niu, SY; Ikeda, T; Jana, NR; Doi, H; Kurosawa, M; Nekooki, M; Nukina, N				Tanaka, M; Machida, Y; Niu, SY; Ikeda, T; Jana, NR; Doi, H; Kurosawa, M; Nekooki, M; Nukina, N			Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease	NATURE MEDICINE			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; EXPANDED CAG REPEAT; CELL-DEATH; IN-VITRO; AGGREGATION; MICE; INHIBITION; DISORDERS; GENE; FIBRILLOGENESIS	Inhibition of polyglutamine-induced protein aggregation could provide treatment options for polyglutamine diseases such as Huntington disease. Here we showed through in vitro screening studies that various disaccharides can inhibit polyglutamine-mediated protein aggregation. We also found that various disaccharides reduced polyglutamine aggregates and increased survival in a cellular model of Huntington disease. Oral administration of trehalose, the most effective of these disaccharides, decreased polyglutamine aggregates in cerebrum and liver, improved motor dysfunction and extended lifespan in a transgenic mouse model of Huntington disease. We suggest that these beneficial effects are the result of trehalose binding to expanded polyglutamines and stabilizing the partially unfolded polyglutamine-containing protein. Lack of toxicity and high solubility, coupled with efficacy upon oral administration, make trehalose promising as a therapeutic drug or lead compound for the treatment of polyglutamine diseases. The saccharide-polyglutamine interaction identified here thus provides a new therapeutic strategy for polyglutamine diseases.	RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan	RIKEN	Nukina, N (corresponding author), RIKEN, Brain Sci Inst, Lab Struct Neuropathol, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	nukina@brain.riken.jp	Tanaka, Motomasa/N-5064-2015; Nukina, Nobuyuki/GPP-6265-2022	Tanaka, Motomasa/0000-0002-2994-7703; Jana, Nihar/0000-0002-6549-4211				Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; FARRER LA, 1985, CLIN GENET, V27, P62; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; Guo N, 2000, NAT BIOTECHNOL, V18, P168, DOI 10.1038/72616; Heiser V, 2002, P NATL ACAD SCI USA, V99, P16400, DOI 10.1073/pnas.182426599; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hughes RE, 2001, NAT MED, V7, P419, DOI 10.1038/86486; Hurlbert MS, 1999, DIABETES, V48, P649, DOI 10.2337/diabetes.48.3.649; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Kandror O, 2002, P NATL ACAD SCI USA, V99, P9727, DOI 10.1073/pnas.142314099; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; Luo YZ, 1998, J MOL BIOL, V279, P49, DOI 10.1006/jmbi.1998.1774; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; McCampbell A, 2001, NAT MED, V7, P528, DOI 10.1038/87842; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Nagai Y, 2000, J BIOL CHEM, V275, P10437, DOI 10.1074/jbc.275.14.10437; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Sathasivam K, 1999, HUM MOL GENET, V8, P813, DOI 10.1093/hmg/8.5.813; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Tanaka M, 2002, BIOCHEMISTRY-US, V41, P10277, DOI 10.1021/bi0258905; Tanaka M, 2001, J BIOL CHEM, V276, P45470, DOI 10.1074/jbc.M107502200; Wang GH, 1999, NEUROREPORT, V10, P2435, DOI 10.1097/00001756-199908200-00001; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	39	578	614	1	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					148	154		10.1038/nm985	http://dx.doi.org/10.1038/nm985			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14730359				2022-12-27	WOS:000188719600033
J	Wang, LH; Yang, XY; Zhang, XH; Mihalic, K; Fan, YX; Xiao, WH; Howard, OMZ; Appella, E; Maynard, AT; Farrar, WL				Wang, LH; Yang, XY; Zhang, XH; Mihalic, K; Fan, YX; Xiao, WH; Howard, OMZ; Appella, E; Maynard, AT; Farrar, WL			Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor	NATURE MEDICINE			English	Article							CELL-CYCLE PROGRESSION; DNA-BINDING DOMAIN; NUCLEOCAPSID PROTEIN; MOLECULAR-MECHANISMS; ANTITUMOR-ACTIVITY; GENE-EXPRESSION; TRICHOSTATIN-A; TUMOR-GROWTH; MCF-7 CELLS; NUDE-MICE	Current antiestrogen therapy for breast cancer is limited by the mixed estrogenic and antiestrogenic activity of selective estrogen receptor modulators. Here we show that the function of zinc fingers in the estrogen receptor DNA-binding domain (DBD) is susceptible to chemical inhibition by electrophilic disulfide benzamide and benzisothiazolone derivatives, which selectively block binding of the estrogen receptor to its responsive element and subsequent transcription. These compounds also significantly inhibit estrogen-stimulated cell proliferation, markedly reduce tumor mass in nude mice bearing human MCF-7 breast cancer xenografts, and interfere with cell-cycle and apoptosis regulatory gene expression. Functional assays and computational analysis support a molecular mechanism whereby electrophilic agents preferentially disrupt the vulnerable C-terminal zinc finger, thus suppressing estrogen receptor-mediated breast carcinoma progression. Our results provide the proof of principle for a new strategy to inhibit breast cancer at the level of DNA binding, rather than the classical antagonism of estrogen binding.	NCI, Basic Res Program, SAIC Frederick, NIH, Frederick, MD 21702 USA; NCI, Cytokine Mol Mech Sect, NIH, Frederick, MD 21702 USA; US FDA, Div Therapeut Prot, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; NCI, Mol Immunoregulat Lab, NIH, Frederick, MD 21702 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, LH (corresponding author), NCI, Basic Res Program, SAIC Frederick, NIH, POB B, Frederick, MD 21702 USA.		Xiao, Weihua/N-2775-2013; Howard, O M Zack/B-6117-2012	Xiao, Weihua/0000-0001-9102-6326; Howard, O M Zack/0000-0002-0505-7052	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010253] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bandyopadhyay A, 2002, CANCER RES, V62, P4690; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431; Huang MJ, 1998, J MED CHEM, V41, P1371, DOI 10.1021/jm9708543; Jordan VC, 1998, J NATL CANCER I, V90, P967, DOI 10.1093/jnci/90.13.967; Ju YH, 2002, CANCER RES, V62, P2474; KYPRIANOU N, 1991, CANCER RES, V51, P162; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lee SH, 2001, ANTIOXID REDOX SIGN, V3, P531, DOI 10.1089/15230860152542907; Liang XS, 1998, MOL CELL ENDOCRINOL, V146, P151, DOI 10.1016/S0303-7207(98)00161-0; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Maynard AT, 2001, J AM CHEM SOC, V123, P1047, DOI 10.1021/ja0011616; Maynard AT, 1998, P NATL ACAD SCI USA, V95, P11578, DOI 10.1073/pnas.95.20.11578; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Ngwenya S, 2003, ENDOCRINOLOGY, V144, P1675, DOI 10.1210/en.2002-0009; Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; PREDKI PF, 1992, J BIOL CHEM, V267, P5842; Rice WG, 1996, REV MED VIROL, V6, P187, DOI 10.1002/(SICI)1099-1654(199612)6:4&lt;187::AID-RMV176&gt;3.0.CO;2-F; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHAFIE SM, 1981, J NATL CANCER I, V67, P51; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Truchet I, 2000, EXP CELL RES, V254, P241, DOI 10.1006/excr.1999.4756; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Tummino PJ, 1996, P NATL ACAD SCI USA, V93, P969, DOI 10.1073/pnas.93.3.969; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Wang LH, 2001, J BIOL CHEM, V276, P31839, DOI 10.1074/jbc.M105185200; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Whittal RM, 2000, BIOCHEMISTRY-US, V39, P8406, DOI 10.1021/bi000282f; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	45	73	79	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					40	47		10.1038/nm969	http://dx.doi.org/10.1038/nm969			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702633				2022-12-27	WOS:000187743600037
J	Amsellem, S; Pflumio, F; Bardinet, D; Izac, B; Charneau, P; Romeo, PH; Dubart-Kupperschmitt, A; Fichelson, S				Amsellem, S; Pflumio, F; Bardinet, D; Izac, B; Charneau, P; Romeo, PH; Dubart-Kupperschmitt, A; Fichelson, S			Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein	NATURE MEDICINE			English	Article							NOD/SCID-REPOPULATING CELLS; IN-VIVO; PROGENITOR CELLS; EXPRESSION; HOMEODOMAIN; THROMBOPOIETIN; PROLIFERATION; PURIFICATION; RECEPTOR	Expansion of human hematopoietic stem cells (HSCs) is a major challenge in cellular therapy, and currently relies on the use of recombinant cytokines or on gene transfer of transcription factors. Of these, the HOXB4 homeoprotein protein is of particular interests as it promotes the expansion of mouse HSCs without inducing the development of leukemia. To eliminate any deleterious effects that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes. Here we show that when cultured on stromal cells genetically engineered to secrete HOXB4, human long-term culture-initiating cells (LTC-ICs) and nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mouse repopulating cells (SRCs) were expanded by more than 20- and 2.5-fold, respectively, over their input numbers. This expansion was associated with enhanced stem cell repopulating capacity in vivo and maintenance of pluripotentiality. This method provides a basis for developing cell therapy strategies using expanded HSCs that are not genetically modified.	Univ Paris 05, Inst Cochin, Dept Hematol, CNRS UMR 8104,INSERM,U567, F-75014 Paris, France; Inst Pasteur, Unite Oncol Virale, F-75015 Paris, France; Hop Cochin, AP HP, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Fichelson, S (corresponding author), Univ Paris 05, Inst Cochin, Dept Hematol, CNRS UMR 8104,INSERM,U567, 123 Bd Port Royal, F-75014 Paris, France.		Romeo, Paul-Henri/L-5989-2017; Dubart-Kupperschmitt, Anne/AAE-9408-2020; CHARNEAU, Pierre/M-1565-2017; Dubart-Kupperschmitt, Anne/G-8191-2015; Pflumio, Francoise/E-2074-2017	Romeo, Paul-Henri/0000-0002-8294-0367; Dubart-Kupperschmitt, Anne/0000-0002-9326-4413; CHARNEAU, Pierre/0000-0003-1184-5773; Dubart-Kupperschmitt, Anne/0000-0002-9326-4413; Pflumio, Francoise/0000-0001-8995-596X				[Anonymous], J MEC THEOR APPL; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Freyssinier JM, 1999, BRIT J HAEMATOL, V106, P912; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; ISSAAD C, 1993, BLOOD, V81, P2916; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Maizel A, 1999, DEVELOPMENT, V126, P3183; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sirven A, 2001, MOL THER, V3, P438, DOI 10.1006/mthe.2001.0282; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Woods NB, 2000, BLOOD, V96, P3725, DOI 10.1182/blood.V96.12.3725.h8003725_3725_3733; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	24	218	243	0	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1423	1427		10.1038/nm953	http://dx.doi.org/10.1038/nm953			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14578882				2022-12-27	WOS:000186319700035
J	Olsson, B; Andersson, PO; Jernas, M; Jacobsson, S; Carlsson, B; Carlsson, LMS; Wadenvik, H				Olsson, B; Andersson, PO; Jernas, M; Jacobsson, S; Carlsson, B; Carlsson, LMS; Wadenvik, H			T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura	NATURE MEDICINE			English	Article							AUTOANTIBODIES; ANTIBODIES; RECEPTORS	Chronic idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder that is characterized by increased platelet destruction and is believed to be autoantibody mediated. In this study, CD3(+) T cells from ITP patients had increased expression of genes involved in cell-mediated cytotoxicity. In addition, cytotoxic cell-mediated lysis of autologous platelets was shown in active ITP. Our data suggest that T-cell-mediated cytotoxicity is an alternative mechanism for platelet destruction in ITP.	Univ Gothenburg, Sahlgrens Univ Hosp, Dept Internal Med, Sect Hematol & Coagulat, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Res Ctr Endocrinol & Metab, SE-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	Andersson, PO (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Dept Internal Med, Sect Hematol & Coagulat, SE-41345 Gothenburg, Sweden.		Carlsson, Lena/F-7570-2018	Carlsson, Lena/0000-0003-4145-6242; Olsson, Bob/0000-0002-6368-6172				BERCHTOLD P, 1993, BLOOD, V81, P1246; Boyington JC, 2001, IMMUNOL REV, V181, P66, DOI 10.1034/j.1600-065X.2001.1810105.x; Brighton TA, 1996, BLOOD, V88, P194; Cines DB, 2002, NEW ENGL J MED, V346, P995, DOI 10.1056/NEJMra010501; HARRINGTON WJ, 1951, J LAB CLIN MED, V38, P1; Hopkins Leann M., 2002, Human Immunology, V63, pS5, DOI 10.1016/S0198-8859(02)00534-7; IMBACH P, 1991, J PEDIATR-US, V118, P535, DOI 10.1016/S0022-3476(05)83373-6; OZSOYLU S, 1991, AM J HEMATOL, V36, P82, DOI 10.1002/ajh.2830360203; Semple JW, 1996, BLOOD, V87, P4245, DOI 10.1182/blood.V87.10.4245.bloodjournal87104245; Stockelberg D, 1996, EUR J HAEMATOL, V56, P72; Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942; Warner MN, 1999, BRIT J HAEMATOL, V104, P442, DOI 10.1046/j.1365-2141.1999.01218.x	12	471	519	0	18	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1123	1124		10.1038/nm921	http://dx.doi.org/10.1038/nm921			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12937414				2022-12-27	WOS:000185061600022
J	Diamond, B				Diamond, B			Govindarajan Padmanaban	NATURE MEDICINE			English	Biographical-Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					985	985		10.1038/nm0803-985	http://dx.doi.org/10.1038/nm0803-985			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12894150				2022-12-27	WOS:000184484900011
J	Taniguchi, T; Tischkowitz, M; Ameziane, N; Hodgson, SV; Mathew, CG; Joenje, H; Mok, SC; D'Andrea, AD				Taniguchi, T; Tischkowitz, M; Ameziane, N; Hodgson, SV; Mathew, CG; Joenje, H; Mok, SC; D'Andrea, AD			Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors	NATURE MEDICINE			English	Article							CANCER CELL-LINES; CARCINOMA CELLS; DRUG-RESISTANCE; BREAST-CANCER; FUNCTIONAL-ACTIVITY; HMLH1 EXPRESSION; NUCLEAR-COMPLEX; GENE-EXPRESSION; PROTEINS; INACTIVATION	Ovarian tumor cells are often genomically unstable and hypersensitive to cisplatin. To understand the molecular basis for this phenotype, we examined the integrity of the Fanconi anemia-BRCA (FANC-BRCA) pathway in those cells. This pathway regulates cisplatin sensitivity and is governed by the coordinate activity of six genes associated with Fanconi anemia (FANCA, FANCC, FANCD2, FANCE, FANCF and FANCG) as well as BRCA1 and BRCA2 (FANCD1). Here we show that the FANC-BRCA pathway is disrupted in a subset of ovarian tumor lines. Mono-ubiquitination of FANCD2, a measure of the function of this pathway, and cisplatin resistance were restored by functional complementation with FANCF, a gene that is upstream in this pathway. FANCF inactivation in ovarian tumors resulted from methylation of its CpG island, and acquired cisplatin resistance correlated with demethylation of FANCF. We propose a model for ovarian tumor progression in which the initial methylation of FANCF is followed by FANCF demethylation and ultimately results in cisplatin resistance.	Guys Kings & St Thomas Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, London, England; Guys Kings & St Thomas Sch Med, Div Genet & Dev, London, England; Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet & Human Genet, Amsterdam, Netherlands; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA USA	University of London; King's College London; University of London; King's College London; Vrije Universiteit Amsterdam; Harvard University; Brigham & Women's Hospital; Harvard Medical School	D'Andrea, AD (corresponding author), Guys Kings & St Thomas Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, London, England.		Tischkowitz, Marc/O-4452-2018; Taniguchi, Toshiyasu/ADD-8489-2022; 高, 雨莉/HGU-8187-2022; Mathew, Christopher G/G-3434-2015	Tischkowitz, Marc/0000-0002-7880-0628; Mathew, Christopher G/0000-0003-4178-1838; Taniguchi, Toshiyasu/0000-0002-7746-3658	NHLBI NIH HHS [R01HL52725, P01HL54785] Funding Source: Medline; NIDDK NIH HHS [R01 DK43889] Funding Source: Medline; PHS HHS [P0150654] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052725, P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043889] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PA, 1992, CANCER RES, V52, P1895; Auersperg N, 1998, SEMIN ONCOL, V25, P281; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Geisler JP, 2002, JNCI-J NATL CANCER I, V94, P61; HAMILTON TC, 1983, CANCER RES, V43, P5379; Harper P, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.33525; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HILLS CA, 1989, BRIT J CANCER, V59, P527, DOI 10.1038/bjc.1989.108; Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Husain A, 1998, GYNECOL ONCOL, V70, P17, DOI 10.1006/gyno.1998.4972; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; JONES A, 1967, ECON BOT, V21, P163, DOI 10.1007/BF02897864; Kiguchi K, 1998, JPN J CANCER RES, V89, P923, DOI 10.1111/j.1349-7006.1998.tb00650.x; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Kuang Y, 2000, BLOOD, V96, P1625, DOI 10.1182/blood.V96.5.1625.h8001625a_1625_1632; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEWIS AD, 1988, CARCINOGENESIS, V9, P1283, DOI 10.1093/carcin/9.7.1283; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Naf D, 1998, MOL CELL BIOL, V18, P5952; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Plumb JA, 2000, CANCER RES, V60, P6039; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; SCHILDER RJ, 1990, INT J CANCER, V45, P416, DOI 10.1002/ijc.2910450306; Shimamura A, 2002, BLOOD, V100, P4649, DOI 10.1182/blood-2002-05-1399; Siddique MA, 2001, EXP HEMATOL, V29, P1448, DOI 10.1016/S0301-472X(01)00754-8; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; WILSON AP, 1984, J NATL CANCER I, V72, P513; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; Yang Y, 2001, BLOOD, V98, P3435, DOI 10.1182/blood.V98.12.3435	45	444	479	1	38	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					568	574		10.1038/nm852	http://dx.doi.org/10.1038/nm852			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692539				2022-12-27	WOS:000182610600038
J	Brancaccio, M; Fratta, L; Notte, A; Hirsch, E; Poulet, R; Guazzone, S; De Acetis, M; Vecchione, C; Marino, G; Altruda, F; Silengo, L; Tarone, G; Lembo, G				Brancaccio, M; Fratta, L; Notte, A; Hirsch, E; Poulet, R; Guazzone, S; De Acetis, M; Vecchione, C; Marino, G; Altruda, F; Silengo, L; Tarone, G; Lembo, G			Melusin, a muscle-specific integrin beta(1)-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload	NATURE MEDICINE			English	Article							SYNTHASE KINASE 3-BETA; IN-VIVO; HEART-FAILURE; HYPERTROPHY; MECHANISMS; STRESS; PATHWAYS; TRANSCRIPTION; ACTIVATION; INTEGRINS	Cardiac hypertrophy is an adaptive response to a variety of mechanical and hormonal stimuli, and represents an early event in the clinical course leading to heart failure. By gene inactivation, we demonstrate here a crucial role of melusin, a muscle-specific protein that interacts with the integrin 1 cytoplasmic domain, in the hypertrophic response to mechanical overload. Melusin-null mice showed normal cardiac structure and function in physiological conditions, but when subjected to pressure overload-a condition that induces a hypertrophic response in wild-type controls-they developed an abnormal cardiac remodeling that evolved into dilated cardiomyopathy and contractile dysfunction. In contrast, the hypertrophic response was identical in wildtype and melusin-null mice after chronic administration of angiotensin II or phenylephrine at doses that do not increase blood pressure-that is, in the absence of cardiac biomechanical stress. Analysis of intracellular signaling events induced by pressure overload indicated that phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) was specifically blunted in melusin-null hearts. Thus, melusin prevents cardiac dilation during chronic pressure overload by specifically sensing mechanical stress.	Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy; IRCCS Neuromed, Dept Angiocardioneurol, I-86077 Pozzilli, IS, Italy; San Giovanni Battista Hosp, Expt Med Res Ctr, I-10126 Turin, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	University of Turin; IRCCS Neuromed; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Sapienza University Rome	Tarone, G (corresponding author), Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy.	guido.tarone@unito.it; lembo@neuromed.it	Hirsch, Emilio/F-4848-2013; Vecchione, Carmine/K-2175-2018; Lembo, Giuseppe/AAE-8096-2020	Hirsch, Emilio/0000-0002-9073-6024; Lembo, Giuseppe/0000-0002-3510-223X; Vecchione, Carmine/0000-0002-2473-4565; Tarone, Guido/0000-0003-4805-086X; maffei, angelo/0000-0002-7491-0344	Telethon [1327] Funding Source: Medline	Telethon(Fondazione Telethon)		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Brancaccio M, 1999, J BIOL CHEM, V274, P29282, DOI 10.1074/jbc.274.41.29282; Brancaccio M, 1998, CELL ADHES COMMUN, V5, P193, DOI 10.3109/15419069809040291; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Fassler R, 1996, J CELL SCI, V109, P2989; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harada K, 1998, CIRCULATION, V97, P1952, DOI 10.1161/01.CIR.97.19.1952; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Keller RS, 2001, AM J PATHOL, V158, P1079, DOI 10.1016/S0002-9440(10)64055-2; Lembo G, 1996, J CLIN INVEST, V98, P2648, DOI 10.1172/JCI119086; MacLellan WR, 2000, CURR OPIN CARDIOL, V15, P128, DOI 10.1097/00001573-200005000-00002; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Norton GR, 2002, J AM COLL CARDIOL, V39, P664, DOI 10.1016/S0735-1097(01)01792-2; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Schultz JEJ, 2002, J CLIN INVEST, V109, P787, DOI 10.1172/JCI200214190; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Shai SY, 2002, CIRC RES, V90, P458, DOI 10.1161/hh0402.105790; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Vecchione C, 2002, CIRCULATION, V105, P1700, DOI 10.1161/01.CIR.0000012750.08480.55; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Wollert KC, 2000, CIRCULATION, V101, P1172, DOI 10.1161/01.CIR.101.10.1172; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221	42	223	234	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					68	75		10.1038/nm805	http://dx.doi.org/10.1038/nm805			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12496958				2022-12-27	WOS:000180209900024
J	Wickham, TJ				Wickham, Thomas J.			Ligand-directed targeting of genes to the site of disease	NATURE MEDICINE			English	Review								Fundamental changes in the understanding of the primary influences that govern specific gene delivery, combined with rational approaches to engineer the gene transfer vectors, are now transforming targeted in vivo gene transfer from concept to reality. Many viral-based vectors have been designed to avoid gene transfer through their native receptors and redirected to a variety of tissue- and tumor-specific receptors. Non-viral vectors have likewise been engineered to avoid nonspecific gene transfer. Future challenges include advancing these vectors into clinical testing, designing improvements to avoid innate and acquired immunity, and elucidating the mechanisms that govern their biodistribution and pharmacokinetics.	GenVec Inc, Gaithersburg, MD USA		Wickham, TJ (corresponding author), GenVec Inc, Gaithersburg, MD USA.	twickham@genvec.com						Bartlett JS, 1999, NAT BIOTECHNOL, V17, P181, DOI 10.1038/6185; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bilbao R, 2000, GENE THER, V7, P1824, DOI 10.1038/sj.gt.3301312; Boerger AL, 1999, P NATL ACAD SCI USA, V96, P9867, DOI 10.1073/pnas.96.17.9867; Buchholz CJ, 1998, NAT BIOTECHNOL, V16, P951, DOI 10.1038/nbt1098-951; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; Croyle MA, 2001, J VIROL, V75, P4792, DOI 10.1128/JVI.75.10.4792-4801.2001; Croyle MA, 2000, HUM GENE THER, V11, P1713, DOI 10.1089/10430340050111368; Curiel D. T., 2002, VECTOR TARGETING THE, P710; DINGLI D, 2002, VECTOR TARGETING THE, P267; Dmitriev I, 2000, J VIROL, V74, P6875, DOI 10.1128/JVI.74.15.6875-6884.2000; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Einfeld DA, 1999, J VIROL, V73, P9130, DOI 10.1128/JVI.73.11.9130-9136.1999; Einfeld DA, 2001, J VIROL, V75, P11284, DOI 10.1128/JVI.75.23.11284-11291.2001; Engelstadter M, 2000, HUM GENE THER, V11, P293, DOI 10.1089/10430340050016030; Fenske DB, 2001, CURR OPIN MOL THER, V3, P153; Fisher KD, 2001, GENE THER, V8, P341, DOI 10.1038/sj.gt.3301389; Girod A, 1999, NAT MED, V5, P1052, DOI 10.1038/12491; Gordon EM, 2001, HUM GENE THER, V12, P1277, DOI 10.1089/104303401750270931; Gordon EM, 2001, HUM GENE THER, V12, P193, DOI 10.1089/104303401750061258; GORDON EM, 2002, VECTOR TARGETING THE, P293; Grifman M, 2001, MOL THER, V3, P964, DOI 10.1006/mthe.2001.0345; Hall FL, 1997, HUM GENE THER, V8, P2183, DOI 10.1089/hum.1997.8.18-2183; Hall FL, 2000, HUM GENE THER, V11, P983, DOI 10.1089/10430340050015293; Hammond AL, 2001, J VIROL, V75, P2087, DOI 10.1128/JVI.75.5.2087-2096.2001; Harari OA, 1999, GENE THER, V6, P801, DOI 10.1038/sj.gt.3300898; Hatziioannou T, 1999, HUM GENE THER, V10, P1533, DOI 10.1089/10430349950017860; Heideman DAM, 2001, CANCER GENE THER, V8, P342, DOI 10.1038/sj.cgt.7700313; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; Kim J, 2002, J VIROL, V76, P1892, DOI 10.1128/JVI.76.4.1892-1903.2002; Kircheis R, 2001, ADV DRUG DELIVER REV, V53, P341, DOI 10.1016/S0169-409X(01)00202-2; Kircheis R, 2002, CANCER GENE THER, V9, P673, DOI 10.1038/sj.cgt.7700487; Kircheis R, 2001, GENE THER, V8, P28, DOI 10.1038/sj.gt.3301351; LeVine AM, 2001, MICROBES INFECT, V3, P161, DOI 10.1016/S1286-4579(00)01363-0; MacLachlan I, 1999, CURR OPIN MOL THER, V1, P252; MALHOTRA R, 1995, TRENDS MICROBIOL, V3, P240, DOI 10.1016/S0966-842X(00)88932-5; MICHAEL SI, 1995, GENE THER, V2, P660; Morling FJ, 1997, VIROLOGY, V234, P51, DOI 10.1006/viro.1997.8628; Nettelbeck DM, 2001, MOL THER, V3, P882, DOI 10.1006/mthe.2001.0342; Nicklin SA, 2001, MOL THER, V4, P174, DOI 10.1006/mthe.2001.0424; Ogris M, 2002, DRUG DISCOV TODAY, V7, P479, DOI 10.1016/S1359-6446(02)02243-2; Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900; Ohno K, 1997, NAT BIOTECHNOL, V15, P763, DOI 10.1038/nbt0897-763; Peng KW, 1999, GENE THER, V6, P1552, DOI 10.1038/sj.gt.3300982; Peng KW, 1997, HUM GENE THER, V8, P729, DOI 10.1089/hum.1997.8.6-729; Pereboev A, 2001, J VIROL, V75, P7107, DOI 10.1128/JVI.75.15.7107-7113.2001; Reading PC, 1997, J VIROL, V71, P8204, DOI 10.1128/JVI.71.11.8204-8212.1997; Reading PC, 1998, J GEN VIROL, V79, P2255, DOI 10.1099/0022-1317-79-9-2255; Reynolds PN, 2001, NAT BIOTECHNOL, V19, P838, DOI 10.1038/nbt0901-838; Ried MU, 2002, J VIROL, V76, P4559, DOI 10.1128/JVI.76.9.4559-4566.2002; Romanczuk H, 1999, HUM GENE THER, V10, P2615, DOI 10.1089/10430349950016654; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; Shayakhmetov DM, 2002, CANCER RES, V62, P1063; Snitkovsky S, 2000, J VIROL, V74, P9540, DOI 10.1128/JVI.74.20.9540-9545.2000; Snitkovsky S, 2002, VIROLOGY, V292, P150, DOI 10.1006/viro.2001.1314; Snitkovsky S, 2001, J VIROL, V75, P1571, DOI 10.1128/JVI.75.3.1571-1575.2001; St Croix B, 2000, SCIENCE, V289, P1197; Thomas CE, 2002, J VIROL, V76, P3452, DOI 10.1128/JVI.76.7.3452-3460.2002; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; VALSESIAWITTMANN S, 1994, J VIROL, V68, P4609, DOI 10.1128/JVI.68.7.4609-4619.1994; Vigne E, 1999, J VIROL, V73, P5156, DOI 10.1128/JVI.73.6.5156-5161.1999; Wickham TJ, 1997, CANCER IMMUNOL IMMUN, V45, P149, DOI 10.1007/s002620050419; Wickham TJ, 2000, GENE THER, V7, P110, DOI 10.1038/sj.gt.3301115; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Xiang ZQ, 2002, J VIROL, V76, P2667, DOI 10.1128/JVI.76.6.2667-2675.2002; Xu LA, 1999, HUM GENE THER, V10, P2941, DOI 10.1089/10430349950016357; Yang QC, 1998, HUM GENE THER, V9, P1929, DOI 10.1089/hum.1998.9.13-1929	69	99	110	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					135	139		10.1038/nm0103-135	http://dx.doi.org/10.1038/nm0103-135			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514727				2022-12-27	WOS:000208640400009
J	Hornung, V; Guenthner-Biller, M; Bourquin, C; Ablasser, A; Schlee, M; Uematsu, S; Noronha, A; Manoharan, M; Akira, S; de Fougerolles, A; Endres, S; Hartmann, G				Hornung, V; Guenthner-Biller, M; Bourquin, C; Ablasser, A; Schlee, M; Uematsu, S; Noronha, A; Manoharan, M; Akira, S; de Fougerolles, A; Endres, S; Hartmann, G			Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7	NATURE MEDICINE			English	Article							DOUBLE-STRANDED-RNA; CPG DNA; NUCLEOSIDE ANALOGS; MESSENGER-RNA; BACTERIAL-DNA; RECOGNITION; ACTIVATION; EXPRESSION; IDENTIFICATION; RESPONSES	Short interfering RNA ( siRNA) is used in RNA interference technology to avoid non-target-related induction of type I interferon (IFN) typical for long double-stranded RNA. Here we show that in plasmacytoid dendritic cells (PDC), an immune cell subset specialized in the detection of viral nucleic acids and production of type I IFN, some siRNA sequences, independent of their GU content, are potent stimuli of IFN-alpha production. Localization of the immunostimulatory motif on the sense strand of a potent IFN-alpha-inducing siRNA allowed dissection of immunostimulation and target silencing. Injection into mice of immunostimulatory siRNA, when complexed with cationic liposomes, induced systemic immune responses in the same range as the TLR9 ligand CpG, including IFN-alpha in serum and activation of T cells and dendritic cells in spleen. Immunostimulation by siRNA was absent in TLR7-deficient mice. Thus sequence-specific TLR7-dependent immune recognition in PDC needs to be considered as an additional biological activity of siRNA, which then should be termed immunostimulatory RNA (isRNA).	Univ Munich, Dept Internal Med, Div Clin Pharmacol, D-80336 Munich, Germany; GSF Munich, Natl Res Ctr & Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany; Alnylam Pharmaceut Inc, Cambridge, MA 02142 USA; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Osaka 5650871, Japan	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Osaka University	Hartmann, G (corresponding author), Univ Munich, Dept Internal Med, Div Clin Pharmacol, Ziemssenstr 1, D-80336 Munich, Germany.	ghartmann@lrz.uni-muenchen.de	Schlee, Martin/AAL-1238-2021; Bourquin, Carole/AAU-1418-2020; Hornung, Veit/C-3565-2012; Hartmann, Gunther/P-7492-2017; Akira, Shizuo/C-3134-2009	Bourquin, Carole/0000-0003-3862-4583; Hornung, Veit/0000-0002-4150-194X; Hartmann, Gunther/0000-0003-1021-2018; Karsten, Maria Margarete/0000-0001-7587-7550; Schlee, Martin/0000-0003-3671-7639				Ahlquist P, 2002, SCIENCE, V296, P1270, DOI 10.1126/science.1069132; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Davidson BL, 2003, NEW ENGL J MED, V349, P2357, DOI 10.1056/NEJMcibr031609; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dittmer U, 2003, CURR OPIN MICROBIOL, V6, P472, DOI 10.1016/j.mib.2003.09.007; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hartmann E, 2003, CANCER RES, V63, P6478; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Heckelsmiller K, 2002, EUR J IMMUNOL, V32, P3235, DOI 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hornung V, 2004, J IMMUNOL, V173, P5935, DOI 10.4049/jimmunol.173.10.5935; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Kariko K, 2004, CELLS TISSUES ORGANS, V177, P132, DOI 10.1159/000079987; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Klein C, 2003, GASTROENTEROLOGY, V125, P9, DOI 10.1016/S0016-5085(03)00720-0; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2003, J IMMUNOL, V170, P3468, DOI 10.4049/jimmunol.170.7.3468; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148; Poeck H, 2004, BLOOD, V103, P3058, DOI 10.1182/blood-2003-08-2972; Rothenfusser S, 2004, BLOOD, V103, P2162, DOI 10.1182/blood-2003-04-1091; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Spies B, 2003, J IMMUNOL, V171, P5908, DOI 10.4049/jimmunol.171.11.5908; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tuschl Thomas, 2002, Mol Interv, V2, P158, DOI 10.1124/mi.2.3.158; Weiner GJ, 2000, CURR TOP MICROBIOL, V247, P157; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	47	960	1119	2	72	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					263	270		10.1038/nm1191	http://dx.doi.org/10.1038/nm1191			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723075				2022-12-27	WOS:000227541300020
J	Lam, TKT; Pocai, A; Gutierrez-Juarez, R; Obici, S; Bryan, J; Aguilar-Bryan, L; Schwartz, GJ; Rossetti, L				Lam, TKT; Pocai, A; Gutierrez-Juarez, R; Obici, S; Bryan, J; Aguilar-Bryan, L; Schwartz, GJ; Rossetti, L			Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis	NATURE MEDICINE			English	Article							INSULIN-RESISTANCE; INDUCED INHIBITION; POTASSIUM CHANNEL; FOOD-INTAKE; GLUCONEOGENESIS; MECHANISMS; CELL; RECEPTORS; LEPTIN; GLYCOGENOLYSIS	Increased glucose production is a hallmark of type 2 diabetes and alterations in lipid metabolism have a causative role in its pathophysiology. Here we postulate that physiological increments in plasma fatty acids can be sensed within the hypothalamus and that this sensing is required to balance their direct stimulatory action on hepatic gluconeogenesis. In the presence of physiologically-relevant increases in the levels of plasma fatty acids, negating their central action on hepatic glucose fluxes through (i) inhibition of the hypothalamic esterification of fatty acids, (ii) genetic deletion (Sur1-deficient mice) of hypothalamic K-ATP channels or pharmacological blockade (KATP blocker) of their activation by fatty acids, or (iii) surgical resection of the hepatic branch of the vagus nerve led to a marked increase in liver glucose production. These findings indicate that a physiological elevation in circulating lipids can be sensed within the hypothalamus and that a defect in hypothalamic lipid sensing disrupts glucose homeostasis.	Yeshiva Univ Albert Einstein Coll Med, Diabet Res Ctr, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Diabet Res Ctr, Dept Neurosci, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Diabet Res Ctr, Dept Mol Pharmacol, Bronx, NY 10461 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Rossetti, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Diabet Res Ctr, Dept Med, 1300 Morris Pk Ave,Belfer 701, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047208, R01DK045024, R01DK057671, P60DK020541, P30DK020541, R37DK048321, R29DK045024, R01DK052771, R01DK048321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021654, T32AG023475] Funding Source: NIH RePORTER; NIA NIH HHS [T32-AG023475, AG 21654] Funding Source: Medline; NIDDK NIH HHS [DK 48321, DK57671, DK52771, DK 20541, DK 47208, DK 45024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Boden G, 2001, DIABETES, V50, P810, DOI 10.2337/diabetes.50.4.810; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Chen XH, 1999, J CLIN INVEST, V103, P365, DOI 10.1172/JCI5479; Chu CA, 2002, AM J PHYSIOL-ENDOC M, V282, pE402, DOI 10.1152/ajpendo.00136.2001; CLORE JN, 1991, AM J PHYSIOL, V261, pE425, DOI 10.1152/ajpendo.1991.261.4.E425; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Gribble FM, 1998, J BIOL CHEM, V273, P26383, DOI 10.1074/jbc.273.41.26383; Hansen AMK, 2002, DIABETES, V51, P2789, DOI 10.2337/diabetes.51.9.2789; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; la Fleur SE, 2003, DIABETES, V52, P2321, DOI 10.2337/diabetes.52.9.2321; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE281, DOI 10.1152/ajpendo.00332.2002; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Matsuhisa M, 2000, METABOLISM, V49, P11, DOI 10.1016/S0026-0495(00)90538-9; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; McKhann GM, 1997, J NEUROSCI, V17, P6850; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; MILLER JC, 1987, J NEUROCHEM, V49, P1507, DOI 10.1111/j.1471-4159.1987.tb01021.x; MOORE MC, 1993, AM J PHYSIOL, V265, pE487, DOI 10.1152/ajpendo.1993.265.3.E487; Morgan K, 2004, J BIOL CHEM, V279, P31139, DOI 10.1074/jbc.M400458200; Morton GJ, 2003, ENDOCRINOLOGY, V144, P2016, DOI 10.1210/en.2002-0115; NORGREN R, 1994, AM J PHYSIOL-REG I, V267, pR1136, DOI 10.1152/ajpregu.1994.267.4.R1136; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Pocai A, 2005, CELL METAB, V1, P53, DOI 10.1016/j.cmet.2004.11.001; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; Roden M, 2000, DIABETES, V49, P701, DOI 10.2337/diabetes.49.5.701; Sclafani A, 2003, PHYSIOL BEHAV, V78, P285, DOI 10.1016/S0031-9384(02)00968-X; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; SHULMAN GI, 2000, J CLIN INVEST, V106, P171, DOI DOI 10.1172/JCI10583; Sindelar DK, 1997, DIABETES, V46, P187, DOI 10.2337/diabetes.46.2.187; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TOMODA H, 1991, J BIOL CHEM, V266, P4214; Vatamaniuk MZ, 2003, LIFE SCI, V72, P1871, DOI 10.1016/S0024-3205(02)02506-7; Wang JL, 2001, DIABETES, V50, P2786, DOI 10.2337/diabetes.50.12.2786; WILLIAMSON JR, 1966, P NATL ACAD SCI USA, V56, P247, DOI 10.1073/pnas.56.1.247; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P4607; WOJTCZAK AB, 1978, BIOCHEM J, V170, P379, DOI 10.1042/bj1700379; Xue CR, 2000, J SURG RES, V90, P19, DOI 10.1006/jsre.2000.5820	49	323	333	0	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					320	327		10.1038/nm1201	http://dx.doi.org/10.1038/nm1201			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15735652				2022-12-27	WOS:000227541300028
J	Nichols, KE; Hom, J; Gong, SY; Ganguly, A; Ma, CS; Cannons, JL; Tangye, SG; Schwartzberg, PL; Koretzky, GA; Stein, PL				Nichols, KE; Hom, J; Gong, SY; Ganguly, A; Ma, CS; Cannons, JL; Tangye, SG; Schwartzberg, PL; Koretzky, GA; Stein, PL			Regulation of NKT cell development by SAP, the protein defective in XLP	NATURE MEDICINE			English	Article							LINKED LYMPHOPROLIFERATIVE-DISEASE; CONTROLS T-CELL; SH2 DOMAIN; MICE DEFICIENT; CUTTING EDGE; MUTANT MICE; B-CELLS; GENE; DIFFERENTIATION; MUTATIONS	The adaptor molecule SAP is expressed in T lymphocytes and natural killer (NK) cells, where it regulates cytokine production and cytotoxicity(1-3). Here, we show that SAP, encoded by the SH2D1A gene locus, also has a crucial role during the development of NKT cells, a lymphocyte subset with immunoregulatory functions in response to infection, cancer and autoimmune disease(4). Following stimulation with the NKT cell-specific agonist alpha-galactosyl ceramide (alpha GC), Sh2d1a(-/-) splenocytes did not produce cytokines or activate other lymphoid lineages in an NKT cell-dependent manner. While evaluating the abnormalities in alpha GC-induced immune responses, we observed that Sh2d1a(-/-) animals lacked NKT cells in the thymus and peripheral organs. The defect in NKT cell ontogeny was hematopoietic cell autonomous and could be rescued by reconstitution of SAP expression within Sh2d1a(-/-) bone marrow cells. Seventeen individuals with X-linked lymphoproliferative disease (XLP), who harbored germline mutations in SH2D1A, also lacked NKT cells. Furthermore, a female XLP carrier showed completely skewed X chromosome inactivation within NKT cells, but not T or B cells. Thus, SAP is a crucial regulator of NKT cell ontogeny in humans and in mice. The absence of NKT cells may contribute to the phenotypes of SAP deficiency, including abnormal antiviral and antitumor immunity and hypogammaglobulinemia.	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Centenary Inst Canc Med & Cell Biol, Newtown, NSW 2014, Australia; NHGRI, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Sydney; Centenary Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Nichols, KE (corresponding author), Childrens Hosp Philadelphia, 4th Floor,3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	nicholsk@email.chop.edu; p-stein2@northwestern.edu	Nichols, Kim/AAP-8592-2020; Tangye, Stuart G/H-4023-2014; S, Cindy/B-2340-2012; Nichols, Kim/E-9353-2016; Koretzky, Gary/AAU-5381-2021; Gong, Shunyou/ABE-1345-2021	Nichols, Kim/0000-0002-5581-6555; Tangye, Stuart G/0000-0002-5360-5180; S, Cindy/0000-0001-5387-8413; Nichols, Kim/0000-0002-5581-6555; Gong, Shunyou/0000-0002-7883-4879	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000123, Z01HG000123] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Cannons JL, 2004, IMMUNITY, V21, P693, DOI 10.1016/j.immuni.2004.09.012; Carnaud C, 1999, J IMMUNOL, V163, P4647; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Eberl G, 1999, J IMMUNOL, V163, P4091; Gadue P, 1999, J EXP MED, V190, P1189, DOI 10.1084/jem.190.8.1189; Galli G, 2003, J EXP MED, V197, P1051, DOI 10.1084/jem.20021616; Hron JD, 2004, J EXP MED, V200, P261, DOI 10.1084/jem.20040526; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Latour S, 2003, IMMUNOL REV, V192, P212, DOI 10.1034/j.1600-065X.2003.00023.x; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; Malbran A, 2004, BLOOD, V103, P1625, DOI 10.1182/blood-2003-07-2525; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PURTILO D T, 1975, Lancet, V1, P935; Roberts TJ, 2004, J IMMUNOL, V172, P3454, DOI 10.4049/jimmunol.172.6.3454; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schuster V, 2000, IMMUNOL REV, V178, P21, DOI 10.1034/j.1600-065X.2000.17819.x; Seemayer TA, 2000, INFEC DIS S, P51; Sharifi R, 2004, BLOOD, V103, P3821, DOI 10.1182/blood-2003-09-3359; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Smyth MJ, 2002, CURR OPIN IMMUNOL, V14, P165, DOI 10.1016/S0952-7915(02)00316-3; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Wang NH, 2004, J EXP MED, V199, P1255, DOI 10.1084/jem.20031835; Wengler GS, 1997, LIFE SCI, V61, P1405, DOI 10.1016/S0024-3205(97)00686-3; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Yin L, 2003, J MED VIROL, V71, P446, DOI 10.1002/jmv.10504	30	302	307	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					340	345		10.1038/nm1189	http://dx.doi.org/10.1038/nm1189			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711562				2022-12-27	WOS:000227541300031
J	Dinulescu, DM; Ince, TA; Quade, BJ; Shafer, SA; Crowley, D; Jacks, T				Dinulescu, DM; Ince, TA; Quade, BJ; Shafer, SA; Crowley, D; Jacks, T			Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer	NATURE MEDICINE			English	Article							GENE-MUTATIONS; P53; INACTIVATION; PROGRESSION; EXPRESSION; INDUCTION; TUMORS	Epithelial ovarian tumors present a complex clinical, diagnostic and therapeutic challenge because of the difficulty of early detection, lack of known precursor lesions and high mortality rates. Endometrioid ovarian carcinomas are frequently associated with endometriosis, but the mechanism for this association remains unknown. Here we present the first genetic models of peritoneal endometriosis and endometrioid ovarian adenocarcinoma in mice, both based on the activation of an oncogenic K-ras allele. In addition, we find that expression of oncogenic K-ras or conditional Pten deletion within the ovarian surface epithelium gives rise to preneoplastic ovarian lesions with an endometrioid glandular morphology. Furthermore, the combination of the two mutations in the ovary leads to the induction of invasive and widely metastatic endometrioid ovarian adenocarcinomas with complete penetrance and a disease latency of only 7 weeks. The ovarian cancer model described in this study recapitulates the specific tumor histomorphology and metastatic potential of the human disease.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst, Cambridge, MA 02142 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Womens & Perinatal Pathol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Jacks, T (corresponding author), MIT, Ctr Canc Res, 40 Ames St, Cambridge, MA 02139 USA.	tjacks@mit.edu		Ince, Tan/0000-0003-0315-6425	NCI NIH HHS [KO8CA92013] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA092013] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amemiya S, 2004, INT J GYNECOL OBSTET, V86, P371, DOI 10.1016/j.ijgo.2004.04.036; Arimoto-Ishida E, 2004, ENDOCRINOLOGY, V145, P2014, DOI 10.1210/en.2003-1199; CLEMENT PB, 2002, BLAUSTEINS PATHOLOGY, P746; Connolly DC, 2003, CANCER RES, V63, P1389; Cuatrecasas M, 1998, CANCER-AM CANCER SOC, V82, P1088; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Grunwald V, 2002, CANCER RES, V62, P6141; HOGAN B, 1994, MANIPULATING MOUSE E, P185; Hogdall EVS, 2003, GYNECOL ONCOL, V89, P31, DOI 10.1016/S0090-8258(03)00005-2; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Obata K, 1998, CANCER RES, V58, P2095; Okuda T, 2003, GYNECOL ONCOL, V88, P318, DOI 10.1016/S0090-8258(02)00149-X; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Otsuka Junko, 2004, Medical Electron Microscopy, V37, P188; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Sato N, 2000, CANCER RES, V60, P7052; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Swiersz LM, 2002, ANN NY ACAD SCI, V955, P281, DOI 10.1111/j.1749-6632.2002.tb02788.x; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; VERCELLINI P, 1994, GYNECOL OBSTET INVES, V38, P70, DOI 10.1159/000292450	22	437	460	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					63	70		10.1038/nm1173	http://dx.doi.org/10.1038/nm1173			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619626				2022-12-27	WOS:000226124900034
J	Moschetta, A; Bookout, AL; Mangelsdorf, DJ				Moschetta, A; Bookout, AL; Mangelsdorf, DJ			Prevention of cholesterol gallstone disease by FXR agonists in a mouse model	NATURE MEDICINE			English	Article							URSODEOXYCHOLIC ACID THERAPY; ORPHAN NUCLEAR RECEPTOR; SALT EXPORT PUMP; BILE-ACIDS; PHENOTYPIC CHARACTERIZATION; CRYSTALLIZATION PATHWAYS; DETERMINE SUSCEPTIBILITY; INBRED MICE; LITH GENES; LIVER	Cholesterol gallstone disease is characterized by several events, including cholesterol precipitation in bile, increased bile salt hydrophobicity and gallbladder inflammation. Here, we describe the same phenotype in mice lacking the bile acid receptor, FXR. Furthermore, in susceptible wild-type mice that recapitulate human cholesterol gallstone disease, treatment with a synthetic FXR agonist prevented sequelae of the disease. These effects were mediated by FXR-dependent increases in biliary bile salt and phospholipid concentrations, which restored cholesterol solubility and thereby prevented gallstone formation. Taken together, these results indicate that FXR is a promising therapeutic target for treating or preventing cholesterol gallstone disease.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	davo.mango@utsouthwestern.edu	Moschetta, Antonio/K-6211-2016; Moschetta, Antonio/AAC-5295-2022	Moschetta, Antonio/0000-0003-2123-6074; Mangelsdorf, David/0000-0002-4355-0796	NIDDK NIH HHS [U19DK62434] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADMIRAND WH, 1968, J CLIN INVEST, V47, P1043, DOI 10.1172/JCI105794; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; ANGELIN B, 1978, J LIPID RES, V19, P1017; Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; CAREY MC, 1978, J LIPID RES, V19, P945; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; FOLCH J, 1957, J BIOL CHEM, V226, P497; FROMM H, 1980, J LIPID RES, V21, P259; Galman C, 2004, GASTROENTEROLOGY, V126, P741, DOI 10.1053/j.gastro.2003.12.009; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Gloor B, 2003, J GASTROINTEST SURG, V7, P372, DOI 10.1016/S1091-255X(02)00418-3; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; HAY DW, 1990, SEMIN LIVER DIS, V10, P159, DOI 10.1055/s-2008-1040470; HEUMAN DM, 1989, J LIPID RES, V30, P719; HEUMAN DM, 1991, HEPATOLOGY, V14, P920, DOI 10.1002/hep.1840140527; HOFMANN AF, 1988, LIVER UPDATE, V2, P1; Huang L, 2003, J BIOL CHEM, V278, P51085, DOI 10.1074/jbc.M308321200; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; KHANUJA B, 1995, P NATL ACAD SCI USA, V92, P7729, DOI 10.1073/pnas.92.17.7729; Kok T, 2003, J BIOL CHEM, V278, P41930, DOI 10.1074/jbc.M306309200; Liu YP, 2003, J CLIN INVEST, V112, P1678, DOI 10.1172/JCI200318945; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; Moschetta A, 2001, J LIPID RES, V42, P1273; Moschetta A, 2001, J HEPATOL, V34, P492, DOI 10.1016/S0168-8278(00)00046-5; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Portincasa P, 1996, HEPATOLOGY, V23, P738, DOI 10.1002/hep.510230414; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; ROSSI SS, 1987, J LIPID RES, V28, P589; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Sandler RS, 2002, GASTROENTEROLOGY, V122, P1500, DOI 10.1053/gast.2002.32978; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; SHODA J, 1995, HEPATOLOGY, V21, P1291, DOI 10.1016/0270-9139(95)90050-0; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; TEPPERMAN J, 1964, AM J PHYSIOL, V206, P628, DOI 10.1152/ajplegacy.1964.206.3.628; Tomida S, 1999, HEPATOLOGY, V30, P6, DOI 10.1002/hep.510300108; TURLEY SD, 1978, J LIPID RES, V19, P924; van Erpecum KJ, 2001, J HEPATOL, V35, P444, DOI 10.1016/S0168-8278(01)00173-8; Wang DQH, 1996, J LIPID RES, V37, P606; Wang DQH, 1997, J LIPID RES, V38, P1395; Wang DQH, 1996, J LIPID RES, V37, P2539; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Wittenburg H, 2003, GASTROENTEROLOGY, V125, P868, DOI 10.1016/S0016-5085(03)01053-9; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Zhang Z, 2001, J LIPID RES, V42, P649	50	238	255	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1352	1358		10.1038/nm1138	http://dx.doi.org/10.1038/nm1138			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15558057				2022-12-27	WOS:000225500900029
J	Wood, A; Grady, C; Emanuel, EJ				Wood, A; Grady, C; Emanuel, EJ			Regional ethics organizations for protection of human research participants	NATURE MEDICINE			English	Editorial Material							MULTICENTER RESEARCH; CLINICAL-TRIALS; BOARDS; COMMITTEES; OVERSIGHT		Univ Calif Berkeley, Sch Law, Berkeley, CA 94720 USA; NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA	University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA	Wood, A (corresponding author), Univ Calif Berkeley, Sch Law, Berkeley, CA 94720 USA.	eemanuel@nih.gov						Ahmed AH, 1996, J MED ETHICS, V22, P263, DOI 10.1136/jme.22.5.263; Bell J, 1998, FINAL REPORT EVALUAT; Christian MC, 2002, NEW ENGL J MED, V346, P1405, DOI 10.1056/NEJM200205023461814; *DHHS OFF INSP GEN, 1998, I REV BOARDS EM IND; *DHHS OFF INSP GEN, 1998, LOW VOL I REV BOARDS; *DHHS OFF INSP GEN, 1998, I REV BOARDS THEIR R; *DHHS OFF INSP GEN, 1998, I REV BOARDS PROM AP; *DHHS OFF INSP GEN, 1998, I REV BOARDS TIM REF; Emanuel EJ, 2004, ANN INTERN MED, V141, P282, DOI 10.7326/0003-4819-141-4-200408170-00008; FEDERMAN A, 2002, RESPONSIBLE RES SYST; *GAO, 2001, BIOM RES HHS DIR NEE; Holt E, 2002, KENNEDY INST ETHIC J, V12, P215, DOI 10.1353/ken.2002.0010; Kelch RP, 2002, NEW ENGL J MED, V346, P285, DOI 10.1056/NEJM200201243460413; Kingdon John., 2002, ETHICAL DIMENSIONS H, P97; McNeill P. M., 1993, ETHICS HUMAN EXPERIM; McWilliams R, 2003, JAMA-J AM MED ASSOC, V290, P360, DOI 10.1001/jama.290.3.360; Meunier F, 2003, LANCET, V362, P663, DOI 10.1016/S0140-6736(03)14163-3; National Bioethics Advisory Commission (NBAC), 2001, ETH POL ISS RES INV; Randal J, 2003, J NATL CANCER I, V95, P636, DOI 10.1093/jnci/95.9.636; Roberts LM, 2004, MED J AUSTRALIA, V180, P139, DOI 10.5694/j.1326-5377.2004.tb05839.x; Shah S, 2004, JAMA-J AM MED ASSOC, V291, P476, DOI 10.1001/jama.291.4.476; Singer EA, 2002, BRIT MED J, V324, P1169, DOI 10.1136/bmj.324.7347.1169; Slater AE, 2001, J ROY SOC MED, V94, P557, DOI 10.1177/014107680109401101; Stair TO, 2001, ACAD EMERG MED, V8, P636, DOI 10.1111/j.1553-2712.2001.tb00177.x; Steinbrook R, 2002, NEW ENGL J MED, V346, P716, DOI 10.1056/NEJM200202283460924; Tully J, 2000, BRIT MED J, V320, P1179, DOI 10.1136/bmj.320.7243.1179; Wagner TH, 2004, MED CARE, V42, P817, DOI 10.1097/01.mlr.0000132395.32967.d4; Wagner TH, 2003, ACAD MED, V78, P638, DOI 10.1097/00001888-200306000-00019	28	19	19	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1283	1288		10.1038/nm1204-1283	http://dx.doi.org/10.1038/nm1204-1283			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15580245				2022-12-27	WOS:000225500900015
J	Schubert, C				Schubert, C			Fish fix	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-27	WOS:000224245800025
J	Madhi, SA; Klugman, KP				Madhi, SA; Klugman, KP		Vaccine Trialist Grp	A role for Streptococcus pneumoniae in virus-associated pneumonia	NATURE MEDICINE			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; RESPIRATORY-TRACT INFECTIONS; AFRICAN CHILDREN; BACTERIAL; DISEASE; TYPE-1; IMMUNOGENICITY; IMPACT	Here we show, in a double-blind, randomized, placebo-controlled trial in 37,107 fully immunized infants in Soweto, South Africa, that a 9-valent pneumococcal conjugate vaccine, PncCV, prevents 31% (95% confidence interval = 15 - 43%) of pneumonias associated with any of seven respiratory viruses in children in hospital. These data suggest that the pneumococcus has a major role in the development of pneumonia associated with these viruses and that viruses contribute to the pathogenesis of bacterial pneumonia.	Emory Univ, Univ Witwatersrand Med Res Council Natl Inst Comm, Atlanta, GA 30332 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Int Hlth, Atlanta, GA 30332 USA; Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30332 USA	Emory University; Emory University; Rollins School Public Health; Emory University	Klugman, KP (corresponding author), Emory Univ, Univ Witwatersrand Med Res Council Natl Inst Comm, Atlanta, GA 30332 USA.	keith.klugman@emory.edu						Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Dagan R, 2001, PEDIATR INFECT DIS J, V20, P951, DOI 10.1097/00006454-200110000-00008; Hament JM, 1999, FEMS IMMUNOL MED MIC, V26, P189, DOI 10.1111/j.1574-695X.1999.tb01389.x; Ishizuka S, 2003, J INFECT DIS, V188, P1928, DOI 10.1086/379833; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; Madhi SA, 2003, CLIN INFECT DIS, V37, P1705, DOI 10.1086/379771; Madhi SA, 2002, CLIN INFECT DIS, V35, P1120, DOI 10.1086/343049; Madhi SA, 2000, PEDIATR INFECT DIS J, V19, P1141, DOI 10.1097/00006454-200012000-00004; Madhi SA, 2000, J PEDIATR-US, V137, P78, DOI 10.1067/mpd.2000.105350; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; Peltola VT, 2004, PEDIATR INFECT DIS J, V23, pS87, DOI 10.1097/01.inf.0000108197.81270.35; Pneumonia Vaccine Trial Investigators' Group, 2001, STAND INT CHEST RAD; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	13	395	423	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					811	813		10.1038/nm1077	http://dx.doi.org/10.1038/nm1077			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15247911	Bronze, Green Published			2022-12-27	WOS:000223055700033
J	Tahara, M; Pergolizzi, RG; Kobayashi, H; Krause, A; Luettich, K; Lesser, ML; Crystal, RG				Tahara, M; Pergolizzi, RG; Kobayashi, H; Krause, A; Luettich, K; Lesser, ML; Crystal, RG			Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency	NATURE MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; BONE-MARROW-TRANSPLANTATION; CELL-MEDIATED-IMMUNITY; CD4(+) T-CELLS; MESSENGER-RNA; LENTIVIRAL VECTORS; GENE-TRANSFER; IN-VIVO; DEFECTIVE EXPRESSION; MICE	X-linked immunodeficiency with hyper-IgM (HIGM1), characterized by failure of immunoglobulin isotype switching, is caused by mutations of the CD40 ligand (CD40L), which is normally expressed on activated CD4(+) T cells. As constitutive expression of CD40L induces lymphomas, we corrected the mutation while preserving the natural regulation of CD40L using pre-mRNA trans-splicing. Bone marrow from mice lacking CD40L was modified with a lentivirus trans-splicer encoding the normal CD40L exons 2 - 5 and was administered to syngenic CD40L-knockout mice. Recipient mice had corrected CD40L mRNA, antigen-specific IgG1 responses to keyhole limpet hemocyanin immunization, regulated CD4(+) T-cell CD40L expression after CD3 stimulation in primary and secondary transplanted mice, attenuation of Pneumocystis carinii pneumonia, and no evidence of lymphoproliferative disease over 1 year. Thus, HIGM1 can be corrected by CD40L trans-splicing, leading to functional correction of the genetic defect without the adverse consequences of unregulated expression of the CD40L gene.	Cornell Univ, Weill Med Coll, Dept Med Genet, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Belfer Gene Therapy Core Facil, New York, NY USA; N Shore Long Isl Jewish Res Inst, Biostat Unit, Manhasset, NY USA	Cornell University; Cornell University; Northwell Health	Crystal, RG (corresponding author), Cornell Univ, Weill Med Coll, Dept Med Genet, New York, NY 10021 USA.	geneticmedicine@med.cornell.edu			NHLBI NIH HHS [U01 HL66952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; Baumgartner RE, 2002, MICROB PATHOGENESIS, V33, P193, DOI 10.1006/mpat.2002.0528; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; Brown MP, 1998, NAT MED, V4, P1253, DOI 10.1038/3233; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; Chao HJ, 2003, NAT MED, V9, P1015, DOI 10.1038/nm900; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Garcia-Blanco MA, 2003, J CLIN INVEST, V112, P474, DOI 10.1172/JCI200319462; GARCIABLANCO MA, 2000, GENE THER REGUL, V1, P141; Gennery AR, 2004, BLOOD, V103, P1152, DOI 10.1182/blood-2003-06-2014; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hadzic N, 2000, NEW ENGL J MED, V342, P320, DOI 10.1056/NEJM200002033420504; Kikuchi T, 2000, NAT MED, V6, P1154, DOI 10.1038/80498; Kolls JK, 1999, J IMMUNOL, V162, P2890; KOLLS JK, 1993, AM J RESP CELL MOL, V8, P370, DOI 10.1165/ajrcmb/8.4.370; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; Liu DL, 2002, CHINESE SCI BULL, V47, P52, DOI 10.1360/02tb9010; Logan AC, 2002, CURR OPIN BIOTECH, V13, P429, DOI 10.1016/S0958-1669(02)00346-4; MacDonald AS, 2002, J IMMUNOL, V168, P4643, DOI 10.4049/jimmunol.168.9.4643; Mansfield SG, 2000, GENE THER, V7, P1885, DOI 10.1038/sj.gt.3301307; MERALI S, 1995, ANTIMICROB AGENTS CH, V39, P1442, DOI 10.1128/AAC.39.7.1442; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Netea MG, 2002, EUR J IMMUNOL, V32, P1455, DOI 10.1002/1521-4141(200205)32:5<1455::AID-IMMU1455>3.0.CO;2-C; Pergolizzi RG, 2003, MOL THER, V8, P999, DOI 10.1016/j.ymthe.2003.08.022; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; Puttaraju M, 2001, MOL THER, V4, P105, DOI 10.1006/mthe.2001.0426; ROY M, 1993, J IMMUNOL, V151, P2497; Sacco MG, 2000, CANCER GENE THER, V7, P1299, DOI 10.1038/sj.cgt.0234; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; Stephens J, 1999, HEPATOLOGY, V30, P27, DOI 10.1002/hep.510300138; Stout RD, 1996, J IMMUNOL, V156, P8; Straw AD, 2003, J IMMUNOL, V170, P727, DOI 10.4049/jimmunol.170.2.727; Sullenger BA, 2003, J CLIN INVEST, V112, P310, DOI 10.1172/JCI200319419; SZILVASSY SJ, 1989, BLOOD, V74, P930; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; THOMAS C, 1995, NEW ENGL J MED, V333, P426, DOI 10.1056/NEJM199508173330705; Thomsen AR, 1998, J IMMUNOL, V161, P4583; Vigna E, 2002, MOL THER, V5, P252, DOI 10.1006/mthe.2002.0542; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Xu KL, 2001, MOL THER, V3, P97, DOI 10.1006/mthe.2000.0238; Zheng MQ, 2001, J CLIN INVEST, V108, P1469, DOI 10.1172/JCI13826	48	70	77	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					835	841		10.1038/nm1086	http://dx.doi.org/10.1038/nm1086			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15273748				2022-12-27	WOS:000223055700038
J	He, ZN; Russell, JE				He, ZN; Russell, JE			Antisickling effects of an endogenous human alpha-like globin	NATURE MEDICINE			English	Article							EMBRYONIC ZETA-GLOBIN; NF-KAPPA-B; GENE; EXPRESSION; PROMOTER; CHAINS	Gene replacement or gene reactivation therapies for sickle-cell disease (SCD) typically target the mutant beta(S)-globin subunits of hemoglobin-S (alpha(2)beta(2)(S)) for substitution by nonpathological beta-like globins. Here we show, in vitro and in vivo in a transgenic mouse model of SCD, that the adverse properties of hemoglobin-S can be reversed by exchanging its normal alpha-globin subunits for zeta-globin, an endogenous, developmentally silenced, non-beta-like globin.	Univ Penn, Sch Med, Dept Med Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat Hematol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Russell, JE (corresponding author), Univ Penn, Sch Med, Dept Med Hematol Oncol, Philadelphia, PA 19104 USA.	jeruss@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067118, R01HL061399] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61399, HL67118, R01 HL067118, R01 HL061399] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bunn H, 1986, HEMOGLOBIN MOL GENET, P502; Chang J, 1996, BLOOD, V88, P1846; CHUI DHK, 1986, NEW ENGL J MED, V314, P76, DOI 10.1056/NEJM198601093140203; EDELSTEIN SJ, 1981, J MOL BIOL, V150, P557, DOI 10.1016/0022-2836(81)90381-8; HE Z, 2002, ANAL BIOCHEM, P349; Huang BL, 1998, P NATL ACAD SCI USA, V95, P14669, DOI 10.1073/pnas.95.25.14669; Liebhaber SA, 1996, MOL CELL BIOL, V16, P2637; Liu JJ, 2003, J BIOL CHEM, V278, P19534, DOI 10.1074/jbc.M212278200; PAPAYANNOPOULOU T, 1991, BLOOD, V77, P2569; PASTZY C, 1997, SCIENCE, V278, P876; TANG WZ, 1993, BLOOD, V81, P1636; Wang ZB, 1999, EMBO J, V18, P2218, DOI 10.1093/emboj/18.8.2218	12	13	13	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					365	367		10.1038/nm1022	http://dx.doi.org/10.1038/nm1022			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034572				2022-12-27	WOS:000220587000026
J	Padua, RA; Larghero, J; Robin, M; le Pogam, C; Schlageter, MH; Muszlak, S; Fric, J; West, R; Rousselot, P; Phan, TH; Mudde, L; Teisserenc, H; Carpentier, AF; Kogan, S; Degos, L; Pla, M; Bishop, JM; Stevenson, F; Charron, D; Chomienne, C				Padua, RA; Larghero, J; Robin, M; le Pogam, C; Schlageter, MH; Muszlak, S; Fric, J; West, R; Rousselot, P; Phan, TH; Mudde, L; Teisserenc, H; Carpentier, AF; Kogan, S; Degos, L; Pla, M; Bishop, JM; Stevenson, F; Charron, D; Chomienne, C			PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; B-CELL LYMPHOMA; RETINOIC ACID; HYBRID PROTEIN; FUSION REGION; FRAGMENT-C; ALPHA; CANCER; MICE; TRANSLOCATION	Despite improved molecular characterization of malignancies and development of targeted therapies, acute leukemia is not curable and few patients survive more than 10 years after diagnosis. Recently, combinations of different therapeutic strategies (based on mechanisms of apoptosis, differentiation and cytotoxicity) have significantly increased survival. To further improve outcome, we studied the potential efficacy of boosting the patient's immune response using specific immunotherapy. In an animal model of acute promyelocytic leukemia, we developed a DNA-based vaccine by fusing the human promyelocytic leukemia-retinoic acid receptor-alpha (PML-RARA) oncogene to tetanus fragment C (FrC) sequences. We show for the first time that a DNA vaccine specifically targeted to an oncoprotein can have a pronounced effect on survival, both alone and when combined with all-trans retinoic acid (ATRA). The survival advantage is concomitant with time-dependent antibody production and an increase in interferon-gamma (IFN-gamma). We also show that ATRA therapy on its own triggers an immune response in this model. When DNA vaccination and conventional ATRA therapy are combined, they induce protective immune responses against leukemia progression in mice and may provide a new approach to improve clinical outcome in human leukemia.	Hop St Louis, LBCH INSERM E0 03, U 462, Inst Univ Hematol,AP HP, F-75010 Paris, France; Hop St Louis, LBCH INSERM E0 03, U 396, Inst Univ Hematol,AP HP, F-75010 Paris, France; Kings Coll London, Dept Med Hematol, London SE5 9NU, England; Cardiff Univ, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA; Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA; Univ Southampton, Tenovus, Southampton SO16 6YD, Hants, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; King's College London; Cardiff University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Southampton	Padua, RA (corresponding author), Hop St Louis, LBCH INSERM E0 03, U 462, Inst Univ Hematol,AP HP, F-75010 Paris, France.	rose.padua@kcl.ac.uk	Muszlak, Sacha/AAV-6110-2020; Moins-Teisserenc, helene/AAL-1566-2021; Frič, Jan/P-7444-2018; Padua, Rose Ann/GVT-5961-2022; PADUA, Rose Ann/E-8621-2019; Fric, Jan/O-5441-2015	Muszlak, Sacha/0000-0001-5739-8564; Moins-Teisserenc, helene/0000-0003-1602-7534; Frič, Jan/0000-0001-6642-797X; PADUA, Rose Ann/0000-0001-9964-7864; Fric, Jan/0000-0001-6642-797X; CHOMIENNE, Christine/0000-0001-5513-5752; Robin, Marie/0000-0003-1388-9876; Stevenson, Freda/0000-0002-0933-5021; Kogan, Scott/0000-0002-2395-8479; Carpentier, Antoine/0000-0003-2926-0060				Bogen B, 1996, EUR J IMMUNOL, V26, P2671, DOI 10.1002/eji.1830261119; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Cassinat B, 2000, LEUKEMIA, V14, P324, DOI 10.1038/sj.leu.2401652; Chen SA, 2000, CLIN CANCER RES, V6, P4381; Delva L, 1999, MOL CELL BIOL, V19, P7158; Dermime S, 1996, CLIN CANCER RES, V2, P593; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DRESSER DW, 1968, NATURE, V217, P527, DOI 10.1038/217527a0; Finn OJ, 2002, CURR OPIN IMMUNOL, V14, P172, DOI 10.1016/S0952-7915(02)00317-5; Forni G, 2000, CANCER RES, V60, P2571; GAMBACORTIPASSERINI C, 1993, BLOOD, V81, P1369; HU J, 1993, J EXP MED, V177, P1681, DOI 10.1084/jem.177.6.1681; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; LUST JA, 1981, J EXP MED, V154, P306, DOI 10.1084/jem.154.2.306; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Parrado A, 2001, NUCLEIC ACIDS RES, V29, P4901, DOI 10.1093/nar/29.24.4901; Rice J, 2001, J IMMUNOL, V167, P1558, DOI 10.4049/jimmunol.167.3.1558; Sambrook J., 2002, MOL CLONING LAB MANU; Spellerberg MB, 1997, J IMMUNOL, V159, P1885; Stephensen CB, 2002, J IMMUNOL, V168, P4495, DOI 10.4049/jimmunol.168.9.4495; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; Westervelt P, 2002, P NATL ACAD SCI USA, V99, P9468, DOI 10.1073/pnas.132657799; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	30	60	69	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1413	1417		10.1038/nm949	http://dx.doi.org/10.1038/nm949			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14566333				2022-12-27	WOS:000186319700033
J	Hallahan, AR; Pritchard, JI; Chandraratna, RAS; Ellenbogen, RG; Geyer, JR; Overland, RP; Strand, AD; Tapscott, SJ; Olson, JM				Hallahan, AR; Pritchard, JI; Chandraratna, RAS; Ellenbogen, RG; Geyer, JR; Overland, RP; Strand, AD; Tapscott, SJ; Olson, JM			BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect	NATURE MEDICINE			English	Article							BONE MORPHOGENETIC PROTEINS; ATHYMIC NUDE-MICE; SPEMANN ORGANIZER; PROGENITOR CELLS; GENE-EXPRESSION; NERVOUS-SYSTEM; GROWTH-FACTOR; ACID; RECEPTOR; DIFFERENTIATION	The mechanisms of retinoid activity in tumors remain largely unknown. Here we establish that retinoids cause extensive apoptosis of medulloblastoma cells. In a xenograft model, retinoids largely abrogated tumor growth. Using receptor-specific retinoid agonists, we defined a subset of mRNAs that were induced by all active retinoids in retinoid-sensitive cell lines. We also identified bone morphogenetic protein-2 (BMP-2) as a candidate mediator of retinoid activity. BMP-2 protein induced medulloblastoma cell apoptosis, whereas the BMP-2 antagonist noggin blocked both retinoid and BMP-2-induced apoptosis. BMP-2 also induced p38 mitogen-activated protein kinase (MAPK), which is necessary for BMP-2- and retinoid-induced apoptosis. Retinoid-resistant medulloblastoma cells underwent apoptosis when treated with BMP-2 or when cultured with retinoid-sensitive medulloblastoma cells. Retinoid-induced expression of BMP-2 is thus necessary and sufficient for apoptosis of retinoid-responsive cells, and expression of BMP-2 by retinoid-sensitive cells is sufficient to induce apoptosis in surrounding retinoid-resistant cells.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Washington, Childrens Hosp, Div Pediat Oncol, Seattle, WA 98105 USA; Allergan Pharmaceut Inc, Retinoid Res, Irvine, CA 92623 USA; Univ Washington, Childrens Hosp, Dept Neurosurg, Seattle, WA 98105 USA; Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Seattle Children's Hospital; University of Washington; University of Washington Seattle; AbbVie; Allergan; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Olson, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.		Hallahan, Andrew R/F-1757-2010	Tapscott, Stephen/0000-0002-0319-0968				Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Caricasole A, 2000, INT J DEV BIOL, V44, P443; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chandraratna RAS, 1996, BRIT J DERMATOL, V135, P18, DOI 10.1111/j.1365-2133.1996.tb15662.x; Conley BA, 1999, CANCER CHEMOTH PHARM, V43, P183, DOI 10.1007/s002800050883; Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189; Evans AE, 1999, CLIN CANCER RES, V5, P3594; Farah MH, 2000, DEVELOPMENT, V127, P693; Ghatpande S, 2002, BLOOD, V99, P2379, DOI 10.1182/blood.V99.7.2379; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; Johnson AT, 1999, BIOORGAN MED CHEM, V7, P1321, DOI 10.1016/S0968-0896(99)00055-3; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; KELES GE, 1993, NEUROSURGERY, V32, P274, DOI 10.1227/00006123-199302000-00017; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu J, 2000, ANTICANCER RES, V20, P2659; MARIA BL, 1989, J NEURO-ONCOL, V7, P329, DOI 10.1007/BF02147090; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; NIE XF, 1995, GENE, V152, P285, DOI 10.1016/0378-1119(94)00696-P; Olson JM, 2001, DEV BIOL, V234, P174, DOI 10.1006/dbio.2001.0245; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Rostomily RC, 1997, CANCER RES, V57, P3526; SHALINSKY DR, 1995, CANCER RES, V55, P3183; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Song QB, 1998, DEV BIOL, V196, P119, DOI 10.1006/dbio.1998.8847; Strand AD, 2002, HUM MOL GENET, V11, P2207, DOI 10.1093/hmg/11.19.2207; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wang Q, 2001, BREAST CANCER RES TR, V67, P157, DOI 10.1023/A:1010643323268; Yamamoto M, 1996, DEV BRAIN RES, V93, P182, DOI 10.1016/0165-3806(96)00038-7; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhu GF, 1999, DEV BIOL, V215, P118, DOI 10.1006/dbio.1999.9431; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	50	150	155	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1033	1038		10.1038/nm904	http://dx.doi.org/10.1038/nm904			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12872164				2022-12-27	WOS:000184484900027
J	Brown, E; McKee, T; diTomaso, E; Pluen, A; Seed, B; Boucher, Y; Jain, RK				Brown, E; McKee, T; diTomaso, E; Pluen, A; Seed, B; Boucher, Y; Jain, RK			Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation	NATURE MEDICINE			English	Article							2ND-HARMONIC GENERATION; MICROSCOPY; RELAXIN; TRANSPORT; DIFFUSION; TISSUE	The content and structure of collagen is essential in governing the delivery of therapeutic molecules in tumors. Thus, simple histological staining of tumor tissue biopsies for collagen could be used to assess the accessibility of molecular therapeutics in tumors. Here we show that it is possible to optically image fibrillar collagen in tumors growing in mice using second-harmonic generation (SHG). Using this noninvasive technique, we estimated relative diffusive hindrance, quantified the dynamics of collagen modification after pharmacologic intervention and provided mechanistic insight into improved diffusive transport induced by the hormone relaxin. This technology could offer basic scientists and clinicians an enhanced ability to estimate the relative penetrabilities of molecular therapeutics.	Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); University of Manchester	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.		McKee, Trevor David/N-4308-2019; Jain, Rakesh K/I-1384-2017; Pluen, Alain/F-5300-2015	McKee, Trevor David/0000-0002-2195-6146; Jain, Rakesh K/0000-0001-7571-3548; Pluen, Alain/0000-0002-5953-8011	NATIONAL CANCER INSTITUTE [P01CA080124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008334] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA80124] Funding Source: Medline; NIGMS NIH HHS [T32GM08334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal A, 2001, TISSUE ENG, V7, P191, DOI 10.1089/107632701300062813; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; BYLANDER JE, 1987, P SOC EXP BIOL MED, V185, P76; Campagnola PJ, 2002, BIOPHYS J, V82, P493, DOI 10.1016/S0006-3495(02)75414-3; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fleischmajer R, 1998, ANN NY ACAD SCI, V857, P212, DOI 10.1111/j.1749-6632.1998.tb10118.x; FREUND I, 1986, BIOPHYS J, V50, P693, DOI 10.1016/S0006-3495(86)83510-X; FRIEDEN EH, 1985, P SOC EXP BIOL MED, V180, P39; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Helmchen F, 2001, NEURON, V31, P903, DOI 10.1016/S0896-6273(01)00421-4; Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778; Moreaux L, 2000, J OPT SOC AM B, V17, P1685, DOI 10.1364/JOSAB.17.001685; Netti PA, 2000, CANCER RES, V60, P2497; Pluen A, 2001, P NATL ACAD SCI USA, V98, P4628, DOI 10.1073/pnas.081626898; Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006-3495(02)73933-7; Seibold JR, 2000, ANN INTERN MED, V132, P871, DOI 10.7326/0003-4819-132-11-200006060-00004; Stoller P, 2002, BIOPHYS J, V82, P3330, DOI 10.1016/S0006-3495(02)75673-7; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; Williams RM, 2001, CURR OPIN CHEM BIOL, V5, P603, DOI 10.1016/S1367-5931(00)00241-6; Zoumi A, 2002, P NATL ACAD SCI USA, V99, P11014, DOI 10.1073/pnas.172368799	20	701	716	1	136	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					796	800		10.1038/nm879	http://dx.doi.org/10.1038/nm879			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12754503				2022-12-27	WOS:000183444100038
J	Riedemann, NC; Guo, RF; Ward, PA				Riedemann, NC; Guo, RF; Ward, PA			Novel strategies for the treatment of sepsis	NATURE MEDICINE			English	Review							MIGRATION-INHIBITORY FACTOR; TUMOR NECROSIS FACTOR; RESPIRATORY-DISTRESS-SYNDROME; RECEPTOR ANTAGONIST TRIAL; ACTIVATED PROTEIN-C; DOUBLE-BLIND; SEPTIC SHOCK; C5A RECEPTOR; MONOCLONAL-ANTIBODIES; IMPROVES SURVIVAL		Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Riedemann, NC (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	pward@umich.edu	Riedemann, Niels C/C-1633-2010					Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Avontuur JAM, 1998, CRIT CARE MED, V26, P660, DOI 10.1097/00003246-199804000-00012; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Bustin M, 1999, MOL CELL BIOL, V19, P5237; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Cohen J, 1999, BRIT MED BULL, V55, P212, DOI 10.1258/0007142991902222; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; DAVIS CE, 1969, J IMMUNOL, V102, P563; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; Dhainaut JFA, 1998, CRIT CARE MED, V26, P1963, DOI 10.1097/00003246-199812000-00021; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1197, DOI 10.1164/rccm.200204-302OC; Fein AM, 1997, JAMA-J AM MED ASSOC, V277, P482, DOI 10.1001/jama.277.6.482; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; Fronhoffs S, 2000, INTENS CARE MED, V26, P1566, DOI 10.1007/s001340000654; Gando S, 2001, INTENS CARE MED, V27, P1187, DOI 10.1007/s001340000818; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDSTEI.IM, 1974, J IMMUNOL, V113, P1583; Group CS, 1963, JAMA-J AM MED ASSOC, V183, P462, DOI DOI 10.1001/JAMA.1963.63700060029012; Guo RF, 2000, J CLIN INVEST, V106, P1271, DOI 10.1172/JCI10793; Healy DP, 2002, ANN PHARMACOTHER, V36, P648; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Kanangat S, 1999, INFECT IMMUN, V67, P2834, DOI 10.1128/IAI.67.6.2834-2840.1999; Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699; LEFERING R, 1995, CRIT CARE MED, V23, P1294, DOI 10.1097/00003246-199507000-00021; Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; Meduri GU, 2002, AM J RESP CRIT CARE, V165, P983, DOI 10.1164/ajrccm.165.7.2106014; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; Meduri GU, 1999, AM J RESP CRIT CARE, V160, P961, DOI 10.1164/ajrccm.160.3.9807080; MICHIE HR, 1988, SURGERY, V104, P280; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Oberholzer C, 2001, FASEB J, V15, P879, DOI 10.1096/fj.00-058rev; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010; Reinhart K, 2001, CRIT CARE MED, V29, pS121, DOI 10.1097/00003246-200107001-00037; Riedemann NC, 2003, J IMMUNOL, V170, P503, DOI 10.4049/jimmunol.170.1.503; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; Riedemann NC, 2002, FASEB J, V16, P887, DOI 10.1096/fj.02-0033fje; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; Sappington PL, 2002, GASTROENTEROLOGY, V123, P790, DOI 10.1053/gast.2002.35391; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; SCHILLING J, 1993, INTENS CARE MED, V19, P227, DOI 10.1007/BF01694775; SCHUMACHER WA, 1991, AGENTS ACTIONS, V34, P345, DOI 10.1007/BF01988727; SHIN HS, 1968, SCIENCE, V162, P361, DOI 10.1126/science.162.3851.361; SPIES CD, 1994, CRIT CARE MED, V22, P1738; Staubach KH, 1998, ARCH SURG-CHICAGO, V133, P94, DOI 10.1001/archsurg.133.1.94; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; van der Poll T, 2001, Lancet Infect Dis, V1, P165, DOI 10.1016/S1473-3099(01)00093-7; Vincent JL, 2002, CLIN INFECT DIS, V34, P1084, DOI 10.1086/339549; Vincent JL, 2001, INTENS CARE MED, V27, P1578, DOI 10.1007/s001340101077; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; WARREN HS, 1993, J EXP MED, V177, P89, DOI 10.1084/jem.177.1.89; Warren HS, 2002, NEW ENGL J MED, V347, P1027, DOI 10.1056/NEJMsb020574; YU MH, 1993, CRIT CARE MED, V21, P1635, DOI 10.1097/00003246-199311000-00010; Zeni F, 1996, CRIT CARE MED, V24, P207, DOI 10.1097/00003246-199602000-00005; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	79	639	702	0	41	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2003	9	5					517	524		10.1038/nm0503-517	http://dx.doi.org/10.1038/nm0503-517			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12724763				2022-12-27	WOS:000182610600031
J	Tomaru, U; Yamano, Y; Nagai, M; Maric, D; Kaumaya, PTP; Biddison, W; Jacobson, S				Tomaru, U; Yamano, Y; Nagai, M; Maric, D; Kaumaya, PTP; Biddison, W; Jacobson, S			Detection of virus-specific T cells and CD8(+) T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections	NATURE MEDICINE			English	Article							NEUROLOGICAL DISEASE; LYMPHOCYTES; MEMORY; HTLV-1; MYELOPATHY; HAM/TSP; LOAD	Antigen-specific CD8(+) T cells acquire peptide-major histocompatibility complex (MHC) clusters through T-cell receptor (TCR)-mediated endocytosis after specific antigen stimulation. We generated an antigen-presenting cell (APC) expressing human leukocyte antigen (HLA)-A*201 coupled to the enhanced green fluorescent protein (GFP), which delivered GFP to an antigen-specific T cell when pulsed with antigenic peptide. We quantitatively identified human T-cell lymphotropic virus type I ( HTLV-I) Tax(11-19) peptide-specific T-cell populations in peripheral blood mononuclear cells (PBMCs) from patients with HTLV-I-associated neurologic disease and defined a new CD8(+) T-cell epitope in the HTLV-I envelope region. Acquisition of peptide-HLA-GFP complexes by antigen-specific T cells could distinguish, with respect to phenotype and perforin production, T cells from the chronic viral infections cytomegalovirus and HTLV-I. This approach will be a powerful tool in understanding the role of antigen-specific T-cell responses in health and disease.	NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA; Kagoshima Univ, Fac Med, Dept Internal Med 3, Kagoshima 890, Japan; NINDS, Neurophysiol Lab, NIH, Bethesda, MD 20892 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Kagoshima University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University System of Ohio; Ohio State University	Jacobson, S (corresponding author), NINDS, Neuroimmunol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.		Yamano, Yoshihisa/AAG-3955-2020; Kaumaya, Pravin T. P/E-3354-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002817, Z01NS002817, Z01NS002603] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Bangham CRM, 2000, CURR OPIN IMMUNOL, V12, P397, DOI 10.1016/S0952-7915(00)00107-2; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Frangione-Beebe M, 2000, VACCINE, V19, P1068, DOI 10.1016/S0264-410X(00)00340-6; GESSAIN A, 1985, LANCET, V2, P407; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Jacobson S, 2002, J INFECT DIS, V186, pS187, DOI 10.1086/344269; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; Kubota R, 2000, J IMMUNOL, V164, P5192, DOI 10.4049/jimmunol.164.10.5192; Mendez E, 1997, J VIROL, V71, P9143; Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225; Osame M, 2002, J NEUROVIROL, V8, P359, DOI 10.1080/13550280260422668; OSAME M, 1986, LANCET, V1, P1031; OSAME M, 1990, HUMAN RETROVIROLOGY : HTLV, P191; PARKER KC, 1994, J IMMUNOL, V152, P163; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; WINTER CC, 1991, J IMMUNOL, V146, P3508; Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88	21	45	51	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					469	475		10.1038/nm845	http://dx.doi.org/10.1038/nm845			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12652294				2022-12-27	WOS:000181987400039
J	Yan, SS; Wu, ZY; Zhang, HP; Furtado, G; Chen, X; Yan, SF; Schmidt, AM; Brown, C; Stern, A; LaFaille, J; Chess, L; Stern, DM; Jiang, H				Yan, SS; Wu, ZY; Zhang, HP; Furtado, G; Chen, X; Yan, SF; Schmidt, AM; Brown, C; Stern, A; LaFaille, J; Chess, L; Stern, DM; Jiang, H			Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system	NATURE MEDICINE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; ALPHA-4 INTEGRIN; BRAIN PARENCHYMA; TRANSGENIC MICE; RECEPTOR; EXPRESSION; RAGE; INFLAMMATION; MECHANISMS	Multiple sclerosis (MS) is a devastating neuroinflammatory disorder of the central nervous system (CNS) in which T cells that are reactive with major components of myelin sheaths have a central role. The receptor for advanced glycation end products (RAGE) is present on T cells, mononuclear phagocytes and endothelium. Its pro-inflammatory ligands, S100-calgranulins, are upregulated in MS and in the related rodent model, experimental autoimmune encephalomyelitis (EAE). Blockade of RAGE suppressed EAE when disease was induced by myelin basic protein (MBP) peptide or encephalitogenic T cells, or when EAE occurred spontaneously in T-cell receptor (TCR)-transgenic mice devoid of endogenous TCR- and TCR-chains. Inhibition of RAGE markedly decreased infiltration of the CNS by immune and inflammatory cells. Transgenic mice with targeted overexpression of dominant-negative RAGE in CD4(+) T cells were resistant to MBP-induced EAE. These data reinforce the importance of RAGE-ligand interactions in modulating properties of CD4(+) T cells that infiltrate the CNS.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Fujian Med Univ, Dept Neurol, Affiliated Hosp 1, Fujian, Peoples R China; NYU, Skirball Inst Biomed Sci, New York, NY USA; NYU Med Ctr, Dept Neurol, New York, NY 10016 USA; Med Coll Georgia, Sch Med, Augusta, GA 30912 USA	Columbia University; Columbia University; Columbia University; Columbia University; Fujian Medical University; New York University; New York University; University System of Georgia; Augusta University	Yan, SS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	sdy1@columbia.edu			NIAID NIH HHS [AI44927, AI46132] Funding Source: Medline; NINDS NIH HHS [NS42855] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI046132, R01AI044927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042855] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adlam M, 1997, INT IMMUNOL, V9, P877, DOI 10.1093/intimm/9.6.877; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Bauer J, 2001, GLIA, V36, P235, DOI 10.1002/glia.1112; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; CARLOS TM, 1990, BLOOD, V76, P965; Farina C, 2001, BRAIN, V124, P705, DOI 10.1093/brain/124.4.705; Girvin AR, 2000, J IMMUNOL, V164, P136, DOI 10.4049/jimmunol.164.1.136; Graesser D, 2000, J NEUROIMMUNOL, V109, P121, DOI 10.1016/S0165-5728(00)00275-7; HAFLER DA, 1995, IMMUNOL REV, V144, P75, DOI 10.1111/j.1600-065X.1995.tb00066.x; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hohlfeld R, 2001, CURR OPIN NEUROL, V14, P299, DOI 10.1097/00019052-200106000-00006; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Howard LM, 1999, J CLIN INVEST, V103, P281, DOI 10.1172/JCI5388; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; Jiang H, 2001, P NATL ACAD SCI USA, V98, P6301, DOI 10.1073/pnas.101123098; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; Karpus WJ, 1998, J IMMUNOL, V161, P2667; KOBAYASHI Y, 1995, CELL IMMUNOL, V164, P295, DOI 10.1006/cimm.1995.1173; Lafaille JJ, 1997, J EXP MED, V186, P307, DOI 10.1084/jem.186.2.307; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; Neuhaus O, 2001, NEUROLOGY, V56, P702, DOI 10.1212/WNL.56.6.702; Nygardas PT, 2000, EUR J IMMUNOL, V30, P1911, DOI 10.1002/1521-4141(200007)30:7<1911::AID-IMMU1911>3.0.CO;2-E; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Owens T, 2001, NAT MED, V7, P161, DOI 10.1038/84603; Pahan K, 2000, NEUROSCI LETT, V287, P17, DOI 10.1016/S0304-3940(00)01167-8; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Smith T, 2000, NAT MED, V6, P62, DOI 10.1038/71548; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Wong FS, 1999, IMMUNOL REV, V169, P93, DOI 10.1111/j.1600-065X.1999.tb01309.x; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	38	152	172	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					287	293		10.1038/nm831	http://dx.doi.org/10.1038/nm831			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12598893				2022-12-27	WOS:000181312300028
J	Zhang, WD; Yang, H; Kong, XY; Mohapatra, S; San Juan-Vergara, H; Hellermann, G; Behera, S; Singam, R; Lockey, RF; Mohapatra, SS				Zhang, WD; Yang, H; Kong, XY; Mohapatra, S; San Juan-Vergara, H; Hellermann, G; Behera, S; Singam, R; Lockey, RF; Mohapatra, SS			Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene	NATURE MEDICINE			English	Article							NONSTRUCTURAL PROTEINS NS1; PROTECTS BALB/C MICE; INTERFERON-GAMMA; CELLS; BRONCHIOLITIS; ASTHMA; INDUCTION; BETA; RNA; RSV	Respiratory syncytial virus (RSV) infection is one of the major causes of respiratory tract infection for which no vaccine or antiviral treatment is available. The RSV NS1 protein seems to antagonize the host interferon (IFN) response; however, its mechanism is unknown. Here, we used a plasmid-borne small interfering RNA targeting the NS1 gene (siNS1) to examine the role of NS1 in modulating RSV infection. RSV replication was reduced in A549 cells, but not IFN-deficient Vero cells, transfected with siNS1. siNS1 induced upregulated expression of IFN-beta and IFN-inducible genes in A549 cells. siNS1-transfected human dendritic cells, upon RSV infection, produced elevated type-1 IFN and induced differentiation of naive CD4+ T cells to T helper type 1 (TH1) cells. Mice treated intranasally with siNS1 nanoparticles before or after infection with RSV showed substantially decreased virus titers in the lung and decreased inflammation and airway reactivity compared to controls. Thus, siNS1 nanoparticles may provide an effective inhibition of RSV infection in humans.	Univ S Florida, Dept Internal Med, Joy McCann Culverhouse Airway Dis Res Ctr, Div Allergy Immunol, Tampa, FL 33612 USA; James A Haley Vet Hosp, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Transgenex Nanobiotech Inc, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; H Lee Moffitt Cancer Center & Research Institute	Mohapatra, SS (corresponding author), Univ S Florida, Dept Internal Med, Joy McCann Culverhouse Airway Dis Res Ctr, Div Allergy Immunol, MDC-19,Rm 2536,12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	smohapat@hsc.usf.edu	Mohapatra, Subhra/A-1381-2012; Mohapatra, Shyam/C-2500-2012; Hellermann, Gary/A-8855-2013	San Juan Vergara, Homero/0000-0002-3808-4647	NHLBI NIH HHS [5R01HL71101-01A2] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD R, 1994, IMMUNOLOGY, V82, P126; Atreya PL, 1998, J VIROL, V72, P1452, DOI 10.1128/JVI.72.2.1452-1461.1998; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Bartz H, 2003, IMMUNOLOGY, V109, P49, DOI 10.1046/j.1365-2567.2003.01629.x; Behera AK, 2002, HUM GENE THER, V13, P1697, DOI 10.1089/104303402760293547; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Bont L, 2000, J INFECT DIS, V181, P1772, DOI 10.1086/315433; Bossert B, 2003, J VIROL, V77, P8661, DOI 10.1128/JVI.77.16.8661-8668.2003; Bossert B, 2002, J VIROL, V76, P4287, DOI 10.1128/JVI.76.9.4287-4293.2002; Brandenburg AH, 2001, VACCINE, V19, P2769, DOI 10.1016/S0264-410X(00)00536-3; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Coffin SE, 1997, ADV PEDIATR INFECT D, V13, P333; COLLINS PL, 2001, FIELDS VIROLOGY, P1443; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; Hall CB, 2001, CLIN INFECT DIS, V33, P792, DOI 10.1086/322657; Hallak LK, 2000, VIROLOGY, V271, P264, DOI 10.1006/viro.2000.0293; Handforth J, 2000, Paediatr Respir Rev, V1, P210, DOI 10.1053/prrv.2000.0050; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hellermann Gary R, 2003, Genet Vaccines Ther, V1, P1; Jin H, 2000, VIROLOGY, V273, P210, DOI 10.1006/viro.2000.0393; Kole R, 2001, CURR OPIN MOL THER, V3, P229; Kumar M, 2002, HUM GENE THER, V13, P1415, DOI 10.1089/10430340260185058; Kumar M, 1999, VACCINE, V18, P558, DOI 10.1016/S0264-410X(99)00185-1; Kumar Mukesh, 2003, Genet Vaccines Ther, V1, P3, DOI 10.1186/1479-0556-1-3; Leaman DW, 2002, VIROLOGY, V292, P70, DOI 10.1006/viro.2001.1213; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; Mohapatra SS, 2003, PEDIATR INFECT DIS J, V22, pS100, DOI 10.1097/00006454-200302001-00015; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; Murphy BR, 2002, J CLIN INVEST, V110, P21, DOI 10.1172/JCI200216077; Pebernard S, 2004, DIFFERENTIATION, V72, P103, DOI 10.1111/j.1432-0436.2004.07202001.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Schlender J, 2000, J VIROL, V74, P8234, DOI 10.1128/JVI.74.18.8234-8242.2000; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SLY PD, 1989, PEDIATR PULM, V7, P153, DOI 10.1002/ppul.1950070307; Spann KM, 2004, J VIROL, V78, P4363, DOI 10.1128/JVI.78.8.4363-4369.2004; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Teng MN, 2000, J VIROL, V74, P9317, DOI 10.1128/JVI.74.19.9317-9321.2000; Teng MN, 1999, J VIROL, V73, P466, DOI 10.1128/JVI.73.1.466-473.1999; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Welliver RC, 2003, J PEDIATR-US, V143, pS112, DOI 10.1067/S0022-3476(03)00508-0; Zhang Weidong, 2004, Genet Vaccines Ther, V2, P8, DOI 10.1186/1479-0556-2-8	48	249	277	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					56	62		10.1038/nm1174	http://dx.doi.org/10.1038/nm1174			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619625				2022-12-27	WOS:000226124900033
J	Evans, BJ; Flockhart, DA; Meslin, EM				Evans, BJ; Flockhart, DA; Meslin, EM			Creating incentives for genomic research to improve targeting of therapies	NATURE MEDICINE			English	Editorial Material							LUNG-CANCER; PHARMACOGENOMICS; MUTATIONS		Indiana Univ, Ctr Bioeth, Pharmacogenom Eth & Publ Policy Program, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Div Clin Pharmacol, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Dept Med, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Bloomington, IN 47405 USA; Indiana Univ Purdue Univ, Dept Philosophy, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis	Evans, BJ (corresponding author), Indiana Univ, Ctr Bioeth, Pharmacogenom Eth & Publ Policy Program, Bloomington, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061373] Funding Source: NIH RePORTER; NIGMS NIH HHS [U-01 GM61373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal M, 2003, JAMA-J AM MED ASSOC, V290, P1075, DOI 10.1001/jama.290.8.1075; DICKSON M, 2003, SURVEY PHARMACOECONO; DODDSSMITH I, 2004, GLOBAL COUNSEL LIFE, P77; Epstein AM, 2004, NEW ENGL J MED, V350, P406, DOI 10.1056/NEJMsb035374; *EUR AG EV MED PRO, 2002, EMEACMP307001; Guttmacher AE, 2003, NEW ENGL J MED, V349, P996, DOI 10.1056/NEJMe038132; Hensley S., 2004, WALL STREET J, pBI; Institute of Medicine, 2002, CAR COV TOO LITTL TO; JESS M, 1997, DOEEIA10309705, pR7; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lesko LJ, 2004, NAT REV DRUG DISCOV, V3, P763, DOI 10.1038/nrd1499; Lesko LJ, 2003, J CLIN PHARMACOL, V43, P342, DOI 10.1177/0091270003252244; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MICHAELS RJ, 1993, REGULATION, V16, P20; Nuffield Council on Bioethics, 2003, PHARM ETH ISS; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; PEAKMAN T, 2001, DRUG DISCOVERY WORLD, V2, P35; RAGO L, 2003, WHO DRUG INFORMATION, V17, P84; Rawlins MD, 2004, NEW ENGL J MED, V351, P1383, DOI 10.1056/NEJMp048221; United States Department of Energy, 1995, DOEEIA06025, P9; *US C BUDG OFF, 1998, EL UT DER STRAND COS; *US DEP HHS, 2004, INN STAGN CHALL OPP; *US DEP HHS, 2004, NAT HLTH EXP TABL TA; *US DEP HHS, 2003, CAG00157N US DEP HLT; *US DOE, 1997, EL REF ABR US INV, pCH2; World Health Organization, 2004, WORLD HLTH REP 2003	26	14	15	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1289	1291		10.1038/nm1204-1289	http://dx.doi.org/10.1038/nm1204-1289			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15580246				2022-12-27	WOS:000225500900016
J	Lee, CG; Link, H; Baluk, P; Homer, RJ; Chapoval, S; Bhandari, V; Kang, MJ; Cohn, L; Kim, YK; McDonald, DM; Elias, JA				Lee, CG; Link, H; Baluk, P; Homer, RJ; Chapoval, S; Bhandari, V; Kang, MJ; Cohn, L; Kim, YK; McDonald, DM; Elias, JA			Vascular endothelial growth factor (VEGF) induces remodeling and enhances T(H)2-mediated sensitization and inflammation in the lung	NATURE MEDICINE			English	Article							PERMEABILITY FACTOR; ASTHMATIC AIRWAYS; IN-VITRO; EXPRESSION; OVEREXPRESSION; ANGIOGENESIS; PROTECTS; PATHOGENESIS; RECRUITMENT; CHILDREN	Exaggerated levels of VEGF (vascular endothelial growth factor) are present in persons with asthma, but the role(s) of VEGF in normal and asthmatic lungs has not been defined. We generated lung-targeted VEGF(165) transgenic mice and evaluated the role of VEGF in T-helper type 2 cell (T(H)2)-mediated inflammation. In these mice, VEGF induced, through IL-13-dependent and -independent pathways, an asthma-like phenotype with inflammation, parenchymal and vascular remodeling, edema, mucus metaplasia, myocyte hyperplasia and airway hyper-responsiveness. VEGF also enhanced respiratory antigen sensitization and T(H)2 inflammation and increased the number of activated DC2 dendritic cells. In antigen-induced inflammation, VEGF was produced by epithelial cells and preferentially by T(H)2 versus T(H)1 cells. In this setting, it had a critical role in T(H)2 inflammation, cytokine production and physiologic dysregulation. Thus, VEGF is a mediator of vascular and extravascular remodeling and inflammation that enhances antigen sensitization and is crucial in adaptive T(H)2 inflammation. VEGF regulation may be therapeutic in asthma and other T(H)2 disorders.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Yale University	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 300 Cedar St,441C TAC, New Haven, CT 06520 USA.	jack.elias@yale.edu	Lee, Chun Geun/AAC-2838-2021; homer, robert/P-3884-2019; Bhandari, Vineet/AAS-3365-2020	homer, robert/0000-0002-2055-5885; Kang, Min-Jong/0000-0003-3245-144X; Lee, Chun Geun/0000-0002-9514-3658; Chapoval, Svetlana/0000-0002-7590-4421	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061904, P50HL056389, R01HL059157, R01HL078744, P01HL024136, P01HL056389] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-78744, HL-61904, R01 HL061904, P01 HL056389, HL-56389, P01 HL024136, HL-59157, R01 HL078744, HL-24136, HL-64642, R01 HL059157, P50 HL056389] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; BALUK P, IN PRESS AM J PATHOL; Charan NB, 1997, EUR RESPIR J, V10, P1173, DOI 10.1183/09031936.97.10051173; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Gabrilovich DI, 1999, CLIN CANCER RES, V5, P2963; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Hahn RG, 2003, J ENDOTOXIN RES, V9, P97, DOI 10.1177/09680519030090020401; Hogg JC, 1999, THORAX, V54, P283, DOI 10.1136/thx.54.4.283; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779; Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee CG, 2000, AM J RESP CELL MOL, V23, P662, DOI 10.1165/ajrcmb.23.5.4188; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lee YC, 2001, J ALLERGY CLIN IMMUN, V107, P1106, DOI 10.1067/mai.2001.115628; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Matsuyama W, 2002, IMMUNOLOGY, V106, P96, DOI 10.1046/j.1365-2567.2002.01395.x; Meyer KC, 2000, J LAB CLIN MED, V135, P332, DOI 10.1067/mlc.2000.105618; Nishigaki Y, 2003, EUR RESPIR J, V21, P774, DOI 10.1183/09031936.03.00085903; Ohta Y, 2002, CHEST, V121, P1624, DOI 10.1378/chest.121.5.1624; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117, DOI 10.1164/ajrccm.164.1.2006003; Partovian C, 2000, AM J RESP CELL MOL, V23, P762, DOI 10.1165/ajrcmb.23.6.4106; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; Schwarze J, 2002, EUR RESPIR J, V19, P341, DOI 10.1183/09031936.02.00254302; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; VERMAELEN KY, 2003, AM J RESP CELL MOL B; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Wang JM, 2000, J IMMUNOL, V165, P2222, DOI 10.4049/jimmunol.165.4.2222; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	51	458	486	3	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1095	1103		10.1038/nm1105	http://dx.doi.org/10.1038/nm1105			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15378055	Green Accepted			2022-12-27	WOS:000224245800040
J	Gomez, MI; Lee, A; Reddy, B; Muir, A; Soong, G; Pitt, A; Cheung, A; Prince, A				Gomez, MI; Lee, A; Reddy, B; Muir, A; Soong, G; Pitt, A; Cheung, A; Prince, A			Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FACTOR-ALPHA; IL-8 EXPRESSION; CELLS; RECEPTOR; VIRULENCE; INFECTION; MONOCYTES; INDUCTION	Staphylococcus aureus is a major human pathogen that is associated with diverse types of local and systemic infection characterized by inflammation dominated by polymorphonuclear leukocytes. Staphylococci frequently cause pneumonia, and these clinical isolates often have increased expression of protein A, suggesting that this protein may have a role in virulence. Here we show that TNFR1, a receptor for tumor-necrosis factor-alpha (TNF-alpha) that is widely distributed on the airway epithelium, is a receptor for protein A. We also show that the protein A - TNFR1 signaling pathway has a central role in the pathogenesis of staphylococcal pneumonia.	Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Dartmouth Coll, Sch Med, Dept Microbiol & Immunol, Hanover, NH 03755 USA	Columbia University; Dartmouth College	Prince, A (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA.	asp7@columbia.edu			NHLBI NIH HHS [R01 HL079395] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079395] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Goerke C, 2000, INFECT IMMUN, V68, P1304, DOI 10.1128/IAI.68.3.1304-1311.2000; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; Hartleib J, 2000, BLOOD, V96, P2149; Hattar K, 2001, J IMMUNOL, V166, P6287, DOI 10.4049/jimmunol.166.10.6287; Herring AC, 2002, INFECT IMMUN, V70, P2959, DOI 10.1128/IAI.70.6.2959-2964.2002; Heyer G, 2002, INFECT IMMUN, V70, P127, DOI 10.1128/IAI.70.1.127-133.2002; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; Li J, 2002, AM J PHYSIOL-LUNG C, V283, pL690, DOI 10.1152/ajplung.00060.2002; Nguyen T, 2000, INFECT IMMUN, V68, P2061, DOI 10.1128/IAI.68.4.2061-2068.2000; Page K, 2003, J IMMUNOL, V170, P5681, DOI 10.4049/jimmunol.170.11.5681; Palma M, 2001, INFECT IMMUN, V69, P7858, DOI 10.1128/IAI.69.12.7858-7865.2001; Palmqvist N, 2002, MICROB PATHOGENESIS, V33, P239, DOI 10.1006/mpat.2002.0533; Rajan S, 2000, AM J RESP CELL MOL, V23, P304, DOI 10.1165/ajrcmb.23.3.4098; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; SOELL M, 1995, INFECT IMMUN, V63, P1380, DOI 10.1128/IAI.63.4.1380-1386.1995; van Heeckeren A, 1997, J CLIN INVEST, V100, P2810, DOI 10.1172/JCI119828; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang JE, 2000, INFECT IMMUN, V68, P3965, DOI 10.1128/IAI.68.7.3965-3970.2000; Watson Bob, 2002, IDrugs, V5, P1151	28	286	307	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					842	848		10.1038/nm1079	http://dx.doi.org/10.1038/nm1079			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15247912				2022-12-27	WOS:000223055700039
J	Moore, JP; Burton, DR				Moore, JP; Burton, DR			Urgently needed: a filter for the HIV-1 vaccine pipeline	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZATION; ANTIBODIES; SENSITIVITY; INFECTION; LENGTH; ASSAYS	Research groups worldwide are trying to make immunogens intended to elicit neutralizing antibody responses as part of a prophylactic vaccine to counter the spread of HIV-1. The relative merits of different designs can only be gauged properly through comparative studies, and particularly by evaluating human or animal antisera under identical, or comparable, conditions. Hence there is a need for assay standardization and for the creation of a centralized testing facility that could distribute consensus protocols and reagents.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA USA	Cornell University; Scripps Research Institute; Scripps Research Institute	Moore, JP (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.	jpm2003@med.cornell.edu; burton@scripps.edu						Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Collis AVJ, 2003, J MOL BIOL, V325, P337, DOI 10.1016/S0022-2836(02)01222-6; Derdeyn CA, 2004, SCIENCE, V303, P2019, DOI 10.1126/science.1093137; Dreyer K, 1999, AIDS RES HUM RETROV, V15, P1563, DOI 10.1089/088922299309856; DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443; Klasse PJ, 2002, J GEN VIROL, V83, P2091, DOI 10.1099/0022-1317-83-9-2091; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; Letvin NL, 2003, NAT MED, V9, P861, DOI 10.1038/nm0703-861; Mascola JR, 2002, J VIROL, V76, P4810, DOI 10.1128/JVI.76.10.4810-4821.2002; Mascola JR, 2002, VACCINE, V20, P1922, DOI 10.1016/S0264-410X(02)00068-3; McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874; Moore JP, 2001, J VIROL, V75, P5721, DOI 10.1128/JVI.75.13.5721-5729.2001; Parren PWHI, 2001, ADV IMMUNOL, V77, P195, DOI 10.1016/S0065-2776(01)77018-6; Pugach P, 2004, VIROLOGY, V321, P8, DOI 10.1016/j.virol.2003.12.012; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Spenlehauer C, 2001, VIROLOGY, V280, P292, DOI 10.1006/viro.2000.0780; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102	18	37	41	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2004	10	8					769	771		10.1038/nm0804-769	http://dx.doi.org/10.1038/nm0804-769			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15286768				2022-12-27	WOS:000223055700011
J	Friedrich, TC; Dodds, EJ; Yant, LJ; Vojnov, L; Rudersdorf, R; Cullen, C; Evans, DT; Desrosiers, RC; Mothe, BR; Sidney, J; Sette, A; Kunstman, K; Wolinsky, S; Piatak, M; Lifson, J; Hughes, AL; Wilson, N; O'Connor, DH; Watkins, DI				Friedrich, TC; Dodds, EJ; Yant, LJ; Vojnov, L; Rudersdorf, R; Cullen, C; Evans, DT; Desrosiers, RC; Mothe, BR; Sidney, J; Sette, A; Kunstman, K; Wolinsky, S; Piatak, M; Lifson, J; Hughes, AL; Wilson, N; O'Connor, DH; Watkins, DI			Reversion of CTL escape-variant immunodeficiency viruses in vivo	NATURE MEDICINE			English	Article							CYTOTOXIC T-LYMPHOCYTES; PEPTIDE-BINDING-SPECIFICITY; CELLULAR IMMUNE-RESPONSES; ACUTE-PHASE; DISEASE PROGRESSION; PRIMARY INFECTION; TYPE-1 INFECTION; VIRAL ESCAPE; HIV; VIREMIA	Engendering cytotoxic T-lymphocyte (CTL) responses is likely to be an important goal of HIV vaccines. However, CTLs select for viral variants that escape immune detection. Maintenance of such escape variants in human populations could pose an obstacle to HIV vaccine development. We first observed that escape mutations in a heterogeneous simian immunodeficiency virus (SIV) isolate were lost upon passage to new animals. We therefore infected macaques with a cloned SIV bearing escape mutations in three immunodominant CTL epitopes, and followed viral evolution after infection. Here we show that each mutant epitope sequence continued to evolve in vivo, often re-establishing the original, CTL-susceptible sequence. We conclude that escape from CTL responses may exact a cost to viral fitness. In the absence of selective pressure upon transmission to new hosts, these original escape mutations can be lost. This suggests that some HIV CTL epitopes will be maintained in human populations.	Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA; Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA; New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Calif State Univ San Marcos, San Marcos, CA 92096 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Northwestern Univ, Sch Med, Chicago, IL 60611 USA; NCI, AIDS Vaccine Program, Frederick, MD 21702 USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of Wisconsin System; University of Wisconsin Madison; California State University System; California State University San Marcos; La Jolla Institute for Immunology; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Watkins, DI (corresponding author), Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.	watkins@primate.wisc.edu	Wolinsky, Steven/B-2893-2012; Sette, Alessandro/AFO-8916-2022; Yant, Levi/ABH-1275-2020	Vojnov, Lara/0000-0003-0488-1012; o'connor, david/0000-0003-2139-470X; Wolinsky, Steven/0000-0002-9625-6697; Yant, Levi/0000-0003-3442-0217; Friedrich, Thomas/0000-0001-9831-6895	NCRR NIH HHS [P51 RR001676-43] Funding Source: Medline; NIAID NIH HHS [R01-AI-46366, R01-AI-49120, R01-AI-52056, N01-AI-95362] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049120, R01AI052056, N01AI095362, R01AI046366] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; FRIEDRICH TC, IN PRESS J VIROL; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Hance AJ, 2001, J VIROL, V75, P6410, DOI 10.1128/JVI.75.14.6410-6417.2001; Ho DD, 2002, CELL, V110, P135, DOI 10.1016/S0092-8674(02)00832-2; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Knapp LA, 1997, TISSUE ANTIGENS, V50, P170, DOI 10.1111/j.1399-0039.1997.tb02856.x; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Mothe BR, 2002, J VIROL, V76, P875, DOI 10.1128/JVI.76.2.875-884.2002; Mothe BR, 2002, J IMMUNOL, V169, P210, DOI 10.4049/jimmunol.169.1.210; O'Connor DH, 2003, J VIROL, V77, P9029, DOI 10.1128/JVI.77.16.9029-9040.2003; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; Peyerl FW, 2003, J VIROL, V77, P12572, DOI 10.1128/JVI.77.23.12572-12578.2003; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Rue SM, 2003, J VIROL, V77, P8009, DOI 10.1128/JVI.77.14.8009-8018.2003; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Sidney J, 2000, J IMMUNOL, V165, P6387, DOI 10.4049/jimmunol.165.11.6387; Vogel TU, 2002, J VIROL, V76, P11623, DOI 10.1128/JVI.76.22.11623-11636.2002; von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003; Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537	38	314	327	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					275	281		10.1038/nm998	http://dx.doi.org/10.1038/nm998			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14966520	Bronze			2022-12-27	WOS:000189297700039
J	Inoue, H; Ogawa, W; Ozaki, M; Haga, S; Matsumoto, M; Furukawa, K; Hashimoto, N; Kido, Y; Mori, T; Sakaue, H; Teshigawara, K; Jin, SY; Iguchi, H; Hiramatsu, R; LeRoith, D; Takeda, K; Akira, S; Kasuga, M				Inoue, H; Ogawa, W; Ozaki, M; Haga, S; Matsumoto, M; Furukawa, K; Hashimoto, N; Kido, Y; Mori, T; Sakaue, H; Teshigawara, K; Jin, SY; Iguchi, H; Hiramatsu, R; LeRoith, D; Takeda, K; Akira, S; Kasuga, M			Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo	NATURE MEDICINE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN SENSITIVITY; GLUCOSE; INTERLEUKIN-6; EXPRESSION; ACTIVATION; GLUCOSE-6-PHOSPHATASE; OVEREXPRESSION; INHIBITION; RECEPTOR	The transcription factor, signal transducer and activator of transcription-3 (STAT-3) contributes to various physiological processes. Here we show that mice with liver-specific deficiency in STAT-3, achieved using the Cre-loxP system, show insulin resistance associated with increased hepatic expression of gluconeogenic genes. Restoration of hepatic STAT-3 expression in these mice, using adenovirus-mediated gene transfer, corrected the metabolic abnormalities and the alterations in hepatic expression of gluconeogenic genes. Overexpression of STAT-3 in cultured hepatocytes inhibited gluconeogenic gene expression independently of peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha), an upstream regulator of gluconeogenic genes. Liver-specific expression of a constitutively active form of STAT-3, achieved by infection with an adenovirus vector, markedly reduced blood glucose, plasma insulin concentrations and hepatic gluconeogenic gene expression in diabetic mice. Hepatic STAT-3 signaling is thus essential for normal glucose homeostasis and may provide new therapeutic targets for diabetes mellitus.	Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med, Kobe, Hyogo 6500017, Japan; Natl Res Inst Child Hlth & Dev, Dept Onnovat Surg, Bioengn Lab, Tokyo 1548567, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Food & Hlth Sci, Okayama 7008558, Japan; Sumitomo Pharmaceut Co Ltd, Genom Sci Labs, Takarazuka, Hyogo 6650051, Japan; NIDDKD, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Bethesda, MD 20892 USA; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Osaka 5650871, Japan	Kobe University; National Center for Child Health & Development - Japan; Okayama University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Osaka University	Kasuga, M (corresponding author), Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med, Kobe, Hyogo 6500017, Japan.	kasuga@med.kobe-u.ac.jp	Sakaue, Hiroshi/ABE-2337-2021; Akira, Shizuo/C-3134-2009; Takeda, Kiyoshi/C-9331-2009; OGAWA, Wataru/AAQ-9586-2020	Sakaue, Hiroshi/0000-0002-2468-2363; Inoue, Hiroshi/0000-0002-7724-6637				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Christ B, 2000, HEPATOLOGY, V31, P461, DOI 10.1002/hep.510310228; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672; Metzger S, 1997, AM J PHYSIOL-ENDOC M, V273, pE262, DOI 10.1152/ajpendo.1997.273.2.E262; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Radziuk J, 2001, DIABETES-METAB RES, V17, P250, DOI 10.1002/dmrr.217; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; ROSELLA G, 1995, MOL ENDOCRINOL, V9, P1396, DOI 10.1210/me.9.10.1396; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; STRASSMANN G, 1993, CYTOKINE, V5, P285, DOI 10.1016/1043-4666(93)90058-D; Sun Y, 2002, J BIOL CHEM, V277, P23301, DOI 10.1074/jbc.M200964200; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Vgontzas AN, 1997, J CLIN ENDOCR METAB, V82, P1313, DOI 10.1210/jc.82.5.1313; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	37	287	300	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					168	174		10.1038/nm980	http://dx.doi.org/10.1038/nm980			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14716305				2022-12-27	WOS:000188719600036
J	Sereda, MW; Horste, GMZ; Suter, U; Uzma, N; Nave, KA				Sereda, MW; Horste, GMZ; Suter, U; Uzma, N; Nave, KA			Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)	NATURE MEDICINE			English	Letter							PERIPHERAL MYELIN PROTEIN-22; SCHWANN-CELLS; GENE-EXPRESSION; BREAST-CANCER; MOUSE MODEL; DUPLICATION; RECEPTOR; RAT; 1A; DIFFERENTIATION	Charcot- Marie- Tooth disease (CMT) is the most common inherited neuropathy. The predominant subtype, CMT- 1A, accounts for more than 50% of all cases(1) and is associated with an interstitial chromosomal duplication of 17p12 (refs. 2,3). We have generated a model of CMT- 1A by introducing extra copies of the responsible disease gene, Pmp22 (encoding the peripheral myelin protein of 22 kDa), into transgenic rats(4). Here, we used this model to test whether progesterone, a regulator of the myelin genes Pmp22 and myelin protein zero (Mpz) in cultured Schwann cells, can modulate the progressive neuropathy caused by moderate overexpression of Pmp22. Male transgenic rats (n = 84) were randomly assigned into three treatment groups: progesterone, progesterone antagonist (onapristone) and placebo control. Daily administration of progesterone elevated the steady- state levels of Pmp22 and Mpz mRNA in the sciatic nerve, resulting in enhanced Schwann cell pathology and a more progressive clinical neuropathy. In contrast, administration of the selective progesterone receptor antagonist reduced overexpression of Pmp22 and improved the CMT phenotype, without obvious side effects, in wild- type or transgenic rats. Taken together, these data provide proof of principle that the progesterone receptor of myelin- forming Schwann cells is a promising pharmacological target for therapy of CMT- 1A.	Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany; Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Clin Neurophysiol, D-37075 Gottingen, Germany; ETH Honggerberg, Swiss Fed Inst Technol, Dept Biol, Inst Cell Biol, CH-8093 Zurich, Switzerland	Max Planck Society; University of Gottingen; University of Gottingen; Swiss Federal Institutes of Technology Domain; ETH Zurich	Nave, KA (corresponding author), Max Planck Inst Expt Med, Dept Neurogenet, Hermann Rein Str 3, D-37075 Gottingen, Germany.		Horste, Gerd Meyer zu/O-9549-2016; Nave, Klaus-Armin/C-8883-2011; Suter, Ueli/A-1624-2010	Horste, Gerd Meyer zu/0000-0002-4341-4719; 				Berger P, 2002, NEUROGENETICS, V4, P1, DOI 10.1007/s10048-002-0130-z; Boerkoel CF, 2002, ANN NEUROL, V51, P190, DOI 10.1002/ana.10089; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; EDWARDS DP, 1995, J STEROID BIOCHEM, V53, P449, DOI 10.1016/0960-0760(95)00091-D; GARCIA CA, 1995, NEUROLOGY, V45, P2090, DOI 10.1212/WNL.45.11.2090; Gopalkrishnan K, 2003, BIOL REPROD, V68, P1959, DOI 10.1095/biolreprod.102.007963; Graham JD, 2002, BREAST CANCER RES, V4, P187, DOI 10.1186/bcr450; Guennoun R, 2001, MOL BRAIN RES, V90, P75, DOI 10.1016/S0169-328X(01)00094-8; Huxley C, 1996, HUM MOL GENET, V5, P563, DOI 10.1093/hmg/5.5.563; Jung-Testas I, 1999, J STEROID BIOCHEM, V69, P97, DOI 10.1016/S0960-0760(98)00149-6; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Lin RJ, 1998, COLD SPRING HARB SYM, V63, P577, DOI 10.1101/sqb.1998.63.577; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; Magyar JP, 1996, J NEUROSCI, V16, P5351; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.3.CO;2-8; Michna H, 1996, Cancer Treat Res, V83, P191; Niemann S, 2000, J NEUROSCI, V20, P4120; Perea J, 2001, HUM MOL GENET, V10, P1007, DOI 10.1093/hmg/10.10.1007; POLLOCK M, 1982, NEUROLOGY, V32, P1311, DOI 10.1212/WNL.32.11.1311; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; Robertson JFR, 1999, EUR J CANCER, V35, P214, DOI 10.1016/S0959-8049(98)00388-8; RUDNIKSCHONEBORN S, 1993, NEUROLOGY, V43, P2011, DOI 10.1212/WNL.43.10.2011; Schumacher M, 2001, BRAIN RES REV, V37, P343, DOI 10.1016/S0165-0173(01)00139-4; Sereda M, 1996, NEURON, V16, P1049, DOI 10.1016/S0896-6273(00)80128-2; SUTER U, 1994, J BIOL CHEM, V269, P25795; Thomas PK, 1997, BRAIN, V120, P465, DOI 10.1093/brain/120.3.465	27	215	232	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1533	1537		10.1038/nm957	http://dx.doi.org/10.1038/nm957			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14608378				2022-12-27	WOS:000186845400038
J	Carrolo, M; Giordano, S; Cabrita-Santos, L; Corso, S; Vigario, AM; Silva, S; Leiriao, P; Carapau, D; Armas-Portela, R; Comoglio, PM; Rodriguez, A; Mota, MM				Carrolo, M; Giordano, S; Cabrita-Santos, L; Corso, S; Vigario, AM; Silva, S; Leiriao, P; Carapau, D; Armas-Portela, R; Comoglio, PM; Rodriguez, A; Mota, MM			Hepatocyte growth factor and its receptor are required for malaria infection	NATURE MEDICINE			English	Article							SCATTER-FACTOR; PLASMODIUM SPOROZOITES; MET; FALCIPARUM; YOELII; HGF; TRANSFORMATION; PROTEOGLYCANS; PROTOONCOGENE; MECHANISM	Plasmodium, the causative agent of malaria, must first infect hepatocytes to initiate a mammalian infection. Sporozoites migrate through several hepatocytes, by breaching their plasma membranes, before infection is finally established in one of them. Here we show that wounding of hepatocytes by sporozoite migration induces the secretion of hepatocyte growth factor (HGF), which renders hepatocytes susceptible to infection. Infection depends on activation of the HGF receptor, MET, by secreted HGF. The malaria parasite exploits MET not as a primary binding site, but as a mediator of signals that make the host cell susceptible to infection. HGF/MET signaling induces rearrangements of the host-cell actin cytoskeleton that are required for the early development of the parasites within hepatocytes. Our findings identify HGF and MET as potential targets for new approaches to malaria prevention.	Gulbenkian Inst Sci, P-2780156 Oeiras, Portugal; NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA; Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy; Univ Autonoma Madrid, Fac Ciencias, Dept Biol, E-28049 Madrid, Spain	New York University; University of Turin; Autonomous University of Madrid	Mota, MM (corresponding author), Gulbenkian Inst Sci, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal.	mmota@igc.gulbenkian.pt	Carrolo, Margarida/AAM-2938-2020; Mota, Maria/AAF-2048-2019; Giordano, Silvia/J-9858-2018; Carapau, Daniel/J-3966-2012; Carrolo, Margarida/C-4781-2009	Giordano, Silvia/0000-0003-1854-1086; Carapau, Daniel/0000-0001-8888-6333; Mota, Maria Manuel/0000-0002-2858-1041; Vigario, Ana Margarida/0000-0001-5679-1196; Comoglio, Paolo/0000-0002-7056-5328; Carrolo, Margarida/0000-0002-6866-9515; CORSO, Simona/0000-0002-5069-1503; Rodriguez, Ana/0000-0002-0060-3405	NIAID NIH HHS [AI49432, AI53698] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053698, R01AI049432] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; CALVOCALLE JM, 1994, EXP PARASITOL, V79, P362, DOI 10.1006/expr.1994.1098; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Gohda Eiichi, 2002, Nihon Yakurigaku Zasshi, V119, P287; Jeffers M, 1996, ONCOGENE, V13, P853; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; Ljubimova JY, 1997, J HISTOCHEM CYTOCHEM, V45, P79, DOI 10.1177/002215549704500111; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; MAZIER D, 1985, SCIENCE, V227, P440, DOI 10.1126/science.3880923; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; MCNEIL PL, 1999, CURRENT PROTOCOLS S, V2; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Morotti A, 2002, ONCOGENE, V21, P4885, DOI 10.1038/sj.onc.1205622; Mota MM, 2002, NAT MED, V8, P1318, DOI 10.1038/nm785; Mota MM, 2000, EXP PARASITOL, V96, P257, DOI 10.1006/expr.2000.4570; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NALDINI L, 1991, ONCOGENE, V6, P501; NAOUMOV NV, 1994, GUT, V35, P1013, DOI 10.1136/gut.35.8.1013; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pinzon-Ortiz C, 2001, J BIOL CHEM, V276, P26784, DOI 10.1074/jbc.M104038200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Pradel G, 2002, MOL MICROBIOL, V45, P637, DOI 10.1046/j.1365-2958.2002.03057.x; Prat M, 1998, J CELL SCI, V111, P237; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Serghides L, 2002, LANCET, V359, P1404, DOI 10.1016/S0140-6736(02)08360-5; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Silvie O, 2003, NAT MED, V9, P93, DOI 10.1038/nm808; THURSZ MR, 1995, NAT MED, V1, P374, DOI 10.1038/nm0495-374; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; TSUJI M, 1994, PARASITOL RES, V80, P16, DOI 10.1007/BF00932618; ZARNEGAR R, 1999, BIOCHEM BIOPH RES CO, V177, P559	35	110	122	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2003	9	11					1363	1369		10.1038/nm947	http://dx.doi.org/10.1038/nm947			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14556002				2022-12-27	WOS:000186319700025
J	Chao, HJ; Mansfield, SG; Bartel, RC; Hiriyanna, S; Mitchell, LG; Garcia-Blanco, M; Walsh, CE				Chao, HJ; Mansfield, SG; Bartel, RC; Hiriyanna, S; Mitchell, LG; Garcia-Blanco, M; Walsh, CE			Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing	NATURE MEDICINE			English	Article							PRE-MESSENGER-RNA; HUMAN-FACTOR VIII; GENE-THERAPY; REPAIR; RESTORATION; EXPRESSION; PROTEIN; VECTOR	Conventional gene therapy of hemophilia A relies on the transfer of factor VIII (FVIII; encoded by the F8 gene) cDNA. We carried out spliceosome-mediated RNA trans-splicing (SMaRT) to repair mutant FVIII mRNA. A pre-trans-splicing molecule (PTM) corrected endogenous FVIII mRNA in F8 knockout mice with the hemophilia A phenotype, producing sufficient functional FVIII to correct the hemophilia A phenotype. This is the first description of phenotypic correction of a genetic defect by RNA repair in a knockout animal model. Our results indicate the feasibility of using SMaRT to repair RNA for the treatment of genetic diseases.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Intronn Inc, Gaithersburg, MD 20878 USA	Icahn School of Medicine at Mount Sinai	Walsh, CE (corresponding author), Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.				PHS HHS [R01-68215] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bi L, 1996, BLOOD, V88, P3446, DOI 10.1182/blood.V88.9.3446.bloodjournal8893446; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Budker V, 1996, GENE THER, V3, P593; Chao HJ, 2000, BLOOD, V95, P1594, DOI 10.1182/blood.V95.5.1594.005k34_1594_1599; Chao HJ, 2001, MOL THER, V4, P217, DOI 10.1006/mthe.2001.0449; Gorman L, 2000, J BIOL CHEM, V275, P35914, DOI 10.1074/jbc.M006259200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herweijer H, 2001, J GENE MED, V3, P280, DOI 10.1002/jgm.178; KARPATI G, 1994, CLIN INVEST MED, V17, P499; KAUFMAN R, 2000, HEMATOLOGY BASIC PRI, V8, P1850; Kikumori T, 2001, HUM GENE THER, V12, P1429, DOI 10.1089/104303401750298580; Koehler DR, 2001, MOL THER, V4, P84, DOI 10.1006/mthe.2001.0435; Lillicrap David, 2000, Haematologica, V85, P108; Liu DL, 2002, CHINESE SCI BULL, V47, P52, DOI 10.1360/02tb9010; Mansfield SG, 2000, GENE THER, V7, P1885, DOI 10.1038/sj.gt.3301307; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; Puttaraju M, 2001, MOL THER, V4, P105, DOI 10.1006/mthe.2001.0426; Roy S, 1999, HAEMOPHILIA, V5, P340; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; Sullenger BA, 1999, GENE THER, V6, P461, DOI 10.1038/sj.gt.3300903; Watanabe T, 2000, ADV DRUG DELIVER REV, V44, P109, DOI 10.1016/S0169-409X(00)00089-2; Yenchitsomanus P, 2001, HAEMOPHILIA, V7, P335, DOI 10.1046/j.1365-2516.2001.00507.x	22	127	140	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1015	1019		10.1038/nm900	http://dx.doi.org/10.1038/nm900			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847523				2022-12-27	WOS:000184484900024
J	Luker, GD; Pica, CM; Song, JL; Luker, KE; Piwnica-Worms, D				Luker, GD; Pica, CM; Song, JL; Luker, KE; Piwnica-Worms, D			Imaging 26S proteasome activity and inhibition in living mice	NATURE MEDICINE			English	Article							DEPENDENT PROTEOLYSIS; UBIQUITIN; PROTEINS; SYSTEM; PS-341	The ubiquitin-proteasome pathway is the central mediator of regulated proteolysis in cells, and defects in this pathway are associated with cancer and neurodegenerative diseases. To assess 26S proteasome function in living animals, we developed a ubiquitin-luciferase reporter for bioluminescence imaging. The reporter was degraded rapidly under steady-state conditions and stabilized in a dose- and time-dependent manner in response to proteasome inhibitors. Using bioluminescence imaging after one dose of the chemotherapeutic proteasome inhibitor bortezomib (PS-341), proteasome function in tumor xenografts was blocked within 30 min and returned to nearly baseline by 46 h. After a 2-week regimen of bortezomib, however, imaging of target tumors showed significantly enhanced proteasome inhibition that no longer returned to baseline. The ubiquitin-luciferase reporter enables repetitive tissue-specific analysis of 26S proteasome activity in vivo and should facilitate development and validation of proteasome inhibitors in mouse models, as well as investigations of the ubiquitin-proteasome pathway in disease pathogenesis.	Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, D (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA.	piwnica-wormsd@mir.wustl.edu		Luker, Kathryn/0000-0001-8314-3370; luker, gary/0000-0001-6832-2581	NCI NIH HHS [P50 CA94056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA094056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Deroo BJ, 2002, J BIOL CHEM, V277, P20120, DOI 10.1074/jbc.C200173200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; LeBlanc R, 2002, CANCER RES, V62, P4996; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lightcap ES, 2000, CLIN CHEM, V46, P673; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Pye J, 2003, AM J PHYSIOL-HEART C, V284, pH919, DOI 10.1152/ajpheart.00851.2002; Sakamoto KM, 2002, MOL GENET METAB, V77, P44, DOI 10.1016/S1096-7192(02)00146-4; Stack JH, 2000, NAT BIOTECHNOL, V18, P1298, DOI 10.1038/82422; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Welsh S, 1997, CURR OPIN BIOTECH, V8, P617, DOI 10.1016/S0958-1669(97)80038-9; Zhang L, 2001, STROKE, V32, P2926, DOI 10.1161/hs1201.100207	22	156	163	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					969	973		10.1038/nm894	http://dx.doi.org/10.1038/nm894			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12819780				2022-12-27	WOS:000183979300041
J	Pope, M; Haase, AT				Pope, M; Haase, AT			Transmission, acute HIV-1 infection and the quest for strategies to prevent infection	NATURE MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; NEUTRALIZING ANTIBODY-RESPONSE; TIGHT EPITHELIAL BARRIERS; IMMATURE DENDRITIC CELLS; HETEROSEXUAL TRANSMISSION; VAGINAL CHALLENGE; TYPE-1 INFECTION; DC-SIGN; INTRAVAGINAL INOCULATION	By the acute stage of HIV-1 infection, the immune system already faces daunting challenges. Research on mucosal barriers and the events immediately after heterosexual transmission that precede this acute stage could facilitate the development of effective microbicides and vaccines.	Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Populat Council, Ctr Biomed Res, New York, NY 10021 USA	University of Minnesota System; University of Minnesota Twin Cities; Population Council	Haase, AT (corresponding author), Univ Minnesota, Dept Microbiol, 420 Delaware St SE, Minneapolis, MN 55455 USA.	ashley@mail.ahc.umn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037356] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA079458] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028246, R01AI048484, R01AI040877, R21AI052060, R37AI040877, P01AI052048] Funding Source: NIH RePORTER; NCI NIH HHS [CA 79458] Funding Source: Medline; NCRR NIH HHS [RR00167] Funding Source: Medline; NIAID NIH HHS [AI52048, AI48484, AI52060, AI40877, AI28246] Funding Source: Medline; NICHD NIH HHS [HD37356, HD41752] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; ANNAN K, 2002, NY TIMES NEW YO 1229, P9; Belec L, 2001, J INFECT DIS, V184, P1412, DOI 10.1086/324375; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; BIBERFELD P, 1986, AM J PATHOL, V125, P436; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Cohn MA, 2001, J INFECT DIS, V184, P410, DOI 10.1086/322780; Collins KB, 2000, NAT MED, V6, P475, DOI 10.1038/74743; COOPER DA, 1985, LANCET, V1, P537; Crotty S, 2001, J VIROL, V75, P7435, DOI 10.1128/JVI.75.16.7435-7452.2001; De Boer RJ, 1998, J THEOR BIOL, V190, P201, DOI 10.1006/jtbi.1997.0548; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Enose Y, 2002, VIROLOGY, V298, P306, DOI 10.1006/viro.2002.1440; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; Frank I., 2002, Current Molecular Medicine (Hilversum), V2, P229, DOI 10.2174/1566524024605716; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Gupta P, 2002, J VIROL, V76, P9868, DOI 10.1128/JVI.76.19.9868-9876.2002; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; Joag SV, 1997, J VIROL, V71, P4016, DOI 10.1128/JVI.71.5.4016-4023.1997; Joag SV, 1998, J VIROL, V72, P9069, DOI 10.1128/JVI.72.11.9069-9078.1998; Johnson RP, 1999, J VIROL, V73, P4952, DOI 10.1128/JVI.73.6.4952-4961.1999; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lavreys L, 2000, CLIN INFECT DIS, V30, P486, DOI 10.1086/313718; Lee B, 2001, J VIROL, V75, P12028, DOI 10.1128/JVI.75.24.12028-12038.2001; Lewis J, 1998, J VIROL, V72, P8943, DOI 10.1128/JVI.72.11.8943-8951.1998; Little SJ, 1999, J EXP MED, V190, P841, DOI 10.1084/jem.190.6.841; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Meng G, 2002, NAT MED, V8, P150, DOI 10.1038/nm0202-150; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; Miller CJ, 1998, J VIROL, V72, P3248, DOI 10.1128/JVI.72.4.3248-3258.1998; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; Miller CJ, 1997, J VIROL, V71, P1911, DOI 10.1128/JVI.71.3.1911-1921.1997; MOSS GB, 1991, J INFECT DIS, V164, P588, DOI 10.1093/infdis/164.3.588; Mothe BR, 2002, J VIROL, V76, P875, DOI 10.1128/JVI.76.2.875-884.2002; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Persaud D, 2003, J VIROL, V77, P1659, DOI 10.1128/JVI.77.3.1659-1665.2003; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; RACZ P, 1986, PROG ALLERGY, V37, P81; Reece JC, 1998, J EXP MED, V187, P1623, DOI 10.1084/jem.187.10.1623; Reilly C, 2002, J AM STAT ASSOC, V97, P943, DOI 10.1198/016214502388618735; Reinhart TA, 1998, J VIROL, V72, P113, DOI 10.1128/JVI.72.1.113-120.1998; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Schacker T, 2000, J INFECT DIS, V181, P354, DOI 10.1086/315178; Schacker TW, 1998, ANN INTERN MED, V128, P613, DOI 10.7326/0003-4819-128-8-199804150-00001; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; Schwartz EJ, 2002, AIDS, V16, P341, DOI 10.1097/00002030-200202150-00004; Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; SWINGLER S, IN PRESS NATURE; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833; Veazey RS, 2003, J INFECT DIS, V187, P769, DOI 10.1086/368386; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; *WHO, 2002, AIDS EP UPD DEC 2002; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zhu TF, 2003, J VIROL, V77, P6108, DOI 10.1128/JVI.77.11.6108-6116.2003	92	276	286	0	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					847	852		10.1038/nm0703-847	http://dx.doi.org/10.1038/nm0703-847			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835704				2022-12-27	WOS:000183979300023
J	Stevenson, M				Stevenson, M			HIV-1 pathogenesis	NATURE MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL DEPLETION; DEFICIENCY-SYNDROME PATIENTS; HUMAN PERIPHERAL-BLOOD; HTLV-III/LAV ENVELOPE; AIDS-RELATED COMPLEX; VIRAL VIF PROTEIN; DENDRITIC CELLS; NUCLEOTIDE-SEQUENCE; NUCLEAR EXPORT	Despite considerable advances in HIV science in the past 20 years, the reason why HIV-1 infection is pathogenic is still debated and the goal of eradicating HIV-1 infection remains elusive. A deeper understanding of the interplay between HIV-1 and its host and why simian immunodeficiency virus (SIV) is nonpathogenic in some natural hosts may provide a few answers.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Stevenson, M (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Biotech 2,Suite 319, Worcester, MA 01605 USA.							ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; ARYA SK, 1986, P NATL ACAD SCI USA, V83, P2209, DOI 10.1073/pnas.83.7.2209; ASJO B, 1986, LANCET, V2, P660; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COHEN EA, 1988, NATURE, V334, P532, DOI 10.1038/334532a0; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Cullen BR, 2002, NAT IMMUNOL, V3, P597, DOI 10.1038/ni0702-597; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Eckstein DA, 2001, IMMUNITY, V15, P671, DOI 10.1016/S1074-7613(01)00217-5; Eckstein DA, 2001, J EXP MED, V194, P1407, DOI 10.1084/jem.194.10.1407; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Etemad-Moghadam B, 2001, J VIROL, V75, P5646, DOI 10.1128/JVI.75.12.5646-5655.2001; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Grossman Z, 2002, NAT MED, V8, P319, DOI 10.1038/nm0402-319; Hatziioannou T, 2003, EMBO J, V22, P385, DOI 10.1093/emboj/cdg042; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Igarashi T, 2001, P NATL ACAD SCI USA, V98, P658, DOI 10.1073/pnas.021551798; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Labonte JA, 2000, J VIROL, V74, P10690, DOI 10.1128/JVI.74.22.10690-10698.2000; LETOURNEAU A, 1985, ANN PATHOL, V5, P137; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060; MULLER H, 1986, J CLIN PATHOL, V39, P1161, DOI 10.1136/jcp.39.10.1161-a; Munk C, 2002, P NATL ACAD SCI USA, V99, P13843, DOI 10.1073/pnas.212400099; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; ORENSTEIN JM, 1988, J VIROL, V62, P2578, DOI 10.1128/JVI.62.8.2578-2586.1988; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON S, 1987, J GEN VIROL, V68, P1177, DOI 10.1099/0022-1317-68-4-1177; Perelson AS, 2002, NAT REV IMMUNOL, V2, P28, DOI 10.1038/nri700; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rey-Cuille MA, 1998, J VIROL, V72, P3872; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Smith BA, 2001, J IMMUNOL, V166, P690, DOI 10.4049/jimmunol.166.1.690; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; Somasundaran M, 2002, P NATL ACAD SCI USA, V99, P9503, DOI 10.1073/pnas.142313699; SPIEGEL H, 1992, AM J PATHOL, V140, P15; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; SWINGLER S, IN PRESS NATURE; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841; Unutmaz D, 1999, J EXP MED, V189, P1735, DOI 10.1084/jem.189.11.1735; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; WONGSTAAL F, 1985, SCIENCE, V229, P759, DOI 10.1126/science.2992084; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a	120	322	349	1	48	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					853	860		10.1038/nm0703-853	http://dx.doi.org/10.1038/nm0703-853			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835705				2022-12-27	WOS:000183979300024
J	Nunes, MC; Roy, NS; Keyoung, HM; Goodman, RR; McKhann, G; Jiang, L; Kang, J; Nedergaard, M; Goldman, SA				Nunes, MC; Roy, NS; Keyoung, HM; Goodman, RR; McKhann, G; Jiang, L; Kang, J; Nedergaard, M; Goldman, SA			Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; FETAL HUMAN BRAIN; CNS STEM-CELLS; IN-VITRO; OLIGODENDROCYTE DEVELOPMENT; SUBVENTRICULAR ZONE; SUBEPENDYMAL CELLS; PRECURSOR CELL; GROWTH-FACTOR; FOREBRAIN	The subcortical white matter of the adult human brain harbors a pool of glial progenitor cells. These cells can be isolated by fluorescence-activated cell sorting (FACS) after either transfection with green fluorescent protein (GFP) under the control of the CNP2 promoter, or A2B5-targeted immunotagging. Although these cells give rise largely to oligodendrocytes, in low-density culture we observed that some also generated neurons. We thus asked whether these nominally glial progenitors might include multipotential progenitor cells capable of neurogenesis. We found that adult human white-matter progenitor cells (WMPCs) could be passaged as neurospheres in vitro and that these cells generated functionally competent neurons and glia both in vitro and after xenograft to the fetal rat brain. WMPCs were able to produce neurons after their initial isolation and did not require in vitro expansion or reprogramming to do so. These experiments indicate that an abundant pool of mitotically competent neurogenic progenitor cells resides in the adult human white matter.	Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; New York Med Coll, Dept Anat & Cell Biol, Valhalla, NY 10595 USA	Cornell University; Columbia University; New York Medical College	Goldman, SA (corresponding author), Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Nunes, Marta/0000-0003-3788-878X; Goldman, Steven/0000-0002-5498-4303	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039559, R01NS033106, R37NS029813] Funding Source: NIH RePORTER; NINDS NIH HHS [R37/R01NS29813, R01NS39559, R01NS33106] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gravel M, 1998, J NEUROSCI RES, V53, P393; Han JJ, 1999, HUM GENE THER, V10, P1867, DOI 10.1089/10430349950017545; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Keyoung HM, 2001, NAT BIOTECHNOL, V19, P843, DOI 10.1038/nbt0901-843; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kukekov VG, 1997, GLIA, V21, P399, DOI 10.1002/(SICI)1098-1136(199712)21:4<399::AID-GLIA7>3.0.CO;2-Z; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Mason JL, 2002, MOL CELL NEUROSCI, V20, P30, DOI 10.1006/mcne.2002.1114; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Roy NS, 2000, NAT MED, V6, P271; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Svendsen CN, 1999, BRAIN PATHOL, V9, P499, DOI 10.1111/j.1750-3639.1999.tb00538.x; TSE FW, 1992, J NEUROSCI, V12, P1781; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397; Yashima K, 1998, CELL GROWTH DIFFER, V9, P805; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	41	568	605	1	26	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					439	447		10.1038/nm837	http://dx.doi.org/10.1038/nm837			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12627226				2022-12-27	WOS:000181987400034
J	Izmailova, E; Bertley, FMN; Huang, Q; Makori, N; Miller, CJ; Young, RA; Aldovini, A				Izmailova, E; Bertley, FMN; Huang, Q; Makori, N; Miller, CJ; Young, RA; Aldovini, A			HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; APOPTOSIS-INDUCING LIGAND; RECOMBINANT ADENOVIRUS; GENE-EXPRESSION; RESPONSE GENE; PROTEIN; INFECTION; TYPE-1; CHEMOKINE; TRANSCRIPTION	Immature dendritic cells are among the first cells infected by retroviruses after mucosal exposure. We explored the effects of human immunodeficiency virus-1 (HIV-1) and its Tat transactivator on these primary antigen-presenting cells using DNA microarray analysis and functional assays. We found that HIV-1 infection or Tat expression induces interferon (IFN)-responsive gene expression in immature human dendritic cells without inducing maturation. Among the induced gene products are chemokines that recruit activated T cells and macrophages, the ultimate target cells for the virus. Dendritic cells in the lymph nodes of macaques infected with simian immunodeficiency virus (SIV) have elevated levels of monocyte chemoattractant protein 2 (MCP-2), demonstrating that chemokine induction also occurs during retroviral infection in vivo. These results show that HIV-1 Tat reprograms host dendritic cell gene expression to facilitate expansion of HIV-1 infection.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Med Sch, Dept Pediat, Boston, MA USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; Univ Calif Davis, Dept Pathol Microbiol & Immunol, Sch Vet Med, Davis, CA 95616 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; MIT, Dept Biol, Cambridge, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Massachusetts Institute of Technology (MIT)	Aldovini, A (corresponding author), Childrens Hosp, Dept Med, Boston, MA 02115 USA.	anna.aldovini@tch.harvard.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Izmailova, Elena/0000-0002-7150-1748	NCRR NIH HHS [RR14555, RR00169] Funding Source: Medline; NIAID NIH HHS [AI41365, AI44476] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR014555, P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI041365, R01AI044476, R01AI041365] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini C, 2000, AM J RESP CRIT CARE, V162, P1466, DOI 10.1164/ajrccm.162.4.2003130; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Chang YJE, 2000, J VIROL, V74, P4174, DOI 10.1128/JVI.74.9.4174-4182.2000; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Engelmayer J, 1999, J IMMUNOL, V163, P6762; Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fujii N, 1999, VIRUS RES, V65, P175, DOI 10.1016/S0168-1702(99)00114-8; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Grosjean I, 1997, J EXP MED, V186, P801, DOI 10.1084/jem.186.6.801; Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Katsikis PD, 1997, J EXP MED, V186, P1365, DOI 10.1084/jem.186.8.1365; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Marzio G, 1999, GENETICA, V106, P125, DOI 10.1023/A:1003797332379; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; Miura Y, 2001, J EXP MED, V193, P651, DOI 10.1084/jem.193.5.651; New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Poon DTK, 1996, J VIROL, V70, P6607, DOI 10.1128/JVI.70.10.6607-6616.1996; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Sen GC, 2000, SEMIN CANCER BIOL, V10, P93, DOI 10.1006/scbi.2000.0312; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Smith SG, 2001, IMMUNOL LETT, V76, P79, DOI 10.1016/S0165-2478(00)00324-2; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Wu L, 2002, P NATL ACAD SCI USA, V99, P1568, DOI 10.1073/pnas.032654399; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Xiao WH, 1998, P NATL ACAD SCI USA, V95, P1085, DOI 10.1073/pnas.95.3.1085; Zhang XT, 2001, CHINESE J CATAL+, V22, P95; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353	45	173	180	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					191	197		10.1038/nm822	http://dx.doi.org/10.1038/nm822			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539042				2022-12-27	WOS:000180801900023
J	Leitner, WW; Hwang, LN; deVeer, MJ; Zhou, AM; Silverman, RH; Williams, BRG; Dubensky, TW; Ying, H; Restifo, NP				Leitner, WW; Hwang, LN; deVeer, MJ; Zhou, AM; Silverman, RH; Williams, BRG; Dubensky, TW; Ying, H; Restifo, NP			Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways	NATURE MEDICINE			English	Article							DOUBLE-STRANDED-RNA; ANTIGEN-PRESENTING CELLS; SEMLIKI-FOREST-VIRUS; NF-KAPPA-B; SINDBIS-VIRUS; DENDRITIC CELLS; IMMUNE-RESPONSES; INTERFERON ACTION; REPLICON VECTORS; GENE-EXPRESSION	Cancer vaccines targeting 'self' antigens that are expressed at consistently high levels by tumor cells are potentially useful in immunotherapy, but immunological tolerance may block their function. Here, we describe a novel, naked DNA vaccine encoding an alphavirus replicon (self-replicating mRNA) and the self/tumor antigen tyrosinase-related protein-1. Unlike conventional DNA vaccines, this vaccine can break tolerance and provide immunity to melanoma. The vaccine mediates production of double-stranded RNA, as evidenced by the autophosphorylation of dsRNA-dependent protein kinase R (PKR). Double-stranded RNA is critical to vaccine function because both the immunogenicity and the anti-tumor activity of the vaccine are blocked in mice deficient for the RNase L enzyme, a key component of the 2',5-linked oligoadenylate synthetase antiviral pathway involved in double-stranded RNA recognition. This study shows for the first time that alphaviral replicon-encoding DNA vaccines activate innate immune pathways known to drive antiviral immune responses, and points the way to strategies for improving the efficacy of immunization with naked DNA.	NCI, NIH, Bethesda, MD 20892 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Clin Chem Program, Cleveland, OH 44115 USA; Chiron Corp, Ctr Gene Therapy, Emeryville, CA 94608 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Novartis	Leitner, WW (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.		Restifo, Nicholas P/A-5713-2008; Restifo, Nicholas Phillip/M-6549-2019; Williams, Bryan R. G./A-5021-2009; Restifo, Nicholas Phillip/Z-1614-2019; Leitner, Wolfgang W/F-5741-2011	Williams, Bryan R. G./0000-0002-4969-1151; Leitner, Wolfgang W/0000-0003-3125-5922; Restifo, Nicholas P./0000-0003-4229-4580	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999, Z01 BC010763-01] Funding Source: Medline; NCI NIH HHS [CA44059, R01 CA044059] Funding Source: Medline; NIAID NIH HHS [R01 AI034039, R01-AI34039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Berglund P, 1998, NAT BIOTECHNOL, V16, P562, DOI 10.1038/nbt0698-562; Blum JS, 1997, CRIT REV IMMUNOL, V17, P411; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; Chattergoon MA, 2000, NAT BIOTECHNOL, V18, P974, DOI 10.1038/79470; Chen Z, 2001, INT J CANCER, V93, P539, DOI 10.1002/ijc.1365; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Dubensky TW, 1996, J VIROL, V70, P508, DOI 10.1128/JVI.70.1.508-519.1996; Hariharan MJ, 1998, J VIROL, V72, P950, DOI 10.1128/JVI.72.2.950-958.1998; HERWEIJER H, 1995, HUM GENE THER, V6, P1161, DOI 10.1089/hum.1995.6.9-1161; ITO S, 1983, J INVEST DERMATOL, V80, P268, DOI 10.1111/1523-1747.ep12534616; JOHANNING FW, 1995, NUCLEIC ACIDS RES, V23, P1495, DOI 10.1093/nar/23.9.1495; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Leitner WW, 2000, CANCER RES, V60, P51; Leitner WW, 1999, VACCINE, V18, P765, DOI 10.1016/S0264-410X(99)00271-6; Leitner WW, 2001, CURR PHARM DESIGN, V7, P1641, DOI 10.2174/1381612013397249; LEITNER WW, 1997, J IMMUNOL, V157, P6119; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Overwijk WW, 1998, J EXP MED, V188, P277, DOI 10.1084/jem.188.2.277; Perri S, 2000, J VIROL, V74, P9802, DOI 10.1128/JVI.74.20.9802-9807.2000; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Restifo NP, 2001, NAT BIOTECHNOL, V19, P527, DOI 10.1038/89255; Revilla Y, 1997, VIROLOGY, V228, P400, DOI 10.1006/viro.1996.8395; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; Sasaki S, 1997, INFECT IMMUN, V65, P3520, DOI 10.1128/IAI.65.9.3520-3528.1997; Sasaki S, 2001, NAT BIOTECHNOL, V19, P543, DOI 10.1038/89289; SCHLESINGER RW, 1980, TOGAVIRUSES, P459; Schlesinger S, 2001, EXPERT OPIN BIOL TH, V1, P177, DOI 10.1517/14712598.1.2.177; Shaif-Muthana M, 2000, CANCER RES, V60, P6441; Surman DR, 1998, J IMMUNOL METHODS, V214, P51, DOI 10.1016/S0022-1759(98)00036-2; Terenzi F, 1999, NUCLEIC ACIDS RES, V27, P4369, DOI 10.1093/nar/27.22.4369; Touloukian CE, 2002, CANCER RES, V62, P5144; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; Wagner H, 2002, CURR OPIN MICROBIOL, V5, P62, DOI 10.1016/S1369-5274(02)00287-4; Weber LW, 1998, J CLIN INVEST, V102, P1258, DOI 10.1172/JCI4004; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51; Ying H, 1999, NAT MED, V5, P823, DOI 10.1038/10548; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; ZHOU X, 1994, VACCINE, V12, P1510, DOI 10.1016/0264-410X(94)90074-4	46	223	260	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					33	39		10.1038/nm813	http://dx.doi.org/10.1038/nm813			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12496961	Green Accepted			2022-12-27	WOS:000180209900019
J	Dietrich, J; Lacagnina, M; Gass, D; Richfield, E; Mayer-Proschel, M; Noble, M; Torres, C; Proschel, C				Dietrich, J; Lacagnina, M; Gass, D; Richfield, E; Mayer-Proschel, M; Noble, M; Torres, C; Proschel, C			EIF2B5 mutations compromise GFAP(+) astrocyte generation in vanishing white matter leukodystrophy	NATURE MEDICINE			English	Article							FIBRILLARY ACIDIC PROTEIN; INITIATION-FACTOR EIF2B; NERVOUS-SYSTEM HYPOMYELINATION; NEUROEPITHELIAL STEM-CELLS; RESTRICTED PRECURSOR CELLS; NUCLEOTIDE EXCHANGE FACTOR; TRANSLATION INITIATION; PROGENITOR CELLS; ALEXANDER-DISEASE; CHILDHOOD ATAXIA	Vanishing white matter disease (VWM) is a heritable leukodystrophy linked to mutations in translation initiation factor 2B (eIF2B). Although the clinical course of this disease has been relatively well described, the cellular consequences of EIF2B mutations on neural cells are unknown. Here we have established cell cultures from the brain of an individual with VWM carrying mutations in subunit 5 of eIF2B (encoded by EIF2B5). Despite the extensive demyelination apparent in this VWM patient, normal-appearing oligodendrocytes were readily generated in vitro. In contrast, few GFAP-expressing (GFAP(+)) astrocytes were present in primary cultures, induction of astrocytes was severely compromised, and the few astrocytes generated showed abnormal morphologies and antigenic phenotypes. Lesions in vivo also lacked GFAP(+) astrocytes. RNAi targeting of EIF2B5 severely compromised the induction of GFAP(+) cells from normal human glial progenitors. This raises the possibility that a deficiency in astrocyte function may contribute to the loss of white matter in VWM leukodystrophy.	Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Aab Inst, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Rochester	Proschel, C (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Aab Inst, 601 Elmwood Ave, Rochester, NY 14642 USA.	chris_proschel@urmc.rochester.edu			NICHD NIH HHS [R01 HD039702, HD39702] Funding Source: Medline; NINDS NIH HHS [NS42820, R01 NS042820, NS047411] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS047411, R01NS042820] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anthony TG, 2000, BBA-GENE STRUCT EXPR, V1492, P56, DOI 10.1016/S0167-4781(00)00062-2; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; Dietrich J, 2002, GLIA, V40, P65, DOI 10.1002/glia.10116; Fogli A, 2004, EUR J HUM GENET, V12, P561, DOI 10.1038/sj.ejhg.5201189; Fogli A, 2002, NEUROLOGY, V59, P1966, DOI 10.1212/01.WNL.0000041666.76863.47; Fogli A, 2002, ANN NEUROL, V52, P506, DOI 10.1002/ana.10339; Francalanci P, 2001, NEUROLOGY, V57, P265, DOI 10.1212/WNL.57.2.265; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; Gorospe JR, 2002, NEUROLOGY, V58, P1494, DOI 10.1212/WNL.58.10.1494; Gregori N, 2002, J NEUROSCI, V22, P248, DOI 10.1523/JNEUROSCI.22-01-00248.2002; Han SSW, 2004, GLIA, V45, P1, DOI 10.1002/glia.10282; HANEFELD F, 1993, NEUROPEDIATRICS, V24, P244, DOI 10.1055/s-2008-1071551; Herrera J, 2001, EXP NEUROL, V171, P11, DOI 10.1006/exnr.2001.7729; Hertz L, 1998, METHODS, V16, P293, DOI 10.1006/meth.1998.0686; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; Nawashiro H, 2000, J CEREBR BLOOD F MET, V20, P1040, DOI 10.1097/00004647-200007000-00003; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Pekny M, 1999, NEUROCHEM RES, V24, P1357, DOI 10.1023/A:1022572304626; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; RAFF MC, 1983, J NEUROSCI, V3, P1289; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Rodriguez D, 2001, AM J HUM GENET, V69, P1134, DOI 10.1086/323799; SCHIFFMANN R, 1994, ANN NEUROL, V35, P331, DOI 10.1002/ana.410350314; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; van der Knaap MS, 2002, ANN NEUROL, V51, P264, DOI 10.1002/ana.10112; van der Knaap MS, 1998, NEUROLOGY, V51, P540, DOI 10.1212/WNL.51.2.540; van der Knaap MS, 2001, DEV MED CHILD NEUROL, V43, P705, DOI 10.1017/S001216220100127X; Van Haren K, 2004, J NEUROPATH EXP NEUR, V63, P618, DOI 10.1093/jnen/63.6.618; vanderKnaap MS, 1997, NEUROLOGY, V48, P845, DOI 10.1212/WNL.48.4.845; Westerlund U, 2003, EXP CELL RES, V289, P378, DOI 10.1016/S0014-4827(03)00291-X; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Wong K, 2000, ACTA NEUROPATHOL, V100, P635, DOI 10.1007/s004010000234; Xu KX, 1999, GLIA, V25, P390, DOI 10.1002/(SICI)1098-1136(19990215)25:4<390::AID-GLIA8>3.0.CO;2-7; YONG VW, 1988, GLIA, V1, P113, DOI 10.1002/glia.440010203	47	95	99	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					277	283		10.1038/nm1195	http://dx.doi.org/10.1038/nm1195			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723074				2022-12-27	WOS:000227541300022
J	Kondoh, G; Tojo, H; Nakatani, Y; Komazawa, N; Murata, C; Yamagata, K; Maeda, Y; Kinoshita, T; Okabe, M; Taguchi, R; Takeda, J				Kondoh, G; Tojo, H; Nakatani, Y; Komazawa, N; Murata, C; Yamagata, K; Maeda, Y; Kinoshita, T; Okabe, M; Taguchi, R; Takeda, J			Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization	NATURE MEDICINE			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PIG-A GENE; PRION PROTEIN; PHOSPHOLIPASE-C; CELL-SURFACE; LIPID RAFTS; DEFICIENCY; KNOCKOUT; SPERM; MICE	The angiotensin-converting enzyme (ACE) is a key regulator of blood pressure. It is known to cleave small peptides, such as angiotensin I and bradykinin and changes their biological activities, leading to upregulation of blood pressure. Here we describe a new activity for ACE: a glycosylphosphatidylinositol (GPI)-anchored protein releasing activity (GPIase activity). Unlike its peptidase activity, GPIase activity is weakly inhibited by the tightly binding ACE inhibitor and not inactivated by substitutions of core amino acid residues for the peptidase activity, suggesting that the active site elements for GPIase differ from those for peptidase activity. ACE shed various GPI-anchored proteins from the cell surface, and the process was accelerated by the lipid raft disruptor filipin. The released products carried portions of the GPI anchor, indicating cleavage within the GPI moiety. Further analysis by high-performance liquid chromatography-mass spectrometry predicted the cleavage site at the mannose-mannose linkage. GPI-anchored proteins such as TESP5 and PH-20 were released from the sperm membrane of wild-type mice but not in Ace knockout sperm in vivo. Moreover, peptidase-inactivated E414D mutant ACE and also PI-PLC rescued the egg-binding deficiency of Ace knockout sperms, implying that ACE plays a crucial role in fertilization through this activity.	Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Med, Dept Metabolome, Bunkyo Ku, Tokyo 1130033, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Osaka Univ, Ctr Adv Sci & Innovat, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; University of Tokyo; Osaka University; Osaka University; Osaka University	Kondoh, G (corresponding author), Kyoto Univ, Lab Anim Expt Regenerat, Inst Frontier Med Sci, Kyoto, Japan.	kondohg@frontier.kyoto-u.ac.jp; takeda@mr-envi.med.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009; Okabe, Masaru/B-6917-2015	Okabe, Masaru/0000-0002-0803-9044				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Alfieri JA, 2003, J CELL SCI, V116, P2149, DOI 10.1242/jcs.00430; Bergaya S, 2001, CIRC RES, V88, P593, DOI 10.1161/01.RES.88.6.593; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Carvajal N, 2004, J INORG BIOCHEM, V98, P1465, DOI 10.1016/j.jinorgbio.2004.05.005; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Doan TN, 2001, CURR OPIN NEPHROL HY, V10, P483, DOI 10.1097/00041552-200107000-00002; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; HANADA K, 1993, J BIOL CHEM, V268, P13820; Honda A, 2002, J BIOL CHEM, V277, P16976, DOI 10.1074/jbc.M112470200; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; KASAHARA Y, 1981, CLIN CHEM, V27, P1922; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; Kondoh G, 1999, FEBS LETT, V458, P299, DOI 10.1016/S0014-5793(99)01172-2; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; Marella M, 2002, J BIOL CHEM, V277, P25457, DOI 10.1074/jbc.M203248200; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; McLeskey SB, 1998, INT REV CYTOL, V177, P57; Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nozaki M, 1999, LAB INVEST, V79, P293; Nyborg Jennifer K, 2004, Biochem J, V381, pe3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Tojo H, 2004, J CHROMATOGR A, V1056, P223, DOI 10.1016/j.chroma.2004.06.122; Tujioka H, 1998, BIOCHEM BIOPH RES CO, V251, P737, DOI 10.1006/bbrc.1998.9542; Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; WATANABE T, 1991, J BIOL CHEM, V266, P21174; WEI L, 1991, J BIOL CHEM, V266, P9002	44	176	193	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					160	166		10.1038/nm1179	http://dx.doi.org/10.1038/nm1179			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665832	Green Published			2022-12-27	WOS:000226797300023
J	Urbich, C; Heeschen, C; Aicher, A; Sasaki, K; Bruhl, T; Farhadi, MR; Vajkoczy, P; Hofmann, WK; Peters, C; Pennacchio, LA; Abolmaali, ND; Chavakis, E; Reinheckel, T; Zeiher, AM; Dimmeler, S				Urbich, C; Heeschen, C; Aicher, A; Sasaki, K; Bruhl, T; Farhadi, MR; Vajkoczy, P; Hofmann, WK; Peters, C; Pennacchio, LA; Abolmaali, ND; Chavakis, E; Reinheckel, T; Zeiher, AM; Dimmeler, S			Cathepsin L is required for endothelial progenitor cell-induced neovascularization	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; CYSTEINE PROTEASES; MICE DEFICIENT; STEM-CELLS; ANGIOGENESIS; INHIBITORS; VIVO; TRANSPLANTATION; CONTRIBUTES; MECHANISMS	Infusion of endothelial progenitor cells (EPC), but not of mature endothelial cells, promotes neovascularization after ischemia. We performed gene expression profiling of EPC and endothelial cells to identify genes that might be important for the neovascularization capacity of EPC. Notably, the protease cathepsin L (CathL) was highly expressed in EPC as opposed to endothelial cells and was essential for matrix degradation and invasion by EPC in vitro. CathL-deficient mice showed impaired functional recovery following hind limb ischemia, supporting the concept of a crucial role for CathL in postnatal neovascularization. Infused CathL-deficient progenitor cells neither homed to sites of ischemia nor augmented neovascularization. Forced expression of CathL in mature endothelial cells considerably enhanced their invasive activity and sufficed to confer their capacity for neovascularization in vivo. We concluded that CathL has a critical role in the integration of circulating EPC into ischemic tissue and is required for EPC-mediated neovascularization.	Goethe Univ Frankfurt, Dept Internal Med 3, D-60590 Frankfurt, Germany; Heidelberg Univ, Dept Neurosurg, Fac Med, D-68167 Mannheim, Germany; Goethe Univ Frankfurt, Dept Hematol & Oncol, D-60590 Frankfurt, Germany; Univ Freiburg, Dept Mol Med & Cell Res, D-79104 Freiburg, Germany; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Genome Sci, Berkeley, CA 94720 USA; Goethe Univ Frankfurt, Inst Diagnost & Intervent Radiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Ruprecht Karls University Heidelberg; Goethe University Frankfurt; University of Freiburg; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Goethe University Frankfurt	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	dimmeler@em.uni-frankfurt.de	Abolmaali, Nasreddin/A-1061-2012; Abolmaali, Nasreddin/AAG-7655-2022; Reinheckel, Thomas/AAL-9761-2021; Guba, Markus/M-4309-2019; Aicher, Alexandra/GZK-8031-2022; Abolmaali, Nasreddin/AFL-7713-2022	Reinheckel, Thomas/0000-0001-9866-9105; Heeschen, Christopher/0000-0002-1158-8554; Pennacchio, Len/0000-0002-8748-3732; Dimmeler, Stefanie/0000-0002-1045-2436; Aicher, Alexandra/0000-0002-8920-9577	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007195] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL071954A] Funding Source: Medline; NIDCR NIH HHS [DE-AC03-76SF00098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chauhan SS, 1998, BIOCHEMISTRY-US, V37, P8584, DOI 10.1021/bi972251z; Dennhofer R, 2003, INT J CANCER, V106, P316, DOI 10.1002/ijc.11255; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Fiebiger E, 2002, J EXP MED, V196, P1263, DOI 10.1084/jem.20020762; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hinds KA, 2003, BLOOD, V102, P867, DOI 10.1182/blood-2002-12-3669; Houseweart MK, 2003, J NEUROBIOL, V56, P315, DOI 10.1002/neu.10253; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kaberdin VR, 2003, GENOME RES, V13, P1961, DOI 10.1101/gr.1277303; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kawamoto A, 2001, CIRCULATION, V103, P634; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Lelongt B, 2001, J EXP MED, V193, P793, DOI 10.1084/jem.193.7.793; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Libby P, 2001, CIRC RES, V89, P195, DOI 10.1161/res.89.3.195; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Premzl A, 2003, EXP CELL RES, V283, P206, DOI 10.1016/S0014-4827(02)00055-1; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rooprai HK, 1997, ANTICANCER RES, V17, P4151; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Stypmann J, 2002, P NATL ACAD SCI USA, V99, P6234, DOI 10.1073/pnas.092637699; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Urbich C, 2003, CIRCULATION, V108, P2511, DOI 10.1161/01.CIR.0000096483.29777.50; Urbich C, 2002, FASEB J, V16, P706, DOI 10.1096/fj.01-0637fje; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Walker B, 2000, BIOCHEM BIOPH RES CO, V275, P401, DOI 10.1006/bbrc.2000.3311	41	242	264	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					206	213		10.1038/nm1182	http://dx.doi.org/10.1038/nm1182			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665831	Green Submitted			2022-12-27	WOS:000226797300029
J	Powell, K				Powell, K			Philippa Marrack - Profile	NATURE MEDICINE			English	Biographical-Item														Marrack, Philippa/0000-0003-1883-3687					0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2004	10	12					1270	1270		10.1038/nm1204-1270	http://dx.doi.org/10.1038/nm1204-1270			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15580239	Bronze			2022-12-27	WOS:000225500900009
J	Ridley, RG				Ridley, RG			Research on infectious diseases requires better coordination	NATURE MEDICINE			English	Editorial Material							PUBLIC-PRIVATE PARTNERSHIPS; NEGLECTED DISEASES; SARS; SURVEILLANCE; EXPERIENCE; HEALTH; TDR	This special supplement of Nature Medicine, directed at the topic of emerging infectious diseases, is very timely. Recent high-profile outbreaks have highlighted the global risk that infectious agents, both new and old, represent for society. The experience of severe acute respiratory syndrome (SARS) shows the risk posed by emerging infectious diseases, but also the power of strongly coordinated global surveillance and public health measures, coupled with scientific research, to keep infection under control(1,2). Diseases such as drug-resistant malaria continue to be threats. There is a need to enhance global resources to investigate, detect and respond to emerging infections, and to appropriately coordinate and direct research efforts to meet the challenges presented by these diseases.	WHO, UNICEF, UNDP, World Bank Special Program Res & Training Trop Di, CH-1211 Geneva, Switzerland	The World Bank; World Health Organization	Ridley, RG (corresponding author), WHO, UNICEF, UNDP, World Bank Special Program Res & Training Trop Di, CH-1211 Geneva, Switzerland.	ridleyr@who.int						Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; [Anonymous], 2004, SCAL HOM BAS MAN MAL; Breman JG, 2004, AM J TROP MED HYG, V71, P1; Brooks MJ, 2004, CURR OPIN PULM MED, V10, P197, DOI 10.1097/00063198-200405000-00009; Costello A, 2000, BRIT MED J, V321, P827, DOI 10.1136/bmj.321.7264.827; Goodman L, 2004, J CLIN INVEST, V114, P868, DOI 10.1172/JCI23259; Heymann D L, 2001, Lancet Infect Dis, V1, P345, DOI 10.1016/S1473-3099(01)00148-7; Heymann DL, 2004, LANCET, V363, P1566, DOI 10.1016/S0140-6736(04)16234-X; Heymann DL, 2004, EMERG INFECT DIS, V10, P173, DOI 10.3201/eid1002.031038; Heymann DL, 2004, PHILOS T ROY SOC B, V359, P1127, DOI 10.1098/rstb.2004.1484; Kachur SP, 2001, TROP MED INT HEALTH, V6, P324, DOI 10.1046/j.1365-3156.2001.0719a.x; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; McNabb SJN, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-2; Morel CM, 2000, PARASITOL TODAY, V16, P522, DOI 10.1016/S0169-4758(00)01815-9; Ntoumi F, 2004, AM J TROP MED HYG, V71, pIV; Nwaka S, 2003, NAT REV DRUG DISCOV, V2, P919, DOI 10.1038/nrd1230; Remme JHF, 2004, TROP MED INT HEALTH, V9, P243, DOI 10.1046/j.1365-3156.2003.01192.x; Remme JHF, 2002, TRENDS PARASITOL, V18, P421, DOI 10.1016/S1471-4922(02)02387-5; Ridley RG, 2003, EMBO REP, V4, pS43, DOI 10.1038/sj.embor.embor858; Ridley RG, 2001, B WORLD HEALTH ORGAN, V79, P694; Rodier G, 2000, Med Trop (Mars), V60, P31; Widdus R, 2001, B WORLD HEALTH ORGAN, V79, P713	22	15	16	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2004	10	12		S			S137	S140		10.1038/nm1153	http://dx.doi.org/10.1038/nm1153			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577932	Green Published			2022-12-27	WOS:000225733900010
J	Cheng, LH; Ding, GL; Qin, QH; Huang, Y; Lewis, W; He, N; Evans, RM; Schneider, MD; Brako, FA; Xiao, Y; Chen, YQE; Yang, QL				Cheng, LH; Ding, GL; Qin, QH; Huang, Y; Lewis, W; He, N; Evans, RM; Schneider, MD; Brako, FA; Xiao, Y; Chen, YQE; Yang, QL			Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy	NATURE MEDICINE			English	Article							SKELETAL-MUSCLE; OBESE RATS; IN-VIVO; HEART; METABOLISM; EXPRESSION; ALPHA; BETA/DELTA; LIVER; CELLS	Fatty acid oxidation (FAO) is a primary energy source for meeting the heart's energy requirements(1-3). Peroxisome proliferator-activated receptor-delta (PPAR-delta) may have important roles in FAO(4-8). But it remains unclear whether PPAR-is required for maintaining basal myocardial FAO. We show that cre-loxP-mediated cardiomyocyte-restricted deletion of PPAR-delta in mice downregulates constitutive expression of key FAO genes and decreases basal myocardial FAO. These mice have cardiac dysfunction, progressive myocardial lipid accumulation, cardiac hypertrophy and congestive heart failure with reduced survival. Thus, chronic myocardial PPAR-delta deficiency leads to lipotoxic cardiomyopathy. Together, our data show that PPAR-delta is a crucial determinant of constitutive myocardial FAO and is necessary to maintain energy balance and normal cardiac function. We suggest that PPAR-delta is a potential therapeutic target in treating lipotoxic cardiomyopathy and other heart diseases.	Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA; Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Morehouse Sch Med, Dept Pharmacol, Atlanta, GA 30310 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA	Morehouse School of Medicine; Emory University; Morehouse School of Medicine; Howard Hughes Medical Institute; Salk Institute; Baylor College of Medicine	Yang, QL (corresponding author), Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA.	qyang@msm.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Schneider, Michael/0000-0001-9645-1938	NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003034] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008248] Funding Source: NIH RePORTER; NCRR NIH HHS [G12-RR03034] Funding Source: Medline; NHLBI NIH HHS [5 UH1 HL03676-02] Funding Source: Medline; NIGMS NIH HHS [S06GM08248] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Chatham JC, 1999, AM J PHYSIOL-ENDOC M, V277, pE342, DOI 10.1152/ajpendo.1999.277.2.E342; Cheng LH, 2004, BIOCHEM BIOPH RES CO, V313, P277, DOI 10.1016/j.bbrc.2003.11.127; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Coven DL, 2003, AM J PHYSIOL-ENDOC M, V285, pE629, DOI 10.1152/ajpendo.00171.2003; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Gilde AJ, 2003, CIRC RES, V92, P518, DOI 10.1161/01.RES.0000060700.55247.7C; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KING MT, 1985, ANAL BIOCHEM, V146, P173, DOI 10.1016/0003-2697(85)90412-9; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; NEELY J R, 1972, Progress in Cardiovascular Diseases, V15, P289, DOI 10.1016/0033-0620(72)90029-1; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; REGAN TJ, 1992, J AM COLL CARDIOL, V19, P1165, DOI 10.1016/0735-1097(92)90318-H; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SHINDO Y, 1978, BIOCHEM PHARMACOL, V27, P2683; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; VANDERVUSSE GJ, 1992, PHYSIOL REV, V72, P881, DOI 10.1152/physrev.1992.72.4.881; VARY TC, 1981, ANNU REV PHYSIOL, V43, P419, DOI 10.1146/annurev.ph.43.030181.002223; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; Yagyu H, 2003, J CLIN INVEST, V111, P419, DOI [10.1172/JCI200316751, 10.1172/JCI16751]; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; ZONERAICH S, 1993, CAN J CARDIOL, V9, P293	26	367	387	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1245	1250		10.1038/nm1116	http://dx.doi.org/10.1038/nm1116			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15475963				2022-12-27	WOS:000224785900048
J	He, WX; Lu, YF; Qahwash, I; Hu, XY; Chang, AS; Yan, RQ				He, WX; Lu, YF; Qahwash, I; Hu, XY; Chang, AS; Yan, RQ			Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation	NATURE MEDICINE			English	Article							GAMMA-SECRETASE COMPLEX; NSP-ENCODED RETICULONS; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; NOGO-A; PRESENILIN; INHIBITOR; CLEAVAGE; LOCALIZATION	Inhibiting the activity of the beta-amyloid converting enzyme 1 (BACE1) or reducing levels of BACE1 in vivo decreases the production of amyloid-beta. The reticulon family of proteins has four members, RTN1, RTN2, RTN3 and RTN4 (also known as Nogo), the last of which is well known for its role in inhibiting neuritic outgrowth after injury. Here we show that reticulon family members are binding partners of BACE1. In brain, BACE1 mainly colocalizes with RTN3 in neurons, whereas RTN4 is more enriched in oligodendrocytes. An increase in the expression of any reticulon protein substantially reduces the production of Abeta. Conversely, lowering the expression of RTN3 by RNA interference increases the secretion of Abeta, suggesting that reticulon proteins are negative modulators of BACE1 in cells. Our data support a mechanism by which reticulon proteins block access of BACE1 to amyloid precursor protein and reduce the cleavage of this protein. Thus, changes in the expression of reticulon proteins in the human brain are likely to affect cellular amyloid-beta and the formation of amyloid plaques.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Pharmacia Corp, Kalamazoo, MI 49007 USA	Cleveland Clinic Foundation; Pfizer	Yan, RQ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.	yanr@ccf.org	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Yan, Riqiang/0000-0001-7195-7617				Bandtlow CE, 2000, GLIA, V29, P175, DOI 10.1002/(SICI)1098-1136(20000115)29:2<175::AID-GLIA11>3.0.CO;2-F; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Citron M, 2002, NAT NEUROSCI, V5, P1055, DOI 10.1038/nn940; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Huber AB, 2002, J NEUROSCI, V22, P3553; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; Oertle T, 2003, J NEUROSCI, V23, P5393; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; Pinnix I, 2001, FASEB J, V15, P1810, DOI 10.1096/fj.00-0891fje; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Trapp BD, 1997, J CELL BIOL, V137, P459, DOI 10.1083/jcb.137.2.459; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; VANDEVELDE HJK, 1994, CANCER RES, V54, P4769; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang XX, 2002, J NEUROSCI, V22, P5505; Woolf CJ, 2003, NEURON, V38, P153, DOI 10.1016/S0896-6273(03)00233-2; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	36	224	241	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					959	965		10.1038/nm1088	http://dx.doi.org/10.1038/nm1088			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15286784				2022-12-27	WOS:000223658400033
J	Singer, M; Martin, LD; Vargaftig, BB; Park, J; Gruber, AD; Li, YH; Adler, KB				Singer, M; Martin, LD; Vargaftig, BB; Park, J; Gruber, AD; Li, YH; Adler, KB			A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; PHORBOL ESTERS; SECRETION; MICE; PHOSPHORYLATION; RELEASE; MUCIN; LEUKOTRIENES; RECRUITMENT; EXOCYTOSIS	Mucus hypersecretion is a crucial feature of pulmonary diseases such as asthma, chronic bronchitis and cystic fibrosis. Despite much research, there is still no effective therapy for this condition. Recently, we showed that the myristoylated, alanine-rich C-kinase substrate (MARCKS) protein is required for mucus secretion by human bronchial epithelial cells in culture 1. Having synthesized a peptide corresponding to the N-terminal domain of MARCKS, we now show that the intratracheal instillation of this peptide blocks mucus hypersecretion in a mouse model of asthma. A missense peptide with the same amino acid composition has no effect. Based on quantitative histochemical analysis of the mouse airways, the peptide seems to act by blocking mucus release from goblet cells, possibly by inhibiting the attachment of MARCKS to membranes of intracellular mucin granules. These results support a pivotal role for MARCKS protein, specifically its N-terminal region, in modulating this secretory process in mammalian airways. Intratracheal administration of this MARCKS-related peptide could therapeutically reduce mucus secretion in the airways of human patients with asthma, chronic bronchitis and cystic fibrosis.	N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA; Inst Pasteur, Unite Pharmacol Cellulaire, F-75724 Paris 15, France; Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, BR-05508900 Sao Paulo, Brazil; Hannover Sch Vet Med, Dept Pathol, D-30559 Hannover, Germany	University of North Carolina; North Carolina State University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidade de Sao Paulo; University of Veterinary Medicine Hannover, Foundation	Adler, KB (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.	Kenneth_Adler@ncsu.edu	Gruber, Achim D./ABA-4514-2021; Vargaftig, Bernardo Boris B.B.J./C-3323-2013		NHLBI NIH HHS [R01-HL36982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Elzagallaai A, 2000, BLOOD, V95, P894, DOI 10.1182/blood.V95.3.894.003k15_894_902; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; Haile S, 1999, AM J RESP CELL MOL, V20, P891, DOI 10.1165/ajrcmb.20.5.3446; Hartness ME, 2001, EUR J NEUROSCI, V13, P925, DOI 10.1046/j.0953-816x.2001.01466.x; Leverkoehne I, 2002, J HISTOCHEM CYTOCHEM, V50, P829, DOI 10.1177/002215540205000609; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Rose SD, 2001, J BIOL CHEM, V276, P36757, DOI 10.1074/jbc.M006518200; Salli U, 2000, BIOL REPROD, V63, P12, DOI 10.1095/biolreprod63.1.12; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; Singer M, 2002, AM J RESP CELL MOL, V26, P74, DOI 10.1165/ajrcmb.26.1.4618; Spizz G, 1997, J BIOL CHEM, V272, P23833, DOI 10.1074/jbc.272.38.23833; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Trifaro JM, 2000, BIOCHIMIE, V82, P339, DOI 10.1016/S0300-9084(00)00193-0; Vargaftig BB, 2003, AM J PHYSIOL-LUNG C, V285, pL808, DOI 10.1152/ajplung.00377.2002; Vargaftig BB, 2003, AM J PHYSIOL-LUNG C, V284, pL260, DOI 10.1152/ajplung.00226.2002; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; Wu TT, 1997, J CELL SCI, V110, P1533	18	127	140	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					193	196		10.1038/nm983	http://dx.doi.org/10.1038/nm983			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14716307				2022-12-27	WOS:000188719600040
J	Hevener, AL; He, WM; Barak, Y; Le, J; Bandyopadhyay, G; Olson, P; Wilkes, J; Evans, RM; Olefsky, J				Hevener, AL; He, WM; Barak, Y; Le, J; Bandyopadhyay, G; Olson, P; Wilkes, J; Evans, RM; Olefsky, J			Muscle-specific Pparg deletion causes insulin resistance	NATURE MEDICINE			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; ADIPOSE-TISSUE; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; ANTIDIABETIC AGENT; ORPHAN RECEPTORS; SKELETAL-MUSCLE; NIDDM PATIENTS	Thiazolidinediones (TZDs) are insulin- sensitizing drugs and are potent agonists of the nuclear peroxisome proliferator- activated receptor-gamma (PPAR-gamma). Although muscle is the major organ responsible for insulin- stimulated glucose disposal, PPAR-gamma is more highly expressed in adipose tissue than in muscle. To address this issue, we used the Cre- loxP system to knock out Pparg, the gene encoding PPAR-gamma, in mouse skeletal muscle. As early as 4 months of age, mice with targeted disruption of PPAR-gamma in muscle showed glucose intolerance and progressive insulin resistance. Using the hyperinsulinemic- euglycemic clamp technique, the in vivo insulin- stimulated glucose disposal rate (IS- GDR) was reduced by similar to80% and was unchanged by 3 weeks of TZD treatment. These effects reveal a crucial role for muscle PPAR-gamma in the maintenance of skeletal muscle insulin action, the etiology of insulin resistance and the action of TZDs.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Calif San Diego, Howard Hughes Med Inst, Salk Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Jackson Laboratory; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	Olefsky, J (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NHLBI NIH HHS [HL56989] Funding Source: Medline; NIDDK NIH HHS [2T32 DK07044-23, DK-60484, DK57978-24, DK-33651] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060484, R37DK057978, T32DK007044, R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; CIARALDI TP, 1990, METABOLISM, V39, P1056, DOI 10.1016/0026-0495(90)90166-A; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; ELKEBBI IM, 1994, METABOLISM, V43, P953, DOI 10.1016/0026-0495(94)90173-2; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FRAYN KN, 1980, J LIPID RES, V21, P139; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; GAVRILOVA O, IN PRESS J BIOL CHEM; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HARRIS PKW, 1994, MOL PHARMACOL, V45, P439; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kumar S, 1996, DIABETOLOGIA, V39, P701; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Loviscach M, 2000, DIABETOLOGIA, V43, P304, DOI 10.1007/s001250050048; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Meigs JB, 2002, AM J MANAG CARE, V8, pS283; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OGOMAN S, 1997, P NATL ACAD SCI USA, V94, P14602; Reaven G, 2002, CIRCULATION, V106, P286, DOI 10.1161/01.CIR.0000019884.36724.D9; REVERS RR, 1984, J CLIN INVEST, V73, P664, DOI 10.1172/JCI111258; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SMITH D, 1987, METABOLISM, V36, P1176; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Wilkes JJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE912, DOI 10.1152/ajpendo.2000.279.4.E912; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; YOUNG PW, 1995, DIABETES, V44, P1087, DOI 10.2337/diabetes.44.9.1087	49	391	410	0	13	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1491	1497		10.1038/nm956	http://dx.doi.org/10.1038/nm956			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625542				2022-12-27	WOS:000186845400032
J	Li, HW; Liu, H; Heller, S				Li, HW; Liu, H; Heller, S			Pluripotent stem cells from the adult mouse inner ear	NATURE MEDICINE			English	Article							HAIR-CELLS; REGENERATIVE PROLIFERATION; NERVOUS-SYSTEM; GROWTH-FACTORS; EXPRESSION; GENE; GENERATION; CULTURE; MATH1; MICE	In mammals, the permanence of acquired hearing loss is mostly due to the incapacity of the cochlea to replace lost mechanoreceptor cells, or hair cells. In contrast, damaged vestibular organs can generate new hair cells, albeit in limited numbers. Here we show that the adult utricular sensory epithelium contains cells that display the characteristic features of stem cells. These inner ear stem cells have the capacity for self-renewal, and form spheres that express marker genes of the developing inner ear and the nervous system. Inner ear stem cells are pluripotent and can give rise to a variety of cell types in vitro and in vivo, including cells representative of ectodermal, endodermal and mesodermal lineages. Our observation that these stem cells are capable of differentiating into hair cell-like cells implies a possible use of such cells for the replacement of lost inner-ear sensory cells.	Harvard Univ, Sch Med, Dept Otolaryngol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	Heller, S (corresponding author), Harvard Univ, Sch Med, Dept Otolaryngol, Boston, MA 02114 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006167] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC006167] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; BODINE DM, 1991, BLOOD, V78, P914; Chen P, 2002, DEVELOPMENT, V129, P2495; Chen P, 1999, DEVELOPMENT, V126, P1581; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Cohen M. M., 1995, HEREDITARY HEARING L, P9; CORWIN JT, 1995, ASS RES OT ABSTR, V18, P87; Davis AC, 1993, HEARING SCI HEARING, P35; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gritti A, 1996, J NEUROSCI, V16, P1091; Groves AK, 2000, DEVELOPMENT, V127, P3489; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Helms AW, 2000, DEVELOPMENT, V127, P1185; HUDSPETH AJ, 1985, SCIENCE, V230, P745, DOI 10.1126/science.2414845; Kopke RD, 2001, P NATL ACAD SCI USA, V98, P5886, DOI 10.1073/pnas.101120898; LAMBERT PR, 1994, LARYNGOSCOPE, V104, P701; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; LUMPKIN EA, IN PRESS GENE EXPRES; Malgrange B, 2002, MECH DEVELOP, V112, P79, DOI 10.1016/S0925-4773(01)00642-6; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Morsli H, 1999, DEVELOPMENT, V126, P2335; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; *NAT CTR HLTH STAT, 2002, VIT HLTH STAT, V10; Oh SH, 1996, J NEUROSCI, V16, P6463; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Sahly I, 1997, ANAT EMBRYOL, V196, P159, DOI 10.1007/s004290050088; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHAART G, 1989, DEVELOPMENT, V107, P585; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; Zheng JL, 1999, J NEUROCYTOL, V28, P901, DOI 10.1023/A:1007078307638; Zheng JL, 1997, J NEUROSCI, V17, P216, DOI 10.1523/JNEUROSCI.17-01-00216.1997; Zheng LL, 2000, CELL, V102, P377, DOI 10.1016/S0092-8674(00)00042-8	43	353	439	4	42	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1293	1299		10.1038/nm925	http://dx.doi.org/10.1038/nm925			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12949502				2022-12-27	WOS:000185669700041
J	Stager, S; Alexander, J; Kirby, AC; Botto, M; Van Rooijen, N; Smith, DF; Brombacher, F; Kaye, PM				Stager, S; Alexander, J; Kirby, AC; Botto, M; Van Rooijen, N; Smith, DF; Brombacher, F; Kaye, PM			Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8(+) T-cell responses	NATURE MEDICINE			English	Article							DENDRITIC CELL; LEISHMANIA-DONOVANI; DEFICIENT MICE; IN-VIVO; B-CELLS; VISCERAL LEISHMANIASIS; PROTECTIVE IMMUNITY; ACQUIRED-IMMUNITY; BONE-MARROW; LINK INNATE	CD8(+) T cells are essential for long-term, vaccine-induced resistance against intracellular pathogens. Here we show that natural antibodies, acting in concert with complement, are endogenous adjuvants for the generation of protective CD8(+) T cells after vaccination against visceral leishmaniasis. IL-4 was crucial for the priming of vaccine-specific CD8(+) T cells, and we defined the primary source of IL-4 as a CD11b(+)CD11c(lo) phagocyte. IL-4 secretion was not observed in antibody-deficient mice and could be reconstituted with serum from normal, but not Btk immune-deficient, mice. Similarly, no IL-4 response or CD8(+) T-cell priming was seen in C1qa(-/-) mice. These results identify a new pathway by which immune complex-mediated complement activation can regulate T-cell-mediated immunity. We propose that this function of natural antibodies could be exploited when developing new vaccines for infectious diseases.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England; Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Immunol, Glasgow G4 0NR, Lanark, Scotland; Univ London Imperial Coll Sci & Technol, Fac Med, Rheumatol Sect, London W12 0NN, England; Vrije Univ Amsterdam, Dept Mol Cell Biol, NL-1081 B5 Amsterdam, Netherlands; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wellcome Trust Labs Mol Parasitol, London SW7 2AZ, England; Univ Cape Town, Sch Med, Groote Schuur Hosp, Dept Immunol, ZA-7925 Cape Town, South Africa	University of London; London School of Hygiene & Tropical Medicine; University of Strathclyde; Imperial College London; Vrije Universiteit Amsterdam; Imperial College London; University of Cape Town	Kaye, PM (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.		Alexander, James/A-4238-2009	Kaye, Paul/0000-0002-8796-4755; Kirby, Alun/0000-0001-5663-2961	Wellcome Trust [061343] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alce TM, 1999, MOL BIOCHEM PARASIT, V102, P191, DOI 10.1016/S0166-6851(99)00074-2; Ato M, 2002, NAT IMMUNOL, V3, P1185, DOI 10.1038/ni861; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; Boes M, 1998, J IMMUNOL, V160, P4776; BONA C, 1980, J EXP MED, V151, P224, DOI 10.1084/jem.151.1.224; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; Carvalho LH, 2002, NAT MED, V8, P166, DOI 10.1038/nm0202-166; Coffman RL, 1997, J EXP MED, V185, P373, DOI 10.1084/jem.185.3.373; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FLEMING TJ, 1993, J IMMUNOL, V151, P2399; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gicheru MM, 2001, INFECT IMMUN, V69, P245, DOI 10.1128/IAI.69.1.245-251.2001; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gurunathan S, 2000, CURR OPIN IMMUNOL, V12, P442, DOI 10.1016/S0952-7915(00)00118-7; Haas KM, 2002, IMMUNITY, V17, P713, DOI 10.1016/S1074-7613(02)00483-1; HARDY RR, 1994, IMMUNOL REV, V137, P91, DOI 10.1111/j.1600-065X.1994.tb00660.x; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; Hayashi N, 1999, J IMMUNOL, V163, P6702; Hochrein H, 2000, J EXP MED, V192, P823, DOI 10.1084/jem.192.6.823; Kalergis AM, 2002, J EXP MED, V195, P1653, DOI 10.1084/jem.20020338; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; King C, 2001, NAT MED, V7, P206, DOI 10.1038/84659; Kopf M, 2002, NAT MED, V8, P373, DOI 10.1038/nm0402-373; Lutz C, 1998, NATURE, V393, P797, DOI 10.1038/31716; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Mohrs M, 1999, J IMMUNOL, V162, P7302; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Murphy ML, 1998, J IMMUNOL, V161, P4153; Naito M, 1996, J LEUKOCYTE BIOL, V59, P133, DOI 10.1002/jlb.59.2.133; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; O'Keeffe M, 2003, BLOOD, V101, P1453, DOI 10.1182/blood-2002-03-0974; Ochsenbein AF, 2000, IMMUNOL TODAY, V21, P624, DOI 10.1016/S0167-5699(00)01754-0; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Qi H, 2001, J IMMUNOL, V167, P4534, DOI 10.4049/jimmunol.167.8.4534; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Reid RR, 1997, J IMMUNOL, V159, P970; Ross TM, 2000, NAT IMMUNOL, V1, P127, DOI 10.1038/77802; Schuler T, 2001, J EXP MED, V194, P1767, DOI 10.1084/jem.194.12.1767; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; Stager S, 2000, J IMMUNOL, V165, P7064, DOI 10.4049/jimmunol.165.12.7064; Suresh M, 2003, J IMMUNOL, V170, P788, DOI 10.4049/jimmunol.170.2.788; SWAIN SL, 1988, IMMUNOL REV, V102, P77, DOI 10.1111/j.1600-065X.1988.tb00742.x; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Wardemann H, 2002, J EXP MED, V195, P771, DOI 10.1084/jem.20011140; Yamaguchi M, 2001, INT IMMUNOL, V13, P843, DOI 10.1093/intimm/13.7.843; Yoshida A, 2001, VACCINE, V19, P4297, DOI 10.1016/S0264-410X(01)00146-3	50	167	173	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1287	1292		10.1038/nm933	http://dx.doi.org/10.1038/nm933			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502281				2022-12-27	WOS:000185669700040
J	During, MJ; Cao, L; Zuzga, DS; Francis, JS; Fitzsimons, HL; Jiao, XY; Bland, RJ; Klugmann, M; Banks, WA; Drucker, DJ; Haile, CN				During, MJ; Cao, L; Zuzga, DS; Francis, JS; Fitzsimons, HL; Jiao, XY; Bland, RJ; Klugmann, M; Banks, WA; Drucker, DJ; Haile, CN			Glucagon-like peptide-1 receptor is involved in learning and neuroprotection	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; BLOOD-BRAIN; EXPRESSION; INSULIN; CELLS; PANCREAS; DEGRADATION; EXENDIN-4; RELEASE	Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser(2)]exendin(1-9) (HSEGTFTSD; homologous to a conserved domain in the glucagon/GLP-1 family) enhance associative and spatial learning through GLP-1R. [Ser(2)]exendin(1-9), but not GLP-1, is also active when administered peripherally. GLP-1R-deficient mice have a phenotype characterized by a learning deficit that is restored after hippocampal Glp1r gene transfer. In addition, rats overexpressing GLP-1R in the hippocampus show improved learning and memory. GLP-1R-deficient mice also have enhanced seizure severity and neuronal injury after kainate administration, with an intermediate phenotype in heterozygotes and phenotypic correction after Glp1r gene transfer in hippocampal somatic cells. Systemic administration of [Ser(2)]exendin(1-9) in wild-type animals prevents kainate-induced apoptosis of hippocampal neurons. Brain GLP-1R represents a promising new target for both cognitive-enhancing and neuroprotective agents.	Univ Auckland, Dept Mol Med & Pathol, Auckland 86716, New Zealand; Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurosurg, CNS Gene Therapy Ctr, Philadelphia, PA 19107 USA; St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63106 USA; St Louis Univ, Sch Med, Vet Affiars Med Ctr St Louis, GRECC, St Louis, MO 63106 USA; Univ Toronto, Toronto Gen Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada	University of Auckland; Jefferson University; Saint Louis University; Geriatric Research Education & Clinical Center; Saint Louis University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	During, MJ (corresponding author), Univ Auckland, Dept Mol Med & Pathol, Private Bag 92019, Auckland 86716, New Zealand.		Drucker, Daniel J/A-4092-2010; Cao, Lei/H-3185-2019; Cao, Lei/E-2841-2011; Banks, William A/K-1330-2017; During, Matthew/AAC-1388-2020	Banks, William A/0000-0002-0496-3619; Cao, Lei/0000-0003-0322-4985; Haile, Colin/0000-0001-8293-7291; Fitzsimons, Helen/0000-0001-7825-3911				Alvarez E, 1996, J NEUROCHEM, V66, P920; Banks WA, 2002, J PHARMACOL EXP THER, V302, P1062, DOI 10.1124/jpet.102.036129; Banks WA, 1999, PEPTIDES, V20, P373, DOI 10.1016/S0196-9781(99)00045-5; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Cashion MF, 1999, BRAIN RES, V822, P26, DOI 10.1016/S0006-8993(99)01069-0; Chowen JA, 1999, NEUROPEPTIDES, V33, P212, DOI 10.1054/npep.1999.0757; DEWIED D, 1971, NATURE, V232, P58, DOI 10.1038/232058a0; Drucker DJ, 2001, ENDOCRINOLOGY, V142, P521, DOI 10.1210/en.142.2.521; Gallwitz B, 2000, REGUL PEPTIDES, V86, P103, DOI 10.1016/S0167-0115(99)00095-6; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; JIN SLC, 1988, J COMP NEUROL, V271, P519, DOI 10.1002/cne.902710405; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kastin AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07; Kern W, 1999, DIABETES, V48, P557, DOI 10.2337/diabetes.48.3.557; Merchenthaler I, 1999, J COMP NEUROL, V403, P261, DOI 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; Perfetti R, 2000, ENDOCRINOLOGY, V141, P4600, DOI 10.1210/en.141.12.4600; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ramanathan M, 1998, PSYCHOPHARMACOLOGY, V135, P361, DOI 10.1007/s002130050523; RAUFMAN JP, 1991, J BIOL CHEM, V266, P2897; SANTUCCI AC, 1990, BEHAV NEURAL BIOL, V53, P321, DOI 10.1016/0163-1047(90)90184-8; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Setlow B, 2000, LEARN MEMORY, V7, P187, DOI 10.1101/lm.7.3.187; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Tseng CC, 1999, AM J PHYSIOL-ENDOC M, V276, pE1049, DOI 10.1152/ajpendo.1999.276.6.E1049; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; VENABLE N, 1990, PSYCHOPHARMACOLOGY, V100, P215, DOI 10.1007/BF02244409; WEATHERLY LS, 1996, BRAIN RES, V716, P29; Weeber EJ, 2002, NEURON, V33, P845, DOI 10.1016/S0896-6273(02)00634-7; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; Zhou J, 1999, DIABETES, V48, P2358, DOI 10.2337/diabetes.48.12.2358	40	615	676	1	63	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1173	1179		10.1038/nm919	http://dx.doi.org/10.1038/nm919			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925848				2022-12-27	WOS:000185061600030
J	Shichiri, M; Ishimaru, S; Ota, T; Nishikawa, T; Isogai, T; Hirata, Y				Shichiri, M; Ishimaru, S; Ota, T; Nishikawa, T; Isogai, T; Hirata, Y			Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities	NATURE MEDICINE			English	Article							ONSET TORSION DYSTONIA; SMOOTH-MUSCLE-CELLS; RECEPTOR GPR14; GROWTH-FACTOR; UROTENSIN-II; ENDOTHELIN-1; PROTEIN; ADRENOMEDULLIN; EXPRESSION; APOPTOSIS	The discovery of endogenous bioactive peptides has typically required a lengthy identification process. Computer-assisted analysis of cDNA and genomic DNA sequence information can markedly shorten the process. A bioinformatic analysis of full-length, enriched human cDNA libraries searching for previously unidentified bioactive peptides resulted in the identification and characterization of two related peptides of 28 and 20 amino acids, which we designated salusin-alpha and salusin-beta. Salusins are translated from an alternatively spliced mRNA of TOR2A, a gene encoding a protein of the torsion dystonia family. Intravenous administration of salusin-alpha or salusin-beta to rats causes rapid, profound hypotension and bradycardia. Salusins increase intracellular Ca2+, upregulate a variety of genes and induce cell mitogenesis. Salusin-beta stimulates the release of argininevasopressin from rat pituitary. Expression of TOR2A mRNA and its splicing into preprosalusin are ubiquitous, and immunoreactive salusin-alpha and salusin-beta are detected in many human tissues, plasma and urine, suggesting that salusins are endocrine and/or paracrine factors.	Tokyo Med & Dent Univ, Hosp Med, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Clin & Mol Endocrinol, Bunkyo Ku, Tokyo 1138519, Japan; Helix Res Inst Inc, Chiba 2920812, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Shichiri, M (corresponding author), Tokyo Med & Dent Univ, Hosp Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.			Shichiri, Masayoshi/0000-0002-5704-1378; ISOGAI, TAKAO/0000-0002-1970-4556				Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Doi M, 2000, HYPERTENS RES, V23, P643, DOI 10.1291/hypres.23.643; Eatman D, 1998, EUR J PHARMACOL, V361, P207, DOI 10.1016/S0014-2999(98)00700-6; EIPPER BA, 1993, ANN NY ACAD SCI, V680, P147, DOI 10.1111/j.1749-6632.1993.tb19681.x; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Ishimaru S, 2001, HYPERTENS RES, V24, P119, DOI 10.1291/hypres.24.119; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; Iwasaki H, 2001, ENDOCR J, V48, P261, DOI 10.1507/endocrj.48.261; JUNG LJ, 1993, RECENT PROG HORM RES, V48, P415; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Matsushita M, 2001, J HYPERTENS, V19, P2185, DOI 10.1097/00004872-200112000-00011; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OTA T, 1988, MICROB COMP GENOMI C, V87; Ozelius LJ, 1999, GENOMICS, V62, P377, DOI 10.1006/geno.1999.6039; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; PROUTY SM, 1993, ONCOGENE, V8, P899; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHICHIRI M, 1989, BIOCHEM BIOPH RES CO, V163, P1332, DOI 10.1016/0006-291X(89)91124-8; Shichiri M, 1999, MOL ENDOCRINOL, V13, P1353, DOI 10.1210/me.13.8.1353; Shichiri M, 2000, ARTERIOSCL THROM VAS, V20, P989, DOI 10.1161/01.ATV.20.4.989; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; Shichiri M, 2003, GENE THER, V10, P827, DOI 10.1038/sj.gt.3301953; Shichiri M, 2002, CANCER RES, V62, P13; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3	32	145	170	1	14	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1166	1172		10.1038/nm913	http://dx.doi.org/10.1038/nm913			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12910263				2022-12-27	WOS:000185061600029
J	Johnson, MD; Kenney, N; Stoica, A; Hilakivi-Clarke, L; Singh, B; Chepko, G; Clarke, R; Sholler, PF; Lirio, AA; Foss, C; Reiter, R; Trock, B; Paik, S; Martin, MB				Johnson, MD; Kenney, N; Stoica, A; Hilakivi-Clarke, L; Singh, B; Chepko, G; Clarke, R; Sholler, PF; Lirio, AA; Foss, C; Reiter, R; Trock, B; Paik, S; Martin, MB			Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland	NATURE MEDICINE			English	Article							TOTAL DIET SAMPLES; EXPOSURE; PESTICIDES; CHEMICALS; ELEMENTS; GERMANY; ADULTS; ALPHA	It has been suggested that environmental contaminants that mimic the effects of estrogen contribute to disruption of the reproductive systems of animals in the wild, and to the high incidence of hormone-related cancers and diseases in Western populations. Previous studies have shown that functionally, cadmium acts like steroidal estrogens in breast cancer cells as a result of its ability to form a high-affinity complex with the hormone binding domain of the estrogen receptor(1,2). The results of the present study show that cadmium also has potent estrogen-like activity in vivo. Exposure to cadmium increased uterine wet weight, promoted growth and development of the mammary glands and induced hormone-regulated genes in ovariectomized animals. In the uterus, the increase in wet weight was accompanied by proliferation of the endometrium and induction of progesterone receptor (PgR) and complement component C3. In the mammary gland, cadmium promoted an increase in the formation of side branches and alveolar buds and the induction of casein, whey acidic protein, PgR and C3. In utero exposure to the metal also mimicked the effects of estrogens. Female offspring experienced an earlier onset of puberty and an increase in the epithelial area and the number of terminal end buds in the mammary gland.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Hampton Univ, Dept Biol, Hampton, VA 23668 USA; Georgetown Univ, Dept Chem, Washington, DC 20007 USA; Univ Pittsburgh, Pittsburgh, PA 15238 USA	Georgetown University; Hampton University; Georgetown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Martin, MB (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA.	martinmb@georgetown.edu	Chepko, Gloria/B-2235-2010; Clarke, Robert/A-6485-2008	Chepko, Gloria/0000-0002-4691-9894; Clarke, Robert/0000-0002-9278-0854; johnson, Michael/0000-0001-6260-7586	NCI NIH HHS [P30-CA51008, P50-CA58185, CA70708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185, P30CA051008, R01CA070708, R03CA070708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antila E, 1996, SCI TOTAL ENVIRON, V186, P251, DOI 10.1016/0048-9697(96)05119-4; CANTOR KP, 1994, J OCCUP MED; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GARTRELL MJ, 1986, J ASSOC OFF ANA CHEM, V69, P146; GARTRELL MJ, 1986, J ASSOC OFF ANA CHEM, V69, P123; HEINEMAN WR, 1984, LAB TECHNIQUES ELECT; HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372; HilakiviClarke L, 1997, J CELL PHYSIOL, V170, P279, DOI 10.1002/(SICI)1097-4652(199703)170:3<279::AID-JCP9>3.0.CO;2-L; *INT AG RES CANC, 1976, IARC MON EV CARC RIS, P48; International Agency for Research on Cancer, 1993, BER CADM MERC EXP GL, P119; Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1; Martin MB, 2003, ENDOCRINOLOGY, V144, P2425, DOI 10.1210/en.2002-221054; Moschandreas DJ, 2002, J EXPO ANAL ENV EPID, V12, P233, DOI 10.1038/sj.jea.7500230; Muller M, 1998, FOOD ADDIT CONTAM, V15, P135, DOI 10.1080/02652039809374622; ROTHSCHILD TC, 1988, EXP MOL PATHOL, V48, P59, DOI 10.1016/0014-4800(88)90046-9; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Sharpe RM, 1995, ENVIRON HEALTH PERSP, V103, P1136, DOI 10.2307/3432610; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; TOMOOKA Y, 1982, J NATL CANCER I, V69, P1347; *US EPA, 1981, EPA600881 OFF RES DE; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; Waalkes MP, 2000, J INORG BIOCHEM, V79, P241, DOI 10.1016/S0162-0134(00)00009-X; WHO (World Health Organization), 2001, WHO TECHN REP SER, V901; Wilhelm M, 2002, SCI TOTAL ENVIRON, V285, P11, DOI 10.1016/S0048-9697(01)01123-8; Ysart G, 2000, FOOD ADDIT CONTAM, V17, P775, DOI 10.1080/026520300415327	25	408	428	2	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2003	9	8					1081	1084		10.1038/nm902	http://dx.doi.org/10.1038/nm902			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12858169				2022-12-27	WOS:000184484900034
J	Stein, C; Schafer, M; Machelska, H				Stein, C; Schafer, M; Machelska, H			Attacking pain at its source: new perspectives on opioids	NATURE MEDICINE			English	Review							PERIPHERAL MORPHINE ANALGESIA; RECEPTORS MEDIATING ANTINOCICEPTION; INTERCELLULAR-ADHESION MOLECULE-1; CORTICOTROPIN-RELEASING FACTOR; RAT SENSORY NEURONS; DORSAL-ROOT GANGLIA; INTRAARTICULAR MORPHINE; INFLAMMATORY PAIN; INFLAMED TISSUE; IMMUNE CELLS	The treatment of severe pain with opioids has thus far been limited by their unwanted central side effects. Recent research promises new approaches, including opioid analgesics acting outside the central nervous system, targeting of opioid peptide-containing immune cells to peripheral damaged tissue, and gene transfer to enhance opioid production at sites of injury.	Free Univ Berlin, Klinikum Benjamin Franklin, Klin Anaesthesiol & Operat Intens Med, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stein, C (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Klin Anaesthesiol & Operat Intens Med, Hindenburgdamm 30, D-12200 Berlin, Germany.			Stein, Christoph/0000-0001-5240-6836; Schaefer, Michael/0000-0002-1581-706X; Machelska, Halina/0000-0001-6315-2958				AKINS PT, 1993, NEUROSCIENCE, V56, P759, DOI 10.1016/0306-4522(93)90372-M; Aley KO, 1995, J NEUROSCI, V15, P8031; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Averbeck B, 2001, NEUROREPORT, V12, P2097, DOI 10.1097/00001756-200107200-00011; BARBER A, 1994, BRIT J PHARMACOL, V113, P1317, DOI 10.1111/j.1476-5381.1994.tb17142.x; Bickel A, 1998, PAIN, V76, P317, DOI 10.1016/S0304-3959(98)00062-1; Binder W, 2000, J PHARMACOL EXP THER, V292, P303; Binder W, 2001, ANESTHESIOLOGY, V94, P1034, DOI 10.1097/00000542-200106000-00018; Borgland SL, 2001, J PHYSIOL-LONDON, V536, P35, DOI 10.1111/j.1469-7793.2001.t01-1-00035.x; Borner C, 2002, MOL PHARMACOL, V61, P800, DOI 10.1124/mol.61.4.800; Braz J, 2001, J NEUROSCI, V21, P7881, DOI 10.1523/JNEUROSCI.21-20-07881.2001; Brower V, 2000, NAT BIOTECHNOL, V18, P387, DOI 10.1038/74438; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Cabot PJ, 2001, PAIN, V93, P207, DOI 10.1016/S0304-3959(01)00322-0; CHAO CC, 1993, INT J IMMUNOPHARMACO, V15, P447, DOI 10.1016/0192-0561(93)90057-6; Coggeshall RE, 1997, BRAIN RES, V764, P126, DOI 10.1016/S0006-8993(97)00446-0; Dehaven-Hudkins DL, 1999, J PHARMACOL EXP THER, V289, P494; Dionne RA, 2001, CLIN PHARMACOL THER, V70, P66, DOI 10.1067/mcp.2001.116443; Duckett JW, 1997, J UROLOGY, V157, P1407, DOI 10.1016/S0022-5347(01)65001-8; Eisenach JC, 2003, PAIN, V101, P89, DOI 10.1016/S0304-3959(02)00259-2; FERREIRA SH, 1984, EUR J PHARMACOL, V99, P23, DOI 10.1016/0014-2999(84)90428-X; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; Gold MS, 1996, NEUROSCI LETT, V212, P83, DOI 10.1016/0304-3940(96)12791-9; HASSAN AHS, 1993, NEUROSCIENCE, V55, P185, DOI 10.1016/0306-4522(93)90465-R; Honore P, 1997, PAIN, V71, P99, DOI 10.1016/S0304-3959(97)03345-9; Houghton AK, 1998, ANESTHESIOLOGY, V89, P190, DOI 10.1097/00000542-199807000-00026; INGRAM SL, 1994, NEURON, V13, P179, DOI 10.1016/0896-6273(94)90468-5; JEANJEAN AP, 1995, NEUROSCIENCE, V68, P151, DOI 10.1016/0306-4522(95)00106-S; Ji RR, 1995, J NEUROSCI, V15, P8156; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3269, DOI 10.1073/pnas.95.6.3269; Jonker JW, 1999, BRIT J PHARMACOL, V127, P43, DOI 10.1038/sj.bjp.0702497; JORIS JL, 1987, ANESTH ANALG, V66, P1277; Kalso E, 2002, PAIN, V98, P269, DOI 10.1016/S0304-3959(02)00019-2; Khodorova A, 2003, NAT MED, V9, P1055, DOI 10.1038/nm885; KHOURY GF, 1992, ANESTHESIOLOGY, V77, P263, DOI 10.1097/00000542-199208000-00007; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; Kolesnikov Y, 1999, J PHARMACOL EXP THER, V290, P247; Koppert W, 1999, ANESTH ANALG, V88, P117, DOI 10.1097/00000539-199901000-00022; Krajnik M, 1999, PAIN, V80, P121, DOI 10.1016/S0304-3959(98)00211-5; Kraus J, 2001, J BIOL CHEM, V276, P43901, DOI 10.1074/jbc.M107543200; Laird JMA, 2002, J NEUROSCI, V22, P8352; Lewanowitsch T, 2002, EUR J PHARMACOL, V445, P61, DOI 10.1016/S0014-2999(02)01715-6; Likar R, 1997, ANESTH ANALG, V84, P1313, DOI 10.1097/00000539-199706000-00025; Likar R, 2001, J PAIN SYMPTOM MANAG, V21, P330, DOI 10.1016/S0885-3924(01)00251-2; Likar R, 1999, BRIT J ANAESTH, V83, P241, DOI 10.1093/bja/83.2.241; Lu CY, 2002, GENE THER, V9, P1008, DOI 10.1038/sj.gt.3301774; Machelska H, 1999, J PHARMACOL EXP THER, V290, P354; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Machelska H, 2002, ANESTH ANALG, V95, P1002, DOI 10.1213/01.ANE.0000024213.38319.27; Machelska H, 2002, J NEUROSCI, V22, P5588; MINAMI M, 1995, MOL BRAIN RES, V30, P203, DOI 10.1016/0169-328X(94)00290-U; MOINICHE S, 1993, ACTA ANAESTH SCAND, V37, P710, DOI 10.1111/j.1399-6576.1993.tb03795.x; Mousa SA, 2000, J NEUROIMMUNOL, V108, P160, DOI 10.1016/S0165-5728(00)00284-8; Mousa SA, 2001, J NEUROIMMUNOL, V115, P71, DOI 10.1016/S0165-5728(01)00271-5; Mousa SA, 2002, J NEUROIMMUNOL, V126, P5, DOI 10.1016/S0165-5728(02)00049-8; Murphy DB, 2000, ANESTH ANALG, V90, P1122, DOI 10.1097/00000539-200005000-00023; Nozaki-Taguchi N, 1999, ANESTHESIOLOGY, V90, P225, DOI 10.1097/00000542-199901000-00029; Pan ZZ, 1998, TRENDS PHARMACOL SCI, V19, P94, DOI 10.1016/S0165-6147(98)01169-9; Pare M, 2001, J NEUROSCI, V21, P7236, DOI 10.1523/JNEUROSCI.21-18-07236.2001; PARSONS CG, 1990, PAIN, V41, P81, DOI 10.1016/0304-3959(90)91112-V; Pertovaara A, 2001, EUR J PHARMACOL, V429, P139, DOI 10.1016/S0014-2999(01)01315-2; PEYMAN GA, 1994, BRIT J OPHTHALMOL, V78, P138, DOI 10.1136/bjo.78.2.138; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; Polydefkis M, 2002, NEUROLOGY, V58, P115, DOI 10.1212/WNL.58.1.115; Poonyachoti S, 2002, CELL TISSUE RES, V307, P23, DOI 10.1007/s00441-001-0480-0; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; Reuben SS, 2001, ANESTHESIOLOGY, V95, P390, DOI 10.1097/00000542-200108000-00021; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; Rorarius M, 1999, PAIN, V79, P83, DOI 10.1016/S0304-3959(98)00157-2; Rosseland LA, 1999, ACTA ANAESTH SCAND, V43, P252, DOI 10.1034/j.1399-6576.1999.430303.x; Sandner-Kiesling A, 2002, PAIN, V96, P13, DOI 10.1016/S0304-3959(01)00398-0; Schafer M, 1996, P NATL ACAD SCI USA, V93, P6096, DOI 10.1073/pnas.93.12.6096; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Schmitt TK, 2003, ANESTHESIOLOGY, V98, P195, DOI 10.1097/00000542-200301000-00030; SCHULTESTEINBERG H, 1995, ANESTHESIOLOGY, V82, P634, DOI 10.1097/00000542-199503000-00004; SELLEY DE, 1993, MOL PHARMACOL, V44, P731; Sengupta JN, 1999, PAIN, V79, P175, DOI 10.1016/S0304-3959(98)00175-4; Shannon HE, 2002, NEUROPHARMACOLOGY, V42, P253, DOI 10.1016/S0028-3908(01)00173-3; SIMON P, 1986, NEPHROLOGIE, V5, P185; Smith EM, 2003, ADV EXP MED BIOL, V521, P51; Stein A, 1999, PAIN, V83, P525, DOI 10.1016/S0304-3959(99)00156-6; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; Stein C, 1996, J CLIN INVEST, V98, P793, DOI 10.1172/JCI118852; STEIN C, 1988, NEUROSCI LETT, V84, P225, DOI 10.1016/0304-3940(88)90412-0; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; Stein C, 2001, Z RHEUMATOL, V60, P416, DOI 10.1007/s003930170004; STEIN C, 1993, ANESTH ANALG, V76, P182; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; TADDESE A, 1995, SCIENCE, V270, P1366, DOI 10.1126/science.270.5240.1366; Taguchi A, 2001, NEW ENGL J MED, V345, P935, DOI 10.1056/NEJMoa010564; Truong W, 2003, ANN NEUROL, V53, P366, DOI 10.1002/ana.10465; Ueda H, 1999, NEUROSCI LETT, V266, P105, DOI 10.1016/S0304-3940(99)00285-2; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Walker J, 1999, PAIN, V83, P509, DOI 10.1016/S0304-3959(99)00158-X; Wenk HN, 1999, J COMP NEUROL, V408, P567, DOI 10.1002/(SICI)1096-9861(19990614)408:4<567::AID-CNE10>3.0.CO;2-Q; Wilson JL, 1998, J RHEUMATOL, V25, P499; YAKSH TL, 1988, BRAIN RES, V458, P319, DOI 10.1016/0006-8993(88)90474-X; YOUNG WS, 1980, SCIENCE, V210, P76, DOI 10.1126/science.6158097; Zhou L, 1998, J PHARMACOL EXP THER, V286, P1000; ZOLLNER C, IN PRESS MOL PHARM	103	441	457	0	42	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1003	1008		10.1038/nm908	http://dx.doi.org/10.1038/nm908			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12894165				2022-12-27	WOS:000184484900022
J	McConkey, SJ; Reece, WHH; Moorthy, VS; Webster, D; Dunachie, S; Butcher, G; Vuola, JM; Blanchard, TJ; Gothard, P; Watkins, K; Hannan, CM; Everaere, S; Brown, K; Kester, KE; Cummings, J; Williams, J; Heppner, DG; Pathan, A; Flanagan, K; Arulanantham, N; Roberts, MTM; Roy, M; Smith, GL; Schneider, J; Peto, T; Sinden, RE; Gilbert, SC; Hill, AVS				McConkey, SJ; Reece, WHH; Moorthy, VS; Webster, D; Dunachie, S; Butcher, G; Vuola, JM; Blanchard, TJ; Gothard, P; Watkins, K; Hannan, CM; Everaere, S; Brown, K; Kester, KE; Cummings, J; Williams, J; Heppner, DG; Pathan, A; Flanagan, K; Arulanantham, N; Roberts, MTM; Roy, M; Smith, GL; Schneider, J; Peto, T; Sinden, RE; Gilbert, SC; Hill, AVS			Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans	NATURE MEDICINE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; HEPATITIS-B-VIRUS; PROTECTIVE EFFICACY; IMMUNE-RESPONSES; ADOPTIVE TRANSFER; TUMOR-REGRESSION; IN-VIVO; INDUCTION; IMMUNIZATION; VACCINATION	In animals, effective immune responses against malignancies and against several infectious pathogens, including malaria, are mediated by T cells. Here we show that a heterologous prime-boost vaccination regime of DNA either intramuscularly or epidermally, followed by intradermal recombinant modified vaccinia virus Ankara (MVA), induces high frequencies of interferon (IFN)-gamma-secreting, antigen-specific T-cell responses in humans to a pre-erythrocytic malaria antigen, thrombospondin-related adhesion protein (TRAP). These responses are five-to tenfold higher than the T-cell responses induced by the DNA vaccine or recombinant MVA vaccine alone, and produce partial protection manifest as delayed parasitemia after sporozoite challenge with a different strain of Plasmodium falciparum. Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Walter Reed Army Inst Res, Malaria Vaccine Program, Silver Spring, MD 20910 USA; PowderJect Vaccines, Madison, WI 53711 USA; Oxford BioBusiness Ctr, Oxxon Pharmaccines, Oxford OX4 4SS, England	University of Oxford; Imperial College London; University of Oxford; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Hill, AVS (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.	adrian.hill@imm.ox.ac.uk	HILL, Adrian V>S>/C-1306-2008; Gilbert, Sarah C./H-2857-2019; Kester, Kent/AAF-8235-2020; Kester, Kent/A-2114-2011; McConkey, Samuel/E-7307-2012; Smith, Geoffrey L/G-2894-2012	Gilbert, Sarah C./0000-0002-6823-9750; Kester, Kent/0000-0002-5056-0802; Kester, Kent/0000-0002-5056-0802; Dunachie, Susanna/0000-0001-5665-6293; peto, tim/0000-0003-3477-8307; McConkey, Samuel/0000-0001-9085-7793; Flanagan, Katie/0000-0002-1575-1953; Smith, Geoffrey L/0000-0002-3730-9955				Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Becker C, 2001, NAT MED, V7, P1159, DOI 10.1038/nm1001-1159; BERTOLETTI A, 1991, P NATL ACAD SCI USA, V88, P10445, DOI 10.1073/pnas.88.23.10445; Boni C, 1998, J CLIN INVEST, V102, P968, DOI 10.1172/JCI3731; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHULAY JD, 1986, AM J TROP MED HYG, V35, P66, DOI 10.4269/ajtmh.1986.35.66; DAVIS JR, 1989, AM J TROP MED HYG, V40, P128, DOI 10.4269/ajtmh.1989.40.128; DAVIS JR, 1989, T ROY SOC TROP MED H, V83, P748, DOI 10.1016/0035-9203(89)90315-5; Doolan DL, 2000, J IMMUNOL, V165, P1453, DOI 10.4049/jimmunol.165.3.1453; FLANAGAN K, IN PRESS AM J TROP M; Gilbert SC, 2002, VACCINE, V20, P1039, DOI 10.1016/S0264-410X(01)00450-9; Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Gupta K, 2002, J ACQ IMMUN DEF SYND, V29, P254, DOI 10.1097/00126334-200203010-00005; Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; Hermsen CC, 2001, MOL BIOCHEM PARASIT, V118, P247, DOI 10.1016/S0166-6851(01)00379-6; HERRINGTON D, 1991, AM J TROP MED HYG, V45, P539, DOI 10.4269/ajtmh.1991.45.539; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074; Marshall E, 2000, SCIENCE, V290, P428, DOI 10.1126/science.290.5491.428; McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001; Moorthy VS, 2003, VACCINE, V21, P1995, DOI 10.1016/S0264-410X(02)00771-5; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12&lt;4345::AID-IMMU4345&gt;3.0.CO;2-P; PONNUDURAI T, 1982, T ROY SOC TROP MED H, V76, P242, DOI 10.1016/0035-9203(82)90289-9; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Robson KJH, 1998, AM J TROP MED HYG, V58, P81, DOI 10.4269/ajtmh.1998.58.81; Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9; Schneider J, 2001, VACCINE, V19, P4595, DOI 10.1016/S0264-410X(01)00260-2; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Schneider J, 1999, IMMUNOL REV, V170, P29, DOI 10.1111/j.1600-065X.1999.tb01326.x; Seki N, 2002, J IMMUNOL, V168, P3484, DOI 10.4049/jimmunol.168.7.3484; Simpson JA, 2002, PARASITOLOGY, V124, P247, DOI 10.1017/S0031182001001202; Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; Villinger F, 2002, BLOOD, V99, P590, DOI 10.1182/blood.V99.2.590; Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; Winter H, 1999, J IMMUNOL, V163, P4462; Zwaveling S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/jimmunol.169.1.350	44	474	500	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					729	735		10.1038/nm881	http://dx.doi.org/10.1038/nm881			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12766765	Bronze			2022-12-27	WOS:000183444100028
J	Otterbein, LE; Zuckerbraun, BS; Haga, M; Liu, F; Song, RP; Usheva, A; Stachulak, C; Bodyak, N; Smith, RN; Csizmadia, E; Tyagi, S; Akamatsu, Y; Flavell, RJ; Billiar, TR; Tzeng, E; Bach, FH; Choi, AMK; Soares, MP				Otterbein, LE; Zuckerbraun, BS; Haga, M; Liu, F; Song, RP; Usheva, A; Stachulak, C; Bodyak, N; Smith, RN; Csizmadia, E; Tyagi, S; Akamatsu, Y; Flavell, RJ; Billiar, TR; Tzeng, E; Bach, FH; Choi, AMK; Soares, MP			Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury	NATURE MEDICINE			English	Article							DEPENDENT KINASE INHIBITOR; MUSCLE CELL-PROLIFERATION; HEME OXYGENASE-1; PROTEIN; EXPRESSION; GROWTH; ATHEROSCLEROSIS; INDUCTION; MODEL; P21	Carbon monoxide (CO), one of the products of heme oxygenase action on heme, prevents arteriosclerotic lesions that occur following aorta transplantation; pre-exposure to 250 parts per million of CO for 1 hour before injury suppresses stenosis after carotid balloon injury in rats as well as in mice. The protective effect of CO is associated with a profound inhibition of graft leukocyte infiltration/activation as well as with inhibition of smooth muscle cell proliferation. The anti-proliferative effect of CO in vitro requires the activation of guanylate cyclase, the generation of cGMP, the activation of p38 mitogen-activated protein kinases and the expression of the cell cycle inhibitor p21(Cip1). These findings demonstrate a protective role for CO in vascular injury and support its use as a therapeutic agent.	Harvard Med Sch, Dept Surg, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Univ Pittsburgh, Sch Med, Montefiore Univ Hosp, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Surg, Montefiore Univ Hosp, Pittsburgh, PA USA; Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Inst Gulbenkian Ciencias, Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Yale University; Howard Hughes Medical Institute; Yale University; Instituto Gulbenkian de Ciencia	Bach, FH (corresponding author), Harvard Med Sch, Dept Surg, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.	fritzhbach@aol.com; choiam@msx.upmc.edu		Soares, Miguel/0000-0002-9314-4833	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057854, R29HL057854, R01HL060234, R01HL058688, R01HL067040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53458, HL5785405, R01 HL057854, HL67040, HL58688, HL60234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; COCEANI F, 1993, SCIENCE, V260, P739, DOI 10.1126/science.8484109; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; INDOLFI C, 1995, CIRCULATION, V92, P1230, DOI 10.1161/01.CIR.92.5.1230; Ishikawa K, 2001, CIRCULATION, V104, P1831, DOI 10.1161/hc3901.095897; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; LINDNER V, 1993, CIRC RES, V73, P792, DOI 10.1161/01.RES.73.5.792; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Murakami S, 2001, ATHEROSCLEROSIS, V157, P361, DOI 10.1016/S0021-9150(00)00743-7; NASEEM KM, 1997, BIOCHEM SOC T, V3, pS396; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; PLISSONNIER D, 1995, TRANSPLANTATION, V60, P414, DOI 10.1097/00007890-199509000-00003; REIDY MA, 1992, CIRCULATION, V86, P43; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yutani C, 1999, PATHOL INT, V49, P273, DOI 10.1046/j.1440-1827.1999.00861.x	41	434	472	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					183	190		10.1038/nm817	http://dx.doi.org/10.1038/nm817			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539038				2022-12-27	WOS:000180801900022
J	Lu, W; Arraes, LC; Ferreira, WT; Andrieu, JM				Lu, W; Arraes, LC; Ferreira, WT; Andrieu, JM			Therapeutic dendritic-cell vaccine for chronic HIV-1 infection	NATURE MEDICINE			English	Article							CD8(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; PBL-SCID MICE; MHC CLASS-II; HEPATITIS-C; NEUTRALIZATION SENSITIVITY; IMMUNE FUNCTION; RESPONSES; INDIVIDUALS; LYMPHOCYTES	We present the results of a preliminary investigation of the efficacy of a therapeutic dendritic cell (DC)-based vaccine for HIV-1. We immunized 18 chronically HIV-1-infected and currently untreated individuals showing stable viral loads for at least 6 months with autologous monocyte-derived DCs loaded with autologous aldrithiol-2-inactivated HIV-1. Plasma viral load levels were decreased by 80% ( median) over the first 112 d following immunization. Prolonged suppression of viral load of more than 90% was seen in 8 individuals for at least 1 year. The suppression of viral load was positively correlated with HIV-1-specifc interleukin-2 or interferon-gamma-expressing CD4(+) T cells and with HIV-1 gag - specific perforin-expressing CD8(+) effector cells, suggesting that a robust virus-specific CD4(+) T-helper type 1 (T(H)1) response is required for inducing and maintaining virus-specific CD8(+) effectors to contain HIV-1 in vivo. The results suggest that inactivated whole virus - pulsed DC vaccines could be a promising strategy for treating people with chronic HIV-1 infection.	Univ Paris 05, Inst Rech Vaccins & Immunotherapie Canc & Sida, F-75006 Paris, France; Univ Paris 05, Ctr Biomed St Peres, Fac Med Rene Descartes, Lab Oncol & Virol Mol, F-75006 Paris, France; Univ Fed Pernambuco, Inst Pesquisa Immunoterap Pernambuco, BR-50670901 Recife, PE, Brazil; Univ Fed Pernambuco, Lab Immunol Keizo Asami, BR-50670901 Recife, PE, Brazil	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universidade Federal de Pernambuco; Universidade Federal de Pernambuco	Lu, W (corresponding author), Univ Paris 05, Inst Rech Vaccins & Immunotherapie Canc & Sida, 45 Rue St Peres, F-75006 Paris, France.	louis.wei-lu@irvics.org; jean-marie.andrieu@irvics.org						Boaz MJ, 2002, J IMMUNOL, V169, P6376, DOI 10.4049/jimmunol.169.11.6376; Buseyne F, 2001, NAT MED, V7, P344, DOI 10.1038/85493; Chougnet C, 1999, J IMMUNOL, V163, P1666; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574; Frank I, 2002, J VIROL, V76, P2936, DOI 10.1128/JVI.76.6.2936-2951.2002; Goepfert PA, 2000, J VIROL, V74, P10249, DOI 10.1128/JVI.74.21.10249-10255.2000; Grassi F, 1999, AIDS, V13, P759, DOI 10.1097/00002030-199905070-00004; Gray CM, 1999, J IMMUNOL, V162, P1780; Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203; Hess C, 2004, LANCET, V363, P863, DOI 10.1016/S0140-6736(04)15735-8; Kalams SA, 1999, J VIROL, V73, P6721, DOI 10.1128/JVI.73.8.6721-6728.1999; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505; Kundu SK, 1998, AIDS RES HUM RETROV, V14, P551, DOI 10.1089/aid.1998.14.551; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; Lapenta C, 2003, J EXP MED, V198, P361, DOI 10.1084/jem.20021924; Lu W, 1999, NAT MED, V5, P1081, DOI 10.1038/12520; Lu W, 2003, NAT MED, V9, P27, DOI 10.1038/nm806; Lu W, 2001, J IMMUNOL, V167, P2929, DOI 10.4049/jimmunol.167.5.2929; Lu W, 2001, J VIROL, V75, P8949, DOI 10.1128/JVI.75.19.8949-8956.2001; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; McIlroy D, 1998, AIDS RES HUM RETROV, V14, P505, DOI 10.1089/aid.1998.14.505; Means RE, 1997, J VIROL, V71, P7895, DOI 10.1128/JVI.71.10.7895-7902.1997; MIOTTI PG, 1989, JAMA-J AM MED ASSOC, V262, P779, DOI 10.1001/jama.262.6.779; Moris A, 2004, BLOOD, V103, P2648, DOI 10.1182/blood-2003-07-2532; O'Sullivan B, 2003, CRIT REV IMMUNOL, V23, P83, DOI 10.1615/CritRevImmunol.v23.i12.50; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Pacanowski J, 2001, BLOOD, V98, P3016, DOI 10.1182/blood.V98.10.3016; Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Sapp M, 1999, IMMUNOL LETT, V66, P121, DOI 10.1016/S0165-2478(98)00169-2; Schirren CA, 2003, J HEPATOL, V39, P397, DOI 10.1016/S0168-8278(03)00266-6; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Szkaradkiewicz A, 2003, VIRUS RES, V97, P127, DOI 10.1016/j.virusres.2003.08.013; Teleshova N, 2004, J IMMUNOL, V173, P1647, DOI 10.4049/jimmunol.173.3.1647; TERPSTRA FG, 1989, EUR J IMMUNOL, V19, P667, DOI 10.1002/eji.1830190415; Ulsenheimer A, 2003, HEPATOLOGY, V37, P1189, DOI 10.1053/jhep.2003.50194; WRIN T, 1995, J VIROL, V69, P39, DOI 10.1128/JVI.69.1.39-48.1995; Yoshida A, 2003, J VIROL, V77, P8719, DOI 10.1128/JVI.77.16.8719-8728.2003; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598; Zaunders JJ, 2003, BLOOD	45	351	394	0	32	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1359	1365		10.1038/nm1147	http://dx.doi.org/10.1038/nm1147			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15568033				2022-12-27	WOS:000225500900030
J	Cheng, IH; Palop, JJ; Esposito, LA; Bien-Ly, N; Yan, FG; Mucke, L				Cheng, IH; Palop, JJ; Esposito, LA; Bien-Ly, N; Yan, FG; Mucke, L			Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; A-BETA; PRECURSOR PROTEIN; PLAQUE-FORMATION; TRANSGENIC MICE; MOUSE MODEL; DEGRADATION; APP	The Arctic mutation within the amyloid-(A) peptide causes Alzheimer disease. In vitro, Arctic-mutant A forms (proto) fibrils more effectively than wild-type A. We generated transgenic mouse lines expressing Arctic-mutant human amyloid precursor proteins (hAPP). Amyloid plaques formed faster and were more extensive in Arctic mice than in hAPP mice expressing wild-type A, even though Arctic mice had lower Abeta(1-42/1-40) ratios. Thus, the Arctic mutation is highly amyloidogenic in vivo.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Mucke, L (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA.	lmucke@gladstone.ucsf.edu	Palop, Jorge/AAH-9014-2020; Palop, Jorge J./D-8128-2011	Palop, Jorge/0000-0001-6086-1070	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011385, P01AG022074, T32AG000278, R37AG011385] Funding Source: NIH RePORTER; NIA NIH HHS [AG022074, AG11385, T32 AG00278] Funding Source: Medline; NINDS NIH HHS [NS41787] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Austen BM, 2000, J PEPT SCI, V6, P459, DOI 10.1002/1099-1387(200009)6:9<459::AID-PSC286>3.0.CO;2-B; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Herzig MC, 2004, NAT NEUROSCI, V7, P954, DOI 10.1038/nn1302; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Murakami K, 2003, J BIOL CHEM, V278, P46179, DOI 10.1074/jbc.M301874200; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Stenh C, 2002, NEUROREPORT, V13, P1857, DOI 10.1097/00001756-200210280-00005; Tsubuki S, 2003, LANCET, V361, P1957, DOI 10.1016/S0140-6736(03)13555-6	15	103	105	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1190	1192		10.1038/nm1123	http://dx.doi.org/10.1038/nm1123			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502844				2022-12-27	WOS:000224785900039
J	Temmerman, S; Pethe, K; Parra, M; Alonso, S; Rouanet, C; Pickett, T; Drowart, A; Debrie, AS; Delogu, G; Menozzi, FD; Sergheraert, C; Brennan, MJ; Mascart, F; Locht, C				Temmerman, S; Pethe, K; Parra, M; Alonso, S; Rouanet, C; Pickett, T; Drowart, A; Debrie, AS; Delogu, G; Menozzi, FD; Sergheraert, C; Brennan, MJ; Mascart, F; Locht, C			Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin	NATURE MEDICINE			English	Article							ADHESIN; IMMUNOGENICITY; IDENTIFICATION; VACCINATION; RESPONSES	Although post-translational modifications of protein antigens may be important componenets of some B cell epitopes, the determinants of T cell immunity are generally nonmodified peptides. Here we show that methylation of the Mycobacterium tuberculosis heparin-binding hemagglutinin ( HBHA) by the bacterium is essential for effective T cell immunity to this antigen in infected healthy humans and in mice. Methylated HBHA provides high levels of protection against M. tuberculosis challenge in mice, whereas nonmethylated HBHA does not. Protective immunity induced by methylated HBHA is comparable to that afforded by vaccination with bacille Calmette et GuErin, the only available anti-tuberculosis vaccine. Thus, post-translational modifications of proteins may be crucial for their ability to induce protective T cell-mediated immunity against infectious diseases such as tuberculosis.	Inst Pasteur, INSERM, U629, F-59019 Lille, France; Free Univ Brussels, Hop Erasme, Immunol Lab, B-1070 Brussels, Belgium; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Brugmann Univ Hosp, Dept Internal Med, B-1020 Brussels, Belgium; Univ Lille 2, Inst Pasteur, CNRS, UMR8525,IBL, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite Libre de Bruxelles; Vrije Universiteit Brussel; US Food & Drug Administration (FDA); Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Locht, C (corresponding author), Inst Pasteur, INSERM, U629, 1 Rue Prof Calmette, F-59019 Lille, France.	camille.locht@pasteur-lille.fr	Delogu, Giovanni/I-3701-2012; Pethe, Kevin/L-1199-2013; Pethe, Kevin/D-4505-2011; Locht, Camille/L-3516-2018; Pethe, Kevin/F-9495-2015	Delogu, Giovanni/0000-0003-0182-8267; Pethe, Kevin/0000-0003-0297-0150; Pethe, Kevin/0000-0003-0916-8873; Rouanet, Carine/0000-0001-9105-1855; Debrie, Anne-Sophie/0000-0003-0570-4413				Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000; Chan WC, 2000, FMOC SOLID PHASE PEP; Chun T, 2001, J EXP MED, V193, P1213, DOI 10.1084/jem.193.10.1213; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Delogu G, 1999, J BACTERIOL, V181, P7464, DOI 10.1128/JB.181.24.7464-7469.1999; Delogu G, 2001, INFECT IMMUN, V69, P5606, DOI 10.1128/IAI.69.9.5606-5611.2001; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Hovav AH, 2003, INFECT IMMUN, V71, P3146, DOI 10.1128/IAI.71.6.3146-3154.2003; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Lenz LL, 1996, IMMUNITY, V5, P63, DOI 10.1016/S1074-7613(00)80310-6; Li ZM, 1999, INFECT IMMUN, V67, P4780, DOI 10.1128/IAI.67.9.4780-4786.1999; Masungi C, 2002, J INFECT DIS, V185, P513, DOI 10.1086/338833; Menozzi FD, 1996, J EXP MED, V184, P993, DOI 10.1084/jem.184.3.993; Menozzi FD, 1998, P NATL ACAD SCI USA, V95, P12625, DOI 10.1073/pnas.95.21.12625; Pethe K, 2002, P NATL ACAD SCI USA, V99, P10759, DOI 10.1073/pnas.162246899; Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083; Pethe K, 2001, MOL MICROBIOL, V39, P89, DOI 10.1046/j.1365-2958.2001.02206.x; Pethe K, 2000, J BIOL CHEM, V275, P14273, DOI 10.1074/jbc.275.19.14273; Reddy VM, 2000, J INFECT DIS, V181, P1189, DOI 10.1086/315327; Schlienger K, 2000, BLOOD, V96, P3490; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233	24	113	123	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					935	941		10.1038/nm1090	http://dx.doi.org/10.1038/nm1090			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15300244	Bronze			2022-12-27	WOS:000223658400030
J	Jimi, E; Aoki, K; Saito, H; D'Acquisto, F; May, MJ; Nakamura, I; Sudo, T; Kojima, T; Okamoto, F; Fukushima, H; Okabe, K; Ohya, K; Ghosh, S				Jimi, E; Aoki, K; Saito, H; D'Acquisto, F; May, MJ; Nakamura, I; Sudo, T; Kojima, T; Okamoto, F; Fukushima, H; Okabe, K; Ohya, K; Ghosh, S			Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo	NATURE MEDICINE			English	Article							RECEPTOR ACTIVATOR; KINASE INHIBITOR; TNF-ALPHA; RANK; DIFFERENTIATION; PEPTIDE; NEMO; MECHANISMS; ARTHRITIS; LIGAND	Bone destruction is a pathological hallmark of several chronic inflammatory diseases, including rheumatoid arthritis and periodontitis. Inflammation-induced bone loss of this sort results from elevated numbers of bone-resorbing osteoclasts. Gene targeting studies have shown that the transcription factor nuclear factor-kappaB (NF-kappaB) has a crucial role in osteoclast differentiation, and blocking NF-kappaB is a potential strategy for preventing inflammatory bone resorption. We tested this approach using a cell-permeable peptide inhibitor of the IkappaB-kinase complex, a crucial component of signal transduction pathways to NF-kappaB. The peptide inhibited RANKL-stimulated NF-kappaB activation and osteoclastogenesis both in vitro and in vivo. In addition, this peptide significantly reduced the severity of collagen-induced arthritis in mice by reducing levels of tumor necrosis factor-alpha and interleukin-1beta, abrogating joint swelling and reducing destruction of bone and cartilage. Therefore, selective inhibition of NF-kappaB activation offers an effective therapeutic approach for inhibiting chronic inflammatory diseases involving bone resorption.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Tokyo Med & Dent Univ, Grad Sch, Dept Hard Tissue Engn, Pharmacol Sect, Tokyo 1138549, Japan; Yugawara Kosei Nenkin Hosp, Dept Orthoped Surg, Kanagawa 2590314, Japan; Toray Industries Ltd, Basic Res Labs, Kamakura, Kanagawa 2480036, Japan; Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sect Cellular Physiol, Fukuoka 8140193, Japan	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Tokyo Medical & Dental University (TMDU); Toray Industries, Inc.; Fukuoka Dental College (FDC)	Ghosh, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	sankar.ghosh@yale.edu	AOKI, Kazuhiro/GRO-6475-2022; D'Acquisto, Fulvio/E-7204-2018	AOKI, Kazuhiro/0000-0001-6643-6315; D'Acquisto, Fulvio/0000-0002-4513-1608; May, Michael/0000-0002-2485-3716; Saito, Hiroaki/0000-0002-8130-0624	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R37-AI33443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; BAROUKH B, 1991, J PERIODONTAL RES, V26, P161, DOI 10.1111/j.1600-0765.1991.tb01640.x; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Choi M, 2003, BLOOD, V102, P2259, DOI 10.1182/blood-2002-09-2960; Cuzzocrea S, 2002, BRIT J PHARMACOL, V135, P496, DOI 10.1038/sj.bjp.0704463; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Feldmann M, 2002, ANN RHEUM DIS, V61, P13; Feldmann M, 2001, CURR DIRECT AUTOIMMU, V3, P188; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HOROWITZ SM, 1995, CALCIFIED TISSUE INT, V57, P301, DOI 10.1007/BF00298886; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2002, ANN RHEUM DIS, V61, P82; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Luross JA, 2001, IMMUNOLOGY, V103, P407, DOI 10.1046/j.1365-2567.2001.01267.x; Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300; Manolagas SC, 1998, AGING-CLIN EXP RES, V10, P182, DOI 10.1007/BF03339652; Mauri C, 1996, EUR J IMMUNOL, V26, P1511, DOI 10.1002/eji.1830260716; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756-3282(99)00020-4; Myers LK, 1997, LIFE SCI, V61, P1861, DOI 10.1016/S0024-3205(97)00480-3; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281-200305000-00016; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Rehman KK, 2003, J BIOL CHEM, V278, P9862, DOI 10.1074/jbc.M207700200; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Seetharaman R, 1999, J IMMUNOL, V163, P1577; Takayanagi H, 1999, J CLIN INVEST, V104, P137, DOI 10.1172/JCI6093; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471-4914(02)02340-7; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521	42	423	457	8	72	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					617	624		10.1038/nm1054	http://dx.doi.org/10.1038/nm1054			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15156202				2022-12-27	WOS:000221759600027
J	Figdor, CG; de Vries, IJM; Lesterhuis, WJ; Melief, CJM				Figdor, CG; de Vries, IJM; Lesterhuis, WJ; Melief, CJM			Dendritic cell immunotherapy: mapping the way	NATURE MEDICINE			English	Article							T-CELLS; MELANOMA PATIENTS; METASTATIC MELANOMA; IN-VIVO; ANTIGEN; VACCINATION; IMMUNE; GENERATION; MATURATION; RESPONSES	Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system, with the potential to either stimulate or inhibit immune responses. Exploiting the immune-regulatory capacities of dendritic cells holds great promise for the treatment of cancer, autoimmune diseases and the prevention of transplant rejection. Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.	Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Leiden, Dept Immunohematol & Blood Transfus, NL-2300 RA Leiden, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC)	Figdor, CG (corresponding author), Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	c.figdor@ncmls.kun.nl	Liu, Xia/L-9425-2013; de Vries, Jolanda I.J.M./F-5563-2010; Figdor, Carl G/A-4232-2010	de Vries, Jolanda I.J.M./0000-0002-8653-4040; Figdor, Carl G/0000-0002-2366-9212; Lesterhuis, Willem Joost/0000-0002-2718-276X				Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; Banchereau J, 2001, CANCER RES, V61, P6451; Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2; BERNHARD H, 1995, CANCER RES, V55, P1099; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Bostanci A, 2002, SCIENCE, V298, P1531; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Cerundolo V, 2004, NAT IMMUNOL, V5, P7, DOI 10.1038/ni0104-7; de Vries IJM, 2003, CANCER RES, V63, P12; de Vries IJM, 2003, CLIN CANCER RES, V9, P5091; Dhodapkar MV, 2000, J CLIN INVEST, V105, pR9, DOI 10.1172/JCI9051; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; Engering A, 2002, TRENDS IMMUNOL, V23, P480, DOI 10.1016/S1471-4906(02)02296-2; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Garg S, 2003, NAT IMMUNOL, V4, P907, DOI 10.1038/ni962; Geiger JD, 2001, CANCER RES, V61, P8513; Gilboa E, 1998, CANCER IMMUNOL IMMUN, V46, P82, DOI 10.1007/s002620050465; Heiser A, 2002, J CLIN INVEST, V109, P409, DOI 10.1172/JCI14364; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Jonuleit H, 2001, INT J CANCER, V93, P243, DOI 10.1002/ijc.1323; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Mackensen A, 2000, INT J CANCER, V86, P385, DOI 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T; Mackensen A, 2000, CANCER IMMUNOL IMMUN, V49, P152, DOI 10.1007/s002620050614; Maraskovsky E, 2000, BLOOD, V96, P878, DOI 10.1182/blood.V96.3.878.015k15_878_884; Martin E, 2003, IMMUNITY, V18, P155, DOI 10.1016/S1074-7613(02)00503-4; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Melief CJM, 2002, IMMUNOL REV, V188, P177, DOI 10.1034/j.1600-065X.2002.18816.x; Miller MJ, 2004, P NATL ACAD SCI USA, V101, P998, DOI 10.1073/pnas.0306407101; Mullins DW, 2003, J EXP MED, V198, P1023, DOI 10.1084/jem.20021348; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Nestle FO, 2001, NAT MED, V7, P761, DOI 10.1038/89863; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Pulendran B, 2000, J IMMUNOL, V165, P566, DOI 10.4049/jimmunol.165.1.566; Ratzinger G, 2002, J IMMUNOL, V168, P4361, DOI 10.4049/jimmunol.168.9.4361; Rea D, 2000, BLOOD, V95, P3162, DOI 10.1182/blood.V95.10.3162.010k18_3162_3167; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Salio M, 2003, EUR J IMMUNOL, V33, P1052, DOI 10.1002/eji.200323676; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schuler-Thurner B, 2002, J EXP MED, V195, P1279, DOI 10.1084/jem.20012100; Steinman RM, 2002, J CLIN INVEST, V109, P1519, DOI 10.1172/JCI200215962; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4	48	788	865	1	91	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					475	480		10.1038/nm1039	http://dx.doi.org/10.1038/nm1039			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15122249				2022-12-27	WOS:000221242400023
J	Nabel, GJ				Nabel, GJ			Genetic, cellular and immune approaches to disease therapy: past and future	NATURE MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CHRONIC LYMPHOCYTIC-LEUKEMIA; T-CELL; RHEUMATOID-ARTHRITIS; DNA VACCINES; ENVELOPE GLYCOPROTEIN; MONOCLONAL-ANTIBODY; VIRUS-INFECTION; STEM-CELLS; FACTOR-IX	Advances in immunology and molecular genetics have accelerated our understanding of the genetic and cellular basis of many diseases. At the same time, remarkable progress in recombinant DNA technology has enabled the development of molecular and cellular treatments for infectious diseases, inherited disorders and cancer. This Perspective is intended to give a sample of the progress over the past ten years in cellular, genetic and immune therapy of disease. During this time, monoclonal antibody technology and cellular transplantation have begun to come of age in biomedicine. Innovations in gene delivery have not only catalyzed the nascent field of human gene therapy, but may also ultimately impact human health by advancing recombinant vaccine technology.	NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Nabel, GJ (corresponding author), NIAID, Vaccine Res Ctr, NIH, Bldg 40,Room 4502,MSC-3005,40 Convent Dr, Bethesda, MD 20892 USA.	gnabel@nih.gov						Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bain B, 2003, NAT REV DRUG DISCOV, V2, P693, DOI 10.1038/nrd1182; Becker SI, 1998, INFECT IMMUN, V66, P3457, DOI 10.1128/IAI.66.7.3457-3461.1998; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Davidson MH, 2003, ATHEROSCLEROSIS, V169, P113, DOI 10.1016/S0021-9150(03)00137-0; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Erin E. M., 2002, Current Drug Targets - Inflammation and Allergy, V1, P201, DOI 10.2174/1568010023344715; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Gardner MJ, 1996, J PHARM SCI-US, V85, P1294, DOI 10.1021/js960147h; Greenberg PD, 1998, CANCER J SCI AM, V4, pS100; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Heslop HE, 1999, J CLIN APHERESIS, V14, P154, DOI 10.1002/(SICI)1098-1101(1999)14:3<154::AID-JCA9>3.0.CO;2-K; Heslop HE, 2002, CYTOTHERAPY, V4, P433, DOI 10.1080/146532402320776071; High KA, 2003, SEMIN THROMB HEMOST, V29, P107, DOI 10.1055/s-2003-37945; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KREITMAN RJ, 1992, BLOOD, V80, P2344; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V90, P13, DOI 10.1016/S1081-1206(10)61654-7; Leinwand LA, 2003, CELL, V114, P658, DOI 10.1016/S0092-8674(03)00718-9; Lin TS, 2003, SEMIN ONCOL, V30, P483, DOI 10.1016/S0093-7754(03)00239-2; Lodmell DL, 1998, NAT MED, V4, P949, DOI 10.1038/nm0898-949; Manickan E, 1995, VIRAL IMMUNOL, V8, P53, DOI 10.1089/vim.1995.8.53; MARTINS LP, 1995, J VIROL, V69, P2574, DOI 10.1128/JVI.69.4.2574-2582.1995; Matthews JB, 2003, AM J TRANSPLANT, V3, P794, DOI 10.1046/j.1600-6135.2003.0154.x; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mullen CA, 1996, HUM GENE THER, V7, P1123, DOI 10.1089/hum.1996.7.9-1123; Nabel GJ, 2003, E SCHERING RES FDN W, V43, P1; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Oldstone M.B.A., 1998, VIRUSES PLAGUES HIST; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Ranga U, 1998, P NATL ACAD SCI USA, V95, P1201, DOI 10.1073/pnas.95.3.1201; Rappuoli R, 2001, Curr Opin Investig Drugs, V2, P45; Riddell S R, 1995, Cancer Treat Res, V76, P337; Riddell SR, 1997, REV MED VIROL, V7, P181, DOI 10.1002/(SICI)1099-1654(199709)7:3<181::AID-RMV200>3.0.CO;2-W; Rittershaus CW, 2000, ARTERIOSCL THROM VAS, V20, P2106, DOI 10.1161/01.ATV.20.9.2106; Rooney CM, 2001, CURR TOP MICROBIOL, V258, P221; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; Scheinfeld Noah, 2003, J Drugs Dermatol, V2, P375; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SMITH GP, 1994, NATURE, V370, P324, DOI 10.1038/370324a0; Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Tang QZ, 2003, J IMMUNOL, V171, P3348, DOI 10.4049/jimmunol.171.7.3348; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; Titus T, 2000, Expert Rev Mol Med, V2, P1, DOI 10.1017/S1462399400001861; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tomita S, 2002, J THORAC CARDIOV SUR, V123, P1132, DOI 10.1067/mtc.2002.120716; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Waldmann TA, 2000, ANN ONCOL, V11, P101, DOI 10.1023/A:1008324701986; Wang LL, 2000, MOL THER, V1, P154, DOI 10.1006/mthe.2000.0031; Weinberg Jeffrey M, 2002, J Drugs Dermatol, V1, P303; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; Woffendin C, 1996, P NATL ACAD SCI USA, V93, P2889, DOI 10.1073/pnas.93.7.2889; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; YOKOYAMA M, 1995, J VIROL, V69, P2684, DOI 10.1128/JVI.69.4.2684-2688.1995; Zelenetz AD, 2003, SEMIN ONCOL, V30, P22, DOI 10.1053/sonc.2003.23803	69	59	61	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					135	141		10.1038/nm990	http://dx.doi.org/10.1038/nm990			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14760423	Green Published			2022-12-27	WOS:000188719600030
J	Kirvan, CA; Swedo, SE; Heuser, JS; Cunningham, MW				Kirvan, CA; Swedo, SE; Heuser, JS; Cunningham, MW			Mimicry and auto antibody-mediated neuronal cell signaling in Sydenham chorea	NATURE MEDICINE			English	Article							GUILLAIN-BARRE-SYNDROME; STREPTOCOCCAL-M-PROTEINS; BETA-D-GLUCOSAMINE; KINASE-II; MONOCLONAL-ANTIBODIES; RHEUMATIC CARDITIS; GANGLIOSIDES; RECOGNIZES; LIPOPOLYSACCHARIDES; LYSOSPHINGOLIPIDS	Streptococcus pyogenes-induced acute rheumatic fever (ARF) is one of the best examples of postinfectious autoimmunity due to molecular mimicry between host and pathogen. Sydenham chorea is the major neurological manifestation of ARF but its pathogenesis has remained elusive, with no candidate autoantigen or mechanism of pathogenesis described. Chorea monoclonal antibodies showed specificity for mammalian lysoganglioside and N-acetyl-beta-D-glucosamine (GlcNAc), the dominant epitope of the group A streptococcal (GAS) carbohydrate. Chorea antibodies targeted the surface of human neuronal cells, with specific induction of calcium/calmodulin-dependent protein (CaM) kinase II activity by monoclonal antibody 24.3.1 and sera from active chorea. Convalescent sera and sera from other streptococcal diseases in the absence of chorea did not activate the kinase. The new evidence implicates anti body-mediated neuronal cell signaling in the immunopathogenesis of Sydenham chorea and will lead to a better understanding of other antibody-mediated neurological disorders.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; NIMH, Pediat & Dev Neuropsychiat Branch, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Cunningham, MW (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA.	madeleine-cunningham@ouhsc.edu		Cunningham, Madeleine/0000-0001-8122-728X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035280, R37HL035280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002666] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35280] Funding Source: Medline; NIAID NIH HHS [T32 AI007633, 1T32-AI07633-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ang CW, 2001, INFECT IMMUN, V69, P2462, DOI 10.1128/IAI.69.4.2462-2469.2001; Antone SM, 1997, J IMMUNOL, V159, P5422; BRONZE MS, 1993, J IMMUNOL, V151, P2820; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Cunningham MW, 2000, EFFECTS OF MICROBES ON THE IMMUNE SYSTEM, P123; Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132; Galvin JE, 2002, AM J PATHOL, V160, P297, DOI 10.1016/S0002-9440(10)64373-8; Giedd JN, 1995, NEUROLOGY, V45, P2199, DOI 10.1212/WNL.45.12.2199; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HUSBY G, 1976, J EXP MED, V144, P1094, DOI 10.1084/jem.144.4.1094; ISHIDA A, 1995, J BIOL CHEM, V270, P2163, DOI 10.1074/jbc.270.5.2163; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Kantor L, 1999, J NEUROSCI, V19, P3801; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Kotani M, 1997, BRAIN RES PROTOC, V1, P152, DOI 10.1016/S1385-299X(96)00025-6; Marques-Dias MJ, 1997, PSYCHIAT CLIN N AM, V20, P809, DOI 10.1016/S0193-953X(05)70346-4; NAUSIEDA PA, 1983, NEUROLOGY, V33, P750, DOI 10.1212/WNL.33.6.750; O'Hanlon GM, 2001, BRAIN, V124, P893, DOI 10.1093/brain/124.5.893; Paparounas K, 1999, BRAIN, V122, P807, DOI 10.1093/brain/122.5.807; Peterson BS, 2000, ARCH GEN PSYCHIAT, V57, P364, DOI 10.1001/archpsyc.57.4.364; Quattrini A, 2001, J NEUROIMMUNOL, V114, P213, DOI 10.1016/S0165-5728(00)00452-5; Quinn A, 2001, INFECT IMMUN, V69, P4072, DOI 10.1128/IAI.69.6.4072-4078.2001; Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076; Schulman H, 1995, PROG BRAIN RES, V105, P95; SHIKHMAN AR, 1993, J IMMUNOL, V151, P3902; SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375; SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Stollerman GH, 2001, CLIN INFECT DIS, V33, P806, DOI 10.1086/322665; Sueyoshi N, 2001, J LIPID RES, V42, P1197; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; SWEDO SE, 1989, AM J PSYCHIAT, V146, P246; SWEDO SE, 1994, JAMA-J AM MED ASSOC, V272, P1788, DOI 10.1001/jama.272.22.1788; SWEDO SE, 1993, PEDIATRICS, V91, P706; Takigawa T, 2000, INTERNAL MED, V39, P123, DOI 10.2169/internalmedicine.39.123; TARANTA A, 1959, NEW ENGL J MED, V260, P1204, DOI 10.1056/NEJM195906112602402; TARANTA A, 1956, AM J MED, V20, P170, DOI 10.1016/0002-9343(56)90186-3; VEASY LG, 1994, J PEDIATR-US, V124, P9, DOI 10.1016/S0022-3476(94)70247-0; Weber F, 2000, MUSCLE NERVE, V23, P1414, DOI 10.1002/1097-4598(200009)23:9<1414::AID-MUS13>3.0.CO;2-0; WENG NP, 1992, J IMMUNOL, V149, P2518; Yuki N, 1997, J INFECT DIS, V176, pS150, DOI 10.1086/513800; Zhao WQ, 1999, J NEUROSCI RES, V55, P557, DOI 10.1002/(SICI)1097-4547(19990301)55:5<557::AID-JNR3>3.3.CO;2-G	44	292	300	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					914	920		10.1038/nm892	http://dx.doi.org/10.1038/nm892			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12819778				2022-12-27	WOS:000183979300033
J	Katsuno, M; Adachi, H; Doyu, M; Minamiyama, M; Sang, C; Kobayashi, Y; Inukai, A; Sobue, G				Katsuno, M; Adachi, H; Doyu, M; Minamiyama, M; Sang, C; Kobayashi, Y; Inukai, A; Sobue, G			Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy	NATURE MEDICINE			English	Article							RECESSIVE BULBOSPINAL NEURONOPATHY; ANDROGEN RECEPTOR PROTEIN; HUNTINGTONS-DISEASE; CAG-REPEAT; HETEROZYGOUS FEMALES; NUCLEAR INCLUSIONS; EXPRESSION; NEURODEGENERATION; NEUROPATHOLOGY; DYSFUNCTION	Spinal and bulbar muscular atrophy (SBMA) is an adult-onset motor neuron disease that affects males. It is caused by the expansion of a polyglutamine (polyQ) tract in androgen receptors. Female carriers are usually asymptomatic. No specific treatment has been established. Our transgenic mouse model carrying a full-length human androgen receptor with expanded polyQ has considerable gender-related motor impairment. This phenotype was abrogated by castration, which prevented nuclear translocation of mutant androgen receptors. We examined the effect of androgen-blockade drugs on our mouse model. Leuprorelin, a lutenizing hormone-releasing hormone (LHRH) agonist that reduces testosterone release from the testis, rescued motor dysfunction and nuclear accumulation of mutant androgen receptors in male transgenic mice. Moreover, leuprorelin treatment reversed the behavioral and histopathological phenotypes that were once caused by transient increases in serum testosterone. Flutamide, an androgen antagonist promoting nuclear translocation of androgen receptors, yielded no therapeutic effect. Leuprorelin thus seems to be a promising candidate for the treatment of SBMA.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp	Adachi, Hiroaki/AAM-7812-2020; KATSUNO, MASAHISA/I-7502-2014	Adachi, Hiroaki/0000-0002-9302-4663; KATSUNO, MASAHISA/0000-0001-9453-9311				Adachi H, 2003, J NEUROSCI, V23, P2203; Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; DOYU M, 1992, ANN NEUROL, V32, P707, DOI 10.1002/ana.410320517; Fischbeck KH, 1999, PHILOS T R SOC B, V354, P1075, DOI 10.1098/rstb.1999.0461; Gottlieb B, 1999, AM J MED GENET, V89, P210, DOI 10.1002/(SICI)1096-8628(19991229)89:4<210::AID-AJMG5>3.0.CO;2-P; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Huggins C, 1941, CANCER RES, V1, P293; IGARASHI S, 1992, NEUROLOGY, V42, P2300, DOI 10.1212/WNL.42.12.2300; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kemppainen JA, 1996, UROLOGY, V48, P157, DOI 10.1016/S0090-4295(96)00117-3; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kobayashi Y, 1998, BIOCHEM BIOPH RES CO, V252, P145, DOI 10.1006/bbrc.1998.9624; LABRIE F, 1993, CANCER-AM CANCER SOC, V72, P3816, DOI 10.1002/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Lieberman AP, 2002, HUM MOL GENET, V11, P1967, DOI 10.1093/hmg/11.17.1967; Lu SF, 1999, J NEUROBIOL, V41, P505, DOI 10.1002/(SICI)1097-4695(199912)41:4<505::AID-NEU6>3.0.CO;2-N; Luo SQ, 1997, UROLOGY, V50, P913, DOI 10.1016/S0090-4295(97)00393-2; MACLEAN HE, 1995, MOL CELL ENDOCRINOL, V112, P133, DOI 10.1016/0303-7207(95)03608-A; Mariotti C, 2000, NEUROMUSCULAR DISORD, V10, P391, DOI 10.1016/S0960-8966(99)00132-7; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Schmidt BJ, 2002, NEUROLOGY, V59, P770, DOI 10.1212/WNL.59.5.770; SOBUE G, 1993, J NEUROL SCI, V117, P74, DOI 10.1016/0022-510X(93)90157-T; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Tanaka F, 1996, HUM MOL GENET, V5, P1253, DOI 10.1093/hmg/5.9.1253; Taylor JP, 2002, TRENDS MOL MED, V8, P195, DOI 10.1016/S1471-4914(02)02332-8; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Walcott JL, 2002, J BIOL CHEM, V277, P50855, DOI 10.1074/jbc.M209466200; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	39	211	231	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					768	773		10.1038/nm878	http://dx.doi.org/10.1038/nm878			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12754502				2022-12-27	WOS:000183444100034
J	Gaide, O; Schneider, P				Gaide, O; Schneider, P			Permanent correction of an inherited ectodermal dysplasia with recombinant EDA	NATURE MEDICINE			English	Article							ECTODYSPLASIN-A; HAIR-FOLLICLES; TABBY MICE; GENE; MUTATIONS; MOUSE; MORPHOGENESIS; HOMOLOG; REVEALS; LIGANDS	X-linked hypohidrotic ectodermal dysplasia (XLHED; OMIM 305100) is a genetic disorder characterized by absence or deficient function of hair, teeth and sweat glands(1). Affected children may experience life-threatening high fever resulting from reduced ability to sweat(2). Mice with the Tabby phenotype share many symptoms with human XLHED patients because both phenotypes are caused by mutations of the syntenic ectodysplasin A gene (Eda) on the X chromosome(3,4). Two main splice variants of Eda, encoding EDA1 and EDA2, engage the tumor necrosis factor (TNF) family receptors EDAR and XEDAR, respectively(5). The EDA1 protein, acting through EDAR, is essential for proper formation of skin appendages; the functions of EDA2 and XEDAR are not known. EDA1 must be proteolytically processed to a soluble form to be active(6-9). Here, we show that treatment of pregnant Tabby mice with a recombinant form of EDA1, engineered to cross the placental barrier, permanently rescues the Tabby phenotype in the offspring. Notably, sweat glands can also be induced by EDA1 after birth. This is the first example of a developmental genetic defect that can be permanently corrected by short-term treatment with a recombinant protein.	Univ Lausanne, Inst Biochem, BIL, Biomed Res Ctr, CH-1066 Epalinges, Switzerland	University of Lausanne	Schneider, P (corresponding author), Univ Lausanne, Inst Biochem, BIL, Biomed Res Ctr, CH-1066 Epalinges, Switzerland.	pascal.schneider@ib.unil.ch		Schneider, Pascal/0000-0003-0677-9409				CLARKE A, 1987, ARCH DIS CHILD, V62, P989, DOI 10.1136/adc.62.10.989; Colcher D, 1998, Q J NUCL MED, V42, P225; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Ersch J, 1999, OBSTET GYNECOL, V94, P753, DOI 10.1016/S0029-7844(99)00379-8; Headon DJ, 2001, NATURE, V414, P913, DOI 10.1038/414913a; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Jauniaux E, 1995, HUM REPROD, V10, P3297, DOI 10.1093/oxfordjournals.humrep.a135906; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Kristenova-Cermakova P, 2002, CONNECT TISSUE RES, V43, P283, DOI 10.1080/03008200290000727; Laurikkala J, 2002, DEVELOPMENT, V129, P2541; Lesot H, 1996, INT J DEV BIOL, V40, P1017; Monreal AW, 1998, AM J HUM GENET, V63, P380, DOI 10.1086/301984; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Montonen O, 1998, J HISTOCHEM CYTOCHEM, V46, P281, DOI 10.1177/002215549804600301; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; PINHEIRO M, 1994, AM J MED GENET, V53, P153, DOI 10.1002/ajmg.1320530207; Rennert PD, 1997, INT IMMUNOL, V9, P1627, DOI 10.1093/intimm/9.11.1627; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Schneider P, 2000, METHOD ENZYMOL, V322, P325; Schneider P, 2001, J BIOL CHEM, V276, P18819, DOI 10.1074/jbc.M101280200; Srivastava AK, 2001, HUM MOL GENET, V10, P2973, DOI 10.1093/hmg/10.26.2973; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; THESLEFF I, 2002, SCI STKE, V131; Tucker AS, 2000, DEVELOPMENT, V127, P4691; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	25	151	160	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					614	618		10.1038/nm861	http://dx.doi.org/10.1038/nm861			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692542	Green Published			2022-12-27	WOS:000182610600044
J	De Rosa, SC; Brenchley, JM; Roederer, M				De Rosa, Stephen C.; Brenchley, Jason M.; Roederer, Mario			Beyond six colors: A new era in flow cytometry	NATURE MEDICINE			English	Article							ANTIGEN-BINDING CELLS; RESPONSES IN-VIVO; CD8(+) T-CELLS; 2 SUBSETS; MEMORY; LYMPHOCYTES; IDENTIFICATION; FLUORESCENCE; SEPARATION; AFFINITY	More than 100 functionally distinct populations of lymphocytes can be identified in the peripheral blood of humans; each of these cell types undoubtedly has a unique role in the organization and effectiveness of an immune response. To distinguish specifically among these cells, however, it is necessary to measure simultaneously at least six to eight different T-cell surface antigens; additional functional correlations require even greater detection capability. For this purpose, flow cytometers capable of independently detecting as many as 12 different molecules now exist. Here we review the history and applications of this technology and discuss future directions.	[De Rosa, Stephen C.; Brenchley, Jason M.; Roederer, Mario] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Roederer, M (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	roederer@nih.gov	Roederer, Mario/G-1887-2011; Brenchley, Jason/AAC-5085-2019	Brenchley, Jason/0000-0001-8357-2984	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005020, ZIAAI005020] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Crowley MP, 2000, SCIENCE, V287, P314, DOI 10.1126/science.287.5451.314; De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hamann D, 1999, INT IMMUNOL, V11, P1027, DOI 10.1093/intimm/11.7.1027; HULETT HR, 1969, SCIENCE, V166, P747, DOI 10.1126/science.166.3906.747; JULIUS MH, 1974, J EXP MED, V140, P904, DOI 10.1084/jem.140.4.904; JULIUS MH, 1972, P NATL ACAD SCI USA, V69, P1934, DOI 10.1073/pnas.69.7.1934; Kern F, 1998, NAT MED, V4, P975, DOI 10.1038/nm0898-975; Kimmig S, 2002, J EXP MED, V195, P789, DOI 10.1084/jem.20011756; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Lu LS, 2002, P NATL ACAD SCI USA, V99, P3007, DOI 10.1073/pnas.052715399; Mitra DK, 1999, INT IMMUNOL, V11, P1801, DOI 10.1093/intimm/11.11.1801; Mueller YM, 2001, IMMUNITY, V15, P871, DOI 10.1016/S1074-7613(01)00246-1; Perez OD, 2002, NAT BIOTECHNOL, V20, P155, DOI 10.1038/nbt0202-155; PICKER LJ, 1993, J IMMUNOL, V150, P1105; Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; Roederer M, 2001, CYTOMETRY, V45, P47, DOI 10.1002/1097-0320(20010901)45:1<47::AID-CYTO1143>3.0.CO;2-A; Roederer M, 2001, CYTOMETRY, V45, P56, DOI 10.1002/1097-0320(20010901)45:1<56::AID-CYTO1144>3.0.CO;2-9; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Shih TAY, 2002, NAT IMMUNOL, V3, P570, DOI 10.1038/ni803; Shih TAY, 2002, NAT IMMUNOL, V3, P399, DOI 10.1038/ni776; Unsoeld H, 2002, J IMMUNOL, V169, P638, DOI 10.4049/jimmunol.169.2.638; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Watanabe N, 1997, BLOOD, V90, P3662, DOI 10.1182/blood.V90.9.3662	28	148	155	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					112	117		10.1038/nm0103-112	http://dx.doi.org/10.1038/nm0103-112			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514723				2022-12-27	WOS:000208640400005
J	Carro, E; Trejo, JL; Gomez-Isla, T; LeRoith, D; Torres-Aleman, I				Carro, E; Trejo, JL; Gomez-Isla, T; LeRoith, D; Torres-Aleman, I			Serum insulin-like growth factor I regulates brain amyloid-levels	NATURE MEDICINE			English	Article							CHOROID-PLEXUS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; BETA-PEPTIDE; CEREBROSPINAL-FLUID; BINDING-PROTEINS; MESSENGER-RNA; RECEPTOR; PLASMA; NEURODEGENERATION	Levels of insulin-like growth factor I (IGF-I), a neuroprotective hormone, decrease in serum during aging, whereas amyloid-beta(Abeta), which is involved in the pathogenesis of Alzheimer disease, accumulates in the brain. High brain Abeta levels are found at an early age in mutant mice with low circulating IGF-I, and Abeta burden can be reduced in aging rats by increasing serum IGF-I. This opposing relationship between serum IGF-I and brain Abeta levels reflects the ability of IGF-I to induce clearance of brain Abeta, probably by enhancing transport of Abeta carrier proteins such as albumin and transthyretin into the brain. This effect is antagonized by tumor necrosis factor-alpha, a proinflammatory cytokine putatively involved in dementia and aging. Because IGF-I treatment of mice overexpressing mutant amyloid markedly reduces their brain Abeta burden, we consider that circulating IGF-I is a physiological regulator of brain amyloid levels with therapeutic potential.	CSIC, Inst Cajal, Neuroendocrinol Lab, E-28002 Madrid, Spain; Univ Navarra, Univ Navarra Clin, E-31080 Pamplona, Spain; NIH, Clin Endocrinol Branch, Bethesda, MD USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); University of Navarra; National Institutes of Health (NIH) - USA	Torres-Aleman, I (corresponding author), CSIC, Inst Cajal, Neuroendocrinol Lab, E-28002 Madrid, Spain.	torres@cajal.csic.es	Trejo, Jose Luis/F-5518-2016; Torres-Aleman, Ignacio/A-1613-2008; Carro, Eva/D-6240-2018	Torres-Aleman, Ignacio/0000-0001-8107-7947; Carro, Eva/0000-0002-6504-4579				Aberg MAI, 2000, J NEUROSCI, V20, P2896; AMADUCCI L, 1994, CURR OPIN NEUROL, V7, P283, DOI 10.1097/00019052-199408000-00001; Arvat E, 2000, DRUG AGING, V16, P29, DOI 10.2165/00002512-200016010-00003; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001; Busiguina S, 2000, NEUROBIOL DIS, V7, P657, DOI 10.1006/nbdi.2000.0311; Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001; Carro E, 2000, J NEUROSCI, V20, P2926; CHANOINE JP, 1992, ENDOCRINOLOGY, V130, P933, DOI 10.1210/en.130.2.933; Chodobski A, 2001, MICROSC RES TECHNIQ, V52, P65; Chun JT, 1999, EXP NEUROL, V157, P194, DOI 10.1006/exnr.1999.7052; Craft S, 2000, ANN NY ACAD SCI, V903, P222, DOI 10.1111/j.1749-6632.2000.tb06371.x; DICKSON PW, 1986, J BIOL CHEM, V261, P3475; Dickstein JB, 2000, AM J PHYSIOL-REG I, V279, pR148, DOI 10.1152/ajpregu.2000.279.1.R148; ELOVAARA I, 1986, ACTA NEUROL SCAND, V74, P245, DOI 10.1111/j.1600-0404.1986.tb07863.x; Fernandez AM, 1998, P NATL ACAD SCI USA, V95, P1253, DOI 10.1073/pnas.95.3.1253; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Kozyraki R, 2001, J MOL MED, V79, P161, DOI 10.1007/s001090100193; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; Lichtenwalner RJ, 2001, NEUROSCIENCE, V107, P603, DOI 10.1016/S0306-4522(01)00378-5; Marino M, 2001, J AM SOC NEPHROL, V12, P637, DOI 10.1681/ASN.V124637; Markowska AL, 1998, NEUROSCIENCE, V87, P559, DOI 10.1016/S0306-4522(98)00143-2; Mustafa A, 1999, DEMENT GERIATR COGN, V10, P446, DOI 10.1159/000017188; Niikura T, 2001, J NEUROSCI, V21, P1902, DOI 10.1523/JNEUROSCI.21-06-01902.2001; Paxinos G., 2004, J CHEM INF MODEL, V5th; Pons S, 2000, J BIOL CHEM, V275, P38620, DOI 10.1074/jbc.M004531200; Pratico D, 2000, NEUROBIOL AGING, V21, P441, DOI 10.1016/S0197-4580(00)00141-X; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Saraiva MJM, 2001, HUM MUTAT, V17, P493, DOI 10.1002/humu.1132; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Strazielle N, 1999, J NEUROSCI, V19, P6275; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; THAM A, 1993, J NEURAL TRANSM-PARK, V5, P165, DOI 10.1007/BF02257671; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; Vaucher E, 2001, J CHEM NEUROANAT, V21, P323, DOI 10.1016/S0891-0618(01)00120-X; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Xie L, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0001.2002; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324	45	425	469	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1390	1397		10.1038/nm793	http://dx.doi.org/10.1038/nm793			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12415260				2022-12-27	WOS:000179552000035
J	Faccio, R; Teitelbaum, SL; Fujikawa, K; Chappel, J; Zallone, A; Tybulewicz, VL; Ross, FP; Swat, W				Faccio, R; Teitelbaum, SL; Fujikawa, K; Chappel, J; Zallone, A; Tybulewicz, VL; Ross, FP; Swat, W			Vav3 regulates osteoclast function and bone mass	NATURE MEDICINE			English	Article							GTP-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; FAMILY PROTEINS; RHO-GTPASES; CYTOSKELETAL ORGANIZATION; INTEGRIN ENGAGEMENT; BETA-3 INTEGRIN; MICE LACKING; KINASE SYK	Osteoporosis, a leading cause of morbidity in the elderly, is characterized by progressive loss of bone mass resulting from excess osteoclastic bone resorption relative to osteoblastic bone formation. Here we identify Vav3, a Rho family guanine nucleotide exchange factor, as essential for stimulated osteoclast activation and bone density in vivo. Vav3-deficient osteoclasts show defective actin cytoskeleton organization, polarization, spreading and resorptive activity resulting from impaired signaling downstream of the M-CSF receptor and alpha(v)beta(3) integrin. Vav3-deficient mice have increased bone mass and are protected from bone loss induced by systemic bone resorption stimuli such as parathyroid hormone or RANKL. Moreover, we provide genetic and biochemical evidence for the role of Syk tyrosine kinase as a crucial upstream regulator of Vav3 in osteoclasts. Thus, Vav3 is a potential new target for antiosteoporosis therapy.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA; Univ Bari, Sch Med, I-70100 Bari, Italy; Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England	Washington University (WUSTL); Washington University (WUSTL); Universita degli Studi di Bari Aldo Moro; MRC National Institute for Medical Research	Swat, W (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	rossf@wustl.edu; swat@pathbox.wustl.edu		Teitelbaum, Steven/0000-0002-4054-6679; Tybulewicz, Victor/0000-0003-2439-0798	NIAMS NIH HHS [AR46523, AR32788, AR46852, AR48812, AR48853] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR046523, R01AR048812, R01AR032788, R01AR046523, R01AR048853, R01AR046852] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Cella M, 2004, J EXP MED, V200, P817, DOI 10.1084/jem.20031847; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924; Faccio R, 2003, J CELL BIOCHEM, V90, P871, DOI 10.1002/jcb.10694; Faccio R, 2002, J CELL SCI, V115, P2919; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Fukuda A, 2003, J BONE MINER RES, V18, pS79; Gakidis MAM, 2004, J CELL BIOL, V166, P273, DOI 10.1083/jcb.200404166; Gotoh A, 1997, CELL GROWTH DIFFER, V8, P721; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Riteau B, 2003, J EXP MED, V198, P469, DOI 10.1084/jem.20021995; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Tybulewicz VLJ, 2003, IMMUNOL REV, V192, P42, DOI 10.1034/j.1600-065X.2003.00032.x; Vaananen HK, 2000, J CELL SCI, V113, P377; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; ZHANG D, 1995, J CELL SCI, V108, P2285; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	50	216	220	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					284	290		10.1038/nm1194	http://dx.doi.org/10.1038/nm1194			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711558				2022-12-27	WOS:000227541300023
J	Greter, M; Heppner, FL; Lemos, MP; Odermatt, BM; Goebels, N; Laufer, T; Noelle, RJ; Becher, B				Greter, M; Heppner, FL; Lemos, MP; Odermatt, BM; Goebels, N; Laufer, T; Noelle, RJ; Becher, B			Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ANTIGEN-PRESENTING CELLS; MARROW-DERIVED ELEMENTS; CLASS-II EXPRESSION; MICROGLIAL CELLS; RESIDENT CELLS; T-CELLS; EX-VIVO; BRAIN	Immunization with myelin antigens leads to the development of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. The disease can also be induced by the transfer of encephalitogenic CD4(+) T helper (TH) lymphocytes into naive mice. These T cells need to re-encounter their cognate antigen in the context of major histocompatibility complex (MHC) class II-bearing antigen-presenting cells (APCs) in order to recognize their target. The cell type and location of the APC mediating T-cell entry into the central nervous system (CNS) remain unknown. Here, we show that APCs of the lymphoreticular system and of the CNS parenchyma are dispensable for the immune invasion of the CNS. We also describe that a discrete population of vessel-associated dendritic cells (DCs) is present in human brain tissue. In mice, CD11c(+) DCs alone are sufficient to present antigen in vivo to primed myelin-reactive T cells in order to mediate CNS inflammation and clinical disease development.	Univ Zurich Hosp, Dept Neurol, Neuroimmunol Unit, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Pathol, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA; Univ Zurich Hosp, Dept Pathol, Inst Clin Pathol, CH-8091 Zurich, Switzerland; Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Lebanon, NH 03755 USA	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Pennsylvania; University of Zurich; University Zurich Hospital; Dartmouth College	Becher, B (corresponding author), Univ Zurich Hosp, Dept Neurol, Neuroimmunol Unit, Frauenklin Str 10, CH-8091 Zurich, Switzerland.	burkhard.becher@usz.ch	Calabrese, Massimiliano/I-6195-2012; Becher, Burkhard/ABE-4225-2020; Heppner, Frank/ABH-8393-2020	Becher, Burkhard/0000-0002-1541-7867; Heppner, Frank/0000-0001-9816-8917; Greter, Melanie/0000-0002-7220-5369	NIAID NIH HHS [AI49580] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049580] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aloisi F, 1998, J IMMUNOL, V160, P4671; Asheuer M, 2004, P NATL ACAD SCI USA, V101, P3557, DOI 10.1073/pnas.0306431101; Becher B, 2000, GLIA, V29, P293; Becher B, 2003, J CLIN INVEST, V112, P1186, DOI 10.1172/JCI200319079; Becher B, 1996, GLIA, V18, P1; Becher B, 2001, J EXP MED, V193, P967, DOI 10.1084/jem.193.8.967; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; FIERZ W, 1985, J IMMUNOL, V134, P3785; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Ford AL, 1996, J EXP MED, V184, P1737, DOI 10.1084/jem.184.5.1737; FORD AL, 1995, J IMMUNOL, V154, P4309; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; Juedes AE, 2001, J IMMUNOL, V166, P5168, DOI 10.4049/jimmunol.166.8.5168; Kivisakk P, 2004, ANN NEUROL, V55, P627, DOI 10.1002/ana.20049; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LEE SC, 1989, J NEUROIMMUNOL, V25, P261, DOI 10.1016/0165-5728(89)90145-8; Lemos MP, 2004, J EXP MED, V199, P725, DOI 10.1084/jem.20030795; Lemos MP, 2003, J IMMUNOL, V171, P5077, DOI 10.4049/jimmunol.171.10.5077; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Matyszak MK, 1999, EUR J IMMUNOL, V29, P3063, DOI 10.1002/(SICI)1521-4141(199910)29:10<3063::AID-IMMU3063>3.0.CO;2-G; Matyszak MK, 1996, NEUROSCIENCE, V74, P599, DOI 10.1016/0306-4522(96)00160-1; McMahon EJ, 2005, NAT MED, V11, P335, DOI 10.1038/nm1202; McMenamin PG, 1999, J COMP NEUROL, V405, P553, DOI 10.1002/(SICI)1096-9861(19990322)405:4<553::AID-CNE8>3.0.CO;2-6; MOSSNER R, 1990, ADV EXP MED BIOL, V276, P647; O'Keeffe M, 2002, BLOOD, V99, P2122, DOI 10.1182/blood.V99.6.2122; PRINEAS JW, 1979, SCIENCE, V203, P1123, DOI 10.1126/science.424741; RAINE CS, 1984, LAB INVEST, V51, P534; Serafini B, 2000, AM J PATHOL, V157, P1991, DOI 10.1016/S0002-9440(10)64838-9; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Slavin AJ, 2001, J CLIN INVEST, V108, P1133, DOI 10.1172/JCI200113360; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Stuve O, 2002, J IMMUNOL, V169, P6720, DOI 10.4049/jimmunol.169.12.6720; ULVESTAD E, 1994, J LEUKOCYTE BIOL, V56, P732, DOI 10.1002/jlb.56.6.732; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0	40	653	674	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					328	334		10.1038/nm1197	http://dx.doi.org/10.1038/nm1197			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15735653				2022-12-27	WOS:000227541300029
J	Arkan, MC; Hevener, AL; Greten, FR; Maeda, S; Li, ZW; Long, JM; Wynshaw-Boris, A; Poli, G; Olefsky, J; Karin, M				Arkan, MC; Hevener, AL; Greten, FR; Maeda, S; Li, ZW; Long, JM; Wynshaw-Boris, A; Poli, G; Olefsky, J; Karin, M			IKK-beta links inflammation to obesity-induced insulin resistance	NATURE MEDICINE			English	Article							KAPPA-B ACTIVATION; TRANSCRIPTION FACTOR; PREVENTION; DISEASE; INTERLEUKIN-6; DISRUPTION; MECHANISMS; SYSTEM; FAILS; PLAYS	Inflammation may underlie the metabolic disorders of insulin resistance and type 2 diabetes. IkappaB kinase beta (IKK-beta, encoded by Ikbkb) is a central coordinator of inflammatory responses through activation of NF-kappaB. To understand the role of IKK-beta in insulin resistance, we used mice lacking this enzyme in hepatocytes (Ikbkb(Deltahep)) or myeloid cells (Ikbkb(Deltamye)). Ikbkb(Deltahep) mice retain liver insulin responsiveness, but develop insulin resistance in muscle and fat in response to high fat diet, obesity or aging. In contrast, Ikbkb(Deltamye) mice retain global insulin sensitivity and are protected from insulin resistance. Thus, IKK-beta acts locally in liver and systemically in myeloid cells, where NF-kappaB activation induces inflammatory mediators that cause insulin resistance. These findings demonstrate the importance of liver cell IKK-beta in hepatic insulin resistance and the central role of myeloid cells in development of systemic insulin resistance. We suggest that inhibition of IKK-beta, especially in myeloid cells, may be used to treat insulin resistance.	Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Turin, Dept Clin & Biol Sci, S Luigi Hosp, I-10043 Turin, Italy	University of California System; University of California San Diego; University of California System; University of California San Diego; H Lee Moffitt Cancer Center & Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Turin	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu; karinoffice@ucsd.edu	Greten, Florian R/AAF-5196-2020	Greten, Florian R/0000-0002-3928-6080	NIDDK NIH HHS [DK60484, DK33651] Funding Source: Medline; NIEHS NIH HHS [ES06376] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060484, R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006376] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARENA FP, 1978, ARCH INTERN MED, V138, P1153, DOI 10.1001/archinte.138.7.1153; Arkan MC, 2001, FREE RADICAL BIO MED, V31, P374, DOI 10.1016/S0891-5849(01)00601-3; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bruun JM, 2002, MOL CELL ENDOCRINOL, V190, P91, DOI 10.1016/S0303-7207(02)00007-2; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Koistinen HA, 2002, ANN MED, V34, P410, DOI 10.1080/078538902321012351; Leffert H L, 1979, Methods Enzymol, V58, P536; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lovejoy Jennifer C, 2002, Curr Diab Rep, V2, P435, DOI 10.1007/s11892-002-0098-y; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Miyazaki Y, 2003, INT J OBESITY, V27, P88, DOI 10.1038/sj.ijo.0802187; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Patti ME, 2004, CURR OPIN CLIN NUTR, V7, P383, DOI 10.1097/01.mco.0000134359.23288.72; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Rohl M, 2004, J CLIN INVEST, V113, P474, DOI 10.1172/JCI200418712; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Sugita H, 2002, AM J PHYSIOL-ENDOC M, V282, pE386, DOI 10.1152/ajpendo.00087.2001; VIRKAMAKI A, 1994, ENDOCRINOLOGY, V134, P2072, DOI 10.1210/en.134.5.2072; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	42	1375	1465	3	91	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					191	198		10.1038/nm1185	http://dx.doi.org/10.1038/nm1185			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685170				2022-12-27	WOS:000226797300027
J	Bosch, X				Bosch, X			Spain launches cancer research project	NATURE MEDICINE			English	News Item								Spain's Catalan government has approved a cancer research project which will focus on translational research on metastasis. The collaborative effort on cancer research will take place between the Barcelona-based Institut de Recerca Biomedica and New York's Memorial Sloan-Kettering Cancer Center.											0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2005	11	2					106	106		10.1038/nm0205-106b	http://dx.doi.org/10.1038/nm0205-106b			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15692577	Bronze			2022-12-27	WOS:000226797300004
J	Issaeva, N; Bozko, P; Enge, M; Protopopova, M; Verhoef, LGGC; Masucci, M; Pramanik, A; Selivanova, G				Issaeva, N; Bozko, P; Enge, M; Protopopova, M; Verhoef, LGGC; Masucci, M; Pramanik, A; Selivanova, G			Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors	NATURE MEDICINE			English	Article							C-TERMINAL DOMAIN; CANCER-CELLS; DNA-BINDING; IN-VIVO; SUPPRESSOR PROTEIN; TRANSFORMED-CELLS; CRYSTAL-STRUCTURE; MDM2; PEPTIDE; COMPLEX	In tumors that retain wild-type p53, its tumor-suppressor function is often impaired as a result of the deregulation of HDM-2, which binds to p53 and targets it for proteasomal degradation. We have screened a chemical library and identified a small molecule named RITA ( reactivation of p53 and induction of tumor cell apoptosis), which bound to p53 and induced its accumulation in tumor cells. RITA prevented p53 - HDM-2 interaction in vitro and in vivo and affected p53 interaction with several negative regulators. RITA induced expression of p53 target genes and massive apoptosis in various tumor cells lines expressing wild-type p53. RITA suppressed the growth of human fibroblasts and lymphoblasts only upon oncogene expression and showed substantial p53-dependent antitumor effect in vivo. RITA may serve as a lead compound for the development of an anticancer drug that targets tumors with wild-type p53.	Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Selivanova, G (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden.	galina.selivanova@mtc.ki.se	Enge, Martin/GYQ-5073-2022; Masucci, Maria/AAC-6666-2019; Issaeva, Natalia/K-4577-2019	Masucci, Maria/0000-0002-5541-2809; Enge, Martin/0000-0001-8748-8931; Issaeva, Natalia/0000-0001-5483-6610; Selivanova, Galina/0000-0002-8698-4332				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burch LR, 2000, FEBS LETT, V472, P93, DOI 10.1016/S0014-5793(00)01427-7; Chene P, 2000, J MOL BIOL, V299, P245, DOI 10.1006/jmbi.2000.3738; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; D'Orazi G, 2000, J GENE MED, V2, P11; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Jabbur JR, 2002, ONCOGENE, V21, P7100, DOI 10.1038/sj.onc.1205856; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lai ZH, 2002, P NATL ACAD SCI USA, V99, P14734, DOI 10.1073/pnas.212428599; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu WL, 2001, J MOL BIOL, V313, P711, DOI 10.1006/jmbi.2001.5082; LUNA RMD, 1995, NATURE, V378, P203; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nieves-Neira W, 1999, MOL PHARMACOL, V56, P478, DOI 10.1124/mol.56.3.478; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pandhare J, 2003, J BIOL CHEM, V278, P48735, DOI 10.1074/jbc.M308976200; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; Rivera MI, 1999, BIOCHEM PHARMACOL, V57, P1283, DOI 10.1016/S0006-2952(99)00046-5; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Zhao JH, 2002, CANCER LETT, V183, P69, DOI 10.1016/S0304-3835(02)00084-8	46	619	649	2	58	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1321	1328		10.1038/nm1146	http://dx.doi.org/10.1038/nm1146			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15558054				2022-12-27	WOS:000225500900025
J	Diamond, B				Diamond, B			Profile: John Hardy	NATURE MEDICINE			English	Biographical-Item																		HARDY JW, PUBLICATION LIST	1	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1009	1009		10.1038/nm1004-1009	http://dx.doi.org/10.1038/nm1004-1009			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459688	Bronze			2022-12-27	WOS:000224245800008
J	Hanada, R; Teranishi, H; Pearson, JT; Kurokawa, M; Hosoda, H; Fukushima, N; Fukue, Y; Serino, R; Fujihara, H; Ueta, Y; Ikawa, M; Okabe, M; Murakami, N; Shirai, M; Yoshimatsu, H; Kangawa, K; Kojima, M				Hanada, R; Teranishi, H; Pearson, JT; Kurokawa, M; Hosoda, H; Fukushima, N; Fukue, Y; Serino, R; Fujihara, H; Ueta, Y; Ikawa, M; Okabe, M; Murakami, N; Shirai, M; Yoshimatsu, H; Kangawa, K; Kojima, M			Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway	NATURE MEDICINE			English	Article							CORTICOTROPIN-RELEASING HORMONE; MESSENGER-RIBONUCLEIC-ACID; BODY-WEIGHT; UNCOUPLING PROTEIN-3; ENERGY HOMEOSTASIS; SUPRAOPTIC NUCLEI; RAT HYPOTHALAMUS; GENE-EXPRESSION; PREPRO-OREXIN; OBESE MICE	Neuromedin U (NMU) is a hypothalamic neuropeptide that regulates body weight and composition. Here we show that mice lacking the gene encoding NMU (Nmu(-/-) mice) develop obesity. Nmu(-/-) mice showed increased body weight and adiposity, hyperphagia, and decreased locomotor activity and energy expenditure. Obese Nmu(-/-) mice developed hyperleptinemia, hyperinsulinemia, late-onset hyperglycemia and hyperlipidemia. Notably, however, treatment with exogenous leptin was effective in reducing body weight in obese Nmu(-/-) mice. In addition, central leptin administration did not affect NMU gene expression in the hypothalamus of rats. These results indicate that NMU plays an important role in the regulation of feeding behavior and energy metabolism independent of the leptin signaling pathway. These characteristic functions of NMU may provide new insight for understanding the pathophysiological basis of obesity.	Kurume Univ, Inst Life Sci, Fukuoka 8390861, Japan; Oita Univ, Fac Med, Dept Internal Med, Oita 8795593, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Cardiac Physiol, Osaka 5658565, Japan; Nagasaki Univ, Sch Med, Dept Anat, Nagasaki 8528523, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Kitakyushu, Fukuoka 8078555, Japan; Osaka Univ, Genome Informat Res Ctr, Dept Expt Genome Res, Suita, Osaka 5650871, Japan; Miyazaki Univ, Fac Agr, Dept Vet Physiol, Miyazaki 8892155, Japan	Kurume University; Oita University; National Cerebral & Cardiovascular Center - Japan; Nagasaki University; National Cerebral & Cardiovascular Center - Japan; University of Occupational & Environmental Health - Japan; Osaka University; University of Miyazaki	Kojima, M (corresponding author), Kurume Univ, Inst Life Sci, Fukuoka 8390861, Japan.	mkojima@lsi.kurume-u.ac.jp	ikawa, masahito/A-5315-2009; Pearson, James T/B-4631-2012; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Pearson, James T/0000-0002-3318-5406; Okabe, Masaru/0000-0002-0803-9044				Abbott CR, 2000, BRAIN RES, V869, P203, DOI 10.1016/S0006-8993(00)02386-6; BALLESTA J, 1988, NEUROSCIENCE, V25, P797, DOI 10.1016/0306-4522(88)90037-1; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Cummings DE, 2003, ANNU REV MED, V54, P453, DOI 10.1146/annurev.med.54.101601.152403; EGAWA M, 1990, NEUROSCIENCE, V34, P771, DOI 10.1016/0306-4522(90)90181-3; Elmquist JK, 2004, SCIENCE, V304, P63, DOI 10.1126/science.1096746; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; Graham ES, 2003, J NEUROCHEM, V87, P1165, DOI 10.1046/j.1471-4159.2003.02079.x; Hanada R, 2001, BIOCHEM BIOPH RES CO, V289, P225, DOI 10.1006/bbrc.2001.5945; Hanada R, 2000, BIOCHEM BIOPH RES CO, V268, P88, DOI 10.1006/bbrc.1999.2081; Hanada T, 2003, BIOCHEM BIOPH RES CO, V311, P954, DOI 10.1016/j.bbrc.2003.10.098; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Isse T, 1999, BRAIN RES, V846, P229, DOI 10.1016/S0006-8993(99)02065-X; Ivanov TR, 2002, ENDOCRINOLOGY, V143, P3813, DOI 10.1210/en.2002-220121; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kojima M, 2000, BIOCHEM BIOPH RES CO, V276, P435, DOI 10.1006/bbrc.2000.3502; Kurokawa M, 2000, PHYSIOL BEHAV, V70, P105, DOI 10.1016/S0031-9384(00)00226-2; Marx J, 2003, SCIENCE, V299, P846, DOI 10.1126/science.299.5608.846; Masaki T, 2003, ENDOCRINOLOGY, V144, P3547, DOI 10.1210/en.2003-0301; Masaki T, 2001, DIABETES, V50, P376, DOI 10.2337/diabetes.50.2.376; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; Mizuno TM, 1999, ENDOCRINOLOGY, V140, P814, DOI 10.1210/en.140.2.814; Moussa NM, 1999, OBES RES, V7, P506, DOI 10.1002/j.1550-8528.1999.tb00440.x; Nakahara K, 2004, BIOCHEM BIOPH RES CO, V318, P156, DOI 10.1016/j.bbrc.2004.04.014; Nakazato M, 2000, BIOCHEM BIOPH RES CO, V277, P191, DOI 10.1006/bbrc.2000.3669; Nicholls DG, 2001, BIOCHEM SOC T, V29, P751, DOI 10.1042/bst0290751; Nomura M, 2003, J NEUROENDOCRINOL, V15, P1054, DOI 10.1046/j.1365-2826.2003.01095.x; Ozaki Y, 2002, ENDOCRINOLOGY, V143, P4320, DOI 10.1210/en.2002-220201; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; Schrauwen P, 2003, P NUTR SOC, V62, P635, DOI 10.1079/PNS2003277; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 1997, DIABETES, V46, P2119, DOI 10.2337/diabetes.46.12.2119; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; WITHERS PC, 1977, J APPL PHYSIOL, V42, P120, DOI 10.1152/jappl.1977.42.1.120; Wren AM, 2002, ENDOCRINOLOGY, V143, P4227, DOI 10.1210/en.2002-220308; Yamamoto Y, 2000, BRAIN RES BULL, V51, P515, DOI 10.1016/S0361-9230(99)00271-3; Yamamoto Y, 2002, PEPTIDES, V23, P1689, DOI 10.1016/S0196-9781(02)00111-0	43	158	165	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1067	1073		10.1038/nm1106	http://dx.doi.org/10.1038/nm1106			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15448684				2022-12-27	WOS:000224245800036
J	Pardoll, D; Allison, J				Pardoll, D; Allison, J			Cancer immunotherapy: breaking the barriers to harvest the crop	NATURE MEDICINE			English	Editorial Material							METASTATIC MELANOMA; ANTIGEN-4 BLOCKADE; T-CELLS; ANTIBODY; THERAPY; AUTOIMMUNITY; REGRESSION; RESPONSES; PLUS	Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Canc Ctr, Baltimore, MD 21218 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Johns Hopkins University; Memorial Sloan Kettering Cancer Center	Pardoll, D (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Canc Ctr, Baltimore, MD 21218 USA.	dmpardol@jhmi.edu		Allison, James/0000-0001-8980-5697				Akhtar S, 2002, NEW ENGL J MED, V346, P1830; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Ergenzinger E, 2003, SCIENTIST, V17, P43; Grilley BJ, 2003, CYTOTHERAPY, V5, P197, DOI 10.1080/14653240310001271; Hersey P, 2003, INTERN MED J, V33, P33, DOI 10.1046/j.1445-5994.2002.00289.x; Levitsky HI, 2000, CANCER J, V6, pS281; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith MA, 2002, ACTA NEUROPATHOL, V104, P110, DOI 10.1007/s00401-002-0572-2; Stolberg Sheryl Gay, 1999, N Y Times Mag, P136; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Waldmann H, 2002, MED ONCOL, V19, pS3, DOI 10.1385/MO:19:2S:S03; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; WINTER G, 1993, TRENDS PHARMACOL SCI, V14, P139, DOI 10.1016/0165-6147(93)90197-R; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099	20	110	114	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					887	892		10.1038/nm0904-887	http://dx.doi.org/10.1038/nm0904-887			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15340404				2022-12-27	WOS:000223658400010
J	Traggiai, E; Becker, S; Subbarao, K; Kolesnikova, L; Uematsu, Y; Gismondo, MR; Murphy, BR; Rappuoli, R; Lanzavecchia, A				Traggiai, E; Becker, S; Subbarao, K; Kolesnikova, L; Uematsu, Y; Gismondo, MR; Murphy, BR; Rappuoli, R; Lanzavecchia, A			An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; SYNCYTIAL VIRUS-INFECTION; HONG-KONG; MOUSE; IDENTIFICATION; GENERATION; DISEASES; MYELOMA; STRAINS; MICE	Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10(-8)M to 10(-11)M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection.	Inst Res Biomed, CH-6500 Belllinzona, Switzerland; Inst Virol, D-35037 Marburg, Germany; NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Chiron Vaccines, I-53100 Siena, Italy; Osped L Sacco, Ist Microbiol, I-20175 Milan, Italy	Universita della Svizzera Italiana; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Novartis; University of Milan; Luigi Sacco Hospital	Lanzavecchia, A (corresponding author), Inst Res Biomed, Via Vela 6, CH-6500 Belllinzona, Switzerland.	lanzavecchia@irb.unisi.ch	traggiai, elisabetta/A-2316-2009; Gismondo, Maria Rita/I-3965-2017	Subbarao, Kanta/0000-0003-1713-3056; Gismondo, Maria Rita/0000-0001-6926-8660	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000934, Z01AI000934] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER S, 1992, MED MICROBIOL IMMUN, V181, P43, DOI 10.1007/BF00193395; BEHRING E, 1965, DEUT MED WOCHENSCHR, V90, P2183; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X; GIACHINO C, 1995, J EXP MED, V181, P1245, DOI 10.1084/jem.181.3.1245; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; Green LL, 1999, J IMMUNOL METHODS, V231, P11, DOI 10.1016/S0022-1759(99)00137-4; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914; Karpas A, 2001, P NATL ACAD SCI USA, V98, P1799, DOI 10.1073/pnas.98.4.1799; Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOZBOR D, 1981, J IMMUNOL, V127, P1275; KOZBOR D, 1982, HYBRIDOMA, V1, P323, DOI 10.1089/hyb.1.1982.1.323; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Perri S, 2003, J VIROL, V77, P10394, DOI 10.1128/JVI.77.19.10394-10403.2003; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Stack AM, 2000, VACCINE, V18, P1412, DOI 10.1016/S0264-410X(99)00399-0; STEINITZ M, 1977, NATURE, V269, P420, DOI 10.1038/269420a0; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004	30	526	677	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					871	875		10.1038/nm1080	http://dx.doi.org/10.1038/nm1080			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15247913	Green Published, Bronze			2022-12-27	WOS:000223055700043
J	Xia, HB; Mao, QW; Eliason, SL; Harper, SQ; Martins, IH; Orr, HT; Paulson, HL; Yang, L; Kotin, RM; Davidson, BL				Xia, HB; Mao, QW; Eliason, SL; Harper, SQ; Martins, IH; Orr, HT; Paulson, HL; Yang, L; Kotin, RM; Davidson, BL			RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia	NATURE MEDICINE			English	Article							SCA1 TRANSGENIC MICE; INDUCED DISEASE; CELLS; INTERFERENCE; TYPE-1; GENES; LOCALIZATION; AGGREGATION; EXPRESSION; VECTORS	The dominant polyglutamine expansion diseases, which include spinocerebellar ataxia type 1 (SCA1) and Huntington disease, are progressive, untreatable, neurodegenerative disorders. In inducible mouse models of SCA1 and Huntington disease, repression of mutant allele expression improves disease phenotypes. Thus, therapies designed to inhibit expression of the mutant gene would be beneficial. Here we evaluate the ability of RNA interference (RNAi) to inhibit polyglutamine-induced neurodegeneration caused by mutant ataxin-1 in a mouse model of SCA1. Upon intracerebellar injection, recombinant adeno-associated virus (AAV) vectors expressing short hairpin RNAs profoundly improved motor coordination, restored cerebellar morphology and resolved characteristic ataxin-1 inclusions in Purkinje cells of SCA1 mice. Our data demonstrate in vivo the potential use of RNAi as therapy for dominant neurodegenerative disease.	Univ Iowa, Program Gene Therapy, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Iowa	Davidson, BL (corresponding author), Univ Iowa, Program Gene Therapy, Iowa City, IA 52242 USA.	beverly-davidson@uiowa.edu	kotin, robert/B-8954-2008	Mao, Qinwen/0000-0001-7876-2046; Orr, Harry/0000-0001-6118-741X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002237, ZIAHL002237] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alisky JM, 2000, NEUROREPORT, V11, P2669, DOI 10.1097/00001756-200008210-00013; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Caplen NJ, 2002, HUM MOL GENET, V11, P175, DOI 10.1093/hmg/11.2.175; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Clark HB, 1997, J NEUROSCI, V17, P7385; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davidson BL, 2004, LANCET NEUROL, V3, P145, DOI 10.1016/S1474-4422(04)00678-7; Diener HC, 1996, CLIN DISORDERS POSTU, P147; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg158; Khvorova A, 2003, CELL, V115, P505, DOI 10.1016/S0092-8674(03)00893-6; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Miller VM, 2003, P NATL ACAD SCI USA, V100, P7195, DOI 10.1073/pnas.1231012100; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; Urabe M, 2002, HUM GENE THER, V13, P1935, DOI 10.1089/10430340260355347; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; ZOGHBI HY, 1995, SEMIN CELL BIOL, V6, P29, DOI 10.1016/1043-4682(95)90012-8	25	511	596	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					816	820		10.1038/nm1076	http://dx.doi.org/10.1038/nm1076			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15235598				2022-12-27	WOS:000223055700035
J	Lindvall, O; Kokaia, Z; Martinez-Serrano, A				Lindvall, O; Kokaia, Z; Martinez-Serrano, A			Stem cell therapy for human neurodegenerative disorders - how to make it work	NATURE MEDICINE			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; NEURAL PROGENITOR CELLS; ADULT-RAT BRAIN; EXPANDED MESENCEPHALIC PRECURSORS; EMBRYONIC SPINAL-CORD; FETAL NIGRAL GRAFTS; PARKINSONS-DISEASE; HUNTINGTONS-DISEASE; DOPAMINERGIC-NEURONS; IN-VITRO	Recent progress shows that neurons suitable for transplantation can be generated from stem cells in culture, and that the adult brain produces new neurons from its own stem cells in response to injury. These findings raise hope for the development of stem cell therapies in human neurodegenerative disorders. Before clinical trials are initiated, we need to know much more about how to control stem cell proliferation and differentiation into specific phenotypes, induce their integration into existing neural and synaptic circuits, and optimize functional recovery in animal models closely resembling the human disease.	Univ Lund Hosp, Wallenberg Neurosci Ctr, Dept Clin Neurosci, Sect Restorat Neurol,Lab Neurogenesis & Cell Ther, SE-22184 Lund, Sweden; Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Lund, Sweden; Univ Lund Hosp, Dept Clin Neurosci, Sect Restorat Neurol, Lab Neural Stem Cell Biol, SE-22184 Lund, Sweden; Autonomous Univ Madrid, Ctr Mol Biol Severo Ochoa, Human Neural Stem Cell Biol & Gene Therapy Grp, Madrid 28049, Spain	Lund University; Skane University Hospital; Lund University; Lund University; Skane University Hospital; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Lindvall, O (corresponding author), Univ Lund Hosp, Wallenberg Neurosci Ctr, Dept Clin Neurosci, Sect Restorat Neurol,Lab Neurogenesis & Cell Ther, SE-22184 Lund, Sweden.	olle.lindvall@neurol.lu.se; zaal.kokaia@neurol.lu.se; amserrano@cbm.uam.es	Kokaia, Zaal/AAL-6009-2020; Martínez-Serrano, Alberto/J-8146-2014	Kokaia, Zaal/0000-0003-2296-2449; Martinez Serrano, Alberto/0000-0003-3927-6699				Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bachoud-Levi A, 2000, LANCET, V356, P1975, DOI 10.1016/S0140-6736(00)03310-9; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Carvey PM, 2001, EXP NEUROL, V171, P98, DOI 10.1006/exnr.2001.7735; Chiba S, 2003, CELL TRANSPLANT, V12, P457, DOI 10.3727/000000003108747019; Chmielnicki E, 2004, J NEUROSCI, V24, P2133, DOI 10.1523/JNEUROSCI.1554-03.2004; Chung S, 2002, EUR J NEUROSCI, V16, P1829, DOI 10.1046/j.1460-9568.2002.02255.x; CLOWRY G, 1991, TRENDS NEUROSCI, V14, P355, DOI 10.1016/0166-2236(91)90162-N; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Daadi MM, 1999, J NEUROSCI, V19, P4484; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Dunnett S B, 2000, Prog Brain Res, V127, P345; Ekdahl CT, 2002, EUR J NEUROSCI, V16, P1463, DOI 10.1046/j.1460-9568.2002.02202.x; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; El-Khodor BF, 2003, EXP NEUROL, V179, P17, DOI 10.1006/exnr.2002.8047; Englund U, 2002, DEV BRAIN RES, V134, P123, DOI 10.1016/S0165-3806(01)00330-3; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Freeman TB, 2000, P NATL ACAD SCI USA, V97, P13877, DOI 10.1073/pnas.97.25.13877; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Fricker-Gates RA, 2002, J NEUROSCI, V22, P4045, DOI 10.1523/JNEUROSCI.22-10-04045.2002; Garbuzova-Davis S, 2001, AMYOTROPH LATERAL SC, V2, P175, DOI 10.1080/14660820152882179; Garbuzova-Davis S, 2002, EXP NEUROL, V174, P169, DOI 10.1006/exnr.2002.7860; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Gates M A, 2000, Prog Brain Res, V127, P115; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; Gustafsson E, 2003, EUR J NEUROSCI, V17, P2667, DOI 10.1046/j.1460-9568.2003.02713.x; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Hagell P, 2001, J NEUROPATH EXP NEUR, V60, P741, DOI 10.1093/jnen/60.8.741; Hauser RA, 2002, NEUROLOGY, V58, P687, DOI 10.1212/WNL.58.5.687; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; Isacson O, 2003, ANN NEUROL, V53, pS135, DOI 10.1002/ana.10482; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jin K, 2002, J CLIN INVEST, V110, P311, DOI 10.1172/JCI200215251; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kalyani A, 1997, DEV BIOL, V186, P202, DOI 10.1006/dbio.1997.8592; Kalyani AJ, 1998, J NEUROSCI, V18, P7856; Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kendall AL, 1998, NAT MED, V4, P727, DOI 10.1038/nm0698-727; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Kordower JH, 1996, J COMP NEUROL, V370, P203; Kordower JH, 1998, MOVEMENT DISORD, V13, P383, DOI 10.1002/mds.870130303; Lescaudron L, 2003, INT J NEUROSCI, V113, P945, DOI 10.1080/00207450390207759; Li RH, 2000, J NEUROSCI RES, V59, P342, DOI 10.1002/(SICI)1097-4547(20000201)59:3<342::AID-JNR7>3.0.CO;2-Z; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Lie DC, 2002, J NEUROSCI, V22, P6639; Lindvall O, 2000, Prog Brain Res, V127, P299; Ma YL, 2002, ANN NEUROL, V52, P628, DOI 10.1002/ana.10359; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mao LM, 2001, DEV BRAIN RES, V131, P57, DOI 10.1016/S0165-3806(01)00260-7; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; Meltzer CC, 2001, NEUROSURGERY, V49, P586, DOI 10.1097/00006123-200109000-00011; Mendez I, 2002, J NEUROSURG, V96, P589, DOI 10.3171/jns.2002.96.3.0589; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Mujtaba T, 1999, DEV BIOL, V214, P113, DOI 10.1006/dbio.1999.9418; Mukhida K, 2001, J NEUROSCI, V21, P3521, DOI 10.1523/JNEUROSCI.21-10-03521.2001; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nelson PT, 2002, AM J PATHOL, V160, P1201, DOI 10.1016/S0002-9440(10)62546-1; Nogradi A, 1996, EUR J NEUROSCI, V8, P2198, DOI 10.1111/j.1460-9568.1996.tb00741.x; Nowakowski RS, 2001, NEUROPSYCHOPHARMACOL, V25, P799, DOI 10.1016/S0893-133X(01)00379-7; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Palfi S, 1998, NAT MED, V4, P963, DOI 10.1038/nm0898-963; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Piccini P, 2000, ANN NEUROL, V48, P689, DOI 10.1002/1531-8249(200011)48:5<689::AID-ANA1>3.0.CO;2-N; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Polgar S, 2003, BRAIN RES BULL, V60, P1, DOI 10.1016/S0361-9230(03)00017-0; Renoncourt Y, 1998, MECH DEVELOP, V79, P185, DOI 10.1016/S0925-4773(98)00189-0; Roy NS, 2004, NAT BIOTECHNOL, V22, P297, DOI 10.1038/nbt944; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Shim JW, 2004, J NEUROSCI, V24, P843, DOI 10.1523/JNEUROSCI.3977-03.2004; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Steece-Collier K, 2003, MOVEMENT DISORD, V18, P1442, DOI 10.1002/mds.10588; Storch A, 2001, EXP NEUROL, V170, P317, DOI 10.1006/exnr.2001.7706; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Studer L, 2000, J NEUROSCI, V20, P7377; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Teramoto T, 2003, J CLIN INVEST, V111, P1125, DOI 10.1172/JCI200317170; Villa A, 2004, EXP CELL RES, V294, P559, DOI 10.1016/j.yexcr.2003.11.025; Vitek JL, 2002, STEREOT FUNCT NEUROS, V78, P119, DOI 10.1159/000068959; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Willing AE, 2001, BRAIN RES BULL, V56, P525, DOI 10.1016/S0361-9230(01)00625-6; Winkler C, 2000, Prog Brain Res, V127, P233; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Yan J, 2001, J NEUROCHEM, V76, P307, DOI 10.1046/j.1471-4159.2001.00073.x; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhang HX, 2003, J CELL BIOL, V163, P1375, DOI 10.1083/jcb.200308040; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhao M, 2003, P NATL ACAD SCI USA, V100, P7925, DOI 10.1073/pnas.1131955100; Zwaka TP, 2003, NAT BIOTECHNOL, V21, P319, DOI 10.1038/nbt788	108	740	813	2	242	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7		S			S42	S50		10.1038/nm1064	http://dx.doi.org/10.1038/nm1064			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	844YU	15272269				2022-12-27	WOS:000223202100007
J	Haagmans, BL; Kuiken, T; Martina, BE; Fouchier, RAM; Rimmelzwaan, GF; van Amerongen, G; van Riel, D; de Jong, T; Itamura, S; Chan, KH; Tashiro, M; Osterhaus, ADME				Haagmans, BL; Kuiken, T; Martina, BE; Fouchier, RAM; Rimmelzwaan, GF; van Amerongen, G; van Riel, D; de Jong, T; Itamura, S; Chan, KH; Tashiro, M; Osterhaus, ADME			Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; REOVIRUS 1/L INDUCTION; DISTRESS-SYNDROME; LUNG PATHOLOGY; VIRUS; IDENTIFICATION; PNEUMONIA; OUTBREAK; FIBROSIS; MICE	The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus(1-7). Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage(2,7,8). Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d. p. i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-alpha (IFN-alpha) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN- yielded intermediate results. We therefore suggest that pegylated IFN-alpha protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy	Erasmus Med Ctr, Dept Virol, NL-3000 DR Rotterdam, Netherlands; Erasmus Med Ctr, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Erasmus Med Ctr, Dept Pathol, NL-3000 DR Rotterdam, Netherlands; Natl Inst Infect Dis, Dept Viral Dis & Vaccine Control, Tokyo 2080011, Japan; Univ Hong Kong, Queen Mary Hosp, Dept Pathol & Microbiol, Hong Kong, Hong Kong, Peoples R China	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; National Institute of Infectious Diseases (NIID); University of Hong Kong	Osterhaus, ADME (corresponding author), Erasmus Med Ctr, Dept Virol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	a.osterhaus@erasmusmc.nl	Haagmans, Bart/E-9791-2015; Chan, Kwok Hung/ABD-5399-2021; Fouchier, Ron A/A-1911-2014	Haagmans, Bart/0000-0001-6221-2015; Fouchier, Ron A/0000-0001-8095-2869; Osterhaus, Albert/0000-0002-6074-1172; van Riel, Debby/0000-0001-9753-3564				BEDROSSIAN CWM, 1984, AM J CLIN PATHOL, V82, P148, DOI 10.1093/ajcp/82.2.148; Bellum SC, 1997, AM J PATHOL, V150, P2243; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Bukowski RM, 2002, CANCER, V95, P389, DOI 10.1002/cncr.10663; Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; FINTER NB, 1985, INTERFERONS IN VIVO, V4; Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; London L, 2002, CLIN IMMUNOL, V103, P284, DOI 10.1006/clim.2002.5214; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Pei JW, 2001, J INTERF CYTOK RES, V21, P1071, DOI 10.1089/107999001317205204; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; SMITH AL, 1987, ANTIVIR RES, V8, P239, DOI 10.1016/S0166-3542(87)80002-5; TSNAG KW, 2003, NEW ENGL J MED, V348, P1977; TURNER RB, 1986, J INFECT DIS, V154, P443, DOI 10.1093/infdis/154.3.443; Van Gool AR, 2003, PSYCHIAT RES, V119, P125, DOI 10.1016/S0165-1781(03)00113-6; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; WILLIAMS MC, 1990, ELECT MICROSCOPY LUN, P121	29	301	323	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					290	293		10.1038/nm1001	http://dx.doi.org/10.1038/nm1001			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14981511	Green Published, Bronze			2022-12-27	WOS:000189297700041
J	Tang, M; Wang, G; Lu, P; Karas, RH; Aronovitz, M; Heximer, SP; Kaltenbronn, KM; Blumer, KJ; Siderovski, DP; Zhu, Y; Mendelsohn, ME				Tang, M; Wang, G; Lu, P; Karas, RH; Aronovitz, M; Heximer, SP; Kaltenbronn, KM; Blumer, KJ; Siderovski, DP; Zhu, Y; Mendelsohn, ME			Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure	NATURE MEDICINE			English	Article							COUPLED RECEPTOR KINASES; LIGHT-CHAIN PHOSPHATASE; NITRIC-OXIDE SYNTHASE; MYOSIN PHOSPHATASE; THROMBOXANE RECEPTOR; THROMBIN RECEPTOR; HUMAN PLATELETS; MICE LACKING; RAT AORTA; I-BETA	Nitric oxide (NO) inhibits vascular contraction by activating cGMP- dependent protein kinase I-alpha (PKGI-alpha), which causes dephosphorylation of myosin light chain (MLC) and vascular smooth muscle relaxation. Here we show that PKGI-alpha attenuates signaling by the thrombin receptor protease- activated receptor- 1 (PAR- 1) through direct activation of regulator of G- protein signaling- 2 (RGS- 2). NO donors and cGMP cause cGMP- mediated inhibition of PAR- 1 and membrane localization of RGS- 2. PKGI-alpha binds directly to and phosphorylates RGS- 2, which significantly increases GTPase activity of G(q), terminating PAR- 1 signaling. Disruption of the RGS- 2- PKGI-alpha interaction reverses inhibition of PAR- 1 signaling by nitrovasodilators and cGMP. Rgs2(-/-) mice develop marked hypertension, and their blood vessels show enhanced contraction and decreased cGMP-mediated relaxation. Thus, PKGI-alpha binds to, phosphorylates and activates RGS- 2, attenuating receptor- mediated vascular contraction. Our study shows that RGS- 2 is required for normal vascular function and blood pressure and is a new drug development target for hypertension.	Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	Tufts Medical Center; Tufts University; Tufts University; Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA.		Siderovski, David Peter/AAA-9603-2019; Blumer, Kendall J/C-5268-2012	Siderovski, David Peter/0000-0002-0688-8210; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL063494, R29HL056235, R01HL055309, R01HL056069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM065533, R01GM062338] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56235, R01 HL56069, P50 HL63494, R01 HL55309] Funding Source: Medline; NIGMS NIH HHS [P01 GM65533, R01 GM62338] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Beinborn M, 1998, J BIOL CHEM, V273, P14146, DOI 10.1074/jbc.273.23.14146; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Davis MJ, 1999, PHYSIOL REV, V79, P387, DOI 10.1152/physrev.1999.79.2.387; Demoliou-Mason CD, 1998, BIOL SIGNAL RECEPT, V7, P90; Feil R, 2002, CIRC RES, V90, P1080, DOI 10.1161/01.RES.0000019586.95768.40; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Hartshorne DJ, 1999, MOL CELL BIOCHEM, V190, P79, DOI 10.1023/A:1006917032557; HAYNES WG, 1993, LANCET, V342, P931, DOI 10.1016/0140-6736(93)91981-Q; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Heximer SP, 2003, J CLIN INVEST, V111, P1259, DOI 10.1172/JCI200318099C; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HIRATA M, 1990, J BIOL CHEM, V265, P1268; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; INGI T, 1999, J NEUROSCI, V274, P19639; ISHII K, 1994, J BIOL CHEM, V269, P1125; Le TH, 2003, J CLIN INVEST, V111, P441, DOI 10.1172/JCI200317836; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lincoln T.M., 1994, CYCLIC GMP BIOCH PHY, P97; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; RAPOPORT RM, 1986, CIRC RES, V58, P407, DOI 10.1161/01.RES.58.3.407; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Xia CZ, 2001, J BIOL CHEM, V276, P19770, DOI 10.1074/jbc.M006266200; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yamamoto S, 2001, ARCH BIOCHEM BIOPHYS, V393, P97, DOI 10.1006/abbi.2001.2505; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	46	291	307	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1506	1512		10.1038/nm958	http://dx.doi.org/10.1038/nm958			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14608379				2022-12-27	WOS:000186845400034
J	McMichael, AJ; Hanke, T				McMichael, AJ; Hanke, T			HIV vaccines 1983-2003	NATURE MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL RESPONSES; IMMUNE-RESPONSES; LYMPHOCYTE RESPONSES; AIDS VACCINE; MONOCLONAL-ANTIBODIES; PASSIVE-IMMUNIZATION; DIRECT VISUALIZATION; NAIROBI PROSTITUTES; PROTECTIVE EFFICACY	Twenty years after the discovery of HIV, there is still no vaccine. This year, an envelope vaccine aimed at stimulating neutralizing antibodies was unable to protect against infection in phase 3 trials. But more than 20 HIV vaccines designed to stimulate T-cell responses are being developed. Will any of them work?.	John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9D5, England		McMichael, AJ (corresponding author), John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9D5, England.	andrew.mcmichael@imm.ox.ac.uk						Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Appay V, 2002, J IMMUNOL, V168, P3660, DOI 10.4049/jimmunol.168.7.3660; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2001, IMMUNOL LETT, V79, P57, DOI 10.1016/S0165-2478(01)00266-8; BAROUCH DH, IN PRESS NATURE; Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320; Berman PW, 1997, J INFECT DIS, V176, P384, DOI 10.1086/514055; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Boyer J D, 1998, Dev Biol Stand, V95, P147; Boyer JD, 2000, J INFECT DIS, V181, P476, DOI 10.1086/315229; BURROWS SR, 1995, J EXP MED, V182, P1703, DOI 10.1084/jem.182.6.1703; Caley IJ, 1997, J VIROL, V71, P3031, DOI 10.1128/JVI.71.4.3031-3038.1997; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Cao H, 2003, J INFECT DIS, V187, P887, DOI 10.1086/368020; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Currier JR, 2002, J IMMUNOL METHODS, V260, P157, DOI 10.1016/S0022-1759(01)00535-X; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; EGAN MA, 1995, J INFECT DIS, V171, P1623, DOI 10.1093/infdis/171.6.1623; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; Fouts T, 2002, P NATL ACAD SCI USA, V99, P11842, DOI 10.1073/pnas.182412199; Fouts TR, 1995, VACCINE, V13, P1697, DOI 10.1016/0264-410X(95)00106-B; Fu TM, 1997, J VIROL, V71, P2715, DOI 10.1128/JVI.71.4.2715-2721.1997; FULTZ PN, 1992, AIDS RES HUM RETROV, V8, P1517, DOI 10.1089/aid.1992.8.1517; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; GIRARD M, 1995, J VIROL, V69, P6239, DOI 10.1128/JVI.69.10.6239-6248.1995; Girard M, 1997, VIROLOGY, V232, P98, DOI 10.1006/viro.1997.8560; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Hanke T, 2000, NAT MED, V6, P951, DOI 10.1038/79626; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0; Hofmann-Lehmann R, 2001, J MED PRIMATOL, V30, P190, DOI 10.1034/j.1600-0684.2001.d01-52.x; HONE DM, 1994, DEV BIOL STAND, V82, P159; Horton H, 2002, J VIROL, V76, P7187, DOI 10.1128/JVI.76.14.7187-7202.2002; Hsu SC, 1998, INT IMMUNOL, V10, P1441, DOI 10.1093/intimm/10.10.1441; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kaul R, 2001, J CLIN INVEST, V107, P1303, DOI 10.1172/JCI12433; Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714; Kent SJ, 1998, J VIROL, V72, P10180, DOI 10.1128/JVI.72.12.10180-10188.1998; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lifson JD, 2001, J VIROL, V75, P10187, DOI 10.1128/JVI.75.21.10187-10199.2001; Lifson JD, 2000, J VIROL, V74, P2584, DOI 10.1128/JVI.74.6.2584-2593.2000; Lubeck MD, 1997, NAT MED, V3, P651, DOI 10.1038/nm0697-651; MACKETT M, 1985, SCIENCE, V227, P433, DOI 10.1126/science.2981435; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; McMichael A, 2002, NAT REV IMMUNOL, V2, P283, DOI 10.1038/nri779; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; Moore JP, 2001, J VIROL, V75, P5721, DOI 10.1128/JVI.75.13.5721-5729.2001; Mossman SP, 1996, J VIROL, V70, P1953, DOI 10.1128/JVI.70.3.1953-1960.1996; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; Mwau M, 2002, AIDS RES HUM RETROV, V18, P611, DOI 10.1089/088922202760019301; O'Connor D, 2001, IMMUNOL REV, V183, P115, DOI 10.1034/j.1600-065x.2001.1830110.x; O'Connor DH, 2002, DNA CELL BIOL, V21, P659, DOI 10.1089/104454902760330192; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PANICALI D, 1983, P NATL ACAD SCI-BIOL, V80, P5364, DOI 10.1073/pnas.80.17.5364; Pantophlet R, 2003, J VIROL, V77, P642, DOI 10.1128/JVI.77.1.642-658.2003; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIALOUX G, 1995, AIDS RES HUM RETROV, V11, P373, DOI 10.1089/aid.1995.11.373; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Poveda E, 2002, AIDS, V16, P1959, DOI 10.1097/00002030-200209270-00014; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; PUTKONEN P, 1992, J MED PRIMATOL, V21, P108; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Ruprecht RM, 2001, TRANSFUS CLIN BIOL, V8, P350, DOI 10.1016/S1246-7820(01)00187-2; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; SCOTT J, 1995, NAT MED, V1, P295, DOI 10.1038/nm0495-295; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Smith JG, 2001, CLIN DIAGN LAB IMMUN, V8, P871, DOI 10.1128/CDLI.8.5.871-879.2001; Sprent J, 2001, SCIENCE, V293, P245, DOI 10.1126/science.1062416; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Tough DF, 2000, VACCINE, V18, P1642, DOI 10.1016/S0264-410X(99)00500-9; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Vogel TU, 2002, J VIROL, V76, P11623, DOI 10.1128/JVI.76.22.11623-11636.2002; Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656; Wee EGT, 2002, J GEN VIROL, V83, P75, DOI 10.1099/0022-1317-83-1-75; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414; Wilson JDK, 2000, AIDS, V14, P225, DOI 10.1097/00002030-200002180-00003; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Xin KQ, 2001, HUM GENE THER, V12, P1047, DOI 10.1089/104303401750214276; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	112	204	230	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					874	880		10.1038/nm0703-874	http://dx.doi.org/10.1038/nm0703-874			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835708	Bronze			2022-12-27	WOS:000183979300027
J	Ishida, S; Yamashiro, K; Usui, T; Kaji, Y; Ogura, Y; Hida, T; Honda, Y; Oguchi, Y; Adamis, AP				Ishida, S; Yamashiro, K; Usui, T; Kaji, Y; Ogura, Y; Hida, T; Honda, Y; Oguchi, Y; Adamis, AP			Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease	NATURE MEDICINE			English	Article							ENDOTHELIAL-CELL APOPTOSIS; OXIDIZED LDL; IN-VIVO; GROWTH; NEOVASCULARIZATION; EXPRESSION; VEGF; INHIBITOR; SYSTEM; DEATH	Retinal ischemia can cause vision-threatening pathological neovascularization. The mechanisms of retinal ischemia are not fully understood, however. Here we have shown that leukocytes prune the retinal vasculature during normal development and obliterate it in disease. Beginning at postnatal day 5 (P5) in the normal rat, vascular pruning began centrally and extended peripherally, leaving behind a less dense, smaller-caliber vasculature. The pruning was correlated with retinal vascular expression of intercellular adhesion molecule-1 (ICAM-1) and coincided with an outward-moving wave of adherent leukocytes composed in part of cytotoxic T lymphocytes. The leukocytes adhered to the vasculature through CD18 and remodeled it through Fas ligand (FasL)-mediated endothelial cell apoptosis. In a model of oxygen-induced ischemic retinopathy, this process was exaggerated. Leukocytes used CD18 and FasL to obliterate the retinal vasculature, leaving behind large areas of ischemic retina. In vitro, T lymphocytes isolated from oxygen-exposed neonates induced a FasL-mediated apoptosis of hyperoxygenated endothelial cells. Targeting these pathways may prove useful in the treatment of retinal ischemia, a leading cause of vision loss and blindness.	Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Angiogenesis Retina Res Lab, Boston, MA 02114 USA; Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan; Univ Tokyo, Fac Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan; Nagoya City Univ, Med Univ, Dept Ophthalmol, Mizuho Ku, Aichi 4678601, Japan; Kyorin Eye Ctr, Tokyo 1818611, Japan; Eyetech Res Ctr, Woburn, MA 01801 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Keio University; Kyoto University; University of Tokyo; Nagoya City University	Adamis, AP (corresponding author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Angiogenesis Retina Res Lab, 325 Cambridge St, Boston, MA 02114 USA.		ISHIDA, SUSUMU/D-7067-2012	Yamashiro, Kenji/0000-0001-9354-8558	NATIONAL EYE INSTITUTE [R01EY011627, R01EY012611] Funding Source: NIH RePORTER; NEI NIH HHS [EY12611, EY11627] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Aoki T, 1997, ADV EXP MED BIOL, V411, P503; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498; DiezRoux G, 1997, DEVELOPMENT, V124, P3633; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HIRAHARA H, 1995, TRANSPLANTATION, V59, P85, DOI 10.1097/00007890-199501150-00015; Hughes S, 2000, MICROCIRCULATION, V7, P317, DOI 10.1038/sj.mn.7300119; Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nishio K, 1998, AM J RESP CRIT CARE, V157, P599, DOI 10.1164/ajrccm.157.2.9704102; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Wigginton JM, 2001, J CLIN INVEST, V108, P51; Willam C, 1999, AM J PHYSIOL-HEART C, V276, pH2044, DOI 10.1152/ajpheart.1999.276.6.H2044; WILSON RW, 1993, J IMMUNOL, V151, P1571; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624	25	189	195	0	11	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					781	788		10.1038/nm877	http://dx.doi.org/10.1038/nm877			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12730690				2022-12-27	WOS:000183444100036
J	Kabashima, K; Sakata, D; Nagamachi, M; Miyachi, Y; Inaba, K; Narumiya, S				Kabashima, K; Sakata, D; Nagamachi, M; Miyachi, Y; Inaba, K; Narumiya, S			Prostaglandin E-2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells	NATURE MEDICINE			English	Article							IMMUNOSTIMULATORY DENDRITIC CELLS; CONTACT HYPERSENSITIVITY; IL-12 PRODUCTION; HUMAN KERATINOCYTES; DOWN-REGULATION; UP-REGULATION; MICE LACKING; LYMPH-NODES; RECEPTOR; EXPRESSION	Antigen-specific immune responses in the skin are initiated by antigen uptake into Langerhans cells and the subsequent migration of these cells to draining lymph nodes. Although prostaglandin E-2 (PGE(2)) is produced substantially in skin exposed to antigen, its role remains unclear. Here we show that although Langerhans cells express all four PGE receptor subtypes, their migration to regional lymph nodes was decreased only in EP4-deficient (Ptger4(-/-)) mice and in wild-type mice treated with an EP4 antagonist. An EP4 agonist promoted the migration of Langerhans cells, increased their expression of costimulatory molecules and enhanced their ability to stimulate T cells in the mixed lymphocyte reaction in vitro. Contact hypersensitivity to antigen was impaired in Ptger4(-/-) mice and in wild-type mice treated with the EP4 antagonist during sensitization. PGE(2)-EP4 signaling thus facilitates initiation of skin immune responses by promoting the migration and maturation of Langerhans cells.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan; Kyoto Univ, Fac Med, Dept Dermatol, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Anim Dev & Physiol, Kyoto 6068502, Japan	Kyoto University; Kyoto University; Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan.		Kabashima, Kenji/G-2521-2014	Kabashima, Kenji/0000-0002-0773-0554				Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2; Chen AI, 1999, IMMUNITY, V11, P689, DOI 10.1016/S1074-7613(00)80143-0; Daugschies A, 1998, INT J PARASITOL, V28, P355, DOI 10.1016/S0020-7519(97)00153-7; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Eberhard J, 2002, CLIN DIAGN LAB IMMUN, V9, P132, DOI 10.1128/CDLI.9.1.132-137.2002; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GRABBE S, 1995, J IMMUNOL, V155, P4207; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; INABA K, 1986, J EXP MED, V164, P605, DOI 10.1084/jem.164.2.605; JAFFER S, 1995, AM J NEPHROL, V15, P300, DOI 10.1159/000168853; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kimber I, 2000, BRIT J DERMATOL, V142, P401, DOI 10.1046/j.1365-2133.2000.03349.x; KURIMOTO I, 1993, J INVEST DERMATOL, V101, P132, DOI 10.1111/1523-1747.ep12363616; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; Luft T, 2002, BLOOD, V100, P1362, DOI 10.1182/blood-2001-12-0360; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Ortner U, 1996, J IMMUNOL METHODS, V193, P71, DOI 10.1016/0022-1759(96)00058-0; RAO TS, 1993, INFLAMMATION, V17, P723, DOI 10.1007/BF00920477; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; RUZICKA T, 1982, INT ARCH ALLER A IMM, V69, P347, DOI 10.1159/000233198; Rys-Sikora KE, 2000, AM J PHYSIOL-CELL PH, V278, pC822, DOI 10.1152/ajpcell.2000.278.4.C822; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shinomiya S, 2001, BIOCHEM PHARMACOL, V61, P1153, DOI 10.1016/S0006-2952(01)00586-X; SILBERBERGSINAKIN I, 1976, CELL IMMUNOL, V25, P137, DOI 10.1016/0008-8749(76)90105-2; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; WARREN HS, 1986, ANNU REV IMMUNOL, V4, P369, DOI 10.1146/annurev.iy.04.040186.002101; Weinlich G, 1998, J INVEST DERMATOL, V110, P441, DOI 10.1046/j.1523-1747.1998.00161.x; Whittaker DS, 2000, J IMMUNOL, V165, P4298, DOI 10.4049/jimmunol.165.8.4298	42	244	257	1	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					744	749		10.1038/nm872	http://dx.doi.org/10.1038/nm872			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740571				2022-12-27	WOS:000183444100030
J	Akbari, O; Stock, P; Meyer, E; Kronenberg, M; Sidobre, S; Nakayama, T; Taniguchi, M; Grusby, MJ; DeKruyff, RH; Umetsu, DT				Akbari, O; Stock, P; Meyer, E; Kronenberg, M; Sidobre, S; Nakayama, T; Taniguchi, M; Grusby, MJ; DeKruyff, RH; Umetsu, DT			Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity	NATURE MEDICINE			English	Article							KILLER T-CELLS; NONOBESE DIABETIC MICE; ALPHA-GALACTOSYLCERAMIDE; INTERLEUKIN (IL)-4; INTERFERON-GAMMA; ASTHMA; RESPONSES; HYPERRESPONSIVENESS; INFLAMMATION; ASSOCIATION	Using natural killer T (NKT) cell-deficient mice, we show here that allergen-induced airway hyperreactivity (AHR), a cardinal feature of asthma, does not develop in the absence of V(alpha)14i NKT cells. The failure of NKT cell-deficient mice to develop AHR is not due to an inability of these mice to produce type 2 T-helper (Th2) responses because NKT cell-deficient mice that are immunized subcutaneously at non-mucosal sites produce normal Th2-biased responses. The failure to develop AHR can be reversed by the adoptive transfer of tetramer-purified NKT cells producing interleukin (IL)-4 and IL-13 to Ja281(-/-) mice, which lack the invariant T-cell receptor (TCR) of NKT cells, or by the administration to Cd1d(-/-) mice of recombinant IL-13, which directly affects airway smooth muscle cells. Thus, pulmonary V(alpha)14i NKT cells crucially regulate the development of asthma and Th2-biased respiratory immunity against nominal exogenous antigens. Therapies that target V(alpha)14i NKT cells may be clinically effective in limiting the development of AHR and asthma.	Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA; La Jolla Inst Allergy & Immunol, Div Dev Immunol, San Diego, CA USA; Chiba Univ, Grad Sch Med, Chiba, Japan; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Stanford University; La Jolla Institute for Immunology; Chiba University; Harvard University; Harvard T.H. Chan School of Public Health	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA.		Taniguchi, Masaru/N-7932-2015; Nakayama, Toshinori/E-1067-2017	Taniguchi, Masaru/0000-0001-7821-7179; Nakayama, Toshinori/0000-0002-1434-2007	NATIONAL CANCER INSTITUTE [R01CA052511] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040171, T32AI007290, R01AI026322, R01AI040171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062135] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52511] Funding Source: Medline; NHLBI NIH HHS [R01 HL62348] Funding Source: Medline; NIAID NIH HHS [T32AI07290, AI40171, R01 AI26322] Funding Source: Medline; NIGMS NIH HHS [GM62135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Carnaud C, 1999, J IMMUNOL, V163, P4647; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Cui JQ, 1999, J EXP MED, V190, P783, DOI 10.1084/jem.190.6.783; Gombert JM, 1996, EUR J IMMUNOL, V26, P2989, DOI 10.1002/eji.1830261226; Haczku A, 2001, AM J RESP CELL MOL, V25, P45, DOI 10.1165/ajrcmb.25.1.4391; Hammond KJL, 1998, J EXP MED, V187, P1047, DOI 10.1084/jem.187.7.1047; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hong S, 2001, NAT MED, V7, P1052, DOI 10.1038/nm0901-1052; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee PT, 2002, J CLIN INVEST, V110, P793, DOI 10.1172/JCI200215832; Lehuen A, 1998, J EXP MED, V188, P1831, DOI 10.1084/jem.188.10.1831; Leishman AJ, 2002, IMMUNITY, V16, P355, DOI 10.1016/S1074-7613(02)00284-4; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Matsuda JL, 2002, NAT IMMUNOL, V3, P966, DOI 10.1038/ni837; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Miyamoto K, 2001, NATURE, V413, P531, DOI 10.1038/35097097; Nieuwenhuis EES, 2002, NAT MED, V8, P588, DOI 10.1038/nm0602-588; SANDER B, 1991, SCAND J IMMUNOL, V33, P287, DOI 10.1111/j.1365-3083.1991.tb01774.x; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wang B, 2001, J EXP MED, V194, P313, DOI 10.1084/jem.194.3.313; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507; 1998, MORB MORTAL WKLY REP, V47, P1022	46	552	596	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					582	588		10.1038/nm851	http://dx.doi.org/10.1038/nm851			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12669034				2022-12-27	WOS:000182610600040
J	Gratton, JP; Yu, J; Griffith, JW; Babbitt, RW; Scotland, RS; Hickey, R; Giordano, FJ; Sessa, WC				Gratton, JP; Yu, J; Griffith, JW; Babbitt, RW; Scotland, RS; Hickey, R; Giordano, FJ; Sessa, WC			Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo	NATURE MEDICINE			English	Article							PROTEIN TRANSDUCTION DOMAIN; INTRACELLULAR DELIVERY; ANGIOGENESIS; PENETRATIN; RETROVIRUS; MOUSE	Small polybasic peptides derived from the transduction domains of certain proteins, such as the third alpha-helix of the Antennapedia (Antp) homeodomain, can cross the cell membrane through a receptor-independent mechanism. These cell-permeable molecules have been used as 'Trojan horses' to introduce biologically active cargo molecules such as DNA, peptides or proteins into cells. Using these cell-permeable peptides, we have developed an efficient and simple method to increase virally mediated gene delivery and protein expression in vitro and in vivo. Here, we show that cell-permeable peptides increase viral cell entry, improve gene expression at reduced titers of virus and improve efficacy of therapeutically relevant genes in vivo.	Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cardiovasc Med,Boyer Ctr Mol Med, Vasc Cell Signaling & Therapeut Program, New Haven, CT 06510 USA	Yale University; Yale University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, New Haven, CT 06510 USA.	william.sessa@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Gratton, Jean-Philippe/0000-0001-9877-8520	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R37HL061371, R01HL064793, R01HL061371] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL57665, HL64793, HL61371] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baek S, 1998, CIRC RES, V82, P295, DOI 10.1161/01.RES.82.3.295; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Cullen BR, 2001, CELL, V105, P697, DOI 10.1016/S0092-8674(01)00392-0; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; Le Doux JM, 2001, HUM GENE THER, V12, P1611, DOI 10.1089/10430340152528110; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Pizzato M, 1999, J VIROL, V73, P8599, DOI 10.1128/JVI.73.10.8599-8611.1999; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scotland RS, 2002, CIRC RES, V90, P904, DOI 10.1161/01.RES.0000016506.04193.96; Sharma S, 2000, J VIROL, V74, P10790, DOI 10.1128/JVI.74.22.10790-10795.2000; Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665	17	157	177	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					357	362		10.1038/nm835	http://dx.doi.org/10.1038/nm835			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12598894				2022-12-27	WOS:000181312300039
J	Ghoreschi, K; Thomas, P; Breit, S; Dugas, M; Mailhammer, R; van Eden, W; van der Zee, R; Biedermann, T; Prinz, J; Mack, M; Mrowietz, U; Christophers, E; Schlondorff, D; Plewig, G; Sander, CA; Rocken, M				Ghoreschi, K; Thomas, P; Breit, S; Dugas, M; Mailhammer, R; van Eden, W; van der Zee, R; Biedermann, T; Prinz, J; Mack, M; Mrowietz, U; Christophers, E; Schlondorff, D; Plewig, G; Sander, CA; Rocken, M			Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease	NATURE MEDICINE			English	Article							RECOMBINANT HUMAN INTERLEUKIN-4; CYTOTOXIC T-LYMPHOCYTE; TUMOR-NECROSIS-FACTOR; PHASE-II; HYPERSENSITIVITY REACTIONS; MULTIPLE-SCLEROSIS; IMMUNE DEVIATION; DENDRITIC CELLS; IN-VITRO; ANTIGEN	Selective skewing of autoreactive interferon-gamma (IFN-gamma)-producing T helper cells (Th1) toward an interleukin-4 (IL-4)-producing (Th2) phenotype can in experimental animals alleviate autoimmune disease without inducing general immunosuppression. In a prospective dose escalation study, we assessed treatment with human IL-4 (rhuIL-4) in 20 patients with severe psoriasis. The therapy was well tolerated, and within six weeks all patients showed decreased clinical scores and 15 improved more than 68%. Stable reduction of clinical scores was significantly better at 0.2-0.5 mug rhuIL-4 than at less than or equal to0.1 mug rhuIL-4 (P = 0.009). In psoriatic lesions, treatment with 0.2-0.5 mug/kg rhuIL-4 reduced the concentrations of IL-8 and IL-19, two cytokines directly involved in psoriasis; the number of chemokine receptor CCR5(+) Th1 cells; and the IFN-gamma/IL-4 ratio. In the circulation, 0.2-0.5 mug/kg rhuIL-4 increased the number of IL-4(+)CD4(+) T cells two- to three-fold. Thus, IL-4 therapy can induce Th2 differentiation in human CD4(+) T cells and has promise as a potential treatment for psoriasis, a prototypic Th1-associated autoimmune disease.	Univ Munich, Dept Dermatol & Allergol, Munich, Germany; Univ Munich, Inst Biometr, Munich, Germany; Univ Munich, Dept Internal Med, Munich, Germany; GSF Munich, Forschungszentrum, Munich, Germany; Univ Utrecht, Fac Vet Med, Inst Infect Dis & Immunol, NL-3508 TC Utrecht, Netherlands; Univ Kiel, Dept Dermatol, D-2300 Kiel, Germany; Univ Tubingen, Dept Dermatol, Tubingen, Germany	University of Munich; University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Utrecht University; University of Kiel; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Rocken, M (corresponding author), Univ Munich, Dept Dermatol & Allergol, Munich, Germany.	mrocken@med.uni-tuebingen.de	Dugas, Susanne/G-6201-2011; Mrowietz, U/B-1645-2010; Prinz, Jörg/AAP-9472-2021; van der Zee, Ruurd/O-5256-2015; Dugas, Martin/F-5454-2011	Mrowietz, U/0000-0002-9539-0712; van der Zee, Ruurd/0000-0002-4331-2755; Rocken, Martin/0000-0003-3795-7001; Biedermann, Tilo/0000-0002-5352-5105; Ghoreschi, Kamran/0000-0002-5526-7517; van Eden, Willem/0000-0003-1272-704X				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abrams JR, 2000, J EXP MED, V192, P681, DOI 10.1084/jem.192.5.681; [Anonymous], 1996, Arch Dermatol, V132, P419; Asadullah K, 2001, J INVEST DERMATOL, V116, P721, DOI 10.1046/j.0022-202x.2001.01317.x; Austin LM, 1999, J INVEST DERMATOL, V113, P752, DOI 10.1046/j.1523-1747.1999.00749.x; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; Biedermann T, 2001, EUR J IMMUNOL, V31, P1582, DOI 10.1002/1521-4141(200105)31:5<1582::AID-IMMU1582>3.0.CO;2-M; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Breit S, 1996, EUR J IMMUNOL, V26, P1860, DOI 10.1002/eji.1830260829; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; Christophers E., 1999, PSORIASIS EPIDERMIS, V5th, P495; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; Granstein RD, 2001, NEW ENGL J MED, V345, P284, DOI 10.1056/NEJM200107263450410; Kalinski P, 2000, J IMMUNOL, V165, P1877, DOI 10.4049/jimmunol.165.4.1877; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Koch AE, 2001, ARTHRITIS RHEUM-US, V44, P31, DOI 10.1002/1529-0131(200101)44:1<31::AID-ANR5>3.0.CO;2-4; Krueger G, 2001, ARCH DERMATOL, V137, P280; Leach MW, 1997, CLIN IMMUNOL IMMUNOP, V83, P12, DOI 10.1006/clin.1997.4304; Lebwohl M, 1998, J AM ACAD DERMATOL, V39, P464, DOI 10.1016/S0190-9622(98)70325-1; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Luftl M, 1997, ARCH DERMATOL, V133, P1597, DOI 10.1001/archderm.133.12.1597; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; MAZZUCCHELLI L, 1994, AM J PATHOL, V144, P997; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NESTLE FO, 1994, J CLIN INVEST, V94, P202, DOI 10.1172/JCI117308; Nickoloff BJ, 1999, AM J PATHOL, V155, P145, DOI 10.1016/S0002-9440(10)65109-7; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Prinz JC, 1999, EUR J IMMUNOL, V29, P3360, DOI 10.1002/(SICI)1521-4141(199910)29:10<3360::AID-IMMU3360>3.0.CO;2-G; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; Reich K, 2001, J INVEST DERMATOL, V116, P319, DOI 10.1046/j.1523-1747.2001.01248.x; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; Rocken M, 1996, IMMUNOL TODAY, V17, P225, DOI 10.1016/0167-5699(96)80556-1; ROCKEN M, 1994, J EXP MED, V179, P1885, DOI 10.1084/jem.179.6.1885; Rodriguez-Palmero M, 1999, EUR J IMMUNOL, V29, P3914; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473; Trepicchio WL, 1999, J CLIN INVEST, V104, P1527, DOI 10.1172/JCI6910; Vokes EE, 1998, CANCER J SCI AM, V4, P46; Whitehead RP, 1998, J IMMUNOTHER, V21, P440, DOI 10.1097/00002371-199811000-00006; WONG HL, 1993, J EXP MED, V177, P775, DOI 10.1084/jem.177.3.775	46	323	344	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					40	46		10.1038/nm804	http://dx.doi.org/10.1038/nm804			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12461524				2022-12-27	WOS:000180209900020
J	Reiter, CD; Wang, XD; Tanus-Santos, JE; Hogg, N; Cannon, RO; Schechter, AN; Gladwin, MT				Reiter, CD; Wang, XD; Tanus-Santos, JE; Hogg, N; Cannon, RO; Schechter, AN; Gladwin, MT			Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease	NATURE MEDICINE			English	Article							REGIONAL BLOOD-FLOW; PULMONARY-HYPERTENSION; MEDIATED VASODILATION; ERYTHROCYTES; ERYTHROPOIETIN; AUTOXIDATION; INSTABILITY; CONSUMPTION; ENDOTHELIUM; DETERMINES	Although the deleterious vasoconstrictive effects of cell-free, hemoglobin-based blood substitutes have been appreciated, the systemic effects of chronic hemolysis on nitric oxide bioavailability have not been considered or quantified. Central to this investigation is the understanding that nitric oxide reacts at least 1,000 times more rapidly with free hemoglobin solutions than with erythrocytes. We hypothesized that decompartmentalization of hemoglobin into plasma would divert nitric oxide from homeostatic vascular function. We demonstrate here that plasma from patients with sickle-cell disease contains cell-free ferrous hemoglobin, which stoichiometrically consumes micromolar quantities of nitric oxide and abrogates forearm blood flow responses to nitric oxide donor infusions. Therapies that inactivate plasma hemoglobin by oxidation or nitric oxide ligation restore nitric oxide bioavailability. Decompartmentalization of hemoglobin and subsequent dioxygenation of nitric oxide may explain the vascular complications shared by acute and chronic hemolytic disorders.	NIDDK, Dept Crit Care Med, Warren G Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NIDDK, Biol Chem Lab, NIH, Bethesda, MD USA; Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Medical College of Wisconsin; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Gladwin, MT (corresponding author), NIDDK, Dept Crit Care Med, Warren G Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA.		Tanus-Santos, Jose/A-4451-2008	Schechter, Alan N/0000-0002-5235-9408	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055792, R01GM055792] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NIGMS NIH HHS [GM55792] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Banerjee D, 2000, KIDNEY INT, V57, P1895, DOI 10.1046/j.1523-1755.2000.00039.x; Belhassen L, 2001, BLOOD, V97, P1584, DOI 10.1182/blood.V97.6.1584; BENSINGER TA, 1974, ARCH INTERN MED, V133, P624, DOI 10.1001/archinte.133.4.624; Browne P, 1998, FREE RADICAL BIO MED, V24, P1040, DOI 10.1016/S0891-5849(97)00391-2; Butler AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; CARLSEN E, 1958, J GEN PHYSIOL, V42, P83, DOI 10.1085/jgp.42.1.83; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; COIN JT, 1979, J BIOL CHEM, V254, P1178; DE CR, 1995, J CLIN INVEST, V96, P60; deFigueiredo LFP, 1997, J TRAUMA, V42, P847; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gladwin MT, 1999, J CLIN INVEST, V104, P937, DOI 10.1172/JCI7637; Han TH, 2002, P NATL ACAD SCI USA, V99, P7763, DOI 10.1073/pnas.122118299; HEBBEL RP, 1988, P NATL ACAD SCI USA, V85, P237, DOI 10.1073/pnas.85.1.237; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Huang KT, 2001, P NATL ACAD SCI USA, V98, P11771, DOI 10.1073/pnas.201276698; Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225; Kaul DK, 2000, AM J PHYSIOL-HEART C, V278, pH1799, DOI 10.1152/ajpheart.2000.278.6.H1799; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LEE R, 1995, J APPL PHYSIOL, V79, P236, DOI 10.1152/jappl.1995.79.1.236; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Morris CR, 2000, BRIT J HAEMATOL, V111, P498, DOI 10.1046/j.1365-2141.2000.02403.x; MURRAY JA, 1995, GASTROENTEROLOGY, V109, P1241, DOI 10.1016/0016-5085(95)90584-7; Nath KA, 2000, AM J PHYSIOL-REG I, V279, pR1949, DOI 10.1152/ajpregu.2000.279.6.R1949; NAUMANN HN, 1971, AM J CLIN PATHOL, V56, P137; POHL U, 1991, BASIC RES CARDIOL, V86, P97; Rassaf T, 2002, J CLIN INVEST, V109, P1241, DOI 10.1172/JCI200214995; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Setty BNY, 1996, BLOOD, V88, P2311, DOI 10.1182/blood.V88.6.2311.bloodjournal8862311; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Ulatowski JA, 1996, CRIT CARE MED, V24, P558, DOI 10.1097/00003246-199604000-00003; Vaughn MW, 1998, AM J PHYSIOL-HEART C, V274, pH1705, DOI 10.1152/ajpheart.1998.274.5.H1705; Vaughn MW, 2000, J BIOL CHEM, V275, P2342, DOI 10.1074/jbc.275.4.2342; VOGEL W, 1986, AM J PHYSIOL, V251, P413	48	948	981	2	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1383	1389		10.1038/nm799	http://dx.doi.org/10.1038/nm799			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12426562				2022-12-27	WOS:000179552000034
J	McShane, H; Pathan, AA; Sander, CR; Keating, SM; Gilbert, SC; Huygen, K; Fletcher, HA; Hill, AVS				McShane, H; Pathan, AA; Sander, CR; Keating, SM; Gilbert, SC; Huygen, K; Fletcher, HA; Hill, AVS			Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans	NATURE MEDICINE			English	Article							MYCOBACTERIUM-BOVIS BCG; T-CELL IMMUNOGENICITY; PROTECTIVE EFFICACY; ENHANCED IMMUNOGENICITY; VACCINATION REGIMEN; ADENOVIRAL VACCINE; INTERFERON-GAMMA; TUBERCULOSIS; DNA; RESPONSES	Protective immunity against Mycobacterium tuberculosis depends on the generation of a T(H)1-type cellular immune response, characterized by the secretion of interferon-gamma (IFN-gamma) from antigen-specific T cells. The induction of potent cellular immune responses by vaccination in humans has proven difficult. Recombinant viral vectors, especially poxviruses and adenoviruses, are particularly effective at boosting previously primed CD4(+) and CD8(+) T-cell responses against a number of intracellular pathogens in animal studies(1-7). In the first phase 1 study of any candidate subunit vaccine against tuberculosis, recombinant modified vaccinia virus Ankara (MVA) expressing antigen 85A (MVA85A) was found to induce high levels of antigen-specific IFN-gamma-secreting T cells when used alone in bacille Calmette-Guerin (BCG)-naive healthy volunteers. In volunteers who had been vaccinated 0.5-38 years previously with BCG, substantially higher levels of antigen-specific IFN-gamma-secreting T cells were induced, and at 24 weeks after vaccination these levels were 5-30 times greater than in vaccinees administered a single BCG vaccination. Boosting vaccinations with MVA85A could offer a practical and efficient strategy for enhancing and prolonging antimycobacterial immunity in tuberculosis-endemic areas.	Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Inst Pasteur, Lab Mycobacterial Immunol, Brussels, Belgium	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	McShane, H (corresponding author), Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, S Parks Rd, Oxford OX3 7LJ, England.	helen.mcshane@ndm.ox.ac.uk	Fletcher, Helen/D-1470-2011; HILL, Adrian V>S>/C-1306-2008; Gilbert, Sarah C./H-2857-2019	Gilbert, Sarah C./0000-0002-6823-9750; Keating, Sheila/0000-0002-8324-3694; Fletcher, Helen/0000-0002-0435-1006; McShane, Helen/0000-0002-2126-5142; Huygen, Kris/0000-0001-7808-0512	Wellcome Trust [063643] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8; Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002; Caruso AM, 1999, J IMMUNOL, V162, P5407; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Cosma A, 2003, VACCINE, V22, P21, DOI 10.1016/S0264-410X(03)00538-3; D'Souza S, 2003, INFECT IMMUN, V71, P483, DOI 10.1128/IAI.71.1.483-493.2003; DEBRUYN J, 1987, MICROB PATHOGENESIS, V2, P351, DOI 10.1016/0882-4010(87)90077-5; Ellner JJ, 2000, CLIN INFECT DIS, V30, pS279, DOI 10.1086/313874; Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6; Gilbert SC, 2002, VACCINE, V20, P1039, DOI 10.1016/S0264-410X(01)00450-9; Godkin AJ, 2002, J IMMUNOL, V169, P2210, DOI 10.4049/jimmunol.169.4.2210; Goonetilleke NP, 2003, J IMMUNOL, V171, P1602, DOI 10.4049/jimmunol.171.3.1602; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; LAUNOIS P, 1994, INFECT IMMUN, V62, P3679, DOI 10.1128/IAI.62.9.3679-3687.1994; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; McShane H, 2002, INFECT IMMUN, V70, P1623, DOI 10.1128/IAI.70.3.1623-1626.2002; McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001; Mwau M, 2004, J GEN VIROL, V85, P911, DOI 10.1099/vir.0.19701-0; Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.3.CO;2-W; Weir RE, 2003, CLIN EXP IMMUNOL, V134, P285, DOI 10.1046/j.1365-2249.2003.02272	28	483	525	1	26	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2004	10	11					1240	1244		10.1038/nm1128	http://dx.doi.org/10.1038/nm1128			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502839				2022-12-27	WOS:000224785900047
J	Rappuoli, R				Rappuoli, R			From Pasteur to genomics: progress and challenges in infectious diseases	NATURE MEDICINE			English	Editorial Material							C CONJUGATE VACCINE; H5N1 INFLUENZA; VIRUS; HIV-1; RESISTANCE; HEALTH; SARS; IDENTIFICATION; CORONAVIRUS; STRATEGIES	Over the past decade, microbiology and infectious disease research have undergone the most profound revolution since the times of Pasteur. Genomic sequencing has revealed the much-awaited blueprint of most pathogens. Screening blood for the nucleic acids of infectious agents has blunted the spread of pathogens by transfusion, the field of antiviral therapeutics has exploded and technologies for the development of novel and safer vaccines have become available. The quantum jump in our ability to detect, prevent and treat infectious diseases resulting from improved technologies and genomics was moderated during this period by the greatest emergence of new infectious agents ever recorded and a worrisome increase in resistance to existing therapies. Dozens of new infectious diseases are expected to emerge in the coming decades. Controlling these diseases will require a better understanding of the worldwide threat and economic burden of infectious diseases and a global agenda.	Chiron Vaccines, I-53100 Siena, Italy	Novartis	Rappuoli, R (corresponding author), Chiron Vaccines, Via Fiorentina 1, I-53100 Siena, Italy.	rino_rappuoli@chiron.com						Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; Behring E, 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI [10.1055/s-0029-1207589, DOI 10.1055/S-0029-1207589]; Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101; Bleharski JR, 2003, SCIENCE, V301, P1527, DOI 10.1126/science.1087785; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Busch MP, 2003, JAMA-J AM MED ASSOC, V289, P959, DOI 10.1001/jama.289.8.959; Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974; Cascales E, 2003, NAT REV MICROBIOL, V1, P137, DOI 10.1038/nrmicro753; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Clifford RJ, 2004, ANN NY ACAD SCI, V1020, P101, DOI 10.1196/annals.1310.011; Cooper BS, 2004, P NATL ACAD SCI USA, V101, P10223, DOI 10.1073/pnas.0401324101; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Cossart P, 1996, SCIENCE, V271, P315, DOI 10.1126/science.271.5247.315; COSTANTINO P, 1992, VACCINE, V10, P691, DOI 10.1016/0264-410X(92)90091-W; De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703; Field H.J., 2004, MICROBIOLOGY TODAY, V31, P58, DOI [DOI 10.1016/J.AGEE.2005.08.0.10, 10.1016/j.agee.2005.08.0.10]; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Flannery B, 2004, JAMA-J AM MED ASSOC, V291, P2197, DOI 10.1001/jama.291.18.2197; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Giles J, 2004, NATURE, V429, P331, DOI 10.1038/429331a; Gostin LO, 2004, JAMA-J AM MED ASSOC, V291, P2623, DOI 10.1001/jama.291.21.2623; Granwehr BP, 2004, LANCET INFECT DIS, V4, P547, DOI 10.1016/S1473-3099(04)01128-4; Guan Y, 2004, P NATL ACAD SCI USA, V101, P8156, DOI 10.1073/pnas.0402443101; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Hamelin ME, 2004, CLIN INFECT DIS, V38, P983, DOI 10.1086/382536; HARRIS DA, 2004, MAD COW DIS RELATED, P219; Houghton M, 2004, NEW GENERATION VACCI, P593; Howard K, 2003, NAT BIOTECHNOL, V21, P1441, DOI 10.1038/nbt1203-1441; Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Leroy EM, 2004, SCIENCE, V303, P387, DOI 10.1126/science.1092528; Levy SB, 2001, CLIN INFECT DIS, V33, pS124, DOI 10.1086/321837; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Lowy FD, 2003, J CLIN INVEST, V111, P1265, DOI 10.1172/JC1200318535; Markina SS, 2000, J INFECT DIS, V181, pS27, DOI 10.1086/315535; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; MCDANIEL TK, 2000, CELLULAR MICROBIOLOG, P333; McHutchison JG, 2004, AM J MANAG CARE, V10, pS21; MCNEILL WH, 1998, PLAGUES PEOPLES, P365; Minor PD, 2004, NAT REV MICROBIOL, V2, P473, DOI 10.1038/nrmicro906; Mora M, 2003, DRUG DISCOV TODAY, V8, P459, DOI 10.1016/S1359-6446(03)02689-8; Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759; Mueller A, 2003, P NATL ACAD SCI USA, V100, P12289, DOI 10.1073/pnas.1635231100; Normile D, 2004, SCIENCE, V305, P321; Ramsay ME, 2001, LANCET, V357, P195, DOI 10.1016/S0140-6736(00)03594-7; Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3; Reacher MH, 2000, BMJ-BRIT MED J, V320, P213, DOI 10.1136/bmj.320.7229.213; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Relman DA, 1999, SCIENCE, V284, P1308, DOI 10.1126/science.284.5418.1308; Roberts L, 2004, SCIENCE, V305, P24, DOI 10.1126/science.305.5680.24; Roig J, 2003, CURR OPIN INFECT DIS, V16, P145, DOI 10.1097/00001432-200304000-00011; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; Schmidt FR, 2004, APPL MICROBIOL BIOT, V63, P335, DOI 10.1007/s00253-003-1344-1; Shiver JW, 2004, ANNU REV MED, V55, P355, DOI 10.1146/annurev.med.55.091902.104344; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775; Steinbrook R, 2004, NEW ENGL J MED, V351, P115, DOI 10.1056/NEJMp048156; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876; Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080; Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; WALTERS MJ, 2003, 6 MODERN PLAGUES, P19	65	80	87	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1177	1185		10.1038/nm1129	http://dx.doi.org/10.1038/nm1129			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15516917	Green Published			2022-12-27	WOS:000224785900037
J	Seo, SK; Choi, JH; Kim, YH; Kang, WJ; Park, HY; Suh, JH; Choi, BK; Vinay, DS; Kwon, BS				Seo, SK; Choi, JH; Kim, YH; Kang, WJ; Park, HY; Suh, JH; Choi, BK; Vinay, DS; Kwon, BS			4-1BB-mediated immunotherapy of rheumatoid arthritis	NATURE MEDICINE			English	Article							T-CELL PROLIFERATION; MONOCLONAL-ANTIBODIES; TRYPTOPHAN CATABOLISM; IN-VIVO; 4-1BB LIGAND; EXPRESSION; PATHOGENESIS; DISEASE	Collagen type II-induced arthritis is a CD4(+) T-cell-dependent chronic inflammation in susceptible DBA/1 mice and represents an animal model of human rheumatoid arthritis. We found that development of this condition, and even established disease, are inhibited by an agonistic anti-4-1BB monoclonal antibody. Anti-4-1BB suppressed serum antibodies to collagen type II and CD4(+) T-cell recall responses to collagen type II. Crosslinking of 4-1BB evoked an antigen-specific, active suppression mechanism that differed from the results of blocking the interaction between 4-1BB and its ligand, 4-1BBL. Anti-4-1BB monoclonal antibodies induced massive, antigen-dependent clonal expansion of CD11c(+)CD8(+) T cells and accumulation of indoleamine 2,3-dioxygenase in CD11b(+) monocytes and CD11c(+) dendritic cells. Both anti-interferon-gamma and 1-methyltryptophan, a pharmacological inhibitor of indoleamine 2,3-dioxygenase, reversed the anti-4-1BB effect. We conclude that the suppression of collagen-induced arthritis was caused by an expansion of new CD11c(+)CD8(+) T cells, and that interferon-gamma produced by these cells suppresses antigen-specific CD4(+) T cells through an indoleamine 2,3-dioxygenase-dependent mechanism.	Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea; Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Pathol, Ulsan 682060, South Korea; Louisiana State Univ, Ctr Eye, Hlth Sci Ctr, New Orleans, LA 70112 USA	University of Ulsan; University of Ulsan; Ulsan University Hospital; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Kwon, BS (corresponding author), Univ Ulsan, Immunomodulat Res Ctr, 29 Mukeo Dong, Ulsan 680749, South Korea.	bskwon@mail.ulsan.ac.kr	康, 宇鎭/GRO-6256-2022	Kang, Woojin/0000-0002-4880-3406	NATIONAL EYE INSTITUTE [R01EY013325, P30EY002377] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY013325, P30EY002377] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arend WP, 1997, ARTHRITIS RHEUM, V40, P595, DOI 10.1002/art.1780400402; Bertram EM, 2002, J IMMUNOL, V168, P3777, DOI 10.4049/jimmunol.168.8.3777; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; EDWARDS D, 1987, BIOMETRICS, V43, P913, DOI 10.2307/2531545; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Foell J, 2003, J CLIN INVEST, V111, P1505, DOI 10.1172/JCI200317662; Futagawa T, 2002, INT IMMUNOL, V14, P275, DOI 10.1093/intimm/14.3.275; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Halstead ES, 2002, NAT IMMUNOL, V3, P536, DOI 10.1038/ni798; Holmdahl R, 2002, AGEING RES REV, V1, P135, DOI 10.1016/S0047-6374(01)00371-2; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; Mellor AL, 2003, J IMMUNOL, V170, P5809, DOI 10.4049/jimmunol.170.12.5809; Milliken G. A., 1984, ANAL MESSY DATA; Mittler RS, 1999, J EXP MED, V190, P1535, DOI 10.1084/jem.190.10.1535; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Myers L, 2003, P NATL ACAD SCI USA, V100, P5348, DOI 10.1073/pnas.0837611100; NAKAJIMA H, 1990, CLIN EXP IMMUNOL, V81, P441; POLLOK KE, 1993, J IMMUNOL, V150, P771; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Sun YL, 2002, NAT MED, V8, P1405, DOI 10.1038/nm796; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; Ye ZM, 2002, NAT MED, V8, P343, DOI 10.1038/nm0402-343; ZVAIFLER NJ, 1983, AM J MED, V75, P3, DOI 10.1016/0002-9343(83)90469-2	28	263	286	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1088	1094		10.1038/nm1107	http://dx.doi.org/10.1038/nm1107			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15448685				2022-12-27	WOS:000224245800039
J	Acevedo, L; Yu, J; Erdjument-Bromage, H; Miao, RQ; Kim, JE; Fulton, D; Tempst, P; Strittmatter, SM; Sessa, WC				Acevedo, L; Yu, J; Erdjument-Bromage, H; Miao, RQ; Kim, JE; Fulton, D; Tempst, P; Strittmatter, SM; Sessa, WC			A new role for Nogo as a regulator of vascular remodeling	NATURE MEDICINE			English	Article							AXONAL REGENERATION; NEURITE OUTGROWTH; INHIBITOR; MYELIN; PROTEIN; INJURY; IDENTIFICATION; RECOMBINANT; APOPTOSIS; IN-1	Although Nogo-A has been identified in the central nervous system as an inhibitor of axonal regeneration, the peripheral roles of Nogo isoforms remain virtually unknown. Here, using a proteomic analysis to identify proteins enriched in caveolae and/or lipid rafts (CEM/LR), we show that Nogo-B is highly expressed in cultured endothelial and smooth muscle cells, as well as in intact blood vessels. The N terminus of Nogo-B promotes the migration of endothelial cells but inhibits the migration of vascular smooth muscle (VSM) cells, processes necessary for vascular remodeling. Vascular injury in Nogo-A/B-deficient mice promotes exaggerated neointimal proliferation, and adenoviral-mediated gene transfer of Nogo-B rescues the abnormal vascular expansion in those knockout mice. Our discovery that Nogo-B is a regulator of vascular homeostasis and remodeling broadens the functional scope of this family of proteins.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Program Vasc Cell Signaling & Therapeut, New Haven, CT 06536 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Yale University; Yale University; Memorial Sloan Kettering Cancer Center	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	Strittmatter, Stephen/F-5739-2011; Sessa, William C/B-6844-2011; Miao, Qing/K-3186-2019; Kim, Jean Jieun/G-5774-2018	Strittmatter, Stephen/0000-0001-8188-3092; Sessa, William C/0000-0001-5759-1938; Miao, Qing/0000-0002-3125-1238; Kim, Jean Jieun/0000-0003-4709-262X; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594				Blanc-Brude OP, 2002, NAT MED, V8, P987, DOI 10.1038/nm750; Brosamle C, 2000, J NEUROSCI, V20, P8061; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huber AB, 2000, BIOL CHEM, V381, P407, DOI 10.1515/BC.2000.053; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Oertle T, 2003, J NEUROSCI, V23, P5393; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Wang XX, 2002, J NEUROSCI, V22, P5505; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Yu J, 2002, LAB INVEST, V82, P825, DOI 10.1097/01.LAB.0000018828.61722.BD; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	22	195	215	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					382	388		10.1038/nm1020	http://dx.doi.org/10.1038/nm1020			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034570				2022-12-27	WOS:000220587000029
J	Gaggar, A; Shayakhmetov, DM; Lieber, A				Gaggar, A; Shayakhmetov, DM; Lieber, A			CD46 is a cellular receptor for group B adenoviruses	NATURE MEDICINE			English	Article							HUMAN CD34(+) CELLS; EFFICIENT TRANSDUCTION; MEASLES-VIRUS; SUBGROUP-B; PROTEIN; VECTORS; BINDING; COMMON; HOST	Group B adenoviruses, a subgenus of human Adenoviridae, are associated with a variety of often-fatal illnesses in immunocompromised individuals, including bone marrow transplant recipients and cancer and AIDS patients(1-3). Recently, group B adenovirus derivatives have gained interest as attractive gene therapy vectors because they can transduce target tissues, such as hematopoietic stem cells, dendritic cells and malignant tumor cells, that are refractory to infection by commonly used adenoviral vectors(4-6). Whereas many adenoviruses infect cells through the coxsackievirus and adenovirus receptor (CAR), group B adenoviruses use an alternate, as-yet-unidentified cellular attachment receptor(7-10). Using mass spectrometric analysis of proteins interacting with a group B fiber, we identified human CD46 as a cellular attachment receptor for most group B adenoviruses. We show that ectopic expression of human CD46 rendered nonhuman cells susceptible to infection with group B viruses in vitro and in vivo. In addition, both siRNA-mediated knockdown of CD46 and a soluble form of CD46 blocked infection of human cell lines and primary human cells. The discovery that group B adenoviruses use CD46, a ubiquitously expressed complement regulatory protein, as a cellular attachment receptor elucidates the diverse clinical manifestation of group B virus infections, and bears directly on the application of these vectors for gene therapy.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Div Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lieber, A (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.			Lieber, Andre/0000-0001-6742-6266	NHLBI NIH HHS [HL-00-008] Funding Source: Medline; NIDDK NIH HHS [DK47754] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047754] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; DEJONG PJ, 1983, LANCET, V1, P1293, DOI 10.1016/S0140-6736(83)92411-X; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Havenga MJE, 2002, J VIROL, V76, P4612, DOI 10.1128/JVI.76.9.4612-4620.2002; HIERHOLZER JC, 1992, CLIN MICROBIOL REV, V5, P262, DOI 10.1128/CMR.5.3.262-274.1992; HSU KHL, 1988, J VIROL, V62, P1647, DOI 10.1128/JVI.62.5.1647-1652.1988; Kemper C, 2001, CLIN EXP IMMUNOL, V124, P180, DOI 10.1046/j.1365-2249.2001.01458.x; Luppi M, 1999, J VIROL, V73, P754, DOI 10.1128/JVI.73.1.754-759.1999; Manchester M, 2002, J VIROL, V76, P6636, DOI 10.1128/JVI.76.13.6636-6642.2002; OGLESBY TJ, 1991, T ASSOC AM PHYSICIAN, V104, P164; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Rea D, 2001, J IMMUNOL, V166, P5236, DOI 10.4049/jimmunol.166.8.5236; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; Ruuskanen Olli, 2002, P515; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Segerman A, 2003, J VIROL, V77, P9183, DOI 10.1128/JVI.77.17.9183-9191.2003; Segerman A, 2003, J VIROL, V77, P1157, DOI 10.1128/JVI.77.2.1157-1162.2003; Seya T, 1999, INT J BIOCHEM CELL B, V31, P1255, DOI 10.1016/S1357-2725(99)00092-8; Shayakhmetov DM, 2000, J VIROL, V74, P2567, DOI 10.1128/JVI.74.6.2567-2583.2000; Shayakhmetov DM, 2003, J VIROL, V77, P3712, DOI 10.1128/JVI.77.6.3712-3723.2003; Shayakhmetov DM, 2002, CANCER RES, V62, P1063; Shenk T, 2001, FIELDS VIROLOGY, V2, P2265; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Wadell G, 1980, Ann N Y Acad Sci, V354, P16, DOI 10.1111/j.1749-6632.1980.tb27955.x; Wu E, 2001, VIROLOGY, V279, P78, DOI 10.1006/viro.2000.0703	28	584	617	0	29	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1408	1412		10.1038/nm952	http://dx.doi.org/10.1038/nm952			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14566335				2022-12-27	WOS:000186319700032
J	Mangi, AA; Noiseux, N; Kong, DL; He, HM; Rezvani, M; Ingwall, JS; Dzau, VJ				Mangi, AA; Noiseux, N; Kong, DL; He, HM; Rezvani, M; Ingwall, JS; Dzau, VJ			Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts	NATURE MEDICINE			English	Article							MARROW STROMAL CELLS; HUMAN BONE-MARROW; SKELETAL MYOBLAST TRANSPLANTATION; IMPROVES CARDIAC-FUNCTION; MYOCARDIAL-INFARCTION; IN-VITRO; CELLULAR CARDIOMYOPLASTY; ISCHEMIC-MYOCARDIUM; PROGENITOR CELLS; ADHERENT CELLS	Transplantation of adult bone marrow-derived mesenchymal stem cells has been proposed as a strategy for cardiac repair following myocardial damage. However, poor cell viability associated with transplantation has limited the reparative capacity of these cells in vivo. In this study, we genetically engineered rat mesenchymal stem cells using ex vivo retroviral transduction to overexpress the prosurvival gene Akt1 (encoding the Akt protein). Transplantation of 5 x 10(6) cells overexpressing Akt into the ischemic rat myocardium inhibited the process of cardiac remodeling by reducing intramyocardial inflammation, collagen deposition and cardiac myocyte hypertrophy, regenerated 80-90% of lost myocardial volume, and completely normalized systolic and diastolic cardiac function. These observed effects were dose (cell number) dependent. Mesenchymal stem cells transduced with Akt1 restored fourfold greater myocardial volume than equal numbers of cells transduced with the reporter gene lacZ. Thus, mesenchymal stem cells genetically enhanced with Akt1 can repair infarcted myocardium, prevent remodeling and nearly normalize cardiac performance.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Dzau, VJ (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035610, R01HL072010, R01HL035610, R01HL058516, F32HL010503, P50HL052320] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 F32 NHL 10503-01, HL058516, HL072010, HL35610, HL52320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkins BZ, 1999, J SURG RES, V85, P234, DOI 10.1006/jsre.1999.5681; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Hunnestad JA, 1999, STEM CELLS, V17, P31, DOI 10.1002/stem.170031; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kawamoto A, 2001, CIRCULATION, V103, P634; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Li RK, 1997, CIRCULATION, V96, P179; LI RK, 1997, CIRCULATION, V96, P186; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Melo LG, 2002, CIRCULATION, V105, P602, DOI 10.1161/hc0502.103363; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Muller-Ehmsen J, 2002, J MOL CELL CARDIOL, V34, P107, DOI 10.1006/jmcc.2001.1491; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; Nwogu JI, 2001, CIRCULATION, V104, P2216, DOI 10.1161/hc4301.097193; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; PFEFFER JM, 1991, AM J PHYSIOL, V260, pH1406, DOI 10.1152/ajpheart.1991.260.5.H1406; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; Reinecke H, 2000, CARDIOVASC PATHOL, V9, P337, DOI 10.1016/S1054-8807(00)00055-7; Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003-4975(02)03517-8; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; Wang JS, 2000, J THORAC CARDIOV SUR, V120, P999, DOI 10.1067/mtc.2000.110250; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6; Williams RS, 2000, J CLIN INVEST, V106, P813, DOI 10.1172/JCI11205; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhang M, 2001, J MOL CELL CARDIOL, V33, P907, DOI 10.1006/jmcc.2001.1367	46	1202	1350	1	64	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1195	1201		10.1038/nm912	http://dx.doi.org/10.1038/nm912			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12910262				2022-12-27	WOS:000185061600033
J	Polack, FP; Hoffman, SJ; Crujeiras, G; Griffin, DE				Polack, FP; Hoffman, SJ; Crujeiras, G; Griffin, DE			A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles	NATURE MEDICINE			English	Article							HUMORAL IMMUNE-RESPONSE; AFFINITY MATURATION; GERMINAL-CENTERS; RHESUS MACAQUES; FC-GAMMA; DISEASE; VACCINE; IMMUNIZATION; RECEPTORS; CD46	In the 1960s, a formalin-inactivated measles vaccine (FIMV) predisposed recipients to atypical measles, an immune complex-mediated disease(1,2). To identify characteristics of the immune priming that leads to atypical measles, responses of monkeys to FIMV were compared with responses to live attenuated virus (LAV) and hemagglutinin (H-DNA) vaccines that do not prime for atypical measles. Antibodies induced by FIMV were transient and avidity did not mature. Antibodies induced by LAV and H-DNA vaccines were sustained and avidity matured over time. After challenge with measles virus, FIMV and H-DNA recipients developed high titers of complement-fixing antibodies. In FIMV recipients, the antibodies were of low avidity, whereas in H-DNA vaccine recipients, the antibodies were of high avidity. Neutralizing capacity in B958 cells correlated with avidity. Only FIMV recipients had immune complex deposition. Failure of FIMV to induce affinity maturation results in anamnestic production of nonprotective, complement-fixing antibodies, immune complex deposition and atypical measles.	Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Maryland Dept Hlth & Mental Hyg, Div Virol Immunol, Baltimore, MD 21203 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Maryland Department of Health & Mental Hygiene	Polack, FP (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.				NIAID NIH HHS [AI-35149] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035149] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso A, 1998, LAB INVEST, V78, P377; CARTER CH, 1962, JAMA-J AM MED ASSOC, V179, P848, DOI 10.1001/jama.1962.03050110016003; CARTER PM, 1973, ANN RHEUM DIS, V32, P265, DOI 10.1136/ard.32.3.265; CHARGELEGUE D, 1995, CLIN EXP IMMUNOL, V99, P175, DOI 10.1111/j.1365-2249.1995.tb05529.x; DEVEY ME, 1990, IMMUNOLOGY, V70, P168; DEVEY ME, 1984, IMMUNOLOGY, V52, P377; DEVEY ME, 1980, IMMUNOLOGY, V41, P303; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Erlenhofer C, 2002, J GEN VIROL, V83, P1431, DOI 10.1099/0022-1317-83-6-1431; Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527; GRADY LJ, 1985, J GEN VIROL, V66, P2773, DOI 10.1099/0022-1317-66-12-2773; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0; KJELLEN L, 1985, J GEN VIROL, V66, P2279, DOI 10.1099/0022-1317-66-10-2279; Klasse PJ, 2002, J GEN VIROL, V83, P2091, DOI 10.1099/0022-1317-83-9-2091; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; NADER PR, 1968, J PEDIATR-US, V72, P22, DOI 10.1016/S0022-3476(68)80396-8; Olszewska W, 2000, VIROLOGY, V272, P98, DOI 10.1006/viro.2000.0285; Polack FP, 2000, NAT MED, V6, P776, DOI 10.1038/77506; Polack FP, 1999, NAT MED, V5, P629, DOI 10.1038/9473; Ruppach H, 2000, J VIROL, V74, P5403, DOI 10.1128/JVI.74.12.5403-5411.2000; Santiago C, 2002, J BIOL CHEM, V277, P32294, DOI 10.1074/jbc.M202973200; SOOTHILL JF, 1971, CLIN EXP IMMUNOL, V9, P193; STEWARD MW, 1991, IMMUNOLOGY, V72, P99; STEWARD MW, 1979, CLIN EXP IMMUNOL, V38, P414; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Voice JK, 1997, EUR J IMMUNOL, V27, P2514, DOI 10.1002/eji.1830271008; Walker LSK, 2000, IMMUNOL TODAY, V21, P333, DOI 10.1016/S0167-5699(00)01636-4; Walport MJ, 1997, ANN NY ACAD SCI, V815, P267, DOI 10.1111/j.1749-6632.1997.tb52069.x; ZIOLA B, 1983, INFECT IMMUN, V41, P578, DOI 10.1128/IAI.41.2.578-583.1983	30	110	116	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1209	1213		10.1038/nm918	http://dx.doi.org/10.1038/nm918			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925847				2022-12-27	WOS:000185061600035
J	Zhou, JY; Payen, JF; Wilson, DA; Traystman, RJ; van Zijl, PCM				Zhou, JY; Payen, JF; Wilson, DA; Traystman, RJ; van Zijl, PCM			Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI	NATURE MEDICINE			English	Article							SATURATION-TRANSFER CEST; MAGNETIZATION-TRANSFER; WATER-CONTENT; CONTRAST AGENTS; EXCHANGE; BRAIN; RESONANCE; RAT; SPECTROSCOPY; INVIVO	In the past decade, it has become possible to use the nuclear (proton, H-1) signal of the hydrogen atoms in water for noninvasive assessment of functional and physiological parameters with magnetic resonance imaging (MRI). Here we show that it is possible to produce pH-sensitive MRI contrast by exploiting the exchange between the hydrogen atoms of water and the amide hydrogen atoms of endogenous mobile cellular proteins and peptides. Although amide proton concentrations are in the millimolar range, we achieved a detection sensitivity of several percent on the water signal (molar concentration). The pH dependence of the signal was calibrated in situ, using phosphorus spectroscopy to determine pH, and proton exchange spectroscopy to measure the amide proton transfer rate. To show the potential of amide proton transfer (APT) contrast for detecting acute stroke, pH effects were noninvasively imaged in ischemic rat brain. This observation opens the possibility of using intrinsic pH contrast, as well as protein- and/or peptide-content contrast, as diagnostic tools in clinical imaging.	Johns Hopkins Univ, Sch Med, Dept Radiol, Div MRI Res, Baltimore, MD 21205 USA; Kennedy Krieger Inst, FM Kirby Res Ctr Funct Brain Imaging, Baltimore, MD 21205 USA; Grenoble Univ, Sch Med, Dept Anesthesiol, F-38000 Grenoble, France; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA	Johns Hopkins University; Kennedy Krieger Institute; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Universite de Franche-Comte; Johns Hopkins University	Zhou, JY (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiol, Div MRI Res, 217 Traylor Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Van Zijl, Peter C/ABF-3732-2020; van Zijl, Peter C/B-8680-2008; Payen, Jean-Francois/L-6667-2014		NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031490] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41 EB015909] Funding Source: Medline; NINDS NIH HHS [NS31490] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aime S, 2002, MAGN RESON MED, V47, P639, DOI 10.1002/mrm.10106; BEHAR KL, 1993, MAGNET RESON MED, V30, P38, DOI 10.1002/mrm.1910300107; COVINGTON AK, 1966, J PHYS CHEM-US, V70, P3820, DOI 10.1021/j100884a011; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; Ewing JR, 1999, MAGN RESON MED, V41, P696, DOI 10.1002/(SICI)1522-2594(199904)41:4<696::AID-MRM7>3.0.CO;2-5; FATOUROS PP, 1991, MAGNET RESON MED, V17, P402, DOI 10.1002/mrm.1910170212; Goffeney N, 2001, J AM CHEM SOC, V123, P8628, DOI 10.1021/ja0158455; Hakumaki JM, 2000, TRENDS BIOCHEM SCI, V25, P357, DOI 10.1016/S0968-0004(00)01614-5; HELPERN JA, 1987, MAGNET RESON MED, V5, P302, DOI 10.1002/mrm.1910050313; Henkelman RM, 2001, NMR BIOMED, V14, P57, DOI 10.1002/nbm.683; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P967, DOI 10.1111/j.1471-4159.1992.tb09350.x; Liepinsh E, 1996, MAGNET RESON MED, V35, P30, DOI 10.1002/mrm.1910350106; Lin WL, 2000, J CEREBR BLOOD F MET, V20, P37, DOI 10.1097/00004647-200001000-00007; Makela HI, 2002, J CEREBR BLOOD F MET, V22, P547; MOON RB, 1973, J BIOL CHEM, V248, P7276; Mori S, 1998, MAGNET RESON MED, V40, P36, DOI 10.1002/mrm.1910400105; Mori S, 1997, J AM CHEM SOC, V119, P6844, DOI 10.1021/ja963351f; Pekar J, 1996, MAGNET RESON MED, V35, P70, DOI 10.1002/mrm.1910350110; SCHOLZ TD, 1993, MAGNET RESON MED, V29, P352, DOI 10.1002/mrm.1910290311; TORACK RM, 1976, J NEUROPATH EXP NEUR, V35, P385, DOI 10.1097/00005072-197607000-00001; Ward KM, 2000, MAGN RESON MED, V44, P799, DOI 10.1002/1522-2594(200011)44:5<799::AID-MRM18>3.0.CO;2-S; Ward KM, 2000, J MAGN RESON, V143, P79, DOI 10.1006/jmre.1999.1956; WOLFF SD, 1990, J MAGN RESON, V86, P164, DOI 10.1016/0022-2364(90)90220-4; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhang SR, 2001, J AM CHEM SOC, V123, P1517, DOI 10.1021/ja005820q; Zhou JY, 1998, MAGNET RESON MED, V40, P712, DOI 10.1002/mrm.1910400511	27	817	878	14	159	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1085	1090		10.1038/nm907	http://dx.doi.org/10.1038/nm907			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12872167				2022-12-27	WOS:000184484900035
J	Zeisberg, M; Hanai, J; Sugimoto, H; Mammoto, T; Charytan, D; Strutz, F; Kalluri, R				Zeisberg, M; Hanai, J; Sugimoto, H; Mammoto, T; Charytan, D; Strutz, F; Kalluri, R			BMP-7 counteracts TGF-beta 1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury	NATURE MEDICINE			English	Article							TGF-BETA SUPERFAMILY; E-CADHERIN; SIGNAL-TRANSDUCTION; SMAD PROTEINS; FIBROSIS; PROMOTER; EXPRESSION; INHIBITOR; ELEMENT; CELLS	Bone morphogenic protein (BMP)-7 is a 35-kDa homodimeric protein and a member of the transforming growth factor (TGF)-beta superfamily(1). BMP-7 expression is highest in the kidney, and its genetic deletion in mice leads to severe impairment of eye, skeletal and kidney development(2). Here we report that BMP-7 reverses TGF-beta1-induced epithelial-to-mesenchymal transition (EMT) by reinduction of E-cadherin, a key epithelial cell adhesion molecule(3). Additionally, we provide molecular evidence for Smad-dependent reversal of TGF-beta1-induced EMT by BMP-7 in renal tubular epithelial cells and mammary ductal epithelial cells. In the kidney, EMT-induced accumulation of myofibroblasts and subsequent tubular atrophy are considered key determinants of renal fibrosis during chronic renal injury. We therefore tested the potential of BMP-7 to reverse TGF-beta1-induced de novo EMT in a mouse model of chronic renal injury(4). Our results show that systemic administration of recombinant human BMP-7 leads to repair of severely damaged renal tubular epithelial cells, in association with reversal of chronic renal injury. Collectively, these results provide evidence of cross talk between BMP-7 and TGF-beta1 in the regulation of EMT in health and disease.	Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Ctr Matrix Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Renal, Ctr Matrix Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Ctr Matrix Biol, Boston, MA 02215 USA.	rkalluri@bidmc.harvard.edu	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; charytan, david/0000-0002-7695-3583	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007199, R01DK051711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 55001, T32 DK07199-25, DK 51711] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Candia AF, 1997, DEVELOPMENT, V124, P4467; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hruska KA, 2000, AM J PHYSIOL-RENAL, V279, pF130, DOI 10.1152/ajprenal.2000.279.1.F130; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Okada H, 1997, AM J PHYSIOL-RENAL, V273, pF563, DOI 10.1152/ajprenal.1997.273.4.F563; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7; Zeisberg M, 2002, AM J PATHOL, V160, P2001, DOI 10.1016/S0002-9440(10)61150-9	28	1108	1199	0	97	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					964	968		10.1038/nm888	http://dx.doi.org/10.1038/nm888			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808448				2022-12-27	WOS:000183979300040
J	Bogdanov, VY; Balasubramanian, V; Hathcock, J; Vele, O; Lieb, M; Nemerson, Y				Bogdanov, VY; Balasubramanian, V; Hathcock, J; Vele, O; Lieb, M; Nemerson, Y			Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein	NATURE MEDICINE			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; SHED MEMBRANE MICROPARTICLES; FACTOR PATHWAY; FACTOR-VIIA; BLOOD; THROMBOSIS; LOCALIZATION; COAGULATION; ANTIBODIES; ACTIVATION	Tissue factor (TF) is an essential enzyme activator that forms a catalytic complex with FVIIa and initiates coagulation by activating FIX and FX, ultimately resulting in thrombin formation(1). TF is found in adventitia of blood vessels(2) and the lipid core of atherosclerotic plaques(3). In unstable coronary syndromes, plaque rupture initiates coagulation by exposing TF to blood(4,5). Biologically active TF has been detected in vessel walls and circulating blood(6). Elevated intravascular TF has been reported in diverse pro-thrombotic syndromes such as myocardial infarction, sepsis, anti-phospholipid syndrome and sickle-cell disease(7-10). It is unclear how TF circulates, although it may be present in pro-coagulant microparticles(11,12). We now report identification of a form of human TF generated by alternative splicing. Our studies indicate that alternatively spliced human tissue factor (asHTF) contains most of the extracellular domain of TF but lacks a transmembrane domain and terminates with a unique peptide sequence. asHTF is soluble, circulates in blood, exhibits pro-coagulant activity when exposed to phospholipids, and is incorporated into thrombi. We propose that binding of asHTF to the edge of thrombi contributes to thrombus growth by creating a surface that both initiates and propagates coagulation.	CUNY Mt Sinai Sch Med, Dept Med, Div Thrombosis Res, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nemerson, Y (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Thrombosis Res, New York, NY 10029 USA.			Bogdanov, Vladimir/0000-0003-4968-1129; Vele, Oana/0000-0002-4132-4832				Ambrose JA, 1997, AM J CARDIOL, V79, P559, DOI 10.1016/S0002-9149(96)00815-6; Amengual O, 1998, THROMB HAEMOSTASIS, V79, P276, DOI 10.1055/s-0037-1614977; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BADIMON L, 1986, ARTERIOSCLEROSIS, V6, P312, DOI 10.1161/01.ATV.6.3.312; BAUMGARTNER HR, 1980, J LAB CLIN MED, V95, P208; Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639; BERG HC, 1993, RANDOM WALKS BIOL, P37; CARSON SD, 1992, BLOOD COAGUL FIBRIN, V3, P779, DOI 10.1097/00001721-199212000-00012; Gando S, 1998, CRIT CARE MED, V26, P2005, DOI 10.1097/00003246-199812000-00030; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GRABOWSKI EF, 1990, BLOOD, V75, P390; Guo WM, 2001, CHINESE MED J-PEKING, V114, P30; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; Key NS, 1998, BLOOD, V91, P4216, DOI 10.1182/blood.V91.11.4216.411k15_4216_4223; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; Parry GCN, 1998, J CLIN INVEST, V101, P560, DOI 10.1172/JCI814; Pawlinski R, 2002, P NATL ACAD SCI USA, V99, P15333, DOI 10.1073/pnas.242501899; Rosseau S, 2000, J IMMUNOL, V164, P427, DOI 10.4049/jimmunol.164.1.427; Suefuji H, 1997, AM HEART J, V134, P253, DOI 10.1016/S0002-8703(97)70132-7; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; Turitto VT, 1998, THROMB RES, V92, pS25, DOI 10.1016/S0049-3848(98)00157-1; Zaman AG, 2000, ATHEROSCLEROSIS, V149, P251, DOI 10.1016/S0021-9150(99)00479-7; ZELDIS SM, 1972, SCIENCE, V175, P766, DOI 10.1126/science.175.4023.766	25	371	387	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					458	462		10.1038/nm841	http://dx.doi.org/10.1038/nm841			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12652293				2022-12-27	WOS:000181987400037
J	Ye, QH; Qin, LX; Forgues, M; He, P; Kim, JW; Peng, AC; Simon, R; Li, Y; Robles, AI; Chen, YD; Ma, ZC; Wu, ZQ; Ye, SL; Liu, YK; Tang, ZY; Wang, XW				Ye, QH; Qin, LX; Forgues, M; He, P; Kim, JW; Peng, AC; Simon, R; Li, Y; Robles, AI; Chen, YD; Ma, ZC; Wu, ZQ; Ye, SL; Liu, YK; Tang, ZY; Wang, XW			Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning	NATURE MEDICINE			English	Article							INTRAHEPATIC METASTASIS; BONE SIALOPROTEIN; OSTEOPONTIN; CANCER; BREAST; IDENTIFICATION; LIVER; CARCINOGENESIS; CLASSIFICATION; MICROARRAY	Hepatocellular carcinoma (HCC) is one of the most common and aggressive human malignancies. Its high mortality rate is mainly a result of intra-hepatic metastases. We analyzed the expression profiles of HCC samples without or with intra-hepatic metastases. Using a supervised machine-learning algorithm, we generated for the first time a molecular signature that can classify metastatic HCC patients and identified genes that were relevant to metastasis and patient survival. We found that the gene expression signature of primary HCCs with accompanying metastasis was very similar to that of their corresponding metastases, implying that genes favoring metastasis progression were initiated in the primary tumors. Osteopontin, which was identified as a lead gene in the signature, was over-expressed in metastatic HCC; an osteopontin-specific antibody effectively blocked HCC cell invasion in vitro and inhibited pulmonary metastasis of HCC cells in nude mice. Thus, osteopontin acts as both a diagnostic marker and a potential therapeutic target for metastatic HCC.	NCI, Human Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA; Fudan Univ, Liver Canc Inst, Shanghai 200433, Peoples R China; Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China; NCI, Biometr Res Branch, Rockville, MD USA; EMMES Corp, Rockville, MD USA; NHGRI, Canc Genet Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fudan University; Fudan University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res, Bldg 37, Bethesda, MD 20892 USA.	xw3u@nih.gov	Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Robles, Ana/0000-0001-5019-4374	NATIONAL CANCER INSTITUTE [Z01BC010313, ZIABC010313] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bolondi L, 2001, GUT, V48, P251, DOI 10.1136/gut.48.2.251; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; CURLEY SA, 1995, ANN SURG, V222, P375, DOI 10.1097/00000658-199509000-00014; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Guo XZ, 1998, HEPATOLOGY, V28, P1481, DOI 10.1002/hep.510280606; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hui AM, 1999, INT J CANCER, V84, P604, DOI 10.1002/(SICI)1097-0215(19991222)84:6<604::AID-IJC11>3.0.CO;2-Y; Izzo F, 1998, ANN SURG, V227, P513, DOI 10.1097/00000658-199804000-00011; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kuriyama S, 1998, ANTICANCER RES, V18, P4181; Larcos G, 1998, AM J ROENTGENOL, V171, P433, DOI 10.2214/ajr.171.2.9694470; Li Y, 2003, J CANCER RES CLIN, V129, P43, DOI 10.1007/s00432-002-0396-4; Lindsay CK, 1997, HEPATOLOGY, V26, P1209; Medico E, 2001, CANCER RES, V61, P5861; Mitsunobu M, 1996, CLIN EXP METASTAS, V14, P520, DOI 10.1007/BF00115112; Oates AJ, 1996, ONCOGENE, V13, P97; Okabe H, 2001, CANCER RES, V61, P2129; Osada T, 1996, HEPATOLOGY, V24, P1460, DOI 10.1002/hep.510240627; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Qin LX, 1999, CANCER RES, V59, P5662; Radmacher MD, 2002, J COMPUT BIOL, V9, P505, DOI 10.1089/106652702760138592; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sharp JA, 1999, LAB INVEST, V79, P869; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Singhal H, 1997, CLIN CANCER RES, V3, P605; Tang ZY, 2001, WORLD J GASTROENTERO, V7, P445; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Wu CG, 2001, ONCOGENE, V20, P3674, DOI 10.1038/sj.onc.1204481; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yang BH, 1997, J CANCER RES CLIN, V123, P357, DOI 10.1007/s004320050070; YUKI K, 1990, CANCER-AM CANCER SOC, V66, P2174, DOI 10.1002/1097-0142(19901115)66:10<2174::AID-CNCR2820661022>3.0.CO;2-A; Zhou XD, 2001, CANCER-AM CANCER SOC, V91, P1479, DOI 10.1002/1097-0142(20010415)91:8<1479::AID-CNCR1155>3.0.CO;2-0	45	678	783	1	106	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2003	9	4					416	423		10.1038/nm843	http://dx.doi.org/10.1038/nm843			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12640447				2022-12-27	WOS:000181987400031
J	Cooley, DA				Cooley, Denton A.			The total artificial heart	NATURE MEDICINE			English	Article								Over the past 50 years, significant advances have been made in the development of total artificial hearts (TAH). These advances have most recently led to a clinical trial of a unique, transcutaneously powered TAH.	Texas Heart Inst, Houston, TX 77025 USA	Texas Heart Institute	Cooley, DA (corresponding author), Texas Heart Inst, Houston, TX 77025 USA.	mmallia@heart.thi.tmc.edu						AKUTSU T, 1963, T AM SOC ART INT ORG, V9, P281; AKUTSU T, 1958, T AM SOC ART INT ORG, V4, P230; BARNARD C N, 1967, South African Medical Journal, V41, P1271; COOLEY DA, 1969, AM J CARDIOL, V24, P723, DOI 10.1016/0002-9149(69)90460-3; COOLEY DA, 1957, SURGERY, V41, P930; COOLEY DA, 1981, CARDIOVASC DIS, V8, P305; COOLEY DA, 1969, ARCH SURG-CHICAGO, V98, P619; Demikhov VP, 1951, B ESKP BIOL MED, V32, P22; DEVRIES WC, 1988, JAMA-J AM MED ASSOC, V259, P849, DOI 10.1001/jama.259.6.849; Frazier O.H., 1996, SUPPORT REPLACEMENT, P147; GIBBON J H Jr, 1954, Minn Med, V37, P171; Gibbs OS, 1930, J PHARMACOL EXP THER, V38, P197; Kung R.T.V., 1993, ASIAO J, V39, P213; LeGallois C. J. J., 1813, EXPERIENCE PRINCIPLE; Lindbergh CA, 1935, J EXP MED, V62, P409, DOI 10.1084/jem.62.3.409; LIOTTA D, 1961, T AM SOC ART INT ORG, V7, P318; Shumacker H.B., 1992, EVOLUTION CARDIAC SU; Watson J.T., 1994, WORKSH ART HEART PLA, P27; Willman V.L., 1998, EXPERT PANEL REV NHL, P2	19	25	25	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					108	111		10.1038/nm0103-108	http://dx.doi.org/10.1038/nm0103-108			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514722				2022-12-27	WOS:000208640400004
J	Hanks, BA; Jiang, JH; Singh, RAK; Song, WT; Barry, M; Huls, MH; Slawin, KM; Spencer, DM				Hanks, BA; Jiang, JH; Singh, RAK; Song, WT; Barry, M; Huls, MH; Slawin, KM; Spencer, DM			Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo	NATURE MEDICINE			English	Article							LIGAND; CD154; INDUCTION; RESPONSES; LIGATION; DISTINCT; SIGNALS; HELP	Modest clinical outcomes of dendritic-cell (DC) vaccine trials call for the refinement of DC vaccine design. Although many potential antigens have been identified, development of methods to enhance antigen presentation by DCs has lagged. We have engineered a potent, drug-inducible CD40 (iCD40) receptor that permits temporally controlled, lymphoid-localized, DC-specific activation. iCD40 is comprised of a membrane-localized cytoplasmic domain of CD40 fused to drug-binding domains. This allows it to respond to a lipid-permeable, high-affinity dimerizer drug while circumventing ectodomain-dependent negative-feedback mechanisms. These modifications permit prolonged activation of iCD40-expressing DCs in vivo, resulting in more potent CD8(+) T-cell effector responses, including the eradication of previously established solid tumors, relative to activation of DCs ex vivo (P < 0.01), typical of most clinical DC protocols. In addition, iCD40-mediated DC activation exceeded that achieved by stimulating the full-length, endogenous CD40 receptor both in vitro and in vivo. Because iCD40 is insulated from the extracellular environment and can be activated within the context of an immunological synapse, iCD40-expressing DCs have a prolonged lifespan and should lead to more potent vaccines, perhaps even in immune-compromised patients.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Med Sci Training Program, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Methodist Hosp, Scott Dept Urol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Spencer, DM (corresponding author), Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA.	dspencer@bcm.tmc.edu	Hanks, Brent A./V-3835-2019	Hanks, Brent A./0000-0002-2803-3272				Ahonen CL, 2004, J EXP MED, V199, P775, DOI 10.1084/jem.20031591; Albert ML, 2001, NAT IMMUNOL, V2, P1010, DOI 10.1038/ni722; Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; BANCHEREAU J, 1998, SCIENCE, V392, P245; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Contin C, 2003, J BIOL CHEM, V278, P32801, DOI 10.1074/jbc.M209993200; Coombes BK, 2001, IMMUNOL LETT, V78, P103, DOI 10.1016/S0165-2478(01)00242-5; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Garlichs CD, 2003, STROKE, V34, P1412, DOI 10.1161/01.STR.0000074032.64049.47; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hermans IF, 2000, J IMMUNOL, V164, P3095, DOI 10.4049/jimmunol.164.6.3095; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iuliucci JD, 2001, J CLIN PHARMACOL, V41, P870, DOI 10.1177/00912700122010771; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; Kikuchi T, 2000, BLOOD, V96, P91, DOI 10.1182/blood.V96.1.91.013k19_91_99; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; Lindmark E, 2000, ARTERIOSCL THROM VAS, V20, P2322, DOI 10.1161/01.ATV.20.10.2322; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; LUTZ MB, 1994, J IMMUNOL METHODS, V174, P269, DOI 10.1016/0022-1759(94)90031-0; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Martin E, 2003, IMMUNITY, V18, P155, DOI 10.1016/S1074-7613(02)00503-4; Mathur RK, 2004, NAT MED, V10, P540, DOI 10.1038/nm1045; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Mazouz Naima, 2002, Cancer Immun, V2, P2; Melter M, 2000, BLOOD, V96, P3801, DOI 10.1182/blood.V96.12.3801.h8003801_3801_3808; Nestle FO, 2001, NAT MED, V7, P761, DOI 10.1038/89863; O'Sullivan BJ, 2002, J IMMUNOL, V168, P5491, DOI 10.4049/jimmunol.168.11.5491; Pettit AR, 1997, J IMMUNOL, V159, P3681; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Ridgway D, 2003, CANCER INVEST, V21, P873, DOI 10.1081/CNV-120025091; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; Seddon B, 2003, CURR OPIN IMMUNOL, V15, P321, DOI 10.1016/S0952-7915(03)00049-9; Singh RAK, 2002, J IMMUNOL, V169, P6779, DOI 10.4049/jimmunol.169.12.6779; Sousa CRE, 2001, IMMUNITY, V14, P495; Sousa CRE, 1999, IMMUNITY, V11, P637, DOI 10.1016/S1074-7613(00)80138-7; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Tone M, 2001, P NATL ACAD SCI USA, V98, P1751, DOI 10.1073/pnas.98.4.1751; Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280; Wong P, 2003, IMMUNITY, V18, P499, DOI 10.1016/S1074-7613(03)00081-5; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059	44	70	87	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					130	137		10.1038/nm1183	http://dx.doi.org/10.1038/nm1183			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665830				2022-12-27	WOS:000226797300019
J	Diamond, B				Diamond, B			Profile - Richard Chaisson	NATURE MEDICINE			English	Biographical-Item																		CHAISON R, PUBLICATION LIST	1	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2005	11	1					8	8		10.1038/nm0105-8	http://dx.doi.org/10.1038/nm0105-8			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15635428				2022-12-27	WOS:000226124900010
J	Geisbert, TW; Jahrling, PB				Geisbert, TW; Jahrling, PB			Exotic emerging viral diseases: progress and challenges	NATURE MEDICINE			English	Review							EBOLA HEMORRHAGIC-FEVER; RIFT-VALLEY FEVER; LASSA VIRUS-INFECTION; MARBURG AGENT DISEASE; RHESUS-MONKEY MODEL; DENDRITIC CELLS; YELLOW-FEVER; CLINICAL PATHOLOGY; NITRIC-OXIDE; DC-SIGN	The agents causing viral hemorrhagic fever (VHF) are a taxonomically diverse group of viruses that may share commonalities in the process whereby they produce systemic and frequently fatal disease. Significant progress has been made in understanding the biology of the Ebola virus, one of the best known examples. This knowledge has guided our thinking about other VHF agents, including Marburg, Lassa, the South American arenaviruses, yellow fever, Crimean-Congo and Rift Valley fever viruses. Comparisons among VHFs show that a common pathogenic feature is their ability to disable the host immune response by attacking and manipulating the cells that initiate the antiviral response. Of equal importance, these comparisons highlight critical gaps in our knowledge of these pathogens.	USA, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA		Jahrling, PB (corresponding author), USA, Med Res Inst Infect Dis, Div Virol, 1425 Porter St, Ft Detrick, MD 21702 USA.	tom.geisbert@amedd.army.mil; peter.jahrling@us.army.mil						Alibek K, 1999, BIOHAZARD CHILLING T; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Asper M, 2004, J VIROL, V78, P3162, DOI 10.1128/JVI.78.6.3162-3169.2004; Baize S, 2004, J IMMUNOL, V172, P2861, DOI 10.4049/jimmunol.172.5.2861; Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; BASKERVILLE A, 1981, J CLIN PATHOL, V34, P871, DOI 10.1136/jcp.34.8.871; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Basler CF, 2004, EBOLA AND MARBURG VIRUSES: MOLECULAR AND CELLULAR BIOLOGY, P305; Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003; BECKER S, 1995, J GEN VIROL, V76, P393, DOI 10.1099/0022-1317-76-2-393; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001; BOWEN ETW, 1978, T ROY SOC TROP MED H, V72, P188, DOI 10.1016/0035-9203(78)90058-5; Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0; BUKREYEV AA, 1993, FEBS LETT, V323, P183, DOI 10.1016/0014-5793(93)81476-G; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Burt FJ, 1997, ARCH PATHOL LAB MED, V121, P839; Bwaka MA, 1999, J INFECT DIS, V179, pS1, DOI 10.1086/514308; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CALLIS RT, 1982, AM J TROP MED HYG, V31, P1038, DOI 10.4269/ajtmh.1982.31.1038; CANONICO PG, 1984, J ANTIMICROB CHEMOTH, V14, P27, DOI 10.1093/jac/14.suppl_A.27; Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079; Centers for Disease Control (CDC), 1988, MMWR Morb Mortal Wkly Rep, V37, P1; Chan SY, 2001, CELL, V106, P117, DOI 10.1016/S0092-8674(01)00418-4; CHILD PL, 1967, ARCH PATHOL, V83, P434; CLAYTON AJ, 1977, B WORLD HEALTH ORGAN, V55, P435; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; Daniel PT, 1998, ADV EXP MED BIOL, V451, P173; de Filippis AMB, 2002, J MED VIROL, V68, P620, DOI 10.1002/jmv.10226; DEBRITO T, 1992, PATHOL RES PRACT, V188, P177, DOI 10.1016/S0344-0338(11)81176-3; Deng IM, 1978, B WORLD HEALTH ORGAN, V56, P247; DENNIS LH, 1969, BRIT J HAEMATOL, V17, P455, DOI 10.1111/j.1365-2141.1969.tb01393.x; EDINGTON GM, 1972, T ROY SOC TROP MED H, V66, P381, DOI 10.1016/0035-9203(72)90268-4; ELSNER B, 1973, AM J TROP MED HYG, V22, P229, DOI 10.4269/ajtmh.1973.22.229; ELTON NW, 1955, AM J CLIN PATHOL, V25, P135; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; ENRIA DA, 1984, LANCET, V2, P255, DOI 10.1016/S0140-6736(84)90299-X; Ergonul O, 2004, CLIN INFECT DIS, V39, P284, DOI 10.1086/422000; Feldmann H, 1996, J VIROL, V70, P2208, DOI 10.1128/JVI.70.4.2208-2214.1996; Fisher-Hoch SP, 2000, J VIROL, V74, P6777, DOI 10.1128/JVI.74.15.6777-6783.2000; Fisher-Hoch Susan P, 2004, Expert Rev Vaccines, V3, P189, DOI 10.1586/14760584.3.2.189; FISHERHOCH S, 1988, J MED VIROL, V26, P127, DOI 10.1002/jmv.1890260204; FISHERHOCH SP, 1995, LANCET, V346, P472, DOI 10.1016/S0140-6736(95)91323-8; FISHERHOCH SP, 1985, J INFECT DIS, V152, P887, DOI 10.1093/infdis/152.5.887; FISHERHOCH SP, 1989, P NATL ACAD SCI USA, V86, P317, DOI 10.1073/pnas.86.1.317; FISHERHOCH SP, 1983, LANCET, V2, P1055; FISHERHOCH SP, 1992, J INFECT DIS, V166, P753, DOI 10.1093/infdis/166.4.753; FISHERHOCH SP, 1987, J INFECT DIS, V155, P465, DOI 10.1093/infdis/155.3.465; Flick R, 2003, J VIROL, V77, P5997, DOI 10.1128/JVI.77.10.5997-6006.2003; Foster GR, 1998, J VIRAL HEPATITIS, V5, P143, DOI 10.1046/j.1365-2893.1998.00103.x; FRAME JD, 1989, REV INFECT DIS, V11, pS783; FRAME JD, 1984, T ROY SOC TROP MED H, V78, P319, DOI 10.1016/0035-9203(84)90107-X; GALLAHER WR, 2001, BMC MICROBIOL, V1; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; GEAR JSS, 1975, BRIT MED J, V4, P489, DOI 10.1136/bmj.4.5995.489; GEDIGK P, 1971, MARBURG VIRUS DIS; Geisbert Thomas W, 2003, Expert Rev Vaccines, V2, P777, DOI 10.1586/14760584.2.6.777; Geisbert TW, 2000, LAB INVEST, V80, P171, DOI 10.1038/labinvest.3780021; Geisbert TW, 2003, J INFECT DIS, V188, P1618, DOI 10.1086/379724; Geisbert TW, 2003, LANCET, V362, P1953, DOI 10.1016/S0140-6736(03)15012-X; Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2; Geisbert TW, 2003, AM J PATHOL, V163, P2371, DOI 10.1016/S0002-9440(10)63592-4; Geisbert TW, 2002, EMERG INFECT DIS, V8, P503; Geisbert TW, 1998, ULTRASTRUCT PATHOL, V22, P3, DOI 10.3109/01913129809032253; GEISBERT TW, 1992, J COMP PATHOL, V106, P137, DOI 10.1016/0021-9975(92)90043-T; Gomez RM, 2003, THROMB HAEMOSTASIS, V90, P326, DOI 10.1160/TH02-09-0043; GONZALEZ PH, 1980, ARCH PATHOL LAB MED, V104, P250; GREENMAN DL, 1987, J TOXICOL ENV HEALTH, V22, P113, DOI 10.1002/jmv.1890220203; Grignani G, 2000, HAEMATOLOGICA, V85, P967; HAVEMANN K, 1971, MARBURG VIRUS DIS; HELLER MV, 1995, THROMB HAEMOSTASIS, V73, P368; HELLER MV, 1992, J INFECT DIS, V166, P1203, DOI 10.1093/infdis/166.5.1203; Hensley LE, 2002, IMMUNOL LETT, V80, P169, DOI 10.1016/S0165-2478(01)00327-3; Hudson NP, 1928, AM J PATHOL, V4, P419; Huggins J, 1999, J INFECT DIS, V179, pS240, DOI 10.1086/514316; Huggins J.W., 1995, ANTIVIR RES, V26, pA301; HUGGINS JW, 1989, REV INFECT DIS, V11, pS750; Ignatiev GM, 2000, IMMUNOL LETT, V71, P131, DOI 10.1016/S0165-2478(99)00169-8; Ignatyev GM, 1996, VOP VIRUSOL+, V41, P206; International Society for Infectious Diseases, 2004, EB LAB ACC DEATH RUS; ISAACSON M, 1978, EBOLA VIRUS HAEMORRH; Jaax NK, 1996, ARCH PATHOL LAB MED, V120, P140; JAHRLING PB, 1980, J INFECT DIS, V141, P580, DOI 10.1093/infdis/141.5.580; Jahrling PB, 1999, J INFECT DIS, V179, pS224, DOI 10.1086/514310; JAHRLING PB, 1985, T ROY SOC TROP MED H, V79, P380, DOI 10.1016/0035-9203(85)90388-8; JONES S, 2003, VRC S VIR HEM FEV BE; JOUBERT JR, 1985, S AFR MED J, V68, P722; KASTELLO MD, 1976, J INFECT DIS, V133, P57, DOI 10.1093/infdis/133.1.57; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Khan AS, 1999, J INFECT DIS, V179, pS76, DOI 10.1086/514306; Kilgore PE, 1997, CLIN INFECT DIS, V24, P718, DOI 10.1093/clind/24.4.718; Klotz O, 1930, AM J PATHOL, V6, P655; KNOBLOCH J, 1980, TROPENMED PARASITOL, V31, P389; LANGE JV, 1985, AM J TROP MED HYG, V34, P999, DOI 10.4269/ajtmh.1985.34.999; LEIFER E, 1970, AM J TROP MED HYG, V19, P677, DOI 10.4269/ajtmh.1970.19.677; Leroy EM, 2000, LANCET, V355, P2210, DOI 10.1016/S0140-6736(00)02405-3; Levi M, 2004, BRIT J HAEMATOL, V124, P567, DOI 10.1046/j.1365-2141.2003.04790.x; LEVIS SC, 1985, J INTERFERON RES, V5, P383, DOI 10.1089/jir.1985.5.383; LEVIS SC, 1984, J INFECT DIS, V149, P428, DOI 10.1093/infdis/149.3.428; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Lukashevich IS, 1999, J MED VIROL, V59, P552, DOI 10.1002/(SICI)1096-9071(199912)59:4<552::AID-JMV21>3.3.CO;2-1; MACKENZIE RB, 1964, AM J TROP MED HYG, V13, P620, DOI 10.4269/ajtmh.1964.13.620; Mahanty S, 2003, J IMMUNOL, V170, P2797, DOI 10.4049/jimmunol.170.6.2797; Mahanty S, 2001, J INFECT DIS, V183, P1713, DOI 10.1086/320722; Maiztegui JI, 1998, J INFECT DIS, V177, P277, DOI 10.1086/514211; MAIZTEGUI JI, 1979, LANCET, V2, P1216; MAIZTEGUI JI, 1975, J INFECT DIS, V132, P35, DOI 10.1093/infdis/132.1.35; Mammen E F, 2000, Clin Lab Sci, V13, P239; Mardani M, 2003, CLIN INFECT DIS, V36, P1613, DOI 10.1086/375058; Marta RF, 1999, AM J TROP MED HYG, V60, P85, DOI 10.4269/ajtmh.1999.60.85; MARTIN MS, 1973, DIGESTION, V8, P22, DOI 10.1159/000197298; Martini G A, 1968, Ger Med Mon, V13, P457; Martini G.A., 1971, MARBURG VIRUS DIS; Marzi A, 2004, J VIROL, V78, P12090, DOI 10.1128/JVI.78.21.12090-12095.2004; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCKEE KT, 1987, J MED VIROL, V22, P99, DOI 10.1002/jmv.1890220202; MCLEOD CG, 1978, AM J TROP MED HYG, V27, P822, DOI 10.4269/ajtmh.1978.27.822; Miura Y, 2001, J EXP MED, V193, P651, DOI 10.1084/jem.193.5.651; MOLINAS FC, 1981, J INFECT DIS, V143, P1, DOI 10.1093/infdis/143.1.1; MOLINAS FC, 1983, J MED VIROL, V12, P281, DOI 10.1002/jmv.1890120408; Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0; Monath TP, 2003, ADV VIRUS RES, V60, P343, DOI 10.1016/S0065-3527(03)60009-6; MONATH TP, 1981, AM J TROP MED HYG, V30, P431, DOI 10.4269/ajtmh.1981.30.431; MORRILL JC, 1991, J INTERFERON RES, V11, P297, DOI 10.1089/jir.1991.11.297; MORRILL JC, 1990, ARCH VIROL, V110, P195, DOI 10.1007/BF01311288; MORROW CA, 1989, J STRUCT GEOL, V11, P815, DOI 10.1016/0191-8141(89)90100-4; Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298; Murphy F.A., 1978, EBOLA VIRUS HAEMORRH; MURPHY FA, 1971, LAB INVEST, V24, P279; Neumann FJ, 1997, ARTERIOSCL THROM VAS, V17, P3399, DOI 10.1161/01.ATV.17.12.3399; Neumann G, 2002, J VIROL, V76, P406, DOI 10.1128/JVI.76.1.406-410.2002; PETERS CJ, 1987, CURR TOP MICROBIOL, V134, P5; PETERS CJ, 1989, REV INFECT DIS, V11, pS743; PETERS CJ, 1988, ARCH VIROL, V99, P31, DOI 10.1007/BF01311021; PETERS CJ, 1997, ATLAS INFECT DIS, V3; PETERS CJ, 1997, CLIN VIROLOGY; Pittman PR, 1999, VACCINE, V18, P181, DOI 10.1016/S0264-410X(99)00218-2; Raftery MJ, 2001, IMMUNITY, V15, P997, DOI 10.1016/S1074-7613(01)00239-4; Reed DS, 2004, VIRAL IMMUNOL, V17, P390, DOI 10.1089/vim.2004.17.390; RIPPEY JJ, 1984, S AFR MED J, V66, P50; Rubins KH, 2004, P NATL ACAD SCI USA, V101, P15190, DOI 10.1073/pnas.0405759101; SALAS R, 1991, LANCET, V338, P1033, DOI 10.1016/0140-6736(91)91899-6; Sanchez A, 2004, J VIROL, V78, P10370, DOI 10.1128/JVI.78.19.10370-10377.2004; SANCHEZ A, 2001, FIELDS VIROLOGY; SANTOS F, 1973, BRASILIA MED, V9, P9; Schmitz H, 2002, MICROBES INFECT, V4, P43, DOI 10.1016/S1286-4579(01)01508-8; Schnittler HJ, 1998, CLIN INFECT DIS, V27, P404, DOI 10.1086/517704; SCOTT SK, 1978, AM J TROP MED HYG, V27, P1232, DOI 10.4269/ajtmh.1978.27.1232; SHEPHERD AJ, 1989, REV INFECT DIS, V11, pS801; Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730; SIMPSON DIH, 1969, T ROY SOC TROP MED H, V63, P303, DOI 10.1016/0035-9203(69)90002-9; Spiropoulou CF, 2002, J VIROL, V76, P5140, DOI 10.1128/JVI.76.10.5140-5146.2002; Stroher U, 2001, J VIROL, V75, P11025, DOI 10.1128/JVI.75.22.11025-11033.2001; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876; SWANEPOEL R, 1989, REV INFECT DIS, V11, pS794; Takabayashi A, 2000, ANTIOXID REDOX SIGN, V2, P673, DOI 10.1089/ars.2000.2.4-673; Takada A, 2004, J VIROL, V78, P2943, DOI 10.1128/JVI.78.6.2943-2947.2004; Takada A, 2000, VIROLOGY, V278, P20, DOI 10.1006/viro.2000.0601; ter Meulen J, 2004, J INFECT DIS, V190, P1821, DOI 10.1086/425016; TERRELL TG, 1973, AM J PATHOL, V73, P477; VALLEJOS DA, 1989, J MED VIROL, V27, P160, DOI 10.1002/jmv.1890270218; Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283; VOLCHKOV VE, 1992, FEBS LETT, V305, P181, DOI 10.1016/0014-5793(92)80662-Z; Volchkov VE, 2001, SCIENCE, V291, P1965, DOI 10.1126/science.1057269; WAGNER FS, 1977, AM J TROP MED HYG, V26, P159, DOI 10.4269/ajtmh.1977.26.159; WALKER DH, 1987, CURR TOP MICROBIOL, V133, P89; WALKER DH, 1982, AM J PATHOL, V107, P349; Wang Q, 2000, BLOOD, V96, P2093; WHITE HA, 1972, T ROY SOC TROP MED H, V66, P390, DOI 10.1016/0035-9203(72)90269-6; WINN WC, 1975, B WORLD HEALTH ORGAN, V52, P535; Yang ZY, 2000, NAT MED, V6, P886, DOI 10.1038/78654; Zaki SR, 1999, CURR TOP MICROBIOL, V235, P97; ZLOTNIK I, 1969, T ROY SOC TROP MED H, V63, P310, DOI 10.1016/0035-9203(69)90003-0	175	351	371	1	74	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12		S			S110	S121		10.1038/nm1142	http://dx.doi.org/10.1038/nm1142			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577929	Bronze			2022-12-27	WOS:000225733900007
J	Evans, R				Evans, R			A transcriptional basis for physiology	NATURE MEDICINE			English	Editorial Material							HUMAN GLUCOCORTICOID RECEPTOR; RETINOID-X-RECEPTOR; ORPHAN NUCLEAR RECEPTOR; THYROID-HORMONE; BILE-ACIDS; FUNCTIONAL DOMAINS; SIGNALING PATHWAY; RESPONSE ELEMENTS; RXR-BETA; IDENTIFICATION		Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Evans, R (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	evans@salk.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; EVANS R, 1979, NATURE, V278, P367, DOI 10.1038/278367a0; EVANS RM, 1977, CELL, V12, P733, DOI 10.1016/0092-8674(77)90273-2; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; HARPOLD MM, 1978, NUCLEIC ACIDS RES, V5, P2039, DOI 10.1093/nar/5.6.2039; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	36	33	34	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1022	1026		10.1038/nm1004-1022	http://dx.doi.org/10.1038/nm1004-1022			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459694				2022-12-27	WOS:000224245800014
J	Jensen, EV				Jensen, EV			From chemical warfare to breast cancer management	NATURE MEDICINE			English	Editorial Material							ESTROGEN-RECEPTOR; ESTRADIOL-RECEPTOR; RAT UTERUS; ANTIBODIES; MECHANISM		Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Dept Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Jensen, EV (corresponding author), Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Dept Biol, Cincinnati, OH 45267 USA.	elwood.jensen@uc.edu						Gorski J, 1968, Recent Prog Horm Res, V24, P45; GREENE GL, 1980, P NATL ACAD SCI-BIOL, V77, P5115, DOI 10.1073/pnas.77.9.5115; GREENE GL, 1977, P NATL ACAD SCI USA, V74, P3681, DOI 10.1073/pnas.74.9.3681; HUGGINS C, 1952, CANCER RES, V12, P134; Jensen E, 1960, BIOL ACTIVITIES STER, P161; Jensen E V, 1987, Breast Cancer Res Treat, V9, P77, DOI 10.1007/BF01807360; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; JENSEN EV, 1976, J STEROID BIOCHEM, V7, P911, DOI 10.1016/0022-4731(76)90010-8; JENSEN EV, 1973, SCIENCE, V182, P126, DOI 10.1126/science.182.4108.126; JENSEN EV, 1971, NATL CANCER I MONOGR, P55; JENSEN EV, 1962, RECENT PROG HORM RES, V18, P387; JENSEN EV, 1965, P CAN CANCER RES C, V6, P143; KHARASCH MS, 1947, IND ENG CHEM, V39, P830, DOI 10.1021/ie50451a006; KHARASCH MS, 1945, SCIENCE, V102, P128, DOI 10.1126/science.102.2640.128; LITTLE M, 1973, H-S Z PHYSIOL CHEM, V354, P1599, DOI 10.1515/bchm2.1973.354.2.1599; LUFT R, 1953, J NEUROSURG, V10, P301, DOI 10.3171/jns.1953.10.3.0301; TOFT D, 1966, P NATL ACAD SCI USA, V55, P1574, DOI 10.1073/pnas.55.6.1574	17	22	22	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1018	1021		10.1038/nm1004-1018	http://dx.doi.org/10.1038/nm1004-1018			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459693				2022-12-27	WOS:000224245800013
J	Schubert, C				Schubert, C			Asthma edges ahead	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-27	WOS:000224245800026
J	Wang, HB; Guo, Y; Wang, DZ; Kingsley, PJ; Marnett, LJ; Das, SK; DuBois, RN; Dey, SK				Wang, HB; Guo, Y; Wang, DZ; Kingsley, PJ; Marnett, LJ; Das, SK; DuBois, RN; Dey, SK			Aberrant cannabinoid signaling impairs oviductal transport of embryos	NATURE MEDICINE			English	Article							RECEPTOR KNOCKOUT MICE; MOUSE UTERUS; CB1 RECEPTOR; MOLECULAR CHARACTERIZATION; ADRENERGIC-RECEPTORS; RABBIT OVIDUCT; ANANDAMIDE; IMPLANTATION; PREGNANCY; LIGAND	Ectopic pregnancy is a major reproductive health issue. Although other underlying causes remain largely unknown, one cause of ectopic pregnancy is embryo retention in the fallopian tube. Here we show that genetic or pharmacologic silencing of cannabinoid receptor CB1 causes retention of a large number of embryos in the mouse oviduct, eventually leading to pregnancy failure. This is reversed by isoproterenol, beta-adrenergic receptor agonist. Impaired oviductal embryo transport is also observed in wild-type mice treated with methanandamide. Collectively, the results suggest that aberrant cannabinoid signaling impedes coordinated oviductal smooth muscle contraction and relaxation crucial to normal oviductal embryo transport. Colocalization of CB1 and beta2-adrenergic receptors in the oviduct muscularis implies that a basal endocannabinoid tone in collaboration with adrenergic receptors coordinates oviductal motility for normal journey of embryos into the uterus. Besides uncovering a new regulatory mechanism, this study could be clinically relevant to ectopic pregnancy.	Vanderbilt Univ, Med Ctr, Inst Biol Chem, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Inst Biol Chem, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Inst Biol Chem, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Div Reprod & Dev Biol, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Div Reprod & Dev Biol, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Div Reprod & Dev Biol, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Dey, SK (corresponding author), Vanderbilt Univ, Med Ctr, Inst Biol Chem, Dept Pediat, 1161 21st Ave S, Nashville, TN 37232 USA.	sk.dey@vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037830, R01HD012304, R37HD012304] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA006668, R01DA006668] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839] Funding Source: Medline; NICHD NIH HHS [HD12304, HD37830] Funding Source: Medline; NIDA NIH HHS [DA06668] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Arbab F, 2002, HUM REPROD, V17, P3053, DOI 10.1093/humrep/17.12.3053; Bisogno T, 1997, BBA-LIPID LIPID MET, V1345, P338, DOI 10.1016/S0005-2760(97)00009-X; Centers for Disease Control and Prevention (CDC), 1995, MMWR-MORBID MORTAL W, V44, P46; Comings DE, 1997, MOL PSYCHIATR, V2, P161, DOI 10.1038/sj.mp.4000247; Compton WM, 2004, JAMA-J AM MED ASSOC, V291, P2114, DOI 10.1001/jama.291.17.2114; DAS SK, 1995, P NATL ACAD SCI USA, V92, P4332, DOI 10.1073/pnas.92.10.4332; DAS SK, 1994, DEVELOPMENT, V120, P1071; De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666; Dennedy MC, 2004, AM J OBSTET GYNECOL, V190, P2, DOI 10.1016/j.ajog.2003.07.013; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; FENG T, 1993, CURR OPIN OBSTET GYN, V5, P16; Fergusson DM, 2002, BJOG-INT J OBSTET GY, V109, P21, DOI 10.1016/S1470-0328(02)01020-0; Fried PA, 2003, NEUROTOXICOL TERATOL, V25, P427, DOI 10.1016/S0892-0362(03)00029-1; Gadzicki D, 1999, MOL CELL PROBE, V13, P321, DOI 10.1006/mcpr.1999.0249; Godecke A, 1998, CIRC RES, V82, P186; Gonzalez S, 2002, BRAIN RES, V954, P73, DOI 10.1016/S0006-8993(02)03344-9; HALBERT SA, 1976, SCIENCE, V191, P1052, DOI 10.1126/science.1251215; Hall W, 1998, LANCET, V352, P1611, DOI 10.1016/S0140-6736(98)05021-1; HEILMAN RD, 1976, FERTIL STERIL, V27, P426; HOWE GR, 1973, J REPROD FERTIL, V33, P425; Huang JC, 2002, J CLIN ENDOCR METAB, V87, P4361, DOI 10.1210/jc.2002-020199; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; KENNEDY DR, 1977, BIOL REPROD, V16, P200, DOI 10.1095/biolreprod16.2.200; Kingsley PJ, 2003, ANAL BIOCHEM, V314, P8, DOI 10.1016/S0003-2697(02)00643-7; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Maccarrone M, 2000, LANCET, V355, P1326, DOI 10.1016/S0140-6736(00)02115-2; Maccarrone M, 2002, VITAM HORM, V65, P225, DOI 10.1016/S0083-6729(02)65066-6; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; PARIA BC, 1995, P NATL ACAD SCI USA, V92, P9460, DOI 10.1073/pnas.92.21.9460; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Racz I, 2003, J NEUROSCI, V23, P2453; ROBLERO LS, 1979, J REPROD FERTIL, V57, P91, DOI 10.1530/jrf.0.0570091; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Saraiya M, 1998, AM J OBSTET GYNECOL, V178, P493, DOI 10.1016/S0002-9378(98)70427-2; Schlicker E, 2003, BRIT J PHARMACOL, V140, P323, DOI 10.1038/sj.bjp.0705449; Schmid PC, 1997, P NATL ACAD SCI USA, V94, P4188, DOI 10.1073/pnas.94.8.4188; SCHUEL H, 1994, P NATL ACAD SCI USA, V91, P7678, DOI 10.1073/pnas.91.16.7678; Schultze JW, 2002, FARADAY DISCUSS, V121, P211, DOI 10.1039/b111216n; Song H, 2002, DEVELOPMENT, V129, P2879; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; TOLSZCZUK M, 1988, MOL CELL ENDOCRINOL, V60, P95, DOI 10.1016/0303-7207(88)90123-2; Wang HB, 2003, P NATL ACAD SCI USA, V100, P14914, DOI 10.1073/pnas.2436379100; Wilcox AJ, 1999, NEW ENGL J MED, V340, P1796, DOI 10.1056/NEJM199906103402304; YOSHINAGA K, 1979, BIOL REPROD, V20, P294, DOI 10.1095/biolreprod20.2.294; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	50	153	163	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1074	1080		10.1038/nm1104	http://dx.doi.org/10.1038/nm1104			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15378054				2022-12-27	WOS:000224245800037
J	Pantaleo, G; Koup, RA				Pantaleo, G; Koup, RA			Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know	NATURE MEDICINE			English	Article							T-CELL RESPONSES; ANTIBODY-RESPONSE; RHESUS-MONKEYS; CLINICAL AIDS; VIRUS-VACCINE; DNA; PREVENTION; INDUCTION; VIREMIA; IMMUNOGENICITY	The field of vaccinology began in ignorance of how protection was instilled in vaccine recipients. Today, a greater knowledge of immunology allows us to better understand what is being stimulated by various vaccines that leads to their protective effects: that is, their correlates of protection. Here we describe what is known about the correlates of protection for existing vaccines against a range of different viral diseases and discuss the correlates of protection against disease during natural infection with HIV-1. We will also discuss why it is important to design phase 3 clinical trials of HIV vaccines to determine the correlates of protection for each individual vaccine.	Univ Lausanne, CHU Vaudois, Dept Med, Div Immunol & Allergy,Lab AIDS Immunopathogenesis, CH-1011 Lausanne, Switzerland; NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Pantaleo, G (corresponding author), Univ Lausanne, CHU Vaudois, Dept Med, Div Immunol & Allergy,Lab AIDS Immunopathogenesis, CH-1011 Lausanne, Switzerland.	giuseppe.pantaleo@chuv.hospvd.ch; rkoup@mil.nih.gov	Pantaleo, Giuseppe/K-6163-2016		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005073, ZIAAI005073] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Appay V, 2002, J IMMUNOL, V168, P3660, DOI 10.4049/jimmunol.168.7.3660; Arvin AM, 1996, INFECT DIS CLIN N AM, V10, P529, DOI 10.1016/S0891-5520(05)70312-3; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2001, IMMUNOL LETT, V79, P57, DOI 10.1016/S0165-2478(01)00266-8; Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320; Bertoletti A, 2003, HEPATOLOGY, V38, P4, DOI 10.1053/jhep.2003.50310; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Boyer JD, 2000, J INFECT DIS, V181, P476, DOI 10.1086/315229; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Callan MFC, 2003, VIRAL IMMUNOL, V16, P3, DOI 10.1089/088282403763635401; Cao H, 2003, J INFECT DIS, V187, P887, DOI 10.1086/368020; Carter JJ, 1997, CLIN DERMATOL, V15, P249; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Cohen J, 2003, SCIENCE, V299, P1290, DOI 10.1126/science.299.5611.1290; Doherty PC, 2001, PHILOS T R SOC B, V356, P581, DOI 10.1098/rstb.2000.0786; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; EGAN MA, 1995, J INFECT DIS, V171, P1623, DOI 10.1093/infdis/171.6.1623; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; GRIFFIN DE, 1995, CURR TOP MICROBIOL, V191, P117; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0; Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kaul R, 2001, J CLIN INVEST, V107, P1303, DOI 10.1172/JCI12433; Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714; Kent SJ, 1998, J VIROL, V72, P10180, DOI 10.1128/JVI.72.12.10180-10188.1998; Kong WP, 2003, J VIROL, V77, P12764, DOI 10.1128/JVI.77.23.12764-12772.2003; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Mascola JR, 2003, CURR MOL MED, V3, P209, DOI 10.2174/1566524033479799; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Schmitz JE, 2003, J VIROL, V77, P2165, DOI 10.1128/JVI.77.3.2165-2173.2003; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Wee EGT, 2002, J GEN VIROL, V83, P75, DOI 10.1099/0022-1317-83-1-75; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; Xin KQ, 2001, HUM GENE THER, V12, P1047, DOI 10.1089/104303401750214276	48	358	381	1	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					806	810		10.1038/nm0804-806	http://dx.doi.org/10.1038/nm0804-806			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15286782	Bronze			2022-12-27	WOS:000223055700032
J	Koistinaho, M; Lin, SZ; Wu, X; Esterman, M; Koger, D; Hanson, J; Higgs, R; Liu, F; Malkani, S; Bales, KR; Paul, SM				Koistinaho, M; Lin, SZ; Wu, X; Esterman, M; Koger, D; Hanson, J; Higgs, R; Liu, F; Malkani, S; Bales, KR; Paul, SM			Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides	NATURE MEDICINE			English	Article							SPORADIC ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; MOUSE MODEL; MICROGLIAL CELLS; PLAQUE-FORMATION; DIFFUSE PLAQUES; TRANSGENIC MICE; RAT-BRAIN; IN-VITRO; PROTEIN	We have previously shown that apolipoprotein E (Apoe) promotes the formation of amyloid in brain and that astrocyte-specific expression of APOE markedly affects the deposition of amyloid-peptides (Abeta) in a mouse model of Alzheimer disease. Given the capacity of astrocytes to degrade Abeta, we investigated the potential role of Apoe in this astrocyte-mediated degradation. In contrast to cultured adult wild-type mouse astrocytes, adult Apoe(-/-) astrocytes do not degrade Abeta present in Abeta plaque-bearing brain sections in vitro. Coincubation with antibodies to either Apoe or Abeta, or with RAP, an antagonist of the low-density lipoprotein receptor family, effectively blocks Abeta degradation by astrocytes. Phase-contrast and confocal microscopy show that Apoe(-/-) astrocytes do not respond to or internalize Abeta deposits to the same extent as do wild-type astrocytes. Thus, Apoe seems to be important in the degradation and clearance of deposited Abeta species by astrocytes, a process that may be impaired in Alzheimer disease.	Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Discovery Informat Technol, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Genom Informat Stat, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly; Eli Lilly	Paul, SM (corresponding author), Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA.	Paul_Steven_M@Lilly.com	Paul, Steve/ABE-5400-2020					AlAli SY, 1996, J ANAT, V188, P257; Bacskai BJ, 2002, J NEUROSCI, V22, P7873; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; DeGroot CJA, 1997, J NEUROSCI RES, V49, P342, DOI 10.1002/(SICI)1097-4547(19970801)49:3<342::AID-JNR9>3.0.CO;2-C; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; Funato H, 1998, AM J PATHOL, V152, P983; Giulian D, 1996, J NEUROSCI, V16, P6021; Guillaume D, 1996, J NEUROCHEM, V66, P2410; Gylys KH, 2003, J NEUROCHEM, V84, P1442, DOI 10.1046/j.1471-4159.2003.01643.x; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Marr RA, 2003, J NEUROSCI, V23, P1992; Matsunaga W, 2003, NEUROSCI LETT, V342, P129, DOI 10.1016/S0304-3940(03)00240-4; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; NITTA T, 1992, NEUROSURGERY, V31, P83, DOI 10.1227/00006123-199207000-00012; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; REBECK GW, 1993, NEURON, V11, P575; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saura J, 2003, J NEUROCHEM, V85, P1455, DOI 10.1046/j.1471-4159.2003.01788.x; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SHAO YP, 1994, GLIA, V11, P147, DOI 10.1002/glia.440110209; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Thal DR, 2000, ACTA NEUROPATHOL, V100, P608, DOI 10.1007/s004010000242; Urmoneit B, 1997, LAB INVEST, V77, P157; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; Wegiel J, 2001, NEUROBIOL AGING, V22, P49, DOI 10.1016/S0197-4580(00)00181-0; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Wisniewski HM, 1996, NEUROPATH APPL NEURO, V22, P3, DOI 10.1046/j.1365-2990.1996.1698016.x; WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535, DOI 10.1017/S0317167100029887; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yamaguchi H, 1998, ACTA NEUROPATHOL, V95, P217, DOI 10.1007/s004010050790	38	445	459	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					719	726		10.1038/nm1058	http://dx.doi.org/10.1038/nm1058			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195085				2022-12-27	WOS:000222460400026
J	Noguchi, H; Matsushita, M; Okitsu, T; Moriwaki, A; Tomizawa, K; Kang, SY; Li, ST; Kobayashi, N; Matsumoto, S; Tanaka, K; Tanaka, N; Matsui, H				Noguchi, H; Matsushita, M; Okitsu, T; Moriwaki, A; Tomizawa, K; Kang, SY; Li, ST; Kobayashi, N; Matsumoto, S; Tanaka, K; Tanaka, N; Matsui, H			A new cell-permeable peptide allows successful allogeneic islet transplantation in mice	NATURE MEDICINE			English	Article							VIVO PROTEIN TRANSDUCTION; CYCLOSPORINE-A; DELIVERY; MECHANISM; FK506	Calcineurin inhibitors such as cyclosporine A and FK506 have been used for transplant therapy and treatment of autoimmune diseases. However, the inhibition of calcineurin outside the immune system has a number of side effects, including hyperglycemia. In the search for safer drugs, we developed a cell-permeable inhibitor of NFAT (nuclear factor of activated T cells) using the polyarginine peptide delivery system(1,2). This peptide provided immunosuppression for fully mismatched islet allografts in mice. In addition, it did not affect insulin secretion, whereas FK506 caused a dose-dependent decrease in insulin secretion. Cell-permeable peptides can thus provide a new strategy for drug development and may eventually be useful clinically.	Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama 7008558, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Gastroenterol Surg Transplant & Surg Oncol, Okayama 7008558, Japan; Kyoto Univ Hosp, Dept Transplantat & Immunol, Sakyo Ku, Kyoto 6068507, Japan; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Ctr Blood Res, Boston, MA 02115 USA; Okayama Univ, Grad Sch Med & Dent, Japan Sci & Technol Corp, Off Technol,Preventure Program, Okayama 7008558, Japan	Okayama University; Okayama University; Kyoto University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Japan Science & Technology Agency (JST); Okayama University	Matsushita, M (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Physiol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	masayuki@cc.okayama-u.ac.jp	Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627; Kang, Sunghyun/0000-0003-1542-9750; Li, Sheng Tian/0000-0002-2836-3802; Noguchi, Hirofumi/0000-0002-0880-6805				Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Dostmann WRG, 2000, P NATL ACAD SCI USA, V97, P14772, DOI 10.1073/pnas.97.26.14772; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Matsui H, 2003, CURR PROTEIN PEPT SC, V4, P151, DOI 10.2174/1389203033487270; Matsushita M, 2001, J NEUROSCI, V21, P6000, DOI 10.1523/JNEUROSCI.21-16-06000.2001; ODOCHA O, 1993, TRANSPLANT P, V25, P2433; Okitsu T, 2001, AM J TRANSPLANT, V1, P138, DOI 10.1034/j.1600-6143.2001.10207.x; Pascual M, 1998, IMMUNOL TODAY, V19, P514, DOI 10.1016/S0167-5699(98)01324-3; PLATZ KP, 1994, TRANSPLANTATION, V58, P170, DOI 10.1097/00007890-199405820-00007; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Redmon JB, 1996, J CLIN INVEST, V98, P2786, DOI 10.1172/JCI119105; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; Todt J, 2000, J IMMUNOL, V164, P4037, DOI 10.4049/jimmunol.164.8.4037; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003	21	229	241	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					305	309		10.1038/nm994	http://dx.doi.org/10.1038/nm994			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14770176				2022-12-27	WOS:000189297700044
J	Spiotto, MT; Rowley, DA; Schreiber, H				Spiotto, MT; Rowley, DA; Schreiber, H			Bystander elimination of antigen loss variants in established tumors	NATURE MEDICINE			English	Article							CLASS-I; T-CELLS; EXPRESSION; REJECTION; TARGET; IMMUNOSELECTION; ANGIOGENESIS; INHIBITOR; MELANOMA; PEPTIDE	Cancers express antigens that are targets for specific cytotoxic T lymphocytes (CTLs)(1,2). However, cancer cells are genetically unstable 3. Consequently, sub-populations of cancer cells that no longer express the target antigen may escape destruction by CTLs and grow progressively(1,4-13). We show that cytotoxic T cells indirectly eliminate these antigen loss variants (ALVs) in a model system when the parental cancer cells express sufficient antigen to be effectively cross-presented by the tumor stroma. When the parental tumor expressed lower levels of antigen, cytotoxic T cells eradicated the antigen-positive parental cancer cells, but the ALVs escaped, grew and killed the host. By contrast, when the parental tumor expressed higher levels of antigen, cytotoxic T cells eradicated not only the parental cancer cells but also the ALVs. This 'bystander' elimination of ALVs required stromal cells expressing major histocompatibility complex (MHC) molecules capable of presenting the antigen, and occurred in tumors showing evidence of stromal destruction. ALVs were apparently eliminated indirectly when tumor-specific CTLs killed stromal cells that were cross-presenting antigen produced by and released from antigen-positive cancer cells. These results highlight the general importance of targeting the tumor stroma to prevent the escape of variant cancer cells.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Spiotto, MT (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	mspiotto@midway.uchicago.edu	Spiotto, Michael/AAC-8331-2021		NCI NIH HHS [P01-CA97296, R01-CA22677, R01-CA37516, CA-14599] Funding Source: Medline; NICHD NIH HHS [HD 07009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097296, R01CA022677, P30CA014599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; DUTZ JP, 1994, MOL IMMUNOL, V31, P967, DOI 10.1016/0161-5890(94)90091-4; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Hanson HL, 2000, IMMUNITY, V13, P265, DOI 10.1016/S1074-7613(00)00026-1; Jager E, 1997, INT J CANCER, V71, P142, DOI 10.1002/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Lee KH, 1998, J IMMUNOL, V161, P4183; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Markiewicz MA, 2003, EUR J IMMUNOL, V33, P2917, DOI 10.1002/eji.200324273; MULLEN CA, 1985, J EXP MED, V162, P1665, DOI 10.1084/jem.162.5.1665; Niederman TMJ, 2002, P NATL ACAD SCI USA, V99, P7009, DOI 10.1073/pnas.092562399; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Plautz GE, 2000, J IMMUNOL, V165, P3656, DOI 10.4049/jimmunol.165.7.3656; Qin ZH, 2000, IMMUNITY, V12, P677, DOI 10.1016/S1074-7613(00)80218-6; Schmollinger JC, 2003, P NATL ACAD SCI USA, V100, P3398, DOI 10.1073/pnas.0530311100; SINGH S, 1992, J EXP MED, V175, P139, DOI 10.1084/jem.175.1.139; Spiotto MT, 2002, IMMUNITY, V17, P737, DOI 10.1016/S1074-7613(02)00480-6; Udaka K, 1996, J IMMUNOL, V157, P670; URBAN JL, 1982, J EXP MED, V156, P1025, DOI 10.1084/jem.156.4.1025; UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040; Valujskikh A, 2002, NAT IMMUNOL, V3, P844, DOI 10.1038/ni831; VASMEL WLE, 1989, J EXP MED, V169, P1233, DOI 10.1084/jem.169.4.1233; WARD PL, 1990, CANCER RES, V50, P3851; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543	30	209	216	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					294	298		10.1038/nm999	http://dx.doi.org/10.1038/nm999			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14981514				2022-12-27	WOS:000189297700042
J	Borsello, T; Clarke, PGH; Hirt, L; Vercelli, A; Repici, M; Schorderet, DF; Bogousslavsky, J; Bonny, C				Borsello, T; Clarke, PGH; Hirt, L; Vercelli, A; Repici, M; Schorderet, DF; Bogousslavsky, J; Bonny, C			A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia	NATURE MEDICINE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; THERAPEUTIC WINDOW; INDUCED APOPTOSIS; INJURY; STROKE; BRAIN; JNK; NEURONS; NUCLEUS; DAMAGE	Neuronal death in cerebral ischemia is largely due to excitotoxic mechanisms, which are known to activate the c-Jun N-terminal kinase (JNK) pathway. We have evaluated the neuroprotective power of a cell-penetrating, protease-resistant peptide that blocks the access of JNK to many of its targets. We obtained strong protection in two models of middle cerebral artery occlusion (MCAO): transient occlusion in adult mice and permanent occlusion in 14-d-old rat pups. In the first model, intraventricular administration as late as 6 h after occlusion reduced the lesion volume by more than 90% for at least 14 d and prevented behavioral consequences. In the second model, systemic delivery reduced the lesion by 78% and 49% at 6 and 12 h after ischemia, respectively. Protection correlated with prevention of an increase in c-Jun activation and c-Fos transcription. In view of its potency and long therapeutic window, this protease-resistant peptide is a promising neuroprotective agent for stroke.	Univ Lausanne, Inst Biol Cellulaire & Morphol, CH-1005 Lausanne, Switzerland; Dept Anat Pharmacol & Forens Med, I-10126 Turin, Italy; CHU Vaudois, Univ Hosp, Div Med Genet, CH-1011 Lausanne, Switzerland; CHU Vaudois, Univ Hosp, Lab Rech Neurol, CH-1011 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Borsello, T (corresponding author), Univ Lausanne, Inst Biol Cellulaire & Morphol, Rue Bugnon 9, CH-1005 Lausanne, Switzerland.		Vercelli, Alessandro E/A-1926-2012; Hirt, Lorenz/G-3553-2010; Borsello, Tiziana/ABG-7759-2020; Borsello, Tiziana/J-8232-2016	Vercelli, Alessandro E/0000-0002-5909-2128; Hirt, Lorenz/0000-0002-2921-5000; Borsello, Tiziana/0000-0002-9729-7642; Repici, Mariaelena/0000-0002-9420-528X				Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brott T, 2000, NEW ENGL J MED, V343, P710, DOI 10.1056/NEJM200009073431007; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coffey ET, 2000, J NEUROSCI, V20, P7602; Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.3.CO;2-I; Dawson DA, 2001, BRAIN RES, V892, P344, DOI 10.1016/S0006-8993(00)03269-8; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Imai H, 2002, J CEREBR BLOOD F MET, V22, P1080, DOI 10.1097/00004647-200209000-00005; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; Ko HW, 1998, J NEUROCHEM, V71, P1390; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Ma JY, 2001, BRIT J PHARMACOL, V133, P345, DOI 10.1038/sj.bjp.0704075; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Morris DC, 2001, STROKE, V32, P2635, DOI 10.1161/hs1101.097390; Namura S, 1998, J NEUROSCI, V18, P3659; Petty MA, 1999, BRAIN RES REV, V31, P58, DOI 10.1016/S0165-0173(99)00025-9; Saporito MS, 1998, NEUROSCIENCE, V86, P461, DOI 10.1016/S0306-4522(98)00059-1; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wu DC, 2000, J CEREBR BLOOD F MET, V20, P1320, DOI 10.1097/00004647-200009000-00007; Yam PS, 2000, J CEREBR BLOOD F MET, V20, P772, DOI 10.1097/00004647-200005000-00003; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; [No title captured]	41	569	618	0	23	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1180	1186		10.1038/nm911	http://dx.doi.org/10.1038/nm911			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12937412				2022-12-27	WOS:000185061600031
J	Bernal-Mizrachi, C; Weng, S; Feng, C; Finck, BN; Knutsen, RH; Leone, TC; Coleman, TY; Mecham, RP; Kelly, DP; Semenkovich, CF				Bernal-Mizrachi, C; Weng, S; Feng, C; Finck, BN; Knutsen, RH; Leone, TC; Coleman, TY; Mecham, RP; Kelly, DP; Semenkovich, CF			Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice	NATURE MEDICINE			English	Article							INDUCED INSULIN-RESISTANCE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; RENAL-TRANSPLANT RECIPIENTS; CHAIN FATTY-ACIDS; DEFICIENT MICE; HEPATIC GLUCONEOGENESIS; METABOLIC SYNDROME; COACTIVATOR PGC-1; CUSHINGS-SYNDROME; BLOOD-PRESSURE	Hypertension and diabetes are common side effects of glucocorticoid treatment. To determine whether peroxisome proliferator-activated receptor-alpha (PPAR-alpha) mediates these sequelae, mice deficient in low-density lipoprotein receptor (Ldlr(-/-)), with (Ppara (+/+)) or without (Ppara(-/-)) PPAR-alpha, were treated chronically with dexamethasone. Ppara (+/+), but not Ppara (-/-), mice developed hyperglycemia, hyperinsulinemia and hypertension. Similar effects on glucose metabolism were seen in a different model using C57BL/6 mice. Hepatic gluconeogenic gene expression was increased and insulin-mediated suppression of endogenous glucose production was less effective in dexamethasone-treated Ppara (+/+) mice. Adenoviral reconstitution of PPAR-alpha in the livers of nondiabetic, normotensive, dexamethasone-treated Ppara -/- mice induced hyperglycemia, hyperinsulinemia and increased gluconeogenic gene expression. It also increased blood pressure, renin activity, sympathetic nervous activity and renal sodium retention. Human hepatocytes treated with dexamethasone and the PPAR-alpha agonist Wy14,643 induced PPARA and gluconeogenic gene expression. These results identify hepatic activation of PPAR-alpha as a mechanism underlying glucocorticoid-induced insulin resistance.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.		Kelly, Daniel/ABG-2056-2021	Semenkovich, Clay/0000-0003-1163-1871; Bernal-Mizrachi, Carlos/0000-0002-8991-7522; Finck, Brian/0000-0001-5411-3674	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, P60DK020579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020091] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427] Funding Source: Medline; NIA NIH HHS [AG20091] Funding Source: Medline; NIDDK NIH HHS [DK56341, DK20579] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrew R, 2002, EXP CLIN ENDOCR DIAB, V110, P284, DOI 10.1055/s-2002-34591; ARNER P, 1983, DIABETES CARE, V6, P23, DOI 10.2337/diacare.6.1.23; Benthem L, 2000, AM J PHYSIOL-ENDOC M, V279, pE1286, DOI 10.1152/ajpendo.2000.279.6.E1286; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bernal-Mizrachi C, 2002, ARTERIOSCL THROM VAS, V22, P961, DOI 10.1161/01.ATV.0000019404.65403.71; Dirlewanger M, 2000, CLIN NUTR, V19, P29, DOI 10.1054/clnu.1999.0064; Djurhuus CB, 2002, AM J PHYSIOL-ENDOC M, V283, pE172, DOI 10.1152/ajpendo.00544.2001; Duclos M, 2001, CLIN ENDOCRINOL, V55, P447, DOI 10.1046/j.1365-2265.2001.01384.x; EKSTRAND A, 1992, METABOLISM, V41, P692, DOI 10.1016/0026-0495(92)90306-U; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Goodpaster BH, 1999, DIABETES, V48, P839, DOI 10.2337/diabetes.48.4.839; GREKIN RJ, 1995, HYPERTENSION, V26, P193, DOI 10.1161/01.HYP.26.1.193; Guerre-Millo M, 2001, DIABETES, V50, P2809, DOI 10.2337/diabetes.50.12.2809; Hawkins M, 1999, J BIOL CHEM, V274, P31312, DOI 10.1074/jbc.274.44.31312; Hermanowski-Vosatka A, 2000, BIOCHEM BIOPH RES CO, V279, P330, DOI 10.1006/bbrc.2000.3966; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; HOWLETT TA, 1985, CLIN ENDOCRINOL META, V14, P911, DOI 10.1016/S0300-595X(85)80083-9; HRICIK DE, 1991, TRANSPLANTATION, V51, P374, DOI 10.1097/00007890-199102000-00020; Khani S, 2001, CLIN SCI, V101, P739, DOI 10.1042/cs1010739; Kopf D, 2001, METABOLISM, V50, P929, DOI 10.1053/meta.2001.24928; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; Levitt NS, 2000, J CLIN ENDOCR METAB, V85, P4611, DOI 10.1210/jc.85.12.4611; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; Marshall BA, 1999, AM J PHYSIOL-ENDOC M, V276, pE390, DOI 10.1152/ajpendo.1999.276.2.E390; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; ORBACH J, 1973, Q J EXP PHYSIOL CMS, V58, P267, DOI 10.1113/expphysiol.1973.sp002214; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Randich A, 2001, NEUROREPORT, V12, P3101, DOI 10.1097/00001756-200110080-00024; Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418; Schreyer SA, 2002, AM J PHYSIOL-ENDOC M, V282, pE207, DOI 10.1152/ajpendo.2002.282.1.E207; TAPPY L, 1994, J CLIN ENDOCR METAB, V79, P1063, DOI 10.1210/jc.79.4.1063; Tauchmanova L, 2002, J CLIN ENDOCR METAB, V87, P4872, DOI 10.1210/jc.2001-011766; Tordjman K, 2002, J LIPID RES, V43, P936; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427; VACCA G, 1994, CARDIOSCIENCE, V5, P261; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Williams LC, 2001, DERMATOL CLIN, V19, P63, DOI 10.1016/S0733-8635(05)70230-8; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	46	163	176	1	13	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1069	1075		10.1038/nm898	http://dx.doi.org/10.1038/nm898			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847522				2022-12-27	WOS:000184484900032
J	Haberman, RP; Samulski, RJ; McCown, TJ				Haberman, RP; Samulski, RJ; McCown, TJ			Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion	NATURE MEDICINE			English	Article							TERM GENE-EXPRESSION; EPILEPSY; BRAIN; CELLS; STIMULATION	Seizure disorders present an attractive gene therapy target, particularly because viral vectors such as adeno-associated virus (AAV) and lentivirus can stably transduce neurons(1,2,3). When we targeted the N-methyl-D-aspartic acid (NMDA) excitatory amino acid receptor with an AAV-delivered antisense oligonucleotide, however, the promoter determined whether focal seizure sensitivity was significantly attenuated or facilitated(4). One potential means to circumvent this liability would be to express an inhibitory neuroactive peptide and constitutively secrete the peptide from the transduced cell. The neuropeptide galanin can modulate seizure activity in vivo(5,6), and the laminar protein fibronectin is usually secreted through a constitutive pathway(7,8). Initially, inclusion of the fibronectin secretory signal sequence (FIB) 9 in an AAV vector caused significant gene product secretion in vitro. More importantly, the combination of this secretory signal with the coding sequence for the active galanin peptide significantly attenuated in vivo focal seizure sensitivity, even with different promoters, and prevented kainic acid-induced hilar cell death. Thus, neuroactive peptide expression and local secretion provides a new gene therapy platform for the treatment of neurological disorders.	Univ N Carolina, Sch Med, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	McCown, TJ (corresponding author), Univ N Carolina, Sch Med, Gene Therapy Ctr, 7119 Thurston Bowles Bldg,CB 7352, Chapel Hill, NC 27599 USA.				NINDS NIH HHS [NS 35633] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035633] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; BENARI Y, 1990, EUR J NEUROSCI, V2, P62, DOI 10.1111/j.1460-9568.1990.tb00381.x; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Burazin TCD, 2000, EUR J NEUROSCI, V12, P2901, DOI 10.1046/j.1460-9568.2000.00184.x; Crawley JN, 1996, LIFE SCI, V58, P2185, DOI 10.1016/0024-3205(96)00093-8; Criswell HE, 1997, NEUROPHARMACOLOGY, V36, P1641, DOI 10.1016/S0028-3908(97)00169-X; Haberman RP, 2000, J VIROL, V74, P8732, DOI 10.1128/JVI.74.18.8732-8739.2000; Haberman RP, 1998, GENE THER, V5, P1604, DOI 10.1038/sj.gt.3300782; Haberman RP, 2002, MOL THER, V6, P495, DOI 10.1006/mthe.2002.0701; Huber A, 2001, P NATL ACAD SCI USA, V98, P7611, DOI 10.1073/pnas.131102898; Hynes RO, 1990, FIBRONECTINS; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Mazarati AM, 1998, J NEUROSCI, V18, P10070; MCCOWN TJ, 1991, BRAIN RES, V567, P25, DOI 10.1016/0006-8993(91)91431-Y; MCCOWN TJ, 1984, EXP NEUROL, V86, P527, DOI 10.1016/0014-4886(84)90087-6; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; NADLER JV, 1981, LIFE SCI, V29, P2031; Paxinos G, 1988, RAT BRAIN STEREOTAXI; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Sarang SS, 2002, PHYSIOL GENOMICS, V11, P45, DOI 10.1152/physiolgenomics.00064.2002; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Zeng G, 1998, BIOTECHNIQUES, V25, P206, DOI 10.2144/98252bm05	26	136	146	1	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1076	1080		10.1038/nm901	http://dx.doi.org/10.1038/nm901			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12858168				2022-12-27	WOS:000184484900033
J	Barre-Sinoussi, F				Barre-Sinoussi, F			The early years of HIV research: integrating clinical and basic research	NATURE MEDICINE			English	Editorial Material							LYMPHADENOPATHY-ASSOCIATED VIRUS; T-LYMPHOTROPIC RETROVIRUS; AIDS; LAV	Between the first analysis of patient samples in early 1983 and the determination of the sequence of HIV-1 in 1985, a vast amount of data was accumulated on HIV through the integrated efforts of clinicians, virologists, immunologists, molecular biologists and epidemiologists. These early years of HIV research quickly led to strategies for the diagnosis, monitoring and treatment of HIV/AIDs.	Inst Pasteur, Retrovirus Biol Unit, Dept Virol, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Barre-Sinoussi, F (corresponding author), Inst Pasteur, Retrovirus Biol Unit, Dept Virol, 28 Rue Docteur Roux, F-75724 Paris 15, France.		Barre-Sinoussi, Françoise/G-8355-2011					ALIZON M, 1984, NATURE, V312, P757, DOI 10.1038/312757a0; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BRUNVEZINET F, 1984, LANCET, V1, P1253; *CDCP, 1981, MMWR-MORBID MORTAL W, V30, P250; CHERMANN JC, 1984, AIDS, P31; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4	8	12	14	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					844	846		10.1038/nm0703-844	http://dx.doi.org/10.1038/nm0703-844			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835702				2022-12-27	WOS:000183979300022
J	Fauci, AS				Fauci, AS			HIV and AIDS: 20 years of science	NATURE MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNE-DEFICIENCY SYNDROME; HISTORICAL ESSAY; HUMAN RETROVIRUS; T-LYMPHOCYTES; INFECTION; PATHOGENESIS; CHEMOKINES; DISEASE	From the identification of HIV as the agent that causes AIDS, to the development of effective antiretroviral drugs, the scientific achievements in HIV research in the past 20 years have been formidable. Some of the other important areas of accomplishment include the development of blood tests for HIV and increased knowledge of the molecular virology, epidemiology and pathogenesis of this virus.	NIAID, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, Dept Hlth & Human Serv, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.							BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; Burton A, 2003, LANCET INFECT DIS, V3, P260, DOI 10.1016/S1473-3099(03)00620-0; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Dybul Mark, 2002, MMWR Recomm Rep, V51, P1; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Fauci AS, 1999, NEW ENGL J MED, V341, P1046, DOI 10.1056/NEJM199909303411406; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FRANCIS DP, 1983, J NATL CANCER I, V71, P1; Gallo RC, 2002, SCIENCE, V298, P1728, DOI 10.1126/science.1078050; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Goulder PJR, 2002, NEW ENGL J MED, V347, P756, DOI 10.1056/NEJMe020091; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Gulick RM, 2003, CLIN MICROBIOL INFEC, V9, P186, DOI 10.1046/j.1469-0691.2003.00570.x; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; *JOINT UN PROGR HI, 2002, AIDS EP UPD; *JOINT UN PROGR HI, 2002, REP GLOB HIV AIDS EP; Kinter A, 2000, IMMUNOL REV, V177, P88, DOI 10.1034/j.1600-065X.2000.17708.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Montagnier L, 2002, SCIENCE, V298, P1727, DOI 10.1126/science.1079027; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Nabel GJ, 2001, NATURE, V410, P1002, DOI 10.1038/35073500; O'Brien SJ, 2000, IMMUNOL REV, V177, P99, DOI 10.1034/j.1600-065X.2000.17710.x; Osmanov S, 2002, J ACQ IMMUN DEF SYND, V29, P184, DOI 10.1097/00042560-200202010-00013; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perkins H A, 1993, J Clin Apher, V8, P110, DOI 10.1002/jca.2920080210; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Raju TNK, 1999, LANCET, V354, P1308, DOI 10.1016/S0140-6736(05)76086-4; Rowland-Jones SL, 2003, NAT REV IMMUNOL, V3, P343, DOI 10.1038/nri1058; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SMITH TF, 1988, NATURE, V333, P573, DOI 10.1038/333573a0; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; 1981, MORB MORTAL WKLY REP, V30, P250; 1981, MORB MORTAL WKLY REP, V30, P305	48	148	166	2	26	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					839	843		10.1038/nm0703-839	http://dx.doi.org/10.1038/nm0703-839			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835701	Bronze, Green Published			2022-12-27	WOS:000183979300021
J	Blattman, JN; Grayson, JM; Wherry, EJ; Kaech, SM; Smith, KA; Ahmed, R				Blattman, JN; Grayson, JM; Wherry, EJ; Kaech, SM; Smith, KA; Ahmed, R			Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo	NATURE MEDICINE			English	Article							DIRECT VISUALIZATION; CUTTING EDGE; INTERLEUKIN-2; MEMORY; MICE; LYMPHOCYTES; ACTIVATION; ALPHA; PERSISTENCE; INDUCTION	Interleukin (IL)-2 is currently used to enhance T-cell immunity but can have both positive and negative effects on T cells. To determine whether these opposing results are due to IL-2 acting differently on T cells depending on their stage of differentiation, we examined the effects of IL-2 therapy during the expansion, contraction and memory phases of the T-cell response in lymphocytic choriomeningitis virus (LCMV)-infected mice. IL-2 treatment during the expansion phase was detrimental to the survival of rapidly dividing effector T cells. In contrast, IL-2 therapy was highly beneficial during the death phase, resulting in increased proliferation and survival of virus-specific T cells. IL-2 treatment also increased proliferation of resting memory T cells in mice that controlled the infection. Virus-specific T cells in chronically infected mice also responded to IL-2 resulting in decreased viral burden. Thus, timing of IL-2 administration and differentiation status of the T cell are critical parameters in designing IL-2 therapies.	Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY USA	Emory University; Cornell University	Ahmed, R (corresponding author), Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA.	ra@microbio.emory.edu	Wherry, John/ABI-1280-2020		NIAID NIH HHS [1F32AI0249-01A1, AI30048] Funding Source: Medline; PHS HHS [A151181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030048, R01AI030048] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; COUSENS LP, 1995, J IMMUNOL, V155, P5690; Dai ZH, 2000, J IMMUNOL, V165, P3031, DOI 10.4049/jimmunol.165.6.3031; Davey RT, 2000, JAMA-J AM MED ASSOC, V284, P183, DOI 10.1001/jama.284.2.183; GILLIS S, 1978, J EXP MED, V148, P18, DOI 10.1084/jem.148.1.18; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Grayson JM, 2001, J IMMUNOL, V166, P795, DOI 10.4049/jimmunol.166.2.795; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; Jin X, 2000, J INFECT DIS, V181, P165, DOI 10.1086/315201; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Komanduri KV, 2001, VIROLOGY, V279, P459, DOI 10.1006/viro.2000.0697; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Kovacs JA, 2001, EUR J IMMUNOL, V31, P1351, DOI 10.1002/1521-4141(200105)31:5<1351::AID-IMMU1351>3.0.CO;2-9; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Kuroda K, 1996, J IMMUNOL, V157, P1422; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LOTZE MT, 1986, CANCER, V58, P2764, DOI 10.1002/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z; LOTZE MT, 1985, J IMMUNOL, V135, P2865; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; MIER JW, 1988, J CLIN IMMUNOL, V8, P426, DOI 10.1007/BF00916947; Murali-Krishna K, 2000, J IMMUNOL, V165, P1733, DOI 10.4049/jimmunol.165.4.1733; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Smith K A, 2000, HIV Clin Trials, V1, P16, DOI 10.1310/4VD1-WGAU-VX2L-V3JE; Smith KA, 2001, THERAPEUTIC IMMUNOLOGY, SECOND EDITION, P240; Smith KA, 2001, CURR OPIN IMMUNOL, V13, P617, DOI 10.1016/S0952-7915(00)00270-3; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; Whitmire JK, 1999, J IMMUNOL, V163, P3194; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Wilson JDK, 2000, AIDS, V14, P225, DOI 10.1097/00002030-200002180-00003; Wong P, 2001, J IMMUNOL, V166, P5864, DOI 10.4049/jimmunol.166.10.5864; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	42	301	327	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2003	9	5					540	547		10.1038/nm866	http://dx.doi.org/10.1038/nm866			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692546				2022-12-27	WOS:000182610600034
J	Sohn, JH; Bora, PS; Suk, HJ; Molina, H; Kaplan, HJ; Bora, NS				Sohn, JH; Bora, PS; Suk, HJ; Molina, H; Kaplan, HJ; Bora, NS			Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells	NATURE MEDICINE			English	Article							IMMUNE DEVIATION ACAID; GROWTH-FACTOR-BETA; ANTERIOR-CHAMBER; ACQUIRED-IMMUNITY; AQUEOUS-HUMOR; TGF-BETA; B-CELLS; T-CELLS; INDUCTION; PRIVILEGE	Systemic tolerance can be induced by the introduction of antigen into an immune-privileged site. Here we investigated the role of complement in the induction of tolerance after intraocular injection. We found that the development of antigen-specific tolerance is dependent on a complement activation product. The ligation of the complement C3 activation product iC3b to complement receptor type 3 (the iC3b receptor) on antigen-presenting cells resulted in the sequential production of transforming growth factor-beta2 and interleukin-10, which is essential for the induction of tolerance. These observations may extend to the development of both neonatal tolerance and other forms of acquired tolerance.	Univ Louisville, Kentucky Lions Eye Ctr, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	University of Louisville; Washington University (WUSTL)	Bora, NS (corresponding author), Univ Louisville, Kentucky Lions Eye Ctr, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.			Bora, Puran/0000-0003-4781-1217	NATIONAL EYE INSTITUTE [R01EY009730, R01EY010543, R01EY013335] Funding Source: NIH RePORTER; NEI NIH HHS [EY 13335, R01 EY013335, EY10543, EY09730] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARVIEUX J, 1988, IMMUNOLOGY, V65, P229; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; COUSINS SW, 1991, INVEST OPHTH VIS SCI, V32, P2201; D'Orazio TJ, 1998, J IMMUNOL, V160, P2089; D'Orazio TJ, 1998, IMMUNOLOGY, V95, P47; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; FORIS G, 1983, IMMUNOL LETT, V6, P7, DOI 10.1016/0165-2478(83)90022-6; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; FRITZINGER DC, 1994, P NATL ACAD SCI USA, V91, P12775, DOI 10.1073/pnas.91.26.12775; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hammerberg C, 1998, J EXP MED, V187, P1133, DOI 10.1084/jem.187.7.1133; Hammerberg C, 1996, J IMMUNOL, V157, P5254; HARA Y, 1993, J IMMUNOL, V151, P5162; JACQUIERSARLIN MR, 1995, IMMUNOLOGY, V84, P164; Kabat EA, 1961, EXPT IMMUNOHISTOCHEM, P133; KALLI KR, 1991, J IMMUNOL, V147, P590; KAPLAN HJ, 1977, J IMMUNOL, V118, P809; KAPLAN HJ, 1978, J IMMUNOL, V120, P689; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kosiewicz MM, 1998, J IMMUNOL, V161, P5382; McQuillen DP, 1999, J INFECT DIS, V179, P124, DOI 10.1086/314545; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Nielsen CH, 2000, IMMUNOLOGY, V100, P4, DOI 10.1046/j.1365-2567.2000.00009.x; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; ROSS GD, 1980, J IMMUNOL METHODS, V37, P197, DOI 10.1016/0022-1759(80)90307-5; ROSS GD, 1993, CLIN EXP IMMUNOL, V92, P181; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; Shankland SJ, 1996, KIDNEY INT, V50, P116, DOI 10.1038/ki.1996.294; Simpson AECM, 1997, INFLAMM RES, V46, P65, DOI 10.1007/s000110050078; Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Streilein JW, 1999, SPRINGER SEMIN IMMUN, V21, P95; STREILEIN JW, 1981, J EXP MED, V153, P1058, DOI 10.1084/jem.153.5.1058; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; TAYLOR AW, 1994, J IMMUNOL, V153, P1080; TAYLOR AW, 1992, CURR EYE RES, V11, P1199, DOI 10.3109/02713689208999545; THOMLINSON S, 1993, CURR OPIN IMMUNOL, V5, P83; Tsuji RF, 1997, J EXP MED, V186, P1015, DOI 10.1084/jem.186.7.1015; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WILBANKS G A, 1992, Regional Immunology, V4, P130; WILBANKS GA, 1990, IMMUNOLOGY, V71, P383; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; Yoshida Y, 1998, J IMMUNOL, V161, P5873	45	146	158	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2003	9	2					206	212		10.1038/nm814	http://dx.doi.org/10.1038/nm814			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12514742	Green Accepted			2022-12-27	WOS:000180801900025
J	Tirona, RG; Lee, W; Leake, BF; Lan, LB; Cline, CB; Lamba, V; Parviz, F; Duncan, SA; Inoue, Y; Gonzalez, FJ; Schuetz, EG; Kim, RB				Tirona, RG; Lee, W; Leake, BF; Lan, LB; Cline, CB; Lamba, V; Parviz, F; Duncan, SA; Inoue, Y; Gonzalez, FJ; Schuetz, EG; Kim, RB			The orphan nuclear receptor HNF4 alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4	NATURE MEDICINE			English	Article							PREGNANE-X-RECEPTOR; HUMAN CYP2B6 GENE; TRANSCRIPTIONAL REGULATION; VISCERAL ENDODERM; ACTIVATION; EXPRESSION; HNF-4; GASTRULATION; REQUIRES; EMBRYOS	The drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is thought to be involved in the metabolism of nearly 50% of all the drugs currently prescribed. Alteration in the activity or expression of this enzyme seems to be a key predictor of drug responsiveness and toxicity(1). Currently available studies indicate that the ligand-activated nuclear receptors pregnane X receptor (PXR; NR1I2) and constitutive androstane receptor (CAR; NR1I3) regulate CYP3A4 expression(2,3). However, in cell-based reporter assays, CYP3A4 promoter activity was most pronounced in liver-derived cells and minimal or modest in non-hepatic cells(2), indicating that a liver-specific factor is required for physiological transcriptional response. Here we show that the orphan nuclear receptor hepatocyte nuclear factor-4alpha (HNF4alpha; HNF4A) is critically involved in the PXR- and CAR-mediated transcriptional activation of CYP3A4. We identified a specific cis-acting element in the CYP3A4 gene enhancer that confers HNF4alpha binding and thereby permits PXR- and CAR-mediated gene activation. Fetal mice with conditional deletion of Hnf4alpha had reduced or absent expression of CYP3A. Furthermore, adult mice with conditional hepatic deletion of Hnf4alpha had reduced basal and inducible expression of CYP3A. These data identify HNF4alpha as an important regulator of coordinate nuclear-receptor-mediated response to xenobiotics.	Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA; Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; NCI, Lab Metab, Div Basic Sci, Bethesda, MD 20892 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA	Vanderbilt University; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Kim, RB (corresponding author), Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA.	richard.kim@vanderbilt.edu	Lee, Wooin/K-7789-2012; Inoue, Yusuke/O-6207-2018; Schuetz, Erin/N-8087-2018; Kim, Richard/D-6971-2011; Cline, Cynthia D/F-7065-2012	Lee, Wooin/0000-0001-7805-869X; Inoue, Yusuke/0000-0002-9710-7482; Kim, Richard/0000-0001-8148-1632; Duncan, Stephen/0000-0002-2507-7827	NIEHS NIH HHS [ES08658] Funding Source: Medline; NIGMS NIH HHS [GM60346, GM31304, GM54724] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304, R55GM054724, R01GM060346, R01GM054724] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Duncan SA, 1997, DEVELOPMENT, V124, P279; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 2002, MOL PHARMACOL, V62, P359, DOI 10.1124/mol.62.2.359; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Huss JM, 1998, J BIOL CHEM, V273, P16155, DOI 10.1074/jbc.273.26.16155; Jover R, 2001, HEPATOLOGY, V33, P668, DOI 10.1053/jhep.2001.22176; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Li JX, 2000, GENE DEV, V14, P464; Ogino M, 1999, ARCH BIOCHEM BIOPHYS, V362, P32, DOI 10.1006/abbi.1998.1012; Parviz F, 2002, GENESIS, V32, P130, DOI 10.1002/gene.10058; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Saito T, 2001, J BIOL CHEM, V276, P38010; Schuetz E, 2002, MOL PHARMACOL, V62, P439, DOI 10.1124/mol.62.3.439; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zhang J, 2001, PHARMACOGENETICS, V11, P555, DOI 10.1097/00008571-200110000-00003	23	374	381	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2003	9	2					220	224		10.1038/nm815	http://dx.doi.org/10.1038/nm815			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12514743				2022-12-27	WOS:000180801900027
J	Brindle, JT; Antti, H; Holmes, E; Tranter, G; Nicholson, JK; Bethell, HWL; Clarke, S; Schofield, PM; McKilligin, E; Mosedale, DE; Grainger, DJ				Brindle, JT; Antti, H; Holmes, E; Tranter, G; Nicholson, JK; Bethell, HWL; Clarke, S; Schofield, PM; McKilligin, E; Mosedale, DE; Grainger, DJ			Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-NMR-based metabonomics	NATURE MEDICINE			English	Article							NMR-SPECTROSCOPY; SMOKING; RISK	Although a wide range of risk factors for coronary heart disease have been identified from population studies, these measures, singly or in combination, are insufficiently powerful to provide a reliable, noninvasive diagnosis of the presence of coronary heart disease. Here we show that pattern-recognition techniques applied to proton nuclear magnetic resonance (H-1-NMR) spectra of human serum can correctly diagnose not only the presence, but also the severity, of coronary heart disease. Application of supervised partial least squares-discriminant analysis to orthogonal signal-corrected data sets allows >90% of subjects with stenosis of all three major coronary vessels to be distinguished from subjects with angiographically normal coronary arteries, with a specificity of >90%. Our studies show for the first time a technique capable of providing an accurate, noninvasive and rapid diagnosis of coronary heart disease that can be used clinically, either in population screening or to allow effective targeting of treatments such as statins.	Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, London, England; Papworth Hosp, NHS Trust, Dept Cardiol, Cambridge CB3 8RE, England; GlaxoSmithKline, Med Res Ctr, Stevenage, Herts, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Imperial College London; Papworth Hospital; GlaxoSmithKline	Grainger, DJ (corresponding author), Addenbrookes Hosp, Dept Med, POB 157, Cambridge CB2 2QQ, England.	djg15@cam.ac.uk	Nicholson, Jeremy K/B-3395-2012; Holmes, Elaine/A-2189-2015; Holmes, Elaine/ABE-6606-2020	Nicholson, Jeremy K/0000-0002-8123-8349; Holmes, Elaine/0000-0002-0556-8389; Tranter, George/0000-0002-2877-1785				AlaKorpela M, 1995, NMR BIOMED, V8, P235, DOI 10.1002/nbm.1940080603; AlaKorpela M, 1995, PROG NUCL MAG RES SP, V27, P475, DOI 10.1016/0079-6565(95)01013-0; Cullen P, 1998, EUR HEART J, V19, pC5; Eriksson L., 1999, INTRO MULTI MEGAVARI; Holmes E, 2000, CHEM RES TOXICOL, V13, P471, DOI 10.1021/tx990210t; Isles CG, 2000, QJM-INT J MED, V93, P567, DOI 10.1093/qjmed/93.9.567; KJELSBERG MO, 1986, PREV MED, V15, P254; Kjelsberg MO, 1997, AM J CLIN NUTR, V65, P191; KULLER LH, 1991, PREV MED, V20, P638, DOI 10.1016/0091-7435(91)90060-H; Lindon JC, 2001, PROG NUCL MAG RES SP, V39, P1, DOI 10.1016/S0079-6565(00)00036-4; Lindon JC, 2000, CONCEPT MAGNETIC RES, V12, P289, DOI 10.1002/1099-0534(2000)12:5<289::AID-CMR3>3.0.CO;2-W; MCILVAIN HE, 1992, AM J PREV MED, V8, P165, DOI 10.1016/S0749-3797(18)30826-2; Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047; NICHOLSON JK, 1995, ANAL CHEM, V67, P793, DOI 10.1021/ac00101a004; NICHOLSON JK, 1989, PROG NUCL MAG RES SP, V21, P449, DOI 10.1016/0079-6565(89)80008-1; OTVOS JD, 1997, HDB LIPOPROTEIN TEST, P497; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Storck T, 2002, CURR OPIN DRUG DISC, V5, P90; Wold S, 1998, CHEMOMETR INTELL LAB, V44, P175, DOI 10.1016/S0169-7439(98)00109-9; 1998, NATL STAT DH1, V31	20	875	987	4	184	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1439	1444		10.1038/nm802	http://dx.doi.org/10.1038/nm802			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12447357				2022-12-27	WOS:000179552000042
J	Novak, K				Novak, K			Mina Bissell - Profile	NATURE MEDICINE			English	Biographical-Item														Novak, Kristine/0000-0001-9314-1803					0	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2005	11	3					242	242		10.1038/nm0305-242	http://dx.doi.org/10.1038/nm0305-242			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15746928				2022-12-27	WOS:000227541300010
J	Cai, DS; Yuan, MS; Frantz, DF; Melendez, PA; Hansen, L; Lee, J; Shoelson, SE				Cai, DS; Yuan, MS; Frantz, DF; Melendez, PA; Hansen, L; Lee, J; Shoelson, SE			Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; FREE FATTY-ACIDS; TYPE-2 DIABETES-MELLITUS; GLUCOSE-METABOLISM; OBESITY; INTERLEUKIN-6; PHOSPHORYLATION; INFLAMMATION; LIVER; RISK	We show that NF-kappaB and transcriptional targets are activated in liver by obesity and high-fat diet (HFD). We have matched this state of chronic, subacute 'inflammation' by low-level activation of NF-kappaB in the liver of transgenic mice, designated LIKK, by selectively expressing constitutively active IKK-beta in hepatocytes. These mice exhibit a type 2 diabetes phenotype, characterized by hyperglycemia, profound hepatic insulin resistance, and moderate systemic insulin resistance, including effects in muscle. The hepatic production of proinflammatory cytokines, including IL-6, IL-1beta and TNF-alpha, was increased in LIKK mice to a similar extent as induced by HFD in in wild-type mice. Parallel increases were observed in cytokine signaling in liver and mucscle of LIKK mice. Insulin resistance was improved by systemic neutralization of IL-6 or salicylate inhibition of IKK-beta. Hepatic expression of the IkappaBalpha superrepressor (LISR) reversed the phenotype of both LIKK mice and wild-type mice fed an HFD. These findings indicate that lipid accumulation in the liver leads to subacute hepatic 'inflammation' through NF-kappaB activation and downstream cytokine production. This causes insulin resistance both locally in liver and systemically.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Shoelson, SE (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02115 USA.	steven.shoelson@joslin.harvard.edu	Lee, Jongsoon/AAG-1674-2020	Lee, Jongsoon/0000-0002-0891-5059	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051729, R37DK051729, P30DK036836, R01DK045943] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK051729, R37 DK051729, R01 DK45493, R01 DK51729, R01 DK045943, P30 DK36836, P30 DK036836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; [Anonymous], 1979, STEREOLOGICAL METHOD; Barzilay JI, 2003, METAB SYNDR RELAT D, V1, P55, DOI 10.1089/154041903321648252; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Haddad E, 2001, BLOOD, V97, P1590, DOI 10.1182/blood.V97.6.1590; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; Kanemaki T, 1998, HEPATOLOGY, V27, P1296, DOI 10.1002/hep.510270515; Kelley DE, 2003, AM J PHYSIOL-ENDOC M, V285, pE906, DOI 10.1152/ajpendo.00117.2003; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Lagathu C, 2003, BIOCHEM BIOPH RES CO, V311, P372, DOI 10.1016/j.bbrc.2003.10.013; Li NX, 2000, METHOD ENZYMOL, V319, P273; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Marchesini G, 2001, LANCET, V358, P893, DOI 10.1016/S0140-6736(01)06042-1; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; *NAT DIAB DAT GROU, 1995, DIAB AM; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V38, P1008, DOI 10.1053/jhep.2003.50420; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Promrat K, 2004, HEPATOLOGY, V39, P188, DOI 10.1002/hep.20012; Radziuk J, 2000, J CLIN ENDOCR METAB, V85, P4426, DOI 10.1210/jc.85.12.4426; Rohl M, 2004, J CLIN INVEST, V113, P474, DOI 10.1172/JCI200418712; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Ryysy L, 2000, DIABETES, V49, P749, DOI 10.2337/diabetes.49.5.749; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; Shoelson S, 2002, J MOL MED-JMM, V80, P618, DOI 10.1007/s00109-002-0383-x; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; Spranger J, 2003, DIABETES, V52, P812, DOI 10.2337/diabetes.52.3.812; STARNES HF, 1990, J IMMUNOL, V145, P4185; VAN AD, 1996, SCIENCE, V274, P787; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	45	1688	1801	4	151	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					183	190		10.1038/nm1166	http://dx.doi.org/10.1038/nm1166			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685173	Green Accepted			2022-12-27	WOS:000226797300026
J	Reynolds, LE; Conti, FJ; Lucas, M; Grose, R; Robinson, S; Stone, M; Saunders, G; Dickson, C; Hynes, RO; Lacy-Hulbert, A; Hodivala-Dilke, K				Reynolds, LE; Conti, FJ; Lucas, M; Grose, R; Robinson, S; Stone, M; Saunders, G; Dickson, C; Hynes, RO; Lacy-Hulbert, A; Hodivala-Dilke, K			Accelerated re-epithelialization in beta(3)-integrin-deficient mice is associated with enhanced TGF-beta 1 signaling	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; EXTRACELLULAR-MATRIX; WOUND REPAIR; TRANSFORMING GROWTH-FACTOR-BETA-1; HUMAN KERATINOCYTES; CELL-MIGRATION; IN-VITRO; EXPRESSION; INTEGRIN	The upregulation of TGF-beta1 and integrin expression during wound healing has implicated these molecules in this process, but their precise regulation and roles remain unclear. Here we report that, notably, mice lacking beta(3)-integrins show enhanced wound healing with re-epithelialization complete several days earlier than in wild-type mice. We show that this effect is the result of an increase in TGF-beta1 and enhanced dermal fibroblast infiltration into wounds of beta(3)-null mice. Specifically, beta(3)-integrin deficiency is associated with elevated TGF-beta receptor I and receptor II expression, reduced Smad3 levels, sustained Smad2 and Smad4 nuclear localization and enhanced TGF-beta1-mediated dermal fibroblast migration. These data indicate that alpha(v)beta(3)-integrin can suppress TGF-beta1-mediated signaling, thereby controlling the rate of wound healing, and highlight a new mechanism for TGF-beta1 regulation by beta(3)-integrins.	Univ London St Bartholomews Hosp Med Coll, Queen Marys Sch Med & Dent, Cell Adhes & Dis Lab, Dept Tumor Biol,Canc Res UK,John Vane Sci Ctr, London EC1M 6BQ, England; Canc Res UK, London Res Inst, Viral Carcinogenesis Lab 213, London WC2A 3PX, England; Univ Edinburgh, MRC Ctr Inflammat Res, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland; MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK; University of Edinburgh; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Hodivala-Dilke, K (corresponding author), Univ London St Bartholomews Hosp Med Coll, Queen Marys Sch Med & Dent, Cell Adhes & Dis Lab, Dept Tumor Biol,Canc Res UK,John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.	kairbaan.hodivala-dilke@cancer.org.uk		Grose, Richard/0000-0002-4738-0173; Lacy-Hulbert, Adam/0000-0003-2162-0156; Robinson, Stephen/0000-0002-6606-7588; Hodivala-Dilke, Kairbaan/0000-0002-2859-749X				Amendt C, 2002, J CELL SCI, V115, P2189; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BASSON CT, 1992, J CELL PHYSIOL, V153, P118, DOI 10.1002/jcp.1041530116; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; CLARK R. A. F., 1995, MOL CELLULAR BIOL WO; Clark RAF, 1996, AM J PATHOL, V148, P1407; Cordeiro MF, 2003, CIRCULATION, V107, pE37, DOI 10.1161/01.CIR.0000053951.16591.20; Crowe MJ, 2000, J INVEST DERMATOL, V115, P3, DOI 10.1046/j.1523-1747.2000.00010.x; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Direkze NC, 2003, STEM CELLS, V21, P514, DOI 10.1634/stemcells.21-5-514; GAILIT J, 1994, J INVEST DERMATOL, V103, P221, DOI 10.1111/1523-1747.ep12393176; GARLICK JA, 1994, LAB INVEST, V70, P916; GARLICK JA, 1994, J INVEST DERMATOL, V103, P554, DOI 10.1111/1523-1747.ep12396847; Greiling D, 1997, J CELL SCI, V110, P861; Grose R, 2002, DEVELOPMENT, V129, P2303; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Huang XZ, 2000, MOL CELL BIOL, V20, P755, DOI 10.1128/MCB.20.3.755-759.2000; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Jang YC, 1999, WOUND REPAIR REGEN, V7, P375, DOI 10.1046/j.1524-475X.1999.00375.x; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; Liaw L, 1998, J CLIN INVEST, V101, P1468; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Martin P, 2003, CURR BIOL, V13, P1122, DOI 10.1016/S0960-9822(03)00396-8; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Owens DM, 2003, J CELL SCI, V116, P3783, DOI 10.1242/jcs.00725; QUAGLINO D, 1991, J INVEST DERMATOL, V97, P34; Reynolds AR, 2004, CANCER RES, V64, P8643, DOI 10.1158/0008-5472.CAN-04-2760; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shah M, 1999, AM J PATHOL, V154, P1115, DOI 10.1016/S0002-9440(10)65364-3; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang LJ, 2001, AM J PATHOL, V159, P2147, DOI 10.1016/S0002-9440(10)63066-0; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	50	110	114	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					167	174		10.1038/nm1165	http://dx.doi.org/10.1038/nm1165			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15654327				2022-12-27	WOS:000226797300024
J	Kuwaki, K; Tseng, YL; Dor, FJMF; Shimizu, A; Houser, SL; Sanderson, TM; Lancos, CJ; Prabharasuth, DD; Cheng, J; Moran, K; Hisashi, Y; Mueller, N; Yamada, K; Greenstein, JL; Hawley, RJ; Patience, C; Awwad, M; Fishman, JA; Robson, SC; Schuurman, HJ; Sachs, DH; Cooper, DKC				Kuwaki, K; Tseng, YL; Dor, FJMF; Shimizu, A; Houser, SL; Sanderson, TM; Lancos, CJ; Prabharasuth, DD; Cheng, J; Moran, K; Hisashi, Y; Mueller, N; Yamada, K; Greenstein, JL; Hawley, RJ; Patience, C; Awwad, M; Fishman, JA; Robson, SC; Schuurman, HJ; Sachs, DH; Cooper, DKC			Heart transplantation in baboons using 1,3-galactosyl transferase gene-knockout pigs as donors: initial experience	NATURE MEDICINE			English	Article							ANTI-GAL-ALPHA-1-3GAL IGM; MONOCLONAL-ANTIBODY; NATURAL ANTIBODIES; VASCULAR REJECTION; ACTIVATION	Hearts from alpha1,3-galactosyltransferase knockout pigs (GalT-KO, n = 8) were transplanted heterotopically into baboons using an anti-CD154 monoclonal antibody-based regimen. The elimination of the galactose-alpha1,3-galactose epitope prevented hyperacute rejection and extended survival of pig hearts in baboons for 2-6 months (median, 78 d); the predominant lesion associated with graft failure was a thrombotic microangiopathy, with resulting ischemic injury. There were no infectious complications directly related to the immunosuppressive regimen. The transplantation of hearts from GalT-KO pigs increased graft survival over previous studies.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02129 USA; Immerge BioTherapeut Inc, Cambridge, MA 02139 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Immunobiol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Cooper, DKC (corresponding author), Univ Pittsburgh, Med Ctr, Starzl Transplantat Inst, Biomed Sci Tower E,Room E1550A,200 Lothrop St, Pittsburgh, PA 15261 USA.	cooperdk@upmc.edu	Robson, Simon C./AAA-8537-2021; Dor, Frank JMF/E-1032-2013; Mueller, Nicolas J./B-6864-2013	Dor, Frank JMF/0000-0001-7845-3075; Mueller, Nicolas J./0000-0002-1059-3191	PHS HHS [1PO1A45897] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Buhler L, 2001, TRANSPLANTATION, V72, P1743, DOI 10.1097/00007890-200112150-00007; COOPER DKC, 1993, LANCET, V342, P682, DOI 10.1016/0140-6736(93)91791-J; COOPER DKC, 1992, CLIN TRANSPLANT, V6, P178; Dor FJMF, 2004, TRANSPLANTATION, V78, P15, DOI 10.1097/01.TP.0000130487.68051.EB; GOOD AH, 1992, TRANSPL P, V24, P559; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Knosalla C, 2002, TRANSPLANTATION, V74, P416, DOI 10.1097/00007890-200208150-00024; Kolber-Simonds D, 2004, P NATL ACAD SCI USA, V101, P7335, DOI 10.1073/pnas.0307819101; Kuwaki K, 2004, AM J TRANSPLANT, V4, P363, DOI 10.1111/j.1600-6143.2004.00353.x; Lin SS, 2000, TRANSPLANTATION, V70, P1667, DOI 10.1097/00007890-200012270-00002; Mueller NJ, 2002, J VIROL, V76, P4734, DOI 10.1128/JVI.76.10.4734-4740.2002; ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031; Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942; Robson SC, 2000, XENOTRANSPLANTATION, V7, P166, DOI 10.1034/j.1399-3089.2000.00067.x; Teranishi K, 2002, XENOTRANSPLANTATION, V9, P148, DOI 10.1034/j.1399-3089.2002.1o058.x	15	528	550	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					29	31		10.1038/nm1171	http://dx.doi.org/10.1038/nm1171			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619628				2022-12-27	WOS:000226124900028
J	Komazawa, N; Matsuda, M; Kondoh, G; Mizunoya, W; Iwaki, M; Takagi, T; Sumikawa, Y; Inoue, K; Suzuki, A; Mak, TW; Nakano, T; Fushiki, T; Takeda, J; Shimomura, I				Komazawa, N; Matsuda, M; Kondoh, G; Mizunoya, W; Iwaki, M; Takagi, T; Sumikawa, Y; Inoue, K; Suzuki, A; Mak, TW; Nakano, T; Fushiki, T; Takeda, J; Shimomura, I			RETRACTED: Enhanced insulin sensitivity, energy expenditure and thermogenesis in adipose-specific Pten suppression in mice (Retracted Article. See vol 11, pg 691, 2005)	NATURE MEDICINE			English	Article; Retracted Publication							TUMOR-SUPPRESSOR; GLUCOSE-TRANSPORT; CRE RECOMBINASE; GENE; PROTEIN; EXPRESSION; OBESITY; TISSUE; MOUSE; ADIPONECTIN	Pten is an important phosphatase, suppressing the phosphatidylinositol-3 kinase/Akt pathway. Here, we generated adipose-specific Pten-deficient (AdipoPten-KO) mice, using newly generated Acdc promoter-driven Cre transgenic mice. AdipoPten-KO mice showed lower body and adipose tissue weights despite hyperphagia and enhanced insulin sensitivity with induced phosphorylation of Akt in adipose tissue. AdipoPten-KO mice also showed marked hyperthermia and increased energy expenditure with induced mitochondriagenesis in adipose tissue, associated with marked reduction of p53, inactivation of Rb, phosphorylation of cyclic AMP response element binding protein (CREB) and increased expression of Ppargc1a, the gene that encodes peroxisome proliferative activated receptor gamma coactivator 1 alpha. Physiologically, adipose Pten mRNA decreased with exposure to cold and increased with obesity, which were linked to the mRNA alterations of mitochondriagenesis. Our results suggest that altered expression of adipose Pten could regulate insulin sensitivity and energy expenditure. Suppression of adipose Pten may become a beneficial strategy to treat type 2 diabetes and obesity.	Osaka Univ, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Social & Environm Med, Suita, Osaka 5650871, Japan; Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Nutr Chem Lab,Sakyo Ku, Kyoto 6068502, Japan; Osaka Univ, Dept Dermatol, Suita, Osaka 5650871, Japan; Akita Univ, Dept Biochem, Akita 0108543, Japan; Univ Toronto, Adv Med Discovery Inst, Toronto, ON M5G 2C1, Canada; Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Osaka Univ, Ctr Adv Sci & Innovat, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, PREST, Kawaguchi, Saitama 3320012, Japan	Osaka University; Osaka University; Kyoto University; Osaka University; Akita University; University of Toronto; Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Shimomura, I (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ichi@imed2.med.osaka-u.ac.jp	Mizunoya, Wataru/W-1674-2019; NAKANO, Takayoshi/F-8140-2011; Takagi, Toshiyuki/S-9785-2019	Mizunoya, Wataru/0000-0002-2258-1964; Takagi, Toshiyuki/0000-0003-1283-4320				Barlow C, 1997, NUCLEIC ACIDS RES, V25, P2543, DOI 10.1093/nar/25.12.2543; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Boord JB, 2002, CURR OPIN LIPIDOL, V13, P141, DOI 10.1097/00041433-200204000-00005; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Fu YC, 2002, ATHEROSCLEROSIS, V165, P259, DOI 10.1016/S0021-9150(02)00305-2; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Hernandez R, 2001, FEBS LETT, V494, P225, DOI 10.1016/S0014-5793(01)02353-5; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Jiang GQ, 2002, FRONT BIOSCI-LANDMRK, V7, pD904; KASHIWAGI A, 1983, J BIOL CHEM, V258, P3685; Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Nishizawa H, 2004, J BIOL CHEM, V279, P19391, DOI 10.1074/jbc.C400066200; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Ono H, 2001, MOL ENDOCRINOL, V15, P1411, DOI 10.1210/me.15.8.1411; Rossmeisl M, 2002, EUR J BIOCHEM, V269, P19, DOI 10.1046/j.0014-2956.2002.02627.x; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takahashi M, 2000, INT J OBESITY, V24, P861, DOI 10.1038/sj.ijo.0801244; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954	39	29	34	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1208	1215		10.1038/nm1117	http://dx.doi.org/10.1038/nm1117			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15489860				2022-12-27	WOS:000224785900042
J	Crittenden, JR; Bergmeier, W; Zhang, YY; Piffath, CL; Liang, YQ; Wagner, DD; Housman, DE; Graybiel, AM				Crittenden, JR; Bergmeier, W; Zhang, YY; Piffath, CL; Liang, YQ; Wagner, DD; Housman, DE; Graybiel, AM			CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation	NATURE MEDICINE			English	Article							NUCLEOTIDE-RELEASING PROTEIN; SMALL GTPASE RAP1; GLYCOPROTEIN VI; R-RAS; ACTIVATION; BINDING; PHOSPHORYLATION; MEGAKARYOCYTES; IDENTIFICATION; ADHESION	Signaling through the second messengers calcium and diacylglycerol (DAG) is a critical element in many biological systems. Integration of calcium and DAG signals has been suggested to occur primarily through protein kinase C family members, which bind both calcium and DAG. However, an alternative pathway may involve members of the CalDAG-GEF/ RasGRP protein family, which have structural features (calcium-binding EF hands and DAG-binding C1 domains) that suggest they can function in calcium and DAG signal integration(1,2). To gain insight into the signaling systems that may be regulated by CalDAG-GEF/ RasGRP family members, we have focused on CalDAG-GEFI, which is expressed preferentially in the brain and blood(1). Through genetic ablation in the mouse, we have found that CalDAG-GEFI is crucial for signal integration in platelets. Mouse platelets that lack CalDAG-GEFI are severely compromised in integrin-dependent aggregation as a consequence of their inability to signal through CalDAG-GEFI to its target, the small GTPase Rap1. These results suggest that analogous signaling defects are likely to occur in the central nervous system when CalDAG-GEFI is absent or compromised in function.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle; Massachusetts Institute of Technology (MIT)	Graybiel, AM (corresponding author), MIT, Dept Brain & Cognit Sci, 45 Carleton St,E25-618, Cambridge, MA 02139 USA.	graybiel@mit.edu	Crittenden, Jill/V-5490-2019	Crittenden, Jill/0000-0002-1981-1917; Graybiel, Ann/0000-0002-4326-7720	NHLBI NIH HHS [P01 HL056949, P01-HL56949, HL66105] Funding Source: Medline; NICHD NIH HHS [R01 HD028341, R01-HD28341] Funding Source: Medline; NIMH NIH HHS [F32-MH065815] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028341] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066105, P01HL056949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH065815] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bergmeier W, 2003, BLOOD, V102, P4229, DOI 10.1182/blood-2003-04-1305; Bergmeier W, 2002, CYTOMETRY, V48, P80, DOI 10.1002/cyto.10114; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bos JL, 2003, BIOCHEM SOC T, V31, P83, DOI 10.1042/bst0310083; Davis RE, 1997, EXP HEMATOL, V25, P638; de Bruyn KMT, 2003, J BIOL CHEM, V278, P22412, DOI 10.1074/jbc.M212036200; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Eto K, 2002, P NATL ACAD SCI USA, V99, P12819, DOI 10.1073/pnas.202380099; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Larson MK, 2003, BLOOD, V101, P1409, DOI 10.1182/blood-2002-05-1533; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; NEWMAN PJ, 1991, P NATL ACAD SCI USA, V88, P3160, DOI 10.1073/pnas.88.8.3160; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200	25	286	297	3	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					982	986		10.1038/nm1098	http://dx.doi.org/10.1038/nm1098			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15334074				2022-12-27	WOS:000223658400036
J	Chen, L; Hamrah, P; Cursiefen, C; Zhang, Q; Pytowski, B; Streilein, JW; Dana, MR				Chen, L; Hamrah, P; Cursiefen, C; Zhang, Q; Pytowski, B; Streilein, JW; Dana, MR			Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity	NATURE MEDICINE			English	Article							LYMPHATIC-SYSTEM; LYMPHANGIOGENESIS; NODES	There are no studies so far linking molecular regulation of lymphangiogenesis and induction of adaptive immunity. Here, we show that blockade of vascular endothelial growth factor receptor-3 (VEGFR-3) signaling significantly suppresses corneal antigen-presenting ( dendritic) cell trafficking to draining lymph nodes, induction of delayed-type hypersensitivity and rejection of corneal transplants. Regulating the function of VEGFR-3 may therefore be a mechanism for modulating adaptive immunity in the periphery.	Schepens Eye Res Inst, Immunol Lab, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; ImClone Syst, New York, NY USA	Harvard University; Schepens Eye Research Institute; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Eli Lilly	Dana, MR (corresponding author), Schepens Eye Res Inst, Immunol Lab, 20 Staniford St, Boston, MA 02114 USA.	dana@vision.eri.harvard.edu	Cursiefen, Claus/ABE-5284-2020	cursiefen, claus/0000-0002-1958-411X				COLLIN HB, 1971, J PATHOL, V104, P99, DOI 10.1002/path.1711040204; Gendron RL, 2001, MOL VIS, V7, P107; Hamrah P, 2003, AM J PATHOL, V163, P57, DOI 10.1016/S0002-9440(10)63630-9; HE YG, 1991, INVEST OPHTH VIS SCI, V32, P2723; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Liu Y, 2002, J EXP MED, V195, P259, DOI 10.1084/jem.20010838; MADER TH, 1991, OPHTHALMOL CLIN N AM, V4, P411; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; STARK WJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P1392; Wang JF, 2001, J BIOL CHEM, V276, P41950, DOI 10.1074/jbc.M101370200; Yamagami S, 2001, INVEST OPHTH VIS SCI, V42, P1293	13	169	180	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					813	815		10.1038/nm1078	http://dx.doi.org/10.1038/nm1078			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15235599				2022-12-27	WOS:000223055700034
J	Hagen, HE; Carlstedt-Duke, J				Hagen, HE; Carlstedt-Duke, J			Building global networks for human diseases: genes and populations	NATURE MEDICINE			English	Editorial Material							CONFERS RISK; STROKE	Biobanks will have a crucial role in the identification of genes associated with disease - a prerequisite to designing adequate diagnostic and therapeutic tools. To maximize their impact and chances of success, collaboration at a global scale is highly desirable.	Wellcome Trust Res Labs, Int Biomed Programme, London, England; Karolinska Inst, Stockholm, Sweden	Karolinska Institutet	Hagen, HE (corresponding author), Wellcome Trust Res Labs, Int Biomed Programme, London, England.	jan.carlstedt-duke@mednut.ki.se						Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Gretarsdottir S, 2002, AM J HUM GENET, V70, P593, DOI 10.1086/339252; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Jimenez-Sanchez G, 2001, NATURE, V409, P853, DOI 10.1038/35057050; Peltonen L, 2001, SCIENCE, V291, P1224, DOI 10.1126/science.291.5507.1224; Rose H, 2003, NATURE, V425, P123, DOI 10.1038/425123a	6	20	23	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					665	667		10.1038/nm0704-665	http://dx.doi.org/10.1038/nm0704-665			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15229504				2022-12-27	WOS:000222460400012
J	Willenbring, H; Bailey, AS; Foster, M; Akkari, Y; Dorrell, C; Olson, S; Finegold, M; Fleming, WH; Grompe, M				Willenbring, H; Bailey, AS; Foster, M; Akkari, Y; Dorrell, C; Olson, S; Finegold, M; Fleming, WH; Grompe, M			Myelomonocytic cells are sufficient for therapeutic cell fusion in liver	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; BONE-MARROW; IN-VIVO; HEREDITARY TYROSINEMIA; MYELOID PROGENITORS; PURKINJE NEURONS; MURINE MODEL; HEPATOCYTES; MUSCLE; MICE	Liver repopulation with bone marrow-derived hepatocytes (BMHs) can cure the genetic liver disease fumarylacetoacetate hydrolase (Fah) deficiency(1). BMHs emerge from fusion between donor bone marrow-derived cells and host hepatocytes(2). To use such in vivo cell fusion efficiently for therapy requires knowing the nature of the hematopoietic cells that fuse with hepatocytes. Here we show that the transplantation into Fah(-/-) mice of hematopoietic stem cells (HSCs) from lymphocyte-deficient Rag1(-/-) mice, lineage-committed granulocyte-macrophage progenitors (GMPs) or bone marrow-derived macrophages (BMMs) results in the robust production of BMHs. These results provide direct evidence that committed myelomonocytic cells such as macrophages can produce functional epithelial cells by in vivo fusion. Because stable bone marrow engraftment or HSCs are not required for this process, macrophages or their highly proliferative progenitors provide potential for targeted and well-tolerated cell therapy aimed at organ regeneration.	Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Oregon Stem Cell Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Div Hematol & Med Oncol, Portland, OR 97239 USA; Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Baylor College of Medicine; Oregon Health & Science University	Willenbring, H (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.	willenbr@ohsu.edu		Grompe, Markus/0000-0002-6616-4345	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067636] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL69133] Funding Source: Medline; NIDDK NIH HHS [R01-DK067636] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bailey AS, 2004, BLOOD, V103, P13, DOI 10.1182/blood-2003-05-1684; BitMansour A, 2002, BLOOD, V100, P4660, DOI 10.1182/blood-2002-05-1552; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Freeman BJ, 1999, BLOOD, V94, P2142, DOI 10.1182/blood.V94.6.2142.418k16_2142_2150; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; VanRooijen N, 1996, HEPATOLOGY, V23, P1239; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2002, AM J PATHOL, V161, P565, DOI 10.1016/S0002-9440(10)64212-5; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053	30	314	331	2	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2004	10	7					744	748		10.1038/nm1062	http://dx.doi.org/10.1038/nm1062			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195088				2022-12-27	WOS:000222460400030
J	Desrosiers, RC				Desrosiers, RC			Prospects for an AIDS vaccine	NATURE MEDICINE			English	Editorial Material							SIMIAN IMMUNODEFICIENCY VIRUS; T-CELL RESPONSES; DISEASE PROGRESSION; VIRAL REPLICATION; IMMUNE-RESPONSES; RHESUS MACAQUES; PROTECTION; CHALLENGE; PREVENTION; STRATEGIES		Harvard Univ, Sch Med, New England Primate Res Ctr, Southborough, MA 01772 USA	Harvard University	Desrosiers, RC (corresponding author), Harvard Univ, Sch Med, New England Primate Res Ctr, Southborough, MA 01772 USA.	ronald_desrosiers@hms.harvard.edu						Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Chen XN, 2001, NAT MED, V7, P1225, DOI 10.1038/nm1101-1225; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Desrosiers RC, 1999, NAT MED, V5, P723, DOI 10.1038/10439; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Horton H, 2002, J VIROL, V76, P7187, DOI 10.1128/JVI.76.14.7187-7202.2002; Johnson RP, 1999, J VIROL, V73, P4952, DOI 10.1128/JVI.73.6.4952-4961.1999; Johnson WE, 2002, ANNU REV MED, V53, P499, DOI 10.1146/annurev.med.53.082901.104053; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; KUIKEN CL, 2002, HIV SEQUENCE COMPEND; Letvin NL, 2001, J VIROL, V75, P4165, DOI 10.1128/JVI.75.9.4165-4175.2001; Lifson JD, 2000, J VIROL, V74, P2584, DOI 10.1128/JVI.74.6.2584-2593.2000; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Nickle DC, 2003, SCIENCE, V299, P1515; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Wyand MS, 1999, J VIROL, V73, P8356, DOI 10.1128/JVI.73.10.8356-8363.1999	19	91	181	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2004	10	3					221	223		10.1038/nm0304-221	http://dx.doi.org/10.1038/nm0304-221			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14991035	Bronze			2022-12-27	WOS:000189297700018
J	Weidenmaier, C; Kokai-Kun, JF; Kristian, SA; Chanturiya, T; Kalbacher, H; Gross, M; Nicholson, G; Neumeister, B; Mond, JJ; Peschel, A				Weidenmaier, C; Kokai-Kun, JF; Kristian, SA; Chanturiya, T; Kalbacher, H; Gross, M; Nicholson, G; Neumeister, B; Mond, JJ; Peschel, A			Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections	NATURE MEDICINE			English	Article							DEFENSINS; CARRIAGE	Colonization of the anterior nares in 37% of the population is a major risk factor for severe Staphylococcus aureus infections. Here we show that wall teichoic acid (WTA), a surface-exposed staphylococcal polymer, is essential for nasal colonization and mediates interaction with human nasal epithelial cells. WTA-deficient mutants were impaired in their adherence to nasal cells, and were completely unable to colonize cotton rat nares. This study describes the first essential factor for S. aureus nasal colonization.	Univ Tubingen, Med Microbiol & Hyg Dept, D-72076 Tubingen, Germany; Biosynexus Inc, Gaithersburg, MD 20877 USA; Univ Tubingen, Dept Transfus Med, D-72076 Tubingen, Germany; Univ Tubingen, Med & Nat Sci Res Ctr, D-72074 Tubingen, Germany; Univ Tubingen, Dept Organ Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Peschel, A (corresponding author), Univ Tubingen, Med Microbiol & Hyg Dept, Elfriede Aulhorn Str 6, D-72076 Tubingen, Germany.	andreas.peschel@uni-tuebingen.de		Weidenmaier, Christopher/0000-0003-4107-739X				ALY R, 1980, J INFECT DIS, V141, P463, DOI 10.1093/infdis/141.4.463; Archer GL, 1998, CLIN INFECT DIS, V26, P1179, DOI 10.1086/520289; Cole AM, 2002, J IMMUNOL, V169, P6985, DOI 10.4049/jimmunol.169.12.6985; ENDL J, 1983, ARCH MICROBIOL, V135, P215, DOI 10.1007/BF00414483; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Kokai-Kun JF, 2003, ANTIMICROB AGENTS CH, V47, P1589, DOI 10.1128/AAC.47.5.1589-1597.2003; Niewiesk S, 2002, LAB ANIM-UK, V36, P357, DOI 10.1258/002367702320389026; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; Palaniyar N, 2002, IMMUNOBIOLOGY, V205, P575, DOI 10.1078/0171-2985-00156; Peacock SJ, 2001, TRENDS MICROBIOL, V9, P605, DOI 10.1016/S0966-842X(01)02254-5; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; PRINCE GA, 1978, AM J PATHOL, V93, P771; Soldo B, 2002, MICROBIOL-SGM, V148, P2079, DOI 10.1099/00221287-148-7-2079; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102	15	402	417	3	35	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					243	245		10.1038/nm991	http://dx.doi.org/10.1038/nm991			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14758355				2022-12-27	WOS:000189297700033
J	Johnstone, TBC; Hogenkamp, DJ; Coyne, L; Su, JP; Halliwell, RF; Tran, MB; Yoshimura, RF; Li, WY; Wang, J; Gee, KW				Johnstone, TBC; Hogenkamp, DJ; Coyne, L; Su, JP; Halliwell, RF; Tran, MB; Yoshimura, RF; Li, WY; Wang, J; Gee, KW			Modifying quinolone antibiotics yields new anxiolytics	NATURE MEDICINE			English	Article							GABA(A) RECEPTORS; BENZODIAZEPINES; ANXIETY	Patients taking fluoroquinolone antibiotics such as norfloxacin exhibit a low incidence of convulsions and anxiety. These side effects probably result from antagonism of the neurotransmitter gamma-aminobutyric acid (GABA) at the brain GABA(A) receptor complex (GRC). Modification of norfloxacin yields molecules such as compound 4 that potentiate GABA action with alpha(2) subunit selectivity. Compound 4 is anxiolytic but does not cause sedation, and may represent a new class of ligands that have anxiolytic activity without sedative liability.	Univ Calif Irvine, Coll Med, Dept Pharmacol, Irvine, CA 92697 USA; Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; Univ Pacific, Thomas J Long Sch Pharm & Hlth Sci, Stockton, CA 95211 USA	University of California System; University of California Irvine; Durham University; University of the Pacific	Gee, KW (corresponding author), Univ Calif Irvine, Coll Med, Dept Pharmacol, Irvine, CA 92697 USA.		Johnstone, Tom/C-5909-2011	Johnstone, Tom/0000-0001-8635-8158; Halliwell, Robert Francis/0000-0003-0397-3740; Coyne, Leanne/0000-0001-7741-9254	NIMH NIH HHS [MH60527] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R41MH060527] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Carboni E, 1996, PSYCHOPHARMACOLOGY, V126, P173, DOI 10.1007/BF02246353; Chebib M, 2000, J MED CHEM, V43, P1427, DOI 10.1021/jm9904349; De Sarro A, 1999, ANTIMICROB AGENTS CH, V43, P1729, DOI 10.1128/AAC.43.7.1729; HALLIWELL RF, 1993, J ANTIMICROB CHEMOTH, V31, P457, DOI 10.1093/jac/31.4.457; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; VOGEL JR, 1971, PSYCHOPHARMACOLOGIA, V21, P1, DOI 10.1007/BF00403989; WIELAND S, 1991, BRAIN RES, V565, P263, DOI 10.1016/0006-8993(91)91658-N	9	41	41	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					31	32		10.1038/nm967	http://dx.doi.org/10.1038/nm967			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14647497				2022-12-27	WOS:000187743600035
J	Wu, ZH; Bensinger, SJ; Zhang, JD; Chen, CQ; Yuan, XL; Huang, XL; Markmann, JF; Kassaee, A; Rosengard, BR; Hancock, WW; Sayegh, MH; Turka, LA				Wu, ZH; Bensinger, SJ; Zhang, JD; Chen, CQ; Yuan, XL; Huang, XL; Markmann, JF; Kassaee, A; Rosengard, BR; Hancock, WW; Sayegh, MH; Turka, LA			Homeostatic proliferation is a barrier to transplantation tolerance	NATURE MEDICINE			English	Article							NAIVE T-CELLS; STAGE RENAL-DISEASE; ALLOGRAFT TOLERANCE; LYMPHOHEMATOPOIETIC CHIMERISM; COSTIMULATORY BLOCKADE; LYMPHOPENIC HOSTS; IMMUNE-RESPONSES; MULTIPLE-MYELOMA; MIXED CHIMERISM; IN-VIVO	Despite the ease of inhibiting immune responses by blockade of T-cell costimulation in naive rodent models, it is difficult to suppress those responses in animals with memory cells(1,2). Studies demonstrating the importance of alloreactive T-cell deletion during tolerance induction have promoted use of peritransplant T-cell-depleting therapies in clinical trials(3-6). But potentially complicating wide-scale, nonspecific T-cell depletion is the finding that extensive T-cell proliferation can occur under conditions of lymphopenia. This process, termed homeostatic proliferation(7,8), may induce acquisition of functional memory T cells(9-13). Here, using clinically relevant mouse models of peripheral T-cell depletion, we show that residual nondepleted T cells undergo substantial homeostatic expansion. In this setting, costimulatory blockade neither significantly suppresses homeostatic proliferation nor prevents allograft rejection. In addition, T cells that have completed homeostatic proliferation show dominant resistance to tolerance when adoptively transferred into wild-type recipients, consistent with known properties of memory cells in vivo. These findings establish the importance of homeostatic proliferation in clinically relevant settings, demonstrate the barrier that homeostatic proliferation can present to the induction of transplantation tolerance, and have important implications for transplantation protocols that use partial or complete peripheral T-cell depletion.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02131 USA; Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Pathol & Biesecker Pediat Liver Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Harvard University; Brigham & Women's Hospital; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Turka, LA (corresponding author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA.			Sayegh, Mohamed/0000-0002-2847-588X	NIAID NIH HHS [P01 AI041521, R21 AI043626, R01 AI062789-01A1, AI-41521, R01 AI043626, AI-43626, AI-37691, R01 AI037691, R01 AI037691-10, R01 AI062789] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI041521, R01AI062789, R01AI043626, R21AI043626, R01AI037691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams AB, 2003, J CLIN INVEST, V111, P1887, DOI 10.1172/JCI200317477; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Buhler LH, 2002, TRANSPLANTATION, V74, P1405, DOI 10.1097/01.TP.0000034627.37442.A4; Chalasani G, 2002, P NATL ACAD SCI USA, V99, P6175, DOI 10.1073/pnas.092596999; Dummer W, 2002, J CLIN INVEST, V110, P185, DOI 10.1172/JCI200215175; Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074-7613(00)80092-8; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; Goldrath AW, 1999, IMMUNITY, V11, P183, DOI 10.1016/S1074-7613(00)80093-X; Goldrath AW, 2000, J EXP MED, V192, P557, DOI 10.1084/jem.192.4.557; Gudmundsdottir H, 2001, J IMMUNOL, V167, P3699, DOI 10.4049/jimmunol.167.7.3699; Hakim FT, 1997, BLOOD, V90, P3789, DOI 10.1182/blood.V90.9.3789; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; Hu HM, 2002, CANCER RES, V62, P3914; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kieper WC, 1999, P NATL ACAD SCI USA, V96, P13306, DOI 10.1073/pnas.96.23.13306; KIRK AD, 2002, AM J TRANSPL S3, V2, P379; KNECHTLE SJ, 2002, AM J TRANSPLANT S3, V2, P459; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Murali-Krishna K, 2000, J IMMUNOL, V165, P1733, DOI 10.4049/jimmunol.165.4.1733; Onodera K, 1997, J IMMUNOL, V159, P1711; Prlic M, 2001, J IMMUNOL, V167, P5664, DOI 10.4049/jimmunol.167.10.5664; Sayegh MH, 1997, TRANSPLANTATION, V64, P1646, DOI 10.1097/00007890-199712270-00003; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Sykes M, 2001, IMMUNITY, V14, P417, DOI 10.1016/S1074-7613(01)00122-4; Valujskikh A, 2002, AM J TRANSPLANT, V2, P501, DOI 10.1034/j.1600-6143.2002.20603.x; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260	30	341	348	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					87	92		10.1038/nm965	http://dx.doi.org/10.1038/nm965			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14647496	Green Accepted			2022-12-27	WOS:000187743600043
J	Haq, S; Kilter, H; Michael, A; Tao, J; O'Leary, E; Sun, XM; Walters, B; Bhattacharya, K; Chen, X; Cui, L; Andreucci, M; Rosenzweig, A; Guerrero, JL; Patten, R; Liao, R; Molkentin, J; Picard, M; Bonventre, JV; Force, T				Haq, S; Kilter, H; Michael, A; Tao, J; O'Leary, E; Sun, XM; Walters, B; Bhattacharya, K; Chen, X; Cui, L; Andreucci, M; Rosenzweig, A; Guerrero, JL; Patten, R; Liao, R; Molkentin, J; Picard, M; Bonventre, JV; Force, T			Deletion of cytosolic phospholipase A(2) promotes striated muscle growth	NATURE MEDICINE			English	Article							KINASE-C-ZETA; INSULIN-RECEPTOR SUBSTRATE-1; SIGNALING PATHWAYS; POSTNATAL-GROWTH; TRANSGENIC MICE; FACTOR-I; CARDIOMYOCYTE HYPERTROPHY; PHOSPHOINOSITIDE 3-KINASE; VENTRICULAR HYPERTROPHY; DIFFERENTIAL ACTIVATION	Generation of arachidonic acid by the ubiquitously expressed cytosolic phospholipase A(2) (PLA(2)) has a fundamental role in the regulation of cellular homeostasis, inflammation and tumorigenesis. Here we report that cytosolic PLA(2) is a negative regulator of growth, specifically of striated muscle. We find that normal growth of skeletal muscle, as well as normal and pathologic stress-induced hypertrophic growth of the heart, are exaggerated in Pla2g4a(-/-) mice, which lack the gene encoding cytosolic PLA(2). The mechanism underlying this phenotype is that cytosolic PLA(2) negatively regulates insulin-like growth factor (IGF)-1 signaling. Absence of cytosolic PLA(2) leads to sustained activation of the IGF-1 pathway, which results from the failure of 3-phosphoinositide-dependent protein kinase (PDK)-1 to recruit and phosphorylate protein kinase C (PKC)-zeta, a negative regulator of IGF-1 signaling. Arachidonic acid restores activation of PKC-zeta, correcting the exaggerated IGF-1 signaling. These results indicate that cytosolic PLA(2) and arachidonic acid regulate striated muscle growth by modulating multiple growth-regulatory pathways.	Tufts Univ, Sch Med, Tufts New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Massachusetts Gen Hosp, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA; Boston Univ, Med Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45229 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Tufts Medical Center; Tufts University; Tufts University; Harvard University; Massachusetts General Hospital; Harvard University; Boston University; Boston University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Haq, S (corresponding author), Tufts Univ, Sch Med, Tufts New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA.		Rosenzweig, Anthony/AAD-7893-2019; Picard, Michael/F-1567-2013	Picard, Michael/0000-0002-9264-3243; Force, Thomas/0000-0002-0450-8659; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067371, R01HL061688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK050282, R29DK050282] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67371, HL61688] Funding Source: Medline; NIDDK NIH HHS [DK50282] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Cittadini A, 2001, ENDOCRINOLOGY, V142, P332, DOI 10.1210/en.142.1.332; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Fazio S, 2000, EUR J ENDOCRINOL, V142, P211, DOI 10.1530/eje.0.1420211; Fernandez AM, 2002, J CLIN INVEST, V109, P347, DOI 10.1172/JCI200213503; Goruppi S, 2002, EMBO J, V21, P5427, DOI 10.1093/emboj/cdf535; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Haq S, 2001, CIRCULATION, V103, P670; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; Kunapuli P, 1998, J BIOL CHEM, V273, P22442, DOI 10.1074/jbc.273.35.22442; Lai J, 1996, AM J PHYSIOL-HEART C, V271, pH2197, DOI 10.1152/ajpheart.1996.271.6.H2197; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Pete G, 1999, ENDOCRINOLOGY, V140, P5478, DOI 10.1210/en.140.12.5478; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; van der Hoeven PCJ, 2000, BIOCHEM J, V347, P781, DOI 10.1042/0264-6021:3470781; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang J, 1999, ENDOCRINOLOGY, V140, P3391, DOI 10.1210/en.140.7.3391; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6	45	71	72	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					944	951		10.1038/nm891	http://dx.doi.org/10.1038/nm891			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808451				2022-12-27	WOS:000183979300037
J	Joseph, SB; Castrillo, A; Laffitte, BA; Mangelsdorf, DJ; Tontonoz, P				Joseph, SB; Castrillo, A; Laffitte, BA; Mangelsdorf, DJ; Tontonoz, P			Reciprocal regulation of inflammation and lipid metabolism by liver X receptors	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; NF-KAPPA-B; MACROPHAGE-GENE-EXPRESSION; OXIDE SYNTHASE GENE; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); REDUCES ATHEROSCLEROSIS; GLUCOCORTICOID RECEPTOR; DEFICIENT MICE; OXIDIZED LDL	Macrophages have important roles in both lipid metabolism and inflammation and are central to the pathogenesis of atherosclerosis. The liver X receptors (LXRs) are established mediators of lipid-inducible gene expression, but their role in inflammation and immunity is unknown. We demonstrate here that LXRs and their ligands are negative regulators of macrophage inflammatory gene expression. Transcriptional profiling of lipopolysaccharide (LPS)-induced macrophages reveals reciprocal LXR-dependent regulation of genes involved in lipid metabolism and the innate immune response. In vitro, LXR ligands inhibit the expression of inflammatory mediators such as inducible nitric oxide synthase, cyclooxygenase (COX)-2 and interleukin-6 (IL-6) in response to bacterial infection or LPS stimulation. In vivo, LXR agonists reduce inflammation in a model of contact dermatitis and inhibit inflammatory gene expression in the aortas of atherosclerotic mice. These findings identify LXRs as lipid-dependent regulators of inflammatory gene expression that may serve to link lipid metabolism and immune functions in macrophages.	Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA.	ptontonoz@mednet.ucla.edu		Mangelsdorf, David/0000-0002-4355-0796; Joseph, Sean/0000-0002-2602-8517	NHLBI NIH HHS [HL 660881] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Callejas NA, 2000, GASTROENTEROLOGY, V119, P493, DOI 10.1053/gast.2000.9374; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2001, J BIOL CHEM, V276, P15854, DOI 10.1074/jbc.M100010200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hansson G K, 1999, Curr Atheroscler Rep, V1, P150, DOI 10.1007/s11883-999-0011-0; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Kuhlencordt PJ, 2001, CIRCULATION, V103, P3099, DOI 10.1161/01.CIR.103.25.3099; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte Bryan A, 2002, Curr Atheroscler Rep, V4, P213; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Liu SX, 1998, ATHEROSCLEROSIS, V136, P43, DOI 10.1016/S0021-9150(97)00185-8; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Pasterkamp G, 2000, ATHEROSCLEROSIS, V150, P245, DOI 10.1016/S0021-9150(99)00371-8; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sheu MY, 2002, J INVEST DERMATOL, V118, P94, DOI 10.1046/j.0022-202x.2001.01626.x; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wu ZL, 1998, CELL BIOCHEM FUNCT, V16, P153, DOI 10.1002/(SICI)1099-0844(199809)16:3<153::AID-CBF778>3.0.CO;2-T	40	972	1016	2	77	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					213	219		10.1038/nm820	http://dx.doi.org/10.1038/nm820			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12524534				2022-12-27	WOS:000180801900026
J	Chan, SM; Ermann, J; Su, L; Fathman, CG; Utz, PJ				Chan, SM; Ermann, J; Su, L; Fathman, CG; Utz, PJ			Protein microarrays for multiplex analysis of signal transduction pathways	NATURE MEDICINE			English	Article							T-CELLS; DOWNSTREAM TARGET; SELF-TOLERANCE; KINASE-C; ACTIVATION; HOMEOSTASIS; RESPONSES; IL-2	We have developed a multiplexed reverse phase protein (RPP) microarray platform for simultaneous monitoring of site-specific phosphorylation of numerous signaling proteins using nanogram amounts of lysates derived from stimulated living cells. We first show the application of RPP microarrays to the study of signaling kinetics and pathway delineation in Jurkat T lymphocytes. RPP microarrays were used to profile the phosphorylation state of 62 signaling components in Jurkat T cells stimulated through their membrane CD3 and CD28 receptors, identifying a previously unrecognized link between CD3 crosslinking and dephosphorylation of Raf-1 at Ser259. Finally, the potential of this technology to analyze rare primary cell populations is shown in a study of differential STAT protein phosphorylation in interleukin (IL)-2-stimulated CD4(+) CD25(+) regulatory T cells. RPP microarrays, prepared using simple procedures and standard microarray equipment, represent a powerful new tool for the study of signal transduction in both health and disease.	Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA	Stanford University	Utz, PJ (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA.	pjutz@stanford.edu	Ermann, Joerg/ABE-4495-2021	Ermann, Joerg/0000-0003-3836-9404; Su, Leon/0000-0001-7654-9997	NHLBI NIH HHS [N01-HV-28183] Funding Source: Medline; NIAID NIH HHS [AI50865, AI50854] Funding Source: Medline; NIAMS NIH HHS [AR49328] Funding Source: Medline; NIDDK NIH HHS [DK61934] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR049328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK061934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almeida ARM, 2002, J IMMUNOL, V169, P4850, DOI 10.4049/jimmunol.169.9.4850; Antov A, 2003, J IMMUNOL, V171, P3435, DOI 10.4049/jimmunol.171.7.3435; BOBROW MN, 1992, J IMMUNOL METHODS, V150, P145, DOI 10.1016/0022-1759(92)90073-3; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Espina V, 2003, PROTEOMICS, V3, P2091, DOI 10.1002/pmic.200300592; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Furtado GC, 2002, J EXP MED, V196, P851, DOI 10.1084/jem.20020190; Haab BB, 2001, GENOME BIOL, V2; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Kleijn M, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-11; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Nielsen UB, 2003, P NATL ACAD SCI USA, V100, P9330, DOI 10.1073/pnas.1633513100; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Robinson WH, 2003, NAT BIOTECHNOL, V21, P1033, DOI 10.1038/nbt859; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Snow JW, 2003, J IMMUNOL, V171, P5042, DOI 10.4049/jimmunol.171.10.5042; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Zhang J, 1999, J IMMUNOL, V162, P3819; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	26	162	172	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1390	1396		10.1038/nm1139	http://dx.doi.org/10.1038/nm1139			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15558056				2022-12-27	WOS:000225500900035
J	Chambon, P				Chambon, P			How I became one of the fathers of a superfamily	NATURE MEDICINE			English	Editorial Material							HUMAN ESTROGEN-RECEPTOR; DEPENDENT RNA-POLYMERASE; LIGAND-BINDING DOMAIN; SV40 EARLY PROMOTER; SIMIAN VIRUS-40 ENHANCER; MAJOR LATE PROMOTER; RETINOIC ACID; NUCLEAR RECEPTORS; TATA BOX; TRANSCRIPTIONAL ACTIVATION		Coll France, CNRS, INSERM, ULP,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Inst Clin Souris, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), Coll France, CNRS, INSERM, ULP,Inst Genet & Biol Mol & Cellulaire, BP10142, F-67404 Illkirch Graffenstaden, France.	chambon@igbmc.u-strasbg.fr						Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BENOIST C, 1980, P NATL ACAD SCI-BIOL, V77, P3865, DOI 10.1073/pnas.77.7.3865; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BREATHNACH R, 1977, NATURE, V270, P314, DOI 10.1038/270314a0; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHAMBON P, 1966, BIOCHEM BIOPH RES CO, V25, P638, DOI 10.1016/0006-291X(66)90502-X; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAMBON P, 1970, COLD SPRING HARB SYM, V35, P693, DOI 10.1101/SQB.1970.035.01.085; CHAMBON P, 1975, ANNU REV BIOCHEM, V44, P613, DOI 10.1146/annurev.bi.44.070175.003145; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; Chapellier B, 2002, EMBO J, V21, P3402, DOI 10.1093/emboj/cdf331; COCHET M, 1979, NATURE, V282, P567, DOI 10.1038/282567a0; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; EVERETT RD, 1983, NUCLEIC ACIDS RES, V11, P2447, DOI 10.1093/nar/11.8.2447; GANNON F, 1979, NATURE, V278, P428, DOI 10.1038/278428a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GROSSCHEDL R, 1981, NATURE, V294, P178, DOI 10.1038/294178a0; HEN R, 1985, CELL, V43, P165; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Laudet V., 2002, NUCL RECEPTOR FACTS; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Mark M, 2003, PURE APPL CHEM, V75, P1709, DOI 10.1351/pac200375111709; MATHIS DJ, 1981, NATURE, V290, P310, DOI 10.1038/290310a0; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; ONATE SA, 1995, SCIENCE, V270, P1354; OUDET P, 1975, CELL, V4, P281, DOI 10.1016/0092-8674(75)90149-X; Oudet Pierre, 2004, Cell, VS116, pS79, DOI 10.1016/S0092-8674(04)00052-2; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAMUZ M, 1965, BIOCHEM BIOPH RES CO, V19, P114, DOI 10.1016/0006-291X(65)90128-2; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; ROEDER RG, 1969, NATURE, V224, P234, DOI 10.1038/224234a0; ROEDER RG, 1979, RNA POLYM, P285; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SKLAR VEF, 1975, P NATL ACAD SCI USA, V72, P348, DOI 10.1073/pnas.72.1.348; STIRPE F, 1967, BIOCHEM J, V105, P779, DOI 10.1042/bj1050779; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WASYLYK B, 1980, P NATL ACAD SCI-BIOL, V77, P7024, DOI 10.1073/pnas.77.12.7024; WASYLYK B, 1983, CELL, V32, P503, DOI 10.1016/0092-8674(83)90470-1; WASYLYK B, 1980, NATURE, V285, P366; WEILL JD, 1963, BIOCHEM BIOPH RES CO, V10, P122, DOI 10.1016/0006-291X(63)90036-6; WEINMANN R, 1974, P NATL ACAD SCI USA, V71, P1790, DOI 10.1073/pnas.71.5.1790; WEISS SB, 1959, J AM CHEM SOC, V81, P4118, DOI 10.1021/ja01524a087; WILDEMAN AG, 1986, MOL CELL BIOL, V6, P2098, DOI 10.1128/MCB.6.6.2098; WU GJ, 1978, P NATL ACAD SCI USA, V75, P2175, DOI 10.1073/pnas.75.5.2175; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	84	23	23	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1027	1031		10.1038/nm1004-1027	http://dx.doi.org/10.1038/nm1004-1027			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459695				2022-12-27	WOS:000224245800015
J	Goldstein, JL				Goldstein, JL			How a jolt and a bolt in a dentist's chair revolutionized cataract surgery	NATURE MEDICINE			English	Editorial Material							PHACO-EMULSIFICATION; PRACTICE STYLES; ASCRS MEMBERS; ASPIRATION; PREFERENCES		Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas		joe.goldstein@utsouthwestern.edu						Apple DJ, 1996, SURV OPHTHALMOL, V40, P279, DOI 10.1016/S0039-6257(96)82003-0; JAFFE NS, 1972, CATARACT SURG ITS CO, P120; KELMAN CD, 1967, AM J OPHTHALMOL, V64, P23, DOI 10.1016/0002-9394(67)93340-5; KELMAN CD, 1973, AM J OPHTHALMOL, V75, P764, DOI 10.1016/0002-9394(73)90878-7; KELMAN CD, 1994, INT OPHTHALMOL CLIN, V34, P1, DOI 10.1097/00004397-199403420-00002; KELMAN CD, 1969, AM J OPHTHALMOL, V67, P464, DOI 10.1016/0002-9394(69)94252-4; KELMAN CD, 1985, MY EYES STORY SURG W, P107; KELMAN CD, 1996, PHACOEMULSIFICATION, P1; KRATZ R, 2004, CATARACT REFRACT SUR, V3, P55; LEAMING DV, 1986, J CATARACT REFR SURG, V12, P380, DOI 10.1016/S0886-3350(86)80100-6; Leaming DV, 2004, J CATARACT REFR SURG, V30, P892, DOI 10.1016/j.jcrs.2004.02.064; Solomon R, 2003, JAMA-J AM MED ASSOC, V290, P248, DOI 10.1001/jama.290.2.248	12	11	12	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1032	1033		10.1038/nm1004-1032	http://dx.doi.org/10.1038/nm1004-1032			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459696				2022-12-27	WOS:000224245800016
J	Lansbury, PT				Lansbury, PT			Back to the future: the 'old-fashioned' way to new medications for neurodegeneration	NATURE MEDICINE			English	Article							AMYLOID PRECURSOR PROTEIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; BETA-SECRETASE; DROSOPHILA; DISCOVERY; MODEL; GENE; POLYMORPHISMS	Despite the increasing prevalence of Alzheimer's disease, Parkinson's disease and less common neurodegenerative diseases-and despite the large amount of primary research that has been carried out into the causes and pathogenic features of these conditions-progress toward effective treatments has been remarkably slow. Why is this, and what can be done to accelerate it? There are a number of obstacles to effective drug discovery for neurodegeneration, but by considering these problems it is possible to identify lessons for the future.	Harvard Ctr Neurodegenerat & Repair, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis,Dept Neurol, Cambridge, MA 02139 USA	Harvard University; Harvard University; Brigham & Women's Hospital	Lansbury, PT (corresponding author), Harvard Ctr Neurodegenerat & Repair, 65 Landsdowne St, Cambridge, MA 02139 USA.	plansbury@rics.bwh.harvard.edu						Alper J, 2003, SCIENCE, V299, P1303, DOI 10.1126/science.299.5611.1303; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Berger E, 2003, NATURE, V426, P154, DOI 10.1038/nature01998; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Cookson MR, 2003, NEURON, V37, P7, DOI 10.1016/S0896-6273(02)01166-2; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; Karlawish JHT, 2003, ANN INTERN MED, V138, P411, DOI 10.7326/0003-4819-138-5-200303040-00011; Kosaka K, 1996, CURR OPIN NEUROL, V9, P271, DOI 10.1097/00019052-199608000-00005; Lansbury PT, 2002, CURR OPIN CELL BIOL, V14, P653, DOI 10.1016/S0955-0674(02)00377-0; Maraganore DM, 1999, NEUROLOGY, V53, P1858, DOI 10.1212/WNL.53.8.1858; Maraganore DM, 2003, MOVEMENT DISORD, V18, P631, DOI 10.1002/mds.10431; Marek K, 2002, JAMA-J AM MED ASSOC, V287, P1653; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; Micchelli CA, 2002, FASEB J, V16, P79, DOI 10.1096/fj.02-0394fje; Momose Y, 2002, ANN NEUROL, V51, P133, DOI 10.1002/ana.10079; Nass R, 2002, P NATL ACAD SCI USA, V99, P3264, DOI 10.1073/pnas.042497999; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Sagi SA, 2003, J BIOL CHEM, V278, P31825, DOI 10.1074/jbc.M303588200; Satoh J, 2001, J NEUROL SCI, V189, P113, DOI 10.1016/S0022-510X(01)00555-X; Schapira AHV, 2004, JAMA-J AM MED ASSOC, V291, P358, DOI 10.1001/jama.291.3.358; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Shorter E, 2002, NAT REV DRUG DISCOV, V1, P1003, DOI 10.1038/nrd964; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Stein RL, 2003, DRUG DISCOV TODAY, V8, P245, DOI 10.1016/S1359-6446(02)02594-1; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang J, 2002, MOVEMENT DISORD, V17, P767, DOI 10.1002/mds.10179; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	39	61	64	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7		S			S51	S57		10.1038/nrn1435	http://dx.doi.org/10.1038/nrn1435			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	844YU	15298008				2022-12-27	WOS:000223202100008
J	Zhang, GJ; Safran, M; Wei, WY; Sorensen, E; Lassota, P; Zhelev, N; Neuberg, DS; Shapiro, G; Kaelin, WG				Zhang, GJ; Safran, M; Wei, WY; Sorensen, E; Lassota, P; Zhelev, N; Neuberg, DS; Shapiro, G; Kaelin, WG			Bioluminescent imaging of Cdk2 inhibition in vivo	NATURE MEDICINE			English	Article							DEPENDENT KINASE INHIBITORS; ANAPHASE-PROMOTING COMPLEX; PROTEIN-KINASE; CYCLIN-A; CELLS; PHOSPHORYLATION; ANTAGONISTS; REPORTERS; CANCER; MODEL	Many proteins and pathways of pharmaceutical interest impinge on ubiquitin ligases or their substrates. The cyclin-dependent kinase (Cdk) inhibitor p27, for example, is polyubiquitylated in a cell cycle-dependent manner by a ubiquitin ligase complex containing the F-box protein Skp2. Regulated turnover of p27 is due, at least partly, to its phosphorylation by Cdk2 on threonine 187, which generates a Skp2-binding site. We made a p27-luciferase (p27Luc) fusion protein and show here that its abundance, like that of p27, is regulated by Skp2 in a cell cycle-dependent manner. As predicted, p27Luc levels increased after blocking Cdk2 activity with inhibitory proteins, peptides or small interfering RNA (siRNA). Accumulation of p27Luc in response to Cdk2 inhibitory drugs (flavopiridol and R-roscovitine) was demonstrable in human tumor cells in vivo using noninvasive bioluminescent imaging. In theory, the approach described here could be used to develop bioluminescent reporters for any drug target that directly or indirectly affects the turnover of a ubiquitin ligase substrate.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; Novartis Inst Biomed Res, Cambridge, MA 02139 USA; Cyclacel Ltd James Lindsay Pl, Dundee DD1 5JJ, Scotland; Univ Abertay, Sch Contemporary Sci, SIMBIOS, CMCBR, Dundee DD1 1HG, Scotland; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Novartis; University of Abertay Dundee; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute	Kaelin, WG (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.	william_kaelin@dfci.harvard.edu	Zhelev, Nikolai Z/A-8589-2012; Zhang, Guo-Jun/H-3890-2015	Zhelev, Nikolai Z/0000-0002-5189-3975; Zhang, Guo-Jun/0000-0001-5182-5887				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; HOLLINGSHEAD MG, 1995, LIFE SCI, V57, P131, DOI 10.1016/0024-3205(95)00254-4; JENKINS TM, 1990, BIOCHEM SOC T, V18, P463, DOI 10.1042/bst0180463; KENDALL J M, 1992, Biochemical Society Transactions, V20, p144S; KREK W, 1995, METHOD ENZYMOL, V254, P114; Laxman B, 2002, P NATL ACAD SCI USA, V99, P16551, DOI 10.1073/pnas.252644499; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; McInnes Campbell, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P57, DOI 10.2174/1568011033353506; Mendoza N, 2003, CANCER RES, V63, P1020; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SALANEWBY GB, 1991, BIOCHEM J, V279, P727, DOI 10.1042/bj2790727; Senderowicz AM, 2002, HEMATOL ONCOL CLIN N, V16, P1229, DOI 10.1016/S0889-8588(02)00049-7; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Toogood PL, 2001, MED RES REV, V21, P487, DOI 10.1002/med.1021; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wang WG, 2003, CANCER BIOL THER, V2, P196, DOI 10.4161/cbt.2.2.347; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798; Zheleva DI, 2002, J PEPT RES, V60, P257, DOI 10.1034/j.1399-3011.2002.21014.x	30	76	85	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					643	648		10.1038/nm1047	http://dx.doi.org/10.1038/nm1047			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15122251				2022-12-27	WOS:000221759600031
J	Wu, XH; Steet, RA; Bohorov, O; Bakker, J; Newell, J; Krieger, M; Spaapen, L; Kornfeld, S; Freeze, HH				Wu, XH; Steet, RA; Bohorov, O; Bakker, J; Newell, J; Krieger, M; Spaapen, L; Kornfeld, S; Freeze, HH			Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder	NATURE MEDICINE			English	Article							GOLGI TRANSPORT COMPLEX; PROTEIN COMPLEX; OLIGOSACCHARIDES; GLYCOSYLATION; DEFECTS; CHAINS; GLYCOSYLTRANSFERASES; IDENTIFICATION; PURIFICATION; BIOSYNTHESIS	The congenital disorders of glycosylation (CDG) are characterized by defects in N-linked glycan biosynthesis that result from mutations in genes encoding proteins directly involved in the glycosylation pathway. Here we describe two siblings with a fatal form of CDG caused by a mutation in the gene encoding COG-7, a subunit of the conserved oligomeric Golgi (COG) complex. The mutation impairs integrity of the COG complex and alters Golgi trafficking, resulting in disruption of multiple glycosylation pathways. These cases represent a new type of CDG in which the molecular defect lies in a protein that affects the trafficking and function of the glycosylation machinery.	Burnham Inst, La Jolla, CA 92037 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Acad Hosp Maastricht, Dept Clin Genet, NL-6229 HX Maastricht, Netherlands; MIT, Dept Biol, Cambridge, MA 02139 USA	Sanford Burnham Prebys Medical Discovery Institute; Washington University (WUSTL); Maastricht University; Maastricht University Medical Centre (MUMC); Massachusetts Institute of Technology (MIT)	Freeze, HH (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hudson@burnham.org	Bakker, J. A./H-7910-2019	Freeze, Hudson/0000-0001-6316-0501; Bakker, Jaap A./0000-0002-2918-7361	NATIONAL CANCER INSTITUTE [R37CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116, R01GM059115, R24GM061894] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA08759] Funding Source: Medline; NIDDK NIH HHS [R01 DK55615] Funding Source: Medline; NIGMS NIH HHS [GM59115, R24 GM61894, U54 GM62116] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blixt O, 2002, J AM CHEM SOC, V124, P5739, DOI 10.1021/ja017881+; Chatterton JE, 1999, P NATL ACAD SCI USA, V96, P915, DOI 10.1073/pnas.96.3.915; Farkas RM, 2003, MOL BIOL CELL, V14, P190, DOI 10.1091/mbc.E02-06-0343; Freeze HH, 2001, GLYCOBIOLOGY, V11, p129R, DOI 10.1093/glycob/11.12.129R; Gedeon AK, 1999, NAT GENET, V22, P400, DOI 10.1038/11976; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; Grunewald S, 2002, PEDIATR RES, V52, P618, DOI 10.1203/01.PDR.0000031921.02259.35; Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200; Kim S, 2001, GLYCOCONJUGATE J, V18, P623, DOI 10.1023/A:1020691619908; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; Loh E, 2002, J BIOL CHEM, V277, P21955, DOI 10.1074/jbc.M202326200; Marquardt T, 2003, EUR J PEDIATR, V162, P359, DOI 10.1007/s00431-002-1136-0; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Oka T, 2004, MOL BIOL CELL, V15, P2423, DOI 10.1091/mbc.E03-09-0699; Olkkonen VM, 2000, NEW ENGL J MED, V343, P1095, DOI 10.1056/NEJM200010123431507; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PODOS SD, 1994, J CELL BIOL, V127, P679, DOI 10.1083/jcb.127.3.679; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; Steet RA, 2000, J BIOL CHEM, V275, P26812; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Suvorova ES, 2001, J BIOL CHEM, V276, P22810, DOI 10.1074/jbc.M011624200; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Walter DM, 1998, J BIOL CHEM, V273, P29565, DOI 10.1074/jbc.273.45.29565; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wopereis S, 2003, CLIN CHEM, V49, P1839, DOI 10.1373/clinchem.2003.022541; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	29	245	249	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					518	523		10.1038/nm1041	http://dx.doi.org/10.1038/nm1041			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15107842				2022-12-27	WOS:000221242400030
J	Goggel, R; Winoto-Morbach, S; Vielhaber, G; Imai, Y; Lindner, K; Brade, L; Brade, H; Ehlers, S; Slutsky, AS; Schutze, S; Gulbins, E; Uhlig, S				Goggel, R; Winoto-Morbach, S; Vielhaber, G; Imai, Y; Lindner, K; Brade, L; Brade, H; Ehlers, S; Slutsky, AS; Schutze, S; Gulbins, E; Uhlig, S			PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide	NATURE MEDICINE			English	Article							PLATELET-ACTIVATING-FACTOR; RESPIRATORY-DISTRESS-SYNDROME; NECROSIS FACTOR-ALPHA; PHOSPHOLIPASE-C; LUNG INJURY; SECRETORY SPHINGOMYELINASE; FACTOR ACETYLHYDROLASE; ENDOTHELIAL APOPTOSIS; CELLS; METABOLISM	Platelet-activating factor (PAF) induces pulmonary edema and has a key role in acute lung injury (ALI). Here we show that PAF induces pulmonary edema through two mechanisms: acid sphingomyelinase (ASM)-dependent production of ceramide, and activation of the cyclooxygenase pathway. Agents that interfere with PAF-induced ceramide synthesis, such as steroids or the xanthogenate D609, attenuate pulmonary edema formation induced by PAF, endotoxin or acid instillation. Our results identify acid sphingomyelinase and ceramide as possible therapeutic targets in acute lung injury.	Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Essen Gesamthsch, D-45122 Essen, Germany	Forschungszentrum Borstel; University of Kiel; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Duisburg Essen	Uhlig, S (corresponding author), Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany.	suhlig@fz-borstel.de	Gulbins, Erich/L-6989-2014; Slutsky, Arthur/M-3325-2019; Imai, Yumiko/GXW-1144-2022; Uhlig, Stefan/A-7290-2014; Schütze, Stefan/C-8596-2011; Slutsky, Arthur S/A-6013-2008; Ehlers, Stefan/B-4075-2010	Gulbins, Erich/0000-0002-3117-1342; Uhlig, Stefan/0000-0003-2332-1280; Slutsky, Arthur S/0000-0002-6063-3876; 				ALBOUZ S, 1986, LIFE SCI, V38, P357, DOI 10.1016/0024-3205(86)90083-4; Balsinde J, 1997, J BIOL CHEM, V272, P20373, DOI 10.1074/jbc.272.33.20373; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BESSIN P, 1983, EUR J PHARMACOL, V86, P403, DOI 10.1016/0014-2999(83)90190-5; Bligh E.G., 1959, CAN J BIOCHEM PHYSIO, V37, P912; BOSCHETTO P, 1991, AM REV RESPIR DIS, V143, P605, DOI 10.1164/ajrccm/143.3.605; BRADE L, 1993, INFECT IMMUN, V61, P4514, DOI 10.1128/IAI.61.10.4514-4517.1993; Carter MB, 1996, J SURG RES, V60, P403, DOI 10.1006/jsre.1996.0066; Chae HJ, 2000, ENDOCRINOLOGY, V141, P2904, DOI 10.1210/en.141.8.2904; CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980; Cowart LA, 2002, J LIPID RES, V43, P2042, DOI 10.1194/jlr.M200241-JLR200; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; DODAM JR, 1994, EXP LUNG RES, V20, P131, DOI 10.3109/01902149409064378; EVANS TW, 1987, J APPL PHYSIOL, V63, P479, DOI 10.1152/jappl.1987.63.2.479; Falk S, 1999, AM J RESP CRIT CARE, V160, P1734, DOI 10.1164/ajrccm.160.5.9902033; Goggel R, 2002, AM J RESP CRIT CARE, V166, P657, DOI 10.1164/rccm.20011.0710C; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HAYTER H, 1999, LIPID 2 MESSENGERS, P17; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Machleidt T, 1996, J EXP MED, V184, P725, DOI 10.1084/jem.184.2.725; Miotla JM, 1998, AM J RESP CELL MOL, V18, P197, DOI 10.1165/ajrcmb.18.2.2846; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; RUSTENBECK I, 1990, J CHROMATOGR-BIOMED, V525, P85, DOI 10.1016/S0378-4347(00)83381-2; Schuster DP, 2003, CRIT CARE MED, V31, P1612, DOI 10.1097/01.CCM.0000063267.79824.DB; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; Taylor A, 1997, LUNG SCI FDN, P1549; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TSCHUGGUEL W, 1995, PFLUG ARCH EUR J PHY, V430, P145, DOI 10.1007/BF00373850; UHLIG S, 1994, J PHARMACOL TOXICOL, V31, P85, DOI 10.1016/1056-8719(94)90047-7; UHLIG S, 1994, J APPL PHYSIOL, V77, P262, DOI 10.1152/jappl.1994.77.1.262; Uhlig S, 1998, METHODS PULMONARY RE, P29; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Vielhaber G, 2001, J INVEST DERMATOL, V117, P1126, DOI 10.1046/j.0022-202x.2001.01527.x; Vielhaber G, 2001, GLYCOBIOLOGY, V11, P451, DOI 10.1093/glycob/11.6.451; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wong ML, 2000, P NATL ACAD SCI USA, V97, P8681, DOI 10.1073/pnas.150098097; WRIGHT SD, 1995, IMMUNOL TODAY, V16, P297, DOI 10.1016/0167-5699(95)80185-5	45	233	245	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					155	160		10.1038/nm977	http://dx.doi.org/10.1038/nm977			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14704790				2022-12-27	WOS:000188719600034
J	Hisaeda, H; Maekawa, Y; Iwakawa, D; Okada, H; Himeno, K; Kishihara, K; Tsukumo, S; Yasutomo, K				Hisaeda, H; Maekawa, Y; Iwakawa, D; Okada, H; Himeno, K; Kishihara, K; Tsukumo, S; Yasutomo, K			Escape of malaria parasites from host immunity requires CD4(+)CD25(+) regulatory T cells	NATURE MEDICINE			English	Article								Infection with malaria parasites frequently induces total immune suppression, which makes it difficult for the host to maintain long-lasting immunity. Here we show that depletion of CD4(+)CD25(+) regulatory T cells (T-reg) protects mice from death when infected with a lethal strain of Plasmodium yoelii, and that this protection is associated with an increased T-cell responsiveness against parasite-derived antigens. These results suggest that activation of T-reg cells contributes to immune suppression during malaria infection, and helps malaria parasites to escape from host immune responses.	Univ Tokushima, Sch Med, Dept Immunol & Parasitol, Tokushima 7708503, Japan; Kyushu Univ, Fac Med Sci, Dept Parasitol, Fukuoka 8128582, Japan	Tokushima University; Kyushu University	Yasutomo, K (corresponding author), Univ Tokushima, Sch Med, Dept Immunol & Parasitol, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	yasutomo@basic.med.tokushima-u.ac.jp		Yasutomo, Koji/0000-0003-0411-2037; Maekawa, Yoichi/0000-0002-3879-5713				BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57; HO M, 1988, J IMMUNOL, V141, P2755; Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3; Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900; VIENS P, 1974, AM J TROP MED HYG, V23, P846, DOI 10.4269/ajtmh.1974.23.846; WILLIAMSON WA, 1978, LANCET, V1, P1328; YOELI M, 1975, ANN TROP MED PARASIT, V69, P173, DOI 10.1080/00034983.1975.11686998	15	277	310	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2004	10	1					29	30		10.1038/nm975	http://dx.doi.org/10.1038/nm975			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702631				2022-12-27	WOS:000187743600034
J	Sheehy, AM; Gaddis, NC; Malim, MH				Sheehy, AM; Gaddis, NC; Malim, MH			The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN; INFECTIVITY; PATHWAY; TSG101; DNA; CD4; TRANSCRIPTION; DEGRADATION; EXPRESSION	The human protein apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like-3G (APOBEC3G), also known as CEM-15, mediates a newly described form of innate resistance to retroviral infection by catalyzing the deamination of deoxycytidine to deoxyuridine in viral cDNA replication intermediates. Because DNA deamination takes place after virus entry into target cells, APOBEC3G function is dependent on its association with the viral nucleoprotein complexes that synthesize cDNA and must therefore be incorporated into virions as they assemble in infected cells. Here we show that the HIV-1 virion infectivity factor (Vif) protein protects the virus from APOBEC3G-mediated inactivation by preventing its incorporation into progeny virions, thus allowing the ensuing infection to proceed without DNA deamination. In addition to helping exclude APOBEC3G from nascent virions, Vif also removes APOBEC3G from virus-producing cells by inducing its ubiquitination and subsequent degradation by the proteasome. Our findings indicate that pharmacologic strategies aimed at stabilizing APOBEC3G in HIV-1 infected cells should be explored as potential HIV/AIDS therapeutics.	Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Infect Dis, London SE1 9RT, England; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	University of London; King's College London; University of Pennsylvania	Malim, MH (corresponding author), Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Infect Dis, London SE1 9RT, England.	michael.malim@kcl.ac.uk	Gaddis, Nathan/GXG-6447-2022; Gaddis, Nathan/GXG-6395-2022	Malim, Michael/0000-0002-7699-2064; Gaddis, Nathan/0000-0001-5205-7138				Camaur D, 1996, J VIROL, V70, P6106, DOI 10.1128/JVI.70.9.6106-6111.1996; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Klarmann GJ, 2003, J BIOL CHEM, V278, P7902, DOI 10.1074/jbc.M207223200; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Levesque K, 2003, J BIOL CHEM, V278, P28346, DOI 10.1074/jbc.M300327200; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; MA XY, 1994, J VIROL, V68, P1714, DOI 10.1128/JVI.68.3.1714-1720.1994; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	25	768	789	0	26	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1404	1407		10.1038/nm945	http://dx.doi.org/10.1038/nm945			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528300				2022-12-27	WOS:000186319700031
J	Matsunaga, T; Takemoto, N; Sato, T; Takimoto, R; Tanaka, I; Fujimi, A; Akiyama, TH; Kuroda, H; Kawano, Y; Kobune, M; Kato, J; Hirayama, Y; Sakamaki, S; Kohda, K; Miyake, K; Niitsu, Y				Matsunaga, T; Takemoto, N; Sato, T; Takimoto, R; Tanaka, I; Fujimi, A; Akiyama, TH; Kuroda, H; Kawano, Y; Kobune, M; Kato, J; Hirayama, Y; Sakamaki, S; Kohda, K; Miyake, K; Niitsu, Y			Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia	NATURE MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; MAINTENANCE INTENSIFICATION THERAPY; DRUG-INDUCED APOPTOSIS; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; HEMATOPOIETIC-CELL; LIGAND-BINDING; SCID MICE; ADHESION; INDUCTION	Bone-marrow minimal residual disease (MRD) causes relapse after chemotherapy in patients with acute myelogenous leukemia (AML). We postulate that the drug resistance is induced by the attachment of very late antigen (VLA)-4 on leukemic cells to fibronectin on bone-marrow stromal cells. We found that VLA-4-positive cells acquired resistance to anoikis (loss of anchorage) or drug-induced apoptosis through the phosphatidylinositol-3-kinase (PI-3K)/AKT/Bcl-2 signaling pathway, which is activated by the interaction of VLA-4 and fibronectin. This resistance was negated by VLA-4-specific antibodies. In a mouse model of MRD, we achieved a 100% survival rate by combining VLA-4-specific antibodies and cytosine arabinoside (AraC), whereas AraC alone prolonged survival only slightly. In addition, overall survival at 5 years was 100% for 10 VLA-4-negative patients and 44.4% for 15 VLA-4-positive patients. Thus, the interaction between VLA-4 on leukemic cells and fibronectin on stromal cells may be crucial in bone marrow MRD and AML prognosis.	Sapporo Med Univ, Sch Med, Dept Internal Med 4, Chuo Ku, Sapporo, Hokkaido 0600061, Japan; Higashi Sapporo Hosp, Dept Internal Med, Shiroishi Ku, Sapporo, Hokkaido 0030003, Japan; Japanese Red Cross Asahikawa Hosp, Dept Internal Med, Asahikawa, Hokkaido 0700061, Japan; Univ Tokyo, Inst Med Sci, Div Infect Genet, Minato Ku, Tokyo 1088639, Japan	Sapporo Medical University; University of Tokyo	Niitsu, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 4, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0600061, Japan.	niitsu@sapmed.ac.jp						AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; Almeida-Porada G, 2002, EXP HEMATOL, V30, P1454, DOI 10.1016/S0301-472X(02)00967-0; Andreeff M, 1999, LEUKEMIA, V13, P1881, DOI 10.1038/sj.leu.2401573; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; BENDALL LJ, 1993, BLOOD, V82, P3125; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; DAWANO Y, 2003, BLOOD, V101, P532; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; GARCIAMEUNIER P, 1993, MAMM GENOME, V4, P695, DOI 10.1007/BF00357792; GARSON OM, 1989, CANCER GENET CYTOGEN, V40, P187, DOI 10.1016/0165-4608(89)90024-1; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Hann IM, 1997, BLOOD, V89, P2311, DOI 10.1182/blood.V89.7.2311; Heinze G, 2003, COMPUT METH PROG BIO, V71, P155, DOI 10.1016/S0169-2607(02)00077-9; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; Kawada H, 1999, EXP HEMATOL, V27, P904, DOI 10.1016/S0301-472X(99)00012-0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kobayashi T, 1996, J CLIN ONCOL, V14, P204, DOI 10.1200/JCO.1996.14.1.204; Lacombe F, 1997, LEUKEMIA, V11, P1878, DOI 10.1038/sj.leu.2400847; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Legras S, 1998, BLOOD, V91, P3401, DOI 10.1182/blood.V91.9.3401.3401_3401_3413; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Mudry RE, 2000, BLOOD, V96, P1926, DOI 10.1182/blood.V96.5.1926.h8001926_1926_1932; OHNO R, 1993, CANCER, V71, P3888, DOI 10.1002/1097-0142(19930615)71:12<3888::AID-CNCR2820711216>3.0.CO;2-G; PREISLER HD, 1989, BRIT J HAEMATOL, V71, P189, DOI 10.1111/j.1365-2141.1989.tb04253.x; Sasaki H, 2002, J IMMUNOL, V168, P5178, DOI 10.4049/jimmunol.168.10.5178; SUGAHARA H, 1994, J EXP MED, V179, P1757, DOI 10.1084/jem.179.6.1757; Tudor G, 2000, CELL DEATH DIFFER, V7, P574, DOI 10.1038/sj.cdd.4400688; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yoshino H, 2000, BONE MARROW TRANSPL, V26, P1211, DOI 10.1038/sj.bmt.1702702; Zhang Y, 2002, J IMMUNOL, V168, P3088, DOI 10.4049/jimmunol.168.6.3088	46	418	446	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2003	9	9					1158	1165		10.1038/nm909	http://dx.doi.org/10.1038/nm909			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12897778				2022-12-27	WOS:000185061600028
J	Autiero, M; Waltenberger, J; Communi, D; Kranz, A; Moons, L; Lambrechts, D; Kroll, J; Plaisance, S; De Mol, M; Bono, F; Kliche, S; Fellbrich, G; Ballmer-Hofer, K; Maglione, D; Mayr-Beyrle, U; Dewerchin, M; Dombrowski, S; Stanimirovic, D; Van Hummelen, P; Dehio, C; Hicklin, DJ; Persico, G; Herbert, JM; Communi, D; Shibuya, M; Collen, D; Conway, EM; Carmeliet, P				Autiero, M; Waltenberger, J; Communi, D; Kranz, A; Moons, L; Lambrechts, D; Kroll, J; Plaisance, S; De Mol, M; Bono, F; Kliche, S; Fellbrich, G; Ballmer-Hofer, K; Maglione, D; Mayr-Beyrle, U; Dewerchin, M; Dombrowski, S; Stanimirovic, D; Van Hummelen, P; Dehio, C; Hicklin, DJ; Persico, G; Herbert, JM; Communi, D; Shibuya, M; Collen, D; Conway, EM; Carmeliet, P			Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1	NATURE MEDICINE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; COLLATERAL VESSEL DEVELOPMENT; PHOSPHOLIPASE-C-GAMMA; AUTOPHOSPHORYLATION SITE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CELL PROLIFERATION; CRYSTAL-STRUCTURE; IN-VIVO; ANGIOGENESIS	Therapeutic angiogenesis is likely to require the administration of factors that complement each other. Activation of the receptor tyrosine kinase (RTK) Flk1 by vascular endothelial growth factor (VEGF) is crucial, but molecular interactions of other factors with VEGF and Flk1 have been studied to a limited extent. Here we report that placental growth factor (PGF, also known as PIGF) regulates inter- and intramolecular cross talk between the VEGF RTKs Flt1 and Flk1. Activation of Flt1 by PGF resulted in intermolecular transphosphorylation of Flk1, thereby amplifying VEGF-driven angiogenesis through Flk1. Even though VEGF and PGF both bind Flt1, PGF uniquely stimulated the phosphorylation of specific Flt1 tyrosine residues and the expression of distinct downstream target genes. Furthermore, the VEGF/PGF heterodimer activated intramolecular VEGF receptor cross talk through formation of Flk1/Flt1 heterodimers. The inter- and intramolecular VEGF receptor cross talk is likely to have therapeutic implications, as treatment with VEGF/PGF heterodimer or a combination of VEGF plus PGF increased ischemic myocardial angiogenesis in a mouse model that was refractory to VEGF alone.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Univ Ulm, Med Ctr, Dept Internal Med 2, D-8908 Ulm, Germany; Sanofi Rech, Haemobiol Dept, F-31036 Toulouse, France; Paul Scherrer Inst, Lab Biomol Res Mol Cell Biol, CH-5232 Villigen, Switzerland; Geymonat SpA, I-03012 Anagni, Italy; Natl Res Council Canada, Inst Biol Sci, Cellular Neurobiol Grp, Ottawa, ON K1A 0R6, Canada; Univ Basel, Bioctr, Div Mol Microbiol, CH-4056 Basel, Switzerland; ImClone Syst Inc, New York, NY 10014 USA; CNR, Ist Int Genet & Biofis, I-80125 Naples, Italy; Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Mol, B-1070 Brussels, Belgium; Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo 1088639, Japan	Flanders Institute for Biotechnology (VIB); KU Leuven; Ulm University; Sanofi-Aventis; Sanofi France; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; National Research Council Canada; University of Basel; Eli Lilly; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Tokyo	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Plaisance, Stephane/B-3488-2009; Dehio, Christoph/R-8277-2016; Kranz, Andrea/D-3617-2012; Verdrengh, Evelien/H-4571-2012; Dehio, Christoph/AAD-5572-2019; Plaisance, Stephane/ABI-6307-2020; Carmeliet, Peter/AAQ-5140-2020; Lambrechts, Diether/AAJ-3167-2020; Waltenberger, Johannes/I-1813-2013	Plaisance, Stephane/0000-0002-1651-241X; Dehio, Christoph/0000-0001-7288-1052; Dehio, Christoph/0000-0001-7288-1052; Plaisance, Stephane/0000-0002-1651-241X; Carmeliet, Peter/0000-0001-7961-1821; Lambrechts, Diether/0000-0002-3429-302X; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Conway, Edward/0000-0003-0081-0305; van hummelen, paul/0000-0002-4801-8600; Ballmer-Hofer, Kurt/0000-0002-3800-9129; Waltenberger, Johannes/0000-0002-2417-9880				Adini A, 2002, CANCER RES, V62, P2749; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161; Couffinhal T, 1999, CIRCULATION, V99, P3188, DOI 10.1161/01.CIR.99.24.3188; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216; De Falco S, 2002, TRENDS CARDIOVAS MED, V12, P241, DOI 10.1016/S1050-1738(02)00168-8; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Gingras D, 2000, BIOCHEM J, V348, P273, DOI 10.1042/0264-6021:3480273; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2001, CANCER RES, V61, P1207; Huang K, 2001, INT J BIOCHEM CELL B, V33, P315, DOI 10.1016/S1357-2725(01)00019-X; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Ito N, 2001, CELL SIGNAL, V13, P849, DOI 10.1016/S0898-6568(01)00209-1; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Odorisio T, 2002, J CELL SCI, V115, P2559; PARK JE, 1994, J BIOL CHEM, V269, P25646; Puskas LG, 2002, BIOTECHNIQUES, V32, P1330, DOI 10.2144/02326mt04; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Waltenberger J, 2001, CARDIOVASC RES, V49, P554, DOI 10.1016/S0008-6363(00)00228-5; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Yu Y, 2001, BIOCHEM J, V358, P465, DOI 10.1042/0264-6021:3580465; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	600	643	1	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					936	943		10.1038/nm884	http://dx.doi.org/10.1038/nm884			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12796773				2022-12-27	WOS:000183979300036
J	Basta, M; Van Goor, F; Luccioli, S; Billings, EM; Vortmeyer, AO; Baranyi, L; Szebeni, J; Alving, CR; Carroll, MC; Berkower, I; Stojilkovic, SS; Metcalfe, DD				Basta, M; Van Goor, F; Luccioli, S; Billings, EM; Vortmeyer, AO; Baranyi, L; Szebeni, J; Alving, CR; Carroll, MC; Berkower, I; Stojilkovic, SS; Metcalfe, DD			F(ab)'(2)-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins	NATURE MEDICINE			English	Article							DOSE INTRAVENOUS IMMUNOGLOBULIN; IMMUNE GLOBULIN; COMPLEMENT; RECEPTORS; ASTHMA; PATHOGENESIS; MODULATION; ACTIVATION; COMPONENTS; FRAGMENTS	High-dose intravenous immunoglobulin (IVIG) prevents immune damage by scavenging complement fragments C3b and C4b. We tested the hypothesis that exogenous immunoglobulin molecules also bind anaphylatoxins C3a and C5a, thereby neutralizing their pro-inflammatory effects. Single-cell calcium measurements in HMC-1 human mast cells showed that a rise in intracellular calcium caused by C3a and C5a was inhibited in a concentration-dependent manner by IVIG, F(ab)'(2)-IVIG and irrelevant human monoclonal antibody. C3a- and C5a-induced thromboxane (TXB2) generation and histamine release from HMC-1 cells and whole-blood basophils were also suppressed by exogenous immunoglobulins. In a mouse model of asthma, immunoglobulin treatment reduced cellular migration to the lung. Lethal C5a-mediated circulatory collapse in pigs was prevented by pretreatment with F(ab)'(2)-IVIG. Molecular modeling, surface plasmon resonance (SPR) and western blot analyses suggested a physical association between anaphylatoxins and the constant region of F(ab)'(2). This binding could interfere with the role of C3a and C5a in inflammation.	NINDS, Neuronal Excitabil Sect, NIH, Bethesda, MD 20892 USA; NICHHD, Sect Cellular Signaling, NIH, Bethesda, MD 20892 USA; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NHLBI, Computat Biophys Sect, NIH, Bethesda, MD 20892 USA; NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Walter Reed Army Inst Res, Dept Membrane Biochem, Silver Spring, MD USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; US FDA, Immunoregulat Lab, Off Vaccines, Ctr Biol, Bethesda, MD 20014 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Harvard University; Harvard Medical School; US Food & Drug Administration (FDA)	Basta, M (corresponding author), NINDS, Neuronal Excitabil Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.			Basta, Milan/0000-0001-5958-9241	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000607, ZIAAI000761, Z01AI000761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baranyi L, 1998, PEPTIDES, V19, P211, DOI 10.1016/S0196-9781(97)00370-7; BASTA M, 1991, BLOOD, V77, P376; Basta M, 1996, J NEUROIMMUNOL, V71, P227, DOI 10.1016/S0165-5728(96)00133-6; BASTA M, 1989, BLOOD, V74, P326; Basta M, 1996, CLIN EXP IMMUNOL, V104, P21, DOI 10.1111/cei.1996.104.s1.21; BASTA M, 1991, BLOOD, V78, P700; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; Bautsch W, 2000, J IMMUNOL, V165, P5401, DOI 10.4049/jimmunol.165.10.5401; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; DEBOER JP, 1992, IMMUNOPHARMACOLOGY, V24, P135, DOI 10.1016/0162-3109(92)90019-9; DWYER JM, 1992, NEW ENGL J MED, V326, P107; Ember JA, 1997, IMMUNOPHARMACOLOGY, V38, P3, DOI 10.1016/S0162-3109(97)00088-X; FISHER MB, 1996, J IMMUNOL, V157, P549; FRANK MM, 1989, FUNDAMENTAL IMMUNOLO, P686; HARTUNG HP, 1983, J IMMUNOL, V130, P1345; HUGLI TE, 1989, CURR TOP MICROBIOL I, V153, P181; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Kekow J, 1998, LANCET, V351, P184, DOI 10.1016/S0140-6736(05)78212-X; Komura H, 2002, MICROBIOL IMMUNOL, V46, P115, DOI 10.1111/j.1348-0421.2002.tb02667.x; LUCCIOLI S, J ALLERGY CLIN IMMUN, V110, P117; Maizel JV, 1971, METHOD VIROL, V5, P179; MORGAN E L, 1986, Complement, V3, P128; MORGAN EL, 1983, J IMMUNOL, V130, P1257; NEZLIN R, 1993, J IMMUNOL METHODS, V163, P269, DOI 10.1016/0022-1759(93)90131-P; NEZLIN R, 1992, EUR J IMMUNOL, V22, P1955, DOI 10.1002/eji.1830220744; NEZLIN R, 1992, MOL IMMUNOL, V30, P935; Nilsson G, 1996, J IMMUNOL, V157, P1693; OPPERMANN M, 1992, IMMUNOPHARMACOLOGY, V24, P119, DOI 10.1016/0162-3109(92)90018-8; Pauwels RA, 1998, CLIN EXP ALLERGY, V28, P1; PLATT JL, 1991, EUR J IMMUNOL, V21, P2887, DOI 10.1002/eji.1830211135; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Szebeni J, 1999, CIRCULATION, V99, P2302, DOI 10.1161/01.CIR.99.17.2302; WEIGLE WO, 1983, SPRINGER SEMIN IMMUN, V6, P173; Zhang T, 1996, PROTEIN SCI, V5, P348	38	182	188	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					431	438		10.1038/nm836	http://dx.doi.org/10.1038/nm836			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12612546				2022-12-27	WOS:000181987400033
J	Raoul, C; Abbas-Terki, T; Bensadoun, JC; Guillot, S; Haase, G; Szulc, J; Henderson, CE; Aebischer, P				Raoul, C; Abbas-Terki, T; Bensadoun, JC; Guillot, S; Haase, G; Szulc, J; Henderson, CE; Aebischer, P			Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU/ZN SUPEROXIDE-DISMUTASE; MOTOR-NEURON DEGENERATION; PROLONGS SURVIVAL; MAMMALIAN-CELLS; MICE; EXPRESSION; MUTATION; VECTOR; SYSTEM	Mutations in Cu/Zn superoxide dismutase ( encoded by SOD1), one of the causes of familial amyotrophic lateral sclerosis (ALS), lead to progressive death of motoneurons through a gain-of-function mechanism. RNA interference (RNAi) mediated by viral vectors allows for long-term reduction in gene expression and represents an attractive therapeutic approach for genetic diseases characterized by acquired toxic properties. We report that in SOD1(G93A) transgenic mice, a model for familial ALS, intraspinal injection of a lentiviral vector that produces RNAi-mediated silencing of SOD1 substantially retards both the onset and the progression rate of the disease.	Ecole Polytech Fed Lausanne, Integrat Biosci Inst, CH-1015 Lausanne, Switzerland; INSERM, U29, Avenir Team, INMED, F-13273 Marseille, France; Dev Biol Inst Marseille, INSERM, UMR 623, F-13288 Marseille, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Aebischer, P (corresponding author), Ecole Polytech Fed Lausanne, Integrat Biosci Inst, CH-1015 Lausanne, Switzerland.	patrick.aebischer@epfl.ch	Dunnett, Stephen B/A-5869-2010; Aebischer, Patrick/E-1387-2013; Raoul, Cedric/H-6517-2016	Dunnett, Stephen B/0000-0003-1826-1578; Raoul, Cedric/0000-0003-0561-6851; Henderson, Christopher/0000-0002-9936-3279				Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Al-Chalabi A, 1998, HUM MOL GENET, V7, P2045, DOI 10.1093/hmg/7.13.2045; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carter RJ, 1999, J NEUROSCI, V19, P3248; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Deglon N, 2000, HUM GENE THER, V11, P179, DOI 10.1089/10430340050016256; Ding HL, 2003, AGING CELL, V2, P209, DOI 10.1046/j.1474-9728.2003.00054.x; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; FINGER S, 1988, J NEUROL SCI, V86, P203, DOI 10.1016/0022-510X(88)90099-8; Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000; Guillot S, 2004, NEUROBIOL DIS, V16, P139, DOI 10.1016/j.nbd.2004.01.017; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Newbery H J, 2001, Trends Genet, V17, pS2, DOI 10.1016/S0168-9525(01)02459-3; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	30	350	412	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					423	428		10.1038/nm1207	http://dx.doi.org/10.1038/nm1207			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15768028				2022-12-27	WOS:000228180500034
J	Morizono, K; Xie, YM; Ringpis, GE; Johnson, M; Nassanian, H; Lee, B; Wu, L; Chen, ISY				Morizono, K; Xie, YM; Ringpis, GE; Johnson, M; Nassanian, H; Lee, B; Wu, L; Chen, ISY			Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection	NATURE MEDICINE			English	Article							VIRUS-DERIVED VIRUSES; COMPLEX CLASS-I; RETROVIRAL VECTORS; GENE-THERAPY; SINDBIS VIRUS; HUMAN-CELLS; EXPRESSION; RECEPTOR; TRANSDUCTION; INFECTION	Targeted gene transduction to specific tissues and organs through intravenous injection would be the ultimate preferred method of gene delivery. Here, we report successful targeting in a living animal through intravenous injection of a lentiviral vector pseudotyped with a modified chimeric Sindbis virus envelope (termed m168). m168 pseudotypes have high titer and high targeting specificity and, unlike other retroviral pseudotypes, have low nonspecific infectivity in liver and spleen. A mouse cancer model of metastatic melanoma was used to test intravenous targeting with m168. Human P-glycoprotein was ectopically expressed on the surface of melanoma cells and targeted by the m168 pseudotyped lentiviral vector conjugated with antibody specific for P-glycoprotein. m168 pseudotypes successfully targeted metastatic melanoma cells growing in the lung after systemic administration by tail vein injection. Further development of this targeting technology should result in applications not only for cancers but also for genetic, infectious and immune diseases.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, AIDS Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chen, ISY (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	syuchen@mednet.ucla.edu	Lee, Benhur/A-8554-2016	Lee, Benhur/0000-0003-0760-1709	NCI NIH HHS [CA-92194] Funding Source: Medline; NIAID NIH HHS [AI039975, AI028697] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039975, P30AI028697] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Akporiaye ET, 1999, CURR OPIN MOL THER, V1, P443; Allen PJ, 2002, CURR OPIN ONCOL, V14, P221, DOI 10.1097/00001622-200203000-00014; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; BERGER W, 1994, INT J CANCER, V59, P717, DOI 10.1002/ijc.2910590522; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Boerger AL, 1999, P NATL ACAD SCI USA, V96, P9867, DOI 10.1073/pnas.96.17.9867; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; Cameron MD, 2000, CANCER RES, V60, P2541; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; HAN XL, 1995, P NATL ACAD SCI USA, V92, P9747, DOI 10.1073/pnas.92.21.9747; HEIDNER HW, 1994, J VIROL, V68, P2683, DOI 10.1128/JVI.68.4.2683-2692.1994; Jiang A, 1999, GENE THER, V6, P1982, DOI 10.1038/sj.gt.3301043; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; Klimstra WB, 1998, J VIROL, V72, P7357, DOI 10.1128/JVI.72.9.7357-7366.1998; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Marin M, 1996, J VIROL, V70, P2957, DOI 10.1128/JVI.70.5.2957-2962.1996; Martin F, 2002, MOL THER, V5, P269, DOI 10.1006/mthe.2002.0550; Martin K, 2003, MOL THER, V8, P485, DOI 10.1016/S1525-0016(03)00182-5; Morizono K, 2001, J VIROL, V75, P8016, DOI 10.1128/JVI.75.17.8016-8020.2001; Muller OJ, 2003, NAT BIOTECHNOL, V21, P1040, DOI 10.1038/nbt856; Nicklin Stuart A., 2002, Current Gene Therapy, V2, P273, DOI 10.2174/1566523023347797; Nilson BHK, 1996, GENE THER, V3, P280; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; Sandrin V, 2003, CURR TOP MICROBIOL, V281, P137; Sawai K, 1998, BIOCHEM BIOPH RES CO, V248, P315, DOI 10.1006/bbrc.1998.8922; SOMIA NV, 1995, P NATL ACAD SCI USA, V92, P7570, DOI 10.1073/pnas.92.16.7570; VALSESIAWITTMANN S, 1994, J VIROL, V68, P4609, DOI 10.1128/JVI.68.7.4609-4619.1994; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P4005, DOI 10.1073/pnas.96.7.4005	33	169	189	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					346	352		10.1038/nm1192	http://dx.doi.org/10.1038/nm1192			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711560				2022-12-27	WOS:000227541300032
J	Muller, AJ; DuHadaway, JB; Donover, PS; Sutanto-Ward, E; Prendergast, GC				Muller, AJ; DuHadaway, JB; Donover, PS; Sutanto-Ward, E; Prendergast, GC			Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy	NATURE MEDICINE			English	Article							TUMOR-SUPPRESSOR; CELL-PROLIFERATION; EXPRESSION; TRYPTOPHAN; MYC; ENDOCYTOSIS; MECHANISM; CARCINOMA; PROTEIN; BIN1/AMPHIPHYSIN-II	Immune escape is a crucial feature of cancer progression about which little is known. Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can facilitate immune escape. Not known is how IDO becomes elevated or whether IDO inhibitors will be useful for cancer treatment. Here we show that IDO is under genetic control of Bin1, which is attenuated in many human malignancies. Mouse knockout studies indicate that Bin1 loss elevates the STAT1- and NF-kappa B-dependent expression of IDO, driving escape of oncogenically transformed cells from T cell-dependent antitumor immunity. In MMTV-Neu mice, an established breast cancer model, we show that small-molecule inhibitors of IDO cooperate with cytotoxic agents to elicit regression of established tumors refractory to single-agent therapy. Our findings suggest that Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors may improve responses to cancer chemotherapy.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergasgt@mlhs.org		Muller, Alexander/0000-0001-7854-6933				BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; BOYLAND E, 1956, BIOCHEM J, V64, P578, DOI 10.1042/bj0640578; Brandt R, 2001, ONCOGENE, V20, P5459, DOI 10.1038/sj.onc.1204709; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Du MX, 2000, J INTERF CYTOK RES, V20, P133, DOI 10.1089/107999000312531; DuHadaway JB, 2003, ONCOGENE, V22, P3578, DOI 10.1038/sj.onc.1206481; DuHadaway JB, 2003, J CELL BIOCHEM, V88, P635, DOI 10.1002/jcb.10380; DuHadaway JB, 2001, CANCER RES, V61, P3151; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Friberg M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Gilmour SK, 1999, CELL GROWTH DIFFER, V10, P739; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang HT, 2000, CANCER RES, V60, P6868; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KOPROWSKI H, 1979, SOMAT CELL GENET, V5, P957, DOI 10.1007/BF01542654; KRUISBEEK AD, 1991, CURRENT PROTOCOLS IM; Leprince C, 2003, J CELL SCI, V116, P1937, DOI 10.1242/jcs.00403; Littlejohn TK, 2000, PROTEIN EXPRES PURIF, V19, P22, DOI 10.1006/prep.2000.1214; Machiels JPH, 2001, CANCER RES, V61, P3689; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Mason K, 2001, INT J ONCOL, V18, P599; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Muller AJ, 2003, MOL CELL BIOL, V23, P4295, DOI 10.1128/MCB.23.12.4295-4306.2003; MULLER AJ, 2004, CANC BIOL THER, V3; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nowak AK, 2003, CANCER RES, V63, P4490; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; ROSE DP, 1967, LANCET, V1, P239; Routhier EL, 2003, ONCOGENE, V22, P637, DOI 10.1038/sj.onc.1206162; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SHIMIZU F, 1978, INFECT IMMUN, V22, P752, DOI 10.1128/IAI.22.3.752-757.1978; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Zelhof AC, 2001, DEVELOPMENT, V128, P5005	50	831	936	2	114	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					312	319		10.1038/nm1196	http://dx.doi.org/10.1038/nm1196			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711557				2022-12-27	WOS:000227541300027
J	Lang, KS; Recher, M; Junt, T; Navarini, AA; Harris, NL; Freigang, S; Odermatt, B; Conrad, C; Ittner, LM; Bauer, S; Luther, SA; Uematsu, S; Akira, S; Hengartner, H; Zinkernagel, RM				Lang, KS; Recher, M; Junt, T; Navarini, AA; Harris, NL; Freigang, S; Odermatt, B; Conrad, C; Ittner, LM; Bauer, S; Luther, SA; Uematsu, S; Akira, S; Hengartner, H; Zinkernagel, RM			Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease	NATURE MEDICINE			English	Article							PLASMACYTOID DENDRITIC CELLS; DOUBLE-STRANDED-RNA; DIABETES-MELLITUS; VIRAL-INFECTION; MOLECULAR MIMICRY; PANCREATIC-ISLETS; IMMUNE-RESPONSES; VIRUS-INFECTION; IFN-ALPHA/BETA; BETA-CELLS	Autoimmune diabetes mellitus in humans is characterized by immunological destruction of pancreatic beta islet cells. We investigated the circumstances under which CD8(+) T cells specific for pancreatic beta-islet antigens induce disease in mice expressing lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) as a transgene under the control of the rat insulin promoter. In contrast to infection with LCMV, immunization with LCMV-GP derived peptide did not induce autoimmune diabetes despite large numbers of autoreactive cytotoxic T cells. Only subsequent treatment with Toll-like receptor ligands elicited overt autoimmune disease. This difference was critically regulated by the peripheral target organ itself, which upregulated class I major histocompatibility complex (MHC) in response to systemic Toll-like receptor-triggered interferon-alpha production. These data identify the 'inflammatory status' of the target organ as a separate and limiting factor determining the development of autoimmune disease.	Univ Zurich Hosp, Inst Expt Immunol, Zurich, Switzerland; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Univ Zurich, Res Lab Calcium Metab, Clin Balgrist, Zurich, Switzerland; Tech Univ Munich, Inst Med Mikrobiol Immunol & Hyg, D-8000 Munich, Germany; Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Osaka Univ, Dept Hosp Defense, Suita, Osaka, Japan	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; Technical University of Munich; University of Lausanne; Osaka University	Lang, KS (corresponding author), Univ Zurich Hosp, Inst Expt Immunol, Schmelzbergstr 12, Zurich, Switzerland.	karl.lang@usz.ch	Luther, Sanjiv A/B-4380-2016; Luther, Sanjiv/AAP-6525-2020; Junt, Tobias/AAE-4389-2021; Navarini, Alexander/C-5504-2014; harris, nicola/E-5342-2019; Lang, Karl S/R-2505-2016; Akira, Shizuo/C-3134-2009; Freigang, Stefan/A-8682-2013; , Sanjiv/B-4380-2016	Luther, Sanjiv A/0000-0002-8758-957X; Luther, Sanjiv/0000-0002-8758-957X; Navarini, Alexander/0000-0001-7059-632X; harris, nicola/0000-0003-2922-0210; Freigang, Stefan/0000-0003-4438-7828; Lang, Karl/0000-0001-9783-7605; , Sanjiv/0000-0002-0614-561X; Conrad, Curdin/0000-0002-2547-3440; Bauer, Stefan/0000-0002-8462-1845; Ittner, Lars/0000-0001-6738-3825; Recher, Mike/0000-0002-9121-6936				Akira S, 2000, CURR OPIN IMMUNOL, V12, P59, DOI 10.1016/S0952-7915(99)00051-5; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; BATTEGAY M, 1992, J VIROL METHODS, V38, P263; Betterle C, 2000, DIABETES CARE, V23, P1177, DOI 10.2337/diacare.23.8.1177; Biron CA, 1998, SEMIN IMMUNOL, V10, P383, DOI 10.1006/smim.1998.0138; Dalod M, 2002, J EXP MED, V195, P517, DOI 10.1084/jem.20011672; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Doughty LA, 2001, J IMMUNOL, V166, P2658, DOI 10.4049/jimmunol.166.4.2658; ERLICH HA, 1991, BAILLIERE CLIN ENDOC, V5, P395, DOI 10.1016/S0950-351X(05)80138-7; EWEL CH, 1992, DIABETES, V41, P1016, DOI 10.2337/diabetes.41.8.1016; Frigerio S, 2002, NAT MED, V8, P1414, DOI 10.1038/nm792; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hiemstra HS, 1998, J IMMUNOL, V161, P4078; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; Hyoty H, 2002, DIABETOLOGIA, V45, P1353, DOI 10.1007/s00125-002-0852-3; ISHIKAWA R, 1993, J IMMUNOL, V150, P3713; Junt T, 2002, J IMMUNOL, V168, P6032, DOI 10.4049/jimmunol.168.12.6032; Kaisho T, 2003, CURR MOL MED, V3, P759, DOI 10.2174/1566524033479366; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5; Malmgaard L, 2002, J VIROL, V76, P4520, DOI 10.1128/JVI.76.9.4520-4525.2002; Meagher C, 2003, ADV EXP MED BIOL, V520, P133; Nansen A, 2000, EUR J IMMUNOL, V30, P1797, DOI 10.1002/1521-4141(200007)30:7<1797::AID-IMMU1797>3.0.CO;2-B; O'Neill L A, 2000, Sci STKE, V2000, pre1; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OHASHI PS, 1993, J IMMUNOL, V150, P5185; Ou R, 2001, J VIROL, V75, P8407, DOI 10.1128/JVI.75.18.8407-8423.2001; Pien GC, 2002, J IMMUNOL, V169, P5827, DOI 10.4049/jimmunol.169.10.5827; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Potena L, 2004, CIRCULATION, V109, P532, DOI 10.1161/01.CIR.0000109485.79183.81; ROEP BO, 1995, DIABETES, V44, P278, DOI 10.2337/diabetes.44.3.278; Roep BO, 1996, DIABETES, V45, P1147, DOI 10.2337/diabetes.45.9.1147; Roep BO, 2002, ANN NY ACAD SCI, V958, P163; Schloot NC, 2001, HUM IMMUNOL, V62, P299, DOI 10.1016/S0198-8859(01)00223-3; SERREZE DV, 1989, J AUTOIMMUN, V2, P759, DOI 10.1016/0896-8411(89)90003-6; Sobel DO, 1998, J AUTOIMMUN, V11, P343, DOI 10.1006/jaut.1998.0203; SOBEL DO, 1992, DIABETES, V41, P515, DOI 10.2337/diabetes.41.4.515; TRUCCO M, 1989, CRIT REV IMMUNOL, V9, P201; vonHerrath MG, 1997, J EXP MED, V185, P531, DOI 10.1084/jem.185.3.531; Yang Y, 2003, DIABETOLOGIA, V46, P1447, DOI 10.1007/s00125-003-1218-1; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	50	315	330	1	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					138	145		10.1038/nm1176	http://dx.doi.org/10.1038/nm1176			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15654326	Green Published, Green Submitted			2022-12-27	WOS:000226797300020
J	Takimoto, E; Champion, HC; Li, MX; Belardi, D; Ren, SX; Rodriguez, ER; Bedja, D; Gabrielson, KL; Wang, YB; Kass, DA				Takimoto, E; Champion, HC; Li, MX; Belardi, D; Ren, SX; Rodriguez, ER; Bedja, D; Gabrielson, KL; Wang, YB; Kass, DA			Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy	NATURE MEDICINE			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; NATRIURETIC-PEPTIDE RECEPTOR; GUANYLYL CYCLASE-A; PROTEIN-KINASE-C; IN-VIVO; NITRIC-OXIDE; MYOCARDIAL-CONTRACTILITY; SIGNALING PATHWAYS; DIASTOLIC FUNCTION; PRESSURE-OVERLOAD	Sustained cardiac pressure overload induces hypertrophy and pathological remodeling, frequently leading to heart failure. Genetically engineered hyperstimulation of guanosine 3',5'-cyclic monophosphate (cGMP) synthesis counters this response. Here, we show that blocking the intrinsic catabolism of cGMP with an oral phosphodiesterase-5A (PDE5A) inhibitor (sildenafil) suppresses chamber and myocyte hypertrophy, and improves in vivo heart function in mice exposed to chronic pressure overload induced by transverse aortic constriction. Sildenafil also reverses pre-established hypertrophy induced by pressure load while restoring chamber function to normal. cGMP catabolism by PDE5A increases in pressure-loaded hearts, leading to activation of cGMP-dependent protein kinase with inhibition of PDE5A. PDE5A inhibition deactivates multiple hypertrophy signaling pathways triggered by pressure load (the calcineurin/NFAT, phosphoinositide-3 kinase (PI3K)/Akt, and ERK1/2 signaling pathways). But it does not suppress hypertrophy induced by overexpression of calcineurin in vitro or Akt in vivo, suggesting upstream targeting of these pathways. PDE5A inhibition may provide a new treatment strategy for cardiac hypertrophy and remodeling.	Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Univ Calif Los Angeles, Dept Anesthesiol, Div Mol Med, David Geffen Sch Med, Los Angeles, CA 90095 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Div Comparat Med, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Kass, DA (corresponding author), Johns Hopkins Med Inst, Dept Med, Div Cardiol, Ross 835,720 Rutland Ave, Baltimore, MD 21205 USA.	dkass@jhmi.edu	Takimoto, Eiki/AAC-5100-2021	Wang, Yibin/0000-0003-0852-0767	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047511, P01HL059408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47511, P01-HL59408] Funding Source: Medline; NIA NIH HHS [AG18324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akao M, 2001, CIRC RES, V88, P1267, DOI 10.1161/hh1201.092094; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Champion HC, 2004, CIRC RES, V94, P657, DOI 10.1161/01.RES.0000119323.79644.20; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Corbin J, 2003, CURR MED RES OPIN, V19, P747, DOI 10.1185/030079903125002522; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Francis SH, 2002, J BIOL CHEM, V277, P47581, DOI 10.1074/jbc.M206088200; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Holtwick R, 2003, J CLIN INVEST, V111, P1399, DOI 10.1172/JCI200317061; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kim D, 2001, CIRCULATION, V104, P2338, DOI 10.1161/hc4401.098432; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Kotera J, 2003, BIOCHEM J, V372, P419, DOI 10.1042/BJ20030107; Massion PB, 2003, CIRC RES, V93, P388, DOI 10.1161/01.RES.0000088351.58510.21; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Matsui T, 2003, CELL CYCLE, V2, P220, DOI 10.4161/cc.2.3.381; Michael A, 2004, J BIOL CHEM, V279, P21383, DOI 10.1074/jbc.M401413200; Minamino T, 2002, P NATL ACAD SCI USA, V99, P3866, DOI 10.1073/pnas.062453699; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Ni XP, 2004, J AM SOC NEPHROL, V15, P1254, DOI 10.1097/01.ASN.0000125613.96927.38; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Reffelmann T, 2003, CIRCULATION, V108, P239, DOI 10.1161/01.CIR.0000081166.87607.E2; Rybalkin SD, 2003, CIRC RES, V93, P280, DOI 10.1161/01.RES.0000087541.15600.2B; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Sastry BKS, 2004, J AM COLL CARDIOL, V43, P1149, DOI 10.1016/j.jacc.2003.10.056; Semeniuk LM, 2003, AM J PHYSIOL-HEART C, V284, pH425, DOI 10.1152/ajpheart.00546.2002; Senzaki H, 2001, FASEB J, V15, P1718, DOI 10.1096/fj.00-0538com; Shin SY, 2002, EXP MOL MED, V34, P444, DOI 10.1038/emm.2002.62; Takimoto E, 2005, CIRC RES, V96, P100, DOI 10.1161/01.RES.0000152262.22968.72; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Walker DK, 1999, XENOBIOTICA, V29, P297, DOI 10.1080/004982599238687; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wollert KC, 2002, HYPERTENSION, V39, P87, DOI 10.1161/hy1201.097292; Zahabi A, 2003, J BIOL CHEM, V278, P47694, DOI 10.1074/jbc.M309661200; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987	50	693	722	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					214	222		10.1038/nm1175	http://dx.doi.org/10.1038/nm1175			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665834				2022-12-27	WOS:000226797300030
J	Germain, RN				Germain, RN			An innately interesting decade of research in immunology	NATURE MEDICINE			English	Review							REGULATORY T-CELLS; TOLL-LIKE RECEPTORS; PLASMACYTOID DENDRITIC CELLS; NATURAL-KILLER-CELLS; CLASS-I; IMMUNE-RESPONSE; NK CELLS; TRANSCRIPTION FACTOR; ANTIGEN PRESENTATION; NEGATIVE SELECTION	Nature has provided, in the white corpuscles as you call them - in the phagocytes as we call them - a natural means of devouring and destroying all disease germs. There is at bottom only one genuinely scientific treatment for all diseases, and that is to stimulate the phagocytes." So opined B. B. in G. B. Shaw's The Doctor's Dilemma(1) in a dramatic restatement of a key portion of Ilya Metchnikoff's Nobel Prize address: "Whenever the organism enjoys immunity, the introduction of infectious microbes is followed by the accumulation of mobile cells, of white corpuscles of the blood in particular which absorb the microbes and destroy them. The white corpuscles and the other cells capable of doing this have been designated 'phagocytes,' (i.e., devouring cells) and the whole function that ensures immunity has been given the name of 'phagocytosis('"2). Based on these insights into the foundation of resistance to infectious disease, Metchnikoff was awarded the 1908 Nobel Prize in Physiology or Medicine together with Paul Ehrlich ( Fig. 1). Although both were cited for discoveries in immunity, the contributions of the two men seem worlds apart. Ehrlich's studies did not deal with generic responses to infection, but rather with the highly specific nature of antibodies and their relationship to the cells producing them: "As the cell receptor is obviously preformed, and the artificially produced antitoxin only the consequence, i.e. secondary, one can hardly fail to assume that the antitoxin is nothing else but discharged components of the cell, namely receptors discharged in excess("3). But biological systems are just that - systems - and the parts need to work together. And so we arrive, a century later, at an appreciation for just how intimately related these two seemingly disparate aspects of host defense really are.	NIAID, Lymphocyte Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Germain, RN (corresponding author), NIAID, Lymphocyte Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.	rgermain@nih.gov	Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000545, ZIAAI000545] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Aliberti J, 2003, BLOOD, V101, P305, DOI 10.1182/blood-2002-04-1088; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Ardavin C, 2003, NAT REV IMMUNOL, V3, P582, DOI 10.1038/nri1127; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; Bakker ABH, 2000, HUM IMMUNOL, V61, P18, DOI 10.1016/S0198-8859(99)00160-3; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Basta S, 2003, VIRAL IMMUNOL, V16, P231, DOI 10.1089/088282403322396064; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; BENACERR.B, 1972, SCIENCE, V175, P273, DOI 10.1126/science.175.4019.273; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berzins SP, 2003, DIABETES, V52, P327, DOI 10.2337/diabetes.52.2.327; Beutler B, 2004, CR BIOL, V327, P571, DOI 10.1016/j.crvi.2004.03.008; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Beutler B, 2003, IMMUNITY, V19, P155, DOI 10.1016/S1074-7613(03)00212-7; Beutler B, 2001, CRIT CARE MED, V29, pS2, DOI 10.1097/00003246-200107001-00002; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Biron CA, 2001, CURR OPIN IMMUNOL, V13, P458, DOI 10.1016/S0952-7915(00)00241-7; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Bottino C, 2004, MOL IMMUNOL, V41, P569, DOI 10.1016/j.molimm.2004.04.004; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Bousso P, 2002, SCIENCE, V296, P1876, DOI 10.1126/science.1070945; BRACK C, 1978, CELL, V15, P1, DOI 10.1016/0092-8674(78)90078-8; Brennan J, 1996, J EXP MED, V183, P1553, DOI 10.1084/jem.183.4.1553; BRENNAN J, 1994, J EXP MED, V180, P2287, DOI 10.1084/jem.180.6.2287; BRENNER S, 2004, NAT BIOTECHNOL, V22, P1191; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; Cahalan MD, 2002, NAT REV IMMUNOL, V2, P872, DOI 10.1038/nri935; Campbell K S, 2001, Int Rev Immunol, V20, P333, DOI 10.3109/08830180109054413; CARAYANNIOTIS G, 1991, MOL IMMUNOL, V28, P261, DOI 10.1016/0161-5890(91)90072-R; Carayannopoulos LN, 2002, J IMMUNOL, V169, P4079, DOI 10.4049/jimmunol.169.8.4079; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Cerwenka A, 2003, TISSUE ANTIGENS, V61, P335, DOI 10.1034/j.1399-0039.2003.00070.x; Cerwenka A, 2001, IMMUNOL REV, V181, P158, DOI 10.1034/j.1600-065X.2001.1810113.x; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chatenoud L, 2001, IMMUNOL REV, V182, P149, DOI 10.1034/j.1600-065X.2001.1820112.x; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Chinen J, 2004, J ALLERGY CLIN IMMUN, V113, P595, DOI 10.1016/j.jaci.2004.01.765; Cristofaro P, 2003, EXPERT OPIN THER TAR, V7, P603, DOI 10.1517/14728222.7.5.603; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Dalod M, 2003, J EXP MED, V197, P885, DOI 10.1084/jem.20021522; DANIELS BF, 1994, J EXP MED, V180, P687, DOI 10.1084/jem.180.2.687; DAVIES DR, 1975, ANNU REV BIOCHEM, V44, P639, DOI 10.1146/annurev.bi.44.070175.003231; Davis MM, 2003, ANNU REV BIOCHEM, V72, P717, DOI 10.1146/annurev.biochem.72.121801.161625; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Defrance T, 2002, ADV CANCER RES, V86, P195, DOI 10.1016/S0065-230X(02)86006-7; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2002, IMMUNOL REV, V188, P9, DOI 10.1034/j.1600-065X.2002.18802.x; Dong C, 2003, IMMUNOL RES, V28, P39, DOI 10.1385/IR:28:1:39; Dorfman JR, 2002, MICROBES INFECT, V4, P547, DOI 10.1016/S1286-4579(02)01571-X; EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78; Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Egen JG, 2002, IMMUNITY, V16, P23, DOI 10.1016/S1074-7613(01)00259-X; Ehrlich P, 1967, NOBEL LECT PHYSL MED; Farrell HE, 1998, SEMIN CELL DEV BIOL, V9, P369, DOI 10.1006/scdb.1998.0246; Fazekas de St Groth B, 2002, IMMUNOL CELL BIOL, V80, P469, DOI 10.1046/j.1440-1711.2002.01117.x; Fehervari Z, 2004, CURR OPIN IMMUNOL, V16, P203, DOI 10.1016/j.coi.2004.01.004; Ferrandon D, 2004, SEMIN IMMUNOL, V16, P43, DOI 10.1016/j.smim.2003.10.008; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Finkelman FD, 1996, J IMMUNOL, V157, P1406; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Fisson S, 2003, J EXP MED, V198, P737, DOI 10.1084/jem.20030686; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Gambineri E, 2003, CURR OPIN RHEUMATOL, V15, P430, DOI 10.1097/00002281-200307000-00010; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Geijtenbeek TBH, 2002, J LEUKOCYTE BIOL, V71, P921; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Germain RN, 2001, SCIENCE, V293, P240, DOI 10.1126/science.1062946; Gett AV, 2000, NAT IMMUNOL, V1, P239, DOI 10.1038/79782; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; GREEN DR, 1993, IMMUNOL TODAY, V14, P523, DOI 10.1016/0167-5699(93)90180-S; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Heath VL, 1998, J AUTOIMMUN, V11, P309, DOI 10.1006/jaut.1998.0210; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; HEBERKATZ E, 1983, J MOL CELL IMMUNOL, V1, P3; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; Heino M, 1999, BIOCHEM BIOPH RES CO, V257, P821, DOI 10.1006/bbrc.1999.0308; Hemmi H, 2003, J IMMUNOL, V170, P3059, DOI 10.4049/jimmunol.170.6.3059; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Herberman R B, 1978, Adv Cancer Res, V27, P305; HERZENBERG LA, 1980, EUR J IMMUNOL, V10, P1, DOI 10.1002/eji.1830100102; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hori S, 2003, ADV IMMUNOL, V81, P331, DOI 10.1016/S0065-2776(03)81008-8; Hornum Lars, 2004, Curr Diab Rep, V4, P135, DOI 10.1007/s11892-004-0069-6; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jahnsen FL, 2002, HUM IMMUNOL, V63, P1201, DOI 10.1016/S0198-8859(02)00759-0; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jankovic M, 2004, ANNU REV IMMUNOL, V22, P485, DOI 10.1146/annurev.immunol.22.012703.104707; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Jarrossay D, 2001, EUR J IMMUNOL, V31, P3388, DOI 10.1002/1521-4141(200111)31:11<3388::AID-IMMU3388>3.0.CO;2-Q; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kamath AT, 2000, J IMMUNOL, V165, P6762, DOI 10.4049/jimmunol.165.12.6762; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Karim M, 2002, CURR OPIN IMMUNOL, V14, P584, DOI 10.1016/S0952-7915(02)00379-5; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kiessling R, 1978, Contemp Top Immunobiol, V8, P171; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; Kim CH, 2003, J IMMUNOL, V171, P152, DOI 10.4049/jimmunol.171.1.152; Krieg AM, 2001, CURR OPIN MOL THER, V3, P15; Krieg AM, 1998, TRENDS MICROBIOL, V6, P23, DOI 10.1016/S0966-842X(97)01145-1; Krummel M, 2000, PHILOS T ROY SOC B, V355, P1071, DOI 10.1098/rstb.2000.0644; Kupfer A, 2003, SEMIN IMMUNOL, V15, P295, DOI 10.1016/j.smim.2003.09.001; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kyewski B, 2004, NAT REV IMMUNOL, V4, P688, DOI 10.1038/nri1436; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lanier LL, 2003, CURR OPIN IMMUNOL, V15, P308, DOI 10.1016/S0952-7915(03)00039-6; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Legge KL, 2002, J EXP MED, V196, P217, DOI 10.1084/jem.20011061; LeibundGut-Landmann S, 2004, NAT IMMUNOL, V5, P899, DOI 10.1038/ni1109; Liston A, 2004, J EXP MED, V200, P1015, DOI 10.1084/jem.20040581; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Long EO, 2002, SEMIN CANCER BIOL, V12, P57, DOI 10.1006/scbi.2001.0398; Lorenzo ME, 2001, SEMIN IMMUNOL, V13, P1, DOI 10.1006/smim.2000.0290; LOTZE MT, 1999, DENDRITIC CELLS BIOL; Lu L, 2002, TRANSPLANTATION, V73, pS19, DOI 10.1097/00007890-200201151-00008; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Maekawa Y, 2003, IMMUNITY, V19, P549, DOI 10.1016/S1074-7613(03)00270-X; Malek TR, 2003, J LEUKOCYTE BIOL, V74, P961, DOI 10.1189/jlb.0603272; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Manz MG, 2001, BLOOD, V97, P3333, DOI 10.1182/blood.V97.11.3333; Maraskovsky E, 1997, ADV EXP MED BIOL, V417, P33; Marshak-Rothstein A, 2004, RHEUM DIS CLIN N AM, V30, P559, DOI 10.1016/j.rdc.2004.04.005; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Meidenbauer N, 2003, METHODS, V31, P160, DOI 10.1016/S1046-2023(03)00126-9; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; METCHNIKOFF II, 1908, PRESENT STATE QUESTI; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Min WP, 2003, J IMMUNOL, V170, P1304, DOI 10.4049/jimmunol.170.3.1304; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Moylett EH, 2004, J ALLERGY CLIN IMMUN, V114, P206, DOI 10.1016/j.jaci.2004.01.782; Murphy, 2003, FUNDAMENTAL IMMUNOLO, P801; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; Naik S, 2003, BLOOD, V102, P601, DOI 10.1182/blood-2002-10-3186; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Newton K, 2000, Adv Immunol, V76, P179; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Palmer E, 2003, NAT REV IMMUNOL, V3, P383, DOI 10.1038/nri1085; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Park BY, 2004, IMMUNITY, V20, P71, DOI 10.1016/S1074-7613(03)00355-8; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Penna G, 2002, HUM IMMUNOL, V63, P1164, DOI 10.1016/S0198-8859(02)00755-3; Pentcheva-Hoang T, 2004, IMMUNITY, V21, P401, DOI 10.1016/j.immuni.2004.06.017; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137; Pisetsky DS, 2000, SPRINGER SEMIN IMMUN, V22, P21, DOI 10.1007/s002810000021; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pulendran B, 2004, IMMUNOL RES, V29, P187, DOI 10.1385/IR:29:1-3:187; Pulendran B, 2004, IMMUNOL REV, V199, P227, DOI 10.1111/j.0105-2896.2004.00144.x; Pulendran B, 2001, J IMMUNOL, V167, P5067, DOI 10.4049/jimmunol.167.9.5067; Radaev S, 2003, ANNU REV BIOPH BIOM, V32, P93, DOI 10.1146/annurev.biophys.32.110601.142347; Ramsdell F, 2003, IMMUNITY, V19, P165, DOI 10.1016/S1074-7613(03)00207-3; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Raulet DH, 2001, ANNU REV IMMUNOL, V19, P291, DOI 10.1146/annurev.immunol.19.1.291; Reid SD, 2000, CURR OPIN IMMUNOL, V12, P114, DOI 10.1016/S0952-7915(99)00059-X; Reijonen H, 2003, METHODS, V29, P282, DOI 10.1016/S1046-2023(02)00350-X; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; Rosatelli MC, 1998, HUM GENET, V103, P428, DOI 10.1007/s004390050846; Rosenberg SA, 2004, NEW ENGL J MED, V350, P1461, DOI 10.1056/NEJMcibr045001; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; Rouse BT, 2004, J IMMUNOL, V173, P2211, DOI 10.4049/jimmunol.173.4.2211; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; Schuler G, 2003, CURR OPIN IMMUNOL, V15, P138, DOI 10.1016/S0952-7915(03)00015-3; Scott HS, 1998, MOL ENDOCRINOL, V12, P1112, DOI 10.1210/me.12.8.1112; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; SHAW GB, DOCTORS DILEMMA; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Smith HRC, 2002, P NATL ACAD SCI USA, V99, P8826, DOI 10.1073/pnas.092258599; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; Stefanova I, 2002, NATURE, V420, P429, DOI 10.1038/nature01146; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; Steinman RM, 2003, APMIS, V111, P675, DOI 10.1034/j.1600-0463.2003.11107802.x; Steinman RM, 2003, ANN NY ACAD SCI, V987, P15, DOI 10.1111/j.1749-6632.2003.tb06029.x; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Steinman RM, 2001, INT J CANCER, V94, P459, DOI 10.1002/ijc.1503; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STOCKINGER B, 1994, INT IMMUNOL, V6, P247, DOI 10.1093/intimm/6.2.247; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; Sun JC, 2004, J IMMUNOL, V172, P3385, DOI 10.4049/jimmunol.172.6.3385; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Sutherland CL, 2001, IMMUNOL REV, V181, P185, DOI 10.1034/j.1600-065X.2001.1810115.x; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Taniguchi M, 2000, SEMIN IMMUNOL, V12, P543, DOI 10.1006/smim.2000.0270; TEIXEIRA HC, 1994, J IMMUNOL, V152, P1873; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; Traver D, 2000, SCIENCE, V290, P2152, DOI 10.1126/science.290.5499.2152; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839; Tsujimura H, 2003, BLOOD, V101, P961, DOI 10.1182/blood-2002-05-1327; Ulevitch R, 2001, CRIT CARE MED, V29, pS6; van Bergen J, 1999, IMMUNOL REV, V172, P87; van der Bruggen P, 2002, IMMUNOL REV, V188, P51, DOI 10.1034/j.1600-065X.2002.18806.x; VERSTEEG R, 1992, IMMUNOL TODAY, V13, P244, DOI 10.1016/0167-5699(92)90003-P; Vivier E, 2004, NAT REV IMMUNOL, V4, P190, DOI 10.1038/nri1306; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; Voigt V, 2003, P NATL ACAD SCI USA, V100, P13483, DOI 10.1073/pnas.2233572100; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; Weighardt H, 2004, EUR J IMMUNOL, V34, P558, DOI 10.1002/eji.200324714; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wilson HL, 2003, IMMUNOL CELL BIOL, V81, P239, DOI 10.1046/j.1440-1711.2003.t01-1-01165.x; Wu L, 2001, BLOOD, V98, P3376, DOI 10.1182/blood.V98.12.3376; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1084/jem.20030422; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; Young J W, 1999, Curr Opin Hematol, V6, P135, DOI 10.1097/00062752-199905000-00003; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; ZHOU D, 2004, SCIENCE         1111, DOI DOI 10.1126/SCIENCE.1103440; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; Zou GM, 2002, EUR CYTOKINE NETW, V13, P186	299	95	102	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1307	1320		10.1038/nm1159	http://dx.doi.org/10.1038/nm1159			14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15580257				2022-12-27	WOS:000225500900024
J	Ritchie, KJ; Hahn, CS; Kim, KI; Yan, M; Rosario, D; Li, L; de la Torre, JC; Zhang, DE				Ritchie, KJ; Hahn, CS; Kim, KI; Yan, M; Rosario, D; Li, L; de la Torre, JC; Zhang, DE			Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection	NATURE MEDICINE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; VESICULAR STOMATITIS-VIRUS; UBIQUITIN-LIKE PROTEIN; SINDBIS-VIRUS; INTERFERON; CELLS; MICE; ALPHA/BETA; RESPONSES; PATHWAYS	Innate immune responses provide the host with an early protection barrier against infectious agents, including viruses, and help shape the nature and quality of the subsequent adaptive immune responses of the host(1). Expression of ISG15 (UCRP), a ubiquitin-like protein, and protein ISGylation are highly increased upon viral infection(2-4). We have identified UBP43 (USP18) as an ISG15 deconjugating protease(5). Protein ISGylation is enhanced in cells deficient in UBP43 (ref. 6). Here we have examined the role of UBP43, encoded by the gene Usp18, in innate immunity to virus infection. Usp18(-/-) mice were resistant to the fatal lymphocytic choriomeningitis and myeloencephalitis that developed in wild-type mice after intracerebral inoculation with lymphocytic choriomeningitis virus ( LCMV) or vesicular stomatitis virus (VSV), respectively. Survival of Usp18(-/-) mice after intracerebral LCMV infection correlated with a severe inhibition of LCMV RNA replication and antigen expression in the brain and increased levels of protein ISGylation. Consistent with these findings, mouse embryonic fibroblasts (MEF) and bone marrow - derived macrophages from Usp18(-/-) mice showed restricted LCMV replication. Moreover, MEF from Usp18(-/-) mice showed enhanced interferon-mediated resistance to the cytopathic effect caused by VSV and Sindbis virus (SNV). This report provides the first direct evidence that the ISG15 protease UBP43 and possibly protein ISGylation have a role in innate immunity against viral infection.	Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Aventis Pharmaceut, Immunol Platform, Bridgewater, NJ 08807 USA	Scripps Research Institute; Scripps Research Institute; Sanofi-Aventis	de la Torre, JC (corresponding author), Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA.	juanct@scripps.edu; dzhang@scripps.edu	KIM, KEUN IL/D-2959-2011	Ritchie, Kenneth/0000-0002-8504-6918	NCI NIH HHS [CA079849] Funding Source: Medline; NIAID NIH HHS [AI047140] Funding Source: Medline; NIGMS NIH HHS [GM066955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI047140, R01AI047140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biron CA, 1999, CURR OPIN MICROBIOL, V2, P374; BUCHMEIER MJ, 2000, FIELDS VIROLOGY, P1635; Cousens LP, 1999, J EXP MED, V189, P1315, DOI 10.1084/jem.189.8.1315; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Doherty P C, 1988, Ann N Y Acad Sci, V540, P228, DOI 10.1111/j.1749-6632.1988.tb27065.x; DUTKO FJ, 1983, J GEN VIROL, V64, P1689, DOI 10.1099/0022-1317-64-8-1689; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; GRESSER I, 1962, VIROLOGY, V16, P428, DOI 10.1016/0042-6822(62)90223-4; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hahn YS, 1999, J IMMUNOL, V162, P69; Hamerman JA, 2002, J IMMUNOL, V168, P2415, DOI 10.4049/jimmunol.168.5.2415; HOLLAND JJ, 1989, J VIROL, V63, P5030, DOI 10.1128/JVI.63.12.5030-5036.1989; Homann D, 1998, J VIROL, V72, P9208, DOI 10.1128/JVI.72.11.9208-9216.1998; ITO Y, 1977, INFECT IMMUN, V18, P23, DOI 10.1128/IAI.18.1.23-27.1977; Kim KI, 2003, BIOCHEM BIOPH RES CO, V307, P431, DOI 10.1016/S0006-291X(03)01216-6; LEIST TP, 1987, J GEN VIROL, V68, P2213, DOI 10.1099/0022-1317-68-8-2213; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; McGavern DB, 2002, J INFECT DIS, V186, pS145, DOI 10.1086/344264; MERIGAN TC, 1977, NATURE, V268, P67, DOI 10.1038/268067a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Ou R, 2001, J VIROL, V75, P8407, DOI 10.1128/JVI.75.18.8407-8423.2001; PFAU CJ, 1983, J GEN VIROL, V64, P1827, DOI 10.1099/0022-1317-64-8-1827; Pinschewer DD, 2003, P NATL ACAD SCI USA, V100, P7895, DOI 10.1073/pnas.1332709100; Ritchie KJ, 2002, GENE DEV, V16, P2207, DOI 10.1101/gad.1010202; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362	30	215	224	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1374	1378		10.1038/nm1133	http://dx.doi.org/10.1038/nm1133			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15531891				2022-12-27	WOS:000225500900032
J	Fan, XH; Ang, A; BarZiv, SMP; Dipchand, AI; Ruiz, P; Wilson, G; Platt, JL; West, LJ				Fan, XH; Ang, A; BarZiv, SMP; Dipchand, AI; Ruiz, P; Wilson, G; Platt, JL; West, LJ			Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation	NATURE MEDICINE			English	Article							REACTIVE LYMPHOCYTES-B; IMMUNE-SYSTEM; CARDIAC TRANSPLANTATION; CLONAL ELIMINATION; ESCAPE TOLERANCE; RENAL-ALLOGRAFTS; SELF-TOLERANCE; ANTIGENS; MAINTENANCE; DELETION	Although over 50 years have passed since its first laboratory description, intentional induction of immune tolerance to foreign antigens has remained an elusive clinical goal. We previously reported that the requirement for ABO compatibility in heart transplantation is not applicable to infants. Here, we show that ABO-incompatible heart transplantation during infancy results in development of B-cell tolerance to donor blood group A and B antigens. This mimics animal models of neonatal tolerance and indicates that the human infant is susceptible to intentional tolerance induction. Tolerance in this setting occurs by elimination of donor-reactive B lymphocytes and may be dependent upon persistence of some degree of antigen expression. These findings suggest that intentional exposure to nonself A and B antigens may prolong the window of opportunity for ABO-incompatible transplantation, and have profound implications for clinical research on tolerance induction to T-independent antigens relevant to xenotransplantation.	Hosp Sick Children, Dept Pediat, Infect Immun Injury & Repair Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Div Cardiol, Toronto, ON M5G 1X8, Canada; Univ Miami, Sch Med, Jackson Mem Hosp, Dept Pathol, Miami, FL 33136 USA; Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Mayo Clin, Dept Transplantat Biol, Rochester, MN 55905 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Miami; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Mayo Clinic	West, LJ (corresponding author), Hosp Sick Children, Dept Pediat, Infect Immun Injury & Repair Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	lori.west@sickkids.ca	Platt, Jeffrey/AHB-0480-2022	West, Lori/0000-0002-1990-3651; Platt, Jeffrey/0000-0002-4915-0419				ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538; BANNETT AD, 1989, TRANSPLANT P, V21, P783; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Burnet FM, 1949, PRODUCTION ANTIBODIE; Cadoz M, 1998, VACCINE, V16, P1391, DOI 10.1016/S0264-410X(98)00097-8; Chelvarajan RL, 1998, J IMMUNOL, V161, P3315; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; CHOPEK MW, 1987, TRANSPLANT P, V19, P4553; COOPER DKC, 1990, TRANSPLANT P, V22, P1457; DORSCH S, 1982, TRANSPLANTATION, V33, P518, DOI 10.1097/00007890-198205000-00011; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FONG SW, 1974, TRANSFUSION, V14, P551, DOI 10.1111/j.1537-2995.1974.tb04576.x; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Gennery AR, 1998, LANCET, V351, P1778, DOI 10.1016/S0140-6736(97)08486-9; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GUGENHEIM J, 1990, LANCET, V336, P519, DOI 10.1016/0140-6736(90)92082-S; Hamano K, 1996, TRANSPLANTATION, V62, P856, DOI 10.1097/00007890-199609270-00026; HAMMARSTROM L, 1986, CLIN EXP IMMUNOL, V66, P457; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Holsapple MP, 2003, BIRTH DEFECTS RES B, V68, P321, DOI 10.1002/bdrb.10035; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Lang J, 2000, EUR J IMMUNOL, V30, P689, DOI 10.1002/1521-4141(200002)30:2<689::AID-IMMU689>3.0.CO;2-I; Lin SS, 2000, TRANSPLANTATION, V70, P1667, DOI 10.1097/00007890-200012270-00002; Luo W, 1999, CELL IMMUNOL, V195, P1, DOI 10.1006/cimm.1999.1516; MCCARTHY SA, 1983, J IMMUNOL, V131, P1676; MOLLISON PL, 1993, BLOOD TRANSFUSION CL, P155; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; MORECKI S, 1987, J EXP MED, V165, P1468, DOI 10.1084/jem.165.6.1468; NAKAFUSA Y, 1993, SURGERY, V114, P183; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Noris M, 2001, J AM SOC NEPHROL, V12, P2815, DOI 10.1681/ASN.V12122815; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PERICO N, 1995, J AM SOC NEPHROL, V5, P1618; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SMALLEY CE, 1983, BRIT J HAEMATOL, V54, P209, DOI 10.1111/j.1365-2141.1983.tb02089.x; SPLAWSKI JB, 1991, J CLIN INVEST, V88, P967, DOI 10.1172/JCI115400; SPRINGER GF, 1969, J CLIN INVEST, V48, P1280, DOI 10.1172/JCI106094; STREILEIN JW, 1991, TRANSPLANTATION, V52, P1, DOI 10.1097/00007890-199107000-00001; SUTHERLAND DER, 1984, TRANSPLANTATION, V38, P619, DOI 10.1097/00007890-198412000-00015; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; Wang CM, 2001, TRANSPLANTATION, V72, P44, DOI 10.1097/00007890-200107150-00011; West LJ, 2002, HUM EXP TOXICOL, V21, P499, DOI 10.1191/0960327102ht288oa; West LJ, 2002, TRANSPL IMMUNOL, V9, P149, DOI 10.1016/S0966-3274(02)00044-8; West LJ, 2001, NEW ENGL J MED, V344, P793, DOI 10.1056/NEJM200103153441102; WILSON CB, 1986, J PEDIATR-US, V108, P1, DOI 10.1016/S0022-3476(86)80761-2; Yamada K, 1997, J EXP MED, V186, P497, DOI 10.1084/jem.186.4.497	50	161	165	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1227	1233		10.1038/nm1126	http://dx.doi.org/10.1038/nm1126			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502841				2022-12-27	WOS:000224785900045
J	Kaneto, H; Nakatani, Y; Miyatsuka, T; Kawamori, D; Matsuoka, T; Matsuhisa, M; Kajimoto, Y; Ichijo, H; Yamasaki, Y; Hori, M				Kaneto, H; Nakatani, Y; Miyatsuka, T; Kawamori, D; Matsuoka, T; Matsuhisa, M; Kajimoto, Y; Ichijo, H; Yamasaki, Y; Hori, M			Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide	NATURE MEDICINE			English	Article							BETA-CELL; PROTEIN TRANSDUCTION; TERMINAL KINASE; NITRIC-OXIDE; APOPTOSIS; DELIVERY; BINDS; ASK1	The JNK pathway is known to be activated in several tissues in the diabetic state, and is possibly involved in the development of insulin resistance and suppression of insulin biosynthesis. Here we show a potential new therapy for diabetes using cell-permeable JNK-inhibitory peptide. Intraperitoneal administration of the peptide led to its transduction into various tissues in vivo, and this treatment markedly improved insulin resistance and ameliorated glucose tolerance in diabetic mice. These data indicate that the JNK pathway is critically involved in diabetes and that the cell-permeable JNK-inhibitory peptide may have promise as a new therapeutic agent for diabetes.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, CREST, Bunkyo Ku, Tokyo 1130033, Japan	Osaka University; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Kaneto, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaneto@medone.med.osaka-u.ac.jp		Ichijo, Hidenori/0000-0002-5005-6438				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; Kawamori D, 2003, DIABETES, V52, P2896, DOI 10.2337/diabetes.52.12.2896; Mandrup-Poulsen T, 2001, DIABETES, V50, pS58, DOI 10.2337/diabetes.50.2007.S58; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Noguchi H, 2004, NAT MED, V10, P305, DOI 10.1038/nm994; Noguchi H, 2003, DIABETES, V52, P1732, DOI 10.2337/diabetes.52.7.1732; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523	25	279	300	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1128	1132		10.1038/nm1111	http://dx.doi.org/10.1038/nm1111			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15448687				2022-12-27	WOS:000224245800045
J	An, J; Muoio, DM; Shiota, M; Fujimoto, Y; Cline, GW; Shulman, GI; Koves, TR; Stevens, R; Millington, D; Newgard, CB				An, J; Muoio, DM; Shiota, M; Fujimoto, Y; Cline, GW; Shulman, GI; Koves, TR; Stevens, R; Millington, D; Newgard, CB			Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance	NATURE MEDICINE			English	Article							FATTY-ACID OXIDATION; SKELETAL-MUSCLE; PPAR-ALPHA; GLUCOSE; METABOLISM; RECEPTOR; OBESITY; MICE; RATS; OVEREXPRESSION	Lipid infusion or ingestion of a high-fat diet results in insulin resistance, but the mechanism underlying this phenomenon remains unclear. Here we show that, in rats fed a high-fat diet, whole-animal, muscle and liver insulin resistance is ameliorated following hepatic overexpression of malonyl-coenzyme A (CoA) decarboxylase (MCD), an enzyme that affects lipid partitioning. MCD overexpression decreased circulating free fatty acid (FFA) and liver triglyceride content. In skeletal muscle, levels of triglyceride and long-chain acyl-CoA (LC-CoA)-two candidate mediators of insulin resistance-were either increased or unchanged. Metabolic profiling of 36 acylcarnitine species by tandem mass spectrometry revealed a unique decrease in the concentration of one lipid-derived metabolite, beta-OH-butyrate, in muscle of MCD-overexpressing animals. The best explanation for our findings is that hepatic expression of MCD lowered circulating FFA levels, which led to lowering of muscle beta-OH-butyrate levels and improvement of insulin sensitivity.	Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06536 USA	Duke University; Duke University; Duke University; Vanderbilt University; Yale University	Newgard, CB (corresponding author), Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA.	newga002@mc.duke.edu	Koves, Tim/I-4806-2012; Shulman, Gerald I./P-7176-2019; Muoio, Debbie Marie/E-1147-2012	Koves, Tim/0000-0001-8763-5866; Shulman, Gerald I./0000-0003-1529-5668; Muoio, Deborah/0000-0003-3760-9277	NIDDK NIH HHS [R01 DK040936, P01DK58398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398, R01DK040936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Buettner R, 2000, AM J PHYSIOL-ENDOC M, V278, pE563, DOI 10.1152/ajpendo.2000.278.3.E563; CHU AC, IN PRESS AM J PHYSL; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Guerre-Millo M, 2001, DIABETES, V50, P2809, DOI 10.2337/diabetes.50.12.2809; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; HOLNESS MJ, 1991, BIOCHEM J, V277, P429, DOI 10.1042/bj2770429; HOPPELER H, 1985, J APPL PHYSIOL, V59, P320, DOI 10.1152/jappl.1985.59.2.320; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MASCARO C, 1995, ARCH BIOCHEM BIOPHYS, V317, P385, DOI 10.1006/abbi.1995.1178; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; MCGARRY JD, 1991, BIOCHIMIE, V73, P77, DOI 10.1016/0300-9084(91)90078-F; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; MILLINGTON DS, 1990, J INHERIT METAB DIS, V13, P321, DOI 10.1007/BF01799385; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; NEWGARD CB, 1984, J BIOL CHEM, V259, P6958; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; RUDERMAN NB, 1977, FED PROC, V36, P171; RUSSELL RR, 1991, J CLIN INVEST, V87, P384, DOI 10.1172/JCI115008; RUSSELL RR, 1992, J CLIN INVEST, V89, P968, DOI 10.1172/JCI115679; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; SINGH BM, 1993, DIABETES RES CLIN PR, V20, P55, DOI 10.1016/0168-8227(93)90023-X; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Tardif A, 2001, AM J PHYSIOL-ENDOC M, V281, pE1205, DOI 10.1152/ajpendo.2001.281.6.E1205; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	46	355	363	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					268	274		10.1038/nm995	http://dx.doi.org/10.1038/nm995			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14770177				2022-12-27	WOS:000189297700038
J	Heikenwalder, M; Polymenidou, M; Junt, T; Sigurdson, C; Wagner, H; Akira, S; Zinkernagel, R; Aguzzi, A				Heikenwalder, M; Polymenidou, M; Junt, T; Sigurdson, C; Wagner, H; Akira, S; Zinkernagel, R; Aguzzi, A			Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; CONTAINING OLIGONUCLEOTIDES; MICE LACKING; RESPONSES; DNA; PATHOGENESIS; ACTIVATION; DISEASE; INTERFERON	DNA containing unmethylated cytidyl guanosyl (CpG) sequences, which are underrepresented in mammalian genomes but prevalent in prokaryotes, is endocytosed by cells of the innate immune system, including macrophages, monocytes and dendritic cells 1, and activates a pathway involving Toll-like receptor-9 (TLR9) 2. CpG-containing oligodeoxynucleotides (CpG-ODN) are potent stimulators of innate immunity, and are currently being tested as adjuvants of antimicrobial, antiallergic, anticancer and antiprion immunotherapy. Little is known, however, about the consequences of repeated CpG-ODN administration, which is advocated for some of these applications. Here we report that daily injection of 60 mug CpG-ODN dramatically alters the morphology and functionality of mouse lymphoid organs. By day 7, lymphoid follicles were poorly defined; follicular dendritic cells (FDC) and germinal center B lymphocytes were suppressed. Accordingly, CpG-ODN treatment for greater than or equal to7 d strongly reduced primary humoral immune responses and immunoglobulin class switching. By day 20, mice developed multifocal liver necrosis and hemorrhagic ascites. All untoward effects were strictly dependent on CpG and TLR9, as neither the CpG-ODN treatment of Tlr9(-/-) mice nor the repetitive challenge of wild-type mice with nonstimulatory ODN (AT-ODN) or with the TLR3 agonist polyinosinic: cytidylic acid (polyl:C) were immunotoxic or hepatotoxic.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Munich; Osaka University	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Aguzzi, Adriano/A-3351-2008; Heikenwalder, Mathias/AAA-2269-2020; Junt, Tobias/AAE-4389-2021; Akira, Shizuo/C-3134-2009; Polymenidou, Magdalini/D-2254-2014	Aguzzi, Adriano/0000-0002-0344-6708	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001802] Funding Source: NIH RePORTER; NIAID NIH HHS [K08-AI01802] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aucouturier P, 2001, J CLIN INVEST, V108, P703, DOI 10.1172/JCI200113155; Binder D, 1997, J EXP MED, V185, P517, DOI 10.1084/jem.185.3.517; Davila E, 2000, J IMMUNOL, V165, P539, DOI 10.4049/jimmunol.165.1.539; Davila E, 2002, BLOOD, V100, P2537, DOI 10.1182/blood-2002-02-0401; Fehr T, 2000, INT IMMUNOL, V12, P1275, DOI 10.1093/intimm/12.9.1275; Gilch S, 2003, J BIOL CHEM, V278, P18524, DOI 10.1074/jbc.M210723200; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Karrer U, 2000, J IMMUNOL, V164, P768, DOI 10.4049/jimmunol.164.2.768; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; ODERMATT B, 1991, P NATL ACAD SCI USA, V88, P8252, DOI 10.1073/pnas.88.18.8252; Oxenius A, 1999, J VIROL, V73, P4120, DOI 10.1128/JVI.73.5.4120-4126.1999; Prinz M, 2003, NATURE, V425, P957, DOI 10.1038/nature02072; Prinz M, 2003, EMBO REP, V4, P195, DOI 10.1038/sj.embor.embor731; RIVIERE Y, 1977, P NATL ACAD SCI USA, V74, P2135, DOI 10.1073/pnas.74.5.2135; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Schmidt U, 1999, CELL MICROBIOL, V1, P61, DOI 10.1046/j.1462-5822.1999.00007.x; Sethi S, 2002, LANCET, V360, P229, DOI 10.1016/S0140-6736(02)09513-2; Sparwasser T, 1999, J IMMUNOL, V162, P2368; Storni T, 2002, J IMMUNOL, V168, P2880, DOI 10.4049/jimmunol.168.6.2880; Vabulas RM, 2000, J IMMUNOL, V164, P2372, DOI 10.4049/jimmunol.164.5.2372	30	369	395	2	30	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					187	192		10.1038/nm987	http://dx.doi.org/10.1038/nm987			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14745443				2022-12-27	WOS:000188719600039
J	Taylor, TE; Fu, WJJ; Carr, RA; Whitten, RO; Mueller, JG; Fosiko, NG; Lewallen, S; Liomba, NG; Molyneux, ME				Taylor, TE; Fu, WJJ; Carr, RA; Whitten, RO; Mueller, JG; Fosiko, NG; Lewallen, S; Liomba, NG; Molyneux, ME			Differentiating the pathologies of cerebral malaria by postmortem parasite counts	NATURE MEDICINE			English	Article							FALCIPARUM-MALARIA; AFRICAN CHILDREN	To study the pathogenesis of fatal cerebral malaria, we conducted autopsies in 31 children with this clinical diagnosis. We found that 23% of the children had actually died from other causes. The remaining patients had parasites sequestered in cerebral capillaries, and 75% of those had additional intra- and perivascular pathology. Retinopathy was the only clinical sign distinguishing malarial from nonmalarial coma. These data have implications for treating malaria patients, designing clinical trials and assessing malaria-specific disease associations.	Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA; Blantyre Malaria Project, Blantyre 3, Malawi; Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA; S Warwickshire Gen Hosp NHS Trust, Pathol Lab, Warwick CV34 5BH, England; Black Hills Pathol, Olympia, WA 98506 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Tumaini Univ, KCMC, Kilimanjaro Ctr Community Ophthalmol, Moshi, Tanzania; Univ Malawi, Coll Med, Dept Histopathol, Blantyre 3, Malawi; Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre 3, Malawi; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Michigan State University; Michigan State University College of Osteopathic Medicine; Michigan State University; Vanderbilt University; University of Malawi; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool	Taylor, TE (corresponding author), Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.	taylort@msu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034969] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90301] Funding Source: Medline; NIAID NIH HHS [R01 AI034969, R01 AO34969] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; Breiman L, 1993, CLASSIFICATION REGRE; Lewallen S, 1999, T ROY SOC TROP MED H, V93, P619, DOI 10.1016/S0035-9203(99)90071-8; Marsh K, 1996, ANN TROP MED PARASIT, V90, P395, DOI 10.1080/00034983.1996.11813068; Newton CRJC, 1998, AM J TROP MED HYG, V58, P673, DOI 10.4269/ajtmh.1998.58.673; SILAMUT K, 1993, T ROY SOC TROP MED H, V87, P436, DOI 10.1016/0035-9203(93)90028-O	6	490	495	0	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2004	10	2					143	145		10.1038/nm986	http://dx.doi.org/10.1038/nm986			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14745442				2022-12-27	WOS:000188719600031
J	Saez, E; Olson, P; Evans, RM				Saez, E; Olson, P; Evans, RM			Genetic deficiency in Pparg does not alter development of experimental prostate cancer	NATURE MEDICINE			English	Article							ACTIVATED RECEPTOR-GAMMA; COLON-CANCER	The role of the nuclear peroxisome proliferator-activated receptor (PPAR)-gamma in cancer has been a subject of debate. The identification of loss-of-function mutations in PPARG in colon and prostate tumors has led to the idea that this gene may function as a tumor suppressor. We have directly tested this notion using a mouse model of prostate cancer. Neither hemizygous deletion of Pparg nor complete ablation of Ppara influenced the development of prostate cancer in our experimental context.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92037 USA	Salk Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	Evans, RM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				Collett GP, 2000, CLIN CANCER RES, V6, P3241; Huss WJ, 2001, SEMIN CANCER BIOL, V11, P245, DOI 10.1006/scbi.2001.0373; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; PATTOO D, 2003, CANC LETT, V191, P67; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5	8	26	28	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1265	1266		10.1038/nm928	http://dx.doi.org/10.1038/nm928			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12960963				2022-12-27	WOS:000185669700035
J	Mazurier, F; Doedens, M; Gan, OI; Dick, JE				Mazurier, F; Doedens, M; Gan, OI; Dick, JE			Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells	NATURE MEDICINE			English	Article							HUMAN HEMATOPOIETIC-CELLS; BONE-MARROW; SEEDING EFFICIENCY; LONG-TERM; IN-VITRO; BLOOD; ENGRAFTMENT; EXPANSION; ASSAY	A major problem hampering effective stem cell-based therapies is the absence of a clear understanding of the human hematopoietic stem cell (HSC) pool composition. The severe combined immunodeficiency (SCID) repopulating cell (SRC) xenotransplant assay system provides a powerful tool for characterizing the frequency, cell surface markers, cell cycle status, homing and response to cytokine stimulation of human HSCs1-3. Clonal tracking of retrovirally transduced SRCs and transplantation of specific subpopulations revealed SRC classes with distinct repopulation potentials(4-7). However, all HSC repopulation assays are based on intravenous injection, a complex process that requires circulation through blood, recognition and extravasation through bone marrow vasculature, and migration to a supportive microenvironment(8-11). Thus, some classes of HSCs may remain undetected. By direct intrafemoral injection, we identified rapid SRCs (R-SRCs) within the Lin(-)CD34(+)CD38(lo)CD36(-) subpopulation. R-SRCs rapidly generate high levels of human myeloid and erythroid cells within the injected femur, migrate to the blood and colonize individual bones of non-obese diabetic (NOD)-SCID mice within 2 weeks after transplantation. Lentivector-mediated clonal analysis of individual R-SRCs revealed heterogeneity in their proliferative and migratory properties. The identification of a new HSC class and an effective intrafemoral assay provide the tools required to develop more effective stem cell-based therapies that rely on rapid reconstitution.	Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Mol Genet & Microbiol, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Dick, JE (corresponding author), Univ Hlth Network, Div Cell & Mol Biol, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.	jdick@uhnres.utoronto.ca		Mazurier, Frederic/0000-0002-6984-7096; Dick, John/0000-0002-9527-8317				Ando K, 2000, EXP HEMATOL, V28, P690, DOI 10.1016/S0301-472X(00)00154-5; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; BOGGS DR, 1984, AM J HEMATOL, V16, P277, DOI 10.1002/ajh.2830160309; Bonnet D, 2002, J PATHOL, V197, P430, DOI 10.1002/path.1153; Cashman JD, 2000, BLOOD, V96, P3979, DOI 10.1182/blood.V96.12.3979.h8003979_3979_3981; Cashman JD, 1997, BLOOD, V89, P4307, DOI 10.1182/blood.V89.12.4307; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Glimm H, 2001, J CLIN INVEST, V107, P199, DOI 10.1172/JCI11519; Guenechea G, 2000, MOL THER, V1, P566, DOI 10.1006/mthe.2000.0077; Guenechea G, 2001, NAT IMMUNOL, V2, P75, DOI 10.1038/83199; Hagglund H, 1998, BONE MARROW TRANSPL, V21, P331, DOI 10.1038/sj.bmt.1701116; Hogan CJ, 2002, P NATL ACAD SCI USA, V99, P413, DOI 10.1073/pnas.012336799; Kerre TCC, 2001, J IMMUNOL, V167, P3692, DOI 10.4049/jimmunol.167.7.3692; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Lemischka IR, 2001, NAT IMMUNOL, V2, P11, DOI 10.1038/83115; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Quesenberry PJ, 1998, P NATL ACAD SCI USA, V95, P15155, DOI 10.1073/pnas.95.26.15155; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; van Hennik PB, 1999, BLOOD, V94, P3055, DOI 10.1182/blood.V94.9.3055.421k05_3055_3061; WANG JC, 2001, HEMATOPOIESIS DEV AP, P99; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Wang JF, 2003, BLOOD, V101, P2924, DOI 10.1182/blood-2002-09-2782; Yahata T, 2003, BLOOD, V101, P2905, DOI 10.1182/blood-2002-07-1995	25	222	240	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					959	963		10.1038/nm886	http://dx.doi.org/10.1038/nm886			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12796774				2022-12-27	WOS:000183979300039
J	Gladwin, MT; Lancaster, JR; Freeman, BA; Schechter, AN				Gladwin, MT; Lancaster, JR; Freeman, BA; Schechter, AN			Nitric oxide's reactions with hemoglobin: a view through the SNO-storm	NATURE MEDICINE			English	Editorial Material							HYPOXIC PULMONARY VASOCONSTRICTION; REGIONAL BLOOD-FLOW; S-NITROSOHEMOGLOBIN; BIOCHEMICAL-CHARACTERIZATION; CORONARY-CIRCULATION; ENDOTHELIAL-CELLS; RELAXING FACTOR; OXYGEN-BINDING; NO; NITROSATION		NIDDKD, Dept Crit Care Med, Warren G Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NIDDKD, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL USA; Univ Alabama Birmingham, UAB Ctr Free Rad Biol, Birmingham, AL USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Gladwin, MT (corresponding author), NIDDKD, Dept Crit Care Med, Warren G Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA.	mgladwin@nih.gov	Freeman, Bruce A/H-9342-2012	Schechter, Alan N/0000-0002-5235-9408	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025093, ZIADK025093] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agvald P, 2002, BRIT J PHARMACOL, V135, P373, DOI 10.1038/sj.bjp.0704489; AMEZCUA JL, 1989, BRIT J PHARMACOL, V97, P1119, DOI 10.1111/j.1476-5381.1989.tb12569.x; Butler AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; CHU A, 1991, J CLIN INVEST, V87, P1964, DOI 10.1172/JCI115223; COIN JT, 1979, J BIOL CHEM, V254, P1178; CRAWFORD JH, 2003, BLOOD           0130, DOI DOI 10.1182/BLOOD-2002-12-3825; Deem S, 2002, CIRC RES, V91, P626, DOI 10.1161/01.RES.0000036268.47509.02; Deem S, 2001, AM J RESP CRIT CARE, V163, P1164, DOI 10.1164/ajrccm.163.5.2007172; Deem S, 1998, AM J RESP CRIT CARE, V157, P1181, DOI 10.1164/ajrccm.157.4.9707165; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Dou Y, 2002, BIOPHYS CHEM, V98, P127, DOI 10.1016/S0301-4622(02)00090-X; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Espey MG, 2002, P NATL ACAD SCI USA, V99, P11127, DOI 10.1073/pnas.152157599; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Fernandez BO, 2003, INORG CHEM, V42, P2, DOI 10.1021/ic020519r; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GAREL MC, 1986, J BIOL CHEM, V261, P4704; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; Han TH, 2002, P NATL ACAD SCI USA, V99, P7763, DOI 10.1073/pnas.122118299; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Hobbs AJ, 2002, TRENDS PHARMACOL SCI, V23, P406, DOI 10.1016/S0165-6147(02)02067-9; Huang KT, 2001, P NATL ACAD SCI USA, V98, P11771, DOI 10.1073/pnas.201276698; Huang Z, 2002, BIOCHEM BIOPH RES CO, V292, P812, DOI 10.1006/bbrc.2002.6730; Huang Z, 2001, BBA-GEN SUBJECTS, V1568, P252, DOI 10.1016/S0304-4165(01)00227-6; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699; Jourd'heuil D, 2000, BIOCHEM BIOPH RES CO, V273, P22, DOI 10.1006/bbrc.2000.2892; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Lim DG, 2002, P NATL ACAD SCI USA, V99, P15941, DOI 10.1073/pnas.232409599; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Luchsinger BP, 2003, P NATL ACAD SCI USA, V100, P461, DOI 10.1073/pnas.0233287100; Marley R, 2001, FREE RADICAL BIO MED, V31, P688, DOI 10.1016/S0891-5849(01)00627-X; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; McMahon TJ, 1999, METHOD ENZYMOL, V301, P99; *NOB FDN, 1999, PRIX NOB 1998, P210; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANZA JA, 1993, CIRCULATION, V87, P1468, DOI 10.1161/01.CIR.87.5.1468; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Perutz MF, 1996, NATURE, V380, P205, DOI 10.1038/380205b0; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; Rassaf T, 2002, J CLIN INVEST, V109, P1241, DOI 10.1172/JCI200214995; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Rossi R, 2001, CIRC RES, V89; Schechter AN, 2002, J CLIN INVEST, V109, P1149, DOI 10.1172/JCI200215637; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Spencer NY, 2002, FREE RADICAL BIO MED, V33, pS381; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Vaughn MW, 1998, AM J PHYSIOL-HEART C, V274, pH1705, DOI 10.1152/ajpheart.1998.274.5.H1705; Vaughn MW, 2000, J BIOL CHEM, V275, P2342, DOI 10.1074/jbc.275.4.2342; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983; Zhang Y, 2002, FREE RADICAL BIO MED, V32, P1212, DOI 10.1016/S0891-5849(02)00829-8	66	239	245	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2003	9	5					496	500		10.1038/nm0503-496	http://dx.doi.org/10.1038/nm0503-496			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12724752				2022-12-27	WOS:000182610600016
J	Hudson, PJ; Souriau, C				Hudson, Peter J.; Souriau, Christelle			Engineered antibodies	NATURE MEDICINE			English	Review							IN-VITRO; MONOCLONAL-ANTIBODIES; AFFINITY MATURATION; DIRECTED EVOLUTION; CAPTURE TECHNOLOGY; HUMAN-IGG; PHAGE; EXPRESSION; FRAGMENTS; BINDING	Engineered antibodies now represent over 30% of biopharmaceuticals in clinical trials, as highlighted by recent approvals from the US Food and Drug Administration. Recombinant antibodies have been reduced in size, rebuilt into multivalent molecules and fused with, for example radionuclides, toxins, enzymes, liposomes and viruses. The emergence of recombinant technologies has revolutionized the selection, humanization and production of antibodies, superseding hybridoma technology and allowing the design of antibody-based reagents of any specificity and for very diverse purposes.	[Hudson, Peter J.; Souriau, Christelle] CSIRO Hlth Sci & Nutr, CRC Diagnost, Parkville, Vic, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Hudson, PJ (corresponding author), CSIRO Hlth Sci & Nutr, CRC Diagnost, Parkville, Vic, Australia.	peter.hudson@csiro.au						Adams GP, 2001, CANCER RES, V61, P4750; [Anonymous], J AM MED ASS; Arafat W, 2000, CANCER GENE THER, V7, P1250, DOI 10.1038/sj.cgt.7700228; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; Cardarelli PM, 2002, CANCER IMMUNOL IMMUN, V51, P15, DOI 10.1007/s00262-001-0247; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Casey JL, 2002, BRIT J CANCER, V86, P1401, DOI 10.1038/sj.bjc.6600198; Chester KA, 2000, DIS MARKERS, V16, P53, DOI 10.1155/2000/672706; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cochet O, 1998, CANCER RES, V58, P1170; Daugherty PS, 2000, J IMMUNOL METHODS, V243, P211, DOI 10.1016/S0022-1759(00)00236-2; de Graaf Michelle, 2002, Methods Mol Biol, V178, P379; de Wildt RMT, 2002, P NATL ACAD SCI USA, V99, P8530, DOI 10.1073/pnas.132008499; Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200; Eshhar Z, 2001, J IMMUNOL METHODS, V248, P67, DOI 10.1016/S0022-1759(00)00343-4; Ewert S, 2002, BIOCHEMISTRY-US, V41, P3628, DOI 10.1021/bi011239a; Fujioka Y, 2001, BIOCONJUGATE CHEM, V12, P178, DOI 10.1021/bc000066j; Goel A, 2001, J NUCL MED, V42, P1519; Goldenberg DM, 2002, J NUCL MED, V43, P693; Goncalves J, 2002, J BIOL CHEM, V277, P32036, DOI 10.1074/jbc.M201906200; Gura T, 2002, NATURE, V417, P584, DOI 10.1038/417584a; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; He YX, 2002, J IMMUNOL, V169, P595, DOI 10.4049/jimmunol.169.1.595; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Huie MA, 2001, P NATL ACAD SCI USA, V98, P2682, DOI 10.1073/pnas.051631798; Irving RA, 2001, J IMMUNOL METHODS, V248, P31, DOI 10.1016/S0022-1759(00)00341-0; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Kim M, 2002, NUCL MED BIOL, V29, P139, DOI 10.1016/S0969-8051(01)00296-7; Kipriyanov SM, 2002, J IMMUNOL, V169, P137, DOI 10.4049/jimmunol.169.1.137; Kousparou CA, 2002, INT J CANCER, V99, P138, DOI 10.1002/ijc.10266; Krebs B, 2001, J IMMUNOL METHODS, V254, P67, DOI 10.1016/S0022-1759(01)00398-2; Kreitman R. J., 2001, Current Pharmaceutical Biotechnology, V2, P313, DOI 10.2174/1389201013378635; Kurtzman AL, 2001, CURR OPIN BIOTECH, V12, P361, DOI 10.1016/S0958-1669(00)00228-7; Lecerf JM, 2001, P NATL ACAD SCI USA, V98, P4764, DOI 10.1073/pnas.071058398; Leong SR, 2001, CYTOKINE, V16, P106, DOI 10.1006/cyto.2001.0936; Liu B, 2002, J MOL BIOL, V315, P1063, DOI 10.1006/jmbi.2001.5276; Lunde E, 2002, J IMMUNOL, V168, P2154, DOI 10.4049/jimmunol.168.5.2154; Marty C, 2002, BRIT J CANCER, V87, P106, DOI 10.1038/sj.bjc.6600423; Maynard JA, 2002, NAT BIOTECHNOL, V20, P597, DOI 10.1038/nbt0602-597; Meanwell NA, 2000, DRUG DISCOV TODAY, V5, P241, DOI 10.1016/S1359-6446(00)01500-2; Mhashilkar AM, 2002, GENE THER, V9, P307, DOI 10.1038/sj.gt.3301656; Milstein C, 2000, IMMUNOL TODAY, V21, P359, DOI 10.1016/S0167-5699(00)01660-1; Muyldermans S, 2001, J Biotechnol, V74, P277; Nagy ZA, 2002, NAT MED, V8, P801, DOI 10.1038/nm736; Neuberger MS, 2000, APPL BIOCHEM BIOTECH, V83, P53, DOI 10.1385/ABAB:83:1-3:53; Newton DL, 2001, EXPERT OPIN BIOL TH, V1, P995, DOI 10.1517/14712598.1.6.995; Nielsen UB, 2000, CANCER RES, V60, P6434; Nowakowski A, 2002, P NATL ACAD SCI USA, V99, P11346, DOI 10.1073/pnas.172229899; Nuttall SD, 2001, MOL IMMUNOL, V38, P313, DOI 10.1016/S0161-5890(01)00057-8; O'Connell D, 2002, J MOL BIOL, V321, P49, DOI 10.1016/S0022-2836(02)00561-2; Ober RJ, 2001, INT IMMUNOL, V13, P1551, DOI 10.1093/intimm/13.12.1551; Park JW, 2002, CLIN CANCER RES, V8, P1172; Parren PWHI, 2001, ADV IMMUNOL, V77, P195, DOI 10.1016/S0065-2776(01)77018-6; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Poltoratsky V, 2001, P NATL ACAD SCI USA, V98, P7976, DOI 10.1073/pnas.141222198; Poul MA, 2000, J MOL BIOL, V301, P1149, DOI 10.1006/jmbi.2000.4026; Powers DB, 2001, J IMMUNOL METHODS, V251, P123, DOI 10.1016/S0022-1759(00)00290-8; Rippmann JF, 2000, BIOCHEM J, V349, P805, DOI 10.1042/bj3490805; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; Sanz L, 2002, GENE THER, V9, P1049, DOI 10.1038/sj.gt.3301725; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Segal DM, 2001, J IMMUNOL METHODS, V248, P1, DOI 10.1016/S0022-1759(00)00338-0; Shi NY, 2001, PHARMACEUT RES, V18, P1091, DOI 10.1023/A:1010910523202; Souriau C, 2001, EXPERT OPIN BIOL TH, V1, P845, DOI 10.1517/14712598.1.5.845; Straten PT, 2001, EUR J IMMUNOL, V31, P250, DOI 10.1002/1521-4141(200101)31:1<250::AID-IMMU250>3.0.CO;2-8; Tahtis K, 2001, CLIN CANCER RES, V7, P1061; Todorovska A, 2001, J IMMUNOL METHODS, V248, P47, DOI 10.1016/S0022-1759(00)00342-2; Tomlinson I, 2000, METHOD ENZYMOL, V326, P461; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; van Beusechem VW, 2002, J VIROL, V76, P2753, DOI 10.1128/JVI.76.6.2753-2762.2002; van den Beucken T, 2001, J MOL BIOL, V310, P591, DOI 10.1006/jmbi.2001.4703; van der Linden RHJ, 2000, J BIOTECHNOL, V80, P261, DOI 10.1016/S0168-1656(00)00274-1; Visintin M, 2002, J MOL BIOL, V317, P73, DOI 10.1006/jmbi.2002.5392; Weng S, 2002, PROTEOMICS, V2, P48, DOI 10.1002/1615-9861(200201)2:1<48::AID-PROT48>3.0.CO;2-I; Willemsen RA, 2001, GENE THER, V8, P1601, DOI 10.1038/sj.gt.3301570; Wilson DS, 2001, P NATL ACAD SCI USA, V98, P3750, DOI 10.1073/pnas.061028198; Wiseman GA, 2002, CANCER, V94, P1349, DOI 10.1002/cncr.10305; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037; Xu LH, 2002, CHEM BIOL, V9, P933, DOI 10.1016/S1074-5521(02)00187-4; Yazaki PJ, 2001, BIOCONJUGATE CHEM, V12, P220, DOI 10.1021/bc000092h	82	341	753	1	85	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					129	134		10.1038/nm0103-129	http://dx.doi.org/10.1038/nm0103-129			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514726				2022-12-27	WOS:000208640400008
J	Kotb, M; Norrby-Teglund, A; McGeer, A; El-Sherbini, H; Dorak, MT; Khurshid, A; Green, K; Peeples, J; Wade, J; Thomson, G; Schwartz, B; Low, DE				Kotb, M; Norrby-Teglund, A; McGeer, A; El-Sherbini, H; Dorak, MT; Khurshid, A; Green, K; Peeples, J; Wade, J; Thomson, G; Schwartz, B; Low, DE			An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections	NATURE MEDICINE			English	Article							TOXIC-SHOCK-SYNDROME; T-CELLS; DISEASE; SUPERANTIGENS; RESPONSES	The role of host genetic factors in conferring predisposition or protection in infectious diseases has become evident. Infection with group A streptococci causes a wide spectrum of disease ranging from pharyngitis to streptococcal toxic shock syndrome. The release of inflammatory cytokines triggered by streptococcal superantigens has a pivotal role in invasive streptococcal disease. However, individuals infected with the same strain can develop very different manifestations. We report here that the immunogenetics of the host influence the outcome of invasive streptococcal infection, and demonstrate the underlying mechanism for these genetic associations. Specific human leukocyte antigen class II haplotypes conferred strong protection from severe systemic disease, whereas others increased the risk of severe disease. Patients with the DRB1*1501/DQB1*0602 haplotype mounted significantly reduced responses and were less likely to develop severe systemic disease (P<0.0001). We propose that human leukocyte antigen class II allelic variation contributes to differences in severity of invasive streptococcal infections through their ability to regulate cytokine responses triggered by streptococcal superantigens.	Vet Affairs Med Ctr, Res Serv, Memphis, TN 38104 USA; Univ Tennessee, Dept Surg & Mol Sci, Memphis, TN USA; Huddinge Univ Hosp, Ctr Infect Dis, Karolinska Inst, Stockholm, Sweden; Univ Toronto, Toronto, ON, Canada; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Ctr Dis Control & Prevent, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; Karolinska Institutet; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California Berkeley; Centers for Disease Control & Prevention - USA	Kotb, M (corresponding author), Vet Affairs Med Ctr, Res Serv, Memphis, TN 38104 USA.		Low, Donald/B-1726-2012; McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040198] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40198] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Basma H, 1999, INFECT IMMUN, V67, P1871; Chatellier S, 2000, INFECT IMMUN, V68, P3523, DOI 10.1128/IAI.68.6.3523-3534.2000; COLMAN G, 1993, J MED MICROBIOL, V39, P165, DOI 10.1099/00222615-39-3-165; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; Doraiswamy PM, 2001, J CLIN PSYCHIAT, V62, P30; Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; Hill AVS, 1999, BRIT MED BULL, V55, P401, DOI 10.1258/0007142991902457; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P384, DOI 10.1001/jama.269.3.384; Kaul R, 1999, CLIN INFECT DIS, V28, P800, DOI 10.1086/515199; Kaul R, 1997, AM J MED, V103, P18, DOI 10.1016/S0002-9343(97)00160-5; KOTB M, 1995, CLIN MICROBIOL REV, V8, P411, DOI 10.1128/CMR.8.3.411; LOW DE, 1998, EMERGING PATHOGENS, V7; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; Newton DW, 1996, J IMMUNOL, V157, P3988; Norrby-Teglund A, 2001, J INFECT DIS, V184, P853, DOI 10.1086/323443; Norrby-Teglund A, 2000, EUR J IMMUNOL, V30, P3247, DOI 10.1002/1521-4141(200011)30:11<3247::AID-IMMU3247>3.0.CO;2-D; NorrbyTeglund A, 1997, INFECT IMMUN, V65, P5209, DOI 10.1128/IAI.65.12.5209-5215.1997; OHNISHI H, 1995, J IMMUNOL, V154, P3180; OLERUP O, 1992, TISSUE ANTIGENS, V39, P2253; STROMBERG A, 1991, J INFECT DIS, V164, P595, DOI 10.1093/infdis/164.3.595; WADE J, 1998, HLA 1998; WATANABEOHNISHI R, 1995, J INFECT DIS, V171, P74, DOI 10.1093/infdis/171.1.74	23	277	289	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1398	1404		10.1038/nm800	http://dx.doi.org/10.1038/nm800			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12436116				2022-12-27	WOS:000179552000036
J	Petzelbauer, P; Zacharowski, PA; Miyazaki, Y; Friedl, P; Wickenhauser, G; Castellino, FJ; Groger, M; Wolff, K; Zacharowski, K				Petzelbauer, P; Zacharowski, PA; Miyazaki, Y; Friedl, P; Wickenhauser, G; Castellino, FJ; Groger, M; Wolff, K; Zacharowski, K			The fibrin-derived peptide B beta(15-42) protects the myocardium against ischemia-reperfusion injury	NATURE MEDICINE			English	Article							ENDOTHELIAL-CELLS; DEFICIENT MICE; BINDING-SITE; BETA-CHAIN; IN-VITRO; LEUKOCYTE TRANSMIGRATION; PROTOFIBRIL FORMATION; PLATELET-AGGREGATION; PULMONARY-FIBROSIS; INFARCT SIZE	In the event of a myocardial infarction, current interventions aim to reopen the occluded vessel to reduce myocardial damage and injury. Although reperfusion is essential for tissue salvage, it can cause further damage and the onset of inflammation. We show a novel anti-inflammatory effect of a fibrin-derived peptide, B beta(15-42). This peptide competes with the fibrin fragment N-terminal disulfide knot-II (an analog of the fibrin E1 fragment) for binding to vascular endothelial (VE)-cadherin, thereby preventing transmigration of leukocytes across endothelial cell monolayers. In acute or chronic rat models of myocardial ischemia-reperfusion injury, B beta(15-42) substantially reduces leukocyte infiltration, infarct size and subsequent scar formation. The pathogenic role of fibrinogen products is further confirmed in fibrinogen knockout mice, in which infarct size was substantially smaller than in wild-type animals. Our findings conclude that the interplay of fibrin fragments, leukocytes and VE-cadherin contribute to the pathogenesis of myocardial damage and reperfusion injury. The naturally occurring peptide B beta(15-42) represents a potential candidate for reperfusion therapy in humans.	Univ Hosp Dusseldorf, Dept Anesthesia, Mol Cardioprotect & Inflammat Grp, D-40225 Dusseldorf, Germany; Med Univ Vienna, Dept Gen Dermatol, A-1090 Vienna, Austria; Med Univ Vienna, Ludwig Boltzmann Inst Angiogenesis Microcirculat, A-1090 Vienna, Austria; Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Medical University of Vienna; Ludwig Boltzmann Institute; Medical University of Vienna; University of Notre Dame	Zacharowski, K (corresponding author), Univ Hosp Dusseldorf, Dept Anesthesia, Mol Cardioprotect & Inflammat Grp, Moorenstr 5, D-40225 Dusseldorf, Germany.	kai.zacharowski@uni-duesseldorf.de	petzelbauer, peter/GLU-3941-2022	Petzelbauer, Peter/0000-0001-7080-5259				ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dempfle CE, 2000, BLOOD, V96, P2793; Drew AF, 2001, BLOOD, V97, P3691, DOI 10.1182/blood.V97.12.3691; Drew AF, 2001, AM J PHYSIOL-RENAL, V281, pF1157, DOI 10.1152/ajprenal.0002.2001; Erlich JH, 2000, AM J PATHOL, V157, P1849, DOI 10.1016/S0002-9440(10)64824-9; Everse SJ, 1998, BIOCHEMISTRY-US, V37, P8637, DOI 10.1021/bi9804129; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FERRANS VJ, 1975, ANN THORAC SURG, V20, P11, DOI 10.1016/S0003-4975(10)63845-3; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; FURLAN M, 1982, THROMB HAEMOSTASIS, V47, P118; Gorlatov S, 2002, BIOCHEMISTRY-US, V41, P4107, DOI 10.1021/bi0160314; Groger M, 1999, J IMMUNOL METHODS, V222, P101, DOI 10.1016/S0022-1759(98)00187-2; Halama T, 2001, J INVEST DERMATOL, V116, P110, DOI 10.1046/j.1523-1747.2001.00176.x; HAMAGUCHI M, 1993, BLOOD, V81, P2348; HARENBERG J, 1985, FIBRINOGEN STRUCTURE, P271; Harley SL, 2000, ARTERIOSCL THROM VAS, V20, P652, DOI 10.1161/01.ATV.20.3.652; Hsieh KH, 1997, BIOCHEMISTRY-US, V36, P9381, DOI 10.1021/bi962741b; Hsieh KH, 1997, THROMB RES, V86, P301, DOI 10.1016/S0049-3848(97)00073-X; Kakkar AK, 2004, CURR OPIN PHARMACOL, V4, P154, DOI 10.1016/j.coph.2004.01.003; Koenig W, 2001, ARTERIOSCL THROM VAS, V21, P1701, DOI 10.1161/hq1001.097020; Kostelansky MS, 2002, BIOCHEMISTRY-US, V41, P12124, DOI 10.1021/bi0261894; KUDRYK B, 1982, THROMB RES, V25, P277, DOI 10.1016/0049-3848(82)90247-X; Latta RV, 2003, ARCH ORAL BIOL, V48, P263, DOI 10.1016/S0003-9969(02)0005-0; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; Lounes KC, 2002, BIOCHEMISTRY-US, V41, P5291, DOI 10.1021/bi011988s; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; OLEXA SA, 1981, BIOCHEMISTRY-US, V20, P6139, DOI 10.1021/bi00524a035; Palumbo JS, 2002, CANCER RES, V62, P6966; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; Ploplis VA, 2000, AM J PATHOL, V157, P703, DOI 10.1016/S0002-9440(10)64582-8; Qi JF, 1997, BLOOD, V90, P3595, DOI 10.1182/blood.V90.9.3595; RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schoots IG, 2003, SURGERY, V133, P411, DOI 10.1067/msy.2003.104; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; Sherman DG, 2000, JAMA-J AM MED ASSOC, V283, P2395, DOI 10.1001/jama.283.18.2395; SIMPSON PJ, 1991, J PHARMACOL EXP THER, V256, P780; Unger RE, 2002, MICROVASC RES, V64, P384, DOI 10.1006/mvre.2002.2434; VALI Z, 1988, BIOCHEMISTRY-US, V27, P1956, DOI 10.1021/bi00406a023; Weber C, 2003, J MOL MED, V81, P4, DOI 10.1007/s00109-002-0391-x; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; Wilberding JA, 2001, ANN NY ACAD SCI, V936, P542; Yokoyama K, 1999, BIOCHEMISTRY-US, V38, P5872, DOI 10.1021/bi9827619; Zacharowski K, 1999, ARTERIOSCL THROM VAS, V19, P2141, DOI 10.1161/01.ATV.19.9.2141	48	165	175	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					298	304		10.1038/nm1198	http://dx.doi.org/10.1038/nm1198			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723073				2022-12-27	WOS:000227541300025
J	Levy, SB; Marshall, B				Levy, SB; Marshall, B			Antibacterial resistance worldwide: causes, challenges and responses	NATURE MEDICINE			English	Review							BETA-LACTAMASE PRODUCTION; STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL RESISTANCE; ESCHERICHIA-COLI; DRUG-RESISTANCE; METHICILLIN-RESISTANT; ANTIBIOTIC-RESISTANCE; STREPTOCOCCUS-PNEUMONIAE; NEISSERIA-GONORRHOEAE; QUINOLONE RESISTANCE	The optimism of the early period of antimicrobial discovery has been tempered by the emergence of bacterial strains with resistance to these therapeutics. Today, clinically important bacteria are characterized not only by single drug resistance but also by multiple antibiotic resistance-the legacy of past decades of antimicrobial use and misuse. Drug resistance presents an ever-increasing global public health threat that involves all major microbial pathogens and antimicrobial drugs.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Ctr Adaptat Genet & Drug Resistance, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Ctr Adaptat Genet & Drug Resistance, Boston, MA 02111 USA	Tufts University; Tufts University	Levy, SB (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Ctr Adaptat Genet & Drug Resistance, Boston, MA 02111 USA.	stuart.levy@tufts.edu; bonnie.marshall@tufts.edu	Kristoffersson, Anders/I-6497-2015	Kristoffersson, Anders/0000-0003-3166-9981				Ainsa J.A., 2002, INT MICROBIOL, V5, P155, DOI [10.1007/s10123-002-0082-z, DOI 10.1007/S10123-002-0082-Z]; Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067, DOI 10.1128/AAC.41.10.2067; ALEKSHUN MSB, 2004, IN PRESS DRUG DISCOV; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 2001, WHO GLOB STRAT CONT; ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; Ash C., 1994, TRENDS MICROBIOL, V2, P341; Balsalobre L, 2003, ANTIMICROB AGENTS CH, V47, P2072, DOI 10.1128/AAC.47.7.2072-2081.2003; BARBER M, 1948, LANCET, V252, P641; Barbosa TM, 2000, DRUG RESIST UPDATE, V3, P303, DOI 10.1054/drup.2000.0167; Barza M, 2002, CLIN INFECT DIS, V34, pS71, DOI 10.1086/340241; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Bradford PA, 2001, CLIN MICROBIOL REV, V14, P933, DOI 10.1128/CMR.14.4.933-951.2001; Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1041; CLEWELL DB, 1986, ANNU REV MICROBIOL, V40, P635, DOI 10.1146/annurev.mi.40.100186.003223; COHEN ML, 1982, ANTIMICROB AGENTS CH, V21, P210, DOI 10.1128/AAC.21.2.210; Cooper BS, 2004, BMJ-BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533; CORPET DE, 1988, NEW ENGL J MED, V318, P1206; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P53, DOI 10.1086/345476; CROFTON J, 1948, BMJ-BRIT MED J, V2, P1009, DOI 10.1136/bmj.2.4588.1009; DATTA N, 1971, LANCET, V1, P312; DEGRAAFF J, 1976, J BACTERIOL, V126, P439, DOI 10.1128/JB.126.1.439-446.1976; Dowson Christopher G., 1994, Trends in Microbiology, V2, P361, DOI 10.1016/0966-842X(94)90612-2; ELWELL LP, 1977, ANTIMICROB AGENTS CH, V11, P528, DOI 10.1128/AAC.11.3.528; Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542; Goossens H, 1999, CURR OPIN INFECT DIS, V12, P537, DOI 10.1097/00001432-199912000-00002; Hall RM, 1999, ANN NY ACAD SCI, V870, P68, DOI 10.1111/j.1749-6632.1999.tb08866.x; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; Hiramatsu K, 1998, DRUG RESIST UPDATE, V1, P135, DOI 10.1016/S1368-7646(98)80029-0; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; Jabeen K, 2005, GENE TRANSFER ENV, V55, P436; Jones RN, 1998, DIAGN MICR INFEC DIS, V31, P437, DOI 10.1016/S0732-8893(98)80002-3; Karlowsky JA, 2002, ANTIMICROB AGENTS CH, V46, P2540, DOI 10.1128/AAC.46.8.2540-2545.2002; Kummerer K, 2003, CLIN MICROBIOL INFEC, V9, P1203, DOI 10.1111/j.1469-0691.2003.00739.x; Levy S B, 1994, Trends Microbiol, V2, P341, DOI 10.1016/0966-842X(94)90607-6; Levy S.B, 1984, ANTIMICROBIALS AGR, P525; Levy S.B., 1989, GENE TRANSFER ENV; LEVY SB, 1982, LANCET, V2, P83; LEVY SB, 1976, NEW ENGL J MED, V295, P583, DOI 10.1056/NEJM197609092951103; Levy SB, 1997, CIBA F SYMP, V207, P1; Levy SB, 1999, ANTIMICROB AGENTS CH, V43, P1523, DOI 10.1128/AAC.43.6.1523; LEVY SB, 1988, ANTIMICROB AGENTS CH, V32, P1801, DOI 10.1128/AAC.32.12.1801; Levy SB, 2001, CLIN INFECT DIS, V33, pS124, DOI 10.1086/321837; Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46; Levy SB, 2002, J ANTIMICROB CHEMOTH, V49, P25, DOI 10.1093/jac/49.1.25; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LEVY SB, 1990, NEW ENGL J MED, V323, P335, DOI 10.1056/NEJM199008023230509; LEVY SB, 1978, J INFECT DIS, V137, P688, DOI 10.1093/infdis/137.5.688; LEVY SB, 1985, ENG ORGANISMS ENV SC, P180; Livermore D, 2004, NAT REV MICROBIOL, V2, P73, DOI 10.1038/nrmicro798; Livermore DM, 2000, CURR OPIN MICROBIOL, V3, P489, DOI 10.1016/S1369-5274(00)00128-4; Manges AR, 2001, NEW ENGL J MED, V345, P1007, DOI 10.1056/NEJMoa011265; Markou N, 2003, CRIT CARE, V7, pR78, DOI 10.1186/cc2358; MARSHALL B, 1984, J INFECT DIS, V149, P1028, DOI 10.1093/infdis/149.6.1028; MARSHALL B, 1990, P NATL ACAD SCI USA, V87, P6609, DOI 10.1073/pnas.87.17.6609; Martinez-Martinez L, 1998, LANCET, V351, P797, DOI 10.1016/S0140-6736(97)07322-4; McCormick AW, 2003, NAT MED, V9, P424, DOI 10.1038/nm839; McMurry LM, 2000, GRAM-POSITIVE PATHOGENS, P660; Meka VG, 2004, CLIN INFECT DIS, V39, P1010, DOI 10.1086/423841; Mellon M., 2001, HOGGING IT ESTIMATES; Miller YW, 1996, J ANTIMICROB CHEMOTH, V38, P829; MOLLER JK, 1977, ANTIMICROB AGENTS CH, V11, P388, DOI 10.1128/AAC.11.3.388; Nandi S, 2004, P NATL ACAD SCI USA, V101, P7118, DOI 10.1073/pnas.0306466101; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Nordmann P, 2002, CLIN MICROBIOL INFEC, V8, P321, DOI 10.1046/j.1469-0691.2002.00401.x; OLARTE J, 1983, APUA NEWSLETTER, V1; Paterson DL, 2004, ANN INTERN MED, V140, P26, DOI 10.7326/0003-4819-140-1-200401060-00008; PEARMAN JW, 1993, APUA NEWSLETTER, V11, P1; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; Piddock LJV, 1999, DRUGS, V58, P11, DOI 10.2165/00003495-199958002-00003; Projan SJ, 2003, CURR OPIN MICROBIOL, V6, P427, DOI 10.1016/j.mib.2003.08.003; Roberts MC, 1996, FEMS MICROBIOL REV, V19, P1, DOI 10.1111/j.1574-6976.1996.tb00251.x; ROLLAND RM, 1985, APPL ENVIRON MICROB, V49, P791, DOI 10.1128/AEM.49.4.791-794.1985; Rubin RJ, 1999, EMERG INFECT DIS, V5, P9, DOI 10.3201/eid0501.990102; Schneiders T, 2003, ANTIMICROB AGENTS CH, V47, P2831, DOI 10.1128/AAC.47.9.2831-2837.2003; Schrag SJ, 2004, ANTIMICROB AGENTS CH, V48, P3016, DOI 10.1128/AAC.48.8.3016-3023.2004; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Sidhu MS, 2002, ANTIMICROB AGENTS CH, V46, P2797, DOI 10.1128/AAC.46.9.2797-2803.2002; Simon L, 2004, CLIN INFECT DIS, V39, P206, DOI 10.1086/421997; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; Summers AO, 2002, CLIN INFECT DIS, V34, pS85, DOI 10.1086/340245; Tanaka M, 2000, J CLIN MICROBIOL, V38, P521, DOI 10.1128/JCM.38.2.521-525.2000; Tenover FC, 2004, ANTIMICROB AGENTS CH, V48, P275, DOI 10.1128/AAC.48.1.275-280.2004; TURNIDGE J, 1989, MED J AUSTRALIA, V150, P65, DOI 10.5694/j.1326-5377.1989.tb136365.x; *US C OFF TECHN AS, 1995, OTAH629 US C; Vandenesch F, 2003, EMERG INFECT DIS, V9, P978; VANKLINGEREN B, 1977, ANTIMICROB AGENTS CH, V11, P383, DOI 10.1128/AAC.11.3.383; Vidaver AK, 2002, CLIN INFECT DIS, V34, pS107, DOI 10.1086/340247; Walsh FM, 2004, CURR OPIN MICROBIOL, V7, P439, DOI 10.1016/j.mib.2004.08.007; Walson JL, 2001, J INFECT DIS, V184, P1163, DOI 10.1086/323647; Wang H, 2001, ANTIMICROB AGENTS CH, V45, P1515, DOI 10.1128/AAC.45.5.1515-1521.2001; Wang MG, 2004, ANTIMICROB AGENTS CH, V48, P1295, DOI 10.1128/AAC.48.4.1295-1299.2004; Wang SA, 2003, CLIN INFECT DIS, V37, P849, DOI 10.1086/377500; WATANABE T, 1963, BACTERIOL REV, V27, P87, DOI 10.1128/MMBR.27.1.87-115.1963; Weigel LM, 2003, SCIENCE, V302, P1569, DOI 10.1126/science.1090956; Weinstein RA, 2001, EMERG INFECT DIS, V7, P188, DOI 10.3201/eid0702.010206; Zervos MJ, 2003, CLIN INFECT DIS, V37, P1643, DOI 10.1086/379709; 2002, EARSS ANN REPORT 200; 1999, J AM MED ASS, V282, P1123	103	2549	2644	64	1444	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12		S			S122	S129		10.1038/nm1145	http://dx.doi.org/10.1038/nm1145			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577930	Bronze			2022-12-27	WOS:000225733900008
J	Peiris, JSM; Guan, Y; Yuen, KY				Peiris, JSM; Guan, Y; Yuen, KY			Severe acute respiratory syndrome	NATURE MEDICINE			English	Review							SYNDROME-ASSOCIATED CORONAVIRUS; SARS-ASSOCIATED CORONAVIRUS; IN-SITU HYBRIDIZATION; SPIKE PROTEIN; FUNCTIONAL RECEPTOR; NEUTRALIZING ANTIBODIES; MOLECULAR EPIDEMIOLOGY; POTENT NEUTRALIZATION; TRANSMISSION DYNAMICS; LABORATORY DIAGNOSIS	Severe acute respiratory syndrome (SARS) was caused by a previously unrecognized animal coronavirus that exploited opportunities provided by 'wet markets' in southern China to adapt to become a virus readily transmissible between humans. Hospitals and international travel proved to be 'amplifiers' that permitted a local outbreak to achieve global dimensions. In this review we will discuss the substantial scientific progress that has been made towards understanding the virus-SARS coronavirus (SARS-CoV)-and the disease. We will also highlight the progress that has been made towards developing vaccines and therapies The concerted and coordinated response that contained SARS is a triumph for global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.	Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China	University of Hong Kong	Peiris, JSM (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.	malik@hkucc.hku.hk		Yuen, Kwok-yung/0000-0002-2083-1552; Guan, Yi/0000-0001-6057-9243	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095357] Funding Source: NIH RePORTER; NIAID NIH HHS [N01AI95357, AI95357] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anderson RM, 2004, PHILOS T R SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490; Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004; Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101; Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101; Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101; Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X; Cavanagh D, 2003, AVIAN PATHOL, V32, P567, DOI 10.1080/03079450310001621198; CDC (Cent. Dis. Control Prev.), 2003, MMWR-MORBID MORTAL W, V52, P986; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P241; Chan KH, 2004, EMERG INFECT DIS, V10, P294, DOI 10.3201/eid1002.030610; Chan PKS, 2004, J MED VIROL, V74, P1, DOI 10.1002/jmv.20138; Chan PKS, 2004, EMERG INFECT DIS, V10, P825, DOI 10.3201/eid1005.030682; Chen JY, 2004, J INTERV CARD ELECTR, V10, P31, DOI 10.1023/B:JICE.0000011482.58569.74; Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7; Chong PY, 2004, ARCH PATHOL LAB MED, V128, P195; Chow KC, 2004, AM J CLIN PATHOL, V121, P574, DOI 10.1309/C0EDU0RAQBTXBHCE; Christian MD, 2004, CLIN INFECT DIS, V38, P1420, DOI 10.1086/420743; Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658; Cinatl J, 2004, CELL MOL LIFE SCI, V61, P2100, DOI 10.1007/s00018-004-4222-9; Davidson A, 2003, CURR OPIN INFECT DIS, V16, P565, DOI 10.1097/00001432-200312000-00009; Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560; Drosten C, 2004, J CLIN MICROBIOL, V42, P2043, DOI 10.1128/JCM.42.5.2043-2047.2004; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Drosten C, 2003, TRENDS MOL MED, V9, P325, DOI 10.1016/S1471-4914(03)00133-3; Enserink M, 2004, SCIENCE, V304, P1097, DOI 10.1126/science.304.5674.1097; Fidler DP, 2004, J CLIN INVEST, V113, P799, DOI 10.1172/JCI200421328; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8; Gao WT, 2003, LANCET, V362, P1895, DOI 10.1016/S0140-6736(03)14962-8; Goh DLM, 2004, EMERG INFECT DIS, V10, P232, DOI 10.3201/eid1002.030676; Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004; Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Han DP, 2004, VIROLOGY, V326, P140, DOI 10.1016/j.virol.2004.05.017; He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002; He ML, 2003, JAMA-J AM MED ASSOC, V290, P2665, DOI 10.1001/jama.290.20.2665; Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482; Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114; Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004; Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI18819, 10.1172/JCI200318819]; Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8; Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058; Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004; Jones BM, 2004, CLIN EXP IMMUNOL, V135, P467, DOI 10.1111/j.1365-2249.2003.02391.x; Kaiser L, 1999, J CLIN VIROL, V14, P191, DOI 10.1016/S1386-6532(99)00058-X; Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013; Kim TW, 2004, J VIROL, V78, P4638, DOI 10.1128/JVI.78.9.4638-4645.2004; Klempner MS, 2004, NEW ENGL J MED, V350, P1171, DOI 10.1056/NEJMp048039; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; LAI MM, 2001, FIELDS VIROLOGY, V2, P1163; Lee CH, 2004, J IMMUNOL, V172, P7841, DOI 10.4049/jimmunol.172.12.7841; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Leung CW, 2004, PEDIATRICS, V113, pE535, DOI 10.1542/peds.113.6.e535; Leung GM, 2004, EMERG INFECT DIS, V10, P1653, DOI 10.3201/eid1009.040155; Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Li LJ, 2003, J CLIN VIROL, V28, P239, DOI 10.1016/S1386-6532(03)00195-1; Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Liang GD, 2004, EMERG INFECT DIS, V10, P1774, DOI 10.3201/eid1010.040445; Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; Loon SC, 2004, BRIT J OPHTHALMOL, V88, P861, DOI 10.1136/bjo.2003.035931; Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222; Lu LQ, 2004, J CLIN MICROBIOL, V42, P1570, DOI 10.1128/JCM.42.4.1570-1576.2004; Mackenzie JS, 2003, J APPL MICROBIOL, V94, p59S; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; Mazzulli T, 2004, EMERG INFECT DIS, V10, P20, DOI 10.3201/eid1001.030404; Nakajima N, 2003, JPN J INFECT DIS, V56, P139; Ng EKO, 2003, CLIN CHEM, V49, P2085, DOI 10.1373/clinchem.2003.024588; Ng EKO, 2003, CLIN CHEM, V49, P1976, DOI 10.1373/clinchem.2003.024125; Ng MHL, 2004, J INFECT DIS, V190, P515, DOI 10.1086/421523; Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286; O'Neill O, 2004, PHILOS T R SOC B, V359, P1133, DOI 10.1098/rstb.2004.1486; OLSEN CW, 1993, VET MICROBIOL, V36, P1, DOI 10.1016/0378-1135(93)90126-R; Openshaw PJM, 2004, CLIN EXP IMMUNOL, V136, P11, DOI 10.1111/j.1365-2249.2004.02448.x; Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Poon LLM, 2003, CLIN CHEM, V49, P953, DOI 10.1373/49.6.953; Poon LLM, 2004, LANCET INFECT DIS, V4, P663, DOI 10.1016/S1473-3099(04)01172-7; POON LLM, IN PRESS J VIROL; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Poutanen SM, 2004, CURR OPIN INFECT DIS, V17, P287, DOI 10.1097/01.qco.0000136924.45049.7e; Poutanen Susan M., 2004, Curr Infect Dis Rep, V6, P220, DOI 10.1007/s11908-004-0012-7; Rainer TH, 2004, CURR OPIN PULM MED, V10, P159, DOI 10.1097/00063198-200405000-00003; ROBERTS A, IN PRESS J VIROL; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9; Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6; Shen Z, 2004, EMERG INFECT DIS, V10, P256, DOI 10.3201/eid1002.030732; SHORTRIDGE KF, 1982, LANCET, V2, P812; Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101; Singer PA, 2003, BRIT MED J, V327, P1342, DOI 10.1136/bmj.327.7427.1342; SMITH MD, 2003, MANSONS TROPICAL DIS, P1125; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x; Spiegel M, 2004, J CLIN VIROL, V30, P211, DOI 10.1016/j.jcv.2003.11.013; Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775; Stohr K, 2003, LANCET, V361, P1730, DOI 10.1016/S0140-6736(03)13376-4; Stroher U, 2004, J INFECT DIS, V189, P1164, DOI 10.1086/382597; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004; Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101; Takasuka N, 2004, INT IMMUNOL, V16, P1423, DOI 10.1093/intimm/dxh143; Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458; Tang L, 2004, DNA CELL BIOL, V23, P391, DOI 10.1089/104454904323145272; ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9; To K, 2004, J PATHOL, V202, P157, DOI 10.1002/path.1510; To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597; Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Wang PG, 2004, BIOCHEM BIOPH RES CO, V315, P439, DOI 10.1016/j.bbrc.2004.01.076; Wang YD, 2004, J VIROL, V78, P5612, DOI 10.1128/JVI.78.11.5612-5618.2004; Wang Z, 2004, J VIROL, V78, P7523, DOI 10.1128/JVI.78.14.7523-7527.2004; Weinstein RA, 2004, NEW ENGL J MED, V350, P2332, DOI 10.1056/NEJMp048082; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358; Wong TW, 2004, EMERG INFECT DIS, V10, P269, DOI 10.3201/eid1002.030452; Wu CJ, 2004, ANTIMICROB AGENTS CH, V48, P2693, DOI 10.1128/AAC.48.7.2693-2696.2004; Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101; Xu RH, 2004, EMERG INFECT DIS, V10, P1030, DOI 10.3201/eid1006.030852; Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Yeh SH, 2004, P NATL ACAD SCI USA, V101, P2542, DOI 10.1073/pnas.0307904100; Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004; Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100; Zeng FY, 2004, BIOCHEM BIOPH RES CO, V315, P1134, DOI 10.1016/j.bbrc.2004.01.166; Zhang H, 2004, J VIROL, V78, P6938, DOI 10.1128/JVI.78.13.6938-6945.2004; Zhang QF, 2004, J MED VIROL, V73, P332, DOI 10.1002/jmv.20095; Zhang XW, 2004, BIOORGAN MED CHEM, V12, P2517, DOI 10.1016/j.bmc.2004.03.035; Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004; Zhang YJ, 2004, FEBS LETT, V560, P141, DOI 10.1016/S0014-5793(04)00087-0; Zhong NS, 2004, PHILOS T R SOC B, V359, P1115, DOI 10.1098/rstb.2004.1491; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2; Zhong NS, 2003, AM J RESP CRIT CARE, V168, P7, DOI 10.1164/rccm.200305-707OE; Zhu MS, 2004, IMMUNOL LETT, V92, P237, DOI 10.1016/j.imlet.2004.01.001	147	674	712	1	119	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12		S			S88	S97		10.1038/nm1143	http://dx.doi.org/10.1038/nm1143			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577937	Green Published, Bronze			2022-12-27	WOS:000225733900005
J	Ptasznik, A; Nakata, Y; Kalota, A; Emerson, SG; Gewirtz, AM				Ptasznik, A; Nakata, Y; Kalota, A; Emerson, SG; Gewirtz, AM			Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells	NATURE MEDICINE			English	Article							ACTIVATION; BIOLOGY	We studied the effects of Lyn ablation on the survival of drug-resistant chronic myelogenous leukemia (CML) blast crisis cells using siRNA. Lyn siRNA reduced Lyn protein in both normal hematopoietic cells and BCR-ABL1-expressing (BCR-ABL1(+)) blasts by 80-95%. Within 48 h, siRNA-treated BCR-ABL1(+) blasts underwent apoptosis, whereas normal cells remained viable. This increased dependence on Lyn signaling for BCR-ABL1(+) blast survival provides the basis for rational treatment of drug-resistant CML blast crisis, particularly when lymphoid in nature.	Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Ptasznik, A (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.	andrzejp@mail.med.upenn.edu; gewirtz@mail.med.upenn.edu			NCI NIH HHS [1R01CA101859-01, R01CA90833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090833, R01CA101859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Luger SM, 2002, BLOOD, V99, P1150, DOI 10.1182/blood.V99.4.1150; NOWELL PC, 1960, SCIENCE, V132, P1497; Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837; Ptasznik A, 2002, J EXP MED, V196, P667, DOI 10.1084/jem.20020519; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200	15	186	204	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1187	1189		10.1038/nm1127	http://dx.doi.org/10.1038/nm1127			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502840				2022-12-27	WOS:000224785900038
J	Wang, H; Liao, H; Ochani, M; Justiniani, M; Lin, XC; Yang, LH; Al-Abed, Y; Wang, HC; Metz, C; Miller, EJ; Tracey, KJ; Ulloa, L				Wang, H; Liao, H; Ochani, M; Justiniani, M; Lin, XC; Yang, LH; Al-Abed, Y; Wang, HC; Metz, C; Miller, EJ; Tracey, KJ; Ulloa, L			Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis	NATURE MEDICINE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; CHROMATIN PROTEIN HMGB1; TUMOR-NECROSIS-FACTOR; MOBILITY GROUP BOX-1; NF-KAPPA-B; SEPTIC SHOCK; DOUBLE-BLIND; SYSTEMIC INFLAMMATION; ULCERATIVE-COLITIS; CONTROLLED-TRIAL	Physiological anti-inflammatory mechanisms can potentially be exploited for the treatment of inflammatory disorders. Here we report that the neurotransmitter acetylcholine inhibits HMGB1 release from human macrophages by signaling through a nicotinic acetylcholine receptor. Nicotine, a selective cholinergic agonist, is more efficient than acetylcholine and inhibits HMGB1 release induced by either endotoxin or tumor necrosis factor-alpha (TNF-alpha). Nicotinic stimulation prevents activation of the NF-kappaB pathway and inhibits HMGB1 secretion through a specific 'nicotinic anti-inflammatory pathway' that requires the alpha7 nicotinic acetylcholine receptor (alpha7nAChR). In vivo, treatment with nicotine attenuates serum HMGB1 levels and improves survival in experimental models of sepsis, even when treatment is started after the onset of the disease. These results reveal acetylcholine as the first known physiological inhibitor of HMGB1 release from human macrophages and suggest that selective nicotinic agonists for the alpha7nAChR might have therapeutic potential for the treatment of sepsis.	N Shore Univ Hosp, N Shore LIJ Res Inst, Ctr Immunol & Inflammat, Manhasset, NY 11030 USA; N Shore Univ Hosp, Ctr Patient Oriented Res, Manhasset, NY 11030 USA; N Shore Univ Hosp, Dept Surg, Manhasset, NY 11030 USA; N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA	Northwell Health; North Shore University Hospital; Northwell Health; North Shore University Hospital; Northwell Health; North Shore University Hospital; Northwell Health; North Shore University Hospital	Ulloa, L (corresponding author), N Shore Univ Hosp, N Shore LIJ Res Inst, Ctr Immunol & Inflammat, 350 Community Dr, Manhasset, NY 11030 USA.	lulloa@nshs.edu	Ulloa, Luis/AAE-8751-2019; Wang, Haichao/AAU-2237-2021; Wang, Haichao/K-6310-2012	Ulloa, Luis/0000-0002-7702-7549; Wang, Haichao/0000-0002-0211-9000; Wang, Haichao/0000-0002-0211-9000; Wang, Hong/0000-0003-4130-8741; Tracey, Kevin J/0000-0003-1884-6314; Christine, Metz/0000-0002-1013-1691				Abraham E, 1998, LANCET, V351, P929; Abraham E, 2001, CRIT CARE MED, V29, P503, DOI 10.1097/00003246-200103000-00006; Andersson U, 2004, J INTERN MED, V255, P344, DOI 10.1111/j.1365-2796.2003.01303.x; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Ando Y, 1997, ANN INTERN MED, V127, P491, DOI 10.7326/0003-4819-127-6-199709150-00019; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bernik TR, 2002, J EXP MED, V195, P781, DOI 10.1084/jem.20011714; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; BUSTIN M, 2002, SCI STKE, V151; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Czura CJ, 2004, ADV IMMUNOL, V84, P181, DOI 10.1016/S0065-2776(04)84005-7; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dinarello CA, 2004, CURR OPIN PHARMACOL, V4, P378, DOI 10.1016/j.coph.2004.03.010; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; ESKANDARI MK, 1992, J IMMUNOL, V148, P2724; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; Guarini S, 2003, CIRCULATION, V107, P1189, DOI 10.1161/01.CIR.0000050627.90734.ED; Hogg RC, 2003, REV PHYSIOL BIOCH P, V147, P1, DOI 10.1007/s10254-003-0005-1; JICK H, 1983, NEW ENGL J MED, V308, P261, DOI 10.1056/NEJM198302033080507; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li JH, 2003, MOL MED, V9, P37, DOI 10.1007/BF03402105; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Marshall JC, 2001, CRIT CARE MED, V29, pS99, DOI 10.1097/00003246-200107001-00032; Martin TR, 2000, NAT MED, V6, P140, DOI 10.1038/72230; RAMPTON DS, 1984, LANCET, V1, P168; Rendon-Mitchell B, 2003, J IMMUNOL, V170, P3890, DOI 10.4049/jimmunol.170.7.3890; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Ulloa L, 2003, ARTHRITIS RHEUM, V48, P876, DOI 10.1002/art.10854; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang HC, 2004, NAT MED, V10, P124, DOI 10.1038/nm0204-124; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wess J, 2004, ANNU REV PHARMACOL, V44, P423, DOI 10.1146/annurev.pharmtox.44.101802.121622; Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100	46	893	960	2	64	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1216	1221		10.1038/nm1124	http://dx.doi.org/10.1038/nm1124			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502843				2022-12-27	WOS:000224785900043
J	Forman, MS; Trojanowski, JQ; Lee, VMY				Forman, MS; Trojanowski, JQ; Lee, VMY			Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs	NATURE MEDICINE			English	Review							FAMILIAL ALZHEIMERS-DISEASE; AMYOTROPHIC-LATERAL-SCLEROSIS; AMYLOID PRECURSOR PROTEIN; MOTOR-NEURON DEGENERATION; ALS-LINKED SOD1; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; TRANSGENIC MICE; MISSENSE MUTATIONS; APOLIPOPROTEIN-E	A wide variety of neurodegenerative diseases are characterized by the accumulation of intracellular or extracellular protein aggregates. More recently, the genetic identification of mutations in familial counterparts to the sporadic disorders, leading to the development of in vitro and in vivo model systems, has provided insights into disease pathogenesis. The effect of many of these mutations is the abnormal processing of misfolded proteins that overwhelms the quality-control systems of the cell, resulting in the deposition of protein aggregates in the nucleus, cytosol and/or extracellular space. Further understanding of mechanisms regulating protein processing and aggregation, as well as of the toxic effects of misfolded neurodegenerative disease proteins, will facilitate development of rationally designed therapies to treat and prevent these disorders.	Univ Penn, Inst Aging, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Lee, VMY (corresponding author), Univ Penn, Inst Aging, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, 36th & Spruce St,Maloney Bldg,3rd Floor, Philadelphia, PA 19104 USA.	vmylee@mail.med.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014449, P01AG014382, P30AG010124, P01AG017586, K08AG020073, P01AG011542, P01AG009215] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG14382, P01 AG11542, P01 AG09215, P01 AG17586, P01 AG14449, K08 AG20073-01, P30 AG10124] Funding Source: Medline; NINDS NIH HHS [P01 NS044233] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Bonini NM, 2003, ANNU REV NEUROSCI, V26, P627, DOI 10.1146/annurev.neuro.26.041002.131425; Brown P, 2002, NEUROLOGY, V58, P1720, DOI 10.1212/WNL.58.12.1720; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Collins SJ, 2004, LANCET, V363, P51, DOI 10.1016/S0140-6736(03)15171-9; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Forman MS, 2004, EXP NEUROL, V187, P229, DOI 10.1016/j.expneurol.2004.01.031; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Giasson BI, 2003, SCIENCE, V300, P636, DOI 10.1126/science.1082324; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Gotz J, 2004, MOL PSYCHIATR, V9, P664, DOI 10.1038/sj.mp.4001508; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ischiropoulos H, 2003, ANN NY ACAD SCI, V991, P93; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Knopman DS, 2003, J NEUROPATH EXP NEUR, V62, P1087, DOI 10.1093/jnen/62.11.1087; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LA SA, 1991, NATURE, V352, P77; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; Launer LJ, 2003, DRUGS, V63, P731, DOI 10.2165/00003495-200363080-00001; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Lewy FH, 1912, HDB NEUROLOGIE, P920; Lin X, 1999, NEURON, V24, P499, DOI 10.1016/S0896-6273(00)81104-6; Lipinski MM, 2004, CURR OPIN PHARMACOL, V4, P85, DOI 10.1016/j.coph.2003.09.008; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; Lomen-Hoerth C, 2003, NEUROLOGY, V60, P1094, DOI 10.1212/01.WNL.0000055861.95202.8D; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Poirier J, 2003, TRENDS MOL MED, V9, P94, DOI 10.1016/S1471-4914(03)00007-8; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wancata J, 2003, EUR PSYCHIAT, V18, P306, DOI 10.1016/j.eurpsy.2003.03.003; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weissmann C, 2003, BRIT MED BULL, V66, P43, DOI 10.1093/bmb/66.1.43; WHO, 2002, ACT AG POL FRAM; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P793, DOI 10.1001/archneur.57.6.793; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Yen SH, 1999, BRAIN PATHOL, V9, P695; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	104	522	567	1	64	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1055	1063		10.1038/nm1113	http://dx.doi.org/10.1038/nm1113			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459709				2022-12-27	WOS:000224245800034
J	Schubert, C				Schubert, C			HIV's lair	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051		10.1038/nm1004-1051	http://dx.doi.org/10.1038/nm1004-1051			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-27	WOS:000224245800024
J	Eichhorst, ST; Krueger, A; Muerkoster, S; Fas, SC; Golks, A; Gruetzner, U; Schubert, L; Opelz, C; Bilzer, M; Gerbes, AL; Krammer, PH				Eichhorst, ST; Krueger, A; Muerkoster, S; Fas, SC; Golks, A; Gruetzner, U; Schubert, L; Opelz, C; Bilzer, M; Gerbes, AL; Krammer, PH			Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice	NATURE MEDICINE			English	Article							SIGNALING COMPLEX; MEDIATED APOPTOSIS; PROSTATE-CANCER; GROWTH-FACTOR; T-CELLS; CASPASE-8; FLICE; ACTIVATION; DISORDERS; MECHANISM	Suramin is a polysulfonated derivative of urea and has been widely used both to treat infections and as a chemotherapeutic drug. Suramin has been shown to inhibit growth factor signaling pathways; however, its effect on apoptosis is unknown. Here we show that suramin inhibits apoptosis induced through death receptors in hepatoma and lymphoma cells. It also inhibits the proapoptotic effect of chemotherapeutic drugs. The antiapoptotic mechanism is specific to cell type and is caused by reduced activation, but not altered composition, of the death-inducing signaling complex (DISC), and by inhibition of the initiator caspases 8, 9 and 10. Suramin also shows similar effects in in vivo models: apoptotic liver damage induced by CD95 stimulation and endotoxic shock mediated by tumor-necrosis factor (TNF) are inhibited in mice, but necrotic liver damage is not inhibited in a rat model of liver transplantation. Thus, the antiapoptotic property of suramin in the liver may be therapeutically exploited.	German Canc Res Ctr, Tumorimmunol Program, Div Immunogenet, D-69120 Heidelberg, Germany; Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 2, D-81377 Munich, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Hosp Schleswig Holstein, Dept Internal Med 1, D-24105 Kiel, Germany; Univ Munich, Univ Hosp Grosshadern, Dept Surg, D-81377 Munich, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Kiel; Schleswig Holstein University Hospital; University of Munich	Krammer, PH (corresponding author), German Canc Res Ctr, Tumorimmunol Program, Div Immunogenet, INF 280, D-69120 Heidelberg, Germany.	p.krammer@dkfz.de	Sebens, Susanne/C-1222-2010; Krueger, Andreas/M-9769-2019; Krueger, Andreas/B-9427-2009	Krueger, Andreas/0000-0001-7873-7334; Krueger, Andreas/0000-0001-7873-7334				ALLOLIO B, 1989, DEUT MED WOCHENSCHR, V114, P381, DOI 10.1055/s-2008-1066605; Chen EY, 2001, CANCER RES, V61, P2429; CHESON BD, 1987, JAMA-J AM MED ASSOC, V258, P1347, DOI 10.1001/jama.258.10.1347; Collette Y, 1997, EUR J IMMUNOL, V27, P3283, DOI 10.1002/eji.1830271227; Eichhorst ST, 2001, CANCER RES, V61, P243; EISENBERGER MA, 1994, CANCER TREAT REV, V20, P259, DOI 10.1016/0305-7372(94)90003-5; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; Huwiler A, 2002, BRIT J PHARMACOL, V136, P520, DOI 10.1038/sj.bjp.0704748; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Kharlamov A, 2002, EXP BRAIN RES, V147, P353, DOI 10.1007/s00221-002-1251-1; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer P H, 1999, Adv Immunol, V71, P163; Krammer PH, 1998, ADV CANCER RES, V75, P251, DOI 10.1016/S0065-230X(08)60744-7; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kuyu H, 1999, ANN ONCOL, V10, P891, DOI 10.1023/A:1008385607847; Lambrecht G, 2002, CURR PHARM DESIGN, V8, P2371, DOI 10.2174/1381612023392973; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; McNally WP, 2000, LIFE SCI, V67, P1847, DOI 10.1016/S0024-3205(00)00767-0; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; MITSUYA H, 1984, SCIENCE, V226, P172, DOI 10.1126/science.6091268; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Rokhlin OW, 1997, CANCER RES, V57, P1758; Scaffidi C, 1999, METHODS, V17, P287, DOI 10.1006/meth.1999.0742; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Small EJ, 2002, J CLIN ONCOL, V20, P3369, DOI 10.1200/JCO.2002.10.022; Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; VOOGD TE, 1993, PHARMACOL REV, V45, P177; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; ZHAO XM, 1995, J IMMUNOL, V155, P3904	39	64	67	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					602	609		10.1038/nm1049	http://dx.doi.org/10.1038/nm1049			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15146177				2022-12-27	WOS:000221759600025
J	Scanlan, TS; Suchland, KL; Hart, ME; Chiellini, G; Huang, Y; Kruzich, PJ; Frascarelli, S; Crossley, DA; Bunzow, JR; Ronca-Testoni, S; Lin, ET; Hatton, D; Zucchi, R; Grandy, DK				Scanlan, TS; Suchland, KL; Hart, ME; Chiellini, G; Huang, Y; Kruzich, PJ; Frascarelli, S; Crossley, DA; Bunzow, JR; Ronca-Testoni, S; Lin, ET; Hatton, D; Zucchi, R; Grandy, DK			3-iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone	NATURE MEDICINE			English	Article							BODY-TEMPERATURE; RECEPTOR; RAT; DOPAMINE; AGENTS; METABOLITES; THYROXINE; SUBTYPE	Thyroxine (T-4) is the predominant form of thyroid hormone (TH). Hyperthyroidism, a condition associated with excess TH, is characterized by increases in metabolic rate, core body temperature and cardiac performance. In target tissues, T-4 is enzymatically deiodinated to 3,5,3-triiodothyronine (T-3), a high-affinity ligand for the nuclear TH receptors TRalpha and TRbeta, whose activation controls normal vertebrate development and physiology(1). T-3-modulated transcription of target genes via activation of TRalpha and TRbeta is a slow process, the effects of which manifest over hours and days. Although rapidly occurring effects of TH have been documented, the molecules that mediate these non-genomic effects remain obscure(2,3). Here we report the discovery of 3-iodothyronamine (T(1)AM), a naturally occurring derivative of TH that in vitro is a potent agonist of the G protein-coupled trace amine receptor TAR1. Administering T(1)AM in vivo induces profound hypothermia and bradycardia within minutes. T(1)AM treatment also rapidly reduces cardiac output in an ex vivo working heart preparation. These results suggest the existence of a new signaling pathway, stimulation of which leads to rapid physiological and behavioral consequences that are opposite those associated with excess TH.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA; Univ Pisa, Sez Biochim, Dipartimento Sci Uomo & Ambiente, I-56100 Pisa, Italy; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Oregon Health & Science University; University of Pisa; University of California System; University of California San Francisco; Oregon Health & Science University; Oregon Health & Science University	Grandy, DK (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	grandyd@ohsu.edu	Zucchi, Riccardo/AAC-8963-2022; Crossley, Dane A/S-4997-2016	Crossley, Dane A/0000-0001-9683-7013; ZUCCHI, RICCARDO/0000-0002-6450-3788	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052798, R01DK052798] Funding Source: NIH RePORTER; NIDA NIH HHS [DA107803, DA07262] Funding Source: Medline; NIDDK NIH HHS [DK-52798] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERT PR, 1990, J BIOL CHEM, V265, P2098; Borowsky B, 2001, P NATL ACAD SCI USA, V98, P8966, DOI 10.1073/pnas.151105198; Branchek TA, 2003, CURR OPIN PHARMACOL, V3, P90, DOI 10.1016/S1471-4892(02)00028-0; Bunzow JR, 2001, MOL PHARMACOL, V60, P1181, DOI 10.1124/mol.60.6.1181; Butz GM, 2001, PHYSIOL GENOMICS, V5, P89, DOI 10.1152/physiolgenomics.2001.5.2.89; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; CLARK WG, 1985, NEUROSCI BIOBEHAV R, V9, P299, DOI 10.1016/0149-7634(85)90052-1; CLARK WG, 1980, NEUROSCI BIOBEHAV R, V4, P281, DOI 10.1016/0149-7634(80)90002-0; CLARK WG, 1980, NEUROSCI BIOBEHAV R, V4, P175, DOI 10.1016/0149-7634(80)90015-9; Davis PJ, 1996, THYROID, V6, P497, DOI 10.1089/thy.1996.6.497; DRATMAN MB, 1974, J THEOR BIOL, V46, P255, DOI 10.1016/0022-5193(74)90151-9; Falkenstein E, 2000, PHARMACOL REV, V52, P513; GRANDY DK, 1991, P NATL ACAD SCI USA, V88, P9175, DOI 10.1073/pnas.88.20.9175; NEELY JR, 1967, AM J PHYSIOL, V212, P804; Pinna G, 2002, ENDOCRINOLOGY, V143, P1789, DOI 10.1210/en.143.5.1789; Stohr R, 1931, H-S Z PHYSIOL CHEM, V201, P142, DOI 10.1515/bchm2.1931.201.3-4.142; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TIBERI M, 1994, J BIOL CHEM, V269, P27925; TOMITA K, 1956, J BIOL CHEM, V219, P595; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0; ZHU MY, 1995, GEN PHARMACOL-VASC S, V26, P681, DOI 10.1016/0306-3623(94)00223-A; ZUCCHI R, 1994, CIRC RES, V74, P271, DOI 10.1161/01.RES.74.2.271	23	349	372	2	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					638	642		10.1038/nm1051	http://dx.doi.org/10.1038/nm1051			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15146179				2022-12-27	WOS:000221759600030
J	Ramanathan, C; Ghanem, RN; Jia, P; Ryu, K; Rudy, Y				Ramanathan, C; Ghanem, RN; Jia, P; Ryu, K; Rudy, Y			Noninvasive electrocardiographic imaging for cardiac electrophysiology and arrhythmia	NATURE MEDICINE			English	Article							ATRIAL-FLUTTER; VENTRICULAR-TACHYCARDIA; EPICARDIAL POTENTIALS; CRISTA TERMINALIS; HUMAN HEART; ACTIVATION; SURFACE; RECONSTRUCTION; REPOLARIZATION; ELECTROGRAMS	Over 7 million people worldwide die annually from erratic heart rhythms (cardiac arrhythmias), and many more are disabled. Yet there is no imaging modality to identify patients at risk, provide accurate diagnosis and guide therapy. Standard diagnostic techniques such as the electrocardiogram (ECG) provide only low-resolution projections of cardiac electrical activity on the body surface. Here we demonstrate the successful application in humans of a new imaging modality called electrocardiographic imaging (ECGI), which noninvasively images cardiac electrical activity in the heart. In ECGI, a multielectrode vest records 224 body-surface electrocardiograms; electrical potentials, electrograms and isochrones are then reconstructed on the heart's surface using geometrical information from computed tomography (CT) and a mathematical algorithm. We provide examples of ECGI application during atrial and ventricular activation and ventricular repolarization in (i) normal heart (ii) heart with a conduction disorder (right bundle branch block) (iii) focal activation initiated by right or left ventricular pacing, and (iv) atrial flutter.	Case Western Reserve Univ, Cardiac Bioelect Res & Training Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Rudy, Y (corresponding author), Case Western Reserve Univ, Cardiac Bioelect Res & Training Ctr, Cleveland, OH 44106 USA.	yxr@po.cwru.edu			NHLBI NIH HHS [R37-HL-33343, R37 HL033343-20, R37 HL033343, R01 HL049054, R01-HL-49054] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049054, R37HL033343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARISI G, 1983, CIRC RES, V52, P706, DOI 10.1161/01.RES.52.6.706; Biermann M, 2003, CARDIAC MAPPING, P15; Burnes JE, 2000, CIRCULATION, V102, P2152, DOI 10.1161/01.CIR.102.17.2152; Burnes JE, 2000, CIRCULATION, V101, P533, DOI 10.1161/01.CIR.101.5.533; Burnes JE, 2001, J AM COLL CARDIOL, V38, P2071, DOI 10.1016/S0735-1097(01)01653-9; Daoud EG, 1998, ANNU REV MED, V49, P77; DURRER D, 1970, CIRCULATION, V41, P899, DOI 10.1161/01.CIR.41.6.899; Ghanem RN, 2003, IEEE T MED IMAGING, V22, P1307, DOI 10.1109/TMI.2003.818263; Ghanem RN, 2001, CIRCULATION, V104, P1306, DOI 10.1161/hc3601.094277; Gima K, 2002, CIRC RES, V90, P889, DOI 10.1161/01.RES.0000016960.61087.86; HAWS CW, 1990, CIRCULATION, V81, P281, DOI 10.1161/01.CIR.81.1.281; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; JOUVE A, 1959, AM HEART J, V59, P856; KUPERSMITH J, 1976, PROG CARDIOVASC DIS, V19, P167, DOI 10.1016/0033-0620(76)90015-3; LIEBMAN J, 1984, J ELECTROCARDIOL, V17, P329, DOI 10.1016/S0022-0736(84)80070-9; LUX RL, 1994, J ELECTROCARDIOL, V27, P100, DOI 10.1016/S0022-0736(94)80065-0; Matsuo K, 2001, AM J PHYSIOL-HEART C, V280, pH1683, DOI 10.1152/ajpheart.2001.280.4.H1683; Oster HS, 1997, CIRCULATION, V96, P1012; Oster HS, 1998, CIRCULATION, V97, P1496; Ramanathan C, 2003, ANN BIOMED ENG, V31, P981, DOI 10.1114/1.1588655; Rodriguez LM, 2001, CIRCULATION, V104, P2545, DOI 10.1161/hc4601.097996; ROOS JP, 1968, BRIT HEART J, V30, P630; RUDY Y, 1992, CRIT REV BIOMED ENG, V20, P25; Rudy Y., 1999, ANN NONINVAS ELECTRO, V4, P340, DOI DOI 10.1111/J.1542-474X.1999.TB00220.X; Sosa E, 1998, J CARDIOVASC ELECTR, V9, P229, DOI 10.1111/j.1540-8167.1998.tb00907.x; SPACH MS, 1977, CIRCULATION, V55, P268, DOI 10.1161/01.CIR.55.2.268; Tikhonov A., 1977, SOLUTION ILL POSED P, P45; WYNDHAM CR, 1979, CIRCULATION, V59, P161, DOI 10.1161/01.CIR.59.1.161; Yamabe H, 2002, PACE, V25, P132, DOI 10.1046/j.1460-9592.2002.00132.x	29	438	482	2	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					422	428		10.1038/nm1011	http://dx.doi.org/10.1038/nm1011			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034569	Green Accepted			2022-12-27	WOS:000220587000036
J	Millar, DG; Garza, KM; Odermatt, B; Elford, AR; Ono, N; Li, Z; Ohashi, PS				Millar, DG; Garza, KM; Odermatt, B; Elford, AR; Ono, N; Li, Z; Ohashi, PS			Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo	NATURE MEDICINE			English	Article							HEAT-SHOCK-PROTEIN; IMMATURE DENDRITIC CELLS; GP96 INDUCES MATURATION; NF-KAPPA-B; CROSS-PRESENTATION; PEPTIDE COMPLEXES; CUTTING EDGE; RECEPTOR; ACTIVATION; INDUCTION	Pathogens or pathogen- associated molecular patterns can signal to cells of the innate immune system and trigger effective adaptive immunity. However, relatively little is known about how the innate immune system detects tissue injury or necrosis. Evidence suggests that the release of heat- shock proteins (HSPs) may provide adjuvant- like signals, but the ability of HSPs to promote activation or tolerance in vivo has not been addressed. In this study we show that Hsp70 promotes dendritic cell (DC) function and, together with antigen, triggers autoimmune disease in vivo.	Ontario Canc Inst, Univ Hlth Network, Dept Immunol, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Univ Hlth Network, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Texas, Dept Biol Sci, El Paso, TX 79968 USA; Univ Zurich Hosp, Dept Expt Pathol, Inst Pathol, CH-8091 Zurich, Switzerland; Univ Connecticut, Ctr Immunotherapy Canc & Infect Dis, Farmington, CT 06030 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Texas System; University of Texas El Paso; University of Zurich; University Zurich Hospital; University of Connecticut	Ohashi, PS (corresponding author), Ontario Canc Inst, Univ Hlth Network, Dept Immunol, Toronto, ON M5G 2M9, Canada.	pohashi@uhnres.utoronto.ca		ONO, NOBUYUKI/0000-0003-0709-4858; Ohashi, Pamela S./0000-0003-2915-9317; Millar, Douglas/0000-0002-8640-7148	NATIONAL CANCER INSTITUTE [K08CA090337] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR008124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008012] Funding Source: NIH RePORTER; NCI NIH HHS [CA90337] Funding Source: Medline; NCRR NIH HHS [SG12RR08124] Funding Source: Medline; NIGMS NIH HHS [S06GM08012] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Asea A, 2000, CELL STRESS CHAPERON, V5, P425, DOI 10.1379/1466-1268(2000)005<0425:HPBAPN>2.0.CO;2; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bansal-Pakala P, 2001, NAT MED, V7, P907, DOI 10.1038/90942; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Breloer M, 1999, J IMMUNOL, V162, P3141; Chan VSF, 2002, EUR J IMMUNOL, V32, P1223, DOI 10.1002/1521-4141(200205)32:5<1223::AID-IMMU1223>3.0.CO;2-5; Chen W, 1999, J IMMUNOL, V162, P3212; CHILLER JM, 1973, J EXP MED, V137, P740, DOI 10.1084/jem.137.3.740; Cho BK, 2000, IMMUNITY, V12, P263, DOI 10.1016/S1074-7613(00)80179-X; Ciupitu AMT, 1998, J EXP MED, V187, P685, DOI 10.1084/jem.187.5.685; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Ehl S, 1998, J EXP MED, V187, P763, DOI 10.1084/jem.187.5.763; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; Garza KM, 2000, J EXP MED, V191, P2021, DOI 10.1084/jem.191.11.2021; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kuppner MC, 2001, EUR J IMMUNOL, V31, P1602, DOI 10.1002/1521-4141(200105)31:5<1602::AID-IMMU1602>3.0.CO;2-W; KYBURZ D, 1993, EUR J IMMUNOL, V23, P1956, DOI 10.1002/eji.1830230834; LIU B, IN PRESS P NATL ACAD; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Moroi Y, 2000, P NATL ACAD SCI USA, V97, P3485, DOI 10.1073/pnas.070550797; Nguyen LT, 2002, J EXP MED, V195, P423, DOI 10.1084/jem.20010032; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; Schuurhuis DH, 2000, J EXP MED, V192, P145, DOI 10.1084/jem.192.1.145; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Somersan S, 2001, J IMMUNOL, V167, P4844, DOI 10.4049/jimmunol.167.9.4844; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Srivastava PK, 1997, METHODS, V12, P165, DOI 10.1006/meth.1997.0464; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Suzue K, 1997, P NATL ACAD SCI USA, V94, P13146, DOI 10.1073/pnas.94.24.13146; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Wang YF, 2001, IMMUNITY, V15, P971, DOI 10.1016/S1074-7613(01)00242-4	55	217	233	1	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2003	9	12					1469	1476		10.1038/nm962	http://dx.doi.org/10.1038/nm962			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625545				2022-12-27	WOS:000186845400029
J	Phan, V; Errington, F; Cheong, SC; Kottke, T; Gough, M; Altmann, S; Brandenburger, A; Emery, S; Strome, S; Bateman, A; Bonnotte, B; Melcher, A; Vile, R				Phan, V; Errington, F; Cheong, SC; Kottke, T; Gough, M; Altmann, S; Brandenburger, A; Emery, S; Strome, S; Bateman, A; Bonnotte, B; Melcher, A; Vile, R			A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines	NATURE MEDICINE			English	Article							RETROVIRAL VECTORS; CLINICAL-TRIAL; VACCINATION; GLYCOPROTEIN; IMMUNITY; THERAPY	Fusion of tumor cells with antigen-presenting cells (APCs) has been proposed for the preparation of cancer vaccines. However, generation of these hybrids, using physical or chemical methods such as electrofusion or polyethylene glycol (PEG), has been difficult to standardize. Characterization of cell fusion has also been problematic because of difficulties in differentiating fusion from cell aggregation, leakage of cellular dyes and dendritic-cell (DC) phagocytosis of tumor material. In this report, we describe a new method to generate hybrid cell vaccines, based on gene transfer of a viral fusogenic membrane glycoprotein (FMG) into tumor cells, and incorporate a genetic method by which true hybrid formation can be unambiguously detected. We describe a new class of tumor cell-DC hybrid that can be rapidly isolated after cell fusion. These hybrids are highly potent in in vitro antigen presentation assays, target lymph nodes in vivo and are powerful immunogens against established metastatic disease.	Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; St James Hosp, CRUK Oncol Unit, Leeds LS9 7TF, W Yorkshire, England; Free Univ Brussels, B-6041 Gosselies, Belgium; AstraZeneca, Alderley Pk SK10, Cheshire, England; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Rochester, MN 55905 USA; Fac Med, INSERM, U517, F-21079 Dijon, France; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Saint James's University Hospital; AstraZeneca; Mayo Clinic; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Mayo Clinic	Vile, R (corresponding author), Mayo Clin & Mayo Fdn, Program Mol Med, 200 1st St SW, Rochester, MN 55905 USA.	vile.richard@mayo.edu	Errington-Mais, Fiona/AAK-7245-2020; Gough, Michael/AAY-3419-2020; Bonnotte, Bernard/ABA-2525-2021	Gough, Michael/0000-0002-5575-0074; Bonnotte, Bernard/0000-0002-1098-4598; Errington-Mais, Fiona/0000-0003-2155-534X	NATIONAL CANCER INSTITUTE [R01CA085931, P50CA091956, R01CA094180] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA91956, R01 CA094180, R01 CA85931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman DG, 1991, PRACTICAL STAT MED R, P365; Bateman A, 2000, CANCER RES, V60, P1492; BATEMAN A, 2002, THESIS OPEN U; Diaz RM, 2000, GENE THER, V7, P1656, DOI 10.1038/sj.gt.3301277; Diaz RM, 1998, J VIROL, V72, P789, DOI 10.1128/JVI.72.1.789-795.1998; Fielding AK, 2000, HUM GENE THER, V11, P817, DOI 10.1089/10430340050015437; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Kikuchi T, 2001, CANCER IMMUNOL IMMUN, V50, P337, DOI 10.1007/s002620100205; Koido S, 2002, J IMMUNOL, V168, P2111, DOI 10.4049/jimmunol.168.5.2111; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Linardakis E, 2002, CANCER RES, V62, P5495; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; Trefzer U, 2000, INT J CANCER, V85, P618; Trefzer U, 2000, METH MOLEC MED, V35, P469, DOI 10.1385/1-59259-086-1:469; Trefzer U, 2000, E SCHERING RES FDN W, V30, P155; Tsujimoto H, 2001, INT J ONCOL, V19, P89; VILE RG, 1995, VIROLOGY, V214, P307, DOI 10.1006/viro.1995.9923; Walden P, 2000, ADV EXP MED BIOL, V465, P347; Wang JL, 1998, J IMMUNOL, V161, P5516	20	60	65	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2003	9	9					1215	1219		10.1038/nm923	http://dx.doi.org/10.1038/nm923			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925849				2022-12-27	WOS:000185061600036
J	Hrachovinova, I; Cambien, B; Hafezi-Moghadam, A; Kappelmayer, J; Camphausen, RT; Widom, A; Xia, LJ; Kazazian, HH; Schaub, RG; McEver, RP; Wagner, DD				Hrachovinova, I; Cambien, B; Hafezi-Moghadam, A; Kappelmayer, J; Camphausen, RT; Widom, A; Xia, LJ; Kazazian, HH; Schaub, RG; McEver, RP; Wagner, DD			Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A	NATURE MEDICINE			English	Article							TISSUE FACTOR; IN-VIVO; TYROSINE PHOSPHORYLATION; GLYCOPROTEIN LIGAND-1; VENOUS THROMBOSIS; SOLUBLE FORM; FACTOR-VIII; EXPRESSION; PLATELETS; ADHESION	High plasma levels of soluble P-selectin are associated with thrombotic disorders and may predict future cardiovascular events. Mice with high levels of soluble P-selectin have more microparticles in their plasma than do normal mice. Here we show that chimeras of P-selectin and immunoglobulin (P-sel-Ig) induced formation of procoagulant microparticles in human blood through P-selectin glycoprotein ligand-1 (PSGL-1; encoded by the Psgl1 gene, officially known as Selpl). In addition, Psgl1(-/-) mice produced fewer microparticles after P-sel-Ig infusion and did not spontaneously increase their microparticle count in old age as do wild-type mice. Injected microparticles specifically bound to thrombi and thus could be involved in thrombin generation at sites of injury. Infusion of P-sel-Ig into hemophilia A mice produced a 20-fold increase over control immunoglobulin in microparticles containing tissue factor. This significantly improved the kinetics of fibrin formation in the hemophilia A mice and normalized their tail-bleeding time. P-sel-Ig treatment could become a new approach to sustained control of bleeding in hemophilia.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Wyeth Res, Cambridge, MA 02140 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Pfizer; University of Pennsylvania; University of Pennsylvania	Wagner, DD (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.	wagner@cbr.med.harvard.edu	Cambien, Béatrice/AAD-8973-2021	Cambien, Béatrice/0000-0002-6914-0525; Hafezi-Moghadam, Ali/0000-0002-5336-0697	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054502, R01HL053756, P01HL056949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54502, R01 HL053756, P01 HL056949, HL56949] Funding Source: Medline; PHS HHS [53756] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Andre P, 2000, P NATL ACAD SCI USA, V97, P13835, DOI 10.1073/pnas.250475997; Barkalow FJ, 2000, BLOOD, V96, P3070; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Burger PC, 2003, BLOOD, V101, P2661, DOI 10.1182/blood-2002-07-2209; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CHONG BH, 1994, BLOOD, V83, P1535; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; DiMichele DM, 2000, HAEMOPHILIA, V6, P38; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; DUNLOP LC, 1992, J EXP MED, V175, P1147, DOI 10.1084/jem.175.4.1147; Evangelista V, 1999, BLOOD, V93, P876, DOI 10.1182/blood.V93.3.876.403k25_876_885; Falati S, 2002, NAT MED, V8, P1175, DOI 10.1038/nm782; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Hartwell DM, 1998, J CELL BIOL, V143, P1129, DOI 10.1083/jcb.143.4.1129; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; Hillis GS, 2002, AM HEART J, V143, P235, DOI 10.1067/mhj.2002.120303; IKEDA H, 1995, CIRCULATION, V92, P1693, DOI 10.1161/01.CIR.92.7.1693; ISHIWATA N, 1994, J BIOL CHEM, V269, P23708; Kumar A, 1999, CIRCULATION, V99, P1363, DOI 10.1161/01.CIR.99.10.1363; Kung SH, 1998, BLOOD, V91, P784, DOI 10.1182/blood.V91.3.784.784_784_790; Lacroix-Desmazes S, 2002, HAEMOPHILIA, V8, P273, DOI 10.1046/j.1365-2516.2002.00624.x; Mannucci PM, 2001, NEW ENGL J MED, V344, P1773, DOI 10.1056/NEJM200106073442307; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 2002, THROMB HAEMOSTASIS, V87, P364; Mehta P, 1997, BLOOD, V90, P2381, DOI 10.1182/blood.V90.6.2381.2381_2381_2389; Michelson AD, 2001, CIRCULATION, V104, P1533, DOI 10.1161/hc3801.095588; Muchitsch EM, 1999, THROMB HAEMOSTASIS, V82, P1371; Myers D, 2002, THROMB HAEMOSTASIS, V87, P374, DOI 10.1055/s-0037-1613014; NEMERSON Y, 1988, BLOOD, V71, P1; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; Parker C, 2001, ATHEROSCLEROSIS, V156, P417, DOI 10.1016/S0021-9150(00)00672-9; Piccardoni P, 2001, BLOOD, V98, P108, DOI 10.1182/blood.V98.1.108; Prorock AJ, 2003, AM J PHYSIOL-HEART C, V284, pH133, DOI 10.1152/ajpheart.00957.2001; Rauch U, 2000, BLOOD, V96, P170, DOI 10.1182/blood.V96.1.170.013k42_170_175; Ridker PM, 2001, CIRCULATION, V103, P491, DOI 10.1161/01.CIR.103.4.491; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SALZMAN EW, 1994, HEMOSTASIS THROMBOSI, P1275; TOOMBS CF, 1995, J PHARMACOL EXP THER, V275, P941; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Wakefield TW, 1996, J SURG RES, V64, P26, DOI 10.1006/jsre.1996.0301; Xia LJ, 2002, J CLIN INVEST, V109, P939	45	247	257	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2003	9	8					1020	1025		10.1038/nm899	http://dx.doi.org/10.1038/nm899			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12858167				2022-12-27	WOS:000184484900025
J	Tan, GD; Debard, C; Tiraby, C; Humphreys, SM; Frayn, KN; Langin, D; Vidal, H; Karpe, F				Tan, GD; Debard, C; Tiraby, C; Humphreys, SM; Frayn, KN; Langin, D; Vidal, H; Karpe, F			A "futile cycle" induced by thiazolidinediones in human adipose tissue?	NATURE MEDICINE			English	Letter							FATTY-ACID METABOLISM; ROSIGLITAZONE		Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Churchill Hosp, Oxford OX3 7LJ, England; Univ Lyon 1, INSERM, U449, R Laennec Fac Med, F-69372 Lyon 08, France; Univ Toulouse 3, Unite Rech Obes, INSERM, U586,Inst Louis Bugnard,Ctr Hosp Univ Toulouse, F-31403 Toulouse 4, France	University of Oxford; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Tan, GD (corresponding author), Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Churchill Hosp, S Parks Rd, Oxford OX3 7LJ, England.	garry.tan@oxlip.ox.ac.uk	Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317; Langin, Dominique/0000-0002-2669-7825; Karpe, Fredrik/0000-0002-2751-1770				Basu A, 2001, AM J PHYSIOL-ENDOC M, V280, pE1000, DOI 10.1152/ajpendo.2001.280.6.E1000; CHAKRABARTY K, 1984, INT J OBESITY, V8, P609; Finegood DT, 2001, DIABETES, V50, P1021, DOI 10.2337/diabetes.50.5.1021; Frayn KN, 2000, METH MOL B, V155, P269; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Jensen MD, 2002, J ROY SOC MED, V95, P3; Maggs DG, 1998, ANN INTERN MED, V128, P176, DOI 10.7326/0003-4819-128-3-199802010-00002; Miyazaki Y, 2001, DIABETOLOGIA, V44, P2210, DOI 10.1007/s001250100031; Racette SB, 2002, METABOLISM, V51, P169, DOI 10.1053/meta.2002.29981	10	29	33	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					811	812		10.1038/nm0703-811	http://dx.doi.org/10.1038/nm0703-811			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835685				2022-12-27	WOS:000183979300010
J	Barozzi, P; Luppi, M; Facchetti, F; Mecucci, C; Alu, M; Sarid, R; Rasini, V; Ravazzini, L; Rossi, E; Festa, S; Crescenzi, B; Wolf, DG; Schulz, TF; Torelli, G				Barozzi, P; Luppi, M; Facchetti, F; Mecucci, C; Alu, M; Sarid, R; Rasini, V; Ravazzini, L; Rossi, E; Festa, S; Crescenzi, B; Wolf, DG; Schulz, TF; Torelli, G			Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors	NATURE MEDICINE			English	Article							HUMAN-HERPESVIRUS-8 INFECTION; HISTOLOGICAL SECTIONS; SPINDLE CELLS; TRANSMISSION; HERPESVIRUS; RECIPIENTS; BLOOD; IDENTIFICATION; MICROCHIMERISM; PRECURSORS	Kaposi sarcoma (KS) is a vascular tumor that can develop in recipients of solid tissue transplants as a result of either primary infection or reactivation of a gammaherpesvirus, the KS-associated herpesvirus, also known as human herpesvirus-8 (HHV-8). We studied whether HHV-8 and the elusive KS progenitor cells could be transmitted from the donor through the grafts. We used a variety of molecular, cytogenetic, immunohistochemical and immunofluorescence methods to show that the HHV-8-infected neoplastic cells in post-transplant KS from five of eight renal transplant patients harbored either genetic or antigenic markers of their matched donors. These data suggest the use of donor-derived HHV-8-specific T cells for the control of post-transplant KS.	Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy; Univ Brescia, Dept Pathol, Brescia, Italy; Univ Perugia, Dept Clin & Expt Med, Sect Hematol & Clin Immunol, I-06100 Perugia, Italy; Univ Modena & Reggio Emilia, Dept Morphol Sci & Forens Med, Sect Forens Med, Modena, Italy; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; Hadassah Univ Hosp, Dept Clin Microbiol & Infect Dis, IL-91120 Jerusalem, Israel; Hannover Med Sch, Dept Virol, D-3000 Hannover, Germany	Universita di Modena e Reggio Emilia; University of Brescia; University of Perugia; Universita di Modena e Reggio Emilia; Bar Ilan University; Hebrew University of Jerusalem; Hannover Medical School	Luppi, M (corresponding author), Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy.		Rossi, Elisa/AAO-8202-2020; Comoli, Patrizia/K-2732-2018; Facchetti, Fabio/E-7190-2010; Rossi, Elisa/D-6387-2014; Luppi, Mario/J-3668-2016; Barozzi, Patrizia/Q-2638-2016; Schulz, Thomas/AAA-1634-2019	Rossi, Elisa/0000-0002-0570-6104; Comoli, Patrizia/0000-0001-5964-0553; Facchetti, Fabio/0000-0003-4975-2388; Rossi, Elisa/0000-0002-0570-6104; Luppi, Mario/0000-0002-0373-1154; Barozzi, Patrizia/0000-0002-8936-1114; Schulz, Thomas/0000-0001-8792-5345				Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Bodo I, 1999, NEW ENGL J MED, V341, P807, DOI 10.1056/NEJM199909093411105; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BROWNING PJ, 1994, BLOOD, V84, P2711, DOI 10.1182/blood.V84.8.2711.bloodjournal8482711; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DICTOR M, 1988, AM J PATHOL, V130, P411; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Kanzler H, 2000, BLOOD, V95, P1023, DOI 10.1182/blood.V95.3.1023.003k07_1023_1031; KOKOVA M, 1993, LANCET, V342, P140; Kruskall MS, 2001, BLOOD, V98, P272, DOI 10.1182/blood.V98.2.272; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Lee TH, 1999, BLOOD, V93, P3127; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Luppi M, 2000, NEW ENGL J MED, V343, P1378, DOI 10.1056/NEJM200011093431905; Luppi M, 2000, BLOOD, V96, P3279; Maloney S, 1999, J CLIN INVEST, V104, P41, DOI 10.1172/JCI6611; Masood S, 1998, ANN CLIN LAB SCI, V28, P215; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Parravicini C, 1997, BLOOD, V90, P2826; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Qian JQ, 1996, AM J PATHOL, V149, P1193; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; Rao AS, 1996, CLIN IMMUNOL IMMUNOP, V80, pS46, DOI 10.1006/clin.1996.0141; Regamey N, 1998, NEW ENGL J MED, V339, P1358, DOI 10.1056/NEJM199811053391903; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; Sarid R, 2001, CLIN INFECT DIS, V32, P1502, DOI 10.1086/320153	26	148	163	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					554	561		10.1038/nm862	http://dx.doi.org/10.1038/nm862			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692543				2022-12-27	WOS:000182610600036
J	Fujimuro, M; Wu, FY; ApRhys, C; Kajumbula, H; Young, DB; Hayward, GS; Hayward, SD				Fujimuro, M; Wu, FY; ApRhys, C; Kajumbula, H; Young, DB; Hayward, GS; Hayward, SD			A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency	NATURE MEDICINE			English	Article							MULTICENTRIC CASTLEMANS-DISEASE; PRIMARY EFFUSION LYMPHOMA; NUCLEAR ANTIGEN; GENE-EXPRESSION; DNA-SEQUENCES; COLON-CARCINOMA; BOX PROTEIN; CYCLIN D1; CELLS; HUMAN-HERPESVIRUS-8	The Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen (LANA) is expressed in all KSHV-associated tumors, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL). We found that beta-catenin is overexpressed in both PEL cells and KS tissue. Introduction of anti-LANA small interfering RNA (siRNA) into PEL cells eliminated beta-catenin accumulation; LANA itself upregulated expression of beta-catenin in transfected cells. LANA stabilizes beta-catenin by binding to the negative regulator GSK-3beta causing a cell cycle-dependent nuclear accumulation of GSK-3beta. The LANA C terminus contains sequences similar to the GSK-3beta-binding domain of Axin. Disruption of this region resulted in a mutant LANA that failed to re-localize GSK-3beta or stabilize beta-catenin. The importance of this pathway to KSHV-driven cell proliferation was highlighted by the observation that LANA, but not mutant LANA, stimulates entry into S phase. Redistribution of GSK-3beta can therefore be a source of beta-catenin dysregulation in human cancers.	Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Hayward, SD (corresponding author), Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.		Fujimuro, Masahiro/AAC-4727-2020	Kajumbula, Henry/0000-0002-2075-0007; Fujimuro, Masahiro/0000-0002-5165-0789	NATIONAL CANCER INSTITUTE [R01CA085151, P01CA081400] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85151, P01 CA81400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Barker N, 2000, ADV CANCER RES, V77, P1; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Fakhari FD, 2002, J VIROL, V76, P6213, DOI 10.1128/JVI.76.12.6213-6223.2002; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hu JH, 2002, J VIROL, V76, P11677, DOI 10.1128/JVI.76.22.11677-11687.2002; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Olsen SJ, 2000, J INFECT DIS, V182, P306, DOI 10.1086/315689; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Polakis P, 2000, GENE DEV, V14, P1837; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443; Wright M, 1999, BIOCHEM BIOPH RES CO, V263, P384, DOI 10.1006/bbrc.1999.1344; Wu FY, 2001, J VIROL, V75, P1487, DOI 10.1128/JVI.75.3.1487-1506.2001	38	250	267	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					300	306		10.1038/nm829	http://dx.doi.org/10.1038/nm829			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12592400				2022-12-27	WOS:000181312300030
J	Tunaru, S; Kero, J; Schaub, A; Wufka, C; Blaukat, A; Pfeffer, K; Offermanns, S				Tunaru, S; Kero, J; Schaub, A; Wufka, C; Blaukat, A; Pfeffer, K; Offermanns, S			PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect	NATURE MEDICINE			English	Article							PROTEIN-COUPLED RECEPTOR; MACROPHAGES; INHIBITION	Nicotinic acid (niacin), a vitamin of the B complex, has been used for almost 50 years as a lipid-lowering drug(1,2). The pharmacological effect of nicotinic acid requires doses that are much higher than those provided by a normal diet(3,4). Its primary action is to decrease lipolysis in adipose tissue by inhibiting hormone-sensitive triglyceride lipase(5). This anti-lipolytic effect of nicotinic acid involves the inhibition of cyclic adenosine monophosphate (cAMP) accumulation in adipose tissue(6) through a G(i)-protein-mediated inhibition of adenylyl cyclase(7-9). A G-protein-coupled receptor for nicotinic acid has been proposed in adipocytes(10,11). Here, we show that the orphan G-protein-coupled receptor, 'protein upregulated in macrophages by interferon-gamma' (mouse PUMA-G, human HM74)(12,13), is highly expressed in adipose tissue and is a nicotinic acid receptor. Binding of nicotinic acid to PUMA-G or HM74 results in a G(i)-mediated decrease in cAMP levels. In mice lacking PUMA-G, the nicotinic acid-induced decrease in free fatty acid (FFA) and triglyceride plasma levels was abrogated, indicating that PUMA-G mediates the anti-lipolytic and lipid-lowering effects of nicotinic acid in vivo. The identification of the nicotinic acid receptor may be useful in the development of new drugs to treat dyslipidemia.	Univ Heidelberg, Inst Pharmacol, D-6900 Heidelberg, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany; Univ Dusseldorf, Inst Med Microbiol, D-4000 Dusseldorf, Germany	Ruprecht Karls University Heidelberg; Technical University of Munich; Heinrich Heine University Dusseldorf	Pfeffer, K (corresponding author), Univ Heidelberg, Inst Pharmacol, D-6900 Heidelberg, Germany.		kero, jukka/G-3448-2014; Tunaru, Sorin/G-8516-2011; Offermanns, Stefan/L-3313-2017	kero, jukka/0000-0001-8767-7222; Tunaru, Sorin/0000-0002-6005-1737; Offermanns, Stefan/0000-0001-8676-6805; Pfeffer, Klaus/0000-0002-5652-6330				AKTORIES K, 1982, N-S ARCH PHARMACOL, V321, P247, DOI 10.1007/BF00498508; AKTORIES K, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1525; AKTORIES K, 1980, FEBS LETT, V115, P11, DOI 10.1016/0014-5793(80)80715-0; AKTORIES K, 1980, N-S ARCH PHARMACOL, V312, P167, DOI 10.1007/BF00569726; Baubet V, 2000, P NATL ACAD SCI USA, V97, P7260, DOI 10.1073/pnas.97.13.7260; BUTCHER RW, 1968, J BIOL CHEM, V243, P17005; CARLSON L A, 1968, Acta Medica Scandinavica, V183, P457; CARLSON LA, 1963, ACTA MED SCAND, V173, P719; FREDHOLM BB, 1981, INT J OBESITY, V5, P643; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; HOTZ W, 1983, ADV LIPID RES, V20, P195; KATHER H, 1983, FEBS LETT, V161, P149, DOI 10.1016/0014-5793(83)80749-2; Knopp RH, 1999, NEW ENGL J MED, V341, P498, DOI 10.1056/NEJM199908123410707; LENTNER C, 1984, GEIGY SCI TABLES, V3, P129; Lorenzen A, 2002, BIOCHEM PHARMACOL, V64, P645, DOI 10.1016/S0006-2952(02)01220-0; Lorenzen A, 2001, MOL PHARMACOL, V59, P349, DOI 10.1124/mol.59.2.349; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Olsson AG, 1994, HDB EXPT PHARM, V109, P349; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rudolph U, 1996, P NATL ACAD SCI USA, V93, P3209, DOI 10.1073/pnas.93.8.3209; Schaub A, 2001, EUR J IMMUNOL, V31, P3714, DOI 10.1002/1521-4141(200112)31:12<3714::AID-IMMU3714>3.0.CO;2-1; SVEDMYR N, 1969, CLIN PHARMACOL THER, V10, P559; Szapary Philippe O., 2001, Current Opinion in Pharmacology, V1, P113, DOI 10.1016/S1471-4892(01)00028-5; Yousefi S, 2000, BIOCHEM BIOPH RES CO, V277, P401, DOI 10.1006/bbrc.2000.3678	25	604	647	2	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					352	355		10.1038/nm824	http://dx.doi.org/10.1038/nm824			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12563315				2022-12-27	WOS:000181312300038
J	Dekel, B; Burakova, T; Arditti, FD; Reich-Zeliger, S; Milstein, O; Aviel-Ronen, S; Rechavi, G; Friedman, N; Kaminski, N; Passwell, JH; Reisner, Y				Dekel, B; Burakova, T; Arditti, FD; Reich-Zeliger, S; Milstein, O; Aviel-Ronen, S; Rechavi, G; Friedman, N; Kaminski, N; Passwell, JH; Reisner, Y			Human and porcine early kidney precursors as a new source for transplantation	NATURE MEDICINE			English	Article							CYTOLYTIC EFFECTOR MOLECULES; BLOOD MONONUCLEAR-CELLS; HUMAN FETAL KIDNEYS; ALLOGRAFT-REJECTION; RADIATION CHIMERA; MEDIATED-IMMUNITY; GENE-EXPRESSION; OSTEOPONTIN; METANEPHROI; CHEMOKINES	Kidney transplantation has been one of the major medical advances of the past 30 years. However, tissue availability remains a major obstacle. This can potentially be overcome by the use of undifferentiated or partially developed kidney precursor cells derived from early embryos and fetal tissue. Here, transplantation in mice reveals the earliest gestational time point at which kidney precursor cells, of both human and pig origin, differentiate into functional nephrons and not into other, non-renal professional cell types. Moreover, successful organogenesis is achieved when using the early kidney precursors, but not later-gestation kidneys. The formed, miniature kidneys are functional as evidenced by the dilute urine they produce. In addition, decreased immunogenicity of the transplants of early human and pig kidney precursors compared with adult kidney transplants is demonstrated in vivo. Our data pinpoint a window of human and pig kidney organogenesis that may be optimal for transplantation in humans.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Dept Pediat, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Funct Genom Unit, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Pediat Hematooncol, IL-52621 Tel Hashomer, Israel; Hebrew Univ Jerusalem, Sch Engn & Comp Sci, Jerusalem, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem	Reisner, Y (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.		Reisner, Yair/AAA-4772-2019; Friedman, Nir/H-9692-2012	Friedman, Nir/0000-0002-9678-3550; Reisner, Yair/0000-0002-3354-6945; Kaminski, Naftali/0000-0001-5917-4601				Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Benichou G, 1999, J IMMUNOL, V162, P352; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; Briscoe DM, 1999, TRANSPLANTATION, V67, P1590, DOI 10.1097/00007890-199906270-00014; Cascalho M, 2001, IMMUNITY, V14, P437, DOI 10.1016/S1074-7613(01)00124-8; Dekel B, 1997, TRANSPLANTATION, V64, P1541, DOI 10.1097/00007890-199712150-00007; Dekel B, 1997, TRANSPLANTATION, V64, P1550, DOI 10.1097/00007890-199712150-00008; Dekel B, 1999, INT IMMUNOL, V11, P1673, DOI 10.1093/intimm/11.10.1673; Dekel B, 2000, TRANSPLANTATION, V69, P1470, DOI 10.1097/00007890-200004150-00044; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GRITSCH HA, 1994, TRANSPLANTATION, V57, P906, DOI 10.1097/00007890-199403270-00024; Hammerman MR, 2002, CURR OPIN NEPHROL HY, V11, P11, DOI 10.1097/00041552-200201000-00002; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Kreisel D, 2002, NAT MED, V8, P233, DOI 10.1038/nm0302-233; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MEDAWAR PB, 1953, SYM SOC EXP BIOL, V7, P320; Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2; O'Regan AW, 2000, IMMUNOL TODAY, V21, P475, DOI 10.1016/S0167-5699(00)01715-1; Oliver JA, 2002, AM J PHYSIOL-RENAL, V283, pF799, DOI 10.1152/ajprenal.00375.2001; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Reisner Y, 1998, TRENDS BIOTECHNOL, V16, P242, DOI 10.1016/S0167-7799(98)01203-7; Rogers SA, 2001, AM J PHYSIOL-REG I, V281, pR661, DOI 10.1152/ajpregu.2001.281.2.R661; Rogers SA, 1998, KIDNEY INT, V54, P27, DOI 10.1046/j.1523-1755.1998.00971.x; Rogers SA, 2001, AM J PHYSIOL-REG I, V280, pR132, DOI 10.1152/ajpregu.2001.280.1.R132; Rogers SA, 2001, AM J PHYSIOL-REG I, V280, pR1865, DOI 10.1152/ajpregu.2001.280.6.R1865; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Segall H, 1996, BLOOD, V88, P721, DOI 10.1182/blood.V88.2.721.bloodjournal882721; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Vermeulen PB, 1996, EUR J CANCER, V32A, P2474, DOI 10.1016/S0959-8049(96)00379-6; WOOLF AS, 1990, KIDNEY INT, V38, P991, DOI 10.1038/ki.1990.303; WOOLF AS, 1999, PEDIAT NEPHROLOGY, P1; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099	37	204	218	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					53	60		10.1038/nm812	http://dx.doi.org/10.1038/nm812			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12496960				2022-12-27	WOS:000180209900022
J	Sun, YL; Chen, HM; Subudhi, SK; Chen, J; Koka, R; Chen, LP; Fu, YX				Sun, YL; Chen, HM; Subudhi, SK; Chen, J; Koka, R; Chen, LP; Fu, YX			Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease	NATURE MEDICINE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-4-1BB MONOCLONAL-ANTIBODIES; T-CELL; MURINE LUPUS; IFN-GAMMA; INTERFERON-GAMMA; IMMUNE-RESPONSES; MRL/LPR MICE; NITRIC-OXIDE; LPR MICE	Humans and mice deficient in Fas, a tumor necrosis factor (TNF)-receptor family member, cannot induce apoptosis of autoreactive cells, and consequently develop progressive lymphoproliferative disorders and lupus-like autoimmune diseases. Previous studies have shown that short-term administrations of agonistic monoclonal antibodies against CD137, another TNF-receptor family member, activate T cells and induce rejection of allografts and established tumors. Here we report that treatment with an agonistic monoclonal antibody to CD137 (2A) blocks lymphadenopathy and spontaneous autoimmune diseases in Fas-deficient MRL/Ipr mice, ultimately leading to their prolonged survival. Notably, 2A treatment rapidly augments IFN-production, and induces the depletion of autoreactive B cells and abnormal double-negative T cells, possibly by increasing their apoptosis through Fas- and TNF receptor-independent mechanisms. This study demonstrates that agonistic monoclonal antibodies specific for costimulatory molecules can be used as novel therapeutic agents to delete autoreactive lymphocytes and block autoimmune disease progression.	Univ Chicago, Dept Pathol & Committee Immunol, Chicago, IL 60637 USA; Mayo Clin, Dept Immunol, Rochester, MN USA	University of Chicago; Mayo Clinic	Fu, YX (corresponding author), Univ Chicago, Dept Pathol & Committee Immunol, Chicago, IL 60637 USA.			Subudhi, Sumit/0000-0001-5208-7732; fu, yang-xin/0000-0001-8441-6617	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R01DK058891, P30DK020595] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-37104] Funding Source: Medline; NIDDK NIH HHS [DK-20595-25, DK-58891] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; Balomenos D, 1998, J CLIN INVEST, V101, P364, DOI 10.1172/JCI750; Blazar BR, 2001, J IMMUNOL, V166, P3174, DOI 10.4049/jimmunol.166.5.3174; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DING AH, 1988, J IMMUNOL, V141, P2407; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; Haas C, 1997, J IMMUNOL, V158, P5484; Haendeler J, 1999, VITAM HORM, V57, P49; Halstead ES, 2002, NAT IMMUNOL, V3, P536, DOI 10.1038/ni798; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hoffman RW, 2001, FRONT BIOSCI-LANDMRK, V6, pD1369, DOI 10.2741/Hoffman; Jacobson BA, 1997, IMMUNOL REV, V156, P103, DOI 10.1111/j.1600-065X.1997.tb00962.x; Kaliyaperumal A, 1999, J IMMUNOL, V162, P5775; Kalled SL, 1998, J IMMUNOL, V160, P2158; Kelley VR, 1999, SEMIN NEPHROL, V19, P57; Kwon B, 2000, MOL CELLS, V10, P119, DOI 10.1007/s10059-000-0119-0; Lawson BR, 2000, J CLIN INVEST, V106, P207, DOI 10.1172/JCI10167; Liang BL, 2000, J IMMUNOL, V165, P3436, DOI 10.4049/jimmunol.165.6.3436; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, CELL IMMUNOL, V190, P167, DOI 10.1006/cimm.1998.1396; Mittler RS, 1999, J EXP MED, V190, P1535, DOI 10.1084/jem.190.10.1535; MOHAN C, 1995, J IMMUNOL, V154, P1470; MORSE HC, 1982, J IMMUNOL, V129, P2612; Nicoletti F, 2000, EUR J IMMUNOL, V30, P438; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; Peng SL, 1997, J CLIN INVEST, V99, P1936, DOI 10.1172/JCI119361; POLLOK KE, 1994, EUR J IMMUNOL, V24, P367, DOI 10.1002/eji.1830240215; POLLOK KE, 1993, J IMMUNOL, V150, P771; Schwarting A, 1998, J IMMUNOL, V161, P494; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; SUDA T, 1997, J ALLERGY CLIN IMMUN, V100, P97; Sun YL, 2002, J IMMUNOL, V168, P1457, DOI 10.4049/jimmunol.168.3.1457; THEOFILOPOULOS AN, 1981, IMMUNOL REV, V55, P179, DOI 10.1111/j.1600-065X.1981.tb00343.x; Vinay DS, 1998, SEMIN IMMUNOL, V10, P481, DOI 10.1006/smim.1998.0157; Wang J, 2001, J CLIN INVEST, V108, P1771, DOI 10.1172/JCI200113827; Wilcox RA, 2002, J CLIN INVEST, V109, P651, DOI 10.1172/JCI200214184; Williams MS, 1998, J IMMUNOL, V161, P6526; WOFSY D, 1984, J IMMUNOL, V132, P2686; Wofsy D, 1993, Immunol Ser, V59, P221	42	151	177	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1405	1413		10.1038/nm796	http://dx.doi.org/10.1038/nm796			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12426559				2022-12-27	WOS:000179552000037
J	McMahon, EJ; Bailey, SL; Castenada, CV; Waldner, H; Miller, SD				McMahon, EJ; Bailey, SL; Castenada, CV; Waldner, H; Miller, SD			Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DENDRITIC CELLS; LYMPH-NODES; ANTIGEN; PROGRESSION; BRAIN; EXPRESSION; RESPONSES; IMMUNITY	Chronic progression of two T cell-mediated central nervous system (CNS) demyelinating models of multiple sclerosis, relapsing EAE (R-EAE) and Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) is dependent on the activation of T cells to endogenous myelin epitopes (epitope spreading). Using transfer of carboxyfluorescein succinyl ester (CFSE)-labeled T-cell receptor (TCR)-transgenic T cells and mixed bone marrow chimeras, we show that activation of naive proteolipid protein (PLP)(139-151)-specific T cells in SJL mice undergoing PLP178-191-induced R-EAE or TMEV-IDD occurs directly in the CNS and not in the cervical lymph nodes or other peripheral lymphoid organs. Examination of the antigen-presentation capacity of antigen-presenting cell (APC) populations purified from the CNS of mice with PLP178-191-induced R-EAE shows that only F4/80(-)CD11c(+)CD45(hi) dendritic cells (DCs) efficiently present endogenous antigen to activate naive PLP139-151-specific T cells in vitro. In contrast, DCs as well as F4/80(+)CD45(hi) macrophages and F4/80(+)CD45(lo) microglia activate a PLP139-151-specific helper T cell line. The data suggest that naive T cells enter the inflamed CNS and are activated by local APCs, possibly DCs, to initiate epitope spreading.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Interdept Immunobiol Ctr, Chicago, IL 60611 USA; Brigham & Womens Hosp, Dept Neurol, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Northwestern University; Northwestern University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Miller, SD (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.	s-d-miller@northwestern.edu			NIAID NIH HHS [AI-07476] Funding Source: Medline; NINDS NIH HHS [NS-23349, NS-30871] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS023349, R01NS030871] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		de Vos AF, 2002, J IMMUNOL, V169, P5415, DOI 10.4049/jimmunol.169.10.5415; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HOCHWALD GM, 1988, INT J NEUROSCI, V39, P299, DOI 10.3109/00207458808985717; Karman J, 2004, J IMMUNOL, V173, P2353, DOI 10.4049/jimmunol.173.4.2353; Katz-Levy Y, 2000, J IMMUNOL, V165, P5304, DOI 10.4049/jimmunol.165.9.5304; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kivisakk P, 2004, ANN NEUROL, V55, P627, DOI 10.1002/ana.20049; Krakowski ML, 2000, EUR J IMMUNOL, V30, P1002, DOI 10.1002/(SICI)1521-4141(200004)30:4<1002::AID-IMMU1002>3.0.CO;2-2; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Ling CY, 2003, J NEUROIMMUNOL, V141, P90, DOI 10.1016/S0165-5728(03)00249-2; Mack CL, 2003, J NEUROIMMUNOL, V144, P68, DOI 10.1016/j.jneuroim.2003.08.032; MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; Muldoon LL, 2004, NEUROPATH APPL NEURO, V30, P70, DOI 10.1046/j.0305-1846.2003.00512.x; Neville KL, 2002, J NEUROIMMUNOL, V123, P18, DOI 10.1016/S0165-5728(01)00479-9; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; OEHMICHEN M, 1979, ACTA NEUROPATHOL, V45, P61, DOI 10.1007/BF00691806; Pashenkov M, 2001, BRAIN, V124, P480, DOI 10.1093/brain/124.3.480; Plumb J, 2003, MULT SCLER, V9, P142, DOI 10.1191/1352458503ms890oa; Serafini B, 2000, AM J PATHOL, V157, P1991, DOI 10.1016/S0002-9440(10)64838-9; Suter T, 2000, EUR J IMMUNOL, V30, P794, DOI 10.1002/1521-4141(200003)30:3<794::AID-IMMU794>3.3.CO;2-H; Tompkins SM, 2002, J IMMUNOL, V168, P4173, DOI 10.4049/jimmunol.168.8.4173; Tuohy VK, 1999, J EXP MED, V189, P1033, DOI 10.1084/jem.189.7.1033; Vanderlugt CL, 2002, NAT REV IMMUNOL, V2, P85, DOI 10.1038/nri724; Vanderlugt CL, 2000, J IMMUNOL, V164, P670, DOI 10.4049/jimmunol.164.2.670; Waldner H, 2000, P NATL ACAD SCI USA, V97, P3412, DOI 10.1073/pnas.97.7.3412; YAMADA S, 1991, AM J PHYSIOL, V261, pH1197, DOI 10.1152/ajpheart.1991.261.4.H1197; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777	30	509	535	2	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					335	339		10.1038/nm1202	http://dx.doi.org/10.1038/nm1202			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15735651				2022-12-27	WOS:000227541300030
J	Girardi, G; Redecha, P; Salmon, JE				Girardi, G; Redecha, P; Salmon, JE			Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation	NATURE MEDICINE			English	Article							IMMUNOGLOBULIN-G FRACTIONS; PLACENTAL THROMBOSIS; ENDOTHELIAL-CELLS; IN-VITRO; RECEPTOR; MICE; C5A; TROPHOBLAST; MODULATION; POLYANIONS	The antiphospholipid syndrome (APS) is defined by thrombosis and recurrent pregnancy loss in the presence of antiphospholipid (aPL) antibodies and is generally treated with anticoagulation therapy. Because complement activation is essential and causative in aPL antibody-induced fetal injury, we hypothesized that heparin protects pregnant APS patients from complications through inhibition of complement. Treatment with heparin (unfractionated or low molecular weight) prevented complement activation in vivo and in vitro and protected mice from pregnancy complications induced by aPL antibodies. Neither fondaparinux nor hirudin, other anticoagulants, inhibited the generation of complement split products or prevented pregnancy loss, demonstrating that anticoagulation therapy is insufficient protection against APS-associated miscarriage. Our data indicate that heparins prevent obstetrical complications in women with APS because they block activation of complement induced by aPL antibodies targeted to decidual tissues, rather than by their anticoagulant effects.	Hosp Special Surg, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Cornell University	Salmon, JE (corresponding author), Hosp Special Surg, Dept Med, 535 E 70th St, New York, NY 10021 USA.	salmonj@hss.edu		Girardi, Guillermina/0000-0002-5797-7731				BAKER PJ, 1975, J IMMUNOL, V114, P554; BLANK M, 1991, P NATL ACAD SCI USA, V88, P3069, DOI 10.1073/pnas.88.8.3069; BRANCH DW, 1990, AM J OBSTET GYNECOL, V163, P210, DOI 10.1016/S0002-9378(11)90700-5; Derksen RHWM, 2004, ARTHRITIS RHEUM-US, V50, P1028, DOI 10.1002/art.20105; Di Simone N, 1999, HUM REPROD, V14, P489, DOI 10.1093/humrep/14.2.489; DiSimone N, 1997, HUM REPROD, V12, P2061, DOI 10.1093/humrep/12.9.2061; Ecker EE, 1929, J INFECT DIS, V44, P250, DOI 10.1093/infdis/44.3.250; Ecker EE, 1941, J IMMUNOL, V40, P73; EDENS RE, 1994, IMMUNOPHARMACOLOGY, V27, P145, DOI 10.1016/0162-3109(94)90049-3; FRIEDRICHS GS, 1994, CIRC RES, V75, P701, DOI 10.1161/01.RES.75.4.701; Girardi G, 2003, J CLIN INVEST, V112, P1644, DOI 10.1172/JCI200318817; Gu JM, 2002, J BIOL CHEM, V277, P43335, DOI 10.1074/jbc.M207538200; Gutierrez G, 2004, AM J REPROD IMMUNOL, V51, P160, DOI 10.1046/j.8755-8920.2003.00131.x; Hirsh J, 2001, CHEST, V119, p64S, DOI 10.1378/chest.119.1_suppl.64S; Holers VM, 2002, J EXP MED, V195, P211, DOI 10.1084/jem.200116116; Ikematsu W, 1998, ARTHRITIS RHEUM-US, V41, P1026, DOI 10.1002/1529-0131(199806)41:6<1026::AID-ART9>3.0.CO;2-1; KAZATCHKINE MD, 1981, J CLIN INVEST, V67, P223, DOI 10.1172/JCI110017; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Levine JS, 2002, NEW ENGL J MED, V346, P752, DOI 10.1056/NEJMra002974; Lockshin MD, 2000, ARTHRITIS RHEUM, V43, P440, DOI 10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N; LOOS M, 1976, IMMUNOCHEMISTRY, V13, P789, DOI 10.1016/0019-2791(76)90202-0; Magid MS, 1998, AM J OBSTET GYNECOL, V179, P226, DOI 10.1016/S0002-9378(98)70277-7; Menon V, 2001, AM J MED, V110, P641, DOI 10.1016/S0002-9343(01)00715-X; Mollnes TE, 2002, BLOOD, V100, P1869; Ninomiya H, 2000, BRIT J HAEMATOL, V109, P875, DOI 10.1046/j.1365-2141.2000.02125.x; OUT HJ, 1991, EUR J OBSTET GYN R B, V41, P179, DOI 10.1016/0028-2243(91)90021-C; Pierangeli SS, 1999, CIRCULATION, V99, P1997, DOI 10.1161/01.CIR.99.15.1997; PIONA A, 1995, SCAND J IMMUNOL, V41, P427, DOI 10.1111/j.1365-3083.1995.tb03588.x; RANKLIN RD, 2003, OBSTET GYNECOL, V101, P455; RENT R, 1976, CLIN EXP IMMUNOL, V23, P264; Rops ALWMM, 2004, KIDNEY INT, V65, P768, DOI 10.1111/j.1523-1755.2004.00451.x; Rote NS, 1998, AM J REPROD IMMUNOL, V39, P125; SALMON JE, 1995, J CLIN INVEST, V95, P2877, DOI 10.1172/JCI117994; SIMANTOV R, 1995, J CLIN INVEST, V96, P2211, DOI 10.1172/JCI118276; WAGENKNECHT DR, 1992, THROMB RES, V68, P495, DOI 10.1016/0049-3848(92)90063-G; Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996; WEILER JM, 1978, J EXP MED, V147, P409, DOI 10.1084/jem.147.2.409; Wetsel RA, 2000, CONT IMMUN, V9, P113; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F	39	476	497	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1222	1226		10.1038/nm1121	http://dx.doi.org/10.1038/nm1121			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15489858				2022-12-27	WOS:000224785900044
J	Goldstein, JL				Goldstein, JL			Towering science: an ounce of creativity is worth a ton of impact	NATURE MEDICINE			English	Editorial Material																			0	6	6	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1015	1017		10.1038/nm1004-1015	http://dx.doi.org/10.1038/nm1004-1015			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459692				2022-12-27	WOS:000224245800012
J	Nygren, JM; Jovinge, S; Breitbach, M; Sawen, P; Roll, W; Hescheler, J; Taneera, J; Fleischmann, BK; Jacobsen, SEW				Nygren, JM; Jovinge, S; Breitbach, M; Sawen, P; Roll, W; Hescheler, J; Taneera, J; Fleischmann, BK; Jacobsen, SEW			Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation	NATURE MEDICINE			English	Article							STEM-CELLS; PROGENITOR CELLS; MYOCARDIAL-INFARCTION; PURKINJE NEURONS; IN-VIVO; TRANSPLANTATION; EXPRESSION; MUSCLE; BLOOD; CARDIOMYOPLASTY	Recent studies have suggested that bone marrow cells might possess a much broader differentiation potential than previously appreciated. In most cases, the reported efficiency of such plasticity has been rather low and, at least in some instances, is a consequence of cell fusion. After myocardial infarction, however, bone marrow cells have been suggested to extensively regenerate cardiomyocytes through transdifferentiation. Although bone marrow-derived cells are already being used in clinical trials, the exact identity, longevity and fate of these cells in infarcted myocardium have yet to be investigated in detail. Here we use various approaches to induce acute myocardial injury and deliver transgenically marked bone marrow cells to the injured myocardium. We show that unfractionated bone marrow cells and a purified population of hematopoietic stem and progenitor cells efficiently engraft within the infarcted myocardium. Engraftment was transient, however, and hematopoietic in nature. In contrast, bone marrow-derived cardiomyocytes were observed outside the infarcted myocardium at a low frequency and were derived exclusively through cell fusion.	Lund Univ, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Hematopoiet Stem Cell Lab, S-22184 Lund, Sweden; Lund Univ, Univ Hosp MAS, Dept Cardiol, S-20502 Malmo, Sweden; Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany; Univ Bonn, Dept Cardiac Surg, D-53105 Bonn, Germany; Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany	Lund University; Lund University; Skane University Hospital; University of Bonn; University of Bonn; University of Cologne	Jacobsen, SEW (corresponding author), Lund Univ, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Hematopoiet Stem Cell Lab, BMC B10,Klin Gatan 26, S-22184 Lund, Sweden.	Sten.Jacobsen@stemcell.lu.se	Jacobsen, Sten Eirik W/D-3974-2018	Jacobsen, Sten Eirik W/0000-0002-1362-3659; Taneera, Jalal/0000-0002-3341-1063; Roell, Wilhelm/0000-0002-2213-5024; Nygren, Jens M/0000-0002-3576-2393				Agbulut O, 2003, CARDIOVASC RES, V58, P451, DOI 10.1016/S0008-6363(03)00281-5; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Bensinger W I, 2001, Rev Clin Exp Hematol, V5, P67, DOI 10.1046/j.1468-0734.2001.00033.x; Borge OJ, 1999, BLOOD, V94, P3781, DOI 10.1182/blood.V94.11.3781.423k04_3781_3790; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Bryder D, 2000, BLOOD, V96, P1748, DOI 10.1182/blood.V96.5.1748.h8001748_1748_1755; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Fleischmann M, 1998, FEBS LETT, V440, P370, DOI 10.1016/S0014-5793(98)01476-8; Geiger H, 2002, BLOOD, V100, P721, DOI 10.1182/blood.V100.2.721; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kawada H, 2001, BLOOD, V98, P2008, DOI 10.1182/blood.V98.7.2008; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kronenwett R, 2000, STEM CELLS, V18, P320, DOI 10.1634/stemcells.18-5-320; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Matsubara H, 2004, LANCET, V363, P746, DOI 10.1016/S0140-6736(04)15713-9; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Roell W, 2002, TRANSPLANTATION, V73, P462, DOI 10.1097/00007890-200202150-00022; Roell W, 2002, CIRCULATION, V105, P2435, DOI 10.1161/01.CIR.0000016063.66513.BB; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2002, AM J PATHOL, V161, P565, DOI 10.1016/S0002-9440(10)64212-5; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	47	813	896	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					494	501		10.1038/nm1040	http://dx.doi.org/10.1038/nm1040			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15107841	Green Published			2022-12-27	WOS:000221242400027
J	Bjorkbacka, H; Kunjathoor, VV; Moore, KJ; Koehn, S; Ordija, CM; Lee, MA; Means, T; Halmen, K; Luster, AD; Golenbock, DT; Freeman, MW				Bjorkbacka, H; Kunjathoor, VV; Moore, KJ; Koehn, S; Ordija, CM; Lee, MA; Means, T; Halmen, K; Luster, AD; Golenbock, DT; Freeman, MW			Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways	NATURE MEDICINE			English	Article							TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; MURINE MODELS; MACROPHAGES; DEFICIENT; LESIONS; EXPRESSION; AORTA	Atherosclerosis, the leading cause of death in developed countries, has been linked to hypercholesterolemia for decades. More recently, atherosclerotic lesion progression has been shown to depend on persistent, chronic inflammation in the artery wall(1). Although several studies have implicated infectious agents in this process, the role of infection in atherosclerosis remains controversial(2-4). Because the involvement of monocytes and macrophages in the pathogenesis of atherosclerosis is well established, we investigated the possibility that macrophage innate immunity signaling pathways normally activated by pathogens might also be activated in response to hyperlipidemia. We examined atherosclerotic lesion development in uninfected, hyperlipidemic mice lacking expression of either lipopolysaccharide (LPS) receptor CD14 or myeloid differentiation protein-88 (MyD88), which transduces cell signaling events downstream of the Toll-like receptors (TLRs), as well as receptors for interleukin-1 (IL-1) and IL-18. Whereas the MyD88-deficient mice evinced a marked reduction in early atherosclerosis, mice deficient in CD14 had no decrease in early lesion development. Inactivation of the MyD88 pathway led to a reduction in atherosclerosis through a decrease in macrophage recruitment to the artery wall that was associated with reduced chemokine levels. These findings link elevated serum lipid levels to a proinflammatory signaling cascade that is also engaged by microbial pathogens.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01655 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Worcester	Freeman, MW (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA.	freeman@molbio.mgh.harvard.edu	Luster, Andrew/ABE-6504-2020; Moore, Kathryn/ABE-6416-2020; Björkbacka, Harry/I-7157-2019	Luster, Andrew/0000-0001-9679-7912; Moore, Kathryn/0000-0003-2505-2547; Björkbacka, Harry/0000-0003-3918-0857	NCRR NIH HHS [RR14466] Funding Source: Medline; NHLBI NIH HHS [HL66678, HL45098] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR014466] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098, U01HL066678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Burke-Gaffney A, 2002, VASC PHARMACOL, V38, P283, DOI 10.1016/S1537-1891(02)00253-7; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; Elhage R, 2003, CARDIOVASC RES, V59, P234, DOI 10.1016/S0008-6363(03)00343-2; Epstein SE, 2000, ARTERIOSCL THROM VAS, V20, P1417, DOI 10.1161/01.ATV.20.6.1417; Frishman William H, 2002, Cardiol Rev, V10, P199, DOI 10.1097/00045415-200207000-00004; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Ismail A, 1999, Heart Dis, V1, P233; Kanters E, 2003, J CLIN INVEST, V112, P1176, DOI 10.1172/JCI18580; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kirii H, 2003, ARTERIOSCL THROM VAS, V23, P656, DOI 10.1161/01.ATV.0000064374.15232.C3; Kunjathoor VV, 2002, ARTERIOSCL THROM VAS, V22, P462, DOI 10.1161/hq0302.105378; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mach F, 2001, Curr Atheroscler Rep, V3, P243, DOI 10.1007/s11883-001-0067-y; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Moore KJ, 1996, J IMMUNOL, V157, P433; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Raschi E, 2003, BLOOD, V101, P3495, DOI 10.1182/blood-2002-08-2349; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Saal LH, 2002, GENOME BIOL, V3; Tanaka E, 2003, ARTERIOSCL THROM VAS, V23, P244, DOI 10.1161/01.ATV.0000051876.26766.FD; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Vink A, 2002, CIRCULATION, V106, P1985, DOI 10.1161/01.CIR.0000032146.75113.EE; Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200; Wright SD, 2000, J EXP MED, V191, P1437, DOI 10.1084/jem.191.8.1437; Xu XH, 2001, CIRCULATION, V104, P3103, DOI 10.1161/hc5001.100631	33	511	547	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					416	421		10.1038/nm1008	http://dx.doi.org/10.1038/nm1008			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034566				2022-12-27	WOS:000220587000035
J	Brander, C; Walker, BD				Brander, C; Walker, BD			Gradual adaptation of HIV to human host populations: good or bad news?	NATURE MEDICINE			English	Article							T-CELL RESPONSES; SIMIAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE RESPONSES; PRIMARY INFECTION; ESCAPE MUTATIONS; VIRAL LOAD; HLA; SELECTION; IMMUNODOMINANT; EVOLUTION	The continuous evolution and adaptation of HIV to its host has produced extensive global viral diversity. Understanding the kinetics and directions of this continuing adaptation and its impact on viral fitness, immunogenicity and pathogenicity will be crucial to the successful design of effective HIV vaccines. Here we discuss some potential scenarios of viral and host coevolution.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Div AIDS, Boston, MA 02114 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Brander, C (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA.			Brander, Christian/0000-0002-0548-5778				Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Altfeld M, 2003, J VIROL, V77, P7330, DOI 10.1128/JVI.77.13.7330-7340.2003; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405; Brander C, 1999, J IMMUNOL, V162, P4796; BRANDER C, 2001, HIV MOL IMMUNOLOGY D; BROWNING MJ, 1990, J IMMUNOL, V145, P985; CALEF C, 2000, HIV MOL IMMUNOLOGY D; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Courgnaud V, 1998, VIROLOGY, V247, P41, DOI 10.1006/viro.1998.9217; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; Draenert R, 2003, J IMMUNOL METHODS, V275, P19, DOI 10.1016/S0022-1759(02)00541-0; FRAHM N, 2002, HIV MOL IMMUNOLOGY D; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Goulder PJR, 2000, J VIROL, V74, P5679, DOI 10.1128/JVI.74.12.5679-5690.2000; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Goulder PJR, 2000, J EXP MED, V192, P1819, DOI 10.1084/jem.192.12.1819; Holmes EC, 2001, BIOL REV, V76, P239, DOI 10.1017/S1464793101005668; Kaur A, 2001, EUR J IMMUNOL, V31, P3207, DOI 10.1002/1521-4141(200111)31:11<3207::AID-IMMU3207>3.0.CO;2-H; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; KORBER B, 2001, HIV MOL IMMUNOLOGY D; Loeb LA, 1999, P NATL ACAD SCI USA, V96, P1492, DOI 10.1073/pnas.96.4.1492; MacDonald KS, 1998, J INFECT DIS, V177, P551, DOI 10.1086/514243; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Norley S, 1999, IMMUNOL LETT, V66, P47, DOI 10.1016/S0165-2478(98)00184-9; OCONNOR DJ, 2001, WHERE HAVE ALL MONKE; PELLETIER E, 1996, J NIH RES, V8, P45; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Rey-Cuille MA, 1998, J VIROL, V72, P3872; Shankar P, 1996, IMMUNOL LETT, V52, P23, DOI 10.1016/0165-2478(96)02574-6; Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893; Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002	38	54	55	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1359	1362		10.1038/nm941	http://dx.doi.org/10.1038/nm941			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14595431	Bronze			2022-12-27	WOS:000186319700024
J	Pearson, H				Pearson, H			Kari Stefansson	NATURE MEDICINE			English	Biographical-Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1099	1099		10.1038/nm0903-1099	http://dx.doi.org/10.1038/nm0903-1099			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12949510	Bronze			2022-12-27	WOS:000185061600007
J	Lu, QL; Mann, CJ; Lou, F; Bou-Gharios, G; Morris, GE; Xue, SA; Fletcher, S; Partridge, TA; Wilton, SD				Lu, QL; Mann, CJ; Lou, F; Bou-Gharios, G; Morris, GE; Xue, SA; Fletcher, S; Partridge, TA; Wilton, SD			Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; REVERTANT FIBERS; SKELETAL-MUSCLES; GENE; THERAPY; MICE; RNA; OLIGONUCLEOTIDES; RESTORATION; EXPRESSION	As a target for gene therapy, Duchenne muscular dystrophy (DMD) presents many obstacles but also an unparalleled prospect for correction by alternative splicing. The majority of mutations in the dystrophin gene occur in the region encoding the spectrin-like central rod domain, which is largely dispensable. Thus, splicing around mutations can generate a shortened but in-frame transcript, permitting translation of a partially functional dystrophin protein. We have tested this idea in vivo in the mdx dystrophic mouse (carrying a mutation in exon 23 of the dystrophin gene) by combining a potent transfection protocol with a 2-O-methylated phosphorothioated antisense oligoribonucleotide (2OMeAO) designed to promote skipping of the mutated exon. The treated mice show persistent production of dystrophin at normal levels in large numbers of muscle fibers and show functional improvement of the treated muscle. Repeated administration enhances dystrophin expression without eliciting immune responses. Our data establishes the realistic practicality of an approach that is applicable, in principle, to a majority of cases of severe dystrophinopathy.	Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England; Univ Western Australia, Queen Elizabeth II Med Ctr, Ctr Neuromuscular & Neurol Disorders, Australian Neuromuscular Res Inst, Nedlands, WA 6009, Australia; Univ Hertfordshire, Dept Biosci, Hatfield AL10 9AB, Herts, England; NE Wales Inst, MRIC Biochem Grp, Wrexham LL11 2AW, Wales; Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Immunol, London W12 0NN, England	Imperial College London; University of Western Australia; University of Hertfordshire; Glyndwr University; Imperial College London	Lu, QL (corresponding author), Hammersmith Hosp, MRC, Ctr Clin Sci, Du Cane Rd, London W12 0NN, England.		Xue, Shao-An/A-2735-2011; lu, qi/HHS-2115-2022	Fletcher, Sue/0000-0002-8632-641X; Wilton, Steve/0000-0002-9400-893X				Aartsma-Rus A, 2002, NEUROMUSCULAR DISORD, V12, pS71, DOI 10.1016/S0960-8966(02)00086-X; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; De Angelis FG, 2002, P NATL ACAD SCI USA, V99, P9456, DOI 10.1073/pnas.142302299; Dickson G, 2002, NEUROMUSCULAR DISORD, V12, pS67, DOI 10.1016/S0960-8966(02)00085-8; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Laing N G, 1993, Mol Cell Biol Hum Dis Ser, V3, P37; Liu F, 2001, MOL THER, V4, P45, DOI 10.1006/mthe.2001.0419; Lou F, 2002, J EXP BIOL, V205, P1585; Lu QL, 2000, J CELL BIOL, V148, P985, DOI 10.1083/jcb.148.5.985; Lu QL, 1998, J HISTOCHEM CYTOCHEM, V46, P977, DOI 10.1177/002215549804600813; Lu QL, 2003, GENE THER, V10, P396, DOI 10.1038/sj.gt.3301913; Lu QL, 2003, GENE THER, V10, P131, DOI 10.1038/sj.gt.3301874; Lynch GS, 2001, J PHYSIOL-LONDON, V535, P591, DOI 10.1111/j.1469-7793.2001.00591.x; Mann CJ, 2002, J GENE MED, V4, P644, DOI 10.1002/jgm.295; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; Rando TA, 2000, P NATL ACAD SCI USA, V97, P5363, DOI 10.1073/pnas.97.10.5363; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; SHERRAT TG, 1993, AM J HUM GENET, V53, P1007; Wagner KR, 2001, ANN NEUROL, V49, P706, DOI 10.1002/ana.1023.abs; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; Watchko J, 2002, HUM GENE THER, V13, P1451, DOI 10.1089/10430340260185085; Wilton SD, 1997, NEUROMUSCULAR DISORD, V7, P329, DOI 10.1016/S0960-8966(97)00058-8; Yuasa K, 2002, GENE THER, V9, P1576, DOI 10.1038/sj.gt.3301829	26	296	334	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1009	1014		10.1038/nm897	http://dx.doi.org/10.1038/nm897			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847521				2022-12-27	WOS:000184484900023
J	Mattiasson, G; Shamloo, M; Gido, G; Mathi, K; Tomasevic, G; Yi, SL; Warden, CH; Castilho, RF; Melcher, T; Gonzalez-Zulueta, M; Nikolich, K; Wieloch, T				Mattiasson, G; Shamloo, M; Gido, G; Mathi, K; Tomasevic, G; Yi, SL; Warden, CH; Castilho, RF; Melcher, T; Gonzalez-Zulueta, M; Nikolich, K; Wieloch, T			Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; PERMEABILITY TRANSITION; MITOCHONDRIAL CONTROL; PROTON LEAK; BETA-CELLS; RAT-BRAIN; SUPEROXIDE; INJURY; MICE	Whereas uncoupling protein 1 (UCP-1) is clearly involved in thermogenesis, the role of UCP-2 is less clear. Using hybridization, cloning techniques and cDNA array analysis to identify inducible neuroprotective genes, we found that neuronal survival correlates with increased expression of Ucp2. In mice overexpressing human UCP-2, brain damage was diminished after experimental stroke and traumatic brain injury, and neurological recovery was enhanced. In cultured cortical neurons, UCP-2 reduced cell death and inhibited caspase-3 activation induced by oxygen and glucose deprivation. Mild mitochondrial uncoupling by 2,4-dinitrophenol (DNP) reduced neuronal death, and UCP-2 activity was enhanced by palmitic acid in isolated mitochondria. Also in isolated mitochondria, UCP-2 shifted the release of reactive oxygen species from the mitochondrial matrix to the extramitochondrial space. We propose that UCP-2 is an inducible protein that is neuroprotective by activating cellular redox signaling or by inducing mild mitochondrial uncoupling that prevents the release of apoptogenic proteins.	Wallenberg Neurosci Ctr, S-22184 Lund, Sweden; AGY Therapeut Inc, San Francisco, CA 94080 USA; Univ Calif Davis, Sch Med, Div Biol Sci, Neurobiol Sect, Davis, CA 95616 USA; State Univ Campinas, Sch Med Sci, Dept Clin Pathol, BR-13083970 Campinas, SP, Brazil	University of California System; University of California Davis; Universidade Estadual de Campinas	Wieloch, T (corresponding author), Wallenberg Neurosci Ctr, BMC A13, S-22184 Lund, Sweden.		Castilho, Roger F/G-3906-2012	Wieloch, Tadeusz/0000-0002-7669-2520; Castilho, Roger/0000-0003-2338-8717	NIDDK NIH HHS [R01 DK53993] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053993] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Arnaiz SL, 1999, NITRIC OXIDE-BIOL CH, V3, P235, DOI 10.1006/niox.1999.0229; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; Casteilla L, 2001, IUBMB LIFE, V52, P181, DOI 10.1080/15216540152845984; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; Castilho RF, 1998, J NEUROSCI, V18, P10277; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Fuller PM, 2000, J APPL PHYSIOL, V89, P1491, DOI 10.1152/jappl.2000.89.4.1491; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Grabb MC, 1999, J NEUROSCI, V19, P1657; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Horvath TL, 2003, INT J OBESITY, V27, P433, DOI 10.1038/sj.ijo.0802257; Jarmuszkiewicz W, 2002, FEBS LETT, V532, P459, DOI 10.1016/S0014-5793(02)03734-1; KATO H, 1995, J CEREBR BLOOD F MET, V15, P60, DOI 10.1038/jcbfm.1995.7; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kowaltowski AJ, 1998, ARCH BIOCHEM BIOPHYS, V359, P77, DOI 10.1006/abbi.1998.0870; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Liu SS, 1997, BIOSCIENCE REP, V17, P259, DOI 10.1023/A:1027328510931; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NOWICKI JP, 1988, J CEREBR BLOOD F MET, V8, P462, DOI 10.1038/jcbfm.1988.87; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shamloo M, 1999, J CEREBR BLOOD F MET, V19, P173, DOI 10.1097/00004647-199902000-00009; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Teranishi M, 2000, EXP MOL PATHOL, V68, P104, DOI 10.1006/exmp.1999.2288; Wieloch T, 2001, IUBMB LIFE, V52, P247, DOI 10.1080/15216540152846064; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	48	425	443	0	27	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1062	1068		10.1038/nm903	http://dx.doi.org/10.1038/nm903			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12858170				2022-12-27	WOS:000184484900031
J	Jain, RK				Jain, RK			Molecular regulation of vessel maturation	NATURE MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; EMBRYONIC STEM-CELLS; SMOOTH-MUSCLE-CELL; BLOOD-VESSELS; PROGENITOR CELLS; BONE-MARROW; HIF-1-ALPHA/VP16 HYBRID; SIGNALING PATHWAYS; TUMOR ANGIOGENESIS; GENE-EXPRESSION	The maturation of nascent vasculature, formed by vasculogenesis or angiogenesis, requires recruitment of mural cells, generation of an extracellular matrix and specialization of the vessel wall for structural support and regulation of vessel function. In addition, the vascular network must be organized so that all the parenchymal cells receive adequate nutrients. All of these processes are orchestrated by physical forces as well as by a constellation of ligands and receptors whose spatio-temporal patterns of expression and concentration are tightly regulated. Inappropriate levels of these physical forces or molecules produce an abnormal vasculature- a hallmark of various pathologies. Normalization of the abnormal vasculature can facilitate drug delivery to tumors and formation of a mature vasculature can help realize the promise of therapeutic angiogenesis and tissue engineering.	Massachusetts Gen Hosp, Dept Radiat Oncol, EL Steele Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, EL Steele Lab, 100 Blossom St, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu	Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548				Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Altavilla D, 2001, DIABETES, V50, P667, DOI 10.2337/diabetes.50.3.667; Baish JW, 2000, CANCER RES, V60, P3683; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bloch W, 2000, FASEB J, V14, P2373; Boardman KC, 2003, CIRC RES, V92, P801, DOI 10.1161/01.RES.0000065621.69843.49; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Cho H, 2003, FASEB J, V17, P440, DOI 10.1096/fj.02-0340fje; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Darland D. C., 2001, Angiogenesis, V4, P11, DOI 10.1023/A:1016611824696; Dellian M, 1996, AM J PATHOL, V149, P59; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gazit Y, 1997, MICROCIRCULATION-LON, V4, P395, DOI 10.3109/10739689709146803; Gohongi T, 1999, NAT MED, V5, P1203, DOI 10.1038/13524; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Helisch A, 2003, MICROCIRCULATION, V10, P83, DOI 10.1038/sj.mn.7800173; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Helmlinger G, 1997, NAT BIOTECHNOL, V15, P778, DOI 10.1038/nbt0897-778; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Hungerford JE, 1999, J VASC RES, V36, P2, DOI 10.1159/000025622; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jain RK, 2001, SCI AM, V285, P38, DOI 10.1038/scientificamerican1201-38; Jain RK, 2002, COLD SPRING HARB SYM, V67, P239, DOI 10.1101/sqb.2002.67.239; Jain RK, 2003, SCIENCE, V299, P209, DOI 10.1126/science.1081345; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Jain RK, 2002, J NATL CANCER I, V94, P417; Jain RK, 2000, NAT MED, V6, P131, DOI 10.1038/72212; Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Kadambi A, 2001, CANCER RES, V61, P2404; KALLURI R, IN PRESS NAT REV CAN; Kluk MJ, 2003, FEBS LETT, V533, P25, DOI 10.1016/S0014-5793(02)03742-0; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Langer R, 2003, SCI AM, V288, P50, DOI 10.1038/scientificamerican0403-50; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Linden T, 2003, FASEB J, V17, P761, DOI 10.1096/fj.02-0586fje; Loughna S, 2001, MATRIX BIOL, V20, P319, DOI 10.1016/S0945-053X(01)00149-4; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Majka SM, 2003, J CLIN INVEST, V111, P71, DOI 10.1172/JCI200316157; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Nagy JA, 2002, COLD SPRING HARB SYM, V67, P227, DOI 10.1101/sqb.2002.67.227; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Nguyen LL, 2001, INT REV CYTOL, V204, P1, DOI 10.1016/S0074-7696(01)04002-5; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Rafii S, 2002, SEMIN CELL DEV BIOL, V13, P61, DOI 10.1006/scdb.2001.0285; Ramanujan S, 2000, CANCER RES, V60, P1442; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Rossant J, 2002, ANNU REV CELL DEV BI, V18, P541, DOI 10.1146/annurev.cellbio.18.012502.105825; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Schmid-Schonbein Geert W, 2003, Lymphat Res Biol, V1, P25, DOI 10.1089/15396850360495664; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Shyu KG, 2002, CARDIOVASC RES, V54, P576, DOI 10.1016/S0008-6363(02)00259-6; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; STOLL BR, IN PRESS BLOOD; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Topper JN, 1999, MOL MED TODAY, V5, P40, DOI 10.1016/S1357-4310(98)01372-0; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621; Vincent KA, 2000, CIRCULATION, V102, P2255; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Wilting Jorg, 2003, Lymphat Res Biol, V1, P33, DOI 10.1089/15396850360495673; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang JW, 2001, NAT BIOTECHNOL, V19, P219, DOI 10.1038/85655; Yurugi-Kobayashi T, 2003, BLOOD, V101, P2675, DOI 10.1182/blood-2002-06-1877; ZAWICKI DF, 1981, MICROVASC RES, V21, P27, DOI 10.1016/0026-2862(81)90003-0	100	1865	1993	5	312	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					685	693		10.1038/nm0603-685	http://dx.doi.org/10.1038/nm0603-685			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12778167				2022-12-27	WOS:000183444100023
J	Curiel, TJ; Wei, S; Dong, HD; Alvarez, X; Cheng, P; Mottram, P; Krzysiek, R; Knutson, KL; Daniel, B; Zimmermann, MC; David, O; Burow, M; Gordon, A; Dhurandhar, N; Myers, L; Berggren, R; Hemminki, A; Alvarez, RD; Emilie, D; Curiel, DT; Chen, LP; Zou, WP				Curiel, TJ; Wei, S; Dong, HD; Alvarez, X; Cheng, P; Mottram, P; Krzysiek, R; Knutson, KL; Daniel, B; Zimmermann, MC; David, O; Burow, M; Gordon, A; Dhurandhar, N; Myers, L; Berggren, R; Hemminki, A; Alvarez, RD; Emilie, D; Curiel, DT; Chen, LP; Zou, WP			Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; T-HELPER; B7 FAMILY; EXPRESSION; CANCER; TUMORS; PROLIFERATION; RECEPTOR; ANTIGEN; INTERLEUKIN-10	Suppression of dendritic cell function in cancer patients is thought to contribute to the inhibition of immune responses and disease progression. Molecular mechanisms of this suppression remain elusive, however. Here, we show that a fraction of blood monocyte-derived myeloid dendritic cells (MDCs) express B7-H1, a member of the B7 family, on the cell surface. B7-H1 could be further upregulated by tumor environmental factors. Consistent with this finding, virtually all MDCs isolated from the tissues or draining lymph nodes of ovarian carcinomas express B7-H1. Blockade of B7-H1 enhanced MDC-mediated T-cell activation and was accompanied by downregulation of T-cell interleukin (IL)-10 and upregulation of IL-2 and interferon (IFN)-gamma. T cells conditioned with the B7-H1-blocked MDCs had a more potent ability to inhibit autologous human ovarian carcinoma growth in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice. Therefore, upregulation of B7-H1 on MDCs in the tumor microenvironment downregulates T-cell immunity. Blockade of B7-H1 represents one approach for cancer immunotherapy.	Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA; Mayo Clin, Dept Immunol, Rochester, MN USA; INSERM, U131, Clamart, France; Univ Washington, Div Oncol, Seattle, WA 98195 USA; Baylor Univ, Med Ctr, Div Gynecol, Dallas, TX USA; Univ Alabama, Gene Therapy Ctr, Birmingham, AL USA	Tulane University; Mayo Clinic; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Washington; University of Washington Seattle; Baylor University; Baylor University Medical Center; University of Alabama System; University of Alabama Birmingham	Zou, WP (corresponding author), Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA.		Burow, Matthew/D-6351-2013	Burow, Matthew/0000-0002-0642-6630; Dong, Haidong/0000-0002-5782-2983; Mottram, Peter/0000-0001-8560-2358	NATIONAL CANCER INSTITUTE [P50CA089019, R01CA097085, R01CA086881, R01CA092562] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067962] Funding Source: NIH RePORTER; NCI NIH HHS [CA8661, CA89019, CA97085, CA092562, CA86881] Funding Source: Medline; NCRR NIH HHS [RR00164] Funding Source: Medline; NHLBI NIH HHS [HL67962] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BROWN LF, 1993, AM J PATHOL, V143, P1255; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760; Dong HD, 2003, J CLIN INVEST, V111, P363, DOI 10.1172/JCI200316015; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; LLORENTE L, 1995, J EXP MED, V181, P839, DOI 10.1084/jem.181.3.839; Loercher AE, 1999, J IMMUNOL, V163, P6251; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Mazanet MM, 2002, J IMMUNOL, V169, P3581, DOI 10.4049/jimmunol.169.7.3581; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Nestle FO, 2001, NAT MED, V7, P761, DOI 10.1038/89863; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Pardoll D, 2001, NATURE, V411, P1010, DOI 10.1038/35082676; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Strome SE, 2002, CANCER RES, V62, P1884; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Tamura H, 2001, BLOOD, V97, P1809, DOI 10.1182/blood.V97.6.1809; Toi M, 1996, CANCER, V77, P1101, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1101::AID-CNCR15>3.0.CO;2-5; Trinchieri G, 1999, CURR TOP MICROBIOL, V238, P57; WANG SD, IN PRESS J EXP MED; Zitvogel L, 1996, ANN NY ACAD SCI, V795, P284, DOI 10.1111/j.1749-6632.1996.tb52678.x; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87; Zou WP, 2000, J IMMUNOL, V165, P4388, DOI 10.4049/jimmunol.165.8.4388; Zou WP, 1995, EUR CYTOKINE NETW, V6, P257; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339	37	948	1067	5	83	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					562	567		10.1038/nm863	http://dx.doi.org/10.1038/nm863			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12704383				2022-12-27	WOS:000182610600037
J	Nicoll, JAR; Wilkinson, D; Holmes, C; Steart, P; Markham, H; Weller, RO				Nicoll, JAR; Wilkinson, D; Holmes, C; Steart, P; Markham, H; Weller, RO			Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report	NATURE MEDICINE			English	Article							PATHOLOGY; MODEL; HEMORRHAGE; MOUSE; TRIAL	Amyloid-beta peptide (Abeta) has a key role in the pathogenesis of Alzheimer disease ( AD). Immunization with Abeta in a transgenic mouse model of AD reduces both age-related accumulation of Abeta in the brain(1) and associated cognitive impairment(2,3). Here we present the first analysis of human neuropathology after immunization with Abeta (AN-1792). Comparison with unimmunized cases of AD (n = 7) revealed the following unusual features in the immunized case, despite diagnostic neuropathological features of AD: (i) there were extensive areas of neocortex with very few Abeta plaques; (ii) those areas of cortex that were devoid of Abeta plaques contained densities of tangles, neuropil threads and cerebral amyloid angiopathy (CAA) similar to unimmunized AD, but lacked plaque-associated dystrophic neurites and astrocyte clusters; (iii) in some regions devoid of plaques, Abeta-immunoreactivity was associated with microglia; (iv) T-lymphocyte meningoencephalitis was present; and (v) cerebral white matter showed infiltration by macrophages. Findings (i)-(iii) strongly resemble the changes seen after Abeta immunotherapy in mouse models of AD(1-6) and suggest that the immune response generated against the peptide elicited clearance of Abeta plaques in this patient. The T-lymphocyte meningoencephalitis is likely to correspond to the side effect seen in some other patients who received AN-1792 (refs. 7-9).	Univ Southampton, Div Clin Neurosci, Southampton, Hants, England; Southampton Gen Hosp, Dept Pathol, Southampton SO9 4XY, Hants, England; Moorgreen Hosp, Memory Assessment & Res Ctr, Southampton, Hants, England	University of Southampton; University of Southampton; University of Southampton	Nicoll, JAR (corresponding author), Univ Southampton, Div Clin Neurosci, Southampton, Hants, England.	J.Nicoll@soton.ac.uk	Markham, Hannah/Y-1632-2019; Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246; Markham, Hannah/0000-0002-1877-6056; Holmes, Clive/0000-0003-1999-6912				Backskai BJ, 2001, NAT MED, V7, P369, DOI 10.1038/85525; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Birmingham K, 2002, NAT MED, V8, P199, DOI 10.1038/nm0302-199b; Bishop GM, 2002, NATURE, V416, P677, DOI 10.1038/416677d; Check E, 2002, NATURE, V415, P462, DOI 10.1038/415462a; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; McCarron MO, 1999, J NEUROPATH EXP NEUR, V58, P711, DOI 10.1097/00005072-199907000-00005; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Weller RO, 2002, ANN NY ACAD SCI, V977, P162, DOI 10.1111/j.1749-6632.2002.tb04812.x	13	1117	1217	2	76	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2003	9	4					448	452		10.1038/nm840	http://dx.doi.org/10.1038/nm840			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12640446	Bronze			2022-12-27	WOS:000181987400035
J	Schmaltz, C; Alpdogan, O; Kappel, BJ; Muriglan, SJ; Rotolo, JA; Ongchin, J; Willis, LM; Greenberg, AS; Eng, JM; Crawford, JM; Murphy, GF; Yagita, H; Walczak, H; Peschon, JJ; van den Brink, MRM				Schmaltz, C; Alpdogan, O; Kappel, BJ; Muriglan, SJ; Rotolo, JA; Ongchin, J; Willis, LM; Greenberg, AS; Eng, JM; Crawford, JM; Murphy, GF; Yagita, H; Walczak, H; Peschon, JJ; van den Brink, MRM			T cells require TRAIL for optimal graft-versus-tumor activity	NATURE MEDICINE			English	Article							APOPTOSIS-INDUCING LIGAND; HOST DISEASE; FAS LIGAND; TUMORICIDAL ACTIVITY; PERFORIN; TRANSPLANTATION; EXPRESSION; METASTASIS; DEFICIENT; LEUKEMIA	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that exhibits specific tumoricidal activity against a variety of tumors(1,2). It is expressed on different cells of the immune system and plays a role in natural killer cell-mediated tumor surveillance(3-5). In allogeneic hematopoietic-cell transplantation, the reactivity of the donor T cell against malignant cells is essential for the graft-versus-tumor (GVT) effect(6). Cytolytic activity of T cells is primarily mediated through the Fas-Fas ligand and perforin-granzyme pathways. However, T cells deficient for both Fas ligand and perforin can still exert GVT activity in vivo in mouse models(7,8). To uncover a potential role for TRAIL in donor T cell-mediated GVT activity, we compared donor T cells from TRAIL-deficient and wild-type mice in clinically relevant mouse bone-marrow transplantation models. We found that alloreactive T cells can express TRAIL, but the absence of TRAIL had no effect on their proliferative and cytokine response to alloantigens. TRAIL-deficient T cells showed significantly lower GVT activity than did TRAIL-expressing T cells, but no important differences in graft-versus-host disease, a major complication of allogeneic hematopoietic cell transplantation, were observed. These data suggest that strategies to enhance TRAIL-mediated GVT activity could decrease relapse rates of malignancies after hematopoietic cell transplantation without exacerbation of graft-versus-host disease.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; Thomas Jefferson Med Ctr, Dept Pathol, Philadelphia, PA USA; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; German Canc Res Ctr, Div Apoptosis Regulat, D-6900 Heidelberg, Germany; Immunex Corp, Dept Mol Immunol, Seattle, WA USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; State University System of Florida; University of Florida; Jefferson University; Juntendo University; Helmholtz Association; German Cancer Research Center (DKFZ); Immunex Corporation	van den Brink, MRM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.		van den Brink, Marcel R. M./HGB-9434-2022	van den Brink, Marcel/0000-0003-0696-4401; Rotolo, Jim/0000-0003-4195-6167; Walczak, Henning/0000-0002-6312-4591	NCI NIH HHS [P30 CA008748] Funding Source: Medline; NHLBI NIH HHS [HL69929, HL72412] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072412, R01HL069929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appelbaum FR, 2001, NATURE, V411, P385, DOI 10.1038/35077251; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BORDIGNON C, 1989, BLOOD, V74, P2237; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Crawford JM., 1997, GRAFT VERSUS HOST DI, P315; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; FERRARA J, 1986, J INVEST DERMATOL, V86, P371, DOI 10.1111/1523-1747.ep12285612; Hattori K, 1998, BLOOD, V91, P4051, DOI 10.1182/blood.V91.11.4051.411k16_4051_4055; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; Schmaltz C, 2001, BLOOD, V97, P2886, DOI 10.1182/blood.V97.9.2886; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; van den Brink MRM, 2000, J IMMUNOL, V164, P469, DOI 10.4049/jimmunol.164.1.469; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Winter H, 1999, J IMMUNOL, V163, P4462	24	124	127	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2002	8	12					1433	1437		10.1038/nm797	http://dx.doi.org/10.1038/nm797			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12426560				2022-12-27	WOS:000179552000041
J	Libby, P; Aikawa, M				Libby, P; Aikawa, M			Stabilization of atherosclerotic plaques: New mechanisms and clinical targets	NATURE MEDICINE			English	Review							TISSUE FACTOR EXPRESSION; VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE SYNTHASE; INCREASES COLLAGEN CONTENT; COA REDUCTASE INHIBITORS; HUMAN ENDOTHELIAL-CELLS; MATRIX METALLOPROTEINASES; HUMAN ATHEROMA; RABBIT ATHEROMA; GENE-EXPRESSION	Research points to pivotal roles for lipids in the development of atherosclerotic plaques. Lipid-lowering statins substantially reduce acute coronary events resulting from plaque development, but only modestly reduce arterial stenosis. This apparent paradox has shifted the goal of therapy toward plaque stabilization rather than enlargement of the lumen. More thorough understanding to the biology of atherosclerosis should enable us to manipulate plaque stability, and reduce further the acute complications of atherosclerosis.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Cardiovasc Div,Leducq Ctr Cardiovasc Res, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Libby, P (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Cardiovasc Div,Leducq Ctr Cardiovasc Res, Boston, MA 02115 USA.		Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X; Aikawa, Masanori/0000-0002-9275-2079				Aikawa M, 2002, CIRCULATION, V106, P1390, DOI 10.1161/01.CIR.0000028465.52694.9B; Aikawa M, 1999, CIRCULATION, V100, P1215, DOI 10.1161/01.CIR.100.11.1215; Aikawa M, 1998, CIRCULATION, V97, P2433, DOI 10.1161/01.CIR.97.24.2433; Aikawa M, 2001, CIRCULATION, V103, P276; AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; BLANKENHORN DH, 1994, ARTERIOSCLER THROMB, V14, P177, DOI 10.1161/01.ATV.14.2.177; Bocan TMA, 2000, ARTERIOSCL THROM VAS, V20, P70, DOI 10.1161/01.ATV.20.1.70; Bourcier T, 2000, ARTERIOSCL THROM VAS, V20, P556, DOI 10.1161/01.ATV.20.2.556; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chen Z, 2001, ARTERIOSCL THROM VAS, V21, P372, DOI 10.1161/01.ATV.21.3.372; Collins AR, 2001, ARTERIOSCL THROM VAS, V21, P365, DOI 10.1161/01.ATV.21.3.365; Comparato C, 2001, NUTR METAB CARDIOVAS, V11, P328; Crisby M, 2001, CIRCULATION, V103, P926, DOI 10.1161/01.cir.103.7.926; Dangas G, 2000, THROMB HAEMOSTASIS, V83, P688; DAVIES MJ, 1993, BRIT HEART J, V69, P377; Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013; Diomede L, 2001, ARTERIOSCL THROM VAS, V21, P1327, DOI 10.1161/hq0801.094222; DRAKE TA, 1989, AM J PATHOL, V134, P1087; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GENG YJ, 1995, AM J PATHOL, V147, P251; Gotto AM, 2001, CURR OPIN LIPIDOL, V12, P391, DOI 10.1097/00041433-200108000-00004; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HACKETT D, 1988, EUR HEART J, V9, P1317, DOI 10.1093/oxfordjournals.eurheartj.a062449; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; Herman MP, 2001, CIRCULATION, V104, P1899, DOI 10.1161/hc4101.097419; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; HernandezPresa M, 1997, CIRCULATION, V95, P1532; Kockx MM, 1998, CIRC RES, V83, P378, DOI 10.1161/01.RES.83.4.378; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Lopez S, 2000, ATHEROSCLEROSIS, V152, P359, DOI 10.1016/S0021-9150(00)00454-8; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Mach F, 1997, CIRCULATION, V96, P396; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Marx N, 2001, CIRCULATION, V103, P213; Marx N, 2002, CIRC RES, V90, P703, DOI 10.1161/01.RES.0000014225.20727.8F; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Nakata Y, 2002, CIRCULATION, V105, P1485, DOI 10.1161/01.CIR.0000012142.69612.25; Neve BP, 2001, CIRCULATION, V103, P207; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Roberts W C, 1972, Mod Concepts Cardiovasc Dis, V41, P7; Rocha R, 2000, ENDOCRINOLOGY, V141, P3871, DOI 10.1210/en.141.10.3871; Saren P, 1996, J IMMUNOL, V157, P4159; Schonbeck U, 2000, P NATL ACAD SCI USA, V97, P7458, DOI 10.1073/pnas.97.13.7458; Smith SC, 1996, CIRCULATION, V93, P2205, DOI 10.1161/01.CIR.93.12.2205; Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; Urbich C, 2002, CIRC RES, V90, P737, DOI 10.1161/01.RES.0000014081.30867.F8; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Wilson SH, 2002, CIRCULATION, V105, P415, DOI 10.1161/hc0402.104119; Wilson SH, 2001, ARTERIOSCL THROM VAS, V21, P122, DOI 10.1161/01.ATV.21.1.122; YANAGI H, 1991, ATHEROSCLEROSIS, V91, P207, DOI 10.1016/0021-9150(91)90168-3	70	436	463	0	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1257	1262		10.1038/nm1102-1257	http://dx.doi.org/10.1038/nm1102-1257			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12411953				2022-12-27	WOS:000179221200031
J	Heppner, FL; Greter, M; Marino, D; Falsig, J; Raivich, G; Hovelmeyer, N; Waisman, A; Rulicke, T; Prinz, M; Priller, J; Becher, B; Aguzzi, A				Heppner, FL; Greter, M; Marino, D; Falsig, J; Raivich, G; Hovelmeyer, N; Waisman, A; Rulicke, T; Prinz, M; Priller, J; Becher, B; Aguzzi, A			Experimental autoimmune encephalomyelitis repressed by microglial paralysis	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ANTIGEN-PRESENTING CELLS; CNS-RESIDENT CELLS; MULTIPLE-SCLEROSIS; THYMIDINE KINASE; TRANSGENIC MICE; HEMATOPOIETIC-CELLS; BONE-MARROW; STEM-CELLS	Although microglial activation occurs in inflammatory, degenerative and neoplastic central nervous system (CNS) disorders, its role in pathogenesis is unclear. We studied this question by generating CD11b-HSVTK transgenic mice, which express herpes simplex thymidine kinase in macrophages and microglia. Ganciclovir treatment of organotypic brain slice cultures derived from CD11b-HSVTK mice abolished microglial release of nitrite, proinflammatory cytokines and chemokines. Systemic ganciclovir administration to CD11b-HSVTK mice elicited hematopoietic toxicity, which was prevented by transfer of wild-type bone marrow. In bone marrow chimeras, ganciclovir blocked microglial activation in the facial nucleus upon axotomy and repressed the development of experimental autoimmune encephalomyelitis. We conclude that microglial paralysis inhibits the development and maintenance of inflammatory CNS lesions. The microglial compartment thus provides a potential therapeutic target in inflammatory CNS disorders. These results validate CD11b-HSVTK mice as a tool to study the impact of microglial activation on CNS diseases in vivo.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurol, Neuroimmunol Unit, CH-8091 Zurich, Switzerland; UCL, Perinatal Brain Repair Grp, Dept Obstet & Gynaecol, London WC1E 6HX, England; UCL, Perinatal Brain Repair Grp, Dept Anat, London WC1E 6HX, England; Univ Cologne, Lab Mol Immunol, Inst Genet, D-50931 Cologne, Germany; Univ Zurich, Inst Lab Anim Sci, CH-8091 Zurich, Switzerland; Humboldt Univ, Dept Psychiat, Charite, D-10117 Berlin, Germany; Humboldt Univ, Dept Expt Neurol, Charite, D-10117 Berlin, Germany	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of London; University College London; University of London; University College London; University of Cologne; University of Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Calabrese, Massimiliano/I-6195-2012; Becher, Burkhard/ABE-4225-2020; Raivich, Gennadij/AAL-7229-2021; Aguzzi, Adriano/A-3351-2008; Heppner, Frank/ABH-8393-2020; Marino, Denis/AAU-7962-2020; Priller, Josef/ABW-3835-2022; Waisman, Ari/C-7383-2015; Raivich, Gennadij/A-6770-2011	Becher, Burkhard/0000-0002-1541-7867; Heppner, Frank/0000-0001-9816-8917; Marino, Denis/0000-0002-5197-6682; Waisman, Ari/0000-0003-4304-8234; Hovelmeyer, Nadine/0000-0002-1807-4556; Aguzzi, Adriano/0000-0002-0344-6708; Greter, Melanie/0000-0002-7220-5369; Priller, Josef/0000-0001-7596-0979				Ambrosini E, 2004, NEUROCHEM RES, V29, P1017, DOI 10.1023/B:NERE.0000021246.96864.89; Asheuer M, 2004, P NATL ACAD SCI USA, V101, P3557, DOI 10.1073/pnas.0306431101; Becher B, 2000, GLIA, V29, P293; Becher B, 2003, J CLIN INVEST, V112, P1186, DOI 10.1172/JCI200319079; Becher B, 2001, J EXP MED, V193, P967, DOI 10.1084/jem.193.8.967; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DZIENNIS S, 1995, BLOOD, V85, P319; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Ellison AR, 1998, BBA-GENE STRUCT EXPR, V1442, P28, DOI 10.1016/S0167-4781(98)00112-2; Fisher RC, 1999, BLOOD, V94, P1283, DOI 10.1182/blood.V94.4.1283.416k16_1283_1290; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; FORD AL, 1995, J IMMUNOL, V154, P4309; FYFE JA, 1978, J BIOL CHEM, V253, P8721; Hailer NP, 1998, BRAIN PATHOL, V8, P459; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Heppner FL, 1998, GLIA, V22, P180, DOI 10.1002/(SICI)1098-1136(199802)22:2<180::AID-GLIA9>3.0.CO;2-B; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Herraiz M, 2003, HUM GENE THER, V14, P463, DOI 10.1089/104303403321467225; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Kerschensteiner M, 2003, ANN NEUROL, V53, P292, DOI 10.1002/ana.10446; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; Martiney JA, 1998, J IMMUNOL, V160, P5588; Matyszak MK, 1999, EUR J IMMUNOL, V29, P3063, DOI 10.1002/(SICI)1521-4141(199910)29:10<3063::AID-IMMU3063>3.0.CO;2-G; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pedchenko TV, 1999, EXP NEUROL, V158, P459, DOI 10.1006/exnr.1999.7125; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Raivich G, 1998, J NEUROSCI, V18, P5804; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Schwartz M, 2001, J NEUROIMMUNOL, V113, P185, DOI 10.1016/S0165-5728(00)00447-1; Steinman L, 2002, ANNU REV NEUROSCI, V25, P491, DOI 10.1146/annurev.neuro.25.112701.142913; Tran EH, 1998, J IMMUNOL, V161, P3767; ULVESTAD E, 1994, J LEUKOCYTE BIOL, V56, P732, DOI 10.1002/jlb.56.6.732; Weiner HL, 2002, NATURE, V420, P879, DOI 10.1038/nature01325; Willenborg DO, 1999, J NEUROIMMUNOL, V100, P21, DOI 10.1016/S0165-5728(99)00212-X; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	46	572	588	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					146	152		10.1038/nm1177	http://dx.doi.org/10.1038/nm1177			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665833				2022-12-27	WOS:000226797300021
J	Kong, WJ; Wei, J; Abidi, P; Lin, MH; Inaba, S; Li, C; Wang, YL; Wang, ZZ; Si, SY; Pan, HN; Wang, SK; Wu, JD; Wang, Y; Li, ZR; Liu, JW; Jiang, JD				Kong, WJ; Wei, J; Abidi, P; Lin, MH; Inaba, S; Li, C; Wang, YL; Wang, ZZ; Si, SY; Pan, HN; Wang, SK; Wu, JD; Wang, Y; Li, ZR; Liu, JW; Jiang, JD			Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins	NATURE MEDICINE			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; STEROL REGULATORY ELEMENT; HUMAN LDL RECEPTOR; BINDING PROTEIN PATHWAY; FEEDBACK-REGULATION; NUCLEAR-PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; IDENTIFICATION; TRANSCRIPTION	We identify berberine (BBR), a compound isolated from a Chinese herb, as a new cholesterol-lowering drug. Oral administration of BBR in 32 hypercholesterolemic patients for 3 months reduced serum cholesterol by 29%, triglycerides by 35% and LDL-cholesterol by 25%. Treatment of hyperlipidemic hamsters with BBR reduced serum cholesterol by 40% and LDL-cholesterol by 42%, with a 3.5-fold increase in hepatic LDLR mRNA and a 2.6-fold increase in hepatic LDLR protein. Using human hepatoma cells, we show that BBR upregulates LDLR expression independent of sterol regulatory element binding proteins, but dependent on ERK activation. BBR elevates LDLR expression through a post-transcriptional mechanism that stabilizes the mRNA. Using a heterologous system with luciferase as a reporter, we further identify the 5' proximal section of the LDLR mRNA 3' untranslated region responsible for the regulatory effect of BBR. These findings show BBR as a new hypolipidemic drug with a mechanism of action different from that of statin drugs.	Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China; Pking Union Med Coll, Beijing 100050, Peoples R China; Nanjing Med Univ, Hosp Nanjing City 1, Mol Med Lab, Nanjing 210006, Peoples R China; Nanjing Med Univ, Div Endocrinol, Nanjing 210006, Peoples R China; Dept Vet Affairs Palo Alto Hlth Care Syst, Res Serv, Palo Alto, CA 94304 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medicinal Biotechnology - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Nanjing Medical University; Nanjing Medical University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Icahn School of Medicine at Mount Sinai	Liu, JW (corresponding author), Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China.	jingwen.liu@med.va.gov; jiandong.jiang@mssm.edu			NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA83648-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ansell BJ, 1999, JAMA-J AM MED ASSOC, V282, P2051, DOI 10.1001/jama.282.21.2051; Bensch WR, 1999, J PHARMACOL EXP THER, V289, P85; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cho E., 1990, PHARMACOPOEIA PEOPLE, P437; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Grand-Perret T, 2001, NAT MED, V7, P1332, DOI 10.1038/nm1201-1332; Grundy SM, 1998, CIRCULATION, V97, P1436; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; Knouff C, 2001, J BIOL CHEM, V276, P3856, DOI 10.1074/jbc.M009423200; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Lau CW, 2001, CARDIOVASC DRUG REV, V19, P234; LIU, 2000, ALTERN MED REV, V5, P175; Liu JW, 1998, CYTOKINE, V10, P295, DOI 10.1006/cyto.1997.0283; Liu JW, 2003, ARTERIOSCL THROM VAS, V23, P90, DOI 10.1161/01.ATV.0000046229.77566.E5; Liu JW, 1997, J LIPID RES, V38, P2035; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Luo L.J., 1955, CHINESE J MED GENET, V41, P452; Nakahara M, 2002, J BIOL CHEM, V277, P37229, DOI 10.1074/jbc.M206749200; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Sakai J, 2001, CURR OPIN LIPIDOL, V12, P261, DOI 10.1097/00041433-200106000-00004; SMITH JR, 1990, J BIOL CHEM, V265, P2306; Sugiura R, 2003, NATURE, V424, P961, DOI 10.1038/nature01907; Ugawa T, 2002, BRIT J PHARMACOL, V137, P561, DOI 10.1038/sj.bjp.0704906; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Wilson GM, 1998, J LIPID RES, V39, P1025; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; Yeung AC, 2002, CIRCULATION, V105, P2937, DOI 10.1161/01.CIR.0000023397.12047.03; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Zhang F, 2002, J LIPID RES, V43, P1477, DOI 10.1194/jlr.M200126-JLR200; ZHAO SP, 1997, CLIN SERUM LIPID, V1, P72	39	1025	1171	16	362	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1344	1351		10.1038/nm1135	http://dx.doi.org/10.1038/nm1135			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15531889				2022-12-27	WOS:000225500900028
J	Liu, D; Cheng, T; Guo, H; Fernandez, JA; Griffin, JH; Song, XM; Zlokovic, BV				Liu, D; Cheng, T; Guo, H; Fernandez, JA; Griffin, JH; Song, XM; Zlokovic, BV			Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C	NATURE MEDICINE			English	Article							CELL-DEATH; WILD-TYPE; APOPTOSIS; TPA; ISCHEMIA; MODEL; RAT	Although thrombolytic effects of tissue plasminogen activator (tPA) are beneficial, its neurotoxicity(1-5) is problematic. Here, we report that tPA potentiates apoptosis in ischemic human brain endothelium and in mouse cortical neurons treated with N-methyl-D-aspartate (NMDA) by shifting the apoptotic pathways from caspase-9 to caspase-8, which directly activates caspase-3 without amplification through the Bid-mediated mitochondrial pathway(6). In vivo, tPA-induced cerebral ischemic injury in mice was reduced by intracerebroventricular administration of caspase-8 inhibitor, but not by caspase-9 inhibitor, in contrast to controls in which caspase-9 inhibitor, but not caspase-8 inhibitor, was protective. Activated protein C (APC), a serine protease with anticoagulant, anti-inflammatory and antiapoptotic activities(7), which is neuroprotective during transient ischemia(8,9) and promotes activation of antiapoptotic mechanisms in brain cells by acting directly on endothelium(9-11) and neurons(12), blocked tPA vascular and neuronal toxicities in vitro and in vivo. APC inhibited tPA-induced caspase-8 activation of caspase-3 in endothelium and caspase-3-dependent nuclear translocation of apoptosis-inducing factor in NMDA-treated neurons and reduced tPA-mediated cerebral ischemic injury in mice. Data suggest that tPA shifts the apoptotic signal in stressed brain cells from the intrinsic to the extrinsic pathway which requires caspase-8. APC blocks tPA's neurovascular toxicity and may add substantially to the effectiveness of tPA therapy for stroke.	Univ Rochester, Med Ctr, Dept Neurosurg, Frank P Smith Lab Neurosci & Neurosurg Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Div Neurovasc Biol, Rochester, NY 14642 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of Rochester; University of Rochester; Scripps Research Institute	Zlokovic, BV (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, Frank P Smith Lab Neurosci & Neurosurg Res, 601 Elmwwood Ave,Box 645, Rochester, NY 14642 USA.	berislav_zlokovic@urmc.rochester.edu	Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [HL63290] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063290] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Griffin JH, 2004, CRIT CARE MED, V32, pS247, DOI 10.1097/01.CCM.0000126127.87484.2B; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Jiang Q, 2000, J CEREBR BLOOD F MET, V20, P21, DOI 10.1097/00004647-200001000-00005; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Lo EH, 2004, STROKE, V35, P354, DOI 10.1161/01.STR.0000115164.80010.8A; Matys T, 2003, NAT MED, V9, P371, DOI 10.1038/nm0403-371; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Pichiule P, 2002, J APPL PHYSIOL, V93, P1131, DOI 10.1152/japplphysiol.00318.2002; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Sharp CD, 2003, AM J PHYSIOL-HEART C, V285, pH2592, DOI 10.1152/ajpheart.00520.2003; Shibata M, 2001, CIRCULATION, V103, P1799, DOI 10.1161/01.CIR.103.13.1799; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tabrizi P, 1999, ARTERIOSCL THROM VAS, V19, P2801, DOI 10.1161/01.ATV.19.11.2801; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100	25	185	198	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1379	1383		10.1038/nm1122	http://dx.doi.org/10.1038/nm1122			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15516929				2022-12-27	WOS:000225500900033
J	Palese, P				Palese, P			Influenza: old and new threats	NATURE MEDICINE			English	Review							1918 SPANISH INFLUENZA; A VIRUS; NEURAMINIDASE; VACCINE; GENES; HEMAGGLUTININ; INFECTIONS; INHIBITION; PROTECTION; VIRULENCE	Influenza remains an important disease in humans and animals. In contrast to measles, smallpox and poliomyelitis, influenza is caused by viruses that undergo continuous antigenic change and that possess an animal reservoir. Thus, new epidemics and pandemics are likely to occur in the future, and eradication of the disease will be difficult to achieve. Although it is not clear whether a new pandemic is imminent, it would be prudent to take into account the lessons we have learned from studying different human and animal influenza viruses. Specifically, reconstruction of the genes of the 1918 pandemic virus and studies on their contribution to virulence will be important steps toward understanding the biological capabilities of this lethal virus. Increasing the availability of new antiviral drugs and developing superior vaccines will provide us with better approaches to control influenza and to have a positive impact on disease load. A concern is that the imposition of new rules for working with infectious influenza viruses under high security and high containment conditions will stifle scientific progress. The complex questions of what makes an influenza virus transmissible from one human to another and from one species to another, as well as how the immune system interacts with the virus, will require the active collaboration and unencumbered work of many scientific groups.	Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Palese, P (corresponding author), Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.	peter.palese@mssm.edu		Palese, Peter/0000-0002-0337-5823				BASLER C, 2002, ENCY MOL MED, P1741; Basler CF, 2001, P NATL ACAD SCI USA, V98, P2746, DOI 10.1073/pnas.031575198; Carr J, 2002, ANTIVIR RES, V54, P79, DOI 10.1016/S0166-3542(01)00215-7; Colman PM, 1999, J ANTIMICROB CHEMOTH, V44, P17, DOI 10.1093/jac/44.suppl_2.17; Dowdle WR, 1999, B WORLD HEALTH ORGAN, V77, P820; Fodor E, 1999, J VIROL, V73, P9679, DOI 10.1128/JVI.73.11.9679-9682.1999; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; Geiss GK, 2002, P NATL ACAD SCI USA, V99, P10736, DOI 10.1073/pnas.112338099; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Hatta M, 2002, TRENDS MICROBIOL, V10, P340, DOI 10.1016/S0966-842X(02)02388-0; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HAYDEN F, 1997, CLIN VIROLOGY, P891; Hoffmann E, 2000, VIROLOGY, V267, P310, DOI 10.1006/viro.1999.0140; Kash JC, 2004, J VIROL, V78, P9499, DOI 10.1128/JVI.78.17.9499-9511.2004; Katz JM, 2003, AVIAN DIS, V47, P914, DOI 10.1637/0005-2086-47.s3.914; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; Kemble G, 2003, VACCINE, V21, P1789, DOI 10.1016/S0264-410X(03)00074-4; KILBOURN.ED, 1971, J INFECT DIS, V124, P449, DOI 10.1093/infdis/124.5.449; Kiso M, 2004, LANCET, V364, P759, DOI 10.1016/S0140-6736(04)16934-1; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Lipatov AS, 2004, J VIROL, V78, P8951, DOI 10.1128/JVI.78.17.8951-8959.2004; Mendel DB, 1998, ANTIMICROB AGENTS CH, V42, P640, DOI 10.1128/AAC.42.3.640; MONTO AS, 1992, CLIN INFECT DIS, V15, P362, DOI 10.1093/clinids/15.2.362; NAKAJIMA K, 1978, NATURE, V274, P334, DOI 10.1038/274334a0; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; PALESE P, 1976, J GEN VIROL, V33, P159, DOI 10.1099/0022-1317-33-1-159; Palese P, 2002, J CLIN INVEST, V110, P9, DOI 10.1172/JCI200215999; PROFETA ML, 1986, ARCH VIROL, V90, P355, DOI 10.1007/BF01317384; Reid AH, 2001, MICROBES INFECT, V3, P81, DOI 10.1016/S1286-4579(00)01351-4; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Shortridge K F, 1992, Semin Respir Infect, V7, P11; Swayne DE, 2003, AVIAN DIS, V47, P1047, DOI 10.1637/0005-2086-47.s3.1047; Talon J, 2000, P NATL ACAD SCI USA, V97, P4309, DOI 10.1073/pnas.070525997; Taubenberger JK, 2001, PHILOS T ROY SOC B, V356, P1829, DOI 10.1098/rstb.2001.1020; TAUBENBERGER JK, IN PRESS CONT TOPICS; Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101; Tumpey TM, 2004, P NATL ACAD SCI USA, V101, P3166, DOI 10.1073/pnas.0308391100; Tumpey TM, 2002, P NATL ACAD SCI USA, V99, P13849, DOI 10.1073/pnas.212519699; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; ZAMARIN D, IN PRESS INT KILM C	43	432	480	2	78	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12		S			S82	S87		10.1038/nm1141	http://dx.doi.org/10.1038/nm1141			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577936	Bronze			2022-12-27	WOS:000225733900004
J	Adachi, T; Weisbrod, RM; Pimentel, DR; Ying, J; Sharov, VS; Schoneich, C; Cohen, RA				Adachi, T; Weisbrod, RM; Pimentel, DR; Ying, J; Sharov, VS; Schoneich, C; Cohen, RA			S-glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide	NATURE MEDICINE			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; ENDOTHELIUM-DEPENDENT RELAXATION; RABBIT CAROTID-ARTERY; SMOOTH-MUSCLE-CELLS; CA-ATPASE; SKELETAL-MUSCLE; SUPEROXIDE-DISMUTASE; TYROSINE NITRATION; POTENTIAL ROLE; NITROSYLATION	Nitric oxide (NO) physiologically stimulates the sarco/endoplasmic reticulum calcium (Ca2+) ATPase (SERCA) to decrease intracellular Ca2+ concentration and relax cardiac, skeletal and vascular smooth muscle. Here, we show that NO-derived peroxynitrite (ONOO-) directly increases SERCA activity by S-glutathiolation and that this modification of SERCA is blocked by irreversible oxidation of the relevant cysteine thiols during atherosclerosis. Purified SERCA was S-glutathiolated by ONOO and the increase in Ca2+-uptake activity of SERCA reconstituted in phospholipid vesicles required the presence of glutathione. Mutation of the SERCA-reactive Cys674 to serine abolished these effects. Because superoxide scavengers decreased S-glutathiolation of SERCA and arterial relaxation by NO, ONOO- is implicated as the intracellular mediator. NO-dependent relaxation as well as S-glutathiolation and activation of SERCA were decreased by atherosclerosis and Cys674 was found to be oxidized to sulfonic acid. Thus, irreversible oxidation of key thiol(s) in disease impairs NO-induced relaxation by preventing reversible S-glutathiolation and activation of SERCA by NO/ONOO-.	Boston Univ, Med Ctr, Whitaker Cardiovasc Inst, Vasc Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Whitaker Cardiovasc Inst, Myocardial Biol Unit, Boston, MA 02118 USA; Univ Kansas, Sch Pharm, Dept Pharmaceut Chem, Lawrence, KS 66047 USA	Boston University; Boston University; University of Kansas	Adachi, T (corresponding author), Boston Univ, Med Ctr, Whitaker Cardiovasc Inst, Vasc Biol Unit, X707,650 Albany St, Boston, MA 02118 USA.	Tadachi@sc.itc.keio.ac.jp; racohen@bumc.bu.edu		/0000-0002-1070-6408; Pimentel, David/0000-0002-0537-7195	NHLBI NIH HHS [R01 HL31607-21, HL55993-06, N01-HV-28178] Funding Source: Medline; NIA NIH HHS [AG P01 12993] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031607, P50HL055993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG012993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Adachi T, 2000, BRIT J PHARMACOL, V129, P1014, DOI 10.1038/sj.bjp.0703127; Adachi T, 2002, CIRC RES, V90, P1114, DOI 10.1161/01.RES.0000019757.57344.D5; Adachi T, 2001, CIRCULATION, V104, P1040, DOI 10.1161/hc3501.093798; Aracena P, 2003, J BIOL CHEM, V278, P42927, DOI 10.1074/jbc.M306969200; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Barry-Lane PA, 2001, J CLIN INVEST, V108, P1513, DOI 10.1172/JCI11927; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BISHOP JE, 1988, BIOCHEMISTRY-US, V27, P5233, DOI 10.1021/bi00414a043; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; Cohen RA, 1997, P NATL ACAD SCI USA, V94, P4193, DOI 10.1073/pnas.94.8.4193; d'Uscio LV, 2003, CIRC RES, V92, P88, DOI 10.1161/01.RES.0000049166.33035.62; Davidson CA, 1997, AM J PHYSIOL-LUNG C, V273, pL437, DOI 10.1152/ajplung.1997.273.2.L437; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Flesch M, 1999, CIRCULATION, V100, P346, DOI 10.1161/01.CIR.100.4.346; Fukai T, 1998, J CLIN INVEST, V101, P2101, DOI 10.1172/JCI2105; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Grover AK, 2003, AM J PHYSIOL-CELL PH, V285, pC1537, DOI 10.1152/ajpcell.00299.2003; Guzik TJ, 2002, HYPERTENSION, V39, P1088, DOI 10.1161/01.HYP.0000018041.48432.B5; Ido Y, 2001, FASEB J, V15, P1419, DOI 10.1096/fj.00-0652fje; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Laursen JB, 2001, CIRCULATION, V103, P1282; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; Misquitta CM, 1999, CELL CALCIUM, V25, P277, DOI 10.1054/ceca.1999.0032; Morikawa K, 2003, J CLIN INVEST, V112, P1871, DOI 10.1172/JCI200319351; Okuda M, 2001, ARTERIOSCL THROM VAS, V21, P1483, DOI 10.1161/hq0901.095550; Pagano PJ, 1999, AM J PHYSIOL-HEART C, V277, pH2109, DOI 10.1152/ajpheart.1999.277.5.H2109; Paolocci N, 2000, AM J PHYSIOL-HEART C, V279, pH1982, DOI 10.1152/ajpheart.2000.279.4.H1982; Plane F, 1998, BRIT J PHARMACOL, V123, P1351, DOI 10.1038/sj.bjp.0701746; RADI R, 1991, J BIOL CHEM, V266, P4244; Sharov VS, 2002, ANAL BIOCHEM, V308, P328, DOI 10.1016/S0003-2697(02)00261-0; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Takagi Y, 1998, LAB INVEST, V78, P957; Trepakova ES, 1999, CIRC RES, V84, P201, DOI 10.1161/01.RES.84.2.201; Tribble DL, 1997, ARTERIOSCL THROM VAS, V17, P1734, DOI 10.1161/01.ATV.17.9.1734; Viner RI, 2000, FREE RADICAL BIO MED, V29, P489, DOI 10.1016/S0891-5849(00)00325-7; Viner RI, 1996, FREE RADICAL RES, V24, P243, DOI 10.3109/10715769609088022; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Weisbrod RM, 1997, ARTERIOSCL THROM VAS, V17, P394, DOI 10.1161/01.ATV.17.2.394; White CR, 1996, P NATL ACAD SCI USA, V93, P8745, DOI 10.1073/pnas.93.16.8745; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200; Xu KY, 1997, CIRC RES, V80, P76, DOI 10.1161/01.RES.80.1.76; Yao Q, 1998, PROTEIN EXPRES PURIF, V13, P191, DOI 10.1006/prep.1998.0892	50	502	515	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1200	1207		10.1038/nm1119	http://dx.doi.org/10.1038/nm1119			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15489859				2022-12-27	WOS:000224785900041
J	O'Garra, A; Vieira, P				O'Garra, A; Vieira, P			Regulatory T cells and mechanisms of immune system control	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MEDIATED SUPPRESSION; TUMOR-IMMUNITY; INTERLEUKIN-10; INDUCTION; TOLERANCE; FOXP3; RESPONSES; BETA; TRANSCRIPTION	The immune system evolved to protect the host against the attack of foreign, potentially pathogenic, microorganisms. It does so by recognizing antigens expressed by those microorganisms and mounting an immune response against all cells expressing them, with the ultimate aim of their elimination. Various mechanisms have been reported to control and regulate the immune system to prevent or minimize reactivity to self-antigens or an overexuberant response to a pathogen, both of which can result in damage to the host. Deletion of autoreactive cells during T- and B-cell development allows the immune system to be tolerant of most self-antigens. Peripheral tolerance to self was suggested several years ago to result from the induction of anergy in peripheral self-reactive lymphocytes(1). More recently, however, it has become clear that avoidance of damage to the host is also achieved by active suppression mediated by regulatory T (T-reg) cell populations(2-5). We discuss here the varied mechanisms used by T-reg cells to suppress the immune system.	Natl Inst Med Res, Div Immunoregulat, London NW7 1AA, England; Inst Pasteur, Unite Dev Lymphocytes, CNRS, URA 1961, F-75015 Paris, France	MRC National Institute for Medical Research; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	O'Garra, A (corresponding author), Natl Inst Med Res, Div Immunoregulat, Mill Hill, London NW7 1AA, England.	aogarra@nimr.mrc.ac.uk	Vieira, Paulo/D-4500-2013	Vieira, Paulo/0000-0003-1307-5119; O'Garra, Anne/0000-0001-9845-6134				Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Baud O, 2001, NEW ENGL J MED, V344, P1758, DOI 10.1056/NEJM200106073442304; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918; Buer J, 1998, J EXP MED, V187, P177, DOI 10.1084/jem.187.2.177; Burkhart C, 1999, INT IMMUNOL, V11, P1625, DOI 10.1093/intimm/11.10.1625; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Cobbold SP, 2003, TRANSPL INT, V16, P66, DOI 10.1111/j.1432-2277.2003.tb00266.x; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; GERSHON RK, 1975, TRANSPLANT REV-DENMA, V26, P170; Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1; Green EA, 2003, P NATL ACAD SCI USA, V100, P10878, DOI 10.1073/pnas.1834400100; Green EA, 2002, IMMUNITY, V16, P183, DOI 10.1016/S1074-7613(02)00279-0; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; JENKINS MK, 1991, ADV EXP MED BIOL, V292, P167; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; KANOF ME, 1991, J IMMUNOL, V147, P155; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080; Kullberg MC, 2002, J EXP MED, V196, P505, DOI 10.1084/jem.20020556; Li C, 1999, INFECT IMMUN, V67, P4435, DOI 10.1128/IAI.67.9.4435-4442.1999; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Miller C, 1999, J EXP MED, V190, P53, DOI 10.1084/jem.190.1.53; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; O'Garra A, 2003, NAT IMMUNOL, V4, P304, DOI 10.1038/ni0403-304; Oida T, 2003, J IMMUNOL, V170, P2516, DOI 10.4049/jimmunol.170.5.2516; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pontoux C, 2002, INT IMMUNOL, V14, P233, DOI 10.1093/intimm/14.2.233; POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Ramsdell F, 2003, IMMUNITY, V19, P165, DOI 10.1016/S1074-7613(03)00207-3; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2000, CURR BIOL, V10, pR572, DOI 10.1016/S0960-9822(00)00617-5; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shimizu J, 1999, J IMMUNOL, V163, P5211; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Sundstedt A, 2003, J IMMUNOL, V170, P1240, DOI 10.4049/jimmunol.170.3.1240; Suri-Payer E, 2001, J AUTOIMMUN, V16, P115, DOI 10.1006/jaut.2000.0473; Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Trinchieri G, 2001, J EXP MED, V194, pF53, DOI 10.1084/jem.194.10.f53; Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986; Walker LSK, 2003, J EXP MED, V198, P249, DOI 10.1084/jem.20030315; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1084/jem.20030422; Zhang XM, 2004, INT IMMUNOL, V16, P249, DOI 10.1093/intimm/dxh029	65	628	658	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					801	805		10.1038/nm0804-801	http://dx.doi.org/10.1038/nm0804-801			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15286781				2022-12-27	WOS:000223055700031
J	Barresi, R; Michele, DE; Kanagawa, M; Harper, HA; Dovico, SA; Satz, JS; Moore, SA; Zhang, WL; Schachter, H; Dumanski, JP; Cohn, RD; Nishino, I; Campbell, KP				Barresi, R; Michele, DE; Kanagawa, M; Harper, HA; Dovico, SA; Satz, JS; Moore, SA; Zhang, WL; Schachter, H; Dumanski, JP; Cohn, RD; Nishino, I; Campbell, KP			LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies	NATURE MEDICINE			English	Article							WALKER-WARBURG-SYNDROME; EYE-BRAIN DISEASE; HUMAN LARGE GENE; SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; EXTRACELLULAR-MATRIX; GALNAC TRANSFERASE; LAMININ; MUTATIONS; GLYCOSYLTRANSFERASE	Several congenital muscular dystrophies caused by defects in known or putative glycosyltransferases are commonly associated with hypoglycosylation of alpha-dystroglycan (alpha-DG) and a marked reduction of its receptor function. We have investigated changes in the processing and function of alpha-DG resulting from genetic manipulation of LARGE, the putative glycosyltransferase mutated both in Large(myd) mice and in humans with congenital muscular dystrophy 1D (MDC1D). Here we show that overexpression of LARGE ameliorates the dystrophic phenotype of Large(myd) mice and induces the synthesis of glycan-enriched alpha-DG with high affinity for extracellular ligands. Notably, LARGE circumvents the alpha-DG glycosylation defect in cells from individuals with genetically distinct types of congenital muscular dystrophy. Gene transfer of LARGE into the cells of individuals with congenital muscular dystrophies restores alpha-DG receptor function, whereby glycan-enriched alpha-DG coordinates the organization of laminin on the cell surface. Our findings indicate that modulation of LARGE expression or activity is a viable therapeutic strategy for glycosyltransferase-deficient congenital muscular dystrophies.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Phys & Biophys,Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Roy J & Luclle A Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Toronto, Hosp Sick Children, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Uppsala, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo 1878502, Japan	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Uppsala University; National Center for Neurology & Psychiatry - Japan	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Phys & Biophys,Dept Neurol, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu	Barresi, Rita/AAB-9569-2022; Nishino, Ichizo/G-2676-2010; Cohn, Ronald/AAC-5835-2021	Barresi, Rita/0000-0001-7351-959X; Nishino, Ichizo/0000-0001-9452-112X; Campbell, Kevin/0000-0003-2066-5889; Dumanski, Jan Piotr/0000-0002-1489-1452; Moore, Steven/0000-0002-6353-7900; Kanagawa, Motoi/0000-0003-0984-6398	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD083284] Funding Source: NIH RePORTER; NICHD NIH HHS [HD83284] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; Chiba A, 1997, J BIOL CHEM, V272, P2156; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; DOBYNS WB, 1989, AM J MED GENET, V32, P195, DOI 10.1002/ajmg.1320320213; Dubowitz T, 2000, ANN NEUROL, V47, P143, DOI 10.1002/1531-8249(200002)47:2<143::AID-ANA2>3.0.CO;2-Y; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2003, P NATL ACAD SCI USA, V100, P8910, DOI 10.1073/pnas.1537554100; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Hayashi YK, 2001, NEUROLOGY, V57, P115, DOI 10.1212/WNL.57.1.115; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 2001, J CELL SCI, V114, P1137; Holt KH, 2000, FEBS LETT, V468, P79, DOI 10.1016/S0014-5793(00)01195-9; Holzfeind PJ, 2002, HUM MOL GENET, V11, P2673, DOI 10.1093/hmg/11.21.2673; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Ishii H, 1997, NEUROMUSCULAR DISORD, V7, P191, DOI 10.1016/S0960-8966(97)00462-8; Jimenez-Mallebrera C, 2003, EUR J PAEDIATR NEURO, V7, P129, DOI 10.1016/S1090-3798(03)00042-4; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Kano H, 2002, BIOCHEM BIOPH RES CO, V291, P1283, DOI 10.1006/bbrc.2002.6608; Kanoff RJ, 1998, PEDIATR NEUROL, V18, P76, DOI 10.1016/S0887-8994(97)00137-9; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Kondo-Iida E, 1999, HUM MOL GENET, V8, P2303, DOI 10.1093/hmg/8.12.2303; Kunz S, 2001, J CELL BIOL, V155, P301, DOI 10.1083/jcb.200104103; Longman C, 2003, NEUROMUSCULAR DISORD, V13, P645; Longman C, 2003, HUM MOL GENET, V12, P2853, DOI 10.1093/hmg/ddg307; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Nguyen HH, 2002, P NATL ACAD SCI USA, V99, P5616, DOI 10.1073/pnas.082613599; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Sabatelli P, 2003, BBA-MOL BASIS DIS, V1638, P57, DOI 10.1016/S0925-4439(03)00040-1; Saito Y, 2000, ANN NEUROL, V47, P756, DOI 10.1002/1531-8249(200006)47:6<756::AID-ANA8>3.3.CO;2-0; Takeda S, 2003, HUM MOL GENET, V12, P1449, DOI 10.1093/hmg/ddg153; Taniguchi K, 2003, HUM MOL GENET, V12, P527, DOI 10.1093/hmg/ddg043; Toda T, 2000, NEUROMUSCULAR DISORD, V10, P153, DOI 10.1016/S0960-8966(99)00109-1; Xia B, 2002, DEV BIOL, V242, P58, DOI 10.1006/dbio.2001.0530; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Zhang WL, 2003, CLIN BIOCHEM, V36, P339, DOI 10.1016/S0009-9120(03)00036-5; Zhang WL, 2002, BIOCHEM J, V361, P153, DOI 10.1042/0264-6021:3610153	39	197	203	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					696	703		10.1038/nm1059	http://dx.doi.org/10.1038/nm1059			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15184894				2022-12-27	WOS:000222460400023
J	Nestor, PJ; Scheltens, P; Hodges, JR				Nestor, PJ; Scheltens, P; Hodges, JR			Advances in the early detection of Alzheimer's disease	NATURE MEDICINE			English	Review							MILD COGNITIVE IMPAIRMENT; TEMPORAL-LOBE ATROPHY; GRAY-MATTER LOSS; GLUCOSE-METABOLISM; ENTORHINAL CORTEX; HIPPOCAMPAL-FORMATION; ACETYLCHOLINESTERASE ACTIVITY; PRECLINICAL PREDICTION; MEMORY IMPAIRMENT; SENILE DEMENTIA	The combination of an aging population and the promise, possibly in the near future, of disease-modifying therapies have made the characterization of the early stages of Alzheimer's disease (AD) a topic of major research interest. In this article we review recent progress in our understanding of the evolution of early AD with particular reference to the symptomatic pre-dementia stage designated 'mild cognitive impairment', emphasizing work on the early cognitive profile and associated neuroimaging studies.	Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Cambridge CB2 2QQ, England; VU Med Centrum, Alzheimer Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands; MRC, Cognit & Brain Sci Unit, Cambridge CB2 2EF, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Hodges, JR (corresponding author), Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Hills Rd, Cambridge CB2 2QQ, England.	john.hodges@mrc-cbu.cam.ac.uk	Nestor, Peter/Y-6106-2018; Scheltens, Philip/AAL-9631-2020	Nestor, Peter/0000-0002-5860-5921; Scheltens, Philip/0000-0002-1046-6408				Albert MS, 2001, J INT NEUROPSYCH SOC, V7, P631, DOI 10.1017/S1355617701755105; Arnaiz E, 2001, NEUROREPORT, V12, P851, DOI 10.1097/00001756-200103260-00045; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Backman L, 1999, NEUROLOGY, V52, P1861, DOI 10.1212/WNL.52.9.1861; Becker JT, 1996, NEUROLOGY, V46, P692, DOI 10.1212/WNL.46.3.692; Blackwell AD, 2004, DEMENT GERIATR COGN, V17, P42, DOI 10.1159/000074081; Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; BONDAREFF W, 1982, NEUROLOGY, V32, P164, DOI 10.1212/WNL.32.2.164; Braak H, 1996, ACTA NEUROL SCAND, V93, P3; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Celsis P, 2000, ANN MED, V32, P6, DOI 10.3109/07853890008995904; Chen P, 2000, NEUROLOGY, V55, P1847, DOI 10.1212/WNL.55.12.1847; Chertkow H, 2002, CURR OPIN NEUROL, V15, P401, DOI 10.1097/00019052-200208000-00001; Chetelat G, 2003, BRAIN, V126, P1955, DOI 10.1093/brain/awg196; Chetelat G, 2003, NEUROLOGY, V60, P1374, DOI 10.1212/01.WNL.0000055847.17752.E6; Chetelat G, 2002, NEUROREPORT, V13, P1939; Darby D, 2002, NEUROLOGY, V59, P1042, DOI 10.1212/WNL.59.7.1042; De Santi S, 2001, NEUROBIOL AGING, V22, P529, DOI 10.1016/S0197-4580(01)00230-5; DeCarli C, 2003, LANCET NEUROL, V2, P15, DOI 10.1016/S1474-4422(03)00262-X; DeKosky ST, 2002, ANN NEUROL, V51, P145, DOI 10.1002/ana.10069; DELACOSTE MC, 1993, NEUROBIOL AGING, V14, P1, DOI 10.1016/0197-4580(93)90015-4; Delacourte A, 1999, NEUROLOGY, V52, P1158, DOI 10.1212/WNL.52.6.1158; Delazer M, 2003, NEUROPSYCHOLOGIA, V41, P1593, DOI 10.1016/S0028-3932(03)00116-7; DELEON MJ, 1993, AM J NEURORADIOL, V14, P897; DELEON MJ, 1993, LANCET, V341, P125, DOI 10.1016/0140-6736(93)92610-6; Devanand DP, 1997, J AM GERIATR SOC, V45, P321, DOI 10.1111/j.1532-5415.1997.tb00947.x; Di Carlo A, 2000, J AM GERIATR SOC, V48, P775, DOI 10.1111/j.1532-5415.2000.tb04752.x; Dickerson BC, 2001, NEUROBIOL AGING, V22, P747, DOI 10.1016/S0197-4580(01)00271-8; Drzezga A, 2003, EUR J NUCL MED MOL I, V30, P1104, DOI 10.1007/s00259-003-1194-1; Du AT, 2001, J NEUROL NEUROSUR PS, V71, P441, DOI 10.1136/jnnp.71.4.441; Dwolatzky Tzvi, 2003, BMC Geriatr, V3, P4, DOI 10.1186/1471-2318-3-4; Estevez-Gonzalez A, 2004, DEMENT GERIATR COGN, V17, P188, DOI 10.1159/000076355; Fabrigoule C, 1998, BRAIN, V121, P135, DOI 10.1093/brain/121.1.135; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fowler K S, 1997, J Int Neuropsychol Soc, V3, P139; Fowler K S, 1995, Appl Neuropsychol, V2, P72, DOI 10.1207/s15324826an0202_4; Fox NC, 1996, LANCET, V348, P94, DOI 10.1016/S0140-6736(96)05228-2; Fox NC, 1998, BRAIN, V121, P1631, DOI 10.1093/brain/121.9.1631; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; FUKUYAMA H, 1991, J NEUROL SCI, V106, P128, DOI 10.1016/0022-510X(91)90249-7; FULD PA, 1990, J CLIN EXP NEUROPSYC, V12, P520, DOI 10.1080/01688639008400998; Galton CJ, 2001, J NEUROL NEUROSUR PS, V70, P165, DOI 10.1136/jnnp.70.2.165; Galton CJ, 2000, BRAIN, V123, P484, DOI 10.1093/brain/123.3.484; Goncharova II, 2001, NEUROBIOL AGING, V22, P737, DOI 10.1016/S0197-4580(01)00270-6; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Grundman M, 2004, ARCH NEUROL-CHICAGO, V61, P59, DOI 10.1001/archneur.61.1.59; Huang CR, 2002, BMC NEUROL, V2, DOI 10.1186/1471-2377-2-9; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; Ishii K, 1998, DEMENT GERIATR COGN, V9, P317, DOI 10.1159/000017083; Ishii K, 1996, J NUCL MED, V37, P1159; Jack CR, 2002, NEUROLOGY, V58, P750, DOI 10.1212/WNL.58.5.750; Jack CR, 1997, NEUROLOGY, V49, P786, DOI 10.1212/WNL.49.3.786; Jack CR, 2004, NEUROLOGY, V62, P591, DOI 10.1212/01.WNL.0000110315.26026.EF; Jack CR, 1999, NEUROLOGY, V52, P1397, DOI 10.1212/WNL.52.7.1397; JAGUST WJ, 1993, BRAIN RES, V629, P189, DOI 10.1016/0006-8993(93)91320-R; Johnson KA, 1998, NEUROLOGY, V50, P1563, DOI 10.1212/WNL.50.6.1563; KADEKARO M, 1985, P NATL ACAD SCI USA, V82, P6010, DOI 10.1073/pnas.82.17.6010; Killiany RJ, 2000, ANN NEUROL, V47, P430, DOI 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I; Killiany RJ, 2002, NEUROLOGY, V58, P1188, DOI 10.1212/WNL.58.8.1188; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Kogure D, 2000, J NUCL MED, V41, P1155; KORF ESC, 2004, IN PRESS NEUROLOGY; Kuhl DE, 1999, NEUROLOGY, V52, P691, DOI 10.1212/WNL.52.4.691; Lee ACH, 2003, EUR J NEUROSCI, V18, P1660, DOI 10.1046/j.1460-9568.2003.02883.x; LINN RT, 1995, ARCH NEUROL-CHICAGO, V52, P485, DOI 10.1001/archneur.1995.00540290075020; MANN DMA, 1984, J NEUROL NEUROSUR PS, V47, P201, DOI 10.1136/jnnp.47.2.201; MASUR DM, 1994, NEUROLOGY, V44, P1427, DOI 10.1212/WNL.44.8.1427; Minoshima S, 1999, ANN NY ACAD SCI, V893, P350, DOI 10.1111/j.1749-6632.1999.tb07852.x; Minoshima S, 1997, ANN NEUROL, V42, P85, DOI 10.1002/ana.410420114; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; Nestor PJ, 2003, EUR J NEUROSCI, V18, P2663, DOI 10.1046/j.1460-9568.2003.02999.x; Nestor PJ, 2003, ANN NEUROL, V54, P343, DOI 10.1002/ana.10669; Orgogozo J.-M., 2000, International Journal of Geriatric Psychopharmacology, V2, P60; Ouchi Y, 1998, NEUROLOGY, V51, P136, DOI 10.1212/WNL.51.1.136; Perry RJ, 2003, EUR J NEUROSCI, V18, P221, DOI 10.1046/j.1460-9568.2003.02754.x; Perry RJ, 1999, BRAIN, V122, P383, DOI 10.1093/brain/122.3.383; Perry RJ, 2000, NEUROPSYCHOLOGIA, V38, P252, DOI 10.1016/S0028-3932(99)00079-2; Petersen R. C., 2003, MILD COGNITIVE IMPAI; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V273, P1274, DOI 10.1001/jama.273.16.1274; Ralph MAL, 2003, BRAIN, V126, P2350, DOI 10.1093/brain/awg236; Rinne JO, 2003, J NEUROL NEUROSUR PS, V74, P113, DOI 10.1136/jnnp.74.1.113; Ritchie K, 2002, LANCET, V360, P1759, DOI 10.1016/S0140-6736(02)11667-9; Ritchie K, 2000, LANCET, V355, P225, DOI 10.1016/S0140-6736(99)06155-3; Ritchie K, 2001, NEUROLOGY, V56, P37, DOI 10.1212/WNL.56.1.37; Rombouts SARB, 2000, NEUROSCI LETT, V285, P231, DOI 10.1016/S0304-3940(00)01067-3; Rubin EH, 1998, ARCH NEUROL-CHICAGO, V55, P395, DOI 10.1001/archneur.55.3.395; Sarter M, 2003, NEUROBIOL LEARN MEM, V80, P245, DOI 10.1016/S1074-7427(03)00070-4; Scahill RI, 2002, P NATL ACAD SCI USA, V99, P4703, DOI 10.1073/pnas.052587399; Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989; Scheltens P, 2002, LANCET NEUROL, V1, P13, DOI 10.1016/S1474-4422(02)00002-9; SCHELTENS P, 1992, J NEUROL NEUROSUR PS, V55, P967, DOI 10.1136/jnnp.55.10.967; Schott JM, 2003, ANN NEUROL, V53, P181, DOI 10.1002/ana.10424; Swainson R, 2001, DEMENT GERIATR COGN, V12, P265, DOI 10.1159/000051269; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Thompson SA, 2002, NEUROPSYCHOLOGY, V16, P344, DOI 10.1037//0894-4105.16.3.344; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; Tiraboschi P, 2000, NEUROLOGY, V55, P1278, DOI 10.1212/WNL.55.9.1278; van der Flier WM, 2002, NEUROLOGY, V59, P874, DOI 10.1212/WNL.59.6.874; Visser PJ, 1999, J NEUROL, V246, P477, DOI 10.1007/s004150050387; Visser PJ, 2002, J NEUROL NEUROSUR PS, V72, P491; WELSH KA, 1992, ARCH NEUROL-CHICAGO, V49, P448, DOI 10.1001/archneur.1992.00530290030008; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Wolf H, 2003, ACTA NEUROL SCAND, V107, P52, DOI 10.1034/j.1600-0404.107.s179.10.x; Xu Y, 2000, NEUROLOGY, V54, P1760, DOI 10.1212/WNL.54.9.1760	107	343	344	1	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7		S			S34	S41		10.1038/nrn1433	http://dx.doi.org/10.1038/nrn1433			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	844YU	15298007				2022-12-27	WOS:000223202100006
J	Mathur, RK; Awasthi, A; Wadhone, P; Ramanamurthy, B; Saha, B				Mathur, RK; Awasthi, A; Wadhone, P; Ramanamurthy, B; Saha, B			Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses	NATURE MEDICINE			English	Article							LEISHMANIA-MAJOR INFECTION; IL-12 PRODUCTION; CYTOKINE PRODUCTION; T-CELLS; INTERLEUKIN-12 INDUCTION; KINASE; MACROPHAGES; TH1; DIFFERENTIATION; ALPHA	Macrophages play host to Leishmania major, a parasite that causes leishmaniasis in 500,000 people annually. Macrophage-expressed CD40, a costimulatory molecule 1, induces interleukin-12 (IL-12)-dependent and interferon-gamma (IFN-gamma)-dependent host-protective immune responses to Leishmania and other intracellular pathogens(2-6). Paradoxically, IL-10, another CD40-induced cytokine in macrophages(7), promotes Leishmania infection(8). How CD40 signaling regulates the secretion of these two counteractive cytokines remains unknown. Here we show that weak CD40 signals induce extracellular stress-related kinase-1/2 (ERK-1/ 2)-dependent IL-10 expression, whereas stronger signals induce p38 mitogen-activated protein kinase (p38MAPK) dependent IL-12 production. p38MAPK and ERK-1/ 2 therefore have counter-regulatory actions. Leishmania skews CD40 signaling toward ERK-1/ 2, inducing IL-10, which inhibits activation of CD40-induced p38MAPK and expression of inducible nitric oxide synthase-2 (iNOS-2) and IL-12. ERK-1/ 2 inhibition or IL-10 neutralization restores CD40-induced p38MAPK activation and parasite killing in macrophages and the BALB/c mouse, a susceptible host. These data uncover a new immune evasion strategy, whereby Leishmania differentially modulates CD40-engaged, reciprocally functioning signaling modules, and provide a new conceptual framework for immune homeostasis.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Saha, B (corresponding author), Natl Ctr Cell Sci, Pune 411007, Maharashtra, India.	sahab@nccs.res.in	Gangalum, Pallavi/H-1354-2013	Gangalum, Pallavi/0000-0002-3258-6523; mathur, Ramkumar/0000-0002-9317-2631				Awasthi A, 2003, J EXP MED, V197, P1037, DOI 10.1084/jem.20022033; Belkaid Y, 1998, EUR J IMMUNOL, V28, P1389, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1389::AID-IMMU1389&gt;3.0.CO;2-1; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Dong C, 2001, CURR OPIN HEMATOL, V8, P47, DOI 10.1097/00062752-200101000-00009; Feng GJ, 1999, J IMMUNOL, V163, P6403; Foey AD, 2000, CYTOKINE, V12, P1496, DOI 10.1006/cyto.2000.0750; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Groux H, 1999, J IMMUNOL, V162, P1723; Heinzel FP, 1998, CELL IMMUNOL, V184, P129, DOI 10.1006/cimm.1998.1267; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Kamanaka M, 1996, IMMUNITY, V4, P275, DOI 10.1016/S1074-7613(00)80435-5; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; LIEW FY, 1989, IMMUNOL TODAY, V10, P40, DOI 10.1016/0167-5699(89)90302-2; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MOSMANN TR, 1991, IMMUNOL TODAY, V12, P49; Padigel UM, 2003, J IMMUNOL, V171, P3705, DOI 10.4049/jimmunol.171.7.3705; Park SJ, 2001, BIOCHEM BIOPH RES CO, V287, P1140, DOI 10.1006/bbrc.2001.5713; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Samten B, 2003, J IMMUNOL, V170, P3180, DOI 10.4049/jimmunol.170.6.3180; Scott P, 1998, IMMUNOL RES, V17, P229, DOI 10.1007/BF02786447; Speirs K, 2002, J IMMUNOL, V168, P4406, DOI 10.4049/jimmunol.168.9.4406; Sutterwala FS, 1997, J EXP MED, V185, P1977, DOI 10.1084/jem.185.11.1977; Tachimoto H, 2000, J ALLERGY CLIN IMMUN, V106, P141, DOI 10.1067/mai.2000.107043; Watts SW, 1996, J PHARMACOL EXP THER, V279, P1541; Xu DM, 1998, J IMMUNOL, V160, P1285; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711	30	195	200	1	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					540	544		10.1038/nm1045	http://dx.doi.org/10.1038/nm1045			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15107845				2022-12-27	WOS:000221242400034
J	Rehwald, WG; Chen, EL; Kim, RJ; Judd, RM				Rehwald, WG; Chen, EL; Kim, RJ; Judd, RM			Noninvasive cineangiography by magnetic resonance global coherent free precession	NATURE MEDICINE			English	Article							SPIRAL COMPUTED-TOMOGRAPHY; CORONARY-ARTERY STENOSES; MR-ANGIOGRAPHY; INTRAVASCULAR ULTRASOUND; FLOW RESERVE; VELOCITY; PLAQUE	Cardiovascular disease is primarily diagnosed using invasive X-ray cineangiography. Here we introduce a new concept in magnetic resonance imaging (MRI) that, for the first time, produces similar images noninvasively and without a contrast agent. Protons in moving blood are 'tagged' every few milliseconds as they travel through an arbitrary region in space. Simultaneous with ongoing tagging of new blood, previously tagged blood is maintained in a state of global coherent free precession (GCFP), which allows acquisition of consecutive movie frames as the heart pushes blood through the vascular bed. Body tissue surrounding the moving blood is never excited and therefore remains invisible. In 18 subjects, pulsating blood could be seen flowing through three-dimensional (3D) space for distances of up to 16 cm outside the stationary excitation region. These data underscore that our approach noninvasively characterizes both anatomy and blood flow in a manner directly analogous to invasive procedures.	Duke Univ, Med Ctr, Duke Cardiovasc Magnet Resonance Ctr, Durham, NC 27710 USA; Siemens Med Syst Inc, Siemens Med Solut USA, Malvern, PA 19355 USA	Duke University; Siemens AG	Judd, RM (corresponding author), Duke Univ, Med Ctr, Duke Cardiovasc Magnet Resonance Ctr, POB 3934, Durham, NC 27710 USA.	Robert.Judd@dcmrc.duhs.duke.edu	Kim, Raymond J/B-1426-2008					Achenbach S, 2004, CIRCULATION, V109, P14, DOI 10.1161/01.CIR.0000111517.69230.0F; Achenbach S, 1998, NEW ENGL J MED, V339, P1964, DOI 10.1056/NEJM199812313392702; American Heart Association, 2003, HEART DIS STROK STAT; Aspelin P, 2003, NEW ENGL J MED, V348, P491, DOI 10.1056/NEJMoa021833; AXEL L, 1986, Magnetic Resonance Imaging, V4, P199, DOI 10.1016/0730-725X(86)91059-3; DIXON WT, 1986, MAGN RESON MED, V3, P454, DOI 10.1002/mrm.1910030311; EDELMAN RR, 1994, MAGNET RESON MED, V31, P233, DOI 10.1002/mrm.1910310219; FEINBERG DA, 1984, RADIOLOGY, V153, P177, DOI 10.1148/radiology.153.1.6473779; FRANK LR, 1992, MAGNET RESON MED, V25, P299, DOI 10.1002/mrm.1910250208; Hademenos GJ, 1997, STROKE, V28, P2067, DOI 10.1161/01.STR.28.10.2067; LIANG ZP, 1999, PRINCIPLES MAGNETIC, pCH4; Manginas A, 1999, AM J CARDIOL, V83, P1562, DOI 10.1016/S0002-9149(99)00149-6; Nieman K, 2002, CIRCULATION, V106, P2051, DOI 10.1161/01.CIR.0000037222.58317.3D; NISHIMURA DG, 1995, MAGNET RESON MED, V33, P549, DOI 10.1002/mrm.1910330414; NISHIMURA DG, 1987, MAGNET RESON MED, V4, P193, DOI 10.1002/mrm.1910040214; OPPELT A, 1986, Electromedica (English Edition), V54, P15; POPOVIC JR, 2001, VITAL HLTH STAT, V13, P1; Reeder SB, 1996, RADIOLOGY, V200, P177, DOI 10.1148/radiology.200.1.8657907; Ropers D, 2003, CIRCULATION, V107, P664, DOI 10.1161/01.CIR.0000055738.31551.A9; Schoenhagen P, 2003, CORONARY ARTERY DIS, V14, P459, DOI 10.1097/00019501-200309000-00007; Schroeder S, 2001, J AM COLL CARDIOL, V37, P1430, DOI 10.1016/S0735-1097(01)01115-9; Shibata M, 1999, J MAGN RESON IMAGING, V10, P563, DOI 10.1002/(SICI)1522-2586(199910)10:4<563::AID-JMRI9>3.0.CO;2-H; SIMONETTI OP, 1991, JMRI-J MAGN RESON IM, V1, P569, DOI 10.1002/jmri.1880010510; SINGER JR, 1983, SCIENCE, V221, P654, DOI 10.1126/science.6867733; Spuentrup E, 2002, RADIOLOGY, V225, P589, DOI 10.1148/radiol.2252011366; Stefansic JD, 1998, MAGNET RESON MED, V40, P261, DOI 10.1002/mrm.1910400212; Stuber M, 2002, MAGNET RESON MED, V47, P322, DOI 10.1002/mrm.10042; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; Waggoner AD, 2001, J AM SOC ECHOCARDIOG, V14, P1143, DOI 10.1067/mje.2001.115391; WEDEEN VJ, 1985, SCIENCE, V230, P946, DOI 10.1126/science.4059917	30	18	20	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					545	549		10.1038/nm1027	http://dx.doi.org/10.1038/nm1027			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15064758				2022-12-27	WOS:000221242400035
J	Torres, VE; Wang, XF; Qian, Q; Somlo, S; Harris, PC; Gattone, VH				Torres, VE; Wang, XF; Qian, Q; Somlo, S; Harris, PC; Gattone, VH			Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease	NATURE MEDICINE			English	Article							RENAL CYSTS; CELLS; CAMP; INHIBITION; SECRETION; FLUID; CA2+	Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2(-/tm1Som)), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.	Mayo Clin, Coll Med, Div Nephrol, Rochester, MN 55905 USA; Yale Univ, Sch Med, Nephrol Sect, New Haven, CT 06536 USA; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA	Mayo Clinic; Yale University; Indiana University System; Indiana University-Purdue University Indianapolis	Torres, VE (corresponding author), Mayo Clin, Coll Med, Div Nephrol, Rochester, MN 55905 USA.	torres.vicente@mayo.edu		Torres, Vicente/0000-0003-2008-1576	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044863] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44863] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; GABOW PA, 1989, KIDNEY INT, V35, P675, DOI 10.1038/ki.1989.38; Gattone VH, 2003, NAT MED, V9, P1323, DOI 10.1038/nm935; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Sweeney WE, 2001, AM J PHYSIOL-CELL PH, V281, pC1695, DOI 10.1152/ajpcell.2001.281.5.C1695; Thibonnier M, 2001, ANNU REV PHARMACOL, V41, P175, DOI 10.1146/annurev.pharmtox.41.1.175; VERANI RR, 1988, MODERN PATHOL, V1, P457; Wallace DP, 2001, AM J PHYSIOL-RENAL, V280, pF1019, DOI 10.1152/ajprenal.2001.280.6.F1019; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Yamaguchi T, 2002, J AM SOC NEPHROL, V13, p105A; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; YE M, 1993, NEW ENGL J MED, V329, P310, DOI 10.1056/NEJM199307293290503	14	352	365	2	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2004	10	4					363	364		10.1038/nm1004	http://dx.doi.org/10.1038/nm1004			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	14991049				2022-12-27	WOS:000220587000025
J	Khanna, C; Wan, XL; Bose, S; Cassaday, R; Olomu, O; Mendoza, A; Yeung, C; Gorlick, R; Hewitt, SM; Helman, LJ				Khanna, C; Wan, XL; Bose, S; Cassaday, R; Olomu, O; Mendoza, A; Yeung, C; Gorlick, R; Hewitt, SM; Helman, LJ			The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis	NATURE MEDICINE			English	Article							CELL; APOPTOSIS; SURVIVAL; BINDING; KINASE; MERLIN; MODEL	Metastatic cancers, once established, are the primary cause of mortality associated with cancer. Previously, we used a genomic approach to identify metastasis-associated genes in cancer 1. From this genomic data, we selected ezrin for further study based on its role in physically and functionally connecting the actin cytoskeleton to the cell membrane 2. In a mouse model of osteosarcoma, a highly metastatic pediatric cancer, we found ezrin to be necessary for metastasis. By imaging metastatic cells in the lungs of mice, we showed that ezrin expression provided an early survival advantage for cancer cells that reached the lung. AKT and MAPK phosphorylation and activity were reduced when ezrin protein was suppressed. Ezrin-mediated early metastatic survival was partially dependent on activation of MAPK, but not AKT. To define the relevance of ezrin in the biology of metastasis, beyond the founding mouse model, we examined ezrin expression in dogs that naturally developed osteosarcoma. High ezrin expression in dog tumors was associated with early development of metastases. Consistent with this data, we found a significant association between high ezrin expression and poor outcome in pediatric osteosarcoma patients.	NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; NCI, Tissue Array Project Lab, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center	Khanna, C (corresponding author), NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA.	khannac@mail.nih.gov	Cassaday, Ryan/AAF-4290-2021	Hewitt, Stephen/0000-0001-8283-1788; GORLICK, RICHARD/0000-0001-8995-2929	NATIONAL CANCER INSTITUTE [Z01BC010566, ZIASC006892, ZIABC010566, Z01SC006892] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chambers A F, 2001, Surg Oncol Clin N Am, V10, P243; Chambers AF, 2000, BREAST CANCER RES, V2, P400, DOI 10.1186/bcr86; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Hiscox S, 1999, J CELL SCI, V112, P3081; Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547; Khanna C, 2002, CLIN CANCER RES, V8, P2406; Khanna C, 2001, CANCER RES, V61, P3750; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Ohtani K, 2002, CANCER LETT, V179, P79, DOI 10.1016/S0304-3835(01)00857-6; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Vail DM, 2000, CANCER INVEST, V18, P781, DOI 10.3109/07357900009012210; Wan XL, 2002, NEOPLASIA, V4, P400, DOI 10.1038/sj.neo.7900242; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; WITHROW SJ, 1991, CLIN ORTHOP RELAT R, P159; Wong CW, 2002, AM J PATHOL, V161, P749, DOI 10.1016/S0002-9440(10)64233-2; Wong CW, 2001, CANCER RES, V61, P333; YU Y, 2004, NAT MED, V10, P48	27	549	654	1	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					182	186		10.1038/nm982	http://dx.doi.org/10.1038/nm982			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14704791				2022-12-27	WOS:000188719600038
J	Aicher, A; Heeschen, C; Mildner-Rihm, C; Urbich, C; Ihling, C; Technau-Ihling, K; Zeiher, AM; Dimmeler, S				Aicher, A; Heeschen, C; Mildner-Rihm, C; Urbich, C; Ihling, C; Technau-Ihling, K; Zeiher, AM; Dimmeler, S			Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM; POSTNATAL NEOVASCULARIZATION; MATRIX METALLOPROTEINASES; ADHESION MOLECULES; TUMOR ANGIOGENESIS; IN-VITRO; GROWTH; RECRUITMENT; MECHANISMS; VEGF	Endothelial nitric oxide synthase (eNOS) is essential for neovascularization. Here we show that the impaired neovascularization in mice lacking eNOS is related to a defect in progenitor cell mobilization. Mice deficient in eNOS <LF>(Nos3(-/-)) show reduced vascular endothelial growth factor (VEGF)-induced mobilization of endothelial progenitor cells (EPCs) and increased mortality after myelosuppression. Intravenous infusion of wild-type progenitor cells, but not bone marrow transplantation, rescued the defective neovascularization of Nos3(-/-) mice in a model of hind-limb ischemia, suggesting that progenitor mobilization from the bone marrow is impaired in Nos3(-/-) mice. Mechanistically, matrix metalloproteinase-9 (MMP-9), which is required for stem cell mobilization, was reduced in the bone marrow of Nos3(-/-) mice. These findings indicate that eNOS expressed by bone marrow stromal cells influences recruitment of stem and progenitor cells. This may contribute to impaired regeneration processes in ischemic heart disease patients, who are characterized by a reduced systemic NO bioactivity.	Goethe Univ Frankfurt, Dept Internal Med 4, D-60590 Frankfurt, Germany; Univ Freiburg, Dept Pathol, D-79104 Freiburg, Germany	Goethe University Frankfurt; University of Freiburg	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de	Guba, Markus/M-4309-2019; Aicher, Alexandra/GZK-8031-2022	Heeschen, Christopher/0000-0002-1158-8554; Dimmeler, Stefanie/0000-0002-1045-2436; Aicher, Alexandra/0000-0002-8920-9577				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Eriksson U, 2002, NAT MED, V8, P775, DOI 10.1038/nm0802-775; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Isner JM, 1999, NAT MED, V5, P491, DOI 10.1038/8374; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Moore MAS, 2001, ANN NY ACAD SCI, V938, P36; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Prosper F, 1998, J CLIN INVEST, V101, P2456, DOI 10.1172/JCI188; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; Shami PJ, 1996, BLOOD, V87, P977, DOI 10.1182/blood.V87.3.977.bloodjournal873977; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Taylor DA, 2002, CIRCULATION, V106, P2, DOI 10.1161/01.CIR.0000024386.99599.4A; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Vermeulen M, 1998, BLOOD, V92, P894, DOI 10.1182/blood.V92.3.894.415k22_894_900; Zeiher AM, 1996, LANCET, V348, pS10, DOI 10.1016/S0140-6736(96)98004-6; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	40	1105	1209	1	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2003	9	11					1370	1376		10.1038/nm948	http://dx.doi.org/10.1038/nm948			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14556003				2022-12-27	WOS:000186319700026
J	Krosl, J; Austin, P; Beslu, N; Kroon, E; Humphries, RK; Sauvageau, G				Krosl, J; Austin, P; Beslu, N; Kroon, E; Humphries, RK; Sauvageau, G			In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein	NATURE MEDICINE			English	Article							BONE-MARROW-CELLS; MAMMALIAN-CELLS; EX-VIVO; TAT; PROLIFERATION; GENERATION; DELIVERY	Hematopoietic stem cells (HSCs) can self-renew extensively after transplantation. The conditions supporting their in vitro expansion are still being defined. Retroviral overexpression of the human homeobox B4 (HOXB4) gene in mouse bone marrow cells enables over 40-fold expansion of HSCs in vitro. To circumvent the requirement for retroviral infection, we used recombinant human TAT-HOXB4 protein carrying the protein transduction domain of the HIV transactivating protein (TAT) as a potential growth factor for stem cells. HSCs exposed to TAT-HOXB4 for 4 d expanded by about four- to sixfold and were 8-20 times more numerous than HSCs in control cultures, indicating that HSC expansion induced by TAT-HOXB4 was comparable to that induced by the human HOXB4 retrovirus during a similar period of observation. Our results also show that TAT-HOXB4-expanded HSC populations retain their normal in vivo potential for differentiation and long-term repopulation. It is thus feasible to exploit recombinant HOXB4 protein for rapid and significant ex vivo expansion of normal HSCs.	Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H2W 1R7, Canada; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Hop Maison Neuve Rosemont, Dept Med, Montreal, PQ H1T 2M4, Canada; Hop Maison Neuve Rosemont, Div Hematol, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; British Columbia Cancer Agency; Universite de Montreal; Universite de Montreal; Universite de Montreal	Sauvageau, G (corresponding author), Univ Montreal, Inst Res Immunol & Canc, Downtown Stn, CP 6128, Montreal, PQ H3C 3J7, Canada.			KROON, EVERT/0000-0002-4069-3644; Humphries, Richard/0000-0003-0540-7005; Sauvageau, Guy/0000-0002-4333-7266				Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; de Haan G, 2003, DEV CELL, V4, P241, DOI 10.1016/S1534-5807(03)00018-2; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Krosl J, 2003, IMMUNITY, V18, P561, DOI 10.1016/S1074-7613(03)00090-6; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Lewis ID, 2001, BLOOD, V97, P3441, DOI 10.1182/blood.V97.11.3441; Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611	22	238	279	0	17	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1428	1432		10.1038/nm951	http://dx.doi.org/10.1038/nm951			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14578881				2022-12-27	WOS:000186319700036
J	Pomerantz, RJ; Horn, DL				Pomerantz, RJ; Horn, DL			Twenty years of therapy for HIV-1 infection	NATURE MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; CD4 CELL COUNTS; DRUG-RESISTANCE; VIRAL-LOAD; POTENT SUPPRESSION; GENITAL SECRETIONS; ANTIVIRAL ACTIVITY; PEPTIDE INHIBITOR; CONTROLLED-TRIAL	Antiretroviral therapy, where available, has transformed HIV-1 disease into a treatable and somewhat chronic infection. This article summarizes the accomplishments thus far and what lies ahead in our struggle to improve the treatment of, and possibly eliminate, HIV-1 infection.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Human Virol & Biodef,Div Infect Dis & Environ, Philadelphia, PA 19107 USA	Jefferson University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Human Virol & Biodef,Div Infect Dis & Environ, 1020 Locust St,Suite 329, Philadelphia, PA 19107 USA.	roger.j.pomerantz@jefferson.edu			NIAID NIH HHS [AI46289] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046289] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander L, 2002, J VIROL, V76, P10533, DOI 10.1128/JVI.76.20.10533-10539.2002; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Cardiello PG, 2003, JAIDS-J ACQ IMM DEF, V32, P375, DOI 10.1097/00126334-200304010-00005; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; Caulfield MJ, 2002, J VIROL, V76, P10038, DOI 10.1128/JVI.76.19.10038-10043.2002; Centers for Disease Control (CDC), 1981, MMWR-MORBID MORTAL W, V30, P250; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004; *DAIDS, 2003, N TRIZ COMP EF PLUS; De Clercq E, 2002, MED RES REV, V22, P531; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Dornadula G, 2001, J INFECT DIS, V183, P1682, DOI 10.1086/320715; DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Dybul Mark, 2002, MMWR Recomm Rep, V51, P1; Dybul Mark, 2002, Curr Infect Dis Rep, V4, P175, DOI 10.1007/s11908-002-0059-2; EZZELL C, 1987, NATURE, V329, P751, DOI 10.1038/329751c0; Farmer P, 2001, NEW ENGL J MED, V345, P208, DOI 10.1056/NEJM200107193450310; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; FURMAN PA, 1988, AM J MED, V85, P176; Gaddis NC, 2003, J VIROL, V77, P5810, DOI 10.1128/JVI.77.10.5810-5820.2003; Gallant JE, 2000, JAMA-J AM MED ASSOC, V283, P1329, DOI 10.1001/jama.283.10.1329; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; Garcia F, 2001, AIDS, V15, pF29, DOI 10.1097/00002030-200106150-00002; GERSHON D, 1991, NATURE, V353, P589, DOI 10.1038/353589b0; Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199; Gulick RM, 2000, ANN INTERN MED, V133, P35, DOI 10.7326/0003-4819-133-1-200007040-00007; Gulick RM, 2003, CLIN MICROBIOL INFEC, V9, P186, DOI 10.1046/j.1469-0691.2003.00570.x; HAGGERTY S, 1991, Viral Immunology, V4, P123, DOI 10.1089/vim.1991.4.123; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hardy Gareth Ad, 2002, J HIV Ther, V7, P40; Hellinger FJ, 2000, J ACQ IMMUN DEF SYND, V24, P182; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kulkosky J, 2002, CLIN INFECT DIS, V35, P1520, DOI 10.1086/344959; Kulkosky J, 2002, J INFECT DIS, V186, P1403, DOI 10.1086/344357; KULKOSKY J, IN PRESS VIROLOGY; LALEZARI JP, 2003, N ENGL J MED; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Minkoff H, 2003, OBSTET GYNECOL, V101, P797, DOI 10.1016/S0029-7844(03)00051-6; Nolte FS, 1999, ARCH PATHOL LAB MED, V123, P1011; Overbaugh J, 1996, AIDS RES HUM RETROV, V12, P107, DOI 10.1089/aid.1996.12.107; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; Pomerantz RJ, 1999, JAMA-J AM MED ASSOC, V282, P1177, DOI 10.1001/jama.282.12.1177; Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256; Pomerantz RJ, 2001, AIDS, V15, P1201, DOI 10.1097/00002030-200107060-00002; Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030-199912240-00002; SELIGMANN M, 1994, LANCET, V343, P871; Sendi P, 2001, PHARMACOECONOMICS, V19, P709, DOI 10.2165/00019053-200119070-00001; Shafer RW, 2002, CLIN MICROBIOL REV, V15, P247, DOI 10.1128/CMR.15.2.247-277.2002; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; SILBERNER J, 1985, SCI NEWS, V127, P148, DOI 10.2307/3969341; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Sterling TR, 2003, CLIN INFECT DIS, V36, P812, DOI 10.1086/367934; Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; VENAUD S, 1992, RES VIROLOGY, V143, P311, DOI 10.1016/S0923-2516(06)80119-6; VOLBERDING PA, 1995, NEW ENGL J MED, V333, P401, DOI 10.1056/NEJM199508173330701; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yang B, 2003, J BIOL CHEM, V278, P6596, DOI 10.1074/jbc.M210164200; Young B, 2002, JAIDS, V31, P478, DOI 10.1097/00126334-200212150-00004; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996; 1996, MMWR MORB MORTAL WKL, V45, P121; 2002, MMWR MORB MORTAL WKL, V51, P592	87	208	219	0	14	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					867	873		10.1038/nm0703-867	http://dx.doi.org/10.1038/nm0703-867			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835707				2022-12-27	WOS:000183979300026
J	McCormick, AW; Whitney, CG; Farley, MM; Lynfield, R; Harrison, LH; Bennett, NM; Schaffner, W; Reingold, A; Hadler, J; Cieslak, P; Samore, MH; Lipsitch, M				McCormick, AW; Whitney, CG; Farley, MM; Lynfield, R; Harrison, LH; Bennett, NM; Schaffner, W; Reingold, A; Hadler, J; Cieslak, P; Samore, MH; Lipsitch, M			Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States	NATURE MEDICINE			English	Article							ANTIBIOTIC-RESISTANCE; CONJUGATE VACCINE; PREVALENCE; EPIDEMIOLOGY; PNEUMOCOCCI; INFECTIONS; SEROTYPES; CARRIAGE; CHILDREN; NETWORK	Resistance of Streptococcus pneumoniae to antibiotics is increasing throughout the United States, with substantial variation among geographic regions. We show that patterns of geographic variation are best explained by the intensity of selection for resistance, which is reflected by differences between the proportions of resistance within individual serotypes, rather than by differences between the frequencies of particular serotypes. Using a mathematical transmission model, we analyzed temporal trends in the proportions of singly and dually resistant organisms and found that pneumococcal strains resistant to both penicillin and erythromycin are increasing faster than strains singly resistant to either. Using the model, we predict that by 1 July 2004, in the absence of a vaccine, 41% of pneumococci at the Centers for Disease Control and Prevention (CDC)'s Active Bacterial Core surveillance (ABCs) sites, taken together, will be dually resistant, with 5% resistant to penicillin only and 5% to erythromycin only.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Ctr Dis Control & Prevent, Act Bacterial Core Surveillance & Emerging Infect, Atlanta, GA USA; Emory Univ, Emory Dept Med, Atlanta, GA 30322 USA; Minnesota Dept Hlth, Minnesota Emerging Infect Program, Minneapolis, MN USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Monroe Cty Hlth Dept, Rochester, NY USA; Vanderbilt Univ, Sch Med, Vanderbilt Med Ctr, Nashville, TN 37212 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Connecticut Dept Publ Hlth, Connecticut Emerging Infect Program, Hartford, CT USA; Dept Human Serv, Oregon Emerging Infect Program, Hlth Serv, Off Dis Prevent & Epidemiol, Portland, OR USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA	Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA; Emory University; Minnesota Department of Health (MHD); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Vanderbilt University; University of California System; University of California Berkeley; Utah System of Higher Education; University of Utah	Lipsitch, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.			Lipsitch, Marc/0000-0003-1504-9213	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048935] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48935] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; Baquero F, 1995, MICROB DRUG RESIST, V1, P115, DOI 10.1089/mdr.1995.1.115; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; de Neeling AJ, 2001, J ANTIMICROB CHEMOTH, V48, P441, DOI 10.1093/jac/48.3.441; Diekema DJ, 2000, EMERG INFECT DIS, V6, P552, DOI 10.3201/eid0605.000519; Doern GV, 2001, CLIN INFECT DIS, V33, pS187, DOI 10.1086/321847; Fenoll A, 1998, J CLIN MICROBIOL, V36, P3447, DOI 10.1128/JCM.36.12.3447-3454.1998; Garcia-Rey C, 2002, J CLIN MICROBIOL, V40, P159, DOI 10.1128/JCM.40.1.159-164.2002; Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608; Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857; Jones ME, 2002, ANTIMICROB AGENTS CH, V46, P3106, DOI 10.1128/AAC.46.9.3106-3107.2002; Lipsitch M, 2001, TRENDS MICROBIOL, V9, P438, DOI 10.1016/S0966-842X(01)02130-8; Lipsitch M, 2001, AM J EPIDEMIOL, V154, P85, DOI 10.1093/aje/154.1.85; McEllistrem MC, 2002, CLIN INFECT DIS, V34, P704, DOI 10.1086/338717; McGee L, 2001, J CLIN MICROBIOL, V39, P2565, DOI 10.1128/JCM.39.7.2565-2571.2001; *NAT CTR HLTH STAT, 2001, NAT HOSP AMB MED CAR; *NAT CTR HLTH STAT, 2001, NAT AMB MED CAR SURV; National Committee for Clinical Laboratory Standards, 2000, M7A5 NCCLS; Pihlajamaki M, 2001, CLIN INFECT DIS, V33, P483, DOI 10.1086/322735; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Schrag SJ, 2000, CLIN MICROBIOL REV, V13, P588, DOI 10.1128/CMR.13.4.588-601.2000; Schuchat A, 2001, EMERG INFECT DIS, V7, P92, DOI 10.3201/eid0701.010114; Scott JAG, 1998, CLIN INFECT DIS, V27, P1442, DOI 10.1086/515013; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; 1999, MMWR MORB MORTAL WKL, V48, P656	27	174	177	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					424	430		10.1038/nm839	http://dx.doi.org/10.1038/nm839			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12627227				2022-12-27	WOS:000181987400032
J	Wyss-Coray, T; Loike, JD; Brionne, TC; Lu, E; Anankov, R; Yan, FR; Silverstein, SC; Husemann, J				Wyss-Coray, T; Loike, JD; Brionne, TC; Lu, E; Anankov, R; Yan, FR; Silverstein, SC; Husemann, J			Adult mouse astrocytes degrade amyloid-beta in vitro and in situ	NATURE MEDICINE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; ALZHEIMERS-DISEASE; SCAVENGER RECEPTOR; MICROGLIAL CELLS; PLAQUE-FORMATION; TRANSGENIC MICE; NERVOUS-SYSTEM; SENILE PLAQUES; GLIAL-CELLS; CHEMOKINES	Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by excessive deposition of amyloid-beta (Abeta) peptides in the brain. One of the earliest neuropathological changes in AD is the accumulation of astrocytes at sites of Abeta deposition(1), but the cause or significance of this cellular response is unclear. Here we show that cultured adult mouse astrocytes migrate in response to monocyte chemoattractant protein-1 (MCP-1), a chemokine present in AD lesions(1), and cease migration upon interaction with immobilized Abeta(1-42). We also show that astrocytes bind and degrade Abeta(1-42). Astrocytes plated on Abeta-laden brain sections from a mouse model of AD associate with the Abeta deposits and reduce overall Abeta levels in these sections. Our results suggest a novel mechanism for the accumulation of astrocytes around Abeta deposits, indicate a direct role for astrocytes in degradation of Abeta and implicate deficits in astroglial clearance of Abeta in the pathogenesis of AD. Treatments that increase removal of Abeta by astrocytes may therefore be a critical mechanism to reduce the neurodegeneration associated with AD.	Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10027 USA; VA Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Gladstone Inst Neurol Dis, San Francisco, CA USA	Columbia University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of California System; University of California San Francisco; The J David Gladstone Institutes	Husemann, J (corresponding author), Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10027 USA.		Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831	NIA NIH HHS [AG-15871, AG-08702, AG-19772] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019772, P50AG008702, R01AG015871] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; DeGroot CJA, 1997, J NEUROSCI RES, V49, P342, DOI 10.1002/(SICI)1097-4547(19970801)49:3<342::AID-JNR9>3.0.CO;2-C; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; HAYASHI M, 1995, J NEUROIMMUNOL, V60, P143, DOI 10.1016/0165-5728(95)00064-9; Heesen M, 1996, J NEUROSCI RES, V45, P382; Husemann J, 2001, J NEUROIMMUNOL, V114, P142, DOI 10.1016/S0165-5728(01)00239-9; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Ishizuka K, 1997, PSYCHIAT CLIN NEUROS, V51, P135, DOI 10.1111/j.1440-1819.1997.tb02375.x; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Kurt MA, 1999, EXP NEUROL, V158, P221, DOI 10.1006/exnr.1999.7096; Mehlhorn G, 2000, INT J DEV NEUROSCI, V18, P423, DOI 10.1016/S0736-5748(00)00012-5; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Rezaie P, 2002, GLIA, V37, P64, DOI 10.1002/glia.1128; Savchenko VL, 2000, NEUROSCIENCE, V96, P195, DOI 10.1016/S0306-4522(99)00538-2; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; TAWIL NJ, 1990, BIOCHEMISTRY-US, V29, P6540, DOI 10.1021/bi00479a028; TERRY RD, 1999, ALZHEIMERS DIS, P390; Tezel G, 2001, GLIA, V34, P178, DOI 10.1002/glia.1052; Thal DR, 2000, ACTA NEUROPATHOL, V100, P608, DOI 10.1007/s004010000242; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yamaguchi H, 1998, ACTA NEUROPATHOL, V95, P217, DOI 10.1007/s004010050790	25	687	702	0	39	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					453	457		10.1038/nm838	http://dx.doi.org/10.1038/nm838			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12612547				2022-12-27	WOS:000181987400036
J	Cheng, T; Liu, D; Griffin, JH; Fernandez, JA; Castellino, F; Rosen, ED; Fukudome, K; Zlokovic, BV				Cheng, T; Liu, D; Griffin, JH; Fernandez, JA; Castellino, F; Rosen, ED; Fukudome, K; Zlokovic, BV			Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective	NATURE MEDICINE			English	Article							CELL-DEATH; GENE-EXPRESSION; SEVERE SEPSIS; P53; RECEPTOR; THROMBIN; HYPOXIA; STROKE; MECHANISMS; BARRIER	Activated protein C (APC) is a systemic anti-coagulant and anti-inflammatory factor(1-3). It reduces organ damage in animal models of sepsis, ischemic injury and stroke(1,4,5) and substantially reduces mortality in patients with severe sepsis(6). It was not known whether APC acts as a direct cell survival factor or whether its neuroprotective effect(5,7) is secondary to its anticoagulant and anti-inflammatory effects(1-3). We report that APC directly prevents apoptosis in hypoxic human brain endothelium through transcriptionally dependent inhibition of tumor suppressor protein p53, normalization of the pro-apoptotic Bax/Bcl-2 ratio and reduction of caspase-3 signaling. These mechanisms are distinct from those involving upregulation of the genes encoding the anti-apoptotic Bcl-2 homolog A1 and inhibitor of apoptosis protein-1 (IAP-1) by APC in umbilical vein endothelial cells(8,9). Cytoprotection of brain endothelium by APC in vitro required endothelial protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1), as did its in vivo neuroprotective activity in a stroke model of mice with a severe deficiency of EPCR10. This is consistent with work showing the direct effects of APC on cultured cells via EPCR and PAR-1 (ref. 9). Moreover, the in vivo neuroprotective effects of low-dose mouse APC seemed to be independent of its anti-coagulant activity. Thus, APC protects the brain from ischemic injury by acting directly on brain cells.	Univ Rochester, Med Ctr, Frank P Smith Neurosurg Res Lab, Dept Neurosurg, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Aging & Dev Biol, Div Neurovasc Biol, Rochester, NY 14642 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Saga Med Sch, Dept Immunol, Saga, Japan; Socratech Labs, Rochester, NY USA	University of Rochester; University of Rochester; Scripps Research Institute; University of Notre Dame; University of Notre Dame; Saga University	Zlokovic, BV (corresponding author), Univ Rochester, Med Ctr, Frank P Smith Neurosurg Res Lab, Dept Neurosurg, Rochester, NY 14642 USA.		Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063290, R37HL052246, R01HL052246] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52246, HL63290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Castellino FJ, 2002, THROMB HAEMOSTASIS, V88, P462; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; Esmon CT, 1999, THROMB HAEMOSTASIS, V82, P251; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Flavin MP, 2000, GLIA, V29, P347, DOI 10.1002/(SICI)1098-1136(20000215)29:4<347::AID-GLIA5>3.3.CO;2-#; Folsom AR, 1999, CIRCULATION, V100, P736, DOI 10.1161/01.CIR.100.7.736; Gale AJ, 1997, PROTEIN SCI, V6, P132; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kimura M, 2001, J BIOL CHEM, V276, P26453, DOI 10.1074/jbc.M101289200; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; MIYASHITA T, 1995, CELL, V80, P293; Mizutani A, 2000, BLOOD, V95, P3781; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Shibata M, 2001, CIRCULATION, V103, P1799, DOI 10.1161/01.CIR.103.13.1799; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Turgeon VL, 1998, J NEUROSCI, V18, P6882; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yamamoto K, 2001, HYPERTENSION, V37, P1341, DOI 10.1161/01.HYP.37.5.1341; Ye XF, 1999, BIOCHEM BIOPH RES CO, V259, P671, DOI 10.1006/bbrc.1999.0846; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	31	491	518	3	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					338	342		10.1038/nm826	http://dx.doi.org/10.1038/nm826			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12563316				2022-12-27	WOS:000181312300035
J	Silvie, O; Rubinstein, E; Franetich, JF; Prenant, M; Belnoue, E; Renia, L; Hannoun, L; Eling, W; Levy, S; Boucheix, C; Mazier, D				Silvie, O; Rubinstein, E; Franetich, JF; Prenant, M; Belnoue, E; Renia, L; Hannoun, L; Eling, W; Levy, S; Boucheix, C; Mazier, D			Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; CELLS; CD9; IDENTIFICATION; ANTIBODY; SURFACE; TAPA-1; TARGET; LIVER; MICE	Plasmodium sporozoites are transmitted through the bite of infected mosquitoes and first invade the liver of the mammalian host, as an obligatory step of the life cycle of the malaria parasite. Within hepatocytes, Plasmodium sporozoites reside in a membrane-bound vacuole, where they differentiate into exoerythrocytic forms and merozoites that subsequently infect erythrocytes and cause the malaria disease. Plasmodium sporozoite targeting to the liver is mediated by the specific binding of major sporozoite surface proteins, the circumsporozoite protein and the thrombospondin-related anonymous protein, to glycosaminoglycans on the hepatocyte surface(1). Still, the molecular mechanisms underlying sporozoite entry and differentiation within hepatocytes are largely unknown. Here we show that the tetraspanin CD81, a putative receptor for hepatitis C virus(2), is required on hepatocytes for human Plasmodium falciparum and rodent Plasmodium yoelii sporozoite infectivity. P. yoelii sporozoites fail to infect CD81-deficient mouse hepatocytes, in vivo and in vitro, and antibodies against mouse and human CD81 inhibit in vitro the hepatic development of P. yoelii and P. falciparum, respectively. We further demonstrate that the requirement for CD81 is linked to sporozoite entry into hepatocytes by formation of a parasitophorous vacuole, which is essential for parasite differentiation into exoerythrocytic forms.	Univ Paris 11, Hop Paul Brousse, INSERM, U268,Inst Andre Lwoff, Villejuif, France; Univ Paris 05, Hop Cochin, Inst Cochin, Dept Immunol, Paris, France; Hop La Pitie Salpetriere, Serv Chirurg Digest Hepatobiliopancreat & Transpl, Paris, France; Univ Med Ctr St Radboud, Dept Med Microbiol, Nijmegen, Netherlands; Stanford Univ, Med Ctr, Dept Med, Div Oncol, Stanford, CA 94305 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Radboud University Nijmegen; Stanford University	Mazier, D (corresponding author), Univ Paris 06, CHU Pitie Salpetriere, INSERM, U Immunobiol Cellulaire & Mol Infect Parasitaires, Paris, France.		Franetich, Jean-François/GZA-9674-2022; Silvie, Olivier/AAF-5437-2021; Renia, Laurent/E-2117-2011; Silvie, Olivier/K-7290-2017; Rubinstein, Eric/B-4650-2019	Silvie, Olivier/0000-0002-0525-6940; Renia, Laurent/0000-0003-0349-1557; Silvie, Olivier/0000-0002-0525-6940; Rubinstein, Eric/0000-0001-7623-9665; Boucheix, Claude/0000-0003-4184-7008	NIAID NIH HHS [AI45900] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; GUGUENGUILLOUZO C, 1982, CELL BIOL INT REP, V6, P625, DOI 10.1016/0309-1651(82)90187-4; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; HOLLINGDALE MR, 1983, AM J TROP MED HYG, V32, P685, DOI 10.4269/ajtmh.1983.32.685; Hulier E, 1996, MOL BIOCHEM PARASIT, V77, P127, DOI 10.1016/0166-6851(96)02584-4; Kelic S, 2001, MOL CELL NEUROSCI, V17, P551, DOI 10.1006/mcne.2000.0955; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Maecker HT, 2000, HYBRIDOMA, V19, P15, DOI 10.1089/027245700315752; Matuschewski K, 2002, EMBO J, V21, P1597, DOI 10.1093/emboj/21.7.1597; MAZIER D, 1985, SCIENCE, V227, P440, DOI 10.1126/science.3880923; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pradel G, 2002, MOL MICROBIOL, V45, P637, DOI 10.1046/j.1365-2958.2002.03057.x; Pradel G, 2001, HEPATOLOGY, V33, P1154, DOI 10.1053/jhep.2001.24237; RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706; RENIA L, 1988, J IMMUNOL METHODS, V112, P201, DOI 10.1016/0022-1759(88)90358-4; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Silvie O, 2002, PARASITE IMMUNOL, V24, P221, DOI 10.1046/j.1365-3024.2002.00450.x; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404	25	236	244	1	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					93	96		10.1038/nm808	http://dx.doi.org/10.1038/nm808			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12483205				2022-12-27	WOS:000180209900028
J	Hallenbeck, JM				Hallenbeck, JM			The many faces of tumor necrosis factor in stroke	NATURE MEDICINE			English	Review							KAPPA-B ACTIVATION; FACTOR-ALPHA; TNF-ALPHA; RAT-BRAIN; SUPEROXIDE-DISMUTASE; CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; HEME OXYGENASE-1; GENE-EXPRESSION; JNK ACTIVATION		NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Hallenbeck, JM (corresponding author), NINDS, Stroke Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	hallenbj@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002924, ZIANS002924] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1999, Neurology, V53, P457; Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Becher H, 2000, J Epidemiol Biostat, V5, P277; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bryl E, 2001, J IMMUNOL, V167, P3231, DOI 10.4049/jimmunol.167.6.3231; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHAO CC, 1995, CRIT REV NEUROBIOL, V9, P189; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Clark WM, 2001, EXPERT OPIN BIOL TH, V1, P227, DOI 10.1517/14712598.1.2.227; Cutler RG, 2001, MECH AGEING DEV, V122, P895, DOI 10.1016/S0047-6374(01)00246-9; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/S0304-3940(96)13116-5; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; EDDY LJ, 1992, BIOCHEM BIOPH RES CO, V184, P1056, DOI 10.1016/0006-291X(92)90698-K; Ellison JA, 1999, ANN NY ACAD SCI, V890, P204, DOI 10.1111/j.1749-6632.1999.tb07996.x; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ginis I, 2002, J CEREBR BLOOD F MET, V22, P142, DOI 10.1097/00004647-200202000-00002; Ginis I, 1999, AM J PHYSIOL-CELL PH, V276, pC1171, DOI 10.1152/ajpcell.1999.276.5.C1171; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; HALLENBECK JM, 1988, STROKE, V19, P863, DOI 10.1161/01.STR.19.7.863; Heyninck Karen, 2001, Molecular Cell Biology Research Communications, V4, P259, DOI 10.1006/mcbr.2001.0295; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hummel V, 2001, J NEUROPATH EXP NEUR, V60, P320, DOI 10.1093/jnen/60.4.320; Inglot Anna D., 1997, Archivum Immunologiae et Therapiae Experimentalis, V45, P353; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Liu J, 2000, AM J PHYSIOL-CELL PH, V278, pC144, DOI 10.1152/ajpcell.2000.278.1.C144; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Mark KS, 2001, J PHARMACOL EXP THER, V297, P1051; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Neumar RW, 2000, ANN EMERG MED, V36, P483, DOI 10.1067/mem.2000.110995; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; Oppenheim JJ, 2001, INT J HEMATOL, V74, P3, DOI 10.1007/BF02982543; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Plutzky J, 2001, AM J CARDIOL, V88, p10K; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Rubin EM, 2000, NATURE, V407, P265, DOI 10.1038/35025236; Ruetzler CA, 2001, J CEREBR BLOOD F MET, V21, P244, DOI 10.1097/00004647-200103000-00008; Sairanen T, 2001, STROKE, V32, P1750, DOI 10.1161/01.STR.32.8.1750; Schlomann U, 2000, J NEUROSCI, V20, P7964; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Siren AL, 2001, MOL MED, V7, P219, DOI 10.1007/BF03401841; Szelenyi J, 2001, BRAIN RES BULL, V54, P329, DOI 10.1016/S0361-9230(01)00428-2; TAKEDA H, IN PRESS STROKE; TAKEDA H, UNPUB STROKE; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; TIPPING PG, 1993, AM J PATHOL, V142, P1721; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Wallach D, 2002, ARTHRITIS RES THER, V4, pS189, DOI 10.1186/ar585; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; Weyand CM, 2001, MAYO CLIN PROC, V76, P1011, DOI 10.4065/76.10.1011; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Yamashita N, 2000, BRIT J PHARMACOL, V131, P415, DOI 10.1038/sj.bjp.0703594; Zaremba J, 2001, ACTA NEUROL SCAND, V104, P288, DOI 10.1034/j.1600-0404.2001.00053.x	78	327	339	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1363	1368		10.1038/nm1202-1363	http://dx.doi.org/10.1038/nm1202-1363			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12457181				2022-12-27	WOS:000179552000031
J	Mackenzie, JS; Gubler, DJ; Petersen, LR				Mackenzie, JS; Gubler, DJ; Petersen, LR			Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses	NATURE MEDICINE			English	Review							PHYLOGENETIC-RELATIONSHIPS; UNITED-STATES; TYPE-2 VIRUS; YELLOW-FEVER; USUTU-VIRUS; MOLECULAR CHARACTERIZATION; ENVELOPE GLYCOPROTEIN; HEMORRHAGIC-FEVER; GENETIC-VARIATION; GENOME SEQUENCES	Mosquito-borne flaviviruses provide some of the most important examples of emerging and resurging diseases of global significance. Here, we describe three of them: the resurgence of dengue in tropical and subtropical areas of the world, and the spread and establishment of Japanese encephalitis and West Nile viruses in new habitats and environments. These three examples also illustrate the complexity of the various factors that contribute to their emergence, resurgence and spread. Whereas some of these factors are natural, such as bird migration, most are due to human activities, such as changes in land use, water impoundments and transportation, which result in changed epidemiological patterns. The three examples also show the ease with which mosquito-borne viruses can spread to and colonize new areas, and the need for continued international surveillance and improved public health infrastructure to meet future emerging disease threats.	Curtin Univ Technol, Australian Biosecur Cooperat Res Ctr, Perth, WA 6001, Australia; Leahi Hosp, Asia Pacific Inst Trop Med & Infect Dis, Honolulu, HI USA; Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA	Curtin University; Centers for Disease Control & Prevention - USA	Mackenzie, JS (corresponding author), Curtin Univ Technol, Australian Biosecur Cooperat Res Ctr, Perth, WA 6001, Australia.	j.mackenzie@curtin.edu.au	/S-4986-2019	/0000-0002-5918-2190				Asahina S, 1968, JPN J SANIT ZOOL, V19, P110; Beasley DWC, 2004, VACCINE, V22, P3722, DOI 10.1016/j.vaccine.2004.03.027; Beasley DWC, 2002, VIROLOGY, V296, P17, DOI 10.1006/viro.2002.1372; Bennett SN, 2003, MOL BIOL EVOL, V20, P1650, DOI 10.1093/molbev/msg182; Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Bhamarapravati N, 2000, VACCINE, V18, P44, DOI 10.1016/S0264-410X(00)00040-2; Billoir F, 2000, J GEN VIROL, V81, P781, DOI 10.1099/0022-1317-81-3-781; Bista MB, 2001, LANCET, V358, P791, DOI 10.1016/S0140-6736(01)05967-0; Buckley A, 2003, J GEN VIROL, V84, P2807, DOI 10.1099/vir.0.19341-0; BUESCHER EL, 1959, AM J TROP MED HYG, V8, P719, DOI 10.4269/ajtmh.1959.8.719; Burke DS, 1988, ARBOVIRUSES EPIDEMIO, V3, P63; Burt FJ, 2002, EMERG INFECT DIS, V8, P820, DOI 10.3201/eid0808.020027; CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1135; Chang Gwong-Jen J, 2004, Expert Rev Vaccines, V3, P199, DOI 10.1586/14760584.3.2.199; Charrel RN, 2003, VIROLOGY, V315, P381, DOI 10.1016/S0042-6822(03)00536-1; CHEN WR, 1992, AM J TROP MED HYG, V47, P61, DOI 10.4269/ajtmh.1992.47.61; CHEN WR, 1990, J GEN VIROL, V71, P2915, DOI 10.1099/0022-1317-71-12-2915; *CHILDR HOSP 1 PAS, 2001, ACC DEV INTR DENG VA; Dhanda V, 1997, INDIAN J MED RES, V106, P4; Diamond MS, 2003, J VIROL, V77, P2578, DOI 10.1128/JVI.77.4.2578-2586.2003; Endy TP, 2002, CURR TOP MICROBIOL, V267, P11; Gaunt MW, 2001, J GEN VIROL, V82, P1867, DOI 10.1099/0022-1317-82-8-1867; Gea-Banacloche J, 2004, ANN INTERN MED, V140, P545, DOI 10.7326/0003-4819-140-7-200404060-00015; Goldman JS, 2004, ALZ DIS ASSOC DIS, V18, P65, DOI 10.1097/01.wad.0000126616.77653.71; Gould EA, 2003, ADV VIRUS RES, V59, P277, DOI 10.1016/S0065-3527(03)59008-X; Gould EA, 2002, CURR TOP MICROBIOL, V267, P391; Gould EA, 2001, ADV VIRUS RES, V57, P71, DOI 10.1016/S0065-3527(01)57001-3; Granwehr BP, 2004, LANCET INFECT DIS, V4, P547, DOI 10.1016/S1473-3099(04)01128-4; Gritsun TS, 2003, ANTIVIR RES, V57, P129, DOI 10.1016/S0166-3542(02)00206-1; Guarner J, 2004, HUM PATHOL, V35, P983, DOI 10.1016/j.humpath.2004.04.008; GUBLER DJ, 1978, AM J TROP MED HYG, V27, P581, DOI 10.4269/ajtmh.1978.27.581; GUBLER DJ, 1989, AM J TROP MED HYG, V40, P571, DOI 10.4269/ajtmh.1989.40.571; GUBLER DJ, 1979, B WORLD HEALTH ORGAN, V57, P931; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; Gubler DJ, 2002, ARCH MED RES, V33, P330, DOI 10.1016/S0188-4409(02)00378-8; Gubler DJ, 2014, DENGUE AND DENGUE HEMORRHAGIC FEVER, 2ND EDITION, P1, DOI 10.1079/9781845939649.0001; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001; Guzman MG, 2004, INT J INFECT DIS, V8, P69, DOI 10.1016/j.ijid.2003.03.003; Hall RA, 2002, CURR TOP MICROBIOL, V267, P253; HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154; Halstead SB, 2002, LANCET, V360, P1243, DOI 10.1016/S0140-6736(02)11276-1; Halstead Scott B., 1992, World Health Statistics Quarterly, V45, P292; HAMMON WM, 1960, T ASSOC AM PHYSICIAN, V73, P140; Hanna JN, 1999, MED J AUSTRALIA, V170, P533, DOI 10.5694/j.1326-5377.1999.tb127878.x; Hanna JN, 1996, MED J AUSTRALIA, V165, P256, DOI 10.5694/j.1326-5377.1996.tb124960.x; HEINZ FX, 2000, VIRUS TAXONOMY, P859; Holmes EC, 2000, TRENDS MICROBIOL, V8, P74, DOI 10.1016/S0966-842X(99)01669-8; Holmes EC, 1999, MOL BIOL EVOL, V16, P405, DOI 10.1093/oxfordjournals.molbev.a026121; Huang CYH, 2000, J VIROL, V74, P3020, DOI 10.1128/JVI.74.7.3020-3028.2000; Hubalek Z, 1999, EMERG INFECT DIS, V5, P643, DOI 10.3201/eid0505.990505; IGARASHI A, 1994, MICROBIOL IMMUNOL, V38, P827, DOI 10.1111/j.1348-0421.1994.tb01866.x; Innis B. L, 1995, EXOTIC VIRAL INFECT, P147; Innis BL, 1995, EXOTIC VIRAL INFECT, P103; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Jia XY, 1999, LANCET, V354, P1971, DOI 10.1016/S0140-6736(99)05384-2; KANAMITSU M, 1979, AM J TROP MED HYG, V28, P351, DOI 10.4269/ajtmh.1979.28.351; Kimura R., 1944, NIPPON IGAKU, V3379, P629; Kinney RM, 2001, INTERVIROLOGY, V44, P176, DOI 10.1159/000050045; Kleinschmidt-DeMasters BK, 2004, ARCH NEUROL-CHICAGO, V61, P1210, DOI 10.1001/archneur.61.8.1210; Komar N, 2003, EMERG INFECT DIS, V9, P311, DOI 10.3201/eid0903.020628; Konishi E, 2000, VACCINE, V18, P1133, DOI 10.1016/S0264-410X(99)00376-X; Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998; KUNO G, 2004, ADV VIRUS RES, V61, P3; Kurane Ichiro, 1997, P273; LANCIOTTI RS, 1994, J GEN VIROL, V75, P65, DOI 10.1099/0022-1317-75-1-65; Lanciotti RS, 2002, VIROLOGY, V298, P96, DOI 10.1006/viro.2002.1449; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Lederberg J., 1992, I MED US COMMITTEE; Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999; LEWIS JA, 1993, VIROLOGY, V197, P216, DOI 10.1006/viro.1993.1582; Lillibridge KM, 2004, AM J TROP MED HYG, V70, P676; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Lounibos LP, 2002, ANNU REV ENTOMOL, V47, P233, DOI 10.1146/annurev.ento.47.091201.145206; Lvov DK, 2004, ARCH VIROL, P85; Ma SP, 2003, AM J TROP MED HYG, V69, P151, DOI 10.4269/ajtmh.2003.69.151; MacKenzie J, 2000, ATMOS OCEAN SCI LIB, V21, P429; Mackenzie JS, 1997, FACTORS IN THE EMERGENCE OF ARBOVIRUS DISEASES, P191; Mackenzie JS, 2002, CURR TOP MICROBIOL, V267, P1; Mackenzie JS, 2002, CURR TOP MICROBIOL, V267, P49; MACKENZIE JS, 1998, WATER RESOURCES HLTH, P108; Malkinson M, 2002, CURR TOP MICROBIOL, V267, P309; MARIN MS, 1995, VIROLOGY, V206, P1133, DOI 10.1006/viro.1995.1038; Marshall I. D., 1988, The arboviruses: epidemiology and ecology. Volume III., P151; McLean RG, 2002, CURR TOP MICROBIOL, V267, P271; Men R, 2000, VACCINE, V18, P3113, DOI 10.1016/S0264-410X(00)00121-3; Messer WB, 2003, EMERG INFECT DIS, V9, P800; Min Ji-guang, 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P810; MING JG, 1993, MED VET ENTOMOL, V7, P323, DOI 10.1111/j.1365-2915.1993.tb00699.x; Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0; Monath TP, 2002, CURR TOP MICROBIOL, V267, P105; Monath TP, 2002, VACCINE, V20, P1004, DOI 10.1016/S0264-410X(01)00457-1; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; Murgue B, 2002, CURR TOP MICROBIOL, V267, P195; Nga PT, 2004, J GEN VIROL, V85, P1625, DOI 10.1099/vir.0.79797-0; NI HL, 1995, J GEN VIROL, V76, P401, DOI 10.1099/0022-1317-76-2-401; O'Leary DR, 2004, VECTOR-BORNE ZOONOT, V4, P61, DOI 10.1089/153036604773083004; Paranjpe S, 1996, VIRUS RES, V42, P107, DOI 10.1016/0168-1702(96)01306-8; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Perelygin AA, 2002, P NATL ACAD SCI USA, V99, P9322, DOI 10.1073/pnas.142287799; Petersen LR, 2001, EMERG INFECT DIS, V7, P611; Petersen LR, 2002, ANN INTERN MED, V137, P173, DOI 10.7326/0003-4819-137-3-200208060-00009; PORTERFIELD JS, 1975, MED BIOL, V53, P400; Prasad S R, 1993, Indian Pediatr, V30, P905; Pyke AT, 2001, AM J TROP MED HYG, V65, P747; Rappole JH, 2003, J APPL MICROBIOL, V94, p47S; RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; Ritchie SA, 1997, AM J TROP MED HYG, V56, P80, DOI 10.4269/ajtmh.1997.56.80; Ritchie SA, 2001, EMERG INFECT DIS, V7, P900; Robertson SE, 1996, JAMA-J AM MED ASSOC, V276, P1157, DOI 10.1001/jama.276.14.1157; ROSEN L, 1977, AM J TROP MED HYG, V26, P337, DOI 10.4269/ajtmh.1977.26.337; SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30; Sanders EJ, 1998, AM J TROP MED HYG, V59, P644, DOI 10.4269/ajtmh.1998.59.644; SCHERER WF, 1959, AM J TROP MED HYG, V8, P644, DOI 10.4269/ajtmh.1959.8.644; Scherret JH, 2002, CURR TOP MICROBIOL, V267, P373; Sejvar JJ, 2003, JAMA-J AM MED ASSOC, V290, P511, DOI 10.1001/jama.290.4.511; Sejvar JJ, 2003, EMERG INFECT DIS, V9, P788, DOI 10.3201/eid0907.030129; Shrestha B, 2004, J VIROL, V78, P8312, DOI [10.1128/JVI.78.15.8312-8321.2004, 10.1128/jvi.78.15.8312-8321.2004]; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Solomon T, 2004, ARCH VIROL, P161; Solomon T, 2004, NEW ENGL J MED, V351, P370, DOI 10.1056/NEJMra030476; Solomon T, 2003, J VIROL, V77, P3091, DOI 10.1128/JVI.77.5.3091-3098.2003; Solomon T, 2002, CURR TOP MICROBIOL, V267, P171; Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0; Solomon T, 2003, LANCET, V361, P821, DOI 10.1016/S0140-6736(03)12709-2; SOUTHAM CM, 1954, AM J TROP MED HYG, V3, P19, DOI 10.4269/ajtmh.1954.3.19; Sun W, 2003, AM J TROP MED HYG, V69, P24; Tolou HJG, 2001, J GEN VIROL, V82, P1283, DOI 10.1099/0022-1317-82-6-1283; Tsai TF, 1997, FACTORS IN THE EMERGENCE OF ARBOVIRUS DISEASES, P179; Tsuchie H, 1997, AM J TROP MED HYG, V56, P153, DOI 10.4269/ajtmh.1997.56.153; Twiddy SS, 2003, INFECT GENET EVOL, V3, P87, DOI 10.1016/S1567-1348(02)00153-3; Twiddy SS, 2003, J GEN VIROL, V84, P429, DOI 10.1099/vir.0.18660-0; Twiddy SS, 2003, MOL BIOL EVOL, V20, P122, DOI 10.1093/molbev/msg010; Uchil PD, 2001, AM J TROP MED HYG, V65, P242, DOI 10.4269/ajtmh.2001.65.242; UMENAI T, 1985, B WORLD HEALTH ORGAN, V63, P625; Uzcategui NY, 2001, J GEN VIROL, V82, P2945, DOI 10.1099/0022-1317-82-12-2945; van den Hurk AF, 2001, T ROY SOC TROP MED H, V95, P595, DOI 10.1016/S0035-9203(01)90090-2; VAUGHN DW, 1992, EPIDEMIOL REV, V14, P197, DOI 10.1093/oxfordjournals.epirev.a036087; Wang T, 2003, J IMMUNOL, V171, P2524, DOI 10.4049/jimmunol.171.5.2524; Watson JT, 2004, ANN INTERN MED, V141, P360, DOI 10.7326/0003-4819-141-5-200409070-00010; Weissenbock H, 2003, MICROBES INFECT, V5, P1132, DOI 10.1016/S1286-4579(03)00204-1; Weissenbock H, 2002, EMERG INFECT DIS, V8, P652, DOI 10.3201/eid0807.020094; Westaway E. G., 1997, P147; Whitehead SS, 2003, VACCINE, V21, P4307, DOI 10.1016/S0264-410X(03)00488-2; Whitehead SS, 2003, J VIROL, V77, P1653, DOI 10.1128/JVI.77.2.1653-1657.2003; WHO, 1997, DENG HAEM FEV DIAGN; Williams DT, 2000, J GEN VIROL, V81, P2471, DOI 10.1099/0022-1317-81-10-2471; Monath T. P., 1989, The arboviruses: epidemiology and ecology. Volume V., P139; World Health Organization, 2000, STRENGTH IMPL GLOB S; Yang Dong Kun, 2004, J Vet Sci, V5, P125; Yun SI, 2003, VIRUS RES, V96, P129, DOI 10.1016/S0168-1702(03)00181-3; Zanotto PMD, 1996, P NATL ACAD SCI USA, V93, P548, DOI 10.1073/pnas.93.2.548; 2004, MMWR MORB MORTAL WKL, V53, P738; 2002, MOOWR MORB MORTAL WK, V51, P877; 2003, MMWR MORB MORTAL WKL, V52, P1017	159	953	1001	1	208	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12		S			S98	S109		10.1038/nm1144	http://dx.doi.org/10.1038/nm1144			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	879RC	15577938	Bronze			2022-12-27	WOS:000225733900006
J	Wang, T; Town, T; Alexopoulou, L; Anderson, JF; Fikrig, E; Flavell, RA				Wang, T; Town, T; Alexopoulou, L; Anderson, JF; Fikrig, E; Flavell, RA			Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis	NATURE MEDICINE			English	Article							B-CELLS; MICROGLIAL ACTIVATION; STRANDED-RNA; IN-VITRO; INFECTION; BARRIER; MICE; PROTEIN; MACROPHAGES; RECOGNITION	West Nile virus (WNV), a mosquito-borne single-stranded ( ss) RNA flavivirus, causes human disease of variable severity. We investigated the involvement of Toll-like receptor (Tlr) 3, which recognizes viral double-stranded (ds) RNA, on WNV infection. Tlr3-deficient (Tlr3(-/-)) mice were more resistant to lethal WNV infection and had impaired cytokine production and enhanced viral load in the periphery, whereas in the brain, viral load, inflammatory responses and neuropathology were reduced compared to wild-type mice. Peripheral WNV infection led to a breakdown of the blood-brain barrier and enhanced brain infection in wildtype but not in Tlr3(-/-) mice, although both groups were equally susceptible upon intracerebroventricular administration of the virus. Tumor necrosis factor-alpha receptor 1 signaling is vital for blood-brain barrier compromise upon Tlr3 stimulation by dsRNA or WNV. Collectively, WNV infection leads to a Tlr3-dependent inflammatory response, which is involved in brain penetration of the virus and neuronal injury.	Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Connecticut Agr Expt Stn, Dept Entomol, New Haven, CT 06504 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; Connecticut Agricultural Experiment Station	Fikrig, E (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, 300 Cedar St, New Haven, CT 06520 USA.	erol.fikrig@yale.edu	Alexopoulou, Lena/A-5041-2017	Alexopoulou, Lena/0000-0003-4619-697X	NIAID NIH HHS [AIO55749] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055749] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Anderson JF, 2002, EMERG INFECT DIS, V8, P107, DOI 10.3201/eid0801.010252; BENNATHAN D, 1989, ARCH VIROL, V109, P1, DOI 10.1007/BF01310513; BenNathan D, 1996, ARCH VIROL, V141, P459, DOI 10.1007/BF01718310; Bieback K, 2002, J VIROL, V76, P8729, DOI 10.1128/JVI.76.17.8729-8736.2002; Brinton MA, 2001, ANN NY ACAD SCI, V951, P207; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Campbell GL, 2002, LANCET INFECT DIS, V2, P519, DOI 10.1016/S1473-3099(02)00368-7; CARDOSA MJ, 1983, J EXP MED, V158, P258, DOI 10.1084/jem.158.1.258; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Diamond MS, 2003, J EXP MED, V198, P1853, DOI 10.1084/jem.20031223; Diamond MS, 2003, J VIROL, V77, P2578, DOI 10.1128/JVI.77.4.2578-2586.2003; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Ferencik M, 2001, Bratisl Lek Listy, V102, P123; Fiala M, 1997, MOL MED, V3, P553, DOI 10.1007/BF03401701; Garden GA, 2002, GLIA, V40, P240, DOI 10.1002/glia.10155; GOLLINS SW, 1985, J GEN VIROL, V66, P1969, DOI 10.1099/0022-1317-66-9-1969; HALEVY M, 1994, ARCH VIROL, V137, P355, DOI 10.1007/BF01309481; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Kakinuma Y, 1998, NAT MED, V4, P1078, DOI 10.1038/2070; KOBILER D, 1989, BRAIN RES, V496, P314, DOI 10.1016/0006-8993(89)91079-2; KULKARNI AB, 1991, IMMUNOL CELL BIOL, V69, P71, DOI 10.1038/icb.1991.12; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lucas M, 2003, IMMUNOL CELL BIOL, V81, P230, DOI 10.1046/j.1440-1711.2003.01166.x; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Lustig S, 2000, VIRAL IMMUNOL, V13, P401, DOI 10.1089/vim.2000.13.401; LUSTIG S, 1992, J EXP MED, V176, P707, DOI 10.1084/jem.176.3.707; Mayhan WG, 2002, BRAIN RES, V927, P144, DOI 10.1016/S0006-8993(01)03348-0; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Michel PP, 2002, REV NEUROL-FRANCE, V158, pS24; Paul R, 2003, BRAIN, V126, P1873, DOI 10.1093/brain/awg171; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Qureshi ST, 2003, GENES IMMUN, V4, P87, DOI 10.1038/sj.gene.6363937; Rassa JC, 2002, P NATL ACAD SCI USA, V99, P2281, DOI 10.1073/pnas.042355399; Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041; Samuel CE, 2002, P NATL ACAD SCI USA, V99, P11555, DOI 10.1073/pnas.202448899; Shrestha B, 2003, J VIROL, V77, P13203, DOI 10.1128/JVI.77.24.13203-13213.2003; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; Wang T, 2003, J IMMUNOL, V171, P2524, DOI 10.4049/jimmunol.171.5.2524; Wang T, 2001, J IMMUNOL, V167, P5273, DOI 10.4049/jimmunol.167.9.5273; Wang Y, 2003, J VIROL, V77, P13323, DOI [10.1128/JVI.77.24.13323-13334.2003, 10.1128/JVi.77.24.13323-13334.2003]; Xiao SY, 2001, EMERG INFECT DIS, V7, P714; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yang JS, 2002, EMERG INFECT DIS, V8, P1379, DOI 10.3201/eid0812.020224; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	48	843	897	1	72	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1366	1373		10.1038/nm1140	http://dx.doi.org/10.1038/nm1140			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15558055				2022-12-27	WOS:000225500900031
J	Yu, LQ; Huang, ZH; Mariani, J; Wang, YM; Moskowitz, M; Chen, JF				Yu, LQ; Huang, ZH; Mariani, J; Wang, YM; Moskowitz, M; Chen, JF			Selective inactivation or reconstitution of adenosine A(2A) receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury	NATURE MEDICINE			English	Article							CEREBRAL-ISCHEMIA; INDUCED EXCITOTOXICITY; NERVOUS-SYSTEM; PROTECTION; RELEASE; A(1); ACTIVATION; BLOCKADE; NEUROPROTECTION; INTERLEUKIN-6	Inactivation of the adenosine A(2A) receptor (A(2A)R) consistently protects against ischemic brain injury and other neural insults, but the relative contribution of A(2A) Rs on peripheral inflammatory cells versus A(2A) Rs expressed on neurons and glia is unknown. We created a chimeric mouse model in which A(2A) Rs on bone marrow-derived cells (BMDCs) were selectively inactivated or reconstituted by bone marrow transplantation. Selective reconstitution of A(2A) Rs on BMDCs (A(2A) R knockout mice transplanted with wild-type bone marrow cells) largely reinstates ischemic brain injury in global A(2A) R knockout mice. Conversely, selective inactivation of A(2A) Rs on BMDCs (wild-type mice transplanted with A(2A) R knockout bone marrow cells) attenuates infarct volumes and ischemia-induced expression of several proinflammatory cytokines in the brain, but exacerbates ischemic liver injury. These results indicate that the A(2A) R-stimulated cascade in BMDCs is an important modulator of ischemic brain injury and that ischemic brain and liver injuries are regulated distinctly by A(2A) Rs on BMDCs.	Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; Harvard Med Sch, Charlestown, MA 02129 USA	Boston University; Harvard University; Massachusetts General Hospital	Chen, JF (corresponding author), Boston Univ, Sch Med, Dept Neurol, 715 Albany St,C329, Boston, MA 02118 USA.	chenjf@bu.edu	Moskowitz, Michael A/D-9916-2011	Chen, Jiang-Fan/0000-0003-3582-3448; Chen, Jiang-Fan/0000-0002-0446-3956	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037403, P01NS010828, R01NS041083, P50NS010828] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-10828, NS37403, NS41083] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acalovschi D, 2003, STROKE, V34, P1864, DOI 10.1161/01.STR.0000079815.38626.44; Aden U, 2003, STROKE, V34, P739, DOI 10.1161/01.STR.0000060204.67672.8B; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Blum D, 2003, J NEUROSCI, V23, P5361; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Castillo J, 2003, ANN NEUROL, V54, P811, DOI 10.1002/ana.10765; Chen JF, 2003, DRUG NEWS PERSPECT, V16, P597, DOI 10.1358/dnp.2003.16.9.829342; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Clark WM, 1999, NEUROL RES, V21, P287, DOI 10.1080/01616412.1999.11740933; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Dall'lgna OP, 2003, BRIT J PHARMACOL, V138, P1207, DOI 10.1038/sj.bjp.0705185; Day YJ, 2004, AM J PHYSIOL-GASTR L, V286, pG285, DOI 10.1152/ajpgi.00348.2003; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; Fink JS, 2004, J NEUROCHEM, V88, P538, DOI 10.1046/j.1471-4159.2003.02145.x; Fiser SM, 2002, J THORAC CARDIOV SUR, V124, P973, DOI 10.1067/mtc.2002.124886; Fredholm BB, 2003, DRUG NEWS PERSPECT, V16, P283, DOI 10.1358/dnp.2003.16.5.829316; Fredholm BB, 2003, CURR TOP MED CHEM, V3, P413, DOI 10.2174/1568026033392200; Gott VL, 2002, ANN THORAC SURG, V74, P849; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Ikeda K, 2002, J NEUROCHEM, V80, P262, DOI 10.1046/j.0022-3042.2001.00694.x; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Marchi M, 2002, BRIT J PHARMACOL, V136, P434, DOI 10.1038/sj.bjp.0704712; Marcoli M, 2003, NEUROPHARMACOLOGY, V45, P201, DOI 10.1016/S0028-3908(03)00156-4; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Minei JP, 2002, J TRAUMA, V53, P229; Monopoli A, 1998, NEUROREPORT, V9, P3955, DOI 10.1097/00001756-199812010-00034; Mroz K, 1999, DEV BIOL, V207, P229, DOI 10.1006/dbio.1998.9160; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; OREGAN MH, 1992, NEUROSCI LETT, V138, P169, DOI 10.1016/0304-3940(92)90498-V; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Ribeiro JA, 2002, PROG NEUROBIOL, V68, P377, DOI 10.1016/S0301-0082(02)00155-7; Rosin DL, 1998, J COMP NEUROL, V401, P163; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; Schwarzschild MA, 2002, NEUROLOGY, V58, P1154, DOI 10.1212/WNL.58.8.1154; Schwarzschild Michael A., 2003, Neurology, V61, pS55; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V253, P95, DOI 10.1016/0014-2999(94)90762-5	50	109	118	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1081	1087		10.1038/nm1103	http://dx.doi.org/10.1038/nm1103			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15448683				2022-12-27	WOS:000224245800038
J	Mori, H; Hanada, R; Hanada, T; Aki, D; Mashima, R; Nishinakamura, H; Torisu, T; Chien, KR; Yasukawa, H; Yoshimura, A				Mori, H; Hanada, R; Hanada, T; Aki, D; Mashima, R; Nishinakamura, H; Torisu, T; Chien, KR; Yasukawa, H; Yoshimura, A			Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity	NATURE MEDICINE			English	Article							BODY-WEIGHT; SIGNAL TRANSDUCER; MICE LACKING; RECEPTOR; GENE; TRANSCRIPTION-3; IDENTIFICATION; DISRUPTION; ACTIVATOR	Leptin is an adipocyte-derived hormone that plays a key role in energy homeostasis, yet resistance to leptin is a feature of most cases of obesity in humans and rodents. In vitro analysis suggested that the suppressor of cytokine signaling-3 (Socs3) is a negative-feedback regulator of leptin signaling involved in leptin resistance. To determine the functional significance of Socs3 in vivo, we generated neural cell specific SOCS3 conditional knockout mice using the Cre-loxP system. Compared to their wild-type littermates, Socs3-deficient mice showed enhanced leptin-induced hypothalamic Stat3 tyrosine phosphorylation as well as pro-opiomelanocortin (POMC) induction, and this resulted in a greater body weight loss and suppression of food intake. Moreover, the Socs3-deficient mice were resistant to high fat diet induced weight gain and hyperleptinemia, and insulin-sensitivity was retained. These data indicate that Socs3 is a key regulator of diet-induced leptin as well as insulin resistance. Our study demonstrates the negative regulatory role of Socs3 in leptin signaling in vivo, and thus suppression of Socs3 in the brain is a potential therapy for leptin-resistance in obesity.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kurume Univ, Inst Life Sci, Dept Mol Genet, Kurume, Fukuoka 8390861, Japan; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Kurume Univ, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Inst Cardiovasc Res, Kurume, Fukuoka 8300011, Japan	Kyushu University; Kurume University; University of California System; University of California San Diego; University of California System; University of California San Diego; Kurume University; Kurume University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	MORI, HIROYUKI/D-3343-2013; Yoshimura, Akihiko/K-5515-2013					Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; Munzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	29	477	502	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					739	743		10.1038/nm1071	http://dx.doi.org/10.1038/nm1071			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15208705				2022-12-27	WOS:000222460400029
J	Friedman, JM				Friedman, JM			Modern science versus the stigma of obesity	NATURE MEDICINE			English	Editorial Material							BODY-MASS INDEX; REVERSES INSULIN-RESISTANCE; EARLY-ONSET OBESITY; DIABETES-MELLITUS; CALORIC RESTRICTION; RECOMBINANT LEPTIN; ENERGY-EXPENDITURE; WEIGHT; MICE; PLASMA		Rockefeller Univ, Howard Hughes Med Inst, Genet Mol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Friedman, JM (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Genet Mol Lab, 1230 York Ave, New York, NY 10021 USA.	friedj@rockefeller.edu	Friedman, Jeffrey M/E-5784-2011					Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Allison DB, 1996, INT J OBESITY, V20, P501; ALLISON DB, 1993, JAMA-J AM MED ASSOC, V270, P1454, DOI 10.1001/jama.270.12.1454; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; BANKS WA, 2003, J PHYSL, V285, pE10; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; BRAY GA, 1990, INT J OBESITY, V14, P909; Brolin RE, 2002, JAMA-J AM MED ASSOC, V288, P2793, DOI 10.1001/jama.288.22.2793; Buchwald H, 2000, OBES SURG, V10, P402, DOI 10.1381/096089200321594255; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; DeFalco J, 2001, SCIENCE, V291, P2608, DOI 10.1126/science.1056602; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Farooqi IS, 2001, NATURE, V414, P34, DOI 10.1038/35102112; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Friedman JM, 2003, SCIENCE, V299, P856, DOI 10.1126/science.1079856; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fulton S, 2000, SCIENCE, V287, P125, DOI 10.1126/science.287.5450.125; Glazer G, 2001, ARCH INTERN MED, V161, P1814, DOI 10.1001/archinte.161.15.1814; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; Heal DJ, 1998, BRIT J PHARMACOL, V125, P301, DOI 10.1038/sj.bjp.0702067; Heisler LK, 2002, SCIENCE, V297, P609, DOI 10.1126/science.1072327; Hetherington AW, 1942, AM J PHYSIOL, V136, P609, DOI 10.1152/ajplegacy.1942.136.4.609; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; KUPFERMANN I, 2000, PRINCIPLES NEURAL SC, P998; Lavoisier A L, 1994, Obes Res, V2, P189; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; Li C, 1998, J BIOL CHEM, V273, P10078, DOI 10.1074/jbc.273.16.10078; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; NEEL JV, 1962, AM J HUM GENET, V14, P353; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; O'Rahilly S, 2003, ENDOCRINOLOGY, V144, P3757, DOI 10.1210/en.2003-0373; Obici S, 2003, ENDOCRINOLOGY, V144, P5172, DOI 10.1210/en.2003-0999; Ogus S, 2003, ENDOCRINOLOGY, V144, P2865, DOI 10.1210/en.2002-0178; Oral EA, 2002, J CLIN ENDOCR METAB, V87, P3110, DOI 10.1210/jc.87.7.3110; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Rubner M., 1894, Z BIOL, V30, P73; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; STUNKARD AJ, 1986, JAMA-J AM MED ASSOC, V256, P51, DOI 10.1001/jama.256.1.51; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; Wadden TA, 1998, J CLIN ENDOCR METAB, V83, P214, DOI 10.1210/jc.83.1.214; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; WEINTRAUB M, 1984, ARCH INTERN MED, V144, P1143, DOI 10.1001/archinte.144.6.1143; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885	78	261	268	0	32	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					563	569		10.1038/nm0604-563	http://dx.doi.org/10.1038/nm0604-563			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15170194				2022-12-27	WOS:000221759600013
J	Guo, ZM; Linn, JF; Wu, GJ; Anzick, SL; Eisenberger, CF; Halachmi, S; Cohen, Y; Fomenkov, A; Hoque, MO; Okami, K; Steiner, G; Engles, JM; Osada, M; Moon, C; Ratovitski, E; Trent, JM; Meltzer, PS; Westra, WH; Kiemeney, LA; Schoenberg, MP; Sidransky, D; Trink, B				Guo, ZM; Linn, JF; Wu, GJ; Anzick, SL; Eisenberger, CF; Halachmi, S; Cohen, Y; Fomenkov, A; Hoque, MO; Okami, K; Steiner, G; Engles, JM; Osada, M; Moon, C; Ratovitski, E; Trent, JM; Meltzer, PS; Westra, WH; Kiemeney, LA; Schoenberg, MP; Sidransky, D; Trink, B			CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer	NATURE MEDICINE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENES; B-CELL LYMPHOMAS; BREAST-CANCER; COPY NUMBER; DNA AMPLIFICATION; LONG ARM; MYC; SEQUENCES; RECEPTOR	Genomic amplification at 20q11-13 is a common event in human cancers. We isolated a germline translocation breakpoint at 20q11 from a bladder cancer patient. We identified CDC91L1, the gene encoding CDC91L1 (also called phosphatidylinositol glycan class U (PIG-U), a transamidase complex unit in the glycosylphosphatidylinositol (GPI) anchoring pathway), as the only gene whose expression was affected by the translocation. CDC91L1 was amplified and overexpressed in about one-third of bladder cancer cell lines and primary tumors, as well as in oncogenic uroepithelial cells transformed with human papillomavirus (HPV) E7. Forced overexpression of CDC91L1 malignantly transformed NIH3T3 cells in vitro and in vivo. Overexpression of CDC91L1 also resulted in upregulation of the urokinase receptor (uPAR), a GPI-anchored protein, and in turn increased STAT-3 phosphorylation in bladder cancer cells. Our findings suggest that CDC91L1 is an oncogene in bladder cancer, and implicate the GPI anchoring system as a potential oncogenic pathway and therapeutic target in human cancers.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Univ Med Ctr, Dept Urol, Dept Epidemiol & Biostat, NL-6500 HB Nijmegen, Netherlands; Johns Hopkins Univ Hosp, Inst Med, Dept Urol, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University; Johns Hopkins University; Radboud University Nijmegen; Johns Hopkins University; Johns Hopkins Medicine	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA.	dsidrans@jhmi.edu; btrink@jhmi.edu	Kiemeney, Lambertus A./D-3357-2009	Kiemeney, Lambertus A./0000-0002-2368-1326; Hoque, Mohammad Obaidul/0000-0001-6701-9978	NCI NIH HHS [5P01CA77664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077664] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Bringuier PP, 1996, ONCOGENE, V12, P1747; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; Forozan F, 2000, CANCER RES, V60, P4519; Friedmann E, 2002, J BIOL CHEM, V277, P35274, DOI 10.1074/jbc.M201044200; Fukushige S, 1997, GENE CHROMOSOME CANC, V19, P161, DOI 10.1002/(SICI)1098-2264(199707)19:3<161::AID-GCC5>3.0.CO;2-W; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Guan XY, 1996, CANCER RES, V56, P3446; Hong YJ, 2003, MOL BIOL CELL, V14, P1780, DOI 10.1091/mbc.E02-12-0794; Hovey RM, 1998, CANCER RES, V58, P3555; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KALLIONIEMI OP, 1993, SEMIN CANCER BIOL, V4, P41; MAGUIRE RT, 1983, P NATL ACAD SCI-BIOL, V80, P1947, DOI 10.1073/pnas.80.7.1947; Memarzedeh S, 2002, P NATL ACAD SCI USA, V99, P10647, DOI 10.1073/pnas.152127499; Mu D, 2003, CANCER CELL, V3, P297, DOI 10.1016/S1535-6108(03)00054-0; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; Schoenberg M, 1996, J UROLOGY, V155, P1035, DOI 10.1016/S0022-5347(01)66380-8; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1996, CANCER RES, V56, P3441; WEINBERG RA, 1994, CA-CANCER J CLIN, V44, P160, DOI 10.3322/canjclin.44.3.160; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Wimmer K, 1999, ONCOGENE, V18, P233, DOI 10.1038/sj.onc.1202287; Wu GJ, 2000, CANCER RES, V60, P5371; Wu GJ, 2001, CANCER RES, V61, P4951; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	34	62	62	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					374	381		10.1038/nm1010	http://dx.doi.org/10.1038/nm1010			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034568				2022-12-27	WOS:000220587000028
J	Passage, E; Norreel, JC; Noack-Fraissignes, P; Sanguedolce, V; Pizant, J; Thirion, X; Robaglia-Schlupp, A; Pellissier, JF; Fontes, M				Passage, E; Norreel, JC; Noack-Fraissignes, P; Sanguedolce, V; Pizant, J; Thirion, X; Robaglia-Schlupp, A; Pellissier, JF; Fontes, M			Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease	NATURE MEDICINE			English	Article							SCHWANN-CELLS; PMP22 GENE; TYPE-1A; MYELIN; MUTATION; DUPLICATION; NEUROPATHY; MICE; DIFFERENTIATION; EXPRESSION	Charcot-Marie-Tooth disease (CMT) is the most common hereditary peripheral neuropathy, affecting 1 in 2,500 people. The only treatment currently available is rehabilitation or corrective surgery. The most frequent form of the disease, CMT-1A, involves abnormal myelination of the peripheral nerves. Here we used a mouse model of CMT-1A to test the ability of ascorbic acid, a known promoter of myelination, to correct the CMT-1A phenotype. Ascorbic acid treatment resulted in substantial amelioration of the CMT-1A phenotype, and reduced the expression of PMP22 to a level below what is necessary to induce the disease phenotype. As ascorbic acid has already been approved by the FDA for other clinical indications, it offers an immediate therapeutic possibility for patients with the disease.	Fac Med Timone, IPHM, INSERM, UMR491, F-13385 Marseille 5, France; CNRS, UPR 9011, F-13402 Marseille 20, France; Fac Med Timone, Lab Sante Publ, EA 3279, F-13385 Marseille 5, France; CHU Timone Adulte, Serv Anat Pathol, F-13385 Marseille 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite	Fontes, M (corresponding author), Fac Med Timone, IPHM, INSERM, UMR491, 27 Bd J Moulin, F-13385 Marseille 5, France.	Michel.Fontes@medecine.univ-mrs.fr						Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; Arrigoni O, 2002, BBA-GEN SUBJECTS, V1569, P1, DOI 10.1016/S0304-4165(01)00235-5; Boerkoel CF, 2002, ANN NEUROL, V51, P190, DOI 10.1002/ana.10089; CAREY DJ, 1987, DEV BRAIN RES, V32, P95, DOI 10.1016/0165-3806(87)90142-8; Carter RJ, 1999, J NEUROSCI, V19, P3248; Chapillon P, 1998, BEHAV BRAIN RES, V93, P77, DOI 10.1016/S0166-4328(97)00137-X; Coschigano KT, 2003, ENDOCRINOLOGY, V144, P3799, DOI 10.1210/en.2003-0374; DYCK PJ, 1981, ANN NEUROL, V10, P222, DOI 10.1002/ana.410100304; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; FENTON CF, 1984, J AM POD ASSOC, V74, P490, DOI 10.7547/87507315-74-10-490; Garcia CA, 1999, ANN NY ACAD SCI, V883, P69, DOI 10.1111/j.1749-6632.1999.tb08570.x; GOULD N, 1984, FOOT ANKLE, V4, P267, DOI 10.1177/107110078400400508; HOOD J, 1969, NEW ENGL J MED, V281, P1292, DOI 10.1056/NEJM196912042812309; Huxley C, 1996, HUM MOL GENET, V5, P563, DOI 10.1093/hmg/5.5.563; Huxley C, 1998, HUM MOL GENET, V7, P449, DOI 10.1093/hmg/7.3.449; Lopez-Lluch G, 1998, BIOCHEM J, V331, P21, DOI 10.1042/bj3310021; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; Melendez RR, 2002, REV INVEST CLIN, V54, P77; Nelis E, 1996, EUR J HUM GENET, V4, P25; Nishikawa Y, 2003, METABOLISM, V52, P760, DOI 10.1016/S0026-0495(03)00069-6; Njegovan M E, 1997, Clin Podiatr Med Surg, V14, P99; Norreel JC, 2001, EUR J NEUROSCI, V13, P1625, DOI 10.1046/j.0953-816x.2001.01535.x; Ouvrier RA, 1995, BRAIN DEV-JPN, V17, P31, DOI 10.1016/0387-7604(94)00127-8; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; Plant GW, 2002, J NEUROSCI, V22, P6083; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; Saberan-Djoneidi D, 2000, GENE, V248, P223, DOI 10.1016/S0378-1119(00)00116-5; Sancho S, 1999, BRAIN, V122, P1563, DOI 10.1093/brain/122.8.1563; SKRE H, 1974, CLIN GENET, V6, P98; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; Yang ZY, 1996, BRAIN RES, V706, P243, DOI 10.1016/0006-8993(95)01135-8	35	247	267	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					396	401		10.1038/nm1023	http://dx.doi.org/10.1038/nm1023			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034573				2022-12-27	WOS:000220587000031
J	Oelke, M; Maus, MV; Didiano, D; June, CH; Mackensen, A; Schneck, JP				Oelke, M; Maus, MV; Didiano, D; June, CH; Mackensen, A; Schneck, JP			Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells	NATURE MEDICINE			English	Article							ADOPTIVE TRANSFER; LYMPHOCYTES; CD8(+); COSTIMULATION; GENERATION; ACTIVATION; RESPONSES; IMMUNITY; AVIDITY; CD4(+)	Adoptive immunotherapy holds promise as a treatment for cancer and infectious diseases, but its development has been impeded by the lack of reproducible methods for generating therapeutic numbers of antigen-specific CD8(+) cytotoxic T lymphocytes (CTLs). As a result, there are only limited reports of expansion of antigen-specific CTLs to the levels required for clinical therapy. To address this issue, artificial antigen-presenting cells (aAPCs) were made by coupling a soluble human leukocyte antigen-immunoglobulin fusion protein (HLA-Ig) and CD28-specific antibody to beads. HLA-Ig-based aAPCs were used to induce and expand CTLs specific for cytomegalovirus (CMV) or melanoma. aAPC-induced cultures showed robust antigen-specific CTL expansion over successive rounds of stimulation, resulting in the generation of clinically relevant antigen-specific CTLs that recognized endogenous antigen-major histocompatibility complex complexes presented on melanoma cells. These studies show the value of HLA-Ig-based aAPCs for reproducible expansion of disease-specific CTLs for clinical approaches to adoptive immunotherapy.	Johns Hopkins Univ, Sch Med, Dept Pathol & Med, Baltimore, MD 21218 USA; Abramson Family Canc Res Inst, Philadelphia, PA USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Regensburg, Dept Hematol Oncol, D-8400 Regensburg, Germany	Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Regensburg	Oelke, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol & Med, Baltimore, MD 21218 USA.			Oelke, Mathias/0000-0003-2253-6167; Maus, Marcela/0000-0002-7578-0393; June, Carl/0000-0003-0241-3557	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029575, R01AI044129] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-44129, AI-29575] Funding Source: Medline; NIDDK NIH HHS [DK07748] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD P, 1991, JNCI-J NATL CANCER I, V83, P932, DOI 10.1093/jnci/83.13.932; Deeths MJ, 1997, EUR J IMMUNOL, V27, P598, DOI 10.1002/eji.1830270305; Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Laux I, 2000, CLIN IMMUNOL, V96, P187, DOI 10.1006/clim.2000.4902; LEE SP, 1993, J VIROL, V67, P7428, DOI 10.1128/JVI.67.12.7428-7435.1993; Levine BL, 1998, J HEMATOTHER, V7, P437, DOI 10.1089/scd.1.1998.7.437; Maus MV, 2002, NAT BIOTECHNOL, V20, P143, DOI 10.1038/nbt0202-143; Oelke M, 2000, CLIN CANCER RES, V6, P1997; Oelke M, 2000, SCAND J IMMUNOL, V52, P544, DOI 10.1046/j.1365-3083.2000.00810.x; Perez-Diez A, 1998, CANCER RES, V58, P5305; Salgaller ML, 1998, PROSTATE, V35, P144, DOI 10.1002/(SICI)1097-0045(19980501)35:2<144::AID-PROS8>3.0.CO;2-J; Tham EL, 2001, J IMMUNOL METHODS, V249, P111, DOI 10.1016/S0022-1759(00)00335-5; Valmori D, 2002, J IMMUNOL, V168, P4231, DOI 10.4049/jimmunol.168.8.4231; Valmori D, 1999, INT IMMUNOL, V11, P1971, DOI 10.1093/intimm/11.12.1971; von Bergwelt-Baildon MS, 2002, BLOOD, V99, P3319, DOI 10.1182/blood.V99.9.3319; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Yee C, 1999, J IMMUNOL, V162, P2227	20	245	298	3	35	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					619	624		10.1038/nm869	http://dx.doi.org/10.1038/nm869			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12704385				2022-12-27	WOS:000182610600045
J	Schmidt, M; Carbonaro, DA; Speckmann, C; Wissler, M; Bohnsack, J; Elder, M; Aronow, BJ; Nolta, JA; Kohn, DB; von Kalle, C				Schmidt, M; Carbonaro, DA; Speckmann, C; Wissler, M; Bohnsack, J; Elder, M; Aronow, BJ; Nolta, JA; Kohn, DB; von Kalle, C			Clonality analysis after retroviral-mediated gene transfer to CD34(+) cells from the cord blood of ADA-deficient SCID neonates	NATURE MEDICINE			English	Article							CLONES; PROGENITOR; THERAPY; DNA	A clinical trial of retroviral-mediated transfer of the adenosine deaminase (ADA) gene into umbilical cord blood CD34(+) cells was started in 1993. ADA-containing peripheral blood mononuclear cells (PBMCs) have persisted in patients from this trial, with T lymphocytes showing the highest prevalence of gene marking(1,2). To gain a greater understanding of the nature and number of the transduced cells that were engrafted, we used linear amplification-mediated PCR (LAM-PCR) to identify clonal vector proviral integrants(3,4). In one patient, a single vector integrant was predominant in T lymphocytes at a stable level over most of the eight-year time span analyzed and was also detected in some myeloid samples. T-cell clones with the predominant integrant, isolated after eight years, showed multiple patterns of T-cell receptor (TCR) gene rearrangement, indicating that a single pre-thymic stem or progenitor cell served as the source of the majority of the gene-marked cells over an extended period of time. It is important to distinguish the stable pattern of monoclonal gene marking that we observed here from the progressive increase of a T-cell clone with monoclonal gene marking that results from leukemic transformation, as observed in two subjects in a clinical trial of gene therapy for X-linked severe combined immunodeficiency (SCID)(5,6).	Childrens Hosp Los Angeles, Div Res Immunol & Bone Marrow Transplantat, Los Angeles, CA 90027 USA; Univ Freiburg, Dept Internal Med 1, Freiburg, Germany; Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany; Univ So Calif, Dept Pediat, Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Dept Microbiol, Keck Sch Med, Los Angeles, CA 90089 USA; Univ Utah, Hlth Sci Ctr, Dept Pediat, Div Pediat Rheumatol & Immunol, Salt Lake City, UT USA; Univ Calif San Francisco, Sch Med, Dept Pediat, Div Pediat Immunol & Allergy, San Francisco, CA 94143 USA; Cincinnati Childrens Hosp, Med Ctr, Childrens Res Fdn, Div Pediat Informat, Cincinnati, OH USA; Cincinnati Childrens Hosp, Med Ctr, Childrens Res Fdn, Div Expt Hematol, Cincinnati, OH USA; Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Children's Hospital Los Angeles; University of Freiburg; University of Freiburg; University of Southern California; University of Southern California; Utah System of Higher Education; University of Utah; University of California System; University of California San Francisco; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Washington University (WUSTL)	Kohn, DB (corresponding author), Childrens Hosp Los Angeles, Div Res Immunol & Bone Marrow Transplantat, Los Angeles, CA 90027 USA.	dkohn@chla.usc.edu	Aronow, Bruce J/F-8438-2012; Kohn, Donald/N-5085-2016	Kohn, Donald/0000-0003-1840-6087; Speckmann, Carsten/0000-0002-6217-1556; Nolta, Jan/0000-0003-4576-8542	NCRR NIH HHS [3 M01 RR0043-35S1] Funding Source: Medline; NHLBI NIH HHS [1P50 HL54850] Funding Source: Medline; NIDDK NIH HHS [R01 DK061848, R01 DK053041-06, R01 DK053041, R01 DK061848-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061848, R01DK053041] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAPEL B, 1990, BLOOD, V75, P2267; Glimm H, 2001, J CLIN INVEST, V107, P199, DOI 10.1172/JCI11519; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Jensen MC, 2000, MOL THER, V1, P49, DOI 10.1006/mthe.1999.0012; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kim HJ, 2000, BLOOD, V96, P1; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Marshall E, 2003, SCIENCE, V299, P320, DOI 10.1126/science.299.5605.320; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Tisdale JF, 1998, BLOOD, V92, P1131, DOI 10.1182/blood.V92.4.1131.416k41_1131_1141; Willenbrock K, 2001, AM J PATHOL, V158, P1851, DOI 10.1016/S0002-9440(10)64141-7	16	112	117	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					463	468		10.1038/nm844	http://dx.doi.org/10.1038/nm844			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12640448				2022-12-27	WOS:000181987400038
J	Pinilla, C; Appel, JR; Borras, E; Houghten, RA				Pinilla, Clemencia; Appel, Jon R.; Borras, Eva; Houghten, Richard A.			Advances in the use of synthetic combinatorial chemistry: Mixture-based libraries	NATURE MEDICINE			English	Article							SOLID-PHASE SYNTHESIS; POSITIONAL-SCANNING LIBRARIES; EXTENDED SUBSTRATE-SPECIFICITY; T-CELL EPITOPES; PEPTIDE LIBRARIES; ORGANIC-SYNTHESIS; BICYCLIC GUANIDINES; CHEMICAL LIBRARIES; POLYMER SUPPORTS; LARGE NUMBERS	The conceptual and technical approaches that led to the explosive growth of combinatorial chemistry began approximately 20 years ago. In the past decade, combinatorial chemistry has continued to expand with new chemistries, technological improvements and, most importantly, a clear demonstration of its utility in the identification of active compounds for research and drug-discovery programs. This article describes the conceptual and practical breakthroughs that have been critical for the development of synthetic combinatorial methods and includes the most recent developments and applications of mixture-based combinatorial libraries.	[Pinilla, Clemencia; Appel, Jon R.; Borras, Eva; Houghten, Richard A.] Torrey Pines Inst Mol Studies, San Diego, CA USA; [Pinilla, Clemencia; Houghten, Richard A.] Mixture Sci Inc, San Diego, CA USA	Torrey Pines Institute for Molecular Studies, California	Houghten, RA (corresponding author), Torrey Pines Inst Mol Studies, San Diego, CA USA.	rhoughten@tpims.org		Borras, Eva/0000-0001-5100-7809	NCI [PO1 CA78040]; NIDA [RO1 DA09410]; MSNRI; NATIONAL CANCER INSTITUTE [P01CA078040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009410] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); MSNRI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank R. Martin and R. Simon for their contributions to the development of the biometrical analysis first used in T-cell studies; C. Dooley for the opioid receptor research; D. Wilson and S. Blondelle for their involvement in the use of combinatorial libraries in many different biological assays; and J. Ostresh, A. Nefzi and the chemistry group at Torrey Pines Institute for Molecular Studies for the continuing development of synthetic chemistry for the preparation of mixture-based combinatorial libraries. Supported by NCI grant PO1 CA78040, NIDA grant RO1 DA09410 and MSNRI funding.	Acharya AN, 2001, J COMB CHEM, V3, P189, DOI 10.1021/cc0000803; Anderson B, 1999, P NATL ACAD SCI USA, V96, P9311, DOI 10.1073/pnas.96.16.9311; Appel JR, 1998, MOL DIVERS, V4, P91, DOI 10.1023/A:1026441400053; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; Barkley A, 2001, CHEM-EUR J, V7, P555, DOI 10.1002/1521-3765(20010202)7:3<555::AID-CHEM555>3.3.CO;2-9; Berman J, 1997, J MED CHEM, V40, P827, DOI 10.1021/jm960702s; Blondelle SE, 1999, ANTIMICROB AGENTS CH, V43, P106, DOI 10.1128/AAC.43.1.106; Boger DL, 2000, J AM CHEM SOC, V122, P6382, DOI 10.1021/ja994192d; Borras E, 2002, J IMMUNOL METHODS, V267, P81; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; BUNIN BA, 1992, J AM CHEM SOC, V114, P10997, DOI 10.1021/ja00053a067; Cheng Y, 2002, BIOORG MED CHEM LETT, V12, P529, DOI 10.1016/S0960-894X(01)00824-1; CROWLEY JI, 1976, ACCOUNTS CHEM RES, V9, P135, DOI 10.1021/ar50100a003; Dauber DS, 2002, J VIROL, V76, P1359, DOI 10.1128/JVI.76.3.1359-1368.2002; Dolle RE, 2001, J COMB CHEM, V3, P477, DOI 10.1021/cc010049g; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; FRANK R, 1983, NUCLEIC ACIDS RES, V11, P4365, DOI 10.1093/nar/11.13.4365; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GIANNIS A, 1993, ANGEW CHEM INT EDIT, V32, P1244, DOI 10.1002/anie.199312441; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Hemmer B, 2000, J IMMUNOL, V164, P861, DOI 10.4049/jimmunol.164.2.861; Hemmer B, 1999, NAT MED, V5, P1375; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; Hiemstra HS, 1997, P NATL ACAD SCI USA, V94, P10313, DOI 10.1073/pnas.94.19.10313; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Houghten RA, 1999, J MED CHEM, V42, P3743, DOI 10.1021/jm990174v; Houghten Richard A., 1994, Methods (Orlando), V6, P354, DOI 10.1006/meth.1994.1035; Judkowski V, 2001, J IMMUNOL, V166, P908, DOI 10.4049/jimmunol.166.2.908; La Rosa C, 2001, BLOOD, V97, P1776; Lam KS, 1997, CHEM REV, V97, P411, DOI 10.1021/cr9600114; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEZNOFF CC, 1973, CAN J CHEM, V51, P3756, DOI 10.1139/v73-561; Linnemann T, 2001, EUR J IMMUNOL, V31, P156, DOI 10.1002/1521-4141(200101)31:1<156::AID-IMMU156>3.0.CO;2-P; LISKAMP RMJ, 1994, ANGEW CHEM INT EDIT, V33, P633, DOI 10.1002/anie.199406331; Mathieu MA, 2002, MOL BIOCHEM PARASIT, V121, P99, DOI 10.1016/S0166-6851(02)00026-9; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Nazif T, 2001, P NATL ACAD SCI USA, V98, P2967, DOI 10.1073/pnas.061028898; Nefzi A, 2000, TETRAHEDRON, V56, P3319, DOI 10.1016/S0040-4020(00)00253-2; Nefzi A, 1997, CHEM REV, V97, P449, DOI 10.1021/cr960010b; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Ostresh JM, 1998, J ORG CHEM, V63, P8622, DOI 10.1021/jo9810617; OSTRESH JM, 1994, P NATL ACAD SCI USA, V91, P11138, DOI 10.1073/pnas.91.23.11138; PINILLA C, 1994, BIOCHEM J, V301, P847, DOI 10.1042/bj3010847; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; Pinilla C, 1999, CURR OPIN IMMUNOL, V11, P193, DOI 10.1016/S0952-7915(99)80033-8; Pinilla C, 2001, CANCER RES, V61, P5153; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Reixach N, 2000, J STRUCT BIOL, V130, P247, DOI 10.1006/jsbi.2000.4245; Rubio-Godoy V, 2002, EUR J IMMUNOL, V32, P2292, DOI 10.1002/1521-4141(200208)32:8<2292::AID-IMMU2292>3.0.CO;2-K; Rubio-Godoy V, 2002, CANCER RES, V62, P2058; Salter JP, 2002, J BIOL CHEM, V277, P24618, DOI 10.1074/jbc.M202364200; Sternson SM, 2001, ORG LETT, V3, P4239, DOI 10.1021/ol016915f; Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Udaka K, 1996, J IMMUNOL, V157, P670; Willoughby CA, 2002, BIOORG MED CHEM LETT, V12, P93, DOI 10.1016/S0960-894X(01)00665-5; WONG JY, 1973, CAN J CHEM, V51, P2452, DOI 10.1139/v73-367; Zhao YD, 2001, J IMMUNOL, V167, P2130, DOI 10.4049/jimmunol.167.4.2130	64	78	96	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					118	122		10.1038/nm0103-118	http://dx.doi.org/10.1038/nm0103-118			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514724				2022-12-27	WOS:000208640400006
J	Oike, Y; Akao, M; Yasunaga, K; Yamauchi, T; Morisada, T; Ito, Y; Urano, T; Kimura, Y; Kubota, Y; Maekawa, H; Miyamoto, T; Miyata, K; Matsumoto, S; Sakai, J; Nakagata, N; Takeya, M; Koseki, H; Ogawa, Y; Kadowaki, T; Suda, T				Oike, Y; Akao, M; Yasunaga, K; Yamauchi, T; Morisada, T; Ito, Y; Urano, T; Kimura, Y; Kubota, Y; Maekawa, H; Miyamoto, T; Miyata, K; Matsumoto, S; Sakai, J; Nakagata, N; Takeya, M; Koseki, H; Ogawa, Y; Kadowaki, T; Suda, T			Angiopoietin-related growth factor antagonizes obesity and insulin resistance	NATURE MEDICINE			English	Article							SKELETAL-MUSCLE; ENERGY-EXPENDITURE; DIABETES-MELLITUS; TRANSGENIC MICE; ADIPOSE-TISSUE; RECEPTOR; EXPRESSION; PROTEIN; COACTIVATOR; METABOLISM	Angiopoietin-related growth factor (AGF), a member of the angiopoietin-like protein (Angptl) family, is secreted predominantly from the liver into the systemic circulation. Here, we show that most (> 80%) of the AGF-deficient mice die at about embryonic day 13, whereas the surviving AGF-deficient mice develop marked obesity, lipid accumulation in skeletal muscle and liver, and insulin resistance accompanied by reduced energy expenditure relative to controls. In parallel, mice with targeted activation of AGF show leanness and increased insulin sensitivity resulting from increased energy expenditure. They are also protected from high-fat diet - induced obesity, insulin resistance and nonadipose tissue steatosis. Hepatic overexpression of AGF by adenoviral transduction, which leads to an approximately 2.5-fold increase in serum AGF concentrations, results in a significant ( P < 0.01) body weight loss and increases insulin sensitivity in mice fed a high-fat diet. This study establishes AGF as a new hepatocyte-derived circulating factor that counteracts obesity and related insulin resistance.	Keio Univ, Sch Med, Sakaguchi Lab, Dept Cell Differentiat,Shinjuku Ku, Tokyo 1608582, Japan; Yamanouchi Pharmaceut Co Ltd, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8600811, Japan; Kumamoto Univ, Dept Pathol, Kumamoto 8600811, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Med & Metab, Tokyo 1010062, Japan	Keio University; Astellas Pharmaceuticals; University of Tokyo; University of Tokyo; Kumamoto University; Kumamoto University; RIKEN; Tokyo Medical & Dental University (TMDU)	Oike, Y (corresponding author), Keio Univ, Sch Med, Sakaguchi Lab, Dept Cell Differentiat,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	oike@sc.itc.keio.ac.jp	Suda, Toshio/H-6761-2013; Miyata, Keishi/HGF-1876-2022; Kubota, Yoshiaki/L-2231-2013; Koseki, Haruhiko/I-3825-2014	Suda, Toshio/0000-0001-7540-1771; Miyata, Keishi/0000-0003-0336-1859; Koseki, Haruhiko/0000-0001-8424-5854; Yasunaga, Kunio/0000-0002-6259-4743; Sakai, Juro/0000-0003-4043-1035; Nakagata, Naomi/0000-0002-5737-9993				Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Camenisch G, 2002, J BIOL CHEM, V277, P17281, DOI 10.1074/jbc.M109768200; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Inaba T, 2003, J BIOL CHEM, V278, P21344, DOI 10.1074/jbc.M213202200; Ito Y, 2003, CANCER RES, V63, P6651; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Levine JA, 1999, SCIENCE, V283, P212, DOI 10.1126/science.283.5399.212; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Matsuzawa Y, 1999, ANN NY ACAD SCI, V892, P146, DOI 10.1111/j.1749-6632.1999.tb07793.x; Moller DE, 2003, INT J OBESITY, V27, pS17, DOI 10.1038/sj.ijo.0802494; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oike Y, 2004, INT J HEMATOL, V80, P21, DOI 10.1532/ijh97.04034; Oike Y, 2004, BLOOD, V103, P3760, DOI 10.1182/blood-2003-04-1272; Oike Y, 2003, P NATL ACAD SCI USA, V100, P9494, DOI 10.1073/pnas.1531901100; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Sarmiento U, 1997, LAB INVEST, V77, P243; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	41	176	193	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					400	408		10.1038/nm1214	http://dx.doi.org/10.1038/nm1214			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15778720				2022-12-27	WOS:000228180500031
J	Ralph, GS; Radcliffe, PA; Day, DM; Carthy, JM; Leroux, MA; Lee, DCP; Wong, LF; Bilsland, LG; Greensmith, L; Kingsman, SM; Mitrophanous, KA; Mazarakis, ND; Azzouz, M				Ralph, GS; Radcliffe, PA; Day, DM; Carthy, JM; Leroux, MA; Lee, DCP; Wong, LF; Bilsland, LG; Greensmith, L; Kingsman, SM; Mitrophanous, KA; Mazarakis, ND; Azzouz, M			(S)ilencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model	NATURE MEDICINE			English	Article							TRANSGENIC MOUSE MODEL; LENTIVIRAL VECTORS; PROLONGS SURVIVAL; NERVOUS-SYSTEM; GENE; EXPRESSION; DEGENERATION; DELIVERY; DISEASE; DEATH	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease resulting in the selective death of motor neurons in the brain and spinal cord(1). Some familial cases of ALS are caused by dominant mutations in the gene encoding superoxide dismutase (SOD1)(2-4). The emergence of interfering RNA (RNAi) for specific gene silencing could be therapeutically beneficial for the treatment of such dominantly inherited diseases(5-7). We generated a lentiviral vector to mediate expression of RNAi molecules specifically targeting the human SOD1 gene ( SOD1). Injection of this vector into various muscle groups of mice engineered to overexpress a mutated form of human SOD1 (SOD1(G93A)) resulted in an efficient and specific reduction of SOD1 expression and improved survival of vulnerable motor neurons in the brainstem and spinal cord. Furthermore, SOD1 silencing mediated an improved motor performance in these animals, resulting in a considerable delay in the onset of ALS symptoms by more than 100% and an extension in survival by nearly 80% of their normal life span. These data are the first to show a substantial extension of survival in an animal model of a fatal, dominantly inherited neurodegenerative condition using RNAi and provide the highest therapeutic efficacy observed in this field to date.	Oxford Biomed UK Ltd, Medawar Ctr, Oxford OX4 4GA, England; Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London WC1N 3BG, England	Oxford Biomedica (UK) Ltd; University of London; University College London	Ralph, GS (corresponding author), Oxford Biomed UK Ltd, Medawar Ctr, Oxford Sci Pk, Oxford OX4 4GA, England.	s.ralph@oxfordbiomedica.co.uk; m.azzouz@oxfordbiomedica.co.uk	Azzouz, Mimoun/B-3979-2009	Azzouz, Mimoun/0000-0001-6564-5967; Shaw, Pamela/0000-0002-8925-2567				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Ding HL, 2003, AGING CELL, V2, P209, DOI 10.1046/j.1474-9728.2003.00054.x; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Martin-Rendon E, 2002, MOL THER, V5, P566, DOI 10.1006/mthe.2002.0576; Maxwell MM, 2004, P NATL ACAD SCI USA, V101, P3178, DOI 10.1073/pnas.0308726100; Mazarakis ND, 2001, HUM MOL GENET, V10, P2109, DOI 10.1093/hmg/10.19.2109; Mitrophanous KA, 1999, GENE THER, V6, P1808, DOI 10.1038/sj.gt.3301023; Mulder D W, 1982, Adv Neurol, V36, P15; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Wong LF, 2004, MOL THER, V9, P101, DOI 10.1016/j.ymthe.2003.09.017; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076	25	362	446	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					429	433		10.1038/nm1205	http://dx.doi.org/10.1038/nm1205			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15768029				2022-12-27	WOS:000228180500035
J	Izumikawa, M; Minoda, R; Kawamoto, K; Abrashkin, KA; Swiderski, DL; Dolan, DF; Brough, DE; Raphael, Y				Izumikawa, M; Minoda, R; Kawamoto, K; Abrashkin, KA; Swiderski, DL; Dolan, DF; Brough, DE; Raphael, Y			Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals	NATURE MEDICINE			English	Article							CHICK BASILAR PAPILLA; INNER-EAR; IN-VIVO; MATH1; EXPRESSION; COCHLEA; NOISE; REORGANIZATION; DEGENERATION; GENERATION	In the mammalian auditory system, sensory cell loss resulting from aging, ototoxic drugs, infections, overstimulation and other causes is irreversible and leads to permanent sensorineural hearing loss. To restore hearing, it is necessary to generate new functional hair cells. One potential way to regenerate hair cells is to induce a phenotypic transdifferentiation of nonsensory cells that remain in the deaf cochlea. Here we report that Atoh1, a gene also known as Math1 encoding a basic helix-loop-helix transcription factor and key regulator of hair cell development, induces regeneration of hair cells and substantially improves hearing thresholds in the mature deaf inner ear after delivery to nonsensory cells through adenovectors. This is the first demonstration of cellular and functional repair in the organ of Corti of a mature deaf mammal. The data suggest a new therapeutic approach based on expressing crucial developmental genes for cellular and functional restoration in the damaged auditory epithelium and other sensory systems.	Univ Michigan, Dept Otolaryngol, Kresge Hearing Res Inst, Ann Arbor, MI 48109 USA; Kansai Med Univ, Dept Otolaryngol, Osaka 5708506, Japan; Kumamoto Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Kumamoto 8608556, Japan; GenVec Inc, Dept Vector Sci, Gaithersburg, MD 20879 USA	University of Michigan System; University of Michigan; Kansai Medical University; Kumamoto University	Raphael, Y (corresponding author), Univ Michigan, Dept Otolaryngol, Kresge Hearing Res Inst, MSRB 3,Room 9303,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	yoash@umich.edu			NIDCD NIH HHS [R01 DC01634, P30 DC05188, DC05401, P30 DC005188] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001634, P30DC005188, R01DC005401] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Beyer LA, 2000, J NEUROCYTOL, V29, P227, DOI 10.1023/A:1026515619443; Brough DE, 1997, J VIROL, V71, P9206, DOI 10.1128/JVI.71.12.9206-9213.1997; Chen P, 2002, DEVELOPMENT, V129, P2495; Cotanche DA, 1995, HEARING RES, V91, P148, DOI 10.1016/0378-5955(95)00185-9; DALLOS P, 1978, J NEUROPHYSIOL, V41, P365, DOI 10.1152/jn.1978.41.2.365; DAVIS H, 1976, ANN OTOL RHINOL LA S, V28, P1; Fekete D M, 2000, Trends Neurosci, V23, P386, DOI 10.1016/S0166-2236(00)01668-4; Fekete DM, 1996, CURR OPIN NEUROBIOL, V6, P533, DOI 10.1016/S0959-4388(96)80061-4; GREENWOOD D, 1961, J ACOUST SOC AM, V33, P1344, DOI 10.1121/1.1908437; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Ishimoto S, 2002, HEARING RES, V173, P187, DOI 10.1016/S0378-5955(02)00579-8; Kawamoto K, 2003, J NEUROSCI, V23, P4395; Li HW, 2003, NAT MED, V9, P1293, DOI 10.1038/nm925; RAPHAEL Y, 1991, CELL MOTIL CYTOSKEL, V18, P215, DOI 10.1002/cm.970180307; RAPHAEL Y, 1993, J COMP NEUROL, V330, P521, DOI 10.1002/cne.903300408; Shou JY, 2003, MOL CELL NEUROSCI, V23, P169, DOI 10.1016/S1044-7431(03)00066-6; TEAS DC, 1975, J ACOUST SOC AM, V58, P1066, DOI 10.1121/1.380766; Torres M, 1998, MECH DEVELOP, V71, P5, DOI 10.1016/S0925-4773(97)00155-X; Turner CW, 2004, J ACOUST SOC AM, V115, P1729, DOI 10.1121/1.1687425; Woods C, 2004, NAT NEUROSCI, V7, P1310, DOI 10.1038/nn1349; Yagi M, 2000, JARO-J ASSOC RES OTO, V1, P315, DOI 10.1007/s101620010011; Yamasoba T, 1997, HEARING RES, V112, P13, DOI 10.1016/S0378-5955(97)00092-0; Zheng JL, 2000, NAT NEUROSCI, V3, P580, DOI 10.1038/75753	24	510	605	3	76	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					271	276		10.1038/nm1193	http://dx.doi.org/10.1038/nm1193			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15711559				2022-12-27	WOS:000227541300021
J	Jankowski, V; Tolle, M; Vanholder, R; Schonfelder, G; van der Giet, M; Henning, L; Schluter, H; Paul, M; Zidek, W; Jankowski, J				Jankowski, V; Tolle, M; Vanholder, R; Schonfelder, G; van der Giet, M; Henning, L; Schluter, H; Paul, M; Zidek, W; Jankowski, J			Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor	NATURE MEDICINE			English	Article							VASCULAR SMOOTH-MUSCLE; RECEPTOR SUBTYPES; P2X RECEPTORS; RAT-KIDNEY; TNP-ATP; ANTAGONIST; CELLS; POLYPHOSPHATES; CHROMATOGRAPHY; AFFINITY	Beyond serving as a mechanical barrier, the endothelium has important regulatory functions. The discovery of nitric oxide 1 revolutionized our understanding of vasoregulation. In contrast, the identity of endothelium-derived vasoconstrictive factors (EDCFs) remains unclear. The supernatant obtained from mechanically stimulated human endothelial cells obtained from dermal vessels elicited a vasoconstrictive response in an isolated perfused rat kidney. A purinoceptor blocker had a greater effect than an endothelin receptor blocker in decreasing endothelially derived vasoconstriction in the isolated perfused rat kidney. The nucleotide uridine adenosine tetraphosphate (Up(4)A) was isolated from the supernatant of stimulated human endothelium and identified by mass spectrometry. Up(4)A is likely to exert vasoconstriction predominantly through P2X1 receptors, and probably also through P2Y2 and P2Y4 receptors. Plasma concentrations of Up(4)A that cause vasoconstriction are found in healthy subjects. Stimulation with adenosine 5'-triphosphate (ATP), uridine 5'-triphosphate (UTP), acetylcholine, endothelin, A23187 and mechanical stress releases Up(4)A from endothelium, suggesting that Up(4)A contributes to vascular autoregulation. To our knowledge, Up(4)A is the first dinucleotide isolated from living organisms that contains both purine and pyrimidine moieties. We conclude that Up(4)A is a novel potent nonpeptidic EDCF. Its vasoactive effects, plasma concentrations and its release upon endothelial stimulation strongly suggest that Up(4)A has a functional vasoregulatory role.	Charite Univ Med Berlin, Med Klin 4, D-12200 Berlin, Germany; Univ Hosp, Dept Internal Med, Nephrol Sect, B-9000 Ghent, Belgium; Charite Univ Med Berlin, Inst Clin Pharmacol & Toxicol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ghent University; Ghent University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Jankowski, J (corresponding author), Charite Univ Med Berlin, Med Klin 4, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	joachim.jankowski@charite.de	Paul, Martin/K-5425-2015; Schluter, Hartmut/D-1371-2015; Tölle, Markus/GPP-7157-2022	Schluter, Hartmut/0000-0002-9358-7036; van der Giet, Markus/0000-0003-3590-5451; Schonfelder, Gilbert/0000-0001-6134-1990				BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; Bo XN, 1998, EUR J PHARMACOL, V353, P59, DOI 10.1016/S0014-2999(98)00383-5; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Gorman MW, 2003, LUMINESCENCE, V18, P173, DOI 10.1002/bio.721; Honore P, 2002, PAIN, V96, P99, DOI 10.1016/S0304-3959(01)00434-1; Jankowski J, 1998, J CHROMATOGR B, V719, P63, DOI 10.1016/S0378-4347(98)00408-3; KASAKOV L, 1982, EUR J PHARMACOL, V86, P291, DOI 10.1016/0014-2999(82)90330-2; King BF, 1999, BRIT J PHARMACOL, V128, P981, DOI 10.1038/sj.bjp.0702876; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Lazarowski ER, 2001, NEWS PHYSIOL SCI, V16, P1; Lewis CJ, 1998, BRIT J PHARMACOL, V124, P1463, DOI 10.1038/sj.bjp.0702001; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pulvirenti TJ, 2000, J NEUROCYTOL, V29, P623, DOI 10.1023/A:1010828302936; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Turner CM, 2003, CELLS TISSUES ORGANS, V175, P105, DOI 10.1159/000073754; van der Giet M, 2001, BRIT J PHARMACOL, V132, P467, DOI 10.1038/sj.bjp.0703817; Vial C, 2002, MOL PHARMACOL, V62, P1438, DOI 10.1124/mol.62.6.1438; Wang LW, 2002, J CARDIOVASC PHARM, V40, P841, DOI 10.1097/00005344-200212000-00005	22	131	134	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					223	227		10.1038/nm1188	http://dx.doi.org/10.1038/nm1188			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15665829				2022-12-27	WOS:000226797300031
J	Gronski, MA; Boulter, JM; Moskophidis, D; Nguyen, LT; Holmberg, K; Elford, AR; Deenick, EK; Kim, HO; Penninger, JM; Odermatt, B; Gallimore, A; Gascoigne, NRJ; Ohashi, PS				Gronski, MA; Boulter, JM; Moskophidis, D; Nguyen, LT; Holmberg, K; Elford, AR; Deenick, EK; Kim, HO; Penninger, JM; Odermatt, B; Gallimore, A; Gascoigne, NRJ; Ohashi, PS			TCR affinity and negative regulation limit autoimmunity	NATURE MEDICINE			English	Article							T-CELL-RECEPTOR; MHC CLASS-I; MOLECULAR MIMICRY; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; TRANSGENIC MODEL; VIRUS-INFECTION; VIRAL ESCAPE; PEPTIDE; ACTIVATION	Autoimmune diseases are often mediated by self-reactive T cells, which must be activated to cause immunopathology. One mechanism, known as molecular mimicry, proposes that self-reactive T cells may be activated by pathogens expressing crossreactive ligands(1-3). Here we have developed a model to investigate how the affinity of the T-cell receptor (TCR) for the activating agent influences autoimmunity. Our model shows that an approximately fivefold difference in the TCR affinity for the activating ligand results in a 50% reduction in the incidence of autoimmunity. A reduction in TCR-ligand affinity to approximately 20 times lower than normal does not induce autoimmunity despite the unexpected induction of cytotoxic T lymphocytes (CTLs) and insulitis. Furthermore, in the absence of a key negative regulatory molecule, Cbl-b(4,5), 100% of mice develop autoimmunity upon infection with viruses encoding the lower-affinity ligand. Therefore, autoimmune disease is sensitive both to the affinity of the activating ligand and to normal mechanisms that negatively regulate the immune response.	Univ Toronto, Inst Breast Canc Res, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Inst Breast Canc Res, Ontario Canc Inst, Dept Immunol, Toronto, ON M5G 2C1, Canada; Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; Univ Zurich Hosp, Dept Expt Pathol, Inst Pathol, CH-8091 Zurich, Switzerland	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Cardiff University; University System of Georgia; Augusta University; Scripps Research Institute; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Zurich; University Zurich Hospital	Ohashi, PS (corresponding author), Univ Toronto, Inst Breast Canc Res, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada.	pohashi@uhnres.utoronto.ca	Penninger, Josef M/I-6860-2013; Deenick, Elissa/AAY-8998-2020	Penninger, Josef M/0000-0002-8194-3777; Deenick, Elissa/0000-0002-9271-0004; Ohashi, Pamela S./0000-0003-2915-9317; Gallimore, Awen/0000-0001-6675-7004; Gronski, Matthew/0000-0003-4779-5720	NIDDK NIH HHS [DK61329] Funding Source: Medline; NIGMS NIH HHS [GM39476] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK061329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039476, R29GM039476] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achour A, 2002, IMMUNITY, V17, P757, DOI 10.1016/S1074-7613(02)00478-8; Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Amrani A, 2000, NATURE, V406, P739, DOI 10.1038/35021081; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bachmann MF, 1998, EUR J IMMUNOL, V28, P3110; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; Boulter JM, 2003, PROTEIN ENG, V16, P707, DOI 10.1093/protein/gzg087; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; GASCOIGNE NR, 2001, EXPERT REV MOL MED, P1; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Holmberg K, 2003, J IMMUNOL, V171, P2427, DOI 10.4049/jimmunol.171.5.2427; Kohm AP, 2003, TRENDS MICROBIOL, V11, P101, DOI 10.1016/S0966-842X(03)00006-4; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; Nguyen LT, 2002, J EXP MED, V195, P423, DOI 10.1084/jem.20010032; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OHASHI PS, 1993, J IMMUNOL, V150, P5185; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; Olson JK, 2002, J IMMUNOL, V169, P2719, DOI 10.4049/jimmunol.169.5.2719; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Reiser JB, 2003, NAT IMMUNOL, V4, P241, DOI 10.1038/ni891; Rosette C, 2001, IMMUNITY, V15, P59, DOI 10.1016/S1074-7613(01)00173-X; Sevilla N, 2000, J VIROL, V74, P3284, DOI 10.1128/JVI.74.7.3284-3292.2000; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; Tissot AC, 2000, J MOL BIOL, V302, P873, DOI 10.1006/jmbi.2000.4501; WEIDT G, 1995, J VIROL, V69, P7147, DOI 10.1128/JVI.69.11.7147-7151.1995; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wucherpfennig KW, 2001, J AUTOIMMUN, V16, P293, DOI 10.1006/jaut.2000.0499; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Yokoi N, 2002, NAT GENET, V31, P391, DOI 10.1038/ng927; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	35	120	125	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1234	1239		10.1038/nm1114	http://dx.doi.org/10.1038/nm1114			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15467726				2022-12-27	WOS:000224785900046
J	Weijer, C; Miller, PB				Weijer, C; Miller, PB			When are research risks reasonable in relation to anticipated benefits?	NATURE MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIALS; CLINICAL-RESEARCH; DEVELOPING-COUNTRIES; ETHICS; TRANSMISSION; EQUIPOISE; CHILDREN		Dalhousie Univ, Dept Bioeth, Halifax, NS B3H 4H7, Canada	Dalhousie University	Weijer, C (corresponding author), Univ Cambridge, Dept Hist & Philosophy Sci, Cambridge CB2 1TN, England.	charles.weijer@dal.ca	Allen, James/B-1349-2013; Weijer, Charles/ABC-5433-2020	Allen, James/0000-0002-5567-6302; Weijer, Charles/0000-0002-5510-1074; Miller, Paul/0000-0002-3766-6223				Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Crouch RA, 1998, HASTINGS CENT REP, V28, P26, DOI 10.2307/3528266; ELLIS G, 1993, 933 OFF PROT RES RIS; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; Fost Norman, 1980, IRB, V2, P5, DOI 10.2307/3564363; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FREEDMAN B, 1993, HASTINGS CENT REP, V23, P13, DOI 10.2307/3562813; FREEDMAN B, 1990, IRB, V12, P31; Freedman Benjamin, 1987, IRB, V9, P7, DOI 10.2307/3563623; Karlawish JHT, 2003, NEW ENGL J MED, V348, P1389, DOI 10.1056/NEJMsb030172; Kopelman LM, 2000, J MED PHILOS, V25, P745; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; McRae AD, 2002, CRIT CARE MED, V30, P1146, DOI 10.1097/00003246-200205000-00032; Miller FG, 2003, HASTINGS CENT REP, V33, P19, DOI 10.2307/3528434; Miller P B, 2000, IRB, V22, P6, DOI 10.2307/3564222; Natl. Comm. Prot. Hum. Subj. Biomed. Behav. Res, 1978, BELM REP ETH PRINC G; *NBAC, 2000, ETH POL ISS RES INV, P69; *NBAC, 2000, ETH POL ISS RES INV; Proposed Regulations on Research Involving Those Institutionalized as Mentally Disabled, 1978, FED REG, V43, p[53, 950]; Shah S, 2004, JAMA-J AM MED ASSOC, V291, P476, DOI 10.1001/jama.291.4.476; Valenzuela TD, 2001, NEW ENGL J MED, V345, P689, DOI 10.1056/NEJM200108303450909; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; Weijer C, 2002, J LAW MED ETHICS, V30, P69, DOI 10.1111/j.1748-720X.2002.tb00721.x; Weijer C, 2002, NEW ENGL J MED, V346, P382; Weijer C, 2000, J LAW MED ETHICS, V28, P344, DOI 10.1111/j.1748-720X.2000.tb00686.x	27	118	119	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2004	10	6					570	573		10.1038/nm0604-570	http://dx.doi.org/10.1038/nm0604-570			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15170195				2022-12-27	WOS:000221759600014
J	Harman, FS; Nicol, CJ; Marin, HE; Ward, JM; Gonzalez, FJ; Peters, JM				Harman, FS; Nicol, CJ; Marin, HE; Ward, JM; Gonzalez, FJ; Peters, JM			Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis	NATURE MEDICINE			English	Article							PPAR-GAMMA; COLORECTAL-CANCER; POLYP FORMATION; PHASE-II; MICE; TROGLITAZONE; SUPPRESSION; DISRUPTION; LIGANDS; GROWTH	Peroxisome proliferator-activated receptor-delta (PPAR-delta; also known as PPAR-beta) is expressed at high levels in colon tumors, but its contribution to colon cancer is unclear. We examined the role of PPAR-delta in colon carcinogenesis using PPAR-delta-deficient (Ppard(-/-)) mice. In both the Min mutant and chemically induced mouse models, colon polyp formation was significantly greater in mice nullizygous for PPAR-delta. In contrast to previous reports suggesting that activation of PPAR-delta potentiates colon polyp formation, here we show that PPAR-delta attenuates colon carcinogenesis.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Grad Program Biochem Microbiol & Mol Biol, University Pk, PA 16802 USA; NCI, Lab Metab, Bethesda, MD 20892 USA; NCI, Vet & Tumor Pathol Sect, Off Lab Anim Resources, Frederick, MD 21702 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Peters, JM (corresponding author), Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA.	jmp21@psu.edu	Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998	NATIONAL CANCER INSTITUTE [R01CA097999, ZIABC005708, R01CA089607, Z01BC005708] Funding Source: NIH RePORTER; NCI NIH HHS [CA97999, CA89607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Burstein HJ, 2003, BREAST CANCER RES TR, V79, P391, DOI 10.1023/A:1024038127156; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kulke MH, 2002, CANCER J, V8, P395, DOI 10.1097/00130404-200209000-00010; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Niho N, 2003, CANCER RES, V63, P6090; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108	15	183	188	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					481	483		10.1038/nm1026	http://dx.doi.org/10.1038/nm1026			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15048110				2022-12-27	WOS:000221242400024
J	Olson, EN				Olson, EN			A decade of discoveries in cardiac biology	NATURE MEDICINE			English	Review							CONGENITAL HEART-DISEASE; CHANNEL RYANODINE RECEPTOR; HEMATOPOIETIC STEM-CELLS; DILATED CARDIOMYOPATHY; PROGENITOR CELLS; GENE-EXPRESSION; ENDOCARDIAL CUSHION; CELLULAR MECHANISMS; SIGNALING PATHWAYS; INFARCTED HEART	The heart is the first organ to form in the embryo, and all subsequent events in the life of the organism depend on its function. Inherited mutations in cardiac regulatory genes give rise to congenital heart disease, the most common form of human birth defects, and abnormalities of the adult heart represent the most prevalent cause of morbidity and mortality in the industrialized world. The past decade has marked a transition from physiological and functional studies of the heart toward a deeper understanding of cardiac function (and dysfunction) at genetic and molecular levels. These discoveries have provided new therapeutic approaches for prevention and palliation of cardiac disease and have raised new questions, challenges and opportunities for the future.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	eric.olson@utsouthwestern.edu						American Heart Association, 2003, HEART DIS STROK STAT; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Bao ZZ, 1999, SCIENCE, V283, P1161, DOI 10.1126/science.283.5405.1161; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BODMER R, 1993, DEVELOPMENT, V118, P719; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Bristow M, 2003, CIRCULATION, V107, P1100, DOI 10.1161/01.CIR.0000054530.87613.36; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Bush E, 2004, P NATL ACAD SCI USA, V101, P2870, DOI 10.1073/pnas.0308723101; Cai CL, 2003, DEV CELL, V5, P877, DOI 10.1016/S1534-5807(03)00363-0; Chien KR, 2004, NATURE, V428, P607, DOI 10.1038/nature02500; Chien KR, 2000, SEMIN ONCOL, V27, P9, DOI 10.1053/sonc.2000.19892; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Dalloz F, 2001, J MOL CELL CARDIOL, V33, P9, DOI 10.1006/jmcc.2000.1289; Dorn GW, 2002, J CARD FAIL, V8, pS370, DOI 10.1054/jcaf.2002.129267; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Epstein JA, 2000, PEDIATR RES, V48, P717, DOI 10.1203/00006450-200012000-00003; Farrell M, 1999, TRENDS CARDIOVAS MED, V9, P214, DOI 10.1016/S1050-1738(00)00023-2; Fatkin D, 2000, J CLIN INVEST, V106, P1351, DOI 10.1172/JCI11093; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Garratt AN, 2003, TRENDS CARDIOVAS MED, V13, P80, DOI 10.1016/S1050-1738(02)00231-1; Gaussin V, 2002, P NATL ACAD SCI USA, V99, P2878, DOI 10.1073/pnas.042390499; Gitler AD, 2003, DEV DYNAM, V228, P643, DOI 10.1002/dvdy.10418; Gourdie RG, 1998, P NATL ACAD SCI USA, V95, P6815, DOI 10.1073/pnas.95.12.6815; Haghighi K, 2003, J CLIN INVEST, V111, P869, DOI 10.1172/JCI200317892; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P155; Hoshijima M, 2002, COLD SPRING HARB SYM, V67, P399, DOI 10.1101/sqb.2002.67.399; Kasahara H, 2001, J CLIN INVEST, V108, P189, DOI 10.1172/JCI200112694; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kelly RG, 2002, TRENDS GENET, V18, P210, DOI 10.1016/S0168-9525(02)02642-2; Kelly RG, 1999, TRENDS CARDIOVAS MED, V9, P3, DOI 10.1016/S1050-1738(98)00034-6; Kim RY, 2001, DEV BIOL, V235, P449, DOI 10.1006/dbio.2001.0284; Kirchhoff S, 2000, CIRC RES, V87, P399; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Konstam MA, 2003, AM J CARDIOL, V91, p9D, DOI 10.1006/S0002-9149(02)03374-X; Kramer KL, 2002, COLD SPRING HARB SYM, V67, P37, DOI 10.1101/sqb.2002.67.37; Lanza R, 2004, CIRC RES, V94, P820, DOI 10.1161/01.RES.0000120863.53562.DF; Leferovich JM, 2001, P NATL ACAD SCI USA, V98, P9830, DOI 10.1073/pnas.181329398; Leinwand LA, 2003, J CLIN INVEST, V112, P302, DOI 10.1172/JCI200319429; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Lowes BD, 2002, NEW ENGL J MED, V346, P1357, DOI 10.1056/NEJMoa012630; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Maass A, 2002, COLD SPRING HARB SYM, V67, P409, DOI 10.1101/sqb.2002.67.409; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; Marban E, 2002, NATURE, V415, P213, DOI 10.1038/415213a; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; Marvin MJ, 2001, GENE DEV, V15, P316, DOI 10.1101/gad.855501; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; McFarlane SI, 2003, ARCH INTERN MED, V163, P2696, DOI 10.1001/archinte.163.22.2696; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Murry CE, 2002, COLD SPRING HARB SYM, V67, P519, DOI 10.1101/sqb.2002.67.519; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nguyen-Tran VTB, 2000, CELL, V102, P671, DOI 10.1016/S0092-8674(00)00089-1; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; PACKER M, 1992, J AM COLL CARDIOL, V20, P248, DOI 10.1016/0735-1097(92)90167-L; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; Rentschler S, 2002, P NATL ACAD SCI USA, V99, P10464, DOI 10.1073/pnas.162301699; Rentschler S, 2001, DEVELOPMENT, V128, P1785; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Schmidt AG, 2001, CARDIOVASC DRUG THER, V15, P387, DOI 10.1023/A:1013381204658; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Schneider VA, 2001, GENE DEV, V15, P304, DOI 10.1101/gad.855601; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Song QJ, 2003, J CLIN INVEST, V111, P859, DOI 10.1172/JCI200316738; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Stuckmann I, 2003, DEV BIOL, V255, P334, DOI 10.1016/S0012-1606(02)00078-7; Sugden PH, 2001, ANN MED, V33, P611; Towbin JA, 2002, NATURE, V415, P227, DOI 10.1038/415227a; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; Wu X, 2004, J AM CHEM SOC, V126, P1590, DOI 10.1021/ja038950i; Yamagishi H, 2001, DEV BIOL, V239, P190, DOI 10.1006/dbio.2001.0417; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	104	231	240	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					467	474		10.1038/nm0504-467	http://dx.doi.org/10.1038/nm0504-467			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15122248				2022-12-27	WOS:000221242400022
J	Braz, JC; Gregory, K; Pathak, A; Zhao, W; Sahin, B; Klevitsky, R; Kimball, TF; Lorenz, JN; Nairn, AC; Liggett, SB; Bodi, I; Wang, S; Schwartz, A; Lakatta, EG; DePaoli-Roach, AA; Robbins, J; Hewett, TE; Bibb, JA; Westfall, MV; Kranias, EG; Molkentin, JD				Braz, JC; Gregory, K; Pathak, A; Zhao, W; Sahin, B; Klevitsky, R; Kimball, TF; Lorenz, JN; Nairn, AC; Liggett, SB; Bodi, I; Wang, S; Schwartz, A; Lakatta, EG; DePaoli-Roach, AA; Robbins, J; Hewett, TE; Bibb, JA; Westfall, MV; Kranias, EG; Molkentin, JD			PKC-alpha regulates cardiac contractility and propensity toward heart failure	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; SARCOPLASMIC-RETICULUM; PHOSPHATASE INHIBITOR-1; CROSS-TALK; PHOSPHOLAMBAN; EXPRESSION; ISOFORMS; PHOSPHORYLATION; TRANSLOCATION; PROGRESSION	The protein kinase C (PKC) family of serine/threonine kinases functions downstream of nearly all membrane- associated signal transduction pathways. Here we identify PKC-alpha as a fundamental regulator of cardiac contractility and Ca2+ handling in myocytes. Hearts of Prkca-deficient mice are hypercontractile, whereas those of transgenic mice overexpressing Prkca are hypocontractile. Adenoviral gene transfer of dominant-negative or wild-type PKC-alpha into cardiac myocytes enhances or reduces contractility, respectively. Mechanistically, modulation of PKC-activity affects dephosphorylation of the sarcoplasmic reticulum Ca2+ ATPase-2 (SERCA-2) pump inhibitory protein phospholamban (PLB), and alters sarcoplasmic reticulum Ca2+ loading and the Ca2+ transient. PKC-directly phosphorylates protein phosphatase inhibitor-1 (I-1), altering the activity of protein phosphatase-1 (PP-1), which may account for the effects of PKC-alpha on PLB phosphorylation. Hypercontractility caused by Prkca deletion protects against heart failure induced by pressure overload, and against dilated cardiomyopathy induced by deleting the gene encoding muscle LIM protein (Csrp3). Deletion of Prkca also rescues cardiomyopathy associated with overexpression of PP-1. Thus, PKC-alpha functions as a nodal integrator of cardiac contractility by sensing intracellular Ca2+ and signal transduction events, which can profoundly affect propensity toward heart failure.	Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Texas SW, Dept Psychiat, Dallas, TX 75390 USA; Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA; Univ Cincinnati, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; NIA, Cardiovasc Sci Lab, Baltimore, MD 21224 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Michigan, Sect Cardiac Surg, Ann Arbor, MI 48109 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Southwestern Medical Center Dallas; University System of Ohio; University of Cincinnati; Yale University; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Indiana University System; Indiana University-Purdue University Indianapolis; University of Michigan System; University of Michigan	Molkentin, JD (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Hewett, Timothy Edwin/GLT-1556-2022; Hewett, Timothy/G-1023-2011; Lakatta, Edward G/AAL-1447-2020; Hewett, Timothy E/E-3241-2011; liggett, stephen b/E-7453-2012	Molkentin, Jeffery/0000-0002-3558-6529; Nairn, Angus/0000-0002-7075-0195; Lakatta, Edward/0000-0002-4772-0035; Westfall, Margaret/0000-0001-9491-0125; Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [5T32 HL07382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Bayer AL, 2003, MOL CELL BIOCHEM, V242, P145, DOI 10.1023/A:1021106232511; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Champion HC, 2003, CIRCULATION, V108, P2790, DOI 10.1161/01.CIR.0000096487.88897.9B; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; Hahn HS, 2003, CIRC RES, V93, P1111, DOI 10.1161/01.RES.0000105087.79373.17; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; Klein L, 2003, AM J CARDIOL, V91, p18F, DOI 10.1016/S0002-9149(02)03336-2; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; Masaki H, 1997, AM J PHYSIOL-HEART C, V272, pH606, DOI 10.1152/ajpheart.1997.272.2.H606; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Neumann J, 2002, BASIC RES CARDIOL, V97, P1; Pass JM, 2001, AM J PHYSIOL-HEART C, V281, pH2500, DOI 10.1152/ajpheart.2001.281.6.H2500; Petrashevskaya NN, 2002, CARDIOVASC RES, V54, P117, DOI 10.1016/S0008-6363(02)00241-9; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; STEENAART NAE, 1992, ARCH BIOCHEM BIOPHYS, V293, P17, DOI 10.1016/0003-9861(92)90359-5; Wang JW, 2003, AM J PHYSIOL-HEART C, V284, pH2277, DOI 10.1152/ajpheart.00142.2002; WARNERSTEVENSON L, 2003, CIRCULATION, V108, P492; Westfall MV, 2003, J BIOL CHEM, V278, P33694, DOI 10.1074/jbc.M305404200	30	457	485	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					248	254		10.1038/nm1000	http://dx.doi.org/10.1038/nm1000			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14966518				2022-12-27	WOS:000189297700035
J	Belghith, M; Bluestone, JA; Barriot, S; Megret, J; Bach, JF; Chatenoud, L				Belghith, M; Bluestone, JA; Barriot, S; Megret, J; Bach, JF; Chatenoud, L			TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; REGULATORY T-CELLS; ANTI-CD3 MONOCLONAL-ANTIBODY; CYTOKINE-RELATED SYNDROME; NOD MICE; ANTIGEN 4; TRANSPLANTATION RESPONSES; L-SELECTIN; PHASE-I; CD4(+)CD25(+)	CD3-specific antibodies have the unique capacity to restore self-tolerance in established autoimmunity. They induce long-term remission of overt diabetes in nonobese diabetic (NOD) mice and in human type I diabetes. The underlying mechanisms had been unclear until now. Here we report that treatment with CD3epsilon-specific antibodies induces transferable T-cell-mediated tolerance involving CD4(+)CD25(+) cells. However, these CD4(+)CD25(+) T cells are distinct from naturally occurring regulatory T cells that control physiological autoreactivity. CD3-specific antibody treatment induced remission in NOD Cd28(-/-) mice that were devoid of such regulatory cells. Remission of diabetes was abrogated by coadministration of a neutralizing transforming growth factor (TGF)-beta-specific antibody. The central role of TGF-beta was further suggested by its increased, long-lasting production by CD4(+) T cells from tolerant mice. These data explain the intriguing tolerogenic effect of CD3-specific antibodies and position them as the first clinically applicable pharmacological stimulant of TGF-beta-producing regulatory CD4(+) T cells.	Hop Necker Enfants Malad, IRNEM, INSERM, U580, F-75015 Paris, France; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Hop Necker Enfants Malad, Fac Necker Enfants Malad, IRNEM, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Chatenoud, L (corresponding author), Hop Necker Enfants Malad, IRNEM, INSERM, U580, 161 Rue Sevres, F-75015 Paris, France.							ABRAMOWICZ D, 1989, TRANSPLANTATION, V47, P606, DOI 10.1097/00007890-198904000-00008; ALEGRE ML, 1995, J IMMUNOL, V155, P1544; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Bach JF, 2001, ANNU REV IMMUNOL, V19, P131, DOI 10.1146/annurev.immunol.19.1.131; BOITARD C, 1989, J EXP MED, V169, P1669, DOI 10.1084/jem.169.5.1669; Bridoux F, 1997, J EXP MED, V185, P1769, DOI 10.1084/jem.185.10.1769; Chatenoud L, 1997, J IMMUNOL, V158, P2947; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; CHATENOUD L, 1982, EUR J IMMUNOL, V12, P979, DOI 10.1002/eji.1830121116; CHATENOUD L, 1991, TRANSPLANTATION, V51, P334, DOI 10.1097/00007890-199102000-00012; CHATENOUD L, 1984, IMMUNOL TODAY, V5, P20, DOI 10.1016/0167-5699(84)90061-6; Chatenoud L, 2001, IMMUNOL REV, V182, P149, DOI 10.1034/j.1600-065X.2001.1820112.x; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; FERRAN C, 1990, EUR J IMMUNOL, V20, P509, DOI 10.1002/eji.1830200308; Friend PJ, 1999, TRANSPLANTATION, V68, P1632, DOI 10.1097/00007890-199912150-00005; Graca L, 2002, J IMMUNOL, V168, P5558, DOI 10.4049/jimmunol.168.11.5558; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; HIRSCH R, 1990, TRANSPLANTATION, V49, P1117, DOI 10.1097/00007890-199006000-00018; HIRSCH R, 1988, J IMMUNOL, V140, P3766; HIRSCH R, 1989, J IMMUNOL, V142, P737; Itoh M, 1999, J IMMUNOL, V162, P5317; Lenschow DJ, 1996, IMMUNITY, V5, P285, DOI 10.1016/S1074-7613(00)80323-4; LEPAULT F, 1995, EUR J IMMUNOL, V25, P1502, DOI 10.1002/eji.1830250605; Levings MK, 2002, J EXP MED, V196, P1335, DOI 10.1084/jem.20021139; LUCAS C, 1990, J IMMUNOL, V145, P1415; Ludviksson BR, 1997, J IMMUNOL, V159, P3622; Luhder F, 1998, J EXP MED, V187, P427, DOI 10.1084/jem.187.3.427; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Papiernik M, 1998, INT IMMUNOL, V10, P371, DOI 10.1093/intimm/10.4.371; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Seddon B, 1999, J EXP MED, V189, P279, DOI 10.1084/jem.189.2.279; Simone EA, 1999, DIABETES CARE, V22, pB7; Stephens LA, 2000, J IMMUNOL, V165, P3105, DOI 10.4049/jimmunol.165.6.3105; SuriPayer E, 1996, J IMMUNOL, V157, P1799; Szanya V, 2002, J IMMUNOL, V169, P2461, DOI 10.4049/jimmunol.169.5.2461; Takahashi T, 1998, INT IMMUNOL, V10, P1969, DOI 10.1093/intimm/10.12.1969; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang B, 1998, DIABETES, V47, P1207, DOI 10.2337/diabetes.47.8.1207; Woodle ES, 1999, TRANSPLANTATION, V68, P608, DOI 10.1097/00007890-199909150-00003; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325	46	481	513	1	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1202	1208		10.1038/nm924	http://dx.doi.org/10.1038/nm924			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12937416				2022-12-27	WOS:000185061600034
J	Samlowski, WE; Petersen, R; Cuzzocrea, S; Macarthur, H; Burton, D; McGregor, JR; Salvemini, D				Samlowski, WE; Petersen, R; Cuzzocrea, S; Macarthur, H; Burton, D; McGregor, JR; Salvemini, D			A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects	NATURE MEDICINE			English	Article							ACTIVATED KILLER-CELLS; NATURAL-KILLER; RECOMBINANT INTERLEUKIN-2; PERITONEAL-MACROPHAGES; NK CELLS; IN-VITRO; INTERFERON; HISTAMINE; CATECHOLAMINES; IMMUNOTHERAPY	Interleukin-2 (IL-2) is used to treat metastatic renal cell carcinoma and malignant melanoma, but its use is limited by the severe hypotension it produces. We have shown here that M40403, a superoxide dismutase (SOD) mimetic, blocked IL-2-induced hypotension and allowed the dose of IL-2 to be increased in mice. The reversal of IL-2-mediated hypotension was associated with an increase in plasma catecholamines. In addition, M40403 increased lymphokine-activated killer (LAK) cell cytotoxicity in vitro and in vivo, through inhibition of macrophage superoxide production. Treatment of methylcholanthrene-induced (Meth A) ascites tumors with IL-2 and 3 mg per kg body weight M40403 induced 50% complete remissions lasting for more than 200 d, which was longer than those of untreated mice (15-d median survival) or mice treated with IL-2 alone (22-d median). Growth of subcutaneous implants of RENCA renal carcinoma was also inhibited by the combination of IL-2 and M40403. These results established that M40403 prevented IL-2 from causing dose-limiting hypotension, while enhancing its anticancer activity.	MetaPhore Pharmaceut, Dept Biol & Pharmacol Res, St Louis, MO 63114 USA; Univ Utah, Huntsman Canc Inst, Melanoma Program, Salt Lake City, UT 84112 USA; Univ Messina, Inst Pharmacol, I-98100 Messina, Italy; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Messina; Saint Louis University	Salvemini, D (corresponding author), MetaPhore Pharmaceut, Dept Biol & Pharmacol Res, 1910 Innerbelt Business Ctr Dr, St Louis, MO 63114 USA.	dsalvemini@metaphore.com		Samlowski, Wolfram/0000-0002-0713-914X	NCI NIH HHS [R43-CA933203] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker JC, 1996, J EXP MED, V183, P2361, DOI 10.1084/jem.183.5.2361; BINDOLI A, 1992, FREE RADICAL BIO MED, V13, P391, DOI 10.1016/0891-5849(92)90182-G; BISHOP DK, 1989, TRANSPLANTATION, V47, P671, DOI 10.1097/00007890-198904000-00020; BRUNDA MJ, 1987, INT J CANCER, V40, P365, DOI 10.1002/ijc.2910400314; DOHLSTEN M, 1986, SCAND J IMMUNOL, V24, P49, DOI 10.1111/j.1365-3083.1986.tb02069.x; ETTINGHAUSEN SE, 1986, CANCER RES, V46, P2784; ETTINGHAUSEN SE, 1988, JNCI-J NATL CANCER I, V80, P177, DOI 10.1093/jnci/80.3.177; FAGGIONI R, 1994, J IMMUNOTHER, V15, P194, DOI 10.1097/00002371-199404000-00005; Fisher RI, 1997, CANCER J SCI AM, V3, pS70; GAYNOR ER, 1988, ANN INTERN MED, V109, P953, DOI 10.7326/0003-4819-109-12-953; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; GRIMM EA, 1985, CELL IMMUNOL, V94, P568, DOI 10.1016/0008-8749(85)90280-1; Hansson M, 1996, J IMMUNOL, V156, P42; HARKER WG, 1990, CANCER RES, V50, P5931; HELLSTRAND K, 1987, J IMMUNOL, V139, P869; HELLSTRAND K, 1986, J IMMUNOL, V137, P656; HELLSTRAND K, 1990, INT ARCH ALLER A IMM, V92, P379, DOI 10.1159/000235169; Hellstrand K, 1997, SCAND J CLIN LAB INV, V57, P193, DOI 10.3109/00365519709060027; HELLSTRAND K, 1994, J LEUKOCYTE BIOL, V55, P392, DOI 10.1002/jlb.55.3.392; JOHNSTON RB, 1978, J EXP MED, V148, P115; Kono K, 1996, EUR J IMMUNOL, V26, P1308, DOI 10.1002/eji.1830260620; Kwak JY, 1998, CELL IMMUNOL, V188, P33, DOI 10.1006/cimm.1998.1337; LANIER LL, 1986, J IMMUNOL, V136, P4480; LEE RE, 1989, J CLIN ONCOL, V7, P7, DOI 10.1200/JCO.1989.7.1.7; LINDEN O, 1987, SCAND J IMMUNOL, V26, P223, DOI 10.1111/j.1365-3083.1987.tb02255.x; Macarthur H, 2000, P NATL ACAD SCI USA, V97, P9753, DOI 10.1073/pnas.97.17.9753; MANN H, 1990, RADIOLOGY, V176, P191, DOI 10.1148/radiology.176.1.2353090; MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; MERTELSMANN R, 1986, IMMUNOBIOLOGY, V172, P400, DOI 10.1016/S0171-2985(86)80121-8; Moulian N, 2001, BLOOD, V97, P3521, DOI 10.1182/blood.V97.11.3521; OGNIBENE FP, 1988, CHEST, V94, P750, DOI 10.1378/chest.94.4.750; PABST MJ, 1980, J EXP MED, V151, P101, DOI 10.1084/jem.151.1.101; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; Salvemini D, 1999, SCIENCE, V286, P304, DOI 10.1126/science.286.5438.304; Samlowski WE, 1995, J IMMUNOTHER, V18, P166, DOI 10.1097/00002371-199510000-00004; Samlowski WE, 2001, PROG INFLAM RES, P249; SEAMAN WE, 1982, J CLIN INVEST, V69, P876, DOI 10.1172/JCI110527; SEAMAN WE, 1981, J CLIN INVEST, V67, P1324, DOI 10.1172/JCI110161; SIEGEL JP, 1991, J CLIN ONCOL, V9, P694, DOI 10.1200/JCO.1991.9.4.694; SUZUKI K, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1176; Uotila P, 1996, CANCER IMMUNOL IMMUN, V43, P1; Weiss Arthur, 1993, P467; YIM CY, 1995, J IMMUNOL, V155, P4382	44	61	74	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					750	755		10.1038/nm874	http://dx.doi.org/10.1038/nm874			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12730689				2022-12-27	WOS:000183444100031
J	Sleeman, MW; Wortley, KE; Lai, KMV; Gowen, LC; Kintner, J; Kline, WO; Garcia, K; Stitt, TN; Yancopoulos, GD; Wiegand, SJ; Glass, DJ				Sleeman, MW; Wortley, KE; Lai, KMV; Gowen, LC; Kintner, J; Kline, WO; Garcia, K; Stitt, TN; Yancopoulos, GD; Wiegand, SJ; Glass, DJ			Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity	NATURE MEDICINE			English	Article							PROTEIN-KINASE-B; INSULIN SENSITIVITY; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; GLUT4 TRANSLOCATION; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; PLASMA MEMBRANE; MICE LACKING; SH2 DOMAIN; ACTIVATION	Genetic ablation of Inppl1, which encodes SHIP2 (SH2-domain containing inositol 5-phosphatase 2), was previously reported to induce severe insulin sensitivity, leading to early postnatal death. In the previous study, the targeting construct left the first eighteen exons encoding Inppl1 intact, generating a Inppl1(EX19-28-/-) mouse, and apparently also deleted a second gene, Phox2a. We report a new SHIP2 knockout (Inppl1(-/-)) targeted to the translation-initiating ATG, which is null for Inppl1 mRNA and protein. Inppl1(-/-) mice are viable, have normal glucose and insulin levels, and normal insulin and glucose tolerances. The Inppl1(-/-) mice are, however, highly resistant to weight gain when placed on a high-fat diet. These results suggest that inhibition of SHIP2 would be useful in the effort to ameliorate diet-induced obesity, but call into question a dominant role of SHIP2 in modulating glucose homeostasis.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Regeneron	Glass, DJ (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	david.glass@regeneron.com	Glass, David/AAI-3910-2021	Morton, Lori/0000-0002-5214-5784				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clement S, 2004, NATURE, V431, P878, DOI 10.1038/nature03003; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; CUATRECASAS P, 1971, J BIOL CHEM, V246, P7265; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREYCHET P, 1971, P NATL ACAD SCI USA, V68, P1833, DOI 10.1073/pnas.68.8.1833; HADARI YR, 1992, J BIOL CHEM, V267, P17483; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; Hill MM, 1999, MOL CELL BIOL, V19, P7771; HOUSE PDR, 1970, BIOCHEM BIOPH RES CO, V41, P541, DOI 10.1016/0006-291X(70)90046-X; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Liu L, 1997, J BIOL CHEM, V272, P8983; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sakoda H, 2003, J BIOL CHEM, V278, P25802, DOI 10.1074/jbc.M301127200; Sleeman MW, 2003, P NATL ACAD SCI USA, V100, P14297, DOI 10.1073/pnas.2335926100; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	40	194	203	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					199	205		10.1038/nm1178	http://dx.doi.org/10.1038/nm1178			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15654325				2022-12-27	WOS:000226797300028
J	Insinga, A; Monestiroli, S; Ronzoni, S; Gelmetti, V; Marchesi, F; Viale, A; Altucci, L; Nervi, C; Minucci, S; Pelicci, PG				Insinga, A; Monestiroli, S; Ronzoni, S; Gelmetti, V; Marchesi, F; Viale, A; Altucci, L; Nervi, C; Minucci, S; Pelicci, PG			Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ONCOGENIC TRANSCRIPTION FACTOR; RAR-ALPHA; FUSION PROTEINS; DECOY RECEPTORS; DIFFERENTIATION; TARGET; CANCER; EXPRESSION	Histone deacetylases (HDACs) regulate transcription and specific cellular functions, such as tumor suppression by p53, and are frequently altered in cancer(1-4). Inhibitors of HDACs (HDACIs) possess antitumor activity and are well tolerated, supporting the idea that their use might develop as a specific strategy for cancer treatment. The molecular basis for their selective antitumor activity is, however, unknown. We investigated the effects of HDACIs on leukemias expressing the PML-RAR or AML1-ETO oncoproteins, known to initiate leukemogenesis through deregulation of HDACs. Here we report that: (i) HDACIs induce apoptosis of leukemic blasts, although oncogene expression is not sufficient to confer HDACI sensitivity to normal cells; (ii) apoptosis is p53 independent and depends, both in vitro and in vivo, upon activation of the death receptor pathway (TRAIL and Fas signaling pathways); (iii) TRAIL, DR5, FasL and Fas are upregulated by HDACIs in the leukemic cells, but not in normal hematopoietic progenitors. These results show that sensitivity to HDACIs in leukemias is a property of the fully transformed phenotype and depends on activation of a specific death pathway.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; IFOM FIRC Inst, I-20139 Milan, Italy; San Raffaele Biomed Sci Pk Rome, I-00161 Rome, Italy; Univ Milan, Dept Vet Pathol, I-20133 Milan, Italy; Univ Naples, Dept Pathol, I-80138 Naples, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of Milan; University of Naples Federico II	Minucci, S (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	saverio.minucci@ifom-ieo-campus.it; piergiuseppe.pelicci@ifom-ieo-campus.it	Insinga, Alessandra/AAR-9551-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Minucci, Saverio/J-9669-2012; Ronzoni, Simona/AAQ-1669-2020; Altucci, Lucia/S-8031-2019; Marchesi, Francesco/ABF-9255-2021	Marchesi, Francesco/0000-0003-1179-5788; altucci, lucia/0000-0002-7312-5387; NERVI, Clara/0000-0001-9341-0188; Insinga, Alessandra/0000-0002-6060-8339				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Ferrara FF, 2001, CANCER RES, V61, P2; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Westervelt P, 2003, BLOOD, V102, P1857, DOI 10.1182/blood-2002-12-3779; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	25	456	475	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					71	76		10.1038/nm1160	http://dx.doi.org/10.1038/nm1160			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619634				2022-12-27	WOS:000226124900035
J	Nebbioso, A; Clarke, N; Voltz, E; Germain, E; Ambrosino, C; Bontempo, P; Alvarez, R; Schiavone, EM; Ferrara, F; Bresciani, F; Weisz, A; de Lera, AR; Gronemeyer, H; Altucci, L				Nebbioso, A; Clarke, N; Voltz, E; Germain, E; Ambrosino, C; Bontempo, P; Alvarez, R; Schiavone, EM; Ferrara, F; Bresciani, F; Weisz, A; de Lera, AR; Gronemeyer, H; Altucci, L			Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells	NATURE MEDICINE			English	Article							HISTONE-DEACETYLASE INHIBITORS; DEATH LIGAND TRAIL; IN-VIVO; GENE-EXPRESSION; VALPROIC ACID; DIFFERENTIATION; APOPTOSIS; CANCER; TRANSCRIPTION; SP3	Chromatin is a dynamic macromolecular structure epigenetically modified to regulate specific gene expression. Altered chromatin function can lead to aberrant expression of growth regulators and may, ultimately, cause cancer. That many human diseases have epigenetic etiology has stimulated the development of 'epigenetic' therapies. Inhibitors of histone deacetylases (HDACIs) induce proliferation arrest, maturation and apoptosis of cancer cells, but not normal cells, in vitro and in vivo, and are currently being tested in clinical trials(1-5). We investigated the mechanism(s) underlying this tumor selectivity. We report that HDACIs induce, in addition to p21, expression of TRAIL (Apo2L, TNFSF10) by directly activating the TNFSF10 promoter, thereby triggering tumor-selective death signaling in acute myeloid leukemia (AML) cells and the blasts of individuals with AML. RNA interference revealed that the induction of p21, TRAIL and differentiation are separable activities of HDACIs. HDACIs induced proliferation arrest, TRAIL-mediated apoptosis and suppression of AML blast clonogenicity irrespective of French-American- British (FAB) classification status, karyotype and immunophenotype. No apoptosis was seen in normal CD34(+) progenitor cells. Our results identify TRAIL as a mediator of the anticancer action of HDACIs.	Seconda Univ Studi Napoli, Dipartimento Patol Gen, I-80138 Naples, Italy; IGBMC, CNRS, INSERM, ULP,Dept Cell Biol & Signal Transduct, F-67404 Illkirch Graffenstaden, CU De Strasbour, France; Univ Vigo, Dept Quim Organ, Fac Ciencias, Vigo, Spain; Osped Antonio Cardarelli, I-80131 Naples, Italy	Universita della Campania Vanvitelli; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universidade de Vigo; Antonio Cardarelli Hospital	Gronemeyer, H (corresponding author), Seconda Univ Studi Napoli, Dipartimento Patol Gen, Vico Luigi de Crecchio 7, I-80138 Naples, Italy.	hg@igbmc.u-strasbg.fr; lucia.altucci@unina2.it	ambrosino, concetta/AAB-3452-2019; Emmanuelle, germain/D-8159-2015; Weisz, Alessandro/A-1317-2014; Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/H-7002-2016; Altucci, Lucia/S-8031-2019; NEBBIOSO, ANGELA/GVS-1294-2022; Garcia, Jose M Esteban/B-7691-2008; Rodríguez, Rosana Alvarez/AAA-1998-2019; Gronemeyer, Hinrich/AAH-5575-2019; germain, Emmanuelle/U-8127-2018; NEBBIOSO, Angela/C-3566-2016	Weisz, Alessandro/0000-0003-0455-2083; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Rodríguez, Rosana Alvarez/0000-0001-5608-7561; Gronemeyer, Hinrich/0000-0001-9454-2449; germain, Emmanuelle/0000-0003-0552-7357; Clarke, Nicole/0000-0002-2770-3289; altucci, lucia/0000-0002-7312-5387; Rodriguez de Lera, Angel/0000-0001-6896-9078; NEBBIOSO, Angela/0000-0001-5374-3527; BONTEMPO, Paola/0000-0002-9834-229X				Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Amin HM, 2001, BRIT J HAEMATOL, V115, P287, DOI 10.1046/j.1365-2141.2001.03123.x; Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ferrara FF, 2001, CANCER RES, V61, P2; Glaser KB, 2003, MOL CANCER THER, V2, P151; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Litwack G, 2004, VITAM HORM, V67, P1; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Rosato RR, 2003, CANCER RES, V63, P3637; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Shiohara M, 1999, BLOOD, V93, P2057, DOI 10.1182/blood.V93.6.2057.406k04_2057_2066; Suzuki T, 1999, J MED CHEM, V42, P3001, DOI 10.1021/jm980565u; Vigushin DM, 2004, CURR CANCER DRUG TAR, V4, P205, DOI 10.2174/1568009043481560; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200	30	442	469	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					77	84		10.1038/nm1161	http://dx.doi.org/10.1038/nm1161			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619633				2022-12-27	WOS:000226124900036
J	Petrova, TV; Karpanen, T; Norrmen, C; Mellor, R; Tamakoshi, T; Finegold, D; Ferrell, R; Kerjaschki, D; Mortimer, P; Yla-Herttuala, S; Miura, N; Alitalo, K				Petrova, TV; Karpanen, T; Norrmen, C; Mellor, R; Tamakoshi, T; Finegold, D; Ferrell, R; Kerjaschki, D; Mortimer, P; Yla-Herttuala, S; Miura, N; Alitalo, K			Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis	NATURE MEDICINE			English	Article							HELIX TRANSCRIPTION FACTORS; SMOOTH-MUSCLE-CELLS; HEREDITARY LYMPHEDEMA; ENDOTHELIAL-CELLS; CARDIOVASCULAR DEVELOPMENT; TYROSINE KINASE; FOXC2 MUTATIONS; GENE-THERAPY; PDGF-B; ANGIOGENESIS	Lymphatic vessels are essential for the removal of interstitial fluid and prevention of tissue edema. Lymphatic capillaries lack associated mural cells, and collecting lymphatic vessels have valves, which prevent lymph backflow. In lymphedema-distichiasis (LD), lymphatic vessel function fails because of mutations affecting the forkhead transcription factor FOXC2. We report that Foxc2(-/-) mice show abnormal lymphatic vascular patterning, increased pericyte investment of lymphatic vessels, agenesis of valves and lymphatic dysfunction. In addition, an abnormally large proportion of skin lymphatic vessels was covered with smooth muscle cells in individuals with LD and in mice heterozygous for Foxc2 and for the gene encoding lymphatic endothelial receptor, Vegfr3 ( also known as Flt4). Our data show that Foxc2 is essential for the morphogenesis of lymphatic valves and the establishment of a pericyte-free lymphatic capillary network and that it cooperates with Vegfr3 in the latter process. Our results indicate that an abnormal interaction between the lymphatic endothelial cells and pericytes, as well as valve defects, underlie the pathogenesis of LD.	Biomedicum Helsinki, Mol Canc Biol Lab, Helsinki 00014, Finland; Biomedicum Helsinki, Ludwig Inst Canc Res, Helsinki 00014, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; St George Hosp, Sch Med, Dermatol Unit, London SW17 0RE, England; Hamamatsu Univ Sch Med, Dept Biochem, Hamamatsu, Shizuoka 4313192, Japan; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Vienna, Sch Med, Dept Pathol, A-1090 Vienna, Austria; Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; St Georges University London; Hamamatsu University School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Vienna; University of Eastern Finland	Alitalo, K (corresponding author), Biomedicum Helsinki, Mol Canc Biol Lab, Haartmaninkatu 8,POB 63, Helsinki 00014, Finland.	kari.alitalo@helsinki.fi	Norrmen, Camilla/B-6406-2016; Alitalo, Kari K/J-5013-2014	Norrmen, Camilla/0000-0001-9045-8864; Alitalo, Kari K/0000-0002-7331-0902; Yla-Herttuala, Seppo/0000-0001-7593-2708; Finegold, David/0000-0001-9901-2578; Karpanen, Terhi/0000-0002-2803-083X				Bell R, 2001, HUM GENET, V108, P546, DOI 10.1007/s004390100528; Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; Brice G, 2002, J MED GENET, V39, P478, DOI 10.1136/jmg.39.7.478; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Fang JM, 2000, AM J HUM GENET, V67, P1382, DOI 10.1086/316915; Finegold DN, 2001, HUM MOL GENET, V10, P1185, DOI 10.1093/hmg/10.11.1185; Furumoto T, 1999, DEV BIOL, V210, P15, DOI 10.1006/dbio.1999.9261; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; GNEPP DR, 1980, LYMPHOLOGY, V13, P91; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; Iida K, 1997, DEVELOPMENT, V124, P4627; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Irrthum A, 2003, AM J HUM GENET, V72, P1470, DOI 10.1086/375614; Kaestner KH, 1996, DEVELOPMENT, V122, P1751; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Kriederman BM, 2003, HUM MOL GENET, V12, P1179, DOI 10.1093/hmg/ddg123; Kume T, 2000, DEVELOPMENT, V127, P1387; Kume T, 2001, GENE DEV, V15, P2470, DOI 10.1101/gad.907301; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Miura N, 1997, GENOMICS, V41, P489, DOI 10.1006/geno.1997.4695; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; SURI C, 1996, CELL, V87, P1161; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; VAJDA J, 1971, ACTA ANAT, V78, P521; Veikkola T, 2003, FASEB J, V17, P2006, DOI 10.1096/fj.03-0179com; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; WILKINSON DG, 1998, IN SITU HYBRIDIZATIO; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Winnier GE, 1999, DEV BIOL, V213, P418, DOI 10.1006/dbio.1999.9382; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yang X, 1999, DEVELOPMENT, V126, P1571; Yanga XL, 2000, FEBS LETT, V470, P29, DOI 10.1016/S0014-5793(00)01285-0	51	424	436	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2004	10	9					974	981		10.1038/nm1094	http://dx.doi.org/10.1038/nm1094			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15322537				2022-12-27	WOS:000223658400035
J	Araki, T; Mohi, MG; Ismat, FA; Bronson, RT; Williams, IR; Kutok, JL; Yang, WT; Pao, LI; Gilliland, DG; Epstein, JA; Neel, BG				Araki, T; Mohi, MG; Ismat, FA; Bronson, RT; Williams, IR; Kutok, JL; Yang, WT; Pao, LI; Gilliland, DG; Epstein, JA; Neel, BG			Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation	NATURE MEDICINE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; JUVENILE MYELOMONOCYTIC LEUKEMIA; GENOTYPE-PHENOTYPE CORRELATION; MYELOPROLIFERATIVE DISORDER; TURNER-PHENOTYPE; GROWTH-FACTOR; ACTIVATION; HEART; SHP-2; ABNORMALITIES	Noonan syndrome is a common human autosomal dominant birth defect, characterized by short stature, facial abnormalities, heart defects and possibly increased risk of leukemia. Mutations of Ptpn11 ( also known as Shp2), which encodes the protein-tyrosine phosphatase Shp2, occur in similar to50% of individuals with Noonan syndrome, but their molecular, cellular and developmental effects, and the relationship between Noonan syndrome and leukemia, are unclear. We generated mice expressing the Noonan syndrome - associated mutant D61G. When homozygous, the D61G mutant is embryonic lethal, whereas heterozygotes have decreased viability. Surviving Ptpn11(D61G/+) embryos (similar to 50%) have short stature, craniofacial abnormalities similar to those in Noonan syndrome, and myeloproliferative disease. Severely affected Ptpn11(D61G/+) embryos (similar to50%) have multiple cardiac defects similar to those in mice lacking the Ras-GAP protein neurofibromin. Their endocardial cushions have increased Erk activation, but Erk hyperactivation is cell and pathway specific. Our results clarify the relationship between Noonan syndrome and leukemia and show that a single Ptpn11 gain-of-function mutation evokes all major features of Noonan syndrome by acting on multiple developmental lineages in a gene dosage - dependent and pathway-selective manner.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Hematol Oncol,Canc Biol Program, Boston, MA 02215 USA; Childrens Hosp Philadelphia, Dept Pediat, Div Cardiol, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Rodent Histopathol Core, Boston, MA 02115 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol Oncol, Boston, MA 02215 USA; Univ Penn Hlth Syst, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Harvard Medical School; Emory University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Pennsylvania	Araki, T (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Hematol Oncol,Canc Biol Program, NRB1038,330 Brookline Ave, Boston, MA 02215 USA.	taraki@bidmc.harvard.edu	Ismat, Fraz Ahmed/AAG-7470-2019; Williams, Ifor R/D-3648-2011	Williams, Ifor R/0000-0002-8810-2911; Ismat, Fraz/0000-0002-2172-146X; Araki, Toshiyuki/0000-0002-1179-4534	NCI NIH HHS [T32CA81156, R01 CA49152] Funding Source: Medline; NHLBI NIH HHS [HL61475, T32HL007915, R01 HL62974] Funding Source: Medline; NIDDK NIH HHS [DK66600, P01 DK50654, DK 64399, R01 DK64730] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA081156, R01CA049152] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062974, R01HL061475, T32HL007915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654, R01DK066600, R01DK064730, R24DK064399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED ML, 1991, ACTA PAEDIATR SCAND, V80, P446, DOI 10.1111/j.1651-2227.1991.tb11880.x; ALLANSON JE, 1987, J MED GENET, V24, P9, DOI 10.1136/jmg.24.1.9; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; BaderMeunier B, 1997, J PEDIATR-US, V130, P885, DOI 10.1016/S0022-3476(97)70273-7; Bahuau M, 1996, AM J MED GENET, V66, P347, DOI 10.1002/(SICI)1096-8628(19961218)66:3<347::AID-AJMG20>3.0.CO;2-L; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Bertola D R, 2000, Arq Bras Cardiol, V75, P409, DOI 10.1590/S0066-782X2000001100005; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Corson LB, 2003, DEVELOPMENT, V130, P4527, DOI 10.1242/dev.00669; COULY GF, 1993, DEVELOPMENT, V117, P409; Dieterlen-Lievre F, 1998, CURR BIOL, V8, pR727, DOI 10.1016/S0960-9822(98)70460-9; Digilio MC, 1998, AM J MED GENET, V80, P160, DOI 10.1002/(SICI)1096-8628(19981102)80:2<160::AID-AJMG13>3.0.CO;2-A; Epstein J A, 2001, Trends Genet, V17, pS13, DOI 10.1016/S0168-9525(01)02450-7; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gitler AD, 2004, PEDIATR RES, V55, P581, DOI 10.1203/01.PDR.0000113462.98851.2E; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOHANNES JM, 1995, PEDIATR HEMAT ONCOL, V12, P571, DOI 10.3109/08880019509030771; Kapoor GS, 2004, MOL CELL BIOL, V24, P823, DOI 10.1128/MCB.24.2.823-836.2004; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kontges G, 1996, DEVELOPMENT, V122, P3229; Kosaki K, 2002, J CLIN ENDOCR METAB, V87, P3529, DOI 10.1210/jc.87.8.3529; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Maheshwari M, 2002, HUM MUTAT, V20, P298, DOI 10.1002/humu.10129; MARINO B, 1995, EUR J PEDIATR, V154, P949, DOI 10.1007/BF01958636; Marino B, 1999, J PEDIATR-US, V135, P703, DOI 10.1016/S0022-3476(99)70088-0; Musante L, 2003, EUR J HUM GENET, V11, P201, DOI 10.1038/sj.ejhg.5200935; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOONAN JA, 1994, CLIN PEDIATR, V33, P548, DOI 10.1177/000992289403300907; NOONAN JA, 1968, AM J DIS CHILD, V116, P373, DOI 10.1001/archpedi.1968.02100020377005; NORA JJ, 1974, AM J DIS CHILD, V127, P48, DOI 10.1001/archpedi.1974.02110200050007; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Sarkozy A, 2003, J MED GENET, V40, P704, DOI 10.1136/jmg.40.9.704; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Side LE, 1997, J PEDIATR-US, V130, P857; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	50	322	339	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					849	857		10.1038/nm1084	http://dx.doi.org/10.1038/nm1084			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15273746				2022-12-27	WOS:000223055700040
J	Demjen, D; Klussmann, S; Kleber, S; Zuliani, C; Stieltjes, B; Metzger, C; Hirt, UA; Walczak, H; Falk, W; Essig, M; Edler, L; Krammer, PH; Martin-Villalba, A				Demjen, D; Klussmann, S; Kleber, S; Zuliani, C; Stieltjes, B; Metzger, C; Hirt, UA; Walczak, H; Falk, W; Essig, M; Edler, L; Krammer, PH; Martin-Villalba, A			Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury	NATURE MEDICINE			English	Article							SIGNALING COMPLEX DISC; KAPPA-B ACTIVATION; DEFICIENT MICE; CELL-DEATH; TNF-ALPHA; AXONAL REGENERATION; NEURITE GROWTH; FAS; RATS; EXPRESSION	The clinical outcome of spinal cord injury (SCI) depends in part on the extent of secondary damage, to which apoptosis contributes. The CD95 and tumor necrosis factor (TNF) ligand/receptor systems play an essential role in various apoptotic mechanisms. To determine the involvement of these ligands in SCI-induced damage, we neutralized the activity of CD95 ligand (CD95L) and/or TNF in spinal cord-injured mice. Therapeutic neutralization of CD95L, but not of TNF, significantly decreased apoptotic cell death after SCI. Mice treated with CD95L-specific antibodies were capable of initiating active hind-limb movements several weeks after injury. The improvement in locomotor performance was mirrored by an increase in regenerating fibers and upregulation of growth-associated protein-43 (GAP-43). Thus, neutralization of CD95L promoted axonal regeneration and functional improvement in injured adult animals. This therapeutic strategy may constitute a potent future treatment for human spinal injury.	German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Radiol, D-69120 Heidelberg, Germany; Apogenix Biotechnol AG, D-69120 Heidelberg, Germany; Dept Internal Med 1, D-93053 Regensburg, Germany; German Canc Res Ctr, Biostat Unit, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Martin-Villalba, A (corresponding author), German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany.	a.martin-villalba@dkfz.de	Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591; essig, marco/0000-0002-7964-2297; Martin-Villalba, Ana/0000-0002-9405-8910				BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Becher B, 1998, NEUROSCIENCE, V84, P627, DOI 10.1016/S0306-4522(97)00455-7; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brosamle C, 2000, J NEUROSCI, V20, P8061; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Dong HX, 2003, J NEUROSCI, V23, P8682; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; Fernandes KJL, 1999, J COMP NEUROL, V414, P495, DOI 10.1002/(SICI)1096-9861(19991129)414:4<495::AID-CNE6>3.0.CO;2-S; Fournier AE, 1997, J NEUROSCI, V17, P4623; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Grill RJ, 1997, EXP NEUROL, V148, P444, DOI 10.1006/exnr.1997.6704; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li GL, 2000, ACTA NEUROPATHOL, V100, P75, DOI 10.1007/s004010051195; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li WP, 2002, J NEUROSCI RES, V69, P189, DOI 10.1002/jnr.10285; Lindenlaub T, 2000, BRAIN RES, V866, P15, DOI 10.1016/S0006-8993(00)02190-9; Lindsey AE, 2000, NEUROREHAB NEURAL RE, V14, P287, DOI 10.1177/154596830001400405; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Ozawa H, 2002, EXP NEUROL, V177, P306, DOI 10.1006/exnr.2002.7998; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Rossignol Serge, 1994, Current Opinion in Neurobiology, V4, P894, DOI 10.1016/0959-4388(94)90139-2; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shackelford DA, 1996, J NEUROCHEM, V66, P286; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Ugolini G, 2003, J NEUROSCI, V23, P8526; Woolf C J, 1994, Drugs, V47 Suppl 5, P1, DOI 10.2165/00003495-199400475-00003; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257	49	162	176	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					389	395		10.1038/nm1007	http://dx.doi.org/10.1038/nm1007			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15004554				2022-12-27	WOS:000220587000030
J	Avecilla, ST; Hattori, K; Heissig, B; Tejada, R; Liao, F; Shido, K; Jin, DK; Dias, S; Zhang, F; Hartman, TE; Hackett, NR; Crystal, RG; Witte, L; Hicklin, DJ; Bohlen, P; Eaton, D; Lyden, D; de Sauvage, F; Rafii, S				Avecilla, ST; Hattori, K; Heissig, B; Tejada, R; Liao, F; Shido, K; Jin, DK; Dias, S; Zhang, F; Hartman, TE; Hackett, NR; Crystal, RG; Witte, L; Hicklin, DJ; Bohlen, P; Eaton, D; Lyden, D; de Sauvage, F; Rafii, S			Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis	NATURE MEDICINE			English	Article							RECOMBINANT HUMAN THROMBOPOIETIN; MPL-DEFICIENT MICE; MICROVASCULAR ENDOTHELIAL-CELLS; PLATELET PRODUCTION; GROWTH-FACTOR; IN-VIVO; MEGAKARYOCYTIC PROGENITORS; RESIDUAL MEGAKARYOCYTE; RECEPTOR CXCR4; KIT-LIGAND	The molecular pathways involved in the differentiation of hematopoietic progenitors are unknown. Here we report that chemokine-mediated interactions of megakaryocyte progenitors with sinusoidal bone marrow endothelial cells (BMECs) promote thrombopoietin (TPO)-independent platelet production. Megakaryocyte-active cytokines, including interleukin-6 (IL-6) and IL-11, did not induce platelet production in thrombocytopenic, TPO-deficient (Thpo(-/-)) or TPO receptor-deficient (Mpl(-/-)) mice. In contrast, megakaryocyte-active chemokines, including stromal-derived factor-1 (SDF-1) and fibroblast growth factor-4 (FGF-4), restored thrombopoiesis in Thpo(-/-) and Mpl(-/-) mice. FGF-4 and SDF-1 enhanced vascular cell adhesion molecule- 1 (VCAM-1)- and very late antigen-4 (VLA-4)-mediated localization of CXCR4(+) megakaryocyte progenitors to the vascular niche, promoting survival, maturation and platelet release. Disruption of the vascular niche or interference with megakaryocyte motility inhibited thrombopoiesis under physiological conditions and after myelosuppression. SDF-1 and FGF-4 diminished thrombocytopenia after myelosuppression. These data suggest that TPO supports progenitor cell expansion, whereas chemokine-mediated interaction of progenitors with the bone marrow vascular niche allows the progenitors to relocate to a microenvironment that is permissive and instructive for megakaryocyte maturation and thrombopoiesis. Progenitor-active chemokines offer a new strategy to restore hematopoiesis in a clinical setting.	Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; ImClone Syst, New York, NY 10014 USA; Genentech Inc, San Francisco, CA 94404 USA; Cornell Univ, Coll Med, Dept Med Genet, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Pediat, New York, NY 10021 USA; Cornell Univ, Coll Med, Childrens Blood Fdn Labs, New York, NY 10021 USA	Cornell University; Eli Lilly; Roche Holding; Genentech; Cornell University; Cornell University; Cornell University	Rafii, S (corresponding author), Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, 1300 York Ave, New York, NY 10021 USA.		Avecilla, Scott/AAR-5873-2021; Heissig, Beate/AAF-6771-2021; Dias, Sergio/L-1250-2014	Avecilla, Scott/0000-0003-0661-9704; Heissig, Beate/0000-0002-0348-5934; Dias, Sergio/0000-0002-7603-4616; Hartman, Travis/0000-0002-3926-6928	NCI NIH HHS [R01-CA-98234] Funding Source: Medline; NHLBI NIH HHS [HL67839, HL66592, R01 HL61849, HL59312] Funding Source: Medline; NIGMS NIH HHS [T32 GM007739, GM07739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098234] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067839, P50HL059312, P01HL059312, R01HL061849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlmeidaPorada G, 1996, J LAB CLIN MED, V128, P399, DOI 10.1016/S0022-2143(96)80012-6; AVRAHAM H, 1992, BLOOD, V80, P1679; AVRAHAM H, 1993, J CLIN INVEST, V91, P2378, DOI 10.1172/JCI116470; AVRAHAM H, 1994, BLOOD, V83, P2126; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Bunting S, 1997, BLOOD, V90, P3423, DOI 10.1182/blood.V90.9.3423; Casella I, 2003, BLOOD, V101, P1316, DOI 10.1182/blood-2002-07-2184; Chen Q, 1998, Stem Cells, V16 Suppl 2, P31; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Delehanty LL, 2003, BLOOD, V101, P1744, DOI 10.1182/blood-2002-04-1278; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; deSauvage FJ, 1996, J EXP MED, V183, P651, DOI 10.1084/jem.183.2.651; Forster R, 1998, J IMMUNOL, V160, P1522; Gainsford T, 1998, BLOOD, V91, P2745, DOI 10.1182/blood.V91.8.2745.2745_2745_2752; Gainsford T, 2000, BLOOD, V95, P528, DOI 10.1182/blood.V95.2.528; GUMEY AL, 1996, STEM CELLS S1, V14, P116; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Hamada T, 1998, J EXP MED, V188, P539, DOI 10.1084/jem.188.3.539; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Kuter DJ, 2002, BLOOD, V100, P3457, DOI 10.1182/blood.V100.10.3457; Kuter DJ, 2002, TRANSFUSION, V42, P279, DOI 10.1046/j.1537-2995.2002.00056.x; KUTER DJ, 1994, P NATL ACAD SCI USA, V91, P11104, DOI 10.1073/pnas.91.23.11104; Lane WJ, 2000, BLOOD, V96, P4152; Levin J, 2001, BLOOD, V98, P1019, DOI 10.1182/blood.V98.4.1019; Liao F, 2002, CANCER RES, V62, P2567; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Majka M, 2000, BLOOD, V96, P4142, DOI 10.1182/blood.V96.13.4142.h8004142_4142_4151; MASEK LC, 1994, EXP HEMATOL, V22, P1203; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Mossuz P, 1997, BRIT J HAEMATOL, V98, P819, DOI 10.1046/j.1365-2141.1997.3013118.x; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Rafii S, 1997, LEUKEMIA LYMPHOMA, V27, P375, DOI 10.3109/10428199709058305; RAFII S, 1994, BLOOD, V84, P10; RAFII S, 1995, BLOOD, V86, P3353, DOI 10.1182/blood.V86.9.3353.bloodjournal8693353; Riviere C, 1999, BLOOD, V93, P1511, DOI 10.1182/blood.V93.5.1511.405k02_1511_1523; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Schabath R, 1999, J LEUKOCYTE BIOL, V66, P996, DOI 10.1002/jlb.66.6.996; Schweitzer KM, 1996, AM J PATHOL, V148, P165; Su WH, 2002, BLOOD, V100, P3597, DOI 10.1182/blood-2002-01-0303; TAVASSOLI M, 1989, BLOOD CELLS, V15, P3; Vadhan-Raj S, 2003, J CLIN ONCOL, V21, P3158, DOI 10.1200/JCO.2003.08.003; Vadhan-Raj S, 2000, ANN INTERN MED, V132, P364, DOI 10.7326/0003-4819-132-5-200003070-00005; Wang JF, 1998, BLOOD, V92, P756, DOI 10.1182/blood.V92.3.756.415k36_756_764; Zucker-Franklin D, 2000, AM J PATHOL, V157, P69, DOI 10.1016/S0002-9440(10)64518-X; Zweegman S, 2000, EXP HEMATOL, V28, P401, DOI 10.1016/S0301-472X(00)00128-4	50	568	601	0	28	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					64	71		10.1038/nm973	http://dx.doi.org/10.1038/nm973			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702636				2022-12-27	WOS:000187743600040
J	Yasoda, A; Komatsu, Y; Chusho, H; Miyazawa, T; Ozasa, A; Miura, M; Kurihara, T; Rogi, T; Tanaka, S; Suda, M; Tamura, N; Ogawa, Y; Nakao, K				Yasoda, A; Komatsu, Y; Chusho, H; Miyazawa, T; Ozasa, A; Miura, M; Kurihara, T; Rogi, T; Tanaka, S; Suda, M; Tamura, N; Ogawa, Y; Nakao, K			Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway	NATURE MEDICINE			English	Article							NATRIURETIC PEPTIDE SYSTEM; GROWTH-FACTOR RECEPTOR-3; PROTEIN-KINASE; SKELETAL OVERGROWTH; BONE-GROWTH; DISTRACTION OSTEOGENESIS; MOLECULAR-BIOLOGY; TRANSGENIC MICE; MESSENGER-RNA; FACTOR-I	Achondroplasia is the most common genetic form of human dwarfism, for which there is presently no effective therapy. C-type natriuretic peptide (CNP) is a newly identified molecule that regulates endochondral bone growth through GC-B, a subtype of particulate guanylyl cyclase. Here we show that targeted overexpression of CNP in chondrocytes counteracts dwarfism in a mouse model of achondroplasia with activated fibroblast growth factor receptor 3 (FGFR-3) in the cartilage. CNP prevented the shortening of achondroplastic bones by correcting the decreased extracellular matrix synthesis in the growth plate through inhibition of the MAPK pathway of FGF signaling. CNP had no effect on the STAT-1 pathway of FGF signaling that mediates the decreased proliferation and the delayed differentiation of achondroplastic chondrocytes. These results demonstrate that activation of the CNP-GC-B system in endochondral bone formation constitutes a new therapeutic strategy for human achondroplasia.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068507, Japan; Daiichi Suntory Inst Biomed Res, Shimamoto, Osaka 6188503, Japan	Kyoto University	Nakao, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.			Ogawa, Yoshihiro/0000-0002-0834-2836				Aldegheri R, 1999, J BONE JOINT SURG AM, V81A, P624, DOI 10.2106/00004623-199905000-00004; BELLUS GA, 1995, AM J HUM GENET, V56, P368; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Bonassar LJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P57, DOI 10.1006/abbi.2000.1820; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; Chusho H, 2000, ENDOCRINOLOGY, V141, P3807, DOI 10.1210/en.141.10.3807; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; Cohen MM, 1997, PEDIATR RADIOL, V27, P442, DOI 10.1007/s002470050165; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Coxam V, 1995, BIOL NEONATE, V68, P368; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DIEUDONNE SC, 1994, J BONE MINER RES, V9, P771; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Garbers D L, 1990, Recent Prog Horm Res, V46, P85; Jaubert J, 1999, P NATL ACAD SCI USA, V96, P10278, DOI 10.1073/pnas.96.18.10278; Kanaka-Gantenbein C, 2001, J PEDIATR ENDOCR MET, V14, P17; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; Mericq V, 2000, PEDIATR RES, V47, P189, DOI 10.1203/00006450-200002000-00007; METSARANTA M, 1995, DEV DYNAM, V204, P202, DOI 10.1002/aja.1002040211; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; NAKAO K, 1992, J HYPERTENS, V10, P907; NAKAO K, 1992, J HYPERTENS, V10, P1111, DOI 10.1097/00004872-199210000-00002; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; Naski MC, 1998, DEVELOPMENT, V125, P4977; Noonan KJ, 1998, J BONE JOINT SURG AM, V80A, P793, DOI 10.2106/00004623-199806000-00003; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; OGAWA Y, 1994, GENOMICS, V24, P383, DOI 10.1006/geno.1994.1633; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sahni M, 2001, DEVELOPMENT, V128, P2119; SCHEVEN BAA, 1991, ACTA ENDOCRINOL-COP, V124, P602, DOI 10.1530/acta.0.1240602; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Suda M, 1998, P NATL ACAD SCI USA, V95, P2337, DOI 10.1073/pnas.95.5.2337; Suganami T, 2001, J AM SOC NEPHROL, V12, P2652, DOI 10.1681/ASN.V12122652; Tanaka H, 1998, EUR J ENDOCRINOL, V138, P275, DOI 10.1530/eje.0.1380275; Toyokuni S, 1997, LAB INVEST, V76, P365; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695; YOKOI H, 1993, BIOCHEM BIOPH RES CO, V195, P769, DOI 10.1006/bbrc.1993.2112; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	44	283	317	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					80	86		10.1038/nm971	http://dx.doi.org/10.1038/nm971			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702637				2022-12-27	WOS:000187743600042
J	Gross, S; Gilead, A; Scherz, A; Neeman, M; Salomon, Y				Gross, S; Gilead, A; Scherz, A; Neeman, M; Salomon, Y			Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI	NATURE MEDICINE			English	Article							IN-VIVO; MELANOMA TUMORS; OXYGENATION; ANGIOGENESIS; XENOGRAFTS; VESSELS	Antivascular photodynamic therapy (PDT) of tumors with palladium-bacteriopheophorbide (TOOKAD) relies on in situ photosensitization of the circulating drug by local generation of cytotoxic reactive oxygen species, which leads to rapid vascular occlusion, stasis, necrosis and tumor eradication. Intravascular production of reactive oxygen species is associated with photoconsumption of O-2 and consequent evolution of paramagnetic deoxyhemoglobin. In this study we evaluate the use of blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for real-time monitoring of PDT efficacy. Using a solid tumor model, we show that TOOKAD-PDT generates appreciable attenuation (25-40%) of the magnetic resonance signal, solely at the illuminated tumor site. This phenomenon is independent of, though augmented by, ensuing changes in blood flow. These results were validated by immunohistochemistry and intravital microscopy. The concept of photosensitized BOLD-contrast MRI may have intraoperative applications in interactive guidance and monitoring of antivascular cancer therapy, PDT treatment of macular degeneration, interventional cardiology and possibly other biomedical disciplines.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Salomon, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yoram.salomon@weizmann.ac.il	Neeman, Michal/A-8264-2008; Neeman, Michal/AAH-9602-2019	Neeman, Michal/0000-0002-6296-816X; Neeman, Michal/0000-0002-6296-816X				Abramovitch R, 1998, BRIT J CANCER, V77, P440, DOI 10.1038/bjc.1998.70; Braun RD, 1997, AM J PHYSIOL-HEART C, V272, pH1444, DOI 10.1152/ajpheart.1997.272.3.H1444; CHEN Q, 2002, PHOTOCHEM PHOTOBIOL, V76, P88; Detre JA, 2001, NEUROSCIENTIST, V7, P64, DOI 10.1177/107385840100700110; Dolmans DEJGJ, 2002, CANCER RES, V62, P2151; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Gilead Assaf, 1999, Neoplasia (New York), V1, P226, DOI 10.1038/sj.neo.7900032; Hopper C, 2000, Lancet Oncol, V1, P212; Howe FA, 2001, NMR BIOMED, V14, P497, DOI 10.1002/nbm.716; Jolesz FA, 1998, JMRI-J MAGN RESON IM, V8, P3, DOI 10.1002/jmri.1880080104; Kelleher DK, 1999, INT J HYPERTHER, V15, P467, DOI 10.1080/026567399285468; Koudinova NV, 2003, INT J CANCER, V104, P782, DOI 10.1002/ijc.11002; Neeman M, 2001, MAGNET RESON MED, V45, P887, DOI 10.1002/mrm.1118; OGAWA S, 1990, MAGNET RESON MED, V16, P9, DOI 10.1002/mrm.1910160103; PREISE D, IN PRESS NEOPLASIA; Scherz A., 2003, U.S. Patent, Patent No. [6569846, 6,569,846]; Schreiber S, 2002, INT J CANCER, V99, P279, DOI 10.1002/ijc.10299; Sitnik TM, 1998, BRIT J CANCER, V77, P1386, DOI 10.1038/bjc.1998.231; Taylor NJ, 2001, J MAGN RESON IMAGING, V14, P156, DOI 10.1002/jmri.1166; Turner R, 1997, ADV EXP MED BIOL, V413, P19; Turner R, 2002, NEUROIMAGE, V16, P1062, DOI 10.1006/nimg.2002.1082; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; Yang M, 2002, P NATL ACAD SCI USA, V99, P3824, DOI 10.1073/pnas.052029099; Zilberstein J, 1997, PHOTOCHEM PHOTOBIOL, V65, P1012, DOI 10.1111/j.1751-1097.1997.tb07962.x; Zilberstein J, 2001, PHOTOCHEM PHOTOBIOL, V73, P257, DOI 10.1562/0031-8655(2001)073<0257:ATOSMT>2.0.CO;2	25	176	187	1	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2003	9	10					1327	1331		10.1038/nm940	http://dx.doi.org/10.1038/nm940			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502284				2022-12-27	WOS:000185669700047
J	Hammarlund, E; Lewis, MW; Hansen, SG; Strelow, LI; Nelson, JA; Sexton, GJ; Hanifin, JM; Slifka, MK				Hammarlund, E; Lewis, MW; Hansen, SG; Strelow, LI; Nelson, JA; Sexton, GJ; Hanifin, JM; Slifka, MK			Duration of antiviral immunity after smallpox vaccination	NATURE MEDICINE			English	Article							CYTOTOXIC T-CELLS; VACCINIA VIRUS; GAMMA-GLOBULIN; NEUTRALIZING ANTIBODIES; LYMPHOCYTES; RESPONSES; PROTECTION; PROPHYLAXIS; GENERATION; INFECTION	Although naturally occurring smallpox was eliminated through the efforts of the World Health Organization Global Eradication Program, it remains possible that smallpox could be intentionally released. Here we examine the magnitude and duration of antiviral immunity induced by one or more smallpox vaccinations. We found that more than 90% of volunteers vaccinated 25-75 years ago still maintain substantial humoral or cellular immunity (or both) against vaccinia, the virus used to vaccinate against smallpox. Antiviral antibody responses remained stable between 1-75 years after vaccination, whereas antiviral T-cell responses declined slowly, with a half-life of 8-15 years. If these levels of immunity are considered to be at least partially protective, then the morbidity and mortality associated with an intentional smallpox outbreak would be substantially reduced because of preexisting immunity in a large number of previously vaccinated individuals.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Dermatol, Clin Res Ctr, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Slifka, MK (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW 185th Ave, Beaverton, OR 97006 USA.	slifkam@ohsu.edu		Lewis, Matthew/0000-0002-6241-3690	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021640, R01AI051346] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00163, P51 RR000163] Funding Source: Medline; NHLBI NIH HHS [T32 HL007781, T32HL07781] Funding Source: Medline; NIAID NIH HHS [AI051346, R01 AI051346, AI21640] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON SG, 1970, B WORLD HEALTH ORGAN, V42, P515; [Anonymous], 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; Appay V, 2002, J IMMUNOL, V168, P5954, DOI 10.4049/jimmunol.168.11.5954; Breman JG, 2002, NEW ENGL J MED, V346, P1300, DOI 10.1056/NEJMra020025; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P236; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P188; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P174; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P183; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P172; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P220; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P191; CUTCHINS E, 1960, J IMMUNOL, V85, P275; CZERNY CP, 1990, J GEN VIROL, V71, P2341, DOI 10.1099/0022-1317-71-10-2341; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; Derby MA, 2001, J IMMUNOL, V166, P1690, DOI 10.4049/jimmunol.166.3.1690; DOWNIE A. W., 1958, JOUR HYGIENE, V56, P479; ELAD B, 1990, J INFECT DIS, V161, P446, DOI 10.1093/infdis/161.3.446; Ennis FA, 2002, J INFECT DIS, V185, P1657, DOI 10.1086/340517; ERICKSON AL, 1993, J GEN VIROL, V74, P751, DOI 10.1099/0022-1317-74-4-751; FENNER F, 1988, PATHOGENESIS IMMUNOL; Frelinger JA, 2002, NEW ENGL J MED, V347, P689; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; Frey SE, 2003, JAMA-J AM MED ASSOC, V289, P3295, DOI 10.1001/jama.289.24.3295; Galmiche MC, 1999, VIROLOGY, V254, P71, DOI 10.1006/viro.1998.9516; Gani R, 2001, NATURE, V414, P748, DOI 10.1038/414748a; Gayton W., 1885, VALUE VACCINATION SH; Hanna W, 2002, Rev Med Virol, V12, P201; HANNA W, 1913, STUDIES SMALLPOX VAC; HEINER GG, 1971, AM J EPIDEMIOL, V94, P252, DOI 10.1093/oxfordjournals.aje.a121319; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; Kaplan EH, 2002, P NATL ACAD SCI USA, V99, P10935, DOI 10.1073/pnas.162282799; KEMPE CH, 1960, PEDIATRICS, V26, P176; KEMPE CH, 1961, B WORLD HEALTH ORGAN, V25, P41; KEMPE CH, 1956, PEDIATRICS, V18, P177; LITTAURA RA, 1992, J VIROL, V66, P2274, DOI 10.1128/JVI.66.4.2274-2280.1992; MACK TM, 1972, J INFECT DIS, V125, P161, DOI 10.1093/infdis/125.2.161; MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214; MCCARTHY K., 1958, JOUR HYGIENE, V56, P466; Meltzer MI, 2001, EMERG INFECT DIS, V7, P959, DOI 10.3201/eid0706.010607; NYERGES G, 1972, ACTA MICROBIOL HUNG, V19, P63; O'Toole T, 2002, CLIN INFECT DIS, V34, P972, DOI 10.1086/339909; PEIRCE ER, 1958, LANCET, V2, P635; PERRIN LH, 1978, MED MICROBIOL IMMUN, V166, P71, DOI 10.1007/BF02121136; PERRIN LH, 1977, J EXP MED, V146, P949, DOI 10.1084/jem.146.4.949; Ramirez JC, 2002, J GEN VIROL, V83, P1059, DOI 10.1099/0022-1317-83-5-1059; SARKAR JK, 1975, B WORLD HEALTH ORGAN, V52, P307; Slifka MK, 2000, J IMMUNOL, V164, P208, DOI 10.4049/jimmunol.164.1.208; Slifka MK, 1996, TRENDS MICROBIOL, V4, P394, DOI 10.1016/0966-842X(96)10059-7; Slifka MK, 1996, J IMMUNOL METHODS, V199, P37, DOI 10.1016/S0022-1759(96)00146-9; Smith GL, 2002, NAT REV IMMUNOL, V2, P521, DOI 10.1038/nri845; Speller SA, 2002, J IMMUNOL METHODS, V262, P167, DOI 10.1016/S0022-1759(02)00025-X; Stienlauf S, 1999, VACCINE, V17, P201, DOI 10.1016/S0264-410X(98)00197-2; Terajima M, 2003, J EXP MED, V197, P927, DOI 10.1084/jem.20022222; Yanai F, 2003, J IMMUNOL, V170, P2205, DOI 10.4049/jimmunol.170.4.2205; ZARLING JM, 1987, J IMMUNOL, V139, P988; ZINKERNAGEL RM, 1977, J EXP MED, V145, P644, DOI 10.1084/jem.145.3.644	56	622	641	3	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2003	9	9					1131	1137		10.1038/nm917	http://dx.doi.org/10.1038/nm917			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925846				2022-12-27	WOS:000185061600024
J	Binder, CJ; Horkko, S; Dewan, A; Chang, MK; Kieu, EP; Goodyear, CS; Shaw, PX; Palinski, W; Witztum, JL; Silverman, GJ				Binder, CJ; Horkko, S; Dewan, A; Chang, MK; Kieu, EP; Goodyear, CS; Shaw, PX; Palinski, W; Witztum, JL; Silverman, GJ			Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; DEFICIENT MICE; MONOCLONAL-ANTIBODIES; RECEPTOR-DEFICIENT; APOPTOTIC CELLS; T15 IDIOTYPE; B-1 CELLS; B-CELLS; EPITOPES; PHOSPHORYLCHOLINE	During the progression of atherosclerosis, autoantibodies are induced to epitopes of oxidized low-density lipoprotein (oxLDL) and active immunization of hypercholesterolemic mice with oxLDL ameliorates atherogenesis. We unexpectedly found that many autoantibodies to oxLDL derived from 'naive' atherosclerotic mice share complete genetic and structural identity with antibodies from the classic anti-phosphorylcholine B-cell clone, T15, which protect against common infectious pathogens, including pneumococci. To investigate whether in vivo exposure to pneumococci can affect atherogenesis, we immunized Ldlr(-/-) mice with Streptococcus pneumoniae. This induced high circulating levels of oxLDL-specific IgM and a persistent expansion of oxLDL-specific T15 IgM-secreting B cells primarily in the spleen, which were cross-reactive with pneumococcal determinants. Pneumococcal immunization decreased the extent of atherosclerosis, and plasma from these mice had an enhanced capacity to block the binding of oxLDL to macrophages. These studies show molecular mimicry between epitopes of oxLDL and S. pneumoniae and indicate that these immune responses can have beneficial effects.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; Univ Oulu, Dept Internal Med, SF-90220 Oulu, Finland; Univ Oulu, Bioctr, SF-90220 Oulu, Finland	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Oulu; University of Oulu	Witztum, JL (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jwitztum@ucsd.edu	Palinski, Wulf/AAW-8032-2021	Goodyear, Carl/0000-0001-5926-5941; Silverman, Gregg/0000-0001-9480-9457; Palinski, Wulf/0000-0002-5113-0169; Binder, Christoph J./0000-0001-8313-7050	NHLBI NIH HHS [HL6946, HL57505, HL56989] Funding Source: Medline; NIAID NIH HHS [AI40305] Funding Source: Medline; NIAMS NIH HHS [P30 AR47360] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057505, P50HL056989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047360] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bendelac A, 2001, NAT REV IMMUNOL, V1, P177, DOI 10.1038/35105052; Berland R, 2002, ANNU REV IMMUNOL, V20, P253, DOI 10.1146/annurev.immunol.20.100301.064833; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; BRILES DE, 1982, J EXP MED, V156, P1177, DOI 10.1084/jem.156.4.1177; BROWN M, 1984, J IMMUNOL, V132, P1323; Caligiuri G, 2002, J CLIN INVEST, V109, P745, DOI 10.1172/JCI200207272; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; Daugherty A, 1997, J CLIN INVEST, V100, P1575, DOI 10.1172/JCI119681; DESAYMARD C, 1984, MOL IMMUNOL, V21, P961, DOI 10.1016/0161-5890(84)90154-8; Freigang S, 1998, ARTERIOSCL THROM VAS, V18, P1972, DOI 10.1161/01.ATV.18.12.1972; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; HALPERN R, 1991, J CLIN INVEST, V88, P476, DOI 10.1172/JCI115328; Hansen PR, 2001, ATHEROSCLEROSIS, V158, P87, DOI 10.1016/S0021-9150(01)00418-X; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Horkko S, 2000, FREE RADICAL BIO MED, V28, P1771, DOI 10.1016/S0891-5849(00)00333-6; Horkko S, 1997, P NATL ACAD SCI USA, V94, P10356, DOI 10.1073/pnas.94.19.10356; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; KEARNEY JF, 1981, EUR J IMMUNOL, V11, P877, DOI 10.1002/eji.1830111106; KENNY JJ, 1992, J EXP MED, V176, P1637, DOI 10.1084/jem.176.6.1637; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; MASMOUDI H, 1990, INT IMMUNOL, V2, P515, DOI 10.1093/intimm/2.6.515; Mi QS, 2000, P NATL ACAD SCI USA, V97, P6031, DOI 10.1073/pnas.110039497; Miller YI, 2003, J BIOL CHEM, V278, P1561, DOI 10.1074/jbc.M209634200; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; PALINSKI W, 1995, P NATL ACAD SCI USA, V92, P821, DOI 10.1073/pnas.92.3.821; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325; Reid RR, 1997, J IMMUNOL, V159, P970; Schenkein HA, 2001, INFECT IMMUN, V69, P6612, DOI 10.1128/IAI.69.11.6612-6617.2001; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Silverman GJ, 2000, J EXP MED, V192, P87, DOI 10.1084/jem.192.1.87; Silverman GJ, 1998, J IMMUNOL, V161, P5720; Silverman GJ, 2000, CURR TOP MICROBIOL, V252, P189; Snapper CM, 2001, TRENDS IMMUNOL, V22, P308, DOI 10.1016/S1471-4906(01)01926-3; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Wardemann H, 2002, J EXP MED, V195, P771, DOI 10.1084/jem.20011140; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597	45	562	590	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					736	743		10.1038/nm876	http://dx.doi.org/10.1038/nm876			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740573				2022-12-27	WOS:000183444100029
J	Pugh, CW; Ratcliffe, PJ				Pugh, CW; Ratcliffe, PJ			Regulation of angiogenesis by hypoxia: role of the HIF system	NATURE MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; PAS DOMAIN PROTEIN-1; FACTOR MESSENGER-RNA; HIPPEL-LINDAU GENE; TRANSCRIPTIONAL ACTIVITY; HIF-1-ALPHA/VP16 HYBRID; PROLINE HYDROXYLATION; CELL-PROLIFERATION; TUMOR SUPPRESSION	The regulation of angiogenesis by hypoxia is an important component of homeostatic mechanisms that link vascular oxygen supply to metabolic demand. Molecular characterization of angiogenic pathways, identification of hypoxia-inducible factor (HIF) as a key transcriptional regulator of these molecules, and the definition of the HIF hydoxylases as a family of dioxygenases that regulate HIF in accordance with oxygen availability have provided new insights into this process. Here we review these findings, and the role of HIF in developmental, adaptive and neoplastic angiogenesis. We also discuss the implications of oncogenic activation of extensive, physiologically interconnected hypoxia pathways for the tumor phenotype.			Ratcliffe, PJ (corresponding author), Henry Wellcome Bldg Genom Med,Roosevelt Dr, Oxford OX3 7BN, England.	pjr@well.ox.ac.uk		Ratcliffe, Peter/0000-0002-2853-806X; Pugh, Chris/0000-0002-5170-1662				Alarcon R, 1999, CANCER RES, V59, P6046; ARAVIND L, 2001, GENOME BIOL, V2, DOI DOI 10.1186/gb-2001-2-3-research0007; ASHTON N, 1954, BRIT J OPHTHALMOL, V38, P397, DOI 10.1136/bjo.38.7.397; Barleon B, 1997, CANCER RES, V57, P5421; Ben-Yosef Y, 2002, CIRC RES, V90, P784, DOI 10.1161/01.RES.0000015588.70132.DC; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Currie MJ, 2002, J PATHOL, V198, P502, DOI 10.1002/path.1228; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Elson DA, 2000, CANCER RES, V60, P6189; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDWASSER E, 1958, BLOOD, V13, P55, DOI 10.1182/blood.V13.1.55.55; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Graham CH, 1998, BLOOD, V91, P3300, DOI 10.1182/blood.V91.9.3300.3300_3300_3307; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hollander AP, 2001, ARTHRITIS RHEUM-US, V44, P1540, DOI 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7; Hopfl G, 2002, CANCER RES, V62, P2962; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JOZSA L, 1980, EUR J APPL PHYSIOL O, V44, P183, DOI 10.1007/BF00421097; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; KNIGHTON DR, 1981, SURGERY, V90, P262; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; Knowles HJ, 2003, CANCER RES, V63, P1764; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; KOONG AC, 1994, CANCER RES, V54, P1425; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; Krishnamachary B, 2003, CANCER RES, V63, P1138; Krogh A, 1919, J PHYSIOL-LONDON, V52, P409, DOI 10.1113/jphysiol.1919.sp001839; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Le NTV, 2002, BBA-REV CANCER, V1603, P31, DOI 10.1016/S0304-419X(02)00068-9; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Lee YM, 2001, DEV DYNAM, V220, P175, DOI 10.1002/1097-0177(20010201)220:2<175::AID-DVDY1101>3.0.CO;2-F; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Mandriota SJ, 2000, AM J PATHOL, V156, P2077, DOI 10.1016/S0002-9440(10)65079-1; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MEININGER CJ, 1988, AM J PHYSIOL, V255, pH554, DOI 10.1152/ajpheart.1988.255.3.H554; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Morita M, 2003, EMBO J, V22, P1134, DOI 10.1093/emboj/cdg117; NECAS E, 1972, AM J PHYSIOL, V222, P1187, DOI 10.1152/ajplegacy.1972.222.5.1187; Negus RPM, 1998, J LEUKOCYTE BIOL, V63, P758, DOI 10.1002/jlb.63.6.758; Norman JT, 2000, KIDNEY INT, V58, P2351, DOI 10.1046/j.1523-1755.2000.00419.x; Nwogu JI, 2001, CIRCULATION, V104, P2216, DOI 10.1161/hc4301.097193; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; PHILLIPS PG, 1995, AM J PHYSIOL-LUNG C, V268, pL789, DOI 10.1152/ajplung.1995.268.5.L789; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Rajakumar A, 2003, PLACENTA, V24, P199, DOI 10.1053/plac.2002.0893; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SAKUDA H, 1992, AM J PATHOL, V141, P1507; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Semenza GL, 2000, GENE DEV, V14, P1983; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SHREENIWAS R, 1991, J CELL PHYSIOL, V146, P8, DOI 10.1002/jcp.1041460103; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Shyu KG, 2002, CARDIOVASC RES, V54, P576, DOI 10.1016/S0008-6363(02)00259-6; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Tucci M, 1997, AM J PHYSIOL-CELL PH, V272, pC1700, DOI 10.1152/ajpcell.1997.272.5.C1700; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Vaux EC, 2001, J BIOL CHEM, V276, P44323, DOI 10.1074/jbc.M104678200; Vincent KA, 2000, CIRCULATION, V102, P2255; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Willam C, 2002, P NATL ACAD SCI USA, V99, P10423, DOI 10.1073/pnas.162119399; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zundel W, 2000, GENE DEV, V14, P391	115	1805	1955	9	314	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					677	684		10.1038/nm0603-677	http://dx.doi.org/10.1038/nm0603-677			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12778166				2022-12-27	WOS:000183444100022
J	Gill, SS; Patel, NK; Hotton, GR; O'Sullivan, K; McCarter, R; Bunnage, M; Brooks, DJ; Svendsen, CN; Heywood, P				Gill, SS; Patel, NK; Hotton, GR; O'Sullivan, K; McCarter, R; Bunnage, M; Brooks, DJ; Svendsen, CN; Heywood, P			Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease	NATURE MEDICINE			English	Article							F-18 DOPA-PET; DOPAMINERGIC-NEURONS; IN-VIVO; GDNF; DELIVERY; NEUROPROTECTION; TRANSPLANTATION; PROGRESSION; MIDBRAIN; SURVIVAL	Glial cell line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor with restorative effects in a wide variety of rodent and primate models of Parkinson disease, but penetration into brain tissue from either the blood or the cerebro-spinal fluid is limited. Here we delivered GDNF directly into the putamen of five Parkinson patients in a phase 1 safety trial. One catheter needed to be repositioned and there were changes in the magnetic resonance images that disappeared after lowering the concentration of GDNF. After one year, there were no serious clinical side effects, a 39% improvement in the off-medication motor sub-score of the Unified Parkinson's Disease Rating Scale (UPDRS) and a 61% improvement in the activities of daily living sub-score. Medication-induced dyskinesias were reduced by 64% and were not observed off medication during chronic GDNF delivery. Positron emission tomography (PET) scans of [F-18] dopamine uptake showed a significant 28% increase in putamen dopamine storage after 18 months, suggesting a direct effect of GDNF on dopamine function. This study warrants careful examination of GDNF as a treatment for Parkinson disease.	Frenchay Hosp, Inst Neurosci, Bristol BS16 1LE, Avon, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, MRC,Clin Sci Ctr, London, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Div Neurosci, London, England; Univ Wisconsin, Waisman Ctr, Stem Cell Res Program, Madison, WI 53705 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA; Univ Wisconsin, Dept Anat, Madison, WI 53706 USA	Imperial College London; Imperial College London; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gill, SS (corresponding author), Frenchay Hosp, Inst Neurosci, Bristol BS16 1LE, Avon, England.	steven.gill@north-bristol.swest.nhs.uk; svendsen@waisman.wisc.edu		Brooks, David/0000-0003-2602-2518; Patel, Nikunj/0000-0001-5438-2356				Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Beck M, 2001, AMYOTROPH LATERAL SC, V2, pS55, DOI 10.1080/146608201300079454; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Bjorklund A, 1997, NEUROBIOL DIS, V4, P186, DOI 10.1006/nbdi.1997.0151; BROOKS DJ, 1990, BRAIN, V113, P1539, DOI 10.1093/brain/113.5.1539; DANIEL SE, 1992, LANCET, V340, P186, DOI 10.1016/0140-6736(92)93275-R; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gash DM, 1998, ANN NEUROL, V44, pS121, DOI 10.1002/ana.410440718; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Goetz CG, 2000, NEUROLOGY, V54, P710, DOI 10.1212/WNL.54.3.710; Golden JP, 1998, J COMP NEUROL, V398, P139, DOI 10.1002/(SICI)1096-9861(19980817)398:1<139::AID-CNE9>3.0.CO;2-2; Grondin R, 2002, BRAIN, V125, P2191, DOI 10.1093/brain/awf234; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Hoffman AF, 1997, EXP NEUROL, V147, P130, DOI 10.1006/exnr.1997.6571; Kordower JH, 1999, ANN NEUROL, V46, P419, DOI 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Kordower JH, 1999, EXP NEUROL, V159, P4, DOI 10.1006/exnr.1999.7156; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindvall O, 2000, Prog Brain Res, V127, P299; McCarter RJ, 2000, J NEUROL NEUROSUR PS, V69, P60, DOI 10.1136/jnnp.69.1.60; Miyoshi Y, 1997, ANN NEUROL, V42, P208, DOI 10.1002/ana.410420212; Morrish PK, 1996, BRAIN, V119, P585, DOI 10.1093/brain/119.2.585; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Ostenfeld T, 2002, J NEUROSCI RES, V69, P955, DOI 10.1002/jnr.10396; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; PETO V, 1995, QUAL LIFE RES, V4, P241, DOI 10.1007/BF02260863; QUINN NP, 1987, J NEUROL NEUROSUR PS, V50, P88, DOI 10.1136/jnnp.50.1.88; Rakshi JS, 1999, BRAIN, V122, P1637, DOI 10.1093/brain/122.9.1637; Rascol O, 2002, LANCET, V359, P1589, DOI 10.1016/S0140-6736(02)08520-3; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Whone AL, 2002, NEUROLOGY, V58, pA82; Zurn AD, 2001, BRAIN RES REV, V36, P222, DOI 10.1016/S0165-0173(01)00098-4	37	967	1138	1	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2003	9	5					589	595		10.1038/nm850	http://dx.doi.org/10.1038/nm850			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12669033				2022-12-27	WOS:000182610600041
J	Huo, YQ; Schober, A; Forlow, SB; Smith, DF; Hyman, MC; Jung, S; Littman, DR; Weber, C; Ley, K				Huo, YQ; Schober, A; Forlow, SB; Smith, DF; Hyman, MC; Jung, S; Littman, DR; Weber, C; Ley, K			Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E	NATURE MEDICINE			English	Article							CELL-ADHESION MOLECULE-1; P-SELECTIN; INTEGRIN AFFINITY; LESION FORMATION; IN-VIVO; RECEPTOR; DEPOSITION; CHEMOKINES; ARREST; THROMBOCYTOPENIA	We studied whether circulating activated platelets and platelet-leukocyte aggregates cause the development of atherosclerotic lesions in apolipoprotein-E-deficient (Apoe(-/-)) mice. Circulating activated platelets bound to leukocytes, preferentially monocytes, to form platelet-monocyte/leukocyte aggregates. Activated platelets and platelet-leukocyte aggregates interacted with atherosclerotic lesions. The interactions of activated platelets with monocytes and atherosclerotic arteries led to delivery of the platelet-derived chemokines CCL5 (regulated on activation, normal T cell expressed and secreted, RANTES) and CXCL4 (platelet factor 4) to the monocyte surface and endothelium of atherosclerotic arteries. The presence of activated platelets promoted leukocyte binding of vascular cell adhesion molecule-1 (VCAM-1) and increased their adhesiveness to inflamed or atherosclerotic endothelium. Injection of activated wild-type, but not P-selectin-deficient, platelets increased monocyte arrest on the surface of atherosclerotic lesions and the size of atherosclerotic lesions in Apoe(-/-) mice. Our results indicate that circulating activated platelets and platelet-leukocyte/monocyte aggregates promote formation of atherosclerotic lesions. This role of activated platelets in atherosclerosis is attributed to platelet P-selectin-mediated delivery of platelet-derived proinflammatory factors to monocytes/leukocytes and the vessel wall.	Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Charlottesville, VA 22903 USA; Univ Virginia, Hlth Sci Ctr, Cardiovasc Res Ctr, Charlottesville, VA USA; Univ Hosp Aachen, Dept Mol Cardiovasc Res, Aachen, Germany; Skirball Inst Biomol Med, New York, NY USA; Howard Hughes Med Inst, New York, NY USA	University of Virginia; University of Virginia; RWTH Aachen University; RWTH Aachen University Hospital; Howard Hughes Medical Institute	Ley, K (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Charlottesville, VA 22903 USA.	klausley@virginia.edu	Schober, Andreas/B-2866-2013; Jung, Steffen/K-1409-2012; Weber, Christian/AAW-2153-2020	Schober, Andreas/0000-0001-7798-136X; Jung, Steffen/0000-0003-4290-5716; Weber, Christian/0000-0003-4610-8714; Smith, David/0000-0002-0048-4012; Hyman, Matthew/0000-0002-4050-6925	NHLBI NIH HHS [HL-58108] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058108] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; BECKER RC, 1994, CORONARY ARTERY DIS, V5, P339, DOI 10.1097/00019501-199404000-00010; Berger G, 1998, BLOOD, V92, P4446, DOI 10.1182/blood.V92.11.4446; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Broijersen A, 1998, ATHEROSCLEROSIS, V137, P107, DOI 10.1016/S0021-9150(97)00260-8; Broijersen A, 1998, THROMB HAEMOSTASIS, V79, P268; BURGER PC, 2002, IN PRESS BLOOD; Chan JR, 2001, J EXP MED, V193, P1149, DOI 10.1084/jem.193.10.1149; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Diacovo TG, 1996, SCIENCE, V273, P252, DOI 10.1126/science.273.5272.252; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; Frenette PS, 1998, BLOOD, V91, P1318, DOI 10.1182/blood.V91.4.1318; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; FRIEDMAN RJ, 1977, J CLIN INVEST, V60, P1191, DOI 10.1172/JCI108872; Furman MI, 1998, J AM COLL CARDIOL, V31, P352, DOI 10.1016/S0735-1097(97)00510-X; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; HAMBURGER SA, 1990, BLOOD, V75, P550; HAWRYLOWICZ CM, 1991, J EXP MED, V174, P785, DOI 10.1084/jem.174.4.785; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Mannaioni PF, 1997, INFLAMM RES, V46, P4, DOI 10.1007/PL00000158; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; MENDELSOHN ME, 1988, J CLIN INVEST, V81, P62, DOI 10.1172/JCI113311; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Newman PM, 2000, BLOOD, V96, P182, DOI 10.1182/blood.V96.1.182.013k18_182_187; NUNNARI JJ, 1989, EXP MOL PATHOL, V51, P1, DOI 10.1016/0014-4800(89)90002-6; Piccardoni P, 2001, BLOOD, V98, P108, DOI 10.1182/blood.V98.1.108; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; RINDER CS, 1992, BLOOD, V79, P1201; RINDER HM, 1991, BLOOD, V78, P1760; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schober A, 2002, CIRCULATION, V106, P1523, DOI 10.1161/01.CIR.0000028590.02477.6F; Theilmeier G, 1999, BLOOD, V94, P2725, DOI 10.1182/blood.V94.8.2725.420k18_2725_2734; Theilmeier G, 2002, BLOOD, V99, P4486, DOI 10.1182/blood.V99.12.4486; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; von Hundelshausen P, 2001, CIRCULATION, V103, P1772, DOI 10.1161/01.CIR.103.13.1772; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	45	796	834	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					61	67		10.1038/nm810	http://dx.doi.org/10.1038/nm810			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12483207				2022-12-27	WOS:000180209900023
J	Levine, MM				Levine, Myron M.			Can needle-free administration of vaccines become the norm in global immunization?	NATURE MEDICINE			English	Article							ORAL CHOLERA VACCINE; HEAT-LABILE TOXIN; ADP-RIBOSYLTRANSFERASE; INFLUENZA VACCINE; UNSAFE INJECTIONS; IMMUNOGENICITY; SAFETY; TRIVALENT; EFFICACY; CHILDREN	If vaccines could be administered without needles and syringes ('sharps'), immunization practice would become safer, more accepted and more suitable for mass use. The author explores the status of technologies that could achieve this aim and the barriers that must be overcome for their implementation.	[Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Levine, MM (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.	mlevine@medicine.umaryland.edu						Agren LC, 1999, J IMMUNOL, V162, P2432; American Academy of Family Physicians American Academy of Pediatrics Advisory Committee on Immunization Practices Public Health Service, 2000, MMWR-MORBID MORTAL W, V49, P631; AYLWARD B, 1995, B WORLD HEALTH ORGAN, V73, P531; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; CANTER J, 1990, ARCH INTERN MED, V150, P1923, DOI 10.1001/archinte.150.9.1923; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P631; Cooper PJ, 2000, J INFECT DIS, V182, P1199, DOI 10.1086/315837; Dilraj A, 2000, LANCET, V355, P798, DOI 10.1016/S0140-6736(99)95140-1; DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; duChatelet IP, 1997, VACCINE, V15, P449, DOI 10.1016/S0264-410X(96)00173-9; Fernandez-de Castro J, 1997, Salud Publica Mex, V39, P53; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; Gluck R, 2000, J INFECT DIS, V181, P1129, DOI 10.1086/315337; GOTUZZO E, 1993, INFECT IMMUN, V61, P3994, DOI 10.1128/IAI.61.9.3994-3997.1993; Guerena-Burgueno F, 2002, INFECT IMMUN, V70, P1874, DOI 10.1128/IAI.70.4.1874-1880.2002; HANLON P, 1987, LANCET, V1, P1342; HINGSON RA, 1963, MIL MED, V128, P516, DOI 10.1093/milmed/128.6.516; Jackson LA, 2001, VACCINE, V19, P4703, DOI 10.1016/S0264-410X(01)00225-0; Jodar L, 2001, VACCINE, V19, P1594, DOI 10.1016/S0264-410X(00)00358-3; JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457; King JC, 1998, J INFECT DIS, V177, P1394, DOI 10.1086/517822; Lagos R, 1999, J INFECT DIS, V180, P1709, DOI 10.1086/315051; Levine MM, 1998, LANCET, V351, P1375, DOI 10.1016/S0140-6736(05)79439-3; Levine MM, 2002, BRIT MED BULL, V62, P1, DOI 10.1093/bmb/62.1.1; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; Levine MM, 1995, B I PASTEUR, V93, P243, DOI 10.1016/0020-2452(96)85758-7; Levine MM, 1999, VACCINE, V17, pS22, DOI 10.1016/S0264-410X(99)00231-5; Mikszta JA, 2002, NAT MED, V8, P415, DOI 10.1038/nm0402-415; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Pasetti MF, 1999, CLIN IMMUNOL, V92, P76, DOI 10.1006/clim.1999.4733; Reis EC, 1998, PEDIATR ANN, V27, P375, DOI 10.3928/0090-4481-19980601-12; Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; Simonsen L, 1999, B WORLD HEALTH ORGAN, V77, P789; TACKET CO, 1994, VACCINE, V12, P1270, DOI 10.1016/S0264-410X(94)80038-2; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; Tacket CO, 2000, CLIN IMMUNOL, V97, P146, DOI 10.1006/clim.2000.4924; Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7; van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778; Yamamoto S, 1997, J EXP MED, V185, P1203, DOI 10.1084/jem.185.7.1203	41	114	119	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					99	103		10.1038/nm0103-99	http://dx.doi.org/10.1038/nm0103-99			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514720				2022-12-27	WOS:000208640400002
J	Polo, JM; Dell'Oso, T; Ranuncolo, SM; Cerchietti, L; Beck, D; Da Silva, GF; Prive, GG; Licht, JD; Melnick, A				Polo, JM; Dell'Oso, T; Ranuncolo, SM; Cerchietti, L; Beck, D; Da Silva, GF; Prive, GG; Licht, JD; Melnick, A			Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells	NATURE MEDICINE			English	Article							GERMINAL-CENTER FORMATION; PROTEIN TRANSDUCTION; CO-REPRESSOR; BTB DOMAIN; DIFFERENTIATION; COREPRESSOR; EXPRESSION; PROTOONCOGENE; INFLAMMATION; SMRT	The BTB/POZ transcriptional repressor and candidate oncogene BCL6 is frequently misregulated in B-cell lymphomas. The interface through which the BCL6 BTB domain mediates recruitment of the SMRT, NCoR and BCoR corepressors was recently identified. To determine the contribution of this interface to BCL6 transcriptional and biological properties, we generated a peptide that specifically binds BCL6 and blocks corepressor recruitment in vivo. This inhibitor disrupts BCL6-mediated repression and establishment of silenced chromatin, reactivates natural BCL6 target genes, and abrogates BCL6 biological function in B cells. In BCL6-positive lymphoma cells, peptide blockade caused apoptosis and cell cycle arrest. BTB domain peptide inhibitors may constitute a novel therapeutic agent for B-cell lymphomas.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Yeshiva University; Albert Einstein College of Medicine; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Icahn School of Medicine at Mount Sinai	Melnick, A (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	amelnick@aecom.yu.edu	Licht, Jonathan/L-4239-2019; Melnick, Ari/AAA-5763-2020; Privé, Gilbert G/A-3039-2008	Licht, Jonathan/0000-0002-3942-1369; Polo, Jose M/0000-0002-2531-778X; Cerchietti, Leandro/0000-0003-0608-1350; Prive, Gilbert/0000-0002-0712-4319; Ranuncolo, Stella/0000-0001-7775-9048	NATIONAL CANCER INSTITUTE [R01CA059936, R21CA099982] Funding Source: NIH RePORTER; NCI NIH HHS [CA99982, CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; Albagli-Curiel O, 2003, ONCOGENE, V22, P507, DOI 10.1038/sj.onc.1206152; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Harris MB, 1999, MOL CELL BIOL, V19, P7264; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Huynh KD, 2000, GENE DEV, V14, P1810; Lopes EC, 2003, LEUKEMIA RES, V27, P413, DOI 10.1016/S0145-2126(02)00216-3; Mehra S, 2002, GENE CHROMOSOME CANC, V33, P225, DOI 10.1002/gcc.10025; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Melnick A, 2002, CURR OPIN HEMATOL, V9, P322, DOI 10.1097/00062752-200207000-00010; Niu HF, 2003, J EXP MED, V198, P211, DOI 10.1084/jem.20021395; Niu HF, 2002, HEMATOL ONCOL, V20, P155, DOI 10.1002/hon.689; Opalinska JB, 2003, BLOOD, V102, p137A; Paterson RLK, 1996, EUR J IMMUNOL, V26, P1979, DOI 10.1002/eji.1830260902; PRIVE GG, 2004, ZINC FINGER PROTEINS; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Vasanwala FH, 2002, J IMMUNOL, V169, P1922, DOI 10.4049/jimmunol.169.4.1922; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BH, 2001, TRANSCRIPTION FACTOR, V1, P271; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326	33	235	247	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1329	1335		10.1038/nm1134	http://dx.doi.org/10.1038/nm1134			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15531890				2022-12-27	WOS:000225500900026
J	Cohen, T; Murray, M				Cohen, T; Murray, M			Modeling epidemics of multidrug-resistant M-tuberculosis of heterogeneous fitness	NATURE MEDICINE			English	Article							TRANSMISSION; COMMUNITY; DYNAMICS; DISEASE	Mathematical models have recently been used to predict the future burden of multidrug-resistant tuberculosis (MDRTB)(1-3). These models suggest the threat of multidrug resistance to TB control will depend on the relative `fitness' of MDR strains and imply that if the average fitness of MDR strains is considerably less than that of drug-sensitive strains, the emergence of resistance will not jeopardize the success of tuberculosis control efforts. Multidrug resistance in M. tuberculosis is conferred by the sequential acquisition of a number of different single-locus mutations that have been shown to have heterogeneous phenotypic effects. Here we model the impact of initial fitness estimates on the emergence of MDRTB assuming that the relative fitness of MDR strains is heterogeneous. We find that even when the average relative fitness of MDR strains is low and a well-functioning control program is in place, a small subpopulation of a relatively fit MDR strain may eventually outcompete both the drug-sensitive strains and the less fit MDR strains. These results imply that current epidemiological measures and short-term trends in the burden of MDRTB do not provide evidence that MDRTB strains can be contained in the absence of specific efforts to limit transmission from those with MDR disease.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Murray, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.	mmurray@hsph.harvard.edu	Cohen, Ted/G-8101-2011	Cohen, Ted/0000-0002-8091-7198	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI055985] Funding Source: NIH RePORTER; NIAID NIH HHS [K08 AI055985, K08 AI055985-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON R M, 1991; Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1998, J MOL MED, V76, P624, DOI 10.1007/s001090050260; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; CastilloChavez C, 1997, J MATH BIOL, V35, P629, DOI 10.1007/s002850050069; Cohen T, 2003, LANCET INFECT DIS, V3, P13, DOI 10.1016/S1473-3099(03)00483-3; Dye C, 2000, P NATL ACAD SCI USA, V97, P8180, DOI 10.1073/pnas.140102797; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; Dye C, 2001, P ROY SOC B-BIOL SCI, V268, P45, DOI 10.1098/rspb.2000.1328; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630; GRENFELL BT, 1989, P ROY SOC LOND B BIO, V22, P213; Khatri GR, 2002, NEW ENGL J MED, V347, P1420, DOI 10.1056/NEJMsa020098; Lipsitch M, 1997, ANTIMICROB AGENTS CH, V41, P363, DOI 10.1128/AAC.41.2.363; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; ORDWAY DJ, 1995, INFECT IMMUN, V63, P741, DOI 10.1128/IAI.63.2.741-743.1995; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; Teixeira L, 2001, INT J TUBERC LUNG D, V5, P321; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; Verver S, 2004, INT J EPIDEMIOL, V33, P351, DOI 10.1093/ije/dyh021; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; *WHO, 2004, 3 WHO; World Health Organization, 1997, WHOCDSTB97220	30	206	213	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1117	1121		10.1038/nm1110	http://dx.doi.org/10.1038/nm1110			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15378056	Green Accepted			2022-12-27	WOS:000224245800043
J	Bossy-Wetzel, E; Schwarzenbacher, R; Lipton, SA				Bossy-Wetzel, E; Schwarzenbacher, R; Lipton, SA			Molecular pathways to neurodegeneration	NATURE MEDICINE			English	Review							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; HUNTINGTONS-DISEASE; ALPHA-SYNUCLEIN; AXONAL-TRANSPORT; A-BETA; MITOCHONDRIAL DYSFUNCTION; SUPEROXIDE-DISMUTASE; CRYSTAL-STRUCTURE; GAMMA-SECRETASE	The molecular bases underlying the pathogenesis of neurodegenerative diseases are gradually being disclosed. One problem that investigators face is distinguishing primary from secondary events. Rare, inherited mutations causing familial forms of these disorders have provided important insights into the molecular networks implicated in disease pathogenesis. Increasing evidence indicates that accumulation of aberrant or misfolded proteins, protofibril formation, ubiquitin-proteasome system dysfunction, excitotoxic insult, oxidative and nitrosative stress, mitochondrial injury, synaptic failure, altered metal homeostasis and failure of axonal and dendritic transport represent unifying events in many slowly progressive neurodegenerative disorders.	Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Burnham Inst, Program Bioinformat & Syst Biol, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute	Bossy-Wetzel, E (corresponding author), Burnham Inst, Ctr Neurosci & Aging, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ebossy-wetzel@burnham.org; slipton@burnham.org		Lipton, Stuart/0000-0002-3490-1259	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005477, R01EY009024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041207, R01NS044314, R01NS047456, R01NS043242, R01NS044326] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY05477, R01 EY016164, R01 EY09024] Funding Source: Medline; NICHD NIH HHS [P01 HD29587] Funding Source: Medline; NINDS NIH HHS [R01 NS047456, R01 NS44326, R01 NS44314, R01 NS41207, R01 NS43242] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Baptista MJ, 2004, NEUROSCIENTIST, V10, P63, DOI 10.1177/1073858403260392; Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2003, ALZ DIS ASSOC DIS, V17, P147, DOI 10.1097/00002093-200307000-00005; BUSH AI, 1993, J BIOL CHEM, V268, P16109; Bush AI, 2002, NEUROBIOL AGING, V23, P1031, DOI 10.1016/S0197-4580(02)00120-3; Casley CS, 2002, NEUROBIOL DIS, V10, P258, DOI 10.1006/nbdi.2002.0516; Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cookson MR, 2003, HUM MOL GENET, V12, P2957, DOI 10.1093/hmg/ddg328; Cookson MR, 2003, NEUROMOL MED, V3, P1, DOI 10.1385/NMM:3:1:1; Cookson MR, 2003, NEURON, V37, P7, DOI 10.1016/S0896-6273(02)01166-2; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Delacourte Andre, 2000, Current Opinion in Neurology, V13, P371, DOI 10.1097/00019052-200008000-00002; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Eriksen JL, 2003, NEURON, V40, P453, DOI 10.1016/S0896-6273(03)00684-6; Feany MB, 2003, NEURON, V40, P1, DOI 10.1016/S0896-6273(03)00600-7; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hardy J, 2003, LANCET NEUROL, V2, P221, DOI 10.1016/S1474-4422(03)00350-8; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Hutton M, 1998, ESSAYS BIOCHEM, V33, P117, DOI 10.1042/bse0330117; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; IRWIN I, 1993, ADV NEUROL, V60, P197; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Li HW, 2004, P NATL ACAD SCI USA, V101, P647, DOI 10.1073/pnas.0305145101; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lipton SA, 2004, NATURE, V428, P473, DOI 10.1038/428473a; Lipton SA, 2004, NAT MED, V10, P347, DOI 10.1038/nm0404-347; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Obrietan K, 2004, J NEUROSCI, V24, P791, DOI 10.1523/JNEUROSCI.3493-03.2004; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; OVADIA A, 1995, NEUROBIOL AGING, V16, P931, DOI 10.1016/0197-4580(95)02012-8; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Pigino G, 2003, J NEUROSCI, V23, P4499; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ray SS, 2004, P NATL ACAD SCI USA, V101, P5701, DOI 10.1073/pnas.0401934101; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSENTHAL FS, 1993, J AEROSOL MED, V6, P177, DOI 10.1089/jam.1993.6.177; Roses AD, 1996, CURR OPIN NEUROL, V9, P265, DOI 10.1097/00019052-199608000-00004; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Singaraja RR, 2002, HUM MOL GENET, V11, P2815, DOI 10.1093/hmg/11.23.2815; Singleton A, 2004, HUM MOL GENET, V13, pR123, DOI 10.1093/hmg/ddh093; Sipione S, 2001, MOL NEUROBIOL, V23, P21; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Stephan A, 2001, J NEUROSCI, V21, P5703, DOI 10.1523/JNEUROSCI.21-15-05703.2001; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Sugars KL, 2004, J BIOL CHEM, V279, P4988, DOI 10.1074/jbc.M310226200; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; YAO D, 2004, IN PRESS P NATL ACAD; Young AB, 2003, J CLIN INVEST, V111, P299, DOI 10.1172/JCI200317742	106	569	593	3	83	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7		S			S2	S9		10.1038/nm1067	http://dx.doi.org/10.1038/nm1067			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	844YU	15272266				2022-12-27	WOS:000223202100002
J	Griffin, LD; Gong, WH; Verot, L; Mellon, SH				Griffin, LD; Gong, WH; Verot, L; Mellon, SH			Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone	NATURE MEDICINE			English	Article							CHLORIDE-ION UPTAKE; NEUROFIBRILLARY TANGLES; CHOLESTEROL; RAT; MICE; GANGLIOSIDE; METABOLISM; MODULATION; STORAGE; NEURONS	Niemann-Pick type C (NP-C) disease is a fatal, autosomal recessive, childhood neurodegenerative disease. The NP-C mouse recapitulates the cholesterol and sphingolipid storage, onset of neurological deficits, histopathological lesions, Purkinje cell loss and early death typical of the most severe form of human NP-C. Neurosteroids, steroids made in the brain, affect neuronal growth and differentiation, and modulate neurotransmitter receptors. Disordered cholesterol trafficking might disrupt neurosteroidogenesis, thereby contributing to the NP-C phenotype. Here we show that NP-C mouse brain contains substantially less neurosteroid than wild-type brain and has an age-related decrease in the ability to synthesize 5alpha-dihydroprogesterone and allopregnanolone. Immunohistochemical assessment confirms a decrease in expression of 5alpha-reductase and 3alpha-hydroxysteroid dehydrogenase, especially in cerebellum. Neonatal administration of allopregnanolone delays the onset of neurological symptoms, increases Purkinje and granule cell survival, reduces cortical GM2 and GM3 ganglioside accumulation and doubles the lifespan of NP-C mice. Earlier administration increases effectiveness of treatment. Decreased production of allopregnanolone apparently contributes to the pathology of NP-C; thus, neurosteroid treatment may be useful in ameliorating progression of the disease.	Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Reprod Sci, San Francisco, CA 94143 USA; Lyon Sud Med Sch & Hosp, Lab Fdn Gillet Merieux, INSERM, U189, F-69310 Pierre Benite, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mellon, SH (corresponding author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 513 Parnassus Ave, San Francisco, CA 94143 USA.	mellon@cgl.ucsf.edu						BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BELELLI D, 1989, EUR J PHARMACOL, V167, P173, DOI 10.1016/0014-2999(89)90760-7; BLACK SM, 1993, ENDOCRINOLOGY, V132, P539, DOI 10.1210/en.132.2.539; BRAAK H, 1983, J NEUROPATH EXP NEUR, V42, P671, DOI 10.1097/00005072-198311000-00007; BRINTON RD, 1994, J NEUROSCI, V14, P2763; Brussaard AB, 2000, P NATL ACAD SCI USA, V97, P3625, DOI 10.1073/pnas.050424697; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; COSTA E, 1991, NEUROSTEROIDS BRAIN; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DOODY KM, 1990, ENDOCRINOLOGY, V126, P2487, DOI 10.1210/endo-126-5-2487; FINK JK, 1989, NEUROLOGY, V39, P1040, DOI 10.1212/WNL.39.8.1040; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; German DC, 2001, J COMP NEUROL, V433, P415, DOI 10.1002/cne.1149; Gondre-Lewis MC, 2003, CURR BIOL, V13, P1324, DOI 10.1016/S0960-9822(03)00531-1; Griffin LD, 2001, ENDOCRINOLOGY, V142, P4617, DOI 10.1210/en.142.11.4617; Griffin LD, 1999, P NATL ACAD SCI USA, V96, P13512, DOI 10.1073/pnas.96.23.13512; Grobin AC, 2003, J NEUROSCI, V23, P1832; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; HIGASHI Y, 1993, ACTA NEUROPATHOL, V85, P175; Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301; KYRKLUND T, 1987, LIPIDS, V22, P274, DOI 10.1007/BF02533991; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MORRIS MD, 1982, AM J PATHOL, V108, P140; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Ong WY, 2001, EXP BRAIN RES, V141, P218, DOI 10.1007/s002210100870; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; Prasad A, 2000, J NEUROCHEM, V75, P1250, DOI 10.1046/j.1471-4159.2000.0751250.x; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; PURDY RH, 1990, STEROIDS, V55, P290, DOI 10.1016/0039-128X(90)90031-6; ROFF CF, 1992, AM J MED GENET, V42, P593, DOI 10.1002/ajmg.1320420433; ROFF CF, 1993, ENDOCRINOLOGY, V133, P2913, DOI 10.1210/en.133.6.2913; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; SUZUKI K, 1995, ACTA NEUROPATHOL, V89, P227; Vanier MT, 2003, CLIN GENET, V64, P269, DOI 10.1034/j.1399-0004.2003.00147.x; Vanier MT, 1996, AM J HUM GENET, V58, P118; VIGER RS, 1994, ENDOCRINOLOGY, V134, P2298, DOI 10.1210/en.134.5.2298; Vincent I, 2003, CURR OPIN NEUROL, V16, P155, DOI 10.1097/00019052-200304000-00006; Voikar V, 2001, PHYSIOL BEHAV, V72, P271, DOI 10.1016/S0031-9384(00)00405-4; Walkley SU, 1998, ANN NY ACAD SCI, V845, P188, DOI 10.1111/j.1749-6632.1998.tb09671.x; Wiebe JP, 1997, BRAIN RES, V764, P158, DOI 10.1016/S0006-8993(97)00452-6; Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200; Xie CL, 2000, J NEUROPATH EXP NEUR, V59, P1106, DOI 10.1093/jnen/59.12.1106; Zervas M, 2001, J NEUROPATH EXP NEUR, V60, P49, DOI 10.1093/jnen/60.1.49; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7	50	281	298	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					704	711		10.1038/nm1073	http://dx.doi.org/10.1038/nm1073			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15208706				2022-12-27	WOS:000222460400024
J	Inoue, M; Rashid, MH; Fujita, R; Contos, JJA; Chun, J; Ueda, H				Inoue, M; Rashid, MH; Fujita, R; Contos, JJA; Chun, J; Ueda, H			Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; SCIATIC-NERVE INJURY; UP-REGULATION; SPINAL-CORD; DORSAL-HORN; MICE; MONONEUROPATHY; SENSITIZATION; GAMMA; HYPERSENSITIVITY	Lysophosphatidic acid (LPA) is a bioactive lipid with activity in the nervous system mediated by G-protein-coupled receptors. Here, we examined the role of LPA signaling in the development of neuropathic pain by pharmacological and genetic approaches, including the use of mice lacking the LPA(1) receptor. Wild-type animals with nerve injury develop behavioral allodynia and hyperalgesia paralleled by demyelination in the dorsal root and increased expression of both the protein kinase C gamma-isoform within the spinal cord dorsal horn and the alpha(2)delta(1) calcium channel subunit in dorsal root ganglia. Intrathecal injection of LPA induced behavioral, morphological and biochemical changes similar to those observed after nerve ligation. In contrast, mice lacking a single LPA receptor (LPA(1), also known as EDG2) that activates the Rho-Rho kinase pathway do not develop signs of neuropathic pain after peripheral nerve injury. Inhibitors of Rho and Rho kinase also prevented these signs of neuropathic pain. These results imply that receptor-mediated LPA signaling is crucial in the initiation of neuropathic pain.	Nagasaki Univ, Grad Sch Biomed Sci, Div Mol Pharmacol & Neurosci, Nagasaki 8528521, Japan; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Scripps Res Inst, Helen L Dorris Inst Neurol & Psychiat Disorders, Dept Mol Biol, La Jolla, CA 92037 USA	Nagasaki University; Fred Hutchinson Cancer Center; Scripps Research Institute	Ueda, H (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Div Mol Pharmacol & Neurosci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	ueda@net.nagasaki-u.ac.jp	Chun, Jerold/Y-4670-2019	Ueda, Hiroshi/0000-0002-8002-0137				Adlkofer K, 1997, J NEUROSCI, V17, P4662; Bennett GJ, 1999, P NATL ACAD SCI USA, V96, P7737, DOI 10.1073/pnas.96.14.7737; Brancolini C, 1999, MOL BIOL CELL, V10, P2441, DOI 10.1091/mbc.10.7.2441; Bridges D, 2001, BRIT J ANAESTH, V87, P12, DOI 10.1093/bja/87.1.12; Carter GT, 1998, ARCH PHYS MED REHAB, V79, P1560, DOI 10.1016/S0003-9993(98)90421-X; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Cui JG, 2000, PAIN, V88, P239, DOI 10.1016/S0304-3959(00)00331-6; Dickinson T, 1999, TRENDS PHARMACOL SCI, V20, P324, DOI 10.1016/S0165-6147(99)01340-1; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fukushima N, 2002, NEUROSCIENTIST, V8, P540, DOI 10.1177/1073858402238513; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gillespie CS, 2000, NEURON, V26, P523, DOI 10.1016/S0896-6273(00)81184-8; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hokfelt T, 2000, NEUROPHARMACOLOGY, V39, P1337, DOI 10.1016/S0028-3908(00)00010-1; Inoue M, 2003, J PHARMACOL EXP THER, V305, P495, DOI 10.1124/jpet.102.046326; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; ISHII I, IN PRESS ANN REV BIO; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kusaka S, 1998, J PHYSIOL-LONDON, V506, P445, DOI 10.1111/j.1469-7793.1998.445bw.x; Lin Q, 1996, J NEUROSCI, V16, P3026; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001; Ma WY, 2002, EUR J NEUROSCI, V15, P1037, DOI 10.1046/j.1460-9568.2002.01940.x; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; Malmberg AB, 1998, PAIN, V76, P215, DOI 10.1016/S0304-3959(98)00045-1; MAO JR, 1995, NEUROSCI LETT, V198, P75, DOI 10.1016/0304-3940(95)11975-3; Miletic V, 2000, NEUROSCI LETT, V288, P199, DOI 10.1016/S0304-3940(00)01237-4; PENTLAND B, 1994, PAIN, V59, P159, DOI 10.1016/0304-3959(94)90068-X; Pezet S, 2002, BRAIN RES REV, V40, P240, DOI 10.1016/S0165-0173(02)00206-0; Ramer MS, 1999, PAIN, pS111, DOI 10.1016/S0304-3959(99)00144-X; Rashid MH, 2003, J PHARMACOL EXP THER, V304, P940, DOI 10.1124/jpet.102.046250; Renback K, 1999, NEUROSCI LETT, V270, P59, DOI 10.1016/S0304-3940(99)00464-4; Renback K, 2000, MOL BRAIN RES, V75, P350, DOI 10.1016/S0169-328X(99)00333-2; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; Sommer C, 1998, BRAIN RES, V784, P154, DOI 10.1016/S0006-8993(97)01327-9; Ueda H, 1999, JPN J PHARMACOL, V79, P263, DOI 10.1254/jjp.79.263; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Weiner JA, 2001, J NEUROSCI, V21, P7069, DOI 10.1523/JNEUROSCI.21-18-07069.2001; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Willis WD, 2001, ANN NY ACAD SCI, V933, P142; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Ye X, 2000, JPN J PHARMACOL, V83, P161, DOI 10.1254/jjp.83.161; Ye XQ, 2002, NEUROREPORT, V13, P2169, DOI 10.1097/00001756-200212030-00002; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	46	418	483	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					712	718		10.1038/nm1060	http://dx.doi.org/10.1038/nm1060			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195086				2022-12-27	WOS:000222460400025
J	Koo, SH; Satoh, H; Herzig, S; Lee, CH; Hedrick, S; Kulkarni, R; Evans, RM; Olefsky, J; Montminy, M				Koo, SH; Satoh, H; Herzig, S; Lee, CH; Hedrick, S; Kulkarni, R; Evans, RM; Olefsky, J; Montminy, M			PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3	NATURE MEDICINE			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; COACTIVATOR PGC-1; HEPATIC GLUCONEOGENESIS; FASTING RESPONSE; GENE-EXPRESSION; NULL MICE; MOUSE; PROTEIN; GLUCOSE; HEPATOCYTES	Insulin resistance is a major hallmark in the development of type 2 diabetes, which is characterized by an impaired ability of insulin to inhibit glucose output from the liver and to promote glucose uptake in muscle(1,2). The nuclear hormone receptor coactivator PGC-1 (peroxisome proliferator-activated (PPAR)-gamma coactivator-1) has been implicated in the onset of type 2 diabetes. Hepatic PGC-1 expression is elevated in mouse models of this disease, where it promotes constitutive activation of gluconeogenesis and fatty acid oxidation through its association with the nuclear hormone receptors HNF-4 and PPAR-alpha, respectively(3-5). Here we show that PGC-1-deficient mice, generated by adenoviral delivery of PGC-1 RNA interference (RNAi) to the liver, experience fasting hypoglycemia. Hepatic insulin sensitivity was enhanced in PGC-1-deficient mice, reflecting in part the reduced expression of the mammalian tribbles homolog TRB-3, a fasting-inducible inhibitor of the serine-threonine kinase Akt/PKB (ref. 6). We show here that, in the liver, TRB-3 is a target for PPAR-alpha. Knockdown of hepatic TRB-3 expression improved glucose tolerance, whereas hepatic overexpression of TRB-3 reversed the insulin-sensitive phenotype of PGC-1-deficient mice. These results indicate a link between nuclear hormone receptor and insulin signaling pathways, and suggest a potential role for TRB-3 inhibitors in the treatment of type 2 diabetes.	Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Gene Express Labs, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Salk Institute; University of California System; University of California San Diego; Salk Institute; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Montminy, M (corresponding author), Salk Inst Biol Studies, Peptide Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	montminy@salk.edu	Evans, Ronald/AAF-4001-2019; Satoh, Hiroaki/E-9096-2017; Koo, Seung-Hoi/E-2763-2015	Evans, Ronald/0000-0002-9986-5965; Satoh, Hiroaki/0000-0002-0353-5807; Koo, Seung-Hoi/0000-0001-8769-2879; Herzig, Stephan/0000-0003-3950-3652	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037828] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM R01 37828] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernal-Mizrachi C, 2003, NAT MED, V9, P1069, DOI 10.1038/nm898; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brown PJ, 2001, BIOORG MED CHEM LETT, V11, P1225, DOI 10.1016/S0960-894X(01)00188-3; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hevener AL, 2001, DIABETES, V50, P2316, DOI 10.2337/diabetes.50.10.2316; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hribal ML, 2002, AM J PHYSIOL-ENDOC M, V282, pE977, DOI 10.1152/ajpendo.00561.2001; IMAI E, 1993, J BIOL CHEM, V268, P5353; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Klingenspor M, 1999, J BIOL CHEM, V274, P23078, DOI 10.1074/jbc.274.33.23078; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Kruszynska YT, 2002, J CLIN ENDOCR METAB, V87, P226, DOI 10.1210/jc.87.1.226; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	28	458	487	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					530	534		10.1038/nm1044	http://dx.doi.org/10.1038/nm1044			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15107844				2022-12-27	WOS:000221242400032
J	Kieran, D; Kalmar, B; Dick, JRT; Riddoch-Contreras, J; Burnstock, G; Greensmith, L				Kieran, D; Kalmar, B; Dick, JRT; Riddoch-Contreras, J; Burnstock, G; Greensmith, L			Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; UP-REGULATION; FACTOR-I; STRESS; TRANSCRIPTION; DEGENERATION; MOTONEURONS; BIMOCLOMOL; ACTIVATION	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis(1,2). This condition has no cure(3) and results in eventual death, usually within 1-5 years of diagnosis(1,2). Although the specific etiology of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1)(4). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathology that are very similar to that seen in human ALS patients(5,6). Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1(G93A)). Arimoclomol-treated SOD1(G93A) mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacological activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.	UCL, Natl Hosp Neurol & Neurosurg, Inst Neurol,Graham Watts Lab, Sobell Dept Motor Neurosci & Movement Disorders, London WC1N 3BG, England; Royal Free & Univ Coll Med Sch, Auton Neurosci Inst, London NW2 3PF, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	Greensmith, L (corresponding author), UCL, Natl Hosp Neurol & Neurosurg, Inst Neurol,Graham Watts Lab, Sobell Dept Motor Neurosci & Movement Disorders, Queen Sq, London WC1N 3BG, England.	l.greensmith@ion.ucl.ac.uk		Kalmar, Bernadett/0000-0003-3747-4843				Batulan Z, 2003, J NEUROSCI, V23, P5789; DICK J, 1995, NEUROMUSCULAR DISORD, V5, P371, DOI 10.1016/0960-8966(94)00088-Q; GAROFALO O, 1991, NEUROPATH APPL NEURO, V17, P39, DOI 10.1111/j.1365-2990.1991.tb00692.x; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hargitai J, 2003, BIOCHEM BIOPH RES CO, V307, P689, DOI 10.1016/S0006-291X(03)01254-3; Kalmar B, 2002, EXP NEUROL, V176, P87, DOI 10.1006/exnr.2002.7945; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Miller RG, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001447; Morrison AJ, 2000, J NEUROCHEM, V75, P363, DOI 10.1046/j.1471-4159.2000.0750363.x; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Shaw PJ, 1999, BMJ-BRIT MED J, V318, P1118, DOI 10.1136/bmj.318.7191.1118; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Vigh L, 1997, NAT MED, V3, P1150, DOI 10.1038/nm1097-1150; Vleminckx V, 2002, J NEUROPATH EXP NEUR, V61, P968, DOI 10.1093/jnen/61.11.968; White CM, 2000, NEUROSCIENCE, V95, P1101; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	20	384	426	1	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2004	10	4					402	405		10.1038/nm1021	http://dx.doi.org/10.1038/nm1021			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034571				2022-12-27	WOS:000220587000032
J	Reece, WHH; Pinder, M; Gothard, PK; Milligan, P; Bojang, K; Doherty, T; Plebanski, M; Akinwunmi, P; Everaere, S; Watkins, KR; Voss, G; Tornieporth, N; Alloueche, A; Greenwood, BM; Kester, KE; McAdam, KPWJ; Cohen, J; Hill, AVS				Reece, WHH; Pinder, M; Gothard, PK; Milligan, P; Bojang, K; Doherty, T; Plebanski, M; Akinwunmi, P; Everaere, S; Watkins, KR; Voss, G; Tornieporth, N; Alloueche, A; Greenwood, BM; Kester, KE; McAdam, KPWJ; Cohen, J; Hill, AVS			A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease	NATURE MEDICINE			English	Article							MALARIA VACCINE; EFFICACY; SURFACE; LYMPHOCYTES; ANTIBODIES; RTS,S/AS02; INDUCTION; SUBSETS; TARGETS	Many human T-cell responses specific for epitopes in Plasmodium falciparum have been described, but none has yet been shown to be predictive of protection against natural malaria infection(1). Here we report a peptide-specific T-cell assay that is strongly associated with protection of humans in The Gambia, West Africa, from both malaria infection and disease. The assay detects interferon-gamma-secreting CD4(+) T cells specific for a conserved sequence from the circumsporozoite protein, which binds to many human leukocyte antigen (HLA)-DR types(2). The correlation was observed using a cultured, rather than an ex vivo, ELISPOT assay that measures central memory-type T cells rather than activated effector T cells(3,4). These findings provide direct evidence for a protective role for CD4(+) T cells in humans, and a precise target for the design of improved vaccines against P. falciparum.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; MRC Labs, Fajara, Gambia; GlaxoSmithKline Biol, B-1330 Rixensart, Belgium; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Walter Reed Army Inst Res, Silver Spring, MD 20910 USA	University of Oxford; MRC Laboratory Molecular Biology; GlaxoSmithKline; University of London; London School of Hygiene & Tropical Medicine; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Hill, AVS (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.	Adrian.Hill@ndm.ox.ac.uk	Kester, Kent/A-2114-2011; HILL, Adrian V>S>/C-1306-2008; Kester, Kent/AAF-8235-2020; Milligan, Paul/D-8985-2017; Plebanski, Magdalena/AAU-3144-2021	Kester, Kent/0000-0002-5056-0802; Kester, Kent/0000-0002-5056-0802; Milligan, Paul/0000-0003-3430-3395; Bojang, Kalifa/0000-0001-7506-0938; , Magdalena/0000-0001-6889-3667				Aidoo M, 2000, PARASITOL TODAY, V16, P50, DOI 10.1016/S0169-4758(99)01592-6; Alloueche A, 2003, AM J TROP MED HYG, V68, P97, DOI 10.4269/ajtmh.2003.68.97; Baron V, 2003, IMMUNITY, V18, P193, DOI 10.1016/S1074-7613(03)00020-7; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Flanagan KL, 2003, AM J TROP MED HYG, V68, P421, DOI 10.4269/ajtmh.2003.68.421; Flanagan KL, 2001, J IMMUNOL, V167, P4729, DOI 10.4049/jimmunol.167.8.4729; Godkin AJ, 2002, J IMMUNOL, V169, P2210, DOI 10.4049/jimmunol.169.4.2210; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; HOFFMAN SL, 1989, J IMMUNOL, V142, P1299; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Pinder M, 2004, CLIN EXP IMMUNOL, V135, P286, DOI 10.1111/j.1365-2249.2004.02371.x; Polley SD, 2003, INFECT IMMUN, V71, P1833, DOI 10.1128/IAI.71.4.1833-1842.2003; RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schwenk R, 2003, PARASITE IMMUNOL, V25, P17, DOI 10.1046/j.1365-3024.2003.00495.x; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; SINIGAGLIA F, 1988, EUR J IMMUNOL, V18, P633, DOI 10.1002/eji.1830180422; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Sun PF, 2003, J IMMUNOL, V171, P6961, DOI 10.4049/jimmunol.171.12.6961; Wang RB, 1996, J IMMUNOL, V157, P4061; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; WIZEL B, 1995, J EXP MED, V182, P1435, DOI 10.1084/jem.182.5.1435; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; ZAVALA F, 1987, J EXP MED, V166, P1591, DOI 10.1084/jem.166.5.1591	29	218	227	0	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					406	410		10.1038/nm1009	http://dx.doi.org/10.1038/nm1009			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034567				2022-12-27	WOS:000220587000033
J	Mandavilli, A				Mandavilli, A			Profile - Marc Tessier-Lavigne	NATURE MEDICINE			English	Biographical-Item																			0	8	8	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					10	10		10.1038/nm0104-10	http://dx.doi.org/10.1038/nm0104-10			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702615				2022-12-27	WOS:000187743600016
J	Wang, TH; Niu, GL; Kortylewski, M; Burdelya, L; Shain, K; Zhang, SM; Bhattacharya, R; Gabrilovich, D; Heller, R; Coppola, D; Dalton, W; Jove, R; Pardoll, D; Yu, H				Wang, TH; Niu, GL; Kortylewski, M; Burdelya, L; Shain, K; Zhang, SM; Bhattacharya, R; Gabrilovich, D; Heller, R; Coppola, D; Dalton, W; Jove, R; Pardoll, D; Yu, H			Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells	NATURE MEDICINE			English	Article							DENDRITIC CELLS; GENE-REGULATION; ANTIGEN; DIFFERENTIATION; TRANSFORMATION; ACTIVATION; REJECTION; INTERLEUKIN-10; LYMPHOCYTES; EXPRESSION	Although tumor progression involves processes such as tissue invasion that can activate inflammatory responses, the immune system largely ignores or tolerates disseminated cancers. The mechanisms that block initiation of immune responses during cancer development are poorly understood. We report here that constitutive activation of Stat-3, a common oncogenic signaling pathway, suppresses tumor expression of proinflammatory mediators. Blocking Stat-3 in tumor cells increases expression of proinflammatory cytokines and chemokines that activate innate immunity and dendritic cells, leading to tumor-specific T-cell responses. In addition, constitutive Stat-3 activity induces production of pleiotropic factors that inhibit dendritic cell functional maturation. Tumor-derived factors inhibit dendritic cell maturation through Stat-3 activation in progenitor cells. Thus, inhibition of antitumor immunity involves a cascade of Stat-3 activation propagating from tumor to dendritic cells. We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system.	Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Immunol Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Clin Invest Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	Johns Hopkins University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Pardoll, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.		Heller, Richard/I-6605-2012; Kortylewski, Marcin/H-8052-2019; Gabrilovich, Dmitry/ABE-7122-2020; Heller, Richard/ABF-1445-2020	Kortylewski, Marcin/0000-0002-6003-1816; Heller, Richard/0000-0003-1899-3859; YU, Hua/0000-0003-0931-1000				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje; Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brossart P, 2000, CANCER RES, V60, P4485; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng FD, 2003, IMMUNITY, V19, P425, DOI 10.1016/S1074-7613(03)00232-2; DAVIDSON JM, 1992, INFLAMMATION BASIC P, P809; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fuchs E J, 1996, Semin Immunol, V8, P271, DOI 10.1006/smim.1996.0035; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Lu ZB, 2000, J EXP MED, V191, P541, DOI 10.1084/jem.191.3.541; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Pardoll DM, 1998, NAT MED, V4, P525, DOI 10.1038/nm0598supp-525; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Sombroek CC, 2002, J IMMUNOL, V168, P4333, DOI 10.4049/jimmunol.168.9.4333; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; URBAN JL, 1982, J EXP MED, V155, P557, DOI 10.1084/jem.155.2.557; UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; WORTZEL RD, 1983, NATURE, V304, P165, DOI 10.1038/304165a0	38	828	889	1	61	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					48	54		10.1038/nm976	http://dx.doi.org/10.1038/nm976			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702634				2022-12-27	WOS:000187743600038
J	Camargo, FD; Green, R; Capetenaki, Y; Jackson, KA; Goodell, MA				Camargo, FD; Green, R; Capetenaki, Y; Jackson, KA; Goodell, MA			Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates	NATURE MEDICINE			English	Article							BONE-MARROW CELLS; MDX MOUSE MUSCLE; IN-VIVO; MUSCULAR-DYSTROPHY; TRANSGENIC MICE; REGENERATION; EXPRESSION; TRANSPLANTATION; MACROPHAGES; FUSION	Recent studies have shown that cells from the bone marrow can give rise to differentiated skeletal muscle fibers. However, the mechanisms and identities of the cell types involved have remained unknown, and the validity of the observation has been questioned. Here, we use transplantation of single CD45(+) hematopoietic stem cells (HSCs) to demonstrate that the entire circulating myogenic activity in bone marrow is derived from HSCs and their hematopoietic progeny. We also show that ongoing muscle regeneration and inflammatory cell infiltration are required for HSC- derived contribution, which does not occur through a myogenic stem cell intermediate. Using a lineage tracing strategy, we show that myofibers are derived from mature myeloid cells in response to injury. Our results indicate that circulating myeloid cells, in response to inflammatory cues, migrate to regenerating skeletal muscle and stochastically incorporate into mature myofibers.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Baylor Coll Med, Mol Cell Biol Dept, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Goodell, MA (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 1 Baylor Plaza,BCM505, Houston, TX 77030 USA.			Goodell, Margaret A./0000-0003-1111-2932				ALVAREZDOLADO M, 2003, NATURE; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Corti S, 2002, EXP CELL RES, V277, P74, DOI 10.1006/excr.2002.5543; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; De la Porte S, 1999, INT REV CYTOL, V191, P99, DOI 10.1016/S0074-7696(08)60158-8; De Luca A, 2002, NEUROMUSCULAR DISORD, V12, pS142, DOI 10.1016/S0960-8966(02)00100-1; Ferrari G, 2001, NATURE, V411, P1014, DOI 10.1038/35082631; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fukada S, 2002, J CELL SCI, V115, P1285; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Goodell MA, 2001, CURR OPIN CELL BIOL, V13, P662, DOI 10.1016/S0955-0674(00)00268-4; GOODELL MA, 2002, CURRENT PROTOCOLS CY, V2; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jorgensen C, 2003, GENE THER, V10, P928, DOI 10.1038/sj.gt.3302019; Kawada H, 2001, BLOOD, V98, P2008, DOI 10.1182/blood.V98.7.2008; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lescaudron L, 1999, NEUROMUSCULAR DISORD, V9, P72, DOI 10.1016/S0960-8966(98)00111-4; Lu QL, 1998, J HISTOCHEM CYTOCHEM, V46, P977, DOI 10.1177/002215549804600813; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; McKinney-Freeman SL, 2003, EXP HEMATOL, V31, P806, DOI 10.1016/S0301-472X(03)00186-3; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; ORIMO S, 1991, MUSCLE NERVE, V14, P515, DOI 10.1002/mus.880140605; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Parrish EP, 1996, GENE THER, V3, P13; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; QUINLAN JG, 1995, MUSCLE NERVE, V18, P201, DOI 10.1002/mus.880180209; RALSTON E, 1989, SCIENCE, V244, P1066, DOI 10.1126/science.2543074; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Vignery A, 2000, INT J EXP PATHOL, V81, P291, DOI 10.1046/j.1365-2613.2000.00164.x; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; WAKEFORD S, 1991, MUSCLE NERVE, V14, P42, DOI 10.1002/mus.880140108; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wong BLY, 2002, J CHILD NEUROL, V17, P183, DOI 10.1177/088307380201700306; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	53	311	337	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1520	1527		10.1038/nm963	http://dx.doi.org/10.1038/nm963			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625546				2022-12-27	WOS:000186845400036
J	Feldmann, M; Maini, RN				Feldmann, M; Maini, RN			TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases	NATURE MEDICINE			English	Editorial Material							TUMOR-NECROSIS-FACTOR; CHIMERIC MONOCLONAL-ANTIBODY; COLLAGEN-INDUCED ARTHRITIS; FACTOR-ALPHA CA2; LETHAL BACTEREMIA; EXPRESSION; INTERLEUKIN-1; METHOTREXATE; INHIBITORS; CYTOKINES		Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst, Div Rheumatol, London W6 8LH, England	Imperial College London; University of Oxford	Feldmann, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst, Div Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.							AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; *ATTRACT STUD GROU, IN PRESS ARTHR RHEUM; BOTTAZZO GF, 1983, LANCET, V2, P1115; BRENNAN FM, 1989, LANCET, V2, P244; BUCHAN G, 1988, CLIN EXP IMMUNOL, V73, P449; Charles P, 1999, J IMMUNOL, V163, P1521; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; Day R, 2002, LANCET, V359, P540, DOI 10.1016/S0140-6736(02)07718-8; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627; HAWORTH C, 1991, EUR J IMMUNOL, V21, P2575, DOI 10.1002/eji.1830211039; JANOSSY G, 1981, LANCET, V2, P839; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KLARESKOG L, 1982, P NATL ACAD SCI-BIOL, V79, P3632, DOI 10.1073/pnas.79.11.3632; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Nishimoto N, 2003, J RHEUMATOL, V30, P1426; Paleolog EM, 1998, ARTHRITIS RHEUM, V41, P1258, DOI 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; Taylor PC, 2000, ARTHRITIS RHEUM-US, V43, P38, DOI 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x	32	464	492	0	27	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1245	1250		10.1038/nm939	http://dx.doi.org/10.1038/nm939			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14520364				2022-12-27	WOS:000185669700022
J	Monk, NJ; Hargreaves, REG; Marsh, JE; Farrar, CA; Sacks, SH; Millrain, M; Simpson, E; Dyson, J; Jurcevic, S				Monk, NJ; Hargreaves, REG; Marsh, JE; Farrar, CA; Sacks, SH; Millrain, M; Simpson, E; Dyson, J; Jurcevic, S			Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade	NATURE MEDICINE			English	Article							RENAL-ALLOGRAFT REJECTION; ANIMAL TRANSPLANT MODEL; NONOBESE DIABETIC MICE; CD40 LIGAND; MONOCLONAL-ANTIBODY; DIABETOGENIC AUTOIMMUNITY; DEFICIENT MICE; FUSION PROTEIN; CUTTING EDGE; TOLERANCE	Although the underlying mechanisms are not well understood, it is generally believed that antigen recognition by T cells in the absence of costimulation may alter the immune response, leading to anergy or tolerance. Further support for this concept comes from animal models of autoimmunity and transplantation, where treatments based on costimulation blockade, in particular CD40 ligand (CD40L)-specific antibodies, have been highly effective. We investigated the mechanisms of action of an antibody to CD40L and provide evidence that its effects are dependent on the constant (Fc) region. Prolongation of graft survival is dependent on both complement- and Fc receptor-mediated mechanisms in a major histocompatibility complex (MHC)-mismatched skin transplant model. These data suggest that antibodies to CD40L act through selective depletion of activated T cells, rather than exerting immune modulation by costimulation blockade as currently postulated. This finding opens new avenues for treatment of immune disorders based on selective targeting of activated T cells.	Imperial Coll Sch Med, Hammersmith Hosp, MRC, Ctr Clin Sci,Transplantat Biol Grp, London W12 0NN, England; Univ London Kings Coll, Guys Kings & St Thomas Med Sch, Guys Hosp, Dept Nephrol & Transplantat, London SE1 9RT, England	Imperial College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Simpson, E (corresponding author), Imperial Coll Sch Med, Hammersmith Hosp, MRC, Ctr Clin Sci,Transplantat Biol Grp, London W12 0NN, England.			Simpson, Elizabeth/0000-0002-2118-3139; Sacks, Steven/0000-0001-6361-9095				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Dharnidharka VR, 2000, NAT MED, V6, P115, DOI 10.1038/72166; Durham MM, 2000, J IMMUNOL, V165, P1, DOI 10.4049/jimmunol.165.1.1; Ferguson TA, 1999, NAT MED, V5, P1231, DOI 10.1038/15180; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; Graca L, 2000, J IMMUNOL, V165, P4783, DOI 10.4049/jimmunol.165.9.4783; Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600-065X.1996.tb00921.x; Gudmundsdottir H, 1999, J AM SOC NEPHROL, V10, P1356; Hancock WW, 1999, CURR OPIN NEPHROL HY, V8, P317, DOI 10.1097/00041552-199905000-00007; Houghton AN, 2000, NAT MED, V6, P373, DOI 10.1038/74621; Illei GG, 2000, CURR OPIN IMMUNOL, V12, P712, DOI 10.1016/S0952-7915(00)00167-9; Iwakoshi NN, 2000, J IMMUNOL, V164, P512, DOI 10.4049/jimmunol.164.1.512; JENKINS MK, 1987, IMMUNOL REV, V95, P113, DOI 10.1111/j.1600-065X.1987.tb00502.x; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; LANE P, 1995, EUR J IMMUNOL, V25, P1788, DOI 10.1002/eji.1830250646; LANE P, 1993, IMMUNOLOGY, V80, P56; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li XC, 2000, CURR OPIN IMMUNOL, V12, P522, DOI 10.1016/S0952-7915(00)00133-3; Li YS, 2000, NAT MED, V6, P115, DOI 10.1038/72168; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Marsh JE, 2001, TRANSPLANTATION, V72, P1310, DOI 10.1097/00007890-200110150-00022; Matzinger P, 1999, NAT MED, V5, P616, DOI 10.1038/9458; Millrain M, 2001, J IMMUNOL, V167, P3756, DOI 10.4049/jimmunol.167.7.3756; PACHECOSILVA A, 1992, EUR J IMMUNOL, V22, P697, DOI 10.1002/eji.1830220312; Park SY, 1998, J CLIN INVEST, V102, P1229, DOI 10.1172/JCI3256; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Simpson E, 1997, ANNU REV IMMUNOL, V15, P39, DOI 10.1146/annurev.immunol.15.1.39; Smiley ST, 2000, TRANSPLANTATION, V70, P415, DOI 10.1097/00007890-200008150-00005; STROM TB, 1993, ANNU REV MED, V44, P343, DOI 10.1146/annurev.med.44.1.343; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; Waldmann H, 1999, NAT MED, V5, P1245, DOI 10.1038/15197; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260; Wells AD, 2001, PHILOS T R SOC B, V356, P617, DOI 10.1098/rstb.2001.0845; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Whitmire JK, 1996, J VIROL, V70, P8375, DOI 10.1128/JVI.70.12.8375-8381.1996; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Zheng XX, 1999, J IMMUNOL, V163, P4041; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	43	120	124	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1275	1280		10.1038/nm931	http://dx.doi.org/10.1038/nm931			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502279				2022-12-27	WOS:000185669700038
J	McDonald, DM; Choyke, PL				McDonald, DM; Choyke, PL			Imaging of angiogenesis: from microscope to clinic	NATURE MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST-CANCER; ULTRASOUND CONTRAST AGENTS; IN-VIVO ASSESSMENT; MICROVESSEL DENSITY; VASCULAR-PERMEABILITY; TUMOR VASCULARITY; BLOOD-VESSELS; CELL PROLIFERATION; PROSTATE-CANCER	Advances in imaging are transforming our understanding of angiogenesis and the evaluation of drugs that stimulate or inhibit angiogenesis in preclinical models and human disease. Vascular imaging makes it possible to quantify the number and spacing of blood vessels, measure blood flow and vascular permeability, and analyze cellular and molecular abnormalities in blood vessel walls. Microscopic methods ranging from fluorescence, confocal and multiphoton microscopy to electron microscopic imaging are particularly useful for elucidating structural and functional abnormalities of angiogenic blood vessels. Magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), ultrasonography and optical imaging provide noninvasive, functionally relevant images of angiogenesis in animals and humans. An ongoing dilemma is, however, that microscopic methods provide their highest resolution on preserved tissue specimens, whereas clinical methods give images of living tissues deep within the body but at much lower resolution and specificity and generally cannot resolve vessels of the microcirculation. Future challenges include developing new imaging methods that can bridge this resolution gap and specifically identify angiogenic vessels. Another goal is to determine which microscopic techniques are the best benchmarks for interpreting clinical images. The importance of angiogenesis in cancer, chronic inflammatory diseases, age-related macular degeneration and reversal of ischemic heart and limb disease provides incentive for meeting these challenges.	Univ Calif San Francisco, Ctr Comprehens Canc, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; NIH, Imaging Sci Program, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA	McDonald, DM (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Cardiovasc Res Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.	dmcd@itsa.ucsf.edu; pchoyke@nih.gov			NATIONAL CANCER INSTITUTE [P50CA090270] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059157, P01HL024136] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA90270] Funding Source: Medline; NHLBI NIH HHS [HL-59157, HL-24136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; Alliot F, 1999, J NEUROSCI RES, V58, P367; Anderson SA, 2000, MAGNET RESON MED, V44, P433, DOI 10.1002/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO;2-9; Bacharach SL, 2002, J NUCL MED, V43, P1542; Bartel H, 2000, J ANAT, V197, P157, DOI 10.1046/j.1469-7580.2000.19720157.x; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bhujwalla ZM, 2001, NEOPLASIA, V3, P143, DOI 10.1038/sj.neo.7900129; Biggerstaff J, 1997, CYTOMETRY, V29, P122, DOI 10.1002/(SICI)1097-0320(19971001)29:2<122::AID-CYTO4>3.0.CO;2-F; Bogdanov A. Jr., 1999, Neoplasia (New York), V1, P438, DOI 10.1038/sj.neo.7900044; Bredow S, 2000, EUR J CANCER, V36, P675, DOI 10.1016/S0959-8049(99)00335-4; Brekken RA, 1998, CANCER RES, V58, P1952; Bremer C, 2003, RADIOLOGY, V226, P214, DOI 10.1148/radiol.2261012140; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Buckley DL, 2002, MAGN RESON MED, V47, P601, DOI 10.1002/mrm.10080; Budinger TF, 1998, SEMIN NUCL MED, V28, P247, DOI 10.1016/S0001-2998(98)80030-5; BURGIO VL, 1994, CLIN EXP IMMUNOL, V96, P170; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Buschard K, 1996, DIABETOLOGIA, V39, P658; Calliada F, 1998, EUR J RADIOL, V27, pS157, DOI 10.1016/S0720-048X(98)00057-6; Campbell RB, 2002, CANCER RES, V62, P6831; Cha S, 2002, RADIOLOGY, V223, P11, DOI 10.1148/radiol.2231010594; Chang SS, 1999, CANCER RES, V59, P3192; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Cho H, 2003, FASEB J, V17, P440, DOI 10.1096/fj.02-0340fje; Costouros NG, 2002, J CELL BIOCHEM, P72, DOI 10.1002/jcb.10426; DELATORRE M, 1995, HUM PATHOL, V26, P180, DOI 10.1016/0046-8177(95)90035-7; Dickson SE, 2001, J ENDOCRINOL, V168, P409, DOI 10.1677/joe.0.1680409; Drevs J, 2002, CANCER RES, V62, P4015; Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100; DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101, DOI 10.1111/j.1749-6632.1992.tb51603.x; Eberhard A, 2000, CANCER RES, V60, P1388; Fleischer AC, 1999, J ULTRAS MED, V18, P547, DOI 10.7863/jum.1999.18.8.547; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; Forsberg F, 1999, RADIOLOGY, V210, P125, DOI 10.1148/radiology.210.1.r99ja11125; Forsberg F, 1998, ULTRASONICS, V36, P695, DOI 10.1016/S0041-624X(97)00123-6; FOX SB, 1993, CANCER RES, V53, P4161; Fukumura D, 1998, CANCER METAST REV, V17, P77, DOI 10.1023/A:1005908805527; Gale NW, 2001, DEV BIOL, V230, P151, DOI 10.1006/dbio.2000.0112; Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6; Griffioen AW, 1996, CANCER RES, V56, P1111; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Haubner R, 2001, CANCER RES, V61, P1781; Hawighorst H, 1997, CANCER RES, V57, P4777; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Herbst RS, 2002, J CLIN ONCOL, V20, P3804, DOI 10.1200/JCO.2002.05.102; Hlatky L, 2002, JNCI-J NATL CANCER I, V94, P883; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Iordanescu I, 2002, RADIOLOGY, V222, P460, DOI 10.1148/radiol.2222010660; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; JAIN RK, 1990, CANCER METAST REV, V9, P253, DOI 10.1007/BF00046364; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778; JOYCE NC, 1985, J CELL BIOL, V100, P1379, DOI 10.1083/jcb.100.5.1379; JOYCE NC, 1985, J CELL BIOL, V100, P1387, DOI 10.1083/jcb.100.5.1387; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kisker O, 2001, CANCER RES, V61, P7669; Kobayashi H, 2001, MAGNET RESON MED, V45, P454, DOI 10.1002/1522-2594(200103)45:3<454::AID-MRM1060>3.0.CO;2-M; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Konerding MA, 1995, SCANNING MICROSCOPY, V9, P1233; Krishna MC, 2001, SEMIN RADIAT ONCOL, V11, P58, DOI 10.1053/srao.2001.18104; Kunstfeld R, 2003, J INVEST DERMATOL, V120, P476, DOI 10.1046/j.1523-1747.2003.12057.x; KUZU I, 1993, LAB INVEST, V69, P322; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; LATKER CH, 1981, INVEST OPHTH VIS SCI, V21, P689; Lee WS, 1998, CIRC RES, V82, P845; Leong-Poi H, 2003, CIRCULATION, V107, P455, DOI 10.1161/01.CIR.0000044916.05919.8B; LESS JR, 1991, CANCER RES, V51, P265; Lewin M, 1999, INT J CANCER, V83, P798, DOI 10.1002/(SICI)1097-0215(19991210)83:6<798::AID-IJC16>3.0.CO;2-W; Li KCP, 2002, J CELL BIOCHEM, P65, DOI 10.1002/jcb.10401; Lichtenbeld Hera C., 1996, Microcirculation (Philadelphia), V3, P349, DOI 10.3109/10739689609148307; Lobo CL, 1999, ARCH OPHTHALMOL-CHIC, V117, P631; MACLENNAN GT, 1995, UROLOGY, V46, P27, DOI 10.1016/S0090-4295(99)80153-8; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; MARTINPADURA I, 1995, J PATHOL, V175, P51, DOI 10.1002/path.1711750109; McDonald DM, 2000, CANCER METAST REV, V19, P109, DOI 10.1023/A:1026529222845; McDonald DM, 2002, CANCER RES, V62, P5381; MIETTINEN M, 1994, MODERN PATHOL, V7, P82; Miles KA, 2000, ACAD RADIOL, V7, P840, DOI 10.1016/S1076-6332(00)80632-7; Mitchell CA, 1998, DEV DYNAM, V213, P322, DOI 10.1002/(SICI)1097-0177(199811)213:3<322::AID-AJA8>3.0.CO;2-E; Modlich U, 1996, LAB INVEST, V74, P771; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; Mueller A. J., 2001, International Ophthalmology, V23, P385, DOI 10.1023/A:1014471118208; Neeman M, 2002, J CELL BIOCHEM, P11, DOI 10.1002/jcb.10399; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147; Nielsen BS, 1997, LAB INVEST, V77, P345; Okuhata Y, 1999, J MAGN RESON IMAGING, V9, P685, DOI 10.1002/(SICI)1522-2586(199905)9:5<685::AID-JMRI10>3.3.CO;2-R; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Padhani AR, 2001, BRIT J RADIOL, V74, P886, DOI 10.1259/bjr.74.886.740886; Padhani AR, 2001, RADIOLOGY, V218, P365, DOI 10.1148/radiology.218.2.r01ja04365; Pasqualini R, 2000, CANCER RES, V60, P722; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 2002, TRENDS MOL MED, V8, P563, DOI 10.1016/S1471-4914(02)02429-2; Pearlman JD, 2002, CURR PHARM DESIGN, V8, P1467, DOI 10.2174/1381612023394395; Pham CD, 1998, CANCER INVEST, V16, P225, DOI 10.3109/07357909809039771; Ran S, 2002, INT J RADIAT ONCOL, V54, P1479, DOI 10.1016/S0360-3016(02)03928-7; RENKONEN R, 1992, AM J PATHOL, V140, P763; ROUSSEL F, 1988, LAB ANIM, V22, P135, DOI 10.1258/002367788780864457; Rubin MA, 1999, UROLOGY, V53, P542, DOI 10.1016/S0090-4295(98)00561-5; Santimaria M, 2003, CLIN CANCER RES, V9, P571; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Schlingemann RO, 1996, J PATHOL, V179, P436; SCHLINGEMANN RO, 1991, AM J PATHOL, V138, P1335; SCHMIDT D, 1995, PATHOL RES PRACT, V191, P410, DOI 10.1016/S0344-0338(11)80727-2; Shirakawa K, 2001, CANCER RES, V61, P445; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; Solovey AN, 2001, J LAB CLIN MED, V138, P322, DOI 10.1067/mlc.2001.118519; St Croix B, 2000, SCIENCE, V289, P1197; Sweeney P, 2002, CLIN CANCER RES, V8, P2714; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; Taylor NJ, 2001, J MAGN RESON IMAGING, V14, P156, DOI 10.1002/jmri.1166; Thomas JP, 2003, J CLIN ONCOL, V21, P223, DOI 10.1200/JCO.2003.12.120; Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TROTTER MJ, 1990, BRIT J CANCER, V62, P903, DOI 10.1038/bjc.1990.406; Turetschek K, 2001, J MAGN RESON IMAGING, V13, P882, DOI 10.1002/jmri.1126; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621; Vale P R, 2001, J Interv Cardiol, V14, P511, DOI 10.1111/j.1540-8183.2001.tb00367.x; Vartanian RK, 1995, LAB INVEST, V73, P844; VARTANIAN RK, 1994, AM J PATHOL, V144, P1188; VRACKO R, 1974, AM J PATHOL, V77, P314; Warren BA, 1979, TUMOR BLOOD CIRCULAT, P1; WEIDNER N, 1995, AM J PATHOL, V147, P9; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Williams BB, 2002, MAGNET RESON MED, V47, P634, DOI 10.1002/mrm.10089; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Yang DJ, 2002, CANCER BIOTHER RADIO, V17, P233, DOI 10.1089/108497802753773856; Yang M, 2002, P NATL ACAD SCI USA, V99, P3824, DOI 10.1073/pnas.052029099; YONEZAWA S, 1987, AM J CLIN PATHOL, V88, P405, DOI 10.1093/ajcp/88.4.405; YUAN F, 1995, CANCER RES, V55, P3752; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521; Zhao DW, 2001, AM J CLIN ONCOL-CANC, V24, P462, DOI 10.1097/00000421-200110000-00010	140	776	808	3	209	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					713	725		10.1038/nm0603-713	http://dx.doi.org/10.1038/nm0603-713			13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12778170				2022-12-27	WOS:000183444100026
J	Obici, S; Feng, ZH; Arduini, A; Conti, R; Rossetti, L				Obici, S; Feng, ZH; Arduini, A; Conti, R; Rossetti, L			Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production	NATURE MEDICINE			English	Article							FATTY-ACID; BODY-WEIGHT; GENE-EXPRESSION; LEPTIN; BRAIN; COA; CARBOXYLASE; PERFORMANCE; RECEPTOR; OBESITY	The enzyme carnitine palmitoyltransferase-1 (CPT1) regulates long-chain fatty acid (LCFA) entry into mitochondria, where the LCFAs undergo beta-oxidation. To investigate the mechanism(s) by which central metabolism of lipids can modulate energy balance, we selectively reduced lipid oxidation in the hypothalamus. We decreased the activity of CPT1 by administering to rats a ribozyme-containing plasmid designed specifically to decrease the expression of this enzyme or by infusing pharmacological inhibitors of its activity into the third cerebral ventricle. Either genetic or biochemical inhibition of hypothalamic CPT1 activity was sufficient to substantially diminish food intake and endogenous glucose production. These results indicated that changes in the rate of lipid oxidation in selective hypothalamic neurons signaled nutrient availability to the hypothalamus, which in turn modulated the exogenous and endogenous inputs of nutrients into the circulation.	Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Mol Pharmacol, Bronx, NY 10461 USA; Sigma Tau Pharmaceut Ind, Dept Endocrinol & Metab, I-00040 Pomezia, Italy	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Leadiant Biosciences	Rossetti, L (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu	Arduini, Arduino/ABH-5284-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048321, R29DK045024, R37DK048321, R01DK045024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45024, DK48321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Air EL, 2002, NAT MED, V8, P179, DOI 10.1038/nm0202-179; ARDUINI A, 1994, J NEUROCHEM, V62, P1530; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; Blazquez C, 1999, J NEUROCHEM, V72, P1759, DOI 10.1046/j.1471-4159.1999.721759.x; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; ESSER V, 1993, J BIOL CHEM, V268, P5817; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; GOTO M, 1971, P SOC EXP BIOL MED, V136, P1294; Goula D, 1998, GENE THER, V5, P712, DOI 10.1038/sj.gt.3300635; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; Kopelman PG, 1998, LANCET, V352, P5; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; Makimura H, 2001, DIABETES, V50, P733, DOI 10.2337/diabetes.50.4.733; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MILLER JC, 1987, J NEUROCHEM, V49, P1507, DOI 10.1111/j.1471-4159.1987.tb01021.x; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Zammit V.A., 1994, DIABETES REV, V2, P132	33	403	420	1	24	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					756	761		10.1038/nm873	http://dx.doi.org/10.1038/nm873			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12754501				2022-12-27	WOS:000183444100032
J	Lindesmith, L; Moe, C; Marionneau, S; Ruvoen, N; Jiang, X; Lindbland, L; Stewart, P; LePendu, J; Baric, R				Lindesmith, L; Moe, C; Marionneau, S; Ruvoen, N; Jiang, X; Lindbland, L; Stewart, P; LePendu, J; Baric, R			Human susceptibility and resistance to Norwalk virus infection	NATURE MEDICINE			English	Article							BLOOD GROUP ANTIGENS; NONBACTERIAL GASTROENTERITIS; MOLECULAR EPIDEMIOLOGY; ENTERIC CALICIVIRUSES; VIRAL GASTROENTERITIS; HIV-1 INFECTION; VOLUNTEERS; OUTBREAKS; RESTRICTION; ANTIBODIES	Infectious diseases have influenced population genetics and the evolution of the structure of the human genome in part by selecting for host susceptibility alleles that modify pathogenesis. Norovirus infection is associated with similar to90% of epidemic non-bacterial acute gastroenteritis worldwide. Here, we show that resistance to Norwalk virus infection is multifactorial. Using a human challenge model, we showed that 29% of our study population was homozygous recessive for the alpha(1,2) fucosyltransferase gene (FUT2) in the ABH histo-blood group family and did not express the H type-1 oligosaccharide ligand required for Norwalk virus binding. The FUT2 susceptibility allele was fully penetrant against Norwalk virus infection as none of these individuals developed an infection after challenge, regardless of dose. Of the susceptible population that encoded a functional FUT2 gene, a portion was resistant to infection, suggesting that a memory immune response or some other unidentified factor also affords protection from Norwalk virus infection.	Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA; Emory Univ, Dept Int Hlth, Atlanta, GA 30322 USA; Inst Biol, Nantes, France; Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH USA; Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; Ecole Natl Vet, Nantes, France	University of North Carolina; University of North Carolina Chapel Hill; Emory University; Cincinnati Children's Hospital Medical Center; University of North Carolina; University of North Carolina Chapel Hill; Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique	Baric, R (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.	rbaric@sph.unc.edu	Marionneau-Lambot, Séverine/AAY-1452-2020; Le Pendu, Jacques/F-4760-2013; Moe, Christine L/G-6118-2012	Marionneau-Lambot, Séverine/0000-0002-5041-8531; Le Pendu, Jacques/0000-0002-4856-0387; 	NCRR NIH HHS [RR00046] Funding Source: Medline; NIAID NIH HHS [AI23946] Funding Source: Medline; NIGMS NIH HHS [GM63228] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063228] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDO T, 1995, J MED VIROL, V47, P145, DOI 10.1002/jmv.1890470207; Ball JM, 1999, GASTROENTEROLOGY, V117, P40, DOI 10.1016/S0016-5085(99)70548-2; Baric RS, 2002, J VIROL, V76, P3023, DOI 10.1128/JVI.76.6.3023-3030.2002; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DOLIN R, 1972, P SOC EXP BIOL MED, V140, P578, DOI 10.3181/00379727-140-36508; Fankhauser RL, 1998, J INFECT DIS, V178, P1571, DOI 10.1086/314525; FRIEDMAN MG, 1982, J IMMUNOL METHODS, V54, P203, DOI 10.1016/0022-1759(82)90061-8; Glass RI, 2000, J INFECT DIS, V181, pS254, DOI 10.1086/315588; GRAHAM DY, 1994, J INFECT DIS, V170, P34, DOI 10.1093/infdis/170.1.34; Harrington PR, 2002, J VIROL, V76, P12335, DOI 10.1128/JVI.76.23.12335-12343.2002; Harrington PR, 2002, J VIROL, V76, P730, DOI 10.1128/JVI.76.2.730-742.2002; HERWALDT BL, 1994, J CLIN MICROBIOL, V32, P861, DOI 10.1128/JCM.32.4.861-866.1994; HO MS, 1989, LANCET, V2, P961; Hutson AM, 2003, J VIROL, V77, P405, DOI 10.1128/JVI.77.1.405-415.2003; Hutson AM, 2002, J INFECT DIS, V185, P1335, DOI 10.1086/339883; JOHNSON PC, 1990, J INFECT DIS, V161, P18, DOI 10.1093/infdis/161.1.18; Koopmans M, 2000, J INFECT DIS, V181, pS262, DOI 10.1086/315573; Marie-Cardine A, 2002, CLIN INFECT DIS, V34, P1170, DOI 10.1086/339807; Marionneau S, 2002, GASTROENTEROLOGY, V122, P1967, DOI 10.1053/gast.2002.33661; Marionneau S, 2001, BIOCHIMIE, V83, P565, DOI 10.1016/S0300-9084(01)01321-9; Matsui SM, 2000, J INFECT DIS, V181, pS331, DOI 10.1086/315587; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; MOE CL, 1994, J CLIN MICROBIOL, V32, P642, DOI 10.1128/JCM.32.3.642-648.1994; MONROE SS, 1993, J CLIN MICROBIOL, V31, P2866, DOI 10.1128/JCM.31.11.2866-2872.1993; OKHUYSEN PC, 1995, J INFECT DIS, V171, P566, DOI 10.1093/infdis/171.3.566; Oriol R, 2000, VOX SANG, V78, P105; PARRINO TA, 1977, NEW ENGL J MED, V297, P86, DOI 10.1056/NEJM197707142970204; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; SAADI AT, 1994, FEMS IMMUNOL MED MIC, V8, P315, DOI 10.1111/j.1574-695X.1994.tb00458.x; Schaeffer AJ, 2001, INT J ANTIMICROB AG, V17, P245, DOI 10.1016/S0924-8579(01)00302-8; Sidmann FK, 1981, TECHNICAL MANUAL AM, V8th, P122; Simell B, 2001, J INFECT DIS, V183, P887, DOI 10.1086/319246; Svensson L, 2000, TRANSFUSION, V40, P856, DOI 10.1046/j.1537-2995.2000.40070856.x; WARD RL, 1992, J MED VIROL, V36, P222, DOI 10.1002/jmv.1890360313; WYATT RG, 1974, J INFECT DIS, V130, P523, DOI 10.1093/infdis/130.5.523; WYATT RG, 1974, J INFECT DIS, V129, P709, DOI 10.1093/infdis/129.6.709	38	754	808	3	142	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2003	9	5					548	553		10.1038/nm860	http://dx.doi.org/10.1038/nm860			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692541				2022-12-27	WOS:000182610600035
J	Chalhoub, N; Benachenhou, N; Rajapurohitam, V; Pata, M; Ferron, M; Frattini, A; Villa, A; Vacher, J				Chalhoub, N; Benachenhou, N; Rajapurohitam, V; Pata, M; Ferron, M; Frattini, A; Villa, A; Vacher, J			Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human	NATURE MEDICINE			English	Article							BONE-RESORPTION; TARGETED DISRUPTION; MICE; GENE; LOCALIZATION; DEFECTS; TRANSPLANTATION; DEFICIENCY; MEMBRANE; SUBUNIT	The spontaneous mouse grey-lethal (gl) mutation is responsible for a coat color defect and for the development of the most severe autosomal recessive form of osteopetrosis. Using a positional cloning approach, we have mapped and isolated the gl locus from a similar to1.5 cM genetic interval. The gl locus was identified in a bacterial artificial chromosome (BAC) contig by functional genetic complementation in transgenic mice. Genomic sequence analysis revealed that the gl mutation is a deletion resulting in complete loss of function. The unique similar to3 kb wild-type transcript is expressed primarily in osteoclasts and melanocytes as well as in brain, kidney, thymus and spleen. The gl gene is predicted to encode a 338-amino acid type I transmembrane protein that localizes to the intracellular compartment. Mutation in the human GL gene leads to severe recessive osteopetrosis. Our studies show that mouse Gl protein function is absolutely required for osteoclast and melanocyte maturation and function.	Univ Montreal, Inst Rech Clin Montreal, Fac Med, Montreal, PQ, Canada; CNR, Ist Tecnol Biomed Avanzate, Segrate, Italy	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Vacher, J (corresponding author), Univ Montreal, Inst Rech Clin Montreal, Fac Med, Montreal, PQ, Canada.	vacherj@ircm.qc.ca	Ferron, Mathieu/M-7794-2013; Frattini, Annalisa/B-7684-2015	Frattini, Annalisa/0000-0002-1166-3091; Villa, Anna/0000-0003-4428-9013				BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BEGG SK, 1993, J EXP MED, V177, P237, DOI 10.1084/jem.177.1.237; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BROWN D, 1988, J CLIN INVEST, V82, P2114, DOI 10.1172/JCI113833; Chalhoub N, 2001, MAMM GENOME, V12, P887, DOI 10.1007/s00335-001-1014-5; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Eapen M, 1998, BONE MARROW TRANSPL, V22, P941, DOI 10.1038/sj.bmt.1701474; EMERSON JA, 1992, DEV DYNAM, V195, P55, DOI 10.1002/aja.1001950106; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; GERRITSEN EJA, 1994, J PEDIATR-US, V125, P896, DOI 10.1016/S0022-3476(05)82004-9; Gruneberg H, 1936, J HERED, V27, P105; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Marcinkiewicz M, 1998, MOL BRAIN RES, V59, P229, DOI 10.1016/S0169-328X(98)00141-7; Palokangas H, 1997, J CELL SCI, V110, P1767; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; Rajapurohitam V, 2001, BONE, V28, P513, DOI 10.1016/S8756-3282(01)00416-1; REEVES JD, 1979, PEDIATRICS, V64, P202; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; THESINGH CW, 1985, BONE, V6, P43, DOI 10.1016/8756-3282(85)90406-5; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; Vacher J, 1999, MAMM GENOME, V10, P239, DOI 10.1007/s003359900980; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wilson CJ, 2000, ARCH DIS CHILD, V83, P449, DOI 10.1136/adc.83.5.449; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	40	197	204	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2003	9	4					399	406		10.1038/nm842	http://dx.doi.org/10.1038/nm842			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12627228				2022-12-27	WOS:000181987400029
J	Waldmann, TA				Waldmann, TA			Immunotherapy: past, present and future	NATURE MEDICINE			English	Review							B-CELL LYMPHOMA; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; MONOCLONAL-ANTIBODY; IN-VIVO; INTERLEUKIN-2 RECEPTOR; RECOMBINANT IMMUNOTOXIN; METASTATIC MELANOMA; ANTITUMOR IMMUNITY; CHEMOTHERAPY PLUS	Harnessing the immune system to treat chronic infectious diseases or cancer is a major goal of immunotherapy. Among others, impediments to this aim include host failure to identify tumor antigens, tolerance to self and negative immunoregulatory mechanisms. But with recent progress, active and passive immunotherapy are proving themselves as effective therapeutic strategies.	NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Waldmann, TA (corresponding author), NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.		Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660	NATIONAL CANCER INSTITUTE [ZIASC004002, Z01SC004002] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlers JD, 1997, J IMMUNOL, V158, P3947; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Axworthy DB, 2000, P NATL ACAD SCI USA, V97, P1802, DOI 10.1073/pnas.97.4.1802; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Baselga J, 1998, CANCER RES, V58, P2825; Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Berzofsky JA, 2001, NAT REV IMMUNOL, V1, P209, DOI 10.1038/35105075; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; COLEY WB, 1896, J HOPKINS HOSP B, V7, P157; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; El-Gabalawy HS, 2002, ARTHRITIS RES THER, V4, pS297, DOI 10.1186/ar568; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337; Gura T, 2002, NATURE, V417, P584, DOI 10.1038/417584a; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Krackhardt AM, 2002, BLOOD, V100, P2123, DOI 10.1182/blood-2002-02-0513; Kreitman RJ, 1999, BLOOD, V94, P3340, DOI 10.1182/blood.V94.10.3340.422k19_3340_3348; Kreitman RJ, 2000, J CLIN ONCOL, V18, P1622, DOI 10.1200/JCO.2000.18.8.1622; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; La Rosa C, 2001, BLOOD, V97, P1776; Labeur MS, 1999, J IMMUNOL, V162, P168; Lenardo MJ, 1996, J EXP MED, V183, P721, DOI 10.1084/jem.183.3.721; LYNCH RG, 1972, P NATL ACAD SCI USA, V69, P1540, DOI 10.1073/pnas.69.6.1540; MALONEY DG, 1994, BLOOD, V84, P2457; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; Onizuka S, 1999, CANCER RES, V59, P3128; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3; Press OW, 2001, BLOOD, V98, P2535, DOI 10.1182/blood.V98.8.2535; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; Ramshaw IA, 2000, IMMUNOL TODAY, V21, P163, DOI 10.1016/S0167-5699(00)01612-1; ROBBINS PF, 1996, CURR OPIN IMMUNOL, V8, P626; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; ROSENBERG SA, 1996, J IMMUNOTHER, V19, P8; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sarobe P, 1998, J CLIN INVEST, V102, P1239, DOI 10.1172/JCI3714; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shimizu J, 1999, J IMMUNOL, V163, P5211; Shimizu K, 2001, CANCER RES, V61, P2618; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Srivastava PK, 2000, NAT IMMUNOL, V1, P363, DOI 10.1038/80795; STEVENSON GT, 1977, FED PROC, V36, P2268; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(01)00093-0; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Zhang ML, 2002, BLOOD, V100, P208, DOI 10.1182/blood-2002-01-0107; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	70	418	494	0	90	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					269	277		10.1038/nm0303-269	http://dx.doi.org/10.1038/nm0303-269			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12612576	Green Published			2022-12-27	WOS:000181312300026
J	Palmer, HG; Larriba, MJ; Garcia, JM; Ordunez-Moran, P; Pena, C; Peiro, S; Puig, I; Rodriguez, R; de la Fuente, R; Bernad, A; Pollan, M; Bonilla, F; Gamallo, C; de Herreros, AG; Munoz, A				Palmer, HG; Larriba, MJ; Garcia, JM; Ordunez-Moran, P; Pena, C; Peiro, S; Puig, I; Rodriguez, R; de la Fuente, R; Bernad, A; Pollan, M; Bonilla, F; Gamallo, C; de Herreros, AG; Munoz, A			The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer	NATURE MEDICINE			English	Article							E-CADHERIN; DIFFERENTIATION	Several non-hypercalcemic analogs of 1alpha,25-dihydroxyvitamin D3 (1,25(OH)(2)D-3) show antitumor activity in a subset of cancer patients. High vitamin D receptor (VDR) expression, which is associated with good prognosis but is lost during tumor progression. We show that the SNAIL transcription factor represses VDR gene expression in human colon cancer cells and blocks the antitumor action of EB1089, a 1,25(OH)(2)D-3 analog, in xenografted mice. In human colon cancers, elevated SNAIL expression correlates with downregulation of VDR.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Hosp Univ Puerta Hierro, E-28035 Madrid, Spain; Univ Pompeu Fabra, Inst Municipal Invest Med, E-08003 Barcelona, Spain; Hosp Virgen Salud, E-45004 Toledo, Spain; Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Ctr Nacl Epidemiol, E-28029 Madrid, Spain; Hosp Univ Princesa, E-28006 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; Pompeu Fabra University; Complejo Hospitalario de Toledo; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Instituto de Salud Carlos III; Centro Nacional de Epidemiologia (CNE); Hospital de La Princesa	Munoz, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain.	amunoz@iib.uam.es	Munoz, Alberto/O-6393-2014; Pollan, Marina/M-3259-2014; Palmer, Héctor G./AAG-8332-2019; Bernad, Antonio/P-8573-2017; LARRIBA, MARIA JESUS/O-4652-2014; de Herreros, A Garcia/H-3104-2014; Ordonez-Moran, Paloma/B-6371-2016	Munoz, Alberto/0000-0003-3890-4251; Pollan, Marina/0000-0002-4328-1565; LARRIBA, MARIA JESUS/0000-0001-9035-7414; de Herreros, A Garcia/0000-0001-5270-0808; Puig Borreil, Isabel/0000-0001-5614-4298; Palmer, Hector/0000-0002-9823-5638; Peiro, Sandra/0000-0001-9519-3877; Bernad, Antonio/0000-0003-0620-9668; Ordonez-Moran, Paloma/0000-0001-7688-1252				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cross HS, 1996, ANTICANCER RES, V16, P2333; Dalhoff K, 2003, BRIT J CANCER, V89, P252, DOI 10.1038/sj.bjc.6601104; Hansen CM, 2001, FRONT BIOSCI-LANDMRK, V6, pD820, DOI 10.2741/Hansen; Huerta S, 2002, CANCER RES, V62, P741; Jurutka P W, 2001, Rev Endocr Metab Disord, V2, P203, DOI 10.1023/A:1010062929140; Kallay E, 2002, FOOD CHEM TOXICOL, V40, P1191, DOI 10.1016/S0278-6915(02)00030-3; Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Palmer HG, 2003, CANCER RES, V63, P7799; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Zinser GM, 2002, CARCINOGENESIS, V23, P2103, DOI 10.1093/carcin/23.12.2103	15	215	223	2	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					917	919		10.1038/nm1095	http://dx.doi.org/10.1038/nm1095			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15322538				2022-12-27	WOS:000223658400027
J	Rosenberg, SA; Yang, JC; Restifo, NP				Rosenberg, SA; Yang, JC; Restifo, NP			Cancer immunotherapy: moving beyond current vaccines	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; PHASE-I TRIAL; METASTATIC MELANOMA PATIENTS; SHOCK-PROTEIN GP96; DENDRITIC CELLS; T-CELLS; CARCINOEMBRYONIC ANTIGEN; IMMUNE-RESPONSES; GP100 MELANOMA; ANTITUMOR IMMUNITY	Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.	NCI, Ctr Canc Res, Surg Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosenberg, SA (corresponding author), NCI, Ctr Canc Res, Surg Branch, Bldg 10,Room 2B42,10 Ctr Dr,MSC 1502, Bethesda, MD 20892 USA.	sar@mail.nih.gov	Restifo, Nicholas P/A-5713-2008; Restifo, Nicholas Phillip/Z-1614-2019; Restifo, Nicholas Phillip/M-6549-2019	Restifo, Nicholas P./0000-0003-4229-4580	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006670] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999, Z01 BC010763-01] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Banchereau J, 2001, CANCER RES, V61, P6451; Belli F, 2002, J CLIN ONCOL, V20, P4169, DOI 10.1200/JCO.2002.09.134; Cebon Jonathan, 2003, Cancer Immun, V3, P7; Conry RM, 1999, CLIN CANCER RES, V5, P2330; Cormier JN, 1997, CANCER J, V3, P37; Dols A, 2003, HUM GENE THER, V14, P1117, DOI 10.1089/104303403322124828; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dudley ME, 2001, J IMMUNOTHER, V24, P363, DOI 10.1097/00002371-200107000-00012; EBERLEIN TJ, 1983, TRANSPLANT P, V15, P396; Eder JP, 2000, CLIN CANCER RES, V6, P1632; Fong L, 2001, P NATL ACAD SCI USA, V98, P8809, DOI 10.1073/pnas.141226398; Geiger JD, 2001, CANCER RES, V61, P8513; Gulley J, 2002, PROSTATE, V53, P109, DOI 10.1002/pros.10130; Hanson HL, 2000, IMMUNITY, V13, P265, DOI 10.1016/S1074-7613(00)00026-1; Hersey P, 2004, CANCER IMMUNOL IMMUN, V53, P125, DOI 10.1007/s00262-003-0429-0; Hodge JW, 2001, VACCINE, V19, P3552, DOI 10.1016/S0264-410X(01)00062-7; Holtl L, 2002, CLIN CANCER RES, V8, P3369; Hori S, 2003, ADV IMMUNOL, V81, P331, DOI 10.1016/S0065-2776(03)81008-8; Horig H, 2000, CANCER IMMUNOL IMMUN, V49, P504, DOI 10.1007/s002620000146; Jager E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497; James K, 1999, J NATL CANCER I, V91, P523, DOI 10.1093/jnci/91.6.523; Janetzki S, 2000, INT J CANCER, V88, P232, DOI 10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8; Kammula US, 2000, J NATL CANCER I, V92, P1336, DOI 10.1093/jnci/92.16.1336; Khleif SN, 1999, J IMMUNOTHER, V22, P155, DOI 10.1097/00002371-199903000-00007; Klebanoff CA, 2004, P NATL ACAD SCI USA, V101, P1969, DOI 10.1073/pnas.0307298101; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Marshall JL, 1999, J CLIN ONCOL, V17, P332, DOI 10.1200/JCO.1999.17.1.332; Marshall JL, 2000, J CLIN ONCOL, V18, P3964, DOI 10.1200/JCO.2000.18.23.3964; May KF, 2002, CANCER RES, V62, P3459; Mazzaferro V, 2003, CLIN CANCER RES, V9, P3235; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Mitchell MS, 2004, CLIN CANCER RES, V10, P76, DOI 10.1158/1078-0432.CCR-0689-3; MORTON DL, 1992, ANN SURG, V482; Nemunaitis J, 2004, J NATL CANCER I, V96, P326, DOI 10.1093/jnci/djh028; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Noguchi M, 2003, PROSTATE, V57, P80, DOI 10.1002/pros.10276; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Panelli MC, 2000, J IMMUNOTHER, V23, P487, DOI 10.1097/00002371-200007000-00013; Peterson AC, 2003, J CLIN ONCOL, V21, P2342, DOI 10.1200/JCO.2003.12.144; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Phan GQ, 2003, J IMMUNOTHER, V26, P349, DOI 10.1097/00002371-200307000-00007; Ribas A, 2003, J CLIN ONCOL, V21, P2415, DOI 10.1200/JCO.2003.06.041; Ridgway D, 2003, CANCER INVEST, V21, P873, DOI 10.1081/CNV-120025091; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rosenberg SA, 1999, J IMMUNOL, V163, P1690; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Rosenberg SA, 1998, J NATL CANCER I, V90, P1894, DOI 10.1093/jnci/90.24.1894; Rosenberg SA, 2003, CLIN CANCER RES, V9, P2973; Rosenberg SA, 2003, HUM GENE THER, V14, P709, DOI 10.1089/104303403765255110; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Salgaller ML, 1996, CANCER RES, V56, P4749; Salgia R, 2003, J CLIN ONCOL, V21, P624, DOI 10.1200/JCO.2003.03.091; Sato Y, 2004, BRIT J CANCER, V90, P1334, DOI 10.1038/sj.bjc.6601711; Scheibenbogen C, 2000, J IMMUNOTHER, V23, P275, DOI 10.1097/00002371-200003000-00012; Schreiber H., 2003, FUNDAMENTAL IMMUNOLO, P1557; Schuler-Thurner B, 2002, J EXP MED, V195, P1279, DOI 10.1084/jem.20012100; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Slingluff CL, 2003, J CLIN ONCOL, V21, P4016, DOI 10.1200/JCO.2003.10.005; Slingluff CL, 2001, CLIN CANCER RES, V7, P3012; Soiffer R, 1998, P NATL ACAD SCI USA, V95, P13141, DOI 10.1073/pnas.95.22.13141; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; Stift A, 2003, J CLIN ONCOL, V21, P135, DOI 10.1200/JCO.2003.02.135; Su Z, 2003, CANCER RES, V63, P2127; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tanaka S, 2003, J IMMUNOTHER, V26, P357, DOI 10.1097/00002371-200307000-00008; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; van Driel WJ, 1999, EUR J CANCER, V35, P946, DOI 10.1016/S0959-8049(99)00048-9; von Mehren M, 2001, CLIN CANCER RES, V7, P1181; von Mehren M, 2000, CLIN CANCER RES, V6, P2219; Vonderheide RH, 2004, CLIN CANCER RES, V10, P828, DOI 10.1158/1078-0432.CCR-0620-3; Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(01)00093-0; Zaks TZ, 1998, CANCER RES, V58, P4902	74	2257	2520	18	730	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					909	915		10.1038/nm1100	http://dx.doi.org/10.1038/nm1100			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15340416	Green Accepted			2022-12-27	WOS:000223658400026
J	Joseph, B; Berishvili, E; Benten, D; Kumaran, V; Liponava, E; Bhargava, K; Palestro, C; Kakabadze, Z; Gupta, S				Joseph, B; Berishvili, E; Benten, D; Kumaran, V; Liponava, E; Bhargava, K; Palestro, C; Kakabadze, Z; Gupta, S			Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions	NATURE MEDICINE			English	Article							HEPATOCYTE TRANSPLANTATION; GENE-EXPRESSION; RAT; REGENERATION; MODEL; RECEPTORS; SURVIVAL; ISOFORMS; PATIENT; FLOW	We determine here the functional integrity of auxiliary livers in containers fashioned from the small intestine. Liver microfragments from dipeptidyl peptidase 4 (DPP4)-deficient rats were transplanted into syngeneic normal animals with isolated intestinal segments characterized by mucosal denudation but intact vascular supply. Transplanted liver fragments were restored to confluent tissue with normal hepatic architecture and development of DPP4-positive vessels, indicating angiogenesis and revascularization. Auxiliary liver units expressed multiple hepatotrophic and angiogenic genes, and transplanted tissues remained intact for up to the 6-week duration of the studies with neither ischemic injury nor significant hepatocellular proliferation. Hepatic metabolic, transport and synthetic functions were preserved in auxiliary livers, including uptake and biliary excretion of Tc-99m-mebrofenin in syngeneic recipients of liver from F344 rats, as well as secretion of albumin in allografted Nagase analbuminemic rats. This ability to produce functionally competent auxiliary livers in vascularized intestinal segments offers therapeutic potential for liver disease and genetic deficiency.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Georgian State Med Acad, Dept Clin Anat & Operat Surg, GE-380079 Tbilisi, Georgia; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Long Isl Jewish Med Ctr, Dept Radiol, Div Nucl Med, New York, NY 11040 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Northwell Health	Gupta, S (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA.	sanjvgupta@pol.net	Kumaran, Vinay/AAF-1889-2019; Berishvili, Ekaterine/AAL-9758-2020; Kakabadze, Zurab/L-6695-2019	Berishvili, Ekaterine/0000-0002-7969-1937; Kakabadze, Zurab/0000-0001-9038-5220; Kumaran, Vinay/0000-0003-0800-6290	NIDDK NIH HHS [R01 DK46952, P30-DK-41296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK046952] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angelis M, 2001, J PEDIATR-US, V138, P120, DOI 10.1067/mpd.2001.109199; Azoulay D, 2001, ANN SURG, V234, P723, DOI 10.1097/00000658-200112000-00003; Berishvili E, 2003, TRANSPLANTATION, V75, P1827, DOI 10.1097/01.TP.0000065297.56712.C1; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; de Jonge J, 1999, J PEDIATR SURG, V34, P1265, DOI 10.1016/S0022-3468(99)90165-3; Durand F, 2002, LIVER TRANSPLANT, V8, P701, DOI 10.1053/jlts.2002.33745; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gaglio PJ, 2002, J HEPATOL, V37, P625, DOI 10.1016/S0168-8278(02)00262-3; GUPTA S, 1992, HEPATOLOGY, V15, P156, DOI 10.1002/hep.1840150126; GUPTA S, 1995, P NATL ACAD SCI USA, V92, P5860, DOI 10.1073/pnas.92.13.5860; Haberal M, 2001, J PEDIATR SURG, V36, P667, DOI 10.1053/jpsu.2001.22317; Ishii H, 2002, ARCH ORAL BIOL, V47, P505, DOI 10.1016/S0003-9969(02)00033-X; Kaibori M, 1998, TRANSPLANTATION, V66, P935, DOI 10.1097/00007890-199810150-00022; Kalyani AJ, 1999, J NEUROBIOL, V38, P207, DOI 10.1002/(SICI)1097-4695(19990205)38:2<207::AID-NEU4>3.0.CO;2-G; Kayler LK, 2002, PEDIATR TRANSPLANT, V6, P295, DOI 10.1034/j.1399-3046.2002.02009.x; Kiuchi T, 1999, TRANSPLANT P, V31, P528, DOI 10.1016/S0041-1345(98)01539-5; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Malhi H, 2002, J NUCL MED, V43, P246; Oh SH, 2000, BIOCHEM BIOPH RES CO, V279, P500, DOI 10.1006/bbrc.2000.3985; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; Rajvanshi P, 1996, HEPATOLOGY, V23, P482; Rela M, 1999, ANN SURG, V229, P565, DOI 10.1097/00000658-199904000-00017; Robotin-Johnson MC, 1998, J THORAC CARDIOV SUR, V116, P805, DOI 10.1016/S0022-5223(98)00436-X; Rudolfsson SH, 2003, BIOL REPROD, V69, P1231, DOI 10.1095/biolreprod.102.013375; Scotte M, 1997, CYTOKINE, V9, P859, DOI 10.1006/cyto.1997.0273; SELDEN C, 1995, HEPATOLOGY, V21, P1405, DOI 10.1016/0270-9139(95)90063-2; Sundback CA, 2000, GASTROENTEROLOGY, V118, P438; Suzuki S, 2002, BIOCHEM BIOPH RES CO, V292, P709, DOI 10.1006/bbrc.2002.6706; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694; Zhao H, 2002, BIOCHEM BIOPH RES CO, V294, P464, DOI 10.1016/S0006-291X(02)00484-9	30	25	26	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					749	753		10.1038/nm1057	http://dx.doi.org/10.1038/nm1057			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15170210				2022-12-27	WOS:000222460400031
J	Rogawski, MA; Loscher, W				Rogawski, MA; Loscher, W			The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions	NATURE MEDICINE			English	Review							GATED SODIUM-CHANNEL; CONSTRICTION INJURY MODEL; PLACEBO-CONTROLLED TRIAL; NEUROPATHIC PAIN; SENSORY NEURONS; STATUS-EPILEPTICUS; COMMON MECHANISM; MESSENGER-RNAS; VALPROIC ACID; UP-REGULATION	Antiepileptic drugs (AEDs) are commonly prescribed for nonepileptic conditions, including migraine headache, chronic neuropathic pain, mood disorders, schizophrenia and various neuromuscular syndromes. In many of these conditions, as in epilepsy, the drugs act by modifying the excitability of nerve (or muscle) through effects on voltage-gated sodium and calcium channels or by promoting inhibition mediated by gamma-aminobutyric acid (GABA) A receptors. In neuropathic pain, chronic nerve injury is associated with the redistribution and altered subunit compositions of sodium and calcium channels that predispose neurons in sensory pathways to fire spontaneously or at inappropriately high frequencies, often from ectopic sites. AEDs may counteract this abnormal activity by selectively affecting pain-specific firing; for example, many AEDs suppress high-frequency action potentials by blocking voltage-activated sodium channels in a use-dependent fashion. Alternatively, AEDs may specifically target pathological channels; for example, gabapentin is a ligand of alpha2delta voltage-activated calcium channel subunits that are overexpressed in sensory neurons after nerve injury. Emerging evidence suggests that effects on signaling pathways that regulate neuronal plasticity and survival may be a factor in the delayed clinical efficacy of AEDs in some neuropsychiatric conditions, including bipolar affective disorder.	NINDS, Epilepsy Res Sect, NIH, Bethesda, MD 20892 USA; Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; Ctr Syst Neurosci, D-30559 Hannover, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Veterinary Medicine Hannover, Foundation	Rogawski, MA (corresponding author), NINDS, Epilepsy Res Sect, NIH, Bethesda, MD 20892 USA.	michael.rogawski@nih.gov	Löscher, Wolfgang/G-9824-2016; Rogawski, Michael A/B-6353-2009	Löscher, Wolfgang/0000-0002-9648-8973; Rogawski, Michael A/0000-0002-3296-8193	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002877] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe M, 2002, SPINE, V27, P1517, DOI 10.1097/00007632-200207150-00007; AKBARIAN S, 1995, ARCH GEN PSYCHIAT, V52, P258, DOI 10.1001/archpsyc.1995.03950160008002; [Anonymous], 2004, MED LETT DRUGS THER, V46, P29; Aronica E, 2001, EUR J NEUROSCI, V13, P1261, DOI 10.1046/j.0953-816x.2001.01502.x; Bartolomei F, 1997, J NEUROCYTOL, V26, P667, DOI 10.1023/A:1018549928277; BEECH J, 1992, MUSCLE NERVE, V15, P932, DOI 10.1002/mus.880150811; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; Beydoun A, 2003, J PAIN SYMPTOM MANAG, V25, pS18, DOI 10.1016/S0885-3924(03)00066-6; Blum BP, 2002, INT J NEUROPSYCHOPH, V5, P159, DOI 10.1017/S1461145702002894; Brandes JL, 2004, JAMA-J AM MED ASSOC, V291, P965, DOI 10.1001/jama.291.8.965; BURCHIEL KJ, 1988, EXP NEUROL, V102, P249, DOI 10.1016/0014-4886(88)90101-X; Cannon SC, 1997, NEUROMUSCULAR DISORD, V7, P241, DOI 10.1016/S0960-8966(97)00430-6; Caress JB, 2002, NEUROLOGIST, V8, P41, DOI 10.1097/00127893-200201000-00005; Chapman V, 1997, PAIN, V71, P285, DOI 10.1016/S0304-3959(97)03365-4; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chudnow RS, 1997, NEUROLOGY, V49, P1441, DOI 10.1212/WNL.49.5.1441; Cizkova D, 2002, EXP BRAIN RES, V147, P456, DOI 10.1007/s00221-002-1217-3; Connor GS, 2002, NEUROLOGY, V59, P132, DOI 10.1212/WNL.59.1.132; Costa E, 2002, CURR OPIN PHARMACOL, V2, P56, DOI 10.1016/S1471-4892(01)00121-7; Coyle JT, 2003, NEURON, V38, P157, DOI 10.1016/S0896-6273(03)00195-8; Craner MJ, 2002, ANN NEUROL, V52, P786, DOI 10.1002/ana.10364; Cummins TR, 2001, J NEUROSCI, V21, P5952, DOI 10.1523/JNEUROSCI.21-16-05952.2001; de-Paris F, 2003, J PSYCHOPHARMACOL, V17, P184; Dib-Hajj SD, 1999, PAIN, V83, P591, DOI 10.1016/S0304-3959(99)00169-4; Dogrul A, 2003, PAIN, V105, P159, DOI 10.1016/S0304-3959(03)00177-5; DRAKE ME, 2001, CEPHALALGIA, V21, P373; Einat H, 2003, J NEUROSCI, V23, P7311; Eisenberg E, 1998, EUR J NEUROL, V5, P167, DOI 10.1046/j.1468-1331.1998.520167.x; Ellerkmann RK, 2003, NEUROSCIENCE, V119, P323, DOI 10.1016/S0306-4522(03)00168-4; FFRENCHMULLEN JMH, 1993, J NEUROSCI, V13, P3211; Field MJ, 2000, BRIT J PHARMACOL, V131, P282, DOI 10.1038/sj.bjp.0703604; FREITAG FG, 1999, HEADACHE, V39, P354; FROMM GH, 1992, DRUGS CONTROL EPILEP, P425; Fukuda M, 1999, MOVEMENT DISORD, V14, P342, DOI 10.1002/1531-8257(199903)14:2<342::AID-MDS1022>3.0.CO;2-7; Gironell A, 1999, ARCH NEUROL-CHICAGO, V56, P475, DOI 10.1001/archneur.56.4.475; Gold MS, 2003, J NEUROSCI, V23, P158; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Guidotti A, 2000, NEUROCHEM RES, V25, P1207, DOI 10.1023/A:1007635927069; Hains BC, 2003, J NEUROSCI, V23, P8881; Happe S, 2003, NEUROPSYCHOBIOLOGY, V48, P82, DOI 10.1159/000072882; Harwood AJ, 2003, BIOCHEM PHARMACOL, V66, P179, DOI 10.1016/S0006-2952(03)00187-4; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Hoopes SP, 2003, J CLIN PSYCHIAT, V64, P1335, DOI 10.4088/JCP.v64n1109; Hord AH, 2003, ANESTH ANALG, V96, P1700, DOI 10.1213/01.ANE.0000062652.66661.97; Hosak L, 2002, EUR PSYCHIAT, V17, P371, DOI 10.1016/S0924-9338(02)00696-X; Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3; Kim CH, 2001, MOL BRAIN RES, V95, P153, DOI 10.1016/S0169-328X(01)00226-1; Kim D, 2003, SCIENCE, V302, P117, DOI 10.1126/science.1088886; Kullmann DM, 2002, BRAIN, V125, P1177, DOI 10.1093/brain/awf130; Lenox RH, 2003, MOL PSYCHIATR, V8, P135, DOI 10.1038/sj.mp.4001306; Li XH, 2002, BIPOLAR DISORD, V4, P137, DOI 10.1034/j.1399-5618.2002.40201.x; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Loscher W, 2002, EPILEPSY RES, V50, P3, DOI 10.1016/S0920-1211(02)00063-3; Loscher W, 2002, CNS DRUGS, V16, P669; Lotze T, 2003, Semin Pediatr Neurol, V10, P68, DOI 10.1016/S1071-9091(02)00012-8; LUBBERS WJ, 1995, J NEUROL NEUROSUR PS, V59, P400, DOI 10.1136/jnnp.59.4.400; Lubrich B, 1999, NEUROPSYCHOPHARMACOL, V21, P519, DOI 10.1016/S0893-133X(99)00037-8; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001; Mai L, 2002, J NEUROCHEM, V82, P75, DOI 10.1046/j.1471-4159.2002.00939.x; Manji H K, 2001, Psychopharmacol Bull, V35, P5; Manji HK, 2001, NAT MED, V7, P541, DOI 10.1038/87865; Mathew NT, 2001, HEADACHE, V41, pS18; Matthews EA, 2001, EUR J PHARMACOL, V415, P141, DOI 10.1016/S0014-2999(01)00812-3; McElroy SL, 2003, AM J PSYCHIAT, V160, P255, DOI 10.1176/appi.ajp.160.2.255; MCGUIRE SA, 1984, ARCH NEUROL-CHICAGO, V41, P395, DOI 10.1001/archneur.1984.04050160057016; Murakami M, 2002, J BIOL CHEM, V277, P40342, DOI 10.1074/jbc.M203425200; Muzina DJ, 2002, EPILEPSY RES, V50, P195, DOI 10.1016/S0920-1211(02)00080-3; MYRICK H, 2003, PRIMARY PSYCHIAT, V10, P59; Newton RA, 2001, MOL BRAIN RES, V95, P1, DOI 10.1016/S0169-328X(01)00188-7; Nicholson B, 2000, ACTA NEUROL SCAND, V101, P359, DOI 10.1034/j.1600-0404.2000.0006a.x; Novakovic SD, 1998, J NEUROSCI, V18, P2174; O'Donnell T, 2000, BRAIN RES, V880, P84, DOI 10.1016/S0006-8993(00)02797-9; Oh SJ, 2003, MUSCLE NERVE, V27, P757, DOI 10.1002/mus.10369; OTTMAN R, 1994, NEUROLOGY, V44, P2105, DOI 10.1212/WNL.44.11.2105; Pahwa R, 2003, AM J MED, V115, P134, DOI 10.1016/S0002-9343(03)00259-6; Pan HL, 1999, J PHARMACOL EXP THER, V288, P1026; Pande AC, 1999, J CLIN PSYCHOPHARM, V19, P341, DOI 10.1097/00004714-199908000-00010; Pappagallo M, 2003, CLIN THER, V25, P2506, DOI 10.1016/S0149-2918(03)80314-4; Patel MK, 2000, BRIT J PHARMACOL, V130, P1731, DOI 10.1038/sj.bjp.0703530; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; Pitkanen A, 2002, EPILEPSY RES, V50, P141, DOI 10.1016/S0920-1211(02)00076-1; Pollack MH, 1998, AM J PSYCHIAT, V155, P992, DOI 10.1176/ajp.155.7.992; Praveen V, 2001, POSTGRAD MED J, V77, P570, DOI 10.1136/pmj.77.911.570; Randall A, 1999, MOL CELL NEUROSCI, V14, P255, DOI 10.1006/mcne.1999.0795; RICHTER A, EUR J PHARM, V369, P335; Rizzo MA, 1997, J NEUROL SCI, V152, P103, DOI 10.1016/S0022-510X(97)00143-3; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Ross EL, 2000, NEUROLOGY, V55, pS41; Roza C, 2003, J PHYSIOL-LONDON, V550, P921, DOI 10.1113/jphysiol.2003.046110; Rozen TD, 2001, HEADACHE, V41, pS25; Rudolph U, 2004, ANNU REV PHARMACOL, V44, P475, DOI 10.1146/annurev.pharmtox.44.101802.121429; Sarantopoulos C, 2002, REGION ANESTH PAIN M, V27, P47, DOI 10.1053/rapm.2002.29124; Shah BS, 2001, NEUROSCI LETT, V309, P1, DOI 10.1016/S0304-3940(01)01976-0; Shah BS, 2000, EUR J NEUROSCI, V12, P3985, DOI 10.1046/j.1460-9568.2000.00294.x; Shimoyama M, 2000, PAIN, V85, P405, DOI 10.1016/S0304-3959(99)00283-3; SIAL KA, 2003, ARCH PHYS MED REHAB, V84, pE23; Silberstein SD, 2001, HEADACHE, V41, pS11; Stanfa LC, 1997, NEUROREPORT, V8, P587, DOI 10.1097/00001756-199702100-00002; Todorovic SM, 2003, BRIT J PHARMACOL, V140, P255, DOI 10.1038/sj.bjp.0705434; Todorovic SM, 2002, BRAIN RES, V951, P336, DOI 10.1016/S0006-8993(02)03350-4; Todorovic SM, 2001, NEURON, V31, P75, DOI 10.1016/S0896-6273(01)00338-5; Tremolizzo L, 2002, P NATL ACAD SCI USA, V99, P17095, DOI 10.1073/pnas.262658999; Vaden DL, 2001, J BIOL CHEM, V276, P15466, DOI 10.1074/jbc.M004179200; Volk DW, 2000, ARCH GEN PSYCHIAT, V57, P237, DOI 10.1001/archpsyc.57.3.237; Whitaker WRJ, 2001, NEUROSCIENCE, V106, P275, DOI 10.1016/S0306-4522(01)00212-3; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; Winterer G, 2000, PHARMACOPSYCHIATRY, V33, P182, DOI 10.1055/s-2000-12981; Young LT, 1999, J AFFECT DISORDERS, V55, P73; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Zhou L, 2002, BRAIN DEV-JPN, V24, P669, DOI 10.1016/S0387-7604(02)00095-5; [No title captured]	113	327	353	1	46	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					685	692		10.1038/nm1074	http://dx.doi.org/10.1038/nm1074			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15229516				2022-12-27	WOS:000222460400021
J	Harrington, EA; Bebbington, D; Moore, J; Rasmussen, RK; Ajose-Adeogun, AO; Nakayama, T; Graham, JA; Demur, C; Hercend, T; Diu-Hercend, A; Su, M; Golec, JMC; Miller, KM				Harrington, EA; Bebbington, D; Moore, J; Rasmussen, RK; Ajose-Adeogun, AO; Nakayama, T; Graham, JA; Demur, C; Hercend, T; Diu-Hercend, A; Su, M; Golec, JMC; Miller, KM			VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo	NATURE MEDICINE			English	Article							PROTEIN-KINASE; A KINASE; MITOTIC PHOSPHORYLATION; COLORECTAL CANCERS; MAMMALIAN-CELLS; CLEAVAGE FURROW; BUDDING YEAST; HISTONE H3; B KINASE; M-PHASE	The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis. Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis. Here we report the discovery of a highly potent and selective small-molecule inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types. This compound causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses. Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.	Vertex Pharmaceut Europe Ltd, Abingdon OX14 4RY, Oxon, England; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA; INSERM, Inst Claudis Regaud, F-31052 Toulouse, France	Vertex Pharmaceuticals; Vertex Pharmaceuticals; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Miller, KM (corresponding author), Vertex Pharmaceut Europe Ltd, 88 Milton Pk, Abingdon OX14 4RY, Oxon, England.	karen_miller@vrtx.com						Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Kawasaki A, 2001, J CELL BIOL, V152, P275, DOI 10.1083/jcb.152.2.275; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; MIHOSHIMA Y, 2003, DEV CELL, V4, P549; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Morrison C, 2002, NUCLEIC ACIDS RES, V30, P5318, DOI 10.1093/nar/gkf665; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Pitt A.M., 1996, J BIOMOL SCREEN, V1, P47, DOI [10.1177/108705719600100115, DOI 10.1177/108705719600100115]; Sakai H, 2002, J BIOL CHEM, V277, P48714, DOI 10.1074/jbc.M208461200; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sawyers CL, 2002, CANCER CELL, V1, P413, DOI 10.1016/S1535-6108(02)00080-6; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Tanaka T, 1999, CANCER RES, V59, P2041; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tien AC, 2004, MOL CELL PROTEOMICS, V3, P93, DOI 10.1074/mcp.M300072-MCP200; WHEATLEY SP, IN PRESS J BIOL CHEM; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125	46	845	962	2	41	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2004	10	3					262	267		10.1038/nm1003	http://dx.doi.org/10.1038/nm1003			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14981513				2022-12-27	WOS:000189297700037
J	Ichikawa, M; Asai, T; Saito, T; Yamamoto, G; Seo, S; Yamazaki, I; Yamagata, T; Mitani, K; Chiba, S; Hirai, H; Ogawa, S; Kurokawa, M				Ichikawa, M; Asai, T; Saito, T; Yamamoto, G; Seo, S; Yamazaki, I; Yamagata, T; Mitani, K; Chiba, S; Hirai, H; Ogawa, S; Kurokawa, M			AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis	NATURE MEDICINE			English	Article							ACUTE-LEUKEMIA; MURINE MODEL; GENE; IDENTIFICATION; AML1-ETO; GATA-1; LEUKEMOGENESIS; ESTABLISHES; EXPRESSION; DEVELOP	Embryonic development of multilineage hematopoiesis requires the precisely regulated expression of lineage-specific transcription factors, including AML-1 (encoded by Runx1; also known as CBFA-2 or PEBP-2alphaB)(1-5). In vitro studies and findings in human diseases, including leukemias(6,7), myelodysplastic syndromes 8 and familial platelet disorder with predisposition to acute myeloid leukemia (AML)(9), suggest that AML-1 has a pivotal role in adult hematopoiesis. However, this role has not been fully uncovered in vivo because of the embryonic lethality of Runx1 knockout in mice. Here we assess the requirement of AML-1/Runx1 in adult hematopoiesis using an inducible gene-targeting method 10. In the absence of AML-1, hematopoietic progenitors were fully maintained with normal myeloid cell development. However, AML-1-deficient bone marrow showed inhibition of megakaryocytic maturation, increased hematopoietic progenitor cells and defective T- and B-lymphocyte development. AML-1 is thus required for maturation of megakaryocytes and differentiation of T and B cells, but not for maintenance of hematopoietic stem cells (HSCs) in adult hematopoiesis.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Regenerat Med Hematopoiesis, Bunkyo Ku, Tokyo 1138655, Japan; Inoue Mem Hosp, Dept Clin Lab & Pathol, Chuo Ku, Chiba 2600027, Japan; Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan	University of Tokyo; University of Tokyo; Dokkyo Medical University	Ogawa, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	sogawa-tky@umin.ac.jp	Ogawa, Seishi/AAE-7088-2019	Ichikawa, Motoshi/0000-0001-6497-0848				BRETONGORIUS J, 1978, BLOOD, V51, P45; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; JACKSON CW, 1984, BLOOD, V63, P768; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; Kaushansky K, 1999, BIOESSAYS, V21, P353, DOI 10.1002/(SICI)1521-1878(199904)21:4<353::AID-BIES12>3.0.CO;2-P; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Rhoades KL, 2000, BLOOD, V96, P2108; SHERWOOD SW, 1995, METHOD CELL BIOL, V46, P77; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x	29	467	475	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					299	304		10.1038/nm997	http://dx.doi.org/10.1038/nm997			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14966519				2022-12-27	WOS:000189297700043
J	Leslie, AJ; Pfafferott, KJ; Chetty, P; Draenert, R; Addo, MM; Feeney, M; Tang, Y; Holmes, EC; Allen, T; Prado, JG; Altfeld, M; Brander, C; Dixon, C; Ramduth, D; Jeena, P; Thomas, SA; St John, A; Roach, TA; Kupfer, B; Luzzi, G; Edwards, A; Taylor, G; Lyall, H; Tudor-Williams, G; Novelli, V; Martinez-Picado, J; Kiepiela, P; Walker, BD; Goulder, PJR				Leslie, AJ; Pfafferott, KJ; Chetty, P; Draenert, R; Addo, MM; Feeney, M; Tang, Y; Holmes, EC; Allen, T; Prado, JG; Altfeld, M; Brander, C; Dixon, C; Ramduth, D; Jeena, P; Thomas, SA; St John, A; Roach, TA; Kupfer, B; Luzzi, G; Edwards, A; Taylor, G; Lyall, H; Tudor-Williams, G; Novelli, V; Martinez-Picado, J; Kiepiela, P; Walker, BD; Goulder, PJR			HIV evolution: CTL escape mutation and reversion after transmission	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYTOTOXIC T-LYMPHOCYTES; PHYLOGENETIC ANALYSIS; GENETIC-VARIATION; HLA-B; RESPONSES; CELL; REPLICATION; AIDS; GAG	Within-patient HIV evolution reflects the strong selection pressure driving viral escape from cytotoxic T-lymphocyte (CTL) recognition. Whether this intrapatient accumulation of escape mutations translates into HIV evolution at the population level has not been evaluated. We studied over 300 patients drawn from the B- and C-clade epidemics, focusing on human leukocyte antigen (HLA) alleles HLA-B57 and HLA-B5801, which are associated with long-term HIV control and are therefore likely to exert strong selection pressure on the virus. The CTL response dominating acute infection in HLAB57/5801-positive subjects drove positive selection of an escape mutation that reverted to wild-type after transmission to HLA-B57/5801-negative individuals. A second escape mutation within the epitope, by contrast, was maintained after transmission. These data show that the process of accumulation of escape mutations within HIV is not inevitable. Complex epitope- and residue-specific selection forces, including CTL-mediated positive selection pressure and virus-mediated purifying selection, operate in tandem to shape HIV evolution at the population level.	Univ Oxford, Fuffield Dept Med, Dept Pediat, Oxford OX1 3SY, England; Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Congella, South Africa; Partners AIDS Res Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Univ Oxford, Dept Zool, Oxford OX1 3SY, England; Hosp Badalona Germans Trias & Pujol, irsiCaixa Fdn, Barcelona 08916, Spain; Queen Elizabeth II Hosp, Bridgetown, Barbados; Univ Bonn, D-53105 Bonn, Germany; High Wycombe Gen Hosp, Dept Genitourinary Med, High Wycombe HP11 2TT, Bucks, England; Radcliffe Infirm Hosp, Harrison Clin, Oxford OX2 6HE, England; St Marys Hosp, Imperial Coll Sch Med, London W2 1NY, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England	University of Oxford; University of Kwazulu Natal; Harvard University; Harvard Medical School; University of Oxford; Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; University of Bonn; Radcliffe Infirmary; Imperial College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Goulder, PJR (corresponding author), Univ Oxford, Fuffield Dept Med, Dept Pediat, Peter Medawar Bldg Pathogen Res, Oxford OX1 3SY, England.	philip.goulder@ndm.ox.ac.uk	Altfeld, Marcus/AAE-7306-2019; Addo, Marylyn M./GNP-2548-2022; Holmes, Edward/GVR-9499-2022; Allen, Todd/F-5473-2011; Holmes, Edward/Y-2789-2019; Prado, Julia Garcia/R-7177-2019; Martinez-Picado, Javier/G-5507-2012	Altfeld, Marcus/0000-0001-5972-2997; Allen, Todd/0000-0002-6609-1318; Holmes, Edward/0000-0001-9596-3552; Prado, Julia Garcia/0000-0002-5439-4645; Martinez-Picado, Javier/0000-0002-4916-2129; leslie, alasdair/0000-0003-2538-6467; Addo, Marylyn/0000-0003-2836-9224; Brander, Christian/0000-0002-0548-5778	NIAID NIH HHS [AI46995-01A1, N01-AI-15442] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015442, R01AI046995] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005; Barber LD, 1997, J IMMUNOL, V158, P1660; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen J, 2003, SCIENCE, V299, P1505, DOI 10.1126/science.299.5612.1505; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; Forshey BM, 2002, J VIROL, V76, P5667, DOI 10.1128/JVI.76.11.5667-5677.2002; FRAHM N, IN PRESS J VIROL; Furuta RA, 1997, FEBS LETT, V415, P231, DOI 10.1016/S0014-5793(97)01132-0; Goulder PJR, 1996, AIDS RES HUM RETROV, V12, P1691, DOI 10.1089/aid.1996.12.1691; Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, J VIROL, V75, P1339, DOI 10.1128/JVI.75.3.1339-1347.2001; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Hayman A, 2001, AIDS RES HUM RETROV, V17, P689, DOI 10.1089/088922201750236960; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KASPER P, 1995, AIDS RES HUM RETROV, V11, P1197, DOI 10.1089/aid.1995.11.1197; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Klenerman P, 2002, CURR OPIN MICROBIOL, V5, P408, DOI 10.1016/S1369-5274(02)00339-9; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; Krogstad P, 2002, VIROLOGY, V294, P282, DOI 10.1006/viro.2001.1319; McMichael A, 2002, SCIENCE, V296, P1410, DOI 10.1126/science.1072492; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Migueles SA, 2003, J VIROL, V77, P6889, DOI 10.1128/JVI.77.12.6889-6898.2003; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002; Novitsky V, 2002, J VIROL, V76, P5435, DOI 10.1128/JVI.76.11.5435-5451.2002; O'Brien SJ, 2001, TRENDS MOL MED, V7, P379, DOI 10.1016/S1471-4914(01)02131-1; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Ross HA, 2002, J VIROL, V76, P11715, DOI 10.1128/JVI.76.22.11715-11720.2002; Singh AR, 2001, VIROLOGY, V279, P257, DOI 10.1006/viro.2000.0706; Swofford DL, 2002, PAUL PHYLOGENETIC AN; Tang JM, 2002, J VIROL, V76, P8276, DOI 10.1128/JVI.76.16.8276-8284.2002; Yang ZH, 2000, J MOL EVOL, V51, P423, DOI 10.1007/s002390010105; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Yu XG, 2002, J VIROL, V76, P8690, DOI 10.1128/JVI.76.17.8690-8701.2002	45	667	696	0	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					282	289		10.1038/nm992	http://dx.doi.org/10.1038/nm992			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14770175				2022-12-27	WOS:000189297700040
J	Gardell, LR; Wang, RZ; Ehrenfels, C; Ossipov, MH; Rossomando, AJ; Miller, S; Buckley, C; Cai, AK; Tse, A; Foley, SF; Gong, BJ; Walus, L; Carmillo, P; Worley, D; Huang, C; Engber, T; Pepinsky, B; Cate, RL; Vanderah, TW; Lai, J; Sah, DWY; Porreca, F				Gardell, LR; Wang, RZ; Ehrenfels, C; Ossipov, MH; Rossomando, AJ; Miller, S; Buckley, C; Cai, AK; Tse, A; Foley, SF; Gong, BJ; Walus, L; Carmillo, P; Worley, D; Huang, C; Engber, T; Pepinsky, B; Cate, RL; Vanderah, TW; Lai, J; Sah, DWY; Porreca, F			Multiple actions of systemic artemin in experimental neuropathy	NATURE MEDICINE			English	Article							EXCITATORY TRANSMITTER RELEASE; NEUROTROPHIC FACTOR; RECEPTOR COMPONENTS; SPINAL DYNORPHIN; SENSORY NEURONS; TYROSINE KINASE; NERVE INJURY; CHRONIC PAIN; GDNF-FAMILY; SUBSTANCE-P	The clinical management of neuropathic pain is particularly challenging. Current therapies for neuropathic pain modulate nerve impulse propagation or synaptic transmission; these therapies are of limited benefit and have undesirable side effects. Injuries to peripheral nerves result in a host of pathophysiological changes associated with the sustained expression of abnormal pain. Here we show that systemic, intermittent administration of artemin produces dose- and time-related reversal of nerve injury-induced pain behavior, together with partial to complete normalization of multiple morphological and neurochemical features of the injury state. These effects of artemin were sustained for at least 28 days. Higher doses of artemin than those completely reversing experimental neuropathic pain did not elicit sensory or motor abnormalities. Our results indicate that the behavioral symptoms of neuropathic pain states can be treated successfully, and that partial to complete reversal of associated morphological and neurochemical changes is achievable with artemin.	Univ Arizona, Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ 85724 USA; Biogen Inc, Cambridge, MA 02142 USA	University of Arizona; University of Arizona Health Sciences; Biogen	Porreca, F (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ 85724 USA.	frankp@u.arizona.edu						Acheson A, 1996, PHILOS T ROY SOC B, V351, P417, DOI 10.1098/rstb.1996.0037; Baloh RH, 1998, P NATL ACAD SCI USA, V95, P5801, DOI 10.1073/pnas.95.10.5801; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Bennett DLH, 1998, J NEUROSCI, V18, P3059; Bennett DLH, 2000, J NEUROSCI, V20, P427, DOI 10.1523/JNEUROSCI.20-01-00427.2000; Boucher TJ, 2000, SCIENCE, V290, P124, DOI 10.1126/science.290.5489.124; Burgess SE, 2002, J NEUROSCI, V22, P5129, DOI 10.1523/JNEUROSCI.22-12-05129.2002; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen JJ, 1996, PEPTIDES, V17, P31, DOI 10.1016/0196-9781(95)02091-8; DEVOR M, 1999, TXB PAIN, P129; Ehrenfels CW, 1999, DEV GENET, V24, P263, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<263::AID-DVG9>3.0.CO;2-D; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Gardell LR, 2003, J NEUROSCI, V23, P8370; Gardell LR, 2002, J NEUROSCI, V22, P6747; Guo A, 1999, EUR J NEUROSCI, V11, P946, DOI 10.1046/j.1460-9568.1999.00503.x; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Lai J, 2002, PAIN, V95, P143, DOI 10.1016/S0304-3959(01)00391-8; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu XG, 2000, PAIN, V84, P309, DOI 10.1016/S0304-3959(99)00211-0; Malan TP, 2000, PAIN, V86, P185, DOI 10.1016/S0304-3959(00)00243-8; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; MCQUAY HJ, 1992, ANAESTHESIA, V47, P757, DOI 10.1111/j.1365-2044.1992.tb03253.x; Merskey H., 1994, CLASSIFICATION CHRON, P40; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MOLLIVER DC, 1995, J COMP NEUROL, V361, P404, DOI 10.1002/cne.903610305; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; Nichols ML, 1999, SCIENCE, V286, P1558, DOI 10.1126/science.286.5444.1558; Orozco OE, 2001, EUR J NEUROSCI, V13, P2177, DOI 10.1046/j.0953-816x.2001.01596.x; Ossipov MH, 2001, PROG PAIN RES MANAG, V21, P107; Ossipov MH, 2002, J NEUROSCI, V22, P9858; Payne R., 1986, CLIN J PAIN, V2, P59; Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166-2236(02)02157-4; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Rose MA, 2002, ANAESTHESIA, V57, P451, DOI 10.1046/j.0003-2409.2001.02399.x; Rosenblad C, 2000, MOL CELL NEUROSCI, V15, P199, DOI 10.1006/mcne.1999.0817; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Suzuki R, 2002, NAT NEUROSCI, V5, P1319, DOI 10.1038/nn966; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; VOLLMER KO, 1986, ARZNEIMITTEL-FORSCH, V36-1, P830; Wang ZJ, 2001, J NEUROSCI, V21, P1779, DOI 10.1523/JNEUROSCI.21-05-01779.2001; Widenfalk J, 1998, EUR J NEUROSCI, V10, P1508, DOI 10.1046/j.1460-9568.1998.00192.x; Worby CA, 1998, J BIOL CHEM, V273, P3502, DOI 10.1074/jbc.273.6.3502; Wu G, 2001, J NEUROSCI, V21	50	122	140	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2003	9	11					1383	1389		10.1038/nm944	http://dx.doi.org/10.1038/nm944			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528299				2022-12-27	WOS:000186319700028
J	Rubio, V; Stuge, TB; Singh, N; Betts, MR; Weber, JS; Roederer, M; Lee, PP				Rubio, V; Stuge, TB; Singh, N; Betts, MR; Weber, JS; Roederer, M; Lee, PP			Ex vivo identification, isolation and analysis of tumor-cytolytic T cells	NATURE MEDICINE			English	Article							FUNCTIONAL AVIDITY; MULTIPEPTIDE VACCINE; METASTATIC MELANOMA; CYTOKINE PRODUCTION; TCR; LYMPHOCYTES; TETRAMERS; ESCAPE; CTL; SELECTION	We isolated pure, viable populations of tumor-cytolytic T cells directly from patient blood samples using flow cytometric quantification of the surface mobilization of CD107a-an integral membrane protein in cytolytic granules-as a marker for degranulation after tumor stimulation. We show that tumor-cytolytic T cells are indeed elicited in patients after cancer vaccination, and that tumor reactivity is strongly correlated with efficient T-cell recognition of peptide-bearing targets. We combined CD107a mobilization with peptide-major histocompatibility complex (P-MHC) tetramer staining to directly correlate antigen specificity and cytolytic ability on a single-cell level. This showed that tumor-cytolytic T cells with high recognition efficiency represent only a minority of peptide-specific T cells elicited in patients after heteroclitic peptide vaccination. We were also able to expand these cells to high numbers ex vivo while maintaining their cytolytic potential. These techniques will be useful not only for immune monitoring of cancer vaccine trials, but also for adoptive cellular immunotherapy after ex vivo expansion. The ability to rapidly identify and isolate tumor-cytolytic T cells would be very useful in cancer immunotherapy.	Stanford Univ, Dept Med, Stanford, CA 94305 USA; NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ So Calif, Norris Canc Ctr, Los Angeles, CA 90033 USA; NIAID, Immunotechnol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Southern California; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lee, PP (corresponding author), Stanford Univ, Dept Med, 269 Campus Dr, Stanford, CA 94305 USA.		Roederer, Mario/G-1887-2011	Stuge, Tor B/0000-0002-6933-8419; Lee, Peter P./0000-0002-2660-4377	NCI NIH HHS [R01CA 090809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005020, Z01AI005020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bachmann MF, 1999, EUR J IMMUNOL, V29, P291, DOI 10.1002/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO;2-K; BETTS M, IN PRESS J IMMUNOL M; Cawthon AG, 2002, J IMMUNOL, V169, P3492, DOI 10.4049/jimmunol.169.7.3492; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Derby MA, 2001, INT IMMUNOL, V13, P817, DOI 10.1093/intimm/13.6.817; Dudley ME, 2002, J IMMUNOTHER, V25, P243, DOI 10.1097/00002371-200205000-00007; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dutoit V, 2002, J IMMUNOL, V168, P1167, DOI 10.4049/jimmunol.168.3.1167; Dutoit V, 2002, EUR J IMMUNOL, V32, P3285, DOI 10.1002/1521-4141(200211)32:11<3285::AID-IMMU3285>3.0.CO;2-9; Echchakir H, 2002, P NATL ACAD SCI USA, V99, P9358, DOI 10.1073/pnas.142308199; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Lee P, 2001, J CLIN ONCOL, V19, P3836, DOI 10.1200/JCO.2001.19.18.3836; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Lim DG, 2000, J IMMUNOL, V165, P6214, DOI 10.4049/jimmunol.165.11.6214; Margulies DH, 2001, NAT IMMUNOL, V2, P669, DOI 10.1038/90601; Molldrem JJ, 2003, J CLIN INVEST, V111, P639, DOI 10.1172/JCI200316398; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; Oh S, 2003, J IMMUNOL, V170, P2523, DOI 10.4049/jimmunol.170.5.2523; Slifka MK, 2001, NAT IMMUNOL, V2, P711, DOI 10.1038/90650; Snyder JE, 2003, NAT MED, V9, P231, DOI 10.1038/nm821; Tomaru U, 2003, NAT MED, V9, P469, DOI 10.1038/nm845; Weber J, 2003, CANCER-AM CANCER SOC, V97, P186, DOI 10.1002/cncr.11045; Whiteside TL, 2003, CLIN CANCER RES, V9, P641; Yee C, 1999, J IMMUNOL, V162, P2227; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099	26	329	352	1	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1377	1382		10.1038/nm942	http://dx.doi.org/10.1038/nm942			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528297				2022-12-27	WOS:000186319700027
J	Brewer, JA; Khor, B; Vogt, SK; Muglia, LM; Fujiwara, H; Haegele, KE; Sleckman, BP; Muglia, LJ				Brewer, JA; Khor, B; Vogt, SK; Muglia, LM; Fujiwara, H; Haegele, KE; Sleckman, BP; Muglia, LJ			T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR MONOCLONAL-ANTIBODY; CYCLOOXYGENASE-2 INHIBITORS; THYMOCYTE DEVELOPMENT; LYMPHOCYTES; EXPRESSION; RELEASE; MOUSE; INTERLEUKIN-6; SELECTION	Glucocorticoids, acting through the glucocorticoid receptor, potently modulate immune function and are a mainstay of therapy for treatment of inflammatory conditions, autoimmune diseases, leukemias and lymphomas(1). Moreover, removal of systemic glucocorticoids, by adrenalectomy in animal models or adrenal insufficiency in humans, has shown that endogenous glucocorticoid production is required for regulation of physiologic immune responses(2). These effects have been attributed to suppression of cytokines, although the crucial cellular and molecular targets remain unknown(3). In addition, considerable controversy remains as to whether glucocorticoids are required for thymocyte development(4-7). To assess the role of the glucocorticoid receptor in immune system development and function, we generated T-cell-specific glucocorticoid receptor knockout mice. Here we show that the T-cell is a critical cellular target of glucocorticoid receptor signaling, as immune activation in these mice resulted in significant mortality. This lethal activation is rescued by cyclooxygenase-2 (COX-2) inhibition but not steroid administration or cytokine neutralization. These studies indicate that glucocorticoid receptor suppression of COX-2 is crucial for curtailing lethal immune activation, and suggest new therapeutic approaches for regulation of T-cell-mediated inflammatory diseases.	Washington Univ, Sch Med, St Louis, MO 63110 USA; Pfizer Inc, Chesterfield, MO 63017 USA	Washington University (WUSTL); Pfizer	Muglia, LJ (corresponding author), Washington Univ, Sch Med, St Louis, MO 63110 USA.		Brewer, Judson/K-2283-2019	Khor, Bernard/0000-0003-4689-5092				Ashwell JD, 2000, IMMUNOL TODAY, V21, P644, DOI 10.1016/S0167-5699(00)01758-8; BERTINI R, 1988, J EXP MED, V167, P1708, DOI 10.1084/jem.167.5.1708; Bethin KE, 2000, P NATL ACAD SCI USA, V97, P9317, DOI 10.1073/pnas.97.16.9317; CHARPENTIER B, 1992, TRANSPLANTATION, V54, P997, DOI 10.1097/00007890-199212000-00011; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Da Silva JAP, 1999, ANN NY ACAD SCI, V876, P102; FERRAN C, 1991, EUR J IMMUNOL, V21, P2349, DOI 10.1002/eji.1830211009; FERRAN C, 1990, TRANSPLANTATION, V50, P642, DOI 10.1097/00007890-199010000-00023; Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768; Gross G, 2000, AM J PHYSIOL-REG I, V278, pR1415, DOI 10.1152/ajpregu.2000.278.6.R1415; Iniguez MA, 1999, J IMMUNOL, V163, P111; Jondal M, 2001, TRENDS IMMUNOL, V22, P185, DOI 10.1016/S1471-4906(01)01871-3; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Merger M, 2002, GUT, V51, P155, DOI 10.1136/gut.51.2.155; MUGLIA LJ, 1994, J CLIN INVEST, V93, P2066, DOI 10.1172/JCI117201; Muglia LJ, 2000, J CLIN INVEST, V105, P1269, DOI 10.1172/JCI5250; Musch MW, 2002, J CLIN INVEST, V110, P1739, DOI 10.1172/JCI200215695; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Purton JF, 2000, IMMUNITY, V13, P179, DOI 10.1016/S1074-7613(00)00018-2; SCOTT DE, 1990, J IMMUNOL, V145, P2183; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Vacchio MS, 1999, J IMMUNOL, V163, P1327; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9	25	105	110	0	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1318	1322		10.1038/nm895	http://dx.doi.org/10.1038/nm895			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12949501				2022-12-27	WOS:000185669700045
J	Gattone, VH; Wang, XF; Harris, PC; Torres, VE				Gattone, VH; Wang, XF; Harris, PC; Torres, VE			Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist	NATURE MEDICINE			English	Article							POLYCYSTIC KIDNEY-DISEASE; MEDULLARY COLLECTING DUCTS; M-1 CELLS; IN-VITRO; CAMP; PROTEIN; PROLIFERATION; NEPHRONOPHTHISIS; EXPRESSION; CA2+	The polycystic kidney diseases (PKDs) are a group of genetic disorders causing significant renal failure and death in children and adults. There are no effective treatments. Two childhood forms, autosomal recessive PKD (ARPKD) and nephronophthisis (NPH), are characterized by collecting-duct cysts(1,2). We used animal models orthologous to the human disorders to test whether a vasopressin V2 receptor (VPV2R) antagonist, OPC31260, would be effective against early or established disease. Adenosine-3',5'-cyclic monophosphate (cAMP) has a major role in cystogenesis(3,4), and the VPV2R is the major cAMP agonist in the collecting duct(5,6). OPC31260 administration lowered renal cAMP, inhibited disease development and either halted progression or caused regression of established disease. These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered.	Mayo Clin & Mayo Fdn, Div Nephrol, Rochester, MN 55905 USA; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA	Mayo Clinic; Indiana University System; Indiana University-Purdue University Indianapolis	Gattone, VH (corresponding author), Mayo Clin & Mayo Fdn, Div Nephrol, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044863] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44863] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cass LA, 1999, MOL CELL BIOL, V19, P5882; Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; GABOW PA, 1989, KIDNEY INT, V35, P675, DOI 10.1038/ki.1989.38; Gattone VH, 1999, DEV GENET, V24, P309, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<309::AID-DVG14>3.0.CO;2-5; Hanaoka K, 2000, J AM SOC NEPHROL, V11, P1179, DOI 10.1681/ASN.V1171179; Hildebrandt F, 2000, J AM SOC NEPHROL, V11, P1753, DOI 10.1681/ASN.V1191753; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; OHNISHI A, 1995, J PHARMACOL EXP THER, V272, P546; Olbrich H, 2003, NAT GENET, V34, P455, DOI 10.1038/ng1216; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Promeneur D, 2000, AM J PHYSIOL-RENAL, V279, pF370, DOI 10.1152/ajprenal.2000.279.2.F370; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Sutters M, 2001, KIDNEY INT, V60, P484, DOI 10.1046/j.1523-1755.2001.060002484.x; Thibonnier M, 2001, ANNU REV PHARMACOL, V41, P175, DOI 10.1146/annurev.pharmtox.41.1.175; VERANI RR, 1988, MODERN PATHOL, V1, P457; Wallace DP, 2001, AM J PHYSIOL-RENAL, V280, pF1019, DOI 10.1152/ajprenal.2001.280.6.F1019; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; WARD CJ, 2003, HUM MOL GENET   0812; Wong LL, 2001, CARDIOVASC RES, V51, P391, DOI 10.1016/S0008-6363(01)00315-7; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Yamaguchi T, 2002, J AM SOC NEPHROL, V13, p105A; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; Yamaguchi T, 1997, AM J KIDNEY DIS, V30, P703, DOI 10.1016/S0272-6386(97)90496-0; YAMAMURA Y, 1992, BRIT J PHARMACOL, V105, P787, DOI 10.1111/j.1476-5381.1992.tb09058.x; Yasuda G, 1998, KIDNEY INT, V54, P80, DOI 10.1046/j.1523-1755.1998.00990.x; Zerres K, 1998, J MOL MED, V76, P303, DOI 10.1007/s001090050221	28	464	483	1	25	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1323	1326		10.1038/nm935	http://dx.doi.org/10.1038/nm935			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502283				2022-12-27	WOS:000185669700046
J	Lee, SH; Prince, JE; Rais, M; Kheradmand, F; Shardonofsky, F; Lu, HF; Beaudet, AL; Smith, CW; Soong, L; Corry, DB				Lee, SH; Prince, JE; Rais, M; Kheradmand, F; Shardonofsky, F; Lu, HF; Beaudet, AL; Smith, CW; Soong, L; Corry, DB			Differential requirement for CD 18 in T-helper effector homing	NATURE MEDICINE			English	Article							AIRWAY HYPERREACTIVITY; EXPERIMENTAL LEISHMANIASIS; INTERFERON-GAMMA; TH2 DEVELOPMENT; DEFICIENT MICE; MURINE MODEL; CELLS; ADHESION; EXPRESSION; INFLAMMATION	To understand the integrin requirements of T-helper (T-H) effector subsets, we investigated the contribution of CD18 (beta(2) integrin) to T(H)1 and T(H)2 function in vitro and in relevant disease models. CD18-deficient (Itgb2(-/-)) T cells showed largely normal in vitro function. Compared with wild-type mice, Itgb2(-/-) mice were better able to resolve Leishmania major infection and generated a superior T(H)1 immune response, as assessed from draining lymph nodes. In contrast, T(H)2-dependent allergic lung disease was markedly impaired in mutant mice. In both models, development of T(H)1 and T(H)2 cells in spleens was normal, but accumulation of T(H)2 (not T(H)1) cells at inflammatory sites was reduced. Thus, CD18 is selectively required for T(H)2, but not T(H)1, homing and has a minimal influence on T-effector development. These findings suggest a new integrin-based therapeutic approach in which the outcomes of diverse diseases may be favorably influenced by altering the homing of T(H)2 cells.	Baylor Coll Med, Biol Inflammat Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston	Corry, DB (corresponding author), Baylor Coll Med, Biol Inflammat Ctr, 1 Baylor Plaza, Houston, TX 77030 USA.		Lee, Seung-Hyo/B-9922-2015	Lee, Seung-Hyo/0000-0003-0010-4072	NHLBI NIH HHS [F32-HL09657-02, HL64061-01, HL69585-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009657, R01HL069585, R01HL064061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abitorabi MA, 1996, J IMMUNOL, V156, P3111; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Brockdorff J, 1998, P NATL ACAD SCI USA, V95, P6959, DOI 10.1073/pnas.95.12.6959; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; CORRY DB, 1994, J IMMUNOL, V153, P4142; FISCHER H, 1992, J IMMUNOL, V148, P1993; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; GREEN JM, 1994, EUR J IMMUNOL, V24, P265, DOI 10.1002/eji.1830240141; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; JONES DA, 1994, J CLIN INVEST, V94, P2443, DOI 10.1172/JCI117612; KANEKO M, 1995, J IMMUNOL, V155, P2631; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; Medoff BD, 2002, J IMMUNOL, V168, P5278, DOI 10.4049/jimmunol.168.10.5278; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; PALLER AS, 1994, J AM ACAD DERMATOL, V31, P316, DOI 10.1016/S0190-9622(94)70162-8; SANDERS VM, 1986, J IMMUNOL, V137, P2395; Sasaki K, 2003, INT IMMUNOL, V15, P701, DOI 10.1093/intimm/dxg066; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schonlau F, 2000, EUR J IMMUNOL, V30, P2729, DOI 10.1002/1521-4141(200009)30:9&lt;2729::AID-IMMU2729&gt;3.0.CO;2-3; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; Syrbe U, 1999, SPRINGER SEMIN IMMUN, V21, P263, DOI 10.1007/BF00812257; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Xu BH, 2003, J EXP MED, V197, P1255, DOI 10.1084/jem.20010685	37	25	26	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1281	1286		10.1038/nm932	http://dx.doi.org/10.1038/nm932			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502280				2022-12-27	WOS:000185669700039
J	Weltzin, R; Liu, J; Pugachev, KV; Myers, GA; Coughlin, B; Blum, PS; Nichols, R; Johnson, C; Cruz, J; Kennedy, JS; Ennis, FA; Monath, TP				Weltzin, R; Liu, J; Pugachev, KV; Myers, GA; Coughlin, B; Blum, PS; Nichols, R; Johnson, C; Cruz, J; Kennedy, JS; Ennis, FA; Monath, TP			Clonal vaccinia virus grown in cell culture as a new smallpox vaccine	NATURE MEDICINE			English	Article							AEROSOL; MICE	Although the smallpox virus was eradicated over 20 years ago, its potential release through bioterrorism has generated renewed interest in vaccination. To develop a modern smallpox vaccine, we have adapted vaccinia virus that was derived from the existing Dryvax vaccine for growth in a human diploid cell line. We characterized six cloned and one uncloned vaccine candidates. One clone, designated ACAM1000, was chosen for development based on its comparability to Dryvax when tested in mice, rabbits and monkeys for virulence and immunogenicity. By most measures, ACAM1000 was less virulent than Dryvax. We compared ACAM1000 and Dryvax in a randomized, double-blind human clinical study. The vaccines were equivalent in their ability to produce major cutaneous reactions ('takes') and to induce neutralizing antibody and cell-mediated immunity against vaccinia virus.	Acambis Inc, Cambridge, MA 02139 USA; PRA Int, Lenexa, KS 66219 USA; Univ Massachusetts, Sch Med, Ctr Infect Dis & Vaccine Res, Worcester, MA 01655 USA	Sanofi-Aventis; University of Massachusetts System; University of Massachusetts Worcester	Monath, TP (corresponding author), Acambis Inc, 38 Sidney St, Cambridge, MA 02139 USA.	richard.weltzin@acambis.com; thomas.monath@acambis.com		Nichols, Rick/0000-0002-2761-3400	PHS HHS [200-2000-00001] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bray M, 2000, J INFECT DIS, V181, P10, DOI 10.1086/315190; *CDC, 2003, MMWR-MORBID MORTAL W, V52, P248; COLE GA, 1982, COMPR IMMUNOL, V9, P1; EHRENGUT W, 1975, ARCH VIROL, V48, P229, DOI 10.1007/BF01317965; Ennis FA, 2002, J INFECT DIS, V185, P1657, DOI 10.1086/340517; FINE HL, 1967, ARCH DERMATOL, V96, P185, DOI 10.1001/archderm.96.2.185; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; HENDERSON DA, 1999, VACCINES, P74; Jezek Z, 1988, HUMAN MONKEYPOX; Kutinova L, 1996, VACCINE, V14, P1045, DOI 10.1016/0264-410X(96)00008-4; KUTINOVA L, 1995, VACCINE, V13, P487, DOI 10.1016/0264-410X(94)00019-J; LeDuc JW, 1999, EMERG INFECT DIS, V5, P593, DOI 10.3201/eid0504.990429; MARENNIKOVA SS, 1969, P S SMALLPOX, P65; MARENNIKOVA SS, 1973, INT S SMALLP VACC BI, V19, P253; Martinez MJ, 2000, ARCH PATHOL LAB MED, V124, P362; MCINTOSH K, 1977, J INFECT DIS, V135, P155, DOI 10.1093/infdis/135.1.155; MORITA M, 1977, MICROBIOL IMMUNOL, V21, P417, DOI 10.1111/j.1348-0421.1977.tb00306.x; NAGAO S, 1976, ARCH DERMATOL RES, V256, P23, DOI 10.1007/BF00561177; PROSS HF, 1981, J CLIN IMMUNOL, V1, P51, DOI 10.1007/BF00915477; REED L. J., 1938, AMER JOUR HYG, V27, P493; Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915; VILESOVA IS, 1985, VOP VIRUSOL+, P477; WILLIAMSON JD, 1990, J GEN VIROL, V71, P2761, DOI 10.1099/0022-1317-71-11-2761	25	110	114	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2003	9	9					1125	1130		10.1038/nm916	http://dx.doi.org/10.1038/nm916			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925845				2022-12-27	WOS:000185061600023
J	Weiss, RA				Weiss, RA			HIV and AIDS: looking ahead	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; IMMUNE-DEFICIENCY-SYNDROME; T-LYMPHOTROPIC RETROVIRUS; SUB-SAHARAN AFRICA; GENETIC-VARIATION; HTLV-III; INFECTION; TRANSMISSION; RISK; RECOMBINATION	Although the future of HIV science is uncertain, we need to reappraise HIV diversity, pathogenesis and immunity. The AIDS pandemic threatens the success of existing vaccine programs and may accelerate the emergence of new infectious diseases.	UCL, Dept Immunol & Mol Pathol, London W1T 4JF, England	University of London; University College London	Weiss, RA (corresponding author), UCL, Dept Immunol & Mol Pathol, 46 Cleveland St, London W1T 4JF, England.	r.weiss@ucl.ac.uk						BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Bartlett JG, 2003, CLIN INFECT DIS, V36, P468, DOI 10.1086/368093; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; Buve A, 2001, AIDS, V15, pS5, DOI 10.1097/00002030-200108004-00002; Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499; Drucker E, 2001, LANCET, V358, P1989, DOI 10.1016/S0140-6736(01)06967-7; ELLRODT A, 1984, LANCET, V1, P1383; Fauci AS, 2003, NAT MED, V9, P839, DOI 10.1038/nm0703-839; FIELDS BN, 1994, NATURE, V369, P95, DOI 10.1038/369095a0; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; Gisselquist D, 2003, INT J STD AIDS, V14, P148, DOI 10.1258/095646203762869151; Gonzalez E, 2001, P NATL ACAD SCI USA, V98, P5199, DOI 10.1073/pnas.091056898; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Hatziioannou T, 2003, EMBO J, V22, P385, DOI 10.1093/emboj/cdg042; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; *JOINT UN PROGR HI, 2003, MAL CIRC CURR EP FIE; *JOINT UN PROGR HI, 2003, EXP GROUP STRESS UNS; Jung A, 2002, NATURE, V418, P144, DOI 10.1038/418144a; Kaye JF, 1998, J VIROL, V72, P5877, DOI 10.1128/JVI.72.7.5877-5885.1998; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; Mbopi-Keou FX, 2000, J INFECT DIS, V182, P1090, DOI 10.1086/315836; McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874; MONTAGNIER L, 1984, ANN INST PASTEUR VIR, V135, P119, DOI 10.1016/S0769-2617(84)80046-5; MOSS JW, 2003, B WORLD HEALTH ORGAN, V81, P61; Nabel GJ, 2003, VIRUS RES, V92, P213, DOI 10.1016/S0168-1702(02)00354-4; O'Brien SJ, 2000, IMMUNOL REV, V177, P99, DOI 10.1034/j.1600-065X.2000.17710.x; Perelson AS, 2002, NAT REV IMMUNOL, V2, P28, DOI 10.1038/nri700; Pomerantz RJ, 2003, NAT MED, V9, P867, DOI 10.1038/nm0703-867; Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; Reeves JD, 2002, J GEN VIROL, V83, P1253, DOI 10.1099/0022-1317-83-6-1253; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Sala M, 2000, J MOL EVOL, V51, P12, DOI 10.1007/s002390010062; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; SIGURDSSON B, 1960, ARCH VIRUSFORSCHUNG, V10, P430; Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853; Subramaniam KS, 2003, J INFECT DIS, V187, P758, DOI 10.1086/368331; Takehisa J, 1999, J VIROL, V73, P6810, DOI 10.1128/JVI.73.8.6810-6820.1999; Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398; Valdiserri RO, 2003, NAT MED, V9, P881, DOI 10.1038/nm0703-881; VILMER E, 1984, LANCET, V1, P753; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231; Walker PR, 2003, NATURE, V422, P679, DOI 10.1038/422679a; Walsh PD, 2003, NATURE, V422, P611, DOI 10.1038/nature01566; Watt G, 2000, LANCET, V356, P475, DOI 10.1016/S0140-6736(00)02557-5; Watt G, 2003, CLIN INFECT DIS, V36, P1067, DOI 10.1086/374600; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Weiss HA, 2000, AIDS, V14, P2361, DOI 10.1097/00002030-200010200-00018; Weiss RA, 1999, IMMUNOL LETT, V66, P3, DOI 10.1016/S0165-2478(98)00178-3; Weiss RA, 2003, EMBO REP, V4, pS10, DOI 10.1038/sj.embor.embor857; Weiss RA, 2001, NATURE, V410, P963, DOI 10.1038/35073632; Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364	58	21	26	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					887	891		10.1038/nm0703-887	http://dx.doi.org/10.1038/nm0703-887			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835710	Green Published, Bronze			2022-12-27	WOS:000183979300029
J	De Palma, M; Venneri, MA; Roca, C; Naldini, L				De Palma, M; Venneri, MA; Roca, C; Naldini, L			Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells	NATURE MEDICINE			English	Letter							BONE-MARROW; LENTIVIRAL VECTORS; EXPRESSION; GROWTH; CANCER; MICE; MACROPHAGES; RECEPTOR; ORIGIN; MARKER	Angiogenic tumor vessels are promising targets for the activity and the selective delivery of cancer therapeutics(1,2). The bone marrow contributes different cell types to the tumor stroma, including hematopoietic cells(3,4) and, as recently suggested, vascular endothelial cells (ECs)(5). Thus, transplantation of genetically modified bone marrow progenitors may represent a vehicle for the transport of gene therapy to tumors. We transduced bone marrow progenitors with lentiviral vectors expressing genes from transcription-regulatory elements of Tie2/Tek gene(6). When tumors were grown in the transplanted mice, the new vector marked a distinct hematopoietic population that 'homed' to the tumor and closely interacted with vascular ECs at the tumor periphery. These Tie2-expressing mononuclear (TEM) cells had a distinguishable phenotype and were present selectively at angiogenic sites. Unexpectedly, we did not find bone marrow-derived ECs in tumor vessels when we transplanted bone marrow progenitors constitutively expressing a marker gene from the Tie2 or ubiquitously active promoters. By delivering a 'suicide' gene, we selectively eliminated the TEM cells and achieved substantial inhibition of angiogenesis and slower tumor growth without systemic toxicity. Thus, TEM cells may account for the proangiogenic activity of bone marrow-derived cells in tumors, may represent a new target for drug development and may provide the means for selective gene delivery and targeted inhibition of tumor angiogenesis.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC,Lab Gene Transfer & Therapy, I-10060 Turin, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC,Div Mol Angiogenesis, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Naldini, L (corresponding author), San Raffaele Telethon Inst Gene Therapy, HSR TIGET, Via Olgettina 58, I-20132 Milan, Italy.		De Palma, Michele/L-5350-2016; Naldini, Luigi/E-9083-2012	De Palma, Michele/0000-0001-9128-5459; NALDINI, Luigi/0000-0002-7835-527X; VENNERI, MARY ANNA/0000-0002-0687-8135	Telethon [A.143] Funding Source: Medline	Telethon(Fondazione Telethon)		Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Davidoff AM, 2001, CLIN CANCER RES, V7, P2870; Folkman J, 2000, NAT REV MOL CELL BIO, V1, P76, DOI 10.1038/35036100; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Follenzi A, 2002, HUM GENE THER, V13, P243, DOI 10.1089/10430340252769770; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; JONES SE, 1967, INT J NONLIN MECH, V2, P257; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Peters KG, 1998, BRIT J CANCER, V77, P51, DOI 10.1038/bjc.1998.8; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tanaka S, 2002, HEPATOLOGY, V35, P861, DOI 10.1053/jhep.2002.32535	25	444	466	3	38	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					789	795		10.1038/nm871	http://dx.doi.org/10.1038/nm871			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740570				2022-12-27	WOS:000183444100037
J	Schwartz, K; Vilquin, JT				Schwartz, K; Vilquin, JT			Building the translational highway: toward new partnerships between academia and the private sector	NATURE MEDICINE			English	Editorial Material							SKELETAL MYOBLAST TRANSPLANTATION; CELL TRANSPLANTATION; ISCHEMIC MYOCARDIUM; CARDIAC-MUSCLE; STEM-CELLS; CARDIOMYOCYTE; HEART; REPAIR; DIFFERENTIATION; REGENERATION	At the crossroads of academia and industry, translational research provides the vehicle for the application of medical discoveries and developments. A productive and expanded relationship between these two sectors is essential for the continued success in translating basic research findings to the clinic.	Grp Hosp Pitie Salpetriere, Inst Myol, INSERM, U582, F-75634 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Schwartz, K (corresponding author), Grp Hosp Pitie Salpetriere, Inst Myol, INSERM, U582, F-75634 Paris, France.	k.schwartz@myologie.chups.jussieu.fr		Vilquin, Jean-Thomas/0000-0003-0050-0219				Al Attar N, 2003, CARDIOVASC RES, V58, P142, DOI 10.1016/S0008-6363(02)00790-3; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Beachy RN, 2003, SCIENCE, V299, P473, DOI 10.1126/science.299.5606.473; Berry C, 2001, EUR J HEART FAIL, V3, P283, DOI 10.1016/S1388-9842(01)00123-4; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Ghostine S, 2002, CIRCULATION, V106, pI131, DOI 10.1161/01.cir.0000032889.55215.f1; Hagege AA, 2003, LANCET, V361, P491, DOI 10.1016/S0140-6736(03)12458-0; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Marelli D, 1992, Cell Transplant, V1, P383; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Minami E, 2003, J AM COLL CARDIOL, V41, P1084, DOI 10.1016/S0735-1097(03)00083-4; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pagani FD, 2003, J AM COLL CARDIOL, V41, P879, DOI 10.1016/S0735-1097(03)00081-0; Pouzet B, 2000, CIRCULATION, V102, P210; Pouzet B, 2001, ANN THORAC SURG, V71, P844, DOI 10.1016/S0003-4975(00)01785-9; Pouzet B, 2001, CIRCULATION, V104, pI223; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Rajnoch C, 2001, J THORAC CARDIOV SUR, V121, P871, DOI 10.1067/mtc.2001.112937; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; Scorsin M, 1997, CIRCULATION, V96, P188; Scorsin M, 2000, J THORAC CARDIOV SUR, V119, P1169, DOI 10.1067/mtc.2000.104865; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; Varki A, 2002, NAT MED, V8, P437, DOI 10.1038/nm0502-437	35	15	15	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2003	9	5					493	495		10.1038/nm0503-493	http://dx.doi.org/10.1038/nm0503-493			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12724751				2022-12-27	WOS:000182610600015
J	Stalmans, I; Lambrechts, D; De smet, F; Jansen, S; Wang, J; Maity, S; Kneer, P; von der Ohe, M; Swillen, A; Maes, C; Gewillig, M; Molin, DGM; Hellings, P; Boetel, T; Haardt, M; Compernolle, V; Dewerchin, M; Plaisance, S; Vlietinck, R; Emanuel, B; Gittenberger-de Groot, AC; Scambler, P; Morrow, B; Driscol, DA; Moons, L; Esguerra, CV; Carmeliet, G; Behn-Krappa, A; Devriendt, K; Collen, D; Conway, SJ; Carmeliet, P				Stalmans, I; Lambrechts, D; De smet, F; Jansen, S; Wang, J; Maity, S; Kneer, P; von der Ohe, M; Swillen, A; Maes, C; Gewillig, M; Molin, DGM; Hellings, P; Boetel, T; Haardt, M; Compernolle, V; Dewerchin, M; Plaisance, S; Vlietinck, R; Emanuel, B; Gittenberger-de Groot, AC; Scambler, P; Morrow, B; Driscol, DA; Moons, L; Esguerra, CV; Carmeliet, G; Behn-Krappa, A; Devriendt, K; Collen, D; Conway, SJ; Carmeliet, P			VEGF: A modifier of the del22q11 (DiGeorge) syndrome?	NATURE MEDICINE			English	Article							MONOZYGOTIC TWINS; 22Q11 DELETION; MICE LACKING; AORTIC-ARCH; GENE; ANGIOGENESIS; TBX1; DEFECTS; REGION; POLYMORPHISM	Hemizygous deletion of chromosome 22q11 (del22q11) causes thymic, parathyroid, craniofacial and life-threatening cardiovascular birth defects in 1 in 4,000 infants. The del22q11 syndrome is likely caused by haploinsufficiency of TBX1, but its variable expressivity indicates the involvement of additional modifiers. Here, we report that absence of the Vegf(164) isoform caused birth defects in mice, reminiscent of those found in del22q11 patients. The close correlation of birth and vascular defects indicated that vascular dysgenesis may pathogenetically contribute to the birth defects. Vegf interacted with Tbx1, as Tbx1 expression was reduced in Vegf(164)-deficient embryos and knocked-down vegf levels enhanced the pharyngeal arch artery defects induced by tbx1 knockdown in zebrafish. Moreover, initial evidence suggested that a VEGF promoter haplotype was associated with an increased risk for cardiovascular birth defects in del22q11 individuals. These genetic data in mouse, fish and human indicate that VEGF is a modifier of cardiovascular birth defects in the del22q11 syndrome.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Louvain, Belgium; Katholieke Univ Leuven, Dept Pediat, Louvain, Belgium; Mermaid Pharmaceut GmbH, Falkenried CiM 88, Hamburg, Germany; Leiden Univ, Dept Anat & Embryol, Med Ctr, Leiden, Netherlands; Univ Maastricht, Dept Populat Genet Genom & Bioinformat, Maastricht, Netherlands; Univ Penn, Sch Med, Dept Pediat,Div Reprod Genet, Dept Obstet & Gynecol,Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Inst Child Hlth, Mol Med Unit, London, England; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA	University System of Georgia; Augusta University; Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven; KU Leuven; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Maastricht University; University of Pennsylvania; University of London; University College London; Yeshiva University; Albert Einstein College of Medicine	Conway, SJ (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.	sconway@mail.mcg.edu; peter.carmeliet@med.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020; Plaisance, Stephane/B-3488-2009; Esguerra, Camila/N-6159-2015; De Smet, Frederik/Q-7808-2016; Scambler, Peter/AAZ-6026-2020; Plaisance, Stephane/ABI-6307-2020; Scambler, Peter J/C-4998-2008; Hellings, Peter W/I-4068-2018; Esguerra, Camila/D-7657-2014; Verdrengh, Evelien/H-4571-2012; Lambrechts, Diether/AAJ-3167-2020	Carmeliet, Peter/0000-0001-7961-1821; Plaisance, Stephane/0000-0002-1651-241X; Esguerra, Camila/0000-0002-2271-8094; De Smet, Frederik/0000-0002-6669-3335; Scambler, Peter/0000-0002-1487-4628; Plaisance, Stephane/0000-0002-1651-241X; Scambler, Peter J/0000-0002-1487-4628; Hellings, Peter W/0000-0001-6898-688X; Esguerra, Camila/0000-0001-7891-1427; Lambrechts, Diether/0000-0002-3429-302X; Maes, Christa/0000-0003-4243-5486; Gewillig, Marc/0000-0002-4595-5922; Maity, Sunit/0000-0001-6667-3249; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Swillen, Ann/0000-0003-4258-4537; Morrow, Bernice/0000-0002-8076-4726	NHLBI NIH HHS [HL60104, HL60714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060104, R01HL060714] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Conway SJ, 2000, CARDIOVASC RES, V47, P314, DOI 10.1016/S0008-6363(00)00098-5; Conway SJ, 1997, DEVELOPMENT, V124, P505; Creazzo TL, 1998, ANNU REV PHYSIOL, V60, P267, DOI 10.1146/annurev.physiol.60.1.267; Driscoll DA, 2001, GENET MED, V3, P14, DOI 10.1097/00125817-200101000-00004; Emanuel B S, 2001, Adv Pediatr, V48, P39; Garg V, 2001, DEV BIOL, V235, P62, DOI 10.1006/dbio.2001.0283; Gong W, 2001, J Med Genet, V38, pE45, DOI 10.1136/jmg.38.12.e45; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Liang D, 2001, MECH DEVELOP, V108, P29, DOI 10.1016/S0925-4773(01)00468-3; Lindsay EA, 2001, NAT REV GENET, V2, P858, DOI 10.1038/35098574; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Lu JH, 2001, PEDIATR CARDIOL, V22, P260, DOI 10.1007/s002460010219; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; Mansir T, 1999, GENET COUNSEL, V10, P67; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; McDermid HE, 2002, AM J HUM GENET, V70, P1077, DOI 10.1086/340363; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Piotrowski T, 2000, DEV BIOL, V225, P339, DOI 10.1006/dbio.2000.9842; Robinson H B Jr, 1975, Perspect Pediatr Pathol, V2, P173; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421; SCHINZEL AAGL, 1979, J PEDIATR-US, V95, P921, DOI 10.1016/S0022-3476(79)80278-4; Schreiber C, 1997, EUR J CARDIO-THORAC, V12, P466, DOI 10.1016/S1010-7940(97)00194-2; Shahbazi M, 2002, J AM SOC NEPHROL, V13, P260, DOI 10.1681/ASN.V131260; SHAM PC, 1995, ANN HUM GENET, V59, P97, DOI 10.1111/j.1469-1809.1995.tb01608.x; Shprintzen RJ, 2000, MENT RETARD DEV D R, V6, P142, DOI 10.1002/1098-2779(2000)6:2<142::AID-MRDD9>3.0.CO;2-H; Shprintzen RJ, 1997, AM J HUM GENET, V61, pA5; Srivastava D, 2001, ANNU REV PHYSIOL, V63, P451, DOI 10.1146/annurev.physiol.63.1.451; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Terwilliger J., 1994, HDB HUMAN GENETIC LI; Vincent MC, 1999, GENET COUNSEL, V10, P43; Vitelli F, 2002, DEVELOPMENT, V129, P4605; Westerfield M, 1994, ZEBRAFISH BOOK GUIDE	43	222	233	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2003	9	2					173	182		10.1038/nm819	http://dx.doi.org/10.1038/nm819			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12539040				2022-12-27	WOS:000180801900021
J	Ciana, P; Raviscioni, M; Mussi, P; Vegeto, E; Que, I; Parker, MG; Lowik, C; Maggi, A				Ciana, P; Raviscioni, M; Mussi, P; Vegeto, E; Que, I; Parker, MG; Lowik, C; Maggi, A			In vivo imaging of transcriptionally active estrogen receptors	NATURE MEDICINE			English	Article							TISSUE-SPECIFIC REGULATION; NUCLEAR RECEPTORS; GENE-EXPRESSION; ACTIVATION; GROWTH	Through intracellular receptors, estrogens control growth, differentiation and function of not only reproductive tissues, but also other systems(1-3). Estrogen receptors are ligand-dependent transcription factors whose activity is modulated either by estrogens, or by alternative intracellular signaling pathways downstream of growth factors and neurotransmitters(4-6). To determine the dynamics of estrogen receptor activity and the dependence of estrogen receptor on 17beta-estradiol in vivo, we generated a transgenic mouse that expresses a luciferase reporter gene under the control of activated estrogen receptors. As expected, luciferase activity, monitored with a cooled charged coupled device camera, paralleled circulating estrogen levels in reproductive tissues and in liver, indicating that the peak transcriptional activity of the estrogen receptor occurred at proestrus. In contrast, in tissues such as bone and brain, the peak activity of estrogen receptors was observed at diestrus. These tissue-specific responses are masked when mice undergo conventional hormone treatment. We also demonstrate that estrogen receptors are active in immature mice before gonadal production of sex hormones as well as in ovariectomized adult mice. These findings emphasize the importance of hormone-independent activation of the estrogen receptor, and have implications for the therapeutic use of estrogens, such as hormone replacement therapy.	Univ Milan, Ctr Excellence Neurodegenerat Dis, Milan, Italy; Univ Milan, Inst Pharmacol Sci, Milan, Italy; Leiden Univ, Med Ctr, Dept Endocrinol, Leiden, Netherlands; Hammersmith Hosp, ICSM, Inst Reprod & Dev Biol, London, England	University of Milan; University of Milan; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Imperial College London	Maggi, A (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Milan, Italy.	adriana.maggi@unimi.it	Ciana, Paolo/F-9224-2012	Maggi, Adriana/0000-0001-5700-5273; CIANA, PAOLO/0000-0001-5771-5638	Telethon [E.0600, E.C0699] Funding Source: Medline	Telethon(Fondazione Telethon)		Ciana P, 2001, MOL ENDOCRINOL, V15, P1104, DOI 10.1210/me.15.7.1104; Ciana P, 2002, EMBO REP, V3, P125, DOI 10.1093/embo-reports/kvf029; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GOMEZBENITEZ J, 1984, REV ESP FISIOL, V40, P311; Hashizume T, 2000, DOMEST ANIM ENDOCRIN, V18, P253, DOI 10.1016/S0739-7240(99)00082-X; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Honigman A, 2001, MOL THER, V4, P239, DOI 10.1006/mthe.2001.0437; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; OVERPECK JG, 1978, J TOXICOL ENV HEALTH, V4, P785, DOI 10.1080/15287397809529700; PLOURDE PV, 1995, J STEROID BIOCHEM, V53, P175, DOI 10.1016/0960-0760(95)00045-2; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; SHUPNIK MA, 1989, MOL ENDOCRINOL, V3, P660, DOI 10.1210/mend-3-4-660; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; VOURET JF, 1991, EMBO J, V10, P1875; WAKELING AE, 1991, CANCER RES, V51, P3867; WENGER NK, 2002, NIH PUBLICATION; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460	25	234	241	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					82	86		10.1038/nm809	http://dx.doi.org/10.1038/nm809			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12483206				2022-12-27	WOS:000180209900026
J	Maier, AG; Duraisingh, MT; Reeder, JC; Patel, SS; Kazura, JW; Zimmerman, PA; Cowman, AF				Maier, AG; Duraisingh, MT; Reeder, JC; Patel, SS; Kazura, JW; Zimmerman, PA; Cowman, AF			Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations	NATURE MEDICINE			English	Article							BLOOD-GROUP; RED-CELLS; MALARIA; RECEPTOR; ANTIGENS; EBA-175; LIGAND; MELANESIANS; MEMBRANE; DELETION	Geographic overlap between malaria and the occurrence of mutant hemoglobin and erythrocyte surface proteins has indicated that polymorphisms in human genes have been selected by severe malaria(1,2). Deletion of exon 3 in the glycophorin C gene (called GYPCDeltaex3 here) has been found in Melanesians; this alteration changes the serologic phenotype of the Gerbich (Ge) blood group system, resulting in Ge negativity(3,4). The GYPCDeltaex3 allele reaches a high frequency (46.5%) in coastal areas of Papua New Guinea where malaria is hyperendemic(5). The Plasmodium falciparum erythrocyte-binding antigen 140 (EBA140, also known as BAEBL)(6-8) binds with high affinity to the surface of human erythrocytes. Here we show that the receptor for EBA140 is glycophorin C (GYPC) and that this interaction mediates a principal P. falciparum invasion pathway into human erythrocytes. EBA140 does not bind to GYPC in Ge-negative erythrocytes, nor can P. falciparum invade such cells using this invasion pathway. This provides compelling evidence that Ge negativity has arisen in Melanesian populations through natural selection by severe malaria.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Papua New Guinea Inst Med Res, Goroka, Papua N Guinea; Case Western Reserve Univ, Div Geog Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Walter & Eliza Hall Institute; PNG Institute Of Medical Research; Case Western Reserve University; University Hospitals of Cleveland	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Maier, Alex G/A-6499-2009; Cowman, Alan F/C-7642-2013	Maier, Alex G/0000-0001-7369-1058; Cowman, Alan F/0000-0001-5145-9004; Reeder, John/0000-0003-1395-1289	NIAID NIH HHS [AI36478-07, AI46919-01A2, K23 AI049390, AI49390-01, R01 AI036478, R01 AI046919] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036478, K23AI049390, R01AI046919, R01AI036478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN SJ, 1992, T ROY SOC TROP MED H, V86, P494, DOI 10.1016/0035-9203(92)90083-O; BOOTH PB, 1972, VOX SANG, V22, P73, DOI 10.1111/j.1423-0410.1972.tb03968.x; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1; Duraisingh MT, 2002, INT J PARASITOL, V32, P81, DOI 10.1016/S0020-7519(01)00345-9; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Haldane J. B. S., 1949, P 8 INT C GEN, P267; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; Issitt, 1998, APPL BLOOD GROUP SER; JUNGERY M, 1983, P NATL ACAD SCI-BIOL, V80, P1018, DOI 10.1073/pnas.80.4.1018; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; Narum DL, 2002, MOL BIOCHEM PARASIT, V119, P159, DOI 10.1016/S0166-6851(01)00428-5; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; PASVOL G, 1978, NATURE, V274, P701, DOI 10.1038/274701a0; PASVOL G, 1984, LANCET, V1, P907; Patel SS, 2001, BLOOD, V98, P3489, DOI 10.1182/blood.V98.12.3489; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; Rubio JP, 1996, EMBO J, V15, P4069, DOI 10.1002/j.1460-2075.1996.tb00780.x; SERJEANTSON SW, 1994, IMMUNOL CELL BIOL, V72, P23, DOI 10.1038/icb.1994.4; SIM BKL, 1994, EXP PARASITOL, V78, P259, DOI 10.1006/expr.1994.1027; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; TELEN MJ, 1987, TRANSFUSION, V27, P309, DOI 10.1046/j.1537-2995.1987.27487264736.x; Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807	29	238	247	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2003	9	1					87	92		10.1038/nm807	http://dx.doi.org/10.1038/nm807			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632EC	12469115	Green Accepted			2022-12-27	WOS:000180209900027
J	Yamada, K; Yazawa, K; Shimizu, A; Iwanaga, T; Hisashi, Y; Nuhn, M; O'Malley, P; Nobori, S; Vagefi, PA; Patience, C; Fishman, J; Cooper, DKC; Hawley, RJ; Greenstein, J; Schuurman, HJ; Awwad, M; Sykes, M; Sachs, DH				Yamada, K; Yazawa, K; Shimizu, A; Iwanaga, T; Hisashi, Y; Nuhn, M; O'Malley, P; Nobori, S; Vagefi, PA; Patience, C; Fishman, J; Cooper, DKC; Hawley, RJ; Greenstein, J; Schuurman, HJ; Awwad, M; Sykes, M; Sachs, DH			Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha 1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue	NATURE MEDICINE			English	Article							MINIATURE SWINE; COMPOSITE THYMOKIDNEYS; LOBE TRANSPLANTATION; TOLERANCE INDUCTION; MISMATCHED BARRIERS; NUCLEAR TRANSFER; PIGS; THYMOPOIESIS; ANTIBODIES	The use of animal organs could potentially alleviate the critical worldwide shortage of donor organs for clinical transplantation. Because of the strong immune response to xenografts, success will probably depend upon new strategies of immune suppression and induction of tolerance. Here we report our initial results using alpha-1,3-galactosyltransferase knockout (GalT-KO) donors and a tolerance induction approach. We have achieved life-supporting pig-to-baboon renal xenograft survivals of up to 83 d with normal creatinine levels.	Massachusetts Gen Hosp East, Transplantat Biol Res Ctr, Boston, MA 02129 USA; Immerge Biotherapeut, Cambridge, MA 02139 USA; Massachusetts Gen Hosp East, Infect Dis Unit, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Sachs, DH (corresponding author), Massachusetts Gen Hosp East, Transplantat Biol Res Ctr, Boston, MA 02129 USA.	sachs@helix.mgh.harvard.edu	Sano, Michael/E-1715-2011		PHS HHS [1P01A45897] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barth RN, 2003, TRANSPLANTATION, V75, P1615, DOI 10.1097/01.TP.0000064335.50622.20; Dai YF, 2002, NAT BIOTECHNOL, V20, P251, DOI 10.1038/nbt0302-251; Galili U, 1999, Subcell Biochem, V32, P79; GOOD AH, 1992, TRANSPL P, V24, P559; Kamano C, 2004, P NATL ACAD SCI USA, V101, P3827, DOI 10.1073/pnas.0306666101; Kobayashi T, 1997, TRANSPLANTATION, V64, P1255, DOI 10.1097/00007890-199711150-00005; Kolber-Simonds D, 2004, P NATL ACAD SCI USA, V101, P7335, DOI 10.1073/pnas.0307819101; Kozlowski T, 1999, TRANSPLANTATION, V67, P18, DOI 10.1097/00007890-199901150-00004; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; LaMattina JC, 2002, TRANSPLANTATION, V73, P826, DOI 10.1097/00007890-200203150-00032; Lambrigts D, 1998, TRANSPLANTATION, V66, P547, DOI 10.1097/00007890-199809150-00001; Xu Y, 1998, TRANSPLANTATION, V65, P172; Yamada K, 2000, J IMMUNOL, V164, P3079, DOI 10.4049/jimmunol.164.6.3079; Yamada K, 2003, TRANSPLANTATION, V76, P530, DOI 10.1097/01.TP.0000080608.42480.E8; Yamada K, 1999, TRANSPLANTATION, V68, P1684, DOI 10.1097/00007890-199912150-00011	15	472	495	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					32	34		10.1038/nm1172	http://dx.doi.org/10.1038/nm1172			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619627				2022-12-27	WOS:000226124900029
J	Kiessling, F; Greschus, S; Lichy, MP; Bock, M; Fink, C; Vosseler, S; Moll, J; Mueller, MM; Fusenig, NE; Traupe, H; Semmler, W				Kiessling, F; Greschus, S; Lichy, MP; Bock, M; Fink, C; Vosseler, S; Moll, J; Mueller, MM; Fusenig, NE; Traupe, H; Semmler, W			Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis	NATURE MEDICINE			English	Article							MR-ANGIOGRAPHY; CANCER; CT; VASCULATURE; MATURATION; THERAPY; GROWTH; FUTURE	Volumetric computed tomography (VCT) is a technology in which area detectors are used for imaging large volumes of a subject with isotropic imaging resolution. We are experimenting with a prototype VCT scanner that uses flat-panel X-ray detectors and is designed for high-resolution three-dimensional (3D) imaging. Using this technique, we have demonstrated microangiography of xeno-transplanted skin squamous cell carcinomas in nude mice. VCT shows the vessel architecture of tumors and animals with greater detail and plasticity than has previously been achieved, and is superior to contrast-enhanced magnetic resonance (MR) angiography. VCT and MR images correlate well for larger tumor vessels, which are tracked from their origin on 3D reconstructions of VCT images. When compared with histology, small tumor vessels with a diameter as small as 50 mum were clearly visualized. Furthermore, imaging small vessel networks inside the tumor tissue improved discrimination of vital and necrotic regions. Thus, VCT substantially improves imaging of vascularization in tumors and offers a promising tool for preclinical studies of tumor angiogenesis and antiangiogenic therapies.	German Canc Res Ctr, Dept Med Phys Radiol, D-69120 Heidelberg, Germany; Univ Giessen, Dept Neuroradiol, D-35385 Giessen, Germany; German Canc Res Ctr, Dept Radiol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Carcinogenesis & Differentiat, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Justus Liebig University Giessen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Kiessling, F (corresponding author), German Canc Res Ctr, Dept Med Phys Radiol, INF 280, D-69120 Heidelberg, Germany.	f.kiessling@dkfz.de	Kiessling, Fabian/Y-2417-2019; Bock, Michael/B-2987-2009	Kiessling, Fabian/0000-0002-7341-0399; Bock, Michael/0000-0001-9720-3506				Barentsz JO, 1999, J MAGN RESON IMAGING, V10, P295, DOI 10.1002/(SICI)1522-2586(199909)10:3<295::AID-JMRI10>3.0.CO;2-Z; Brix G, 1999, RADIOLOGY, V210, P269, DOI 10.1148/radiology.210.1.r99ja46269; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Fan XB, 2001, MAGNET RESON MED, V45, P1046, DOI 10.1002/mrm.1139; Fink C, 2003, J MAGN RESON IMAGING, V18, P59, DOI 10.1002/jmri.10318; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; Fox SB, 2001, LANCET ONCOL, V2, P278, DOI 10.1016/S1470-2045(00)00323-5; Fusenig NE, 1998, MOL CARCINOGEN, V23, P144, DOI 10.1002/(SICI)1098-2744(199811)23:3<144::AID-MC3>3.0.CO;2-U; Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6; HEIKEN JP, 1993, RADIOLOGY, V189, P647, DOI 10.1148/radiology.189.3.8234684; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Idee JM, 2001, INVEST RADIOL, V36, P41, DOI 10.1097/00004424-200101000-00006; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kiessling F, 2003, INT J CANCER, V104, P113, DOI 10.1002/ijc.10913; Kobayashi H, 2001, J MAGN RESON IMAGING, V14, P705, DOI 10.1002/jmri.10025; Lawler Leo P., 2002, Critical Reviews in Computed Tomography, V43, P77; Maehara N, 2003, EUR RADIOL, V13, P1559, DOI 10.1007/s00330-002-1729-z; Miles KA, 2001, RADIOLOGY, V220, P548, DOI 10.1148/radiology.220.2.r01au26548; Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092; Port RE, 1999, JMRI-J MAGN RESON IM, V10, P233; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Wiart M, 2001, INVEST RADIOL, V36, P547, DOI 10.1097/00004424-200109000-00007; ZANG M, 1997, RADIOLOGY, V205, P471	28	174	176	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1133	1138		10.1038/nm1101	http://dx.doi.org/10.1038/nm1101			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15361864				2022-12-27	WOS:000224245800046
J	Schubert, C				Schubert, C			Cancer's weak moment	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2022-12-27	WOS:000224245800027
J	Koo, EH; Kopan, R				Koo, EH; Kopan, R			Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration	NATURE MEDICINE			English	Review							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE CLEAVAGE; P75 NEUROTROPHIN RECEPTOR; NF-KAPPA-B; ALZHEIMERS-DISEASE; INTRAMEMBRANE PROTEOLYSIS; INTRACELLULAR DOMAIN; BETA-CATENIN; NOTCH LIGANDS; MUTATIONS	Neurodegenerative diseases can be genetic or sporadic in origin. Genetic analysis has changed the study of the pathogenesis of these disorders by showing the causative functions of rare mutations. Yet, in the most common age-associated neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, the causes of neurodegeneration remain to be clarified. The observations that presenilin modulates proteolysis and turnover of several signaling molecules have led to speculations that pathways that are important in development may contribute to neurodegeneration. In this article, the possibility that these presenilin-regulated molecules may contribute to neurodegeneration is reviewed.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	University of California System; University of California San Diego; Washington University (WUSTL); Washington University (WUSTL)	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	edkoo@ucsd.edu	Kopan, Raphael/AAF-1357-2022; Kopan, Raphael/AFG-3275-2022	Kopan, Raphael/0000-0002-0350-2730	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS028121] Funding Source: NIH RePORTER; NIA NIH HHS [AG05131] Funding Source: Medline; NIGMS NIH HHS [GM 55479] Funding Source: Medline; NINDS NIH HHS [NS 28121] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amtul Z, 2002, NEUROBIOL DIS, V9, P269, DOI 10.1006/nbdi.2001.0473; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Barker N, 2000, ADV CANCER RES, V77, P1; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Berezovska O, 1998, J NEUROPATH EXP NEUR, V57, P738, DOI 10.1097/00005072-199808000-00003; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Costa RM, 2003, CURR BIOL, V13, P1348, DOI 10.1016/S0960-9822(03)00492-5; Crone SA, 2002, ANN NY ACAD SCI, V971, P547, DOI 10.1111/j.1749-6632.2002.tb04525.x; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; GUO Q, 1997, J NEUROSCI, V272, P3590; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hashimoto Y, 2003, J PHARMACOL EXP THER, V306, P889, DOI 10.1124/jpet.103.051383; Heber S, 2000, J NEUROSCI, V20, P7951; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; KOPAN R, IN PRESS NAT REV MOL; Kwok JBJ, 2003, J BIOL CHEM, V278, P6748, DOI 10.1074/jbc.M211827200; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Livesey FJ, 1999, CELL MOL LIFE SCI, V56, P62, DOI 10.1007/s000180050006; Lleo A, 2003, J BIOL CHEM, V278, P47370, DOI 10.1074/jbc.M308480200; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Lu DC, 2003, ANN NEUROL, V54, P781, DOI 10.1002/ana.10761; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattson MP, 2001, BIOESSAYS, V23, P733, DOI 10.1002/bies.1103; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; Neve RL, 2000, BRAIN RES, V886, P54, DOI 10.1016/S0006-8993(00)02869-9; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Prasher VP, 1998, ANN NEUROL, V43, P380, DOI 10.1002/ana.410430316; Presente A, 2004, P NATL ACAD SCI USA, V101, P1764, DOI 10.1073/pnas.0308259100; Presente A, 2001, NEUROREPORT, V12, P3321, DOI 10.1097/00001756-200110290-00035; Redmond L, 2001, CURR OPIN NEUROBIOL, V11, P111, DOI 10.1016/S0959-4388(00)00181-1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rozmahel R, 2002, NEUROBIOL AGING, V23, P187, DOI 10.1016/S0197-4580(01)00267-6; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Schulz JG, 2003, J BIOL CHEM, V278, P48651, DOI 10.1074/jbc.M308424200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Siman R, 2000, J NEUROSCI, V20, P8717; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Suh YH, 1997, J NEUROCHEM, V68, P1781; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Taniguchi Y, 2003, J BIOL CHEM, V278, P30425, DOI 10.1074/jbc.C300239200; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Terry RD, 2001, ANN NEUROL, V49, P684, DOI 10.1002/ana.1042; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yang Y, 2004, NEUROSCIENCE, V124, P501, DOI 10.1016/j.neuroscience.2003.11.029; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Zhao Q, 2003, BIOCHEMISTRY-US, V42, P3627, DOI 10.1021/bi027117f; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	111	132	135	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7		S			S26	S33		10.1038/nm1065	http://dx.doi.org/10.1038/nm1065			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	844YU	15272268				2022-12-27	WOS:000223202100005
J	Vila, M; Przedborski, S				Vila, M; Przedborski, S			Genetic clues to the pathogenesis of Parkinson's disease	NATURE MEDICINE			English	Article							UBIQUITIN-PROTEIN LIGASE; EARLY-ONSET PARKINSONISM; BOUND ALPHA-SYNUCLEIN; PARK6-LINKED PARKINSONISM; ANDROGEN RECEPTOR; DEFICIENT MICE; LEWY BODIES; DJ-1; MUTATIONS; DYSFUNCTION	Recent years have seen an explosion in the rate of discovery of genetic defects linked to Parkinson's disease. These breakthroughs have not provided a direct explanation for the disease process. Nevertheless, they have helped transform Parkinson's disease research by providing tangible clues to the neurobiology of the disorder.	Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Vila, M (corresponding author), Columbia Univ, Dept Neurol, New York, NY 10032 USA.	sp30@columbia.edu		Vila, Miquel/0000-0002-1352-989X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038370, R01NS042269, R01NS038586, R29NS037345, P01NS011766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021617] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG021617-01] Funding Source: Medline; NINDS NIH HHS [P01 NS11766-27A1, R29 NS37345, R01 NS38586, NS42269, P50 NS38370] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Abou-Sleiman PM, 2003, ANN NEUROL, V54, P283, DOI 10.1002/ana.10675; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; CHARTIERHARLIN MC, IN PRESS LANCET; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cookson MR, 2003, NEURON, V37, P7, DOI 10.1016/S0896-6273(02)01166-2; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; Hemelaar J, 2004, MOL CELL BIOL, V24, P84, DOI 10.1128/MCB.24.1.84-95.2004; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Khan NL, 2002, ANN NEUROL, V52, P849, DOI 10.1002/ana.10417; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lee HJ, 2004, J NEUROSCI, V24, P1888, DOI 10.1523/JNEUROSCI.3809-03.2004; LEROY E, 2004, NATURE, V55, P512; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Lo Bianco C, 2002, P NATL ACAD SCI USA, V99, P10813, DOI 10.1073/pnas.152339799; Maraganore DM, 2004, ANN NEUROL, V55, P512, DOI 10.1002/ana.20017; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Nakajima A, 2003, CANCER LETT, V201, P195, DOI 10.1016/S0304-3835(03)00443-9; Niki T, 2003, MOL CANCER RES, V1, P247; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Payton JE, 2004, J MOL BIOL, V337, P1001, DOI 10.1016/j.jmb.2004.02.014; Pesah Y, 2004, DEVELOPMENT, V131, P2183, DOI 10.1242/dev.01095; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Quigley PM, 2003, P NATL ACAD SCI USA, V100, P3137, DOI 10.1073/pnas.0530312100; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Valente EM, 2002, ANN NEUROL, V51, P14, DOI 10.1002/ana.10053; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Valente EM, 2001, AM J HUM GENET, V68, P895, DOI 10.1086/319522; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	54	197	212	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7		S			S58	S62		10.1038/nm1068	http://dx.doi.org/10.1038/nm1068			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	844YU	15272270				2022-12-27	WOS:000223202100009
J	Woodley, DT; Keene, DR; Atha, T; Huang, Y; Lipman, K; Li, W; Chen, M				Woodley, DT; Keene, DR; Atha, T; Huang, Y; Lipman, K; Li, W; Chen, M			Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa	NATURE MEDICINE			English	Article							EXPRESSION; FORMS	Dystrophic epidermolysis bullosa (DEB) is a family of inherited mechano-bullous disorders that are caused by mutations in the type VII collagen gene and for which ex vivo gene therapy has been considered. To develop a simpler approach for treating DEB, we evaluated the feasibility of protein-based therapy by intradermally injecting human recombinant type VII collagen into mouse skin and a DEB human skin equivalent transplanted onto mice. The injected collagen localized to the basement membrane zone of both types of tissues, was organized into human anchoring fibril structures and reversed the features of DEB disease in the DEB skin equivalent.	Univ So Calif, Div Dermatol, Dept Med, Los Angeles, CA 90033 USA; Shriners Hosp Children, Portland, OR 97201 USA	University of Southern California	Chen, M (corresponding author), Univ So Calif, Div Dermatol, Dept Med, CRL 204,1303 Mission Rd, Los Angeles, CA 90033 USA.	chenm@usc.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033625, R01AR047981] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR33625, R01 AR47981] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRIGGAMAN RA, 1975, J INVEST DERMATOL, V65, P71, DOI 10.1111/1523-1747.ep12598050; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chen M, 2002, NAT GENET, V32, P670, DOI 10.1038/ng1041; Chen M, 1997, J INVEST DERMATOL, V108, P68, DOI 10.1111/1523-1747.ep12285634; Chen M, 2002, J BIOL CHEM, V277, P2118, DOI 10.1074/jbc.M108779200; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; KIM YH, 1992, J INVEST DERMATOL, V98, P191, DOI 10.1111/1523-1747.ep12555849; Lin AN, 1992, EPIDERMOLYSIS BULLOS; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; Ortiz-Urda S, 2002, NAT MED, V8, P1166, DOI 10.1038/nm766; Ortiz-Urda S, 2003, J CLIN INVEST, V111, P251, DOI 10.1172/JCI200317193; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; UITTO J, 1994, ARCH DERMATOL RES, V287, P16, DOI 10.1007/BF00370713; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; Woodley DT, 2003, J INVEST DERMATOL, V121, P1021, DOI 10.1046/j.1523-1747.2003.12571.x	15	97	108	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					693	695		10.1038/nm1063	http://dx.doi.org/10.1038/nm1063			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195089				2022-12-27	WOS:000222460400022
J	Kolonin, MG; Saha, PK; Chan, L; Pasqualini, R; Arap, W				Kolonin, MG; Saha, PK; Chan, L; Pasqualini, R; Arap, W			Reversal of obesity by targeted ablation of adipose tissue	NATURE MEDICINE			English	Article							PHAGE DISPLAY; IN-VIVO; DIABETES-MELLITUS; INDUCED APOPTOSIS; BLOOD-VESSELS; ANGIOGENESIS; PROHIBITIN; PROTEINS; RECEPTOR; VASCULATURE	Obesity is an increasingly prevalent human condition in developed societies. Despite major progress in the understanding of the molecular mechanisms leading to obesity, no safe and effective treatment has yet been found. Here, we report an antiobesity therapy based on targeted induction of apoptosis in the vasculature of adipose tissue. We used in vivo phage display to isolate a peptide motif (sequence CKGGRAKDC) that homes to white fat vasculature. We show that the CKGGRAKDC peptide associates with prohibitin, a multifunctional membrane protein, and establish prohibitin as a vascular marker of adipose tissue. Targeting a proapoptotic peptide to prohibitin in the adipose vasculature caused ablation of white fat. Resorption of established white adipose tissue and normalization of metabolism resulted in rapid obesity reversal without detectable adverse effects. Because prohibitin is also expressed in blood vessels of human white fat, this work may lead to the development of targeted drugs for treatment of obese patients.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Pasqualini, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rpasqual@mdanderson.org; warap@mdanderson.org		Kolonin, Mikhail/0000-0002-3743-7869	NATIONAL CANCER INSTITUTE [R01CA088106, R01CA078512, P50CA090270, U54CA090810] Funding Source: NIH RePORTER; NCI NIH HHS [CA82976, CA078512, CA103042, CA88106, CA90810, CA90270] Funding Source: Medline; NHLBI NIH HHS [HL51586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cinti S, 2000, Eat Weight Disord, V5, P132; Clapham JC, 2001, PHARMACOL THERAPEUT, V89, P81, DOI 10.1016/S0163-7258(00)00105-4; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Greene AK, 2003, ANN SURG, V237, P530, DOI 10.1097/00000658-200304000-00015; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; Kolonin MG, 2002, P NATL ACAD SCI USA, V99, P13055, DOI 10.1073/pnas.162468499; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Lamers MC, 1997, INT ARCH ALLERGY IMM, V113, P146, DOI 10.1159/000237530; LEIBEL RL, 1989, ANNU REV NUTR, V9, P417, DOI 10.1146/annurev.nu.09.070189.002221; LEIBOWITZ SF, 1995, OBES RES, V3, P573; Licinio J, 2004, P NATL ACAD SCI USA, V101, P4531, DOI 10.1073/pnas.0308767101; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; McConkey DJ, 1996, ONCOGENE, V13, P1693; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PASQUALINI R, 2000, PHAGE DISPLAY LAB MA; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Sumi T, 2001, INT J MOL MED, V8, P533; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; WASSERMANN F., 1965, HANDBOOK PHYSIOL, V5, P87; Woods SC, 2000, NUTRITION, V16, P894, DOI 10.1016/S0899-9007(00)00454-8; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	43	431	496	2	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					625	632		10.1038/nm1048	http://dx.doi.org/10.1038/nm1048			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15133506				2022-12-27	WOS:000221759600028
J	Iwawaki, T; Akai, R; Kohno, K; Miura, M				Iwawaki, T; Akai, R; Kohno, K; Miura, M			A transgenic mouse model for monitoring endoplasmic reticulum stress	NATURE MEDICINE			English	Article							UNFOLDED-PROTEIN RESPONSE; ER STRESS; MESSENGER-RNA; CELL-DEATH; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; GENE-EXPRESSION; IRE1; HOMOCYSTEINE; ACTIVATION	Endoplasmic reticulum (ER) stress is caused by the accumulation of unfolded proteins in the ER lumen, and is associated with vascular and neurodegenerative diseases. Although the connection between ER stress and some disease-related proteins has been studied using animal models of these diseases, no in vivo data concerning ER stress are available. Here we report a new method for monitoring ER stress in vivo, based on XBP-1 mRNA splicing by inositol requiring-1 (IRE-1) during ER stress. The stress indicator was constructed by fusing XBP-1 and venus, a variant of green fluorescent protein. During stress, the spliced indicator mRNA is translated into an XBP-1-venus fusion protein, which can be detected by its fluorescence. We used transgenic animals expressing the ER stress indicator to show that it can be used to monitor physiological and pathological ER stress in vivo.	RIKEN, Brain Sci Inst, Lab Cell Recovery Mech, Wako, Saitama 3510198, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Genet, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); University of Tokyo	Miura, M (corresponding author), RIKEN, Brain Sci Inst, Lab Cell Recovery Mech, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551; Iwawaki, Takao/0000-0001-8753-1979				Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Duell PB, 1997, CURR OPIN LIPIDOL, V8, P28, DOI 10.1097/00041433-199702000-00007; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mudd S., 2001, METABOLIC MOL BASES, P2007; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reimold AM, 2000, GENE DEV, V14, P152; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	26	313	321	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					98	102		10.1038/nm970	http://dx.doi.org/10.1038/nm970			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702639				2022-12-27	WOS:000187743600045
J	Tugizov, SM; Berline, JW; Palefsky, JM				Tugizov, SM; Berline, JW; Palefsky, JM			Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells	NATURE MEDICINE			English	Article							CARCINOMA-CELLS; B-CELLS; HUMAN CYTOMEGALOVIRUS; FIBRONECTIN RECEPTOR; MIGRATION STRATEGIES; MATRIX INTERACTIONS; REPLICATION; LYMPHOCYTES; EXPRESSION; ENTRY	Epstein-Barr virus (EBV) initially enters the body through the oropharyngeal mucosa and subsequently infects B lymphocytes through their CD21 (CR2) complement receptor. Mechanisms of EBV entry into and release from epithelial cells are poorly understood. To study EBV infection in mucosal oropharyngeal epithelial cells, we established human polarized tongue and pharyngeal epithelial cells in culture. We show that EBV enters these cells through three CD21-independent pathways: (i) by direct cell-to-cell contact of apical cell membranes with EBV-infected lymphocytes; (ii) by entry of cell-free virions through basolateral membranes, mediated in part through an interaction between beta(1) or alpha(5)beta(1) integrins and the EBV BMRF-2 protein; and (iii) after initial infection, by virus spread directly across lateral membranes to adjacent epithelial cells. Release of progeny virions from polarized cells occurs from both their apical and basolateral membranes. These data indicate that multiple approaches to prevention of epithelial infection with EBV will be necessary.	Univ Calif San Francisco, Sch Dent, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tugizov, SM (corresponding author), Univ Calif San Francisco, Sch Dent, Dept Stomatol, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE007946] Funding Source: NIH RePORTER; NCRR NIH HHS [5 M01-RR-00079] Funding Source: Medline; NIDCR NIH HHS [P01 DE07946] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; Borza CM, 2002, NAT MED, V8, P594, DOI 10.1038/nm0602-594; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; Chang Y, 1999, J VIROL, V73, P8857, DOI 10.1128/JVI.73.10.8857-8866.1999; Chang Y, 1998, LAB INVEST, V78, P715; DINGWELL KS, 1994, J VIROL, V68, P834, DOI 10.1128/JVI.68.2.834-845.1994; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; Friedl P, 1998, MICROSC RES TECHNIQ, V43, P369, DOI 10.1002/(SICI)1097-0029(19981201)43:5<369::AID-JEMT3>3.0.CO;2-6; Friedl P, 1998, CELL ADHES COMMUN, V6, P225, DOI 10.3109/15419069809004478; Gavrilovskaya IN, 1999, J VIROL, V73, P3951, DOI 10.1128/JVI.73.5.3951-3959.1999; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; Haan KM, 2000, J VIROL, V74, P2451, DOI 10.1128/JVI.74.5.2451-2454.2000; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HANZEL D, 1991, CELL BIOL, V2, P341; HURLEY EA, 1991, J VIROL, V65, P3958, DOI 10.1128/JVI.65.7.3958-3963.1991; Imai S, 1998, J VIROL, V72, P4371, DOI 10.1128/JVI.72.5.4371-4378.1998; Iwata S, 2000, J DERMATOL SCI, V23, P75, DOI 10.1016/S0923-1811(99)00096-1; Jackson T, 1997, J VIROL, V71, P8357, DOI 10.1128/JVI.71.11.8357-8361.1997; Jackson T, 2000, J VIROL, V74, P4949, DOI 10.1128/JVI.74.11.4949-4956.2000; Janz A, 2000, J VIROL, V74, P10142, DOI 10.1128/JVI.74.21.10142-10152.2000; Johnson DC, 2002, J VIROL, V76, P1, DOI 10.1128/JVI.76.1.1-8.2002; KIM LT, 1992, J CELL SCI, V103, P743; Lagenaur LA, 1999, J VIROL, V73, P6566, DOI 10.1128/JVI.73.8.6566-6572.1999; Lembo D, 1998, J GEN VIROL, V79, P2803, DOI 10.1099/0022-1317-79-11-2803; LEMON SM, 1977, NATURE, V268, P268, DOI 10.1038/268268a0; Li QX, 1997, J VIROL, V71, P4657, DOI 10.1128/JVI.71.6.4657-4662.1997; MODROW S, 1992, ARCH VIROL, V127, P379, DOI 10.1007/BF01309601; Molesworth SJ, 2000, J VIROL, V74, P6324, DOI 10.1128/JVI.74.14.6324-6332.2000; Nemerow GR, 2000, VIROLOGY, V274, P1, DOI 10.1006/viro.2000.0468; Palefsky J M, 1997, Oral Dis, V3 Suppl 1, pS171; Penaranda ME, 1998, J GEN VIROL, V79, P1321; Penaranda ME, 1997, J GEN VIROL, V78, P3361; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; Tugizov S, 1996, J GEN VIROL, V77, P61, DOI 10.1099/0022-1317-77-1-61; Tugizov S, 1998, J VIROL, V72, P7374, DOI 10.1128/JVI.72.9.7374-7386.1998; Wang X, 1998, J VIROL, V72, P5552, DOI 10.1128/JVI.72.7.5552-5558.1998; Wang X, 1998, J VIROL, V72, P158, DOI 10.1128/JVI.72.1.158-163.1998; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOLF H, 1984, J VIROL, V51, P795, DOI 10.1128/JVI.51.3.795-798.1984; Yoshiyama H, 1997, J VIROL, V71, P5688, DOI 10.1128/JVI.71.7.5688-5691.1997; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	47	197	204	2	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					307	314		10.1038/nm830	http://dx.doi.org/10.1038/nm830			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12592401				2022-12-27	WOS:000181312300031
J	He, ZH; Ong, CHP; Halper, J; Bateman, A				He, ZH; Ong, CHP; Halper, J; Bateman, A			Progranulin is a mediator of the wound response	NATURE MEDICINE			English	Article							FIBROBLAST GROWTH-FACTOR; EPITHELIAL-CELL GROWTH; ANGIOGENESIS IN-VITRO; GRANULIN/EPITHELIN PRECURSOR; GENE-EXPRESSION; IDENTIFICATION; ACROGRANIN; MODULATION; GRANULINS; COLLAGEN	Annually, 1.25 million individuals suffer burns in the United States and 6.5 million experience chronic skin ulcers, often from diabetes, pressure or venous stasis(1). Growth factors are essential mediators of wound repair(1,2), but their success as therapeutics in wound treatment has, so far, been limited(1,2). Therefore, there is a need to identify new wound-response regulatory factors, but few have appeared in recent years(1,2). Progranulin(3) (also called granulin or epithelin precursor(4), acrogranin(5) or PC-derived growth factor(6)) is a growth factor involved in tumorigenesis(6-11) and development(12,13). Peptides derived from progranulin have been isolated from inflammatory cells(14), which led to suggestions that progranulin gene products are involved in the wound response(10,14), but this remains undemonstrated. We report that in murine transcutaneous puncture wounds, progranulin mRNA is expressed in the inflammatory infiltrate and is highly induced in dermal fibroblasts and endothelia following injury. When applied to a cutaneous wound, progranulin increased the accumulation of neutrophils, macrophages, blood vessels and fibroblasts in the wound. It acts directly on isolated dermal fibroblasts and endothelial cells to promote division, migration and the formation of capillary-like tubule structures. Progranulin is, therefore, a probable wound-related growth factor.	McGill Univ, Div Expt Med, Montreal, PQ, Canada; Royal Victoria Hosp, Endocrine Res Lab, Montreal, PQ H3A 1A1, Canada; Univ Georgia, Coll Vet Med, Dept Pathol, Soft Tissue Ctr, Athens, GA 30602 USA	McGill University; McGill University; Royal Victoria Hospital; University System of Georgia; University of Georgia	Bateman, A (corresponding author), McGill Univ, Div Expt Med, Montreal, PQ, Canada.		Halper, Jaroslava/AAE-6674-2020; Halper, Jaroslava/AAF-8245-2020	Bateman, Andrew/0000-0003-0597-769X	NCI NIH HHS [CA71023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R15CA071023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; Carter Bobbie J., 1996, Wound Repair and Regeneration, V4, P259, DOI 10.1046/j.1524-475X.1996.40215.x; CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Diaz-Cueto L, 2000, DEV BIOL, V217, P406, DOI 10.1006/dbio.1999.9564; FIDDES JC, 1991, ANN NY ACAD SCI, V638, P316; He ZH, 1999, CANCER RES, V59, P3222; He ZH, 2002, CANCER RES, V62, P5590; Kitajima I, 1999, ANTISENSE NUCLEIC A, V9, P233, DOI 10.1089/oli.1.1999.9.233; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Liau LM, 2000, CANCER RES, V60, P1353; LU R, 1998, P NATL ACAD SCI USA, V97, P3993; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; NICOSIA RF, 1990, IN VITRO CELL DEV B, V26, P119; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Suzuki M, 1998, NEUROSCI LETT, V242, P127, DOI 10.1016/S0304-3940(98)00008-1; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; ZHOU J, 1993, J BIOL CHEM, V268, P10863	25	383	405	2	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2003	9	2					225	229		10.1038/nm816	http://dx.doi.org/10.1038/nm816			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12524533				2022-12-27	WOS:000180801900028
J	Frigerio, S; Junt, T; Lu, B; Gerard, C; Zumsteg, U; Hollander, GA; Piali, L				Frigerio, S; Junt, T; Lu, B; Gerard, C; Zumsteg, U; Hollander, GA; Piali, L			beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis	NATURE MEDICINE			English	Article							MONOCYTE CHEMOATTRACTANT; MOLECULAR-CLONING; INTERFERON-GAMMA; CHEMOKINE; EXPRESSION; IDENTIFICATION; PROGRESSION; PROTEIN-1; CYTOKINE; RANTES	T cell-mediated loss of insulin-secreting betacells in the islets of Langerhans is the hallmark of type 1 diabetes. The molecular basis for the directed migration of autoreactive T cells leading to insulitis is presently unknown. Here we demonstrate that in response to inflammation, betacells secrete the chemokines CXC ligand 10 and CXC ligand 9, which specifically attract T-effector cells via the CXC chemokine receptor 3. In mice deficient for this receptor, the onset of type 1 diabetes is substantially delayed. Thus, in the absence of known etiological agents, CXC receptor 3 represents a novel target for therapeutic interference early in type 1 diabetes.	Res Dept, Basel, Switzerland; Dept Clin Biol Sci, Basel, Switzerland; Univ Childrens Hosp, Basel, Switzerland; Univ Zurich, Inst Expt Immunol, CH-8006 Zurich, Switzerland; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Perlmutter Lab, Boston, MA 02115 USA	University of Zurich; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Hollander, GA (corresponding author), Res Dept, Basel, Switzerland.	georg-a.hollaender@unibas.ch	Junt, Tobias/AAE-4389-2021	Hollander, Georg/0000-0002-8790-0874				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Andre I, 1996, P NATL ACAD SCI USA, V93, P2260, DOI 10.1073/pnas.93.6.2260; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ASSAN R, 1990, DIABETES, V39, P768, DOI 10.2337/diabetes.39.7.768; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Cardozo AK, 2001, DIABETES, V50, P909, DOI 10.2337/diabetes.50.5.909; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Chen MC, 2001, DIABETOLOGIA, V44, P325, DOI 10.1007/s001250051622; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Falcone M, 1999, CLIN IMMUNOL, V90, P2, DOI 10.1006/clim.1998.4619; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; HAMAGUCHI K, 1991, DIABETES, V40, P842, DOI 10.2337/diabetes.40.7.842; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Kagi D, 1997, J EXP MED, V186, P989, DOI 10.1084/jem.186.7.989; Kagi D, 1996, J EXP MED, V183, P2143, DOI 10.1084/jem.183.5.2143; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Lu B, 1999, EUR J IMMUNOL, V29, P3804, DOI 10.1002/(SICI)1521-4141(199911)29:11<3804::AID-IMMU3804>3.0.CO;2-9; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nansen A, 2000, EUR J IMMUNOL, V30, P1797, DOI 10.1002/1521-4141(200007)30:7<1797::AID-IMMU1797>3.0.CO;2-B; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Savinov AY, 2001, J IMMUNOL, V167, P6637, DOI 10.4049/jimmunol.167.11.6637; SCHALL TJ, 1992, EUR J IMMUNOL, V22, P1477, DOI 10.1002/eji.1830220621; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Suri A, 1999, IMMUNOL REV, V169, P55, DOI 10.1111/j.1600-065X.1999.tb01306.x; Tabiin MT, 2001, J AUTOIMMUN, V17, P229, DOI 10.1006/jaut.2001.0539; VANGURI P, 1990, J BIOL CHEM, V265, P15049; vonHerrath MG, 1997, J EXP MED, V185, P531, DOI 10.1084/jem.185.3.531; Wang B, 1997, P NATL ACAD SCI USA, V94, P13844, DOI 10.1073/pnas.94.25.13844; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; Zumsteg U, 2000, DIABETES, V49, P39, DOI 10.2337/diabetes.49.1.39	45	236	248	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1414	1420		10.1038/nm792	http://dx.doi.org/10.1038/nm792			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12415259				2022-12-27	WOS:000179552000038
J	Peters, BA; Diaz, LA; Polyak, K; Meszler, L; Romans, K; Guinan, EC; Antin, JH; Myerson, D; Hamilton, SR; Vogelstein, B; Kinzler, KW; Lengauer, C				Peters, BA; Diaz, LA; Polyak, K; Meszler, L; Romans, K; Guinan, EC; Antin, JH; Myerson, D; Hamilton, SR; Vogelstein, B; Kinzler, KW; Lengauer, C			Contribution of bone marrow-derived endothelial cells to human tumor vasculature	NATURE MEDICINE			English	Article							PROGENITOR CELLS; ANGIOGENESIS; GROWTH; HEPATOCYTES; FUSION	It has been shown that bone marrow-derived stem cells can form a major fraction of the tumor endothelium in mouse tumors. To determine the role of such cells in human tumor angiogenesis, we studied six individuals who developed cancers after bone marrow transplantation with donor cells derived from individuals of the opposite sex. By performing fluorescence in situ hybridization (FISH) with sex chromosome-specific probes in conjunction with fluorescent antibody staining, we found that such stem cells indeed contributed to tumor endothelium, but at low levels, averaging only 4.9% of the total. These results illustrate substantial differences between human tumors and many mouse models with respect to angiogenesis and have important implications for the translation of experimental antiangiogenic therapies to the clinic.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21231 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Div Pathol & Lab Med, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lengauer, C (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St, Baltimore, MD 21231 USA.	lengauer@jhmi.edu	Diaz, Luis A/A-6018-2008	Myerson, David/0000-0002-2628-940X; Peters, Brock/0000-0002-5137-3902; Diaz, Luis/0000-0002-7079-8914	NCI NIH HHS [CA57345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Davidoff AM, 2001, CLIN CANCER RES, V7, P2870; De Palma M, 2003, HUM GENE THER, V14, P1193, DOI 10.1089/104303403322168028; Hilbe W, 2004, J CLIN PATHOL, V57, P965, DOI 10.1136/jcp.2004.016444; Jiang SG, 2004, P NATL ACAD SCI USA, V101, P16891, DOI 10.1073/pnas.0404398101; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Man YG, 2003, PATHOL RES PRACT, V199, P815, DOI 10.1078/0344-0338-00501; Natori T, 2002, BIOCHEM BIOPH RES CO, V297, P1058, DOI 10.1016/S0006-291X(02)02335-5; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; SCHLEGELBERGER YZ, 2000, METHOS MOL BIOL, P379; Sikder H, 2003, CANCER CELL, V4, P291, DOI 10.1016/S1535-6108(03)00245-9; Stoll BR, 2003, BLOOD, V102, P2555, DOI 10.1182/blood-2003-02-0365; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531	15	402	445	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					261	262		10.1038/nm1200	http://dx.doi.org/10.1038/nm1200			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723071				2022-12-27	WOS:000227541300019
J	Ready, T				Ready, T			Profile - Susan Hockfield	NATURE MEDICINE			English	Biographical-Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2005	11	2					110	110		10.1038/nm0205-110	http://dx.doi.org/10.1038/nm0205-110			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15692584	Bronze			2022-12-27	WOS:000226797300009
J	Zhao, L; Moos, MPW; Grabner, R; Pedrono, F; Fan, JJ; Kaiser, B; John, N; Schmidt, S; Spanbroek, R; Lotzer, J; Huang, L; Cui, JS; Rader, DJ; Evans, JF; Habenicht, AJR; Funk, CD				Zhao, L; Moos, MPW; Grabner, R; Pedrono, F; Fan, JJ; Kaiser, B; John, N; Schmidt, S; Spanbroek, R; Lotzer, J; Huang, L; Cui, JS; Rader, DJ; Evans, JF; Habenicht, AJR; Funk, CD			The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm	NATURE MEDICINE			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; RECEPTOR-DEFICIENT MICE; MATRIX METALLOPROTEINASES; CHEMOTACTIC CYTOKINES; INFLAMMATION; CELLS; GENE; ATHEROGENESIS; EXPRESSION; MACROPHAGES	Activation of the 5-lipoxygenase (5-LO) pathway leads to the biosynthesis of proinflammatory leukotriene lipid mediators. Genetic studies have associated 5-LO and its accessory protein, 5-LO-activating protein, with cardiovascular disease, myocardial infarction and stroke. Here we show that 5-LO-positive macrophages localize to the adventitia of diseased mouse and human arteries in areas of neoangiogenesis and that these cells constitute a main component of aortic aneurysms induced by an atherogenic diet containing cholate in mice deficient in apolipoprotein E. 5-LO deficiency markedly attenuates the formation of these aneurysms and is associated with reduced matrix metalloproteinase-2 activity and diminished plasma macrophage inflammatory protein-1alpha (MIP-1alpha; also called CCL3), but only minimally affects the formation of lipid-rich lesions. The leukotriene LTD4 strongly stimulates expression of MIP-1alpha in macrophages and MIP-2 (also called CXCL2) in endothelial cells. These data link the 5-LO pathway to hyperlipidemia-dependent inflammation of the arterial wall and to pathogenesis of aortic aneurysms through a potential chemokine intermediary route.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Jena, Inst Vasc Med, D-07743 Jena, Germany; Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Merck & Co Inc, Dept Cardiovasc Dis, Rahway, NJ 07065 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Friedrich Schiller University of Jena; Queens University - Canada; Queens University - Canada; Merck & Company; University of Pennsylvania; University of Pennsylvania	Funk, CD (corresponding author), Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.	funkc@post.queensu.ca	Habenicht, Andreas/HGA-2184-2022; Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233; habenicht, andreas/0000-0003-2901-3027	NHLBI NIH HHS [HL53558, HL55323, HL70128] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL055323, R01HL055323, R01HL053558, P50HL070128] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593; Apostolopoulos J, 1996, ARTERIOSCL THROM VAS, V16, P1007, DOI 10.1161/01.ATV.16.8.1007; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Basso K, 2004, J EXP MED, V199, P59, DOI 10.1084/jem.20031175; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Bruemmer D, 2003, J CLIN INVEST, V112, P1318, DOI 10.1172/JCI200318141; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; Cyrus T, 2002, CIRCULATION, V106, P1282, DOI 10.1161/01.CIR.0000027816.54430.96; Daugherty A, 2004, ARTERIOSCL THROM VAS, V24, P429, DOI 10.1161/01.ATV.0000118013.72016.ea; Daugherty A, 2001, BRIT J PHARMACOL, V134, P865, DOI 10.1038/sj.bjp.0704331; DECATERINA R, 1988, BIOMED BIOCHIM ACTA, V47, pS182; Dollery CM, 2003, CIRCULATION, V107, P2829, DOI 10.1161/01.CIR.0000072792.65250.4A; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Houtkamp MA, 2001, J PATHOL, V193, P263, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH774>3.0.CO;2-N; KOCH AE, 1993, AM J PATHOL, V142, P1423; Kuhel DG, 2002, ARTERIOSCL THROM VAS, V22, P955, DOI 10.1161/01.ATV.0000017994.77066.75; KUMAMOTO M, 1995, HUM PATHOL, V26, P450, DOI 10.1016/0046-8177(95)90148-5; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993; Manning MW, 2002, VASC MED, V7, P45, DOI 10.1191/1358863x02vm413ra; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Mehrabian M, 2001, CIRC RES, V89, P125, DOI 10.1161/hh1401.093458; PATRIGNANI P, 1992, J CARDIOVASC PHARM, V20, pS208, DOI 10.1097/00005344-199204002-00059; Pelus LM, 2004, BLOOD, V103, P110, DOI 10.1182/blood-2003-04-1115; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Shi WB, 2003, ARTERIOSCL THROM VAS, V23, P1901, DOI 10.1161/01.ATV.0000091249.34404.B7; Silence J, 2001, ARTERIOSCL THROM VAS, V21, P1440, DOI 10.1161/hq0901.097004; Sinha S, 1998, J CLIN PHARMACOL, V38, P1077; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211; Subbarao K, 2004, ARTERIOSCL THROM VAS, V24, P369, DOI 10.1161/01.ATV.0000110503.16605.15; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Ward MR, 2000, CIRCULATION, V102, P1186, DOI 10.1161/01.CIR.102.10.1186; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216	50	288	297	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					966	973		10.1038/nm1099	http://dx.doi.org/10.1038/nm1099			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15322539				2022-12-27	WOS:000223658400034
J	Novak, K				Novak, K			Irving Weissman - Profile	NATURE MEDICINE			English	Biographical-Item														Novak, Kristine/0000-0001-9314-1803				Pearson H, 2004, NAT MED, V10, P445, DOI 10.1038/nm0504-445; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; 2003, NAT MED, V9, P156	3	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2004	10	8					766	766		10.1038/nm0804-766	http://dx.doi.org/10.1038/nm0804-766			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15286766				2022-12-27	WOS:000223055700009
J	Svendsen, CN; Langston, JW				Svendsen, CN; Langston, JW			Stem cells for Parkinson disease and ALS: replacement or protection?	NATURE MEDICINE			English	Editorial Material							MOTOR-NEURONS; TRANSPLANTATION; MODEL; BRAIN		Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Parkinsons Inst, Sunnyvale, CA 94089 USA	University of Wisconsin System; University of Wisconsin Madison	Svendsen, CN (corresponding author), Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA.	svenden@waisman.wisc.edu						Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Imura T, 2003, J NEUROSCI, V23, P2824; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Tai YT, 2004, CURR OPIN PHARMACOL, V4, P98, DOI 10.1016/j.coph.2003.09.006; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8	12	60	63	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2004	10	3					224	225		10.1038/nm0304-224	http://dx.doi.org/10.1038/nm0304-224			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14991036				2022-12-27	WOS:000189297700019
J	Yu, YL; Khan, J; Khanna, C; Helman, L; Meltzer, PS; Merlino, G				Yu, YL; Khan, J; Khanna, C; Helman, L; Meltzer, PS; Merlino, G			Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators	NATURE MEDICINE			English	Article							GENE-EXPRESSION; ERM PROTEINS; CELL-ADHESION; VERTEBRATE MUSCLE; CDNA MICROARRAYS; TUMOR-SUPPRESSOR; RHO-GTPASES; MODEL; RHABDOMYOSARCOMA; PHOSPHORYLATION	Patients presenting with metastatic rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, have a very poor clinical prognosis. This is due, in large part, to our rudimentary knowledge of the molecular events that dictate metastatic potential. We used cDNA microarray analysis of RMS cell lines, derived from Ink4a/Arf-deficient mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF), to identify a set of genes whose expression was significantly different between highly and poorly metastatic cells. Subsequent in vivo functional studies revealed that the actin filament-plasma membrane linker ezrin (encoded by Vil2) and the homeodomain-containing transcription factor Six-1 (sine oculis-related homeobox-1 homolog) had essential roles in determining the metastatic fate of RMS cells. VIL2 and SIX1 expression was enhanced in human RMS tissue, significantly correlating with clinical stage. The identification of ezrin and Six-1 as critical regulators of metastasis in RMS provides new mechanistic and therapeutic insights into this pediatric cancer.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Merlino, G (corresponding author), NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov	Khan, Javed/P-9157-2014		NATIONAL CANCER INSTITUTE [ZIABC010566, Z01SC010366, Z01BC010566, Z01SC006892, ZIASC006892, ZIASC010366] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen Y., 1997, BIOMED OPTICS, V2, P364; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Dagher R, 1999, Oncologist, V4, P34; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Kardon G, 2002, DEV DYNAM, V224, P350, DOI 10.1002/dvdy.10107; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547; Khanna C, 2001, CANCER RES, V61, P3750; KHANNA C, IN PRESS NAT MED; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Laclef C, 2003, DEVELOPMENT, V130, P2239, DOI 10.1242/dev.00440; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Nestl A, 2001, CANCER RES, V61, P1569; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Relaix F, 1999, GENE DEV, V13, P3171, DOI 10.1101/gad.13.24.3171; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ringner M, 2002, PHARMACOGENOMICS, V3, P403, DOI 10.1517/14622416.3.3.403; Ruymann FB, 2000, CANCER INVEST, V18, P223, DOI 10.3109/07357900009031827; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schafer K, 1999, NAT GENET, V23, P213, DOI 10.1038/13843; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yu YL, 2002, CANCER RES, V62, P2951; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	45	377	475	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					175	181		10.1038/nm966	http://dx.doi.org/10.1038/nm966			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14704789				2022-12-27	WOS:000188719600037
J	Moers, A; Nieswandt, B; Massberg, S; Wettschureck, N; Gruner, S; Konrad, I; Schulte, V; Aktas, B; Gratacap, MP; Simon, MI; Gawaz, M; Offermanns, S				Moers, A; Nieswandt, B; Massberg, S; Wettschureck, N; Gruner, S; Konrad, I; Schulte, V; Aktas, B; Gratacap, MP; Simon, MI; Gawaz, M; Offermanns, S			G(13) is an essential mediator of platelet activation in hemostasis and thrombosis	NATURE MEDICINE			English	Article							SIGNALING PATHWAYS; SHAPE CHANGE; G-PROTEIN; RHO-KINASE; IN-VIVO; PHOSPHORYLATION; AGGREGATION; MYOSIN; G-ALPHA(13); RECEPTORS	Platelet activation at sites of vascular injury is essential for primary hemostasis, but also underlies arterial thrombosis leading to myocardial infarction or stroke(1,2). Platelet activators such as adenosine diphosphate, thrombin or thromboxane A(2) (TXA(2)) activate receptors that are coupled to heterotrimeric G proteins(1,3). Activation of platelets through these receptors involves signaling through G(q), G(i) and G(z) (refs. 4- 6). However, the role and relative importance of G(12) and G(13), which are activated by various platelet stimuli(7-9), are unclear. Here we show that lack of Galpha(13), but not Galpha(12), severely reduced the potency of thrombin, TXA(2) and collagen to induce platelet shape changes and aggregation in vitro. These defects were accompanied by reduced activation of RhoA and inability to form stable platelet thrombi under high shear stress ex vivo. Galpha(13) deficiency in platelets resulted in a severe defect in primary hemostasis and complete protection against arterial thrombosis in vivo. We conclude that G(13)-mediated signaling processes are required for normal hemostasis and thrombosis and may serve as a new target for antiplatelet drugs.	Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany; Tech Univ Munich, Med Klin 1, D-80636 Munich, Germany; Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany; CALTECH, Div Biol 147 75, Pasadena, CA 91125 USA	Ruprecht Karls University Heidelberg; University of Wurzburg; Technical University of Munich; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; California Institute of Technology	Offermanns, S (corresponding author), Univ Heidelberg, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.		Massberg, Steffen/AAN-6054-2021; Wettschureck, Nina/L-3651-2017; Offermanns, Stefan/L-3313-2017	Wettschureck, Nina/0000-0001-6858-1460; Offermanns, Stefan/0000-0001-8676-6805; Gratacap, Marie-Pierre/0000-0003-4362-6401				ABRAMS CS, 2001, HEMOSTASIS THROMBOSI, P541; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Dorsam RT, 2002, J BIOL CHEM, V277, P47588, DOI 10.1074/jbc.M208778200; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; Massberg S, 2003, J EXP MED, V197, P41, DOI 10.1084/jem.20020945; Missy K, 2001, THROMB HAEMOSTASIS, V85, P514, DOI 10.1055/s-0037-1615614; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Savage B, 2001, CURR OPIN HEMATOL, V8, P270, DOI 10.1097/00062752-200109000-00002; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; Yang J, 2002, J BIOL CHEM, V277, P46035, DOI 10.1074/jbc.M208519200	28	191	198	0	11	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1418	1422		10.1038/nm943	http://dx.doi.org/10.1038/nm943			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528298				2022-12-27	WOS:000186319700034
J	Schubert, C				Schubert, C			Patrick Brown - Profile	NATURE MEDICINE			English	Biographical-Item																		BROWN PM, PUBLICATION LIST	1	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1339	1339		10.1038/nm1103-1339	http://dx.doi.org/10.1038/nm1103-1339			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14595417	Bronze			2022-12-27	WOS:000186319700007
J	Uyttenhove, C; Pilotte, L; Theate, I; Stroobant, V; Colau, D; Parmentier, N; Boon, T; Van den Eynde, BJ				Uyttenhove, C; Pilotte, L; Theate, I; Stroobant, V; Colau, D; Parmentier, N; Boon, T; Van den Eynde, BJ			Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase	NATURE MEDICINE			English	Article							T-CELL PROLIFERATION; TRANSFER-RNA SYNTHETASE; DENDRITIC CELLS; METASTATIC MELANOMA; FETAL REJECTION; PEPTIDE; CATABOLISM; GENE; INHIBITION; EXPRESSION	T lymphocytes undergo proliferation arrest when exposed to tryptophan shortage, which can be provoked by indoleamine 2,3-dioxygenase (IDO), an enzyme that is expressed in placenta and catalyzes tryptophan degradation. Here we show that most human tumors constitutively express IDO. We also observed that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice. This effect is accompanied by a lack of accumulation of specific T cells at the tumor site and can be partly reverted by systemic treatment of mice with an inhibitor of IDO, in the absence of noticeable toxicity. These results suggest that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor.	Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Cellular Genet Unit, B-1200 Brussels, Belgium; Univ Catholique Louvain, Dept Pathol, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Van den Eynde, BJ (corresponding author), Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium.			Pilotte, Luc/0000-0001-6761-6836				Bilsborough J, 2002, J IMMUNOL, V169, P3053, DOI 10.4049/jimmunol.169.6.3053; Boon T, 2003, CURR OPIN IMMUNOL, V15, P129, DOI 10.1016/S0952-7915(03)00010-4; Brandle D, 1998, EUR J IMMUNOL, V28, P4010, DOI 10.1002/(SICI)1521-4141(199812)28:12<4010::AID-IMMU4010>3.0.CO;2-5; CADY SG, 1991, ARCH BIOCHEM BIOPHYS, V291, P326, DOI 10.1016/0003-9861(91)90142-6; Fallarino F, 2002, INT IMMUNOL, V14, P65, DOI 10.1093/intimm/14.1.65; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Friberg M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645; Frumento G, 2001, TRANSPLANT P, V33, P428, DOI 10.1016/S0041-1345(00)02078-9; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; HABARAOHKUBO A, 1991, GENE, V105, P221, DOI 10.1016/0378-1119(91)90154-4; Hwu P, 2000, J IMMUNOL, V164, P3596, DOI 10.4049/jimmunol.164.7.3596; Jager E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497; Jorgensen R, 2000, J BIOL CHEM, V275, P16820, DOI 10.1074/jbc.275.22.16820; Kudo Y, 2000, BBA-MOL BASIS DIS, V1500, P119, DOI 10.1016/S0925-4439(99)00096-4; Kudo Y, 2001, J PHYSIOL-LONDON, V535, P207, DOI 10.1111/j.1469-7793.2001.00207.x; Kudo Y, 2001, J PHYSIOL-LONDON, V531, P405, DOI 10.1111/j.1469-7793.2001.0405i.x; LETHE B, 1992, EUR J IMMUNOL, V22, P2283, DOI 10.1002/eji.1830220916; Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Pawelec G, 2000, CRIT REV ONCOGENESIS, V11, P97; Praetorius-Ibba M, 2000, BIOCHEMISTRY-US, V39, P13136; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Suzuki S, 2001, BIOCHEM J, V355, P425, DOI 10.1042/0264-6021:3550425; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Uno T, 1997, INVEST OPHTH VIS SCI, V38, P2531; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; VANPEL A, 1985, SOMAT CELL MOLEC GEN, V11, P467; Wenkel H, 1999, INVEST OPHTH VIS SCI, V40, P3202	38	1705	1886	3	178	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1269	1274		10.1038/nm934	http://dx.doi.org/10.1038/nm934			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502282				2022-12-27	WOS:000185669700037
J	Tong, MH; Jiang, H; Liu, P; Lawson, JA; Brass, LF; Song, WC				Tong, MH; Jiang, H; Liu, P; Lawson, JA; Brass, LF; Song, WC			Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice	NATURE MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; HUMAN PLATELETS CONTAIN; UTERINE TISSUE FACTOR; STEROID SULFOTRANSFERASES; CRYSTALLOGRAPHIC ANALYSIS; SUBSTRATE-SPECIFICITY; ORAL-CONTRACEPTIVES; EPITHELIAL-CELLS; RECEPTOR-BETA; EXPRESSION	Estrogen sulfotransferase (EST, encoded by SULT1E1) catalyzes the sulfoconjugation and inactivation of estrogens. Despite decades of biochemical study and the recognition that high levels of estrogen sulfates circulate in the blood of pregnant and nonpregnant women, the physiological role of estrogen sulfation remains poorly understood. Here we show that ablation of the mouse Sult1e1 gene caused placental thrombosis and spontaneous fetal loss. This phenotype was associated with elevated free estrogen levels systemically and in the amniotic fluid, increased tissue factor expression in the placenta and heightened platelet sensitivity to agonist-induced activation ex vivo. Treatment of pregnant Sult1e1-null mice with either an anticoagulant or antiestrogen prevented the fetal loss phenotype. Our results thus identify Est as a critical estrogen modulator in the placenta and suggest a link between estrogen excess and thrombotic fetal loss. These findings may have implications for understanding and treating human pregnancy failure and intrauterine growth retardation.	Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Song, WC (corresponding author), Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.	song@spirit.gcrc.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042767] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181, P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45181, HL-40387] Funding Source: Medline; NICHD NIH HHS [HD-42767] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adamson SL, 2002, DEV BIOL, V250, P358, DOI 10.1006/dbio.2002.0773; Backlin BM, 1998, APMIS, V106, P785, DOI 10.1111/j.1699-0463.1998.tb00225.x; Buchner Virginia, 2002, Rev Environ Health, V17, P249; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Falany JL, 1996, CANCER RES, V56, P1551; Falany JL, 1997, ONCOL RES, V9, P589; Franklin GC, 1996, PLACENTA, V17, P3, DOI 10.1016/S0143-4004(05)80638-1; Georgiades P, 2001, P NATL ACAD SCI USA, V98, P4522, DOI 10.1073/pnas.081540898; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HENRIKSON KP, 1992, ENDOCRINOLOGY, V130, P2669, DOI 10.1210/en.130.5.2669; HOBKIRK R, 1983, BIOCHEM J, V216, P451, DOI 10.1042/bj2160451; HOBKIRK R, 1985, CAN J BIOCHEM CELL B, V63, P1127, DOI 10.1139/o85-141; Jayachandran M, 2003, PLATELETS, V14, P75, DOI 10.1080/0953710031000080562; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, BIOCHEM PHARMACOL, V55, P313, DOI 10.1016/S0006-2952(97)00465-6; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Khetawat G, 2000, BLOOD, V95, P2289, DOI 10.1182/blood.V95.7.2289.007k03_2289_2296; Koh KK, 1999, THROMB HAEMOSTASIS, V82, P626, DOI 10.1055/s-0037-1615889; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; Mahendroo MS, 1997, MOL ENDOCRINOL, V11, P917, DOI 10.1210/me.11.7.917; Miozzo M, 2002, BIOL NEONATE, V81, P217, DOI 10.1159/000056752; MOORE SS, 1988, AUST J BIOL SCI, V41, P333; Moro L, 2005, BLOOD, V105, P115, DOI 10.1182/blood-2003-11-3840; Nealen ML, 2001, CIRC RES, V88, P438; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; Qian YM, 1998, J PHARMACOL EXP THER, V286, P555; Qian YM, 2001, ENDOCRINOLOGY, V142, P5342, DOI 10.1210/en.142.12.5342; Qian YM, 1999, J STEROID BIOCHEM, V71, P123, DOI 10.1016/S0960-0760(99)00131-4; QUIRK SM, 1995, ENDOCRINE, V3, P177, DOI 10.1007/BF02990070; Rocca B, 2000, NAT MED, V6, P219, DOI 10.1038/72334; Rosendaal FR, 2002, ARTERIOSCL THROM VAS, V22, P201, DOI 10.1161/hq0202.102318; Safe SH, 2000, ENVIRON HEALTH PERSP, V108, P487, DOI 10.2307/3454608; SCARABIN PY, 1995, THROMB HAEMOSTASIS, V74, P928; Shevtsov S, 2003, ENVIRON HEALTH PERSP, V111, P884, DOI 10.1289/ehp.6056; Song WC, 1997, ENDOCRINOLOGY, V138, P5006, DOI 10.1210/en.138.11.5006; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Stanley EL, 2001, J CLIN ENDOCR METAB, V86, P5944, DOI 10.1210/jc.86.12.5944; STONE R, 1994, SCIENCE, V265, P308, DOI 10.1126/science.8023147; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; Suzuki T, 2003, CANCER RES, V63, P2762; Tong MH, 2002, ENDOCRINOLOGY, V143, P3144, DOI 10.1210/en.143.8.3144; TSENG L, 1985, J STEROID BIOCHEM, V22, P611, DOI 10.1016/0022-4731(85)90213-4	44	81	84	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					153	159		10.1038/nm1184	http://dx.doi.org/10.1038/nm1184			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685171				2022-12-27	WOS:000226797300022
J	Gaston, SM; Soares, MA; Siddiqui, MM; Vu, D; Lee, JM; Goldner, DL; Brice, MJ; Shih, JC; Upton, MP; Perides, G; Baptista, J; Lavin, PT; Bloch, BN; Genega, EM; Rubin, MA; Lenkinski, RE				Gaston, SM; Soares, MA; Siddiqui, MM; Vu, D; Lee, JM; Goldner, DL; Brice, MJ; Shih, JC; Upton, MP; Perides, G; Baptista, J; Lavin, PT; Bloch, BN; Genega, EM; Rubin, MA; Lenkinski, RE			Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule	NATURE MEDICINE			English	Article							GENE-EXPRESSION ANALYSIS; CANCER; PROTEOMICS; BIOMARKER; COLLAGEN; MARKERS	Molecular profiling of human biopsies and surgical specimens is frequently complicated by their inherent biological heterogeneity and by the need to conserve tissue for clinical diagnosis. We have developed a set of novel 'tissue print' and 'print-phoresis' technologies to facilitate tissue and tumor-marker profiling under these circumstances. Tissue printing transfers cells and extracellular matrix components from a tissue surface onto nitrocellulose membranes, generating a two-dimensional anatomical image on which molecular markers can be visualized by specific protein and RNA- and DNA-detection techniques. Print-phoresis is a complementary new electrophoresis method in which thin strips from the print are subjected to polyacrylamide gel electrophoresis, providing a straightforward interface between the tissue-print image and gel-based proteomic techniques. Here we have utilized these technologies to identify and characterize markers of tumor invasion of the prostate capsule, an event generally not apparent to the naked eye that may result in tumor at the surgical margins ('positive margins'). We have also shown that tissue-print technologies can provide a general platform for the generation of marker maps that can be superimposed directly onto histopathological and radiological images, permitting molecular identification and classification of individual malignant lesions.	Beth Israel Deaconess Med Ctr, Dept Surg, Div Urol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Tufts Univ New England Med Ctr, Dept Surg, Boston, MA 02111 USA; Averion Biostat, Framingham, MA 01701 USA; Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tufts Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Gaston, SM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, Div Urol, 330 Brookline Ave, Boston, MA 02215 USA.	sgaston@bidmc.harvard.edu	Siddiqui, Mohummad/V-1196-2019; Gaston, Sandra/AAN-4088-2021; Soares, Miguel P/G-4188-2011; Lenkinski, Robert/F-9045-2014	Goldner, Dana/0000-0002-1514-9735; Siddiqui, Mohummad/0000-0002-4484-6820; Rubin, Mark/0000-0002-8321-9950; Lenkinski, Robert/0000-0001-7371-5048; Bloch, B Nicolas/0000-0001-8040-159X	NATIONAL CANCER INSTITUTE [R21CA086365, R33CA086365] Funding Source: NIH RePORTER; NCI NIH HHS [CA86365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Burns-Cox N, 2001, J UROLOGY, V166, P1698, DOI 10.1016/S0022-5347(05)65656-X; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Celis JE, 2003, CANCER CELL, V3, P9, DOI 10.1016/S1535-6108(02)00242-8; Chan TY, 2001, J UROLOGY, V166, P2181, DOI 10.1016/S0022-5347(05)65530-9; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Emmert-Buck MR, 2000, J MOL DIAGN, V2, P60, DOI 10.1016/S1525-1578(10)60617-4; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Friedberg MH, 1998, CANCER, V82, P923, DOI 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2; Hornebeck W, 2002, SEMIN CANCER BIOL, V12, P231, DOI 10.1016/S1044-579X(02)00026-3; Issaq HJ, 2002, BIOCHEM BIOPH RES CO, V292, P587, DOI 10.1006/bbrc.2002.6678; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; KLEINMAN HK, 1998, CURRENT PROTOCOLS CE; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; LaTulippe E, 2002, CANCER RES, V62, P4499; Lichtinghagen R, 2003, ANTICANCER RES, V23, P2617; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Luo J, 2001, CANCER RES, V61, P4683; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; NAGLE RB, 1995, AM J PATHOL, V146, P1498; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; SCOPES RK, 2002, CURRENT PROTOCOLS MO; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; VARNER JE, 1994, FASEB J, V8, P378, DOI 10.1096/fasebj.8.6.8168688; Welsh JB, 2001, CANCER RES, V61, P5974; Wise AM, 2002, UROLOGY, V60, P264, DOI 10.1016/S0090-4295(02)01728-4; YOUNG RH, 2000, ATLAS TUMOR PATHOL, P4	30	22	24	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					95	101		10.1038/nm1169	http://dx.doi.org/10.1038/nm1169			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619629				2022-12-27	WOS:000226124900039
J	Meselson, M				Meselson, M			Explorations in the land of DNA and beyond	NATURE MEDICINE			English	Editorial Material							BDELLOID ROTIFERS; RESTRICTION; EVOLUTION; COLI		Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Meselson, M (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	msm@wjh.harvard.edu						Arkhipova I, 2000, P NATL ACAD SCI USA, V97, P14473, DOI 10.1073/pnas.97.26.14473; BRENNER S, 1961, NATURE, V190, P576, DOI 10.1038/190576a0; DAVERN CI, 1960, J MOL BIOL, V2, P153, DOI 10.1016/S0022-2836(60)80017-4; HOLMES LF, 2001, MESELSON STAHL REPLI; Judson H. F., 1996, 8 DAY CREATION; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; MESELSON M, 1957, P NATL ACAD SCI USA, V43, P581, DOI 10.1073/pnas.43.7.581; Meselson M., 1967, Heritage from Mendel., P81; MESELSON M, 1961, P NATL ACAD SCI USA, V47, P857, DOI 10.1073/pnas.47.6.857; MESELSON M, 1972, ANNU REV BIOCHEM, V41, P447, DOI 10.1146/annurev.bi.41.070172.002311; MESELSON M, 1968, NATURE, V217, P1110, DOI 10.1038/2171110a0; MESELSON M, 1988, RECOMBINATION GENETI, P91; Schrodinger E., 1945, WHAT IS LIFE; WAGNER R, 1976, P NATL ACAD SCI USA, V73, P4135, DOI 10.1073/pnas.73.11.4135; Welch DM, 2000, SCIENCE, V288, P1211, DOI 10.1126/science.288.5469.1211; Welch JLM, 2004, P NATL ACAD SCI USA, V101, P1618, DOI 10.1073/pnas.0307677100	16	1	1	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1034	1037		10.1038/nm1004-1034	http://dx.doi.org/10.1038/nm1004-1034			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459697				2022-12-27	WOS:000224245800017
J	Conejo-Garcia, JR; Benencia, F; Coureges, MC; Kang, E; Mohamed-Hadley, A; Buckanovich, RJ; Holtz, DO; Jenkins, A; Na, HN; Zhang, L; Wagner, DS; Katsaros, D; Caroll, R; Coukos, G				Conejo-Garcia, JR; Benencia, F; Coureges, MC; Kang, E; Mohamed-Hadley, A; Buckanovich, RJ; Holtz, DO; Jenkins, A; Na, HN; Zhang, L; Wagner, DS; Katsaros, D; Caroll, R; Coukos, G			Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SYNGENEIC MOUSE MODEL; CD34(+) CELLS; MONOCYTES; GENES; MICE; ANGIOGENESIS; MARKERS; DIFFERENTIATION; EXPRESSION	The involvement of immune mechanisms in tumor angiogenesis is unclear. Here we describe a new mechanism of tumor vasculogenesis mediated by dendritic cell (DC) precursors through the cooperation of beta-defensins and vascular endothelial growth factor-A (Vegf-A). Expression of mouse beta-defensin-29 recruited DC precursors to tumors and enhanced tumor vascularization and growth in the presence of increased Vegf-A expression. A new leukocyte population expressing DC and endothelial markers was uncovered in mouse and human ovarian carcinomas coexpressing Vegf- A and beta-defensins. Tumor-infiltrating DCs migrated to tumor vessels and independently assembled neovasculature in vivo. Bone marrow - derived DCs underwent endothelial-like differentiation ex vivo, migrated to blood vessels and promoted the growth of tumors expressing high levels of Vegf- A. We show that beta-defensins and Vegf- A cooperate to promote tumor vasculogenesis by carrying out distinct tasks: beta-defensins chemoattract DC precursors through CCR6, whereas Vegf- A primarily induces their endothelial-like specialization and migration to vessels, which is mediated by Vegf receptor-2.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Turin, Dept Obstet & Gynecol, I-10126 Turin, Italy	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Turin	Coukos, G (corresponding author), Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	gcks@mail.med.upenn.edu	Holtz, David O./AAM-9866-2020; Coukos, George/ABG-7389-2020; Zhang, Lin/K-8478-2012; Conejo-Garcia, Jose R/V-1897-2019; Wagner, Daniel S/C-9379-2009; Benencia, Fabian/AAH-1613-2020	Conejo-Garcia, Jose R/0000-0001-6431-4074; Wagner, Daniel S/0000-0002-0595-2436; Benencia, Fabian/0000-0003-3049-6150; Coukos, George/0000-0001-8813-7367	FOGARTY INTERNATIONAL CENTER [D43TW000671] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA083638, R01CA098951] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW00671] Funding Source: Medline; NCI NIH HHS [P01-CA83638, R01 CA098951] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ardavin C, 2001, TRENDS IMMUNOL, V22, P691, DOI 10.1016/S1471-4906(01)02059-2; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bhardwaj N, 2001, TRENDS MOL MED, V7, P388, DOI 10.1016/S1471-4914(01)02101-3; Biragyn A, 2001, J IMMUNOL, V167, P6644, DOI 10.4049/jimmunol.167.11.6644; Chiodoni C, 1999, J EXP MED, V190, P125, DOI 10.1084/jem.190.1.125; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; Duncan GS, 1999, J IMMUNOL, V162, P3022; Fend F, 1999, AM J PATHOL, V154, P61, DOI 10.1016/S0002-9440(10)65251-0; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P111, DOI 10.1006/cimm.1996.0140; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harraz M, 2001, STEM CELLS, V19, P304, DOI 10.1634/stemcells.19-4-304; Havemann K, 2003, ADV EXP MED BIOL, V522, P47; Langeggen H, 2002, INFLAMMATION, V26, P103, DOI 10.1023/A:1015585530204; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Moldovan NI, 2000, CIRC RES, V87, P378; Nakul-Aquaronne D, 2003, CARDIOVASC RES, V57, P816, DOI 10.1016/S0008-6363(02)00776-9; Nowicki A, 1996, INT J CANCER, V65, P112, DOI 10.1002/(SICI)1097-0215(19960103)65:1<112::AID-IJC19>3.3.CO;2-R; Ohm JE, 2001, IMMUNOL RES, V23, P263, DOI 10.1385/IR:23:2-3:263; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72; Pujol BF, 2001, EUR J CELL BIOL, V80, P99, DOI 10.1078/0171-9335-00136; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Ronchetti A, 1999, J IMMUNOL, V163, P130; Schmeisser A, 2003, ADV EXP MED BIOL, V522, P59; Schmeisser A, 2001, CARDIOVASC RES, V49, P671, DOI 10.1016/S0008-6363(00)00270-4; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; St Croix B, 2000, SCIENCE, V289, P1197; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Sumpio BE, 2002, INT J BIOCHEM CELL B, V34, P1508, DOI 10.1016/S1357-2725(02)00075-4; Vicari AP, 2002, J EXP MED, V196, P541, DOI 10.1084/jem.20020732; Vicari AP, 2002, SEMIN CANCER BIOL, V12, P33, DOI 10.1006/scbi.2001.0400; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang L, 2002, AM J PATHOL, V161, P2295, DOI 10.1016/S0002-9440(10)64505-1; Zhao Y, 2003, P NATL ACAD SCI USA, V100, P2426, DOI 10.1073/pnas.0536882100	44	359	394	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					950	958		10.1038/nm1097	http://dx.doi.org/10.1038/nm1097			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15334073				2022-12-27	WOS:000223658400032
J	Matte, CC; Liu, JL; Cormier, J; Anderson, BE; Athanasiadis, I; Jain, D; McNiff, J; Shlomchik, W				Matte, CC; Liu, JL; Cormier, J; Anderson, BE; Athanasiadis, I; Jain, D; McNiff, J; Shlomchik, W			Donor APCs are required for maximal GVHD but not for GVL	NATURE MEDICINE			English	Article							VERSUS-HOST-DISEASE; CHRONIC MYELOGENOUS LEUKEMIA; T-CELL RESPONSE; DENDRITIC CELLS; PHILADELPHIA-CHROMOSOME; MEMORY CELLS; BONE-MARROW; NAIVE; ANTIGEN; INDUCTION	Graft-versus-host disease (GVHD) is a major source of morbidity in allogenic stem cell transplantation(1). We previously showed that recipient antigen-presenting cells (APCs) are required for CD8-dependent GVHD in a mouse model across only minor histocompatibility antigens ( minor H antigens)(2). However, these studies did not address the function of donor-derived APCs after GVHD is initiated. Here we show that GVHD develops in recipients of donor major histocompatibility complex class I - deficient (MHC I-) bone marrow. Thus, after initial priming, CD8 cells caused GVHD without a further requirement for hematopoietic APCs, indicating that host APCs are necessary and sufficient for GHVD. Nonetheless, GVHD was less severe in recipients of MHC I- bone marrow. Therefore, once initiated, GVHD is intensified by donor-derived cells, most probably donor APCs cross-priming alloreactive CD8 cells. Nevertheless, donor APCs were not required for CD8-mediated graft-versus-leukemia (GVL) against a mouse model of chronic-phase chronic myelogenous leukemia. These studies identify donor APCs as a new target for treating GVHD, which may preserve GVL.	Yale Univ, Sch Med, Sect Med Oncol, New Haven, CT 06520 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA	Yale University; University of Massachusetts System; University of Massachusetts Amherst; Yale University; Yale University; Yale University	Shlomchik, W (corresponding author), Yale Univ, Sch Med, Sect Med Oncol, POB 208032,333 Cedar St, New Haven, CT 06520 USA.	warren.shlomchik@yale.edu			NATIONAL CANCER INSTITUTE [R01CA096943] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003979, R01HL066279, T32HL007974] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA96943] Funding Source: Medline; NHLBI NIH HHS [T32 HL007974, K08HL03979, HL66279] Funding Source: Medline; NIAID NIH HHS [T32 AI071019-23-25] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson BE, 2003, J CLIN INVEST, V112, P101, DOI 10.1172/JCI200317601; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; BLAND PW, 1992, IMMUNOLOGY, V75, P366; Chakrabarti S, 2002, BLOOD, V99, P4357, DOI 10.1182/blood.V99.12.4357; Cho BK, 1999, P NATL ACAD SCI USA, V96, P2976, DOI 10.1073/pnas.96.6.2976; Choudhury A, 1997, BLOOD, V89, P1133, DOI 10.1182/blood.V89.4.1133; Cragg L, 2000, BIOL BLOOD MARROW TR, V6, P441, DOI 10.1016/S1083-8791(00)70036-X; CROFT M, 1994, J IMMUNOL, V152, P2675; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Goker H, 2001, EXP HEMATOL, V29, P259, DOI 10.1016/S0301-472X(00)00677-9; Hoffmann TK, 2001, J IMMUNOTHER, V24, P162, DOI 10.1097/00002371-200103000-00011; HOROWITZ MM, 1990, BLOOD, V75, P555; Hu HM, 2002, J IMMUNOL, V169, P4897, DOI 10.4049/jimmunol.169.9.4897; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kedl RM, 1998, J IMMUNOL, V161, P674; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; London CA, 2000, J IMMUNOL, V164, P265, DOI 10.4049/jimmunol.164.1.265; Matte CC, 2004, BLOOD, V103, P4353, DOI 10.1182/blood-2003-10-3735; Mintern JD, 2002, J IMMUNOL, V168, P977, DOI 10.4049/jimmunol.168.3.977; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Sprent J, 2002, CURR BIOL, V12, pR174, DOI 10.1016/S0960-9822(02)00735-2; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; Zimmermann C, 1999, EUR J IMMUNOL, V29, P284, DOI 10.1002/(SICI)1521-4141(199901)29:01<284::AID-IMMU284>3.0.CO;2-C	29	251	263	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					987	992		10.1038/nm1089	http://dx.doi.org/10.1038/nm1089			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15286785				2022-12-27	WOS:000223658400037
J	Moyron-Quiroz, JE; Rangel-Moreno, J; Kusser, KR; Hartson, L; Sprague, F; Goodrich, S; Woodland, DL; Lund, FE; Randall, TD				Moyron-Quiroz, JE; Rangel-Moreno, J; Kusser, KR; Hartson, L; Sprague, F; Goodrich, S; Woodland, DL; Lund, FE; Randall, TD			Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity	NATURE MEDICINE			English	Article							ALPHA-DEFICIENT MICE; TUMOR-NECROSIS-FACTOR; T-CELL; ORGAN CHEMOKINE; CUTTING EDGE; BONE-MARROW; LYMPHOTOXIN; RESPONSES; RECEPTOR; LUNG	Bronchus-associated lymphoid tissue (BALT) is occasionally found in the lungs of mice and humans; however, its role in respiratory immunity is unknown. Here we show that mice lacking spleen, lymph nodes and Peyer's patches generate unexpectedly robust primary B- and T-cell responses to influenza, which seem to be initiated at sites of induced BALT (iBALT). Areas of iBALT have distinct B- cell follicles and T-cell areas, and support T and B- cell proliferation. The homeostatic chemokines CXCL13 and CCL21 are expressed independently of TNFalpha and lymphotoxin at sites of iBALT formation. In addition, mice with iBALT, but lacking peripheral lymphoid organs, clear influenza infection and survive higher doses of virus than do normal mice, indicating that immune responses generated in iBALT are not only protective, but potentially less pathologic, than systemic immune responses. Thus, iBALT functions as an inducible secondary lymphoid tissue for respiratory immune responses.	Trudeau Inst Inc, Saranac Lake, NY 12983 USA	Trudeau Institute	Randall, TD (corresponding author), Trudeau Inst Inc, 154 Algonquin Ave, Saranac Lake, NY 12983 USA.	trandall@trudeauinstitute.org		Rangel-Moreno, Javier/0000-0002-9738-1182	NHLBI NIH HHS [HL63925, HL69409] Funding Source: Medline; NIAID NIH HHS [AI50844, AI57158] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057158, R01AI050844] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; BANKS TA, 1995, J IMMUNOL, V155, P1685; BARKER CF, 1968, J EXP MED, V128, P197, DOI 10.1084/jem.128.1.197; BIENENSTOCK J, 1976, LAB INVEST, V35, P343; Bienenstock J, 1974, Adv Exp Med Biol, V45, P47; Brimnes MK, 2003, J EXP MED, V198, P133, DOI 10.1084/jem.20030266; Chen HD, 2001, NAT IMMUNOL, V2, P1067, DOI 10.1038/ni727; Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JCI200216109; DELVENTHAL S, 1992, INT J EXP PATHOL, V73, P351; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Feuerer M, 2003, NAT MED, V9, P1151, DOI 10.1038/nm914; Fu YX, 1997, P NATL ACAD SCI USA, V94, P5739, DOI 10.1073/pnas.94.11.5739; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Goodnow CC, 1997, IMMUNOL REV, V156, P5, DOI 10.1111/j.1600-065X.1997.tb00954.x; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Guo Z, 2001, J IMMUNOL, V167, P4796, DOI 10.4049/jimmunol.167.9.4796; Harmsen A, 2002, J IMMUNOL, V168, P986, DOI 10.4049/jimmunol.168.3.986; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L; Kang HS, 2003, J EXP MED, V198, P1643, DOI 10.1084/jem.20021784; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; Lakkis FG, 2000, NAT MED, V6, P686, DOI 10.1038/76267; Lee BJ, 2000, J VIROL, V74, P2786, DOI 10.1128/JVI.74.6.2786-2792.2000; Lo JC, 2003, J CLIN INVEST, V112, P1495, DOI 10.1172/JCI200319188; Lund FE, 2002, J IMMUNOL, V169, P5236, DOI 10.4049/jimmunol.169.9.5236; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Nakano H, 2001, J IMMUNOL, V166, P361, DOI 10.4049/jimmunol.166.1.361; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; PLESCH BEC, 1983, DEV COMP IMMUNOL, V7, P179, DOI 10.1016/0145-305X(83)90066-6; Rennert PD, 2001, J EXP MED, V193, P1227, DOI 10.1084/jem.193.11.1227; Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; Tripp RA, 1997, J IMMUNOL, V158, P3716; Tschernig T, 2000, PATHOBIOLOGY, V68, P1, DOI 10.1159/000028109; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953; Xu BH, 2003, J EXP MED, V197, P1255, DOI 10.1084/jem.20010685; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	41	545	562	3	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					927	934		10.1038/nm1091	http://dx.doi.org/10.1038/nm1091			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15311275				2022-12-27	WOS:000223658400029
J	Vogelstein, B; Kinzler, KW				Vogelstein, B; Kinzler, KW			Cancer genes and the pathways they control	NATURE MEDICINE			English	Review							GASTROINTESTINAL STROMAL TUMORS; ACUTE MYELOID-LEUKEMIA; GENOMIC INSTABILITY; SUPPRESSOR GENES; LUNG-CANCER; MUTATIONS; CARCINOGENESIS; DISCOVERY; GROWTH; CELLS	The revolution in cancer research can be summed up in a single sentence: cancer is, in essence, a genetic disease. In the last decade, many important genes responsible for the genesis of various cancers have been discovered, their mutations precisely identified, and the pathways through which they act characterized. The purposes of this review are to highlight examples of progress in these areas, indicate where knowledge is scarce and point out fertile grounds for future investigation.	Johns Hopkins Univ, Inst Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Univ, Inst Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Vogelstein, B (corresponding author), Johns Hopkins Univ, Inst Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA.	vogelbe@welch.jhu.edu; kinzlke@jhmi.edu	Cooper, fabienne/F-6784-2011		NATIONAL CANCER INSTITUTE [R37CA043460, R01CA043460, R37CA057345, P50CA062924, R01CA057345] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Albertson DG, 2003, HUM MOL GENET, V12, pR145, DOI 10.1093/hmg/ddg261; Altaba ARI, 2004, CANCER LETT, V204, P145, DOI 10.1016/S0304-3835(03)00451-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Berking C, 2001, HISTOL HISTOPATHOL, V16, P669, DOI 10.14670/HH-16.669; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; BOS JL, 1989, CANCER RES, V49, P4682; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bronner-Fraser M, 2004, SCIENCE, V303, P966, DOI 10.1126/science.1094732; Brown F. A., 1937, Bulletin of the Illinois Natural History Survey, V21, P33; Brown JM, 2001, DRUG RESIST UPDATE, V4, P135, DOI 10.1054/drup.2001.0193; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cech TR, 2004, CELL, V116, P273, DOI 10.1016/S0092-8674(04)00038-8; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diaz R, 2002, CANCER RES, V62, P4514; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Druker B J, 2001, Hematology Am Soc Hematol Educ Program, P87; Duensing A, 2004, CANCER INVEST, V22, P106, DOI 10.1081/CNV-120027585; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; HONCHEL R, 1995, SEMIN CELL BIOL, V6, P45, DOI 10.1016/1043-4682(95)90014-4; Hope KJ, 2003, ARCH MED RES, V34, P507, DOI 10.1016/j.arcmed.2003.08.007; Horvitz HR, 2003, CHEMBIOCHEM, V4, P697, DOI 10.1002/cbic.200300614; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hunter KW, 2004, BRIT J CANCER, V90, P752, DOI 10.1038/sj.bjc.6601590; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ichimura K, 2000, CANCER RES, V60, P417; JEN J, 1994, CANCER RES, V54, P5523; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klein G, 2002, FRONT BIOSCI-LANDMRK, V7, pD268, DOI 10.2741/klein; Knudson AG, 2002, AM J MED GENET, V111, P96, DOI 10.1002/ajmg.10320; Komarova NL, 2003, J THEOR BIOL, V223, P433, DOI 10.1016/S0022-5193(03)00120-6; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Langer CJ, 2004, INT J RADIAT ONCOL, V58, P991, DOI 10.1016/j.ijrobp.2003.09.099; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Luo J, 2003, CANCER INVEST, V21, P937, DOI 10.1081/CNV-120025096; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Maley CC, 2004, CANCER RES, V64, P3414, DOI 10.1158/0008-5472.CAN-03-3249; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Masayesva BG, 2004, P NATL ACAD SCI USA, V101, P8715, DOI 10.1073/pnas.0400027101; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Mechtersheimer G, 2004, VIRCHOWS ARCH, V444, P108, DOI 10.1007/s00428-003-0945-5; Miklos GLG, 2004, NAT BIOTECHNOL, V22, P615, DOI 10.1038/nbt965; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nowell PC, 2002, SEMIN CANCER BIOL, V12, P261, DOI 10.1016/S1044-579X(02)00012-3; Nygren P, 2003, J INTERN MED, V253, P46, DOI 10.1046/j.1365-2796.2003.01098.x; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pegram M D, 2000, Cancer Treat Res, V103, P57; Pihan G, 2003, CANCER CELL, V4, P89, DOI 10.1016/S1535-6108(03)00195-8; Plas David R, 2002, Trends Endocrinol Metab, V13, P75, DOI 10.1016/S1043-2760(01)00528-8; Polyak K, 2001, J CLIN ONCOL, V19, P2948, DOI 10.1200/JCO.2001.19.11.2948; PRETLOW TP, 1995, GASTROENTEROLOGY, V108, P600, DOI 10.1016/0016-5085(95)90092-6; Prives C, 1999, J PATHOL, V187, P112; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Rosenblatt KP, 2004, ANNU REV MED, V55, P97, DOI 10.1146/annurev.med.55.091902.105237; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Schadt EE, 2003, BIOCHEM SOC T, V31, P437, DOI 10.1042/BST0310437; Schmitt CA, 1999, J PATHOL, V187, P127; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sherr CJ, 2000, CANCER RES, V60, P3689; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shih LY, 2004, CLIN CANCER RES, V10, P1326, DOI 10.1158/1078-0432.CCR-0835-03; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Stewart SA, 2002, ONCOGENE, V21, P627, DOI 10.1038/sj.onc.1205062; Strausberg RL, 2003, NAT REV GENET, V4, P409, DOI 10.1038/nrg1085; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Verheul HMW, 2004, J PATHOL, V202, P5, DOI 10.1002/path.1473; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang TL, 2002, P NATL ACAD SCI USA, V99, P3076, DOI 10.1073/pnas.261714699; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Yamamoto H, 2002, J GASTROENTEROL, V37, P153, DOI 10.1007/s005350200015; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zur Hausen H, 2001, ONCOGENE, V20, P7820, DOI 10.1038/sj.onc.1204958; [No title captured]; [No title captured]	117	2994	3150	6	571	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					789	799		10.1038/nm1087	http://dx.doi.org/10.1038/nm1087			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15286780				2022-12-27	WOS:000223055700030
J	Satchi-Fainaro, R; Puder, M; Davies, JW; Tran, HT; Sampson, DA; Greene, AK; Corfas, G; Folkman, J				Satchi-Fainaro, R; Puder, M; Davies, JW; Tran, HT; Sampson, DA; Greene, AK; Corfas, G; Folkman, J			Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470	NATURE MEDICINE			English	Article							ENZYME PRODRUG THERAPY; CATHEPSIN-B; PHASE-I; INHIBITOR TNP-470; ENDOTHELIAL-CELLS; AGENT TNP-470; SOLID TUMORS; BRAIN-TUMORS; HUMAN PLASMA; CANCER	Angiogenesis is crucial for tumor growth. Angiogenesis inhibitors, such as O-(chloracetyl-carbamoyl) fumagillol (TNP-470), are thus emerging as a new class of anticancer drugs. In clinical trials, TNP-470 slowed tumor growth in patients with metastatic cancer. However, at higher doses necessary for tumor regression, many patients experienced neurotoxicity. We therefore synthesized and characterized a water-soluble conjugate of N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer, Gly-Phe-Leu-Gly linker and TNP-470. This conjugate accumulated selectively in tumor vessels because of the enhanced permeability and retention (EPR) effect. HPMA copolymer-TNP-470 substantially enhanced and prolonged the activity of TNP-470 in vivo in tumor and hepatectomy models. Polymer conjugation prevented TNP-470 from crossing the blood-brain barrier (BBB) and decreased its accumulation in normal organs, thereby avoiding drug-related toxicities. Treatment with TNP-470 caused weight loss and neurotoxic effects in mice, whereas treatment with the conjugate did not. This new approach for targeting angiogenesis inhibitors specifically to the tumor vasculature may provide a new strategy for the rational design of cancer therapies.	Boston Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; Boston Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Polymer Labs, Church Stretton SY6 6EA, Shrops, England; Univ Texas, MD Anderson Canc Ctr, Div Canc Med & Pharm, Houston, TX 77030 USA; Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Boston Children's Hospital	Folkman, J (corresponding author), Boston Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA.	judah.folkman@childrens.harvard.edu	Satchi-Fainaro, Ronit/F-9137-2011; Corfas, Gabriel/AAH-2378-2020	Satchi-Fainaro, Ronit/0000-0002-7360-7837; Corfas, Gabriel/0000-0001-5412-9473; Tran, Hai/0000-0003-4065-9355				ANTOINE N, 1994, CANCER RES, V54, P2073; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Bhargava P, 1999, CLIN CANCER RES, V5, P1989; DUNCAN R, 1983, MAKROMOL CHEM, V184, P1997; DUNCAN R, 1986, BIOSCIENCE REP, V6, P869, DOI 10.1007/BF01116240; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Duncan R, 2001, J CONTROL RELEASE, V74, P135, DOI 10.1016/S0168-3659(01)00328-5; Duncan R, 1998, HUM EXP TOXICOL, V17, P93, DOI 10.1191/096032798678908378; DVORAK HF, 1988, AM J PATHOL, V133, P95; Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; Folkman J, 1998, ACCOMPLISHMENTS CANC, P32; Folkman J, 2003, CANC MED, P161; Francis G. E., 1992, STABILITY PROTEIN PH, P235; Gianasi E, 1999, EUR J CANCER, V35, P994, DOI 10.1016/S0959-8049(99)00030-1; Greene AK, 2003, ANN SURG, V237, P530, DOI 10.1097/00000658-200304000-00015; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Herbst RS, 2002, J CLIN ONCOL, V20, P4440, DOI 10.1200/JCO.2002.04.006; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Kim Edward S, 2002, Curr Oncol Rep, V4, P325, DOI 10.1007/s11912-002-0008-0; Kudelka AP, 1997, CLIN CANCER RES, V3, P1501; Kudelka AP, 1998, NEW ENGL J MED, V338, P991, DOI 10.1056/NEJM199804023381412; Lah TT, 2000, HUM PATHOL, V31, P149, DOI 10.1016/S0046-8177(00)80214-2; Logothetis CJ, 2001, CLIN CANCER RES, V7, P1198; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Nagabuchi E, 1997, J PEDIATR SURG, V32, P287, DOI 10.1016/S0022-3468(97)90196-2; Ong VS, 1998, J CHROMATOGR B, V710, P173, DOI 10.1016/S0378-4347(98)00111-X; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Paxinos G., 2001, MOUSE BRAIN STEREOTA; RIHOVA B, 1989, BIOMATERIALS, V10, P335, DOI 10.1016/0142-9612(89)90075-6; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Satchi R, 2001, BRIT J CANCER, V85, P1070, DOI 10.1054/bjoc.2001.2026; Satchi-Fainaro R, 2003, BIOCONJUGATE CHEM, V14, P797, DOI 10.1021/bc020091k; Satchi-Fainaro R, 2002, J DRUG TARGET, V10, P529, DOI 10.1080/1061186021000051062; SCHOOF DD, 1993, INT J CANCER, V55, P630, DOI 10.1002/ijc.2910550419; SEYMOUR LW, 1994, BRIT J CANCER, V70, P636, DOI 10.1038/bjc.1994.363; SEYMOUR LW, 1991, BRIT J CANCER, V63, P859, DOI 10.1038/bjc.1991.190; SEYMOUR LW, 1990, BIOCHEM PHARMACOL, V39, P1125, DOI 10.1016/0006-2952(90)90293-T; Stadler WM, 1999, J CLIN ONCOL, V17, P2541, DOI 10.1200/JCO.1999.17.8.2541; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Strojnik T, 2000, PFLUG ARCH EUR J PHY, V439, pR122, DOI 10.1007/s004240000114; Vasey PA, 1999, CLIN CANCER RES, V5, P83; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; WAYNFORTH HB, 1980, EXPT SURG TECHNIQUE, V2, P34; Whalen CT, 2002, J CHROMATOGR SCI, V40, P214, DOI 10.1093/chromsci/40.4.214; Yeh JRJ, 2000, P NATL ACAD SCI USA, V97, P12782, DOI 10.1073/pnas.97.23.12782; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427	49	292	325	2	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					255	261		10.1038/nm1002	http://dx.doi.org/10.1038/nm1002			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14981512				2022-12-27	WOS:000189297700036
J	Alexandrakis, G; Brown, EB; Tong, RT; McKee, TD; Campbell, RB; Boucher, Y; Jain, RK				Alexandrakis, G; Brown, EB; Tong, RT; McKee, TD; Campbell, RB; Boucher, Y; Jain, RK			Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors	NATURE MEDICINE			English	Article							IN-VIVO MEASUREMENT; CORRELATION SPECTROSCOPY; PHOTOBLEACHING RECOVERY; HYALURONIC-ACID; DIFFUSION; MACROMOLECULES; INTERSTITIUM; COLLAGEN; ANGIOGENESIS; CONVECTION	Transport parameters determine the access of drugs to tumors. However, technical difficulties preclude the measurement of these parameters deep inside living tissues. To this end, we adapted and further optimized two-photon fluorescence correlation microscopy (TPFCM) for in vivo measurement of transport parameters in tumors. TPFCM extends the detectable range of diffusion coefficients in tumors by one order of magnitude, and reveals both a fast and a slow component of diffusion. The ratio of these two components depends on molecular size and can be altered in vivo with hyaluronidase and collagenase. These studies indicate that TPFCM is a promising tool to dissect the barriers to drug delivery in tumors.	Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; Northeastern Univ, Bouve Coll Hlth Sci, Dept Pharmaceut Sci, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Northeastern University	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu	Jain, Rakesh K/I-1384-2017; McKee, Trevor David/N-4308-2019	Jain, Rakesh K/0000-0001-7571-3548; McKee, Trevor David/0000-0002-2195-6146	NCI NIH HHS [F32 CA097818, T32CA73479, F32CA97818, P01CA80124, R24CA85140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA073479, P01CA080124, R24CA085140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; BECKENLEHNER K, 1992, J CANCER RES CLIN, V118, P591, DOI 10.1007/BF01211802; Berk DA, 1997, P NATL ACAD SCI USA, V94, P1785, DOI 10.1073/pnas.94.5.1785; BERLAND KM, 1995, BIOPHYS J, V68, P694, DOI 10.1016/S0006-3495(95)80230-4; Brock R, 1999, P NATL ACAD SCI USA, V96, P10123, DOI 10.1073/pnas.96.18.10123; Brock R, 1998, BIOPHYS J, V75, P2547, DOI 10.1016/S0006-3495(98)77699-4; Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879; Brown EB, 1999, BIOPHYS J, V77, P2837, DOI 10.1016/S0006-3495(99)77115-8; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; CHARY SR, 1989, P NATL ACAD SCI USA, V86, P5385, DOI 10.1073/pnas.86.14.5385; DE SMEDT SC, 1994, MACROMOLECULES, V27, P141, DOI 10.1021/ma00079a021; ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102; FLAMION B, 1991, BIOPHYS J, V60, P1229, DOI 10.1016/S0006-3495(91)82157-9; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; JAIN RK, 1987, CANCER RES, V47, P3039; LEUNIG M, 1992, CANCER RES, V52, P6553; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; Masuda A, 2001, J AM CHEM SOC, V123, P11468, DOI 10.1021/ja016401b; Netti PA, 2000, CANCER RES, V60, P2497; Pluen A, 1999, BIOPHYS J, V77, P542, DOI 10.1016/S0006-3495(99)76911-0; Pluen A, 2001, P NATL ACAD SCI USA, V98, P4628, DOI 10.1073/pnas.081626898; QIAN H, 1991, APPL OPTICS, V30, P1185, DOI 10.1364/AO.30.001185; Qiu XL, 1999, LUNG, V177, P273, DOI 10.1007/PL00007647; Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006-3495(02)73933-7; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Shenoy V, 1995, MACROMOLECULES, V28, P8751, DOI 10.1021/ma00130a007; Smith KJ, 1997, J AM ACAD DERMATOL, V36, P239, DOI 10.1016/S0190-9622(97)70288-3; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343; Wohland T, 2001, BIOPHYS J, V80, P2987, DOI 10.1016/S0006-3495(01)76264-9	30	139	141	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					203	207		10.1038/nm981	http://dx.doi.org/10.1038/nm981			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14716306				2022-12-27	WOS:000188719600042
J	Pendergraft, WF; Preston, GA; Shah, RR; Tropsha, A; Carter, CW; Jennette, JC; Falk, RJ				Pendergraft, WF; Preston, GA; Shah, RR; Tropsha, A; Carter, CW; Jennette, JC; Falk, RJ			Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3	NATURE MEDICINE			English	Article							ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; SMALL-VESSEL VASCULITIS; MYASTHENIA-GRAVIS; SYSTEMIC VASCULITIS; PEPTIDE VACCINE; MOLECULAR CHARACTERIZATION; ANTIIDIOTYPIC ANTIBODIES; ACETYLCHOLINE-RECEPTOR; THYROID-DISEASE	It remains unclear how and why autoimmunity occurs. Here we show evidence for a previously unrecognized and possibly general mechanism of autoimmunity. This new finding was discovered serendipitously using material from patients with inflammatory vascular disease caused by antineutrophil cytoplasmic autoantibodies (ANCA) with specificity for proteinase-3 (PR-3). Such patients harbor not only antibodies to the autoantigen (PR-3), but also antibodies to a peptide translated from the antisense DNA strand of PR-3 (complementary PR-3, cPR-3) or to a mimic of this peptide. Immunization of mice with the middle region of cPR-3 resulted in production of antibodies not only to cPR-3, but also to the immunogen's sense peptide counterpart, PR-3. Both human and mouse antibodies to PR-3 and cPR-3 bound to each other, indicating idiotypic relationships. These findings indicate that autoimmunity can be initiated through an immune response against a peptide that is antisense or complementary to the autoantigen, which then induces anti-idiotypic antibodies (autoantibodies) that cross-react with the autoantigen.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Div Nephrol & Hypertens, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Falk, RJ (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.	ronald_falk@med.unc.edu	Tropsha, Alexander/G-6245-2014; Tropsha, Alexander/AAB-8324-2020	Jennette, John Charles/0000-0002-8081-6565	NCI NIH HHS [P30 CA008748] Funding Source: Medline; NIDDK NIH HHS [DK-58335-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araga S, 1999, J IMMUNOL, V163, P476; ARAGA S, 1993, P NATL ACAD SCI USA, V90, P8747, DOI 10.1073/pnas.90.18.8747; Araga S, 1994, Immunomethods, V5, P130, DOI 10.1006/immu.1994.1047; Araga S, 2000, FASEB J, V14, P185, DOI 10.1096/fasebj.14.1.185; Araga S, 1996, J IMMUNOL, V157, P386; BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; Benoist C, 1998, NATURE, V394, P227, DOI 10.1038/28282; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Carter CW, 2002, MOL CELL, V10, P705, DOI 10.1016/S1097-2765(02)00688-3; CHARLES LA, 1991, J LEUKOCYTE BIOL, V50, P539, DOI 10.1002/jlb.50.6.539; DAU PC, 1977, NEW ENGL J MED, V297, P1134, DOI 10.1056/NEJM197711242972102; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; DWYER DS, 1983, NATURE, V301, P611, DOI 10.1038/301611a0; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FALK RJ, 1990, ANN INTERN MED, V113, P656, DOI 10.7326/0003-4819-113-9-656; Falk RJ, 1997, J AM SOC NEPHROL, V8, P314; Heal JR, 2002, CHEMBIOCHEM, V3, P137, DOI 10.1002/1439-7633(20020301)3:2/3<136::AID-CBIC136>3.0.CO;2-7; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Hellmich B, 2001, CLIN RHEUMATOL, V20, P441, DOI 10.1007/PL00011214; Hemmer B, 1999, NAT MED, V5, P1375; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1990, BLOOD, V75, P2263; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Jethwa HS, 2000, J IMMUNOL, V165, P3890, DOI 10.4049/jimmunol.165.7.3890; Kirvan CA, 2003, NAT MED, V9, P914, DOI 10.1038/nm892; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; LEJOHN HB, 1994, J BIOL CHEM, V269, P4523; Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509; MEKLER LB, 1973, ONCOLOGY-BASEL, V27, P286; MENDLOVIC S, 1988, P NATL ACAD SCI USA, V85, P2260, DOI 10.1073/pnas.85.7.2260; MEZZANO S, 1993, ADV EXP MED BIOL, V336, P449; Morales R, 1999, BIOCHEMISTRY-US, V38, P15764, DOI 10.1021/bi991578s; Ohlsson S, 2003, CLIN EXP IMMUNOL, V131, P528, DOI 10.1046/j.1365-2249.2003.02083.x; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; PASCUAL D W, 1989, Peptide Research, V2, P207; PUDIFIN DJ, 1994, CLIN EXP IMMUNOL, V97, P48, DOI 10.1111/j.1365-2249.1994.tb06578.x; Routsias JG, 2003, J AUTOIMMUN, V21, P17, DOI 10.1016/S0896-8411(03)00063-5; Routsias JG, 2002, MOL MED, V8, pA3, DOI 10.1007/BF03402155; Ruiz-Opazo N, 1998, MOL MED, V4, P96, DOI 10.1007/BF03401733; RUIZOPAZO N, 1995, NAT MED, V1, P1074, DOI 10.1038/nm1095-1074; Selo I, 2002, IMMUNOL LETT, V80, P133, DOI 10.1016/S0165-2478(01)00319-4; SHOENFELD Y, 1994, FASEB J, V8, P1296, DOI 10.1096/fasebj.8.15.8001742; SMITH LR, 1987, J IMMUNOL, V138, P7; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Stassi G, 2002, NAT REV IMMUNOL, V2, P195, DOI 10.1038/nri750; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Tropsha Alexander, 1992, Journal of Molecular Recognition, V5, P43, DOI 10.1002/jmr.300050202; Tzioufas AG, 2002, CLIN EXP RHEUMATOL, V20, P289; van der Geld YM, 2001, KIDNEY INT, V59, P147, DOI 10.1046/j.1523-1755.2001.00475.x; Weathington Nathaniel M, 2003, Expert Rev Vaccines, V2, P61, DOI 10.1586/14760584.2.1.61; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Yang JJ, 2002, KIDNEY INT, V62, P1638, DOI 10.1046/j.1523-1755.2002.00619.x; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Yu M, 1995, Adv Exp Med Biol, V380, P165; ZHOU SR, 1993, J IMMUNOL, V150, P1629; Zhou SR, 1996, J NEUROSCI RES, V45, P439, DOI 10.1002/(SICI)1097-4547(19960815)45:4<439::AID-JNR13>3.0.CO;2-W	59	255	270	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2004	10	1					72	79		10.1038/nm968	http://dx.doi.org/10.1038/nm968			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14661018				2022-12-27	WOS:000187743600041
J	Corbel, SY; Lee, A; Yi, L; Duenas, J; Brazelton, TR; Blau, HM; Rossi, FMV				Corbel, SY; Lee, A; Yi, L; Duenas, J; Brazelton, TR; Blau, HM; Rossi, FMV			Contribution of hematopoietic stem cells to skeletal muscle	NATURE MEDICINE			English	Letter							BONE-MARROW; MYOGENIC SPECIFICATION; IN-VIVO; FUSION; REGENERATION; TRANSPLANTATION; PLASTICITY; EXPRESSION; MOUSE	Cells from adult bone marrow participate in the regeneration of damaged skeletal myofibers. However, the relationship of these cells with the various hematopoietic and nonhematopoietic cell types found in bone marrow is still unclear. Here we show that the progeny of a single cell can both reconstitute the hematopoietic system and contribute to muscle regeneration. Integration of bone marrow cells into myofibers occurs spontaneously at low frequency and increases with muscle damage. Thus, classically defined single hematopoietic stem cells can give rise to both blood and muscle.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Stanford Univ, Dept Mol Pharmacol, Sch Med, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	University of British Columbia; Stanford University; Stanford University	Rossi, FMV (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Rossi, Fabio MV/B-5587-2013	Rossi, Fabio MV/0000-0002-0368-2620	NHLBI NIH HHS [HL65572] Funding Source: Medline; NIA NIH HHS [AG2096L, AG09521] Funding Source: Medline; NICHD NIH HHS [HD18179] Funding Source: Medline; NIGMS NIH HHS [GM07149] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, R01AG009521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Brazelton TR, 2003, DEV BIOL, V262, P64, DOI 10.1016/S0012-1606(03)00357-9; Corti S, 2002, EXP CELL RES, V277, P74, DOI 10.1006/excr.2002.5543; Dixon RW, 1996, J NEUROPATH EXP NEUR, V55, P1230, DOI 10.1097/00005072-199612000-00006; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 2002, J CLIN INVEST, V110, P807, DOI 10.1172/JCI200216098; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WEIMANN JM, IN PRESS NAT CELL BI; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999	25	197	209	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1528	1532		10.1038/nm959	http://dx.doi.org/10.1038/nm959			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625543				2022-12-27	WOS:000186845400037
J	Eriksson, U; Ricci, R; Hunziker, L; Kurrer, MO; Oudit, GY; Watts, TH; Sonderegger, I; Bachmaier, K; Kopf, M; Penninger, JM				Eriksson, U; Ricci, R; Hunziker, L; Kurrer, MO; Oudit, GY; Watts, TH; Sonderegger, I; Bachmaier, K; Kopf, M; Penninger, JM			Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity	NATURE MEDICINE			English	Article							DILATED CARDIOMYOPATHY; MYOCARDITIS; MICE; CD40; ACTIVATION; PROTECTION; INFECTION; DISEASE; EPITOPE; IL-12	Genetic susceptibility and autoimmunity triggered by microbial infections are factors implicated in the pathogenesis of dilated cardiomyopathy, the most common cause of heart failure in young patients. Here we show that dendritic cells (DCs) loaded with a heart- specific self peptide induce CD4+ T- cell- mediated myocarditis in nontransgenic mice. Toll- like receptor (TLR) stimulation, in concert with CD40 triggering of self peptide- loaded dendritic cells, was shown to be required for disease induction. After resolution of acute myocarditis, DC- immunized mice developed heart failure, and TLR stimulation of these mice resulted in relapse of inflammatory infiltrates. Injection of damaged, syngeneic cardiomyocytes also induced myocarditis in mice if TLRs were activated in vivo. DC- induced myocarditis provides a unifying theory as to how tissue damage and activation of TLRs during infection can induce autoimmunity, relapses and cardiomyopathy.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; Univ Basel Hosp, Dept Res & Med A, CH-4031 Basel, Switzerland; Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence Cardi, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; Swiss Fed Inst Technol, CH-8952 Zurich, Switzerland; Univ Toronto, Princess Margaret Hosp, Dept Med Biophys, Univ Hlth Network, Toronto, ON M5G 2C1, Canada	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Basel; University of Zurich; University Zurich Hospital; University of Toronto; University of Toronto; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Eriksson, U (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	ueriksson@uhbs.ch; josef.penninger@oeaw.ac.at	Kopf, Manfred/B-6907-2009; Ricci, Romeo/K-3009-2013; Penninger, Josef M/I-6860-2013; Bachmaier, Kurt/B-6331-2014; Bachmaier, Kurt/AHC-5491-2022	Kopf, Manfred/0000-0002-0628-7140; Ricci, Romeo/0000-0002-9766-4369; Penninger, Josef M/0000-0002-8194-3777; Bachmaier, Kurt/0000-0002-0299-2707; Bachmaier, Kurt/0000-0002-0299-2707; Hunziker, Lukas/0000-0003-0081-8518; Eriksson, Urs/0000-0003-1217-9696				Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; Caforio ALP, 2002, EUR J HEART FAIL, V4, P411, DOI 10.1016/S1388-9842(02)00010-7; Calabrese F, 2002, DIAGN MOL PATHOL, V11, P212, DOI 10.1097/00019606-200212000-00004; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Dittel BN, 1999, J IMMUNOL, V163, P32; DONERMEYER DL, 1995, J EXP MED, V182, P1291, DOI 10.1084/jem.182.5.1291; Eriksson U, 2003, J EXP MED, V197, P323, DOI 10.1084/jem.20021788; Eriksson U, 2003, CIRCULATION, V107, P320, DOI 10.1161/01.CIR.0000043802.38699.66; Eriksson U, 2001, J IMMUNOL, V167, P5464, DOI 10.4049/jimmunol.167.9.5464; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Hoshino K, 1999, J IMMUNOL, V162, P3749; Howard LM, 2001, J IMMUNOL, V166, P1547, DOI 10.4049/jimmunol.166.3.1547; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Labow M, 1997, J IMMUNOL, V159, P2452; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mann DL, 2002, CIRC RES, V91, P988, DOI 10.1161/01.RES.0000043825.01705.1B; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; NEU N, 1987, J IMMUNOL, V139, P3630; Pulendran B, 2001, SCIENCE, V293, P253, DOI 10.1126/science.1062060; Pummerer CL, 1996, J CLIN INVEST, V97, P2057, DOI 10.1172/JCI118642; Roig E, 1998, AM J CARDIOL, V82, P688, DOI 10.1016/S0002-9149(98)00388-9; ROSE NR, 1988, IMMUNOL TODAY, V9, P117, DOI 10.1016/0167-5699(88)91282-0; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Turley SJ, 2002, CURR OPIN IMMUNOL, V14, P765, DOI 10.1016/S0952-7915(02)00399-0	39	310	331	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2003	9	12					1484	1490		10.1038/nm960	http://dx.doi.org/10.1038/nm960			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625544				2022-12-27	WOS:000186845400031
J	Ting, SB; Wilanowski, T; Auden, A; Hall, M; Voss, AK; Thomas, T; Parekh, V; Cunningham, JM; Jane, SM				Ting, SB; Wilanowski, T; Auden, A; Hall, M; Voss, AK; Thomas, T; Parekh, V; Cunningham, JM; Jane, SM			Inositol- and folate-resistant neural tube defects in mice lacking the epithelial-specific factor Grhl-3	NATURE MEDICINE			English	Article							CURLY-TAIL MOUSE; DEVELOPMENTAL TRANSCRIPTION FACTORS; CELL-PROLIFERATION; CHICK-EMBRYO; SPINA-BIFIDA; BMP ACTIVITY; FOLIC-ACID; DROSOPHILA; MUTANT; GRAINYHEAD	The neural tube defects (NTDs) spina bifida and anencephaly are widely prevalent severe birth defects. The mouse mutant curly tail (ct/ ct) has served as a model of NTDs for 50 years, even though the responsible genetic defect remained unrecognized. Here we show by gene targeting, mapping and genetic complementation studies that a mouse homolog of the Drosophila grainyhead (grh) gene, grainyhead- like- 3 (Grhl3), is a compelling candidate for the gene underlying the curly tail phenotype. The NTDs in Grhl3- null mice are more severe than those in the curly tail strain, as the Grhl3 alleles in ct/ ct mice are hypomorphic. Spina bifida in ct/ ct mice is folate resistant, but its incidence can be markedly reduced by maternal inositol supplementation periconceptually. The NTDs in Grhl3 (-/-) embryos are also folate resistant, but unlike those in ct/ ct mice, they are resistant to inositol. These findings suggest that residual Grhl3 expression in ct/ ct mice may be required for inositol rescue of folate- resistant NTDs.	Rotary Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Div Dev & Neurobiol, Parkville, Vic 3050, Australia; St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38101 USA	Walter & Eliza Hall Institute; St Jude Children's Research Hospital	Jane, SM (corresponding author), Rotary Bone Marrow Res Labs, Royal Melbourne Hosp Post Off,Grattan St, Parkville, Vic 3050, Australia.	jane@wehi.edu.au	Voss, Anne K/F-5110-2013; Wilanowski, Tomasz/R-4077-2016; Jane, Stephen/D-6659-2011; Parekh, Vishwas/B-7162-2014	Voss, Anne K/0000-0002-3853-9381; Parekh, Vishwas/0000-0003-3131-2958; Jane, Stephen Marsden/0000-0002-1045-0481; Thomas, Tim/0000-0002-7623-8344; Wilanowski, Tomasz/0000-0003-4447-8164	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTARDI LD, 1993, P NATL ACAD SCI USA, V90, P10563, DOI 10.1073/pnas.90.22.10563; Barth KA, 1999, DEVELOPMENT, V126, P4977; BEIER DR, 1995, MAMM GENOME, V6, P269, DOI 10.1007/BF00352414; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; BROOK FA, 1991, DEVELOPMENT, V113, P671; CARTER CO, 1974, DEV MED CHILD NEUROL, V16, P3; CHEN WH, 1995, DEVELOPMENT, V121, P681; Colas JF, 2001, DEV DYNAM, V221, P117, DOI 10.1002/dvdy.1144; COPP AJ, 1988, DEVELOPMENT, V104, P285; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; Greene NDE, 1997, NAT MED, V3, P60, DOI 10.1038/nm0197-60; GRUNEBERG H, 1954, J GENET, V52, P52, DOI 10.1007/BF02981490; Hackett DA, 1997, DEV DYNAM, V210, P397, DOI 10.1002/(SICI)1097-0177(199712)210:4<397::AID-AJA4>3.0.CO;2-B; Harris MJ, 2001, TERATOLOGY, V63, P165, DOI 10.1002/tera.1030; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; Jacinto A, 2002, DEV CELL, V3, P9, DOI 10.1016/S1534-5807(02)00208-3; Juriloff DM, 2000, HUM MOL GENET, V9, P993, DOI 10.1093/hmg/9.6.993; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; Lawson T, 2001, ANAT RECORD, V262, P153, DOI 10.1002/1097-0185(20010201)262:2<153::AID-AR1021>3.0.CO;2-W; LETTS VA, 1995, GENOMICS, V29, P719, DOI 10.1006/geno.1995.9946; Liaw GJ, 1995, GENE DEV, V9, P3163, DOI 10.1101/gad.9.24.3163; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; Martin P, 2002, CURR OPIN CELL BIOL, V14, P569, DOI 10.1016/S0955-0674(02)00369-1; MCBRIDE ML, 1979, AM J MED GENET, V3, P377, DOI 10.1002/ajmg.1320030409; MOURY JD, 1995, DEV DYNAM, V204, P232; NEUMANN PE, 1994, NAT GENET, V6, P357, DOI 10.1038/ng0494-357; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Peeters MCE, 1997, ANAT EMBRYOL, V195, P259, DOI 10.1007/s004290050045; Peeters MCE, 1998, DEV DYNAM, V211, P382, DOI 10.1002/(SICI)1097-0177(199804)211:4<382::AID-AJA9>3.3.CO;2-S; Ray JG, 2002, LANCET, V360, P2047, DOI 10.1016/S0140-6736(02)11994-5; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SELLER MJ, 1994, CIBA F SYMP, V181, P161; SELLER MJ, 1987, J CRAN GENET DEV BIO, V7, P321; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Streit A, 1999, MECH DEVELOP, V82, P51, DOI 10.1016/S0925-4773(99)00013-1; Ting SB, 2003, BIOCHEM J, V370, P953, DOI 10.1042/BJ20021476; Uv AE, 1997, MOL CELL BIOL, V17, P6727, DOI 10.1128/MCB.17.11.6727; van Straaten HWM, 2001, ANAT EMBRYOL, V203, P225, DOI 10.1007/s004290100169; Venkatesan K, 2003, NUCLEIC ACIDS RES, V31, P4304, DOI 10.1093/nar/gkg644; Wilanowski T, 2002, MECH DEVELOP, V114, P37, DOI 10.1016/S0925-4773(02)00046-1; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Wilson SI, 2001, NATURE, V411, P325, DOI 10.1038/35077115	46	146	147	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1513	1519		10.1038/nm961	http://dx.doi.org/10.1038/nm961			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14608380				2022-12-27	WOS:000186845400035
J	Di Pasquale, G; Davidson, BL; Stein, CS; Martins, IS; Scudiero, D; Monks, A; Chiorini, JA				Di Pasquale, G; Davidson, BL; Stein, CS; Martins, IS; Scudiero, D; Monks, A; Chiorini, JA			Identification of PDGFR as a receptor for AAV-5 transduction	NATURE MEDICINE			English	Article							ADENOASSOCIATED VIRUS TYPE-2; GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; TUMOR-CELL-LINES; GENE-TRANSFER; SIALIC-ACID; VECTORS; EXPRESSION; INTERNALIZATION; BINDING	Understanding the process of vector transduction has important implications for the application and optimal use of a vector system for human gene therapy. Recent studies with vectors based on adeno-associated virus type 5 (AAV-5) have shown utility, of this vector system in the lung, central nervous system, muscle and eye. To understand the natural tropism of this virus and to identify proteins necessary for AAV-5 transduction, we characterized 43 cell lines as permissive or nonpermissive for AAV-5 transduction and compared the gene expression profiles derived from cDNA microarray analyses of those cell lines. A statistically significant correlation was observed between expression of the platelet-derived growth factor receptor (PDGFR-alpha-polypeptide) and AAV-5 transduction. Subsequent experiments confirmed the role of PDGFR-alpha and PDGFR-beta as receptors for AAV-5. The tropism of AAV-5 in vivo also correlated with the expression pattern of PDGFR-alpha.	Natl Inst Dent & Craniofacial Res, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; SAIC Frederick, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Iowa; University of Iowa; University of Iowa; Science Applications International Corporation (SAIC); SAIC-Frederick	Chiorini, JA (corresponding author), Natl Inst Dent & Craniofacial Res, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA.							Alisky JM, 2000, NEUROREPORT, V11, P2669, DOI 10.1097/00001756-200008210-00013; Bantel-Schaal U, 2002, J VIROL, V76, P2340, DOI 10.1128/JVI.76.5.2340-2349.2002; Bantel-Schaal U, 1999, J VIROL, V73, P939, DOI 10.1128/JVI.73.2.939-947.1999; Chiorini JA, 1997, J VIROL, V71, P6823, DOI 10.1128/JVI.71.9.6823-6833.1997; Chiorini JA, 1999, J VIROL, V73, P1309, DOI 10.1128/JVI.73.2.1309-1319.1999; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; Davidson BL, 2000, P NATL ACAD SCI USA, V97, P3428, DOI 10.1073/pnas.050581197; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Fessler MB, 2002, J BIOL CHEM, V277, P31291, DOI 10.1074/jbc.M200755200; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; GEORGFRIES B, 1984, VIROLOGY, V134, P64, DOI 10.1016/0042-6822(84)90272-1; Hildinger M, 2001, J VIROL, V75, P6199, DOI 10.1128/JVI.75.13.6199-6203.2001; HOSANG M, 1988, J RECEPTOR RES, V8, P455, DOI 10.3109/10799898809049004; Kaludov N, 2001, J VIROL, V75, P6884, DOI 10.1128/JVI.75.15.6884-6893.2001; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Koo HM, 1996, CANCER RES, V56, P5211; LEE JS, 1994, MOL PHARMACOL, V46, P627; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; Mizukami H, 1996, VIROLOGY, V217, P124, DOI 10.1006/viro.1996.0099; Muramatsu S, 1996, VIROLOGY, V221, P208, DOI 10.1006/viro.1996.0367; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; Oumesmar BN, 1997, J NEUROSCI, V17, P125, DOI 10.1523/JNEUROSCI.17-01-00125.1997; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rutledge EA, 1998, J VIROL, V72, P309, DOI 10.1128/JVI.72.1.309-319.1998; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Walters RW, 2001, J BIOL CHEM, V276, P20610, DOI 10.1074/jbc.M101559200; Wang YZ, 2000, J BIOL CHEM, V275, P22550, DOI 10.1074/jbc.M909785199; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILLIAMS LT, 1989, CLIN RES, V37, P564; Xiao WD, 1999, J VIROL, V73, P3994, DOI 10.1128/JVI.73.5.3994-4003.1999; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zabner J, 2000, J VIROL, V74, P3852, DOI 10.1128/JVI.74.8.3852-3858.2000; Zaharevitz DW, 2002, J MOL GRAPH MODEL, V20, P297, DOI 10.1016/S1093-3263(01)00126-7	40	263	279	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1306	1312		10.1038/nm929	http://dx.doi.org/10.1038/nm929			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502277	Green Published			2022-12-27	WOS:000185669700043
J	Goldstein, JL				Goldstein, JL			It's a grand year for celebrating science - Foreword	NATURE MEDICINE			English	Editorial Material																			0	1	1	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1237	1238		10.1038/nm937	http://dx.doi.org/10.1038/nm937			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14520362				2022-12-27	WOS:000185669700020
J	Roeder, RG				Roeder, RG			The eukaryotic transcriptional machinery: complexities and mechanisms unforeseen	NATURE MEDICINE			English	Editorial Material							RNA-POLYMERASE-II; ACCURATE TRANSCRIPTION; COACTIVATOR COMPLEX; GENE-TRANSCRIPTION; MULTIPLE FACTORS; DNA; INITIATION; ACTIVATION; PROMOTER; MEDIATOR		Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Roeder, RG (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.							BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; NG SY, 1979, P NATL ACAD SCI USA, V76, P136, DOI 10.1073/pnas.76.1.136; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; PARKER CS, 1977, P NATL ACAD SCI USA, V74, P44, DOI 10.1073/pnas.74.1.44; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; ROEDER RG, 1969, NATURE, V224, P234, DOI 10.1038/224234a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROEDER RG, 1970, P NATL ACAD SCI USA, V65, P675, DOI 10.1073/pnas.65.3.675; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SKLAR VEF, 1975, P NATL ACAD SCI USA, V72, P348, DOI 10.1073/pnas.72.1.348; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WEIL PA, 1979, CELL, V18, P469; WEINMANN R, 1974, P NATL ACAD SCI USA, V71, P1790, DOI 10.1073/pnas.71.5.1790; WEINMANN R, 1974, P NATL ACAD SCI USA, V71, P3426, DOI 10.1073/pnas.71.9.3426; WIDNELL CC, 1966, BIOCHIM BIOPHYS ACTA, V3, P478; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	31	50	51	0	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1239	1244		10.1038/nm938	http://dx.doi.org/10.1038/nm938			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14520363				2022-12-27	WOS:000185669700021
J	Mongkolsapaya, J; Dejnirattisai, W; Xu, XN; Vasanawathana, S; Tangthawornchaikul, N; Chairunsri, A; Sawasdivorn, S; Duangchinda, T; Dong, T; Rowland-Jones, S; Yenchitsomanus, PT; McMichael, A; Malasit, P; Screaton, G				Mongkolsapaya, J; Dejnirattisai, W; Xu, XN; Vasanawathana, S; Tangthawornchaikul, N; Chairunsri, A; Sawasdivorn, S; Duangchinda, T; Dong, T; Rowland-Jones, S; Yenchitsomanus, PT; McMichael, A; Malasit, P; Screaton, G			Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever	NATURE MEDICINE			English	Article							CYTOTOXIC T-LYMPHOCYTES; HETEROLOGOUS ANTIVIRAL IMMUNITY; VIRUS-INFECTION; CHORIOMENINGITIS VIRUS; DISEASE SEVERITY; PERSISTENT VIRUS; CELLS; RESPONSES; ANTIBODY; IMMUNOPATHOGENESIS	Dengue virus presents a growing threat to public health in the developing world. Four major serotypes of dengue virus have been characterized, and epidemiological evidence shows that dengue hemorrhagic fever (DHF), the more serious manifestation of the disease, occurs more frequently upon reinfection with a second serotype. We have studied dengue virus-specific T-cell responses in Thai children. During acute infection, few dengue-responsive CD8(+) T cells were recovered; most of those present showed an activated phenotype and were undergoing programmed cell death. Many dengue-specific T cells were of low affinity for the infecting virus and showed higher affinity for other, probably previously encountered strains. Profound T-cell activation and death may contribute to the systemic disturbances leading to DHF, and original antigenic sin in the T-cell responses may suppress or delay viral elimination, leading to higher viral loads and increased immunopathology.	John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England; Mahidol Univ, Siriraj Hosp, Fac Med, Med Mol Biol Unit, Bangkok 10700, Thailand; Minist Publ Hlth, Khon Kaen Hosp, Dept Pediat, Khon Kaen 40000, Thailand; Natl Sci & Technol Dev Agcy, Natl Ctr Genet Engn & Biotechnol, Med Biotechnol Unit, Pathum Thani 12120, Thailand; John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; Queen Sirikit Natl Inst Child Hlth, Bangkok 10400, Thailand	University of Oxford; Mahidol University; Ministry of Public Health - Thailand; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); University of Oxford	Screaton, G (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.			Dong, Tao/0000-0003-3545-3758; Screaton, Gavin/0000-0002-3549-4309				Aichele P, 1997, IMMUNITY, V6, P519, DOI 10.1016/S1074-7613(00)80340-4; AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Chandanayingyong D, 1997, HUM IMMUNOL, V53, P174, DOI 10.1016/S0198-8859(96)00284-4; Chen HD, 2001, NAT IMMUNOL, V2, P1067, DOI 10.1038/ni727; CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561; Combadiere B, 1998, J EXP MED, V187, P349, DOI 10.1084/jem.187.3.349; Davenport MP, 2002, J IMMUNOL, V168, P3309, DOI 10.4049/jimmunol.168.7.3309; DESTGROTH SF, 1966, J EXP MED, V124, P331, DOI 10.1084/jem.124.3.331; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Guzman MG, 2000, AM J EPIDEMIOL, V152, P793, DOI 10.1093/aje/152.9.793; HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154; Halstead SB, 2002, EMERG INFECT DIS, V8, P1474, DOI 10.3201/eid0812.020170; HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0; HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; Klenerman P, 1997, IMMUNOL REV, V159, P5, DOI 10.1111/j.1600-065X.1997.tb01003.x; Klenerman P, 1998, NATURE, V394, P482, DOI 10.1038/28860; KRAUSA P, 1995, EUR J IMMUNOGENET, V22, P283, DOI 10.1111/j.1744-313X.1995.tb00243.x; Kurane I, 1994, Curr Top Microbiol Immunol, V189, P93; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Libraty DH, 2001, J VIROL, V75, P3501, DOI 10.1128/JVI.75.8.3501-3508.2001; Mathew A, 1996, J CLIN INVEST, V98, P1684, DOI 10.1172/JCI118964; Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656; RUSSELL PK, 1967, J IMMUNOL, V99, P285; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705; Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215; Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907; VonHerrath MG, 1997, VIROLOGY, V229, P349, DOI 10.1006/viro.1997.8442; VORRIDAM V, 1997, DENGUE DENGUE HEMORR, P313; WHO, 1997, DENG HAEM FEV DIAGN; *WHO, 2002, 117 WHO; Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553; Yenchitsomanus Pa-Thai, 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P228; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zivna I, 2002, J IMMUNOL, V168, P5959, DOI 10.4049/jimmunol.168.11.5959	39	605	629	0	42	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2003	9	7					921	927		10.1038/nm887	http://dx.doi.org/10.1038/nm887			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12808447				2022-12-27	WOS:000183979300034
J	Scaffidi, P; Misteli, T				Scaffidi, P; Misteli, T			(R)eversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome	NATURE MEDICINE			English	Article							A-TYPE LAMINS; ANTISENSE OLIGOMERS; MORPHOLINO; MUTATIONS; MISREGULATION; DEFECTS	Hutchinson-Gilford progeria syndrome (HGPS) is a childhood premature aging disease caused by a spontaneous point mutation in lamin A ( encoded by LMNA), one of the major architectural elements of the mammalian cell nucleus(1-4). The HGPS mutation activates an aberrant cryptic splice site in LMNA pre-mRNA, leading to synthesis of a truncated lamin A protein and concomitant reduction in wild-type lamin A(3,4). Fibroblasts from individuals with HGPS have severe morphological abnormalities in nuclear envelope structure. Here we show that the cellular disease phenotype is reversible in cells from individuals with HGPS. Introduction of wild-type lamin A protein does not rescue the cellular disease symptoms. The mutant LMNA mRNA and lamin A protein can be efficiently eliminated by correction of the aberrant splicing event using a modified oligonucleotide targeted to the activated cryptic splice site. Upon splicing correction, HGPS fibroblasts assume normal nuclear morphology, the aberrant nuclear distribution and cellular levels of lamina-associated proteins are rescued, defects in heterochromatin-specific histone modifications are corrected and proper expression of several misregulated genes is reestablished. Our results establish proof of principle for the correction of the premature aging phenotype in individuals with HGPS.	NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Misteli, T (corresponding author), NCI, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	mistelit@mail.nih.gov	Scaffidi, Paola/GRS-9019-2022	Scaffidi, Paola/0000-0002-3642-4193	NCI NIH HHS [Z01 BC010309-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010309, ZIABC010309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Csoka AB, 2004, AGING CELL, V3, P235, DOI 10.1111/j.1474-9728.2004.00105.x; Csoka AB, 2004, J MED GENET, V41, P304, DOI 10.1136/jmg.2003.015651; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; DEBUSK FL, 1972, J PEDIATR-US, V80, P697, DOI 10.1016/S0022-3476(72)80229-4; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; Gebski BL, 2003, HUM MOL GENET, V12, P1801, DOI 10.1093/hmg/ddg196; Giles RV, 1999, ANTISENSE NUCLEIC A, V9, P213, DOI 10.1089/oli.1.1999.9.213; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Holt I, 2003, J CELL SCI, V116, P3027, DOI 10.1242/jcs.00599; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson BR, 2004, P NATL ACAD SCI USA, V101, P9677, DOI 10.1073/pnas.0403250101; LIN F, 1993, J BIOL CHEM, V268, P16321; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Moulton HM, 2004, BIOCONJUGATE CHEM, V15, P290, DOI 10.1021/bc034221g; Mounkes LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631; Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63; Uitto Jouni, 2002, Trends in Endocrinology and Metabolism, V13, P140, DOI 10.1016/S1043-2760(02)00595-7; Vaughan OA, 2001, J CELL SCI, V114, P2577; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983	22	420	445	3	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					440	445		10.1038/nm1204	http://dx.doi.org/10.1038/nm1204			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15750600	Green Accepted			2022-12-27	WOS:000228180500037
J	Harada, M; Qin, YJ; Takano, H; Minamino, T; Zou, YZ; Toko, H; Ohtsuka, M; Matsuura, K; Sano, M; Nishi, J; Iwanaga, K; Akazawa, H; Kunieda, T; Zhu, WD; Hasegawa, H; Kunisada, K; Nagai, T; Nakaya, H; Yamauchi-Takihara, K; Komuro, I				Harada, M; Qin, YJ; Takano, H; Minamino, T; Zou, YZ; Toko, H; Ohtsuka, M; Matsuura, K; Sano, M; Nishi, J; Iwanaga, K; Akazawa, H; Kunieda, T; Zhu, WD; Hasegawa, H; Kunisada, K; Nagai, T; Nakaya, H; Yamauchi-Takihara, K; Komuro, I			G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; ISCHEMIC-MYOCARDIUM; SIGNAL TRANSDUCER; ANNEXIN-V; REGENERATION; PROTEINS; SURVIVAL; RECEPTOR; NEOVASCULARIZATION	Granulocyte colony-stimulating factor (G-CSF) was reported to induce myocardial regeneration by promoting mobilization of bone marrow stem cells to the injured heart after myocardial infarction, but the precise mechanisms of the beneficial effects of G-CSF are not fully understood. Here we show that G-CSF acts directly on cardiomyocytes and promotes their survival after myocardial infarction. G-CSF receptor was expressed on cardiomyocytes and G-CSF activated the Jak/Stat pathway in cardiomyocytes. The G-CSF treatment did not affect initial infarct size at 3 d but improved cardiac function as early as 1 week after myocardial infarction. Moreover, the beneficial effects of G-CSF on cardiac function were reduced by delayed start of the treatment. G-CSF induced antiapoptotic proteins and inhibited apoptotic death of cardiomyocytes in the infarcted hearts. G-CSF also reduced apoptosis of endothelial cells and increased vascularization in the infarcted hearts, further protecting against ischemic injury. All these effects of G-CSF on infarcted hearts were abolished by overexpression of a dominant-negative mutant Stat3 protein in cardiomyocytes. These results suggest that G-CSF promotes survival of cardiac myocytes and prevents left ventricular remodeling after myocardial infarction through the functional communication between cardiomyocytes and noncardiomyocytes.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Osaka Univ, Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol, Chuo Ku, Chiba 2608670, Japan	Chiba University; Osaka University; Chiba University	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp	Minamino, Tohru/P-8145-2018	Minamino, Tohru/0000-0003-1627-6151; Akazawa, Hiroshi/0000-0002-3574-9607				Aarts LHJ, 2004, BLOOD, V103, P571, DOI 10.1182/blood-2003-07-2250; Adachia Y, 2004, J MOL CELL CARDIOL, V36, P707, DOI 10.1016/j.yjmcc.2004.03.005; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BERLINER N, 1995, BLOOD, V85, P799, DOI 10.1182/blood.V85.3.799.bloodjournal853799; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; DEMETRI GD, 1991, BLOOD, V78, P2791; Dumont EAWJ, 2000, CIRCULATION, V102, P1564, DOI 10.1161/01.CIR.102.13.1564; El-Adawi H, 2003, CARDIOVASC RES, V57, P129, DOI 10.1016/S0008-6363(02)00614-4; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Ikeda K, 2000, LIFE SCI, V67, P2991, DOI 10.1016/S0024-3205(00)00879-1; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood-2004-04-1488; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200; Minatoguchi S, 2004, CIRCULATION, V109, P2572, DOI 10.1161/01.CIR.0000129770.93985.3E; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Norol F, 2003, BLOOD, V102, P4361, DOI 10.1182/blood-2003-03-0685; Ohtsuka M, 2004, FASEB J, V18, P851, DOI 10.1096/fj.03-0637fje; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; van Heerde WL, 2000, CARDIOVASC RES, V45, P549, DOI 10.1016/S0008-6363(99)00396-X; Zou YZ, 2003, CIRCULATION, V108, P748, DOI 10.1161/01.CIR.0000081773.76337.44; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	29	452	483	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2005	11	3					305	311		10.1038/nm1199	http://dx.doi.org/10.1038/nm1199			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905BA	15723072				2022-12-27	WOS:000227541300026
J	Jonker, JW; Merino, G; Musters, S; van Herwaarden, AE; Bolscher, E; Wagenaar, E; Mesman, E; Dale, TC; Schinkel, AH				Jonker, JW; Merino, G; Musters, S; van Herwaarden, AE; Bolscher, E; Wagenaar, E; Mesman, E; Dale, TC; Schinkel, AH			The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk	NATURE MEDICINE			English	Article							DIETARY CARCINOGEN; FOOD MUTAGEN; TRANSPORT; CELLS; CIMETIDINE; EXPOSURE; HIV-1; RATS	Contamination of milk with drugs, pesticides and other xenotoxins can pose a major health risk to breast-fed infants and dairy consumers. Here we show that the multidrug transporter BCRP (encoded by ABCG2) is strongly induced in the mammary gland of mice, cows and humans during lactation and that it is responsible for the active secretion of clinically and toxicologically important substrates such as the dietary carcinogen PhIP, the anticancer drug topotecan and the antiulcerative cimetidine into mouse milk.	Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Univ Wales Coll Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Netherlands Cancer Institute; Netherlands Cancer Institute; Cardiff University	Schinkel, AH (corresponding author), Netherlands Canc Inst, Div Expt Therapy, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.schinkel@nki.nl	Dale, Trevor C/D-3749-2009; Herwaarden, A.E./L-4369-2015; Jonker, Johan W./ABE-6853-2020; Merino, Gracia/H-8811-2015	Dale, Trevor C/0000-0002-4880-9963; Jonker, Johan W./0000-0002-3919-5437; Merino, Gracia/0000-0002-7620-3475				Alcorn J, 2002, ANTIMICROB AGENTS CH, V46, P1831, DOI 10.1128/AAC.46.6.1831-1836.2002; ANDERSON PO, 1991, CLIN PHARMACY, V10, P594; Boelaert JR, 2001, AIDS, V15, P2205, DOI 10.1097/00002030-200111090-00024; Chen ZS, 2003, CANCER RES, V63, P4048; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; JAGERSTAD IM, 1994, CARCINOGENESIS, V15, P2479, DOI 10.1093/carcin/15.11.2479; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Martin FL, 2000, CARCINOGENESIS, V21, P799, DOI 10.1093/carcin/21.4.799; McNamara PJ, 1996, J PHARMACOL EXP THER, V277, P1615; Paulsen JE, 1999, CARCINOGENESIS, V20, P1277, DOI 10.1093/carcin/20.7.1277; Pavek P, 2005, J PHARMACOL EXP THER, V312, P144, DOI 10.1124/jpet.104.073916; Shennan DB, 2000, PHYSIOL REV, V80, P925, DOI 10.1152/physrev.2000.80.3.925; Suzuki M, 2003, J BIOL CHEM, V278, P22644, DOI 10.1074/jbc.M212399200; van Herwaarden AE, 2003, CANCER RES, V63, P6447; Wang X, 2003, MOL PHARMACOL, V63, P65, DOI 10.1124/mol.63.1.65	15	326	336	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					127	129		10.1038/nm1186	http://dx.doi.org/10.1038/nm1186			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685169				2022-12-27	WOS:000226797300018
J	Bitko, V; Musiyenko, A; Shulyayeva, O; Barik, S				Bitko, V; Musiyenko, A; Shulyayeva, O; Barik, S			Inhibition of respiratory viruses by nasally administered siRNA	NATURE MEDICINE			English	Article							SYNCYTIAL VIRUS; RNA INTERFERENCE; F-PROTEIN; GENE-EXPRESSION; INFECTED MICE; DISEASE; TYPE-3; FUSION; MODEL; ACTIN	Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens of paramount medical significance that exert high mortality. At present, there is no reliable vaccine or antiviral drug against either virus. Using an RNA interference (RNAi) approach, we show that individual as well as joint infection by RSV and PIV can be specifically prevented and inhibited by short interfering RNAs (siRNAs), instilled intranasally in the mouse, with or without transfection reagents. The degree of protection matched the antiviral activity of the siRNA in cell culture, allowing an avenue for quick screening of an efficacious siRNA. When targeting both viruses in a joint infection, excess of one siRNA moderated the inhibitory effect of the other, suggesting competition for the RNAi machinery. Our results suggest that, if properly designed, low dosages of inhaled siRNA might offer a fast, potent and easily administrable antiviral regimen against respiratory viral diseases in humans.	Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, Mobile, AL 36688 USA	University of South Alabama	Barik, S (corresponding author), Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, MSB 2370,307 Univ Blvd, Mobile, AL 36688 USA.	sbarik@jaguar1.usouthal.edu			NATIONAL EYE INSTITUTE [R01EY013826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI049682] Funding Source: NIH RePORTER; NEI NIH HHS [EY013826] Funding Source: Medline; NIAID NIH HHS [AI049682] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barik S, 2004, VIRUS RES, V102, P27, DOI 10.1016/j.virusres.2004.01.012; Bernhard W, 2001, AM J RESP CELL MOL, V25, P725, DOI 10.1165/ajrcmb.25.6.4616; Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Burke E, 2000, J VIROL, V74, P669, DOI 10.1128/JVI.74.2.669-675.2000; Burke E, 1998, VIROLOGY, V252, P137, DOI 10.1006/viro.1998.9471; Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008; Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004; Durbin AP, 2000, VACCINE, V18, P2462, DOI 10.1016/S0264-410X(99)00575-7; Durbin JE, 2002, J IMMUNOL, V168, P2944, DOI 10.4049/jimmunol.168.6.2944; Easton AJ, 2004, CLIN MICROBIOL REV, V17, P390, DOI 10.1128/CMR.17.2.390-412.2004; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; Gupta S, 1998, J VIROL, V72, P2655, DOI 10.1128/JVI.72.4.2655-2662.1998; Haeberle HA, 2001, J VIROL, V75, P878, DOI 10.1128/JVI.75.2.878-890.2001; Haller AA, 2003, J GEN VIROL, V84, P2153, DOI 10.1099/vir.0.19079-0; Haynes LM, 2003, J VIROL, V77, P9831, DOI 10.1128/JVI.77.18.9831-9844.2003; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Khvorova A, 2003, CELL, V115, P505, DOI 10.1016/S0092-8674(03)00893-6; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Maggon K, 2004, REV MED VIROL, V14, P149, DOI 10.1002/rmv.423; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; Morton CJ, 2003, VIROLOGY, V311, P275, DOI 10.1016/S0042-6822(03)00115-6; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Openshaw PJM, 2002, RESPIR RES, V3, DOI 10.1186/rr184; Peebles RS, 2003, VIRAL IMMUNOL, V16, P25, DOI 10.1089/088282403763635429; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781; Ramaswamy M, 2004, AM J RESP CELL MOL, V30, P893, DOI 10.1165/rcmb.2003-0410OC; Razinkov V, 2002, ANTIVIR RES, V55, P189, DOI 10.1016/S0166-3542(02)00050-5; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Schlender J, 2000, J VIROL, V74, P8234, DOI 10.1128/JVI.74.18.8234-8242.2000; Schmidt AC, 2001, J VIROL, V75, P4594, DOI 10.1128/JVI.75.10.4594-4603.2001; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Sullender WM, 2000, CLIN MICROBIOL REV, V13, P1, DOI 10.1128/CMR.13.1.1-15.2000; Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101; UEBA O, 1978, ACTA MED OKAYAMA, V32, P265; van Schaik SM, 1998, J INFECT DIS, V177, P269, DOI 10.1086/514208; VOLOVITZ B, 1988, PEDIATR RES, V24, P504, DOI 10.1203/00006450-198810000-00018; Welliver RC, 2003, J INFECT DIS, V187, P1773, DOI 10.1086/375277	45	562	704	2	56	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2005	11	1					50	55		10.1038/nm1164	http://dx.doi.org/10.1038/nm1164			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619632				2022-12-27	WOS:000226124900032
J	Cheng, KW; Lahad, JP; Kuo, WL; Lapuk, A; Yamada, K; Auersperg, N; Liu, JS; Smith-McCune, K; Lu, KH; Fishman, D; Gray, JW; Mills, GB				Cheng, KW; Lahad, JP; Kuo, WL; Lapuk, A; Yamada, K; Auersperg, N; Liu, JS; Smith-McCune, K; Lu, KH; Fishman, D; Gray, JW; Mills, GB			The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers	NATURE MEDICINE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; GENE-EXPRESSION PATTERNS; PUTATIVE ONCOGENE; PROTEIN; IMBALANCES; PATHWAY; MARKERS; KIDNEY; TUMORS; BAX	High-density array comparative genomic hybridization (CGH)(1) showed amplification of chromosome 1q22 centered on the RAB25 small GTPase(2), which is implicated in apical vesicle trafficking(3), in approximately half of ovarian and breast cancers. RAB25 mRNA levels were selectively increased in stage III and IV serous epithelial ovarian cancers compared to other genes within the amplified region, implicating RAB25 as a driving event in the development of the amplicon. Increased DNA copy number or RNA level of RAB25 was associated with markedly decreased disease-free survival or overall survival in ovarian and breast cancers, respectively. Forced expression of RAB25 markedly increased anchorage-dependent and anchorage-independent cell proliferation, prevented apoptosis and anoikis, including that induced by chemotherapy, and increased aggressiveness of cancer cells in vivo. The inhibition of apoptosis was associated with a decrease in expression of the proapoptotic molecules, BAK and BAX, and activation of the antiapoptotic phosphatidylinositol 3 kinase (PI3K) and AKT pathway, providing potential mechanisms for the effects of RAB25 on tumor aggressiveness. Overall, these studies implicate RAB25, and thus the RAB family of small G proteins, in aggressiveness of epithelial cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77054 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V6H 3V5, Canada; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94143 USA; NYU, Sch Med, Dept Obstet & Gynecol, New York, NY 10016 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of British Columbia; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco; New York University	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77054 USA.	gmills@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA064602, P30CA016672, P50CA083639] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA83639, P30 CA16672-28, P01 CA64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Berchuck A, 1997, BIOCHEM PHARMACOL, V54, P541, DOI 10.1016/S0006-2952(97)00061-0; Calvo A, 2002, CANCER RES, V62, P5325; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; Fukushi Y, 2001, EUR J GYNAECOL ONCOL, V22, P23; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kiechle M, 2001, CANCER, V91, P534, DOI 10.1002/1097-0142(20010201)91:3<534::AID-CNCR1031>3.3.CO;2-K; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; Lu YJ, 2002, LANCET, V360, P385, DOI 10.1016/S0140-6736(02)09596-X; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Milhavet O, 2003, PHARMACOL REV, V55, P629, DOI 10.1124/pr.55.4.1; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Mor O, 2003, ONCOGENE, V22, P7702, DOI 10.1038/sj.onc.1207039; Patael-Karasik Y, 2000, CANCER GENET CYTOGEN, V121, P26, DOI 10.1016/S0165-4608(00)00224-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Suzuki S, 2000, CANCER RES, V60, P5382; Wang WG, 2002, CANCER RES, V62, P6278; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zudaire I, 2002, HISTOPATHOLOGY, V40, P547, DOI 10.1046/j.1365-2559.2002.01413.x	29	368	406	2	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2004	10	11					1251	1256		10.1038/nm1125	http://dx.doi.org/10.1038/nm1125			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	866PR	15502842				2022-12-27	WOS:000224785900049
J	Hunter, CJ; Dejam, A; Blood, AB; Shields, H; Kim-Shapiro, D; Machado, RF; Tarekegn, S; Mulla, N; Hopper, AO; Schechter, AN; Power, GG; Gladwin, MT				Hunter, CJ; Dejam, A; Blood, AB; Shields, H; Kim-Shapiro, D; Machado, RF; Tarekegn, S; Mulla, N; Hopper, AO; Schechter, AN; Power, GG; Gladwin, MT			Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator	NATURE MEDICINE			English	Article							S-NITROSOHEMOGLOBIN; OXIDE THERAPY; DEOXYHEMOGLOBIN; HYPERTENSION; NITROSOTHIOLS; MECHANISM; SIZE; IRON; COST	The blood anion nitrite contributes to hypoxic vasodilation through a heme-based, nitric oxide (NO)-generating reaction with deoxyhemoglobin and potentially other heme proteins(1). We hypothesized that this biochemical reaction could be harnessed for the treatment of neonatal pulmonary hypertension, an NO-deficient state characterized by pulmonary vasoconstriction, right-to-left shunt pathophysiology and systemic hypoxemia(2). To test this, we delivered inhaled sodium nitrite by aerosol to newborn lambs with hypoxic and normoxic pulmonary hypertension. Inhaled nitrite elicited a rapid and sustained reduction (similar to 65%) in hypoxia-induced pulmonary hypertension, with a magnitude approaching that of the effects of 20 p. p. m. NO gas inhalation. This reduction was associated with the immediate appearance of NO in expiratory gas. Pulmonary vasodilation elicited by aerosolized nitrite was deoxyhemoglobin- and pH-dependent and was associated with increased blood levels of iron-nitrosyl-hemoglobin. Notably, from a therapeutic standpoint, short-term delivery of nitrite dissolved in saline through nebulization produced selective, sustained pulmonary vasodilation with no clinically significant increase in blood methemoglobin levels. These data support the concept that nitrite is a vasodilator acting through conversion to NO, a process coupled to hemoglobin deoxygenation and protonation, and evince a new, simple and inexpensive potential therapy for neonatal pulmonary hypertension.	NHLBI, Dept Crit Care Med, Ctr Clin, NIH, Bethesda, MD 20892 USA; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; Loma Linda Univ, Sch Med, Dept Physiol, Ctr Perinatal Biol, Loma Linda, CA 92350 USA; Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Loma Linda University; Wake Forest University; Loma Linda University	Gladwin, MT (corresponding author), NHLBI, Dept Crit Care Med, Ctr Clin, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	gpower@som.llu.edu; mgladwin@nih.gov	Hunter, Christian/N-1397-2017; Kim-Shapiro, Daniel/HGA-2682-2022; Blood, Arlin/AAG-8897-2020	Hunter, Christian/0000-0003-4744-463X; Blood, Arlin/0000-0002-4803-5021; Machado, Roberto/0000-0002-3722-5954; Schechter, Alan N/0000-0002-5235-9408	NHLBI NIH HHS [HL58091, R01 HL058091, HL654941] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058091, R29HL058091, R37HL058091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025093] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Clark RH, 2000, NEW ENGL J MED, V342, P469, DOI 10.1056/NEJM200002173420704; CLAY MM, 1983, THORAX, V38, P755, DOI 10.1136/thx.38.10.755; Coates AL, 2001, CHEST, V119, P1123, DOI 10.1378/chest.119.4.1123; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; FURCHGOTT RF, 1953, J PHARMACOL EXP THER, V108, P129; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2004, J CLIN INVEST, V113, P19, DOI 10.1172/JCI200420664; HUNTER CJ, 2004, IN PRESS PEDIAT CRIT; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; KIMURA H, 1975, J BIOL CHEM, V250, P8016; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; Kinsella JP, 2002, PEDIATRICS, V109, P158, DOI 10.1542/peds.109.1.158; Kinsella JP, 2000, SEMIN PERINATOL, V24, P387, DOI 10.1053/sper.2000.20085; Lauer T, 2001, P NATL ACAD SCI USA, V98, P12814, DOI 10.1073/pnas.221381098; Martin RJ, 2003, NEW ENGL J MED, V349, P2157, DOI 10.1056/NEJMe038165; McMahon TJ, 2003, NEW ENGL J MED, V349, P403; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Pawloski JR, 2003, NEW ENGL J MED, V349, P403; Pierce CM, 2002, BRIT MED J, V325, P336, DOI 10.1136/bmj.325.7359.336; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; ROBERTS JD, 1993, CIRC RES, V72, P246, DOI 10.1161/01.RES.72.2.246; Schreiber MD, 2003, NEW ENGL J MED, V349, P2099, DOI 10.1056/NEJMoa031154; Stork E, 1997, NEW ENGL J MED, V336, P597; Subhedar NV, 2002, LANCET, V359, P1781, DOI 10.1016/S0140-6736(02)08632-4; Xu XL, 2003, P NATL ACAD SCI USA, V100, P11303, DOI 10.1073/pnas.2033883100; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	30	234	249	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1122	1127		10.1038/nm1109	http://dx.doi.org/10.1038/nm1109			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15361865				2022-12-27	WOS:000224245800044
J	Quaratino, S; Badami, E; Pang, YY; Bartok, I; Dyson, J; Kioussis, D; Londei, M; Maiuri, L				Quaratino, S; Badami, E; Pang, YY; Bartok, I; Dyson, J; Kioussis, D; Londei, M; Maiuri, L			Degenerate self-reactive human T-cell receptor causes spontaneous autoimmune disease in mice	NATURE MEDICINE			English	Article							THYROID-DISEASE; CRYSTAL-STRUCTURE; THYMIC SELECTION; RECOGNITION; HLA; EPITOPE; SUSCEPTIBILITY; EXPRESSION; CLONES; POPULATION	Thyroid autoimmune disorders comprise more than 30% of all organ-specific autoimmune diseases and are characterized by autoantibodies and infiltrating T cells. The pathologic role of infiltrating T cells is not well defined. To address this issue, we generated transgenic mice expressing a human T-cell receptor derived from the thyroid-infiltrating T cell of a patient with thyroiditis and specific for a cryptic thyroid-peroxidase epitope. Here we show that mouse major histocompatibility complex molecules sustain selection and activation of the transgenic T cells, as coexpression of histocompatibility leukocyte antigen molecules was not needed. Furthermore, the transgenic T cells had an activated phenotype in vivo, and mice spontaneously developed destructive thyroiditis with histological, clinical and hormonal signs comparable with human autoimmune hypothyroidism. These results highlight the pathogenic role of human T cells specific for cryptic self epitopes. This new 'humanized' model will provide a unique tool to investigate how human pathogenic self-reactive T cells initiate autoimmune diseases and to determine how autoimmunity can be modulated in vivo.	Univ Southampton, Canc Sci Div, Canc Res UK Oncol Unit, Southampton SO16 6YD, Hants, England; Hammersmith Hosp, Imperial Coll Sch Med, MRC, Ctr Clin Sci, London W12 0NN, England; Natl Inst Med Res, Div Mol Immunol, London NW7 1AA, England; UCL, Inst Child Hlth, London WC1N 1EH, England	University of Southampton; Imperial College London; MRC National Institute for Medical Research; University of London; University College London	Quaratino, S (corresponding author), Univ Southampton, Canc Sci Div, Canc Res UK Oncol Unit, MP824, Southampton SO16 6YD, Hants, England.	s.quaratino@soton.ac.uk		Badami, Ester/0000-0002-0154-6270				Anderton SM, 2002, NAT IMMUNOL, V3, P175, DOI 10.1038/ni756; Ban Y, 2002, CLIN ENDOCRINOL, V57, P81, DOI 10.1046/j.1365-2265.2002.01566.x; BECKS GP, 1991, MED CLIN N AM, V75, P121, DOI 10.1016/S0025-7125(16)30475-8; Boyle LH, 2001, J IMMUNOL, V167, P2619, DOI 10.4049/jimmunol.167.5.2619; Chen KM, 2003, J IMMUNOL, V171, P6236, DOI 10.4049/jimmunol.171.11.6236; Chen KM, 2002, J IMMUNOL, V169, P6530, DOI 10.4049/jimmunol.169.11.6530; Cucca F, 2001, HUM MOL GENET, V10, P2025, DOI 10.1093/hmg/10.19.2025; Dayan CM, 1996, NEW ENGL J MED, V335, P99, DOI 10.1056/NEJM199607113350206; DAYAN CM, 1991, P NATL ACAD SCI USA, V88, P7415, DOI 10.1073/pnas.88.16.7415; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; GERMAIN RN, 1985, P NATL ACAD SCI USA, V82, P2940, DOI 10.1073/pnas.82.9.2940; Ignatowicz L, 1997, IMMUNITY, V7, P179, DOI 10.1016/S1074-7613(00)80521-X; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; Kong YCM, 2003, AUTOIMMUNITY, V36, P397, DOI 10.1080/08916930310001603028; KOTANI T, 1990, CLIN EXP IMMUNOL, V80, P11; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Lacorazza HD, 2001, J IMMUNOL, V166, P3184, DOI 10.4049/jimmunol.166.5.3184; LECHLER RI, 1988, J IMMUNOL, V141, P3003; Lee KH, 2001, NAT IMMUNOL, V2, P501, DOI 10.1038/88694; LONDEI M, 1985, SCIENCE, V228, P85, DOI 10.1126/science.3871967; Madsen LS, 1999, NAT GENET, V23, P343, DOI 10.1038/15525; Maiuri L, 2000, GASTROENTEROLOGY, V119, P996, DOI 10.1053/gast.2000.18149; Maiuri L, 2003, LANCET, V362, P30, DOI 10.1016/S0140-6736(03)13803-2; Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754; McDevitt HO, 1998, CURR OPIN IMMUNOL, V10, P677, DOI 10.1016/S0952-7915(98)80088-5; Ng HP, 2004, ENDOCRINOLOGY, V145, P809, DOI 10.1210/en.2003-0656; Panciera DL, 2001, VET CLIN N AM-SMALL, V31, P935, DOI 10.1016/S0195-5616(01)50006-6; PODOLIN PL, 1993, J EXP MED, V178, P793, DOI 10.1084/jem.178.3.793; QUARATINO S, 1995, P NATL ACAD SCI USA, V92, P10398, DOI 10.1073/pnas.92.22.10398; Quaratino S, 2000, P NATL ACAD SCI USA, V97, P10911, DOI 10.1073/pnas.190204697; Quaratino S, 1996, J EXP MED, V183, P349, DOI 10.1084/jem.183.2.349; Roddis M, 2004, J IMMUNOL, V172, P155, DOI 10.4049/jimmunol.172.1.155; SALGAME P, 1991, P NATL ACAD SCI USA, V88, P2598, DOI 10.1073/pnas.88.6.2598; Siebold C, 2004, P NATL ACAD SCI USA, V101, P1999, DOI 10.1073/pnas.0308458100; Stassi G, 2002, NAT REV IMMUNOL, V2, P195, DOI 10.1038/nri750; Tyznik AJ, 2004, J EXP MED, V199, P559, DOI 10.1084/jem.20031961; Verma S, 2000, EUR J IMMUNOL, V30, P1191, DOI 10.1002/(SICI)1521-4141(200004)30:4<1191::AID-IMMU1191>3.0.CO;2-L; VINEY JL, 1993, INT IMMUNOL, V5, P1541, DOI 10.1093/intimm/5.12.1541; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Weetman AP, 2001, NAT IMMUNOL, V2, P769, DOI 10.1038/ni0901-769; WICK G, 1989, ADV IMMUNOL, V47, P433, DOI 10.1016/S0065-2776(08)60666-5; WORTSMAN J, 1987, AM J MED, V82, P207, DOI 10.1016/0002-9343(87)90057-X; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	45	50	53	1	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					920	926		10.1038/nm1092	http://dx.doi.org/10.1038/nm1092			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15311276				2022-12-27	WOS:000223658400028
J	Andreoletti, O; Simon, S; Lacroux, C; Morel, N; Tabouret, G; Chabert, A; Lugan, S; Corbiere, F; Ferre, P; Foucras, G; Laude, H; Eychenne, F; Grassi, J; Schelcher, F				Andreoletti, O; Simon, S; Lacroux, C; Morel, N; Tabouret, G; Chabert, A; Lugan, S; Corbiere, F; Ferre, P; Foucras, G; Laude, H; Eychenne, F; Grassi, J; Schelcher, F			PrPSc accumulation in myocytes from sheep incubating natural scrapie	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; BRITISH SHEEP; PRION PROTEIN; TISSUES; RISK	Because variant Creutzfeldt-Jakob disease (vCJD) in humans probably results from consumption of products contaminated with tissue from animals with bovine spongiform encephalopathy, whether infectious prion protein is present in ruminant muscles is a crucial question. Here we show that experimentally and naturally scrapie-affected sheep accumulate the prion protein PrPSc in a myocyte subset. In naturally infected sheep, PrPSc is detectable in muscle several months before clinical disease onset. The relative amounts of PrPSc suggest a 5,000-fold lower infectivity for muscle as compared to brain.	Ecole Natl Vet Toulouse, UMR INRA ENVT 1225, F-31076 Toulouse, France; CEA Saclay, DRM, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; Ecole Natl Vet Toulouse, UMR INRA ENVT 181, F-31076 Toulouse, France; INRA, F-78350 Jouy En Josas, France; INRA, F-31450 Pompertuzat, France	INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse; CEA; UDICE-French Research Universities; Universite Paris Saclay; INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE	Andreoletti, O (corresponding author), Ecole Natl Vet Toulouse, UMR INRA ENVT 1225, 23 Chemin Capelles, F-31076 Toulouse, France.	o.andreoletti@envt.fr	FOUCRAS, Gilles/A-3061-2014; Simon, Stephanie/E-4289-2012; Morel, Nathalie/O-9012-2016	FOUCRAS, Gilles/0000-0002-0363-0337; Simon, Stephanie/0000-0002-6071-8255; CORBIERE, Fabien/0000-0003-3006-5561; Ferre, Pierre/0000-0001-6828-1433; TABOURET, Guillaume/0000-0002-7976-4438				Andreoletti O, 2002, J HISTOCHEM CYTOCHEM, V50, P1357, DOI 10.1177/002215540205001009; Bosque PJ, 2002, P NATL ACAD SCI USA, V99, P3812, DOI 10.1073/pnas.052707499; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Ferguson NM, 2002, NATURE, V415, P420, DOI 10.1038/nature709; Glatzel M, 2003, NEW ENGL J MED, V349, P1812, DOI 10.1056/NEJMoa030351; Kao RR, 2002, SCIENCE, V295, P332, DOI 10.1126/science.1067475; THORNZIG A, 2003, EMBO REP, V4, P530; van Duijn CM, 1998, LANCET, V351, P1081, DOI 10.1016/S0140-6736(97)09468-3; vanKeulen LJM, 1996, J CLIN MICROBIOL, V34, P1228, DOI 10.1128/JCM.34.5.1228-1231.1996; Vilotte JL, 2001, J VIROL, V75, P5977, DOI 10.1128/JVI.75.13.5977-5984.2001; Watanabe Kouichi, 1999, Okajimas Folia Anatomica Japonica, V76, P203	11	114	117	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					591	593		10.1038/nm1055	http://dx.doi.org/10.1038/nm1055			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15156203				2022-12-27	WOS:000221759600023
J	Xu, LT; Zhang, L; Yi, YJ; Kang, HK; Datta, SK				Xu, LT; Zhang, L; Yi, YJ; Kang, HK; Datta, SK			Human lupus T cells resist inactivation and escape death by upregulating COX-2	NATURE MEDICINE			English	Article							APOPTOSIS; EXPRESSION; ACTIVATION; SURVIVAL; PROTEIN; ERYTHEMATOSUS; INHIBITORS; PATHWAYS; DEFECTS; LIGAND	Autoimmune T-helper cells drive pathogenic autoantibody production in systemic lupus erythematosus (SLE), but the mechanisms maintaining those T cells are unknown. Autoreactive T cells are normally eliminated by functional inactivation (anergy) and activation-induced cell death (AICD) or apoptosis through death receptor (Fas) signaling(1-3). However, mutations in the genes encoding Fas and its ligand (FasL) are rare in classical SLE4. By gene microarray profiling, validated by functional and biochemical studies, we establish here that activated T cells of lupus patients resist anergy and apoptosis by markedly upregulating and sustaining cyclooxygenase-2 (COX-2) expression. Inhibition of COX-2 caused apoptosis of the anergy-resistant lupus T cells by augmenting Fas signaling and markedly decreasing the survival molecule c-FLIP (cellular homolog of viral FLICE inhibitory protein). Studies with COX-2 inhibitors and Cox-2-deficient mice confirmed that this COX-2/FLIP antiapoptosis program is used selectively by anergy-resistant lupus T cells, and not by cancer cells or other autoimmune T cells. Notably, the gene encoding COX-2 is located in a lupus-susceptibility region on chromosome 1. We also found that only some COX-2 inhibitors were able to suppress the production of pathogenic autoantibodies to DNA by causing autoimmune T-cell apoptosis, an effect that was independent of prostaglandin E 2 (PGE(2)). These findings could be useful in the design of lupus therapies.	Northwestern Univ, Feinberg Sch Med, Dept Med, Div Rheumatol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Datta, SK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Rheumatol, 303 E Chicago Ave, Chicago, IL 60611 USA.	skd257@northwestern.edu			NIAID NIH HHS [R01-AI41985] Funding Source: Medline; NIAMS NIH HHS [R37-AR39157] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR039157] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; Dixon DA, 2003, J EXP MED, V198, P475, DOI 10.1084/jem.20030616; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jones RG, 2002, J EXP MED, V196, P335, DOI 10.1084/jem.20020307; Kaliyaperumal A, 2002, J IMMUNOL, V168, P2530, DOI 10.4049/jimmunol.168.5.2530; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Lander SA, 2002, LUPUS, V11, P340, DOI 10.1191/0961203302lu204oa; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Lin ZS, 2003, LAB INVEST, V83, P765, DOI 10.1097/01.LAB.0000073130.58435.E5; Lu LJ, 1999, J CLIN INVEST, V104, P345, DOI 10.1172/JCI6801; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Pablos JL, 1999, CLIN EXP IMMUNOL, V115, P86; Parfenova H, 2001, AM J PHYSIOL-CELL PH, V281, pC166, DOI 10.1152/ajpcell.2001.281.1.C166; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Schirmer M, 1998, J IMMUNOL, V161, P1018; Sharief MK, 2001, J NEUROIMMUNOL, V119, P358, DOI 10.1016/S0165-5728(01)00389-7; Stack E, 2001, GASTROENTEROL CLIN N, V30, P1001, DOI 10.1016/S0889-8553(05)70225-9; Vaishnaw AK, 1999, ARTHRITIS RHEUM, V42, P1833, DOI 10.1002/1529-0131(199909)42:9<1833::AID-ANR7>3.0.CO;2-Q; Wakeland EK, 2001, IMMUNITY, V15, P397, DOI 10.1016/S1074-7613(01)00201-1; Yi YJ, 2000, J IMMUNOL, V165, P6627, DOI 10.4049/jimmunol.165.11.6627; Zheng Y, 2003, J EXP MED, V197, P861, DOI 10.1084/jem.20021610; Zhu JX, 2002, JNCI-J NATL CANCER I, V94, P1745	25	109	113	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					411	415		10.1038/nm1005	http://dx.doi.org/10.1038/nm1005			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	14991050				2022-12-27	WOS:000220587000034
J	Gupta, RA; Wang, DZ; Katkuri, S; Wang, HB; Dey, SK; DuBois, RN				Gupta, RA; Wang, DZ; Katkuri, S; Wang, HB; Dey, SK; DuBois, RN			Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth	NATURE MEDICINE			English	Article							PPAR-DELTA; COLORECTAL-CANCER; INFLAMMATION; PROMOTES	We treated Apc(min) mice, which are predisposed to intestinal polyposis, with a selective synthetic agonist of peroxisome proliferator-activated receptor-delta0 (PPAR-delta). Exposure of Apc(min) mice to the PPAR-ligand GW501516 resulted in a significant increase in the number and size of intestinal polyps. The most prominent effect was on polyp size; mice treated with the PPAR-delta activator had a fivefold increase in the number of polyps larger than 2 mm. Our results implicate PPAR-delta in the regulation of intestinal adenoma growth.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Pediat & Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	DuBois, RN (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA.	raymond.dubois@vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020		NCI NIH HHS [P0-CA-77839] Funding Source: Medline; NICHD NIH HHS [R37-HD12304, HD 33994] Funding Source: Medline; NIDDK NIH HHS [R37-DK47297, R01DK47279] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012304] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kim EC, 1997, GASTROENTEROL CLIN N, V26, P1, DOI 10.1016/S0889-8553(05)70280-6; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	14	244	248	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					245	247		10.1038/nm993	http://dx.doi.org/10.1038/nm993			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14758356				2022-12-27	WOS:000189297700034
J	Sinha, G				Sinha, G			Profile - Otmar Wiestler	NATURE MEDICINE			English	Biographical-Item																		WIESTLER OD, PUBLICATION LIST	1	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2004	10	3					219	219		10.1038/nm0304-219	http://dx.doi.org/10.1038/nm0304-219			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14991034	Bronze			2022-12-27	WOS:000189297700017
J	Willett, CG; Boucher, Y; di Tomaso, E; Duda, DG; Munn, LL; Tong, RT; Chung, DC; Sahani, DV; Kalva, SP; Kozin, SV; Mino, M; Cohen, KS; Scadden, DT; Hartford, AC; Fischman, AJ; Clark, JW; Ryan, DP; Zhu, AX; Blaszkowsky, LS; Chen, HX; Shellito, PC; Lauwers, GY; Jain, RK				Willett, CG; Boucher, Y; di Tomaso, E; Duda, DG; Munn, LL; Tong, RT; Chung, DC; Sahani, DV; Kalva, SP; Kozin, SV; Mino, M; Cohen, KS; Scadden, DT; Hartford, AC; Fischman, AJ; Clark, JW; Ryan, DP; Zhu, AX; Blaszkowsky, LS; Chen, HX; Shellito, PC; Lauwers, GY; Jain, RK			Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS; THERAPY; CELLS	The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.	Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, AIDS Res Ctr Expt Hematol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Nucl Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; NCI, Canc Therapy Evaluat Program, Rockville, MD 20852 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu	Duda, Dan G/H-8523-2014; Munn, Lance L/L-3950-2016; Jain, Rakesh K/I-1384-2017	Duda, Dan G/0000-0001-7065-8797; Munn, Lance L/0000-0003-0698-7232; Jain, Rakesh K/0000-0001-7571-3548	NATIONAL CANCER INSTITUTE [P01CA080124, R21CA099237] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA080124, P01 CA080124-030002, P01 CA080124-089001, P01 CA80124, P01 CA080124-01A19001, P01 CA080124-059001, P01 CA080124-039001, P01 CA080124-06A29001, P01 CA080124-080006, P01 CA080124-01A1S19001, R21 CA099237, R21 CA099237-02, P01 CA080124-01A10002, P01 CA080124-020002, P01 CA080124-029001, P01 CA080124-01A1S10002, P01 CA080124-049001, P01 CA080124-079001, P01 CA080124-070006, P01 CA080124-040002, P01 CA080124-050002, P01 CA080124-06A20006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Lee CG, 2000, CANCER RES, V60, P5565; Mancuso P, 2001, BLOOD, V97, P3658, DOI 10.1182/blood.V97.11.3658; McCarthy M, 2003, LANCET, V361, P1959, DOI 10.1016/S0140-6736(03)13603-3; Monestiroli S, 2001, CANCER RES, V61, P4341; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Teicher BA, 1996, CANCER METAST REV, V15, P247, DOI 10.1007/BF00437479; Wildiers H, 2003, BRIT J CANCER, V88, P1979, DOI 10.1038/sj.bjc.6601005; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	15	1531	1664	4	122	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					145	147		10.1038/nm988	http://dx.doi.org/10.1038/nm988			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14745444	Green Accepted			2022-12-27	WOS:000188719600032
J	Ambati, J; Anand, A; Fernandez, S; Sakurai, E; Lynn, BC; Kuziel, WA; Rollins, BJ; Ambati, BK				Ambati, J; Anand, A; Fernandez, S; Sakurai, E; Lynn, BC; Kuziel, WA; Rollins, BJ; Ambati, BK			An animal model of age-related macular degeneration in senescent Ccl-2-or Ccr-2-deficient mice	NATURE MEDICINE			English	Article							RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS; CHLAMYDIA-PNEUMONIAE INFECTION; HIGH-FAT DIET; CHOROIDAL NEOVASCULARIZATION; BRUCHS MEMBRANE; COMPLEMENT ACTIVATION; TARGETED DISRUPTION; DEPOSIT FORMATION	The study and treatment of age-related macular degeneration (AMD), a leading cause of blindness, has been hampered by a lack of animal models. Here we report that mice deficient either in monocyte chemoattractant protein-1 (Ccl-2; also known as MCP-1) or its cognate C-C chemokine receptor-2 (Ccr-2) develop cardinal features of AMD, including accumulation of lipofuscin in and drusen beneath the retinal pigmented epithelium (RPE), photoreceptor atrophy and choroidal neovascularization (CNV). Complement and IgG deposition in RPE and choroid accompanies senescence in this model, as in human AMD. RPE or choroidal endothelial production of Ccl-2 induced by complement C5a and IgG may mediate choroidal macrophage infiltration into aged wild-type choroids. Wild-type choroidal macrophages degrade C5 and IgG in eye sections of Ccl2(-/-) or Ccr2(-/-) mice. Impaired macrophage recruitment may allow accumulation of C5a and IgG, which induces vascular endothelial growth factor (VEGF) production by RPE, possibly mediating development of CNV. These models implicate macrophage dysfunction in AMD pathogenesis and may be useful as a platform for validating therapies.	Univ Kentucky, Dept Ophthalmol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40506 USA; Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30907 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Texas System; University of Texas Austin; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; University System of Georgia; Augusta University	Ambati, J (corresponding author), Univ Kentucky, Dept Ophthalmol, 740 S Limestone St, Lexington, KY 40536 USA.		Mohammed, Imran/J-8271-2012	Mohammed, Imran/0000-0002-8412-0768; Lynn, Bert/0000-0001-8426-3024				Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582; Bian ZM, 1996, J LEUKOCYTE BIOL, V60, P405, DOI 10.1002/jlb.60.3.405; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Brons RH, 2001, ANN RHEUM DIS, V60, P1097, DOI 10.1136/ard.60.12.1097; Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047; Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496; Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643; Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035; DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899; GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519; Grossniklaus HE, 2002, MOL VIS, V8, P119; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; GURNE DH, 1991, OPHTHALMOLOGY, V98, P602; Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6; Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629; Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Kothe H, 2000, CIRCULATION, V101, P1760, DOI 10.1161/01.CIR.101.15.1760; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; LEYS A, 1990, GRAEF ARCH CLIN EXP, V228, P499, DOI 10.1007/BF00918479; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936; Meda L, 1996, J IMMUNOL, V157, P1213; Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033; Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2; Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6; Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919; Roberts WG, 1997, CANCER RES, V57, P765; RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097; SCHULZE M, 1993, AM J PATHOL, V142, P179; Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7; Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	47	489	552	0	34	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1390	1397		10.1038/nm950	http://dx.doi.org/10.1038/nm950			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14566334				2022-12-27	WOS:000186319700029
J	Wang, XY; Lee, SR; Arai, K; Lee, SR; Tsuji, K; Rebeck, GW; Lo, EH				Wang, XY; Lee, SR; Arai, K; Lee, SR; Tsuji, K; Rebeck, GW; Lo, EH			Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator	NATURE MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; METHYL-D-ASPARTATE; EXTRACELLULAR PROTEOLYSIS; PROTEIN; THROMBOLYSIS; EXPRESSION; LRP; INVOLVEMENT; INHIBITION; SCAVENGER	Although thrombolysis with tissue plasminogen activator (tPA) is a stroke therapy approved by the US Food and Drug Administration, its efficacy may be limited by neurotoxic side effects(1,2). Recently, proteolytic damage involving matrix metalloproteinases (MMPs) have been implicated. In experimental embolic stroke models, MMP inhibitors decreased cerebral hemorrhage and injury after treatment with tPA(3,4). MMPs comprise a family of zinc endopeptidases that can modify several components of the extracellular matrix(5,6). In particular, the gelatinases MMP-2 and MMP-9 can degrade neurovascular matrix integrity. MMP-9 promotes neuronal death by disrupting cell-matrix interactions(7), and MMP-9 knockout mice have reduced blood-brain barrier leakage and infarction after cerebral ischemia(8). Hence it is possible that tPA upregulates MMPs in the brain, and that subsequent matrix degradation causes brain injury. Here we show that tPA upregulates MMP-9 in cell culture and in vivo. MMP-9 levels were lower in tPA knockouts compared with wild-type mice after focal cerebral ischemia. In human cerebral microvascular endothelial cells, MMP-9 was upregulated when recombinant tPA was added. RNA interference (RNAi) suggested that this response was mediated by the low-density lipoprotein receptor-related protein (LRP), which avidly binds tPA(9) and possesses signaling properties(10). Targeting the tPA-LRP signaling pathway in brain may offer new approaches for decreasing neurotoxicity and improving stroke therapy.	Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA; Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Georgetown University	Lo, EH (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, MGH E 149-2401, Charlestown, MA 02129 USA.	wangxi@helix.mgh.harvard.edu; lo@helix.mgh.harvard.edu	Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037074, R01NS040529, R01NS038731, P50NS010828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014473] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG14473] Funding Source: Medline; NINDS NIH HHS [R01-NS37074, R01-NS38731, R01-NS40529, P50-NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Del Zoppo GJ, 1998, NAT MED, V4, P148, DOI 10.1038/nm0298-148; Fini ME, 1998, BIOL EXTRAC, P299; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hacke W, 1999, NEUROLOGY, V53, pS3; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hiltunen TP, 1998, CIRCULATION, V97, P1079, DOI 10.1161/01.CIR.97.11.1079; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; Lapchak PA, 2000, STROKE, V31, P3034, DOI 10.1161/01.STR.31.12.3034; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Mataga N, 2002, P NATL ACAD SCI USA, V99, P7717, DOI 10.1073/pnas.102088899; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Nagai N, 2001, J CEREBR BLOOD F MET, V21, P631, DOI 10.1097/00004647-200106000-00001; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	28	368	399	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2003	9	10					1313	1317		10.1038/nm926	http://dx.doi.org/10.1038/nm926			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12960961				2022-12-27	WOS:000185669700044
J	Feuerer, M; Beckhove, P; Garbi, N; Mahnke, Y; Limmer, A; Hommel, M; Hammerling, GJ; Kyewski, B; Hamann, A; Umansky, V; Schirrmacher, V				Feuerer, M; Beckhove, P; Garbi, N; Mahnke, Y; Limmer, A; Hommel, M; Hammerling, GJ; Kyewski, B; Hamann, A; Umansky, V; Schirrmacher, V			Bone marrow as a priming site for T-cell responses to blood-borne antigen	NATURE MEDICINE			English	Article							DENDRITIC CELLS; IN-VIVO; LYMPH-NODES; IMMUNE-RESPONSE; TUMOR-CELLS; MICE; CD8(+); TOLERANCE; TISSUE; NAIVE	Although bone marrow is known as a primary lymphoid organ, its potential to serve as a secondary immune organ has hardly been explored. Here we demonstrate that naive, antigen-specific T cells home to bone marrow, where they can be primed. Antigen presentation to T cells in bone marrow is mediated via resident CD11c(+) dendritic cells. They are highly efficient in taking up exogenous blood-borne antigen and processing it via major histocompatibility complex class I and class II pathways. T-cell activation correlates with dendritic cell-T cell clustering in bone marrow stroma. Primary CD4(+) and CD8(+) T-cell responses generated in bone marrow occur in the absence of secondary lymphoid organs. The responses are not tolerogenic and result in generation of cytotoxic T cells, protective anti-tumor immunity and immunological memory. These findings highlight the uniqueness of bone marrow as an organ important for hemato- and lymphopoiesis and for systemic T cell-mediated immunity.	German Canc Res Ctr DKFZ, Tumor Immunol Program, Heidelberg, Germany; Univ Clin, Inst Mol Med & Expt Immunol, Bonn, Germany; Humboldt Univ, Charite, Dept Expt Rheumatol, Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schirrmacher, V (corresponding author), German Canc Res Ctr DKFZ, Tumor Immunol Program, Heidelberg, Germany.		Garbi, Natalio/H-7666-2014; Garbi, Natalio/B-9147-2009; Hommel, Mirja/C-9791-2019	Hommel, Mirja/0000-0002-4788-6932; Mahnke, Yolanda/0000-0002-2727-9887				Aichele P, 1997, IMMUNITY, V6, P519, DOI 10.1016/S1074-7613(00)80340-4; BAIN BJ, 2001, BONE MARROW PATHOLOG, P114; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; Chin R, 2001, NAT MED, V7, P1165, DOI 10.1038/nm1101-1165a; Coles RM, 2002, J IMMUNOL, V168, P834, DOI 10.4049/jimmunol.168.2.834; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; Feuerer M, 2001, NAT MED, V7, P452, DOI 10.1038/86523; Feuerer M, 2001, INT J CANCER, V92, P96, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q; Forg P, 1998, GENE THER, V5, P789, DOI 10.1038/sj.gt.3300628; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hommel M, 2003, J EXP MED, V197, P269, DOI 10.1084/jem.20021512; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kamath AT, 2000, J IMMUNOL, V165, P6762, DOI 10.4049/jimmunol.165.12.6762; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; KRUGER A, 1994, INT J CANCER, V58, P275, DOI 10.1002/ijc.2910580222; Kuroda MJ, 2000, BLOOD, V96, P1474, DOI 10.1182/blood.V96.4.1474.h8001474_1474_1479; Lakkis FG, 2000, NAT MED, V6, P686, DOI 10.1038/76267; Lanzavecchia A, 2001, CURR OPIN IMMUNOL, V13, P291, DOI 10.1016/S0952-7915(00)00218-1; Li M, 2001, J IMMUNOL, V166, P6099, DOI 10.4049/jimmunol.166.10.6099; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; Marshall DR, 2001, P NATL ACAD SCI USA, V98, P6313, DOI 10.1073/pnas.101132698; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Muller M, 1998, CANCER RES, V58, P5439; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; OSMOND DG, 1994, ADV EXP MED BIOL, V355, P15; Robertson JM, 2000, J IMMUNOL, V164, P4706, DOI 10.4049/jimmunol.164.9.4706; Ruedl C, 2000, J IMMUNOL, V165, P4910, DOI 10.4049/jimmunol.165.9.4910; Tripp RA, 1997, J IMMUNOL, V158, P3716; Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907	39	257	264	0	14	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1151	1157		10.1038/nm914	http://dx.doi.org/10.1038/nm914			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12910264				2022-12-27	WOS:000185061600027
J	Yla-Herttuala, S; Alitalo, K				Yla-Herttuala, S; Alitalo, K			Gene transfer as a tool to induce therapeutic vascular growth	NATURE MEDICINE			English	Review							CORONARY-ARTERY DISEASE; CHRONIC MYOCARDIAL-ISCHEMIA; PLASMID-LIPOSOME COMPLEXES; LOWER-LIMB ARTERY; IN-VIVO; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; DOUBLE-BLIND; INTRAMYOCARDIAL INJECTION; INTRAMUSCULAR INJECTION	Therapeutic induction of vascular growth may provide a treatment option for those patients with myocardial or peripheral ischemia who are not suited to conventional revascularization therapies. Some lymphatic vascular disorders may also be amenable to this therapy. However, clear evidence of efficacy must be obtained from phase 2 and 3 clinical trials before these new treatments can be entered into clinical practice. Apart from the clinical applications, gene transfer aimed at stimulating or blocking vascular growth with various growth factors, cytokines, transcription factors and receptors or their antagonists is useful for analyzing the effects of those molecules on the vasculature, especially when gene targeting results in lethality or when large animal models are required.	Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Med, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Gene Therapy Unit, FIN-70211 Kuopio, Finland; Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Haartman Inst, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Biomedicum Helsinki, FIN-00014 Helsinki, Finland	University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; Ludwig Institute for Cancer Research; University of Helsinki; Helsinki University Central Hospital	Yla-Herttuala, S (corresponding author), Univ Kuopio, AI Virtanen Inst, POB 1627, FIN-70211 Kuopio, Finland.	Seppo.Ylaherttuala@uku.fi; Kari.Alitalo@Helsinki.fi	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Yla-Herttuala, Seppo/0000-0001-7593-2708				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Airenne KJ, 2000, GENE THER, V7, P1499, DOI 10.1038/sj.gt.3301269; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Arras M, 1998, NAT BIOTECHNOL, V16, P159, DOI 10.1038/nbt0298-159; Arsic N, 2003, MOL THER, V7, P450, DOI 10.1016/S1525-0016(03)00034-0; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bryant M, 2000, HUM GENE THER, V11, P2143, DOI 10.1089/104303400750001444; Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848; Chae JK, 2000, ARTERIOSCL THROM VAS, V20, P2573, DOI 10.1161/01.ATV.20.12.2573; Champion HC, 2002, CIRCULATION, V106, P25; Clackson T, 2000, GENE THER, V7, P120, DOI 10.1038/sj.gt.3301120; Comerota AJ, 2002, J VASC SURG, V35, P930, DOI 10.1067/mva.2002.123677; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Deodato B, 2002, GENE THER, V9, P777, DOI 10.1038/sj.gt.3301697; Di Peppe SR, 2002, GENE THER, V9, P1271, DOI 10.1038/sj.gt.3301798; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Dufourcq P, 2002, CIRCULATION, V106, P3097, DOI 10.1161/01.CIR.0000039342.85015.5C; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Emanueli C, 2000, ARTERIOSCL THROM VAS, V20, P2379, DOI 10.1161/01.ATV.20.11.2379; Emanueli C, 2002, CIRCULATION, V106, P2257, DOI 10.1161/01.CIR.0000033971.56802.C5; Fataccioli V, 2002, HUM GENE THER, V13, P1461, DOI 10.1089/10430340260185094; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FUKUMURA M, 2000, J GEN MED S, V2, P24; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Greco O, 2002, GENE THER, V9, P1403, DOI 10.1038/sj.gt.3301823; Grines CL, 2002, CIRCULATION, V105, P1291, DOI 10.1161/hc1102.105595; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; HEDMAN M, IN PRESS CIRCULATION; Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A; Hiltunen MO, 2000, FASEB J, V14, P2230, DOI 10.1096/fj.00-0145com; Hiltunen MO, 2000, CIRCULATION, V102, P2262; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Isner JM, 2001, CIRC RES, V89, P389, DOI 10.1161/hh1701.096259; Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741-5214(98)70022-9; Ito WD, 1997, CIRC RES, V80, P829; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; KASTRUP J, 2003, J AM COLL CARDIOL, V41, P1603; KOOTSTRA NA, 2002, ANN REV PHARM TOXICO, V43, P413; Koponen JK, 2003, GENE THER, V10, P459, DOI 10.1038/sj.gt.3301889; Kubo H, 2002, P NATL ACAD SCI USA, V99, P8868, DOI 10.1073/pnas.062040199; Laitinen M, 2000, HUM GENE THER, V11, P263, DOI 10.1089/10430340050016003; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Laitinen M, 1997, HUM GENE THER, V8, P1645, DOI 10.1089/hum.1997.8.14-1645; Lederman RJ, 2002, LANCET, V359, P2053, DOI 10.1016/S0140-6736(02)08937-7; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Losordo DW, 2002, CIRCULATION, V105, P2012, DOI 10.1161/01.CIR.0000015982.70785.B7; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638; Marshall E, 2003, SCIENCE, V299, P320, DOI 10.1126/science.299.5605.320; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MESRI EA, 1995, CIRC RES, V76, P161, DOI 10.1161/01.RES.76.2.161; Miller DL, 2000, MOL CELL BIOL, V20, P2260, DOI 10.1128/MCB.20.6.2260-2268.2000; Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109; Morishita R, 1999, HYPERTENSION, V33, P1379, DOI 10.1161/01.HYP.33.6.1379; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Pakkanen TM, 2000, J GENE MED, V2, P52, DOI 10.1002/(SICI)1521-2254(200001/02)2:1<52::AID-JGM82>3.0.CO;2-4; PARK JE, 1994, J BIOL CHEM, V269, P25646; Penta K, 1999, J BIOL CHEM, V274, P11101, DOI 10.1074/jbc.274.16.11101; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Pislaru S, 2002, CIRCULATION, V106, P631, DOI 10.1161/01.CIR.0000019621.18368.B7; Rajagopalan S, 2003, J AM COLL CARDIOL, V41, p304A; Rajagopalan S, 2001, CIRCULATION, V104, P753, DOI 10.1161/hc3201.095192; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Rissanen TT, 2002, FASEB J, V16, P100, DOI 10.1096/fj.02-0377fje; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; Rissanen TT, 2001, EUR J CLIN INVEST, V31, P651, DOI 10.1046/j.1365-2362.2001.00864.x; RISSANEN TT, IN PRESS CIRC RES; Rockson SG, 2001, AM J MED, V110, P288, DOI 10.1016/S0002-9343(00)00727-0; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Saaristo A, 2002, ANN NY ACAD SCI, V979, P94, DOI 10.1111/j.1749-6632.2002.tb04871.x; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Sarkar N, 2001, J INTERN MED, V250, P373, DOI 10.1046/j.1365-2796.2001.00905.x; Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188; Seiler C, 2001, CIRCULATION, V104, P2012, DOI 10.1161/hc4201.097835; Shyu KG, 2003, AM J MED, V114, P85, DOI 10.1016/S0002-9343(02)01392-X; Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081; Simons M, 2000, CIRCULATION, V102, pE73, DOI 10.1161/01.CIR.102.11.e73; Simons M, 2002, CIRCULATION, V105, P788, DOI 10.1161/hc0802.104407; Smith RS, 2002, ARTERIOSCL THROM VAS, V22, P1279, DOI 10.1161/01.ATV.0000026613.18742.67; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Svensson EC, 1999, CIRCULATION, V99, P201, DOI 10.1161/01.CIR.99.2.201; Symes JF, 1999, ANN THORAC SURG, V68, P830, DOI 10.1016/S0003-4975(99)00807-3; Szuba A, 2002, FASEB J, V16, P1985, DOI 10.1096/fj.02-0401fje; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Trono D, 2000, GENE THER, V7, P20, DOI 10.1038/sj.gt.3301105; Vale PR, 2000, CIRCULATION, V102, P965, DOI 10.1161/01.CIR.102.9.965; Vale PR, 2001, CIRCULATION, V103, P2138; Villanueva FS, 1998, CIRCULATION, V98, P1, DOI 10.1161/01.CIR.98.1.1; Vincent KA, 2000, CIRCULATION, V102, P2255; VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wright MJ, 2001, GENE THER, V8, P1833, DOI 10.1038/sj.gt.3301614; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830	110	311	338	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					694	701		10.1038/nm0603-694	http://dx.doi.org/10.1038/nm0603-694			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12778168				2022-12-27	WOS:000183444100024
J	Pym, AS; Brodin, P; Majlessi, L; Brosch, R; Demangel, C; Williams, A; Griffiths, KE; Marchal, G; Leclerc, C; Cole, ST				Pym, AS; Brodin, P; Majlessi, L; Brosch, R; Demangel, C; Williams, A; Griffiths, KE; Marchal, G; Leclerc, C; Cole, ST			Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis	NATURE MEDICINE			English	Article							MYCOBACTERIUM-BOVIS BCG; T-CELL ANTIGENS; COMPARATIVE GENOMICS; GUINEA-PIGS; VACCINES; IMMUNITY; PROTEIN; IDENTIFICATION; VACCINATION; EPITOPES	The live tuberculosis vaccines Mycobacterium bovis BCG (bacille Calmette-Guerin) and Mycobacterium microti both lack the potent, secreted T-cell antigens ESAT-6 (6-kDa early secretory antigenic target) and CFP-10 (10-kDa culture filtrate protein). This is a result of independent deletions in the region of deletion-1 (RD1) locus, which is intact in virulent members of the Mycobacterium tuberculosis complex. To increase their immunogenicity and protective capacity, we complemented both vaccines with different constructs containing the esxA and esxB genes, which encode ESAT-6 and CFP-10 respectively, as well as a variable number of flanking genes. Only reintroduction of the complete locus, comprising at least 11 genes, led to full secretion of the antigens and resulted in specific ESAT-6-dependent immune responses; this suggests that the flanking genes encode a secretory apparatus. Mice and guinea pigs vaccinated with the recombinant strain BCG:: RD1-2F9 were better protected against challenge with M. tuberculosis, showing less severe pathology and reduced dissemination of the pathogen, as compared with control animals immunized with BCG alone.	Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Inst Pasteur, INSERM, EO352, Unite Biol Regulat Immunitaires, F-75724 Paris, France; Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England; Inst Pasteur, Lab Reference Mycobacteries, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Liverpool School of Tropical Medicine; University of Liverpool; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cole, ST (corresponding author), Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France.		Brosch, Roland/ABB-4108-2021; Brodin, Priscille/E-5802-2014; Demangel, Caroline/H-9570-2014; Brosch, Roland/AAZ-3850-2021; Brodin, Priscille/N-6979-2019	Brodin, Priscille/0000-0003-0991-7344; Demangel, Caroline/0000-0001-7848-586X; Brosch, Roland/0000-0003-2587-3863; Brodin, Priscille/0000-0003-0991-7344; deboosere, Nathalie/0000-0002-2873-5485; Pym, Alexander/0000-0002-6260-8180				Baldwin SL, 1998, INFECT IMMUN, V66, P2951, DOI 10.1128/IAI.66.6.2951-2959.1998; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Behr MA, 1997, NATURE, V389, P133, DOI 10.1038/38151; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; BOESEN H, 1995, INFECT IMMUN, V63, P1491, DOI 10.1128/IAI.63.4.1491-1497.1995; Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002; Brandt L, 1996, J IMMUNOL, V157, P3527; Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000; Brodin P, 2002, INFECT IMMUN, V70, P5568, DOI 10.1128/IAI.70.10.5568-5578.2002; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Chambers MA, 2000, INFECT IMMUN, V68, P7094, DOI 10.1128/IAI.68.12.7094-7099.2000; Colangeli R, 2000, INFECT IMMUN, V68, P990, DOI 10.1128/IAI.68.2.990-993.2000; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Coler RN, 2001, J IMMUNOL, V166, P6227, DOI 10.4049/jimmunol.166.10.6227; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Garay S, 1996, TUBERCULOSIS, P373; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Harboe M, 1998, INFECT IMMUN, V66, P717, DOI 10.1128/IAI.66.2.717-723.1998; Harboe M, 1996, INFECT IMMUN, V64, P16, DOI 10.1128/IAI.64.1.16-22.1996; HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293; Hondalus MK, 2000, INFECT IMMUN, V68, P2888, DOI 10.1128/IAI.68.5.2888-2898.2000; Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; HUYGEN K, 1994, INFECT IMMUN, V62, P363, DOI 10.1128/IAI.62.2.363-370.1994; Jackson M, 1999, INFECT IMMUN, V67, P2867, DOI 10.1128/IAI.67.6.2867-2873.1999; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; Lagranderie MRR, 1996, INFECT IMMUN, V64, P1; LECLERC C, 1991, J VIROL, V65, P711, DOI 10.1128/JVI.65.2.711-718.1991; Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Neuwald AF, 1999, GENOME RES, V9, P27; Page AL, 2002, MOL MICROBIOL, V46, P1, DOI 10.1046/j.1365-2958.2002.03138.x; Pallen MJ, 2002, TRENDS MICROBIOL, V10, P209, DOI 10.1016/S0966-842X(02)02345-4; Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; Skjot RLV, 2000, INFECT IMMUN, V68, P214, DOI 10.1128/IAI.68.1.214-220.2000; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; SULA L, 1976, J HYG EPID MICROB IM, V20, P1; Tekaia F., 1999, Tubercle and Lung Disease, V79, P329, DOI 10.1054/tuld.1999.0220; Van Pittius NG, 2001, GENOME BIOL, V2; Williams A, 2000, CLIN INFECT DIS, V30, pS299, DOI 10.1086/313878; YOUNG DB, 1997, NEW GENERATION VACCI, P631	44	504	554	2	34	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					533	539		10.1038/nm859	http://dx.doi.org/10.1038/nm859			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692540	Bronze			2022-12-27	WOS:000182610600033
J	Grassme, H; Jendrossek, V; Riehle, A; von Kurthy, G; Berger, J; Schwarz, H; Weller, M; Kolesnick, R; Gulbins, E				Grassme, H; Jendrossek, V; Riehle, A; von Kurthy, G; Berger, J; Schwarz, H; Weller, M; Kolesnick, R; Gulbins, E			Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts	NATURE MEDICINE			English	Article							ORDERED LIPID DOMAINS; EPITHELIAL-CELLS; INDUCED APOPTOSIS; PHORBOL ESTERS; ENTRY; SPHINGOMYELINASE; CLEARANCE; TRAFFICKING; CHOLESTEROL; CAVEOLAE	Pseudomonas aeruginosa infection is a serious complication in patients with cystic fibrosis and in immunocompromised individuals. Here we show that P. aeruginosa infection triggers activation of the acid sphingomyelinase and the release of ceramide in sphingolipid-rich rafts. Ceramide reorganizes these rafts into larger signaling platforms that are required to internalize P. aeruginosa, induce apoptosis and regulate the cytokine response in infected cells. Failure to generate ceramide-enriched membrane platforms in infected cells results in an unabated inflammatory response, massive release of interleukin (IL)-1 and septic death of mice. Our findings show that ceramide-enriched membrane platforms are central to the host defense against this potentially lethal pathogen.	Univ Essen Gesamthsch, Dept Biol Mol, Essen, Germany; Univ Tubingen, Dept Radiat Oncol, Tubingen, Germany; Univ Tubingen, Dept Neurol, Tubingen, Germany; Max Planck Inst Dev Biol, Tubingen, Germany; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	University of Duisburg Essen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Max Planck Society; Memorial Sloan Kettering Cancer Center	Gulbins, E (corresponding author), Univ Essen Gesamthsch, Dept Biol Mol, Essen, Germany.	erich.gulbins@uni-essen.de	Jendrossek, Verena/AAH-4967-2019; Gulbins, Erich/L-6989-2014	Jendrossek, Verena/0000-0003-1058-2107; Gulbins, Erich/0000-0002-3117-1342; Weller, Michael/0000-0002-1748-174X	NCI NIH HHS [CA85704, CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA085704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; CROUCH BS, 1996, CHEST, V109, P1019, DOI DOI 10.1378/CHEST.109.4.1019; Esen M, 2001, INFECT IMMUN, V69, P281, DOI 10.1128/IAI.69.1.281-287.2001; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hauser AR, 1999, INFECT IMMUN, V67, P5530, DOI 10.1128/IAI.67.10.5530-5537.1999; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; INOUE H, 1994, AM J RESP CELL MOL, V11, P651, DOI 10.1165/ajrcmb.11.6.7946394; Jan JT, 2000, J VIROL, V74, P6425, DOI 10.1128/JVI.74.14.6425-6432.2000; Jendrossek V, 2001, INFECT IMMUN, V69, P2675, DOI 10.1128/IAI.69.4.2675-2683.2001; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Manie SN, 2000, J VIROL, V74, P305, DOI 10.1128/JVI.74.1.305-311.2000; Olliaro P, 1997, INT J PARASITOL, V27, P1007, DOI 10.1016/S0020-7519(97)00083-0; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Rajan S, 2000, AM J RESP CELL MOL, V23, P304, DOI 10.1165/ajrcmb.23.3.4098; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; Schroeder TH, 2001, J IMMUNOL, V166, P7410, DOI 10.4049/jimmunol.166.12.7410; Schultz MJ, 2002, AM J PHYSIOL-LUNG C, V282, pL285, DOI 10.1152/ajplung.00461.2000; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Vidal F, 1996, ARCH INTERN MED, V156, P2121, DOI 10.1001/archinte.156.18.2121; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wooldridge KG, 1996, MICROB PATHOGENESIS, V21, P299, DOI 10.1006/mpat.1996.0063; Xue ML, 2001, CURR EYE RES, V23, P406	37	428	441	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					322	330		10.1038/nm823	http://dx.doi.org/10.1038/nm823			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12563314				2022-12-27	WOS:000181312300033
J	Isermann, B; Sood, R; Pawlinski, R; Zogg, M; Kalloway, S; Degen, JL; Mackman, N; Weiler, H				Isermann, B; Sood, R; Pawlinski, R; Zogg, M; Kalloway, S; Degen, JL; Mackman, N; Weiler, H			The thrombomodulin-protein C system is essential for the maintenance of pregnancy	NATURE MEDICINE			English	Article							TISSUE FACTOR; PLASMINOGEN-ACTIVATOR; THROMBIN RECEPTOR; BLEEDING EVENTS; FETAL LOSS; EXPRESSION; MICE; APOPTOSIS; PLACENTA; WOMEN	Disruption of the mouse gene encoding the blood coagulation inhibitor thrombomodulin (Thbd) leads to embryonic lethality caused by an unknown defect in the placenta. We show that the abortion of thrombomodulin-deficient embryos is caused by tissue factor-initiated activation of the blood coagulation cascade at the feto-maternal interface. Activated coagulation factors induce cell death and growth inhibition of placental trophoblast cells by two distinct mechanisms. The death of giant trophoblast cells is caused by conversion of the thrombin substrate fibrinogen to fibrin and subsequent formation of fibrin degradation products. In contrast, the growth arrest of trophoblast cells is not mediated by fibrin, but is a likely result of engagement of protease-activated receptors (PAR)-2 and PAR-4 by coagulation factors. These findings show a new function for the thrombomodulin-protein C system in controlling the growth and survival of trophoblast cells in the placenta. This function is essential for the maintenance of pregnancy.	Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53233 USA; Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA	Versiti Blood Center of Wisconsin; Scripps Research Institute; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Medical College of Wisconsin	Weiler, H (corresponding author), Blood Ctr SE Wisconsin Inc, Blood Res Inst, 1701 W Wisconsin Ave, Milwaukee, WI 53233 USA.	hweiler@bcsew.edu	PAwlinski, Rafal/AAD-6090-2022; Sood, Rashmi/AAT-2491-2020	Sood, Rashmi/0000-0002-4523-9512	NHLBI NIH HHS [HL-60655] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blumenfeld Z, 1999, FERTIL STERIL, V72, P765, DOI 10.1016/S0015-0282(99)00360-X; BRAISSANT O, 1998, BIOCHEMICA, V3, P10; Brenner B, 1999, THROMB HAEMOSTASIS, V82, P6; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Crawley JTB, 2002, THROMB HAEMOSTASIS, V88, P259; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Erlich J, 1999, P NATL ACAD SCI USA, V96, P8138, DOI 10.1073/pnas.96.14.8138; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Fazel A, 1998, PLACENTA, V19, P261, DOI 10.1016/S0143-4004(98)90057-1; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GOGJIAN MA, 1981, LAB ANIM SCI, V31, P710; Greer IA, 1999, LANCET, V353, P1258, DOI 10.1016/S0140-6736(98)10265-9; Gu JM, 2002, J BIOL CHEM, V277, P43335, DOI 10.1074/jbc.M207538200; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Hu ZY, 1999, J ANAT, V194, P183, DOI 10.1046/j.1469-7580.1999.19420183.x; Isermann B, 2001, J CLIN INVEST, V108, P537, DOI 10.1172/JCI13077; Isermann B, 2001, DEVELOPMENT, V128, P827; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; OUT HJ, 1991, EUR J OBSTET GYN R B, V41, P179, DOI 10.1016/0028-2243(91)90021-C; Parry GCN, 1998, J CLIN INVEST, V101, P560, DOI 10.1172/JCI814; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Ratts VS, 2000, PLACENTA, V21, P361, DOI 10.1053/plac.1999.0486; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Taylor FB, 2001, BLOOD, V97, P1685, DOI 10.1182/blood.V97.6.1685; Teesalu T, 1998, DEV DYNAM, V213, P27, DOI 10.1002/(SICI)1097-0177(199809)213:1<27::AID-AJA3>3.3.CO;2-0; Toki T, 1999, MOL HUM REPROD, V5, P246, DOI 10.1093/molehr/5.3.246; Toomey JR, 1996, BLOOD, V88, P1583; TSUMAGARI T, 1984, KIDNEY INT, V26, P712, DOI 10.1038/ki.1984.206; Wang W, 2000, J BIOL CHEM, V275, P22942, DOI 10.1074/jbc.M001760200; Weiler-Guettler H, 1998, J CLIN INVEST, V101, P1983, DOI 10.1172/JCI2006; WeilerGuettler H, 1996, CIRC RES, V78, P180, DOI 10.1161/01.RES.78.2.180; WeilerGuettler H, 1996, DEVELOPMENT, V122, P2271; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; Zhang YM, 1998, J CLIN INVEST, V101, P1301, DOI 10.1172/JCI925; ZIVELIN A, 1993, J CLIN INVEST, V92, P2131, DOI 10.1172/JCI116814	45	210	212	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2003	9	3					331	337		10.1038/nm825	http://dx.doi.org/10.1038/nm825			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12579195				2022-12-27	WOS:000181312300034
J	McClain, MT; Heinlen, LD; Dennis, GJ; Roebuck, J; Harley, JB; James, JA				McClain, MT; Heinlen, LD; Dennis, GJ; Roebuck, J; Harley, JB; James, JA			Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; B-CELL EPITOPES; AUTOANTIBODIES; ERYTHEMATOSUS; ANTIBODIES; INFECTION; RESPONSES; PEPTIDES; INDUCE; RO60	The origins of autoimmunity in systemic lupus erythematosus (SLE) are thought to involve both genetic and environmental factors. To identify environmental agents that could potentially incite autoimmunity, we have traced the autoantibody response in human SLE back in time, prior to clinical disease onset, and identified the initial autoantigenic epitope for some lupus patients positive for antibodies to 60 kDa Ro. This initial epitope directly cross-reacts with a peptide from the latent viral protein Epstein-Barr virus nuclear antigen-1 (EBNA-1). Animals immunized with either the first epitope of 60 kDa Ro or the cross-reactive EBNA-1 epitope progressively develop autoantibodies binding multiple epitopes of Ro and spliceosomal autoantigens. They eventually acquire clinical symptoms of lupus such as leukopenia, thrombocytopenia and renal dysfunction. These data support the hypothesis that some humoral autoimmunity in human lupus arises through molecular mimicry between EBNA-1 and lupus autoantigens and provide further evidence to suspect an etiologic role for Epstein-Barr virus in SLE.	Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73104 USA; Dept Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA; Walter Reed Army Med Ctr, Dept Rheumatol, Washington, DC 20307 USA; NIAMSD, Bethesda, MD 20892 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	James, JA (corresponding author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.	jamesj@omrf.ouhsc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR014467, P20RR015577, P20RR020143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI054117, T32AI007633, R01AI024717, R01AI047575, R37AI024717, R21AI053747, R01AI031584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR048940, R03AR045084, R29AR045451, R01AR042460, P50AR045231, R01AR045451, R01AR048045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015223] Funding Source: NIH RePORTER; NCRR NIH HHS [RR20143, RR14467, RR15577] Funding Source: Medline; NIAID NIH HHS [AI53747, T32 AI007633, AI54117, AI31584, AI24717, AI47575] Funding Source: Medline; NIAMS NIH HHS [AR48045, AR48940, AR45451, AR45084, AR45231, AR42460] Funding Source: Medline; NIDCR NIH HHS [DE015223] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arbuckle MR, 1999, SCAND J IMMUNOL, V50, P447; Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Ascherio A, 2001, JAMA-J AM MED ASSOC, V286, P3083, DOI 10.1001/jama.286.24.3083; DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583; Deshmukh US, 2000, J IMMUNOL, V164, P6655, DOI 10.4049/jimmunol.164.12.6655; Deshmukh US, 1999, J EXP MED, V189, P531, DOI 10.1084/jem.189.3.531; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Harley JB, 1998, IMMUNOLOGIST, V6, P79; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; HUANG SC, 1997, J CLIN IMMUNOL, V156, P4059; James JA, 1997, J CLIN INVEST, V100, P3019, DOI 10.1172/JCI119856; JAMES JA, 1992, J IMMUNOL, V148, P2074; James JA, 2001, ARTHRITIS RHEUM-US, V44, P1122, DOI 10.1002/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D; JAMES JA, 1997, ANN NY ACAD SCI, V5, P124; Kang I, 2004, J IMMUNOL, V172, P1287, DOI 10.4049/jimmunol.172.2.1287; Kirvan CA, 2003, NAT MED, V9, P914, DOI 10.1038/nm892; Kong PL, 2003, ANN NY ACAD SCI, V987, P60, DOI 10.1111/j.1749-6632.2003.tb06033.x; Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509; McClain MT, 2004, P NATL ACAD SCI USA, V101, P3551, DOI 10.1073/pnas.0306267101; McClain MT, 2003, J MED VIROL, V70, P253, DOI 10.1002/jmv.10385; McClain MT, 2002, SCAND J IMMUNOL, V56, P399, DOI 10.1046/j.1365-3083.2002.01141.x; McClain MT, 2002, J IMMUNOL, V168, P2054, DOI 10.4049/jimmunol.168.4.2054; McClain MT, 2001, FRONT BIOSCI-LANDMRK, V6, pE137, DOI 10.2741/McClain; Olsen JK, 2001, J CLIN INVEST, V108, P311; Riemekasten G, 1998, J CLIN INVEST, V102, P754, DOI 10.1172/JCI2749; Routsias JG, 1998, SCAND J IMMUNOL, V47, P280; SABBATINI A, 1993, EUR J IMMUNOL, V23, P1146, DOI 10.1002/eji.1830230525; Scofield AN, 2001, LUPUS, V10, P547, DOI 10.1191/096120301701549679; Thompson MP, 2004, CLIN CANCER RES, V10, P803, DOI 10.1158/1078-0432.CCR-0670-3; VAUGHAN JH, 1995, J CLIN INVEST, V95, P1316, DOI 10.1172/JCI117782	30	296	307	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					85	89		10.1038/nm1167	http://dx.doi.org/10.1038/nm1167			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15619631				2022-12-27	WOS:000226124900037
J	Sano, S; Chan, KS; Carbajal, S; Clifford, J; Peavey, M; Kiguchi, K; Itami, S; Nickoloff, BJ; DiGiovanni, J				Sano, S; Chan, KS; Carbajal, S; Clifford, J; Peavey, M; Kiguchi, K; Itami, S; Nickoloff, BJ; DiGiovanni, J			Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model	NATURE MEDICINE			English	Article							RECOMBINANT GAMMA-INTERFERON; BONE-MARROW TRANSPLANTATION; GROWTH-FACTOR RECEPTOR; CELL-GROWTH; TRANSCRIPTION FACTOR; PLAQUE PSORIASIS; HAIR FOLLICLE; SKIN; EXPRESSION; INHIBITION	Here we report that epidermal keratinocytes in psoriatic lesions are characterized by activated Stat3. Transgenic mice with keratinocytes expressing a constitutively active Stat3 (K5.Stat3C mice) develop a skin phenotype either spontaneously, or in response to wounding, that closely resembles psoriasis. Keratinocytes from K5. Stat3C mice show upregulation of several molecules linked to the pathogenesis of psoriasis. In addition, the development of psoriatic lesions in K5. Stat3C mice requires cooperation between Stat3 activation in keratinocytes and activated T cells. Finally, abrogation of Stat3 function by a decoy oligonucleotide inhibits the onset and reverses established psoriatic lesions in K5. Stat3C mice. Thus, targeting Stat3 may be potentially therapeutic in the treatment of psoriasis.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; Louisiana State Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Feist Weiller Canc Ctr, Shreveport, LA 71130 USA; Osaka Univ, Grad Sch, Dept Dermatol, Suita, Osaka 5650871, Japan; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Microbiol & Immunol, Maywood, IL 60153 USA	University of Texas System; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Osaka University; Loyola University Chicago; Loyola University Chicago	DiGiovanni, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, 1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	ssano@mdanderson.org; jdigiovanni@sprd1.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA076520, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784, U01ES011047] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA76520] Funding Source: Medline; NIAMS NIH HHS [AR40065] Funding Source: Medline; NIEHS NIH HHS [U01ES11047, ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAKER BS, 1988, SCAND J IMMUNOL, V28, P735, DOI 10.1111/j.1365-3083.1988.tb01507.x; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Bos JD, 1999, IMMUNOL TODAY, V20, P40, DOI 10.1016/S0167-5699(98)01381-4; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Christophers E, 1996, INT ARCH ALLERGY IMM, V110, P199, DOI 10.1159/000237288; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; EEDY DJ, 1990, BRIT MED J, V300, P908, DOI 10.1136/bmj.300.6729.908; GARDEMBASPAIN M, 1990, ARCH DERMATOL, V126, P1523, DOI 10.1001/archderm.1990.01670350139033; Ghadially R, 1996, J INVEST DERMATOL, V107, P558, DOI 10.1111/1523-1747.ep12582813; Gilhar A, 1997, J INVEST DERMATOL, V109, P283, DOI 10.1111/1523-1747.ep12335758; Gottlieb AB, 2002, CLIN IMMUNOL, V105, P105, DOI 10.1006/clim.2002.5289; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Koo J, 1997, Adv Dermatol, V12, P47; Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; LEUNG DYM, 1995, J CLIN INVEST, V96, P2106, DOI 10.1172/JCI118263; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lew W, 2004, TRENDS IMMUNOL, V25, P295, DOI 10.1016/j.it.2004.03.006; LEWIS HM, 1993, BRIT J DERMATOL, V129, P514, DOI 10.1111/j.1365-2133.1993.tb00477.x; Li AG, 2004, EMBO J, V23, P1770, DOI 10.1038/sj.emboj.7600183; McKenzie RC, 2003, EXP DERMATOL, V12, P337, DOI 10.1034/j.1600-0625.2003.00100.x; MILLER RAW, 1982, INT J DERMATOL, V21, P192, DOI 10.1111/j.1365-4362.1982.tb02070.x; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; Nickoloff BJ, 1999, AM J PATHOL, V155, P145, DOI 10.1016/S0002-9440(10)65109-7; Ortonne JP, 1996, BRIT J DERMATOL, V135, P1, DOI 10.1111/j.1365-2133.1996.tb15660.x; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Sano S, 2001, J INVEST DERM SYMP P, V6, P43, DOI 10.1046/j.0022-202x.2001.00004.x; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sato T, 1997, BLOOD, V90, P4749, DOI 10.1182/blood.V90.12.4749.4749_4749_4758; Schon MP, 1999, J INVEST DERMATOL, V112, P405, DOI 10.1046/j.1523-1747.1999.00538.x; Takeda J, 2000, J DERMATOL SCI, V23, P147, DOI 10.1016/S0923-1811(00)00082-7; THEWES M, 1991, ARCH DERMATOL RES, V283, P465, DOI 10.1007/BF00371784; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; VALDIMARSSON H, 1995, IMMUNOL TODAY, V16, P145, DOI 10.1016/0167-5699(95)80132-4; WroneSmith T, 1996, J CLIN INVEST, V98, P1878, DOI 10.1172/JCI118989; Xia YP, 2003, BLOOD, V102, P161, DOI 10.1182/blood-2002-12-3793	46	538	596	3	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					43	49		10.1038/nm1162	http://dx.doi.org/10.1038/nm1162			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15592573				2022-12-27	WOS:000226124900031
J	Spanagel, R; Pendyala, G; Abarca, C; Zghoul, T; Sanchis-Segura, C; Magnone, MC; Lascorz, J; Depner, M; Holzberg, D; Soyka, M; Schreiber, S; Matsuda, F; Lathrop, M; Schumann, G; Albrecht, U				Spanagel, R; Pendyala, G; Abarca, C; Zghoul, T; Sanchis-Segura, C; Magnone, MC; Lascorz, J; Depner, M; Holzberg, D; Soyka, M; Schreiber, S; Matsuda, F; Lathrop, M; Schumann, G; Albrecht, U			The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption	NATURE MEDICINE			English	Article							AMINO-ACIDS; COCAINE SENSITIZATION; CIRCADIAN GENES; ACAMPROSATE; ETHANOL; DEPENDENCE; DOPAMINE; EXPRESSION; REWARD; NEUROBIOLOGY	Period (Per) genes are involved in regulation of the circadian clock and are thought to modulate several brain functions. We demonstrate that Per2(Brdm1) mutant mice, which have a deletion in the PAS domain of the Per2 protein, show alterations in the glutamatergic system. Lowered expression of the glutamate transporter Eaat1 is observed in these animals, leading to reduced uptake of glutamate by astrocytes. As a consequence, glutamate levels increase in the extracellular space of Per2(Brdm1) mutant mouse brains. This is accompanied by increased alcohol intake in these animals. In humans, variations of the PER2 gene are associated with regulation of alcohol consumption. Acamprosate, a drug used to prevent craving and relapse in alcoholic patients is thought to act by dampening a hyper-glutamatergic state. This drug reduced augmented glutamate levels and normalized increased alcohol consumption in Per2(Brdm1) mutant mice. Collectively, these data establish glutamate as a link between dysfunction of the circadian clock gene Per2 and enhanced alcohol intake.	Cent Inst Mental Hlth, Dept Psychopharmacol, D-68159 Mannheim, Germany; Cent Inst Mental Hlth, Dept Psychiat, D-68159 Mannheim, Germany; Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland; Free Univ Brussels, Dept Pharmaceut Chem, B-1090 Brussels, Belgium; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany; Univ Munich, Dept Psychiat & Psychotherapy, D-80336 Munich, Germany; Univ Kiel, Inst Clin Mol Biol, UKSH Kiel, D-24098 Kiel, Germany; Ctr Natl Genotypage, F-91057 Evry, France	Central Institute of Mental Health; Central Institute of Mental Health; University of Fribourg; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Max Planck Society; University of Munich; University of Kiel; Schleswig Holstein University Hospital; CEA; UDICE-French Research Universities; Universite Paris Saclay	Spanagel, R (corresponding author), Cent Inst Mental Hlth, Dept Psychopharmacol, J5, D-68159 Mannheim, Germany.	spanagel@zi-mannheim.de; urs.albrecht@unifr.ch	Sanchis-Segura, Carla/C-5222-2012; Albrecht, Urs/A-9831-2011; Matsuda, Fumihiko/B-9893-2009; Schumann, Gunter/H-1013-2013; Jansen, Heiko T./A-5770-2008; s, c/Y-9655-2019	Sanchis-Segura, Carla/0000-0002-6951-5972; Albrecht, Urs/0000-0002-0663-8676; Jansen, Heiko T./0000-0003-0178-396X; s, c/0000-0002-6951-5972				Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099; Albrecht U, 2001, J BIOL RHYTHM, V16, P100, DOI 10.1177/074873001129001791; Albrecht U, 2002, J APPL PHYSIOL, V92, P1348, DOI 10.1152/japplphysiol.00759.2001; Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Aronica E, 2003, EUR J NEUROSCI, V17, P2106, DOI 10.1046/j.1460-9568.2003.02657.x; BUCHOLZ KK, 1994, J STUD ALCOHOL, V55, P149, DOI 10.15288/jsa.1994.55.149; Buijs RM, 2001, NAT REV NEUROSCI, V2, P521, DOI 10.1038/35081582; Cano-Cebrian MJ, 2003, N-S ARCH PHARMACOL, V368, P324, DOI 10.1007/s00210-003-0795-3; Dahchour A, 2000, PROG NEUROBIOL, V60, P343, DOI 10.1016/S0301-0082(99)00031-3; Dahchour A, 2003, ALCOHOL CLIN EXP RES, V27, P465, DOI 10.1097/01.ALC.0000056617.68874.18; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Ebling FJP, 1996, PROG NEUROBIOL, V50, P109, DOI 10.1016/S0301-0082(96)00032-9; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; Heinz A, 2003, PHARMACOPSYCHIATRY, V36, pS255; Jelic P, 1998, PSYCHOPHARMACOLOGY, V138, P143, DOI 10.1007/s002130050656; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Koob GF, 2002, ALCOHOL CLIN EXP RES, V26, P586, DOI 10.1111/j.1530-0277.2002.tb02578.x; Krystal JH, 2003, PHARMACOL THERAPEUT, V99, P79, DOI 10.1016/S0163-7258(03)00054-8; Le AD, 2002, PHARMACOL THERAPEUT, V94, P137, DOI 10.1016/S0163-7258(02)00200-0; LITTLETON J, 1995, ADDICTION, V90, P1179, DOI 10.1046/j.1360-0443.1995.90911793.x; LIU Y, IN PRESS NEUROPSYCHO; Mann K, 2004, ALCOHOL CLIN EXP RES, V28, P51, DOI 10.1097/01.ALC.0000108656.81563.05; Masubuchi S, 2000, EUR J NEUROSCI, V12, P4206, DOI 10.1046/j.1460-9568.2000.01313.x; Matsumoto H, 2002, ADDICT BIOL, V7, P5, DOI 10.1080/135562101200100553; McQuade JA, 2003, ADDICT BIOL, V8, P295, DOI 10.1080/13556210310001602202; Nikaido T, 2001, MOL PHARMACOL, V59, P894, DOI 10.1124/mol.59.4.894; Pulvirenti L, 2001, REV NEUROSCIENCE, V12, P141; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rogers H Lynn, 2002, AAOHN J, V50, P449; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Salamone JD, 2003, J PHARMACOL EXP THER, V305, P1, DOI 10.1124/jpet.102.035063; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; Schreiber R, 2000, Med Sci Monit, V6, P649; Schumann G, 2003, BIOL PSYCHIAT, V54, P1422, DOI 10.1016/S0006-3223(03)00635-8; Siggins GR, 2003, ANN NY ACAD SCI, V1003, P196, DOI 10.1196/annals.1300.012; SMOLDERS I, 1995, J NEUROSCI METH, V57, P47, DOI 10.1016/0165-0270(94)00124-Y; Spanagel R, 2002, J NEUROSCI, V22, P8676; Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(97)89800-8; Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2; SPANAGEL R, 2002, IONOTROPIC GLUTAMATE, P1; Trinkoff AM, 1998, AM J IND MED, V34, P266, DOI 10.1002/(SICI)1097-0274(199809)34:3<266::AID-AJIM9>3.3.CO;2-#; Tsai GC, 1998, ANNU REV MED, V49, P173; Weiss F, 2002, J NEUROSCI, V22, P3332; Yan L, 2002, EUR J NEUROSCI, V16, P1531, DOI 10.1046/j.1460-9568.2002.02224.x; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	48	440	448	4	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2005	11	1					35	42		10.1038/nm1163	http://dx.doi.org/10.1038/nm1163			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	884ZJ	15608650	Green Submitted			2022-12-27	WOS:000226124900030
J	Shibata, R; Ouchi, N; Ito, M; Kihara, S; Shiojima, I; Pimentel, DR; Kumada, M; Sato, K; Schiekofer, S; Ohashi, K; Funahashi, T; Colucci, WS; Walsh, K				Shibata, R; Ouchi, N; Ito, M; Kihara, S; Shiojima, I; Pimentel, DR; Kumada, M; Sato, K; Schiekofer, S; Ohashi, K; Funahashi, T; Colucci, WS; Walsh, K			Adiponectin-mediated modulation of hypertrophic signals in the heart	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; FATTY-ACID OXIDATION; INSULIN-RESISTANCE; PRESSURE-OVERLOAD; STIMULATES ANGIOGENESIS; GLUCOSE-TRANSPORT; ENDOTHELIAL-CELLS; GLOBULAR DOMAIN; ADIPOCYTES	Patients with diabetes and other obesity-linked conditions have increased susceptibility to cardiovascular disorders(1). The adipocytokine adiponectin is decreased in patients with obesity-linked diseases(2). Here, we found that pressure overload in adiponectin-deficient mice resulted in enhanced concentric cardiac hypertrophy and increased mortality that was associated with increased extracellular signal-regulated kinase (ERK) and diminished AMP-activated protein kinase (AMPK) signaling in the myocardium. Adenovirus-mediated supplemention of adiponectin attenuated cardiac hypertrophy in response to pressure overload in adiponectin-deficient, wild-type and diabetic db/db mice. In cultures of cardiac myocytes, adiponectin activated AMPK and inhibited agonist-stimulated hypertrophy and ERK activation. Transduction with a dominant-negative form of AMPK reversed these effects, suggesting that adiponectin inhibits hypertrophic signaling in the myocardium through activation of AMPK signaling. Adiponectin may have utility for the treatment of hypertrophic cardiomyopathy associated with diabetes and other obesity-related diseases.	Boston Univ, Sch Med, Mol Cardiol Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Myocardial Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Cardiovasc Med Sect, Boston, MA 02118 USA; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan	Boston University; Boston University; Boston University; Osaka University	Walsh, K (corresponding author), Boston Univ, Sch Med, Mol Cardiol Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.	kxwalsh@bu.edu	OUCHI, Noriyuki/I-7306-2014	Walsh, Kenneth/0000-0001-7580-2276; Colucci, Wilson/0000-0002-0576-9420; Pimentel, David/0000-0002-0537-7195	NHLBI NIH HHS [HL66957, T32 HL007224, P01 HL066957, HL61639, HL20612, P01 HL066957-030004, R01 HL061639] Funding Source: Medline; NIAMS NIH HHS [R01 AR040197-14, AR40197, R01 AR040197] Funding Source: Medline; NIA NIH HHS [AG17241, R01 AG017241-03, R01 AG015052-02, R01 AG017241, R37 AG015052, AG15052, R01 AG015052] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007224, R01HL061639, P01HL066957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG017241, R01AG015052] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Chan AYM, 2004, J BIOL CHEM, V279, P32771, DOI 10.1074/jbc.M403528200; Esposito G, 2001, CIRCULATION, V103, P1453, DOI 10.1161/01.CIR.103.10.1453; Ilercil A, 2001, AM HEART J, V141, P992, DOI 10.1067/mhj.2001.115302; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Reilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; Rutter MK, 2003, CIRCULATION, V107, P448, DOI 10.1161/01.CIR.0000045671.62860.98; Schannwell CM, 2002, CARDIOLOGY, V98, P33, DOI 10.1159/000064682; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shibata R, 2004, J BIOL CHEM, V279, P28670, DOI 10.1074/jbc.M402558200; Tian R, 2001, CIRCULATION, V104, P1664, DOI 10.1161/hc4001.097183; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355; Xiao L, 2001, J MOL CELL CARDIOL, V33, P779, DOI 10.1006/jmcc.2001.1348; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	24	562	612	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2004	10	12					1384	1389		10.1038/nm1137	http://dx.doi.org/10.1038/nm1137			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	876MK	15558058	Green Accepted			2022-12-27	WOS:000225500900034
J	Zaph, C; Uzonna, J; Beverley, SM; Scott, P				Zaph, C; Uzonna, J; Beverley, SM; Scott, P			Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites	NATURE MEDICINE			English	Article							LYMPHOCYTES IN-VIVO; PROTECTIVE IMMUNITY; EFFECTOR; VACCINE; INFECTION; ANTIGEN; SUBSETS; IMMUNOLOGY; GENERATION; INDUCTION	Infection with Leishmania major induces a protective immune response and long-term resistance to reinfection, which is thought to depend upon persistent parasites. Here we demonstrate that although effector CD4(+) T cells are lost in the absence of parasites, central memory CD4(+) T cells are maintained. Upon secondary infection, these central memory T cells become tissue-homing effector T cells and mediate protection. Thus, immunity to L. major is mediated by at least two distinct populations of CD4(+) T cells: short-lived pathogen-dependent effector cells and long-lived pathogen-independent central memory cells. These data suggest that central memory T cells should be the targets for nonlive vaccines against infectious diseases requiring cell-mediated immunity.	Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA; Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA	University of Pennsylvania; Washington University (WUSTL)	Scott, P (corresponding author), Univ Penn, Dept Pathobiol, 3800 Spruce St, Philadelphia, PA 19104 USA.	pscott@vet.upenn.edu		Zaph, Colby/0000-0002-9889-9848; Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI35914] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035914, R21AI035914] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; BRADLEY LM, 1994, J EXP MED, V180, P2401, DOI 10.1084/jem.180.6.2401; Brodskyn C, 2000, CLIN EXP IMMUNOL, V119, P299, DOI 10.1046/j.1365-2249.2000.01122.x; Bunce C, 1997, J EXP MED, V185, P767, DOI 10.1084/jem.185.4.767; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; Desrosiers RC, 2004, NAT MED, V10, P221, DOI 10.1038/nm0304-221; Doyle AM, 2001, J EXP MED, V194, P893, DOI 10.1084/jem.194.7.893; Flynn JL, 2004, TUBERCULOSIS, V84, P93, DOI 10.1016/j.tube.2003.08.010; Garcia S, 1999, IMMUNITY, V11, P163, DOI 10.1016/S1074-7613(00)80091-6; Gicheru MM, 2001, INFECT IMMUN, V69, P245, DOI 10.1128/IAI.69.1.245-251.2001; Gray D, 2002, NAT REV IMMUNOL, V2, P60, DOI 10.1038/nri706; Gurunathan S, 1998, NAT MED, V4, P1409, DOI 10.1038/4000; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Harbertson J, 2002, J IMMUNOL, V168, P1095, DOI 10.4049/jimmunol.168.3.1095; Iezzi G, 2001, J EXP MED, V193, P987, DOI 10.1084/jem.193.8.987; JUNG TM, 1988, J IMMUNOL, V141, P4110; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; Lanzavecchia A, 2002, NAT REV IMMUNOL, V2, P982, DOI 10.1038/nri959; London CA, 1999, J IMMUNOL, V162, P766; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Mocci S, 1997, J IMMUNOL, V158, P1559; MOCCI S, 1995, J IMMUNOL, V154, P3779; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; PICKER LJ, 1990, J IMMUNOL, V145, P3247; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Rhee EG, 2002, J EXP MED, V195, P1565, DOI 10.1084/jem.20020147; Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SCOTT P, 1987, J IMMUNOL, V139, P221; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; Uzonna JE, 2001, J IMMUNOL, V167, P6967, DOI 10.4049/jimmunol.167.12.6967; Wang XW, 2001, J EXP MED, V194, P1069, DOI 10.1084/jem.194.8.1069; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Zaph C, 2003, J IMMUNOL, V171, P4726, DOI 10.4049/jimmunol.171.9.4726; Zinkernagel RM, 2003, ANNU REV IMMUNOL, V21, P515, DOI 10.1146/annurev.immunol.21.120601.141045	41	263	275	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1104	1110		10.1038/nm1108	http://dx.doi.org/10.1038/nm1108			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15448686				2022-12-27	WOS:000224245800041
J	Miyahara, N; Swanson, BJ; Takeda, K; Taube, C; Miyahara, S; Kodama, T; Dakhama, A; Ott, VL; Gelfand, EW				Miyahara, N; Swanson, BJ; Takeda, K; Taube, C; Miyahara, S; Kodama, T; Dakhama, A; Ott, VL; Gelfand, EW			Effector CD8(+) T cells mediate inflammation and airway hyper-responsiveness	NATURE MEDICINE			English	Article							ASTHMA; MICE; LYMPHOCYTES; INTERLEUKIN-13; RESPONSES; IL-13	Allergic asthma is a complex syndrome characterized by airway obstruction, airway inflammation and airway hyperresponsiveness (AHR). Using a mouse model of allergen-induced AHR, we previously demonstrated that CD8-deficient mice develop significantly lower AHR, eosinophilic inflammation and interleukin (IL)-13 levels in bronchoalveolar lavage fluid compared with wild-type mice. These responses were restored by adoptive transfer of antigen-primed CD8(+) T cells(1). Previously, two distinct populations of antigen-experienced CD8(+) T cells, termed effector (T-EFF) and central memory (T-CM) cells, have been described(2-5). After adoptive transfer into CD8-deficient mice, T-EFF, but not T-CM, cells restored AHR, eosinophilic inflammation and IL-13 levels. T-EFF, but not T-CM, cells accumulated in the lungs, and intracellular cytokine staining showed that the transferred T-EFF cells were a source of IL-13. These data suggest an important role for effector CD8(+) T cells in the development of AHR and airway inflammation, which may be associated with their Tc2-type cytokine production and their capacity to migrate into the lung.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO USA	National Jewish Health; National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA.	gelfande@njc.org			NHLBI NIH HHS [HL-36577, HL-61005] Funding Source: Medline; NIAID NIH HHS [AI-42246, AI-52225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061005, P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052225, R21AI042246, R01AI042246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; DeSanctis GT, 1997, NAT MED, V3, P460, DOI 10.1038/nm0497-460; FABIEN N, 1995, J AUTOIMMUN, V8, P323, DOI 10.1006/jaut.1994.0025; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; Grunstein MM, 2002, AM J PHYSIOL-LUNG C, V282, pL520, DOI 10.1152/ajplung.00343.2001; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hoshino T, 1999, J IMMUNOL, V162, P5070; Manjunath N, 2001, J CLIN INVEST, V108, P871, DOI 10.1172/JCI13296; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Miyahara N, 2004, J IMMUNOL, V172, P2549, DOI 10.4049/jimmunol.172.4.2549; O'Sullivan S, 2001, AM J RESP CRIT CARE, V164, P560, DOI 10.1164/ajrccm.164.4.2102018; Oshiba A, 1997, J IMMUNOL, V159, P4056; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Swanson BJ, 2002, IMMUNITY, V17, P605, DOI 10.1016/S1074-7613(02)00456-9; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; WATANABE A, 1995, J CLIN INVEST, V96, P1303, DOI 10.1172/JCI118165; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	25	139	148	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2004	10	8					865	869		10.1038/nm1081	http://dx.doi.org/10.1038/nm1081			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	843DK	15258576				2022-12-27	WOS:000223055700042
J	Basu, P				Basu, P			Profile - Clive Svendsen	NATURE MEDICINE			English	Biographical-Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2004	10	7					659	659		10.1038/nm0704-659	http://dx.doi.org/10.1038/nm0704-659			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15229500				2022-12-27	WOS:000222460400008
J	Howard, JK; Cave, BJ; Oksanen, LJ; Tzameli, I; Bjorbaek, C; Flier, JS				Howard, JK; Cave, BJ; Oksanen, LJ; Tzameli, I; Bjorbaek, C; Flier, JS			Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3	NATURE MEDICINE			English	Article							HYPOTHALAMIC NEURONS; INSULIN SENSITIVITY; BODY-WEIGHT; IN-VIVO; RESISTANCE; RECEPTOR; IDENTIFICATION; CHANNELS	Leptin is an adipocyte-derived hormone that regulates energy balance and neuroendocrine function primarily by acting on specific hypothalamic pathways(1,2). Resistance to the weight reducing effects of leptin is a feature of most cases of human and rodent obesity(1,2), yet the molecular basis of leptin resistance is poorly understood. We have previously identified suppressor of cytokine signaling-3 (Socs3) as a leptin-induced negative regulator of leptin receptor signaling and potential mediator of leptin resistance(3-5). However, due to the non-viability of mice with targeted disruption of Socs3 (ref. 6), the importance of Socs3 in leptin action in vivo was unclear. To determine the functional significance of Socs3 in energy balance in vivo we undertook studies in mice with heterozygous Socs3 deficiency (Socs3(+/-)). We report here that Socs3(+/-) mice display greater leptin sensitivity than wild-type control mice: Socs3(+/-) mice show both enhanced weight loss and increased hypothalamic leptin receptor signaling in response to exogenous leptin administration. Furthermore, Socs3(+/-) mice are significantly protected against the development of diet-induced obesity and associated metabolic complications. The level of Socs3 expression is thus a critical determinant of leptin sensitivity and obesity susceptibility in vivo and this molecule is a potential target for therapeutic intervention.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Flier, JS (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA.	jflier@bidmc.harvard.edu	Bjorbaek, Christian/S-4727-2019; Flier, jeffrey/AAG-6223-2019	Howard, Jane/0000-0003-2754-8300				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lin S, 2000, INT J OBESITY, V24, P639, DOI 10.1038/sj.ijo.0801209; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; SALMON DMW, 1985, INT J OBESITY, V9, P443; Scarpace PJ, 2002, ENDOCRINOLOGY, V143, P3026, DOI 10.1210/en.143.8.3026; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; SHI H, IN PRESS J BIOL CHEM; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Wang ZW, 2000, BIOCHEM BIOPH RES CO, V277, P20, DOI 10.1006/bbrc.2000.3615; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X	29	362	387	7	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					734	738		10.1038/nm1072	http://dx.doi.org/10.1038/nm1072			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15220914				2022-12-27	WOS:000222460400028
J	Brozovic, S; Nagaishi, T; Yoshida, M; Betz, S; Salas, A; Chen, DH; Kaser, A; Glickman, J; Kuo, T; Little, A; Morrison, J; Corazza, N; Kim, JY; Colgan, SP; Young, SG; Exley, M; Blumberg, RS				Brozovic, S; Nagaishi, T; Yoshida, M; Betz, S; Salas, A; Chen, DH; Kaser, A; Glickman, J; Kuo, T; Little, A; Morrison, J; Corazza, N; Kim, JY; Colgan, SP; Young, SG; Exley, M; Blumberg, RS			CD1d function is regulated by microsomal triglyceride transfer protein	NATURE MEDICINE			English	Article							NKT CELLS; LIVER; RECOGNITION	CD1d is a major histocompatibility complex (MHC) class I-related molecule that functions in glycolipid antigen presentation to distinct subsets of T cells that express natural killer receptors and an invariant T-cell receptor-alpha chain (invariant NKT cells)(1-3). The acquisition of glycolipid antigens by CD1d occurs, in part, in endosomes through the function of resident lipid transfer proteins, namely saposins(4-10). Here we show that microsomal triglyceride transfer protein (MTP), a protein that resides in the endoplasmic reticulum of hepatocytes and intestinal epithelial cells (IECs) and is essential for lipidation of apolipoprotein B-11,B-12, associates with CD1d in hepatocytes. Hepatocytes from animals in which Mttp (the gene encoding MTP) has been conditionally deleted, and IECs in which Mttp gene products have been silenced, are unable to activate invariant NKT cells. Conditional deletion of the Mttp gene in hepatocytes is associated with a redistribution of CD1d expression, and Mttp-deleted mice are resistant to immunopathologies associated with invariant NKT cell-mediated hepatitis and colitis. These studies indicate that the CD1d-regulating function of MTP in the endoplasmic reticulum is complementary to that of the saposins in endosomes in vivo.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Gastroenterol Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94110 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco; The J David Gladstone Institutes; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Blumberg, RS (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Gastroenterol Div, Boston, MA 02115 USA.	rblumberg@partners.org	Eckhardt, Erik/G-1567-2010; Salas, Azucena/AAN-7035-2020; Colgan, Sean P./B-4573-2009	Salas, Azucena/0000-0003-4572-2907; Young, Stephen/0000-0001-7270-3176; Exley, Mark/0000-0002-5088-1032; Little, Alicia/0000-0003-0066-9372; KIM, JINYONG/0000-0003-2068-7287	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044319, R37DK044319, R01DK051362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51362, DK44319] Funding Source: Medline; NIGMS NIH HHS [T32 GM007205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Behar SM, 1999, J IMMUNOL, V162, P161; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Bjorkegren J, 2002, J BIOL CHEM, V277, P5476, DOI 10.1074/jbc.M108514200; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; Chen DH, 2004, J IMMUNOL, V172, P3535, DOI 10.4049/jimmunol.172.6.3535; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; De Silva AD, 2002, J IMMUNOL, V168, P723, DOI 10.4049/jimmunol.168.2.723; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Kang SJ, 2002, J BIOL CHEM, V277, P44838, DOI 10.1074/jbc.M207831200; KANT SJ, 2004, NAT IMMUNOL, V5, P175; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; Nieuwenhuis EES, 2002, NAT MED, V8, P588, DOI 10.1038/nm0602-588; Osman Y, 2000, EUR J IMMUNOL, V30, P1919, DOI 10.1002/1521-4141(200007)30:7<1919::AID-IMMU1919>3.0.CO;2-3; Park JJ, 2004, P NATL ACAD SCI USA, V101, P1022, DOI 10.1073/pnas.0307847100; Prigozy TI, 2001, SCIENCE, V291, P664, DOI 10.1126/science.291.5504.664; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; RALF K, 1995, SCIENCE, V269, P1427; Roberts TJ, 2002, J IMMUNOL, V168, P5409, DOI 10.4049/jimmunol.168.11.5409; van de Wal Y, 2003, GASTROENTEROLOGY, V124, P1420, DOI 10.1016/S0016-5085(03)00219-1; Vincent MS, 2003, NAT IMMUNOL, V4, P517, DOI 10.1038/ni0603-517; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; Winau F, 2004, NAT IMMUNOL, V5, P169, DOI 10.1038/ni1035; Zhou DP, 2004, SCIENCE, V303, P523, DOI 10.1126/science.1092009	30	139	143	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					535	539		10.1038/nm1043	http://dx.doi.org/10.1038/nm1043			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15107843				2022-12-27	WOS:000221242400033
J	Callewaert, N; Van Vlierberghe, H; Van Hecke, A; Laroy, W; Delanghe, J; Contreras, R				Callewaert, N; Van Vlierberghe, H; Van Hecke, A; Laroy, W; Delanghe, J; Contreras, R			Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; ASIALOGLYCOPROTEIN RECEPTOR; BIOCHEMICAL MARKERS; DISEASE; COMPLICATIONS; EXPRESSION; FIBROSIS; BIOPSY	We applied our 'clinical glycomics' technology, based on DNA sequencer/fragment analyzers, to generate profiles of serum protein N-glycans of liver disease patients. This technology yielded a biomarker that distinguished compensated cirrhotic from noncirrhotic chronic liver disease patients, with 79% sensitivity and 86% specificity (100% sensitivity and specificity for decompensated cirrhosis). In combination with the clinical chemistry-based Fibrotest biomarker, compensated cirrhosis was detected with 100% specificity and 75% sensitivity. The current 'gold standard' for liver cirrhosis detection is an invasive, costly, often painful liver biopsy. Consequently, the highly specific set of biomarkers presented could obviate biopsy in many cirrhosis patients. This biomarker combination could eventually be used in follow-up examinations of chronic liver disease patients, to yield a warning that cirrhosis has developed and that the risk of complications (such as hepatocellular carcinoma) has increased considerably. Our clinical glycomics technique can easily be implemented in existing molecular diagnostics laboratories.	Univ Ghent, Dept Mol Biomed Res, B-9052 Zwijnaarde, Belgium; VIB, B-9052 Zwijnaarde, Belgium; Ghent Univ Hosp, Dept Gastroenterol & Hepatol, B-9000 Ghent, Belgium; Ghent Univ Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Callewaert, N (corresponding author), Swiss Fed Inst Technol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.	natmedcontact@dmbr.Ugent.be		Van Vlierberghe, Hans/0000-0003-0647-9238; Callewaert, Nico/0000-0003-2069-6917; Van Hecke, Annelies/0000-0002-3010-8034				ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Cadranel JF, 2000, HEPATOLOGY, V32, P477, DOI 10.1053/jhep.2000.16602; Callewaert N, 2001, GLYCOBIOLOGY, V11, P275, DOI 10.1093/glycob/11.4.275; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; HENDERSON AR, 1993, ANN CLIN BIOCHEM, V30, P521, DOI 10.1177/000456329303000601; Imbert-Bismut F, 2001, LANCET, V357, P1069, DOI 10.1016/S0140-6736(00)04258-6; Ise H, 2001, BIOCHEM BIOPH RES CO, V285, P172, DOI 10.1006/bbrc.2001.5139; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; Kuper H, 2001, HEPATOLOGY, V34, P714, DOI 10.1053/jhep.2001.28233; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; Menon KVN, 2000, MAYO CLIN PROC, V75, P501; Miyoshi E, 1995, HEPATOLOGY, V22, P1847, DOI 10.1002/hep.1840220634; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7; Poynard T, 2002, J VIRAL HEPATITIS, V9, P128, DOI 10.1046/j.1365-2893.2002.00341.x; SAWAMURA T, 1984, GASTROENTEROLOGY, V87, P1217; Staudt LM, 2003, NEW ENGL J MED, V348, P1777, DOI 10.1056/NEJMra020067; STIBLER H, 1991, CLIN CHEM, V37, P2029; Wulfkuhle JD, 2003, NAT REV CANCER, V3, P267, DOI 10.1038/nrc1043	22	331	361	5	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					429	434		10.1038/nm1006	http://dx.doi.org/10.1038/nm1006			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15152612				2022-12-27	WOS:000220587000037
J	Yan, JJ; Jung, JS; Lee, JE; Lee, J; Huh, SO; Kim, HS; Jung, KC; Cho, JY; Nam, JS; Suh, HW; Kim, YH; Song, DK				Yan, JJ; Jung, JS; Lee, JE; Lee, J; Huh, SO; Kim, HS; Jung, KC; Cho, JY; Nam, JS; Suh, HW; Kim, YH; Song, DK			Therapeutic effects of lysophosphatidylcholine in experimental sepsis	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN T-LYMPHOCYTES; HUMAN-MONOCYTES; INDUCED APOPTOSIS; GROWTH-FACTOR; ACTIVATION; MACROPHAGES; MORTALITY; LIGAND; MODEL	Sepsis represents a major cause of death in intensive care units. Here we show that administration of lysophosphatidylcholine (LPC), an endogenous lysophospholipid, protected mice against lethality after cecal ligation and puncture (CLP) or intraperitoneal injection of Escherichia coli. In vivo treatment with LPC markedly enhanced clearance of intraperitoneal bacteria and blocked CLP-induced deactivation of neutrophils. In vitro, LPC increased bactericidal activity of neutrophils, but not macrophages, by enhancing H2O2 production in neutrophils that ingested E. coli. Incubation with an antibody to the LPC receptor, G2A, inhibited LPC-induced protection from CLP lethality and inhibited the effects of LPC in neutrophils. G2A-specific antibody also blocked the inhibitory effects of LPC on certain actions of lipopolysaccharides (LPS), including lethality and the release of tumor necrosis factor-alpha (TNF-alpha) from neutrophils. These results suggest that LPC can effectively prevent and treat sepsis and microbial infections.	Hallym Univ, Inst Nat Med, Coll Med, Dept Pharmacol, Chunchon 200702, Gangwon Do, South Korea; Hallym Univ, Inst Nat Med, Coll Med, Dept Pathol, Chunchon 200702, Gangwon Do, South Korea; Hallym Univ, Biosynergen Inc, Chunchon 200702, Gangwon Do, South Korea	Hallym University; Hallym University; Hallym University	Song, DK (corresponding author), Hallym Univ, Inst Nat Med, Coll Med, Dept Pharmacol, 1 Okchon Dong, Chunchon 200702, Gangwon Do, South Korea.	dksong@hallym.ac.kr	Jung, Kyeong Choen/C-6068-2011	Jung, Kyeong Choen/0000-0002-7741-7184; Suh, HongWon/0000-0001-8691-6797				ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; Ayala A, 1998, BLOOD, V91, P1362, DOI 10.1182/blood.V91.4.1362; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; CORR PB, 1982, AM J PHYSIOL, V243, pH187, DOI 10.1152/ajpheart.1982.243.2.H187; Coutant F, 2002, J IMMUNOL, V169, P1688, DOI 10.4049/jimmunol.169.4.1688; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; De Vries HE, 1998, FASEB J, V12, P111, DOI 10.1096/fasebj.12.1.111; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Drobnik W, 2003, J LIPID RES, V44, P754, DOI 10.1194/jlr.M200401-JLR200; Gomez-Munoz A, 1999, J LIPID RES, V40, P988; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hoyert D L, 1999, Natl Vital Stat Rep, V47, P1; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Huber-Lang MS, 2001, FASEB J, V15, P568; Kabarowski JHS, 2002, BIOCHEM PHARMACOL, V64, P161, DOI 10.1016/S0006-2952(02)01179-6; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Kobold ACM, 2000, INTENS CARE MED, V26, P883, DOI 10.1007/s001340051277; Liu-Wu Y, 1998, ATHEROSCLEROSIS, V137, P351, DOI 10.1016/S0021-9150(97)00295-5; Macphee Colin H., 2001, Current Opinion in Pharmacology, V1, P121, DOI 10.1016/S1471-4892(01)00024-8; Matsumoto T, 1997, FEMS IMMUNOL MED MIC, V17, P171, DOI 10.1016/S0928-8244(97)00005-9; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; Nakahata E, 2001, COMP BIOCHEM PHYS A, V130, P653, DOI 10.1016/S1095-6433(01)00396-8; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NGWENYA BZ, 1986, CANCER IMMUNOL IMMUN, V21, P174; Nishi E, 1998, CIRC RES, V83, P508, DOI 10.1161/01.RES.83.5.508; Nishi E, 1997, CIRC RES, V80, P638, DOI 10.1161/01.RES.80.5.638; Nishioka H, 1998, FEBS LETT, V441, P63, DOI 10.1016/S0014-5793(98)01526-9; Okajima F, 1998, BIOCHEM J, V336, P491, DOI 10.1042/bj3360491; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Qureshi M.A., 1995, METHODS IMMUNOTOXICO, V2, P119; Ramos MA, 1998, ARTERIOSCL THROM VAS, V18, P1188, DOI 10.1161/01.ATV.18.7.1188; Remick DG, 2001, CRIT CARE MED, V29, P473, DOI 10.1097/00003246-200103000-00001; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SAVAGE JE, 1993, J INVEST DERMATOL, V101, P532, DOI 10.1111/1523-1747.ep12365905; Silliman CC, 2003, J LEUKOCYTE BIOL, V73, P511, DOI 10.1189/jlb.0402179; SOLOMKIN JS, 1981, SURGERY, V90, P319; SZUCS S, 1994, J IMMUNOL METHODS, V167, P245, DOI 10.1016/0022-1759(94)90093-0; Tzianabos AO, 1999, J IMMUNOL, V163, P893; WANG SD, 1994, J IMMUNOL, V152, P5014; Weighardt H, 2002, ANN SURG, V235, P560, DOI 10.1097/00000658-200204000-00015; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Zantl N, 1998, INFECT IMMUN, V66, P2300, DOI 10.1128/IAI.66.5.2300-2309.1998; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	47	255	275	2	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					161	167		10.1038/nm989	http://dx.doi.org/10.1038/nm989			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14716308				2022-12-27	WOS:000188719600035
J	Cosby, K; Partovi, KS; Crawford, JH; Patel, RP; Reiter, CD; Martyr, S; Yang, BK; Waclawiw, MA; Zalos, G; Xu, XL; Huang, KT; Shields, H; Kim-Shapiro, DB; Schechter, AN; Cannon, RO; Gladwin, MT				Cosby, K; Partovi, KS; Crawford, JH; Patel, RP; Reiter, CD; Martyr, S; Yang, BK; Waclawiw, MA; Zalos, G; Xu, XL; Huang, KT; Shields, H; Kim-Shapiro, DB; Schechter, AN; Cannon, RO; Gladwin, MT			Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE RELAXATION; REGIONAL BLOOD-FLOW; S-NITROSOHEMOGLOBIN; SODIUM-NITRITE; XANTHINE-OXIDASE; AUTOCATALYTIC OXIDATION; GLYCERYL TRINITRATE; BIOLOGICAL-SYSTEMS; SYNTHASE ACTIVITY; HUMAN-HEMOGLOBIN	Nitrite anions comprise the largest vascular storage pool of nitric oxide (NO), provided that physiological mechanisms exist to reduce nitrite to NO. We evaluated the vasodilator properties and mechanisms for bioactivation of nitrite in the human forearm. Nitrite infusions of 36 and 0.36 mumol/ min into the forearm brachial artery resulted in supra- and near- physiologic intravascular nitrite concentrations, respectively, and increased forearm blood flow before and during exercise, with or without NO synthase inhibition. Nitrite infusions were associated with rapid formation of erythrocyte iron- nitrosylated hemoglobin and, to a lesser extent, S- nitroso- hemoglobin. NO- modified hemoglobin formation was inversely proportional to oxyhemoglobin saturation. Vasodilation of rat aortic rings and formation of both NO gas and NO- modified hemoglobin resulted from the nitrite reductase activity of deoxyhemoglobin and deoxygenated erythrocytes. This finding links tissue hypoxia, hemoglobin allostery and nitrite bioactivation. These results suggest that nitrite represents a major bioavailable pool of NO, and describe a new physiological function for hemoglobin as a nitrite reductase, potentially contributing to hypoxic vasodilation.	NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; Univ Alabama, Dept Pathol, Ctr Free Rad Biol, Birmingham, AL 35294 USA; NIDDKD, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Off Biostat Res, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; Wake Forest Univ, Sch Med, Dept Biomed Engn, Winston Salem, NC 27157 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Wake Forest University; Wake Forest University	Gladwin, MT (corresponding author), NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bldg 10,10 Ctr Dr,Room 7D43, Bethesda, MD 20892 USA.		Kim-Shapiro, Daniel/HGA-2682-2022	Patel, Rakesh/0000-0002-1526-4303; Schechter, Alan N/0000-0002-5235-9408	NHLBI NIH HHS [HL58091, R01 HL058091, R01HL70146] Funding Source: Medline; NIGMS NIH HHS [T32GM08361] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005063, R29HL058091, R01HL058091, R37HL058091, R01HL070146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008361] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agvald P, 2002, BRIT J PHARMACOL, V135, P373, DOI 10.1038/sj.bjp.0704489; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; Cicinelli E, 1999, CLIN PHYSIOL, V19, P440, DOI 10.1046/j.1365-2281.1999.00200.x; Crawford JH, 2003, BLOOD, V101, P4408, DOI 10.1182/blood-2002-12-3825; Demoncheaux EAG, 2002, CLIN SCI, V102, P77, DOI 10.1042/CS20010232; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; Fernandez BO, 2003, INORG CHEM, V42, P2, DOI 10.1021/ic020519r; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; GLADWIN MT, 2002, J BIOL CHEM, V21, P21; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; Huang KT, 2001, P NATL ACAD SCI USA, V98, P11771, DOI 10.1073/pnas.201276698; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KOSAKA H, 1987, ENVIRON HEALTH PERSP, V73, P147, DOI 10.2307/3430605; KOSAKA H, 1982, BIOCHIM BIOPHYS ACTA, V702, P237; Lauer T, 2001, P NATL ACAD SCI USA, V98, P12814, DOI 10.1073/pnas.221381098; LAUSTIOLA KE, 1991, PHARMACOL TOXICOL, V68, P60, DOI 10.1111/j.1600-0773.1991.tb01209.x; Li HT, 2003, BIOCHEMISTRY-US, V42, P1150, DOI 10.1021/bi026385a; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Luchsinger BP, 2003, P NATL ACAD SCI USA, V100, P461, DOI 10.1073/pnas.0233287100; MATSUNAGA K, 1989, J PHARMACOL EXP THER, V248, P687; MCMAHON TJ, 2002, NAT MED, V3, P3; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; MILLAR TM, 1997, BIOCHEM SOC T, V25, P528; Modin A, 2001, ACTA PHYSIOL SCAND, V171, P9, DOI 10.1046/j.1365-201x.2001.171001009.x; MOULDS RFW, 1981, BRIT J CLIN PHARMACO, V11, P57, DOI 10.1111/j.1365-2125.1981.tb01102.x; PANZA JA, 1993, CIRCULATION, V87, P1468, DOI 10.1161/01.CIR.87.5.1468; Rassaf T, 2002, J CLIN INVEST, V109, P1241, DOI 10.1172/JCI200214995; Rassaf T, 2003, NAT MED, V9, P481, DOI 10.1038/nm0503-481; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Rodriguez J, 2003, P NATL ACAD SCI USA, V100, P336, DOI 10.1073/pnas.0234600100; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Schechter AN, 2003, NEW ENGL J MED, V348, P1483, DOI 10.1056/NEJMcibr023045; Schechter AN, 2002, J CLIN INVEST, V109, P1149, DOI 10.1172/JCI200215637; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; WATANABE S, 1981, ACTA MED OKAYAMA, V35, P173; Xu XL, 2003, P NATL ACAD SCI USA, V100, P11303, DOI 10.1073/pnas.2033883100; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3	46	1385	1443	4	165	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1498	1505		10.1038/nm954	http://dx.doi.org/10.1038/nm954			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14595407				2022-12-27	WOS:000186845400033
J	Okazaki, T; Tanaka, Y; Nishio, R; Mitsuiye, T; Mizoguchi, A; Wang, J; Ishida, M; Hiai, H; Matsumori, A; Minato, N; Honjo, T				Okazaki, T; Tanaka, Y; Nishio, R; Mitsuiye, T; Mizoguchi, A; Wang, J; Ishida, M; Hiai, H; Matsumori, A; Minato, N; Honjo, T			Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice	NATURE MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; VIRUS MYOCARDITIS; ANTIBODIES; PROTEINS; MODEL; CELLS; IMMUNOADSORPTION; IDENTIFICATION; HYPERTROPHY; MUTATIONS	We recently reported that mice deficient in the programmed cell death- 1 (PD- 1) immunoinhibitory coreceptor develop autoimmune dilated cardiomyopathy (DCM), with production of high- titer autoantibodies against a heart- specific, 30- kDa protein. In this study, we purified the 30- kDa protein from heart extract and identified it as cardiac troponin I (cTnI), encoded by a gene in which mutations can cause familial hypertrophic cardiomyopathy (HCM). Administration of monoclonal antibodies to cTnI induced dilatation and dysfunction of hearts in wild- type mice. Monoclonal antibodies to cTnI stained the surface of cardiomyocytes and augmented the voltage- dependent L- type Ca (2+) current of normal cardiomyocytes. These findings suggest that antibodies to cTnI induce heart dysfunction and dilatation by chronic stimulation of Ca2+ influx in cardiomyocytes.	Kyoto Univ, Dept Med Chem & Mol Biol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Dept Immunol & Cell Biol, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ Hosp, Div Emergency Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Physiol & Biophys, Sakyo Ku, Kyoto 6068501, Japan; Mie Univ, Dept Anat, Grad Sch Med, Tsu, Mie 5148507, Japan; Kyoto Univ, Dept Pathol & Biol Dis, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; Kyoto University; Kyoto University; Mie University; Kyoto University	Honjo, T (corresponding author), Kyoto Univ, Dept Med Chem & Mol Biol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016	Okazaki, Taku/0000-0003-4790-1925; Tanaka, Yoshimasa/0000-0002-5024-0614				ALVAREZ FL, 1987, CLIN IMMUNOL IMMUNOP, V43, P129, DOI 10.1016/0090-1229(87)90164-4; Cohn JN, 1997, CIRCULATION, V95, P766; Felix SB, 2002, J AM COLL CARDIOL, V39, P646, DOI 10.1016/S0735-1097(01)01794-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERSKOWITZ A, 1993, J AM COLL CARDIOL, V22, P1385, DOI 10.1016/0735-1097(93)90547-E; ISENBERG G, 1982, PFLUG ARCH EUR J PHY, V395, P6, DOI 10.1007/BF00584963; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Keffer JH, 1996, AM J CLIN PATHOL, V105, P305; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; MAISCH B, 1983, AM J CARDIOL, V52, P1072, DOI 10.1016/0002-9149(83)90535-0; Matsui S, 1997, J MOL CELL CARDIOL, V29, P641, DOI 10.1006/jmcc.1996.0307; MATSUMORI A, 1982, CIRCULATION, V65, P1230, DOI 10.1161/01.CIR.65.6.1230; Matsumori A, 2002, CIRC J, V66, P323, DOI 10.1253/circj.66.323; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; NEU N, 1990, J IMMUNOL, V145, P4094; NEU N, 1987, J IMMUNOL, V139, P3630; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishio R, 2002, J AM COLL CARDIOL, V40, P1506, DOI 10.1016/S0735-1097(02)02166-6; Okazaki T, 2002, CURR OPIN IMMUNOL, V14, P779, DOI 10.1016/S0952-7915(02)00398-9; Pankuweit S, 1997, J MOL CELL CARDIOL, V29, P77, DOI 10.1006/jmcc.1996.0253; POWELL T, 1980, J PHYSIOL-LONDON, V302, P131; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; SCHULTHEISS HP, 1988, J EXP MED, V168, P2105, DOI 10.1084/jem.168.6.2105; SCHULTHEISS HP, 1986, ANN NY ACAD SCI, V488, P44; Schulze K, 1999, CARDIOVASC RES, V44, P91, DOI 10.1016/S0008-6363(99)00204-7; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Solaro RJ, 1999, CIRC RES, V84, P122; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Staudt A, 2001, EUR J PHARMACOL, V423, P115, DOI 10.1016/S0014-2999(01)01113-X; Staudt A, 2001, CIRCULATION, V103, P2681; Takagi S, 1998, AM J PHYSIOL-REG I, V274, pR348, DOI 10.1152/ajpregu.1998.274.2.R348; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3	38	480	518	3	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2003	9	12					1477	1483		10.1038/nm955	http://dx.doi.org/10.1038/nm955			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14595408				2022-12-27	WOS:000186845400030
J	Oudit, GY; Sun, H; Trivieri, MG; Koch, SE; Dawood, F; Ackerley, C; Yazdanpanah, M; Wilson, GJ; Schwartz, A; Liu, PP; Backx, PH				Oudit, GY; Sun, H; Trivieri, MG; Koch, SE; Dawood, F; Ackerley, C; Yazdanpanah, M; Wilson, GJ; Schwartz, A; Liu, PP; Backx, PH			L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy	NATURE MEDICINE			English	Article							BETA-THALASSEMIA MAJOR; METAL-ION TRANSPORTER; HEREDITARY HEMOCHROMATOSIS; LIPID-PEROXIDATION; CALCIUM CHANNELS; HEART-CELLS; ANTIOXIDANT STATUS; MASS-SPECTROMETRY; CARDIAC MYOCYTES; ALPHA-TOCOPHEROL	Under conditions of iron overload, which are now reaching epidemic proportions worldwide, iron-overload cardiomyopathy is the most important prognostic factor in patient survival. We hypothesize that in iron-overload disorders, iron accumulation in the heart depends on ferrous iron (Fe2+) permeation through the L-type voltage-dependent Ca2+ channel (LVDCC), a promiscuous divalent cation transporter. Iron overload in mice was associated with increased mortality, systolic and diastolic dysfunction, bradycardia, hypotension, increased myocardial fibrosis and elevated oxidative stress. Treatment with LVDCC blockers (CCBs; amlodipine and verapamil) at therapeutic levels inhibited the LVDCC current in cardiomyocytes, attenuated myocardial iron accumulation and oxidative stress, improved survival, prevented hypotension and preserved heart structure and function. Consistent with the role of LVDCCs in myocardial iron uptake, iron-overloaded transgenic mice with cardiac-specific overexpression of the LVDCC alpha(1)-subunit had twofold higher myocardial iron and oxidative stress levels, as well as greater impairment in cardiac function, compared with littermate controls; LVDCC blockade was again protective. Our results indicate that cardiac LVDCCs are key transporters of iron into cardiomyocytes under iron-overloaded conditions, and potentially represent a new therapeutic target to reduce the cardiovascular burden from iron overload.	Univ Toronto, Dept Med, Heart Stroke Richard Lewar Ctr Excellence, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Physiol, Heart Stroke Richard Lewar Ctr Excellence, Toronto, ON M5S 3E2, Canada; Hosp Sick Children, Dept Pathol, Toronto, ON M5G 1X8, Canada; Univ Cincinnati, Med Ctr, CVRC, Inst Mol Phamracol & Biophys, Cincinnati, OH 45267 USA; Univ Hlth Network, Div Cardiol, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University System of Ohio; University of Cincinnati; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Backx, PH (corresponding author), Univ Toronto, Dept Med, Heart Stroke Richard Lewar Ctr Excellence, Toronto, ON M5S 3E2, Canada.				NHLBI NIH HHS [T32 HL07382, P01 HL22619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, T32HL007382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abernethy DR, 1999, NEW ENGL J MED, V341, P1447, DOI 10.1056/NEJM199911043411907; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Andrews NC, 2002, CURR OPIN CHEM BIOL, V6, P181, DOI 10.1016/S1367-5931(02)00307-1; Azancot I, 2003, CIRCULATION, V107, P422, DOI 10.1161/01.CIR.0000046488.52939.BF; Ballas SK, 2001, SEMIN HEMATOL, V38, P30, DOI 10.1053/shem.2001.20142; Barton JC, 1996, NAT MED, V2, P394, DOI 10.1038/nm0496-394; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; BUJA LM, 1971, AM J MED, V51, P209, DOI 10.1016/0002-9343(71)90240-3; Carvalho M, 2001, BIOPHARM DRUG DISPOS, V22, P383, DOI 10.1002/bdd.282; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CECCHETTI G, 1991, EUR HEART J, V12, P224, DOI 10.1093/oxfordjournals.eurheartj.a059873; Chaston TB, 2003, AM J HEMATOL, V73, P200, DOI 10.1002/ajh.10348; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Dilger K, 1999, BRIT J CLIN PHARMACO, V47, P413, DOI 10.1046/j.1365-2125.1999.00910.x; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Fuhr U, 2002, EUR J CLIN PHARMACOL, V58, P45, DOI 10.1007/s00228-002-0436-7; Galanello R, 2001, SEMIN HEMATOL, V38, P73, DOI 10.1053/shem.2001.20147; Gharzuddine W S, 2002, Eur J Echocardiogr, V3, P47, DOI 10.1053/euje.2001.0114; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; HERSHKO C, 1987, J LAB CLIN MED, V110, P355; Jensen CE, 1997, EUR J HAEMATOL, V59, P76; KASS RS, 1989, AM J CARDIOL, V64, P351; Kivisto KT, 1997, HUM EXP TOXICOL, V16, P35, DOI 10.1177/0960327197016001071; KREMASTINOS DT, 1993, CIRCULATION, V88, P1127, DOI 10.1161/01.CIR.88.3.1127; KREMASTINOS DT, 1995, CIRCULATION, V91, P66, DOI 10.1161/01.CIR.91.1.66; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Ligon B, 1998, J BIOL CHEM, V273, P13905, DOI 10.1074/jbc.273.22.13905; LINK G, 1985, J LAB CLIN MED, V106, P147; Link G, 1999, J LAB CLIN MED, V133, P179, DOI 10.1016/S0022-2143(99)90011-2; LIU P, 1994, CARDIOVASC DRUG THER, V8, P101, DOI 10.1007/BF00877096; Livrea MA, 1996, BLOOD, V88, P3608, DOI 10.1182/blood.V88.9.3608.bloodjournal8893608; Low LCK, 1997, J PEDIATR ENDOCR MET, V10, P175; LUO XP, 1995, ANAL BIOCHEM, V228, P294, DOI 10.1006/abio.1995.1353; Mason RP, 1999, AM J CARDIOL, V84, p16L; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; MIKUS G, 1990, J PHARMACOL EXP THER, V253, P1042; Modell B, 2000, LANCET, V355, P2051, DOI 10.1016/S0140-6736(00)02357-6; Muhlestein JB, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P297; MULLER FB, 1986, BRIT J CLIN PHARMACO, V21, pS143, DOI 10.1111/j.1365-2125.1986.tb02863.x; Muth JN, 2001, TRENDS PHARMACOL SCI, V22, P526, DOI 10.1016/S0165-6147(00)01797-1; Nawrath H, 1997, N-S ARCH PHARMACOL, V355, P79; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056/NEJM199907083410207; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; Palka P, 2002, J AM SOC ECHOCARDIOG, V15, P884, DOI 10.1067/mje.2002.118032; Parkes JG, 1997, TOXICOLOGY, V117, P141, DOI 10.1016/S0300-483X(96)03566-4; Peri R, 2001, J BIOL CHEM, V276, P31667, DOI 10.1074/jbc.M102613200; RANDELL EW, 1994, J BIOL CHEM, V269, P16046; Roy CN, 2001, HUM MOL GENET, V10, P2181, DOI 10.1093/hmg/10.20.2181; Rychkov G, 2001, HEPATOLOGY, V33, P938, DOI 10.1053/jhep.2001.23051; Song LS, 2002, CIRC RES, V90, P174, DOI 10.1161/hh0202.103230; Strohmeyer G, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P268; Templeton DM, 2003, BBA-GEN SUBJECTS, V1619, P113, DOI 10.1016/S0304-4165(02)00497-X; Tsushima RG, 1999, CIRC RES, V84, P1302, DOI 10.1161/01.RES.84.11.1302; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; Weatherall DJ, 2001, NAT REV GENET, V2, P245, DOI 10.1038/35066048; Weatherall DJ, 1996, NAT MED, V2, P847, DOI 10.1038/nm0896-847; Weatherall DJ, 2001, B WORLD HEALTH ORGAN, V79, P704; WINEGAR BD, 1991, J GEN PHYSIOL, V97, P351, DOI 10.1085/jgp.97.2.351; YOUNG IS, 1994, FREE RADICAL BIO MED, V16, P393, DOI 10.1016/0891-5849(94)90041-8; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	65	356	370	1	27	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1187	1194		10.1038/nm920	http://dx.doi.org/10.1038/nm920			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12937413				2022-12-27	WOS:000185061600032
J	Seki, Y; Inoue, H; Nagata, N; Hayashi, K; Fukuyama, S; Matsumoto, K; Komine, O; Hamano, S; Himeno, K; Inagaki-Ohara, K; Cacalano, N; O'Garra, A; Oshida, T; Saito, H; Johnston, JA; Yoshimura, A; Kubo, M				Seki, Y; Inoue, H; Nagata, N; Hayashi, K; Fukuyama, S; Matsumoto, K; Komine, O; Hamano, S; Himeno, K; Inagaki-Ohara, K; Cacalano, N; O'Garra, A; Oshida, T; Saito, H; Johnston, JA; Yoshimura, A; Kubo, M			SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses	NATURE MEDICINE			English	Article							CYTOKINE SIGNALING SOCS; LINEAGE COMMITMENT; TH2 DIFFERENTIATION; ATOPIC-DERMATITIS; T-CELLS; SUPPRESSORS; EXPRESSION; RECEPTOR; MICE; PROTEINS	Members of the suppressor of cytokine signaling (SOCS) family are involved in the pathogenesis of many inflammatory diseases. SOCS-3 is predominantly expressed in T-helper type 2 (T(H)2) cells, but its role in T(H)2-related allergic diseases remains to be investigated. In this study we provide a strong correlation between SOCS-3 expression and the pathology of asthma and atopic dermatitis, as well as serum IgE levels in allergic human patients. SOCS-3 transgenic mice showed increased T(H)2 responses and multiple pathological features characteristic of asthma in an airway hypersensitivity model system. In contrast, dominant-negative mutant SOCS-3 transgenic mice, as well as mice with a heterozygous deletion of Socs3, had decreased T(H)2 development. These data indicate that SOCS-3 has an important role in regulating the onset and maintenance of T(H)2-mediated allergic immune disease, and suggest that SOCS-3 may be a new therapeutic target for the development of antiallergic drugs.	Sci Univ Tokyo, Res Inst Biol Sci, Noda, Chiba 2780022, Japan; Kyushu Univ, Grad Sch Med Sci, Res Inst Dis chest, Higashi Ku, Fukuoka 8128582, Japan; Genox Res Inc, Kawasaki, Kanagawa 2190001, Japan; Kyushu Univ, Fac Med Sci, Dept Parasitol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Radiat Oncol, Los Angeles, CA 90095 USA; Natl Inst Med Res, Immunoregulat Lab, London NW7 1AA, England; Natl Res Inst Child Hlth & Dev, RIKEN Res Ctr Allergy & Immunol, Setagaya Ku, Tokyo 1548567, Japan; Queens Univ Belfast, Dept Immunol, Belfast BT9 7BL, Antrim, North Ireland	Tokyo University of Science; Kyushu University; Kyushu University; Kyushu University; University of California System; University of California Los Angeles; MRC National Institute for Medical Research; National Center for Child Health & Development - Japan; RIKEN; Queens University Belfast	Kubo, M (corresponding author), Sci Univ Tokyo, Res Inst Biol Sci, 2669 Yamazaki, Noda, Chiba 2780022, Japan.		Yoshimura, Akihiko/K-5515-2013; Komine, Okiru/I-6155-2014; Hamano, Shinjiro/A-7932-2011	Hamano, Shinjiro/0000-0003-3881-8337; Saito, Hirohisa/0000-0002-6630-8337; O'Garra, Anne/0000-0001-9845-6134				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bour-Jordan H, 2003, NAT IMMUNOL, V4, P182, DOI 10.1038/ni884; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kibe A, 2003, AM J RESP CRIT CARE, V167, P50, DOI 10.1164/rccm.2110084; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Krebs DL, 2000, J CELL SCI, V113, P2813; Kubo M, 1999, J IMMUNOL, V163, P2432; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Makino S, 2000, INT ARCH ALLERGY IMM, V121, P1; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 2003, J EXP MED, V197, P425, DOI 10.1084/jem.20020939; MATSUMOTO Y, IN PRESS INT ARCH AL; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; Ring J, 2001, Curr Allergy Rep, V1, P39, DOI 10.1007/s11882-001-0095-2; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Seki Y, 2002, P NATL ACAD SCI USA, V99, P13003, DOI 10.1073/pnas.202477099; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; WUTHRICH B, 1978, CLIN ALLERGY, V8, P241, DOI 10.1111/j.1365-2222.1978.tb03220.x; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	37	286	325	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1047	1054		10.1038/nm896	http://dx.doi.org/10.1038/nm896			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847520				2022-12-27	WOS:000184484900029
J	Bezard, E; Ferry, S; Mach, U; Stark, H; Leriche, L; Boraud, T; Gross, C; Sokoloff, P				Bezard, E; Ferry, S; Mach, U; Stark, H; Leriche, L; Boraud, T; Gross, C; Sokoloff, P			Attenuation of levodopa-induced dyskinesia by normalizing dopamine D-3 receptor function	NATURE MEDICINE			English	Article							PARKINSONS-DISEASE; NIGROSTRIATAL DEGENERATION; BEHAVIORAL SENSITIZATION; SUBSTANTIA-NIGRA; MONKEY STRIATUM; MESSENGER-RNA; CELL-LINE; EXPRESSION; NEURONS; ANTAGONIST	In monkeys rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), expression of the dopamine D 3 receptor was decreased. However, levodopa-induced dyskinesia (LID), similar to the debilitating and pharmacoresistant involuntary movements elicited after long-term treatment with levodopa in patients with Parkinson disease (PD), was associated with overexpression of this receptor. Administration of a D-3 receptor-selective partial agonist strongly attenuated levodopa-induced dyskinesia, but left unaffected the therapeutic effect of levodopa. In contrast, attenuation of dyskinesia by D-3 receptor antagonists was accompanied by the reappearance of PD-like symptoms. These results indicated that the D-3 receptor participated in both dyskinesia and the therapeutic action of levodopa, and that partial agonists may normalize D-3 receptor function and correct side effects of levodopa therapy in patients with PD.	INSERM, U573, Unite Neurobiol & Pharmacol Mol, F-75014 Paris, France; Univ Victor Segalen, Basal Gang, Neurophysiol Lab, CNRS,UMR 5543, F-33076 Bordeaux, France; Univ Frankfurt, Biozentrum, D-60439 Frankfurt, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Goethe University Frankfurt	Bezard, E (corresponding author), INSERM, U573, Unite Neurobiol & Pharmacol Mol, F-75014 Paris, France.		Stark, Holger/A-4235-2009; Boraud, Thomas/A-6260-2008; Bezard, Erwan/A-8173-2008; Bezard, Erwan/ABD-5153-2021	Stark, Holger/0000-0003-3336-1710; Bezard, Erwan/0000-0002-0410-4638				Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Bezard E, 2001, NAT REV NEUROSCI, V2, P577, DOI 10.1038/35086062; Boraud T, 2001, BRAIN, V124, P546, DOI 10.1093/brain/124.3.546; Bordet R, 1997, P NATL ACAD SCI USA, V94, P3363, DOI 10.1073/pnas.94.7.3363; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Carlsson A, 2001, SCIENCE, V294, P1021, DOI 10.1126/science.1066969; COTZIAS GC, 1969, NEW ENGL J MED, V280, P337, DOI 10.1056/NEJM196902132800701; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Grondin R, 2000, N-S ARCH PHARMACOL, V361, P181, DOI 10.1007/s002109900167; Guillin O, 2001, NATURE, V411, P86, DOI 10.1038/35075076; Gurevich EV, 1997, ARCH GEN PSYCHIAT, V54, P225; HORNYKIEWICZ O., 1963, WIENER KLIN WOCHENSCHR, V75, P309; Hurley MJ, 1996, NEUROSCI LETT, V214, P75, DOI 10.1016/0304-3940(96)12884-6; Imbert C, 2000, J NEUROSCI METH, V96, P71, DOI 10.1016/S0165-0270(99)00184-3; Jenner P, 2002, NEUROLOGY, V58, pS1, DOI 10.1212/WNL.58.suppl_1.S1; Levant B, 1996, SYNAPSE, V24, P60; LEVESQUE D, 1995, P NATL ACAD SCI USA, V92, P1719, DOI 10.1073/pnas.92.5.1719; Millan MJ, 2000, J PHARMACOL EXP THER, V293, P1048; Morissette M, 1998, EUR J NEUROSCI, V10, P2565, DOI 10.1046/j.1460-9568.1998.00264.x; Pearce RKB, 1995, MOVEMENT DISORD, V10, P731, DOI 10.1002/mds.870100606; Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944; PILON C, 1994, EUR J PHARM-MOLEC PH, V268, P129, DOI 10.1016/0922-4106(94)90182-1; Pulvirenti L, 2002, TRENDS PHARMACOL SCI, V23, P151, DOI 10.1016/S0165-6147(00)01991-X; Quik M, 2000, NEUROSCIENCE, V98, P263, DOI 10.1016/S0306-4522(00)00130-5; Rascol O, 2000, ANN NEUROL, V47, pS179; Reavill C, 2000, J PHARMACOL EXP THER, V294, P1154; Ryoo HL, 1998, MOVEMENT DISORD, V13, P788, DOI 10.1002/mds.870130506; Sautel F, 1995, J PHARMACOL EXP THER, V275, P1239; SOKOLOFF P, 1992, EUR J PHARM-MOLEC PH, V225, P331, DOI 10.1016/0922-4106(92)90107-7; Suzuki M, 1998, BRAIN RES, V779, P58, DOI 10.1016/S0006-8993(97)01078-0; Weber B, 2001, BRIT J PHARMACOL, V133, P1243, DOI 10.1038/sj.bjp.0704192	33	331	338	2	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					762	767		10.1038/nm875	http://dx.doi.org/10.1038/nm875			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740572				2022-12-27	WOS:000183444100033
J	Carmeliet, P				Carmeliet, P			Angiogenesis in health and disease	NATURE MEDICINE			English	Review							ENDOTHELIAL-GROWTH-FACTOR; HEMATOPOIETIC STEM-CELLS; TUMOR ANGIOGENESIS; ADULT NEOVASCULARIZATION; PULMONARY-HYPERTENSION; RETINAL ANGIOGENESIS; VESSEL DEVELOPMENT; BLOOD-VESSELS; SMOOTH-MUSCLE; GENE-THERAPY	Blood vessels constitute the first organ in the embryo and form the largest network in our body but, sadly, are also often deadly. When dysregulated, the formation of new blood vessels contributes to numerous malignant, ischemic, inflammatory, infectious and immune disorders. Molecular insights into these processes are being generated at a rapidly increasing pace, offering new therapeutic opportunities that are currently being evaluated.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821				Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; Ahmad SA, 2001, CANCER RES, V61, P1255; Asahara T, 2002, J HEMATOTH STEM CELL, V11, P171, DOI 10.1089/152581602753658385; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Bernardini G, 2003, J IMMUNOL METHODS, V273, P83, DOI 10.1016/S0022-1759(02)00420-9; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Boudier HAJS, 1999, DRUGS, V58, P37; Buschmann IR, 2001, ATHEROSCLEROSIS, V159, P343, DOI 10.1016/S0021-9150(01)00637-2; CAO R, 2003, NAT MED; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Carmeliet P, 2000, NATURE, V408, P43, DOI 10.1038/35040684; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2001, SCIENCE, V293, P1602, DOI 10.1126/science.1064981; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chang E, 2002, J INVEST DERMATOL, V118, P752, DOI 10.1046/j.1523-1747.2002.01714.x; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; D'Amore PA, 2002, TRENDS MOL MED, V8, P313, DOI 10.1016/S1471-4914(02)02367-5; de la Torre JC, 2002, J ALZHEIMERS DIS, V4, P497, DOI 10.3233/jad-2002-4606; Dinehart SM, 2001, DERMATOL SURG, V27, P475, DOI 10.1046/j.1524-4725.2001.00227.x; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Dormond O, 2001, DRUG RESIST UPDATE, V4, P314, DOI 10.1054/drup.2001.0219; Du Lingling, 2003, New England Journal of Medicine, V348, P500, DOI 10.1056/NEJMoa021650; English D, 2002, BBA-MOL CELL BIOL L, V1582, P228, DOI 10.1016/S1388-1981(02)00176-2; Fernandez PM, 2002, CURR OPIN HEMATOL, V9, P401, DOI 10.1097/00062752-200209000-00003; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gale NW, 2001, DEV BIOL, V230, P151, DOI 10.1006/dbio.2000.0112; Gennaro G, 2003, CIRCULATION, V107, P230, DOI 10.1161/01.CIR.0000050652.47145.4C; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128; Hangai M, 2002, AM J PATHOL, V161, P1429, DOI 10.1016/S0002-9440(10)64418-5; Harada K, 2000, ANTICANCER RES, V20, P4519; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Helisch A, 2003, MICROCIRCULATION, V10, P83, DOI 10.1038/sj.mn.7800173; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hewett P, 2002, AM J PATHOL, V160, P773, DOI 10.1016/S0002-9440(10)64899-7; Hoefer IE, 2002, CIRCULATION, V105, P1639, DOI 10.1161/01.CIR.0000014987.32865.8E; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Humbert M, 2002, EUR RESPIR J, V20, P741, DOI 10.1183/09031936.02.02702002; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Jackson C, 2002, CURR OPIN NEPHROL HY, V11, P295, DOI 10.1097/00041552-200205000-00005; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jain RK, 2000, NAT MED, V6, P131, DOI 10.1038/72212; Jenkinson L, 2002, DIGEST DIS SCI, V47, P1857, DOI 10.1023/A:1016469217449; Kalimo H, 2002, BRAIN PATHOL, V12, P371; Kamihata H, 2002, ARTERIOSCL THROM VAS, V22, P1804, DOI 10.1161/01.ATV.0000039168.95670.B9; Kang DH, 2001, AM J KIDNEY DIS, V37, P601, DOI 10.1053/ajkd.2001.22087; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Lamouille S, 2002, BLOOD, V100, P4495, DOI 10.1182/blood.V100.13.4495; Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3; Lawson ND, 2001, DEVELOPMENT, V128, P3675; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Li XF, 2001, J CLIN ENDOCR METAB, V86, P1823, DOI 10.1210/jc.86.4.1823; Loughna S, 2001, MOL CELL, V7, P233, DOI 10.1016/S1097-2765(01)00171-X; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2002, TRENDS CARDIOVAS MED, V12, P88, DOI 10.1016/S1050-1738(01)00152-9; Luttun A, 2000, Curr Atheroscler Rep, V2, P407, DOI 10.1007/s11883-000-0079-z; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Martinez P, 2002, OSTEOPOROSIS INT, V13, P874, DOI 10.1007/s001980200120; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Mikkola HKA, 2002, J HEMATOTH STEM CELL, V11, P9, DOI 10.1089/152581602753448504; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Norrby K, 2002, APMIS, V110, P355, DOI 10.1034/j.1600-0463.2002.100501.x; Nykanen AI, 2003, CIRCULATION, V107, P1308, DOI 10.1161/01.CIR.0000054623.35669.3F; Ohm JE, 2002, ONCOLOGY-NY, V16, P11; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346; Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Ruoslahti E, 2002, DRUG DISCOV TODAY, V7, P1138, DOI 10.1016/S1359-6446(02)02501-1; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Schmeisser A, 2002, J HEMATOTH STEM CELL, V11, P69, DOI 10.1089/152581602753448540; Schonfeld CL, 1996, GER J OPHTHALMOL, V5, P224; Shim WSN, 2002, EXP CELL RES, V279, P299, DOI 10.1006/excr.2002.5597; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Sica A, 2002, INT IMMUNOPHARMACOL, V2, P1045, DOI 10.1016/S1567-5769(02)00064-4; Simon AM, 2002, DEV BIOL, V251, P206, DOI 10.1006/dbio.2002.0826; Sood AK, 2002, J SOC GYNECOL INVEST, V9, P2, DOI 10.1016/S1071-5576(01)00147-2; Srinivasan S, 2003, HUM MOL GENET, V12, P473, DOI 10.1093/hmg/ddg050; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Stalmans I, 2003, NAT MED, V9, P173, DOI 10.1038/nm819; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Takagi H, 2003, INVEST OPHTH VIS SCI, V44, P393, DOI 10.1167/iovs.02-0276; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Trikha M, 2002, SEMIN THROMB HEMOST, V28, P39, DOI 10.1055/s-2002-20563; Vacca A, 1998, INT J CLIN LAB RES, V28, P55, DOI 10.1007/s005990050018; Vailhe B, 2003, CURR PHARM DESIGN, V9, P583, DOI 10.2174/1381612033391342; van den Driesche S, 2003, CARDIOVASC RES, V58, P20, DOI 10.1016/S0008-6363(02)00852-0; van Royen N, 2002, FASEB J, V16, P432, DOI 10.1096/fj.01-0563fje; VanBelle E, 1997, CIRCULATION, V96, P2667, DOI 10.1161/01.CIR.96.8.2667; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; Voelkel NF, 2002, CRIT CARE MED, V30, pS251, DOI 10.1097/00003246-200205001-00013; Voskuil M, 2003, AM J PHYSIOL-HEART C, V284, pH1422, DOI 10.1152/ajpheart.00506.2002; Waltenberger J, 2001, CARDIOVASC RES, V49, P554, DOI 10.1016/S0008-6363(00)00228-5; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Yeager ME, 2001, CIRC RES, V88, pE2; Yin GY, 2002, MOL THER, V5, P547, DOI 10.1006/mthe.2002.0590; Zhang XQ, 2001, BLOOD, V98, P1028, DOI 10.1182/blood.V98.4.1028; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	132	3205	3408	6	354	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					653	660		10.1038/nm0603-653	http://dx.doi.org/10.1038/nm0603-653			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12778163				2022-12-27	WOS:000183444100019
J	Doll, JA; Stellmach, VM; Bouck, NP; Bergh, ARJ; Lee, C; Abramson, LP; Cornwell, ML; Pins, MR; Borensztajn, J; Crawford, SE				Doll, JA; Stellmach, VM; Bouck, NP; Bergh, ARJ; Lee, C; Abramson, LP; Cornwell, ML; Pins, MR; Borensztajn, J; Crawford, SE			Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VENTRAL PROSTATE; TISSUE MASS; FACTOR PEDF; CELL-DEATH; BLOOD-FLOW; IN-VIVO; ANGIOGENESIS; CASTRATION; CANCER	Angiogenesis sustains tumor growth and metastasis, and recent studies indicate that the vascular endothelium regulates tissue mass. In the prostate, androgens drive angiogenic inducers to stimulate growth, whereas androgen withdrawal leads to decreased vascular endothelial growth factor, vascular regression and epithelial cell apoptosis. Here, we identify the angiogenesis inhibitor pigment epithelium-derived factor (PEDF) as a key inhibitor of stromal vasculature and epithelial tissue growth in mouse prostate and pancreas. In PEDF-deficient mice, stromal vessels were increased and associated with epithelial cell hyperplasia. Androgens inhibited prostatic PEDF expression in cultured cells. In vivo, androgen ablation increased PEDF in normal rat prostates and in human cancer biopsies. Exogenous PEDF induced tumor epithelial apoptosis in vitro and limited in vivo tumor xenograft growth, triggering endothelial apoptosis. Thus, PEDF regulates normal pancreas and prostate mass. Its androgen sensitivity makes PEDF a likely contributor to the anticancer effects of androgen ablation.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA; Childrens Mem Hosp, Div Surg, Chicago, IL 60614 USA; Umea Univ, Dept Biomed Sci, S-90187 Umea, Sweden	Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Umea University	Crawford, SE (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NCI NIH HHS [CA64329] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramson LP, 2003, J PEDIATR SURG, V38, P336, DOI 10.1053/jpsu.2003.50104; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; Burchardt M, 2000, PROSTATE, V43, P184, DOI 10.1002/(SICI)1097-0045(20000515)43:3<184::AID-PROS4>3.0.CO;2-6; Buttyan R, 2000, Curr Opin Urol, V10, P415, DOI 10.1097/00042307-200009000-00009; Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.3.CO;2-D; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; CHUNG LWK, 1995, CANCER SURV, V23, P33; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Crawford SE, 2001, J CELL SCI, V114, P4421; Cvetkovic D, 2001, UROLOGY, V57, P821, DOI 10.1016/S0090-4295(00)01044-X; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Doll JA, 2001, PROSTATE, V49, P293, DOI 10.1002/pros.10025; Folkman J, 1998, ENDOCRINOLOGY, V139, P441, DOI 10.1210/en.139.2.441; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Franck-Lissbrant I, 1998, ENDOCRINOLOGY, V139, P451, DOI 10.1210/en.139.2.451; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Joseph IBJK, 1997, CLIN CANCER RES, V3, P2507; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Lekas E, 1997, UROL RES, V25, P309, DOI 10.1007/BF01294656; Liu XH, 1999, CLIN EXP METASTAS, V17, P687, DOI 10.1023/A:1006728119549; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Offield MF, 1996, DEVELOPMENT, V122, P983; PIGNOLO RJ, 1995, J CELL PHYSIOL, V162, P110, DOI 10.1002/jcp.1041620113; Rowley DR, 1998, CANCER METAST REV, V17, P411, DOI 10.1023/A:1006129420005; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shabisgh A, 1999, ENDOCRINOLOGY, V140, P1920, DOI 10.1210/en.140.4.1920; Shabsigh A, 2001, J CELL BIOCHEM, V81, P437, DOI 10.1002/1097-4644(20010601)81:3<437::AID-JCB1057>3.3.CO;2-Y; Shabsigh A, 1998, PROSTATE, V36, P201, DOI 10.1002/(SICI)1097-0045(19980801)36:3<201::AID-PROS9>3.0.CO;2-J; Sordello S, 1998, BIOCHEM BIOPH RES CO, V251, P287, DOI 10.1006/bbrc.1998.9328; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Tombran-Tink J, 1996, Mol Vis, V2, P11; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; van Bokhoven A, 2001, CANCER RES, V61, P6340; Wong YC, 2000, INT REV CYTOL, V199, P65, DOI 10.1016/S0074-7696(00)99002-8	45	256	270	0	9	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2003	9	6					774	780		10.1038/nm870	http://dx.doi.org/10.1038/nm870			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12740569				2022-12-27	WOS:000183444100035
J	Rafii, S; Lyden, D				Rafii, S; Lyden, D			Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration	NATURE MEDICINE			English	Review							BONE-MARROW-CELLS; ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; ENHANCES COLLATERAL PERFUSION; BLOOD MONONUCLEAR-CELLS; HEMATOPOIETIC STEM; ISCHEMIC MYOCARDIUM; REGIONAL FUNCTION; IN-VITRO; AUTOLOGOUS TRANSPLANTATION	Emerging evidence suggests that bone marrow-derived endothelial, hematopoietic stem and progenitor cells contribute to tissue vascularization during both embryonic and postnatal physiological processes. Recent preclinical and pioneering clinical studies have shown that introduction of bone marrow-derived endothelial and hematopoietic progenitors can restore tissue vascularization after ischemic events in limbs, retina and myocardium. Corecruitment of angiocompetent hematopoietic cells delivering specific angiogenic factors facilitates incorporation of endothelial progenitor cells (EPCs) into newly sprouting blood vessels. Identification of cellular mediators and tissue-specific chemokines, which facilitate selective recruitment of bone marrow-derived stem and progenitor cells to specific organs, will open up new avenues of research to accelerate organ vascularization and regeneration. In addition, identification of factors that promote differentiation of the progenitor cells will permit functional incorporation into neo-vessels of specific tissues while diminishing potential toxicity to other organs. In this review, we discuss the clinical potential of vascular progenitor and stem cells to restore long-lasting organ vascularization and function.	Cornell Univ, Coll Med, Dept Hematol Oncol & Genet Med, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Pediat, New York, NY 10021 USA; Cornell Univ, Coll Med, Childrens Blood Fdn Labs, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Rafii, S (corresponding author), Cornell Univ, Coll Med, Dept Hematol Oncol & Genet Med, New York, NY 10021 USA.	srafii@med.cornell.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061849] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL67839, R01 HL66592, R01 HL61849, R01 HL59312, HL66592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abtahian F, 2003, SCIENCE, V299, P247, DOI 10.1126/science.1079477; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581; Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848; Caplice NM, 2003, P NATL ACAD SCI USA, V100, P4754, DOI 10.1073/pnas.0730743100; Caprioli A, 1998, P NATL ACAD SCI USA, V95, P1641, DOI 10.1073/pnas.95.4.1641; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Crisa L, 1999, BLOOD, V94, P3928, DOI 10.1182/blood.V94.11.3928.423k02_3928_3940; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Dahlqvist A, 1999, AM J RESP CELL MOL, V20, P237, DOI 10.1165/ajrcmb.20.2.3081; Davidoff AM, 2001, CLIN CANCER RES, V7, P2870; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; DIPIETRO LA, 1993, AM J PATHOL, V143, P678; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; DRANCOURT M, 1992, J INFECT DIS, V166, P660, DOI 10.1093/infdis/166.3.660; Edelberg JM, 2002, CIRC RES, V90, pE89, DOI 10.1161/01.RES.0000020861.20064.7E; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; Eriksson U, 2002, NAT MED, V8, P775, DOI 10.1038/nm0802-775; Ezaki T, 2001, AM J PATHOL, V158, P2043, DOI 10.1016/S0002-9440(10)64676-7; Folkman J, 1998, CIRCULATION, V97, P1108, DOI 10.1161/01.CIR.97.12.1108; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fuchs S, 2001, J AM COLL CARDIOL, V37, P1726, DOI 10.1016/S0735-1097(01)01200-1; Gehling UM, 2000, BLOOD, V95, P3106; GEORGE F, 1991, J IMMUNOL METHODS, V139, P65, DOI 10.1016/0022-1759(91)90352-G; GEORGE F, 1992, THROMB HAEMOSTASIS, V67, P147; Gill M, 2001, CIRC RES, V88, P167; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hatzopoulos AK, 1998, DEVELOPMENT, V125, P1457; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hillebrands JL, 2003, ARTERIOSCL THROM VAS, V23, P380, DOI 10.1161/01.ATV.0000059337.60393.64; Hillebrands JL, 2002, NAT MED, V8, P194, DOI 10.1038/nm0302-194; Hillebrands JL, 2001, J CLIN INVEST, V107, P1411, DOI 10.1172/JCI10233; Hu YH, 2002, CIRCULATION, V106, P1834, DOI 10.1161/01.CIR.0000031333.86845.DD; Huang YQ, 2000, BLOOD, V95, P1993, DOI 10.1182/blood.V95.6.1993; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Iba O, 2002, CIRCULATION, V106, P2019, DOI 10.1161/01.CIR.0000031332.45480.79; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Isner JM, 2001, ANN NY ACAD SCI, V953, P75, DOI 10.1111/j.1749-6632.2001.tb02075.x; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kamihata H, 2002, ARTERIOSCL THROM VAS, V22, P1804, DOI 10.1161/01.ATV.0000039168.95670.B9; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Kawamoto A, 2001, CIRCULATION, V103, P634; Khurana R, 2003, TRENDS CARDIOVAS MED, V13, P116, DOI 10.1016/S1050-1738(02)00259-1; Kobayashi T, 2000, J SURG RES, V89, P189, DOI 10.1006/jsre.2000.5828; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Lee RJ, 2000, CIRCULATION, V102, P898; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2002, TRENDS CARDIOVAS MED, V12, P88, DOI 10.1016/S1050-1738(01)00152-9; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Majka SM, 2003, J CLIN INVEST, V111, P71, DOI 10.1172/JCI200316157; Marchetti S, 2002, J CELL SCI, V115, P2075; McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39, DOI 10.1164/ajrccm.164.supplement_2.2106065; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Moore MAS, 2002, J CLIN INVEST, V109, P313, DOI 10.1172/JCI200214940; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Murasawa S, 2002, CIRCULATION, V106, P1133, DOI 10.1161/01.CIR.0000027584.85865.B4; Mutunga M, 2001, AM J RESP CRIT CARE, V163, P195, DOI 10.1164/ajrccm.163.1.9912036; Noishiki Y, 1996, NAT MED, V2, P90, DOI 10.1038/nm0196-90; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, ANN NY ACAD SCI, V938, P221; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Pintucci G, 2002, THROMB HAEMOSTASIS, V88, P834, DOI 10.1055/s-0037-1613311; POLVERINI PJ, 1984, LAB INVEST, V51, P635; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; Quirici N, 2001, BRIT J HAEMATOL, V115, P186, DOI 10.1046/j.1365-2141.2001.03077.x; Rabbany SY, 2003, TRENDS MOL MED, V9, P109, DOI 10.1016/S1471-4914(03)00021-2; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Rafii S, 2003, NAT MED, V9, P166, DOI 10.1038/nm0203-166; Rafii S, 2002, GENE THER, V9, P631, DOI 10.1038/sj.gt.3301723; Rafii S, 1995, ANN THORAC SURG, V60, P1627, DOI 10.1016/0003-4975(95)00807-1; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Ribatti D, 2000, J HEMATOTH STEM CELL, V9, P13, DOI 10.1089/152581600319577; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Saaristo A, 2002, ANN NY ACAD SCI, V979, P94, DOI 10.1111/j.1749-6632.2002.tb04871.x; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087; Schmeisser A, 2001, CARDIOVASC RES, V49, P671, DOI 10.1016/S0008-6363(00)00270-4; Schuh AC, 1999, P NATL ACAD SCI USA, V96, P2159, DOI 10.1073/pnas.96.5.2159; Segal MS, 2002, AM J PHYSIOL-RENAL, V283, pF11, DOI 10.1152/ajprenal.00008.2002; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shi Q, 2002, ANN VASC SURG, V16, P314, DOI 10.1007/s10016-001-0238-x; SHI Q, 1994, J VASC SURG, V20, P546, DOI 10.1016/0741-5214(94)90279-8; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; Solovey AN, 2001, J LAB CLIN MED, V138, P322, DOI 10.1067/mlc.2001.118519; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Szuba A, 2002, FASEB J, V16, P1985, DOI 10.1096/fj.02-0401fje; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; Tordjman R, 2001, BLOOD, V97, P1968, DOI 10.1182/blood.V97.7.1968; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; van Royen N, 2003, CIRC RES, V92, P218, DOI 10.1161/01.RES.0000052313.23087.3F; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Waltenberger J, 2000, CIRCULATION, V102, P185, DOI 10.1161/01.CIR.102.2.185; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Wartiovaara U, 1998, THROMB HAEMOSTASIS, V80, P171, DOI 10.1055/s-0037-1615158; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830; Young PP, 2002, P NATL ACAD SCI USA, V99, P11951, DOI 10.1073/pnas.182215799; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	143	1293	1425	4	176	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2003	9	6					702	712		10.1038/nm0603-702	http://dx.doi.org/10.1038/nm0603-702			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	688PH	12778169				2022-12-27	WOS:000183444100025
J	Krutzik, SR; Ochoa, MT; Sieling, PA; Uematsu, S; Ng, YW; Legaspi, A; Liu, PT; Cole, ST; Godowski, PJ; Maeda, YM; Sarno, EN; Norgard, MV; Brennan, PJ; Akira, S; Rea, TH; Modlin, RL				Krutzik, SR; Ochoa, MT; Sieling, PA; Uematsu, S; Ng, YW; Legaspi, A; Liu, PT; Cole, ST; Godowski, PJ; Maeda, YM; Sarno, EN; Norgard, MV; Brennan, PJ; Akira, S; Rea, TH; Modlin, RL			Activation and regulation of Toll-like receptors 2 and 1 in human leprosy	NATURE MEDICINE			English	Article							MYD88-DEPENDENT SIGNALING PATHWAY; MYCOBACTERIUM-TUBERCULOSIS; HOST-DEFENSE; CUTTING EDGE; BACTERIAL LIPOPROTEINS; MICROBIAL LIPOPROTEINS; ANTIMICROBIAL ACTIVITY; CYTOKINE PRODUCTION; IMMUNE-RESPONSE; T-CELLS	The expression and activation of Toll-like receptors (TLRs) was investigated in leprosy, a spectral disease in which clinical manifestations correlate with the type of immune response mounted toward Mycobacterium leprae. TLR2-TLR1 heterodimers mediated cell activation by killed M. leprae, indicating the presence of triacylated lipoproteins. A genome-wide scan of M. leprae detected 31 putative lipoproteins. Synthetic lipopeptides representing the 19-kD and 33-kD lipoproteins activated both monocytes and dendritic cells. Activation was enhanced by type-1 cytokines and inhibited by type-2 cytokines. In addition, interferon (IFN)-gamma and granulocyte-macrophage colony-stimulating factor (GM-CSF) enhanced TLR1 expression in monocytes and dendritic cells, respectively, whereas IL-4 downregulated TLR2 expression. TLR2 and TLR1 were more strongly expressed in lesions from the localized tuberculoid form (T-lep) as compared with the disseminated lepromatous form (L-lep) of the disease. These data provide evidence that regulated expression and activation of TLRs at the site of disease contribute to the host defense against microbial pathogens.	Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol & Immunol, Los Angeles, CA USA; Osaka Univ, Japan Sci & Technol Corp, Microbial Dis Res Inst, Dept Host Def, Osaka, Japan; Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Natl Inst Infect Dis, Leprosy Res Ctr, Dept Microbiol, Tokyo, Japan; Inst Oswaldo Cruz, Leprosy Lab, BR-20001 Rio De Janeiro, Brazil; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Univ So Calif, Sch Med, Dermatol Sect, Los Angeles, CA 90033 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Japan Science & Technology Agency (JST); Osaka University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Roche Holding; Genentech; National Institute of Infectious Diseases (NIID); Fundacao Oswaldo Cruz; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Colorado State University; University of Southern California	Modlin, RL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA.		Liu, Philip/C-2524-2009; Modlin, Robert L/M-7941-2014; Akira, Shizuo/C-3134-2009; Liu, Philip/C-9638-2011	Modlin, Robert L/0000-0003-4720-031X; Ochoa, Maria T/0000-0001-6550-5008; Nunes Sarno, Euzenir/0000-0003-0129-2159; Liu, Philip/0000-0002-6144-0304	NIAID NIH HHS [AI22553, AI47866, AI07126] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI022553, R01AI047866, R01AI022553] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; ANDERSON GW, 1980, INFECT IMMUN, V28, P132, DOI 10.1128/IAI.28.1.132-136.1980; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CROSS A, 1995, J CLIN INVEST, V96, P676, DOI 10.1172/JCI118110; Flo TH, 2001, J LEUKOCYTE BIOL, V69, P474; Garcia VE, 1999, J IMMUNOL, V162, P6114; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kang TJ, 2001, FEMS IMMUNOL MED MIC, V31, P53, DOI 10.1111/j.1574-695X.2001.tb01586.x; Maeda Y, 2002, INFECT IMMUN, V70, P4106, DOI 10.1128/IAI.70.8.4106-4111.2002; Means TK, 1999, J IMMUNOL, V163, P3920; Means TK, 1999, J IMMUNOL, V163, P6748; Medina E, 1998, IMMUNOLOGY, V93, P270, DOI 10.1046/j.1365-2567.1998.00419.x; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MODLIN RL, 1984, J IMMUNOL, V132, P3085; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Ochoa MT, 2001, NAT MED, V7, P174, DOI 10.1038/84620; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Post FA, 2001, INFECT IMMUN, V69, P1433, DOI 10.1128/IAI.69.3.1433-1439.2001; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SIELING PA, 1994, J IMMUNOL, V153, P3639; Staege H, 2000, IMMUNOL LETT, V71, P1, DOI 10.1016/S0165-2478(99)00168-6; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Wang XR, 2002, J IMMUNOL, V168, P810, DOI 10.4049/jimmunol.168.2.810; WEINSTEIN DL, 1986, CELL IMMUNOL, V102, P68, DOI 10.1016/0008-8749(86)90326-6; Wooten RM, 2002, J IMMUNOL, V168, P348, DOI 10.4049/jimmunol.168.1.348; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yeremeev VV, 2000, TUBERCLE LUNG DIS, V80, P243, DOI 10.1054/tuld.2000.0252	46	252	260	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2003	9	5					525	532		10.1038/nm864	http://dx.doi.org/10.1038/nm864			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	673ZD	12692544				2022-12-27	WOS:000182610600032
J	Fan, J; Malik, AB				Fan, J; Malik, AB			Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors	NATURE MEDICINE			English	Article							KAPPA-B ACTIVATION; KINASE; MICE; LIPOPOLYSACCHARIDE; DESENSITIZATION; CXCR2; BACTERIAL; ENDOTOXIN; GENE; IDENTIFICATION	Polymorphonuclear leukocytes (PMNs) are critical effector cells of the innate immune system that protect the host by migrating to inflammatory sites and killing pathogenic microbes. We addressed the role of chemokine receptor desensitization induced by G-protein-coupled receptor kinases (GRKs) in the feedback control of PMN migration. We show that the chemokine macrophage inflammatory protein-2 (MIP-2) induces GRK2 and GRK5 expression in PMNs through phosphoinositide-3-kinase (PI3K)-gamma signaling. We also show that lipopolysaccharide (LPS)-activated signaling through the Toll-like receptor (TLR)-4 pathway transcriptionally downregulates the expression of GRK2 and GRK5 in response to MIP-2. The reduced expression of GRKs lowers chemokine receptor desensitization and markedly augments the PMN migratory response. These data indicate that TLR4 modulation of PMN surface chemokine receptor expression subsequent to the downregulation of GRK2 and GRK5 expression is a critical determinant of PMN migration.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Malik, AB (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60680 USA.			Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL027016, P01HL060678, T32HL007829, R01HL045638, R01HL027016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60678, HL27016, HL45638, T32 HL07829] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Eckhart AD, 2002, MOL PHARMACOL, V61, P749, DOI 10.1124/mol.61.4.749; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Fan J, 2002, J BIOL CHEM, V277, P3404, DOI 10.1074/jbc.M110054200; Fan J, 2002, J IMMUNOL, V168, P5252, DOI 10.4049/jimmunol.168.10.5252; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Hisatomi O, 1998, FEBS LETT, V424, P159, DOI 10.1016/S0014-5793(98)00162-8; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huang J, 1999, J IMMUNOL, V162, P2217; HUNTER R, 1970, P SOC EXP BIOL MED, V133, P989; JOHNSTON JA, 1994, J IMMUNOL, V153, P1762; KALMAR JR, 1994, METHOD ENZYMOL, V236, P58; Kaplan AP, 2001, INT ARCH ALLERGY IMM, V124, P423, DOI 10.1159/000053777; Khandaker MH, 1999, BLOOD, V93, P2173, DOI 10.1182/blood.V93.7.2173.407a06_2173_2185; Khandaker MH, 1998, J IMMUNOL, V161, P1930; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lira S, 1999, Forum (Genova), V9, P286; LLOYD AR, 1995, J BIOL CHEM, V270, P28188; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; PENN RB, 1994, J BIOL CHEM, V269, P14924; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SZUCS S, 1994, J IMMUNOL METHODS, V167, P245, DOI 10.1016/0022-1759(94)90093-0; Ulevitch RJ, 1999, NATURE, V401, P755, DOI 10.1038/44490; Wiekowski MT, 2001, J IMMUNOL, V167, P7102, DOI 10.4049/jimmunol.167.12.7102; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	37	209	224	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					315	321		10.1038/nm832	http://dx.doi.org/10.1038/nm832			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12592402				2022-12-27	WOS:000181312300032
J	Stears, RL; Martinsky, T; Schena, M				Stears, Robin L.; Martinsky, Todd; Schena, Mark			Trends in microarray analysis	NATURE MEDICINE			English	Review								Microarrays permit the analysis of gene expression, DNA sequence variation, protein levels, tissues, cells and other biological and chemical molecules in a massively parallel format. Robust microarray manufacture, hybridization, detection and data analysis technologies permit novice users to adapt this exciting technology readily, and more experienced users to push the boundaries of discovery.	[Stears, Robin L.; Martinsky, Todd; Schena, Mark] TeleChem Int Inc, Sunnyvale, CA USA		Stears, RL (corresponding author), TeleChem Int Inc, Sunnyvale, CA USA.	mark@arrayit.com						Al-Khaldi SF, 2002, J AOAC INT, V85, P906; Bao P, 2002, ANAL CHEM, V74, P1792, DOI 10.1021/ac0111964; Beaucage SL, 2001, CURR MED CHEM, V8, P1213, DOI 10.2174/0929867013372463; Bellenson J.L., 2000, DNA MICROARRAYS PRAC, P139; Bjorkholm B, 2001, INFECT IMMUN, V69, P7832, DOI 10.1128/IAI.69.12.7832-7838.2001; Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536; Carr D.B., 1997, STAT COMPUTING GRAPH, V8, P20; Chen B, 2002, CHEM MATER, V14, P1891, DOI 10.1021/cm0116828; Chizhikov V, 2001, APPL ENVIRON MICROB, V67, P3258, DOI 10.1128/AEM.67.7.3258-3263.2001; Cho RJ, 1998, P NATL ACAD SCI USA, V95, P3752, DOI 10.1073/pnas.95.7.3752; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eickhoff Holger, 2002, Adv Biochem Eng Biotechnol, V77, P103; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evertsz E, 2000, MICROARRAY BIOCHIP TECHNOLOGY, P149; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Gao XL, 2001, NUCLEIC ACIDS RES, V29, P4744, DOI 10.1093/nar/29.22.4744; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Haab BB, 2001, GENOME BIOL, V2; Hacia JG, 1999, NAT GENET, V22, P164, DOI 10.1038/9674; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; JACKSON DA, 1972, P NATL ACAD SCI USA, V69, P2904, DOI 10.1073/pnas.69.10.2904; Kane MD, 2000, NUCLEIC ACIDS RES, V28, P4552, DOI 10.1093/nar/28.22.4552; Kipps TJ, 2002, SEMIN ONCOL, V29, P98, DOI 10.1053/sonc.2002.30146; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lau WK, 2002, BIOTECHNIQUES, V33, P564, DOI 10.2144/02333st07_11821a; Lesaicherre ML, 2002, J AM CHEM SOC, V124, P8768, DOI 10.1021/ja0265963; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MacBeath G, 2000, SCIENCE, V289, P1760; Michaels G S, 1998, Pac Symp Biocomput, P42; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; Rose D, 2000, MICROARRAY BIOCHIP TECHNOLOGY, P19; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; Schena M, 1996, BIOESSAYS, V18, P427, DOI 10.1002/bies.950180513; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schena M., 2002, MICROARRAY ANAL, P387; Selaru FM, 2002, GASTROENTEROLOGY, V122, P606, DOI 10.1053/gast.2002.31904; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Singh-Gasson S, 1999, NAT BIOTECHNOL, V17, P974, DOI 10.1038/13664; Sniegowski P, 1999, CURR BIOL, V9, pR897, DOI 10.1016/S0960-9822(00)80078-0; Soini H, 2001, CLIN CHEM, V47, P809; Southern EM, 2000, TRENDS BIOCHEM SCI, V25, P585, DOI 10.1016/S0968-0004(00)01702-3; Stears RL, 2000, PHYSIOL GENOMICS, V3, P93, DOI 10.1152/physiolgenomics.2000.3.2.93; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Syvanen AC, 1999, HUM MUTAT, V13, P1; Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757; Theriault T.P., 2000, DNA MICROARRAYS PRAC, P101; Tonisson N, 2000, MICROARRAY BIOCHIP TECHNOLOGY, P247; Wang DN, 2002, NAT BIOTECHNOL, V20, P275, DOI 10.1038/nbt0302-275; Wilson DS, 2002, CURR OPIN CHEM BIOL, V6, P81, DOI 10.1016/S1367-5931(01)00281-2; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Xiong MM, 2001, MOL GENET METAB, V73, P239, DOI 10.1006/mgme.2001.3193; Yguerabide J, 2001, J CELL BIOCHEM, V84, P71, DOI 10.1002/jcb.10077; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; Zhou YX, 2000, MICROARRAY BIOCHIP TECHNOLOGY, P167; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	64	193	217	1	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2003	9	1					140	145		10.1038/nm0103-140	http://dx.doi.org/10.1038/nm0103-140			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	V27VJ	12514728				2022-12-27	WOS:000208640400010
J	Dowsett, M; Howell, A				Dowsett, M; Howell, A			Breast cancer: Aromatase inhibitors take on tamoxifen	NATURE MEDICINE			English	Editorial Material							ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE THERAPY; LETROZOLE; RESISTANT		Royal Marsden NHS Trust, Acad Dept Biochem, London, England; Univ Manchester, Christie Hosp NHS Trust, Dept Med Oncol, Canc Res UK, Manchester, Lancs, England	Royal Marsden NHS Foundation Trust; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Dowsett, M (corresponding author), Royal Marsden NHS Trust, Acad Dept Biochem, Fulham Rd, London, England.	mitch@icr.ac.uk		Howell, Anthony/0000-0002-6233-719X				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Baum M, 2002, LANCET, V359, P2131; Bentrem D J, 2002, Minerva Endocrinol, V27, P127; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; Buzdar A, 2001, CLIN CANCER RES, V7, P2620; Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2; Cuzick J, 2002, LANCET, V360, P817; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fuqua SAW, 2000, CANCER RES, V60, P4026; Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.2002.20.3.751; Harper-Wynne C, 2002, CANCER EPIDEM BIOMAR, V11, P614; Heshmati HM, 2002, J BONE MINER RES, V17, P172, DOI 10.1359/jbmr.2002.17.1.172; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Howell A, 1997, BRIT MED J, V315, P863, DOI 10.1136/bmj.315.7112.863; Kurokawa H, 2000, CANCER RES, V60, P5887; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; Zhang QX, 1997, CANCER RES, V57, P1244	20	26	26	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1341	1344		10.1038/nm1202-1341	http://dx.doi.org/10.1038/nm1202-1341			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12457166				2022-12-27	WOS:000179552000015
J	Rebar, EJ; Huang, Y; Hickey, R; Nath, AK; Meoli, D; Nath, S; Chen, BL; Xu, L; Liang, YX; Jamieson, AC; Zhang, L; Spratt, SK; Case, CC; Wolffe, A; Giordano, FJ				Rebar, EJ; Huang, Y; Hickey, R; Nath, AK; Meoli, D; Nath, S; Chen, BL; Xu, L; Liang, YX; Jamieson, AC; Zhang, L; Spratt, SK; Case, CC; Wolffe, A; Giordano, FJ			Induction of angiogenesis in a mouse model using engineered transcription factors	NATURE MEDICINE			English	Article							GENE-TRANSFER; ZINC FINGERS; SELECTION; ACTIVATION; DESIGN	The relationship between the structure of zinc-finger protein (ZFP) transcription factors and DNA sequence binding specificity has been extensively studied(1). Advances in this field have made it possible to design ZFPs de novo that will bind to specific targeted DNA sequences(2-10). It has been proposed that such designed ZFPs may eventually be useful in gene therapy(6,7,10). A principal advantage of this approach is that activation of an endogenous gene ensures expression of the natural array of splice variants(2). Preliminary studies in tissue culture have validated the feasibility of this approach(2-4). The studies reported here were intended to test whether engineered transcription factors are effective in a whole-organism model. ZFPs were designed to regulate the endogenous gene encoding vascular endothelial growth factor-A (Vegfa). Expression of these new ZFPs in vivo led to induced expression of the protein VEGF-A, stimulation of angiogenesis and acceleration of experimental wound healing. In addition, the neovasculature resulting from ZFP-induced expression of Vegfa was not hyperpermeable as was that produced by expression of murine Vegfa(164) cDNA. These data establish, for the first time, that specifically designed transcription factors can regulate an endogenous gene in vivo and evoke a potentially therapeutic biophysiologic effect.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Sangamo Biosci, Richmond, CA USA	Yale University; Sangamo Therapeutics, Inc.	Giordano, FJ (corresponding author), Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA.	fjg9@email.med.yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064001] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL64001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Low QEH, 2001, AM J PATHOL, V159, P457, DOI 10.1016/S0002-9440(10)61717-8; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Vale PR, 2000, CIRCULATION, V102, P965, DOI 10.1161/01.CIR.102.9.965; Vincent KA, 2000, CIRCULATION, V102, P2255; Wolffe A., 1998, CHROMATIN STRUCTURE; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	22	207	264	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2002	8	12					1427	1432		10.1038/nm795	http://dx.doi.org/10.1038/nm795			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	620UZ	12415262				2022-12-27	WOS:000179552000040
